<SEC-DOCUMENT>0001213900-22-004359.txt : 20220131
<SEC-HEADER>0001213900-22-004359.hdr.sgml : 20220131
<ACCEPTANCE-DATETIME>20220131080103
ACCESSION NUMBER:		0001213900-22-004359
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		137
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20220131
DATE AS OF CHANGE:		20220131

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Universe Pharmaceuticals INC
		CENTRAL INDEX KEY:			0001809616
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			F4
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40231
		FILM NUMBER:		22571379

	BUSINESS ADDRESS:	
		STREET 1:		265 JINGJIU AVENUE
		STREET 2:		JINGGANGSHAN ECON. AND TECH. DEV. ZONE
		CITY:			JI'AN, JIANGXI
		STATE:			F4
		ZIP:			343100
		BUSINESS PHONE:		86-0796-8403309

	MAIL ADDRESS:	
		STREET 1:		265 JINGJIU AVENUE
		STREET 2:		JINGGANGSHAN ECON. AND TECH. DEV. ZONE
		CITY:			JI'AN, JIANGXI
		STATE:			F4
		ZIP:			343100
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>f20f2021_universe.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sat Jan 29 18:38:59 UTC 2022 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:upc="http://www.UniversePharmaceuticalsINC.com/20210930" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WASHINGTON,
D.C. 20549</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM&#160;<ix:nonNumeric contextRef="c0" name="dei:DocumentType">20-F</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement">&#9744;</ix:nonNumeric>&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b>REGISTRATION STATEMENT PURSUANT TO SECTION&#160;12(b)&#160;OR (g)&#160;OF THE SECURITIES<br/> EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric>&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE <br/>
ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate">September&#160;30, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric></ix:nonNumeric></b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric>&#160;<b>TRANSITION
REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE<br/> ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport">&#9744;</ix:nonNumeric>&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHELL
COMPANY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES<br/> EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of event requiring this shell company report</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from &#160; to</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-40231</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Universe
Pharmaceuticals INC</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Registrant as specified in its charter)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of Registrant&#8217;s name into English)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cayman
Islands</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Jurisdiction
of incorporation or organization)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">265
Jingjiu Avenue,</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2">Jinggangshan Economic and Technological Development Zone</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ji&#8217;an,
Jiangxi Province</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>People&#8217;s
Republic of <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">China</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>+86-571-87555823</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName">Gang
Lai</ix:nonNumeric>, Chief Executive Officer</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telephone:
+86-0796-8403309</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Email:
<ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelEmailAddress">gang.lai@universe-pharmacy.com</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1">265
Jingjiu Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2">Jinggangshan Economic and Technological Development Zone</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ji&#8217;an,
Jiangxi Province</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>People&#8217;s
Republic of <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">China</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered or to be registered pursuant to Section&#160;12(b)&#160;of the Act.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary Shares</b></span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UPC</b></span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Stock Market</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered pursuant to Section&#160;12(g)&#160;of the Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of Class)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
for which there is a reporting obligation pursuant to Section&#160;15(d)&#160;of the Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of Class)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered
by the annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
aggregate of <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">21,750,000</ix:nonFraction> ordinary shares, par value $0.003125 per share, as of September 30, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes&#160;&#9744;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric>&#160;&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13
or 15(d)&#160;of the Securities Exchange Act of 1934.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes&#160;&#9744;
<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric>&#160;&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2)&#160;has been subject to such filing requirements for the past 90 days.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>&#160;&#9746;
No&#160;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405
of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>&#160;&#9746;
No&#160;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth
company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221;
in Rule&#160;12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 5%">&#9744;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging&#160;growth&#160;company</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section&#160;13(a)&#160;of the Exchange Act. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the
registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-0">U.S. GAAP</span> &#9746;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Financial Reporting Standards as issued by the</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Accounting Standards Board &#9744;</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other </span>&#9744;</td></tr> </table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the
registrant has elected to follow. Item 17 &#9744; Item 18 &#9744;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange
Act). Yes&#160;&#9744; <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">No</ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes&#160;&#9744;&#160;No&#160;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#k_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTRODUCTION</span></a></td>
    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#k_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART&#160;I</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFER STATISTICS AND EXPECTED TIMETABLE</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KEY INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION ON THE COMPANY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">27</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNRESOLVED STAFF COMMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">51</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">51</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_009">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">83</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFER AND LISTING</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">92</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADDITIONAL INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">93</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">110</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_015">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#k_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART&#160;II</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">112<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">112</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTROLS AND PROCEDURES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">112</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[RESERVED]</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">114</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUDIT COMMITTEE FINANCIAL EXPERT</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">114</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CODE OF ETHICS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">114</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">115</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16E.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16F.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16G.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CORPORATE GOVERNANCE</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16H.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MINE SAFETY DISCLOSURE</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">116</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16I.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSEPCTIONS.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">116</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="#k_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART&#160;III</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    17.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    18.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">117</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    19.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><a href="#k_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">117</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="k_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTRODUCTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this annual report on Form 20-F, unless the context otherwise requires, references to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;China&#8221;
    or the &#8220;PRC&#8221; are to the People&#8217;s Republic of China, excluding Taiwan and the special administrative regions of
    Hong Kong and Macau for the purposes of this annual report only;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Jiangxi
    Universe&#8221; are to Jiangxi Universe Pharmaceuticals Co., Ltd., a limited liability company organized under the laws of the PRC,
    which is wholly owned by Universe Technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;RMB&#8221;
    and Renminbi&#8221; are to the legal currency of China;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;shares&#8221;
    or &#8220;ordinary shares&#8221; are to the ordinary shares of the Company, par value $0.003125 per share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;TCM&#8221;
    are to traditional Chinese medicine;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;TCMD&#8221;
    are to traditional Chinese medicine derivatives;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Universe
    HK&#8221; are to Universe INC&#8217;s wholly owned subsidiary, Universe Pharmaceuticals Group (International) Limited, a company
    incorporated in Hong Kong;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Universe
    Technology&#8221; are to Jiangxi Universe Pharmaceuticals Technology Co., Ltd., a limited liability company organized under the laws
    of the PRC, and is wholly owned by Universe HK;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Universe
    Trade&#8221; are to Jiangxi Universe Pharmaceuticals Trade Co., Ltd., a PRC company formed in 2010, a wholly-owned subsidiary of
    Jiangxi Universe;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;US$,&#8221;
    &#8220;U.S. dollars,&#8221; &#8220;$&#8221; and &#8220;dollars&#8221; are to the legal currency of the United States; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;we,&#8221;
    &#8220;us,&#8221; &#8220;our Company,&#8221; or the &#8220;Company&#8221;, are to one or more of Universe Pharmaceuticals INC, a
    company incorporated in the Cayman Islands and our holding company, and its subsidiaries, as the case may be.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report on Form&#160;20-F includes our audited consolidated financial statements for the fiscal years ended September&#160;30,
2021, 2020, and 2019. In this annual report, we refer to assets, obligations, commitments, and liabilities in our consolidated financial
statements in United States dollars. These dollar references are based on the exchange rate of RMB to United States dollars, determined
as of a specific date or for a specific period. Changes in the exchange rate will affect the amount of our obligations and the value
of our assets in terms of United States dollars which may result in an increase or decrease in the amount of our obligations and the
value of our assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report contains translations of certain RMB amounts into U.S. dollars at specified rates. Unless otherwise stated, the following
exchange rates are used in this annual report:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">September 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">US$ Exchange Rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; width: 64%; text-align: left">At the end of the year - RMB</td><td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">RMB</td><td style="white-space: nowrap; width: 9%; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">6.4580 to $1.00</p></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">RMB</td><td style="white-space: nowrap; width: 9%; text-align: right">6.8033 to $1.00</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">RMB</td><td style="white-space: nowrap; width: 9%; text-align: right">7.1378 to $1.00</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: left">Average rate for the year - RMB</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">RMB</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5095 to $1.00</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">RMB</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.0077 to $1.00</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">RMB</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8729 to $1.00</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="k_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part&#160;I</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
2. OFFER STATISTICS AND EXPECTED TIMETABLE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
3. KEY INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
<span style="text-decoration:underline">[Reserved]</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
<span style="text-decoration:underline">Capitalization and Indebtedness</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
<span style="text-decoration:underline">Reasons for the Offer and Use of Proceeds</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
<span style="text-decoration:underline">Risk Factors</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business and Industry</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Price
increases in raw materials and sourced products could harm our financial results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal raw materials include angelica, codonopsis, poria mushroom isatis root, and other herbs and plant extracts. These raw materials
are subject to price volatility and inflationary pressures. Our success is dependent, in part, on our ability to reduce our exposure
to increases in such costs through a variety of ways, while maintaining and improving margins and market share. The manufacturers of
such raw materials are also subject to price volatility and labor cost and other inflationary pressures, which may in turn result in
an increase in the amount we pay for sourced products. Raw materials and sourced product price increases may offset our productivity
gains and price increases and may adversely impact our financial results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>High
quality materials for our products may be difficult to obtain or substantially increase our production costs.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw
materials account for a portion of our manufacturing costs and we rely on third-party suppliers to provide almost all raw materials.
Suppliers may be unable or unwilling to provide the raw materials we need in the quantities requested, at prices we are willing to pay,
or that meet our quality standards. We are also subject to potential delays in the delivery of raw materials caused by events beyond
our control, including transportation interruptions, delivery delays, labor disputes and changes in government regulations. Our business
could be adversely affected if we are unable to obtain reliable sources of the raw materials used in the manufacturing of our products
that meet our quality standards. Any significant delay in or disruption of the supply of raw materials could, among other things, substantially
increase the cost of such materials, require reformulation or repackaging of products, require the qualification of new suppliers, or
result in our inability to meet customer demands, which could in turn adversely affect our financial results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
operate in a highly competitive industry. Our failure to compete effectively could adversely affect our market share, revenues and growth
prospects</i></b><i>.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chinese patent medicine industry in the PRC is subject to significant competition and pricing pressures. We will experience significant
competitive pricing pressures as well as competitive products. Several significant competitors may offer products at the same or lower
prices than our products. The market is highly sensitive to the introduction of new products, which may rapidly capture a significant
share of the market. It is possible that one or more of our competitors could develop a significant research advantage over us that allows
them to provide superior products that are more attractive to consumers, which could put us in a competitive disadvantage. Continued
pricing pressure or improvements in research and shifts in customer preference could adversely impact our customer base or pricing structure
and have a material and adverse effect on our business, financial conditions, results of operations and cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to maintain or enhance our brands or image could have a material adverse effect on our business and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe several of our brands, such as &#8220;Bai Nian Dan (&#30334;&#24180;&#20025;)&#8221;, &#8220;Hu Zhuo Ren (&#32993;&#21331;&#20161;)&#8221;
and &#8220;Long Zhong (&#40857;&#31181;)&#8221;, are well-recognized among our clients and other Chinese patent medicine industry players.
Our brand is integral to our sales and marketing efforts. Our continued success in maintaining and enhancing our brand and image depends
to a large extent on our ability to satisfy customer needs by further developing effective and better-quality products, as well as our
ability to respond to competitive pressures. If we are unable to satisfy customer needs or if our public image or reputation were otherwise
diminished, our business transactions with our customers may decline, which could in turn adversely affect our results of operations.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
failure to appropriately respond to changing consumer preferences and demand for new products could significantly harm our customer relationships
and product sales.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is particularly subject to changing consumer trends and preferences. Our continued success depends in part on our ability to
anticipate and respond to these changes, and we may not be able to respond in a timely or commercially appropriate manner to these changes.
If we are unable to do so, our customer relationships and product sales could be harmed significantly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the Chinese patent medicine industry is characterized by rapid and frequent changes in demand and new product introductions. Our failure
to accurately depict these trends could negatively impact consumer opinion of our stores as a source for latest products. This could
harm our customer relationships and cause losses to our market share. The success of our new product offerings depends upon a number
of factors, including our ability to: accurately anticipate customer needs; innovate and develop new products; successfully commercialize
new products in a timely manner; price our products competitively; manufacture and deliver our products in sufficient volumes and in
a timely manner; and differentiate our product offerings from those our competitors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not introduce new products or make enhancements to meet the changing needs of our customers in a timely manner, some of our products
could become obsolete, which could have a material adverse effect on our revenues and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our products do not have the effects intended or cause undesirable side effects, our business may suffer</i>.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the ingredients in our current products have a long history of human consumption, and although we believe that all of these products
and the combinations of ingredients in them are safe when taken as directed, the products could have certain undesirable side effects
if not taken as directed or if taken by a consumer who has certain medical conditions. In addition, these products may not have the effect
intended if they are not taken in accordance with instructions, which may include dietary restrictions. Furthermore, there can be no
assurance that any of these products, even when used as directed, will have the effects intended or will not have harmful side effects
in an unforeseen way or on an unforeseen cohort. If any of our products or products we develop or commercialize in the future are shown
to be harmful or generate negative publicity from perceived harmful effects, our business, financial condition, results of operations,
and prospects could be harmed significantly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have made substantial investment in advertising
our products in order to improve our brand awareness and our market position, which efforts may not be successful, and in such event,
our financial position and results of operations may be materially and negatively affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have made substantial investment in advertising
our products in order to improve our brand awareness and our market position. In particular, in the fiscal year ended September 30, 2021,
we started to advertise our products through television advertisement. For example, on September 6, 2021, we entered into a service agreement
with an advertising agency, engaging such agency to develop and produce a television advertisement for our signature TCMD products, Bai
Nian Dan and Guben Yanlin Pill, and to coordinate with a television channel to air the advertisement to audience in certain our target
markets, with a term of one year from October 1, 2021 to September 30, 2022. In connection with this agreement, we prepaid $7.5 million
to the advertising agency. We cannot guarantee that the advertising agency or the television station will fully fulfill their obligations
under the agreement. If the advertisement was not produced or aired in the ways agreed upon in the agreement, we may not be able to get
any of the prepaid expenses back. In addition, we incurred substantial advertising expenditures to maintain and enhance our brand and
our products, which may not prove successful. Television advertising and other brand promotion activities may not generate customer awareness
or increase revenue, and even if they do, any increase in revenue may not offset the expenses we incur in building our brand. Additionally,
there could be a negative reaction to certain advertising campaigns. If we fail to promote our brand, or if we incur excessive expenses
in this effort, we may fail to attract or retain customers necessary to realize a sufficient return on our brand-building efforts or to
achieve the desired brand awareness that is critical for our success.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future success depends in part on our
ability to increase our production capacity, and we may not able to do so in a cost-effective manner. We have engaged a third-party sub-contractor
to build manufacturing facilities and an office building for us, and we may encounter challenges relating to the construction, management
and operation of such facilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent we are successful in growing our
business, we may need to increase our production capacity. We entered into a construction agreement with a sub-contractor, who will construct
four manufacturing plants and an office building for us, with a total maximum budget of approximately $25.5 million. The construction
started on August 8, 2021 and we expect the construction of the properties to be complete by August 2023. Our ability to construct such
additional facilities is subject to risks and uncertainties. The construction of any new facilities will be subject to risks inherent
in the development and construction, including risks of delays and cost overruns as a result of factors outside of our control, which
may include delays in government approvals, burdensome permitting conditions, and delays in the delivery of manufacturing equipment or
raw materials required for the construction. Additionally, we also depend on the third-party sub-contractor for the development of new
facilities, and as such, we are subject to the risk that such third parties do not fulfill their obligations to us under the contraction
agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the sub-contractor is unable to deliver the
new facilities to us on time, or if we are unable to expand our manufacturing facilities in general, we may be unable to further scale
our business, which would negatively affect our results of operations and financial condition. If we are unable to transition manufacturing
operations to such new facilities in a cost-efficient and timely manner, then we may experience disruptions in operations, which could
negatively impact our business and financial results. Further, if the demand for our products decreases or if we do not produce the expected
output after any such new facilities are operational, we may not be able to spread a significant amount of our fixed costs over the production
volume, thereby increasing our per product fixed cost, which would have a negative impact on our business, financial condition and results
of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have internal control deficiency in our internal
control system and deficiencies in our corporate governance. If we fail to improve our internal control function and corporate governance,
we may be subject to increased risk of fraud or misuse of corporate assets, which may materially and negatively impact our financial condition
and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have internal control deficiency in our internal
control system and deficiency in our corporate governance. In the fiscal year ended September 30, 2021, we entered into several material
business transactions, including a construction agreement with a third-party sub-contractor to construct manufacturing facilities and
an office building for us, a real estate property purchase agreement with a related party for the purchase of certain real properties,
and an advertising service agreement with a third-party advertising agency to air our television advertisements. These transactions were
not submitted for approval by our board of directors or any of its committees. We are initiating plans to improve our internal control
procedures and corporate governance as a public company, and intend to obtain board approval prior to entering into any future material
business transaction. If we fail to implement remedial measures to improve our internal control and corporate governance function, we
may be subject to increased risk of fraud or misuse of corporate assets, which may materially and negatively impact our financial condition
and results of operations.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to evolving regulatory requirements, non-compliance with which, or changes in which, may adversely affect our business and
prospects.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a manufacturer of products designed for human consumption, we are subject to legal and regulatory requirements applicable to the Chinese
patent medicine industry in the PRC. We have been subject to penalties by PRC regulatory authorities in the past due to our failure to
comply with their requirements, including noncompliance with the Good Manufacturing Practice for Drugs and the National Drug Standard.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations to which we are subject in this area are evolving. As a result, the interpretation of these laws and their enforcement is
often uncertain. Predicting the application of these laws can be difficult, and unexpected outcomes in the interpretation and enforcement
of the applicable regulations may have an adverse impact on our business and operations. Additionally, any future changes in regulations
may render our business non-compliant or require changes to our business practices or licensing arrangements to ensure compliance. These
changes may involve significant costs, which in turn may adversely affect our business and financial prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
regulatory authorities of the PRC government regulate the manufacturing and trading of Chinese patent medicine. Violations of regulations
may lead to the imposition of significant penalties which may affect our business, operations, reputation and financial prospects. See
&#8220;I<span>tem 4. Information on the Company&#8212;B. Business Overview&#8212;</span>Regulations&#8221;
for details.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we introduce new products to our customers, we may be required to comply with additional laws and regulations that are yet to be determined.
To comply with such additional laws and regulations, we may be required to obtain necessary certificates, licenses or permits, as well
as expend additional resources to monitor regulatory and policy developments. Our failure to adequately comply with such additional laws
and regulations may delay, or possibly prevent, some of our products from being offered to customers, which may have a material adverse
effect on our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to maintain or renew requisite licenses, permits, registrations and filings applicable to our business operations, or fail to
obtain additional licenses, permits, registrations or filings that become necessary as a result of new enactment or promulgation of government
policies, laws or regulations or the expansion of our business, our business and results of operations may be materially and adversely
affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chinese patent medicine industry in China is highly regulated, and multiple licenses, permits, filings and approvals are required to
operate our business. Currently, through our PRC subsidiaries, we have obtained a valid pharmaceutical manufacturing license, a medical
device selling license, and a pharmaceutical trade license. We have made efforts to obtain all applicable approvals, licenses and permits,
but due to the complexities, uncertainties and frequent changes in laws, rules, regulations and their interpretation and implementation,
we may not always be able to do so, and we may be penalized by governmental authorities for conducting pharmaceutical manufacturing or
sales activities without proper approvals, licenses or permits. Moreover, as we continue to increase our product variety, we may also
become subject to new or existing laws and regulations that did not affect us in the past. Failure to obtain, renew or retain requisite
licenses, permits or approvals may adversely affect our ability to conduct or expand our business, and may have a material adverse impact
on our business prospects, results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is subject to inherent risks relating to product liability and personal injury claims.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a manufacturer of products designed for human consumption, we are subject to product liability claims if the use of our products is alleged
to have resulted in injury. For instance, adverse reactions resulting from human consumption of the ingredients contained in our products
could occur. We may also be obligated to recall affected products. If we are found liable for product liability claims, we could be required
to pay substantial monetary damages. Furthermore, even if we successfully defend ourselves against this type of claim, we could be required
to spend significant management, financial and other resources, which could disrupt our business, and our reputation as well as our brand
name may also suffer. We, like many other similar companies in China, do not carry product liability insurance. As a result, any imposition
of product liability could materially harm our business, financial condition and results of operations. In addition, we do not have any
business interruption insurance, due to the limited coverage of any available business interruption insurance in China, and as a result,
any business disruption or natural disaster could severely disrupt our business and operations and significantly decrease our revenue
and profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in expanding a distribution network.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we intend to expand our distribution network to include additional cities and rural areas in the PRC in an effort to increase our geographic
presence, our distribution, logistics and products may encounter competition from various similar or substitutive businesses. Therefore,
the success of expansion will depend upon many factors, including our ability to form relationships with, and manage an increasing number
of, customers base and optimize our distribution network. If we fail to expand our distribution network as planned, our business, financial
condition and results of operations may be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
global spread of COVID-19 pandemic could materially and adversely affect our business and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the COVID-19 outbreak, our factory was closed during the first two weeks of February 2020 at the mandate of the Chinese government,
and reopened on February 13, 2020. Our factory has been fully running as normal since March 2, 2020. Our business operations has been
affected and may continue to be affected by the ongoing COVID-19 pandemic.&#160;Although we resumed our operations since early March
2020 and the impact of COVID-19 on our operating results and financial performance for the fiscal years 2020 and 2021 were minimal, any
resurgence could negatively affect the execution of customer contracts, the collection of customer payments, or disrupt our supply chain,
and the continued uncertainties associated with the COVID 19 pandemic may cause our revenue and cash flows to underperform in the next
12 months from the date of this annual report. The extent of the future impact of the COVID-19 pandemic on our business and results of
operations is still uncertain.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic continues to have a severe and negative impact on the Chinese and the global economy. Whether this will lead to a prolonged
downturn in the economy is still unknown. The global spread of the COVID-19 pandemic in major countries of the world has and may continue
to result in global economic distress, and the nature of and extent to which it may affect our results of operations will depend on future
developments of the COVID-19 pandemic, which are highly uncertain and difficult to predict. Any resurgence could negatively affect the
execution of customer contracts, the collection of customer payments, or disrupt our supply chain, and the continued uncertainties associated
with COVID 19 may cause our revenue and cash flows to underperform in the next 12 months. The extent of the future impact of COVID-19
is still considered to be uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent on certain key personnel and loss of these key personnel could have a material effect on our business, financial condition
and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success is, to a certain extent, attributable to the management, sales and marketing, and research and development expertise of key personnel.
We are dependent upon the services of Mr. Gang Lai, the chairman of our board of directors and our chief executive officer, for the continued
growth and operation of our Company, due to his industry experiences and management experiences. Although we have no reason to believe
that Mr. Gang Lai will discontinue his services with us, the interruption or loss of his services would adversely affect our ability
to effectively run our business and pursue our business strategy as well as our results of operation. We currently do not have &#8220;key
person&#8221; insurance on any of our executives or employees. There can be no assurance that we will be able to retain our key personnel
after the terms of their employment expire. The loss of the services of one or more of our key personnel could have a material adverse
effect upon our business, financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not effectively manage our growth, which could materially harm our business</i></b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our business will continue to grow, which may place a significant strain on our management, personnel, systems and resources.
We must continue to improve our operational and financial systems and managerial controls and procedures, and we will need to continue
to expand, train and manage our technology and workforce. We must also maintain close coordination among our compliance, accounting,
finance, marketing and sales organizations. We cannot assure you that we will manage our growth effectively. If we fail to do so, our
business could be materially harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
continued growth will require an increased investment by us in technology, facilities, personnel and financial and management systems
and controls. It also will require expansion of our procedures for monitoring and assuring our compliance with applicable regulations,
and we will need to integrate, train and manage a growing employee base. The expansion of our existing businesses, any expansion into
new businesses and the resulting growth of our employee base will increase our need for internal audit and monitoring processes that
are more extensive and broader in scope than those we have historically acquired. We may not be successful in identifying or implementing
all of the processes that are necessary. Further, unless our growth results in an increase in our revenues that is proportionate to the
increase in our costs associated with this growth, our operating margins and profitability will be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to hire and retain qualified personnel to support our growth and if we are unable to retain and hire these personnel
in the future, our ability to improve our products and implement our business objects could be adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
must attract, recruit and retain a sizeable workforce of technically competent employees. Competition for senior management and personnel
in the PRC is intense and the pool of qualified candidates in the PRC is very limited. We may not be able to retain the services of our
senior executives or personnel, or attract and retain high-quality senior executives or personnel in the future. This failure could materially
and adversely affect our future growth and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success depends on our ability to protect our intellectual property.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently own 22 patents and 99 trademarks in China. We believe that our success depends on our ability to obtain and maintain patent
protection for products developed utilizing our technologies, in the PRC and in other countries, and to enforce these patents. There
is no assurance that any of our existing and future patents will be deemed to be valid and enforceable against third-party infringement
or that our products will not infringe any third-party patent or intellectual property by a court or administrative body having jurisdiction
over such matters. Although we have filed additional patent applications with Patent Administration Department of PRC, there is no assurance
that they will be granted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
patents relating to our technologies may not be sufficiently broad to protect our products. In addition, our patents may be challenged,
potentially invalidated or potentially circumvented. Our patents may not afford us protection against competitors with similar technology
or permit the commercialization of our products without infringing third-party patents or other intellectual property rights.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely, or intend to rely, on our trademarks, trade names and brand names to distinguish our products from the products of our competitors,
and have registered or will apply to register a number of these trademarks. However, third parties may oppose our trademark applications
or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to
rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing
these new brands. Further, our competitors may infringe our trademarks, or we may not have adequate resources to enforce our trademarks.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we also have trade secrets, non-patented proprietary expertise and continuing technological innovations that we expect to seek
to protect, in part, by entering into confidentiality agreements with licensees, suppliers, employees and consultants. These agreements
may be breached and there may not be adequate remedies in the event of a breach. Disputes may arise concerning the ownership of intellectual
property or the applicability of confidentiality agreements. Moreover, our trade secrets and proprietary technology may otherwise become
known or be independently developed by our competitors. If patents are not issued with respect to products arising from research, we
may not be able to maintain the confidentiality of information relating to these products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the application and interpretation of China&#8217;s intellectual property laws are still evolving and are uncertain. If we are found
to have violated the intellectual property rights of others, we may be subject to liability and penalty for our infringement activities
or may be prohibited from using such intellectual property, and we may incur licensing fees or be forced to develop alternatives of our
own. In addition, we may incur significant expenses, and may be forced to divert management&#8217;s time and other resources from our
business and operations to defend against these infringement claims, regardless of their merits. Successful infringement or licensing
claims made against us may result in significant monetary liabilities and may materially disrupt our reputation, business and operations
by restricting or prohibiting our use of the intellectual property at issue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
we rely on our manufacturing operations to produce a significant amount of the products we sell, disruptions in our manufacturing system
or losses of manufacturing certifications could adversely affect our sales and customer relationships.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
manufacturing operations produced approximately 61.6%, 59.8%, and 62.9% of the total value of the products we sold for the fiscal year
ended September 30, 2021, 2020, and 2019, respectively. Our products are produced in our manufacturing facility located in Jinggangshan,
Jiangxi Province, China. For the fiscal year ended September 30, 2021, no supplier accounted for more than 10% of our total purchases.
For the fiscal year ended September 30, 2020, two suppliers accounted for approximately 19.6% and 13.6% of our total purchases, respectively.
For the fiscal year ended September 30, 2019, one supplier accounted for approximately 14.1% of our total purchases. In the event any
of our third-party suppliers or vendors becomes unable or unwilling to continue to provide raw materials in the required volumes or quality
levels or in a timely manner, we would be required to identify and obtain acceptable replacement supply sources. If we are unable to
identity and obtain alternative supply sources, our business could be adversely affected. Any significant disruption in our operations
at our manufacturing facility for any reason, including government-imposed regulatory requirements, the loss of certifications, power
interruptions, fires, war, or other force of nature, could disrupt our supply of products, adversely affecting our sales and customer
relationships.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face risks related to our sales of products obtained from third-party suppliers.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
sell a significant number of products that are manufactured by third-party suppliers over which we have no direct control. While we have
implemented processes and procedures to try to ensure that the suppliers we use are complying with all applicable regulations, there
can be no assurance that such suppliers in all instances will comply with such processes and procedures or otherwise with applicable
regulations. Noncompliance could result in our marketing and distribution of contaminated or dangerous products which would subject us
to liabilities and could result in the imposition by government authorities of penalties that could restrict or eliminate our ability
to purchase products. Any or all of these effects could adversely affect our business, financial condition and results of operation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
growth of our business depends on our ability to finance new product innovations and these increased costs may reduce our cash flows
and, if the products in which we have invested fail, it would reduce our profitability.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in the Chinese patent medicine industry, which is characterized by significant competition and rapid change. New products appear
with increasing frequency to supplant existing products. If we fail to adapt to those conditions in a timely and efficient manner, our
revenues and profits would likely decline. To remain competitive, we must continue to incur significant costs in product research and
development, marketing, equipment and facilities and to make capital investment. These costs may increase, resulting in greater fixed
costs and operating expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the fiscal year ended September 30, 2021,
we incurred $5.47 million of research and development expenses, a 837.3% increase compared to the expenses in the fiscal year ended September
30, 2020. In order to diversify our profit portfolio, a large portion of the research and development expenses in the fiscal year ended
September 30, 2021 was spent on developing and testing eight new products.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future operating results will depend to a
significant extent on our ability to continue to provide new products that compare favorably based on time to market, cost and performance
with the design and manufacturing capabilities and competing third-party suppliers and technologies. Furthermore, our research and development
efforts may not produce successful results, and our new products may not achieve market acceptance, create additional revenue for us,
or bring us profits. Our failure to increase our net sales sufficient to offset these increased costs would reduce our profitability and
may materially and adversely affect our business operations and results of operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
acquisitions may have an adverse effect on our ability to manage our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may acquire businesses, technologies, services or products which are complementary to our core business of manufacturing and selling
TCMD products. Future acquisitions may expose us to potential risks, including risks associated with: the integration of new products,
services and personnel; unforeseen or hidden liabilities; the diversion of resources from our existing business; our potential inability
to generate sufficient revenue to offset new costs; the expenses of acquisitions; or the potential loss of or harm to relationships with
both employees and advertising clients resulting from our integration of new businesses.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the potential risks listed above could have a material and adverse effect on our ability to manage our business, our revenues and
net income. We may need to raise additional debt funding or sell additional equity securities to make such acquisitions. The raising
of additional debt funding by us, if required, would result in increased debt service obligations and could result in additional operating
and financing covenants, or liens on our assets, that could restrict our operations. The sale of additional equity securities could result
in additional dilution to our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Increase
in labor costs in the PRC may adversely affect our business and our profitability.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China&#8217;s
economy has experienced increases in labor costs in recent years, and the average wage in China are expected to continue to grow. The
average wage level for our employees has also increased in recent years. We expect that our labor costs, including wages and employee
benefits, will continue to increase as we continue to grow our business. Unless we are able to pass on these increased labor costs to
our customers by increasing prices for our products or services, our profitability and results of operations may be materially adversely
affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have been subject to stricter regulatory requirements in terms of entering into labor contracts with our employees and paying
various statutory employee benefits, including pensions, housing fund, medical insurance, work-related injury insurance, unemployment
insurance and childbearing insurance to designated government agencies for the benefit of our employees. Pursuant to the PRC Labor Contract
Law (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#27861;&#12299;) (the &#8220;Labor Contract Law&#8221;)
that became effective in January 2008 and its implementing rules that became effective in September 2008 and its amendments that became
effective in July 2013, employers are subject to stricter requirements in terms of signing labor contracts, minimum wages, paying remuneration,
determining the term of employees&#8217; probation and unilaterally terminating labor contracts. In the event that we decide to terminate
some of our employees or otherwise change our employment or labor practices, the Labor Contract Law and its implementation rules may
limit our ability to effect any such terminations or those changes in a desirable or cost-effective manner, which could adversely affect
our business and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, we believe that we are in substantial compliance with labor-related laws and regulations in China,
and we have not been notified of any instance of noncompliance. As the interpretation and implementation of labor-related laws and regulations
are still evolving, we cannot assure you that our employment practice will not violate labor-related laws and regulations in China, which
may subject us to labor disputes or government investigations. If we are deemed to have violated relevant labor laws and regulations,
we could be required to provide additional compensation to our employees and our business, financial condition and results of operations
could be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Natural
disasters (whether or not caused by climate change), unusually adverse weather conditions, pandemic outbreaks, terrorist acts and global
political events could cause permanent or temporary distribution center or store closures, impair our ability to purchase, receive or
replenish inventory, or cause customer traffic to decline, all of which could result in lost sales and otherwise adversely affect our
financial performance.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of one or more natural disasters, such as hurricanes, fires, floods and earthquakes (whether or not caused by climate change),
unusually adverse weather conditions, pandemic outbreaks, terrorist acts or disruptive global political events, such as civil unrest
in countries in which our suppliers are located, or similar disruptions could adversely affect our operations and financial performance.
To the extent these events result in the closure of one or more of our distribution centers, a significant number of stores, a manufacturing
facility or our corporate headquarters, or impact one or more of our key suppliers, our operations and financial performance could be
materially adversely affected through an inability to make deliveries to our stores and through lost sales. In addition, these events
could result in increases in fuel (or other energy) prices or a fuel shortage, decrease in available raw materials of sufficient quality
and in sufficient amounts, delays in opening new stores, the temporary lack of an adequate work force in a market, the temporary or long-term
disruption in the supply of products from some local and overseas suppliers, the temporary disruption in the transport of goods from
overseas, delay in the delivery of goods to our distribution centers or stores, the temporary reduction in the availability of products
in our stores and disruption to our information systems. These events also could have indirect consequences, such as increases in the
cost of insurance, if any of such events was to result in significant loss of property or other insurable damage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Doing Business in China</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
PRC government has significant authority to intervene or influence the China operations of an offshore holding company, such as ours,
at any time. The PRC government may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers.
If the PRC government exerts more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based
issuers and we were to be subject to such oversight and control, it may result in a material adverse change to our business operations,
significantly limit or completely hinder our ability to offer or continue to offer securities to investors, and cause the ordinary shares
to significantly decline in value or become worthless.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business, prospects, financial condition, and results of operations may be influenced to a significant degree by political, economic,
and social conditions in China generally. The PRC government has significant authority to intervene or influence the China operations
of an offshore holding company at any time, which could result in a material adverse change to our operations and the value of the ordinary
shares. The PRC government has recently indicated an intent to exert more oversight and control over listings conducted overseas and/or
foreign investment in China-based issuers. Any such action may hinder our ability to offer or continue to offer our securities to investors,
result in a material adverse change to our business operations, and damage our reputation, which could cause the ordinary shares to significantly
decline in value or become worthless. See also &#8220;&#8212;Failure to comply with cybersecurity, data privacy, data protection, or
any other laws and regulations related to data may materially and adversely affect our business, financial condition, and results of
operations.&#8221;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Uncertainties
arising from the legal system in China, including uncertainties regarding the interpretation and enforcement of PRC laws and the possibility
that regulations and rules can change quickly with little advance notice, could hinder our ability to offer or continue to offer the
ordinary shares, result in a material adverse change to our business operations, and damage our reputation, which would materially and
adversely affect our financial condition and results of operations and cause the ordinary shares to significantly decline in value or
become worthless.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legal system in China is a civil law system based on written statutes. Unlike common law systems, it is a system in which decided legal
cases may be cited for reference but have less precedential value. The laws, regulations, and legal requirements in China are quickly
evolving and their interpretation and enforcement involve uncertainties. These uncertainties could limit the legal protections available
to you and us. In addition, we cannot predict the effect of future developments in the PRC legal system, particularly with regard to
new economies, including the promulgation of new laws, changes to existing laws or the interpretation or enforcement thereof, or the
preemption of local regulations by national laws. Furthermore, the PRC legal system is based in part on government policies and internal
rules, some of which are not published on a timely basis or at all. As a result, we may not be aware of our potential violation of these
policies and rules. In addition, any administrative and court proceedings in China may be protracted and result in substantial costs
and diversion of resources and management attention.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
laws and regulations may be enacted from time to time and substantial uncertainties exist regarding the interpretation and implementation
of current and any future PRC laws and regulations applicable to our businesses. In particular, the PRC government authorities may continue
to promulgate new laws, regulations, rules and guidelines governing companies in the patent medicine industry with respect to a wide
range of issues, such as intellectual property, unfair competition and antitrust, privacy and data protection, and other matters. Compliance
with these laws, regulations, rules, guidelines, and implementations may be costly, and any incompliance or associated inquiries, investigations,
and other governmental actions may divert significant management time and attention and our financial resources, bring negative publicity,
subject us to liabilities or administrative penalties, or materially and adversely affect our business, financial condition, results
of operations, and the value of the ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ordinary shares may be delisted or prohibited from being traded over-the-counter under the Holding Foreign Companies Accountable Act,
if the U.S. Public Company Accounting Oversight Board, or the PCAOB, is unable to inspect our auditors. The delisting or the cessation
of trading of our ordinary shares, or the threat of their being delisted or prohibited from being traded, may materially and adversely
affect the value of your investment. Additionally, the inability of the PCAOB to conduct inspections would deprive our investors with
the benefits of such inspections. Our auditor has not been inspected by the PCAOB, but according to our auditor, it will be inspected
by the PCAOB on a regular basis.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Holding Foreign Companies Accountable Act, or the HFCA Act, was enacted on December 18, 2020. The HFCA Act states if the SEC determines
that we have filed audit reports issued by a registered public accounting firm that has not been subject to inspection by the PCAOB for
three consecutive years, the SEC shall prohibit our shares from being traded on a national securities exchange or in the over the counter
trading market in the U.S.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
auditor, the independent registered public accounting firm that issues the audit report included elsewhere in this annual report, as
an auditor of companies that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the
United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards.
Our auditor is headquartered in California and has not been inspected by the PCAOB, but according to our auditor, it will be inspected
by the PCAOB on a regular basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2021, the SEC adopted interim final rules relating to the implementation of certain disclosure and documentation requirements
of the Holding Foreign Companies Accountable Act. We will be required to comply with these rules if the SEC identifies us as having a
&#8220;non-inspection&#8221; year under a process to be subsequently established by the SEC. The SEC is assessing how to implement other
requirements of the Holding Foreign Companies Accountable Act, including the listing and trading prohibition requirements described above.
In May 2021, the PCAOB issued for public comment a proposed rule related to the PCAOB&#8217;s responsibilities under the Holding Foreign
Companies Accountable Act, which, according to the PCAOB, would establish a framework for the PCAOB to use when determining, as contemplated
under the Holding Foreign Companies Accountable Act, whether the PCAOB is unable to inspect or investigate completely registered public
accounting firms located in a foreign jurisdiction because of a position taken by one or more authorities in that jurisdiction. The proposed
rule was adopted by the PCAOB in September 2021, pending the final approval of the SEC to become effective.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act, which, if passed by the U.S. House
of Representatives and signed into law, would reduce the number of consecutive non-inspection years required for triggering the prohibitions
under the Holding Foreign Companies Accountable Act from three years to two.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 2, 2021, the SEC issued amendments to finalize rules implementing the submission and disclosure requirements in the Holding
Foreign Companies Accountable Act. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit
report issued by a registered public accounting firm that is located in a foreign jurisdiction and that PCAOB is unable to inspect or
investigate completely because of a position taken by an authority in foreign jurisdictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 16, 2021, the PCAOB issued a report on
its determination that it is unable to inspect or investigate completely PCAOB-registered public accounting firms headquartered in China
and in Hong Kong because of positions taken by PRC and Hong Kong authorities in those jurisdictions. The PCAOB has made such determination
as mandated under the Holding Foreign Companies Accountable Act. Pursuant to each annual determination by the PCAOB, the SEC will, on
an annual basis, identify issuers that have used non-inspected audit firms and thus are at risk of such suspensions in the future. Our
auditor is headquartered in California and is not subject to this determination announced by the PCAOB.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC may propose additional rules or guidance that could impact us if our auditor is not subject to PCAOB inspection. For example, on
August 6, 2020, the President&#8217;s Working Group on Financial Markets, or the PWG, issued the Report on Protecting United States Investors
from Significant Risks from Chinese Companies to the then President of the United States. This report recommended that the SEC implement
five measures to address companies from jurisdictions that do not provide the PCAOB with sufficient access to fulfil its statutory mandate.
Some of the concepts of these recommendations were implemented with the enactment of the Holding Foreign Companies Accountable Act. However,
some of the recommendations were more stringent than the Holding Foreign Companies Accountable Act. For example, if a company was not
subject to PCAOB inspection, the report recommended that the transition period before a company would be delisted would end on January
1, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has announced that the SEC staff is preparing a consolidated proposal for the rules regarding the implementation of the Holding Foreign
Companies Accountable Act and to address the recommendations in the PWG report. It is unclear when the SEC will complete its rulemaking
and when such rules will become effective and what, if any, of the PWG recommendations will be adopted. The SEC has also announced amendments
to various annual report forms to accommodate the certification and disclosure requirements of the Holding Foreign Companies Accountable
Act. There could be additional regulatory or legislative requirements or guidance that could impact us if our auditor is not subject
to PCAOB inspection. The implications of this possible regulation or guidance, in addition to the requirements of the Holding Foreign
Companies Accountable Act, are uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
for whatever reason, the PCAOB is unable to conduct full inspections of our auditor, uncertainty under the HFCA Act could cause the market
price of our ordinary shares to be materially and adversely affected, and our securities could be delisted or prohibited from being traded
&#8220;over-the-counter&#8221;. The risk and uncertainty associated with a potential delisting would have a negative impact on the price
of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing recent developments would add uncertainties to our future offerings and may result in prohibitions on the trading of our ordinary
shares on the Nasdaq Stock Market, if our auditors fail to meet the PCAOB inspection requirement in time. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with cybersecurity, data privacy, data protection, or any other laws and regulations related to data may materially and adversely
affect our business, financial condition, and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to a variety of cybersecurity, data privacy, data protection, and other laws and regulations related to data, including
those relating to the collection, use, sharing, retention, security, disclosure, and transfer of confidential and private information,
such as personal information and other data. These laws and regulations apply not only to third-party transactions, but also to transfers
of information within our organization. These laws and regulations may restrict our business activities and require us to incur increased
costs and efforts to comply, and any breach or noncompliance may subject us to proceedings against us, damage our reputation, or result
in penalties and other significant legal liabilities, and thus may materially and adversely affect our business, financial condition,
and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
China, the cybersecurity, data privacy, data protection, or other data-related laws and regulations are relatively new and evolving,
and their interpretation and application may be uncertain. For example, on November 14, 2021, the Administration Regulations on Cyber
Data Security (Draft for Comments) (the &#8220;Draft Regulation&#8221;) was proposed by the Cyberspace Administration of China, or the
CAC, for public comments until December 13, 2021. The Draft Regulation reiterates that data processors which process the personal information
of at least one million users must apply for a cybersecurity review if they plan on listing its securities overseas, and the Draft Regulation
further requires the data processors to apply for cybersecurity review in accordance with relevant laws and regulations under the following
circumstances: (i) such data processor engages in merger, reorganization or division of internet platform operators that have gathered
a large number of data resources related to national security, economic development and public interests affects or may affect national
security; (ii) the listing of such data processor overseas affects or may affect national security; and (iii) such data processor engages
in other data processing activities that affect or may affect national security. Any failure to comply with such requirements may subject
us to, among others, suspension of services, fines, revocation of relevant business permits or business licenses, and/or penalties. Since
the CAC is still seeking comments on the Draft Regulation from the public as of the date of this annual report, the Draft Regulation
(especially its operative provisions) and its anticipated adoption or effective date are subject to further changes with substantial
uncertainty.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, we have not engaged in the relevant businesses provided in the Draft Regulation. As such, we currently
do not expect the draft measures by the CAC or other recent regulations will have an impact on our business or results of operations,
and we believe that we are compliant with the regulations and policies that have been issued by the CAC to date. As of the date of this
annual report, we have not received any investigation, notice, warning, or sanction from applicable government authorities (including
the CAC) with regard to our business operations concerning any issues related to cybersecurity and data security. In addition, we have
not been involved in any review, investigation, enquiry, penalty, or other legal proceedings initiated by applicable governmental or
regulatory authorities or third parties in relation to in relation to cyber security or data protection. However, we still face uncertainties
regarding the interpretation and implementation of these laws and regulations in the future. Cybersecurity review could result in disruption
in our operations, negative publicity with respect to our Company, and diversion of our managerial and financial resources. Furthermore,
if we were found to be in violation of applicable laws and regulations in China during such review, we could be subject to fines or other
government sanctions and reputational damage. Therefore, potential cybersecurity review, if applicable to us, could materially and adversely
affect our business, financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the PRC Data Security Law, which was promulgated by the Standing Committee of the National People&#8217;s Congress (the &#8220;SCNPC&#8221;)
on June 10, 2021 and took effect on September 1, 2021, requires data collection to be conducted in a legitimate and proper manner, and
stipulates that, for the purpose of data protection, data processing activities must be conducted based on data classification and hierarchical
protection system for data security. Furthermore, the recently issued Opinions on Strictly Cracking Down Illegal Securities Activities
require (i) speeding up the revision of the provisions on strengthening the confidentiality and archives management relating to overseas
issuance and listing of securities and (ii) improving the laws and regulations relating to data security, cross-border data flow, and
management of confidential information. The PRC Personal Information Protection Law, which was promulgated by the SCNPC on August 20,
2021 and took effect on November 1, 2021, integrates the scattered rules with respect to personal information rights and privacy protection
and applies to the processing of personal information within China as well as certain personal information processing activities outside
China, including those for the provision of products and services to natural persons within China or for the analysis and assessment
of acts of natural persons within China. There remain uncertainties regarding the further interpretation and implementation of those
laws and regulations, if they are deemed to be applicable to us, we cannot assure you that we will be compliant with such new regulations
in all respects, and we may be ordered to rectify and terminate any actions that are deemed illegal by the government authorities and
become subject to fines and other government sanctions, which may materially and adversely affect our business, financial condition,
and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
approval and/or other requirements of the China Securities Regulatory Commission, or the CSRC, or other PRC governmental authorities
may be required in connection with an offering under PRC rules, regulations or policies, and, if required, we cannot predict whether
or how soon we will be able to obtain such approval.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&amp;A Rules, purport to require offshore
special purpose vehicles that are controlled by PRC companies or individuals and that have been formed for the purpose of seeking a public
listing on an overseas stock exchange through acquisitions of PRC domestic companies or assets to obtain CSRC approval prior to publicly
listing their securities on an overseas stock exchange. The interpretation and application of the regulations remain unclear. If a governmental
approval is required, it is uncertain how long it will take for us to obtain such approval, and, even if we obtain such approval, the
approval could be rescinded. Any failure or delay in obtaining the requisite governmental approval for an offering, or a rescission of
such CSRC approval, if obtained by us, may subject us to sanctions imposed by the relevant PRC regulatory authority, which could include
fines and penalties on our operations in China, restrictions or limitations on our ability to pay dividends outside of China, and other
forms of sanctions that may materially and adversely affect our business, financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
PRC counsel has advised us that, based on its understanding of the current PRC laws and regulations, we will not be required to submit
an application to the CSRC for the approval under the M&amp;A Rules for an offering because (i) the CSRC currently has not issued any
definitive rule or interpretation concerning whether offerings like ours are subject to this regulation; and (ii) we did not acquire
any equity interests or assets of a &#8220;PRC domestic company&#8221; as such terms are defined under the M&amp;A Rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">However,
our PRC counsel has further advised us that there remains some uncertainty as to how the M&amp;A Rules will be interpreted or implemented
in the context of an overseas offering, and its opinions summarized above are subject to any new laws, rules and regulations or detailed
implementations and interpretations in any form relating to the M&amp;A Rules. We cannot assure you that relevant PRC governmental authorities,
including the CSRC, would reach the same conclusion as our PRC counsel, and hence, we may face regulatory actions or other sanctions
from them. Furthermore, relevant PRC governmental authorities promulgated the Opinions on Strictly Cracking Down Illegal Securities Activities,
which provided that the administration and supervision of overseas-listed China-based companies will be strengthened, and the special
provisions of the State Council on overseas issuance and listing of shares by such companies will be revised, clarifying the responsibilities
of domestic industry competent authorities and regulatory authorities. However, the Opinions on Strictly Cracking Down Illegal Securities
Activities were only issued recently, leaving uncertainties regarding the interpretation and implementation of these opinions. It is
possible that any new rules or regulations may impose additional requirements on us. In addition, on July 10, 2021 and November 14, 2021,
the CAC issued a revised draft of the Measures for Cybersecurity Review and a draft of the Regulations on the Network Data Security,
respectively, for public comments, according to which, among others, operators of &#8220;critical information infrastructure&#8221; or
data processors holding over one million users&#8217; personal information shall apply to the Cybersecurity Review Office for a cybersecurity
review before any listing on a foreign stock exchange. It is uncertain when the final measures will be issued and take effect, how they
will be enacted, interpreted or implemented, and whether they will affect us. If it is determined in the future that CSRC approval or
other procedural requirements are required to be met for and prior to an offering, it is uncertain whether we can or how long it will
take us to obtain such approval or complete such procedures and any such approval could be rescinded. Any failure to obtain or delay
in obtaining such approval or completing such procedures for an offering, or a rescission of any such approval, could subject us to sanctions
by the relevant PRC governmental authorities. The governmental authorities may impose restrictions and penalties on our operations in
China, such as the suspension of our apps and services, revocation of our licenses, shutting down part or all of our operations, limiting
our ability to pay dividends outside of China, delaying or restricting the repatriation of the proceeds from an offering into China,
or may take other actions that could have a material adverse effect on our business, financial condition, results of operations and prospects,
as well as the trading price of the ordinary shares. The PRC governmental authorities may also take actions requiring us, or making it
advisable for us, to halt an offering before settlement and delivery of the ordinary shares offered hereby. Consequently, if you engage
in market trading or other activities in anticipation of and prior to settlement and delivery, you do so at the risk that settlement
and delivery may not occur. In addition, if the PRC governmental authorities later promulgate new rules or requirements that we obtain
their approvals for filings, registrations or other kinds of authorizations for an offering, we cannot assure you that we can obtain
the approval, authorizations, or complete required procedures or other requirements in a timely manner, or at all, or obtain a waiver
of the requisite requirements if and when procedures are established to obtain such a waiver.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>PRC
regulation of loans to, and direct investments in, PRC entities by offshore holding companies may delay or prevent us from using proceeds
from our offerings and/or other financing activities to make loans or additional capital contributions to our PRC operating subsidiaries.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an offshore holding company with PRC subsidiaries, we may transfer funds to our PRC subsidiaries or finance our operating entity by means
of loans or capital contributions. Any capital contributions or loans that we, as an offshore entity, make to our Company&#8217;s PRC
subsidiaries are subject to PRC regulations. Any loans to our PRC subsidiaries, which are foreign-invested enterprises, cannot exceed
statutory limits based on the difference between the amount of our investments and registered capital in such subsidiaries, and shall
be registered with China&#8217;s State Administration of Foreign Exchange (&#8220;SAFE&#8221;), or its local counterparts. Furthermore,
any capital increase contributions we make to our PRC subsidiaries, which are foreign-invested enterprises, are subject to the requirement
of making necessary filings in the Foreign Investment Comprehensive Management Information System, or FICMIS, and registration with other
government authorities in China. We may not be able to obtain these government registrations or approvals on a timely basis, if at all.
If we fail to obtain such approvals or make such registration, our ability to make equity contributions or provide loans to our Company&#8217;s
PRC subsidiaries or to fund their operations may be negatively affected, which may adversely affect their liquidity and ability to fund
their working capital and expansion projects and meet their obligations and commitments. As a result, our liquidity and our ability to
fund and expand our business may be negatively affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
must remit proceeds of any future offerings to China before they may be used to benefit our business in China, and this process may take
several months to complete.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds of our future offerings must be sent back to China, and the process for sending such proceeds back to China may take as long
as six months after the closing of an offering. As an offshore holding company of our PRC operating subsidiaries, we may make loans to
our PRC subsidiaries, or we may make additional capital contributions to our PRC subsidiaries. Any loans to our PRC subsidiaries are
subject to PRC regulations. For example, loans by us to our subsidiaries in China, which are foreign-invested enterprises, to finance
their activities cannot exceed statutory limits and must be registered with SAFE.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
remit the proceeds of our offerings, we must take the following steps:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First,
    we will open a special foreign exchange account for capital account transactions. To open this account, we must submit to SAFE certain
    application forms, identity documents, transaction documents, form of foreign exchange registration of overseas investments of the
    domestic residents, and foreign exchange registration certificate of the invested company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
    we will remit the offering proceeds into this special foreign exchange account.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third,
    we will apply for settlement of the foreign exchange. In order to do so, we must submit to SAFE certain application forms, identity
    documents, payment order to a designated person, and a tax certificate.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timing of the process is difficult to estimate because the efficiencies of different SAFE branches can vary significantly. Ordinarily
the process takes several months but is required by law to be accomplished within 180 days of application.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also decide to finance our subsidiaries by means of capital contributions. These capital contributions must be subject to the requirement
of making necessary filings in the FICMIS, and registration with other government authorities in China. We cannot assure you that we
will be able to obtain these government approvals on a timely basis, if at all, with respect to future capital contributions by us to
our subsidiaries. If we fail to receive such approvals, our ability to use the proceeds of any future offerings and to capitalize our
Chinese operations may be negatively affected, which could adversely affect our liquidity and our ability to fund and expand our business.
If we fail to receive such approvals, our ability to use the proceeds of our future offerings and to capitalize our Chinese operations
may be negatively affected, which could adversely affect our liquidity and our ability to fund and expand our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may rely on dividends paid by our subsidiaries for our cash needs, and any limitation on the ability of our subsidiaries to make payments
to us could have a material adverse effect on our ability to conduct business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a holding company, we conduct substantially all of our business through our consolidated subsidiaries incorporated in China. We may rely
on dividends paid by these PRC subsidiaries for our cash needs, including the funds necessary to pay any dividends and other cash distributions
to our shareholders, to service any debt we may incur and to pay our operating expenses. The payment of dividends by entities established
in China is subject to limitations. Regulations in China currently permit payment of dividends only out of accumulated profits as determined
in accordance with accounting standards and regulations in China. In accordance with the Article 166, 168 of the Company Law of the PRC
(Amended in 2018) (the &#8220;PRC Company Law&#8221;), each of our PRC subsidiaries is required to set aside at least 10% of its after-tax
profit based on PRC accounting standards each year to its general reserves or statutory capital reserve fund until the aggregate amount
of such reserves reaches 50% of its respective registered capital. A company may discontinue the contribution when the aggregate sum
of the statutory surplus reserve is more than 50% of its registered capital. The statutory common reserve fund of a company shall be
used to cover the losses of the company, expand the business and production of the company or be converted into additional capital. As
a result, our PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to us in the form of dividends.
In addition, if any of our PRC subsidiaries incurs debt on its own behalf in the future, the instruments governing the debt may restrict
its ability to pay dividends or make other distributions to us. Any limitations on the ability of our PRC subsidiaries to transfer funds
to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business,
pay dividends and otherwise fund and conduct our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adverse
changes in political, economic and social conditions, as well as government policies in China could have a material adverse effect on
our business results of operations, financial conditions and prospects.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of our business operations are conducted in China. Accordingly, our financial condition, results of operations and prospects are,
to a material extent, subject to economic, political and legal developments in China. The economy in China differs from the economies
of developed countries in many respects, including, among other things, the degree of government involvement, control of investment,
level of economic development, growth rate, foreign exchange controls and resource allocation. Although the economy in China has been
transitioning from a planned economy to a more market-oriented economy for about four decades, a substantial portion of productive assets
in China is still owned by the PRC government. The PRC government also exercises significant control over the economic growth of China
through allocating resources, controlling payments of foreign currency denominated obligations, setting monetary policy and providing
preferential treatment to particular industries or companies. In recent years, the PRC government has implemented measures emphasizing
the utilization of market forces in economic reform, the reduction of state ownership of productive assets and the establishment of sound
corporate governance practices in business enterprises. Some of these measures benefit the overall economy in China, but may adversely
affect us. For example, our financial condition and results of operations may be adversely affected by government policies on the Chinese
patent medicine industry in China or changes in tax regulations applicable to us. If the business environment in China deteriorates,
our business in China may also be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
to the PRC legal system could have an adverse effect on us.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PRC legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions under the civil
law system may be cited for reference but have limited precedential value. Since these laws and regulations are relatively new and the
PRC legal system continues to rapidly evolve, the interpretations of many laws, regulations and rules are not always uniform and the
enforcement of these laws, regulations and rules involves uncertainties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
1979, the PRC government began to promulgate a comprehensive system of laws and regulations governing economic matters in general. The
overall effect of legislation over the past decades has significantly enhanced the protections afforded to various forms of foreign investments
in China. However, recently enacted laws and regulations may not sufficiently cover all aspects of economic activities in China. In particular,
the interpretation and&#160;enforcement of these laws and regulations involve uncertainties. Since PRC administrative and court authorities
have significant&#160;discretion in interpreting and implementing statutory provisions and contractual terms, it may be difficult to
evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy. These uncertainties may affect
our judgment on the relevance of legal requirements and our ability to enforce our contractual rights or tort claims.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or
at all and may have retroactive effect. As a result, we may not be aware of our violation of any of these policies and rules until sometime
after the violation. In addition, any administrative and court&#160;proceedings in China may be protracted, resulting in substantial
costs and diversion of resources and management attention.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Labor
Contract Law and other labor-related laws in the PRC may adversely affect our business and our results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2012, the PRC government released the revision of the Labor Contract Law, which became effective on July 1, 2013. Pursuant
to the Labor Contract Law, employers are subject to stricter requirements in terms of signing labor contracts, minimum wages, paying
remuneration, determining the term of employees&#8217; probation and unilaterally terminating labor contracts. In the event that we decide
to terminate some of our employees or otherwise change our employment or labor practices, the Labor Contract Law and its implementation
rules may limit our ability to effect those changes in a desirable or cost-effective manner, which could adversely affect our business
and results of operations. According to the PRC Social Insurance Law (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#31038;&#20250;&#20445;&#38505;&#27861;&#12299;),
employees must participate in pension insurance, work-related injury insurance, medical insurance, unemployment insurance and maternity
insurance and the employers must, together with their employees or separately, pay the social insurance premiums for such employees.
As the interpretation and implementation of labor-related laws and regulations are still evolving, we cannot assure you that our employment
practices do not and will not violate labor-related laws and regulations in China, which may subject us to labor disputes or government
investigations. As of the date of this annual report, we believe that we are in substantial compliance with labor-related laws and regulations
in China, and we have not been notified of any instance of noncompliance. We cannot assure you that we will be able to comply with all
labor-related law and regulations regarding including those relating to obligations to make social insurance payments and contribute
to the housing provident fund. If we are deemed to have violated relevant labor laws and regulations, we could be required to provide
additional compensation to our employees and our business, financial condition and results of operations will be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
are significant uncertainties under the Enterprise Income Tax Law, or the EIT Law, relating to the withholding tax liabilities of our
PRC subsidiaries, and dividends payable by our PRC subsidiaries to our offshore subsidiaries may not qualify to enjoy certain treaty
benefits.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China
passed the EIT Law, and it is implementing rules, both of which became effective on January 1, 2008. Under the PRC EIT Law and its implementation
rules, the profits of an FIE generated through operations, which are distributed to its immediate holding company outside the PRC, will
be subject to a withholding tax rate of 10%. Pursuant to a special arrangement between Hong Kong and the PRC, such rate may be reduced
to 5% if a Hong Kong resident enterprise owns more than 25% of the equity interest in the PRC company. Our PRC subsidiaries, Universe
Technology, Jiangxi Universe and Universe Trade, are wholly-owned by our Hong Kong subsidiary. Moreover, under the Notice of the State
Administration of Taxation on Issues regarding the Administration of the Dividend Provision in Tax Treaties promulgated on February 20,
2009, the taxpayer needs to satisfy certain conditions to enjoy the benefits under a tax treaty. The beneficial owner of the relevant
dividends and the corporate shareholder to receive dividends from the PRC subsidiary must have continuously met the direct ownership
thresholds during the 12 consecutive months preceding the receipt of the dividends. Further, the State Administration of Taxation (the
&#8220;SAT&#8221;) promulgated the Notice on How to Comprehend and Determine the &#8220;Beneficial Owner&#8221; in Tax Treaties (&#12298;&#22269;&#23478;&#31246;&#21153;&#24635;&#23616;&#20851;&#20110;&#31246;&#25910;&#21327;&#23450;&#20013;&#8221;&#21463;&#30410;&#25152;&#26377;&#20154;&#8221;&#26377;&#20851;&#38382;&#39064;&#30340;&#20844;&#21578;&#12299;)
on February 3, 2018, which limits the &#8220;beneficial owner&#8221; to individuals, projects or other organizations normally engaged
in substantive operations, and sets forth certain detailed factors in determining the &#8220;beneficial owner&#8221; status. In current
practice, a Hong Kong enterprise must obtain a tax resident certificate from the relevant Hong Kong tax authority to apply for the 5%
lower PRC withholding tax rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case basis, we
cannot assure you that we will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority. As of the date
of this annual report, we have not commenced the application process for a Hong Kong tax resident certificate from the relevant Hong
Kong tax authority, and there is no assurance that we will be granted such a Hong Kong tax resident certificate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
after we obtain the Hong Kong tax resident certificate, we are required by applicable tax laws and regulations to file required forms
and materials with relevant PRC tax authorities to prove that we can enjoy 5% lower PRC withholding tax rate. Universe HK intends to
obtain the required materials and file with the relevant tax authorities when it plans to declare and pay dividends, but there is no
assurance that the PRC tax authorities will approve the 5% withholding tax rate on dividends received from Universe HK.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to qualify for or obtain any preferential tax treatments that are available in China could adversely affect our results of operations
and financial condition.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EIT Law and its implementation rules generally impose a uniform income tax rate of 25% on all enterprises, but grant preferential treatment
to &#8220;high and new technology enterprises strongly supported by the state,&#8221; or HNTEs, with a preferential enterprise tax rate
of 15%. Our subsidiary, Jiangxi Universe, is currently accredited as an HNTE and will enjoy the reduced income tax rate of 15% for three
years through December 2022. According to the relevant administrative measures, to qualify as an &#8220;HNTE,&#8221; Jiangxi Universe
must meet certain financial and non-financial criteria and complete verification procedures with the administrative authorities. Continued
qualification as an HNTE is subject to review by the relevant government authorities in China every three years, and in practice, certain
local tax authorities may require annual evaluation of the qualification. In the event that Jiangxi Universe fails to renew its status
as&#160;HNTE&#160;with the local tax authority, it will be subject to the standard PRC enterprise income tax rate of 25%.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Under
the EIT Law, we may be classified as a &#8220;Resident Enterprise&#8221; of China. Such classification will likely result in unfavorable
tax consequences to us and our non-PRC shareholders.&#160;</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EIT Law and its implementing rules became effective on December 9, 2019. Under the EIT Law, an enterprise established outside of China
with &#8220;de facto management bodies&#8221; within China is considered a &#8220;resident enterprise,&#8221; meaning that it can be
treated in a manner similar to a Chinese enterprise for enterprise income tax purposes. The implementing rules of the EIT Law define
de facto management as &#8220;substantial and overall management and control over the production and operations, personnel, accounting,
and properties&#8221; of the enterprise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the PRC tax authorities determine that we are a &#8220;resident enterprise&#8221; for PRC enterprise income tax purposes, a number of
unfavorable PRC tax consequences could follow. First, we may be subject to the enterprise income tax at a rate of 25% on our worldwide
taxable income as well as PRC enterprise income tax reporting obligations. In our case, this would mean that income such as non-China
source income would be subject to PRC enterprise income tax at a rate of 25%. Currently, we do not have any non-China source income,
as we conduct our sales in China. Second, under the EIT Law and its implementing rules, dividends paid to us from our PRC subsidiaries
would be deemed as &#8220;qualified investment income between resident enterprises&#8221; and therefore qualify as &#8220;tax-exempt
income&#8221; pursuant to the clause 26 of the EIT Law. Finally, it is possible that future guidance issued with respect to the new &#8220;resident
enterprise&#8221; classification could result in a situation in which the dividends we pay with respect to our ordinary shares, or the
gain our non-PRC shareholders may realize from the transfer of our ordinary shares, may be treated as PRC-sourced income and may therefore
be subject to a 10% PRC withholding tax. The EIT Law and its implementing regulations are, however, relatively new and ambiguities exist
with respect to the interpretation and identification of PRC-sourced income, and the application and assessment of withholding taxes.
If we are required under the EIT Law and its implementing regulations to withhold PRC income tax on dividends payable to our non-PRC
shareholders, or if non-PRC shareholders are required to pay PRC income tax on gains on the transfer of their ordinary shares, our business
could be negatively impacted and the value of your investment may be materially reduced. Further, if we were to be treated as a &#8220;resident
enterprise&#8221; by PRC tax authorities, we would be subject to taxation in both China and such countries in which we have taxable income,
and our PRC tax may not be creditable against such other taxes.<b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be exposed to liabilities under the Foreign Corrupt Practices Act and Chinese anti-corruption law.&#160;</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), and other laws that prohibit improper payments or offers
of payments to foreign governments and their officials and political parties by U.S. persons and issuers, as defined by the statute,
for the purpose of obtaining or retaining business. We are also subject to Chinese anti-corruption laws, which strictly prohibit the
payment of bribes to government officials. We have operations, agreements with third parties, and make sales in China, which may expose
us to claims of corruption. Our activities in China create the risk of unauthorized payments or offers of payments by one of the employees
of our Company, because these parties are not always subject to our control.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that, as of the date of this annual report on Form 20-F, we have complied in all material respects with the provisions of
the FCPA and Chinese anti-corruption law, our existing safeguards and any future improvements may prove to be less than effective, and
the employees of our Company may engage in conduct for which we might be held responsible. Violations of the FCPA or Chinese anti-corruption
law may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively affect our business,
operating results and financial condition. In addition, the government may seek to hold our Company liable for successor liability FCPA
violations committed by companies in which we invest or that we acquire.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
enforcement of stricter advertisement laws and regulations in the PRC may adversely affect our business and our profitability.</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2018, the SCNPC promulgated the PRC Advertising Law, effective on October 26, 2018. According to the Advertising Law, advertisements
shall not have any false or misleading content, or defraud or mislead consumers. Furthermore, an advertisement will be deemed as a &#8220;false
advertisement&#8221; if any of the following situations exist: (i) the advertised product or service does not exist; (ii) there is any
inconsistency that has a material impact on the decision to purchase in what is included in the advertisement with the actual circumstances
with respect to the product&#8217;s performance, functions, place of production, uses, quality, specification, ingredient, price, producer,
term of validity, sales condition, and honors received, among others, or the service&#8217;s contents, provider, form, quality, price,
sales condition, and honors received, among others, or any commitments, among others, made on the product or service; (iii) fabricated,
forged or unverifiable scientific research results, statistical data, investigation results, excerpts, quotations, or other information
have been used as supporting material; (iv) effect or results of using the good or receiving the service are fabricated; or (v) other
circumstances where consumers are defrauded or misled by any false or misleading content.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current marketing relies on advertisements on media platforms. The laws and regulations of advertising are relatively new and evolving
and there is substantial uncertainty as to the interpretation of &#8220;false advertisement&#8221; by the State Administration for Industry
and Commerce (the &#8220;SAIC&#8221;). If any of the advertisements published by our customers is deemed to be a &#8220;false advertisement&#8221;
by the SAIC or its local branch, we could be subject to various penalties, such as discontinuation of publishing the target advertisement,
imposition of fines and obligations to eliminate any adverse effects incurred by such&#160;false advertisement. Any such penalties may
disrupt our business and our competition with competitors, and could affect our results of operations and financial conditions.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
were not in compliance with the PRC&#8217;s regulations relating to employee&#8217;s social insurance and housing funds prior to April
2020, and as a result, we may be subject to penalties for such non-compliance.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Social Insurance Law of the PRC (the &#8220;Social Insurance Law&#8221;), which was promulgated by the SCNPC on October 28, 2010
and amended on December 29, 2018, and the Administrative Regulations on the Housing Provident Funds, which was promulgated by the State
Council on April 3, 1999 and last amended on March 24, 2019, employers are required to make contributions, on behalf of their employees,
to a number of social security funds, including funds for basic pension insurance, unemployment insurance, basic medical insurance, occupational
injury insurance, maternity insurance and to housing provident funds. Prior to April 2020, we only contributed to the social insurance
and housing provident funds for some, but not all, of our employees. Since April 2020, we have started contributing to the social insurance
and housing funds for our eligible full-time employees in accordance with the aforementioned PRC laws and regulations. Even though we
are currently making contributions in accordance with applicable PRC laws, there is a risk that the labor security administration authority
may take enforcement action to collect from us all the outstanding contributions of the social insurance and housing provident funds
required to be made for the employees in the past, and we may be subject to a late charge at the rate of 0.05% per day on the total outstanding
contribution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
regulatory bodies may be limited in their ability to conduct investigations or inspections of our operations in China.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), the U.S. Department of Justice and other U.S. authorities may also have
difficulties in bringing and enforcing actions against us or our directors or executive officers in the PRC. The SEC has stated that
there are significant legal and other obstacles to obtaining information needed for investigations or litigation in China. Although the
authorities in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or
region to implement cross-border supervision and administration, such cooperation with the securities regulatory authorities in Hong
Kong or other jurisdictions may not be efficient in the absence of mutual and practical cooperation mechanism. Furthermore, China has
recently adopted a revised securities law that became effective on March 1, 2020, Article 177 of which provides, among other things,
that no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities within the territory
of the PRC. Accordingly, without governmental approval in China, no entity or individual in China may provide documents and information
relating to securities business activities to overseas regulators when it is under direct investigation or evidence discovery conducted
by overseas regulators. While detailed interpretation of or implementation rules under Article 177 have yet to be promulgated, it could
present significant legal and other obstacles to obtaining information needed for investigations and litigation conducted outside of
China, which may further increase difficulties faced by you in protecting your interests. See also &#8220;<span>&#8212;You
may experience difficulty in effecting service of process, enforcing foreign judgments or bringing actions against our directors and
officers.&#8221;</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>You
may experience difficulty in effecting service of process, enforcing foreign judgments or bringing actions against our directors and
officers.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Cayman Islands exempted company with limited liability and most of our assets are located outside of the United States. In addition,
all of our directors and executive officers are residents of the PRC, and substantially all of their assets and our assets are located
in the PRC. As a result, it may be difficult or impossible for you to effect service of process within the United States upon our directors
and executive officers. It may also be difficult for you to enforce in the United States courts judgments obtained in the United States
courts based on the civil liability provisions of the United States federal securities laws against us and our officers and directors
who reside and whose assets are located outside the United States.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there is uncertainty as to whether the courts of the Cayman Islands or the PRC would recognize or enforce judgments of the
United States courts against us or such persons predicated upon the civil liability provisions of the securities laws of the United States
or any state. The recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may
recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties
between China and the country where the judgment is made or on principles of reciprocity between jurisdictions. China does not have any
treaties or other forms of reciprocity with the United States that provide for the reciprocal recognition and enforcement of foreign
judgments. In addition, according to the PRC Civil Procedures Law, the PRC courts will not enforce a foreign judgment against us or our
directors and officers if they decide that the judgment violates the basic principles of PRC laws or national sovereignty, security or
public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the
United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
pursuant to the PRC Civil Procedures Law, any matter, including matters arising under U.S. federal securities laws, in relation to assets
or personal relationships may be brought as an original action in China, only if the institution of such action satisfies the conditions
specified in the PRC Civil Procedures Law. As a result of the conditions set forth in the PRC Civil Procedures Law and the discretion
of the PRC courts to determine whether the conditions are satisfied and whether to accept the action for adjudication, there remains
uncertainty as to whether an investor will be able to bring an original action in a PRC court based on U.S. federal securities laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
our business is conducted in the RMB and the price of our ordinary shares is quoted in United States dollars, changes in currency conversion
rates may affect the value of your investments.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is conducted in the PRC, our books and records are maintained in the RMB, the legal currency of the PRC, and the financial statements
that we file with the SEC and provide to our shareholders are presented in United States dollars. Changes in the exchange rate between
the RMB and U.S. dollars affect the value of our assets and the results of our operations in U.S. dollars. The value of the RMB against
the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in the PRC&#8217;s political and economic
conditions and perceived changes in the economy of the PRC and the United States. Any significant revaluation of the RMB may materially
and adversely affect our cash flows, revenue and financial condition. Further, our securities will be offered in United States dollars,
and we will need to convert any net proceeds we receive into RMB in order to use the funds for our business. Changes in the conversion
rate between the United States dollar and the RMB will affect that amount of proceeds we will have available for our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Government
control in currency conversion may adversely affect our financial condition, our ability to remit dividends, and the value of your investment.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PRC government imposes controls on the convertibility of the Renminbi into foreign currencies and, in certain cases, the remittance of
currency out of China. We receive substantially all of our revenues in Renminbi. Under our current corporate structure, our Cayman Islands
holding company may rely on dividend payments from our PRC subsidiaries to fund any cash and financing requirements we may have.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
existing PRC foreign exchange regulations, the Renminbi cannot be freely converted into any foreign currency, and conversion and remittance
of foreign currencies are subject to PRC foreign exchange regulations. It cannot be guaranteed that under a certain exchange rate, we
will have sufficient foreign exchange to meet our foreign exchange requirements. Under the current PRC foreign exchange control system,
foreign exchange transactions under the current account conducted by us, including the payment of dividends, do not require advance approval
from SAFE, but we are required to present documentary evidence of such transactions and conduct such transactions at designated foreign
exchange banks within China that have the licenses to carry out foreign exchange business. Foreign exchange transactions under the capital
account conducted by us, however, must be approved in advance by SAFE.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
existing foreign exchange regulations, we are able to pay dividends in foreign currencies without prior approval from SAFE by complying
with certain procedural requirements. However, we cannot assure you that these foreign exchange policies regarding payment of dividends
in foreign currencies will continue in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
fact, in light of the flood of capital outflows of China in 2016 due to the weakening Renminbi, the PRC government has imposed more restrictive
foreign exchange policies and stepped up scrutiny of major outbound capital movement including overseas direct investment. More restrictions
and substantial vetting process may be put in place by SAFE to regulate cross-border transactions falling under the capital account.
If any of our shareholders regulated by such policies fails to satisfy the applicable overseas direct investment filing or approval requirement
timely or at all, it may be subject to penalties from the relevant PRC authorities. The PRC government may, at its discretion, further
restrict access in the future to foreign currencies for current account transactions. If the foreign exchange control system prevents
us from obtaining sufficient foreign currencies to satisfy our foreign currency demands, we may not be able to pay dividends in foreign
currencies to our shareholders, including holders of the ordinary shares. Our capital expenditure plans and our business, operating results
and financial condition may be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business may be materially and adversely affected if any of our PRC subsidiaries declare bankruptcy or become subject a dissolution or
liquidation proceeding.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Enterprise Bankruptcy Law of the PRC, or the Bankruptcy Law, came into effect on June 1, 2007. The Bankruptcy Law provides that an enterprise
will be liquidated if the enterprise fails to settle its debts as and when they fall due and if the enterprise&#8217;s assets are, or
are demonstrably, insufficient to clear such debts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
PRC subsidiaries hold certain assets that are important to our business operations. If any of our PRC subsidiaries undergoes a voluntary
or involuntary liquidation proceeding, unrelated third-party creditors may claim rights to some or all of these assets, thereby hindering
our ability to operate our business, which could materially and adversely affect our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our PRC subsidiaries undergoes a voluntary or involuntary liquidation proceeding, prior approval from SAFE for remittance of foreign
exchange to our shareholders abroad is no longer required, but we still need to conduct a registration process with the SAFE local branch.
It is not clear whether &#8220;registration&#8221; is a mere formality or involves the kind of substantive review process undertaken
by SAFE and its relevant branches in the past.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current corporate structure and business operations may be affected by the newly enacted PRC Foreign Investment Law.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2019, the National People&#8217;s Congress approved the Foreign Investment Law, which became effective on January 1, 2020.
The PRC Foreign Investment Law defines the &#8220;foreign investment&#8221; as the investment activities in China conducted directly
or indirectly by foreign investors in the following manners: (i) the foreign investor, by itself or together with other investors establishes
a foreign invested enterprises in China; (ii) the foreign investor acquires shares, equities, asset tranches, or similar rights and interests
of enterprises in China; (iii) the foreign investor, by itself or together with other investors, invests and establishes new projects
in China; (iv) the foreign investor invests through other approaches as stipulated by laws, administrative regulations or otherwise regulated
by the State Council. If our PRC subsidiaries are recognized as &#8220;foreign investment enterprises,&#8221; PRC governmental authorities
will regulate foreign investment by applying the principle of re-entry national treatment together with a &#8220;negative list,&#8221;
which will be promulgated by or promulgated with approval by the State Council. Foreign investors are prohibited from making any investments
in the industries which are listed as &#8220;prohibited&#8221; in such negative list; and, after satisfying certain additional requirements
and conditions as set forth in the &#8220;negative list,&#8221; are allowed to make investments in industries which are listed as &#8220;restricted&#8221;
in such negative list. For any foreign investor that fails to comply with the negative list, the competent authorities are entitled to
ban its investment activities, require such investor to take measures to correct its non-compliance and impose other penalties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
production and distribution activities that we conduct through our PRC subsidiaries are not subject to foreign investment restrictions
or prohibitions set forth in the Special Administrative Measures for the Access of Foreign Investment (Negative List) (Edition 2020)
(the &#8220;2020 Negative List&#8221;). We do not intend to conduct any types of business activities restricted or prohibited under the
2020 Negative List in the future. However, it is unclear whether any updated &#8220;negative list&#8221; to be published by the State
Council in the future will be different from the 2020 Negative List. If future laws, administrative regulations or provisions of the
State Council set forth restrictions or prohibitions on foreign investment in our current business activities, and that our PRC subsidiaries
are recognized as &#8220;foreign investment enterprises,&#8221; we may be required to take appropriate and timely measures to comply
with such regulatory requirements. If we fail to do so, our business operations could be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with PRC regulations relating to the establishment of offshore special purpose companies by PRC residents may subject our PRC
resident shareholders to personal liability, may limit our ability to acquire PRC companies or to inject capital into our PRC subsidiaries,
may limit the ability of our PRC subsidiaries to distribute profits to us or may otherwise materially and adversely affect us</i></b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Circular on relevant issues concerning Foreign Exchange Administration of Overseas Investment and Financing and Return Investments
Conducted by Domestic Residents through Overseas Special Purpose Vehicle (the &#8220;Circular 37&#8221;), which was promulgated by SAFE,
and became effective on July 4, 2014, (1) a PRC resident must register with the local SAFE branch before he or she contributes assets
or equity interests in an overseas special purpose vehicle, or an Overseas SPV, that is directly established or indirectly controlled
by the PRC resident for the purpose of conducting investment or financing; and (2) following the initial registration, the PRC resident
is also required to register with the local SAFE branch for any major change, in respect of the Overseas SPV, including, among other
things, a change in the Overseas SPV&#8217;s PRC resident shareholder, name of the Overseas SPV, term of operation, or any increase or
reduction of the contributions by the PRC resident, share transfer or swap, and merger or division. Additionally, pursuant to the Circular
of SAFE on Further Simplifying and Improving the Direct Investment-related Foreign Exchange Administration Policies (the &#8220;Circular
13&#8221;), which was promulgated on February 13, 2015 and became effective on June 1, 2015, the aforesaid registration shall be directly
reviewed and handled by qualified banks in accordance with the Circular 13, and SAFE and its branches shall perform indirect regulation
over the foreign exchange registration via qualified banks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Gang Lai completed the initial foreign exchange registration on June 3, 2019. As it remains unclear how Circular 37 and Circular 13 will
be interpreted and implemented, and how or whether SAFE will apply them to us. Therefore, we cannot predict how they will affect our
business operations or future strategies. For example, the ability of our present and prospective PRC subsidiaries to conduct foreign
exchange activities, such as the remittance of dividends and foreign currency-denominated borrowings, may be subject to compliance with
Circular 37 and Circular 13 by our PRC resident beneficial holders. In addition, as we have little control over either our present or
prospective, direct or indirect shareholders or the outcome of such registration procedures, we cannot assure you that these shareholders
who are PRC residents will amend or update their registration as required under Circular 37 and Circular 13 in a timely manner or at
all. Failure of our present or future shareholders who are PRC residents to comply with Circular 37 and Circular 13 could subject these
shareholders to fines or legal sanctions, restrict our overseas or cross-border investment activities, limit the ability of our PRC subsidiaries
to make distributions or pay dividends or affect our ownership structure, which could adversely affect our business and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to complete a business combination transaction efficiently or on favorable terms due to complicated merger and acquisition
regulations and certain other PRC regulations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2006, six PRC regulatory authorities, including the Ministry of Commerce of the People&#8217;s Republic of China, or MOFCOM,
the State Assets Supervision and Administration Commission, the SAT, the SAIC, the CSRC and the SAFE, jointly issued the M&amp;A Rules,
which became effective on September 8, 2006 and was amended in June 2009. The M&amp;A Rules, governing the approval process by which
a PRC company may participate in an acquisition of assets or equity interests by foreign investors, requires the PRC parties to make
a series of applications and supplemental applications to the government agencies, depending on the structure of the transaction. In
some instances, the application process may require presentation of economic data concerning a transaction, including appraisals of the
target business and evaluations of the acquirer, which are designed to allow the government to assess the transaction. Accordingly, due
to the M&amp;A Rules, our ability to engage in business combination transactions has become significantly more complicated, time-consuming
and expensive, and we may not be able to negotiate a transaction that is acceptable to our Shareholders or sufficiently protect their
interests in a transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
M&amp;A Rules allow PRC government agencies to assess the economic terms of a business combination transaction. Parties to a business
combination transaction may have to submit to the MOFCOM and other relevant government agencies an appraisal report, an evaluation report
and the acquisition agreement, all of which form part of the application for approval, depending on the structure of the transaction.
The M&amp;A Rules also prohibit a transaction at an acquisition price obviously lower than the appraised value of the business or assets
in China and in certain transaction structures, require that consideration must be paid within defined periods, generally not in excess
of a year. In addition, the M&amp;A Rules also limit our ability to negotiate various terms of the acquisition, including aspects of
the initial consideration, contingent consideration, holdback provisions, indemnification provisions and provisions relating to the assumption
and allocation of assets and liabilities. Transaction structures involving trusts, nominees and similar entities are prohibited. Therefore,
such regulation may impede our ability to negotiate and complete a business combination transaction on legal and/or financial terms that
satisfy our investors and protect our shareholders&#8217; economic interests.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding companies.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SAT released a circular on December 15, 2009 that addresses the transfer of shares by nonresident companies, generally referred to as
Circular 698. Circular 698, which became effective retroactively to January 1, 2008, may have a significant impact on many companies
that use offshore holding companies to invest in China. Circular 698 has the effect of taxing foreign companies on gains derived from
the indirect sale of a PRC company. Where a foreign investor indirectly transfers equity interests in a PRC resident enterprise by selling
the shares in an offshore holding company, and the latter is located in a country or jurisdiction that has an effective tax rate less
than 12.5% or does not tax foreign income of its residents, the foreign investor must report this indirect transfer to the tax authority
in charge of that PRC resident enterprise. Using a &#8220;substance over form&#8221; principle, the PRC tax authority may disregard the
existence of the overseas holding company if it lacks a reasonable commercial purpose and was established for the purpose of avoiding
PRC tax. As a result, gains derived from such indirect transfer may be subject to PRC withholding tax at a rate of up to 10.0%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SAT
subsequently released public notices to clarify issues relating to Circular 698, including the Announcement on Several Issues concerning
the EIT on the Indirect Transfers of Properties by Nonresident Enterprises (the &#8220;SAT Notice 7&#8221;), which became effective on
February 3, 2015. SAT Notice 7 abolished the compulsive reporting obligations originally set out in Circular 698. Under SAT Notice 7,
if a non-resident enterprise transfers its shares in an overseas holding company, which directly or indirectly owns PRC taxable properties,
including shares in a PRC company, via an arrangement without reasonable commercial purpose, such transfer shall be deemed as indirect
transfer of the underlying PRC taxable properties. Accordingly, the transferee shall be deemed as a withholding agent with the obligation
to withhold and remit the EIT to the competent PRC tax authorities. Factors that may be taken into consideration when determining whether
there is a &#8220;reasonable commercial purpose&#8221; include, among other factors, the economic essence of the transferred shares,
the economic essence of the assets held by the overseas holding company, the taxability of the transaction in offshore jurisdictions,
and economic essence and duration of the offshore structure. SAT Notice 7 also sets out safe harbors for the &#8220;reasonable commercial
purpose&#8221; test.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 17, 2017, the SAT released the Notice on Several Issues concerning the Withholding and Collection of Income Tax of Non-resident
Enterprises from the Source (the &#8220;SAT Notice 37&#8221;). SAT Notice 37 clarifies: (1) matters concerning the withholding and collection
of corporate income tax, and property transfer of non-resident enterprises based on the EIT Law; (2) the currencies required to be used
by the withholding agents (when the payments is made in a currency rather than RMB), as well as the time, venue and business for the
performance of the withholding and collection obligations; and (3) the abolishment of Circular 698.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is little guidance and practical experience regarding the application of SAT Notice 7 and SAT Notice 37 and the related SAT notices.
Moreover, the relevant authority has not yet promulgated any formal provisions or formally declared or stated how to calculate the effective
tax rates in foreign tax jurisdictions. As a result, due to our complex offshore restructuring, we may become at risk of being taxed
under SAT Notice 7 and SAT Notice 37 and we may be required to expend valuable resources to comply with SAT Notice 7 and SAT Notice 37
or to establish that we should not be taxed under SAT Notice 7 and SAT Notice 37, which could have a material adverse effect on our financial
condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Ordinary Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
share price may be volatile and could decline substantially.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our ordinary shares may be volatile, both because of actual and perceived changes in the company&#8217;s financial results
and prospects, and because of general volatility in the stock market. The factors that could cause fluctuations in our share price may
include, among other factors discussed in this section, the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in the financial results and prospects of the company or other companies in the pharmaceutical business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in financial estimates by research analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the market valuations of other education technology companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of new education services, expansions, investments, acquisitions, strategic partnerships or joint ventures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mergers
    or other business combinations involving us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    and departures of key personnel and senior management;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting principles;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    passage of legislation or other developments affecting us or our industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    trading volume of our ordinary shares in the public market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    release of lockup, escrow or other transfer restrictions on our outstanding equity securities or sales of additional equity securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    litigation or regulatory investigations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in economic conditions, including fluctuations in global and Chinese economies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    market conditions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
    disasters, terrorist acts, acts of war or periods of civil unrest; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    realization of some or all of the risks described in this section.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock markets have experienced significant price and trading volume fluctuations from time to time, and the market prices
of the equity securities of pharmaceutical companies are sometimes subject to sharp price and trading volume changes. These broad market
fluctuations may materially and adversely affect the market price of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may issue additional ordinary shares or other equity securities without your approval, which would dilute your ownership interests and
may depress the market price of our ordinary shares.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue additional ordinary shares or our other securities to investors. We may also issue additional ordinary shares or other equity
securities of equal or senior rank in the future for any reason or in connection with, among other things, future acquisitions or repayment
of outstanding indebtedness, without shareholder approval, in a number of circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
issuance of additional ordinary shares or other equity securities of equal or senior rank would have the following effects:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    existing shareholders&#8217; proportionate ownership interest in us will decrease;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of cash available per share, including for payment of dividends in the future, may decrease;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative voting strength of each previously outstanding share may be diminished; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market price of our ordinary shares may decline.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently do not expect to pay dividends on our ordinary shares in the foreseeable future.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not expect to pay dividends on our ordinary shares in the foreseeable future. Instead, for the foreseeable future, it is
expected that we will continue to retain any earnings to finance the development and expansion of its business, and not to pay any cash
dividends on its ordinary shares. Consequently, you should not rely on an investment in the Company as a source for any future dividend
income.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has complete discretion as to whether to distribute dividends, subject to applicable laws. Even if our board of directors
decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on, among other things, our
future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us
from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors.
Accordingly, the return on your investment in our ordinary shares will likely depend entirely upon any future price appreciation of our
ordinary shares. We cannot guarantee that our ordinary shares will appreciate in value or even maintain the price at which you purchased
the ordinary shares. You may not realize a return on your investment in our ordinary shares and you may even lose your entire investment
in our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about us or our business, our ordinary
share price and trading volume could decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our ordinary shares will depend in part on the research and reports that securities or industry analysts publish about
us or our business. Securities and industry analysts do not currently, and may never, publish research on us If no securities or industry
analysts commence coverage of our Company, the trading price for its ordinary shares would likely be negatively impacted. In the event
securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade its securities or publish inaccurate
or unfavorable research about its business, its stock price would likely decline. If one or more of these analysts cease coverage of
our Company or fail to publish reports on our Company, demand for its ordinary shares could decrease, which might cause its ordinary
share price and trading volume to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a &#8220;controlled company&#8221; within the meaning of the Nasdaq Stock Market Rules and, as a result, may rely on exemptions from
certain corporate governance requirements that provide protection to shareholders of other companies.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;controlled company&#8221; as defined under Rule 5615(c)(1) of the Nasdaq Marketplace Rules because Mr. Gang Lai holds more
than 50% of our voting power, and we expect we will continue to be a controlled company. For so long as we remain a controlled company
under that definition, we are permitted to elect to rely, and may rely, on certain exemptions from the obligation to comply with certain
corporate governance requirements, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    requirement that our director nominees must be selected or recommended solely by independent directors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    requirement that we have a corporate governance and nominating committee that is composed entirely of independent directors with
    a written charter addressing the committee&#8217;s purpose and responsibilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, you will not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance
requirements of the Nasdaq Stock Market Rules, if we utilize such exemptions. We currently do not intend to utilize the controlled company
exemptions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
sale or perceived sale of a substantial number of our ordinary shares may cause the price of our ordinary shares to decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our shareholders sell substantial amounts of our ordinary shares in the public market, the market price of our ordinary shares could
fall. Moreover, the perceived risk of this potential dilution could cause shareholders to attempt to sell their shares and investors
to short our ordinary shares. These sales also make it more difficult for us to sell equity-related securities in the future at a time
and price that we deem reasonable or appropriate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
incur substantial increased costs being a public company.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incur significant legal, accounting and other expenses as a public company that we did not incur as a private company. The Sarbanes-Oxley
Act of 2002, as well as rules subsequently implemented by the SEC and Nasdaq, impose various requirements on the corporate governance
practices of public companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with these rules and regulations increases our legal and financial compliance costs and makes some corporate activities more time-consuming
and costlier. We have incurred additional costs in obtaining director and officer liability insurance. In addition, we incur additional
costs associated with our public company reporting requirements. It may also be more difficult for us to find qualified persons to serve
on our board of directors or as executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act and will remain an emerging growth company until the earlier
of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering, (b) in which
we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means
the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the prior March 31, and (2) the date
on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. An emerging growth company
may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies.
These provisions include exemption from the auditor attestation requirement under Section 404 in the assessment of the emerging growth
company&#8217;s internal control over financial reporting and permission to delay adopting new or revised accounting standards until
such time as those standards apply to private companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
we are no longer an &#8220;emerging growth company,&#8221; or until five years following the completion of our initial public offering,
whichever is earlier, we expect to incur significant additional expenses and devote substantial management effort toward ensuring compliance
with the requirements of Section 404 and the other rules and regulations of the SEC. For example, as a public company, we have been required
to increase the number of independent directors and adopt policies regarding internal controls and disclosure controls and procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently evaluating and monitoring developments with respect to these rules and regulations, and we cannot predict or estimate with
any degree of certainty the amount of additional costs we may incur or the timing of such costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
can be no assurance that we will not be a passive foreign investment company (&#8220;PFIC&#8221;) for United States federal income tax
purposes for any taxable year, which could subject United States holders of our ordinary shares could be subject to adverse United States
federal income tax consequences.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-United States corporation will be a PFIC for United States federal income tax purposes for any taxable year if either (i) at least
75% of its gross income for such taxable year is passive income or (ii) at least 50% of the value of its assets (based on average of
the quarterly values of the assets) during such year is attributable to assets that that produce or are held for the production of passive
income. Based on the current and anticipated value of our assets and the composition of our income assets, we do not expect to be a PFIC
for United States federal income tax purposes for our current taxable year ending September 30, 2022 or in the foreseeable future. However,
the determination of whether or not we are a PFIC according to the PFIC rules is made on an annual basis and depend on the composition
of our income and assets and the value of our assets from time to time. Therefore, changes in the composition of our income or assets
or value of our assets may cause us to become a PFIC. The determination of the value of our assets (including goodwill not reflected
on our balance sheet) may be based, in part, on the quarterly market value of ordinary shares, which is subject to change and may be
volatile.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
classification of certain of our income as active or passive, and certain of our assets as producing active or passive income, and hence
whether we are or will become a PFIC, depends on the interpretation of certain United States Treasury Regulations as well as certain
IRS guidance relating to the classification of assets as producing active or passive income. Such regulations guidance are potentially
subject to different interpretations. If due to different interpretations of such regulations and guidance the percentage of our passive
income or the percentage of our assets treated as producing passive income increases, we may be a PFIC in one of more taxable years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC for any taxable year during which a United States person holds ordinary shares, certain adverse United States federal income
tax consequences could apply to such United States person. See &#8220;Item 10. Additional Information<span>&#8212;E.
</span>Taxation<span>&#8212;</span>United States Federal Income Taxation<span>&#8212;</span>PFIC.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For
as long as we are an emerging growth company, we will not be required to comply with certain reporting requirements, including those
relating to accounting standards and disclosure about our executive compensation, that apply to other public companies.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are classified as an &#8220;emerging growth company&#8221; under the JOBS Act. For as long as we are an emerging growth company, unlike
other public companies, we will not be required to, among other things, (i) provide an auditor&#8217;s attestation report on management&#8217;s
assessment of the effectiveness of our system of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley
Act, (ii) comply with any new requirements adopted by the Public Company Accounting Oversight Board, or the PCAOB, requiring mandatory
audit firm rotation or a supplement to the auditor&#8217;s report in which the auditor would be required to provide additional information
about the audit and the financial statements of the issuer, (iii) provide certain disclosure regarding executive compensation required
of larger public companies, or (iv) hold nonbinding advisory votes on executive compensation. We will remain an emerging growth company
for up to five years, although we will lose that status sooner if we have more than $1.07 billion of revenues in a fiscal year, have
more than $700 million in market value of our ordinary shares held by non-affiliates, or issue more than $1.0 billion of non-convertible
debt over a three-year period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that we rely on any of the exemptions available to emerging growth companies, you will receive less information about our
executive compensation and internal control over financial reporting than issuers that are not emerging growth companies. If some investors
find our ordinary shares to be less attractive as a result, there may be a less active trading market for our ordinary shares and our
share price may be more volatile.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to produce accurate financial statements have been materially adversely affected by our failure to establish proper internal
financial reporting controls. If we fail to establish and maintain proper internal financial reporting controls in a reasonably timely
manner, our ability to produce accurate financial statements or comply with applicable regulations may continue to be impaired.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent registered public accounting firm has not conducted an audit of our internal control over financial reporting. In the course
of auditing our consolidated financial statements for the year ended September 30, 2021, we identified material weaknesses in our internal
control over financial reporting and other control deficiencies as of September 30, 2021. A &#8220;material weakness&#8221; is a deficiency,
or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material
misstatement of the company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material weakness identified to date relate to a lack of proper internal audit function.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the identification of the material weaknesses and control deficiencies, we have undertaken certain remedial steps and plan to continue
taking remedial measures, including (i) hiring qualified personnel to set up an internal audit function; (ii) establishing an annual
plan of internal audit and getting approval from the audit committee; and (iii) engaging an external consulting firm to assist us in
conducting internal audit programs, if necessary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
implementation of these measures may not fully address the material weaknesses in our internal control over financial reporting, and
we cannot conclude that they have been fully remedied. Our failure to correct theses material weaknesses or our failure to discover and
address any other material weaknesses could result in inaccuracies in our financial statements and could also impair our ability to comply
with applicable financial reporting requirements and related regulatory filings on a timely basis. As a result, our business, financial
condition, results of operations and prospects, as well as the trading price of our ordinary shares, may be materially and adversely
affected. Moreover, ineffective internal control over financial reporting significantly hinders our ability to prevent fraud.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we will be subject to Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act. Since we qualify as an &#8220;emerging growth
company&#8221; pursuant to the JOBS Act with less than US$1.07&#160;billion in revenue for our last fiscal year. An emerging growth company
may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies.
These provisions include exemption from the auditor attestation requirement under Section&#160;404 of the Sarbanes-Oxley&#160;Act of
2002, or Section 404, in the assessment of the emerging growth company&#8217;s internal control over financial reporting. Moreover, even
if management concludes that our internal control over financial reporting is effective, our independent registered public accounting
firm, after conducting its own independent testing, may issue a report that is qualified if it is not satisfied with our internal controls
or the level at which our controls are documented, designed, operated or reviewed, or if it interprets the relevant requirements differently
from us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the course of documenting and testing our internal control procedures, we may identify other weaknesses and deficiencies in its internal
control over financial reporting. In addition, if we fail to maintain the adequacy of our internal control over financial reporting,
as these standards are modified, supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we
have effective internal control over financial reporting in accordance with Section&#160;404. Generally speaking, if we fail to achieve
and maintain an effective internal control environment, we could suffer material misstatements in our financial statements and fail to
meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. This could
in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the trading price of our securities.
Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate
assets and subject us to potential delisting from the stock exchange on which we list, regulatory investigations and civil or criminal
sanctions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
a foreign private issuer, we are not subject to certain U.S. securities law disclosure requirements that apply to a domestic U.S. issuer,
which may limit the information publicly available to our shareholders.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a foreign private issuer we are not required to comply with all of the periodic disclosure and current reporting requirements of the
Exchange Act and therefore there may be less publicly available information about us than if we were a U.S. domestic issuer. We are exempt
from certain provisions of the securities rules and regulations in the United States that are applicable to U.S. domestic issuers, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q or current reports on Form 8-K;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect of a security registered
    under the Exchange Act;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability
    for insiders who profit from trades made in a short period of time; and the selective disclosure rules by issuers of material non-public
    information under Regulation FD.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to file an annual report on Form 20-F within four months of the end of each fiscal year. However, the information we are
required to file with or furnish to the SEC will be less extensive and less timely compared to that required to be filed with the SEC
by U.S. domestic issuers. As a result, you may not be afforded the same protections or information that would be made available to you
were you investing in a U.S. domestic issuer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ
significantly from the Nasdaq listing standards. These practices may afford less protection to shareholders than they would enjoy if
we complied fully with corporate governance listing standards.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a foreign private issuer, we are permitted to take advantage of certain provisions in the Nasdaq listing standards that allow us to follow
Cayman Islands law for certain governance matters. Certain corporate governance practices in the Cayman Islands may differ significantly
from corporate governance listing standards as, except for general fiduciary duties and duties of care, Cayman Islands law has no corporate
governance regime which prescribes specific corporate governance standards. Currently, we do not intend to rely on home country practice
with respect to our corporate governance. However, if we choose to follow home country practice in the future, our shareholders may be
afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic issuers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed above, we are a foreign private issuer, and therefore, we are not required to comply with all of the periodic disclosure and
current reporting requirements of the Exchange Act. The determination of foreign private issuer status is made annually on the last business
day of an issuer&#8217;s most recently completed second fiscal quarter. We would lose our foreign private issuer status if, for example,
more than 50% of our ordinary shares are directly or indirectly held by residents of the U.S. and we fail to meet additional requirements
necessary to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required
to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive
than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements, and
our officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of
Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance requirements
under the Nasdaq listing standards. As a U.S. listed public company that is not a foreign private issuer, we will incur significant additional
legal, accounting and other expenses that we will not incur as a foreign private issuer, and accounting, reporting and other expenses
in order to maintain a listing on a U.S. securities exchange.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><br/>
The laws of the Cayman Islands may not provide our shareholders with benefits comparable to those provided to shareholders of corporations
incorporated in the United States.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate affairs are governed by our amended and restated memorandum and articles of association, by the Companies Act (2021 Revision)
of the Cayman Islands and by the common law of the Cayman Islands. The rights of shareholders to take action against our directors, actions
by minority shareholders and the fiduciary responsibilities of our directors to us under Cayman Islands law are to a large extent governed
by the common law of the Cayman Islands. The common law in the Cayman Islands is derived in part from comparatively limited judicial
precedent in the Cayman Islands and from English common law. Decisions of the Privy Council (which is the final Court of Appeal for British
overseas territories such as the Cayman Islands) are binding on a court in the Cayman Islands. Decisions of the English courts, and particularly
the Supreme Court and the Court of Appeal are generally of persuasive authority but are not binding in the courts of the Cayman Islands.
Decisions of courts in other Commonwealth jurisdictions are similarly of persuasive but not binding authority. The rights of our shareholders
and the fiduciary responsibilities of our directors under Cayman Islands law are not as clearly established as they would be under statutes
or judicial precedents in the United States. In particular, the Cayman Islands has a less developed body of securities laws relative
to the United States. Therefore, our public shareholders may have more difficulty protecting their interests in the face of actions by
our management, directors or controlling shareholders than would shareholders of a corporation incorporated in a jurisdiction in the
United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>You
may be unable to present proposals before annual general meetings or extraordinary general meetings not called by shareholders.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman
Islands law provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any
right to put any proposal before a general meeting. These rights, however, may be provided in a company&#8217;s amended and restated
articles of association. Our amended and restated articles of association allow our shareholders holding shares representing in aggregate
not less than 10% of our voting share capital in issue, to requisition a general meeting of our shareholders, in which case our directors
are obliged to call such meeting. Advance notice of at least 21 clear days is required for the convening of our annual general shareholders&#8217;
meeting and at least 14 days&#8217; notice any other general meeting of our shareholders. A quorum required for a meeting of shareholders
consists of at least one shareholder present or by proxy, representing not less than one-third of the total issued shares carrying the
right to vote at a general meeting of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
obligation to disclose information publicly may put us at a disadvantage to competitors that are private companies.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a public company in the United States. As a public company, we will be required to file periodic reports with the SEC upon the occurrence
of matters that are material to our Company and shareholders. Although we may be able to attain confidential treatment of some of our
developments, in some cases, we will need to disclose material agreements or results of financial operations that we would not be required
to disclose if we were a private company. Our competitors may have access to this information, which would otherwise be confidential.
This may give them advantages in competing with our Company. Similarly, as a U.S. public company, we will be governed by U.S. laws that
our competitors, which are mostly private Chinese companies, are not required to follow. To the extent compliance with U.S. laws increases
our expenses or decreases our competitiveness against such companies, our public company status could affect our results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
4. INFORMATION ON THE COMPANY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
<span style="text-decoration:underline">History and Development of the Company</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a Cayman Islands holding company and not a PRC operating company.
As a holding company with no material operations of our own, our operations are conducted in China by our PRC subsidiaries.&#160;We
directly hold 100% equity interests in our subsidiaries, and we do not currently use a variable interest entity (&#8220;VIE&#8221;) structure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face legal and operational risks associated with having the majority of our operations in China. The Chinese government has significant
authority to exert influence on the ability of a China-based company, such as us, to conduct its business. Therefore, investors of our
company and our business face potential uncertainty from the PRC government. Changes in China&#8217;s economic, political or social conditions
or government policies could materially adversely affect our business and results of operations. These risks could result in a material
change in our operations and/or the value of our ordinary shares or could significantly limit or completely hinder our ability to offer
or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless. In particular,
recent statements and regulatory actions by China&#8217;s government, such as those related to the use of variable interest entities
and data security or anti-monopoly concerns, as well as the PCAOB&#8217;s ability to inspect our auditors, may impact our Company&#8217;s
ability to conduct our business, accept foreign investments, or be listed on a U.S. or other foreign stock exchange. See &#8220;Item
3. Key Information &#8212; D. Risk Factors &#8212; Risks Related to Doing Business in China &#8212; The PRC government has significant
authority to intervene or influence the China operations of an offshore holding company, such as ours, at any time. The PRC government
may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers. If the PRC government exerts
more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers and we were to
be subject to such oversight and control, it may result in a material adverse change to our business operations, significantly limit
or completely hinder our ability to offer or continue to offer securities to investors, and cause the ordinary shares to significantly
decline in value or become worthless&#8221; and &#8220;Item 3. Key Information &#8212; D. Risk Factors &#8212; Risks Related to Doing
Business in China &#8212; Uncertainties arising from the legal system in China, including uncertainties regarding the interpretation
and enforcement of PRC laws and the possibility that regulations and rules can change quickly with little advance notice, could hinder
our ability to offer or continue to offer the ordinary shares, result in a material adverse change to our business operations, and damage
our reputation, which would materially and adversely affect our financial condition and results of operations and cause the ordinary
shares to significantly decline in value or become worthless.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we and our subsidiaries have obtained all material licenses and approvals necessary to operate in China and are not required
to obtain approval from any PRC government authorities, including the CSRC or the CAC, or any other government entity, to issue our ordinary
shares to foreign investors. Since the recent regulatory actions are new, however, it is highly uncertain how soon legislative or administrative
regulation making bodies will respond and what existing or new laws or regulations or detailed implementations and interpretations will
be modified or promulgated, if any, and the potential impact such modified or new laws and regulations will have on our daily business
operation, ability to accept foreign investments, and listing on the Nasdaq Stock Market. If we do not receive or maintain the approvals,
or we inadvertently conclude that such approvals are not required, or applicable laws, regulations, or interpretations change such that
we are required to obtain approval in the future, we may be subject to an investigation by competent regulators, fines or penalties,
ordered to suspend our relevant business and rectify, prohibited from engaging in relevant business, or subject to an order prohibiting
us from conducting an offering, and these risks could result in a material adverse change in our operations, significantly limit or completely
hinder our ability to continue to offer securities to investors, or cause such securities to significantly decline in value or become
worthless. See &#8220;Item 3. Key Information&#8212;Risk Factors&#8212;Risks Relating to Doing Business in China&#8212;Failure to comply
with cybersecurity, data privacy, data protection, or any other laws and regulations related to data may materially and adversely affect
our business, financial condition, and results of operations.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, trading in our securities may be
prohibited under the HFCA Act if the PCAOB determines that it cannot inspect the workpapers prepared by our auditor, and that as a result
an exchange may determine to delist our securities. On June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies
Accountable Act, which, if passed by the U.S. House of Representatives and signed into law, would reduce the period of time for foreign
companies to comply with PCAOB audits to two consecutive years instead of three, thus reducing the time period for triggering the prohibition
on trading. On December 16, 2021, the PCAOB issued a report on its determination that it is unable to inspect or investigate completely
PCAOB-registered public accounting firms headquartered in China and in Hong Kong because of positions taken by PRC and Hong Kong authorities
in those jurisdictions. Our auditor, the independent registered public accounting firm that issues the audit report included elsewhere
in this annual report, as an auditor of companies that are traded publicly in the U.S.&#160;and a firm registered with the PCAOB, is subject
to laws in the U.S., pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional
standards. Our auditor is headquartered in California and has not been inspected by the PCAOB, but according to our auditor, it will be
inspected by the PCAOB on a regular basis. Our auditor is not subject to the determination issued by the PCAOB on December 16, 2021. See
&#8220;Item 3. Key Information &#8212; D. Risk Factors &#8212;&#160;Risks Related to Doing Business in China &#8212; Our ordinary shares
may be delisted or prohibited from being traded over-the-counter under the Holding Foreign Companies Accountable Act, if the U.S. Public
Company Accounting Oversight Board, or the PCAOB, is unable to inspect our auditors. The delisting or the cessation of trading of our
ordinary shares, or the threat of their being delisted or prohibited from being traded, may materially and adversely affect the value
of your investment. Additionally, the inability of the PCAOB to conduct inspections would deprive our investors with the benefits of such
inspections. Our auditor has not been inspected by the PCAOB, but according to our auditor, it will be inspected by the PCAOB on a regular
basis.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flows have occurred between our Cayman Islands holding company and our subsidiaries. Our Cayman Islands holding company had not received
cash transfers from its subsidiaries for the years ended September 30, 2019, 2020 and 2021. There was no distribution of earnings by
our PRC subsidiaries to our Cayman Islands holding company during the years ended September 30, 2021, 2020 and 2019. For the fiscal year
ended September 30, 2021, our Cayman Islands holding company, via Universe HK and Universe Technology, transferred cash in the amount
of $6,807,507 to our PRC operating subsidiaries to be used for general corporate purposes. For the years ended September 30, 2020 and
2019, there was no cash transferred from our Cayman Islands holding company to its PRC subsidiaries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Cayman Islands holding company has not declared or paid dividends in the past, nor any dividends or distributions were made by a subsidiary
to the Cayman Islands holding company. Our board of directors has complete discretion on whether to distribute dividends, subject to
applicable laws. We do not have any current plan to declare or pay any cash dividends on our ordinary shares in the foreseeable future.
See &#8220;Item 3. Key Information &#8212; D. Risk Factors &#8212; Risks Related to Our Ordinary Shares&#8212;We currently do not expect
to pay dividends on our ordinary shares in the foreseeable future.&#8221; Subject to certain contractual, legal and regulatory restrictions,
cash and capital contributions may be transferred among our Cayman Islands holding company and our subsidiaries. If needed, our Cayman
Islands holding company can transfer cash to our PRC subsidiaries through loans and/or capital contributions, and our PRC subsidiaries
can transfer cash to our Cayman Islands holding company through issuing dividends or other distributions. Cash transfers from our Cayman
Islands holding company are subject to applicable PRC laws and regulations on loans and direct investment. For details, see &#8220;Item
3. Key Information &#8212; D. Risk Factors &#8212; Risks Related to Doing Business in China &#8212; PRC regulation of loans to, and direct
investments in, PRC entities by offshore holding companies may delay or prevent us from using proceeds from our offerings and/or other
financing activities to make loans or additional capital contributions to our PRC operating subsidiaries.&#8221; In addition, current
PRC regulations permit our PRC subsidiaries to pay dividends to their respective shareholders only out of their accumulated profits,
if any, determined in accordance with PRC accounting standards and regulations. For details, see &#8220;Item 3. Key Information &#8212;
D. Risk Factors &#8212; Risks Related to Doing Business in China &#8212; We may rely on dividends paid by our subsidiaries for our cash
needs, and any limitation on the ability of our subsidiaries to make payments to us could have a material adverse effect on our ability
to conduct business.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Corporate History and Structure</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
initially conducted our business through Jiangxi Universe, a PRC company formed in 1998 and Universe Trade, a PRC company formed in 2010,
a wholly-owned subsidiary of Jiangxi Universe.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the growth of our business and in order to facilitate international capital investment in our Company, we underwent an offshore reorganization
in 2019 and 2020. On December 11, 2019, our holding company, Universe Pharmaceuticals INC, was incorporated under the laws of the Cayman
Islands as an exempted company with limited liability. Our wholly owned subsidiary Universe HK was formed in Hong Kong on May 21, 2014
as an intermediate holding company. Universe HK in turn holds all the capital stocks of Universe Technology, a wholly foreign owned enterprise
incorporated in China on Aril 8, 2019. Universe Technology holds all the capital stocks and controls Jiangxi Universe. Jiangxi Universe
holds 100% of the equity interests in Universe Trade.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
holding company has no business operation other than holding the shares in Universe HK. Universe HK is a pass-through entity with no
business operation. Universe Technology is exclusively engaged in the business of managing the operation of Jiangxi Universe. Jiangxi
Universe specializes in manufacturing our own TCMD products. Universe Trade specializes in the distribution and sales of our own TCMD
products and third-party pharmaceutical products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foshan
Shangyu Investment Holding Co., Ltd. (&#8220;Foshan Shangyu&#8221;) is our affiliated entity, 90% owned by and controlled by Mr. Gang
Lai, our controlling shareholder. Foshan Shangyu was formed in 2004 in China as a holding company of Mr. Gang Lai. Foshan Shangyu has
no business operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following diagram illustrates our corporate structure as of the date of this annual report:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="img_001.jpg"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji&#8217;an,
Jiangxi Province, People&#8217;s Republic of China, and our phone number is +86-0796-8403309. Our registered office in the Cayman Islands
is located at Vistra (Cayman) Limited, P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KYI &#8211; 1205
Cayman Islands, and the phone number of our registered office is +1-(345)769-9372. We maintain a corporate website at http://www.universe-pharmacy.com.
The information contained in, or accessible from, our website or any other website does not constitute a part of this annual report.
Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York,
NY 10168.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains a website at www.sec.gov that contains reports, proxy, and information statements, and other information regarding issuers
that file electronically with the SEC using its EDGAR system.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
information regarding our principal capital expenditures, see &#8220;Item 5. Operating and Financial Review and Prospects&#8212;B. Liquidity
and Capital Resources&#8212;Capital Expenditures.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
<span style="text-decoration:underline">Business Overview</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TCM
is a comprehensive form of healthcare that has been widely adopted in China for more than 23 centuries. TCM rests upon the assumption
that the human body is an ecosystem, embodying the fusion of Shen (psyche), Essence (soma), Qi, Moisture (body fluids), and Blood (tissue).
Health in the context of TCM is more than just the absence of diseases, but to identify imbalance in human body and restore harmony.
TCM is not only intended to cure diseases but to enhance the capacity for fulfillment, happiness and general well-being of people.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pharmaceutical company based in Jiangxi, China, specializing in the manufacturing, marketing, sales and distribution of TCMD products
targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being.
We have registered and obtained approval for 26 varieties of TCMD products from the National Medical Products Administration (the &#8220;NMPA&#8221;),
and we currently produce 13 varieties of TCMD products, which are sold in approximately 202 cities of 30 provinces in China. In addition,
through our subsidiary Universe Trade, we sell not only our own TCMD products, but also biomedical drugs medical instruments, Traditional
Chinese Medicine Pieces (&#8220;TCMPs&#8221;), and dietary supplements manufactured by third-party pharmaceutical companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Products manufactured by us.&#160;</i>The 13
TCMD products currently manufactured by us fall into two categories: (1) treatment and relief for common chronic health conditions in
the elderly designed to achieve physical wellness and longevity (&#8220;chronic condition treatments&#8221;), and (2) cold and flu medications.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="width: 98%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Chronic condition treatments</b>: Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal Liquor.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 96%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cold
    and flu medicines</b>: Paracetamol Granule for Children, Isatis Root Granule and Qiangli Pipa Syrup.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As people age, they have an increasing risk of
developing chronic health conditions. According to a report published by the Chinese Center for Disease Control and Prevention in March
2019, 75.8% of seniors have at least one chronic health condition, and 35.1% of them have two or more. Some of the most common chronic
diseases in the elderly include arthritis, chronic kidney disease, fatigue, and low back pain. Our products under the category of chronic
condition treatments are designed to address some of the aforementioned diseases. Our cold and flu medicines, on the other hand, include
products designed to treat and relieve symptoms of respiratory illnesses caused by bacteria and viruses.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Our third-party products.&#160;</i>Through
our subsidiary, Universe Trade, we also distribute and sell products manufactured by third-party producers, including biomedical drugs,
medical instruments, TCMPs and dietary supplements. For the year ended September 30, 2021, we distributed around 2,766 types of third-party
products.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our&#160;<i>Customers.&#160;</i>Our
major customers are pharmaceutical distributors, hospitals, clinics and drugstore chains, primarily located in Jiangxi Province, Jiangsu
Province, Guangdong Province, Hubei Province, Fujian Province, Guangxi Province and Shandong Province, and 23 other provinces in China.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe we have implemented a successful business model, and our business has grown substantially since our inception. Our customer base
decreased from a total of 2,603 customers as of September 30, 2019 decreased to 2,209 as of September 30, 2020 due to the impact of the
COVID-19 pandemic. In fiscal year 2021, our business operations gradually recovered from the negative impact of COVID-19 and our customer
base increased to 2,708 as of September 30, 2021. Our revenues from selling our own products decreased from $20,895,542 for the fiscal
year ended September 30, 2019 to $18,374,751 for the fiscal year ended September 30, 2020 due to the impact of COVID-19 pandemic and
strong market competition, and increased to $29,559,286 for the fiscal year ended September 30, 2021. Our revenues from distributing
and selling products manufactured by third-party companies slightly decreased from $12,333,774 for the fiscal year ended September 30,
2019 to $12,329,209 for the year ended September 30, 2020, and increased to $18,422,745 for the fiscal year ended September 30, 2021.
Our net income was $7,551,465 for the fiscal year ended September 30, 2019, $7,558,222 for the fiscal year ended September 30, 2020,
and $11,319,952 for the fiscal year ended September 30, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Competitive Strengths</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe we have the following competitive strengths:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
recognized manufacturer of TCMD products in China&#8217;s rapidly growing health and wellness market</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a recognized manufacturer of TCMD products in China&#8217;s rapidly growing health and wellness market. We own a number of famous
brands in the industry, which are also our registered trademarks in China. For instance, our brand &#8220;Hu Zhuo Ren (&#32993;&#21331;&#20161;)&#8221;
is especially well-recognized in Jiangxi Province. Further, our brand &#8220;Bai Nian Dan (&#30334;&#24180;&#20025;)&#8221; is famous
for specializing in products targeted at the physical wellness of older population. Our other recognized brands include &#8220;Long Zhong
(&#40857;&#31181;)&#8221;, &#8220;Yi Ke Ting (&#30410;&#20811;&#20572;)&#8221;, &#8220;Xue Li (&#34880;&#21147;)&#8221;, &#8220;Duo Lai
Mei (&#26421;&#26469;&#32654;)&#8221;, &#8220;Shu Er Kang (&#33298;&#20799;&#24247;)&#8221;, &#8220;Hu Zhuo Ren (&#32993;&#21331;&#20161;)&#8221;,
&#8220;Ai Bi Xin (&#29233;&#24517;&#27427;)&#8221;, and &#8220;Yong He Shuang Feng (&#27704;&#21644;&#21452;&#20964;)&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chinese patent medicine industry is growing rapidly and steadily in China. The primary growth drivers of China&#8217;s Chinese patent
medicine industry include the increasing disposable income and healthcare awareness in China, growing aging population and the prevalence
of chronic diseases, and favorable governmental policies and regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
attribute our success to our recognized brand names, strong relationships with our suppliers, loyal and stable customer base, and proven
capability to develop and manufacture TCMD products aligned with the preferences of end consumers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rigorous
quality control standards and manufacturing protocols</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the quality of our products is crucial to our success as a pharmaceutical company, and we have implemented an overall quality
control system, as well as strict manufacturing protocols specifically designed for each product. Our quality control system starts from
procurement. The raw materials we source from our suppliers must first be examined and certified for quality. We review the performance
of our suppliers based on the quality of their products and adjust future orders from them accordingly. Further, an average of three
inspections are made by our personnel throughout the manufacturing process to ensure that the manufacturing protocols are strictly followed,
and that the quality of semi-products are at or above standard. After completion of manufacturing, our personnel will perform an overall
quality examination. Through the implementation of a quality control system, we are able to identify the weakness in our production process
and improve our operations over time. We believe our quality control standards and manufacturing protocols have contributed to the high
quality and consistency of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Visionary
management team with substantial industry experience</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
visionary management team is the bedrock of our success. Many members of our leadership possess extensive experience in the pharmaceutical,
biomedical, chemical and related industries. For instance, our chief executive officer, Mr. Gang Lai, has about 30 years of corporate
management experiences. Mr. Xiaojun Deng, the deputy manufacturing manager of Jiangxi Universe, holds a degree in Traditional Chinese
Medicine Manufacturing from Jiangxi Medical School with over 25 years of working experience in the Chinese patent medicine industry.
Ms. Lin Yang, our chief financial officer, has over 14 years of finance and management experience working in pharmaceutical companies.
Mr. Yajun Hu, the general manager of Jiangxi Universe, has over five years of experiences in managing a pharmaceutical company. Mr. Baochang
Liu, our chief operating officer, has over 17 years of experience in pharmaceutical marketing and had previously held marketing and management
positions at a number of listed pharmaceutical companies in China. Moreover, many members of the team have worked together for an extended
period of time and helped build the Company from the ground up. The rapport that the team has built extends beyond the talent and skills
of individual team members and contributes to a collective sense of mission.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Strong
record of growth and profitability</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been profitable since 2008 and we believe we are well-positioned to benefit from the rapid growth of the TCMD market in China and
to leverage the leading market position of our flagship products in order to further grow our business. Due to the impact of COVID-19
pandemic, our revenue from sales of TCMD products was decreased from $20,895,542 for the fiscal year ended September 30, 2019 to $18,374,751
for the fiscal year ended September 30, 2020. In response to the COVID-19 pandemic, we made certain strategic decisions to mitigate the
negative impacts, including our decision to focus on selling third-party products during February and March 2020 when our factory was
closed. In addition, in August and September 2019, we conducted maintenance and upgrade of our manufacturing facilities, which enabled
us to streamline our manufacturing process, manage the workflow effectively, improve product quality, and boost our manufacturing productivity
to lower down our manufacturing costs to certain extent. This contributed to a decrease in the cost of revenue associated with the sales
of our TCMD products by 27.8% in fiscal year 2020 as compared to fiscal year 2019. As a result of the change in product mix and decrease
in our cost of revenue, our net income increased slightly from $7,551,465 for the fiscal year ended September 30, 2019 to $7,558,222
for the fiscal year ended September 30, 2020. We gradually recovered from the negative impact of the COVID-19 impact on our business
operations. Our revenue for the fiscal year ended September 30, 2021 increased from $30,703,960 for the fiscal year ended September 30,
2020 to $47,982,031 for the fiscal year ended September 30, 2021, and our net income increased from $7,558,222 for the fiscal year ended
September 30, 2020 to $11,319,952 for the fiscal year ended September 30, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Growth Strategy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Build
a Strong Brand Image to Achieve National Recognition</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that broader recognition and favorable
perception of our brand by consumers in our target markets are crucial to our future success. Our brand has gained a solid reputation
in Southern China, especially Jiangxi Province, and we plan to increase the awareness of our brand among consumers in other parts of China.
Specifically, we plan to build a strong brand image that we are a TCMD producer specializing in the development and manufacture of products
designed to address the physical conditions of the elderly during the aging process and to promote their general well-being. To achieve
our goal, we plan to spend most of our efforts on the development and marketing of our brand &#8220;Bai Nian Dan (<span style="font-family: Times New Roman, Times, Serif">&#30334;&#24180;&#20025;</span>)&#8221;
as the brand to be associated with our ideal brand image because &#8220;Bai Nian&#8221; (<span style="font-family: Times New Roman, Times, Serif">&#30334;&#24180;</span>)
signifies longevity in the Chinese language, and &#8220;Dan&#8221; (<span style="font-family: Times New Roman, Times, Serif">&#20025;</span>)
alludes to our signature product, Guben Yanlin Pill. In the fiscal year ended September 30, 2021, we started to advertise our products
through television advertisement. We also intend to advertise targeting at older customers, including transmitting our advertisements
through additional traditional media platforms such as live radio stations, newspapers, as well as in-person marketing at drug stores
and clinics.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Enhance
Our Distribution Network to Increase Market Penetration and Customer Stickiness</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
our products are sold in 30 provinces in China. We plan to enter the markets in other parts of China. To achieve this goal, we have made
efforts to further strengthen and expand our distribution network through connecting with more local distributors, chain drugstores,
malls and supermarkets in other parts of China. Currently, our strategic focus is to attract more marketing talents and build a stronger
sales and marketing team to keep us on top of the latest information of local markets, customer preferences and industry trends. We also
plan to create an online store to reach a wider consumer demographic. In the future, we plan to start our own retail chain stores and
further diversify our distribution channels to increase our market penetration and customer base.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Integrate
Our Internal Manufacturing Capability to Ensure Productivity, Supply, and Selection of Products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to further optimize our production facilities to increase the productivity, supply and selection of our products, so that we may
gain competitive edges over our competitors. Specifically, we intend to increase productivity and supply by expanding the existing production
lines and converting them into automated production lines. To increase the selection of our products, we plan to build additional production
facilities for our licensed TCMD products to be launched in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Further
Grow Our Research and Development Capacities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The size of the Chinese patent medicine market
has been growing steadily. To respond to increasing market demand, we will continue to provide financial and operational resources to
focus on the research and development of TCMD products and dietary supplements designed to address the physical conditions of the elderly
during the aging process and promote their general well-being.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Manufactured Products</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We manufacture, market and sell 13 different TCMD
products to customers in 30 different provinces in China. Our TCMD products fall under two categories: chronic condition treatments and
cold and flu medications. The following list outlines our current products:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Percentage of<br/>
Gross Sales</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Product&#160;Category</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Product Name</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Posology</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2019</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Intended Uses</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 18%; text-align: center"><span style="font-size: 10pt"><b>Chronic Condition Treatments</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center"><span style="font-size: 10pt">Guben Yanling Pill</span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 10%; text-align: center"><span style="font-size: 10pt">Pills</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 4%; text-align: right"><span style="font-size: 10pt">40.3</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 5%; text-align: right"><span style="font-size: 10pt">38.2</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%; text-align: right"><span style="font-size: 10pt">32.4</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 30%; text-align: center"><span style="font-size: 10pt">To relieve fatigue, palpitation, low back pain, and generalized weakness and soreness.</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Shenrong Weisheng Pill</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Pills</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4.7</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">4.6</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5.3</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">To relieve fatigue, dizziness, excessive sweating, and pain in the waist and the knees.</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Quanlu Pill</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Pills</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1.5</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">0.8</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">0.4</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">To improve kidney functions and spleen functions, and relieve fatigue, low back pain, and knee pain.</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Wuzi Yanzong Oral Liquid</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Oral liquid</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">0.4</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">0.6</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">0.7</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">To improve kidney functions.</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Yangxue Danggui Syrup</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Syrup</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">0.9</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1.6</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3.5</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">To improve blood circulation and treating dizziness, headaches and menstrual pains.</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Fengshitong Medicinal Liquor</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Medicinal liquor</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1.1</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1.6</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">0.2</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">To treat low back pain and numbness in the feet and hands, and relieve rheumatoid arthritis pain.</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Shiquan Dabu Medicinal Liquor</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Medicinal liquor</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1.3</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1.8</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1.9</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">To treat dizziness, palpitation, fatigue, and weakness, and ease menstrual flow.</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Fengtong Medicinal Liquor</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Medicinal liquor</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">0.3</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">0.2</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2.9</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">To treat low back pain and numbness in the feet and hands, and relieve symptoms of arthritis.</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Shenrong Medicinal Liquor</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Medicinal liquor</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">0.7</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1.4</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1.6</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">To improve blood circulation and relieve symptoms of fatigue, low back pain and leg pain.</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Qishe Medicinal Liquor</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Medicinal liquor</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">0.4</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">0.3</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">0.4</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">To treat blood stasis, arthritis, and numbness in the feet and hands.</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>Cold and Flu Medicines Medicinal Liquor</b></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Qiangli Pipa Syrup</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Syrup</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">9.6</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3.3</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">6.9</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Relieve cough and reduce mucus and phlegm.</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Paracetamol Granule for Children</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Granules</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2.7</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1.9</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">1.6</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">To relieve children&#8217;s headaches, muscle aches, toothaches, colds and fevers.</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Isatis Root Granule</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Granules</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">2.4</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">3.6</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">5.0</span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">To treat common colds and other infections of the upper respiratory tract.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the 13 TCMD products we manufacture, Guben Yanlin Pill is our signature product. For the fiscal years ended September 30, 2021, 2020,
and 2019, the revenue derived from the sale of Guben Yanlin Pill represented 40.3%, 38.2%, and 32.4% of our total revenue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Manufacturing Process</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following chart illustrates our main manufacturing process from raw material purchase to marketing:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="img_002.jpg"/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
Raw Materials and Suppliers</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
select our raw materials for the manufacturing of our products strictly in accordance with the guidance in Pharmacopoeia of the People&#8217;s
Republic of China (&#12298;&#20013;&#21326;&#33647;&#20856;&#12299;) (the &#8220;PPRC&#8221;), an official compendium of drugs covering
both TCM and western medications complied by the Pharmacopoeia Commission of the Ministry of Health of People&#8217;s Republic of China.
The PPRC specifies the standards of description, dosage, purity, storage, and other material information for each drug. In the manufacturing
of our TCMD products, a total of more than 110 raw materials are regularly used, among which angelica, codonopsis, poria mushroom, isatis
root, loquat leaves, safflower, and Baijiu liquor represent our main raw materials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we have stable access to all the raw materials necessary for our production. There are many suppliers in the industry for the regularly
used raw materials, and therefore we are not relying on a single supplier for any of our raw materials. If we are unable to purchase
any of the raw materials from one supplier, we do not expect to face material difficulties in locating another supplier at substantially
the same price. While the prices of such raw materials may vary greatly from time to time due to market forces beyond our control, we
believe we can hedge such risk by adjusting our price, or absorbing higher costs if and when necessary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To source the raw materials required
for our products, we regularly contract with our suppliers by placing bulk orders with them at below market prices. Our raw material
suppliers include mostly traditional Chinese medicine manufacturers and pharmaceutical trading companies. After years of business cooperation,
we believe that our relationships with our current suppliers are strong and stable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
We consider our raw materials suppliers whose sales to us accounted for more than 10% of our overall purchases in any given period to
be our major suppliers for such period. For the fiscal year ended September 30, 2021, no supplier accounted for more than 10% of our
total purchases. For the fiscal year ended September 30, 2020, two suppliers accounted for approximately 19.6% and 13.6% of our total
purchases, respectively. For the fiscal year ended September 30, 2019, one supplier accounted for approximately 14.1% of our total purchases.
We had two such supplier during the fiscal year ended September 30, 2020, Jiangxi Hongjing Pharmaceutical Co., Ltd. and Jiangxi Kangxin
Pharmaceutical Packaging Co., Ltd., whose sales to us accounted for approximately 19.6% and 13.6% of our overall purchases in the fiscal
year, respectively. We had one such supplier during the fiscal year ended September 30, 2019, Jiangxi Hongjing Pharmaceutical Co., Ltd.,
whose sales to us accounted for approximately 14.1% of our overall purchases in that fiscal year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Manufacturing
Process</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a brief description of the manufacturing process of the TCMD products we currently produce by dosage forms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Pill
Products</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
make our pill products, the raw materials first go through a preparation process, during which such materials are dried, roughly ground
and sterilized. Processed raw materials are then finely ground, mixed with honey, and made into pills before they are finally packaged.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Granule
Products</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
raw materials of our granule products typically go through a purifying process, during which such materials are stewed, filtered, condensed,
and let stand. Processed raw materials are then mixed with supplemental ingredients before they are made into granules, dried, and finally
packaged.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Syrup
Products</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
raw materials of our syrup products are first stewed together and condensed. Condensed liquid is then filtered and mixed with supplemental
ingredients before it is bottled and packaged.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Oral
Liquid Products</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
raw materials of our oral liquid products are first filtered, condensed, and fixed with other supplemental ingredients. The processed
materials are then further filtered and sterilized before being bottled and packaged.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Medicinal
Liquor Products</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
raw materials of our medicinal liquor products first go through a purifying process, during which such materials are selected, cut, rinsed,
stewed, and refrigerated. Processed raw materials then go through an extraction process that involves mixing with solvents and filtering.
Then, the liquor products are bottled and packaged.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Quality
Control and Assurance</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to ensure the high quality of our products through our quality control system and by conducting product testing and review. Our
entire manufacturing process is strictly supervised pursuant to internal quality control standards that have been set up in strict adherence
to the guidelines provided in PPRC. We conduct our quality testing by examining the quality of each and every type of raw materials.
If the raw materials meet our quality standards, we start the manufacturing process, during which we continue our quality testing for
every substantial procedure, including filtering, grinding, mixing, and pill making. After our products are packaged, we will examine
various features of our final products thoroughly, including appearance, weight, taste, water content, and microorganism content.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Third-party
Product Distribution</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to manufacturing our own products, we also distribute and sell, through our subsidiary Universe Trade, biomedical drugs, medical
instruments, TCMPs and dietary supplements manufactured by third-party pharmaceutical companies. For the fiscal year ended September
30, 2021, we had distributed roughly 2,766 third-party products, of which approximately 87.30% are biochemical drugs, such as liquid
glucose, prednisolone, and citicoline, approximately 12.58% are medical instruments, such as drug-eluting stents, surgical tubes and
syringes, approximately 0.11% are TCMPs, such as red sage tables, Longdan Xiegan pills, and Chinese skullcap capsules and approximately
0.01% are dietary supplements, such as vitamins, probiotic powder, and calcium tablets. For the fiscal year ended September 30, 2020,
we had distributed roughly 2,785 third-party products, of which approximately 83.75% are biochemical drugs, such as liquid glucose, prednisolone,
and citicoline, approximately 15.82% are medical instruments, such as drug-eluting stents, surgical tubes and syringes, approximately
0.38% are TCMPs, such as red sage tables, Longdan Xiegan pills, and Chinese skullcap capsules and approximately 0.05% are dietary supplements,
such as vitamins, probiotic powder, and calcium tablets. For the year ended September 30, 2019, we had distributed roughly 3,590 third-party
products, of which approximately 71.55% are biochemical drugs, such as liquid glucose, prednisolone, and citicoline, approximately 18.68%
are medical instruments, such as drug-eluting stents, surgical tubes and syringes, approximately 9.05% are TCMPs, such as red sage tables,
Longdan Xiegan pills, and Chinese skullcap capsules and approximately 0.72% are dietary supplements, such as vitamins, probiotic powder,
and calcium tablets. We distribute these products to hospitals, drugstore chains, clinics, and pharmaceutical distributors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Suppliers of Third-party Products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
source third-party pharmaceutical products from their manufacturers in China. Our third-party product suppliers include mostly medical
instrument manufacturers, pharmaceutical product manufacturers and dietary supplement manufacturers. For all of the products that we
source and sell, we can generally find similar replacements in the market from the competitors of our current suppliers. Accordingly,
we do not have any continuous or long-term supply agreements with any of these suppliers. We purchase third-party medical products from
our suppliers on a per purchase order basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended September 30, 2021, 2020 and 2019, we purchased products from over 665, 728 and 650 suppliers, respectively. For
the fiscal years ended September 30, 2021, 2020 and 2019, we did not have any supplier of third-party products whose sales to us accounted
for more than 10% of our overall purchases of that fiscal year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Customers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
customers are mostly pharmaceutical distributors, hospitals, clinics and drugstore chains with pharmaceutical business qualification
certificates, awarded and authorized by the NMPA and are authorized to sell and deliver our products to end consumers. As of the date
of this annual report, our customers are scattered over 202 cities of 30 provinces in China. We determine whether to establish long-term
business relationships with our customers primarily based on two factors, their ability to promote our products and their ability to
make payments on time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2021, we have total of 2,708 customers, of which 1,422 were pharmaceutical distributors, 542 were clinics, 489 were
drug stores, and 255 were hospitals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended September 30, 2021, our revenues generated from sales to pharmaceutical distributors, hospitals, clinics and drugstore
chains represented 59.78%, 29.63%, 10.24% and 0.35% of our total revenues, respectively. For the fiscal year ended September 30, 2020,
our revenues generated from sales to pharmaceutical distributors, hospitals, clinics and drugstore chains represented 63.8%, 22.4%, 13.3%
and 0.5% of our total revenues, respectively. For the fiscal year ended September 30, 2019, our revenues generated from sales to pharmaceutical
distributors, hospitals, clinics and drugstore chains represented 58.89%, 21.22%, 19.40%, and 0.48% of our total revenues, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our customers generated more than 10% of our revenue for the fiscal years ended September 30, 2021, 2020 and 2019. However, our top
10 customers aggregately accounted for 30.4%, 33.3% and 34.5% of our total revenue for the fiscal years ended September 30, 2021, 2020
and 2019, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketing
and Sales</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that marketing activities are crucial to our success in the competitive Chinese patent medicine industry. As of September 30,
2021, we had a total of 81 employees in our marketing department. Employees in our marketing department are mainly responsible for performing
various marketing activities, including researching the most updated industry and market information, analyzing market trends and consumer
preferences, setting up marketing strategies, executing sales contracts, communicating with existing customers and networking with potential
customers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
marketing and sales initiatives for the next several years will focus on three objectives: developing a strong brand image, building
a successful marketing team, and expanding retail channels. To develop our brand image as a producer of TCMD products aiming at addressing
the physical conditions of the elderly during the aging process and promoting their general well-being, we seek to promote our brand
&#8220;Bai Nian Dan (&#30334;&#24180;&#20025;)&#8221; utilizing both online marketing channels such as WeChat official account and other
social media and traditional platforms such as television, newspapers, and live radio stations. As part of the efforts to build a successful
marketing team, we intend to hire additional sales talents and provide monetary and equity incentives to sales employees. For purposes
of expanding our retail channels, we plan to open an online retail store, and according to the preferences of online shoppers, we may
adjust the sizes, packaging, or prices of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
established a research and development department in 1998. Our research and development team has been focusing on the upgrade of current
products and the development of production techniques to increase productivity. After years of continued development, our research and
development department has become the core of our technological innovation efforts. As of September 30, 2021, we had 24 employees dedicated
to research and development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>R&amp;D
Achievements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development team has invented patented technologies to enhance the quality of our products and our manufacturing efficiency.
For instance, our patented TCM mixer is able to mix powders more evenly and thoroughly compared to a traditional mixing machine, thereby
increasing the quality of the mixed medicine powder. The special design of our patented TCM concentration device is able to increase
the contact area of the liquid medicine as compared to a regular concentration device, thereby increasing the manufacturing efficiency
of our products in liquid dosage form.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of our efforts, our subsidiary, Jiangxi Universe, became certified as a National High-Tech Enterprise by the Science and Technology
Department of Jiangxi Province in December 2013, with a term of three years. We successfully renewed the certificate in December 2019.
This certification entitles us to a favorable corporate income tax of 15%, rather than the unified tax rate of 25% we would pay if we
were not certified.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>R&amp;D
Development Plan</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
further our strong brand image, we plan to develop products designed to address the physical conditions of the elderly during the aging
process and promoting their general well-being, including TCMD products and dietary supplements. In the upcoming years, we intend to
focus on the development of immunity boost products and sleep aids.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our own efforts, our research and development team also intends to collaborate with other industry professionals and TCM
experts with respect to the development of products we plan to launch in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compete with pharmaceutical companies in China that manufacture and sell products similar to ours. Furthermore, many of these companies
are more established than we are, and have significantly greater financial, technical, and other resources than we presently possess.
Some of our competitors may be able to respond more quickly to new opportunities, market changes or changes of customer preferences,
and may be able to undertake more extensive promotional activities, offer more attractive terms to distributors, and adopt more aggressive
pricing strategies than we are. Despite that, we believe we are well-positioned to compete in this market with our diversified product
portfolio, recognized brand name, established sales and marketing network and experienced management team with a proven track record.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Competitors of our products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the competitors
of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 45%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Products</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 54%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competitors</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guben
    Yanling Pill</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiyuan
    Daningtang Pharmaceuticals Co., Ltd.;<br/>
    Shenyang Dongxin Pharmaceutical Industry Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shenrong
    Weisheng Pill</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China
    Beijing Tong Ren Tang Group Co., Ltd.;<br/>
    Jiangxi Zhongyuan Pharmaceutical Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quanlu
    Pill</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renhe
    Pharmaceuticals Co.;<br/>
    Guangzhou Pharmaceutical Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fuzi
    Lizhong Pill</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China
    Beijing Tong Ren Tang Group Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yangxue
    Danggui Syrup</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sichuan
    Tiancheng Pharmaceuticals Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qiangli
    Pipa Syrup</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangzhong
    Pharmaceuticals Co., Ltd.;<br/>
    China Resources Sanjiu Medical &amp; Pharmaceuticals Co., Ltd.;<br/>
    Jiangxi Tengwangge Pharmaceuticals Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paracetamol
    and Chlorpheniramine Maleate<br/>
    Granules for Children</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China
    Resources Sanjiu Medical &amp; Pharmaceuticals Co., Ltd.; Sunflower Pharmaceutical Group Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Isatis
    Root Granules</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guangzhou
    Pharmaceuticals Co., Ltd.;<br/>
    China Resources Sanjiu Medicine &amp; Pharmaceuticals Co., Ltd.;<br/>
    China Beijing Tong Ren Tang Group Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wuzi
    Yanzong Oral Liquid</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China
    Beijing Tong Ren Tang Group Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuquan
    Dabu Medicinal Liquor</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Puzheng Pharmaceuticals Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shenrong
    Medicinal Liquor</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Puzheng Pharmaceuticals Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qishe
    Medicinal Liquor</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Zhongyuan Pharmaceuticals Co., Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fengtong
    Medicinal Liquor</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Zhongyuan Pharmaceuticals Co., Ltd.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Competitors
of Third-party Products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors of pharmaceutical products, including biochemical drugs and TCMPs, are many internationally and nationally well-known manufacturers
and distributors, including China Beijing Tong Ren Tang Group Co., Ltd., Yunnan Baiyao Group, China Resources Sanjiu Medicine &amp; Pharmaceuticals
Co., Ltd., and Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors in the medical instrument market include many well-known manufacturers and distributors of medical instruments, including
Shinva Medical Instrument Co., Ltd., Jiangsu Yuyue Medical Equipment &amp; Supply Co., Ltd., Lepu Medical Technology (Beijing) Co., Ltd.,
and Shanghai Runda Medical Technology Co., Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors in the dietary supplement market include internationally and nationally well-known manufacturers and distributors of dietary
supplements, such as By-health Co., Ltd., Amway (China) Co., Ltd., and Perfect (China) Co., Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to compete with these larger companies by appealing to the specific needs and preferences of our customers and offering competitive
prices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2021, 2020, and 2019, we had a total of 263, 169, and 176 employees, all of which are located in China. The following
table sets forth the number of our employees by function as of September 30, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Function</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.95pt 0pt 13.95pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>% of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.1pt 0pt 13.1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Purchasing Department</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">9</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Warehouse Department</td><td>&#160;</td>
    <td style="text-align: center">14</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Manufacturing Department</td><td>&#160;</td>
    <td style="text-align: center">102</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Quality Control Department</td><td>&#160;</td>
    <td style="text-align: center">18</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research and Development Department</td><td>&#160;</td>
    <td style="text-align: center">24</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Marketing Department</td><td>&#160;</td>
    <td style="text-align: center">81</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Finance Department</td><td>&#160;</td>
    <td style="text-align: center">8</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Administration Department</td><td>&#160;</td>
    <td style="text-align: center">7</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Total</td><td>&#160;</td>
    <td style="text-align: center">263</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on our ability to attract, retain and motivate qualified personnel. As part of our human resources strategy, we offer
employees competitive salaries and other bonuses and incentives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
primarily recruit our employees in China through direct hiring. We provide training to new employees that we hire. We also conduct regular
and specialized internal training to meet the need of our employees in different departments. We believe that such training is effective
in equipping our employees with the skill set and worth ethics we require.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
required under PRC regulations, we participate in various employee social security plans that are organized by applicable local municipal
and provincial governments, including housing, pension, medical, work-related injury, maternity and unemployment benefit plans.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into standard contracts and agreements regarding confidentiality, intellectual property, employment, ethic policies and non-competition
with most of our executive officers, managers and employees. These contracts typically include a non-competition provision effective
during and up to one year after termination of their employment with us and a confidentiality provision effective during and up to one
year after their employment with us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees have not formed any employee union or association. We believe that we maintain a good working relationship with our employees
and we have not experienced any difficulty in recruiting staff for our operations as of the date of this annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Properties
and Facilities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate headquarters are located in Jinggangshan,
Jiangxi Province, China. We own properties in Jingggangshan as office spaces, storage facilities and manufacturing facilities with an
aggregate gross floor area of approximately 825,563 square feet. We believe that our existing facilities are generally adequate to meet
our current needs, but we expect to seek additional space as needed to accommodate future growth. Following is a list of our properties
all of which we own the land use rights to:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Land
    Use Right Holder</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
    Address</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
    of<br/>
    Property</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Area
    in<br/>
    Square Feet</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms
    of Use</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265
    Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">173,467</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2053</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265
    Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">470,921</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2053</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265
    Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,010</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2053</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265
    Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Storage</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,426</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2053</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265
    Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,276</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2053</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265
    Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Storage</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,083</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2053</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Universe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">265
    Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&#8217;an, Jiangxi, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,380</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2053</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
manufacture all of our products at the properties listed above. Currently, we are capable of producing a maximum of approximately 12
million bottles of liquid products, 13 million boxes of pill products, and 10 million boxes of solid products annually.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We regard our patents, trademarks, domain names
and other intellectual property critical to our business operations. We rely on laws and regulations on patents, trademarks and domain
names to protect our intellectual property. As of the date of this annual report, we have registered 13 patents in China, including 11
utility model patents and two invention patents, and 99 trademarks in China, including our well-recognized brands &#8220;Bai Nian Dan
(<span style="font-family: Times New Roman, Times, Serif">&#30334;&#24180;&#20025;</span>)&#8221;, &#8220;Hu Zhuo Ren (<span style="font-family: Times New Roman, Times, Serif">&#32993;&#21331;&#20161;</span>)&#8221;
and &#8220;Long Zhong (<span style="font-family: Times New Roman, Times, Serif">&#40857;&#31181;</span>).&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
implement a set of comprehensive measures to protect our intellectual property, in addition to making trademark and patent registration
application. Key measures include : (i) timely registration, filing and application for ownership of our intellectual property, (ii)
actively tracking the registration and authorization status of our intellectual property and take action in a timely manner if any potential
conflicts with our intellectual property are identified, (iii) clearly stating all rights and obligations regarding the ownership and
protection of our intellectual property in all employment contracts and commercial contracts we enter into.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, we have not been subject to any material dispute or claims for infringement upon third parties&#8217;
trademarks, licenses and other intellectual property rights in China.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Seasonality</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not experience seasonality in our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Environmental
Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
comply with the Environmental Protection Law of China as well as applicable local regulations. In addition to statutory and regulatory
compliance, we actively ensure the environmental sustainability of our operations. Parties may be levied upon us if we fail to adhere
to and maintain certain standards. Such failure has not occurred in the past, and we generally do not anticipate that it will occur in
the future, but no assurance can be given in this regard.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insurance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain certain insurance policies to safeguard us against risks and unexpected events. For example, we provide social security insurance
including pension insurance, unemployment insurance, work-related injury insurance and medical insurance for our employees in compliance
with applicable PRC laws. We do not maintain business interruption insurance or product liability insurance, which are not mandatory
under PRC laws. We do not maintain key man insurance, insurance policies covering damages to our network infrastructures or information
technology systems nor any insurance policies for our properties. During the fiscal years ended September 30, 2021, 2020 and 2019, we
did not make any material insurance claims in relation to our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may from time to time become a party to various legal administrative proceedings arising in our ordinary course of our business. As of
the date of this annual report, neither we nor any of our subsidiaries is a party of any material legal proceeding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section sets forth a summary of the principal PRC laws, regulations, and rules relevant to our PRC operating entities&#8217; business
and operations in China.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pharmaceutical manufacturer in China. This section sets forth a summary of applicable laws, rules, regulations, government and
industry policies and requirement that have a significant impact on our operations and business in China. This summary does not purport
to be a complete description of all laws and regulations, which apply to our business and operations. Investors should note that the
following summary is based on relevant laws and regulations in force as of the date of this annual report, which may be subject to change.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Major
Regulatory Authorities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical industry in the PRC is mainly administered by four governmental agencies: (i) the NMPA, a department under the State Administration
for Market Regulation (the &#8220;SAMR&#8221;) (&#22269;&#23478;&#24066;&#22330;&#30417;&#30563;&#31649;&#29702;&#24635;&#23616;), (ii)
the National Health Commission (the &#8220;NHC&#8221;) (&#22269;&#23478;&#21355;&#29983;&#20581;&#24247;&#22996;&#21592;&#20250;), (iii)
the National Administration of Traditional Chinese Medicine (the &#8220;NATCM&#8221;) (&#22269;&#23478;&#20013;&#21307;&#33647;&#31649;&#29702;&#23616;),
and (iv) the National Healthcare Bureau (the &#8220;NHB&#8221;) (&#22269;&#23478;&#21307;&#30103;&#20445;&#38556;&#23616;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NMPA, whose predecessor is the China Food and Drug Administration, or the CFDA, is the primary regulator of almost all key stages of
the life-cycle of pharmaceutical products, including non-clinical researches, clinical trials, marketing approvals, manufacturing, advertising
and promotion, distribution and pharmacovigilance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NHC, formerly known as the National Health and Family Planning Commission, is the principal regulator of healthcare in China. It is primarily
responsible for drafting national healthcare policies and regulating public health, medical services and health contingency system, coordinating
the healthcare reform and overseeing the operation of medical institutions and professional practice of medical personnel. The NHC is
responsible for (1) the research, production, circulation and use of Chinese medicines, including traditional Chinese medicine; (2) the
preparation and publication of the Chinese Pharmacopoeia; and (3) the supervision of the selection, approval, distribution and revision
of the National OTC Drug Catalogue. In addition, the CFDA and its local administrative authorities may take a number of enforcement actions
to enforce their regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NATCM is an agency under the NHC that oversees China&#8217;s traditional Chinese medicine industry.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NHB, a new authority established in May 2018, is responsible for (1) drafting and implementing policies, plans and standards on medical
insurance, maternity insurance and medical assistance; (2) administering healthcare fund; (3) formulating a uniform medical insurance
catalogue and payment standards on drugs, medical disposables and healthcare services; and (4) formulating and administering the bidding
and tendering policies for drugs and medical disposables.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulations
Related to Pharmaceutical Manufacture</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Manufacturing
License</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Pharmaceutical Administration Law of the People&#8217;s Republic of China (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#33647;&#21697;&#31649;&#29702;&#27861;&#12299;),
which was promulgated in 1984 by the SCNPC and last amended in April 2015, a pharmaceutical manufacturer is required to obtain its manufacturing
license from the NMPA before it starts to manufacture pharmaceutical products. Prior to granting such permit, the relevant government
authority will inspect the applicant&#8217;s production facilities, and assess whether the sanitary conditions, quality assurance system,
management structure and equipment at the production facilities have met the required standards. A manufacturing license is valid for
a period of five years and the manufacturer is required to apply for renewal within six months prior to its expiration date. The manufacturer
will be subject to reassessment by the authority in accordance with then prevailing legal and regulatory requirements for the purposes
of such renewal. Currently, our subsidiary Jiangxi Universe holds a valid manufacturing license from the NMPA issued on December 21,
2020 and valid until December 20, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contract
Manufacturing of Drugs</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Administrative Regulations for the Contract Manufacturing of Drugs (&#12298;&#33647;&#21697;&#22996;&#25176;&#29983;&#20135;&#30417;&#30563;&#31649;&#29702;&#35268;&#23450;&#12299;)
(the &#8220;Contract Manufacturing Regulations&#8221;) issued by the NMPA in August 2014, in the event that a drug manufacturer in China
with drug marketing authorization temporarily lacks manufacturing capability as a result of technology upgrade or is unable to meet market
demand due to insufficient manufacturing capacity, it may use contract manufacturer for its drug manufacturing. Contract manufacturing
arrangements need to be approved by the provincial branch of the NMPA. The Contract Manufacturing Regulations prohibit contract manufacturing
arrangements for certain special drugs, including narcotic drugs, psychoactive drugs, biochemical drugs and active pharmaceutical ingredients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Regulations in relation to the Pharmaceutical Industry</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#8220;Two-vote
system&#8221; for drug sales</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NHC and other six ministries and commissions issued the Notice on the Opinions on the Implementation of the &#8220;Two-Invoice System&#8221;
in Drug Procurement by Public Medical Institutions (for Trial Implementation) (&#12298;&#20851;&#20110;&#22312;&#20844;&#31435;&#21307;&#30103;&#26426;&#26500;&#33647;&#21697;&#37319;&#36141;&#20013;&#25512;&#34892;&#8220;&#20004;&#31080;&#21046;&#8221;&#30340;&#23454;&#26045;&#24847;&#35265;
(&#35797;&#34892;) &#30340;&#36890;&#30693;&#12299;) (the &#8220;Notice on Two-Invoice System&#8221;) on January 11, 2017. &#8220;Two-invoice
system&#8221; means that one invoice shall be issued by a pharmaceutical manufacturer to a distributor, and another invoice shall be
issued by the distributor to a hospital. An internal transfer of drugs from a group pharmaceutical distributor to its wholly owned or
controlled subsidiary or a transfer of drugs between such wholly owned subsidiaries may not be deemed as &#8220;one invoice&#8221; however,
the invoicing for the whole group can be done only once. Pharmaceutical manufacturers and distributors shall reasonably determine the
markup level in the spirit of fairness, legality, legitimacy and integrity. Public medical institutions is encouraged to settle the payment
for drugs directly with pharmaceutical manufacturers, and pharmaceutical manufacturers and are encouraged to settle the delivery cost
with distributors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the sale of drugs, drug manufacturers and distributors shall issue value-added tax (&#8220;VAT&#8221;) special invoices or normal VAT
invoices in accordance with the regulations regarding invoice control. The sold drug shall also be delivered in a way that confirms to
the requirements of the Good Supply Practice for Pharmaceutical Products (2016 version) (&#12298;&#33647;&#21697;&#32463;&#33829;&#36136;&#37327;&#31649;&#29702;&#35268;&#33539;(2016&#20462;&#35746;)&#12299;),
and the names of the purchaser and seller on the invoices shall be consistent with the delivery form, payment flow and amount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Drug
Advertisements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Interim Administrative Measures for the Review of Advertisements for Drugs, Medical Devices, Health Food and Formula Food for
Special Medical Purposes (&#12298;&#33647;&#21697;&#12289;&#21307;&#30103;&#22120;&#26800;&#12289;&#20445;&#20581;&#39135;&#21697;&#12289;&#29305;&#27530;&#21307;&#23398;&#29992;&#36884;&#37197;&#26041;&#39135;&#21697;&#24191;&#21578;&#23457;&#26597;&#31649;&#29702;&#26242;&#34892;&#21150;&#27861;&#12299;)
promulgated on December 24, 2019 and effective on March 1, 2020, an enterprise seeking to advertise its drugs must apply for an advertising
approval code. An advertising approval code shall expire on the earlier of the expiration dates of the product&#8217;s registration certificate,
filing certificate or production license. If an expiration date is not prescribed in the product&#8217;s registration certificate, filing
certificate or production license, the advertising approval code shall be valid for two years. The contents of an approved advertisement
shall not be altered without prior approval. Where an advertisement needs to be edited, the enterprise shall submit an application for
a new advertisement approval code.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Insert
Sheet, Labels and Packaging of Pharmaceutical Products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Measures for the Administration of the Insert Sheets and Labels of Drugs (&#12298;&#33647;&#21697;&#35828;&#26126;&#20070;&#21644;&#26631;&#31614;&#31649;&#29702;&#35268;&#23450;&#12299;)
effective on June 1, 2006, the insert sheets and labels of a pharmaceutical product shall be reviewed and approved by the NMPA. A drug
insert sheet should include the scientific data, conclusions and information concerning drug safety and efficacy in order to direct the
safe and reasonable use of pharmaceutical products. The inner label of a pharmaceutical product shall indicate the product name, indication
or function, strength, dose and usage, production date, batch number, expiration date and drug manufacturer, and the outer label of a
pharmaceutical product shall indicate the product name, ingredients, description, indication or function, strength, dose and usage and
adverse reactions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Measures for the Administration of Pharmaceutical Packaging (&#12298;&#33647;&#21697;&#21253;&#35013;&#31649;&#29702;&#21150;&#27861;&#12299;)
effective on September 1, 1988, pharmaceutical packaging must comply with national and professional standards. If no national or professional
standards are available, a manufacturer can formulate and implement its own standards after it receives approval from the provincial
food and drug administration or bureau of standards. The company shall reapply for approval if it were to change its own packaging standards.
Pharmaceutical products with no approved packing standards shall not be sold or traded in the PRC, except for drugs for military use.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Drug
Technology Transfer</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 19, 2009, the NMPA promulgated the Administrative Regulations for Technology Transfer Registration of Drugs (&#12298;&#33647;&#21697;&#25216;&#26415;&#36716;&#35753;&#27880;&#20876;&#31649;&#29702;&#35268;&#23450;&#12299;)
(the &#8220;Technology Transfer Regulations&#8221;) to regulate the drug technology transfer process, including the application, evaluation,
examination, approval and monitoring of, drug technology transfer. Drug technology transfer means that the owner transfers its pharmaceutical
manufacturing technology to a pharmaceutical manufacturer and that the transferee applies for drug registration pursuant to the Technology
Transfer Regulations. Drug technology transfer includes the transfer of new drug technology and drug manufacturing technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applications
for drug technology transfer shall be submitted to the provincial drug regulatory authority where the transferee is located. The drug
regulatory authority examines application materials and conducts on-site inspections of the transferee&#8217;s manufacturing facilities.
If the transferor and the transferee are located in different provinces, the provincial drug regulatory authority where the transferor
is located shall issue examination opinions as well. The Center for Drug Evaluation (the &#8220;CDE&#8221;), a branch of the NMPA, shall
further review the application materials, provide technical evaluation opinions and form a comprehensive evaluation opinion based on
the on-site inspection reports and the testing results of the samples. The NMPA shall determine whether to approve the application according
to the comprehensive evaluation opinion of the CDE. An approval letter of supplementary application and a drug approval number will be
issued for qualified applications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Price
of drugs</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Drug Administration Law (&#12298;&#33647;&#21697;&#31649;&#29702;&#27861;&#12299;), for those drugs whose prices are determined
by market, manufacturers and distributors of pharmaceutical products and medical institutions shall set the prices in accordance with
the principles of fairness, rationality, and good faith, and provide consumers with drugs at reasonable prices. Pharmaceutical product
manufacturers, distributors and medical institutions shall determine and indicate their products&#8217; retail prices in accordance with
the regulations over drug prices promulgated by the pricing department of the State Council of the People&#8217;s Republic of China (the
&#8220;State Council&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 4, 2015, the National Development and Reform Commission, the National Health and Family Planning Commission, the Ministry of Human
Resources and Social Security, the Ministry of Industry and Information Technology, the Ministry of Finance, the MOFCOM and the NMPA
jointly issued the Notice Regarding Reforms to the Price of Medical Products (&#12298;&#20851;&#20110;&#21360;&#21457;&#25512;&#36827;&#33647;&#21697;&#20215;&#26684;&#25913;&#38761;&#24847;&#35265;&#30340;&#36890;&#30693;&#12299;),
pursuant to which, since June 1, 2015, other than anesthetics and Class 1 psychotropic drugs, the actual price of pharmaceutical products
shall be decided by market instead of by the government. As of the date of this annual report, the actual price of all products we sell,
including TCMD products and third-party products, are determined by market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
in relation to medical device registration</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Regulations on Supervision and Administration of Medical Devices (&#12298;&#21307;&#30103;&#22120;&#26800;&#30417;&#30563;&#31649;&#29702;&#26465;&#20363;&#12299;)
promulgated by the State Council of China with the last amendment effective on June 1, 2021, medical devices are classified based on
the invasiveness of, and risks associated with, each medical device. Class I medical devices have relatively low risks, whose safety
and effectiveness can be guaranteed through routine administration. Class II medical devices have moderate risks and require strict control
and administration to ensure their safety and effectiveness. Class III medical devices have relatively high risks and require especially
strict control and administration measures to ensure their safety and effectiveness. Pursuant to the Administrative Measures for the
Medical Devices Registration and Record (&#12298;&#21307;&#30103;&#22120;&#26800;&#27880;&#20876;&#19982;&#22791;&#26696;&#31649;&#29702;&#21150;&#27861;&#12299;),
which became effective on October 1, 2021, manufacturers of Class I medical devices are required to file with the local food and drug
administrative authority at the city level. Manufacturers of Class II medical devices shall obtain product registration certificates
from and be subject to the inspection and approval of the drug administrative authority at the provincial level. Manufacturers of Class
III medical devices shall obtain product registration certificates from the NMPA and be subject to its inspection and approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this annual report, we are engaged in the business of selling medical devices. We sell medical devices categorized as
Class I, Class II and Class III under the Regulation on Supervision and Administration of Medical Devices in the PRC, and we obtained
our medical device selling license in April 2020 in compliance with the applicable PRC laws and regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
relating to Company Establishment and Foreign Investment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PRC Company Law applies to the establishment, operation and management of both PRC domestic companies and foreign-invested enterprises.
Foreign investment in the PRC corporate entities are also regulated by the oreign-Owned Enterprise Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#36164;&#20225;&#19994;&#27861;&#12299;)
(the &#8220;Foreign-Owned Enterprise Law&#8221;) promulgated on April 12, 1986 and amended on October 31, 2000 and September 3, 2016,
the Implementing Rules for the Foreign-Owned Enterprise Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#36164;&#20225;&#19994;&#27861;&#23454;&#26045;&#32454;&#21017;&#12299;)
promulgated on December 12, 1990 and amended on April 12, 2001 and February 19, 2014, and the Interim Administrative Measures for the
Record-filing of the Incorporation and Change of Foreign-invested Enterprises (&#12298;&#22806;&#21830;&#25237;&#36164;&#20225;&#19994;&#35774;&#31435;&#21450;&#21464;&#26356;&#22791;&#26696;&#31649;&#29702;&#26242;&#34892;&#21150;&#27861;&#12299;)
(the &#8220;Record-filing Measures&#8221;) promulgated on October 8, 2016 and amended on July 30, 2017 and June 29, 2018. Under these
laws and regulations, the establishment of a wholly foreign-owned enterprise is subject to the approval of, or the filing with the MOFCOM
or its local counterpart, and such wholly foreign-owned enterprises must register and file with the appropriate administrative bureau
of industry and commerce.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Foreign Investment Law of the People&#8217;s Republic of China (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#21830;&#25237;&#36164;&#27861;&#12299;)
(the &#8220;Foreign Investment Law&#8221;), which was promulgated by the National People&#8217;s Congress On March 15, 2019, and came
into effect on January 1, 2020, provides that foreign investment refers to the investment activities in China carried out directly or
indirectly by foreign natural persons, enterprises or other organizations (the &#8220;Foreign Investors&#8221;), including the following:
(1) Foreign Investors establishing foreign-invested enterprises in China alone or collectively with other investors; (2) Foreign Investors
acquiring shares, equities, properties or other similar rights of Chinese domestic enterprises; (3) Foreign Investors investing in new
projects in China alone or collectively with other investors; and (4) Foreign Investors investing through other ways prescribed by laws
and regulations or the State Council. The State adopts the management system of pre-establishment national treatment and negative list
for foreign investment. The pre-entry national treatment means the treatment given to Foreign Investors and their investments at the
stage of investment access is not lower than that of domestic investors and their investments. The negative list management system means
that the state implements special administrative measures for access of foreign investment in specific fields. Foreign investors shall
not invest in any forbidden fields stipulated in the negative list and shall mean the conditions stipulated in the negative list before
investing in any restricted fields. The negative list is released upon approval of the State Council. After the Foreign Investment Law
came into effect, it replaced the Foreign-Owned Enterprise Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Implementation Regulations for the Foreign Investment Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#21830;&#25237;&#36164;&#27861;&#23454;&#26045;&#26465;&#20363;&#12299;)
(the &#8220;Implementation Regulations for the FIL&#8221;) was adopted at the 74th executive meeting of the State Council on December
12, 2019 and came into effect on January 1, 2020. The purpose of the Implementation Regulations for the FIL is to encourage and promote
foreign investment, protect the legitimate rights and interests of investors, regulate the administration of foreign investment, and
continuously optimize the foreign investment environment. For those foreign-invested enterprises established prior to the implementation
of the Foreign Investment Law and established in accordance with the Law of the People&#8217;s Republic of China on Sino-foreign Joint
Ventures (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#20013;&#22806;&#21512;&#36164;&#32463;&#33829;&#20225;&#19994;&#27861;&#12299;),
the Law of the People&#8217;s Republic of China on Foreign-invested Enterprises, and the Law of the People&#8217;s Republic of China
on Sino-Foreign Cooperative Enterprises, they can modify or retain their organizational forms and organizational structures in accordance
with the PRC Company Law, Partnership Law of the People&#8217;s Republic of China and other applicable laws within 5 years since the
implementation of the Foreign Investment Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
investment in China shall comply with the Catalogue for the Guidance of Foreign Investment Industries (2017 Revision) (&#12298;&#22806;&#21830;&#25237;&#36164;&#20135;&#19994;&#25351;&#23548;&#30446;&#24405;(2017&#24180;&#20462;&#35746;)&#12299;)
(the &#8220;2017 Catalogue&#8221;), which was promulgated on June 28, 2017 and became effective on July 28, 2017, and the Special Administrative
Measures for the Access of Foreign Investment (Negative List) (Edition 2018) (&#12298;&#22806;&#21830;&#25237;&#36164;&#20934;&#20837;&#29305;&#21035;&#31649;&#29702;&#25514;&#26045;(&#36127;&#38754;&#28165;&#21333;)
(2018&#24180;&#29256;)&#12299;) (the &#8220;2018 Negative List&#8221;) which were promulgated on June 28, 2018 and became effective on
July 28, 2018. The Catalogue classifies foreign-invested industries into two categories, (1) encouraged foreign-invested industries;
and (2) foreign-invested industries that are subject to the 2018 Negative List. The 2018 Negative List set out restrictions such as shareholding
requirements and qualifications of the senior management. According to the Record-filing Measures, foreign investments that are not subject
to special access administrative measures are only required to complete an online filing with the MOFCOM or its local counterpart. The
Catalogue for Encouraged Foreign Investment (2020 Revision) (&#12298;&#40723;&#21169;&#22806;&#21830;&#25237;&#36164;&#20135;&#19994;&#30446;&#24405;(2020&#24180;&#29256;)&#12299;),
or the 2020 Catalogue, and the Special Administrative Measures for the Access of Foreign Investment (Negative List) (Edition 2021) (&#12298;&#22806;&#21830;&#25237;&#36164;&#20934;&#20837;&#29305;&#21035;&#31649;&#29702;&#25514;&#26045;(&#36127;&#38754;&#28165;&#21333;)
(2021&#24180;&#29256;)&#12299;), or the 2021 Negative List, which were issued on September 18, 2021 and came into effect on December
27, 2021, further reduced restrictions on foreign investment. The 2020 Catalogue and the 2021 Negative List replaced the 2017 Catalogue
and the 2018 Negative List. The scope of our business as approved by the licensing authority and the actual scope of our business are
not subject to the restrictions set forth in the 2021 Negative List.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
M&amp;A Rules were jointly promulgated by the MOFCOM, the State-Owned Assets Supervision and Administration Commission of the State Council,
the SAT, the SAIC, the CSRC, and the SAFE on August 8, 2006 and was amended by MOFCOM on June 22, 2009. The M&amp;A Rules provides that
a foreign investor is required to obtain necessary approvals when it: (1) acquires equity interests in a domestic enterprise or subscribes
to additional shares in a domestic enterprise; (2) purchases the assets of a domestic enterprise through establishment of a foreign-invested
enterprise; or (3) establishes a foreign-invested enterprise through which it purchases the assets of a domestic enterprise and operates
these assets. In particular, any PRC company, enterprise or individual is required to obtain approval from the MOFCOM and comply with
applicable laws and regulations if it establishes an offshore company and attempts to acquire a domestic enterprise related to such offshore
company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
in relation to Intellectual Property Rights</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
terms of international conventions, China has entered into (including but not limited to) the Agreement on Trade-Related Aspects of Intellectual
Property Rights (&#12298;&#19982;&#36152;&#26131;&#26377;&#20851;&#30340;&#30693;&#35782;&#20135;&#26435;&#21327;&#23450;&#12299;), the
Paris Convention for the Protection of Industrial Property (&#12298;&#20445;&#25252;&#24037;&#19994;&#20135;&#26435;&#24052;&#40654;&#20844;&#32422;&#12299;),
the Madrid Agreement Concerning the International Registration of Marks (&#12298;&#21830;&#26631;&#22269;&#38469;&#27880;&#20876;&#39532;&#24503;&#37324;&#21327;&#23450;&#12299;)
and the Patent Cooperation Treaty (&#12298;&#19987;&#21033;&#21512;&#20316;&#21327;&#23450;&#12299;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patents</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Patent Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#19987;&#21033;&#27861;&#12299;), or the
Patent Law, promulgated by the SCNPC on March 12, 1984 and last amended on October 17, 2020 and effective from June 1, 2021 and the Implementation
Rules of the Patent Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#19987;&#21033;&#27861;&#23454;&#26045;&#32454;&#21017;&#12299;),
promulgated by the State Council on June 15, 2001 and amended on December 28, 2002 and January 9, 2010, respectively, patents in China
fall into three categories: invention patents, utility model patents and design patents. The term of patent protection starts from the
date of application and lasts 20 years for invention patents and 10 years for utility model patents and design patents. Any individual
or entity that utilizes a patent or conducts any other activity that infringes a patent without the patent holder&#8217;s authorization
shall pay compensation to the patent holder and be subject to a fine imposed by regulatory authorities and, if such behavior constitutes
a crime, shall be held criminally liable in accordance with applicable laws. According to the Patent Law, for public health purposes,
the State Intellectual Property Office of the PRC, or SIPO, may grant a compulsory license for manufacturing patented drugs and exporting
them to countries or regions covered under relevant international treaties to which PRC has acceded. In addition, under the Patent Law,
any organization or individual that applies for a patent in a foreign country for an invention or utility model patent established in
China is required to report to the SIPO for confidentiality examination. Patent holders may apply for extending the terms of patented
drugs to compensate for commercialization delays due to regulatory review, and may seek punitive damages for willful patent infringement
under severe circumstances.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trade
Secrets</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the PRC Anti-Unfair Competition Law (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21453;&#19981;&#27491;&#24403;&#31454;&#20105;&#27861;&#12299;)
promulgated by the SCNPC in September 1993, as amended on November 4, 2017 and April 23, 2019 respectively, the term &#8220;trade secrets&#8221;
refers to technical and business information that is unknown to the public, has utility, may create business interests or profits for
its legal owners or holders, and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law,
business persons are prohibited from infringing others&#8217; trade secrets by: (1) obtaining trade secrets from the legal owners or
holders by any unfair methods, such as theft, bribery, fraud, coercion, electronic intrusion, or any other illicit means; (2) disclosing,
using or permitting others to use the trade secrets obtained illegally under item (1) above; or (3) disclosing, using or permitting others
to use the trade secrets, in violation of any contractual agreements or any requirements of the legal owners or holders to keep such
trade secrets in confidence. If a third party knows or should have known of the above- mentioned illegal conduct but nevertheless obtains,
uses or discloses trade secrets of others, the third party may be deemed to have committed a misappropriation of the others&#8217; trade
secrets. The parties whose trade secrets are being misappropriated may petition for administrative corrections, and regulatory authorities
may stop any illegal activities and impose fines on the infringing parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trademarks</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the Trademark Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21830;&#26631;&#27861;&#12299;)
(the &#8220;Trademark Law&#8221;), which was promulgated by the SCNPC on August 23, 1982, and was last amended on April 23, 2019 and
came into effect on November 1, 2019, any trademark which is registered with the approval of the Trademark Office is a registered trademark,
including commodity trademark, service trademark, collective trademark, certification trademark, and the trademark registrant has the
exclusive right to use a registered trademark and such right is protected by law. A registered trademark is valid for a period of 10
years commencing from the date on which the registration is approved. Upon expiration of the trademark, the registrant shall apply for
renewal within twelve months prior to the expiration date if it intends to maintain exclusive use of the trademark. If the registrant
fails to apply for renewal, a grace period of six months may be granted. In the absence of a renewal upon the expiration of a trademark
registration, the registered trademark shall be canceled. Use of a trademark that is identical with or similar to a registered trademark,
for the same kind of or similar commodities, without authorization of the trademark registrant, constitutes infringement of the exclusive
right to use a registered trademark. Industrial and commercial administrative authorities have the authority to investigate any behavior
that may constitute an infringement of the exclusive right under a registered trademark.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Domain
names</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Domain
names are protected under the Administrative Measures on the Internet Domain Names (&#12298;&#20114;&#32852;&#32593;&#22495;&#21517;&#31649;&#29702;&#21150;&#27861;&#12299;),
which was promulgated by the Ministry of Industry and Information Technology, or the MIIT, on August 24, 2017 and came into effect on
November 1, 2017, and the Implementing Rules of China Internet Network Information Center on the Registration of Domain Names (&#12298;&#20013;&#22269;&#20114;&#32852;&#32593;&#32476;&#20449;&#24687;&#20013;&#24515;&#22495;&#21517;&#27880;&#20876;&#23454;&#26045;&#32454;&#21017;&#12299;)
issued by China Internet Network Information Center (the &#8220;CNNIC&#8221;) on May 28, 2012 and came into effect on May 29, 2012. Domain
name registrations are handled through domain name service agencies established under the relevant regulations, and the applicant becomes
domain name holder upon successful registration. Domain name disputes shall be submitted to an organization authorized by CNNIC for resolution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
laws</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
Liability</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Product Quality Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#20135;&#21697;&#36136;&#37327;&#27861;&#12299;),
promulgated by the SCNPC on February 22, 1993 and last amended on December 29, 2018, governs the supervision and administration of product
quality and specifies the liabilities of manufacturers and sellers. A manufacture shall be liable for compensating for any bodily injuries
or property damages, other than the defective product itself, resulting from the defects in the product, unless the manufacturer is able
to prove that: (1) the product has never been distributed; (2) the defects causing injuries or damage did not exist at the time when
the product was distributed; or (3) the science and technology at the time when the product was distributed was at a level incapable
of detecting the defects. A seller shall pay compensation if it fails to indicate either the manufacturer or the supplier of the defective
product. A person who is injured or whose property is damaged by the defects in the product may claim for compensation from the manufacturer
or the seller.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Civil Code of the People&#8217;s Republic of China (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#27665;&#27861;&#20856;&#12299;),
promulgated by the SCNPC on May 28, 2020 and became effective on January 1, 2021, manufacturers shall assume tort liabilities where the
defects in products cause damage to others. Sellers shall assume tort liability where the defects in products that have caused damage
to others are attributable to the sellers. The aggrieved party may claim for compensation from the manufacturer or the seller of the
defected product that has caused damage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Environmental
Protection</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Environmental Protection Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#29615;&#22659;&#20445;&#25252;&#27861;&#12299;)
promulgated by the SCNPC on December 26, 1989 and amended on April 24, 2014, the Environmental Impact Assessment Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#29615;&#22659;&#24433;&#21709;&#35780;&#20215;&#27861;&#12299;),
promulgated by the SCNPC on October 28, 2002 and amended on July 2, 2016 and December 29, 2018 respectively, the Administrative Regulations
on the Environmental Protection of Construction Project (&#12298;&#24314;&#35774;&#39033;&#30446;&#29615;&#22659;&#20445;&#25252;&#31649;&#29702;&#26465;&#20363;&#12299;)
promulgated by the State Council on November 29, 1998 and amended on July 16, 2017, and other applicable environmental laws and regulations,
an enterprise with a project construction plan shall submit an environmental impact assessment report, stating the environmental impacts
the project is likely to have, to the administrative authority of environmental protection for approval. Enterprises shall engage qualified
institutions to issue the environmental impact assessment reports.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Law of the PRC on the Prevention and Control of Water Pollution (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#27700;&#27745;&#26579;&#38450;&#27835;&#27861;&#12299;)
promulgated by the SCNPC on May 11, 1984 and last amended on June 27, 2017, and effective on January 1, 2018, the Law of the PRC on the
Prevention and Control of Atmospheric Pollution (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22823;&#27668;&#27745;&#26579;&#38450;&#27835;&#27861;&#12299;)
promulgated by the SCNPC on September 5, 1987 and last amended on October 26, 2018, the Law of the PRC on the Prevention and Control
of Pollution from Environmental Noise (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#29615;&#22659;&#22122;&#22768;&#27745;&#26579;&#38450;&#27835;&#27861;&#12299;)
promulgated by the SCNPC on October 29, 1996 and amended on December 29, 2018, and the Law of the PRC on the Prevention and Control of
Environmental Pollution of Solid Waste (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22266;&#20307;&#24223;&#29289;&#27745;&#26579;&#29615;&#22659;&#38450;&#27835;&#27861;&#12299;),
promulgated by the SCNPC on October 30, 1995 and last amended on April 29, 2020, all the enterprises that may cause environmental pollution
in the course of their business operation shall implement preventive and curative environmental protection measures in their plants and
establish a reliable environmental protection system.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strictly complied with the applicable environmental laws and regulations in constructing our factory. On December 8, 2004, the environmental
protection bureau of local government determined that the environmental protection facilities we constructed for our factory satisfied
the relevant standards. According to the certificate issued by the ecological environment bureau of local government (the &#8220;Bureau&#8221;),
our factory has not been assessed on its environmental impacts since its establishment in 2004. Although there were certain procedural
defects in the original construction process, we constructed our environmental protection facilities for our factory in strict compliance
with the requirements of applicable PRC environmental laws and regulations. Our environmental protection facilities were approved by
the Bureau in December 2004 and have since been under normal operations. As of the date of the date of this annual report, we have not
been found in violation of applicable environmental laws or regulations, or imposed of administrative penalties by environmental protection
authorities in the past three years. No environmental pollution incident has occurred on our manufacturing facility.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Exchange Control</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Foreign Exchange Administration Regulations of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#27719;&#31649;&#29702;&#26465;&#20363;&#12299;),
as amended on August 5, 2008, and the Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment (&#12298;&#32467;&#27719;&#12289;&#21806;&#27719;&#21450;&#20184;&#27719;&#31649;&#29702;&#35268;&#23450;&#12299;),
or the Settlement Regulations, promulgated by the People&#8217;s Bank of China on June 20, 1996 and came into effect on July 1, 1996,
foreign exchanges required for profit distributions and dividend payments may be purchased from designated foreign exchange banks in
the PRC upon presentation of a board resolution authorizing distribution of profits or payment of dividends.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Notice of SAFE on Further Improving and Adjusting Foreign Exchange Administration Policies on Direct Investment (&#12298;&#22269;&#23478;&#22806;&#27719;&#31649;&#29702;&#23616;&#20851;&#20110;&#36827;&#19968;&#27493;&#25913;&#36827;&#21644;&#35843;&#25972;&#30452;&#25509;&#25237;&#36164;&#22806;&#27719;&#31649;&#29702;&#25919;&#31574;&#30340;&#36890;&#30693;&#12299;)
(the &#8220;Circular No. 59&#8221;), promulgated on November 19, 2012 and last amended on December 30, 2019 by the State Administration
of Exchange Control, or the SAFE, (1) the opening of and payment into foreign exchange accounts under direct investment accounts are
no longer subject to approval by the SAFE; (2) reinvestment with legal income of foreign investors in China is no longer subject to approval
by SAFE; (3) the procedures for capital verification and confirmation that foreign-funded enterprises need to go through are simplified;
(4) purchase and external payment of foreign exchange under direct investment accounts are no longer subject to approval by SAFE; (5)
domestic transfer of foreign exchange under direct investment account is no longer subject to approval by SAFE; and (6) the administration
over the conversion of foreign exchange capital of foreign-invested enterprises is improved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Circular on Further Simplifying and Improving the Direct Investment-related Foreign Exchange Administration Policies (&#12298;&#20851;&#20110;&#36827;&#19968;&#27493;&#31616;&#21270;&#21644;&#25913;&#36827;&#30452;&#25509;&#25237;&#36164;&#22806;&#27719;&#31649;&#29702;&#25919;&#31574;&#30340;&#36890;&#30693;&#12299;)
(the &#8220;SAFE Circular No. 13&#8221;), which was promulgated on February 13, 2015 and became effective on June 1, 2015, the foreign
exchange registration under domestic direct investment and the foreign exchange registration under foreign direct investment is directly
reviewed and handled by banks in accordance with the Circular No. 13, and the SAFE and its branches shall perform indirect regulation
over the foreign exchange registration via banks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises
(&#12298;&#22269;&#23478;&#22806;&#27719;&#31649;&#29702;&#23616;&#20851;&#20110;&#25913;&#38761;&#22806;&#21830;&#25237;&#36164;&#20225;&#19994;&#22806;&#27719;&#36164;&#26412;&#37329;&#32467;&#27719;&#31649;&#29702;&#26041;&#24335;&#30340;&#36890;&#30693;&#12299;)
promulgated by the SAFE on March 30, 2015 and became effective on June 1, 2015, and the Circular on the Reform and Standardization of
the Management Policy of the Settlement of Capital Projects (&#12298;&#22269;&#23478;&#22806;&#27719;&#31649;&#29702;&#23616;&#20851;&#20110;&#25913;&#38761;&#21644;&#35268;&#33539;&#36164;&#26412;&#39033;&#30446;&#32467;&#27719;&#31649;&#29702;&#25919;&#31574;&#30340;&#36890;&#30693;&#12299;)
promulgated by the SAFE on June 9, 2016, the settlement of foreign exchange by foreign invested enterprises shall be governed by the
policy of foreign exchange settlement on a discretionary basis. However, the settlement of foreign exchange shall only be used for its
own operation purposes within the business scope of the foreign invested enterprises in accordance with the principle of authenticity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Circular 37, a PRC resident shall register with the local SAFE branch before he or she contributes assets or equity interests
in an overseas special purpose vehicle (&#8220;Overseas SPV&#8221;) , that is directly established or controlled by the PRC Resident
for the purpose of conducting investment for financing. Failure to comply with the SAFE registration requirements could result in penalties
for evasion of foreign exchange controls. The Circular No. 13 provides that banks can directly handle the initial foreign exchange registration
and amendment registration under the Circular 37. Mr. Gang Lai completed the initial foreign registration on June 3, 2019.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Labor
and Social Insurance</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Labor Contract Law (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#21512;&#21516;&#27861;&#12299;),
which was promulgated by the SCNPC on June 29, 2007 and became effective on January 1, 2008, and amended on December 28, 2012 and became
effective on July 1, 2013, and the Implementing Regulations of the Labor Contracts Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#21512;&#21516;&#27861;&#23454;&#26045;&#26465;&#20363;&#12299;),
which was promulgated by the State Council on September 18, 2008, labor contracts shall be concluded in writing if employment relationships
are to be or have been established between employers and employees. In addition, employee wages cannot be lower than local standards
on minimum wages.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Labor Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#27861;&#12299;), which
was promulgated by the SCNPC on July 5, 1994 and last amended and came into effect on December 29, 2018, employers shall establish and
improve their system of workplace safety and sanitation, strictly abide by state rules and standards on workplace safety, educate employees
in occupational safety and sanitation in the PRC. Occupational safety and sanitation facilities shall comply with state-fixed standards.
Enterprises and institutions shall provide employees whose work involves occupational hazards with health examinations on a regular basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Social Insurance Law, the Interim Regulations on the Collection and Payment of Social Security Funds (&#12298;&#31038;&#20250;&#20445;&#38505;&#36153;&#24449;&#32564;&#26242;&#34892;&#26465;&#20363;&#12299;),
which was promulgated by the State Council on January 22, 1999 and amended on March 24, 2019, and the Administrative Regulations on the
Housing Provident Funds (&#12298;&#20303;&#25151;&#20844;&#31215;&#37329;&#31649;&#29702;&#26465;&#20363;&#12299;), which was promulgated
by the State Council on April 3, 1999 and last amended on March 24, 2019, employers are required to make contributions, on behalf of
their employees, to a number of social security funds, including funds for basic pension insurance, unemployment insurance, basic medical
insurance, occupational injury insurance, maternity insurance and to housing provident funds. Any employer who fails to make contributions
may be fined and ordered to make good the deficit within a stipulated time limit.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to April 2020, we only contributed to the social insurance and housing provident funds for some, but not all, of our employees. There
is a risk that the labor security administration authority may take enforcement action to collect from us all the outstanding contributions
of the social insurance and housing provident funds required to be made for the employees in the past, and we may be subject to a late
charge at the rate of 0.2% per day on the total outstanding contribution. We started to contribute to the social insurance and housing
provident funds for all of our employees since April 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
April 2020, we have been contributing to the social insurance and housing provident funds for our employees in accordance with the minimum
contribution requirements. Pursuant to the aforementioned applicable laws and regulations, the government or an employee has the right
to demand us to contribute to the employee&#8217;s social insurance and housing provident funds calculated based on his or her actual
salary, and an employee who has not received contributions from us has the right to demand us to contribute to his or her social insurance
and housing provident funds. As confirmed in writing by the local government, our contributions of the social insurance and housing provident
funds are in compliance with the PRC laws and the local regulations and policies, and therefore the local government is very unlikely
to impose any penalty on us for our contributions since April 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Enterprise
Income Tax</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the EIT Law, promulgated by the National People&#8217;s Congress on March 16, 2007, effective on January 1, 2008 and last amended
on December 29, 2018, and the Implementation Regulations for the Enterprise Income Tax Law of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#20225;&#19994;&#25152;&#24471;&#31246;&#27861;&#23454;&#26045;&#26465;&#20363;&#12299;)
promulgated by the State Council on December 6, 2007 and amended on April 23, 2019, other than a few exceptions, the income tax rate
for both domestic enterprises and foreign-invested enterprises is 25%. Enterprise taxpayers are classified as either resident enterprises
or non-resident enterprises. Resident enterprises are defined as enterprises that are established in China in accordance with PRC laws,
or that are established in accordance with the laws of foreign countries but whose actual or de facto management bodies are located in
China. Non-resident enterprise refers to an entity established under foreign law whose de facto management bodies are not within the
PRC but which have an establishment or place of business in the PRC, or which do not have an establishment or place of business in the
PRC but have income sourced within the PRC. An income tax rate of 10% will normally be applicable to dividends declared to non-PRC resident
enterprise investors that do not have an establishment or place of business in the PRC, or that have such establishment or place of business
but the relevant income is not effectively connected with the establishment or place of business, to the extent such dividends are derived
from sources within the PRC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Arrangement between the Mainland of China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation
and Prevention of Fiscal Evasion with respect to Taxes on Incomes (&#12298;&#20869;&#22320;&#21644;&#39321;&#28207;&#29305;&#21035;&#34892;&#25919;&#21306;&#20851;&#20110;&#23545;&#25152;&#24471;&#36991;&#20813;&#21452;&#37325;&#24449;&#31246;&#21644;&#38450;&#27490;&#20599;&#28431;&#31246;&#30340;&#23433;&#25490;&#12299;),
or the Double Tax Avoidance Arrangement, and other applicable PRC laws, 5% withholding tax rate shall apply to the dividends paid by
a PRC company to a Hong Kong resident, provided that such Hong Kong resident directly holds at least 25% of the equity interests in the
PRC company, and 10% of withholding tax rate shall apply if the Hong Kong resident holds less than 25% of the equity interests in the
PRC company. However, pursuant to the Circular on Certain Issues Relating to the Implementation of Dividend Provisions in Tax Treaties
(&#12298;&#20851;&#20110;&#25191;&#34892;&#31246;&#25910;&#21327;&#23450;&#32929;&#24687;&#26465;&#27454;&#26377;&#20851;&#38382;&#39064;&#30340;&#36890;&#30693;&#12299;)
issued on February 20, 2009 by the SAT, if a PRC tax authority determines, in its discretion, that a company benefits from such reduced
income tax rate as a result of an arrangement that is primarily tax-driven, such PRC tax authority may adjust the preferential tax treatment
of the company. Based on the Announcement on Certain Issues with Respect to the Beneficial Owner in Tax Treaties (&#12298;&#22269;&#23478;&#31246;&#21153;&#24635;&#23616;&#20851;&#20110;&#31246;&#25910;&#21327;&#23450;&#20013;&#21463;&#30410;&#25152;&#26377;&#20154;&#26377;&#20851;&#38382;&#39064;&#30340;&#20844;&#21578;&#12299;)
issued by the SAT on February 3, 2018 and effective on April 1, 2018, if an applicant&#8217;s business activities do not constitute substantive
business activities, it could result in the negative determination of the applicant&#8217;s status as a beneficial owner, and consequently,
the applicant could be precluded from enjoying the above-mentioned reduced income tax rate of 5% under the Double Tax Avoidance Arrangement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
<span style="text-decoration:underline">Organizational Structure</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;&#8212;A. History and Development of the Company.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">D.
Property, Plants and Equipment</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;&#8212;B. Business Overview&#8212;Properties and Facilities.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
4A. UNRESOLVED STAFF COMMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion of our financial condition and results of operations is based upon and should be read in conjunction with our consolidated
financial statements and their related notes included in this annual report. This report contains forward-looking statements. In evaluating
our business, you should carefully consider the information provided under the caption &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221;
in this annual report. We caution you that our businesses and financial performance are subject to substantial risks and uncertainties.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
<span style="text-decoration:underline">Operating Results</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pharmaceutical company specializing in the development, manufacturing, marketing and sale of TCMD products targeted to the elderly
to address their physical conditions in the aging process and to promote their general well-being. We have registered and obtained approval
for 26 varieties of TCMD products from the NMPA, and we currently produce 13 varieties of TCMD products and sell them in 202 cities in
30 provinces in China as of the date of this annual report. In addition, we also sell biomedical drugs, medical instruments, TCMPs and
dietary supplements manufactured by third-party pharmaceutical companies (collectively referred to as &#8220;third-party products&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
major customers are pharmaceutical distributors, hospitals, clinics and drugstore chains, primarily located in Jiangxi Province, Jiangsu
Province, Guangdong Province, Hubei Province, Fujian Province, Guangxi Province and Shandong Province, and 23 other provinces in China.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been profitable since 2015 and we believe we are well-positioned to benefit from the rapid growth of the TCMD market in China and
to leverage the leading market position of our flagship products in order to further grow our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent developments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Completion
of the Initial Public Offering (&#8220;IPO&#8221;)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 25, 2021, we closed our IPO of 5,000,000 ordinary shares, par value $0.003125 per share at a public offering price of $5.00 per
share. On March 29, 2021, the underwriter exercised in full its over-allotment option to purchase an additional 750,000 ordinary shares.&#160;<span>The
closing for the sale of the over-allotment shares took place on March 31, 2021. Gross proceeds of our IPO, including the proceeds from
the sale of the over-allotment shares, totaled $28.75 million, before deducting underwriting discounts and other related expenses</span>.
Net proceeds of our IPO, including over-allotment shares, were approximately $25.6 million. In connection with the IPO, our ordinary
shares began trading on the Nasdaq Global Market&#160;under the symbol &#8220;UPC&#8221; on March 23, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Newly
Established Subsidiary</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2021, through our PRC subsidiary, Jiangxi Universe, we established a wholly owned subsidiary, Guangzhou Universe Hanhe Medical
Research Co., Ltd. (&#8220;Universe Hanhe&#8221;) in Guangzhou City, China, for the purpose of conducting research and development of
new pharmaceutical products in order to diversify our product offerings in the near future. As of the date of this annual report, Universe
Hanhe has no active business operations.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prepayment
for Construction-in-progress Project (the &#8220;CIP Project&#8221;)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 25, 2021, we entered into a construction contract with a sub-contractor, Jiangxi Chenyuan Construction Project Co., Ltd. (&#8220;Chenyuan&#8221;),
pursuant to which, Chenyuan will construct four manufacturing plants and an office building with a total maximum budget of RMB165 million
(approximately $25.5 million). The construction work started on August 8, 2021, with an estimated completion date on August 8, 2023.
As of September 30, 2021, we had made prepayment of approximately RMB69.2 million (approximately $10.7 million) to Chenyuan to start
the construction, including land improvement, building foundation and the construction of the manufacturing plants. As of September 30,
2021, the $10.7 million prepayment to Chenyuan was recorded as prepayment for CIP Project on the balance sheets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2021, future additional capital
expenditure on this CIP Project was estimated to be approximately RMB95.8 million (equivalent to $14.8 million), among which approximately
$3.8 million is required for the 12 months ending September 30, 2022. The Company currently plans to support its ongoing CIP Project through
cash flows from operations, proceeds received from the IPO, and if necessary, borrowings from banks. The CIP Project is expected to be
fully completed, and the new manufacturing plants and office building are expected to be put into use by August 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For a discussion of potential risks associated with
our construction agreement and the CIP Project, see &#8220;Item 3. Key Information &#8212; D. Risk Factors &#8212; Risks Related to Our
Business and Industry &#8212; Our future success depends in part on our ability to increase our production capacity, and we may not able
to do so in a cost-effective manner. We have engaged a third-party sub-contractor to build manufacturing facilities and an office building
for us, and we may encounter challenges relating to the construction, management and operation of such facilities.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Prepayment for Advertising</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 6, 2021, we entered into an advertising
service agreement with a third party, Guangdong Fengyang Legend Consulting Co., Ltd. (&#8220;Fengyang Legend&#8221;), pursuant to which
Fengyang Legend agreed to assist us in developing and producing a TV advertisement for promoting our representative TCMD products, Bai
Nian Dan and Guben Yanling Pill, and coordinating with a TV channel to broadcast the advertisement to targeted geographic market areas.
The total advertising service fee under this agreement is RMB55 million (approximately $8.5 million) with a service period of one year,
from October 1, 2021 to September 30, 2022. Pursuant to the terms under this agreement, we made an advance payment in the amount of 30%
of the total advertising service fee to Fengyang Legend, and we will be required to pay Fengyang Legend in the amount of 58% of the total
advertising service fee once the TV channel on which the advertisement will be broadcasted is determined. As of September 30, 2021, a
total of RMB48.4 million (approximately $7.5 million) had been paid to Fengyang Legend and was recorded as prepayment for advertising
services on the balance sheets. Such prepayment had been expensed when the advertising was first broadcasted in October 2021. The remaining
RMB6.6 million (approximately $1 million) represents the monthly advertising fees to be paid in 13 installments throughout the period
when the advertisement is broadcasted through the designated TV channel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For a discussion of potential risks associated with
our advertising service agreement, see &#8220;Item 3. Key Information &#8212; D. Risk Factors &#8212; Risks Related to Our Business and
Industry &#8212; We have made substantial investment in advertising our products in order to improve our brand awareness and our market
position, which efforts may not be successful, and in such event, our financial position and results of operations may be materially and
negatively affected.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Entry
Into a Strategic Cooperation Agreement with a Japanese Pharmaceutical Company</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2021, we entered into certain agreements (the &#8220;Agreements&#8221;) with Kitanihon Pharmaceutical Co., Ltd. (&#8220;Kitanihon&#8221;),
a Japanese pharmaceutical company, pursuant to which (i) both parties will build a manufacturing facility in Ji&#8217;an, Jiangxi, China,
for the manufacturing and research and development of traditional Chinese medicine derivatives products, with an aggregate area of over
430,000 square feet, and the Company will bear the costs associated with building the facility, and (ii) the Company will purchase 464
shares of Kitanihon for an aggregate of JPY176.32 million (approximately US$1.56 million).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
relation to the Agreements, Sununion Holding Group Limited (&#8220;Sununion&#8221;), the controlling shareholder of the Company wholly
owned by Mr. Gang Lai, the chief executive officer and chairman of the board of directors of the Company, entered into an agreement with
Mr. Gang Lai and Kitanihon on December 1, 2021, pursuant to which Kitanihon authorizes the Company to use certain of its intangible assets,
including technologies and certain intellectual properties, in exchange for which Mr. Gang Lai will transfer ordinary shares of Sununion
owned by him and valued at US$2.5 million to Kitanihon. The share transfer is currently in progress.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>COVID-19
Impact</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations have been affected and may continue to be affected by the ongoing COVID-19 pandemic.&#160;Although we resumed our
operations since early March 2020 and the impact of COVID-19 on our operating results and financial performance for the fiscal years
2020 and 2021 were minimal any resurgence could negatively affect the execution of customer contracts, the collection of customer payments,
or disrupt our supply chain, and the continued uncertainties associated with the COVID 19 pandemic may cause our revenue and cash flows
to underperform in the next 12 months from the date of this annual report. The extent of the future impact of the COVID-19 pandemic on
our business and results of operations is still uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Factors that Affect Our Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the following key factors may affect our financial condition and results of operations:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Ability to Attract Additional Customers and Increase the Spending Per Customer</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
major customers are pharmaceutical distributors, hospitals, clinics and drugstore chains. We currently sell our products to these customers
in 202 cities in 30 provinces in China, with significant customers located in Jiangxi Province, Jiangsu Province, Guangdong Province,
Hubei Province, Fujian Province, Guangxi Province and Shandong Province in China. For the years ended September 30, 2021, 2020 and 2019,
we had a total of 2,708, 2,209 and 2,603 customers, respectively, and no single customer accounted for more than 10% of our total revenue
of any of these fiscal years. However, our top 10 customers in the aggregate accounted for 30.4%, 33.3% and 34.5% of our total revenues
for the years ended September 30, 2021, 2020 and 2019, respectively. Our dependence on a small number of larger customers could expose
us to the risk of substantial losses if a single large customer stops purchasing our products, purchases fewer of our products or goes
out of business and we cannot find substitute customers on equivalent terms. If any of our significant customers reduces the quantity
of the products they purchase from us or stops purchasing from us, our net revenues would be materially and adversely affected. Therefore,
the success of our business in the future depends on our effective marketing efforts to expand our distribution network including additional
cities and rural areas in the PRC in an effort to increase our geographic appearance. The success of expansion will depend upon many
factors, including our ability to form relationships with, and manage an increasing number of, customers base and optimize our distribution
network. If our marketing efforts fail to convince customers to accept our products, we may find it difficult to maintain the existing
level of sales or to increase such sales. Should this happen, our net revenues would decline and our growth prospectus would be severely
impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Ability to Increase Awareness of Our Brand and Develop Customer Loyalty</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our brands, such as &#8220;Bai Nian Dan
(</span><span style="font-family: MS Mincho">&#30334;&#24180;&#20025;</span><span style="font-family: Times New Roman, Times, Serif">)&#8221;
and &#8220;Hu Zhuo Ren (</span><span style="font-family: MS Mincho">&#32993;&#21331;&#20161;</span><span style="font-family: Times New Roman, Times, Serif">)&#8221;,
are well-recognized among our clients and other Chinese medicine industry players. Our brand is integral to our sales and marketing efforts.
We believe that maintaining and enhancing our brand name recognition in a cost-effective manner is critical to achieving widespread acceptance
of our current and future products and is an important element in our effort to increase our customer base. Successful promotion of our
brand name will depend largely on our marketing efforts and ability to provide reliable and quality products at competitive prices. Brand
promotion activities may not necessarily yield increased revenue, and even if they do, any increased revenue may not offset the expenses
we will incur in marketing activities. If we fail to successfully promote and maintain our brand, if we incur substantial expenses in
an unsuccessful attempt to promote and maintain our brand, or if we fail to generate the desired level of brand recognition and awareness
through our recent television advertising efforts, or at all, we may fail to attract new customers or retain our existing customers, in
which case our business, operating results and financial condition, would be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Ability to Control Costs and Expenses and Improve Our Operating Efficiency</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business growth is dependent on our ability to attract and retain qualified and productive employees, identify business opportunities,
secure new contracts with customers and our ability to control costs and expenses to improve our operating efficiency. Our inventory
costs (including raw materials, labor, packaging cost, depreciation and amortization, freight costs, overhead and third-party products
purchase costs) have a direct impact on our profitability. The raw materials used in manufacturing of our TCMD products are subject to
price volatility and inflationary pressures. Our success is dependent, in part, on our ability to reduce our exposure to increase in
those costs through a variety of ways, while maintaining and improving margins and market share. We also rely on third-party manufacturers
as a source for a portion of components for a portion of components for our products. These manufacturers are also subject to price volatility
and labor cost and other inflationary pressures, which may, in turn, result in an increase in the amount we pay for sourced products.
Raw materials and sourced product price increases may offset our productivity gains and price increases and may adversely impact our
financial results. In addition, our staffing costs (including payroll and employee benefit expense) and administrative expenses also
have a direct impact on our profitability. Our ability to drive the productivity of our staff and enhance our operating efficiency affects
our profitability. To the extent that the costs we are required to pay to our suppliers and our staffs exceed our estimates, our profit
may be impaired. If we fail to implement initiatives to control costs and improve our operating efficiency over time, our profitability
will be negatively impacted.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Ability to Compete Successfully</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chinese patent medicine industry we are in is highly competitive and evolving in China. The development and commercialization of new
pharmaceutical products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant
competition and a strong emphasis on intellectual property. We will face competition with respect to our current and future pharmaceutical
product candidates from major pharmaceutical companies in China. Potential competitors also include academic institutions, government
agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative
arrangements for research, development, manufacturing and commercialization of pharmaceutical products. Some of our current or potential
competitors may have significantly greater financial resources and expertise in research and development, manufacturing, product testing,
obtaining regulatory approvals and marketing approved products than we do, and in the event that any of these happens, our competitors
may be able to establish a strong market position before our new products are able to enter the market. Additionally, technologies developed
by our competitors may render our product candidates uneconomical or obsolete. If we do not compete effectively, our operating results
could be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
Severe or Prolonged Slowdown in the Global or Chinese Economy Could Materially and Adversely Affect Our Business and Our Financial Condition</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rapid growth of the Chinese economy has slowed down since 2012 and this slowdown may continue in the future. There is considerable uncertainty
over trade conflicts between the United States and China and the long-term effects of the expansionary monetary and fiscal policies adopted
by the central banks and financial authorities of some of the world&#8217;s leading economies, including the United States and China.
The withdrawal of these expansionary monetary and fiscal policies could lead to a contraction. There continue to be concerns over unrest
and terrorist threats in the Middle East, Europe, and Africa, which have resulted in volatility in oil and other markets. There are also
concerns about the relationships between China and other Asian countries, which may result in or intensify potential conflicts in relation
to territorial disputes. The eruption of armed conflict could adversely affect global or Chinese discretionary spending, either of which
could have a material and adverse effect on our business, results of operation in financial condition. Economic conditions in China are
sensitive to global economic conditions, as well as changes in domestic economic and political policies and the expected or perceived
overall economic growth rate in China. Any severe or prolonged slowdown in the global or Chinese economy would likely materially and
adversely affect our business, results of operations and financial condition. In addition, continued turbulence in the international
markets may adversely affect our ability to access capital markets to meet liquidity needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COVID-19
Impact</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations has been affected and may continue to be affected by the ongoing COVID-19 pandemic.&#160;Although we resumed our
operations since early March 2020 and the impact of COVID-19 on our operating results and financial performance for the fiscal years
2020 and 2021 were minimal any resurgence could negatively affect the execution of customer contracts, the collection of customer payments,
or disrupt our supply chain, and the continued uncertainties associated with COVID 19 may cause our revenue and cash flows to underperform
in the next 12 months from the date of this annual report. The extent of the future impact of the COVID-19 pandemic on our business and
results of operations is still uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i>&#160;</i></b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Financial Performance Indicators </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing our financial performance, we consider a variety of financial performance measures, including principal growth in net revenue
and gross profit, our ability to control costs and operating expenses to improve our operating efficiency and net income. Our review
of these indicators facilitates timely evaluation of the performance of our business and effective communication of results and key decisions,
allowing our business to respond promptly to competitive market conditions and different demands and preferences from our customers.
The key measures that we use to evaluate the performance of our business are set forth below and are discussed in greater details under
&#8220;&#8212;Results of Operations&#8221;:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Net Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our revenue is reported net of all value added
taxes (&#8220;VAT&#8221;). Our products are sold with no right of return and we do not provide other credits or sales incentive to customers.
Our revenue is driven by changes in the number of customers, sales volume, selling price, and mix of products sold.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0in; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance<br/>
 comparing<br/>
 2021 to 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance<br/>
 comparing<br/>
 2020 to 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; width: 40%; text-align: left">Revenue from sales of self-manufactured TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">61.6</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">59.8</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">62.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.8</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(3.1</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0in; text-align: left; padding-bottom: 1.5pt">Revenue from sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.8</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: left; padding-bottom: 4pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; padding-bottom: 1.5pt">Number of customers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,708</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,603</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: left">Sales volume by unit- TCMD products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,206,150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,652,999</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,766,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11.9</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0in; text-align: left; padding-bottom: 1.5pt">Sales volume by unit- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,364,391</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,763,577</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,734,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4.6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: left; padding-bottom: 4pt">Total sales volume</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">25,570,541</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24,416,576</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">25,500,882</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.7</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(4.3</td><td style="padding-bottom: 4pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; padding-bottom: 1.5pt">Average selling price per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.72</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0in; padding-bottom: 1.5pt">Average selling price per unit- Third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.59</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">79.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from sales of TCMD products manufactured by us accounted for 61.6%,
59.8% and 62.9% of our total revenues for the fiscal years ended September 30, 2021, 2020 and 2019, respectively. The 13 TCMD products
manufactured by us fall into two categories: chronic condition treatments and cold and flu medications. Our chronic condition treatments
primarily include Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid, Fengtong Medicinal
Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal Liquor, and our cold
and flu medications primarily include Paracetamol Granule for Children, Isatis Root Granule and Qiangli Pipa Syrup.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales volume of our TCMD products increased by
1,553,151 units, or 9.9%, from 15,652,999 units sold in fiscal year 2020 to 17,206,150 units sold in fiscal year 2021. The number of customers
purchasing our products increased by 22.6%, from 2,209 customers in fiscal year 2020 to 2,708 customers in fiscal year 2021. The increase
in the number of customers in fiscal year 2021 led to an increased number of customer orders for our products, resulting in increased
sales volume of our TCMD products. Among the increase in total sales volume of 1,553,151 units, most of such increase related to our cold
and flu medications because of strong market demand. The average selling price of our TCMD products increased by 46.3%, from $1.17 per
unit in fiscal year 2020 to $1.72 per unit in fiscal year 2021, because we increased selling prices of our TCMD products in response to
increased raw material costs and general inflation. These factors led to an increase in our revenue from sales of our TCMD products from
fiscal year 2020 to fiscal year 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales volume of our TCMD products decreased by
2,113,550 units, or 11.9%, from 17,766,549 units sold in fiscal year 2019 to 15,652,999 units sold in fiscal year 2020. The decrease in
our sales volume was twofold: (i) due to the outbreak and spread of COVID-19, we temporarily closed down our manufacturing facilities
and we had limited support from our employees during the period from February to early March 2020, and as a result, we were unable to
timely fulfill the orders of our customer during this period of time; and (ii) among the decrease in total sales volume of 2,113,550 units,
99% of such decrease related to our cold and flu medications because of strong market competition. The average selling price of our TCMD
products decreased by 0.5%, from $1.18 per unit in fiscal year 2019 to $1.17 per unit in fiscal year 2020, because we lowered the selling
price of certain TCMD products in order to promote the sales. In addition, the number of our customers decreased by 15.1%, from 2,603
in fiscal year 2019 to 2,209 in fiscal year 2020, because we experienced delay in shipping and delivering our products to our customers
located in remote geographic areas as a result of the COVID-19 related transportation restrictions. These factors led to a 12.1% decrease
in our revenue from sales of our TCMD products from fiscal year 2019 to fiscal year 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 58; Options: NewSection; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to diversify our product offerings and
product mix, in addition to selling self-manufactured TCMD products, we also sell products manufactured by third-party pharmaceutical
companies, including (i) biomedical drugs, such as liquid glucose, prednisolone, and citicoline, (ii) medical instruments, such as drug-eluting
stents, surgical tubes and syringes, (iii) TCMPs, such as red sage tables, Longdan Xiegan pills, and Chinese skullcap capsules, and (iv)
dietary supplements, such as vitamins, probiotic powder, and calcium tablets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from sales of third-party products accounted
for 38.4%, 40.2% and 37.1% of our total revenues for the fiscal years ended September 30, 2021, 2020 and 2019, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales volume of third-party products decreased
by 399,186 units, or 4.6%, from 8,763,577 units sold in fiscal year 2020 to 8,364,391 units sold in fiscal year 2021, because we put more
efforts in promoting the sales of our TCMD products in fiscal year 2021. The average selling price of third-party products increased by
79.6%, from $1.41 per unit in fiscal year 2020 to $2.20 per unit in fiscal year 2021, due to increased purchase costs of third-party products,
as affected by the COVID-19 pandemic and general inflation, and the changes in product mix based on customer orders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales volume of third-party products increased
by 1,029,244 units, or 13.3%, from 7,734,333 units sold in fiscal year 2019 to 8,763,577 units sold in fiscal year 2020, while the average
selling price of third-party products decreased by 11.5% from $1.59 per unit in fiscal year 2019 to $1.41 per unit in fiscal year 2020,
as affected by changes in product mix based on customer orders. These factors led to a 0.04% decrease in our revenue from sales of our
third-party products from fiscal year 2019 to in fiscal year 2020. To compensate the negative impact from the COVID-19 pandemic, we increased
our purchase of third party products to fulfill our sales orders in fiscal year 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For future third-party product sales, our strategy
is to select and distribute certain high-quality products with higher margin. We do not expect that the sales of third party products
will outpace the sales of our own TCMD products going forward.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Gross Profit</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gross profit is equal to net revenue minus cost
of goods sold. Cost of goods sold primarily includes inventory costs (raw materials, labor, packaging cost, depreciation and amortization,
third-party products purchase price, freight costs and overhead). Cost of goods sold generally changes as our production costs change,
which are affected by factors including the market price of raw materials, labor productivity, or the purchase price of third-party products,
and as the customer and product mix changes. Our cost of revenues accounted for 47.2%, 54.1% and 59.7% of our total revenue for the fiscal
year 2021, 2020 and 2019, respectively. We expect our cost of revenues to increase as we further expand our operations in the foreseeable
future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our gross margin was 52.8%, 45.9% and 40.3% for
the years ended September 30, 2021, 2020 and 2019, respectively. Our gross profit and gross margin are affected by the different product
mix of those products sold during each reporting period. Our gross margin increases when more products with lower costs and higher margin
are sold, while our gross margin decreases when more products with higher costs and lower margin are sold. See detailed discussion under
&#8220;&#8211;Results of Operation&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operating expenses consist of selling expenses,
general and administrative expenses and research and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our selling expenses primarily include salary and welfare benefit expenses
paid to our sales personnel, advertising expenses to increase the awareness of our brand, shipping ad delivery expenses, expenses incurred
for our business travel, meals and other sales promotion and marketing activities related expenses. Our selling expenses accounted for
6.2%, 5.1% and 4.8% of our total revenue for the years ended September 30, 2021, 2020 and 2019, respectively. We expect our overall selling
expenses, including but not limited to, advertising expenses, brand promotion expenses and salaries, to increase in the foreseeable future,
especially when our capitalized advertising costs will be expensed in subsequent period and when we continue to expand our business and
promote our products to customers located at extended geographic areas.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 59; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our general and administrative expenses primarily
consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve expenses, inspection and maintenance expenses,
office supply and utility expenses, business travel and meals expenses, land and property taxes and professional service expenses. General
and administrative expenses were 6.9%, 5.5% and 4.4% of our revenue for the years ended September 30, 2021, 2020 and 2019, respectively.
We expect our general and administrative expenses, including, but not limited to, salaries and business consulting expenses, to continue
to increase in the foreseeable future, as we plan to hire additional personnel and incur additional expenses in connection with the expansion
of our business operations. We expect our professional fees for legal, audit, and advisory services to increase as we became a public
company in March 2021 when we completed the IPO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Chinese patent medicine industry is characterized
by rapid and frequent changes in customer demand and launches of new products. If we do not launch new products or improve our existing
products to meet the changing demands of our customers in a timely manner, some of our products could become uncompetitive in the market,
thereby adversely affecting on our revenues and operating results. Our research and development expenses primarily consist of salaries,
welfare and insurance expenses paid to our employees involved in the research and development activities, materials and supplies used
in the development and testing of new TCMD products, depreciation, and other miscellaneous expenses. Research and development expenses
were 11.4%, 1.9% and 1.9% of our revenue for the years ended September 30, 2021, 2020 and 2019, respectively. As we continue to develop
new products and diversify our product offerings to satisfy customer demand, we expect our research and development expenses to continue
to increase in the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth a summary of our
consolidated results of operations for the periods presented, both in absolute amount and as a percentage of our total operating revenue
for the years presented. This information should be read together with our consolidated financial statements and related notes included
elsewhere in this annual report. The results of operations in any period are not necessarily indicative of our future trends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Year ended September 30, 2021 compared to year ended September
30, 2020</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended September 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% of revenue</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% of revenue</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">%</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%">REVENUE</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47,982,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,703,960</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,278,071</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">56.3</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">COST OF REVENUE</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,655,854</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,610,140</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,045,714</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">36.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">GROSS PROFIT</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,326,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,093,820</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,232,357</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">79.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,973,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,555,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,417,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,296,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,703,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,593,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,465,662</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">583,125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,882,538</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">837.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,736,037</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,842,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,893,942</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">205.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">INCOME FROM OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,590,140</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,251,725</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,338,415</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">OTHER INCOME (EXPENSE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(101,604</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.2)</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(123,760</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.4)</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17.9)</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(80,434</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.1)</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(49,352</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.2)</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,594</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Income from short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Equity investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,827</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,820</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,007</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,338</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(151,292</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.5)</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">239,630</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(158.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">INCOME BEFORE INCOME TAX</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,678,478</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,100,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,578,045</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">PROVISION FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,358,526</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,542,211</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(183,685</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7.2</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">NET INCOME</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,319,952</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">23.6</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,558,222</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24.6</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,761,730</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">49.8</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 60; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue:</b> Our total revenues increased by
$17,278,071, or 56.3%, to $47,982,031 for the year ended September 30, 2021 from $30,703,960 for the year ended September 30, 2020. The
increase in our revenues was attributable to (i) an increased number of customers by 22.6%, from 2,209 customers in fiscal year 2020 to
2,708 customers in fiscal year 2021; (ii) increased sales volume of our TCMD products by 9.9%, from 15,652,999 units sold in fiscal year
2020 to 17,206,150 units sold in fiscal year 2021; (iii) increased average selling price of our TCMD products by 46.3% and increased average
selling price of third-party products by 79.6%, in response to increased raw material costs and third-party products purchase costs as
affected by the COVID-19 pandemic and general inflation; and (vi) an appreciation of RMB against U.S. dollars in fiscal year 2021, with
the average exchange rate between RMB and US$ being US$1.00 to RMB 7.0077 in fiscal year 2020, as compared to that of US$1.00 to RMB 6.5104
in fiscal year 2021. The appreciation of RMB against US$ had a 7.1% positive impact on our reported total revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Revenue from sales of self-manufactured TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,559,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,374,751</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,184,535</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">60.9</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue from sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,093,536</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,278,071</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">56.3</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue from sales of our TCMD products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of our TCMD products increased by $11,184,535,
or 60.9%, from $18,374,751 in fiscal year 2020 to $29,559,286 in fiscal year 2021, because the sales volume of our TCMD products increased
by 9.9% from 15,652,999 units sold in fiscal year 2020 to 17,206,150 units sold in fiscal year 2021, and the average selling price of
our TCMD products increased by 46.3% from $1.17 per unit in fiscal year 2020 to $1.72 per unit in fiscal year 2021. The increase in the
sales of our TCMD product was due to the following specific reasons:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the 13 varieties of TCMD products we manufacture, the sales of Guben Yanling Pill, one of our key&#160;Chronic Condition Treatment products,
accounted for 40.3% and 38.2% of our total revenue in fiscal year 2021 and 2020, respectively. The sales of Guben Yanling Pill increased
by $6,702,397, or 494,932 units from fiscal year 2020 to fiscal year 2021.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of customers purchasing our products increased by 22.6%, from 2,209 customers in fiscal year 2020 to 2,708 customers in fiscal
year 2021. The increase in the number of customers led to an increase in the number of customer orders for our products, resulting increased
sales volume of our TCMD products.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our flu and cold medication products (including Qiangli Pipa Syrup and Paracetanol Granule For Children) increased in fiscal year
2021 due to strong market demand. Sales volume of our Qiangli Pipa Syrup and Paracetanol Granule For Children increased by 964,266 units
and 1,297,349 units, respectively, in fiscal year 2021 as compared to fiscal year 2020. On the other hand, as affected by inflation and
increased market prices of raw materials, we adjusted our selling prices and the average selling price of our Qiangli Pipa Syrup, Isatis
Root Granule and Paracetanol Granule For Children increased by $0.20 per unit, $0.22 per unit and $0.09 per unit, or 41.5%, 34.8% and
32.5%, respectively, in fiscal year 2021 compared to fiscal year 2020.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
average exchange rate between RMB and US$ was US$1.00 to RMB 7.0077 in fiscal year 2020 as compared to an average rate of US$1.00 to
RMB 6.5104 in fiscal year 2021. The appreciation of RMB against US$ had a 7.1% positive impact on our reported total revenues.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue from sales of third-party products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of third-party products increased by $6,093,536,
or 49.4%, from $12,329,209 in fiscal year 2020 to $18,422,745 in fiscal year 2021. Sales volume of third-party products slightly decreased
by 4.6%, from 8,763,577 units sold in 2020 to 8,364,391 units sold in 2021. In 2021, due to an overall increase in the market prices of
raw materials used in the manufacturing of third-party products, we paid higher purchase prices for products from third-party pharmaceutical
companies and accordingly, our average selling price of third-party products in fiscal year 2021 was higher than in fiscal year 2020.
Our average selling price of third-party products increased by 79.6%, from $1.41 per unit in fiscal year 2020 to $2.20 per unit in fiscal
year 2021. Among the total sales of third-party products, sales of biochemical drugs increased by 44.7%, or $4,968,438, from $10,325,411
in fiscal year 2020 to $16,082,546 in fiscal year 2021, because of a 51.7% increase in average selling price, while changes in sales of
traditional Chinese medicine pieces, medical instruments, and dietary supplements from fiscal year 2020 to fiscal year 2021 were relatively
immaterial. In addition, the average exchange rate between RMB and US$ was US$1.00 to RMB 7.0077 in fiscal year 2020, as compared to an
average rate of US$1.00 to RMB 6.5095 in fiscal year 2021. The appreciation of RMB against US$ had a 7.1% positive impact on our reported
revenue from sales of third-party products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 61; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Revenues.&#160;</i></b>Our cost
of revenues primarily consists of inventory costs (raw materials, labor, packaging cost, depreciation and amortization, third-party products
purchase price, freight costs and overhead) and business tax. Cost of revenues generally changes as our production costs change, which
are affected by factors including the market price of raw materials, labor productivity, or the purchase price of third-party products,
and as the customer and product mix changes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cost of revenue- TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,162,847</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,581,939</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,580,908</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">30.1</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of revenue- third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,493,007</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,028,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,464,807</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total cost of revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">22,655,854</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,610,140</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,045,714</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">36.4</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cost of revenues increased by $6,045,714,
or 36.4%, from $16,610,140 in fiscal year 2020 to $22,655,854 in fiscal year 2021. The increase in our cost of revenues was primarily
due to increased sales volume, increased raw material and third-party product purchase costs, and a 7.1% exchange rate impact as discussed
in more details below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of revenues of TCMD products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues of TCMD products accounted for
49.3% and 51.7% of our total costs of revenues for the years ended September 30, 2021 and 2020, respectively. Cost of revenues of TCMD
products increased by $2,580,908, or 30.1%, from $8,581,939 in fiscal year 2020 to $11,162,847 in fiscal year 2021. The increase in cost
of revenues of our TCMD products was due to the following reasons:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sales volume of TCMD products increased by 9.9%, from 15,652,999 units sold in fiscal year 2020 to 17,206,150 units sold in fiscal year
2021. As sales volume increased in fiscal year 2021, raw materials, labor, packaging, freight and overhead costs associated with our
TCMD product sales also increased.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of inflation and increased market prices of raw materials, the average per unit cost of our TCMD products increased by $0.10,
or 9.9%, from $0.55 per unit in fiscal year 2020 to $0.65 per unit in fiscal year 2021. Among the 13 varieties of TCMD products, cost
of revenues of Guben Yanling Pill, one of our key products, accounted for 23.3% and 22.7% of our total cost of revenues in fiscal years
2021 and 2020, respectively. Costs of Guben Yanling Pill increased by $1,229,987 in fiscal year 2021 as compared to fiscal year 2022,
when sales volume of Guben Yanling Pill increased by 12.1%. In addition, unit production cost of Qiangli Pipa Syrup and Paracetamol Granule
for Children increased by 43.2% and 51.4%, respectively, in fiscal year 2021 as compared to fiscal year 2022, due to increased raw material
costs, which led to corresponding increases in cost of revenues associated with these TCMD products, by $610,916 and $451,504, respectively.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify">The average exchange rate between RMB and US$ was US$1.00 to
RMB 7.0077 in fiscal year 2020 as compared to an average rate of US$1.00 to RMB 6.5104 in fiscal year 2021.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt">The appreciation of RMB against US$ had a 7.1% positive impact on our cost of revenues from sales of TCMD products. &#160; The increase in our cost of revenues of our TCMD products in fiscal year 2021 as compared to fiscal year 2020 reflected the above-mentioned factors combined.&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of revenues of third-party products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues of third-party products accounted
for 50.7% and 48.2% of our total costs of revenues for the years ended September 30,2021 and 2020, respectively. Cost of revenues of third-party
products increased by $3,464,807, or 43.2%, from $8,028,200 in fiscal year 2020 to $11,493,007 in 2021, because of an increase in average
unit cost of third-party products by $0.79 per unit, or 79.6%, from $1.41 per unit in 2020 to $2.20 per unit in fiscal year 2021, offset
by a decrease in sales volume of third-party products by 4.6%. In fiscal year 2021, due to an overall increase in the market prices of
raw materials used in the manufacturing of third-party products, we sourced third-party products at higher prices from third-party pharmaceutical
companies. In addition, the average exchange rate between RMB and US$ was US$1.00 to RMB 7.0077 in fiscal year 2020 as compared to an
average rate of US$1.00 to RMB 6.5104 in fiscal year 2021. The appreciation of RMB against US$ had a 7.1% positive impact on our cost
of revenues from sales of third-party products. These factors led to the increase in cost of revenues associated with third-party product
sales in fiscal year 2021 as compared to fiscal year 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 62; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Gross profit</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our gross profit increased by $11,232,356, from
$14,093,821 in fiscal year 2020 to $25,326,177 in fiscal year 2021. Our gross margin increased by 6.9% from 45.9% in fiscal year 2020
to 52.8% in fiscal year 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Gross profit- TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,396,439</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,792,811</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,603,627</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">87.9</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross profit- third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,929,738</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,301,009</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,628,729</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total gross profit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,326,177</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,093,820</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,232,356</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">79.7</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross margin- TCMD products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross margin- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total gross margin</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Average selling price per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.72</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Average cost per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.65</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Average selling price per unit- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.80</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Average cost per unit - third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.92</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gross profit from the sales of our TCMD products
increased by $8,603,627, or 87.9%, from $9,792,811 in 2020 to $18,396,439 in 2021, and the gross margin of our TCMD products increased
by 8.9%, from 53.3% in 2020 to 62.2% in 2021. The increase in our gross profit from the sales of TCMD products was due to the following
reasons: (i) as discussed above, the sales volume of our TCMD products increased by 9.9%, from 15,652,999 units sold in fiscal year 2020
to 17,206,150 units sold in fiscal year 2021, and the average selling price of our TCMD products increased by 46.3% from $1.17 per unit
in fiscal year 2020 to $1.72 per unit in fiscal year 2021. Although inflation and increased market prices of raw materials led to an increase
in the average cost of our TCMD products by 18.6%, the increase in the average selling price outpaced the increase in average unit costs
of our TCMD products by $0.44 per unit, which increased our profitability from sales of TCMD products; (ii) our gross profit and gross
margin were affected by the different product mix of the products sold during each reporting period. During fiscal year 2021, more higher-margin
and lower-cost TCMD products were sold as compared to fiscal year 2020; and (iii) the appreciation of RMB against US$ had a 7.1% positive
impact on our gross profit from sales of TCMD products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gross profit from third-party product sales increased
by $2,628,729, or 61.1%, from $4,301,009 in fiscal year 2020 to $6,929,738 in fiscal year 2021, while the gross margin of third-party
product sales increased by 2.7%, from 34.9% in fiscal year 2020 to 37.6% in fiscal year 2021. The average unit selling price of third-party
products increased by 56.6%, or $0.80 per unit, while average unit cost of third-party products also increased by 50.6%, or $0.46 per
unit. The increase in the average selling price outpaced the increase in average unit cost of third-party products by $0.34 per unit.
The increase in our gross profit from third-party products was affected by changes in the product mix of the products sold in fiscal year
2021 as compared to fiscal year 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the breakdown of
our operating expenses for fiscal years 2021 and 2020:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/>
 revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/>
 revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-align: left">Total revenue</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">47,982,031</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">100.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">30,703,960</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">100.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">17,278,071</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">56.3</td><td style="width: 1%; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,973,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,555,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,417,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.25in; padding-left: 0.25in; text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,296,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,703,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,593,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,465,662</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">583,125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,882,537</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">837.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total operating expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,736,037</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24.5</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,842,095</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12.5</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,893,942</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">205.5</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 63; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Selling expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our selling expenses primarily include salaries
and welfare benefit expenses paid to our sales personnel, advertising expenses to increase our brand awareness, shipping and delivery
expenses, expenses incurred for our business travel, meals and other sales promotion and marketing activities related expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">Salary and employee benefit expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">859,436</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">586,632</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37.7</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">272,804</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">46.5</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Advertising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,316,654</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">343,962</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">972,692</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">282.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shipping and delivery expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">701,997</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">576,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,201</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Business travel and meals expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,155</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other sales promotion related expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,879</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,746</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">133</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total selling expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,973,531</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,555,546</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,417,985</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">91.2</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our selling expenses increased by $1,417,985,
or 91.2%, from $1,555,546 in fiscal year 2020 to $2,973,531 in fiscal year 2021, primarily attributable to (i) an increase in advertising
expenses by $972,692, or 282.8%, from $343,962 in fiscal year 2020 to $1,316,654 in fiscal year 2021. In fiscal year 2020, we used outdoor
billboards, magazines and social media such as WeChat and Weibo to advertise our brand and products in order to increase customer awareness.
In fiscal year 2021, in connection with the sales and promotion of our TCMD products to targeted customers, we engaged a local advertising
agency to develop and produce a TV advertisement for promoting the sales of our major TCMD products, Bai Nian Dan and Guben Yanling Pill,
and coordinate with a TV channel to broadcast the advertisement to targeted geographic market areas. As a result of our advertising efforts
in fiscal year 2021, we spent more on advertising than we did in fiscal year 2020, which led to higher advertising expenses in fiscal
year 2021. In addition, we expect that our capitalized advertising costs will be expensed, and increase our future advertising expenses
in subsequent period, starting from when the advertisement was first broadcasted; (ii) an increase in salary and benefit expenses paid
to our sales employees by $272,804, or 46.5%, from $586,632 in fiscal year 2020 to $859,436 in fiscal year 2021, and an increase in business
travel and meals expense by $47,155 or 150.1%, from $31,410 in fiscal year 2020 to $78,565 in fiscal year 2021, primarily due to our increased
sales activities in fiscal year 2021; and (iii) an increase in shipping and delivery expenses by $125,201, or 21.7%, from $576,796 in
fiscal year 2020 to $701,997 in fiscal year 2021, due to our increased sales volume and an increase in the number of sales orders fulfilled
in fiscal year 2021. These above-mentioned factors combined led to the increase in our selling expenses in fiscal year 2021 as compared
to fiscal year 2020. As a percentage of revenues, our selling expenses accounted for 6.2% and 5.1% of our total revenue for the years
ended September 30, 2021 and 2020, respectively.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our general and administrative expenses primarily
consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve expenses, inspection and maintenance expenses,
office supply and utility expenses, business travel and meals expenses, land and property taxes and professional service expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">Salary and employee benefit expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">657,543</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">19.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">464,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">193,013</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41.6</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172,453</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,217</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.6)</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Bad debt reserve expenses (recovery)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(230,175</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.0)</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(328,276</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(334.6)</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Land and property tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,412</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Office supply and utility expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">376,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,891</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transportation, business travel and meals expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,047</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,896</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Consulting fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,967,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">616,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,350,876</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">218.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Inspection and maintenance fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,939</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,825</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">179.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Stamp tax and other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,524</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,289</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total general and administrative expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,296,844</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,703,424</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,593,420</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">93.5</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our general and administrative expenses increased
by $1,593,420 or 93.5% from $1,703,424 in fiscal year 2020 to $3,296,844 in fiscal year 2021, primarily attributable to (i) an increase
in our professional service fees by $1,350,876 in fiscal year 2021 as compared to fiscal year 2020, primarily due to increased audit fees,
legal fees, business consulting fees in connection with our public offering; (ii) an increase in our office supply and utility expenses
by $260,313, or 224.6%, to support our administration activities; and (iii) an increase in our salaries, welfare expenses and insurance
expenses paid to administration employees by $193,013, or 41.6%, because higher amount of annual bonus was distributed to administrative
staffs in fiscal year 2021 as compared to fiscal year 2020, offset by a decrease in bad debt expense by $328,276 because we accrued more
bad debt expenses in fiscal year 2020 based on estimated accounts receivable collection trend, and approximately $0.2 million bad debt
accrual in prior periods was collected in fiscal year 2021, which led to a bad debt recovery in 2021. The overall increase in our general
and administrative expenses in fiscal year 2021 as compared to fiscal year 2020 reflected the above-mentioned factors combined. As a percentage
of revenues, general and administrative expenses were 6.9% and 5.5% of our revenue in fiscal years 2021 and 2020, respectively.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 64; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and development expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development expenses primarily
consist of salaries, welfare and insurance expenses paid to our employees involved in the research and development activities, materials
and supplies used in the development and testing new TCMD products, depreciation and other miscellaneous expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">Salary and employee benefit expenses to R&amp;D staff</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">155,940</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">97,444</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16.7</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">58,496</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">60.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Materials used in R&amp;D activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">836,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">469,788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">366,922</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Expenditure on new product development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,454,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,454,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Depreciation and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,719</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total R&amp;D expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,465,662</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">583,125</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,882,537</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">837.3</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased by
$4,882,537, or 837.3%, from $583,125 in fiscal year 2020 to $5,465,662 in fiscal year 2021, primarily attributable to (i) an increase
in research and development expense of $4,454,400 in order to develop and test eight new Chinese medicine products in order to diversify
our future product portfolio. In fiscal year 2021, we entered into several cooperative agreements with external academic and research
institutions to jointly conduct the new product development and accordingly incurred significant amount of R&amp;D expense in connection
with such efforts; and (ii) an increase in the materials used in the research and development (&#8220;R&amp;D&#8221;) activities by $366,922.
In fiscal year 2021, in order to develop new products and improve the formulation of several existing products, we conducted more testing
on product stability and safety, and as a result, more materials were used in our R&amp;D activities in fiscal year 2021 than in fiscal
year 2020. As a percentage of revenues, research and development expenses were 11.4% and 1.9% of our revenue in fiscal years 2021 and
2020, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other income (expenses), net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our other income (expenses) primarily includes
interest expenses incurred on our short-term bank loans, gain or loss from disposal of fixed assets, investment income from our long-term
investment in exchange for a 5% ownership interest in a local bank, and income generated from our short-term investments to purchase wealth
management products from financial institutions. Total other income, net, increased by $239,630 or 158.4%, from net other expenses of
$151,292 in fiscal year 2020 to net other income of $88,338 in fiscal year 2021 due to the following reasons:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses decreased by $22,156, or 17.9%,
from $123,760 in fiscal year 2020 to $101,604 in fiscal year 2021. The decrease in our interest expenses was due to lower amount of outstanding
loans we carried during fiscal year 2021 as compared to fiscal year 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other expense increased by $31,082, from other
expense of $49,352 in fiscal year 2020 to other expense of $80,434 in fiscal year 2021, primarily due to payment of work injury compensation
to workers in fiscal year 2021 and foreign currency transaction loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investment income was $30,827 and $21,820
in fiscal years 2021 and 2020, respectively. From March 2009 to September 2017, we invested approximately RMB5 million ($0.7 million)
in Jiangxi Jian Rural Commercial Bank (&#8220;JX RCB Bank&#8221;) in exchange for a 5% ownership interest in the bank. The purpose of
this investment was to earn investment income as JX RCB Bank continues to grow. We account for this investment using the measurement alternative
in accordance with ASC 321. As of September 30, 2021 and 2020, the value of this investment amounted to $744,924 and $735,000, respectively,
and was reported as long-term investment in equity investee on our consolidated balance sheets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Income from short-term investments increased from
Nil in fiscal year 2020 to $239,549 in fiscal year 2021. Our short-term&#160;investments consist of wealth management financial products
purchased from a financial institution, which can be redeemed anytime at our discretion. The financial institution put our investments
in certain financial instruments, including money market funds and bonds, to generate investment income. In fiscal year 2021, we used
available cash to purchase such wealth management financial products from financial institution and generated $239,549 investment income
in fiscal year 2021. There was no such income in fiscal year 2020.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 65; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provision for Income Taxes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our provision for income taxes was $2,358,526
in fiscal year 2021, a decrease of $183,685, from $2,542,211 in fiscal year 2020. Under the Enterprise Income Tax Law, or the EIT Law,
domestic enterprises and foreign investment enterprises are usually subject to a unified 25% enterprise income tax rate while preferential
tax rates, tax holidays and even tax exemption may be granted on a case-by-case basis. The EIT Law grants preferential tax treatment to
High and New Technology Enterprises (&#8220;HNTEs&#8221;, individually an &#8220;HNTE&#8221;). Under this preferential tax treatment,
HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years.
Jiangxi Universe, one of our main operating subsidiaries in the PRC, was approved as an HNTE and was entitled to a reduced income tax
rate of 15% beginning November&#160;2016 with a term of three years. Jiangxi Universe&#8217;s HNTE status was successfully renewed in
December 2019 for a term of three additional years. The EIT Law is typically enforced by the local tax authorities in the PRC. Each local
tax authority has the discretion to grant tax holidays to local enterprises as a way to encourage entrepreneurship and stimulate local
economy. The corporate income taxes for the fiscal years 2021 and 2020 were reported at a blended reduced rate since Jiangxi Universe
enjoys a 15% reduced income tax rate due to its HNTE status and Universe Trade, a wholly owned subsidiary of Jiangxi Universe, is subject
to a standard 25% income tax rate. The impact of the tax holidays noted above decreased PRC corporate income taxes by $1,518,979 and $118,986
for the years ended September 30, 2021, and 2020, respectively. The benefit of the tax holidays on net income per share (basic and diluted)
$0.09 and $0.01 for the years ended September 30, 2021 and 2020, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the foregoing, we reported a net
income of $11,319,952 in fiscal year 2021, representing a $3,761,730 increase from a net income of $7,558,222 in fiscal year 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Year ended September 30, 2020 compared to year ended September
30, 2019</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-indent: -9pt; padding-left: 0.125in">REVENUE</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,703,960</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">33,229,316</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,525,356</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7.6</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.125in">COST OF REVENUE</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,610,140</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,821,831</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">59.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,211,691</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16.2</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.125in">GROSS PROFIT</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,093,820</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,407,485</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">686,335</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.125in">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.125in">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,555,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,578,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,280</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.5</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.125in">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,703,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,457,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">246,031</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.125in">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">583,125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">618,437</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35,312</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5.7</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.125in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,842,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,654,656</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">187,439</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.125in">INCOME FROM OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,251,725</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,752,829</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">498,896</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.125in">OTHER INCOME (EXPENSE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.125in">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(123,760</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(129,268</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,508</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4.3</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.125in">Other income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,532</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,501</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(57,033</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(193.3</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.125in">Total other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(151,292</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(99,767</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.3</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,525</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.125in">INCOME BEFORE INCOME TAX PROVISION</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,100,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,653,062</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">447,371</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.125in">PROVISION FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,542,211</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,101,597</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">440,614</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.125in">NET INCOME</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,558,222</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24.6</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,551,465</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">22.7</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,757</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.1</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 66; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenues. </i></b>We currently produce and
sell 13 varieties of TCMD products and also sell products manufactured by third-party pharmaceutical companies, to our customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Revenue - TCMD products sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,374,751</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,895,542</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,520,791</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(12.1</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Revenue &#8211; third-party products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,333,774</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,565</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.0</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total revenue</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">33,229,316</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(2,525,356</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(7.6</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our total revenues decreased by $2,525,356, or
7.6%, to $30,703,960 for the year ended September 30, 2020 from $33,229,316 for the year ended September 30, 2019. The decrease in our
revenues was attributable to the following reasons: (i) among the total $2.5 million revenue decrease in fiscal year 2020, our revenue
decreased by approximately $2.6 million in the first half of fiscal 2020 as compared to the same period of 2019, while our revenue in
the second half of 2020 increased by approximately $0.1 million compared to the same period of 2019. The decrease in sales volume by 4.3%
from 25,500,882 units of TCMD and third-party products sold in fiscal year 2019 to 24,416,576 units of TCMD and third-party products sold
in fiscal year 2020 was largely affected by the COVID-19 pandemic. Due to the outbreak and spread of COVID-19, we temporarily closed down
our manufacturing facilities from February to early March 2020, and as a result, our production and sales of TCMD products decreased during
this period, and we experienced difficulty delivering our products to our customers on a timely basis; (ii) due to strong market competition,
sales volume of our flu and cold medication products (including Qiangli Pipa Syrup, Isatis Root Granule and Paracetanol Granule For Children)
decreased significantly by approximately 2.3 million units; (iii) in order to compensate decreased sales volume from our TCMD products,
we increased our purchase of third-party products to fulfill customer orders. As a result, our sales volume of TCMD products decreased
by 11.9% and sales volume of third-party products increased by 13.3% in fiscal year 2020 as compared to fiscal year 2019; (iv) due to
the COVID-19 pandemic, the shipping and delivery of our products to customers located in remote geographic areas was also negatively impacted,
which led to the decrease in the total number of customers by 15.1% from 2,603 in fiscal year 2019 to 2,209 in fiscal year 2020; (v) the
weighted average per unit selling price of our TCMD products decreased by 0.5%, from $1.18 per unit in fiscal year 2019 to $1.17 per unit
in fiscal year 2020, and the weighted average per unit selling price of third-party products decreased by 11.5%, from $1.59 per unit in
fiscal year 2019 to $1.41 per unit in fiscal year 2020; and (vi) the average exchange rate between RMB and US$ was US$1.00 to RMB 6.8729
in fiscal year 2019 as compared to the average rate of US$1.00 to RMB 7.0077 in fiscal year 2020. The depreciation of RMB against US$
had a 2.0% negative impact on our reported total revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our average monthly revenue was approximately
$2.5 million in fiscal year 2020 and $2.7 million in fiscal year 2019. Our monthly revenue normally does not fluctuate significantly except
under unusual circumstances. In fiscal year 2020, we closed our facilities for about one month in response to the COVID-19 outbreak, and
therefore our revenue decreased by $2.5 million, or 7.6% as compared to fiscal year 2019. After we resumed our business operation on March
2, 2020, our monthly revenue has remained relatively stable, ranging from $2.1 million per month to $2.8 million per month from April
2020 to September 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These factors all contributed to the decrease
in our revenues by 7.6% from fiscal year 2019 to fiscal year 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 67; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue from sales of our TCMD products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our TCMD products primarily include chronic condition
treatments such as Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid, Fengtong
Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal Liquor,
as well as our cold and flu medications such as Paracetamol Granule for Children, Isatis Root Granule and Qiangli Pipa Syrup. Revenue
from sales of our TCMD products accounted for 59.8% and 62.9% of our total revenue for the years ended September 30, 2020 and 2019, respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of our TCMD products decreased by $2,520,791,
or 12.1%, from $20,895,542 in fiscal year 2019 to $18,374,751 in fiscal year 2020, because the sales volume of our TCMD products decreased
by 11.9% from 17,766,549 units sold in fiscal year 2019 to 15,652,999 units sold in fiscal year 2020, and the average selling price of
our TCMD products decreased by 0.5% from $1.18 per unit in fiscal year 2019 to $1.17 per unit in fiscal year 2020. The decrease in the
sales of our TCMD product was due to the following specific reasons:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the 13 varieties of TCMD products we manufacture, the sales of Guben Yanling Pill, one of our representative products, accounted for
38.2% and 32.4% of our total revenue for the years ended September 30, 2020 and 2019, respectively. The sales of Guben Yanling Pill increased
by $964,984, or 847,528 units, or 26.2% from fiscal year 2019 to fiscal year 2020. In August and September 2019, we conducted maintenance
for our manufacturing facility. We completed the upgrade and maintenance of our manufacturing facilities in late September 2019, which
enabled us to streamline our manufacturing process, manage the workflow effectively, improve product quality, and boost manufacturing
productivity to lower down our manufacturing cost to certain extent in fiscal year 2020. Our research and development efforts in improving
the formulation of our Guben Yanling Pill helped us lower the production costs, allowing us to sell this product at lower prices. Weighted
average selling price of our Guben Yanling Pill decreased by $0.45 per unit, or 13.4%, from $3.33 per unit in fiscal year 2019 to $2.88
per unit in fiscal year 2020. The lower selling price contributed to the increase in sales volume of our Guben Yanling Pill in fiscal
year 2020.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the outbreak of COVID-19, from February to early March 2020, we had to temporarily close down our manufacturing facilities due to government restrictions. This led to a decrease in the production and sales of our TCMD products for approximately one month. In addition, due to transportation and travel restrictions, we experienced difficulties shipping and delivering our products to customers located in remote geographic areas, which led to a decrease in the number of customers by 15.1% from 2,603 in fiscal year 2019 to 2,209 in fiscal year 2020. As a result, the sales of Fengtong Medicinal liquor, Shenrong Weisheng Pill and Yangxue Danggui Syrup decreased by $500,050, $331,105 and $670,525, representing a 51.5%, 18.9% and 57.5% decrease, respectively, and their sales volume decreased by 34.8%, 7.1% and 48.8% from fiscal year 2019 to fiscal year 2020, respectively. On the other hand, we adjusted the selling prices of our products to promote the products to customers, and as a result, the average selling price of our Fengtong Medicinal liquor, Shenrong Weisheng Pill and Yangxue Danggui Syrup decreased by 25.1%, 24.2% and 16.9%, respectively, in the fiscal year 2020 compared to fiscal year 2019. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales of our flu and cold medication products (including Qiangli Pipa Syrup, Isatis Root Granule and Paracetanol Granule For Children) decreased significantly in fiscal year 2020 due to strong market competition and the impact of COVID-19 pandemic. Some of our competitors are larger pharmaceutical companies with well-known brand and/or greater financial resources and can offer similar products at lower prices. As a result, sales of our Qiangli Pipa Syrup and Isatis Root Granule decreased by $1,294,802 and $547,604, representing a 56.1% and 33.1% decrease, respectively, and their sales volume decreased by 44.2% and 18.1% from fiscal year 2019 to fiscal year 2020, respectively. On the other hand, we adjusted our selling price to promote our products to customers, and as a result, the average selling price of our Qiangli Pipa Syrup and Isatis Root Granule decreased by 21.3% and 18.3%, respectively, in fiscal year 2020 compared to the fiscal year 2019. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 68; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue from sales of third-party products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to diversify our product portfolio and
offerings and to increase our sales, we also sell pharmaceutical products manufactured by third-party companies, including (i) biochemical
drugs, such as such as liquid glucose, prednisolone, and citicoline, (ii) medical instruments, such as drug-eluting stents, surgical tubes
and syringes, (iii) TCMPs, such as red sage tables, Longdan Xiegan pills, and Chinese skullcap capsules and (iv) dietary supplements,
including vitamins, probiotic powder, and calcium tablets. Revenue generated from sales of third-party products accounted for 40.2% and
37.1% of our total revenue for the years ended September 30, 2020 and 2019, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160; &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of third-party products slightly decreased
by $4,565, or 0.04%, from $12,333,774 in fiscal year 2019 to $12,329,209 in fiscal year 2020. Sales volume of third-party products increased
by 13.3%, from 7,734,333 units sold in fiscal year 2019 to 8,763,577 units sold in fiscal year 2020. However, average selling price of
third-party products decreased by 11.2%, from $1.59 per unit in fiscal year 2019 to $1.41 per unit in fiscal year 2020. Among the total
sales of third-party products, sales of biochemical drugs increased by 8.6%, or $816,595, from $9,508,816 in fiscal year 2019 to $10,325,411
in fiscal year 2020, because of a 17.1% increase in sales volume, while sales of TCMPs, medical instruments and dietary supplements decreased
by $95,311, $718,184 and $7,665, respectively, when their sales volume decreased by 59.2%, 30.5% and 30.6%, respectively. In fiscal year
2019, due to an overall increase in the market prices of raw materials used in the manufacturing of third-party products, we paid higher
purchase prices for products from third-party pharmaceutical companies and accordingly our average selling price of third-party products
in fiscal year 2019 was higher than in fiscal year 2020. To compensate the negative impact from the COVID-19 pandemic, we increased our
purchase of third party products to fulfill our sales orders in fiscal year 2020. We adopted a strategy to select and distribute certain
high-quality products with higher margin in fiscal year 2020. As a result, the average selling price of biochemical drugs, TCMPs and dietary
supplements decreased by 7.3%, 18.9% and 34.1%, respectively, in fiscal year 2020 as compared to fiscal year 2019. On the other hand,
average selling price of medical instruments increased by 5.2% to tailor higher purchase costs from third-parties. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of Revenues. </i></b>Our cost of revenues
primarily consists of inventory costs (raw materials, labor, packaging cost, depreciation and amortization, third-party products purchase
price, freight costs and overhead) and business tax. Cost of revenues generally changes as our production costs change, which are affected
by factors including the market price of raw materials, labor productivity, or the purchase price of third-party products, and as the
customer and product mix changes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cost of revenue- TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,581,940</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,894,117</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,312,177</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(27.8</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of revenue- third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,028,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,927,714</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,486</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total cost of revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,610,140</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,821,831</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(3,211,691</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(16.2</td><td style="padding-bottom: 4pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cost of revenues decreased by $3,211,691,
or 16.2%, from $19,821,831 in fiscal year 2019 to $16,610,140 in fiscal year 2020. The decrease in our cost of revenues was due to the
following reasons:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed above, we temporarily suspended our manufacturing activities for one month from the beginning of February to early March 2020
due to the COVID-19 pandemic. In addition, as a result of strong market competition, sales of our flu and cold medication products decreased
significantly. Also, the total number of customers decreased by 15.1%, from 2,603 in fiscal year 2019 to 2,209 in fiscal year 2020. These
factors contributed to a decrease in the sales volume of our TCMD products by 11.9%, from 17,766,549 units of&#160;products sold in fiscal
year 2019, to 15,652,999&#160;&#160;units of products sold in fiscal year 2020. As sales volume decreased, raw materials, labor, packaging,
freight and overhead costs associated with our TCMD product sales also decreased. In addition, in August and September 2019, in connection
with our renewal of GMP Certificate with the Jiangxi FDA, we conducted maintenance for our manufacturing facility. The maintenance and
upgrade of our manufacturing facilities enabled us to streamline our manufacturing process, manage the workflow effectively, improve
product quality, and boost our manufacturing productivity to lower down our manufacturing costs to certain extent. As a result, the weighted
cost per unit for our TCMD products decreased by 18.1%, from $0.67 per unit in fiscal year 2019 to $0.55 per unit in fiscal year 2020.&#160;&#160;The
above combined factors contributed to a 27.8% decrease in our cost of revenue associated with our TCMD products sales.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 69; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal year 2020, when we chose third party products to purchase, we decided to remove approximately 1,102 products with lower margin
from the previous purchase list and added 1,765 new products with higher margin to our purchase list. As a result of the change in product
mix, the weighted average cost per unit for third-party products decreased by 10.6%, from $1.03 per unit in fiscal year 2019 to $0.92
per unit in fiscal year 2020 due to lower purchase costs of third-party products. As a result of the above, weighted per unit cost for
all of our products sold during fiscal year 2020 decreased by $0.10, or 12.5%, from $0.78 in fiscal year 2019 to $0.68 in fiscal year
2020.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
average exchange rate between RMB and U.S. dollars was US$1.00 to RMB 6.8729 in fiscal year 2019 as compared to an average rate of US$1.00
to RMB 7.0077 in fiscal year 2020. The depreciation of RMB against U.S. dollars had a 2.0% negative impact on our reported cost of revenues.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of revenues of TCMD products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues of TCMD products accounted for
51.7% and 60.0% of our total costs of revenues for the fiscal years 2020 and 2019, respectively. Cost of revenues of TCMD products decreased
by $3,312,177, or 27.8%, from $11,894,117 in fiscal year 2019 to $8,581,940 in fiscal year 2020. The increase in cost of revenues of our
TCMD products was due to the following reasons:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The decrease in cost of revenues of our TCMD products
was due to the following reasons:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales volume of TCMD products decreased by 11.9%, from 17,766,549 units sold in fiscal year 2019 to 15,652,999 units sold in fiscal year 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The maintenance and upgrade of our manufacturing facility in September 2019 enabled us to streamline our manufacturing process, manage the workflow effectively, improve product quality, and boost our manufacturing productivity to lower down our manufacturing cost to certain extent. As a result, the average per unit cost of our TCMD products decreased by $0.12, or 18.1%, from $0.67 in fiscal year 2019 to $0.55 in fiscal year 2020. Among the 13 varieties of TCMD products, cost of revenues of Guben Yanling Pill, one of our representative products, accounted for 22.7% and 24.3% of our total cost of revenues in fiscal years 2020 and 2019, respectively. Costs of Guben Yanling Pill decreased from $1.49 per unit in fiscal year 2019 to $0.92 per unit in fiscal year 2020, thereby decreasing the total cost of revenues of Guben Yanling Pill by $1,039,788. In addition, unit production cost of Shiquan Dabu medicinal liquor, Fengtong medicinal liquor, Qishe medicinal liquor, Yangxue Danggui Syrup, Qiangli Pipa Syrup, Isatis Root Granule and Paracetamol Granule for Children decreased by 16.0%, 18.7%, 12.1%, 3.9%, 20.4%, 21.9% and 9.1%, respectively, which led to corresponding decreases in cost of revenues associated with these TCMD products by $74,783, $301,698, $24,481, $429,690, $933,074, $489,913 and $45,535, respectively. The decrease in cost of revenue of Qiangli Pipa Syrup and Isatis Root Granule was also due to decreased sales volume by 44.2% and 18.1%, respectively, due to strong market competition of flu and cold medication products as discussed above. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) </span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An average exchange rate between RMB and U.S.
    dollars and the depreciation of RMB against U.S. dollars had a 2.0% negative impact on our reported cost of revenues when comparing fiscal
    year 2020 to fiscal year 2019.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The decrease in the cost of revenues of our TCMD
    products in fiscal year 2020 as compared to fiscal year 2019 reflected the above-mentioned factors combined.&#160;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 70; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of revenues of third-party products </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues of third-party products accounted
for 48.3% and 40.0% of our total costs of revenues for the fiscal years 2020 and 2019, respectively. Cost of revenues of third-party products
increased by $100,487, or 1.3%, from $7,927,714 in fiscal year 2019 to $8,028,200 in fiscal year 2020, because of an increase in sales
volume by 13.3%, from 7,734,333 units sold in fiscal year 2019 to 8,763,577 units sold in fiscal year 2020, offset by a decrease in the
average unit cost of third-party products by $0.11 per unit, or 10.6%, from $1.03 per unit in fiscal year 2019 to $0.92 per unit in fiscal
year 2020. In fiscal year 2019, due to an overall increase in the market prices of raw materials used in the manufacturing of third-party
products, we sourced third-party products at higher prices from third-party pharmaceutical companies. However, in fiscal year 2020, when
we chose third party products to purchase, we decided to remove approximately 1,102 products with lower margin from the purchase list
and added 1,765 new products with higher margin to our purchase list. This led to a decrease in the average unit cost of third-party products
by $0.11 per unit, or 10.6%, in fiscal year 2020. The average unit cost of biochemical drugs, TCMPs and dietary supplements products decreased
by 5.2%, 41.5% and 19.9%, respectively, and as a result, our unit cost on biochemical drugs, TCMPs and dietary supplements was adjusted
to tailor this change, and decreased by $0.05, $0.91 and $0.6 per unit, respectively. The average unit cost of medical instruments increased
by 4.0%, or $0.11 per unit due to higher purchase costs from third-party suppliers. Furthermore, the average exchange rate between RMB
and U.S. dollars in fiscal year 2020 and the depreciation of RMB against U.S. dollars had a 2.0% negative impact on our reported cost
of revenues when comparing fiscal year 2020 to fiscal year 2019. These factors led to the increase in cost of revenues associated with
third-party product sales in fiscal year 2020 as compared to fiscal year 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Gross profit </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our gross profit increased by $686,335, from $13,407,485
in fiscal year 2019 to $14,093,820 in fiscal year 2020. Our gross margin increased by 5.6% from 40.3% in fiscal year 2019 to 45.9% in
fiscal year 2020. Our gross profit and gross margin were affected by the sales of different product mix during each reporting period.
Although our total revenue and total sales volume decreased by 7.6% and 4.3%, respectively, the increase in our gross profit and gross
margin was because: (i) as discussed above, the increase in productivity as a result of the maintenance and upgrade of our facility in
fiscal year 2019 enabled us to lower our manufacturing cost and adjust the selling price of our TCMD products to stimulate customer orders
in fiscal year 2020; and (ii) our gross margin was affected by the different product mix of the products sold during each reporting period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Gross profit- TCMD products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,792,811</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,001,425</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">791,386</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross profit- third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,301,009</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,406,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(105,051</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total gross profit</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,093,820</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13,407,485</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">686,335</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5.1</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross margin- TCMD products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross margin- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">35.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.8</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total gross margin</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Average selling price per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.01</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Average cost per unit- TCMD products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.67</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.12</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18.2</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Average selling price per unit- third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.59</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.18</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Average cost per unit - third party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.92</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.03</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.11</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11.1</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gross profit from the sales of our TCMD products
increased by $791,387, or 8.8%, from $9,001,425 in fiscal year 2019 to $9,792,812 in fiscal year 2020, and the gross margin of TCMD products
increased by 10.2%, from 43.1% in fiscal year 2019 to 53.3% in fiscal year 2020. The increase in our gross profit from the sales of TCMD
products was due to the following reasons:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(a)</td><td style="text-align: justify">Although revenue and sales volume of our TCMD products decreased
by 12.1% and 11.9%, respectively, as affected by the COVID-19 pandemic as well as strong market competition as discussed above, the increase
in productivity as a result of the maintenance and upgrade of our facility in fiscal year 2019 enabled us to streamline our manufacturing
process and lower our manufacturing cost of our TCMD products.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 71; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(b)</td><td style="text-align: justify">Average unit cost of our TCMD products decreased by 18.2%, or $0.12 per unit, from $0.67 per unit in fiscal
year 2019, to $0.55 per unit in fiscal year 2020. The decrease in average unit cost enabled us to lower our average selling price of TCMD
products by $0.01 per unit, or 0.5%, from $1.18 per unit in fiscal year 2019 to $1.17 per unit in fiscal year 2020. The decrease in average
unit cost outpaced the decrease in average selling price by $0.11 per unit. When cost of revenue decreased more than revenue decrease,
our gross profit from TCMD products increased. For example, when comparing fiscal year 2020 to fiscal year 2019, largest portion of our
increase in gross profit was associated with our Guben Yanling Pill. Gross profit for Guben Yanling Pill increased by $2,004,772, or 33.6%,
from $5,958,502 in fiscal year 2019 to $7,963,274 in fiscal year 2020, because average unit cost of Guben Yanling Pill decreased by 37.9%,
or $0.56 per unit, from $1.49 per unit in fiscal year 2019 to 0.92 per unit in fiscal year 2020 as a result of the manufacturing process
improvement. Although we also lowered down the selling price of Guben Yanling Pill by 14.0% from $3.33 per unit in fiscal year 2019 to
$2.88 per unit in fiscal year 2020, the decrease in average unit cost outpaced the decrease in average selling price of Guben Yanling
Pill by $0.09 per unit. On the other hand, the increase in our gross profit associated with our Guben Yanling Pill was offset by the decrease
in gross profit associated with our Fengtong Medicinal Liquor, Shengrong Weisheng Pill, Yangxue Danggui Syrup and Qiangli Pipa Syrup by
$193,352, $404,656, $240,835 and $361,728, respectively, when sales volume of these TCMD products decreased as affected by COVID-19 impact
and reduced number of customers.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gross profit from third-party product sales decreased
by $105,051, or 2.4%, from $4,406,060 in the fiscal year 2019 to $4,301,009 in the fiscal year 2020, while the gross margin of third-party
product sales decreased by 0.8%, from 35.7% in the fiscal year 2019 to 34.9% in the fiscal year 2020. The average unit selling price of
third-party products decreased by 11.5%, or $0.18 per unit, while the average unit cost of third-party products decreased by 11.1%, or
$0.11 per unit. The decrease in the average selling price outpaced the decrease in the average unit cost of third-party products by $0.07
per unit. Due to the COVID-19 pandemic, we increased our purchase of third-party products to fulfill customer orders in the fiscal year
2020. The decrease in our gross profit from third-party products was affected by changes in sales of different product mix in the fiscal
year 2020 as compared to the fiscal year 2019. For example, the largest portion of decrease in gross profit from third-party products
was associated with medical instrument products, which decreased by $304,160 when the average unit purchase cost increased by 3.3%, or
$0.09 per unit when comparing fiscal year 2020 to fiscal year 2019. Higher purchase prices of medical instrument products lowered down
our gross profit in fiscal year 2020. In fiscal year 2020, when we chose third-party products to purchase from various suppliers, we decided
to remove approximately 1,102 products with lower margin from the previous purchase list and added 1,765 new products with higher margin
to our purchase list. However, under the competitive environment, we had to adjust our selling prices to promote the products to customers.
For future third-party product sales, our strategy is to select and distribute certain high-quality products with higher margin. We do
not expect that the sales of third party products will continue to outpace the sales of our own TCMD products going forward.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the breakdown of
our operating expenses for the fiscal years ended September 30, 2020 and 2019:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/>
 revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of<br/>
 revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-align: left">Total revenue</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">30,703,960</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">100.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">33,229,316</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">100.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(2,525,356</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(7.6</td><td style="width: 1%; font-weight: bold; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,555,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,578,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,280</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.5</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,703,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,457,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">246,031</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">583,125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">618,437</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35,312</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5.7</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total operating expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,842,095</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12.5</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,654,656</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">187,439</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.1</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 72; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Selling expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our selling expenses primarily include salaries
and welfare benefit expenses paid to our sales personnel, advertising expenses to increase our brand awareness, shipping ad delivery expenses,
expenses incurred for our business travel and meals, and other sales promotion and marketing activities related expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and employee benefit expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">586,632</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37.7</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">657,370</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41.6</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(70,738</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(10.8</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Advertising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">343,962</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">367,513</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,551</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.4</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shipping and delivery expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">576,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457,407</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119,389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Business travel and meals expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,465</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(28,055</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47.2</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other sales promotion related expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,746</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,071</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,325</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54.8</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total selling expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,555,546</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,578,826</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(23,280</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1.5</td><td style="padding-bottom: 4pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our selling expenses decreased by $23,280, or
1.5%, from $1,578,826 in fiscal year 2019 to $1,555,546 in fiscal year 2020, primarily attributable to (i) a decrease in advertising expenses
by $23,551, or 6.4%, from $367,513 in fiscal year 2019 to $343,962 in fiscal year 2020. We used outdoor billboard, magazine and social
media such as WeChat and Weibo to advertise our brand and products in order to increase customer awareness. In fiscal year 2019, in connection
with our sales promotion of several new products to targeted customers, we spent more on advertising than we did in fiscal year 2020,
which led to higher advertising expenses in fiscal 2019; (ii) a decrease in our salary and benefit expenses paid to our sales employees
by $70,738, or 10.8%, from $657,370 in fiscal year 2019 to $586,632 in fiscal year 2020, and a decrease in business travel and meals expense
by $28,055 or 47.2%, from $59,465 in fiscal year 2019 to $31,410 in fiscal year 2020, primarily due to our reduced sales activities from
early February to early March 2020 as affected by the COVID-19 pandemic. During the one-month temporary closure of our facilities in response
to the COVID-19 outbreak, we reduced business travels and we only paid basic salary to our sales personnel during this period of time;
and (iii) an increase in shipping and delivery expenses by $119,389, or 26.1%, from $457,407 in fiscal year 2019 to $576,796 in fiscal
year 2020, because we outsourced most of the shipping and delivery services to third-party logistic companies and used more express shipping
services in order to timely deliver products to our customers in response to transportation and logistics disruptions caused by the COVID-19
pandemic, especially to customers located at remote geographic areas. This resulted in higher shipping and delivery expenses in the fiscal
year 2020 as compared to the fiscal year 2019. These above-mentioned factors combined led to the decrease in our selling expenses in the
fiscal year 2020 as compared to the fiscal year 2019. As a percentage of revenues, our selling expenses accounted for 5.1% and 4.8% of
our total revenue for the years ended September 30, 2020 and 2019, respectively.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our general and administrative expenses primarily
consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve expenses, inspection and maintenance expenses,
office supply and utility expenses, business travel and meals expenses, land and property taxes and professional service expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and employee benefit expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">464,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">529,745</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">36.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(65,215</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(12.3</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">209,194</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,524</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9.8</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Bad debt reserve expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">297,972</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(199,871</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(67.1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Land and property tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,904</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.9</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Office supply and utility expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,891</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,448</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Transportation, business travel and meals expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,553</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,402</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18.2</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Consulting fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">616,982</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,906</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">562,076</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1023.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Inspection and maintenance fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,825</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,919</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44,094</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(66.9</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Stamp tax and other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,718</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,483</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18.8</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total general and administrative expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,703,424</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,457,393</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">246,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16.9</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 73; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our general and administrative expenses increased
by $246,031, or 16.9% from $1,457,393 in fiscal year 2019 to $1,703,424 in fiscal year 2020, primarily attributable to (i) an increase
in our professional service fees by $562,076 in fiscal year 2020 as compared to fiscal year 2019, primarily due to increased audit fee
in connection with the audits of our financial statements for the years ended September 30, 2020, 2019 and 2018 for our IPO, and (ii)
an increase in our office supply and utility expenses by $38,448, or 49.6%, to support our administration activities, offset by (x) a
decrease in our salaries, welfare expenses and insurance expenses paid to administration employees by $65,215, or 12.3%, because lower
amount of annual bonus was distributed to administrative staffs in fiscal year 2020 as compared to fiscal year 2019, and (y) a decrease
in bad debt expense by $199,871, or 67.1%. We generally extend our customers a credit term of 90 days. Based on our management&#8217;s
assessment of the collectability of our outstanding accounts receivable, we accrued increased bad debt reserve in fiscal year 2019 than
we did in fiscal year 2020. The overall increase in our general and administrative expenses in fiscal year 2020 as compared to fiscal
year 2019 reflected the above-mentioned factors combined. As a percentage of revenues, general and administrative expenses were 5.5% and
4.4% of our revenue for the years ended September 30, 2020 and 2019, respectively.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and development expenses </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development expenses primarily
consist of salaries, welfare and insurance expenses paid to our employees involved in the research and development activities, materials
and supplies used in the development and testing new TCMD products, depreciation and other miscellaneous expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and employee benefit expenses to R&amp;D staff</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">97,444</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16.7</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">76,973</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12.4</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,471</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">26.6</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Materials used in R&amp;D activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">469,788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">524,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(54,306</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10.4</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,893</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,370</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,477</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8.5</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total R&amp;D expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">583,125</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">618,437</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(35,312</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(5.7</td><td style="padding-bottom: 4pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses decreased by
$35,312, or 5.7%, from $618,437 for the fiscal year 2019 to $583,125 for the fiscal year 2020, primarily attributable to a decrease in
the materials used in the R&amp;D activities by $54,306. In fiscal year 2019, in order to develop new products and improve the formulation
of several existing products, we conducted more testing on product stability and safety, and as a result, more materials were used in
our R&amp;D activities in fiscal year 2019 than in fiscal year 2020. As a percentage of revenues, research and development expenses were
1.9% and 1.9% of our revenue for the years ended September 30, 2020 and 2019, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 74; Value: 55 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other income (expenses), net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our other income (expenses) primarily include
interest expenses incurred on our short-term bank loans, gain or loss from disposal of fixed assets, and investment income from our long-term
investment in exchange for a 5% ownership interest in a local bank. Total other expenses, net, increased by $51,525 or 51.6%, from $99,767
in fiscal year 2019 to $151,292 in fiscal year 2020, due to the following reasons:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses decreased by $5,508, or 4.3%,
from $129,268 in fiscal year 2019 to $123,760 in fiscal year 2020. The decrease in our interest expenses was affected by 2.0% negative
impact from foreign exchange rate fluctuation when the average rate used to convert RMB into U.S. dollars changed from US$1.00 to RMB
6.8729 in fiscal year 2019 to US$1.00 to RMB 7.0077 in fiscal year 2020. As of September 30, 2020 and 2019, we carried a total of RMB18
million ($2.5 million) outstanding bank loans that we borrowed from Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) for
working capital purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other expense increased by $52,112, from other
income of $2,760 in fiscal year 2019 to other expense of $49,352 in fiscal year 2020, because we paid RMB330,000 (US$49,252) as work injury
compensation to one worker in fiscal year 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity investment income was $21,820 and $26,741
for the years ended September 30, 2020 and 2019, respectively. From March 2009 to September 2017, we invested approximately RMB5 million
($0.7 million) in JX RCB Bank in exchange for a 5% ownership interest in the bank. The purpose of this investment was to earn investment
income as JX RCB Bank continues to grow. We account for this investment using the measurement alternative in accordance with ASC 321.
As of September 30, 2020 and 2019, the value of this investment amounted to $735,000 and $700,500, respectively, and was reported as long-term
investment in equity investee on our consolidated balance sheets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provision for Income Taxes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our provision for income taxes was $2,542,211
in fiscal year 2020, an increase of, $440,614, or 21.0% from $2,101,597 in fiscal year 2019 due to our increased taxable income. Under
the EIT Law, domestic enterprises and FIEs are usually subject to a unified 25% enterprise income tax rate while preferential tax rates,
tax holidays and even tax exemption may be granted on a case-by-case basis. The EIT Law grants preferential tax treatment to HNTEs. Under
this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for their
HNTE status every three years. Jiangxi Universe, one of our main operating subsidiaries in the PRC, was approved as an HNTE and was entitled
to a reduced income tax rate of 15% beginning November&#160;2016 with a term of three years. Jiangxi Universe&#8217;s HNTE status was
successfully renewed in December 2019 for a term of three additional years. The EIT Law is typically enforced by the local tax authorities
in the PRC. Each local tax authority has the discretion to grant tax holidays to local enterprises as a way to encourage entrepreneurship
and stimulate local economy. The corporate income taxes for the years ended September 30, 2020 and 2019 were reported at a blended reduced
rate since Jiangxi Universe enjoys a 15% reduced income tax rate due to its HNTE status and Universe Trade is subject to a standard 25%
income tax rate. The impact of the tax holidays noted above decreased PRC corporate income taxes by $118,986 and $312,357 for the years
ended September 30, 2020 and 2019, respectively. The benefit of the tax holidays on net income per share (basic and diluted) $0.01 and
$0.02 for the years ended September 30, 2020 and 2019, respectively.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the foregoing, we reported a net
income of $7,558,222 for the fiscal year ended September 30, 2020, representing a $6,757 increase from a net income of $7,551,465 for
the fiscal year ended September 30, 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. <span style="text-decoration:underline">Liquidity and Capital Resources</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2021, we closed our IPO of 5,000,000
ordinary shares, par value $0.003125 per share at a public offering price of $5.00 per share. On March 29, 2021, the underwriter exercised
in full its over-allotment option to purchase an additional 750,000 ordinary shares.&#160;<span>The closing
for the sale of the over-allotment shares took place on March 31, 2021. Gross proceeds of our IPO, including the proceeds from the sale
of the over-allotment shares, totaled $28.75 million, before deducting underwriting discounts and other related expenses</span>. Net proceeds
of our IPO, including over-allotment shares, were approximately $25.6 million. In connection with the IPO, our ordinary shares began trading
on the Nasdaq Global Market&#160;under the symbol &#8220;UPC&#8221; on March 23, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2021, we had $8,077,908 in cash
on hand. We also had short-term investments of $13.7 million in wealth management financial products from financial institutions to generate
investment income, which we purchased with the proceeds from the IPO proceeds. Such short-term investment can be redeemed anytime at our
discretion and is highly liquid. As of September 30, 2021, we also had $15,573,742 in accounts receivable. Our accounts receivable primarily
include balance due from customers for our pharmaceutical products sold and delivered to customers. No single customer accounts for more
than 10% of our total accounts receivable balance as of September 30, 2021. Approximately 75.4%, or $11.7 million, of our net accounts
receivable balance as of September 30, 2021 had been subsequently collected during the period from October 2021 to December 31, 2021.
Collected accounts receivable will be used as working capital in our operations, if necessary.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 75; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes our accounts receivable
and subsequent collection by aging bucket:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Accounts Receivable by aging bucket</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance as of <br/> September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Subsequent <br/> collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of <br/> subsequent <br/> collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Less than 3 months</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,587,490</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,991,589</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">69.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>From 4 to 6 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,922,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,541,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>From 7 to 9 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">356,267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>From 10 to 12 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,124</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,193</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Over 1 year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,162</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total gross accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,020,269</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,739,179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(446,527</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Accounts Receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,573,742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,739,179</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">75.4</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160; &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, our inventory balance
amounted to $2,462,542, primarily consisting of raw materials and work-in-progress and finished TCMD products, which we believe are able
to be sold quickly based on the analysis of the current trends in demand for our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also had advance to suppliers balance of $2,738,313,
representing prepayment to our raw material suppliers to ensure continuous supply of high-quality raw materials at favorable purchase
prices. As of the date of this annual report, 66.1% of the advance to supplier balance has been realized when we received the purchased
raw materials from our suppliers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, we also had prepayment
to an advertising agency of $7.5 million. On September 6, 2021, we entered into an advertising service agreement with a third party, Fengyang
Legend, pursuant to which, Fengyang Legend agreed to assist us in developing and producing a TV advertisement for promoting the sales
of our major TCMD products, Bai Nian Dan and Guben Yanling Pill, and coordinating with a TV channel to broadcast the advertisement to
targeted geographic market areas. The total advertising service fee under this agreement is RMB55 million (approximately $8.5 million)
with a service period of one year, from October 1, 2021 to September 30, 2022. Pursuant to the terms under this agreement, we made an
advance payment in the amount of 30% of the total advertising service fee to Fengyang Legend, and we will be required to pay Fengyang
Legend in the amount of 58% of the total advertising service fee once the TV channel on which the advertisement will be broadcasted is
determined. As of September 30, 2021, a total of RMB48.4 million (approximately $7.5 million) had been paid to Fengyang Legend and was
recorded as prepayment for advertising services on the balance sheets, which has been expensed since the time when our TV advertisement
was first broadcasted on October 31, 2021.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year 2021, we also started to
construct new manufacturing facilities in order to expand our future production capacity. On June 25, 2021, we entered into a construction
contract with a sub-contractor, Chenyuan, pursuant to which, Chenyuan will construct four manufacturing plants and an office building
with a total estimated maximum budget of RMB165 million (approximately $25.5 million). The construction work stated on August 8, 2021,
with an estimated completion date on August 7, 2023. As of September 30, 2021, we had made prepayment of approximately RMB69.2 million
(approximately $10.7 million) to Chenyuan to start the CIP project, including land improvement, building foundation and the construction
of the manufacturing plants. As of September 30, 2021, the $10.7 million prepayment to Chenyuan was recorded as prepayment for CIP Project
on the balance sheets. As of September 30, 2021, future additional capital expenditure on this CIP Project was estimated to be approximately
RMB95.8 million (equivalent to $14.8 million), among which approximately $3.8 million is required for the next 12 months ending September
30, 2022. We currently plan to support our ongoing CIP Project through cash flows from operations, proceeds received from the IPO, and
borrowings from banks, if necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 76; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, we also made a prepayment
of $2,476,800 to a related party in order to purchase certain residential and commercial property. On May 6, 2021, we entered into a real
estate property purchase agreement with a related party, Jiangxi Yueshang Investment Co., Ltd. (&#8220;Jiangxi Yueshang&#8221;), an entity
in which our CEO, Mr. Gang Lai, owns 5% equity interest. Pursuant to this purchase agreement, Jiangxi Yueshang will sell and we will purchase
certain residential apartments and commercial office space totaling 2,749.30 square meters, with a total purchase price of RMB32 million
(approximately $4.95 million). Pursuant to this purchase agreement, we were required to make a prepayment in the amount of 50% of the
total purchase price, with 20% of the total purchase price payable when certificate of occupancy is available to us, and 30% of the total
purchase price payable upon delivery of the property. As of September 30, 2021, we had made prepayment of RMB16 million ($2,476,800) to
Jiangxi Yueshang. The remaining balance is expected to be paid by August 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, we also had short-term
bank loans of $4,334,400 that we obtained from LRC Bank for working capital purposes. We expect that we will be able to renew all of the
existing bank loans upon their maturity based on our past experiences and our outstanding credit history. The balance of our due to related
parties was $19,723 as of September 30, 2021, representing cash advances from our controlling shareholders to be used as our working capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, our working capital
balance was $39,270,636. In assessing our liquidity, management monitors and analyzes our cash on-hand, our ability to generate sufficient
revenue in the future, and our operating and capital expenditure commitments. We believe that our current cash and cash flows provided
by operating activities, borrowings from banks and from our principal shareholders and proceeds received from the IPO will be sufficient
to meet our working capital needs in the next 12 months from the date the audited financial statements were issued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160; &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth summary of our
cash flows for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash provided by (used in) operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,055,847</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,115,157</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,203,755</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,059,958</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(51,798</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(86,033</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash used in financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,581,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">470,136</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,003,857</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effect of exchange rate change on cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">553,702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">347,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(126,720</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,980,294</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,880,881</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,012,855</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,058,202</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,177,321</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,190,176</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Cash, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,077,908</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,058,202</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,177,321</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities was $2,055,847
for the year ended September 30, 2021, primarily consisting of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income of $11,319,952 for the fiscal year.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">An increase in accounts receivable of $3,867,457. Our accounts receivable
primarily includes balance due from customers for our pharmaceutical products sold and delivered to customers. As of September 30, 2021,
most of our outstanding accounts receivable aged below six months. Approximately 75.4% of our net accounts receivable balance as of September
30, 2021 have been subsequently collected as of the date of this annual report. Collected accounts receivable will be used as working
capital in our operations, if necessary.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in inventory balance of $451,634 because we increased the stockpile of raw materials in order to meet the future production need.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in advance to suppliers of $2,717,085, representing prepayments made to certain suppliers to ensure continuous supply of raw materials at favorable purchase prices. Approximately 66.1% of the advance to suppliers balance as of September 30, 2021 has been subsequently realized when we received the purchased raw materials from the suppliers as of the date of this annual report.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 77; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">An increase in prepayment to an advertising agency of $7,434,240 in
order to engage this advertising agency to develop and produce TV advertisement for promoting the sales of our major TCMD product, Bai
Nian Dan and Guben Yanling Pill, and coordinate with a TV channel to broadcast the advertisement to targeted geographic market areas.
&#160;Such prepayment has been charged to expense when our TV advertisement was first broadcasted in October 2021.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in accounts payable of $2,457,337 primarily due to increased purchase of inventories and we have not received related invoices from the suppliers and accordingly such payable had not been settled as of September 30, 2021. Most of the outstanding accounts payable balance has been subsequently settled as of the date of this annual report.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by operating activities was
$6,115,157 for the year ended September 30, 2020, primarily consisting of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income of $7,558,222 for the fiscal year ended September 30, 2020.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in accounts receivable of $4,107,520. Our accounts receivable primarily includes balance due from customers for our pharmaceutical products sold and delivered to customers. As of September 30, 2020, most of our outstanding accounts receivable aged below six months. Approximately 99% of our net accounts receivable balance as of September 30, 2020 have been subsequently collected as of the date of this annual report. Collected accounts receivable will be used as working capital in our operations, if necessary. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in inventory balance of $888,607 because in fiscal year 2020, we have implemented our&#160;inventory control policy based on sales order level in order to avoid over-stockpile of raw materials and third-party products to reduce risks associated with slow-moving and obsolete in inventories.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in accounts payable of $639,427 because we normally arrange the payment to suppliers upon receipt of the invoices from them. As of September 30, 2020, the increase in accounts payable was largely due to pending invoices from suppliers. Approximately 80% of the September 30, 2020 accounts payable balance has been subsequently settled as of the date of this annual report. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in taxes payable of $731,518 primarily due to an increased taxable income.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by operating activities was
$13,203,755 for the year ended September 30, 2019, primarily consisting of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income of $7,551,466 for the fiscal year ended September 30, 2019.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in accounts receivable of $665,485 because we collected the same amount of accounts receivable. Our accounts receivable primarily includes balance due from customers for our pharmaceutical products sold and delivered to customers. As of date of this annual report, approximately 98%, or $6.3 million of our net accounts receivable balance as of September 30, 2019 have been subsequently collected. Collected accounts receivable will be used as working capital in our operations, if necessary. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in inventory balance of $5,586,177. As discussed above, our manufacturing activities were temporarily suspended from August 2019 and September 2019 we conducted maintenance for our manufacturing facility to improve its environment, including cleaning and upgrading the machineries and equipment, in order to both meet the strict requirements for the renewal of our GMP Certificate renewal and ensure the quality and safety of our products. During the period when our business was temporarily closed, we reduced the purchase of our raw material inventories, which led a decrease in our ending inventory balance as of September 30, 2019. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 78; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in accounts payable of $924,444 for the fiscal year. The decrease in our accounts payable balance as of September 30, 2019 was largely attributable to our temporary suspension of our manufacturing activities in August 2019 and September 2019 as discussed above. During this period, we conducted maintenance for our manufacturing facility to improve its environment, including cleaning and upgrading the machineries and equipment, in order to both meet the strict requirements for the renewal of our GMP Certificate renewal and ensure the quality and safety of our products. As a result, we reduced the purchase of raw materials on credit from our suppliers, which led to a decrease in our accounts payable balance as of September 30, 2019.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in taxes payable of $320,611 for the fiscal year primarily due to our reduced VAT tax payable from decrease in the amount of &#160;raw materials purchased in August 2019 and September 2019 when our manufacturing facility was temporarily closed.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities amounted to
$27,059,958 for the year ended September 30, 2021 and primarily included (i) purchase of fixed assets of $444,505; (ii) prepayment of
$2,457,600 made to a related party to purchase residential and commercial property; (iii) prepayment of $10,629,120 made to a sub-contractor
in order to complete the CIP Project, including four manufacturing plants and an office building, with estimated project completion in
August 2023; (iv) purchase of short-term investments of $15,330,660 because we used part of the IPO proceeds to purchase certain wealth
management financial products from financial institutions in order to earn investment income; and (v) redemption of short-term investments
of $1,801,927.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in investing activities amounted
to $51,798 for the year ended September 30, 2020, and primarily included the purchase of fixed assets in the same amount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in investing activities amounted
to $86,033 for the year ended September 30, 2019, and primarily included the purchase of fixed assets of $86,324 and proceeds of $291
from disposal of fixed assets.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities amounted
to $26,581,809 for the year ended September 30, 2021, primarily include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from short-term bank loans of $4,300,800 and offset by repayment of bank loans of $2,764,800 upon loan maturity. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net proceeds of $25,957,457 received upon completion of our IPO in March 2021.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment of related party borrowings of $911,648. The balance due to related party mainly consisted of advances from our principal shareholder for working capital purposes during our normal course of business. These advances were non-interest bearing and due on demand. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities amounted
to $470,136 for the year ended September 30, 2020, primarily include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from short-term bank loans of $1,427,000 and repayment of bank loans of $1,427,000. During fiscal year 2020, our subsidiary Universe Trade repaid RMB8 million loan to LRC Bank upon maturity and at the same time, renewed the loan agreement to borrow RMB8 million for additional six months until March 31, 2021.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment for deferred public offering costs of $441,064. Deferred offering costs consisted principally of legal, underwriting, and other professional service expenses in connection with the IPO of our ordinary shares. As of September 30, 2020, we capitalized $441,064 of deferred offering costs. Such costs were deferred until the closing of the IPO, at which time the deferred costs were offset against the offering proceeds.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 79; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from related party borrowings of $911,200. The balance due to related party mainly consisted of advances from our principal shareholder for working capital purposes during our normal course of business. These advances were non-interest bearing and due on demand. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in financing activities amounted
to $16,003,857 for the year ended September 30, 2019, primarily include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from short-term bank loans of $3,055,500. During fiscal year 2019, our subsidiaries, Jiangxi Universe and Universe Trade, obtained additional loans in an aggregate amount of RMB21 million ($3.1 million) from LRC Bank for working capital purposes. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: .25in">&#160;</td>
    <td style="width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment of short-term bank loans of $3,055,500 upon loan maturities. In fiscal year 2018, our subsidiaries, Jiangxi Universe and Universe Trade, obtained additional loans in an aggregate amount of RMB21 million from LRC Bank for working capital purposes. We repaid these loans upon maturity and entered into new loan contracts with LRC bank during fiscal year 2019.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend payment of $16,005,000. On September 21, 2016, September 13, 2017, February 2, 2018, September 20, 2018 and February 21, 2019, the board of directors of our subsidiary, Jiangxi Universe, adopted resolutions to pay cash dividends of RMB40 million, RMB30 million, RMB20 million, RMB10 million and RMB30 million, respectively, to its shareholders at the time of record out of the retained earnings balance of Jiangxi Universe, to be paid to these shareholders when Jiangxi Universe has sufficient available earnings funds. A total of $19.1 million (RMB130 million) cash dividend was declared from September 2016 to February 2019, among which $3.1 million (RMB20 million) was paid in cash to its shareholders in fiscal year 2018 and the remaining $16 million (RMB 110 million) was paid to its shareholders in fiscal year 2019.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: .25in">&#160;</td>
    <td style="width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from related party borrowings of $1,143. The balance due to related party mainly consisted of advances from our principal shareholder for working capital purposes during our normal course of business. These advances were non-interest bearing and due on demand.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Commitments and contingencies </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we are a party to various legal
actions arising in the ordinary course of business. We accrue costs associated with these matters when they become probable and the amount
can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. For the years ended
September 30, 2021, 2020 and 2019, we did not have any material legal claims or litigation that, individually or in aggregate, could have
a material adverse impact on our consolidated financial position, results of operations and cash flows.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160; <b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of September 30, 2021, we had the following contractual obligations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Payment Due by Period</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Contractual obligations</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Less than 1 year</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">1-2 years</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2-3 years</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Debt obligations (1), (2) and (3)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">4,334,400</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,334,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Payment for advertising fees (4)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,013,760</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,013,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Capital expenditure commitment on CIP project (5)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">14,829,840</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,831,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,721,440</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,277,100</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,178,000</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,179,460</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">9,721,440</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,277,100</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td>
    <td style="text-align: justify">On June 16, 2021, the Company&#8217;s subsidiary, Jiangxi Universe,
signed a loan agreement with LRC Bank to borrow RMB10 million (equivalent to $1,548,000) as working capital for one year, with the maturity
date on June 15, 2022. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for this loan.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) </span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On June 30, 2021, the Company&#8217;s subsidiary, Jiangxi Universe,
signed a loan agreement with Bank of Communications to borrow RMB10 million (equivalent to $1,548,000) as working capital for one year,
with the maturity date on June 18, 2022. The fixed interest rate of the loan was 4.5% per annum. Certain related parties of the Company,
including Mr. Gang Lai, our chief executive officer and controlling shareholder, Mr. Gang Lai&#8217;s spouse, Ms. Xing Wu, and our subsidiary,
Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) </span></td>
    <td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">On March 18, 2021, the Company&#8217;s subsidiary Universe Trade signed
a loan agreement with LRC Bank to borrow RMB8 million (equivalent to $1,238,400) as working capital for one year, with the maturity date
on March 17, 2022. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for this loan.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(4) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">On September 6, 2021, we entered into an advertising service agreement with a third party, Fengyang Legend, pursuant to which Fengyang Legend agreed to assist us in developing and producing a TV advertisement for promoting our representative TCMD products, Bai Nian Dan and Guben Yanling Pill, and coordinating with a TV channel to broadcast the advertisement to targeted geographic market areas. The total advertising service fee under this agreement is RMB55 million (approximately $8.5 million) with a service period of one year, from October 1, 2021 to September 30, 2022. Pursuant to the terms under this agreement, we made an advance payment in the amount of 30% of the total advertising service fee to Fengyang Legend, and we will be required to pay Fengyang Legend in the amount of 58% of the total advertising service fee once the TV channel on which the advertisement will be broadcasted is determined. As of September 30, 2021, a total of RMB48.4 million (approximately $7.5 million) had been paid to Fengyang Legend and was recorded as prepayment for advertising services on the balance sheets. Such prepayment had been expensed when the advertising was first broadcasted in October 2021. The remaining RMB6.6 million (approximately $1 million) represents the monthly advertising fees to be paid in 13 installments throughout the period when the advertisement is broadcasted through the designated TV channel and will be expensed as incurred. </span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5) </span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 25, 2021, the Company signed a construction
    sub-contract with sub-contractor Chenyuan, pursuant to which, Chenyuan will construct four manufacturing plants and an office building
    with a total estimated maximum budget of RMB165 million (approximately $25.5 million). The construction work started on August 8, 2021,
    with an estimated completion date on August 7, 2023. As of September 30, 2021, we had made prepayment of approximately RMB69.2 million
    (approximately $10.7 million) to Chenyuan for land improvement, building foundation and the construction of the manufacturing plants.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, the $10.7 million prepayment
    to Chenyuan was recorded as prepayment for CIP Project on the balance sheets.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, future additional capital
    expenditure on this CIP Project is estimated to be approximately RMB95.8 million (equivalent to $14.8 million), among which approximately
    $3.8 million is required for the next 12 months ending September 30, 2022. The Company currently plans to support its ongoing CIP Project
    through cash flows from operations, proceeds received from the IPO, and borrowings from banks, if necessary. The CIP Project is expected
    to be fully completed, and the new manufacturing plants and office building are expected to be put into use by August 2023.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not have any off-balance sheet arrangements
as of September 30, 2021, 2020 and 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Inflation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inflation does not materially affect our business
or the results of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Seasonality </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Seasonality does not materially affect our business
or the results of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. <span style="text-decoration:underline">Research and Development, Patents and
Licenses,&#160;etc.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Item 4. Information on the Company&#8212;B.
Business Overview&#8212;Intellectual Property&#8221; and &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Research
and Development.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. <span style="text-decoration:underline">Trend Information</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than as disclosed below and elsewhere in
this annual report on Form&#160;20-F, we are not aware of any trends, uncertainties, demands, commitments, or events for the period from
October&#160;1, 2020 to September 30, 2021 that are reasonably likely to have a material adverse effect on our net revenue, income, profitability,
liquidity, or capital resources, or that caused the disclosed financial information to be not necessarily indicative of future operating
results or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. <span style="text-decoration:underline">Critical Accounting Estimates</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our discussion and analysis of our financial condition
and results of operations are based upon our consolidated financial statements. These financial statements are prepared in accordance
with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;), which requires us to make estimates
and assumptions that affect the reported amounts of our assets and liabilities and revenues and expenses, to disclose contingent assets
and liabilities on the date of the consolidated financial statements, and to disclose the reported amounts of revenues and expenses incurred
during the financial reporting period. The most significant estimates and assumptions include the valuation of accounts receivable and
inventories, realizability of advance to suppliers and prepaid advertising costs, useful lives of property, plant and equipment and intangible
assets, the recoverability of long-lived assets, the impairment of the short-term investments, provision necessary for contingent liabilities,
and revenue recognition. We continue to evaluate these estimates and assumptions that we believe to be reasonable under the circumstances.
We rely on these evaluations as the basis for making judgments about the carrying values of assets and liabilities that are not readily
apparent from other sources. Since the use of estimates is an integral component of the financial reporting process, actual results could
differ from those estimates. Some of our accounting policies require higher degrees of judgment than others in their application. We believe
critical accounting policies as disclosed in this annual report reflect the more significant judgments and estimates used in preparation
of our consolidated financial statements.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 81; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our main operation is located in the PRC. Accordingly,
our business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC,
as well as by the general state of the PRC economy. Our results may be adversely affected by changes in the political, regulatory and
social conditions in the PRC. Although we have not experienced losses from these situations and believes that we are in compliance with
existing laws and regulations including our organization and structure, this may not be indicative of future results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business, financial condition and results
of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics and
other catastrophic incidents, such as the COVID-19 pandemic, which could significantly disrupt our operations.&#160;Our operations may
be further affected by the COVID-19 pandemic.&#160;To reduce the spread of the COVID-19, the Chinese government has employed measures
including city lockdowns, quarantines, travel restrictions, suspension of business activities and school closures. Due to difficulties
resulting from the COVID-19 pandemic, including, but not limited to, the temporary closure of our factory and operations beginning in
early February until to March 2, 2020, limited support from our employees, delayed access to raw material supplies and inability to deliver
products to customers on a timely basis, our business was negatively impacted and generated lower revenue and net income during the period
from February to March 2020. Although we resumed our operations on March 2, 2020 and the COVID-19 impact on our operating results and
financial performance for fiscal years 2020 and 2021 were minimal, any resurgence could negatively affect the execution of customer contracts
and the collection of customer payments, or disrupt our supply chain, and the continued uncertainties associated with the COVID 19 pandemic
may negatively impact our revenue and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercialization of new pharmaceutical
products is highly competitive, and the industry currently is characterized by rapidly changing technologies, significant competition
and a strong emphasis on intellectual property. We may face competition with respect to our current and future pharmaceutical product
candidates from major pharmaceutical companies in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following critical accounting policies rely
upon assumptions and estimates and were used in the preparation of our consolidated financial statements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Uses of estimates</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing the consolidated financial statements
in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant
estimates required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, the
realizability of advance to suppliers, inventory valuation, useful lives of property, plant and equipment, intangible assets, the recoverability
of long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual
results could differ from those estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Accounts receivable, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are presented net of allowance
for doubtful accounts. We determine the adequacy of reserves for doubtful accounts based on individual account analysis and historical
collection trend. We establish a provision for doubtful receivables when there is objective evidence that we may not be able to collect
amounts due. The allowance is based on management&#8217;s best estimate of specific losses on individual exposures, as well as a provision
on historical trends of collections. Actual amounts received may differ from management&#8217;s estimate of credit worthiness and the
economic environment. Delinquent account balances are written-off against the allowance for doubtful accounts after management has determined
that the likelihood of collection is not probable. Allowance for uncollectable balances amounted to $446,527 and $639,991 as of September
30, 2021 and 2020, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><!-- Field: Page; Sequence: 82; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inventories, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at net realizable value
using weighted average method. Costs include the cost of raw materials, freight, direct labor and related production overhead. Any excess
of the cost over the net realizable value of each item of inventories is recognized as a provision for diminution in the value of inventories.
Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. We
evaluate inventories on a quarterly basis for its net realizable value adjustments, and reduces the carrying value of those inventories
that are obsolete or in excess of the forecasted usage to their estimated net realizable value based on various factors including aging,
expiration dates, as applicable, taking into consideration historical and expected future product sales. We recorded inventory reserve
of $116,453 and $110,585 as of September 30, 2021 and 2020, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160; &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue recognition</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To determine revenue recognition for contracts
with customers, we perform the following five steps : (i) identify the contract(s) with the customer, (ii) identify the performance obligations
in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant
future reversal will <i>not</i> occur, (iv) allocate the transaction price to the respective performance obligations in the contract,
and (v) recognize revenue when (or as) we satisfy the performance obligation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recognize revenue when we transfers our goods
and services to customers in an amount that reflects the consideration to which we expect to be entitled in such exchange. We account
for the revenue generated from sales of our TCMD and third-party products on a gross basis as we are acting as a principal in these transactions,
are subject to inventory risk, have latitude in establishing prices, and are responsible for fulfilling the promise to provide customers
the specified goods, which we have control of the goods and has the ability to direct the use of goods to obtain substantially all the
benefits. All of our contracts have one single performance obligation as the promise is to transfer the individual goods to customers,
and there is no separately identifiable other promises in the contracts. Our revenue streams are recognized at a point in time when title
and risk of loss passes and the customer accepts the goods, which generally occurs at delivery. Our products are sold with no right of
return and we do not provide other credits or sales incentive to customers. Revenue is reported net of all VAT.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Contract Assets and Liabilities </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment terms are established on our pre-established
credit requirements based upon an evaluation of customers&#8217; credit quality. Contract assets are recognized for in related accounts
receivable. Contract liabilities are recognized for contracts where payment has been received in advance of delivery. The contract liability
balance can vary significantly depending on the timing when an order is placed and when shipment or delivery occurs. As of September 30,
2021 and 2020, other than accounts receivable and advances from customers, we had no other material contract assets, contract liabilities
or deferred contract costs recorded on its consolidated balance sheet. Costs of fulfilling customers&#8217; purchase orders, such as shipping,
handling and delivery, which occur prior to the transfer of control, are recognized in selling, general and administrative expense when
incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disaggregation of Revenues</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We disaggregate our revenue from contracts by
product types, as we believe it best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows are affected
by economic factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 83; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The summary of our total revenues by product categories
for the years ended September 30, 2021, 2020 and 2019 was as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Revenue by product source </span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Sales of TCMD products manufactured by the Company</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,559,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,374,751</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,895,542</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,333,774</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">33,229,316</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Revenue by product categories </span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Sales of TCMD products:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Medicinal liquor products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,951,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,616,080</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,356,015</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other chronic condition treatment products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,978,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,059,403</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,056,228</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Cold and flu medicines</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,629,606</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,699,268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,483,299</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Sub-total of TCMD products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,559,286</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,374,751</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,895,542</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Sales of third-party products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Biochemical drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,082,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,325,411</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,508,816</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Traditional Chinese medicine pieces</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,097</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,409</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,318,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,950,238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,668,422</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Dietary supplements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,463</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,127</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Subtotal of third-party products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,333,774</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Total revenue</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">33,229,316</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We account for current income taxes in accordance
with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases
of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period
including the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An uncertain tax position is recognized only if
it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination. The amount recognized is the largest
amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more
likely than not&#8221; test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income tax are classified
as income tax expense in the period incurred. No significant penalties or interest relating to income taxes have been incurred during
the years ended September 30, 2021, 2020 and 2019. We do not believe there was any uncertain tax provision at September 30, 2021, 2020
and 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operating subsidiaries in China are subject
to the income tax laws of the PRC. No significant income was generated outside the PRC for the years ended September 30, 2021, 2020 and
2019. As of September 30, 2021 and 2020, all of our tax returns of our PRC subsidiaries remain open for statutory examination by PRC tax
authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 84; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recently Issued Accounting Pronouncements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Recent&#160;Adopted Accounting Pronouncements&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2018, the FASB Accounting Standards
Board issued ASU No. 2018-13, &#8220;Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for
Fair Value Measurement&#8221; (&#8220;ASU 2018-13&#8221;). ASU 2018-13 modifies the disclosure requirements on fair value measurements.
ASU 2018-13 is effective for all entities for fiscal years and interim periods within those fiscal years beginning after December 15,
2019, with early adoption permitted for any removed or modified disclosures. The removed and modified disclosures were adopted on a retrospective
basis and the new disclosures were adopted on a prospective basis. The adoption of this guidance had no material impact on the Company&#8217;s
consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Recent Accounting Pronouncements&#160;not yet
adopted</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February&#160;2016, the FASB issued Accounting
Standards Update (ASU) No.&#160;2016-02,&#160;Leases (Topic 842), which requires lessees to recognize a right-of-use asset and lease liability
on the balance sheet for all leases, including operating leases, with a term in excess of 12 months. The guidance also expands the quantitative
and qualitative disclosure requirements. The new guidance requires the lessee to record operating leases on the balance sheet with a right-of-use
asset and corresponding liability for future payment obligations. In July&#160;2018, FASB issued ASU 2018-11 Leases (Topic 842) &#8211;
Targeted Improvements&#160;that reduces costs and eases implementation of the leases standard for financial statement preparers. The ASU
simplifies transition requirements and, for lessors, provides a practical expedient for the separation of non-lease components from lease
components. ASU 2016-02 was further amended in November&#160;2019 by ASU 2019-10 and in June&#160;2020 by ASU 2020-05, which deferred
the effective date of new lease standard. As a result, ASC 842, Leases, is effective for public companies for annual reporting periods
and interim periods within those years beginning after December&#160;15, 2018. For all other entities, the guidance is effective for fiscal
years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022. As an emerging
growth company, the Company elects to apply for the new and revised accounting standards at the effective date for a private company and
to adopt this guidance effective October 1, 2021. As an emerging growth company, the Company elects to apply for the new and revised accounting
standards at the effective date for a private company and to adopt this guidance effective October&#160;1, 2021. The Company is currently
evaluating the impact of adopting this standard on its consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June&#160;2016, the FASB issued Accounting Standards
Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected
credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and
supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost. ASU 2016-13 was subsequently amended by Accounting Standards Update 2018-19,&#160;Codification Improvements
to Topic 326, Financial Instruments &#8212; Credit&#160;Losses, Accounting Standards Update 2019-04&#160;Codification Improvements to
Topic 326, Financial Instruments &#8212; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, and
Accounting Standards Update 2019-05,&#160;Targeted Transition Relief.&#160;In November&#160;2019, the FASB issued ASU 2019-10, which
extends the effective date for adoption of ASU 2016-13. In November&#160;2019, the FASB issued ASU 2019-11 to clarify its new credit
impairment guidance in ASU 326. Accordingly, for public entities that are not smaller reporting entities, ASU 2016-13 and its amendments
is effective for fiscal years, and interim periods within&#160;those fiscal years, beginning after December&#160;15, 2019. For all other
entities, this guidance and its amendments will be effective for fiscal years beginning after December&#160;15, 2022, including interim
periods within those fiscal years. As an emerging growth company, the Company plans to adopt this guidance effective October 1, 2023.
The Company is currently evaluating the impact of its pending adoption of ASU 2016-13 on its consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 85; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU No. 2019-12,
Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes. ASU 2019-12 is intended to simplify accounting for income
taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application.
ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years, which is the
fiscal year ended September 30, 2021 for us, with early adoption permitted. The Company does not expect adoption of the new guidance to
have a significant impact on our financial statements.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2020, the FASB issued ASU 2020-02,
&#8220;Financial Instruments &#8211; Credit Losses (Topic 326) and Leases (topic 842) Amendments to SEC Paragraphs Pursuant to SEC Staff
Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (topic
842)&#8221;. This ASU provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses.
This ASU is effective for interim and annual periods beginning after December 15, 2019, and early adoption is permitted. The Company is
evaluating the impact of this guidance on its consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. <span style="text-decoration:underline">Directors and Senior Management</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information regarding
our directors and executive officers as of the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 28%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 6%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 64%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position(s)</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gang Lai</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors and Chief Executive Officer</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lin Yang</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Baochang Liu</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiawen Pang</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H. David Sherman</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ding Zheng</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a brief biography of each of
our executive officers and directors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mr. Gang Lai</i></b><i>&#160;</i>is our
chief executive officer and chairman of the board. Mr. Lai has served as the chief executive officer of Jiangxi Universe since 2004 and
founded Universe Trade in 2010. Before joining us, Mr. Lai was a successful entrepreneur. He founded Jiangxi Lvzhouyuan Timber Joint Stock
Co., Ltd. in 2001, a company listed on PRC National Equities Exchange and Quotations (NEEQ: 838893), and has since served as its chairman
of the board. Mr. Lai graduated from Jingdezhen Ceramic Institute with a bachelor&#8217;s degree in mechanical engineering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Ms. Lin Yang</i></b>&#160;is our chief financial
officer and director. Ms. Lin Yang has served as the financial director of Jiangxi Universe since April 2006. Before joining us, Ms. Yang
served as an accountant at Jiangxi Automobile Engineering Plastic Co., Ltd. from 1998 to March 2006. Ms. Yang graduated from Jiangxi University
of Finance and Economics with a bachelor&#8217;s degree in accounting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mr. Baochang Liu</i></b> has served as our
chief operating officer since December 2021. Mr. Liu has over 17 years of experience in pharmaceutical marketing. Since December 2019,
Mr. Baochang Liu has been working as the vice president of marketing and general manager of OTC department at China Shineway Pharmaceutical
Group Ltd. (HKEX: 2877). From November 2015 to December 2019, Mr. Baochang Liu served as the general manager of OTC department at Chengdu
Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773). Prior to that, Mr. Liu worked as the general marketing manager at Chengdu Rongyao
Industry (Group) Co., Ltd. from December 2012 to November 2015. Mr. Baochang Liu obtained his bachelor&#8217;s degree in accounting and
in marketing management from Harbin University of Commerce in 2004.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 86; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mr. Jiawen Pang</i></b>&#160;has served
as our independent director since March 2021. Mr. Jiawen Pang has served as the marketing director at Shanghai Raas Blood Products Co.,
Ltd. since September 2014, a company listed on the Shenzhen Stock Exchange (SZSE: 002252). Mr. Xiao served as the business and marketing
director at Shandong Bausch &amp; Lomb Freda Pharmaceutical Co., Ltd. from May 2011 to August 2014. Prior to that, Mr. Xiao served as
the marketing director at Guangdong Bangmin Pharmaceutical Co., Ltd. from July 2001 to April 2011. Mr. Xiao graduated from Sun Yat-sen
University with a master of business administration in healthcare and medicine. We believe Mr. Pang is qualified to serve on our board
of directors as one of our independent directors due to his over substantial work experience and expertise in the pharmaceutical industry,
and his significant management experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mr. H David Sherman</i></b>&#160;has served
as our independent director since March 2021. Mr. H David Sherman has served as a full-time professor at Northeastern University since
1985. Mr. Sherman has extensive experience serving as independent director of public companies listed on Nasdaq. Since 2020, Mr. Sherman
served as an independent director and chair of the audit committee of Skillful Craftsman Education Technology Ltd. (Nasdaq: EDTK). Since
2019, Mr. Sherman has served as an independent director of Newborn Acquisition Corp. (Nasdaq: NBAC). From From April 2020 to August 2021,
Mr. Sherman has served as an independent director and chair of the audit committee of China Liberal Education Holdings Limited (Nasdaq:
CLEU). From December 2017 to August 2019, Mr. Sherman served as an independent director and chair of audit committee of Dunxin financial
Holdings from (NYSE American: DXF) January 2018 to August 2019. From January 2010 to August 2012, Mr. Sherman served as the chair of the
audit committee of China HGS Real Estate Inc. (Nasdaq: HGSH). From January 2012 to November 2014, Mr. Sherman served as chair the audit
committee and compensation committee of Agfeed Corporation (OTC: FEED). Mr. Sherman received his bachelor&#8217;s degree in economics
from Brandies University in 1969, his master&#8217;s in business administration from Harvard University in 1971, and his doctorate degree
in business administration from Harvard University in 1981. Mr. Sherman is a member of the American Institute of Certified Public Accountant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mr. Ding Zheng</i></b><i>&#160;</i>has served
as our independent director since March 2021. Mr. Ding Zheng has served as the chairman of the board at Guangzhou Roujing Sunshade Energy-saving
Technology Co., Ltd. since 2019. Mr. Zheng has also served as the general manager at Hande Manufacturing (China) Co., Ltd., since 2015.
From 2007 to 2015, Mr. Zheng served as the financial director at Hunter Douglas (China) Holdings Co., Ltd. Prior to that, Mr. Zheng served
as the manager of finance at Esquel Group from 2005 to 2007. Mr. Zheng obtained a bachelor&#8217;s degree in technology economics from
Shanghai Jiao Tong University and a master of business administration degree from Tsinghua University. Mr. Zheng is a member of the China
Institute of Certified Public Accountants (CICPA). We believe Mr. Zheng is qualified to serve on our board of directors as one of our
independent directors due to his deep financial expertise and his substantial experience in the financial industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Diversity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below provides certain information regarding
the diversity of our board of directors as of the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Diversity Matrix</b></span></p><div>



</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Country of Principal Executive Offices:</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign Private Issuer</span></td>
    <td>&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Prohibited under Home Country Law</span></td>
    <td>&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Number of Directors</span></td>
    <td>&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center">
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></p></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt 0.5pt 1.5pt; text-align: center; width: 49%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 11%; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Female</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 11%; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Male</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; width: 11%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Non-
                                            </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Binary</b></p></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 12%; padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Did
    Not<br/>
    Disclose<br/>
    Gender</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part
    I: Gender Identity</b></span></td>
    <td colspan="7" style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td>&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td>&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part
    II: Demographic Background</b></span></td>
    <td colspan="7" style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underrepresented
    Individual in Home Country Jurisdiction</span></td>
    <td colspan="7" style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LGBTQ+</span></td>
    <td colspan="7" style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did
    Not Disclose Demographic Background</span></td>
    <td colspan="7" style="padding-top: 0.25pt; padding-right: 0.5pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  </table><div>

</div><p style="margin: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 87; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of our directors or executive officers has
a family relationship as defined in Item 401 of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Controlled Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Gang Lai, our chief executive officer, director,
and chairman of the board of directors, currently beneficially own approximately 59.43% of the aggregate voting power of our outstanding
ordinary shares. As a result, we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing rules. As a controlled
company, we are permitted to elect to rely on certain exemptions from the obligations to comply with certain corporate governance requirements,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: .25in">&#160;</td>
    <td style="width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that a majority of the board of directors consist of independent directors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that our director nominees be selected or recommended solely by independent directors; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that we have a nominating and corporate governance committee and a compensation committee that are composed entirely of independent directors with a written charter addressing the purposes and responsibilities of the committees.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we do not intend to rely on the controlled
company exemptions under the Nasdaq listing rules even if we are a controlled company, we could elect to rely on these exemptions in the
future, and if so, you would not have the same protection afforded to shareholders of companies that are subject to all of the corporate
governance requirements of Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="text-decoration:underline">Compensation</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the fiscal year ended September 30, 2021,
we paid an aggregate of $74,188 as compensation to our executive officers and directors. None of our non-employee directors have any service
contracts with us that provide for benefits upon termination of employment. We have not set aside or accrued any amount to provide pension,
retirement, or other similar benefits to our directors and executive officers. Our PRC subsidiaries are required by law to make contributions
equal to certain percentages of each employee&#8217;s salary for his or her pension insurance, medical insurance, unemployment insurance,
and other statutory benefits and a housing provident fund.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. <span style="text-decoration:underline">Board Practices</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors consist of five directors,
including three independent directors. A director is not required to hold any shares in our company to qualify to serve as a director.
A director may vote with respect to any contract, proposed contract or arrangement in which he is materially interested, provided that
(a) such director, if his or her interest in such contract or arrangement is material, has declared the nature of his or her interest
at the earliest meeting of the board at which it is practicable for him or her to do so, either specifically or by way of a general notice
and (b) if such contract or arrangement is a transaction with a related party, such transaction has been approved by the audit committee.
The directors may exercise all the powers of the company to borrow money, mortgage its undertaking, property and uncalled capital, and
issue debentures or other securities whenever money is borrowed or as security for any obligation of the company or of any third party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 88; Value: 55 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have established three committees under the
board of directors: an audit committee, a compensation committee, and a nominating and corporate governance committee. We have adopted
a charter for each of the three committees. Each committee&#8217;s members and functions are described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Audit Committee.</i>&#160;Our audit committee
consists of Jiawen Pang, H. David Sherman, and Ding Zheng. H. David Sherman serves as the chairman of our audit committee. We have determined
that Jiawen Pang, H. David Sherman, and Ding Zheng satisfy the &#8220;independence&#8221; requirements of&#160;<span>Rule
5605(a)(2) of the Listing Rules of the Nasdaq Stock Market</span>&#160;and Rule 10A-3 under the Securities Exchange Act. Our board also
has determined that H. David Sherman qualifies as an audit committee financial expert within the meaning of the SEC rules or possesses
financial sophistication within the meaning of the Nasdaq corporate governance rules. The audit committee oversees our accounting and
financial reporting processes and the audits of the financial statements of our company. The audit committee is responsible for, among
other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing the independent auditors and pre-approving all auditing and non-auditing services permitted to be performed by the independent auditors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing with the independent auditors any audit problems or difficulties and management&#8217;s response;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing the annual audited financial statements with management and the independent auditors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures and any steps taken to monitor and control major financial risk exposures;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving all proposed related party transactions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting separately and periodically with management and the independent auditors; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Committee.</i>&#160;Our compensation
committee consists of Jiawen Pang, H. David Sherman, and Ding Zheng. Jiawen Pang serves as the chairperson of our compensation committee.
We have determined that Jiawen Pang, H. David Sherman, and Ding Zheng satisfy the &#8220;independence&#8221; requirements of&#160;<span>Rule
5605(a)(2) of the Listing Rules of the Nasdaq Stock Market</span>&#160;and Rule 10C-1 under the Securities Exchange Act. The compensation
committee assists the board in reviewing and approving the compensation structure, including all forms of compensation, relating to our
directors and executive officers. Our chief executive officer may not be present at any committee meeting during which his compensation
is deliberated. The compensation committee is responsible for, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving the total compensation package for our most senior executive officers;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving and overseeing the total compensation package for our executives other than the most senior executive officers;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending to the board with respect to the compensation of our directors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing periodically and approving any long-term incentive compensation or equity plans;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting compensation consultants, legal counsel or other advisors after taking into consideration all factors relevant to that person&#8217;s independence from management; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing programs or similar arrangements, annual bonuses, employee pension and welfare benefit plans.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 89; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Nominating and Corporate Governance Committee.</i>&#160;Our
nominating and corporate governance committee consists of Jiawen Pang, H. David Sherman and Ding Zheng. Ding Zheng serves as the chairperson
of our nominating and corporate governance committee. Jiawen Pang, H. David Sherman, and Ding Zheng satisfy the &#8220;independence&#8221;
requirements of&#160;<span>Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock Market</span>. The
nominating and corporate governance committee assists the board of directors in selecting individuals qualified to become our directors
and in determining the composition of the board and its committees. The nominating and corporate governance committee is responsible for,
among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying and recommending nominees for election or re-election to our board of directors or for appointment to fill any vacancy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing annually with our board of directors its current composition in light of the characteristics of independence, age, skills, experience and availability of service to us;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying and recommending to our board the directors to serve as members of committees;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advising the board periodically with respect to significant developments in the law and practice of corporate governance as well as our compliance with applicable laws and regulations, and making recommendations to our board of directors on all matters of corporate governance and on any corrective action to be taken; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Duties of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Cayman Islands law, all of our directors
owe three types of duties to us: (i) statutory duties, (ii) fiduciary duties, and (iii) common law duties. The Companies Act (Revised)
of the Cayman Islands imposes a number of statutory duties on a director. A Cayman Islands director&#8217;s fiduciary duties are not codified,
however, the courts of the Cayman Islands have held that a director owes the following fiduciary duties: (a) a duty to act in what the
director <i>bona fide</i> considers to be in the best interests of the company, (b) a duty to exercise their powers for the purposes they
were conferred, (c) a duty to avoid fettering his or her discretion in the future and (d) a duty to avoid conflicts of interest and of
duty. The common law duties owed by a director are those to act with skill, care and diligence that may reasonably be expected of a person
carrying out the same functions as are carried out by that director in relation to the company and, also, to act with the skill, care
and diligence in keeping with a standard of care commensurate with any particular skill they have which enables them to meet a higher
standard than a director without those skills. In fulfilling their duty of care to us, our directors must ensure compliance with our amended
and restated articles of association. We have the right to seek damages if a duty owed by any of our directors is breached.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has all powers necessary
for managing, and for directing and supervising, our business affairs. The functions and powers of our board of directors include, among
others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convening shareholders&#8217; annual general meetings and reporting its work to shareholders at such meetings;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">declaring dividends and distributions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing officers and determining the terms of office of the officers;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercising the borrowing powers of our company and mortgaging the property of our Company; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving the transfer of shares in our Company, including the registration of such shares in our share register.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Terms of Directors and Executive Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our directors may be elected by a resolution of
our board of directors or by an ordinary resolution of our shareholders. Our directors are not subject to a term of office and hold office
until such time as they are removed from office by ordinary resolution of the shareholders. A director will cease to be a director if,
among other things, the director (i) becomes bankrupt or makes any arrangement or composition with his creditors; (ii) dies or is found
by our company to be or becomes of unsound mind; (iii) resigned his or her office by notice in writing to the company; or (iv) without
special leave of absence from our board, is absent from three consecutive board meetings and our directors resolve that his office be
vacated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our officers are elected by and serve at the discretion
of the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 90; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Qualification</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is currently no shareholding qualification
for directors, although a shareholding qualification for directors may be fixed by our shareholders by ordinary resolution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreements and Indemnification Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into employment agreements with
each of our executive officers. Pursuant to these employment agreements, we agree to employ each of our executive officers for a specified
time period, which may be renewed automatically unless either party gives the other party a two-month prior written notice before the
end of the current employment term. We may terminate the employment for cause, at any time, without notice or remuneration, for certain
acts of the executive officer, including but not limited to, the commitments of any serious or persistent breach or non-observance of
the terms and conditions of the employment, conviction of a criminal offense, willful disobedience of a lawful and reasonable order, fraud
or dishonesty, receipt of bribery, or severe neglect of his or her duties. An executive officer may terminate his or her employment at
any time with a two-month prior written notice. Each executive officer agrees to hold, both during and after the employment agreement
expires, in strict confidence and not to use or disclose to any person, corporation or other entity without written consent, any confidential
information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have also entered into indemnification agreements
with each of our directors and executive officers. Under these agreements, we agree to indemnify our directors and executive officers
against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being a director or
officer of our Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Insider Participation Concerning Executive
Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our director, Mr. Gang Lai, was making all determinations
regarding executive officer compensation from the inception of the Company until our Compensation Committee was set up in March 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Code of Business Conduct and Ethics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has adopted a code of business
conduct and ethics, which is applicable to all of our directors, officers, and employees. Our code of business conduct and ethics is publicly
available on our website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. <span style="text-decoration:underline">Employees</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Item 4. Information on the Company&#8212;B.
Business Overview&#8212;Employees.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. <span style="text-decoration:underline">Share Ownership</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information with
respect to the beneficial ownership, within the meaning of Rule 13d-3 under the Exchange Act, of our ordinary shares as of the date of
this annual report for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors and executive officers; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person known to us to own beneficially more than 5% of our ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beneficial ownership includes voting or investment
power with respect to the securities. Except as indicated below, and subject to applicable community property laws, the persons named
in the table have sole voting and investment power with respect to all ordinary shares shown as beneficially owned by them. Percentage
of beneficial ownership of each listed person is based on 21,750,000 ordinary shares outstanding as of the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information with respect to beneficial ownership
has been furnished by each director, officer, or beneficial owner of 5% or more of our ordinary shares. Beneficial ownership is determined
in accordance with the rules of the SEC and generally requires that such person have voting or investment power with respect to securities.
In computing the number of ordinary shares beneficially owned by a person listed below and the percentage ownership of such person, ordinary
shares underlying options, warrants, or convertible securities held by each such person that are exercisable or convertible within 60
days of the date of this annual report are deemed outstanding, but are not deemed outstanding for computing the percentage ownership of
any other person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary <br/> Shares <br/> Beneficially <br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Voting Power</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors and Executive Officers<sup>*</sup>:</b></span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gang Lai<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12,480,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">57.38</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">57.38</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Lin Yang</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Baochang Liu</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Jiawen Pang</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">H. David Sherman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Ding Zheng</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">All directors and executive officers as a group:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,480,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57.38</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57.38</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">5% Shareholders:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sununion Holding Group Limited<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,480,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57.38</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57.38</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise indicated, the business address of each of our directors and officers is 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji&#8217;an, Jiangxi, People&#8217;s Republic of China.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents 12,480,000 ordinary shares held by Sununion Holding Group Limited, a business company incorporated in the British Virgin Islands, which is 100% owned by Mr. Gang Lai. The registered address of Sununion Holding Group Limited is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, approximately
42.62% of our issued and outstanding ordinary shares are held in the United States by one record holder (Cede and Company).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 1, 2021, Sununion Holding Group Limited
(&#8220;Sununion&#8221;), our controlling shareholder wholly owned by Mr. Gang Lai, our chief executive officer and chairman of the board
of directors, entered into an agreement with Mr. Gang Lai and Kitanihon Pharmaceutical Co., Ltd. (&#8220;Kitanihon&#8221;), a Japanese
pharmaceutical company, pursuant to which Kitanihon authorizes the Company to use certain of its intangible assets, including technologies
and certain intellectual properties, in exchange for which Mr. Gang Lai will transfer ordinary shares of Sununion owned by him and valued
at US$2.5 million, or 8.60% of the equity interests in Sununion, to Kitanihon. Such share transfer is currently in progress and has not
been completed as of the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not aware of any other arrangement that
may, at a subsequent date, result in a change of control of our Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. <span style="text-decoration:underline">Major Shareholders</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Item 6. Directors, Senior Management
and Employees&#8212;E. Share Ownership.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="text-decoration:underline">Related Party Transactions</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Item 6. Directors, Senior Management
and Employees&#8212;C. Board Practices&#8212;Employment Agreements and Indemnification Agreements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 92; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Material Transactions with Related Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Nature of relationships with elated parties</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 39%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship
    with the Company</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-top: Black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gang Lai</span></td>
    <td>&#160;</td>
    <td style="border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive
    Officer and chairman of the Board of Directors</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Lin Yang</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greatest Group (China) Financial Management Limited
    ("Greatest Group")</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One of our minority shareholders</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foshan Shangyu</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our affiliated entity,
    90% owned by and controlled by our CEO, Mr. Gang Lai </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Due from related parties</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, 2020 and 2019, the balances
due from related parties were $236,982, $nil and $nil, respectively, which were interest free and due on demand. The balance due from
related parties as of September 30, 2021 consisted of due from Greatest Group in the amount of $235,438 and due from Foshan Shangyu in
the amount of $1,554. The September 30, 2021 due from related parties balance has been subsequently collected back and we do not have
any intention to make additional cash advance to related parties going forward.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Due to related parties</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, 2020 and 2019, the balances
due to related parties were $19,723, $956,492 and $54,705, respectively, which mainly consisted of advances from our related parties for
working capital purposes in our normal course of business. These advances are non-interest bearing and due on demand. As of September
30, 2021, the balance consisted of balance due to Ms. Lin Yang in the amount of $19,723. As of September 30, 2020, the balance consisted
of balance due to Mr. Gang Lai in the amount of $956,492. As of September 30, 2019, the balance consisted of balance due to Mr. Gang Lai
in the amount of $54,705.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Prepayment for purchase of a property </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2021, we entered into a real estate
property purchase agreement with a related party, Jiangxi Yueshang, in which our CEO, Mr. Gang Lai, owns 5% equity interest. Pursuant
to this purchase agreement, Jiangxi Yueshang will sell and we will purchase certain residential apartments and commercial office space
totaling 2,749.30 square meters, with total purchase price of RMB32 million (approximately $4.95 million). Pursuant to this purchase agreement,
we were required to make a prepayment in the amount of 50% of the total purchase price, with 20% of the total purchase price payable when
certificate of occupancy is available to us, and 30% of the total purchase price payable upon delivery of the property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, we had made a prepayment
in the amount of RMB16 million ($2,476,800) to Jiangxi Yueshang. The remaining balance is expected to be paid by August 2024. Since the
property is located at urban downtown of Ji&#8217;an City, we plan to use the property as our offices in late 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 13, 2022, Mr. Gang Lai transferred
the 5% equity interest he owned in Jiangxi Yueshang to a third party. As such, after this date, Jiangxi Yueshang is no longer our related
party.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Loan guarantee provided by related parties</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with our borrowings from LRC Bank,
our controlling shareholder and chief executive officer, Mr. Gang Lai, and Foshan Shangyu jointly signed a guarantee agreement with LRC
Bank to provide credit guarantee for our borrowings from LRC Bank.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company&#8217;s bank borrowings
from Bank of Communications, certain related parties of the Company, including Mr. Gang Lai, the Company&#8217;s controlling shareholder,
Mr. Gang Lai&#8217;s spouse, Ms. Xing Wu, and the Company&#8217;s subsidiary, Universe Trade, jointly signed guarantee agreements with
Bank of Communications to provide credit guarantee for this loan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. <span style="text-decoration:underline">Interests of Experts and Counsel</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="k_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8. FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. <span style="text-decoration:underline">Consolidated Statements and Other Financial
Information</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have appended consolidated financial statements
filed as part of this annual report. See &#8220;Item 18. Financial Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 93; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may become a party to various
legal or administrative proceedings arising in the ordinary course of our business, including actions with respect to intellectual property
infringement, violation of third-party licenses or other rights, breach of contract, and labor and employment claims. We are currently
not a party to, and we are not aware of any threat of, any legal or administrative proceedings that, in the opinion of our management,
are likely to have any material and adverse effect on our business, financial condition, cash flow, or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, Universe
Pharmaceuticals INC has transferred the net proceeds from our initial public offering, through Universe HK and Universe Technology, to
Jiangxi Universe in the amount of RMB43,976,156 (approximately $6,807,507).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, none of
our subsidiaries have made any dividends or distributions to Universe Pharmaceuticals INC and Universe Pharmaceuticals INC has not made
any dividends or distributions to U.S. investors. We intend to keep any future earnings to finance the expansion of our business, and
we do not anticipate that any cash dividends will be paid in the foreseeable future. Subject to the PFIC rules, the gross amount of distributions
we make to investors with respect to our ordinary shares (including the amount of any taxes withheld therefrom) will be taxable as a dividend,
to the extent that the distribution is paid out of our current or accumulated earnings and profits, as determined under U.S. federal income
tax principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has discretion on whether
to distribute dividends. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount
recommended by our board of directors. In either case, all dividends are subject to certain restrictions under Cayman Islands law, namely
that the company may only pay dividends out of profits or share premium, and provided always that in no circumstances may a dividend be
paid if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business. Even if we
decide to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and
surplus, general financial condition, contractual restrictions and other factors that the board of directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an exempted company with limited liability
incorporated in the Cayman Islands. We may rely on dividends from our subsidiaries in China for our cash requirements, including any payment
of dividends to our shareholders. PRC regulations may restrict the ability of our PRC subsidiaries to pay dividends to us, and as a holding
company, we will be dependent on receipt of funds from our Hong Kong subsidiary, Universe HK.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current PRC regulations permit our indirect PRC
subsidiaries to pay dividends to Universe HK only out of their accumulated profits, if any, determined in accordance with Chinese accounting
standards and regulations. In addition, each of our subsidiaries in China is required to set aside at least 10% of its after-tax profits
each year, if any, to fund a statutory reserve until such reserve reaches 50% of its registered capital. Each of such entity in China
is also required to further set aside a portion of its after-tax profits to fund the employee welfare fund, although the amount to be
set aside, if any, is determined at the discretion of its board of directors. Although the statutory reserves can be used, among other
ways, to increase the registered capital and eliminate future losses in excess of retained earnings of the respective companies, the reserve
funds are not distributable as cash dividends except in the event of liquidation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PRC government also imposes controls on the
conversion of RMB into foreign currencies and the remittance of currencies out of the PRC. Therefore, we may experience difficulties in
complying with the administrative requirements necessary to obtain and remit foreign currency for the payment of dividends from our profits,
if any. Furthermore, if our subsidiaries and affiliates in the PRC incur debt on their own in the future, the instruments governing the
debt may restrict their ability to pay dividends or make other payments. If we or our subsidiaries are unable to receive all of the revenue
from our operations, we may be unable to pay dividends on our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash dividends, if any, on our ordinary shares
will be paid in U.S. dollars. Universe HK may be considered a non-resident enterprise for tax purposes, so that any dividends our PRC
subsidiaries pay to Universe HK may be regarded as China-sourced income and as a result may be subject to PRC withholding tax at a rate
of up to 10%. See &#8220;<span>Item 10. Additional Information&#8212;E. Taxation&#8212;</span>People&#8217;s
Republic of China Taxation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 94; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order for us to pay dividends to our shareholders,
we will rely on payments made from Universe Technology&#8217;s subsidiary, Jiangxi Universe, to Universe Technology and from Universe
Technology to Universe HK and then to our Company. According to the EIT Law, such payments from subsidiaries to parent companies in China
are subject to the PRC enterprise income tax at a rate of 25%. In addition, if Jiangxi Universe or its subsidiary or branches incur debt
on their own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions
to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Double Tax Avoidance Arrangement,
the 10% withholding tax rate may be lowered to 5% if a Hong Kong resident enterprise owns no less than 25% of a PRC project. The 5% withholding
tax rate, however, does not automatically apply and certain requirements must be satisfied, including without limitation that (a) the
Hong Kong project must be the beneficial owner of the relevant dividends; and (b) the Hong Kong project must directly hold no less than
25% share ownership in the PRC project during the 12 consecutive months preceding its receipt of the dividends. In current practice, a
Hong Kong project must obtain a tax resident certificate from the Hong Kong tax authority to apply for the 5% lower PRC withholding tax
rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case basis, we cannot assure you that we
will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority and enjoy the preferential withholding tax
rate of 5% under the Double Taxation Arrangement with respect to any dividends paid by our PRC subsidiaries to its immediate holding company,
Universe HK. As of the date of this annual report, we have not applied for the tax resident certificate from the relevant Hong Kong tax
authority. Universe HK intends to apply for the tax resident certificate if and when Universe Technology plan to declare and pay dividends
to Universe HK. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212; There are significant uncertainties under the Enterprise
Income Tax Law, or the EIT Law, relating to the withholding tax liabilities of our PRC subsidiaries, and dividends payable by our PRC
subsidiaries to our offshore subsidiaries may not qualify to enjoy certain treaty benefits.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. <span style="text-decoration:underline">Significant Changes</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as disclosed elsewhere in this annual report,
we have not experienced any significant changes since the date of our audited consolidated financial statements included in this annual
report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9. THE OFFER AND LISTING</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. <span style="text-decoration:underline">Offer and Listing Details.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ordinary shares have been listed on the Nasdaq
Global Market since March 23, 2021 under the symbol &#8220;UPC.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. <span style="text-decoration:underline">Plan of Distribution</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. <span style="text-decoration:underline">Markets</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ordinary shares have been listed on the Nasdaq
Global Market since March 23, 2021 under the symbol &#8220;UPC.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. <span style="text-decoration:underline">Selling Shareholders</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. <span style="text-decoration:underline">Dilution</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 95; Value: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. <span style="text-decoration:underline">Expenses of the Issue</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 10. ADDITIONAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. <span style="text-decoration:underline">Share Capital</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. <span style="text-decoration:underline">Memorandum and Articles of Association</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an exempted company incorporated under
the laws of the Cayman Islands and our affairs are governed by our amended and restated memorandum and articles of association, as amended
and restated from time to time, and Companies Act (As Revised) of the Cayman Islands, which we refer to as the Companies Act below, and
the common law of the Cayman Islands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporate by reference into this annual report
the description of our amended and restated memorandum and articles of association, which was filed as Exhibits 3.1 and 3.2 to our registration
statement on Form F-1 (File No.&#160;333-248067), as amended, initially filed with the SEC on August 17, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Registered Office</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our registered office in the Cayman Islands is
located at Vistra (Cayman) Limited, P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KYI &#8211; 1205 Cayman
Islands, and the phone number of our registered office is +1-(345)769-9372.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Item 6. Directors, Senior Management
and Employees.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Ordinary Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our issued and outstanding ordinary shares
are fully paid and non-assessable. Our ordinary shares are issued in registered form, and are issued when registered in our register of
members. Unless the board of directors determine otherwise, each holder of our ordinary shares will not receive a certificate in respect
of such ordinary shares. Our shareholders who are non-residents of the Cayman Islands may freely hold and vote their ordinary shares.
We may not issue shares or warrants to bearer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized share capital is $312,500 divided
into 100,000,000 ordinary shares, par value $0.003125 per share. Subject to the provisions of the Companies Act and our articles regarding
redemption and purchase of the shares, the directors have general and unconditional authority to allot (with or without confirming rights
of renunciation), grant options over or otherwise deal with any unissued shares to such persons, at such times and on such terms and conditions
as they may decide. Such authority could be exercised by the directors to allot shares which carry rights and privileges that are preferential
to the rights attaching to ordinary shares. No share may be issued at a discount except in accordance with the provisions of the Companies
Act. The directors may refuse to accept any application for shares, and may accept any application in whole or in part, for any reason
or for no reason.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 96; Options: NewSection; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dividends</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of the Companies Act
and any rights attaching to any class or classes of shares under and in accordance with the articles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the directors may declare dividends or distributions out of our funds which are lawfully available for that purpose; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company&#8217;s shareholders may, by ordinary resolution, declare dividends but no such dividend shall exceed the amount recommended by the directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the requirements of the Companies Act
regarding the application of a company&#8217;s share premium account and with the sanction of an ordinary resolution, dividends may also
be declared and paid out of any share premium account. The directors when paying dividends to shareholders may make such payment either
in cash or in specie.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless provided by the rights attached to a share,
no dividend shall bear interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Voting Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to any rights or restrictions as to voting
attached to any shares, unless any share carries special voting rights, on a show of hands every shareholder who is present in person
and every person representing a shareholder by proxy shall have one vote per ordinary share. On a poll, every shareholder who is present
in person and every person representing a shareholder by proxy shall have one vote for each share of which he or the person represented
by proxy is the holder. In addition, all shareholders holding shares of a particular class are entitled to vote at a meeting of the holders
of that class of shares. Votes may be given either personally or by proxy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Variation of Rights of Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whenever our capital is divided into different
classes of shares, the rights attaching to any class of share (unless otherwise provided by the terms of issue of the shares of that class)
may be varied either with the consent in writing of the holders of not less than two-thirds of the issued shares of that class, or with
the sanction of a resolution passed by a majority of not less than two-thirds of the holders of shares of the class present in person
or by proxy at a separate general meeting of the holders of shares of that class.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the terms on which a class of shares was
issued state otherwise, the rights conferred on the shareholder holding shares of any class shall not be deemed to be varied by the creation
or issue of further shares ranking pari passu with the existing shares of that class.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Alteration of Share Capital</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Companies Act, our shareholders
may, by ordinary resolution:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase our share capital by new shares of the amount fixed by that ordinary resolution and with the attached rights, priorities and privileges set out in that ordinary resolution;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidate and divide all or any of our share capital into shares of larger amount than our existing shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convert all or any of our paid up shares into stock, and reconvert that stock into paid up shares of any denomination;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sub-divide our shares or any of them into shares of an amount smaller than that fixed, so, however, that in the sub-division, the proportion between the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share is derived; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel shares which, at the date of the passing of that ordinary resolution, have not been taken or agreed to be taken by any person and diminish the amount of our share capital by the amount of the shares so cancelled or, in the case of shares without nominal par value, diminish the number of shares into which our capital is divided.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the Companies Act and to any rights for the time being conferred
on the shareholders holding a particular class of shares, our shareholders may, by special resolution, reduce its share capital in any
way.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Calls on Shares and Forfeiture</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms of allotment, the directors
may make calls on the shareholders in respect of any monies unpaid on their shares including any premium and each shareholder shall (subject
to receiving at least 14 clear days&#8217; notice specifying when and where payment is to be made), pay to us the amount called on his
shares. Shareholders registered as the joint holders of a share shall be jointly and severally liable to pay all calls in respect of the
share. If a call remains unpaid after it has become due and payable the person from whom it is due and payable shall pay interest on the
amount unpaid from the day it became due and payable until it is paid at the rate fixed by the terms of allotment of the share or in the
notice of the call or if no rate is fixed, at the rate of ten percent per annum. The directors may, at their discretion, waive payment
of the interest wholly or in part.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a first and paramount lien on all shares
(whether fully paid up or not) registered in the name of a shareholder (whether solely or jointly with others). The lien is for all monies
payable to us by the shareholder or the shareholder&#8217;s estate:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">either alone or jointly with any other person, whether or not that other person is a shareholder; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether or not those monies are presently payable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time the directors may declare any share
to be wholly or partly exempt from the lien on shares provisions of the articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell, in such manner as the directors may
determine, any share on which the sum in respect of which the lien exists is presently payable, if due notice that such sum is payable
has been given (as prescribed by the articles) and, within 14 days of the date on which the notice is deemed to be given under the articles,
such notice has not been complied with.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Unclaimed Dividend</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A dividend that remains unclaimed for a period
of six years after it became due for payment shall be forfeited to, and shall cease to remain owing by, the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Forfeiture or Surrender of Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a shareholder fails to pay any capital call,
the directors may give to such shareholder not less than 14 clear days&#8217; notice requiring payment and specifying the amount unpaid
including any interest which may have accrued, any expenses which have been incurred by us due to that person&#8217;s default and the
place where payment is to be made. The notice shall also contain a warning that if the notice is not complied with, the shares in respect
of which the call is made will be liable to be forfeited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If such notice is not complied with, the directors
may, before the payment required by the notice has been received, resolve that any share the subject of that notice be forfeited (which
forfeiture shall include all dividends or other monies payable in respect of the forfeited share and not paid before such forfeiture).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A forfeited share may be sold, re-allotted or
otherwise disposed of on such terms and in such manner as the directors determine and at any time before a sale, re-allotment or disposition
the forfeiture may be cancelled on such terms as the directors think fit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A person whose shares have been forfeited shall
cease to be a shareholder in respect of the forfeited shares, but shall, notwithstanding such forfeiture, remain liable to pay to us all
monies which at the date of forfeiture were payable by him to us in respect of the shares, together with all expenses and interest from
the date of forfeiture or surrender until payment, but his liability shall cease if and when we receive payment in full of the unpaid
amount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A declaration, whether statutory or under oath,
made by a director or the secretary shall be conclusive evidence that the person making the declaration is our director or secretary and
that the particular shares have been forfeited or surrendered on a particular date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the execution of an instrument of transfer,
if necessary, the declaration shall constitute good title to the shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Share Premium Account</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors shall establish a share premium
account and shall carry the credit of such account from time to time to a sum equal to the amount or value of the premium paid on the
issue of any share or capital contributed or such other amounts required by the Companies Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Redemption and Purchase of Own Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Companies Act and any rights for
the time being conferred on the shareholders holding a particular class of shares, we may by action of our directors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue shares that are to be redeemed or liable to be redeemed, at our option or the shareholder holding those redeemable shares, on the terms and in the manner our directors determine before the issue of those shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with the consent by special resolution of the shareholders holding shares of a particular class, vary the rights attaching to that class of shares so as to provide that those shares are to be redeemed or are liable to be redeemed at our option on the terms and in the manner which the directors determine at the time of such variation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchase all or any of our own shares of any class including any redeemable shares on the terms and in the manner which the directors determine at the time of such purchase.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may make a payment in respect of the redemption
or purchase of its own shares in any manner authorized by the Companies Act, including out of any combination of capital, our profits
and the proceeds of a fresh issue of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When making a payment in respect of the redemption
or purchase of shares, the directors may make the payment in cash or in specie (or partly in one and partly in the other) if so authorized
by the terms of the allotment of those shares or by the terms applying to those shares, or otherwise by agreement with the shareholder
holding those shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Transfer of Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provided that a transfer of ordinary shares complies
with applicable rules of Nasdaq, a shareholder may transfer ordinary shares to another person by completing an instrument of transfer
in a common form or in a form prescribed by Nasdaq or in any other form approved by the directors, executed:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the ordinary shares are fully paid, by or on behalf of that shareholder; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the ordinary shares are partly paid, by or on behalf of that shareholder and the transferee.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transferor shall be deemed to remain the holder
of an ordinary share until the name of the transferee is entered into the register of members of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors may, in its absolute discretion,
decline to register any transfer of any ordinary share that has not been fully paid up or is subject to a company lien. Our board of directors
may also decline to register any transfer of such ordinary share unless:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is lodged with the Company, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is in respect of only one class of ordinary shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is properly stamped, if required;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ordinary shares transferred is fully paid and free of any lien in favor of us;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fee related to the transfer has been paid to us; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the transfer is not to more than four joint holders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our directors refuse to register a transfer,
they are required, within three months after the date on which the instrument of transfer was lodged, to send to each of the transferor
and the transferee notice of such refusal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This, however, is unlikely to affect market transactions
of the ordinary shares purchased by investors in the public offering. The legal title to such ordinary shares and the registration details
of those ordinary shares in the Company&#8217;s register of members will remain with Depository Trust Company (&#8220;DTC&#8221;). All
market transactions with respect to those ordinary shares will then be carried out without the need for any kind of registration by the
directors, as the market transactions will all be conducted through the DTC systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registration of transfers may, on 14 calendar
days&#8217; notice being given by advertisement in such one or more newspapers or by electronic means, be suspended and our register of
members closed at such times and for such periods as our board of directors may from time to time determine. The registration of transfers,
however, may not be suspended, and the register may not be closed, for more than 30 days in any year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inspection of Books and Records</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of our ordinary shares will have no general
right under the Companies Act to inspect or obtain copies of our register of members or our corporate records.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General Meetings</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a Cayman Islands exempted company, we are not
obligated by the Companies Act to call shareholders&#8217; annual general meetings; accordingly, we may, but shall not be obliged to,
in each year hold a general meeting as an annual general meeting. Any annual general meeting held shall be held at such time and place
as may be determined by our board of directors. All general meetings other than annual general meetings shall be called extraordinary
general meetings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may convene general meetings whenever
they think fit. General meetings shall also be convened on the written requisition of one or more of the shareholders entitled to attend
and vote at our general meetings who (together) hold not less than ten percent of the rights to vote at such general meeting in accordance
with the notice provisions in the articles, specifying the purpose of the meeting and signed by each of the shareholders making the requisition.
If the directors do not convene such meeting for a date not later than 21 clear days&#8217; after the date of receipt of the written requisition,
those shareholders who requested the meeting may convene the general meeting themselves within three months after the end of such period
of 21 clear days in which case reasonable expenses incurred by them as a result of the directors failing to convene a meeting shall be
reimbursed by us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At least 14 days&#8217; notice of an extraordinary
general meeting and 21 days&#8217; notice of an annual general meeting shall be given to shareholders entitled to attend and vote at such
meeting. The notice shall specify the place, the day and the hour of the meeting and the general nature of that business. In addition,
if a resolution is proposed as a special resolution, the text of that resolution shall be given to all shareholders. Notice of every general
meeting shall also be given to the directors and our auditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Companies Act and with the consent
of the shareholders who, individually or collectively, hold at least 90 percent of the voting rights of all those who have a right to
vote at a general meeting, a general meeting may be convened on shorter notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A quorum shall consist of the presence (whether
in person or represented by proxy) of one or more shareholders holding shares that represent not less than one-third of the outstanding
shares carrying the right to vote at such general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If, within 15 minutes from the time appointed
for the general meeting, or at any time during the meeting, a quorum is not present, the meeting, if convened upon the requisition of
shareholders, shall be cancelled. In any other case it shall stand adjourned to the same time and place seven days or to such other time
or place as is determined by the directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The chairman may, with the consent of a meeting
at which a quorum is present, adjourn the meeting. When a meeting is adjourned for seven days or more, notice of the adjourned meeting
shall be given in accordance with the articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any general meeting a resolution put to the
vote of the meeting shall be decided on a show of hands, unless a poll is (before, or on, the declaration of the result of the show of
hands) demanded by the chairman of the meeting or by at least two shareholders having the right to vote on the resolutions or one or more
shareholders present who together hold not less than ten percent of the voting rights of all those who are entitled to vote on the resolution.
Unless a poll is so demanded, a declaration by the chairman as to the result of a resolution and an entry to that effect in the minutes
of the meeting, shall be conclusive evidence of the outcome of a show of hands, without proof of the number or proportion of the votes
recorded in favor of, or against, that resolution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a poll is duly demanded it shall be taken in
such manner as the chairman directs and the result of the poll shall be deemed to be the resolution of the meeting at which the poll was
demanded.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the case of an equality of votes, whether on
a show of hands or on a poll, the chairman of the meeting at which the show of hands takes place or at which the poll is demanded, shall
not be entitled to a second or casting vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may by ordinary resolution, from time to time,
fix the maximum and minimum number of directors to be appointed. Under the articles, we are required to have a minimum of one director
and the maximum number of directors shall be unlimited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director may be appointed by ordinary resolution
or by the directors. Any appointment may be to fill a vacancy or as an additional director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the remuneration of the directors is determined
by the shareholders by ordinary resolution, the directors shall be entitled to such remuneration as the directors may determine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shareholding qualification for directors may
be fixed by our shareholders by ordinary resolution and unless and until so fixed no share qualification shall be required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless removed or re-appointed, each director
shall be appointed for a term expiring at the next-following annual general meeting, if one is held. At any annual general meeting held,
our directors will be elected by an ordinary resolution of our shareholders. At each annual general meeting, each director so elected
shall hold office for a one-year term and until the election of their respective successors in office or removed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director may be removed by ordinary resolution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director may at any time resign or retire from
office by giving us notice in writing. Unless the notice specifies a different date, the director shall be deemed to have resigned on
the date that the notice is delivered to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of the articles, the
office of a director may be terminated forthwith if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is prohibited by the law of the Cayman Islands from acting as a director;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is made bankrupt or makes an arrangement or composition with his creditors generally;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he resigns his office by notice to us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he only held office as a director for a fixed term and such term expires;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the opinion of a registered medical practitioner by whom he is being treated he becomes physically or mentally incapable of acting as a director;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is given notice by the majority of the other directors (not being less than two in number) to vacate office (without prejudice to any claim for damages for breach of any agreement relating to the provision of the services of such director);</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is made subject to any law relating to mental health or incompetence, whether by court order or otherwise; or</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">without the consent of the other directors, he is absent from meetings of directors for continuous period of six months.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the compensation committee and the nominating
and corporate governance committee shall consist of at least three directors and the majority of the committee members shall be independent
within the meaning of Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock Market. The audit committee shall consist of at least three
directors, all of whom shall be independent within the meaning of Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock Market and
will meet the criteria for independence set forth in Rule 10A-3 or Rule 10C-1 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Powers and Duties of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of the Companies Act
and our memorandum and articles of association, our business shall be managed by the directors, who may exercise all our powers. No prior
act of the directors shall be invalidated by any subsequent alteration of our memorandum or articles of association. To the extent allowed
by the Companies Act, however, shareholders may by special resolution validate any prior or future act of the directors which would otherwise
be in breach of their duties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may delegate any of their powers
to any committee consisting of one or more persons who need not be shareholders and may include non-directors so long as the majority
of those persons are directors; any committee so formed shall in the exercise of the powers so delegated conform to any regulations that
may be imposed on it by the directors. Our board of directors have established an audit committee, compensation committee, and nomination
and corporate governance committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board of directors may establish any local
or divisional board of directors or agency and delegate to it its powers and authorities (with power to sub-delegate) for managing any
of our affairs whether in the Cayman Islands or elsewhere and may appoint any persons to be members of a local or divisional board of
directors, or to be managers or agents, and may fix their remuneration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may from time to time and at any
time by power of attorney or in any other manner they determine appoint any person, either generally or in respect of any specific matter,
to be our agent with or without authority for that person to delegate all or any of that person&#8217;s powers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may from time to time and at any
time by power of attorney or in any other manner they determine appoint any person, whether nominated directly or indirectly by the directors,
to be our attorney or our authorized signatory and for such period and subject to such conditions as they may think fit. The powers, authorities
and discretions, however, must not exceed those vested in, or exercisable, by the directors under the articles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board of directors may remove any person so
appointed and may revoke or vary the delegation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may exercise all of our powers to
borrow money and to mortgage or charge its undertaking, property and assets both present and future and uncalled capital or any part thereof,
to issue debentures and other securities whether outright or as collateral security for any debt, liability or obligation of ours or our
parent undertaking (if any) or any subsidiary undertaking of us or of any third party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director shall not, as a director, vote in respect
of any contract, transaction, arrangement or proposal in which he has an interest which (together with any interest of any person connected
with him) is a material interest (otherwise than by virtue of his interests, direct or indirect, in shares or debentures or other securities
of, or otherwise in or through, us) and if he shall do so his vote shall not be counted, nor in relation thereto shall he be counted in
the quorum present at the meeting, but (in the absence of some other material interest than is mentioned below) none of these prohibitions
shall apply to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the giving of any security, guarantee or indemnity in respect of:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">money lent or obligations incurred by him or by any other person for our benefit or any of our subsidiaries; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a debt or obligation of ours or any of our subsidiaries for which the director himself has assumed responsibility in whole or in part and whether alone or jointly with others under a guarantee or indemnity or by the giving of security;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where we or any of our subsidiaries is offering securities in which offer the director is or may be entitled to participate as a holder of securities or in the underwriting or sub-underwriting of which the director is to or may participate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any contract, transaction, arrangement or proposal affecting any other body corporate in which he is interested, directly or indirectly and whether as an officer, shareholder, creditor or otherwise howsoever, provided that he (together with persons connected with him) does not to his knowledge hold an interest representing one percent or more of any class of the equity share capital of such body corporate (or of any third body corporate through which his interest is derived) or of the voting rights available to shareholders of the relevant body corporate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any act or thing done or to be done in respect of any arrangement for the benefit of the employees of us or any of our subsidiaries under which he is not accorded as a director any privilege or advantage not generally accorded to the employees to whom such arrangement relates; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any matter connected with the purchase or maintenance for any director of insurance against any liability or (to the extent permitted by the Companies Act) indemnities in favor of directors, the funding of expenditure by one or more directors in defending proceedings against him or them or the doing of anything to enable such director or directors to avoid incurring such expenditure.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director may, as a director, vote (and be counted
in the quorum) in respect of any contract, transaction, arrangement or proposal in which he has an interest which is not a material interest
or as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Capitalization of Profits</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The directors may resolve to capitalize:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any part of our profits not required for paying any preferential dividend (whether or not those profits are available for distribution); or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any sum standing to the credit of our share premium account or capital redemption reserve, if any.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount resolved to be capitalized must be
appropriated to the shareholders who would have been entitled to it had it been distributed by way of dividend and in the same proportions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidation Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are wound up, the shareholders may, subject
to the articles and any other sanction required by the Companies Act, pass a special resolution allowing the liquidator to do either or
both of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to divide in specie among the shareholders the whole or any part of our assets and, for that purpose, to value any assets and to determine how the division shall be carried out as between the shareholders or different classes of shareholders; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to vest the whole or any part of the assets in trustees for the benefit of shareholders and those liable to contribute to the winding up.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors have the authority to present a
petition for our winding up to the Grand Court of the Cayman Islands on our behalf without the sanction of a resolution passed at a general
meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Register of Members</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Companies Act, we must keep a register
of members and there should be entered therein:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the names and addresses of our shareholders, a statement of the shares held by each shareholder, and of the amount paid or agreed to be considered as paid, on the shares of each shareholder;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which the name of any person was entered on the register as a shareholder; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which any person ceased to be a shareholder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Companies Act, the register of members
of our company is prima facie evidence of the matters set out therein (that is, the register of members will raise a presumption of fact
on the matters referred to above unless rebutted) and a shareholder registered in the register of members is deemed as a matter of the
Companies Act to have legal title to the shares as set against its name in the register of members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the name of any person is incorrectly entered
in or omitted from our register of members, or if there is any default or unnecessary delay in entering on the register the fact of any
person having ceased to be a shareholder of our company, the person or shareholder aggrieved (or any shareholder of our company or our
company itself) may apply to the Grand Court of the Cayman Islands for an order that the register be rectified, and the Court may either
refuse such application or it may, if satisfied of the justice of the case, make an order for the rectification of the register.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. <span style="text-decoration:underline">Material Contracts</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not entered into any material contracts
other than in the ordinary course of business and other than those described in &#8220;Item 4. Information on the Company&#8221; or elsewhere
in this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. <span style="text-decoration:underline">Exchange Controls</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Item 4. Information on the Company&#8212;B.
Business Overview&#8212;Regulations&#8212;Other Laws&#8212;Foreign Exchange Control.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. <span style="text-decoration:underline">Taxation</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>People&#8217;s Republic of China Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following brief description of Chinese enterprise
laws is designed to highlight the enterprise-level taxation on our earnings, which will affect the amount of dividends, if any, we are
ultimately able to pay to our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Enterprise Income Tax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Enterprise Income Tax Law of
the People&#8217;s Republic of China, or the EIT Law, which was promulgated by the SCNPC on March 16, 2007, and became effective on January
1, 2008, and then amended on February 24, 2017, and the Implementation Rules of the EIT Law, or the Implementation Rules, which were promulgated
by the State Council on December 6, 2007, effective on January 1, 2008, and amended on April 23, 2019, enterprises are divided into resident
enterprises and non-resident enterprises. Resident enterprises pay enterprise income tax on their incomes obtained in and outside the
PRC at the rate of 25%. Non-resident enterprises setting up institutions in the PRC pay enterprise income tax on the incomes obtained
by such institutions in and outside the PRC at the rate of 25%. Non-resident enterprises with no institutions in the PRC, and non-resident
enterprises with income having no substantial connection with their institutions in the PRC, pay enterprise income tax on their income
obtained in the PRC at a reduced rate of 10%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an exempted company incorporated with limited
liability in the Cayman Islands and we gain substantial income by way of dividends paid to us from our PRC subsidiaries, Universe Technology,
Jiangxi Universe, and Universe Trade. The EIT Law and its implementation rules provide that China-sourced income of foreign enterprises,
such as dividends paid by a PRC subsidiary to its equity holders that are non-resident enterprises, will normally be subject to PRC withholding
tax at a rate of 10%, unless any such foreign investor&#8217;s jurisdiction of incorporation has a tax treaty with China that provides
for a preferential tax rate or a tax exemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the EIT Law, an enterprise established outside
of China with a &#8220;de facto management body&#8221; within China is considered a &#8220;resident enterprise,&#8221; which means that
it is treated in a manner similar to a Chinese enterprise for enterprise income tax purposes. Although the implementation rules of the
EIT Law define &#8220;de facto management body&#8221; as a managing body that actually, comprehensively manage and control the production
and operation, staff, accounting, property and other aspects of an enterprise, the only official guidance for this definition currently
available is set forth in SAT Notice 82, which provides guidance on the determination of the tax residence status of a Chinese-controlled
offshore incorporated enterprise, defined as an enterprise that is incorporated under the laws of a foreign country or territory and that
has a PRC enterprise or enterprise group as its primary controlling shareholder. Although Universe INC does not have a PRC enterprise
or enterprise group as our primary controlling shareholder and is therefore not a Chinese-controlled offshore incorporated enterprise
within the meaning of SAT Notice 82, in the absence of guidance specifically applicable to us, we have applied the guidance set forth
in SAT Notice 82 to evaluate the tax residence status of Universe INC and its subsidiaries organized outside the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to SAT Notice 82, a Chinese-controlled
offshore incorporated enterprise will be regarded as a PRC tax resident by virtue of having a &#8220;de facto management body&#8221; in
China and will be subject to PRC enterprise income tax on its worldwide income only if all of the following criteria are met: (i) the
places where senior management and senior management departments that are responsible for daily production, operation and management of
the enterprise perform their duties are mainly located within the territory of China; (ii) financial decisions (such as money borrowing,
lending, financing and financial risk management) and personnel decisions (such as appointment, dismissal and salary and wages) are decided
or need to be decided by organizations or persons located within the territory of China; (iii) main property, accounting books, corporate
seal, the board of directors and files of the minutes of shareholders&#8217; meetings of the enterprise are located or preserved within
the territory of China; and (iv) one half (or more) of the directors or senior management staff having the right to vote habitually reside
within the territory of China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that we do not meet some of the conditions
outlined in the immediately preceding paragraph. For example, as a holding company, the key assets and records of Universe INC, including
the resolutions and meeting minutes of our board of directors and the resolutions and meeting minutes of our shareholders, are located
and maintained outside the PRC. In addition, we are not aware of any offshore holding companies with a corporate structure similar to
ours that has been deemed a PRC &#8220;resident enterprise&#8221; by the PRC tax authorities. Accordingly, we believe that Universe INC
and its offshore subsidiaries should not be treated as a &#8220;resident enterprise&#8221; for PRC tax purposes if the criteria for &#8220;de
facto management body&#8221; as set forth in SAT Notice 82 were deemed applicable to us. However, as the tax residency status of an enterprise
is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#8220;de
facto management body&#8221; as applicable to our offshore entities, we will continue to monitor our tax status.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The implementation rules of the EIT law provides
that, (i) if the enterprise that distributes dividends is domiciled in the PRC or (ii) if gains are realized from transferring equity
interests of enterprises domiciled in the PRC, then such dividends or gains are treated as China-sourced income. It is not clear how &#8220;domicile&#8221;
may be interpreted under the EIT Law, and it may be interpreted as the jurisdiction where the enterprise is a tax resident. Therefore,
if we are considered as a PRC tax resident enterprise for PRC tax purposes, any dividends we pay to our overseas shareholders which are
non-resident enterprises as well as gains realized by such shareholders from the transfer of our shares may be regarded as China-sourced
income and as a result become subject to PRC withholding tax at a rate of up to 10%. AllBright Law Offices, our PRC counsel, is unable
to provide a &#8220;will&#8221; opinion because it believes that it is more likely than not that we and our offshore subsidiaries would
be treated as non-resident enterprises for PRC tax purposes because we do not meet some of the conditions outlined in SAT Notice 82. In
addition, AllBright Law Offices is not aware of any offshore holding companies with a corporate structure similar to ours that has been
deemed a PRC &#8220;resident enterprise&#8221; by the PRC tax authorities as of the date of this annual report. Therefore, AllBright Law
Offices believes that it is possible but highly unlikely that the income received by our overseas shareholders will be regarded as China-sourced
income. See &#8220;Item 3. Key Information&#8212;Risk Factors&#8212;Risks Related to Doing Business in China&#8212;Under the EIT Law,
we may be classified as a &#8216;Resident Enterprise&#8217; of China. Such classification will likely result in unfavorable tax consequences
to us and our non-PRC shareholders.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, as resident enterprises in the PRC,
Universe Technology as well as Jiangxi Universe and its subsidiary in PRC are subject to the enterprise income tax at the rate of 25%,
except that once an enterprise meets certain requirements and is identified as a small-scale minimal profit enterprise, the part of its
taxable income not more than RMB1 million is subject to a reduced rate of 5% and the part between RMB1 million and 3 million is subject
to a reduced rate of 10%. The EIT is calculated based on the entity&#8217;s global income as determined under PRC tax laws and accounting
standards. If the PRC tax authorities determine that Jiangxi Universe is a PRC resident enterprise for enterprise income tax purposes,
we may be required to withhold a 10% withholding tax from dividends we pay to our shareholders that are non-resident enterprises. In addition,
non-resident enterprise shareholders may be subject to a 10% PRC withholding tax on gains realized on the sale or other disposition of
our ordinary shares, if such income is treated as sourced from within the PRC. It is unclear whether our non-PRC individual shareholders
would be subject to any PRC tax on dividends or gains obtained by such non-PRC individual shareholders in the event we are determined
to be a PRC resident enterprise. If any PRC tax were to apply to dividends or gains realized by non-PRC individuals, it would generally
apply at a rate of 20% unless a reduced rate is available under an applicable tax treaty. However, it is also unclear whether our non-PRC
shareholders would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the event that
we are treated as a PRC resident enterprise. There is no guidance from the PRC government to indicate whether or not any tax treaties
between the PRC and other countries would apply in circumstances where a non-PRC company was deemed to be a PRC tax resident, and thus
there is no basis for expecting how tax treaty between the PRC and other countries may impact non-resident enterprises.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Value-added Tax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Provisional Regulations on Value-Added
Tax of the PRC (<span style="font-family: Times New Roman, Times, Serif">&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22686;&#20540;&#31246;&#26242;&#34892;&#26465;&#20363;&#12299;</span>),
or the VAT Regulations, which were promulgated by the State Council on December 13, 1993, and amended on November 10, 2008, February 6,
2016, and November 19, 2017, respectively, and the Implementation Rules of the Provisional Regulations on Value Added Tax of the PRC (<span style="font-family: Times New Roman, Times, Serif">&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22686;&#20540;&#31246;&#26242;&#34892;&#26465;&#20363;&#23454;&#26045;&#32454;&#21017;&#12299;</span>)
promulgated by the MOF on December 25, 1993 and amended on December 15, 2008 and October 28, 2011, respectively, entities and individuals
that sell goods or labor services of processing, repair or replacement, sell services, intangible assets, or immovables, or import goods
within the territory of the People&#8217;s Republic of China are taxpayers of value-added tax.&#160;The VAT rate is 17% for taxpayers
selling goods, labor services, or tangible movable property leasing services or importing goods, except otherwise specified; 11% for taxpayers
selling goods, labor services, or tangible movable property leasing services or importing goods, except otherwise specified; 6% for taxpayers
selling services or intangible assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to Provisions in the Notice on Adjusting
the Value added Tax Rates (Cai Shui [2018] No. 32), or the Notice, issued by the SAT and the MOF, where taxpayers make VAT taxable sales
or import goods, the applicable tax rates shall be adjusted from 17% to 16% and from 11% to 10%, respectively. The Notice took effect
on May 1, 2018, and the adjusted VAT rates took effect at the same time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 23, 2016, the MOF and the SAT jointly
issued the Circular of Full Implementation of Business Tax to VAT Reform (the &#8220;Circular 36&#8221;) (<span style="font-family: Times New Roman, Times, Serif">&#12298;&#20851;&#20110;&#20840;&#38754;&#25512;&#24320;&#33829;&#19994;&#31246;&#25913;&#24449;&#22686;&#20540;&#31246;&#35797;&#28857;&#30340;&#36890;&#30693;&#12299;</span>),
which confirms that business tax will be completely replaced by VAT from May 1, 2016. The Notice of the MOF and the SAT on the Adjustment
to VAT Rates (<span style="font-family: Times New Roman, Times, Serif">&#12298;&#20851;&#20110;&#35843;&#25972;&#22686;&#20540;&#31246;&#31246;&#29575;&#30340;&#36890;&#30693;&#12299;</span>),
promulgated on April 4, 2018 and effective as of May 1, 2018, adjusted the applicative rate of VAT. The deduction rates of 17% and 11%
applicable to the taxpayers who have VAT taxable sales activities or imported goods are adjusted to 16% and 10%, respectively. For the
export goods to which a tax rate of 17% was originally applicable and the export rebate rate was 17%, the export rebate rate is adjusted
to 16%. For the export goods and cross-border taxable activities to which a tax rate of 11% was originally applicable and the export rebate
rate was 11%, the export rebate rate is adjusted to 10%. Pursuant to such circular, the Value Added Tax Pilot Program has been applicable
nationwide since May 1, 2016.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequently, the Notice on Policies for Deepening
Reform of Value-added Tax was issued by the SAT, the MOF and the General Administration of Customs on March 30, 2019 and took effective
on April 1, 2019, which further adjusted the applicable tax rate for taxpayers making VAT taxable sales or importing goods. The applicable
tax rates shall be adjusted from 16% to 13% and from 10% to 9%, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the VAT Regulations and the related
rules, as of the date of this annual report, as taxpayers selling goods, Jiangxi Universe and its consolidated affiliated entities are
generally subject to 13% VAT rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividend Withholding Tax</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Arrangement between Mainland China
and Hong Kong for the Avoidance of Double Taxation and Prevention of Fiscal Evasion with respect to Taxes on Income (<span style="font-family: Times New Roman, Times, Serif">&#12298;&#20869;&#22320;&#21644;&#39321;&#28207;&#29305;&#21035;&#34892;&#25919;&#21306;&#20851;&#20110;&#25152;&#24471;&#31246;&#36991;&#20813;&#21452;&#37325;&#24449;&#31246;&#21644;&#38450;&#27490;&#20599;&#31246;&#28431;&#31246;&#30340;&#23433;&#25490;&#12299;</span>)
effective on August 21, 2006, no more than 5% withholding tax rate applies to dividends paid by a PRC company to a Hong Kong resident,
provided that the recipient is a company that holds at least 25% of the capital of the PRC company. The 10% withholding tax rate applies
to dividends paid by a PRC company to a Hong Kong resident if the recipient is a company that holds less than 25% of the capital of the
PRC company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, pursuant to the Notice of the SAT
on Issues Relating to the Implementation of Dividend Clauses in Tax Treaties (Guo Shui Han [2009] No.81) (<span style="font-family: Times New Roman, Times, Serif">&#12298;&#22269;&#23478;&#31246;&#21153;&#24635;&#23616;&#20851;&#20110;&#25191;&#34892;&#31246;&#25910;&#21327;&#23450;&#32929;&#24687;&#26465;&#27454;&#26377;&#20851;&#38382;&#39064;&#30340;&#36890;&#30693;&#12299;&#65288;&#22269;&#31246;&#20989;</span>[2009]
81<span style="font-family: Times New Roman, Times, Serif">&#21495;&#65289;</span>), which was promulgated and effective on February 20,
2009, all of the following requirements should be satisfied where a fiscal resident of the other party to the tax agreement needs to be
entitled to such tax agreement treatment as being taxed at a tax rate specified in the tax agreement for the dividends paid to it by a
PRC resident company: (1) such a fiscal resident who obtains dividends should be a company as provided in the tax agreement; (2) owner&#8217;s
equity interests and voting shares of the PRC resident company directly owned by such a fiscal resident reaches a specified percentage;
and (3) the equity interests of the PRC resident company directly owned by such a fiscal resident, at any time during the 12 months prior
to the acquisition of the dividends, reaches a percentage specified in the tax agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, according to the Administrative Measures
on Non-resident Taxpayers Enjoying Treaty Benefits (<span style="font-family: Times New Roman, Times, Serif">&#12298;&#38750;&#23621;&#27665;&#32435;&#31246;&#20154;&#20139;&#21463;&#21327;&#23450;&#24453;&#36935;&#31649;&#29702;&#21150;&#27861;&#12299;</span>)
promulgated by the SAT on October 14, 2019 and became effective on January 1, 2020, non-resident taxpayers claiming treaty benefits shall
adhere to the principle of &#8220;self-assessment, claiming benefits, retention of the relevant materials for future inspection.&#8221;
Where a non-resident taxpayer self-assesses and concludes that it satisfies the criteria for claiming treaty benefits, it may enjoy treaty
benefits at the time of tax declaration or withholding. However such non-resident taxpayers shall retain relevant tax-reporting materials
pursuant to the provisions of these Measures for potential future inspection, and accept follow-up administration by relevant tax authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this annual report, when considered
as a non-PRC resident investor, which is much more likely to happen than not, Universe HK shall be subject to the dividend withholding
tax at the rate of 10%. Upon identified as the Hong Kong resident enterprise stipulated by the Double Tax Avoidance Arrangement and other
applicable laws, the withholding tax may be reduced to 5%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Hong Kong Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Entities incorporated in Hong Kong are subject
to profits tax in Hong Kong at the rate of 16.5% for each of the fiscal years ended September 30, 2021, 2020 and 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>United States Federal Income Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following does not address the tax consequences
to any particular investor or to persons in special tax situations such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial institutions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance companies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulated investment companies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">real estate investment trusts;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that elect to mark their securities to market;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. expatriates or former long-term residents of the U.S.;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">governments or agencies or instrumentalities thereof;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt entities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons liable for alternative minimum tax;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our ordinary shares as part of a straddle, hedging, conversion or integrated transaction;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that actually or constructively own 10% or more of our voting power or value (including by reason of owning our ordinary shares);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons who acquired our ordinary shares pursuant to the exercise of any employee share option or otherwise as compensation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our ordinary shares through partnerships or other pass-through entities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">beneficiaries of a Trust holding our ordinary shares; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our ordinary shares through a Trust.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discussion set forth below is addressed only
to U.S. Holders that purchase our ordinary shares. Prospective purchasers are urged to consult their own tax advisors about the application
of the U.S. federal income tax rules to their particular circumstances as well as the state, local, foreign, and other tax consequences
to them of the purchase, ownership, and disposition of our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Material Tax Consequences Applicable to
U.S. Holders of Our Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following sets forth the material U.S. federal
income tax consequences related to the ownership and disposition of our ordinary shares. It is directed to U.S. Holders (as defined below)
of our ordinary shares and is based upon laws and relevant interpretations thereof in effect as of the date of this annual report, all
of which are subject to change. This description does not deal with all possible tax consequences relating to ownership and disposition
of our ordinary shares or U.S. tax laws, other than the U.S. federal income tax laws, such as the tax consequences under non-U.S. tax
laws, state, local, and other tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following brief description applies only to
U.S. Holders (defined below) that hold ordinary shares as capital assets and that have the U.S. dollar as their functional currency. This
brief description is based on the federal income tax laws of the United States in effect as of the date of this annual report and on U.S.
Treasury regulations in effect or, in some cases, proposed, as of the date of this annual report, as well as judicial and administrative
interpretations thereof available on or before such date. All of the foregoing authorities are subject to change, which change could apply
retroactively and could affect the tax consequences described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The brief description below of the U.S. federal
income tax consequences to &#8220;U.S. Holders&#8221; will apply to you if you are a beneficial owner of ordinary shares and you are,
for U.S. federal income tax purposes,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is a citizen or resident of the United States;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof or the District of Columbia;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust that (1) is subject to the primary supervision of a court within the United States and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of Dividends and Other Distributions
on Our Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the PFIC rules discussed below, the
gross amount of distributions made by us to you with respect to the ordinary shares (including the amount of any taxes withheld therefrom)
will generally be includable in your gross income as dividend income on the date of receipt by you, but only to the extent that the distribution
is paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). With respect
to corporate U.S. Holders, the dividends will not be eligible for the dividends-received deduction allowed to corporations in respect
of dividends received from other U.S. corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to non-corporate U.S. Holders, including
individual U.S. Holders, dividends will be taxed at the lower capital gains rate applicable to qualified dividend income, provided that
(1) the ordinary shares are readily tradable on an established securities market in the United States, or we are eligible for the benefits
of an approved qualifying income tax treaty with the United States that includes an exchange of information program, (2) we are not a
PFIC for either our taxable year in which the dividend is paid or the preceding taxable year, and (3) certain holding period requirements
are met. Because there is no income tax treaty between the United States and the Cayman Islands, clause (1) above can be satisfied only
if the ordinary shares are readily tradable on an established securities market in the United States. Under U.S. Internal Revenue Service
authority, ordinary shares are considered for purpose of clause (1) above to be readily tradable on an established securities market in
the United States if they are listed on certain exchanges, which presently includes the NYSE and the Nasdaq Stock Market. You are urged
to consult your tax advisors regarding the availability of the lower rate for dividends paid with respect to our ordinary shares, including
the effects of any change in law after the date of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends will constitute foreign source income
for foreign tax credit limitation purposes. If the dividends are taxed as qualified dividend income (as discussed above), the amount of
the dividend taken into account for purposes of calculating the foreign tax credit limitation will be limited to the gross amount of the
dividend, multiplied by the reduced rate divided by the highest rate of tax normally applicable to dividends. The limitation on foreign
taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, dividends distributed
by us with respect to our ordinary shares will constitute &#8220;passive category income&#8221; but could, in the case of certain U.S.
Holders, constitute &#8220;general category income.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that the amount of the distribution
exceeds our current and accumulated earnings and profits (as determined under U.S. federal income tax principles), it will be treated
first as a tax-free return of your tax basis in your ordinary shares, and to the extent the amount of the distribution exceeds your tax
basis, the excess will be taxed as capital gain. We do not intend to calculate our earnings and profits under U.S. federal income tax
principles. Therefore, a U.S. Holder should expect that a distribution will be treated as a dividend even if that distribution would otherwise
be treated as a non-taxable return of capital or as capital gain under the rules described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of Dispositions of Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the PFIC rules discussed below, you
will recognize taxable gain or loss on any sale, exchange, or other taxable disposition of a share equal to the difference between the
amount realized (in U.S. dollars) for the share and your tax basis (in U.S. dollars) in the ordinary shares. The gain or loss will be
capital gain or loss. If you are a non-corporate U.S. Holder, including an individual U.S. Holder, who has held the ordinary shares for
more than one year, you will generally be eligible for reduced tax rates. The deductibility of capital losses is subject to limitations.
Any such gain or loss that you recognize will generally be treated as United States source income or loss for foreign tax credit limitation
purposes which will generally limit the availability of foreign tax credits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PFIC</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A non-U.S. corporation is considered a PFIC, as
defined in Section 1297(a) of the U.S. Internal Revenue Code, for any taxable year if either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 75% of its gross income for such taxable year is passive income; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income (the &#8220;asset test&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Passive income generally includes dividends, interest,
rents and royalties (other than rents or royalties derived from the active conduct of a trade or business), and gains from the disposition
of passive assets. We will be treated as owning our proportionate share of the assets and earning our proportionate share of the income
of any other corporation in which we own, directly or indirectly, at least 25% (by value) of the stock. In determining the value and composition
of our assets for purposes of the PFIC asset test, the value of our assets must be determined based on the market value of our ordinary
shares from time to time, which could cause the value of our non-passive assets to be less than 50% of the value of all of our assets
on any particular quarterly testing date for purposes of the asset test.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on our operations and the composition of
our assets we do not expect to be treated as a PFIC under the current PFIC rules. We must make a separate determination each year as to
whether we are a PFIC, however, and there can be no assurance with respect to our status as a PFIC for our current taxable year or any
future taxable year. Depending on the amount of assets held for the production of passive income, it is possible that, for our current
taxable year or for any subsequent taxable year, more than 50% of our assets may be assets held for the production of passive income.
We will make this determination following the end of any particular tax year. In addition, because the value of our assets for purposes
of the asset test will generally be determined based on the market price of our ordinary shares, our PFIC status will depend in large
part on the market price of our ordinary shares. Accordingly, fluctuations in the market price of the ordinary shares may cause us to
become a PFIC. In addition, the application of the PFIC rules is subject to uncertainty in several respects and the composition of our
income and assets will be affected by how, and how quickly, we spend our liquid assets. We are under no obligation to take steps to reduce
the risk of our being classified as a PFIC, and as stated above, the determination of the value of our assets will depend upon material
facts (including the market price of our ordinary shares from time to time) that may not be within our control. If we are a PFIC for any
year during which you hold ordinary shares, we will continue to be treated as a PFIC for all succeeding years during which you hold ordinary
shares. If we cease to be a PFIC and you did not previously make a timely &#8220;mark-to-market&#8221; election as described below, however,
you may avoid some of the adverse effects of the PFIC regime by making a &#8220;purging election&#8221; (as described below) with respect
to the ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are a PFIC for your taxable year(s) during
which you hold ordinary shares, you will be subject to special tax rules with respect to any &#8220;excess distribution&#8221; that you
receive and any gain you realize from a sale or other disposition (including a pledge) of the ordinary shares, unless you make a &#8220;mark-to-market&#8221;
election as discussed below. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions
you received during the shorter of the three preceding taxable years or your holding period for the ordinary shares will be treated as
an excess distribution. Under these special tax rules:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the excess distribution or gain will be allocated ratably over your holding period for the ordinary shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to your current taxable year, and any amount allocated to any of your taxable year(s) prior to the first taxable year in which we were a PFIC, will be treated as ordinary income, and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to each of your other taxable year(s) will be subject to the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tax liability for amounts allocated to years
prior to the year of disposition or &#8220;excess distribution&#8221; cannot be offset by any net operating losses for such years, and
gains (but not losses) realized on the sale of the ordinary shares cannot be treated as capital, even if you hold the ordinary shares
as capital assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder of &#8220;marketable stock&#8221;
(as defined below) in a PFIC may make a mark-to-market election under Section 1296 of the US Internal Revenue Code for such stock to elect
out of the tax treatment discussed above. If you make a mark-to-market election for first taxable year which you hold (or are deemed to
hold) ordinary shares and for which we are determined to be a PFIC, you will include in your income each year an amount equal to the excess,
if any, of the fair market value of the ordinary shares as of the close of such taxable year over your adjusted basis in such ordinary
shares, which excess will be treated as ordinary income and not capital gain. You are allowed an ordinary loss for the excess, if any,
of the adjusted basis of the ordinary shares over their fair market value as of the close of the taxable year. Such ordinary loss, however,
is allowable only to the extent of any net mark-to-market gains on the ordinary shares included in your income for prior taxable years.
Amounts included in your income under a mark-to-market election, as well as gain on the actual sale or other disposition of the ordinary
shares, are treated as ordinary income. Ordinary loss treatment also applies to any loss realized on the actual sale or disposition of
the ordinary shares, to the extent that the amount of such loss does not exceed the net mark-to-market gains previously included for such
ordinary shares. Your basis in the ordinary shares will be adjusted to reflect any such income or loss amounts. If you make a valid mark-to-market
election, the tax rules that apply to distributions by corporations which are not PFICs would apply to distributions by us, except that
the lower applicable capital gains rate for qualified dividend income discussed above under &#8220;&#8212;Taxation of Dividends and Other
Distributions on our Ordinary Shares&#8221; generally would not apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The mark-to-market election is available only
for &#8220;marketable stock,&#8221; which is stock that is traded in other than de minimis quantities on at least 15 days during each
calendar quarter (&#8220;regularly traded&#8221;) on a qualified exchange or other market (as defined in applicable U.S. Treasury regulations),
including the Nasdaq Capital Market. If the ordinary shares are regularly traded on the Nasdaq Capital Market and if you are a holder
of ordinary shares, the mark-to-market election would be available to you were we to be or become a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alternatively, a U.S. Holder of stock in a PFIC
may make a &#8220;qualified electing fund&#8221; election under Section 1295(b) of the US Internal Revenue Code with respect to such PFIC
to elect out of the tax treatment discussed above. A U.S. Holder who makes a valid qualified electing fund election with respect to a
PFIC will generally include in gross income for a taxable year such holder&#8217;s pro rata share of the corporation&#8217;s earnings
and profits for the taxable year. The qualified electing fund election, however, is available only if such PFIC provides such U.S. Holder
with certain information regarding its earnings and profits as required under applicable U.S. Treasury regulations. We do not currently
intend to prepare or provide the information that would enable you to make a qualified electing fund election. If you hold ordinary shares
in any taxable year in which we are a PFIC, you will be required to file U.S. Internal Revenue Service Form 8621 in each such year and
provide certain annual information regarding such ordinary shares, including regarding distributions received on the ordinary shares and
any gain realized on the disposition of the ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you do not make a timely &#8220;mark-to-market&#8221;
election (as described above), and if we were a PFIC at any time during the period you hold our ordinary shares, then such ordinary shares
will continue to be treated as stock of a PFIC with respect to you even if we cease to be a PFIC in a future year, unless you make a &#8220;purging
election&#8221; for the year we cease to be a PFIC. A &#8220;purging election&#8221; creates a deemed sale of such ordinary shares at
their fair market value on the last day of the last year in which we are treated as a PFIC. The gain recognized by the purging election
will be subject to the special tax and interest charge rules treating the gain as an excess distribution, as described above. As a result
of the purging election, you will have a new basis (equal to the fair market value of the ordinary shares on the last day of the last
year in which we are treated as a PFIC) and holding period (which new holding period will begin the day after such last day) in your ordinary
shares for tax purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IRC Section 1014(a) provides for a step-up in
basis to the fair market value for our ordinary shares when inherited from a decedent that was previously a holder of our ordinary shares.
However, if we are determined to be a PFIC and a decedent that was a U.S. Holder did not make either a timely qualified electing fund
election for our first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) our ordinary shares, or a mark-to-market
election and ownership of those ordinary shares are inherited, a special provision in IRC Section 1291(e) provides that the new U.S. Holder&#8217;s
basis should be reduced by an amount equal to the Section 1014 basis minus the decedent&#8217;s adjusted basis just before death. As such
if we are determined to be a PFIC at any time prior to a decedent&#8217;s passing, the PFIC rules will cause any new U.S. Holder that
inherits our ordinary shares from a U.S. Holder to not get a step-up in basis under Section 1014 and instead will receive a carryover
basis in those ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You are urged to consult your tax advisors regarding
the application of the PFIC rules to your investment in our ordinary shares and the elections discussed above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Information Reporting and Backup Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividend payments with respect to our ordinary
shares and proceeds from the sale, exchange, or redemption of our ordinary shares may be subject to information reporting to the U.S.
Internal Revenue Service and possible U.S. backup withholding under Section 3406 of the U.S. Internal Revenue Code with at a current flat
rate of 24%. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification number and makes
any other required certification on U.S. Internal Revenue Service Form W-9 or who is otherwise exempt from backup withholding. U.S. Holders
who are required to establish their exempt status generally must provide such certification on U.S. Internal Revenue Service Form W-9.
U.S. Holders are urged to consult their tax advisors regarding the application of the U.S. information reporting and backup withholding
rules.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Backup withholding is not an additional tax. Amounts
withheld as backup withholding may be credited against your U.S. federal income tax liability, and you may obtain a refund of any excess
amounts withheld under the backup withholding rules by filing the appropriate claim for refund with the U.S. Internal Revenue Service
and furnishing any required information. We do not intend to withhold taxes for individual shareholders. Transactions effected through
certain brokers or other intermediaries, however, may be subject to withholding taxes (including backup withholding), and such brokers
or intermediaries may be required by law to withhold such taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Hiring Incentives to Restore Employment
Act of 2010, certain U.S. Holders are required to report information relating to our ordinary shares, subject to certain exceptions (including
an exception for ordinary shares held in accounts maintained by certain financial institutions), by attaching a complete Internal Revenue
Service Form 8938, Statement of Specified Foreign Financial Assets, with their tax return for each year in which they hold ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F. <span style="text-decoration:underline">Dividends and Paying Agents</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>G. <span style="text-decoration:underline">Statement by Experts</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>H. <span style="text-decoration:underline">Documents on Display</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have previously filed with the SEC our registration
statements on Form&#160;F-1 (File No. 333-248067), as amended, to register our ordinary shares in connection with our initial public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to the periodic reporting and other
informational requirements of the Exchange Act. Under the Exchange Act, we are required to file reports and other information with the
SEC. Specifically, we are required to file annually a Form&#160;20-F within four months after the end of each fiscal year. Copies of reports
and other information, when so filed, may be inspected without charge and may be obtained at prescribed rates at the public reference
facilities maintained by the SEC at Judiciary Plaza, 100 F Street, N.E., Washington, D.C. 20549. The public may obtain information regarding
the Washington, D.C. Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains a website at <span style="text-decoration:underline;text-decoration: none">http://www.sec.gov</span>
that contains reports, proxy and information statements, and other information regarding registrants that make electronic filings with
the SEC using its EDGAR system. As a foreign private issuer, we are exempt from the rules&#160;of the Exchange Act prescribing, among
other things, the furnishing and content of proxy statements to shareholders, and our executive officers, directors and principal shareholders
are exempt from the reporting and short-swing profit recovery provisions contained in Section&#160;16 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>I. <span style="text-decoration:underline">Subsidiary Information</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Exchange Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Substantially all of our revenues are denominated
in Renminbi. The Renminbi is not freely convertible into foreign currencies for capital account transactions. The value of the Renminbi
against the U.S. dollar and other currencies is affected by, among other things, changes in China&#8217;s political and economic conditions
and China&#8217;s foreign exchange policies. On July 21, 2005, the PRC government changed its decade-old policy of pegging the value of
the Renminbi to the U.S. dollar, and the Renminbi appreciated more than 20% against the U.S. dollar over the following three years. Between
July 2008 and June 2010, this appreciation halted and the exchange rate between the Renminbi and the U.S. dollar remained within a narrow
band. Since June 2010, the Renminbi has fluctuated against the U.S. dollar, at times significantly and unpredictably. It is difficult
to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the Renminbi and the U.S. dollar in
the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have not entered into any hedging
transactions in an effort to reduce our exposure to foreign currency exchange risk. To the extent that we need to convert U.S. dollars
we received from our initial public offering in March 2021 into Renminbi for our operations or capital expenditures, appreciation of the
Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount we would receive from the conversion. Conversely,
if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or for
other business purposes, appreciation of the U.S. dollar against the Renminbi would have a negative effect on the U.S. dollar amount available
to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, we had U.S. dollar-denominated
cash and cash equivalents of US$8.1 million. A 10% depreciation of U.S. dollar against the Renminbi based on the foreign exchange rate
on September 30, 2021 would result in a decrease of RMB5.3 million in cash and cash equivalents. A 10% appreciation of U.S. dollar against
the Renminbi based on the foreign exchange rate on September 30, 2021 would result in an increase of RMB5.3 million in cash and cash equivalents.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Credit Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are typically unsecured and
derived from revenue earned from customers, thereby exposed to credit risk. The risk is mitigated by our assessment of its customers&#8217;
creditworthiness and its ongoing monitoring of outstanding balances.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Interest Rate Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not used derivative financial instruments
to hedge interest rate risk. Interest-earning instruments carry a degree of interest rate risk. We have not been exposed, nor do we anticipate
being exposed to material risks due to changes in market interest rates. However, our future interest income may fall short of expectations
due to changes in market interest rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inflation Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In recent years, inflation has not had a material
impact on our results of operations. According to the National Bureau of Statistics of China, the consumer price index in China increased
by 2.1%, 2.9%, and 2.5% in 2018, 2019, and 2020, respectively. Although we have not in the past been materially affected by inflation
since our inception, we can provide no assurance that we will not be affected in the future by higher rates of inflation in China. If
inflation rises, it may materially and adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. <span style="text-decoration:underline">Debt Securities</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. <span style="text-decoration:underline">Warrants and Rights</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>C. <span style="text-decoration:underline">Other Securities</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. <span style="text-decoration:underline">American Depositary Shares</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 114; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="k_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Part&#160;II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 14. MATERIAL MODIFICATIONS TO THE RIGHTS
OF SECURITY HOLDERS AND USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;Item 10. Additional Information&#8221;
for a description of the rights of securities holders, which remain unchanged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Proceeds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following &#8220;Use of Proceeds&#8221; information
relates to the registration statement on Form&#160;F-1 (File Number 333-248067), as amended, which was declared effective by the SEC on
March 22, 2021, for our initial public offering, which was closed on March 25, 2021. We issued and sold an aggregate of 5,750,000 ordinary
shares, at a price of $5.00 per share with gross proceeds of $28.75 million. Univest Securities, LLC was the underwriter of our initial
public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incurred approximately $2,953,114 in expenses
in connection with our initial public offering and $178,758 in expenses in connection with the issuance of overallotment shares. None
of the transaction expenses included payments to directors or officers of our company or their associates, persons owning more than 10%
or more of our equity securities or our affiliates. None of the net proceeds we received from the initial public offering were paid, directly
or indirectly, to any of our directors or officers or their associates, persons owning 10% or more of our equity securities or our affiliates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds raised from the initial public offering were $25,618,128
after deducting underwriting discounts and the offering expenses payable by us. For the period from the effectiveness of the registration
statement on Form F-1 to September 30, 2021, we used $2,382,627 of the net proceeds from our initial public offering for research and
development purposes, and $4,424,880 of the net proceeds for upgrading and expanding our manufacturing facilities. We still intend to
use the remaining proceeds from our initial public offering in the manner disclosed in our registration statement on Form&#160;F-1, as
amended (File Number 333-248067).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="k_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 15. CONTROLS AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management, with the participation of our
chief executive officer and chief financial officer, has performed an evaluation of the effectiveness of our disclosure controls and procedures
(as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report, as required by Rule 13a-15(b)
under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon this evaluation, our management has
concluded that, as of September 30, 2021, our existing disclosure controls and procedures were ineffective because of a material weakness
in our internal control over financial reporting, which related to the fact that our internal audit function was not set up properly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Management&#8217;s Annual Report on Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the
Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of consolidated financial statements in accordance with U.S. GAAP and includes those policies
and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions
and dispositions of a company&#8217;s assets, (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit
preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that a company&#8217;s
receipts and expenditures are being made only in accordance with authorizations of a company&#8217;s management and directors, and (iii)&#160;provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of a company&#8217;s assets
that could have a material effect on the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management, with the participation of our
chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of our Company&#8217;s internal control
over financial reporting as of September 30, 2021 based on criteria established in Internal Control&#8212;Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway Commission (COSO 2013 Framework). Based on this evaluation, we identified
one deficiency, which related to the fact that our internal audit function was not setup properly, and which we believe to be a material
weakness as of September 30, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the above material weakness, management
has concluded that our internal control over financial reporting was ineffective as of September 30, 2021. To remedy our identified material
weakness as of September 30, 2021, we have undertaken the remedial steps and also plan to adopt certain measures to improve our internal
control over financial reporting as set forth below under &#8220;<i>Remediation plan of the Material Weaknesses in Internal Control over
Financial Reporting Reported as of September 30, 2021</i>&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of its inherent limitations, internal
control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness
of our internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because
of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Remediation plan of the Material Weakness
in Internal Control over Financial Reporting Reported as of September 30, 2021</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since very few companies in Ji&#8217;an, Jiangxi
Province, the area in which our main PRC operating subsidiaries are located, have sought public listing on a U.S. exchange, we were not
able to identify qualified accounting candidates with relevant U.S. GAAP experience and expertise from this area. As such, our implementation
process to search for qualified personnel for internal audit became longer than we expected. Therefore, we are still in the process of
implementing the following remedial measures:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">i.</td><td style="text-align: justify">hiring qualified personnel to set up an internal audit function;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">ii.</td><td style="text-align: justify">establishing an annual plan of internal audit and getting approval from audit committee; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">iii.</td><td style="text-align: justify">engaging an external consulting firm to assist us in conducting internal audit programs, if necessary.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Attestation Report of the Registered Public
Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This annual report on Form 20-F does not include
an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management&#8217;s
report was not subject to attestation by our registered public accounting firm pursuant to rules&#160;of the SEC where domestic and foreign
registrants that are non-accelerated filers, which we are, and &#8220;emerging growth companies,&#8221; which we also are, are not required
to provide the auditor attestation report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2020, we identified the following
internal control deficiencies that we believed to be material weaknesses:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">i.</td><td style="text-align: justify">a lack of accounting staff and resources with appropriate knowledge of U.S. GAAP and SEC reporting and
compliance requirements;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">ii.</td><td style="text-align: justify">a lack of sufficient documented financial closing policies and procedures;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">iii.</td><td style="text-align: justify">a lack of independent directors and an audit committee;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">iv.</td><td style="text-align: justify">lack of risk assessment in accordance with the requirement of COSO 2013 framework; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">v.</td><td style="text-align: justify">a lack of an effective review process by the accounting manager which led to material audit adjustments
to the financial statements.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the fiscal year ended September 30, 2021, we
standardized essential business processes according to the requirements of our internal control system for accounting rules and financial
reporting, to ensure the authenticity and integrity of our financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We implemented the following remedial measures
during the fiscal year ended September 30, 2021, which addressed most of the material weaknesses identified as of September 30, 2020:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">i.</td><td style="text-align: justify">we appointed our independent directors and established an audit committee;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">ii.</td><td style="text-align: justify">we engaged an internal control consulting firm to assist us in assessing the compliance requirements under
Sarbanes-Oxley and improving our overall internal control function, with a special focus on addressing our material weaknesses identified
as of September 30, 2020;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">iii.</td><td style="text-align: justify">we set up an internal control team led by our chief executive officer and chief financial officer, which
is responsible for designing internal control procedures, supervising the implementation of our internal control system, and assessing
the effectiveness of our internal controls;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">iv.</td><td style="text-align: justify">we set up standard risk assessment framework in accordance with the requirement of COSO 2013 framework,
to identify potential risks and establish corresponding supervision and improvement mechanism;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">v.</td><td style="text-align: justify">we distributed study materials regarding U.S. GAAP, SEC financial reporting and compliance requirements
to and provided training sessions for our accounting and financial reporting personnel;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">vi.</td><td style="text-align: justify">we fully set up effective review process to further enhance the effectiveness of our financial review,
including the analysis and monitoring of financial information in a consistent and thorough manner, to detect potential misstatement and
assure the accuracy of the financial statements;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">vii.</td><td style="text-align: justify">we applied the documented policy and checklist for financial closing to standardize financial closing
and reviewing procedures; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">viii.</td><td style="text-align: justify">we engaged a financial consulting firm with requisite knowledge and experience in application of U.S.
GAAP to assist us in preparing the financial statements and relevant disclosures under U.S. GAAP and SEC reporting and compliance requirements.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than as described above, there were no changes
in our internal controls over financial reporting that occurred during the period covered by this annual report on Form&#160;20-F&#160;that
have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16. [RESERVED]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. H. David Sherman qualifies as an &#8220;audit
committee financial expert&#8221; as defined in Item 16A of Form&#160;20-F. Mr.&#160;H. David Sherman satisfies the &#8220;independence&#8221;
requirements of Section&#160;5605(a)(2)&#160;of the NASDAQ Listing Rules&#160;as well as the independence requirements of Rule&#160;10A-3
under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16B. CODE OF ETHICS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has adopted a code of business
conduct and ethics, which is applicable to all of our directors, officers, and employees. Our code of business conduct and ethics is publicly
available on our website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the aggregate
fees by categories specified below in connection with certain professional services rendered and billed by Friedman LLP and YCM CPA INC.,
our independent registered public accounting firms for the periods indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Friedman LLP</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">365,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">260,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related fees <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">All other fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">365,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">260,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>YCM CPA INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Years Ended September 30,</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2019</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 67%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees <sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related fees <sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees <sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All other fees</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,000</span></td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees include the aggregate fees billed for each of the fiscal years for professional services rendered by our independent registered public accounting firm for the audit of our annual financial statements or for the audits of our financial statements and review of the interim financial statements in connection with our initial public offering in 2021.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit related fees include the aggregate fees billed for related services by our principal accountant that are reasonably related to the performance of the audit or review of our financial statements and are not reported under audit fees.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees represents the aggregated fees billed for professional services rendered by our independent registered public accounting firm for tax compliance, tax advice, and tax planning. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audit committee of our board of directors
has established its pre-approval policies and procedures, pursuant to which the audit committee approved the foregoing audit, tax and
non-audit services provided by YCM CPA INC. in fiscal year 2021 and Friedman LLP in fiscal years 2019 and 2020. Consistent with our audit
committee&#8217;s responsibility for engaging our independent auditors, all audit and permitted non-audit services require pre-approval
by the audit committee. The full audit committee approves proposed services and fee estimates for these services. One or more independent
directors serving on the audit committee may be delegated by the full audit committee to pre-approve any audit and non-audit services.
Any such delegation shall be presented to the full audit committee at its next scheduled meeting. Pursuant to these procedures, the audit
committee approved the foregoing audit services provided by YCM CPA INC. and Friedman LLP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="k_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16D. EXEMPTIONS FROM THE LISTING STANDARDS
FOR AUDIT COMMITTEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16E. PURCHASES OF EQUITY SECURITIES BY
THE ISSUER AND AFFILIATED PURCHASERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING
ACCOUNTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 7, 2021, we appointed YCM CPA INC.
(&#8220;YCM&#8221;) as its independent registered public accounting firm, effective on the same day. YCM replaces Friedman LLP (&#8220;Friedman&#8221;),
our former independent registered public accounting firm, which we dismissed on December 1, 2021. The appointment of YCM was made after
careful consideration and evaluation process by the Company and has been approved by the audit committee of our board of directors. Our
decision to make this change was not the result of any disagreement between the Company and Friedman on any matter of accounting principles
or practices, financial statement disclosure, or auditing scope or procedure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audit report of Friedman on the consolidated
financial statements of the Company as of September 30, 2019 and 2020 and for the fiscal years ended September 30, 2019 and 2020 did not
contain an adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, scope of accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the two most recent fiscal years and any
subsequent interim periods prior to the engagement of YCM, neither the Company, nor someone on behalf of the Company, has consulted YCM
regarding either (a) the application of accounting principles to a specified transaction, either completed or proposed; or the type of
audit opinion that might be rendered on the Company&#8217;s consolidated financial statements, and neither a written report was provided
to the Company or oral advice was provided that YCM concluded was an important factor considered by the Company in reaching a decision
as to the accounting, auditing or financial reporting issue; or (b) any matter that was the subject of a disagreement as defined in Item
16F(a)(1)(iv) of Form 20-F and related instructions to Item 16F of Form 20-F, or any reportable events as described in Item 16F(a)(1)(v)
of Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16G. CORPORATE GOVERNANCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a Cayman Islands company listed on the Nasdaq
Global Market, we are subject to the Nasdaq corporate governance listing standards. Nasdaq rules, however,&#160;permit a foreign private
issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in the Cayman
Islands, which is our home country, may differ significantly from the Nasdaq corporate governance listing standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq Listing Rule 5635 generally provides that shareholder approval is
required of U.S. domestic companies listed on Nasdaq prior to issuance (or potential issuance) of securities (i) equaling 20% or more
of the company&#8217;s common stock or voting power for less than the greater of market or book value (ii) resulting in a change of control
of the company; and (iii) which is being issued pursuant to a stock option or purchase plan to be established or materially amended or
other equity compensation arrangement made or materially amended. Notwithstanding this general requirement, Nasdaq Listing Rule 5615(a)(3)(A)
permits foreign private issuers to follow their home country practice rather than these shareholder approval requirements. The Companies
Act does not require shareholder approval prior to any of the foregoing types of issuances. We, therefore, are not required to obtain
such shareholder approval prior to entering into a transaction with the potential to issue securities as described above. Specifically,
our board of directors has elected to follow our home country rules and be exempt from the requirements to obtain shareholder approval
for the issuance of 20% or more of our outstanding ordinary shares under Nasdaq Listing Rule 5635(d).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nasdaq Listing Rule 5605(b)(1) requires listed
companies to have, among other things, a majority of its board members be independent. As a foreign private issuer, however, we are permitted
to, and we may follow home country practice in lieu of the above requirements. The corporate governance practice in our home country,
the Cayman Islands, does not require a majority of our board to consist of independent directors. Currently, a majority of our board members
are independent. However, if we change our board composition such that independent directors do not constitute a majority of our board
of directors, our shareholders may be afforded less protection than they would otherwise enjoy under Nasdaq&#8217;s corporate governance
requirements applicable to U.S. domestic issuers. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Our
Ordinary Shares&#8212; As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate
governance matters that differ significantly from the Nasdaq listing standards. These practices may afford less protection to shareholders
than they would enjoy if we complied fully with corporate governance listing standards.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than those described above, there are no
significant differences between our corporate governance practices and those followed by U.S. domestic companies under Nasdaq corporate
governance listing standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16H. MINE SAFETY DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 119; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="k_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Part III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 17. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have elected to provide financial statements
pursuant to Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 18. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of Universe
Pharmaceuticals INC and its subsidiaries are included at the end of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 19. EXHIBITS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBIT INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="text-decoration: none; font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="text-decoration: none">
    <td style="text-decoration: none; vertical-align: top; width: 9%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="text-decoration: none; vertical-align: top; width: 1%">&#160;</td>
    <td style="text-decoration: none; vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="text-decoration: none; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-decoration: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="text-decoration: none">&#160;</td>
    <td style="text-decoration: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex3-1_universepharm.htm">Amended and Restated Memorandum of Association (incorporated by reference to Exhibit 3.1 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="text-decoration: none; vertical-align: top; ">
    <td style="text-decoration: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</span></td>
    <td style="text-decoration: none">&#160;</td>
    <td style="text-decoration: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex3-2_universepharm.htm">Amended and Restated Articles of Association (incorporated by reference to Exhibit 3.2 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="text-decoration: none; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-decoration: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="text-decoration: none">&#160;</td>
    <td style="text-decoration: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex4-1_universepharm.htm">Specimen Certificate for Ordinary Shares (incorporated by reference to Exhibit 4.1 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="text-decoration: none; vertical-align: top; ">
    <td style="text-decoration: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="text-decoration: none">&#160;</td>
    <td style="text-decoration: none; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1809616/000121390020037560/ea129847ex4-2_universe.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriter Warrants (incorporated by reference to Exhibit 4.2 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</span></a></td></tr>
  <tr style="text-decoration: none; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-decoration: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3*</span></td>
    <td style="text-decoration: none">&#160;</td>
    <td style="text-decoration: none; text-align: justify"><a href="f20f2021ex2-3_universephar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities</span></a></td></tr>
  <tr style="text-decoration: none; vertical-align: top; ">
    <td style="text-decoration: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="text-decoration: none">&#160;</td>
    <td style="text-decoration: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex10-1_universepharm.htm">Form of Employment Agreement by and between executive officers and the Registrant (incorporated by reference to Exhibit 10.1 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="text-decoration: none; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-decoration: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="text-decoration: none">&#160;</td>
    <td style="text-decoration: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex10-2_universepharm.htm">Form of Indemnification Agreement with the Registrant&#8217;s directors and officers (incorporated by reference to Exhibit 10.2 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="text-decoration: none; vertical-align: top; ">
    <td style="text-decoration: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="text-decoration: none">&#160;</td>
    <td style="text-decoration: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex10-3_universepharm.htm">English Translation of the Working Capital Loan Contract between Jiangxi Universe and Jiangxi Liuling Rural Commercial Bank Co., Ltd., dated June 26, 2019 (incorporated by reference to Exhibit 10.3 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="text-decoration: none; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-decoration: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="text-decoration: none">&#160;</td>
    <td style="text-decoration: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex10-3_universepharm.htm">English Translation of the Working Capital Loan Contract between Universe Trade and Jiangxi Liuling Rural Commercial Bank Co., Ltd., dated September 26, 2019 (incorporated by reference to Exhibit 10.4 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="text-decoration: none; vertical-align: top; ">
    <td style="text-decoration: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="text-decoration: none">&#160;</td>
    <td style="text-decoration: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex10-5_universepharm.htm">English Translation of the Loan Guarantee Contract among Jiangxi Universe, Xing Wu, Universe Trade, and Jiangxi Liuling Rural Commercial Bank Co., Ltd., dated September 26, 2019 (incorporated by reference to Exhibit 10.5 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="text-decoration: none; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-decoration: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="text-decoration: none">&#160;</td>
    <td style="text-decoration: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex10-6_universepharm.htm">English Translation of the Loan Guarantee Contract among Gang Lai, Lin Yang, Jiangxi Universe, Foshan Shangyu Investment Holding Co., Ltd., Fujing Wang, Universe Trade, and Jiangxi Liuling Rural Commercial Bank Co., Ltd., dated September 26, 2019 (incorporated by reference to Exhibit 10.6 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>

<tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex10-7_universepharm.htm">Form of Sales and Distribution Agreement by and between Universe Trade and customers (incorporated by reference to Exhibit 10.7 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390021064704/ea152145ex1-1_universepharma.htm">Strategic Cooperation Agreement by and between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd., dated December 1, 2021 (incorporated by reference to Exhibit 1.1 of our Current Report on Form 6-K (file No. 001-40231), filed with the Securities and Exchange Commission on December 10, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390021064704/ea152145ex1-2_universepharma.htm">Share Purchase Agreement by and among Universe Pharmaceuticals INC, Kitanihon Pharmaceutical Co., Ltd., and Nishimura Ichiro, dated December 1, 2021 (incorporated by reference to Exhibit 1.2 of our Current Report on Form 6-K (file No. 001-40231), filed with the Securities and Exchange Commission on December 10, 2021)</a></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="text-decoration: none; font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390021064704/ea152145ex1-3_universepharma.htm">Cooperation Agreement on Manufacturing Facility Construction Project by and between Universe Pharmaceuticals INC and Kitanihon Pharmaceutical Co., Ltd., dated December 1, 2021 (incorporated by reference to Exhibit 1.3 of our Current Report on Form 6-K (file No. 001-40231), filed with the Securities and Exchange Commission on December 10, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1809616/000121390021064704/ea152145ex1-4_universepharma.htm">Share Transfer Agreement by and among Sununion Holding Group Ltd., Kitanihon Pharmaceutical Co., Ltd., and Gang Lai, dated December 1, 2021 (incorporated by reference to Exhibit 1.4 of our Current Report on Form 6-K (file No. 001-40231), filed with the Securities and Exchange Commission on December 10, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex4-12_universephar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">English translation of the working capital loan contract entered into by and between Universe Trade and Jiangxi Liuling Rural Commercial Bank Co., Ltd., dated March 18, 2021</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex4-13_universephar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">English translation of the real estate property purchase agreement entered into by and between Jiangxi Universe and Jiangxi Yueshang Investment Co., Ltd., dated May 16, 2021</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex4-14_universephar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">English translation of the working capital loan contract entered into by and between Jiangxi Universe and Jiangxi Liuling Rural Commercial Bank Co., Ltd., dated June 16, 2021</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex4-15_universephar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">English translation of the construction agreement entered into by and between Jiangxi Universe and Jiangxi Chenyuan Construction Project Co., Ltd., dated June 25, 2021</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex4-16_universephar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">English translation of the working capital loan contract entered into by and between Jiangxi Universe and Bank of Communications, dated June 30, 2021</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex4-17_universephar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">English translation of the advertising service agreement entered into by and between Jiangxi Universe and Guangdong Fengyang Legend Consulting Co., Ltd., dated September 6, 2021</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex8-1_universephar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of subsidiaries of the Registrant</span></a></td></tr>

<tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1809616/000121390020022480/ea125531ex99-1_universepharm.htm">Code of Business Conduct and Ethics of the Registrant &#160;(incorporated by reference to Exhibit 99.1 of our Registration Statement on Form F-1 (file No. 333-248067), as amended, initially filed with the Securities and Exchange Commission on August 17, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex12-1_universephar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex12-2_universephar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1 **</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex13-1_universephar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2 **</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex13-2_universephar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex15-1_universephar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of AllBright Law Offices</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following financial
    statements from the Company&#8217;s Annual Report on Form 20-F for the fiscal year ended September 30, 2021, formatted in Inline
    XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations and Comprehensive Income, (iii) Consolidated Statements
    of Changes in Equity, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial Statements, tagged as blocks
    of text and including detailed tags</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table><div>
</div><p style="margin: 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed with this annual report on Form&#160;20-F</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished with this annual report on Form&#160;20-F</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registrant hereby certifies that it meets
all of the requirements for filing on Form&#160;20-F and that it has duly caused and authorized the undersigned to sign this annual report
on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td colspan="2" style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Pharmaceuticals INC</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%; padding-right: 0.8pt">&#160;</td>
    <td style="width: 4%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="width: 36%; border-bottom: black 1.5pt solid; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gang Lai</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gang Lai</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Director, and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: January&#160;31, 2022</span></td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
    Financial Statements</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-align: justify; text-indent: -9pt"><a href="#fin_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reports of Independent Registered Public Accounting Firm</span>s</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">F-2 &#8211; F-3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_002">Consolidated Balance Sheets as of September 30, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_003">Consolidated Statements of Income and Comprehensive Income for the years ended September 30, 2021, 2020 and 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_004">Consolidated Statements of Changes in Shareholders&#8217; Equity for the years ended September 30, 2021, 2020 and 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-align: justify; text-indent: -9pt"><a href="#fin_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the years ended September 30, 2021, 2020 and 2019</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-align: justify; text-indent: -9pt"><a href="#fin_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8
&#8211; F-35</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 123; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><img alt="" src="fin_002.jpg" style="width: 102px; height: 58px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span><b>REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Board of Directors and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shareholders of Universe Pharmaceuticals INC</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span><b>Opinion on
the Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>We have audited
the accompanying consolidated balance sheets of </span>Universe Pharmaceuticals INC <span>and subsidiaries
(collectively, the &#8220;Company&#8221;) as of September&#160;30, 2021, and the related consolidated statements of operations and comprehensive
income (loss), changes in stockholders&#8217; equity, and cash flows for the year ended September&#160;30, 2021, and the related notes
(collectively referred to as the &#8220;financial statements&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>In our opinion,
the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company
as of September&#160;30, 2021, and the results of its operations and its cash flows for the period ended September&#160;30, 2021, in conformity
with accounting principles generally accepted in the United States of America.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span><b>Basis for
Opinion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>These consolidated
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>We conducted
our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are
required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on
the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>Our audit included
performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud,
and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts
and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the consolidated financial statement. We believe that
our audit provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span>/s/ YCM CPA, Inc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span>We have served as the Company&#8217;s
auditor since 2021.<br/>
Irvine, California<br/>
January 31, 2022</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 124 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<img alt="" src="fin_001.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">To
the Board of Directors and shareholders of </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Universe
Pharmaceuticals Inc. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Opinion
on the Financial Statements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">We
have audited the accompanying consolidated balance sheet of Universe Pharmaceuticals Inc. and its subsidiaries (collectively, the &#8220;Company&#8221;)
as of September 30, 2020, and the related consolidated statements of income and comprehensive income, changes in shareholders&#8217;
equity, and cash flows for each of the years in the two-year period ended September 30, 2020, and the related notes (collectively referred
to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in
all material respects, the financial position of the Company as of September 30, 2020, and the results of its operations and its cash
flows for each of the years in the two-year period ended September 30, 2020, in conformity with accounting principles generally accepted
in the United States of America. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Basis
for Opinion</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audit we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statement.
We believe that our audits provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">/s/
Friedman LLP</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">We
have served as the Company&#8217;s auditor since 2019.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">New
York, New York</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">February
24, 2021</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p><div>


</div><!-- Field: Page; Sequence: 125 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="fin_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="font-weight: bold; text-align: center">ASSETS</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">CURRENT ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 10pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">8,077,908</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">10,058,202</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: justify; padding-left: 10pt">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">13,725,204</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="0" unitRef="usd">15,573,742</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="0" unitRef="usd">10,871,778</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 10pt">Inventories, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,462,542</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">1,906,232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Due from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromRelatedParties" scale="0" unitRef="usd">236,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 10pt">Advance to suppliers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:AdvanceToSuppliersNet" scale="0" unitRef="usd">2,738,313</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Prepayment for advertising</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentForAdvertising" scale="0" unitRef="usd">7,492,320</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 10pt">Deferred initial public offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsCurrent" scale="0" unitRef="usd">443,709</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="0" unitRef="usd">174,053</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">TOTAL CURRENT ASSETS</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">50,481,064</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">23,279,921</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">4,681,353</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">4,428,064</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Prepayments made to a related party for purchase of property</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" scale="0" unitRef="usd">2,476,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt">Prepayments for construction in progress</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentsForConstructionInProgress" scale="0" unitRef="usd">10,712,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 10pt">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="0" unitRef="usd">178,483</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="0" unitRef="usd">174,776</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 10pt">Investment in equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:InvestmentInEquitySecurities" scale="0" unitRef="usd">744,924</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="upc:InvestmentInEquitySecurities" scale="0" unitRef="usd">735,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 10pt">Deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" unitRef="usd">869,997</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" unitRef="usd">186,537</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">TOTAL NONCURRENT ASSETS</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd">19,663,717</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd">5,524,377</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">TOTAL ASSETS</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">70,144,781</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">28,804,298</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 10pt">Short-term bank loans</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" unitRef="usd">4,334,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" unitRef="usd">2,646,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">5,310,526</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">2,691,193</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 10pt">Taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd">1,101,460</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd">1,331,749</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" unitRef="usd">19,723</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" unitRef="usd">956,492</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">444,319</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">375,960</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">TOTAL CURRENT LIABILITIES</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">11,210,428</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">8,001,394</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 20pt">Ordinary shares, $<ix:nonFraction contextRef="c2" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.003125</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">21,750,000</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">16,000,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2021 and 2020, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">67,969</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">29,279,159</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">3,679,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 10pt">Statutory reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:StatutoryReserve" scale="0" unitRef="usd">2,439,535</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="upc:StatutoryReserve" scale="0" unitRef="usd">2,439,535</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Retained earnings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" unitRef="usd">25,058,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" unitRef="usd">13,738,979</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">2,088,759</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">895,390</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">TOTAL SHAREHOLDERS&#8217; EQUITY</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">58,934,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">20,802,904</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">70,144,781</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">28,804,298</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;</b></span></p><div>

</div><div><a id="fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF INCOME AND COMPREHENSIVE INCOME</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">47,982,031</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">30,703,960</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">33,229,316</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cost of revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">22,655,854</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">16,610,140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">19,821,831</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">25,326,177</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">14,093,820</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">13,407,485</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd">2,973,531</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd">1,555,546</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd">1,578,826</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">3,296,844</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,703,424</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,457,393</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">5,465,662</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">583,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">618,437</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">11,736,037</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">3,842,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">3,654,656</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income from operations</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd">13,590,140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd">10,251,725</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd">9,752,829</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">101,604</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">123,760</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">129,268</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expenses), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" sign="-" unitRef="usd">80,434</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" sign="-" unitRef="usd">49,352</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd">2,760</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Short-term investments income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:ShorttermInvestmentIncome" scale="0" sign="-" unitRef="usd">239,549</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd">30,827</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd">21,820</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd">26,741</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd">88,338</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">151,292</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">99,767</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Income before income tax provision</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd">13,678,478</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd">10,100,433</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" unitRef="usd">9,653,062</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax provision</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,358,526</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,542,211</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,101,597</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Net income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">11,319,952</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,551,465</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Other comprehensive income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd">1,193,369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd">860,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" unitRef="usd">645,978</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Comprehensive income</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">12,513,321</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">8,418,845</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">6,905,487</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Earnings per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" unitRef="usdPershares">0.60</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" unitRef="usdPershares">0.47</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" unitRef="usdPershares">0.47</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">18,980,822</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">16,000,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">16,000,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEARS ENDED SEPTEMBER 30, 2021, 2020 AND 2019</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Paid in</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Statutory</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Retained</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Comprehensive</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Shareholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Reserve</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Earnings</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 30%; font-weight: bold">Balance at September 30,&#160;2018</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">16,000,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">3,679,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,439,535</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,832,292</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">680,745</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">9,681,572</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Dividend declared</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" scale="0" unitRef="usd">4,203,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" scale="0" unitRef="usd">4,203,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net income for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,551,465</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,551,465</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd">645,978</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd">645,978</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Balance at September 30,&#160;2019</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">16,000,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">3,679,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,439,535</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">6,180,757</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">34,767</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">12,384,059</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net income for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd">860,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd">860,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Balance at September 30,&#160;2020</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">16,000,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">3,679,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,439,535</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">13,738,979</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">895,390</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">20,802,904</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">5,750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">17,969</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">28,732,031</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">28,750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Capitalized initial public offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" scale="0" sign="-" unitRef="usd">3,131,872</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" scale="0" sign="-" unitRef="usd">3,131,872</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net income for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">11,319,952</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">11,319,952</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd">1,193,369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd">1,193,369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Balance at September 30,&#160;2021</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">21,750,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">67,969</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">29,279,159</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,439,535</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">25,058,931</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">2,088,759</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">58,934,353</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the&#160;years&#160;ended&#160;September&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flows from operating activities</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Net income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">11,319,952</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,551,465</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">446,878</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">410,079</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">418,431</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Loss from disposal of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="0" sign="-" unitRef="usd">1,559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="0" sign="-" unitRef="usd">2,085</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Allowance for doubtful accounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd">230,175</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd">98,102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd">297,972</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Inventory reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" sign="-" unitRef="usd">75,391</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" sign="-" unitRef="usd">187,271</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Deferred income tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">668,341</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">9,886</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">39,625</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Short-term investments income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeShortTermInvestmentOther" scale="0" unitRef="usd">239,549</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Accounts receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">3,867,457</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">4,107,520</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd">665,485</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Inventory, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd">451,634</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd">888,607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd">5,586,177</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Advance to suppliers, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" scale="0" unitRef="usd">2,717,085</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Prepayment for advertising</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidAdvertising" scale="0" unitRef="usd">7,434,240</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Advances to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" unitRef="usd">237,720</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd">168,188</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd">12,407</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd">8,449</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd">2,457,337</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd">639,427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" sign="-" unitRef="usd">924,444</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable" scale="0" sign="-" unitRef="usd">298,620</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable" scale="0" unitRef="usd">731,518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable" scale="0" sign="-" unitRef="usd">320,611</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 19.2pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" unitRef="usd">31,436</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" sign="-" unitRef="usd">30,408</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" unitRef="usd">162,540</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Net cash provided by (used in) operating activities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">2,055,847</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" unitRef="usd">6,115,157</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" unitRef="usd">13,203,755</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">444,505</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">51,798</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">86,324</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Proceeds from disposal of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="0" unitRef="usd">291</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Prepayments made to a related party for purchase of property</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" scale="0" unitRef="usd">2,457,600</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Prepayments for construction in progress</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfAdvancesForConstruction" scale="0" unitRef="usd">10,629,120</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Payments for short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" scale="0" unitRef="usd">15,330,660</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 13.2pt">Redemption of short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:RedemptionOfShorttermInvestments" scale="0" unitRef="usd">1,801,927</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">27,059,958</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">51,798</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">86,033</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Proceeds from short-term bank loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" unitRef="usd">4,300,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" unitRef="usd">1,427,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" unitRef="usd">3,055,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Repayment of bank loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd">2,764,800</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd">1,427,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd">3,055,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Dividend payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDividends" scale="0" unitRef="usd">16,005,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Gross proceeds from initial public offerings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" unitRef="usd">28,750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Payment for deferred initial public offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" scale="0" unitRef="usd">2,792,543</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" scale="0" unitRef="usd">441,064</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.9pt; padding-left: 0.1in">Proceeds from (prepayments for) related parties borrowings</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings" scale="0" unitRef="usd">911,648</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings" scale="0" sign="-" unitRef="usd">911,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings" scale="0" sign="-" unitRef="usd">1,143</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Net cash provided by (used in) financing activities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">26,581,809</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">470,136</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" sign="-" unitRef="usd">16,003,857</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Effect of exchange rate changes on cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="0" unitRef="usd">553,702</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="0" unitRef="usd">347,386</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="0" sign="-" unitRef="usd">126,720</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">1,980,294</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">6,880,881</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">3,012,855</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Cash, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">10,058,202</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">3,177,321</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">6,190,176</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Cash, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">8,077,908</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">10,058,202</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">3,177,321</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Supplemental disclosure information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 13.2pt">Cash paid for interest expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">149,303</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">157,528</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">135,717</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 13.2pt">Cash paid for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd">3,271,219</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd">2,167,963</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd">2,257,893</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;
The accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="clear: both"><br/></span></span></p><div>

</div><div><a id="fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8212; ORGANIZATION AND BUSINESS DESCRIPTION</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:nonNumeric><div>

</div><div>

</div><ix:nonNumeric contextRef="c43" name="upc:EntityIncorporationDateDescription"><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
Pharmaceuticals Inc. (&#8220;Universe INC&#8221; or the &#8220;Company&#8221;) was incorporated under the laws of the Cayman Islands
on December 11, 2019 as an exempted company with limited liability.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:nonNumeric contextRef="c44" name="upc:EntityIncorporationDateDescription"><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
INC. owns <ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% equity interest of Universe Pharmaceuticals (International) Group (&#8220;Universe HK&#8221;), an entity incorporated
on May 21, 2014 in accordance with the laws and regulations in Hong Kong.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
Universe Pharmaceuticals Technology Co., Ltd. <ix:nonNumeric contextRef="c46" name="upc:EntityIncorporationDateDescription">(&#8220;Universe Technology&#8221;) was formed on April 8, 2019, as a Wholly Foreign-Owned
Enterprise (&#8220;WOFE&#8221;) in the People&#8217;s Republic of China (&#8220;PRC&#8221;).</ix:nonNumeric> The registered capital of Universe Technology
is approximately $<ix:nonFraction contextRef="c47" decimals="-5" format="ixt:num-dot-decimal" name="upc:AmountOfRegisteredCapital" scale="6" unitRef="usd">4.3</ix:nonFraction> million (RMB <ix:nonFraction contextRef="c47" decimals="-5" format="ixt:num-dot-decimal" name="upc:AmountOfRegisteredCapital" scale="6" unitRef="cny">30.5</ix:nonFraction> million). In December 2019, the Company made capital contribution of $<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="upc:CapitalContribution" scale="0" unitRef="usd">500,000</ix:nonFraction> to Universe Technology.
Pursuant to the article of incorporation, the remaining capital contribution of approximately $<ix:nonFraction contextRef="c48" decimals="-5" format="ixt:num-dot-decimal" name="upc:RemainingCapitalContribution" scale="6" unitRef="usd">3.8</ix:nonFraction> million for Universe Technology is
required to be completed before 2038.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
INC, Universe HK and Universe Technology are currently not engaging in any active business operations and merely acting as holding companies.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
Universe Pharmaceuticals Co., Ltd. <ix:nonNumeric contextRef="c49" name="upc:EntityIncorporationDateDescription">(&#8220;Jiangxi Universe&#8221;) was incorporated on March 2, 1998 in accordance with PRC laws and
is engaged in research and development and manufacturing of modernized traditional Chinese medicines.</ix:nonNumeric> Jiangxi Universe owns <ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of the
equity of Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (&#8220;Universe Trade&#8221;) which was incorporated on March
10, 2010 to handle the sales and distribution of the pharmaceutical products manufactured by Jiangxi Universe.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reorganization</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reorganization of our legal structure (&#8220;Reorganization&#8221;) was completed on December 11, 2019. The reorganization involved
the incorporation of Universe INC and Universe Technology, and the transfer of the <ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% equity interest of Jiangxi Universe to Universe
Technology. Consequently, Universe INC, through its subsidiary Universe HK, directly controls Universe Technology and Jiangxi Universe,
and became the ultimate holding company of all other entities mentioned above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Reorganization has been accounted for as a recapitalization among entities under common control since the same controlling shareholders
controlled all these entities before and after the Reorganization. The consolidation of the Company and its subsidiaries has been accounted
for at historical cost and prepared on the basis as if the aforementioned transactions had become effective as of the beginning of the
first period presented in the accompanying consolidated financial statements. Results of operations for the periods presented comprise
those of the previously separate entities combined from the beginning of the period to the end of the period, eliminating the effects
of intra-entity transactions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 25, 2021, the Company closed its IPO of <ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">5,000,000</ix:nonFraction> ordinary shares, par value $<ix:nonFraction contextRef="c52" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">0.003125</ix:nonFraction> per share (the &#8220;ordinary shares&#8221;)
at a public offering price of $<ix:nonFraction contextRef="c52" decimals="2" format="ixt:num-dot-decimal" name="upc:PublicOfferingPrice" scale="0" unitRef="usdPershares">5.00</ix:nonFraction> per share. On March 29, 2021, the underwriter exercised in full its over-allotment option to purchase
an additional <ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">750,000</ix:nonFraction> ordinary shares.&#160;<span>The closing for the sale of the over-allotment shares
took place on March 31, 2021. Gross proceeds from the IPO totaled $<ix:nonFraction contextRef="c54" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd">28.75</ix:nonFraction> million. </span>Net proceeds of the IPO, including over-allotment
shares, were approximately $<ix:nonFraction contextRef="c55" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd">25.6</ix:nonFraction> million. In connection with the IPO, the Company&#8217;s ordinary shares began trading on the Nasdaq
Global Market&#160;under the symbol &#8220;UPC&#8221; on March 23, 2021.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2021, through the Company&#8217;s PRC subsidiary Jiangxi Universe, the Company established a wholly controlled subsidiary, Guangzhou
Universe Hanhe Medical Research Co., Ltd. (&#8220;Universe Hanhe&#8221;) in Guangzhou City, China, for the business purpose of conducting
research and development of new pharmaceutical products in order to diversify the Company&#8217;s product offerings in the near future.
As of September 30, 2021 and as of the date of this report, Universe Hanhe has no active business operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8212; ORGANIZATION AND BUSINESS DESCRIPTION (continued)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the subsidiaries of the Company as of September 30, 2021 were set out below:&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_13" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Entity </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
    of<br/>
    Incorporation </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place
    of<br/>
    Incorporation </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%
    of&#160;<br/>
    Ownership </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    Activities </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    INC </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c43" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation">December&#160;11,&#160;2019</ix:nonNumeric> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c43" name="upc:PlaceOfIncorporation">Cayman&#160;Islands</ix:nonNumeric> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent, <ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c43" name="upc:PrincipalActivities">Investment holding</ix:nonNumeric> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    HK </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c44" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation">May 21, 2014</ix:nonNumeric> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c44" name="upc:PlaceOfIncorporation">Hong Kong</ix:nonNumeric> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c56" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c44" name="upc:PrincipalActivities">Investment holding</ix:nonNumeric> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    Technology </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c57" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation">April 18, 2019</ix:nonNumeric> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c57" name="upc:PlaceOfIncorporation">PRC</ix:nonNumeric> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c57" name="upc:PrincipalActivities">WOFE, Investment holding</ix:nonNumeric> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Universe </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c49" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation">March 2, 1998</ix:nonNumeric> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c49" name="upc:PlaceOfIncorporation">PRC</ix:nonNumeric> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c58" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c49" name="upc:PrincipalActivities">Research and development and manufacturing of modernized traditional Chinese medicines</ix:nonNumeric> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    Trade</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c59" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation">March 10, 2010</ix:nonNumeric> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c59" name="upc:PlaceOfIncorporation">PRC</ix:nonNumeric> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c59" name="upc:PrincipalActivities">Sales of modernized traditional Chinese medicines</ix:nonNumeric> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    Hanhe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c60" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2021</span></ix:nonNumeric></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c60" name="upc:PlaceOfIncorporation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></ix:nonNumeric></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c61" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c60" name="upc:PrincipalActivities"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of new pharmaceutical products</span></ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, through its wholly-owned subsidiaries, is primarily engaged in the development, manufacturing and sale of traditional Chinese
medicines derivatives (&#8220;TCMD&#8221;) products targeted to the elderly to address their physical conditions in the aging process
and to promote their general well-being. In addition, the Company also sells biochemical drugs, medical instruments, traditional Chinese
medicine pieces products and dietary supplements (together &#8220;third-party products&#8221;). All of these TCMD and third-party products
are currently sold to customers including pharmaceutical companies, hospitals, clinics and drugstore chains throughout China.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of consolidation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b>&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the financial statements of Universe INC, Universe HK, Universe Technology, Jiangxi
Universe, Universe Trade and Universe Hanhe. All inter-company balances and transactions are eliminated upon consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Uses
of estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America
(&#8220;US GAAP&#8221;), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant estimates
required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, the realizability
of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of
long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual
results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
and Uncertainties</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main operation of the Company is located in the PRC. Accordingly, the Company&#8217;s business, financial condition, and results of operations
may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The
Company&#8217;s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although
the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations
including its organization and structure disclosed in Note 1, this may not be indicative of future results.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by
rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition
with respect to our current and future pharmaceutical product candidates from major pharmaceutical companies in China.&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_4" id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters,
extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company&#8217;s
operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operations may be further affected by the ongoing outbreak of COVID-19 which in March 2020, had been declared as a pandemic
by the World Health Organization.&#160;To reduce the spread of the COVID-19, the Chinese government has employed measures including city
lockdowns, quarantines, travel restrictions, suspension of business activities and school closures. Due to difficulties resulting from
the COVID-19 outbreak, including, but not limited to, the temporary closure of the Company&#8217;s factory and operations beginning in
early February until to March 2, 2020, limited support from the Company&#8217;s employees, delayed access to raw material supplies and
inability to deliver products to customers on a timely basis, the Company&#8217;s business was negatively impacted and generated lower
revenue and net income during the period from February to March 2020. Although the Company resumed its operations on March 2, 2020 and
the COVID-19 impact on the Company&#8217;s operating results and financial performance for fiscal year 2020 and 2021 seems to be temporary,
a resurgence could negatively affect the execution of customer contracts, the collection of customer payments, or disrupt the Company&#8217;s
supply chain, and the continued uncertainties associated with COVID 19 may negatively impact the Company&#8217;s revenue and cash flows.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of
its bank accounts in the PRC. Cash balances in bank accounts in PRC are not insured by the Federal Deposit Insurance Corporation or other
programs.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts
receivable, net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are presented net of allowance for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts
based on individual account analysis and historical collection trend. The Company establishes a provision for doubtful receivables when
there is objective evidence that the Company may not be able to collect amounts due. The allowance is based on management&#8217;s best
estimate of specific losses on individual exposures, as well as a provision on historical trends of collections. Actual amounts received
may differ from management&#8217;s estimate of credit worthiness and the economic environment. Delinquent account balances are written-off
against the allowance for doubtful accounts after management has determined that the collection is not probable. Allowance for uncollectable
balances amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:AllowanceForUncollectableBalancesAmount" scale="0" unitRef="usd">446,527</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:AllowanceForUncollectableBalancesAmount" scale="0" unitRef="usd">639,991</ix:nonFraction> as of September 30, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="clear: both"><br/></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventories,
net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and
related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision
for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less
any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments,
and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable
value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future
product sales. The Company recorded inventory reserve of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">116,453</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">110,585</ix:nonFraction> as of September 30, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" continuedAt="_AdvancesToSuppliersNetPolicyTextBlock-c0_cont_1" escape="true" name="upc:AdvancesToSuppliersNetPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><b><i>Advances
to suppliers, net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation id="_AdvancesToSuppliersNetPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances
to suppliers represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices for raw materials. These
advances are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time
to make cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company
when the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific
allowances when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September
30, 2021 and 2020, no allowance for doubtful accounts was deemed necessary as the Company believes that all advances to suppliers fully
realizable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" continuedAt="_DeferredChargesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DeferredChargesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Deferred&#160;initial
public&#160;offering (&#8220;IPO&#8221;) costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation id="_DeferredChargesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the requirement of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212;
&#8220;Expenses of Offering&#8221;. Deferred offering costs consist of underwriting, legal, accounting and other expenses incurred through
the balance sheet date that are directly related to the intended IPO. Deferred offering costs will be charged to shareholders&#8217;
equity upon the completion of the IPO. Should the IPO prove to be unsuccessful, these deferred costs, as well as additional expenses
to be incurred, will be charged to operations. The balance of deferred initial public offering costs amounted to <span style="-sec-ix-hidden: hidden-fact-71">Nil</span> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:DeferredInitialPublicOfferingCosts" scale="0" unitRef="usd">443,709</ix:nonFraction> as
of September 30, 2021 and 2020, respectively. Payment for deferred IPO offering costs amounted to $<ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd">2,792,543</ix:nonFraction>, $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd">441,064</ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-72">Nil</span> for the
years ended September 30, 2021, 2020 and 2019, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" continuedAt="_HeldToMaturityInvestmentPolicyTextBlock-c0_cont_1" escape="true" name="upc:HeldToMaturityInvestmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Short-term&#160;investments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation id="_HeldToMaturityInvestmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s short-term&#160;investments
consist of wealth management financial products purchased from financial institution, which can be redeemed anytime. The financial institution
invests the Company&#8217;s fund in certain financial instruments including money market funds and bonds to generate investment income.
The short-term investments are deemed to be trading securities and are measured subsequently at fair value in the statement of financial
position. Unrealized holding gains and losses for investment is included in the consolidated statements of operations and comprehensive
income (loss) over the investment period (see Note&#160;7).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
value of financial instruments</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#8201;&#8212;&#8201;inputs
    to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#8201;&#8212;&#8201;inputs
    to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for
    identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived
    from or corroborated by observable market data. </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#8201;&#8212;&#8201;inputs
    to the valuation methodology are unobservable. </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise disclosed, the fair value of the Company&#8217;s financial instruments, including cash, accounts receivable, inventories, short-term
investments, advance to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses
and other current liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities
as of September 30, 2021 and 2020 based upon the short-term nature of the assets and liabilities. The Company&#8217;s investment in equity
securities is accounted for using the measurement alternative in accordance with ASC 321, which also approximate its recorded value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;
</i></b>&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property,
plant and equipment</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and
equipment is provided using the straight-line method over their expected useful lives, as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:nonNumeric contextRef="c0" escape="true" name="upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    life </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Buildings </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c67" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">20</ix:nonNumeric> years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c68" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c69" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric> years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automobiles </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c70" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office and electric equipment
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c72" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c73" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> years </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditures
for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures
for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated
depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated
statements of income and other comprehensive income in other income or expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_5" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
reviews the carrying value of property, plant, and equipment for impairment whenever events and circumstances indicate that the carrying
value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition.
In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an
amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment
include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand,
competition and other economic factors. Based on this assessment, no impairment expenses for property, plant, and equipment were recorded
in operating expenses for the years ended September 30, 2021, 2020 and 2019, respectively.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>
</div><div>


</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_6" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intangible
Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_7" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_6"><ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist primarily of land use rights and software. Under the PRC law, all land in the PRC is owned by the government and cannot
be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for specified periods
of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using the straight-line method
with the following estimated useful lives:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_8" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_7"><ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    life </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land use rights
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c74" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">50</ix:nonNumeric> years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c75" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">3</ix:nonNumeric> years </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_8">The Company
reviews the carrying value of land use rights for impairment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where
undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which
the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current
operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors.</ix:continuation> Based on this assessment, no impairment of land use rights was deemed necessary for the years ended September
30, 2021, 2020 and 2019, respectively.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:nonNumeric contextRef="c0" continuedAt="_ConstructionContractorsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConstructionContractorsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Construction-in-Progress
(&#8220;CIP&#8221;)</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:continuation id="_ConstructionContractorsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction-in-progress
represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct
costs attributable to the construction. Construction-in-progress is not depreciated. Upon completion and ready for intended use, construction-in-progress
is reclassified to the appropriate category within property, plant and equipment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of long-lived Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets with finite lives, primarily
property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash flows from the use of the asset and its
eventual disposition below are the asset&#8217;s carrying value, then the asset is deemed to be impaired and written down to its fair
value. There were no impairments of these assets as of September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:nonNumeric contextRef="c0" continuedAt="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investments
in Equity Securities </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_2" id="_InvestmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its equity investments
in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 321 &#8220;Investments&#8212;Equity Securities&#8221; (&#8220;ASC
321&#8221;). In accordance with ASC 321, equity investment which the Company has no significant influence (generally less than a <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">20</ix:nonFraction>% ownership
interest) with readily determinable fair values are accounted for at fair value based on quoted market prices with the changes in fair
value recognized as unrealized gains or losses in earnings. Equity investments without readily determinable fair values are accounted
for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured
at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical
or a similar investment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_3" id="_InvestmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
March 2009 to September 2017, the Company invested approximately $<ix:nonFraction contextRef="c63" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="6" unitRef="usd">0.7</ix:nonFraction> million (RMB <ix:nonFraction contextRef="c63" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="6" unitRef="cny">5</ix:nonFraction> million) in Jiangxi Jian Rural Commercial Bank (&#8220;JX
RCB Bank&#8221;) in exchange for <ix:nonFraction contextRef="c64" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">5</ix:nonFraction>% ownership interest in the bank. The purpose of entering into these equity investment agreements with
JX RCB Bank was to earn investment income as the bank continues to grow. The Company determined that this investment in equity securities
does not have a readily determinable fair value and, accordingly, elected the measurement alternative noted above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_4" id="_InvestmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company initially recorded the investments at historical cost and subsequently records any dividends received from the net accumulated
earnings of the investee as income. As of September 30, 2021 and 2020, this investment amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="0" unitRef="usd">744,924</ix:nonFraction> (RMB <ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="6" unitRef="cny">5</ix:nonFraction> million) and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="0" unitRef="usd">735,000</ix:nonFraction>
(RMB <ix:nonFraction contextRef="c4" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="6" unitRef="cny">5</ix:nonFraction> million), respectively, and was reported as long-term investment in equity investee on the consolidated balance sheets. Investment
income amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetInvestmentIncome" scale="0" unitRef="usd">30,827</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetInvestmentIncome" scale="0" unitRef="usd">21,820</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetInvestmentIncome" scale="0" unitRef="usd">26,741</ix:nonFraction> for the years ended September 31, 2021, 2020 and 2019, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investments in equity securities are evaluated for impairment when facts or circumstances indicate that the fair value of the investment
is less than its carrying value. An impairment is recognized when a decline in fair value is determined to be other-than-temporary. The
Company reviews several factors to determine whether a loss is other-than-temporary. These factors include, but are not limited to, the:
(i) nature of the investment; (ii) cause and duration of the impairment; (iii) extent to which fair value is less than cost; (iv) financial
condition and near term prospects of the investments; and (v) ability to hold the investment for a period of time sufficient to allow
for any anticipated recovery in fair value. There was no impairment for the Company&#8217;s investments in equity securities as of September
30, 2021 and 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
recognition</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s)
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will <i>not</i> occur, (iv) allocate the transaction
price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance
obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its TCMD and third-party
products on a gross basis as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in
establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods, which the Company has control
of the goods and has the ability to direct the use of goods to obtain substantially all the benefits. All of the Company&#8217;s contracts
have one single performance obligation as the promise is to transfer the individual goods to customers, and there is no separately identifiable
other promise in the contracts. The Company&#8217;s revenue streams are recognized at a point in time when title and risk of loss passes
and the customer accepts the goods, which generally occurs at delivery. The Company&#8217;s products are sold with no right of return
and the Company does not provide other credits or sales incentive to customers. Revenue is reported net of all value added taxes (&#8220;VAT&#8221;).&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:nonNumeric contextRef="c0" continuedAt="_ContractAssetsAndLiabilitiesPolicyTextBlock-c0_cont_1" escape="true" name="upc:ContractAssetsAndLiabilitiesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contract
Assets and Liabilities </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:continuation id="_ContractAssetsAndLiabilitiesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
terms are established on the Company&#8217;s pre-established credit requirements based upon an evaluation of customers&#8217; credit
quality. Contract assets are recognized for in related accounts receivable. Contract liabilities are recognized for contracts where payment
has been received in advance of delivery. The contract liability balance can vary significantly depending on the timing when an order
is placed and when shipment or delivery occurs. As of September 30, 2021 and 2020, the Company did not have contract assets and contract
liabilities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;<b>&#160;</b></i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:nonNumeric contextRef="c0" continuedAt="_DisaggregationOfRevenuesPolicyTextBlock-c0_cont_1" escape="true" name="upc:DisaggregationOfRevenuesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disaggregation
of Revenues</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:continuation id="_DisaggregationOfRevenuesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing
and uncertainty of the revenue and cash flows are affected by economic factors. The Company&#8217;s disaggregation of revenues for the
years ended September 30, 2021, 2020 and 2019 are disclosed in Note 17 of this consolidation financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:nonNumeric contextRef="c0" continuedAt="_CostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Cost of revenue</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:continuation id="_CostOfSalesPolicyTextBlock-c0_cont_1"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Cost of revenue consists primarily of the costs of raw materials, freight
charges, direct labor, depreciation of plants and machinery, warehousing and overhead associated with the manufacturing process.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and development expenses</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses all internal research and development costs as incurred, which primarily comprise employee costs, internal and external
costs related to execution of studies, including manufacturing costs, facility costs of the research center, and amortization and depreciation
to intangible assets and property, plant and equipment used in the research and development activities. For the years ended September
30, 2021, 2020 and 2019, total research and development expense were approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">5,465,662</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">583,125</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">618,437</ix:nonFraction>, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:nonNumeric contextRef="c0" continuedAt="_ShippingAndHandlingCostPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ShippingAndHandlingCostPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shipping and handling costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:continuation id="_ShippingAndHandlingCostPolicyTextBlock-c0_cont_1"><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Shipping and handling costs are expensed as incurred. Inbound shipping
and handling cost associated with bringing the purchased raw materials and third-party products from suppliers to the Company&#8217;s
warehouse are included in cost of revenue. Outbound shipping and handling costs associated with shipping and delivery the products to
customers are included in selling expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:nonNumeric contextRef="c0" continuedAt="_AdvertisingCostsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advertising
expense</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:continuation id="_AdvertisingCostsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising expenses primarily relate to promotion of the Company&#8217;s
brand name and products through outdoor billboards, social media such as Weibo and WeChat and TV advertisement. Advertising costs is expensed
as incurred or deferred and then expensed the first time the advertising takes place. Advertising expenses are included in selling expenses
in the consolidated statements of income and comprehensive income. Advertising expenses amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd">1,316,654</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd">343,962</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="0" unitRef="usd">367,513</ix:nonFraction>
for the years ended September 30, 2021, 2020 and 2019, respectively.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_62" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Segment Reporting</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_63" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62"><ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the management approach in determining
reportable operating segments. The management approach considers the internal reporting used by the Company&#8217;s chief operating decision
maker for making operating decisions about the allocation of resources of the segment and the assessment of its performance in determining
the Company&#8217;s reportable operating segments. Management has determined that the Company has one operating segment (See Note 17).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_64" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
taxes</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_65" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized
when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial
statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary,
to reduce deferred tax assets to the amount expected to be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_66" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
uncertain tax position is recognized only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax
examination. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination.
For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest
relating to income taxes have been incurred during the years ended September 30, 2021, 2020 and 2019. The Company does not believe there
was any uncertain tax provision at September 30, 2021 and 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_67" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operating subsidiary in China is subject to the income tax laws of the PRC. No significant income was generated outside
the PRC for the fiscal years ended September 30, 2021, 2020 and 2019. As of September 30, 2021, all of the Company&#8217;s tax returns
of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_68" id="_SignificantAccountingPoliciesTextBlock-c0_cont_67"><ix:nonNumeric contextRef="c0" continuedAt="_ValueAddedTaxPolicyTextBlock-c0_cont_1" escape="true" name="upc:ValueAddedTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Value
added tax (&#8220;VAT&#8221;)</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.1pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_69" id="_SignificantAccountingPoliciesTextBlock-c0_cont_68"><ix:continuation id="_ValueAddedTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
revenue represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="upc:PercentageOfVatRate" scale="-2" unitRef="pure">17</ix:nonFraction>% (starting
from May 1, 2018, VAT rate was lowered to <ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="upc:PercentageOfVatRate" scale="-2" unitRef="pure">16</ix:nonFraction>%, and starting from April 1, 2019, VAT rate was further lowered to <ix:nonFraction contextRef="c66" decimals="2" format="ixt:num-dot-decimal" name="upc:PercentageOfVatRate" scale="-2" unitRef="pure">13</ix:nonFraction>%), depending on the
type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of
producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the accompanying consolidated
financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_70" id="_SignificantAccountingPoliciesTextBlock-c0_cont_69"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Earnings
per Share</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_71" id="_SignificantAccountingPoliciesTextBlock-c0_cont_70"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes earnings per share (&#8220;EPS&#8221;) in accordance with ASC 260, &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;).
ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided
by the weighted average common shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential
common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented,
or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or
decrease loss per share) are excluded from the calculation of diluted EPS. For the years ended September 30, 2021, 2020 and 2019, there
were no dilutive shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_72" id="_SignificantAccountingPoliciesTextBlock-c0_cont_71"><ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
currency translation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_73" id="_SignificantAccountingPoliciesTextBlock-c0_cont_72"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The functional currency for Universe INC is the
U.S Dollar (&#8220;US$&#8221;). Universe HK uses Hong Kong dollar as its functional currency. However, Universe INC and Universe HK currently
only serve as the holding companies and did not have active operation as of the date of this annual report. The Company operates only
in the PRC, the Company&#8217;s functional currency is the Chinese Yuan (&#8220;RMB&#8221;). The Company&#8217;s consolidated financial
statements have been translated into the reporting currency U.S. Dollars (&#8220;US$&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_74" id="_SignificantAccountingPoliciesTextBlock-c0_cont_73"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical
rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation
adjustments are reported under other comprehensive income (loss). Gains and losses resulting from the translations of foreign currency
transactions and balances are reflected in the results of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_75" id="_SignificantAccountingPoliciesTextBlock-c0_cont_74"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions.
No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_76" id="_SignificantAccountingPoliciesTextBlock-c0_cont_75"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_5" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table outlines the currency exchange rates that were used in creating the consolidated financial statements in this report:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_77" id="_SignificantAccountingPoliciesTextBlock-c0_cont_76"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30, 2021</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30, 2020</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30, 2019</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: left">Year-end spot rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center"><ix:nonNumeric contextRef="c0" name="upc:DescriptionOfYearEndSpotRate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.4580</span></ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center"><ix:nonNumeric contextRef="c4" name="upc:DescriptionOfYearEndSpotRate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.8033</span></ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center"><ix:nonNumeric contextRef="c5" name="upc:DescriptionOfYearEndSpotRate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1= RMB 7.1378</span></ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c0" name="upc:DescriptionOfAverageRate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.5095</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c4" name="upc:DescriptionOfAverageRate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 7.0077</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c5" name="upc:DescriptionOfAverageRate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.8729</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_78" id="_SignificantAccountingPoliciesTextBlock-c0_cont_77"><ix:nonNumeric contextRef="c0" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comprehensive
income </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_79" id="_SignificantAccountingPoliciesTextBlock-c0_cont_78"><ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
income consists of two components, net income and other comprehensive income (loss). The foreign currency translation gain or loss resulting
from translation of the financial statements expressed in RMB to US$ is reported in other comprehensive income (loss) in the consolidated
statements of income and comprehensive income.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_80" id="_SignificantAccountingPoliciesTextBlock-c0_cont_79"><ix:nonNumeric contextRef="c0" continuedAt="_StatementOfCashFlowsPolicyTextBlock-c0_cont_1" escape="true" name="upc:StatementOfCashFlowsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Statement
of Cash Flows</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_81" id="_SignificantAccountingPoliciesTextBlock-c0_cont_80"><ix:continuation id="_StatementOfCashFlowsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 230, &#8220;Statement of Cash Flows&#8221;, cash flows from the Company&#8217;s operations are formulated based upon
the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily
agree with changes in the corresponding balances on the balance sheets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_82" id="_SignificantAccountingPoliciesTextBlock-c0_cont_81"><ix:nonNumeric contextRef="c0" continuedAt="_EmployeeDefinedContributionPlanPolicyTextBlock-c0_cont_1" escape="true" name="upc:EmployeeDefinedContributionPlanPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
Defined Contribution Plan</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_83" id="_SignificantAccountingPoliciesTextBlock-c0_cont_82"><ix:continuation id="_EmployeeDefinedContributionPlanPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which
pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to
eligible full-time employees. The relevant labor regulations require the Company&#8217;s subsidiaries in the PRC to pay the local labor
and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government.
The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying
statements of income and comprehensive income amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd">617,145</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd">347,312</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd">274,091</ix:nonFraction> for the years ended September 30, 2021, 2020
and 2019, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;
<b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_84" id="_SignificantAccountingPoliciesTextBlock-c0_cont_83"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_85" id="_SignificantAccountingPoliciesTextBlock-c0_cont_84"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent&#160;Adopted
Accounting Pronouncements&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_86" id="_SignificantAccountingPoliciesTextBlock-c0_cont_85"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB Accounting Standards Board issued ASU No. 2018-13, &#8220;Fair Value Measurement (Topic 820): Disclosure Framework
Changes to the Disclosure Requirements for Fair Value Measurement&#8221; (&#8220;ASU 2018-13&#8221;). ASU 2018-13 modifies the disclosure
requirements on fair value measurements. ASU 2018-13 is effective for all entities for fiscal years and interim periods within those
fiscal years beginning after December 15, 2019, with early adoption permitted for any removed or modified disclosures. The removed and
modified disclosures were adopted on a retrospective basis and the new disclosures were adopted on a prospective basis. The adoption
of this guidance had no material impact on the Company&#8217;s consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_87" id="_SignificantAccountingPoliciesTextBlock-c0_cont_86"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent
Accounting Pronouncements&#160;not yet adopted</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_88" id="_SignificantAccountingPoliciesTextBlock-c0_cont_87"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February&#160;2016, the FASB issued Accounting
Standards Update (ASU) No.&#160;2016-02,&#160;Leases (Topic 842), which requires lessees to recognize a right-of-use asset and lease liability
on the balance sheet for all leases, including operating leases, with a term in excess of 12 months. The guidance also expands the quantitative
and qualitative disclosure requirements. The new guidance requires the lessee to record operating leases on the balance sheet with a right-of-use
asset and corresponding liability for future payment obligations. In July&#160;2018, FASB issued ASU 2018-11 Leases (Topic 842) &#8211;
Targeted Improvements&#160;that reduces costs and eases implementation of the leases standard for financial statement preparers. The ASU
simplifies transition requirements and, for lessors, provides a practical expedient for the separation of non-lease components from lease
components. ASU 2016-02 was further amended in November&#160;2019 by ASU 2019-10 and in June&#160;2020 by ASU 2020-05, which deferred
the effective date of new lease standard. As a result, ASC 842, Leases, is effective for public companies for annual reporting periods
and interim periods within those years beginning after December&#160;15, 2018. For all other entities, the guidance is effective for fiscal
years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022. As an emerging
growth company, the Company elects to apply for the new and revised accounting standards at the effective date for a private company and
to adopt this guidance effective October 1, 2021. The Company is currently evaluating the impact of adopting this standard on its consolidated
financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160; &#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_89" id="_SignificantAccountingPoliciesTextBlock-c0_cont_88"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June&#160;2016, the FASB issued Accounting
Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all
expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable
and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost. ASU 2016-13 was subsequently amended by Accounting Standards Update 2018-19,&#160;Codification Improvements
to Topic 326, Financial Instruments &#8212; Credit&#160;Losses, Accounting Standards Update 2019-04&#160;Codification Improvements to
Topic 326, Financial Instruments &#8212; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, and
Accounting Standards Update 2019-05,&#160;Targeted Transition Relief.&#160;In November&#160;2019, the FASB issued ASU 2019-10, which extends
the effective date for adoption of ASU 2016-13. In November&#160;2019, the FASB issued ASU 2019-11 to clarify its new credit impairment
guidance in ASU 326. Accordingly, for public entities that are not smaller reporting entities, ASU 2016-13 and its amendments is effective
for fiscal years, and interim periods within&#160;those fiscal years, beginning after December&#160;15, 2019. For all other entities,
this guidance and its amendments will be effective for fiscal years beginning after December&#160;15, 2022, including interim periods
within those fiscal years. As an emerging growth company, the Company plans to adopt this guidance effective October 1, 2023. The Company
is currently evaluating the impact of its pending adoption of ASU 2016-13 on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_90" id="_SignificantAccountingPoliciesTextBlock-c0_cont_89"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_7" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU No. 2019-12,
Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes. ASU 2019-12 is intended to simplify accounting for income
taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application.
ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years, which is fiscal
2021 for us, with early adoption permitted. The Company does not expect adoption of the new guidance to have a significant impact on our
financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_90"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2020, the FASB issued ASU 2020-02,
&#8220;Financial Instruments &#8211; Credit Losses (Topic 326) and Leases (topic 842) Amendments to SEC Paragraphs Pursuant to SEC Staff
Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (topic
842)&#8221;. This ASU provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses.
This ASU is effective for interim and annual periods beginning after December 15, 2019, and early adoption is permitted. The Company is
evaluating the impact of this guidance on its consolidated financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8212; ACCOUNTS RECEIVABLE, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_2" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_3" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" unitRef="usd">16,020,269</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="0" unitRef="usd">11,511,769</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd">446,527</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" unitRef="usd">639,991</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Accounts receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">15,573,742</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">10,871,778</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c0" name="upc:AccountsReceivableDescription"><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_4" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s accounts receivable primarily
includes balance due from customers when the Company&#8217;s pharmaceutical products are sold and delivered to customers. All of the Company&#8217;s
accounts receivable balance at September 30, 2020 has been collected in fiscal year 2021. As of date of this report, approximately 75.4%,
or $11.7 million, of the Company&#8217;s net account receivable balance at September 30, 2021 has been subsequently collected and the
remaining balance is expected to be substantially collected before March 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_5" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the Company&#8217;s
accounts receivable and subsequent collection by aging bucket:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_6" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Accounts Receivable by aging bucket</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance as of <br/> September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Subsequent <br/> collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of <br/> subsequent <br/> collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Less than 3 months</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="upc:AccountsReceivableBeforeGrossValue" scale="0" unitRef="usd">11,587,490</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="upc:SubsequentCollection" scale="0" unitRef="usd">7,991,589</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c77" decimals="3" format="ixt:num-dot-decimal" name="upc:PercentageOfSubsequentCollection" scale="-2" unitRef="pure">69.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>From 4 to 6 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="upc:AccountsReceivableBeforeGrossValue" scale="0" unitRef="usd">3,922,226</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="upc:SubsequentCollection" scale="0" unitRef="usd">3,541,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c79" decimals="3" format="ixt:num-dot-decimal" name="upc:PercentageOfSubsequentCollection" scale="-2" unitRef="pure">90.3</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>From 7 to 9 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="upc:AccountsReceivableBeforeGrossValue" scale="0" unitRef="usd">356,267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="upc:SubsequentCollection" scale="0" unitRef="usd">199,853</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="3" format="ixt:num-dot-decimal" name="upc:PercentageOfSubsequentCollection" scale="-2" unitRef="pure">56.1</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>From 10 to 12 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="upc:AccountsReceivableBeforeGrossValue" scale="0" unitRef="usd">66,124</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="upc:SubsequentCollection" scale="0" unitRef="usd">5,193</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c83" decimals="3" format="ixt:num-dot-decimal" name="upc:PercentageOfSubsequentCollection" scale="-2" unitRef="pure">7.9</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Over 1 year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="upc:AccountsReceivableBeforeGrossValue" scale="0" unitRef="usd">88,162</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="upc:SubsequentCollection" scale="0" unitRef="usd">584</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c85" decimals="3" format="ixt:num-dot-decimal" name="upc:PercentageOfSubsequentCollection" scale="-2" unitRef="pure">0.7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total gross accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGross" scale="0" unitRef="usd">16,020,269</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:SunsequentCollectionsTotalGrossAccountsReceivable" scale="0" unitRef="usd">11,739,179</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="upc:TotalGrossAccountsReceivablePercentage" scale="-2" unitRef="pure">73.3</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndFinancingReceivableAllowanceForCreditLoss" scale="0" unitRef="usd">446,527</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Accounts Receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd">15,573,742</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:SunsequentCollectionAccountsReceivableNet" scale="0" unitRef="usd">11,739,179</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="upc:AccountsReceivableNetPercentage" scale="-2" unitRef="pure">75.4</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8212; ACCOUNTS RECEIVABLE, NET (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_7" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Allowance for doubtful accounts movement is as
follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Beginning balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd">639,991</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd">517,754</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="0" unitRef="usd">93,907</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bad debt recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="0" unitRef="usd">225,660</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" scale="0" unitRef="usd">32,196</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" scale="0" unitRef="usd">28,330</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd">446,527</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd">639,991</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_InventoryDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8212; INVENTORY, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_InventoryDisclosureTextBlock-c0_cont_2" id="_InventoryDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consists of the following:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_InventoryDisclosureTextBlock-c0_cont_3" id="_InventoryDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd">607,661</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd">553,982</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Finished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd">1,971,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd">1,462,835</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Inventory valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">116,453</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" unitRef="usd">110,585</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total inventory, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">2,462,542</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">1,906,232</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation id="_InventoryDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Impairment
of inventories is recorded in cost of goods sold. For the years ended September 30, 2021, the Company had no provision for impairment
of inventory in regards to slow moving or obsolete items. For the years ended September 30, 2020 and 2019, recovery of previously accrued
inventory allowance amounted to $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" sign="-" unitRef="usd">75,391</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="0" sign="-" unitRef="usd">187,271</ix:nonFraction>, respectively. </span></p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AdvancesToSuppliersTextBlock-c0_cont_1" escape="true" name="upc:AdvancesToSuppliersTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8212; ADVANCE TO SUPPLIERS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_AdvancesToSuppliersTextBlock-c0_cont_2" id="_AdvancesToSuppliersTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advances to suppliers  consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_AdvancesToSuppliersTextBlock-c0_cont_3" id="_AdvancesToSuppliersTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="upc:ScheduleOfAdvancesToSuppliersNet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&#160;30, <br/>
2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&#160;30, <br/>
2020</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Advances to suppliers for inventory raw material purchase</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="0" unitRef="usd">2,738,313</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Advances to suppliers</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToSuppliersAndEmployees" scale="0" unitRef="usd">2,738,313</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_AdvancesToSuppliersTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advances to suppliers represent prepayments made
to suppliers to ensure continuous high-quality supplies and favorable purchase prices for raw materials. During 2021, due to supply chain
disruption caused by COVID-19, the market price for raw materials continued to increase. In order to ensure sufficient raw materials for
production and lock the favorite purchase price, the Company made advance payment to suppliers. As of the date of this report, <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="upc:RawMaterialsPurchased" scale="-2" unitRef="pure">66.1</ix:nonFraction>% of
the September 30, 2021 balance has been realized when the Company received the purchased raw materials and the remaining balance is expected
to be realized by March 2022.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PrepaymentForAdvertistingTextBlock-c0_cont_1" escape="true" name="upc:PrepaymentForAdvertistingTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8212; PREPAYMENT FOR ADVERTISTING
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_PrepaymentForAdvertistingTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 6, 2021, the Company entered into an advertising service agreement
with third-party Guangdong Fengyang Legend Consulting Co., Ltd., (&#8220;Fengyang Legend&#8221;), pursuant to which, Fengyang Legend will
assist the Company to develop and produce TV advertising film for the Company in order to promote the Company&#8217;s sales of its major
TCMD product, Bainian Pill and Guben Yanling Pill, coordinate the specific TV Channel to broadcast the advertising film to targeted geographic
market areas. Total contracted advertising service fee is RMB <ix:nonFraction contextRef="c86" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" scale="6" unitRef="cny">55</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c86" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" scale="6" unitRef="usd">8.5</ix:nonFraction> million) with adverting consulting service
period of one year from October 1, 2021 to September 30, 2022. Based on contract terms, the Company is required to make <ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="upc:PercentageOfAdvancePayment" scale="-2" unitRef="pure">30</ix:nonFraction>% advance payment
to Fengyang Legend within 7 business days upon signing the service agreement and make additional <ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="upc:AdditionalContractPricePercentage" scale="-2" unitRef="pure">58</ix:nonFraction>% of the contract price to Fengyang
Legend once the specific TV channel used for broadcast the TV film is determined. As of September 30, 2021, total RMB <ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="6" unitRef="cny">48.4</ix:nonFraction> million (approximately
$<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="6" unitRef="usd">7.5</ix:nonFraction> million) has been prepaid to Fengyang Legend for TV film production and coordinating the TV channels for broadcasting, and was recorded
as prepayment for advertising services on the balance sheets. Such prepayment has been expensed when the first time the advertising took
place, in October 2021. The remaining RMB <ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" unitRef="cny">6.6</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" unitRef="usd">1</ix:nonFraction> million) represents the monthly advertising fees to be paid in
13 installments when the advertising film is broadcasted through the designated TV channels and will be expensed as occurred.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_HeldToMaturityInvestmentDisclosureTextBlock-c0_cont_1" escape="true" name="upc:HeldToMaturityInvestmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 &#8212;&#160;SHORT-TERM&#160;INVSTMENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_HeldToMaturityInvestmentDisclosureTextBlock-c0_cont_2" id="_HeldToMaturityInvestmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s short-term&#160;investments
consist of wealth management financial products purchased from financial institution, which can be redeemed anytime at the Company&#8217;s
discretion. The financial institution invests the Company&#8217;s fund in certain financial instruments including money market funds and
bonds to generate investment income. Short-term&#160;investments consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_HeldToMaturityInvestmentDisclosureTextBlock-c0_cont_3" id="_HeldToMaturityInvestmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:HeldToMaturitySecuritiesTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: justify">Add: purchase wealth management financial products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:AddPurchaseWealthManagementFinancialProducts" scale="0" unitRef="usd">15,330,660</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Less: redemption</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" unitRef="usd">1,801,927</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Accrued investment income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable" scale="0" unitRef="usd">239,549</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="0" sign="-" unitRef="usd">43,078</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Ending balance of short-term investments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">13,725,204</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_HeldToMaturityInvestmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investment income generated from such short-term&#160;investments amounted
to $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermInvestments" scale="0" unitRef="usd">239,549</ix:nonFraction>, <span style="-sec-ix-hidden: hidden-fact-88">Nil</span> and <span style="-sec-ix-hidden: hidden-fact-89">Nil</span> for the&#160;years ended September 30, 2021, 2020 and 2019, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 &#8212; PROPERTY, PLANT AND EQUIPMENT,
NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property, plant and equipment, net, consists of
the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center">Useful life</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2021</b></p></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2020</b></p></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Buildings</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%"><ix:nonNumeric contextRef="c67" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">20</ix:nonNumeric> years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">7,808,006</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">7,414,580</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c68" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric>-<ix:nonNumeric contextRef="c69" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">2,047,338</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">1,534,015</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Automobiles</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c70" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">116,370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">140,346</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Office and electric equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c72" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c73" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">489,886</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">434,075</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Subtotal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">10,461,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">9,523,016</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">5,780,247</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">5,094,952</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">4,681,353</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">4,428,064</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-align: justify; text-indent: -0.4in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">441,355</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">404,948</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">413,199</ix:nonFraction> for the years
ended September 30, 2021, 2020 and 2019, respectively. Loss from disposal of fixed assets amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="0" sign="-" unitRef="usd">1,559</ix:nonFraction>, <span style="-sec-ix-hidden: hidden-fact-90">Nil</span> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="0" sign="-" unitRef="usd">2,085</ix:nonFraction> for the years
ended September 30, 2021, 2020 and 2019, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-align: justify; text-indent: -0.4in"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-align: justify; text-indent: -0.4in"><b>NOTE 9 &#8212;
INTANGIBLE ASSETS, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_2" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets, net consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_3" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Useful life</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2021</b></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2020</b></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Land use rights</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%"><ix:nonNumeric contextRef="c74" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">50</ix:nonNumeric> years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">278,327</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">264,304</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c75" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">3</ix:nonNumeric> years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">23,364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">22,186</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">301,691</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">286,490</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" sign="-" unitRef="usd">123,208</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" sign="-" unitRef="usd">111,714</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">178,483</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd">174,776</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_4" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">5,523</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">5,131</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">5,232</ix:nonFraction>
for the years ended September 30, 2021, 2020 and 2019, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_5" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Estimated future amortization expense for intangible
assets is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IntangibleAssetsDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Years ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization<br/>
 expense</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" unitRef="usd">5,567</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" scale="0" unitRef="usd">5,567</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" scale="0" unitRef="usd">5,567</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" scale="0" unitRef="usd">5,567</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="upc:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" scale="0" unitRef="usd">5,567</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" scale="0" unitRef="usd">150,648</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">178,483</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PrepaymentForConstructionInProgressTextBlock-c0_cont_1" escape="true" name="upc:PrepaymentForConstructionInProgressTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 &#8212; PREPAYMENT FOR CONSTRUCTION-IN-PROGRESS
(&#8220;CIP&#8221;) PROJECT </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PrepaymentForConstructionInProgressTextBlock-c0_cont_2" id="_PrepaymentForConstructionInProgressTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Construction-in-progress (&#8220;CIP&#8221;) represents direct costs of
construction incurred for the Company&#8217;s manufacturing facilities. On June 25, 2021, the Company signed a construction sub-contract
with sub-contractor Jiangxi Chenyuan Construction Project Co., Ltd. (&#8220;Chenyuan&#8221;), pursuant to which, Chenyuan will help the
Company to construct 4 manufacturing plant buildings and an office building with total estimated budget of RMB <ix:nonFraction contextRef="c100" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InvestmentBuildingAndBuildingImprovements" scale="6" unitRef="cny">165</ix:nonFraction> million (approximately
$<ix:nonFraction contextRef="c100" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentBuildingAndBuildingImprovements" scale="6" unitRef="usd">25.5</ix:nonFraction> million). The construction work started on August 8, 2021, with estimated completion date on August 7, 2023. As of September 30,
2021, the Company has made prepayment of approximately RMB<ix:nonFraction contextRef="c101" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentBuildingAndBuildingImprovements" scale="6" unitRef="cny">69.2</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c101" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentBuildingAndBuildingImprovements" scale="6" unitRef="usd">10.7</ix:nonFraction> million) to Chenyuan for land improvement,
building foundation and the construction of the main body of the manufacturing plants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PrepaymentForConstructionInProgressTextBlock-c0_cont_3" id="_PrepaymentForConstructionInProgressTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, the $<ix:nonFraction contextRef="c102" decimals="-5" format="ixt:num-dot-decimal" name="upc:Prepayment" scale="6" unitRef="usd">10.7</ix:nonFraction> million prepayment
to Chenyuan was recorded as prepayment for CIP project on the balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PrepaymentForConstructionInProgressTextBlock-c0_cont_4" id="_PrepaymentForConstructionInProgressTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, future additional capital expenditure on this
CIP project is estimated to be approximately RMB <ix:nonFraction contextRef="c103" decimals="-5" format="ixt:num-dot-decimal" name="upc:CapitalExpenditure" scale="6" unitRef="cny">95.8</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c103" decimals="-5" format="ixt:num-dot-decimal" name="upc:CapitalExpenditure" scale="6" unitRef="usd">14.8</ix:nonFraction> million), among which approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="upc:CapitalExpenditure" scale="6" unitRef="usd">3.8</ix:nonFraction> million is
required for the next 12 months. The Company currently plans to support its ongoing CIP project construction through cash flows from operations,
proceeds received from the IPO and borrowing additional bank loans from PRC banks in the future and use such bank borrowings to support
the CIP project, if necessary. The construction of this new manufacturing facility is expected to be fully completed and put into production
by August 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PrepaymentForConstructionInProgressTextBlock-c0_cont_5" id="_PrepaymentForConstructionInProgressTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, future minimum capital
expenditures on the Company&#8217;s CIP project are estimated as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PrepaymentForConstructionInProgressTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Years ending September 30,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Capital<br/>
 Expenditure</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>on CIP</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" unitRef="usd">3,831,300</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" unitRef="usd">9,721,440</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" unitRef="usd">1,277,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">14,829,840</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PrepaymentForPurchaseOfAPropertyTextBlock-c0_cont_1" escape="true" name="upc:PrepaymentForPurchaseOfAPropertyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 &#8212; PREPAYMENT FOR PURCHASE OF
A PROPERTY </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PrepaymentForPurchaseOfAPropertyTextBlock-c0_cont_2" id="_PrepaymentForPurchaseOfAPropertyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2021, the Company entered into a real
estate property purchase agreement with related party Jiangxi Yueshang Investment Co., Ltd. (&#8220;Jiangxi Yueshang&#8221;), the Company&#8217;s
CEO Mr. Gang Lai owns <ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure">5</ix:nonFraction>% equity interest in this entity, pursuant to the purchase agreement, Jiangxi Yueshang will sell and the Company
will purchase certain residential apartment and commercial office space totaling <ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="upc:OfficeSpaceSquareMeters" scale="0" unitRef="pure">2,749</ix:nonFraction>.30 square meters with total purchase price of RMB
<ix:nonFraction contextRef="c106" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SupplementalDeferredPurchasePrice" scale="6" unitRef="cny">32</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c106" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:SupplementalDeferredPurchasePrice" scale="6" unitRef="usd">4.95</ix:nonFraction> million). Pursuant to the agreement, the Company is required to make <ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="upc:PercentageOfPrepayment" scale="-2" unitRef="pure">50</ix:nonFraction>% prepayment, with remaining <ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure">20</ix:nonFraction>%
payable when certificate of occupancy is available and <ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="upc:PayableDeliveryPropertyPercentage" scale="-2" unitRef="pure">30</ix:nonFraction>% payable upon delivery of the property.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PrepaymentForPurchaseOfAPropertyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, the Company has made
prepayment of RMB <ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="6" unitRef="cny">16</ix:nonFraction> million ($<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="0" sign="-" unitRef="usd">2,476,800</ix:nonFraction>) to Jiangxi Yueshang. The remaining balance is expected to be paid by August, 2024. Since the
property is located at urban downtown of Ji&#8217;an City, the Company plans to use the property as offices in late 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12 &#8212; SHORT-BANK LOANS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Short-term bank loans consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_3" id="_DebtDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShortTermDebtTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Short-term bank loans:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 9pt">Maturity date on March 31, 2021, interest rate 4.81% per annum</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,176,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Maturity date on June 18, 2021, interest rate 4.81% per annum</td><td>&#160;</td>
    <td style="text-align: center">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,470,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Maturity date on June 15, 2022, interest rate 4.81% per annum</td><td>&#160;</td>
    <td style="text-align: center">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,548,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Maturity date on June 30, 2022, interest rate 4.5% per annum</td><td>&#160;</td>
    <td style="text-align: center">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,548,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Maturity date on March 17, 2022, interest rate 4.81% per annum</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">(5)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,238,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total short-term bank loans</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">4,334,400</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">2,646,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_4" id="_DebtDisclosureTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td> <td style="text-align: justify">On September 26, 2019, the Company&#8217;s subsidiary Jiangxi Universe
signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB <ix:nonFraction contextRef="c108" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="6" unitRef="cny">8</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="0" unitRef="usd">1,176,000</ix:nonFraction>)
as working capital for <ix:nonNumeric contextRef="c110" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, with the maturity date on March 31, 2021. The fixed interest rate of the loan was <ix:nonFraction contextRef="c108" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.81</ix:nonFraction>% per annum. Related
parties including Mr. Gang Lai, the Company&#8217;s controlling shareholder, and Foshan Shangyu Investment Holding Co., Ltd., an affiliated
entity controlled by Mr. Gang Lai, and three unrelated individuals jointly signed a guarantee agreement with LRC Bank to provide credit
guarantee for this loan. The loan was fully repaid upon maturity.</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_5" id="_DebtDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) </span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 19, 2020, the Company&#8217;s subsidiary Jiangxi Universe signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB <ix:nonFraction contextRef="c111" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="6" unitRef="cny">10</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="0" unitRef="usd">1,470,000</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c112" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, with the maturity date on June 18, 2021. The fixed interest rate of the loan was <ix:nonFraction contextRef="c111" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.81</ix:nonFraction>% per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity. </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_6" id="_DebtDisclosureTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) </span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 16, 2021, the Company&#8217;s subsidiary Jiangxi Universe signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB <ix:nonFraction contextRef="c113" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="6" unitRef="cny">10</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="0" unitRef="usd">1,548,000</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c114" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, with the maturity date on June 15, 2022. The fixed interest rate of the loan was <ix:nonFraction contextRef="c113" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.81</ix:nonFraction>% per annum. There was no guarantee requirement for this loan. </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12 &#8212; SHORT-BANK LOANS (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_7" id="_DebtDisclosureTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) </span></td> <td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">On June 30, 2021, the Company&#8217;s subsidiary Jiangxi Universe signed
a loan agreement with Bank of Communications to borrow RMB <ix:nonFraction contextRef="c115" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="6" unitRef="cny">10</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="0" unitRef="usd">1,548,000</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c116" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, with
the maturity date on June 18, 2022. The fixed interest rate of the loan was <ix:nonFraction contextRef="c115" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.5</ix:nonFraction>% per annum. Certain related parties of the Company, including
Mr. Gang Lai, the Company&#8217;s controlling shareholder, Mr. Gang Lai&#8217;s spouse, Mrs. Xing Wu, and the Company&#8217;s subsidiary,
Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_8" id="_DebtDisclosureTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5) </span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 18, 2021, the Company&#8217;s subsidiary Universe Trade signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB <ix:nonFraction contextRef="c117" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="6" unitRef="cny">8</ix:nonFraction> million (equivalent to $<ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayableToBankCurrent" scale="0" unitRef="usd">1,238,400</ix:nonFraction>) as working capital for <ix:nonNumeric contextRef="c118" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, with the maturity date on March 17, 2022. The fixed interest rate of the loan was <ix:nonFraction contextRef="c117" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.81</ix:nonFraction>% per annum. There was no guarantee requirement for this loan. </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the above-mentioned loans, the Company recorded
a total interest expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">149,303</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">157,528</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">135,717</ix:nonFraction> for the years ended September 30, 2021, 2020 and 2019, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 &#8212; RELATED PARTY TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature of relationships with related parties</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;  border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 39%; font-weight: bold; text-align: justify">Name</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 60%; font-weight: bold; text-align: justify">Relationship with the Company</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Mr. Gang Lai</td><td>&#160;</td>
    <td style="text-align: left"><ix:nonNumeric contextRef="c129" name="us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement">Chief Executive Officer (&#8220;CEO&#8221;), chairman of the Board of Directors</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Mrs. Lin Yang</td><td>&#160;</td>
    <td style="text-align: left"><ix:nonNumeric contextRef="c130" name="us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement">Chief Financial Officer and Director</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Greatest Group (China) Financial Management Limited (&#8220;Greatest Group&#8221;)</td><td>&#160;</td>
    <td style="text-align: left"><ix:nonNumeric contextRef="c131" name="us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement">One of the Company&#8217;s minority shareholders owns 8.7% of the ownership interest in this entity</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Foshan Shangyu Investment Holding Co., Ltd (&#8220;Foshan Shangyu&#8221;)</td><td>&#160;</td>
    <td style="text-align: left"><ix:nonNumeric contextRef="c132" name="us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement">An affiliated entity of the Company, 90% owned by and controlled by the Company&#8217;s CEO.</ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Due from related parties</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="upc:ScheduleOfDueFromRelatedPartiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Name</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Greatest Group</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedPartiesCurrent" scale="0" unitRef="usd">235,438</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foshan Shangyu</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedPartiesCurrent" scale="0" unitRef="usd">1,544</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total due from related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedPartiesCurrent" scale="0" unitRef="usd">236,982</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_6" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s due from related parties were
interest free and due on demand. The September 30, 2021 due from related parties balance has been subsequently collected back and the
Company does not have the intention to make additional cash advance to related parties going forward.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_7" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Due to related parties</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_8" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="upc:ScheduleOfDueToRelatedPartiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Name</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Mr. Gang Lai</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="0" unitRef="usd">956,492</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Mrs. Lin Yang</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="0" unitRef="usd">19,723</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#12288;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total due to related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="0" unitRef="usd">19,723</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="0" unitRef="usd">956,492</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_9" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, the balance
due to related parties mainly consisted of advances from the Company&#8217;s principal shareholder for working capital purposes during
the Company&#8217;s normal course of business. These advances are non-interest bearing and due on demand.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 &#8212; RELATED PARTY TRANSACTIONS
(continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_10" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loan guarantee provided by related parties</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_11" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Company&#8217;s bank borrowings
from LRC Bank, the Company&#8217;s chief executive officer Mr. Gang Lai and Foshan Shangyu Investment Holding Co., Ltd., an affiliated
entity controlled by him, jointly signed a guarantee agreement with LRC Bank to provide credit guarantee for the Company&#8217;s loans
from LRC Bank within the loan period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_12" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Company&#8217;s bank borrowings
from Bank of Communications, certain related parties of the Company, including Mr. Gang Lai, the Company&#8217;s controlling shareholder,
Mr. Gang Lai&#8217;s spouse, Ms. Xing Wu, and the Company&#8217;s subsidiary, Universe Trade, jointly signed guarantee agreements with
Bank of Communications to provide credit guarantee for this loan (see Note 12).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_13" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prepayment to related party for property purchase</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c106" name="us-gaap:DeconsolidationRelatedPartyDescription">As disclosed in Note 11, on May 6, 2021, the Company
entered into a real estate property purchase agreement with related party Jiangxi Yueshang to purchase certain residential apartment and
commercial office space totaling 2,749.30 square meters with total purchase price of RMB32 million (approximately $4.95 million).</ix:nonNumeric> As of
September 30, 2021, the Company had made prepayment of RMB<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="6" unitRef="cny">16</ix:nonFraction> million ($<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="0" sign="-" unitRef="usd">2,476,800</ix:nonFraction>) to Jiangxi Yueshang. The remaining balance is expected
to be paid by August 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 &#8212; TAXES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate Income Taxes (&#8220;CIT&#8221;)</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Cayman Islands</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the current tax laws of the Cayman Islands,
Universe INC is not subject to tax on its income or capital gains. In addition, no Cayman Islands withholding tax will be imposed upon
the payment of dividends by the Company to its shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Hong Kong</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Universe HK is incorporated in Hong Kong and is
subject to profit taxes in Hong Kong at a rate of <ix:nonFraction contextRef="c140" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" scale="-2" unitRef="pure">16.5</ix:nonFraction>%. However, Universe HK did not generate any assessable profits derived from Hong
Kong sources for the fiscal years ended September 30, 2021, 2020 and 2019, and accordingly no provision for Hong Kong profits tax has
been made in these periods.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160; &#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">PRC</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Enterprise Income Tax (&#8220;EIT&#8221;)
Law of PRC, domestic enterprises and Foreign Investment Enterprises (&#8220;FIEs&#8221;) are usually subject to a unified <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" unitRef="pure">25</ix:nonFraction>% enterprise
income tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on a case-by-case basis. EIT grants preferential
tax treatment to High and New Technology Enterprises (&#8220;HNTEs&#8221;). <ix:nonNumeric contextRef="c0" name="upc:PreferentialTaxTreatmentDescription">Under this preferential tax treatment, HNTEs are entitled
to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. Jiangxi Universe, one
of the Company&#8217;s main operating subsidiaries in PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15%
beginning November&#160;2016 with a term of three years. In December 2019, Jiangxi Universe successfully renewed its HNTE certification
with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through December 2022. Universe
Trade, the Company&#8217;s another operating subsidiary in PRC, was approved as a HNTE and is entitled to a reduced income tax rate of
15% beginning December&#160;2020 with a term of three years. EIT is typically governed by the local tax authority in PRC. Each local tax
authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The
corporate income taxes for the years ended September 30, 2021, 2020 and 2019 were reported at a blended reduced rate as a result of Jiangxi
Universe and Universe Trade being approved as a HNTE and enjoying a 15% reduced income tax rate.</ix:nonNumeric> The impact of the tax holidays noted
above decreased PRC corporate income taxes by $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrentAndNoncurrent" scale="0" unitRef="usd">1,518,979</ix:nonFraction>, $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrentAndNoncurrent" scale="0" unitRef="usd">118,986</ix:nonFraction> and $<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrentAndNoncurrent" scale="0" unitRef="usd">312,357</ix:nonFraction> for the years ended September 30, 2021, 2020 and 2019,
respectively. The benefit of the tax holidays on net income per share (basic and diluted) $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" unitRef="usdPershares">0.09</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" unitRef="usdPershares">0.01</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" unitRef="usdPershares">0.02</ix:nonFraction> for the years ended September
30, 2021, 2020 and 2019, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160; <b>&#160;</b>&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 &#8212; TAXES (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of the income tax provision (benefit)
are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current income tax provision</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Cayman Island</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; padding-left: 9pt">PRC</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">3,026,867</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,552,097</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,141,222</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">3,026,867</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,552,097</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,141,222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred income tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Cayman Island</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">PRC</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">668,341</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">9,886</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">39,625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total income tax provision</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,358,526</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,542,211</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">2,101,597</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_11" id="_IncomeTaxDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table reconciles the China statutory
rates to the Company&#8217;s effective tax rate for the years ended September 30, 2021, 2020 and 2019:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_12" id="_IncomeTaxDisclosureTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Statutory PRC income tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">25.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">25.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">25.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effect of income tax holiday</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays" scale="-2" unitRef="pure">11.0</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays" scale="-2" unitRef="pure">1.1</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays" scale="-2" unitRef="pure">3.3</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent difference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" unitRef="pure">0.1</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-PRC entities not subject to PRC income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure">2.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure">1.3</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impact on DTA due to change in applicable income tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" unitRef="pure">0.6</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure">0.5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">17.1</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">25.2</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">21.8</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_13" id="_IncomeTaxDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company continually evaluates expiring statutes
of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. As of September 30, 2021, all of the Company&#8217;s
tax returns of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_14" id="_IncomeTaxDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred tax assets are composed of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_15" id="_IncomeTaxDisclosureTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 10pt">Net operating loss carry-forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd">785,550</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd">186,537</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="0" unitRef="usd">84,447</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">&#8212;&#160;&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" unitRef="usd">869,997</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" unitRef="usd">186,537</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">&#8212;&#160;&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">&#8212;&#160;&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">869,997</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">186,537</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_16" id="_IncomeTaxDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company periodically evaluates the likelihood
of the realization of deferred tax assets, and reduces the carrying amount of the deferred tax assets by a valuation allowance to the
extent it believes a portion will not be realized. Management considers new evidence, both positive and negative, that could affect the
Company&#8217;s future realization of deferred tax assets including its recent cumulative earnings experience, expectation of future income,
the carry forward periods available for tax reporting purposes and other relevant factors. Although Jiangxi Universe incurred a net loss
during the year ended September 30, 2021, the Company determined that it is more likely than not its deferred tax assets could be realized
due to the estimated future earnings in Jiangxi Universe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_17" id="_IncomeTaxDisclosureTextBlock-c0_cont_16"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Taxes payable</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_18" id="_IncomeTaxDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Taxes payable consist of the following:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" escape="true" name="upc:ScheduleOfTaxPayableTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Income tax payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd">669,780</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd">767,297</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Value added tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="0" unitRef="usd">326,468</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="0" unitRef="usd">433,838</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other taxes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="0" unitRef="usd">105,212</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="0" unitRef="usd">130,614</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total taxes payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd">1,101,460</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd">1,331,749</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160; <b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14 &#8212; CONCENTRATIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_2" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A majority of the Company&#8217;s revenue and
expense transactions are denominated in RMB and a significant portion of the Company and its subsidiaries&#8217; assets and liabilities
are denominated in RMB. RMB is not freely convertible into foreign currencies. In the PRC, certain foreign exchange transactions are required
by law to be transacted only by authorized financial institutions at exchange rates set by the People&#8217;s Bank of China (&#8220;PBOC&#8221;).
Remittances in currencies other than RMB by the Company in China must be processed through the PBOC or other China foreign exchange regulatory
bodies which require certain supporting documentation in order to affect the remittance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_3" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignFinancialInstitutionsMandatedDeposits" scale="0" unitRef="usd">5,892,655</ix:nonFraction>
and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignFinancialInstitutionsMandatedDeposits" scale="0" unitRef="usd">10,027,666</ix:nonFraction> of the Company&#8217;s cash was on deposit at financial institutions in the PRC where there currently is no rule or regulation
requiring such financial institutions to maintain insurance to cover bank deposits in the event of bank failure. For the years ended September
30, 2021, 2020 and 2019, the Company&#8217;s substantial assets were located in the PRC and the Company&#8217;s substantial revenues were
derived from its subsidiaries located in the PRC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_4" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended September 30, 2021, 2020 and
2019, no single customer accounted for more than <ix:nonFraction contextRef="c149" decimals="2" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c150" decimals="2" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">10</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the Company&#8217;s total revenue. The Company&#8217;s top 10 customers aggregately
accounted for <ix:nonFraction contextRef="c152" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">30.4</ix:nonFraction>%, <ix:nonFraction contextRef="c153" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">33.3</ix:nonFraction>% and <ix:nonFraction contextRef="c154" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">34.5</ix:nonFraction>% of the total revenue for the years ended September 30, 2021, 2020 and 2019, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_5" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of one of the Company&#8217;s major products, Guben Yanling Pill,
accounted for <ix:nonFraction contextRef="c155" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">40.3</ix:nonFraction>%, <ix:nonFraction contextRef="c156" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">38.2</ix:nonFraction>% and <ix:nonFraction contextRef="c157" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">32.4</ix:nonFraction>% of the Company&#8217;s total revenue for the years ended September 30, 2021, 2020 and 2019, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_6" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, no customer accounted
for more than <ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% of the total accounts receivable balance. As of September 30, 2020, one customer accounted for <ix:nonFraction contextRef="c159" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">13.0</ix:nonFraction>% of the total accounts
receivable balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_7" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, two suppliers accounted
for <ix:nonFraction contextRef="c160" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">35.3</ix:nonFraction>% and <ix:nonFraction contextRef="c161" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">28.0</ix:nonFraction>% of the total advance to supplier balance. No supplier accounted for more than <ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% of the Company&#8217;s total advance
to supplier balance as of September 30, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_ConcentrationRiskDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended September 30, 2021, no supplier
accounted for more than <ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% of the total purchases, respectively. For the year ended September 30, 2020, two suppliers accounted for approximately
<ix:nonFraction contextRef="c164" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">19.6</ix:nonFraction>% and <ix:nonFraction contextRef="c165" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">13.6</ix:nonFraction>% of the total purchases, respectively. For the year ended September 30, 2019, one supplier accounted for approximately
<ix:nonFraction contextRef="c166" decimals="3" format="ixt:num-dot-decimal" name="upc:ConcentrationRiskThresholdPercentage" scale="-2" unitRef="pure">14.1</ix:nonFraction>% of the total purchases.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 15 &#8212; SHAREHOLDERS&#8217; EQUITY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Ordinary Shares</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Universe INC was incorporated under the laws of
the Cayman Islands on December 11, 2019. The original authorized number of ordinary shares was <ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">50,000</ix:nonFraction> shares with par value of US$<ix:nonFraction contextRef="c167" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">1.00</ix:nonFraction>
per share and <ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">50,000</ix:nonFraction> shares were issued. On August 7, 2020, the Company amended its Memorandum of Association to increase the authorized
number of shares to <ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction> shares with par value of $<ix:nonFraction contextRef="c168" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.003125</ix:nonFraction> per share, and subdivide the original issued shares from <ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">50,000</ix:nonFraction> shares
at par value of $<ix:nonFraction contextRef="c169" decimals="2" format="ixt:num-dot-decimal" name="upc:OriginalSharesParValue" scale="0" unitRef="usdPershares">1.00</ix:nonFraction> per share to <ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">16,000,000</ix:nonFraction> ordinary shares with par value of $<ix:nonFraction contextRef="c169" decimals="6" format="ixt:num-dot-decimal" name="upc:OrdinarySharesParValue" scale="0" unitRef="usdPershares">0.003125</ix:nonFraction> per share. <ix:nonNumeric contextRef="c170" name="upc:OrdinarySharesOutstandingDescription">As a result of this forward split
of the outstanding ordinary shares at a ratio of 320-for-1 share, there is a total of 16,000,000 shares issued and outstanding.</ix:nonNumeric>&#160;The
issuance of these <ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="upc:ReorganizationShares" scale="0" unitRef="shares">16,000,000</ix:nonFraction> shares is considered as a part of the Reorganization of the Company, which was retroactively applied as if
the transaction occurred at the beginning of the period presented (see Note 1).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Initial Public Offering</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2021, the Company closed its IPO
of <ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">5,000,000</ix:nonFraction> ordinary shares, par value $<ix:nonFraction contextRef="c171" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.003125</ix:nonFraction> per share (the &#8220;ordinary shares&#8221;) at a public offering price of $<ix:nonFraction contextRef="c171" decimals="2" format="ixt:num-dot-decimal" name="upc:PublicOfferingPrice" scale="0" unitRef="usdPershares">5.00</ix:nonFraction> per
share. On March 29, 2021, the underwriter exercised in full its over-allotment option to purchase an additional <ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="upc:OptionToPurchaseAdditionalShares" scale="0" unitRef="shares">750,000</ix:nonFraction> ordinary shares.&#160;<span>The
closing for the sale of the over-allotment shares took place on March 31, 2021. Gross proceeds of the IPO, including the proceeds from
the sale of the over-allotment shares, totaled $<ix:nonFraction contextRef="c171" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="6" unitRef="usd">28.75</ix:nonFraction> million, before deducting underwriting discounts and other related expenses</span>.
Net proceeds of our IPO, including over-allotment shares, were approximately $<ix:nonFraction contextRef="c173" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd">25.6</ix:nonFraction> million. In connection with the IPO, the Company&#8217;s
ordinary shares began trading on the Nasdaq Global Market&#160;under the symbol &#8220;UPC&#8221; on March 23, 2021.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, the Company
had total of <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">21,750,000</ix:nonFraction> and <ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">16,000,000</ix:nonFraction> shares ordinary shares issued and outstanding, respectively<b>.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Underwriter warrants </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company&#8217;s IPO, the Company also agreed to
issue warrants to the underwriter, for a nominal consideration of $<ix:nonFraction contextRef="c175" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per warrant, to purchase <ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">300,000</ix:nonFraction> ordinary shares of the Company
(equal to <ix:nonFraction contextRef="c176" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" scale="-2" unitRef="pure">6</ix:nonFraction>% of the total number of Ordinary Shares sold in the IPO, but not including any over-allotment Ordinary Shares sold in the
over-allotment option) (the &#8220;Underwriter Warrants&#8221;). These warrants have warrant term of five years, with an exercise price
of $<ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">5.50</ix:nonFraction> per share (equal to <ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">110</ix:nonFraction>% of the Company&#8217;s IPO offering price of $<ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">5.00</ix:nonFraction> per share). The Underwriter Warrants may be purchased
in cash or via cashless exercise, will be exercisable for five (5) years, and will terminate on the fifth anniversary of the date thereafter.
Management determined that these warrants meet the requirements for equity classification under ASC 815-40 because they are indexed to
its own stock. As of September 30, 2021, these underwriter warrants were issued and outstanding but none of the warrants has been exercised.
For the year ended September 30, 2021, these underwriter warrants were antidilutive and accordingly were not included in the diluted EPS
calculation based on treasury stock method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash dividends </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 21, 2016, September 13, 2017, February
2, 2018, September 20, 2018 and February 21, 2019, the board of directors of Jiangxi Universe approved resolutions to pay cash dividend
of RMB<ix:nonFraction contextRef="c178" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsShareBasedCompensationCash" scale="6" unitRef="cny">40</ix:nonFraction> million, RMB<ix:nonFraction contextRef="c179" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsShareBasedCompensationCash" scale="6" unitRef="cny">30</ix:nonFraction> million, RMB<ix:nonFraction contextRef="c180" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsShareBasedCompensationCash" scale="6" unitRef="cny">20</ix:nonFraction> million, RMB<ix:nonFraction contextRef="c181" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsShareBasedCompensationCash" scale="6" unitRef="cny">10</ix:nonFraction> million and RMB<ix:nonFraction contextRef="c182" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DividendsShareBasedCompensationCash" scale="6" unitRef="cny">30</ix:nonFraction> million, respectively, to its shareholders at the time of record
out of the retained earnings balance of Jiangxi Universe, to be paid to these shareholders when there are sufficient available earnings
and the Company has sufficient funds. <ix:nonNumeric contextRef="c183" name="upc:CashDividendDescription">A total of RMB130 million (approximately $19.1 million) cash dividend was declared from September
2016 to February 2019, among which approximately RMB20 million ($3.1 million) was paid in cash to its shareholders in 2018 and the remaining
RMB 110 million ($16 million) was paid to its shareholders in 2019.</ix:nonNumeric> There was no additional cash dividends paid during the years ended
September 30, 2021 and 2020.</p></ix:continuation><div>


</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 15 &#8212; SHAREHOLDERS&#8217; EQUITY
(continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except for the dividends declared mentioned above,
the Company has not declared or paid dividends to its shareholders in the past, and may not choose to make additional distributions in
the future. Any decision as to the payment of dividends will depend on the available earnings, the capital requirements of the Company,
the Company&#8217;s general financial condition and other factors deemed pertinent by the board of directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;<i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Statutory reserve and restricted net assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s PRC subsidiaries are restricted
in their ability to transfer a portion of their net assets to the Company. The payment of dividends by entities organized in China is
subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated
profits as determined in accordance with accounting standards and regulations in China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is required to make appropriations
to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income
determined in accordance with generally accepted accounting principles of the PRC (&#8220;PRC GAAP&#8221;). Appropriations to the statutory
surplus reserve are required to be at least <ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="upc:StatutorySurplusPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% of the after-tax net income determined in accordance with PRC GAAP until the reserve is
equal to <ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="upc:ReserveIsEqualPercentage" scale="-2" unitRef="pure">50</ix:nonFraction>% of the entity&#8217;s registered capital. Appropriations to the discretionary surplus reserve are made at the discretion
of the board of directors. The statutory reserve may be applied against prior year losses, if any, and may be used for general business
expansion and production or increase in registered capital, but are not distributable as cash dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Relevant PRC laws and regulations restrict the
Company&#8217;s PRC subsidiaries from transferring a portion of their net assets, equivalent to its statutory reserves and their share
capital, to the Company in the form of loans, advances or cash dividends. Only PRC entities&#8217; accumulated profits may be distributed
as dividends to the Company without the consent of a third party. As of September 30, 2021 and 2020, the restricted amounts as determined
pursuant to PRC statutory laws totaled $<ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="0" unitRef="usd">2,439,535</ix:nonFraction> and $<ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="0" unitRef="usd">2,439,535</ix:nonFraction>, respectively, and total restricted net assets amounted to $<ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="upc:RestrictedNetAssets" scale="0" unitRef="usd">31,786,663</ix:nonFraction>
and $<ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="upc:RestrictedNetAssets" scale="0" unitRef="usd">6,168,535</ix:nonFraction>, respectively.<b>&#160;</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash transfer between the Company and its
subsidiaries </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended September 30, 2021, the Company
transferred cash in the amount of $<ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">11,358,764</ix:nonFraction> to its subsidiary in Hong Kong, and the Company&#8217;s Hong Kong subsidiary, via the WFOE,
further transferred cash in the amount of $<ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">6,807,507</ix:nonFraction> to the PRC subsidiaries. For the year ended September 30, 2020 and 2019, there was
no cash transferred from the Company to its PRC subsidiaries. The assets transfer was for business operation purpose. There was no distribution
of earnings by the PRC operating subsidiaries to the Company during the years ended September 30, 2021, 2020 and 2019, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 16 &#8212; COMMITMENTS AND CONTINGENCIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is a party to various
legal actions arising in the ordinary course of business. The Company accrues costs associated with these matters when they become probable
and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. For the
years ended September 30, 2021, 2020 and 2019, the Company did not have any material legal claims or litigation that, individually or
in aggregate, could have a material adverse impact on the Company&#8217;s consolidated financial position, results of operations and cash
flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has an ongoing CIP project associated
with the construction of a new manufacturing facility. As of September 30, 2021, future minimum capital expenditures on the Company&#8217;s
CIP project amounted to approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="6" unitRef="usd">14.8</ix:nonFraction> million, among which approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseCapitalSecurities" scale="6" unitRef="usd">3.8</ix:nonFraction> million is required for the next 12 months from the
date of this report (see Note 7).</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 17 &#8212; SEGMENT REPORTING</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_2" id="_SegmentReportingDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An operating segment is a component of the Company
that engages in business activities from which it may earn revenues and incur expenses, and is identified on the basis of the internal
financial reports that are provided to and regularly reviewed by the Company&#8217;s chief operating decision maker in order to allocate
resources and assess performance of the segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_3" id="_SegmentReportingDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The management of the Company concludes that it
has only <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="pure">one</ix:nonFraction> reporting segment. The Company develops, manufactures and sells traditional Chinese medicine derivatives (&#8220;TCMD&#8221;)
products targeted to the elderly to address their physical conditions in the aging process and to promote their general well-being. In
addition, the Company also sells biochemical drugs, medical instruments, Traditional Chinese Medicine Pieces products and dietary supplements
manufactured by third-party pharmaceutical companies (&#8220;third-party products&#8221;). All of these products are currently sold in
China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_4" id="_SegmentReportingDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s products have similar economic
characteristics with respect to raw materials, vendors, marketing and promotions, customers and methods of distribution. The Company&#8217;s
chief operating decision maker has been identified as the Chief Executive Officer, who reviews consolidated results when making decisions
about allocating resources and assessing performance of the Company, rather than by product types or geographic area; hence the Company
has only one reporting segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_5" id="_SegmentReportingDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Revenue by product source </span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_6" id="_SegmentReportingDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Sales of TCMD products manufactured by the Company</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfOtherPropertyOperatingExpense" scale="0" unitRef="usd">29,559,286</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfOtherPropertyOperatingExpense" scale="0" unitRef="usd">18,374,751</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfOtherPropertyOperatingExpense" scale="0" unitRef="usd">20,895,542</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd">18,422,745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd">12,329,209</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd">12,333,774</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">47,982,031</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">30,703,960</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">33,229,316</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 17 &#8212; SEGMENT REPORTING (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_7" id="_SegmentReportingDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Revenue by product categories </span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_8" id="_SegmentReportingDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The summary of our total revenues by product categories
for the years ended September 30, 2021, 2020 and 2019 was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SegmentReportingDisclosureTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Sales of TCMD products:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Medicinal liquor products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">1,951,679</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">1,616,080</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">2,356,015</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other chronic condition treatment products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">22,978,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">14,059,403</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">14,056,228</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Cold and flu medicines</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">4,629,606</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">2,699,268</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">4,483,299</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Sub-total of TCMD products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">29,559,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">18,374,751</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfTCMDProductsSales" scale="0" unitRef="usd">20,895,542</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Sales of third-party products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Biochemical drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">16,082,546</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">10,325,411</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">9,508,816</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Traditional Chinese medicine pieces</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">20,705</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">47,097</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">142,409</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">2,318,536</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">1,950,238</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">2,668,422</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Dietary supplements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">958</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">6,463</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">14,127</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Subtotal of third-party products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">18,422,745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">12,329,209</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="upc:SubtotalOfThirdpartyProductsSales" scale="0" unitRef="usd">12,333,774</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Total revenue</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">47,982,031</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">30,703,960</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">33,229,316</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 18 &#8212; SUBSEQUENT EVENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 1, 2021, the Company entered into
definitive agreements (the &#8220;Agreements&#8221;) with Kitanihon Pharmaceutical Co., Ltd. (&#8220;Kitanihon&#8221;), a Japanese pharmaceutical
company, pursuant to which <ix:nonNumeric contextRef="c211" name="us-gaap:SubsequentEventDescription">(i) both parties will build a manufacturing facility in Ji&#8217;an, Jiangxi, China, for the manufacturing
and research and development of traditional Chinese medicine derivatives products, with an aggregate area of over 430,000 square feet,
and the Company will bear the costs associated with building the facility, and (ii) the Company will purchase 464 shares of Kitanihon
for an aggregate of JPY176.32 million (approximately US$1.56 million)</ix:nonNumeric>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In relation to the Agreements, Sununion Holding
Group Limited (&#8220;Sununion&#8221;), the controlling shareholder of the Company wholly owned by Mr. Gang Lai, the chief executive officer
and chairman of the board of directors of the Company, entered into an agreement with Mr. Gang Lai and Kitanihon on December 1, 2021,
pursuant to which Kitanihon authorizes the Company to use certain of its intangible assets, including technologies and certain intellectual
properties, in exchange for which Mr. Gang Lai will transfer ordinary shares of Sununion owned by him and valued at US$<ix:nonFraction contextRef="c211" decimals="-5" format="ixt:num-dot-decimal" name="upc:IntangibleAssets" scale="6" unitRef="usd">2.5</ix:nonFraction> million to
Kitanihon.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated the subsequent event through
the date of this report, and concluded that there are no material reportable subsequent events need to be disclosed. &#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 19 &#8212; CONDENSED FINANCIAL INFORMATION
OF THE PARENT COMPANY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_2" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Rule 12-04(a),
5-04(c) and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when the restricted
net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal
year. The Company performed a test on the restricted net assets of consolidated subsidiaries in accordance with such requirement and concluded
that it was applicable to the Company as the restricted net assets of the Company&#8217;s PRC subsidiary exceeded <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="upc:MinorityInterestsOwnershipPercentageByParent" scale="-2" unitRef="pure">25</ix:nonFraction>% of the consolidated
net assets of the Company. Therefore, the condensed financial statements for the parent company are included herein.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_3" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the above test, restricted net
assets of consolidated subsidiaries shall mean that amount of the Company&#8217;s proportionate share of net assets of consolidated subsidiaries
(after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries
in the form of loans, advances or cash dividends without the consent of a third party.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_4" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The condensed financial information of the parent
company has been prepared using the same accounting policies as set out in the Company&#8217;s consolidated financial statements except
that the parent company used the equity method to account for investment in its subsidiaries. Such investment is presented on the condensed
balance sheets as &#8220;Investment in subsidiaries&#8221; and the respective profit or loss as &#8220;Equity in earnings of subsidiaries&#8221;
on the condensed statements of income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_5" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The footnote disclosures contain supplemental
information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the
consolidated financial statements of the Company. Certain information and footnote disclosures normally included in financial statements
prepared in accordance with U.S GAAP have been condensed or omitted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_6" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, there were
no material contingencies, significant provisions for long-term obligations, or guarantees of the Company, except for those which have
been separately disclosed in the consolidated financial statements, if any.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PARENT COMPANY BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_7" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: justify">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">110,393</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">13,725,204</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">13,835,597</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 9pt; padding-left: 9pt">Investment in subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="0" unitRef="usd">45,098,756</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="0" unitRef="usd">20,802,904</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">58,934,353</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">20,802,904</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt">Ordinary shares, $<ix:nonFraction contextRef="c212" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c213" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.003125</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c212" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c213" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c212" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c212" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">21,750,000</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction contextRef="c213" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c213" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">16,000,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2021 and 2020, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">67,969</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 10pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">29,279,159</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">3,679,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Retained earnings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" unitRef="usd">27,498,466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" unitRef="usd">16,178,514</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">2,088,759</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">895,390</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">58,934,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">20,802,904</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 20pt">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">58,934,353</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">20,802,904</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>


</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PARENT COMPANY STATEMENTS OF INCOME AND COMPREHENSIVE
INCOME</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_8" id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="srt:CondensedStatementOfComprehensiveIncomeTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating costs and expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 9pt">General and administrative expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" sign="-" unitRef="usd">1,177,869</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expenses):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Income from short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOtherShortTermBorrowings" scale="0" unitRef="usd">239,549</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd">60,751</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity in earnings of subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd">12,319,023</ix:nonFraction></td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd">7,551,465</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">11,319,952</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,551,465</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" scale="0" unitRef="usd">1,193,369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" scale="0" unitRef="usd">860,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" scale="0" sign="-" unitRef="usd">645,978</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive income attributable to the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" unitRef="usd">12,513,321</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" unitRef="usd">8,418,845</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" unitRef="usd">6,905,487</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PARENT COMPANY STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="srt:ScheduleOfCondensedCashFlowStatementTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 10pt">Net income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">11,319,952</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,558,222</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd">7,551,465</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 10pt">Adjustments to reconcile net cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 8.3pt; padding-left: 20pt">Equity in earnings of subsidiary</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="upc:EquityInEarningsOfSubsidiary" scale="0" sign="-" unitRef="usd">12,319,027</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="upc:EquityInEarningsOfSubsidiary" scale="0" sign="-" unitRef="usd">7,558,222</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="upc:EquityInEarningsOfSubsidiary" scale="0" sign="-" unitRef="usd">7,551,465</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 30pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">999,075</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 28.3pt">Payment for short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" scale="0" sign="-" unitRef="usd">15,330,660</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 28.3pt">Redemption of short-term investments </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" unitRef="usd">1,801,927</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">13,528,733</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 28.3pt">Net proceeds from issuance of ordinary shares in IPO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">25,957,457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 21.3pt">&#160;&#160;Cash lent to subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="upc:CashLentToSubsidiaries" scale="0" sign="-" unitRef="usd">11,358,764</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">14,598,693</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="0" unitRef="usd">39,508</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">CHANGES IN CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">110,393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">CASH, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">CASH, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="upc:CashAndCashEquivalentAtCarryingValue" scale="0" unitRef="usd">110,393</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">F-35</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>




</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentAccountingStandard">U.S. GAAP</ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:DueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="upc:AdvanceToSuppliersNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="upc:PrepaymentForAdvertising" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-5" name="us-gaap:DeferredCostsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="us-gaap:PrepaidExpenseAndOtherAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-7" name="upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-8" name="upc:PrepaymentsForConstructionInProgress" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-9" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-10" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-11" name="upc:ShorttermInvestmentIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-12" name="upc:ShorttermInvestmentIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-13" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-14" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-15" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-16" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-17" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-18" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-19" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-20" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-21" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-22" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-23" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-24" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-25" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-26" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-27" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-28" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-29" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-30" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-31" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-32" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-33" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-34" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-35" name="upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-36" name="upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-37" name="upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-38" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-39" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-40" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-41" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-42" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-43" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-44" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-45" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-46" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-47" name="us-gaap:InventoryLIFOReservePeriodCharge" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-48" name="us-gaap:InterestIncomeShortTermInvestmentOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-49" name="us-gaap:InterestIncomeShortTermInvestmentOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-50" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-51" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-52" name="us-gaap:IncreaseDecreaseInPrepaidAdvertising" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-53" name="us-gaap:IncreaseDecreaseInPrepaidAdvertising" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-54" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-55" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-56" name="us-gaap:ProceedsFromSaleOfProductiveAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-57" name="us-gaap:ProceedsFromSaleOfProductiveAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-58" name="upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-59" name="upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-60" name="us-gaap:RepaymentsOfAdvancesForConstruction" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-61" name="us-gaap:RepaymentsOfAdvancesForConstruction" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-62" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-63" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-64" name="upc:RedemptionOfShorttermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-65" name="upc:RedemptionOfShorttermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-66" name="us-gaap:PaymentsOfDividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-67" name="us-gaap:PaymentsOfDividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-68" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-69" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-70" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-71" name="upc:DeferredInitialPublicOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-72" name="us-gaap:DeferredOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-73" name="upc:SunsequentCollectionAllowanceForDoubtfulAccounts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-74" name="upc:AllowanceForDoubtfulAccountsReceivablePercentage" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-75" name="us-gaap:PropertyPlantAndEquipmentAdditions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-76" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-77" name="us-gaap:InventoryRawMaterialsAndSupplies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-78" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-79" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-80" name="us-gaap:PaymentsToSuppliersAndEmployees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-81" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-82" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-83" name="upc:AddPurchaseWealthManagementFinancialProducts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-84" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-85" name="us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-86" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-87" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-88" name="us-gaap:OtherShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-89" name="us-gaap:OtherShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-90" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c119" id="hidden-fact-91" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c121" id="hidden-fact-92" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c124" id="hidden-fact-93" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c126" id="hidden-fact-94" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c128" id="hidden-fact-95" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:footnote id="ix_0_footnote" xml:lang="en-US">On June 19, 2020, the Company&#8217;s subsidiary Jiangxi Universe signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB 10 million (equivalent to $1,470,000) as working capital for one year, with the maturity date on June 18, 2021. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of short-term bank loans-->
<ix:footnote id="ix_1_footnote" xml:lang="en-US">On June 30, 2021, the Company&#8217;s subsidiary Jiangxi Universe signed a loan agreement with Bank of Communications to borrow RMB 10 million (equivalent to $1,548,000) as working capital for one year, with the maturity date on June 18, 2022. The fixed interest rate of the loan was 4.5% per annum. Certain related parties of the Company, including Mr. Gang Lai, the Company&#8217;s controlling shareholder, Mr. Gang Lai&#8217;s spouse, Mrs. Xing Wu, and the Company&#8217;s subsidiary, Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of short-term bank loans-->
<ix:nonFraction contextRef="c134" id="hidden-fact-96" name="us-gaap:DueFromOtherRelatedPartiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c136" id="hidden-fact-97" name="us-gaap:DueFromOtherRelatedPartiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-98" name="us-gaap:DueFromOtherRelatedPartiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c137" id="hidden-fact-99" name="us-gaap:DueToRelatedPartiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c141" id="hidden-fact-100" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c142" id="hidden-fact-101" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c143" id="hidden-fact-102" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-103" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c144" id="hidden-fact-104" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c145" id="hidden-fact-105" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c141" id="hidden-fact-106" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c142" id="hidden-fact-107" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c143" id="hidden-fact-108" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-109" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c144" id="hidden-fact-110" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c145" id="hidden-fact-111" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-112" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-113" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-114" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-115" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-116" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-117" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-118" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-119" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-120" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-121" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c213" id="hidden-fact-122" name="us-gaap:Cash" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c213" id="hidden-fact-123" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c213" id="hidden-fact-124" name="us-gaap:AssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c212" id="hidden-fact-125" name="us-gaap:Liabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c213" id="hidden-fact-126" name="us-gaap:Liabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-127" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-128" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-129" name="us-gaap:InterestExpenseOtherShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-130" name="us-gaap:InterestExpenseOtherShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-131" name="us-gaap:OtherNoncashIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-132" name="us-gaap:OtherNoncashIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-133" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-134" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-135" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-136" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-137" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-138" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-139" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-140" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-141" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-142" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-143" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-144" name="upc:CashLentToSubsidiaries" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-145" name="upc:CashLentToSubsidiaries" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-146" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-147" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-148" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-149" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-150" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-151" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c213" id="hidden-fact-152" name="upc:CashAndCashEquivalentAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c217" id="hidden-fact-153" name="upc:CashAndCashEquivalentAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c218" id="hidden-fact-154" name="upc:CashAndCashEquivalentAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c213" id="hidden-fact-155" name="upc:CashAndCashEquivalentAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c217" id="hidden-fact-156" name="upc:CashAndCashEquivalentAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c1" name="dei:CityAreaCode">+86</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate">--09-30</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">000000</ix:nonNumeric>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode">000000</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001809616</ix:nonNumeric>
<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber">0796-8403309</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="upc-20210930.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship fromRefs="hidden-fact-92 ix_0_fact" toRefs="ix_0_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_1_fact hidden-fact-94" toRefs="ix_1_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseHKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JiangxiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-12-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JiangxiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-25</xbrli:startDate>
    <xbrli:endDate>2021-03-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-25</xbrli:startDate>
    <xbrli:endDate>2021-03-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseHKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseHanheMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseHanheMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JxRcbBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2009-03-01</xbrli:startDate>
    <xbrli:endDate>2017-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JxRcbBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-04-25</xbrli:startDate>
    <xbrli:endDate>2018-05-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-03-25</xbrli:startDate>
    <xbrli:endDate>2019-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:LessThan3MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:LessThan3MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From4To6MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From4To6MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From7To9MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From7To9MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From10To12MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From10To12MonthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:Over1YearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:Over1YearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-01</xbrli:startDate>
    <xbrli:endDate>2021-09-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ChenyuanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ChenyuanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7sSbeKneEPlmLktMHZBhwtLx19hpHJOdjKf2eyiP0jq4gpLMoHnWAqkCyHBHyDK9GdQmqqId3PEwCOX17Vhl0ye9OCleikRMpiLr3TIPdJKhXs3yZdg2Uc+UwRFAIl8XyfUVRuc3/PImA==] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">upc:CapitalExpenditureMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-05-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-09-01</xbrli:startDate>
    <xbrli:endDate>2019-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:Maturity30To90DaysMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:Maturity30To90DaysMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOver90DaysMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOver90DaysMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrsLinYangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GreatestGroupMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:FoshanShangyuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GreatestGroupMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GreatestGroupMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:FoshanShangyuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:FoshanShangyuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrsLinYangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:TotalRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:TotalRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:TotalRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomersOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-08-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-02</xbrli:startDate>
    <xbrli:endDate>2020-08-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-25</xbrli:startDate>
    <xbrli:endDate>2021-03-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-09-02</xbrli:startDate>
    <xbrli:endDate>2016-09-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-09-02</xbrli:startDate>
    <xbrli:endDate>2017-09-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-28</xbrli:startDate>
    <xbrli:endDate>2018-02-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-09-02</xbrli:startDate>
    <xbrli:endDate>2018-09-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-02</xbrli:startDate>
    <xbrli:endDate>2019-02-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:PRCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-24</xbrli:startDate>
    <xbrli:endDate>2021-12-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2020-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-10-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001809616</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="cny">
  <xbrli:measure>iso4217:CNY</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.3
<SEQUENCE>2
<FILENAME>f20f2021ex2-3_universephar.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 2.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Description of Rights of Each Class of Securities<BR>
Registered under Section 12 of the Securities Exchange Act of 1934, as Amended (the &ldquo;Exchange Act&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary shares, par value $0.003125 per share
(&ldquo;Ordinary Shares&rdquo;), of Universe Pharmaceuticals INC (&ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;our company,&rdquo; or &ldquo;us&rdquo;)
are registered under Section 12(b) of the Exchange Act and our Ordinary Shares are listed and traded on the Nasdaq Global Market. This
exhibit contains a description of the rights of the holders of Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Description of Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of material provisions
of our currently effective amended and restated memorandum of association and articles of association (the &ldquo;Memorandum and Articles
of Association&rdquo;), as well as the Companies Act (Revised) of the Cayman Islands (the &ldquo;Cayman Companies Act&rdquo;) insofar
as they relate to the material terms of our Ordinary Shares. Notwithstanding this, because it is a summary, it may not contain all the
information that you may otherwise deem important. For more complete information, you should read the entire Memorandum and Articles of
Association, which have been filed with the U.S. Securities and Exchange Commission as exhibits to our Registration Statement on Form
F-1 (File No. 333-248067), as amended, initially filed with the U.S. Securities and Exchange Commission on August 17, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Type and Class of Securities (Item 9.A.5 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Ordinary Share has a par value of $0.003125
each. The number of Ordinary Shares that have been issued as of the last day of the financial year ended September 30, 2021 is provided
on the cover of the annual report on Form 20-F filed on January&nbsp;31, 2022 (the &ldquo;2021 Form 20-F&rdquo;). Our Ordinary Shares may
be held in either certificated or uncertificated form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Preemptive Rights (Item 9.A.3 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Ordinary Shares are not subject to any pre-emptive
or similar rights under the Cayman Companies Act or pursuant to the Memorandum and Articles of Association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Limitations or Qualifications (Item 9.A.6 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Ordinary Share entitles the holder thereof
to one vote on all matters subject to the vote at general meetings of our company, voting together as one class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Rights of Other Types of Securities (Item 9.A.7 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Rights of Class A Ordinary Shares (Item 10.B.3 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Ordinary Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized share capital is $312,500 divided
into 100,000,000 Ordinary Shares, par value $0.003125 per share. All of our issued and outstanding Ordinary Shares are fully paid and
non-assessable. Shareholders who are non-residents of the Cayman Islands may freely hold and transfer their ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of the Cayman Companies
Act and any rights attaching to any class or classes of shares under and in accordance with the articles:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
directors may declare dividends or distributions out of our funds which are lawfully available for that purpose; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Company&rsquo;s shareholders may, by ordinary resolution, declare dividends but no such dividend shall exceed the amount recommended
by the directors.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the requirements of the Cayman Companies
Act regarding the application of a company&rsquo;s share premium account and with the sanction of an ordinary resolution, dividends may
also be declared and paid out of any share premium account. The directors when paying dividends to shareholders may make such payment
either in cash or in specie.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless provided by the rights attached to a share,
no dividend shall bear interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to any rights or restrictions as to voting
attached to any shares, unless any share carries special voting rights, on a show of hands every shareholder who is present in person
and every person representing a shareholder by proxy shall have one vote per Ordinary Share. On a poll, every shareholder who is present
in person and every person representing a shareholder by proxy shall have one vote for each share of which he or the person represented
by proxy is the holder. In addition, all shareholders holding shares of a particular class are entitled to vote at a meeting of the holders
of that class of shares. Votes may be given either personally or by proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Calls on shares and forfeiture</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms of allotment, the directors
may make calls on the shareholders in respect of any monies unpaid on their shares including any premium and each shareholder shall (subject
to receiving at least 14 clear days&rsquo; notice specifying when and where payment is to be made), pay to us the amount called on his
shares. Shareholders registered as the joint holders of a share shall be jointly and severally liable to pay all calls in respect of the
share. If a call remains unpaid after it has become due and payable the person from whom it is due and payable shall pay interest on the
amount unpaid from the day it became due and payable until it is paid at the rate fixed by the terms of allotment of the share or in the
notice of the call or if no rate is fixed, at the rate of ten percent per annum. The directors may, at their discretion, waive payment
of the interest wholly or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a first and paramount lien on all shares
(whether fully paid up or not) registered in the name of a shareholder (whether solely or jointly with others). The lien is for all monies
payable to us by the shareholder or the shareholder&rsquo;s estate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">either
alone or jointly with any other person, whether or not that other person is a shareholder; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
or not those monies are presently payable.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time the directors may declare any share
to be wholly or partly exempt from the lien on shares provisions of the articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell, in such manner as the directors may
determine, any share on which the sum in respect of which the lien exists is presently payable, if due notice that such sum is payable
has been given (as prescribed by the articles) and, within 14 days of the date on which the notice is deemed to be given under the articles,
such notice has not been complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Unclaimed Dividend</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A dividend that remains unclaimed for a period
of six years after it became due for payment shall be forfeited to, and shall cease to remain owing by, the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Forfeiture or Surrender of Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a shareholder fails to pay any capital call,
the directors may give to such shareholder not less than 14 clear days&rsquo; notice requiring payment and specifying the amount unpaid
including any interest which may have accrued, any expenses which have been incurred by us due to that person&rsquo;s default and the
place where payment is to be made. The notice shall also contain a warning that if the notice is not complied with, the shares in respect
of which the call is made will be liable to be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If such notice is not complied with, the directors
may, before the payment required by the notice has been received, resolve that any share the subject of that notice be forfeited (which
forfeiture shall include all dividends or other monies payable in respect of the forfeited share and not paid before such forfeiture).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A forfeited share may be sold, re-allotted or
otherwise disposed of on such terms and in such manner as the directors determine and at any time before a sale, re-allotment or disposition
the forfeiture may be cancelled on such terms as the directors think fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A person whose shares have been forfeited shall
cease to be a shareholder in respect of the forfeited shares, but shall, notwithstanding such forfeiture, remain liable to pay to us all
monies which at the date of forfeiture were payable by him to us in respect of the shares, together with all expenses and interest from
the date of forfeiture or surrender until payment, but his liability shall cease if and when we receive payment in full of the unpaid
amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A declaration, whether statutory or under oath,
made by a director or the secretary shall be conclusive evidence that the person making the declaration is our director or secretary and
that the particular shares have been forfeited or surrendered on a particular date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the execution of an instrument of transfer, if necessary,
the declaration shall constitute good title to the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Share Premium Account</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors shall establish a share premium
account and shall carry the credit of such account from time to time to a sum equal to the amount or value of the premium paid on the
issue of any share or capital contributed or such other amounts required by the Cayman Companies Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Redemption and Purchase of Own Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Cayman Companies Act and any rights
for the time being conferred on the shareholders holding a particular class of shares, we may by action of our directors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue shares that are to be redeemed or liable to be redeemed, at our option or the shareholder holding those redeemable shares, on the terms and in the manner our directors determine before the issue of those shares;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with the consent by special resolution of the shareholders holding shares of a particular class, vary the rights attaching to that class of shares so as to provide that those shares are to be redeemed or are liable to be redeemed at our option on the terms and in the manner which the directors determine at the time of such variation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchase all or any of our own shares of any class including any redeemable shares on the terms and in the manner which the directors determine at the time of such purchase.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may make a payment in respect of the redemption
or purchase of its own shares in any manner authorized by the Cayman Companies Act, including out of any combination of capital, our profits
and the proceeds of a fresh issue of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When making a payment in respect of the redemption
or purchase of shares, the directors may make the payment in cash or in specie (or partly in one and partly in the other) if so authorized
by the terms of the allotment of those shares or by the terms applying to those shares, or otherwise by agreement with the shareholder
holding those shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Transfer of Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provided that a transfer of Ordinary Shares complies
with applicable rules of the Nasdaq Global Market, a shareholder may transfer Ordinary Shares to another person by completing an instrument
of transfer in a common form or in a form prescribed by Nasdaq or in any other form approved by the directors, executed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
the Ordinary Shares are fully paid, by or on behalf of that shareholder; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
the Ordinary Shares are partly paid, by or on behalf of that shareholder and the transferee.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transferor shall be deemed to remain the holder
of an Ordinary Share until the name of the transferee is entered into the register of members of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors may, in its absolute discretion,
decline to register any transfer of any Ordinary Share that has not been fully paid up or is subject to a company lien. Our board of directors
may also decline to register any transfer of such Ordinary Share unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is lodged with the Company, accompanied by the certificate for the Ordinary Shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is in respect of only one class of Ordinary Shares;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is properly stamped, if required;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Ordinary Share transferred is fully paid and free of any lien in favor of us;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fee related to the transfer has been paid to us; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the transfer is not to more than four joint holders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our directors refuse to register a transfer,
they are required, within three months after the date on which the instrument of transfer was lodged, to send to each of the transferor
and the transferee notice of such refusal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This, however, is unlikely to affect market transactions
of the Ordinary Shares purchased by investors in the public offering. Once the Ordinary Shares have been listed, the legal title to such
Ordinary Shares and the registration details of those Ordinary Shares in our register of members will remain with Depository Trust Company
(&ldquo;DTC&rdquo;)/Cede &amp; Co. All market transactions with respect to those Ordinary Shares will then be carried out without the
need for any kind of registration by the directors, as the market transactions will all be conducted through the DTC systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registration of transfers may, on 14 calendar
days&rsquo; notice being given by advertisement in such one or more newspapers or by electronic means, be suspended and our register of
members closed at such times and for such periods as our board of directors may from time to time determine. The registration of transfers,
however, may not be suspended, and the register may not be closed, for more than 30 days in any year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Capitalization of Profits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The directors may resolve to capitalize:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
part of our profits not required for paying any preferential dividend (whether or not those profits are available for distribution);
or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
sum standing to the credit of our share premium account or capital redemption reserve, if any.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount resolved to be capitalized must be
appropriated to the shareholders who would have been entitled to it had it been distributed by way of dividend and in the same proportions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are wound up, the shareholders may, subject
to the articles and any other sanction required by the Cayman Companies Act, pass a special resolution allowing the liquidator to do either
or both of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
divide in specie among the shareholders the whole or any part of our assets and, for that purpose, to value any assets and to determine
how the division shall be carried out as between the shareholders or different classes of shareholders; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
vest the whole or any part of the assets in trustees for the benefit of shareholders and those liable to contribute to the winding up.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors have the authority to present a
petition for our winding up to the Grand Court of the Cayman Islands on our behalf without the sanction of a resolution passed at a general
meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Requirements to Change the Rights of Holders of Ordinary Shares
(Item 10.B.4 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Variations of Rights of Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whenever our capital is divided into different
classes of shares, the rights attaching to any class of share (unless otherwise provided by the terms of issue of the shares of that class)
may be varied either with the consent in writing of the holders of not less than two-thirds of the issued shares of that class, or with
the sanction of a resolution passed by a majority of not less than two-thirds of the holders of shares of the class present in person
or by proxy at a separate general meeting of the holders of shares of that class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the terms on which a class of shares was
issued state otherwise, the rights conferred on the shareholder holding shares of any class shall not be deemed to be varied by the creation
or issue of further shares ranking pari passu with the existing shares of that class.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Limitations on the Rights to Own Ordinary Shares (Item 10.B.6
of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no limitations under the laws of the
Cayman Islands or under the Memorandum and Articles of Association that limit the right of non-resident or foreign owners to hold or vote
ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Provisions Affecting Any Change of Control (Item 10.B.7 of Form
20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Anti-Takeover Provisions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some provisions of the Memorandum and Articles
of Association may discourage, delay, or prevent a change in control of our company or management that shareholders may consider favorable,
including, among other things, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions
that authorize our board of directors to issue shares with preferred, deferred, or other special rights or restrictions without any further
vote or action by our shareholders; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provisions
that restrict the ability of our shareholders to call meetings and to propose special matters for consideration at shareholder meetings.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Cayman Companies Act, our directors
may only exercise the rights and powers granted to them under our articles for what they believe in good faith to be in the best interests
of our company and for a proper purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Ownership Threshold (Item 10.B.8 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no provisions under the Cayman Companies
Act or under the Memorandum and Articles of Association that govern the ownership threshold above which shareholder ownership must be
disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Differences Between the Law of Different Jurisdictions (Item
10.B.9 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Cayman Companies Act is derived, to a large
extent, from the older Companies Acts of England and Wales but does not follow recent United Kingdom statutory enactments, and accordingly
there are significant differences between the Cayman Companies Act and the current Companies Act of the UK. In addition, the Cayman Companies
Act differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of certain significant
differences between the provisions of the Cayman Companies Act applicable to us and the comparable laws applicable to companies incorporated
in the State of Delaware in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cayman Islands</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Title of Organizational Documents</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation and Bylaws</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation and Memorandum and Articles of Association</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Duties of Directors</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, the business and affairs of a corporation are managed by or under the direction of its board of directors. In exercising their powers, directors are charged with a fiduciary duty of care to protect the interests of the corporation and a fiduciary duty of loyalty to act in the best interests of its shareholders. The duty of care requires that directors act in an informed and deliberative manner and inform themselves, prior to making a business decision, of all material information reasonably available to them. The duty of care also requires that directors exercise care in overseeing and investigating the conduct of the corporation&rsquo;s employees. The duty of loyalty may be summarized as the duty to act in good faith, not out of self-interest, and in a manner which the director reasonably believes to be in the best interests of the shareholders.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a matter of Cayman Islands law, a director owes three types of duties to the company: (i) statutory duties, (ii) fiduciary duties, and (iii) common law duties. The Cayman Companies Act imposes a number of statutory duties on a director. A Cayman Islands director&rsquo;s fiduciary duties are not codified, however the courts of the Cayman Islands have held that a director owes the following fiduciary duties (a) a duty to act in what the director bona fide considers to be in the best interests of the company, (b) a duty to exercise their powers for the purposes they were conferred, (c) a duty to avoid fettering his or her discretion in the future and (d) a duty to avoid conflicts of interest and of duty. The common law duties owed by a director are those to act with skill, care and diligence that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the company and, also, to act with the skill, care and diligence in keeping with a standard of care commensurate with any particular skill they have which enables them to meet a higher standard than a director without those skills. In fulfilling their duty of care to us, our directors must ensure compliance with our amended articles of association, as amended and restated from time to time. We have the right to seek damages if a duty owed by any of our directors is breached.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Limitations on Personal Liability of Directors</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the limitations described below, a certificate of incorporation may provide for the elimination or limitation of the personal liability of a director to the corporation or its shareholders for monetary damages for a breach of fiduciary duty as a director. Such provision cannot limit liability for breach of loyalty, bad faith, intentional misconduct, unlawful payment of dividends or unlawful share purchase or redemption. In addition, the certificate of incorporation cannot limit liability for any act or omission occurring prior to the date when such provision becomes effective.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Islands law does not limit the extent to which a company&rsquo;s articles of association may provide for indemnification of Officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Indemnification of Directors, Officers, Agents, and Others</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A corporation has the power to indemnify any director, officer, employee, or agent of corporation who was, is, or is threatened to be made a party who acted in good faith and in a manner he believed to be in the best interests of the corporation, and if with respect to a criminal proceeding, had no reasonable cause to believe his conduct would be unlawful, against amounts actually and reasonably incurred.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cayman Islands law does not limit the extent to
    which a company&rsquo;s memorandum and articles of association may provide for indemnification of directors and officers, except to the
    extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification
    against the consequences of committing a crime, or against the indemnified person&rsquo;s own fraud or dishonesty.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated articles of association
    provide to the extent permitted by law, we shall indemnify each existing or former secretary, director (including alternate director),
    and any of our other officers (including an investment adviser or an administrator or liquidator) and their personal representatives against:
    (a) all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by the existing or former
    director (including alternate director), secretary or officer in or about the conduct of our business or affairs or in the execution or
    discharge of the existing or former director (including alternate director), secretary&rsquo;s or officer&rsquo;s duties, powers, authorities
    or discretions; and (b) without limitation to paragraph (a) above, all costs, expenses, losses or liabilities incurred by the existing
    or former director (including alternate director), secretary or officer in defending (whether successfully or otherwise) any civil, criminal,
    administrative or investigative proceedings (whether threatened, pending or completed) concerning us or our affairs in any court or tribunal,
    whether in the Cayman Islands or elsewhere.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No such existing or former director (including
    alternate director), secretary or officer, however, shall be indemnified in respect of any matter arising out of his own dishonesty.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent permitted by law, we may make a
    payment, or agree to make a payment, whether by way of advance, loan or otherwise, for any legal costs incurred by an existing or former
    director (including alternate director), secretary or any of our officers in respect of any matter identified in above on condition that
    the director (including alternate director), secretary or officer must repay the amount paid by us to the extent that it is ultimately
    found not liable to indemnify the director (including alternate director), the secretary or that officer for those legal costs.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interested Directors</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, a transaction in which a director who has an interest in such transaction would not be voidable if (i) the material facts as to such interested director&rsquo;s relationship or interests are disclosed or are known to the board of directors and the board in good faith authorizes the transaction by the affirmative vote of a majority of the disinterested directors, even though the disinterested directors are less than a quorum, (ii) such material facts are disclosed or are known to the shareholders entitled to vote on such transaction and the transaction is specifically approved in good faith by vote of the shareholders, or (iii) the transaction is fair as to the corporation as of the time it is authorized, approved or ratified. Under Delaware law, a director could be held liable for any transaction in which such director derived an improper personal benefit.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interested director transactions are governed by the terms of a company&rsquo;s memorandum and articles of association.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting Requirements</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The certificate of incorporation may include a
    provision requiring supermajority approval by the directors or shareholders for any corporate action.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, under Delaware law, certain business
    combinations involving interested shareholders require approval by a supermajority of the non-interested shareholders.</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the protection of shareholders, certain matters
    must be approved by special resolution of the shareholders as a matter of Cayman Islands law, including alteration of the memorandum or
    articles of association, appointment of inspectors to examine company affairs, reduction of share capital (subject, in relevant circumstances,
    to court approval), change of name, authorization of a plan of merger or transfer by way of continuation to another jurisdiction or consolidation
    or voluntary winding up of the company.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Cayman Companies Act requires that a special
    resolution be passed by a majority of at least two-thirds or such higher percentage as set forth in the memorandum and articles of association,
    of shareholders being entitled to vote and do vote in person or by proxy at a general meeting, or by unanimous written consent of shareholders
    entitled to vote at a general meeting.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting for Directors</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, unless otherwise specified in the certificate of incorporation or bylaws of the corporation, directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Act defines &ldquo;special resolutions&rdquo; only. A company&rsquo;s memorandum and articles of association can therefore tailor the definition of &ldquo;ordinary resolutions&rdquo; as a whole, or with respect to specific provisions.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cumulative Voting</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No cumulative voting for the election of directors unless so provided in the certificate of incorporation.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No cumulative voting for the election of directors unless so provided in the memorandum and articles of association.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Directors&rsquo; Powers Regarding Bylaws</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The certificate of incorporation may grant the directors the power to adopt, amend or repeal bylaws.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The memorandum and articles of association may only be amended by a special resolution of the shareholders.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nomination and Removal of Directors and Filling Vacancies on Board</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders may generally nominate directors if they comply with advance notice provisions and other procedural requirements in company bylaws. Holders of a majority of the shares may remove a director with or without cause, except in certain cases involving a classified board or if the company uses cumulative voting. Unless otherwise provided for in the certificate of incorporation, directorship vacancies are filled by a majority of the directors elected or then in office.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nomination and removal of directors and filling of board vacancies are governed by the terms of the memorandum and articles of association.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Mergers and Similar Arrangements</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Delaware law, with certain exceptions, a
    merger, consolidation, exchange or sale of all or substantially all the assets of a corporation must be approved by the board of directors
    and a majority of the outstanding shares entitled to vote thereon. Under Delaware law, a shareholder of a corporation participating in
    certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights pursuant to which such shareholder
    may receive cash in the amount of the fair value of the shares held by such shareholder (as determined by a court) in lieu of the consideration
    such shareholder would otherwise receive in the transaction.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delaware law also provides that a parent corporation,
    by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90% of each class of capital stock without
    a vote by shareholders of such subsidiary. Upon any such merger, dissenting shareholders of the subsidiary would have appraisal rights.</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: justify">The Cayman Companies Act permits mergers
    and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies. For these purposes,
    (a) &ldquo;merger&rdquo; means the merging of two or more constituent companies and the vesting of their undertaking, property and liabilities
    in one of such companies as the surviving company, and (b) a &ldquo;consolidation&rdquo; means the combination of two or more constituent
    companies into a consolidated company and the vesting of the undertaking, property and liabilities of such companies to the consolidated
    company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger
    or consolidation, which must then be authorized by (a) a special resolution of the shareholders of each constituent company, and (b) such
    other authorization, if any, as may be specified in such constituent company&rsquo;s articles of association. The plan must be filed with
    the Registrar of Companies together with a declaration as to the solvency of the consolidated or surviving company, a list of the assets
    and liabilities of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will be given
    to the shareholders and creditors of each constituent company and that notification of the merger or consolidation will be published in
    the Cayman Islands Gazette. Court approval is not required for a merger or consolidation which is effected in compliance with these statutory
    procedures.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A merger between a Cayman Islands parent company
    and its Cayman Islands subsidiary or subsidiaries does not require authorization by a resolution of shareholders. For this purpose a subsidiary
    is a company of which at least 90% of the issued shares entitled to vote are owned by the parent company.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consent of each holder of a fixed or floating
    security interest of a constituent company is required unless this requirement is waived by a court in the Cayman Islands.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except in certain limited circumstances, a dissenting
    shareholder of a Cayman Islands constituent company is entitled to payment of the fair value of his or her shares upon dissenting from
    a merger or consolidation. The exercise of such dissenter rights will preclude the exercise by the dissenting shareholder of any other
    rights to which he or she might otherwise be entitled by virtue of holding shares, except for the right to seek relief on the grounds
    that the merger or consolidation is void or unlawful.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, there are statutory provisions that
    facilitate the reconstruction and amalgamation of companies, provided that the arrangement is approved by a majority in number of each
    class of shareholders and creditors with whom the arrangement is to be made, and who must, in addition, represent three-fourths in value
    of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting,
    or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand
    Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the transaction ought
    not to be approved, the court can be expected to approve the arrangement if it determines that: (a) the statutory provisions as to the
    required majority vote have been met; (b) the shareholders have been fairly represented at the meeting in question and the statutory majority
    are acting bona fide without coercion of the minority to promote interests adverse to those of the class; (c) the arrangement is such
    that may be reasonably approved by an intelligent and honest man of that class acting in respect of his interest; and (d) the arrangement
    is not one that would more properly be sanctioned under some other provision of the Cayman Companies Act.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When a takeover offer is made and accepted by
    holders of 90% of the shares affected within four months the offeror may, within a two-month period commencing on the expiration of such
    four month period, require the holders of the remaining shares to transfer such shares on the terms of the offer. An objection can be
    made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless
    there is evidence of fraud, bad faith or collusion.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an arrangement and reconstruction is thus approved,
    or if a takeover offer is made and accepted, a dissenting shareholder would have no rights comparable to appraisal rights, which would
    otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for
    the judicially determined value of the shares.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder Suits</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class actions and derivative actions generally are available to shareholders under Delaware law for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In such actions, the court generally has discretion to permit the winning party to recover attorneys&rsquo; fees incurred in connection with such action.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In principle, we will normally be the proper plaintiff and as a general rule a derivative action may not be brought by a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands courts can be expected to follow and apply the common law principles (namely the rule in Foss v. Harbottle and the exceptions thereto) so that a non-controlling shareholder may be permitted to commence a class action against or derivative actions in the name of the company to challenge: (a) an act which is illegal or ultra vires with respect to the company and is therefore incapable of ratification by the shareholders; (b) an act which, although not ultra vires, requires authorization by a qualified (or special) majority (that is, more than a simple majority) which has not been obtained; and (c) an act which constitutes a &ldquo;fraud on the minority&rdquo; where the wrongdoers are themselves in control of the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Inspection of Corporate Records</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, shareholders of a Delaware corporation have the right during normal business hours to inspect for any proper purpose, and to obtain copies of list(s) of shareholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%; padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders of a Cayman Islands exempted company have no general right under Cayman Islands law to inspect or obtain copies of a list of shareholders or other corporate records (other than the register of mortgages or charges) of the company. However, these rights may be provided in the company&rsquo;s memorandum and articles of association.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder Proposals</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless provided in the corporation&rsquo;s certificate of incorporation or bylaws, Delaware law does not include a provision restricting the manner in which shareholders may bring business before a meeting.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Act provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company&rsquo;s articles of association. Our articles provide that general meetings shall be convened on the written requisition of one or more of the shareholders entitled to attend and vote at our general meetings who (together) hold not less than 10 percent of the rights to vote at such general meeting in accordance with the notice provisions in the articles, specifying the purpose of the meeting and signed by each of the shareholders making the requisition. If the directors do not convene such meeting for a date not later than twenty-one clear days&rsquo; after the date of receipt of the written requisition, those shareholders who requested the meeting may convene the general meeting themselves within three months after the end of such period of twenty-one clear days in which case reasonable expenses incurred by them as a result of the directors failing to convene a meeting shall be reimbursed by us. Our articles provide no other right to put any proposals before annual general meetings or extraordinary general meetings. As a Cayman Islands exempted company, we are not obligated by law to call shareholders&rsquo; annual general meetings. However, our corporate governance guidelines require us to call such meetings every year.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Approval of Corporate Matters by Written Consent</I></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware law permits shareholders to take action by written consent signed by the holders of outstanding shares having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting of shareholders.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%; padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Act allows a special resolution to be passed in writing if signed by all the voting shareholders (if authorized by the memorandum and articles of association).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Calling of Special Shareholders Meetings</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware law permits the board of directors or any person who is authorized under a corporation&rsquo;s certificate of incorporation or bylaws to call a special meeting of shareholders.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Act does not have provisions governing the proceedings of shareholders meetings which are usually provided in the memorandum and articles of association. Please see above.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dissolution; Winding Up</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&rsquo;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board of directors.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Cayman Companies Act and our amended and restated articles, the Company may be wound up by a special resolution of our shareholders, or if the winding up is initiated by our board of directors, by either a special resolution of our members or, if our company is unable to pay its debts as they fall due, by an ordinary resolution of our members. In addition, a company may be wound up by an order of the courts of the Cayman Islands. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do so.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Changes in Capital (Item 10.B.10 of Form 20-F)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the Cayman Companies Act, we may, by ordinary resolution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
our share capital by new shares of the amount fixed by that ordinary resolution and with the attached rights, priorities and privileges
set out in that ordinary resolution;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidate
and divide all or any of our share capital into shares of larger amount than our existing shares;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">convert
all or any of our paid up shares into stock, and reconvert that stock into paid up shares of any denomination;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sub-divide
our shares or any of them into shares of an amount smaller than that fixed, so, however, that in the sub-division, the proportion between
the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the
reduced share is derived; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel
shares which, at the date of the passing of that ordinary resolution, have not been taken or agreed to be taken by any person and diminish
the amount of our share capital by the amount of the shares so cancelled or, in the case of shares without nominal par value, diminish
the number of shares into which our capital is divided.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Cayman Companies Act and to any
rights for the time being conferred on the shareholders holding a particular class of shares, we may, by special resolution, reduce our
share capital in any way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Debt Securities (Item 12.A of Form&nbsp;20-F)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants and Rights (Item 12.B of Form&nbsp;20-F)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other Securities (Item 12.C of Form&nbsp;20-F)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Description of American Depositary Shares (Items 12.D.1 and 12.D.2
of Form 20-F)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.12
<SEQUENCE>3
<FILENAME>f20f2021ex4-12_universephar.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE WORKING CAPITAL LOAN CONTRACT ENTERED INTO BY AND BETWEEN UNIVERSE TRADE AND JIANGXI LIULING RURAL COMMERCIAL BANK CO., LTD., DATED MARCH 18, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.12</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2021] L.L.N.S.H.L.J.Z. No. <U>172292021031810030001
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Working Capital Loan Contract </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Jiangxi Universe Pharmaceuticals Commerce and Trade Co., Ltd. </U></I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lender</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Jiangxi Luling Rural Commercial Bank Co., Ltd.</U></I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-top: 6pt; padding-bottom: 6pt; text-align: justify; layout-grid-mode: char; font-size: 10pt"><IMG SRC="ex4-12_001.jpg" ALT=""></TD>
    <TD STYLE="width: 95%; padding-top: 6pt; padding-bottom: 6pt; text-align: justify; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-size: 12pt"><B>Jiangxi Rural Commercial Bank</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special Notice: In order to protect the legitimate
rights and interests of the Borrower, the Lender hereby requests the Borrower to give full attention to all provisions concerning the
rights and obligations of the parties, especially those shown in bold. If the Borrower has any objection, it shall raise the objection
to the Lender. Otherwise, after this Contract is entered into by and between the Borrower and the Lender, all the terms and conditions
herein represent the true intention of both parties, are protected by law and shall be legally binding on both parties herein. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Working Capital Loan Contract </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2021] L.L.N.S.H.L.J.Z. No. <U>172292021031810030001
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower: <U>Jiangxi Universe Pharmaceuticals
Commerce and Trade Co., Ltd. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business License No.: <U>______________________________________________________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative / Person in Charge: <U>LAI
Gang ________________________________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Domicile: <U>Jingjiu Avenue, Jinggangshan Economic
and Technological Development Zone ___________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mailing Address: <U>The same as above___________________________________________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Postal Code: <U>343100</U> Tel.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Electronic Contact Information (Email and WeChat
Account No.): <U>_____________________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lender: <U>Jiangxi Luling</U> Rural Commercial
Bank Co., Ltd. _____________________________________________________<U> </U>_</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative/Person-in-Charge: <U>HU Fuliang
_______________________________________________________ </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Domicile: <U>No.205 Fuchuan Road, Ji&rsquo;an County ____________________________________________________________
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Postal Code: <U>343100 ________________________________________________________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel.: Fax: ________________________________________________________________________________________<U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the laws and regulations of the People&rsquo;s
Republic of China and other relevant regulations, the Borrower and the Lender have reached an agreement with respect to the matter that
the Lender grants a working capital loan to the Borrower, and hereby execute this Contract by consensus, which shall be binding on both
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chapter 1 Execution Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1 Loan Amount and Currency </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loan Amount (in words): <U>CNY Eight Million</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>(In figures) CNY 8,000,000.00. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan amount under this Contract is: <FONT STYLE="font-family: Wingdings">&uml;</FONT>revolving
borrowing limit <FONT STYLE="font-family: Wingdings">&thorn;</FONT>non-revolving loan amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2 Loan Term </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valid loan term under this Contract shall
be: <U>12</U> months from <U>March 18, 2021</U> to <U>March 17, 2022</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &#9744; In the event that the loan amount
hereunder is a revolving borrowing limit, the term of borrowing limit shall be the same as the valid loan term as agreed herein. The
term of each loan shall be subject to the term recorded in the loan note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&thorn;</FONT> In
the event that the loan amount hereunder is a non-revolving borrowing limit, the loan term shall be the same as the valid loan term as
agreed herein. The specific loan term shall be subject to the term recorded in the loan note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower has any default circumstance
listed in Article 19 of this Contract, and the Borrower agrees that the Lender may recover the loan in advance, then the Lender may announce
that the date of recovering the loan in advance is the due date of the loan. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3 Loan Purpose </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan borrowed hereunder shall be used for
<I><U>turnover of working capital</U></I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without the written consent of the Lender, the
Borrower may neither change the loan purpose nor use the loan for any other purposes. The Lender shall have the right to supervise the
Borrower&rsquo;s use of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4 Loan Interest Rate, Interest Calculation
and Settlement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. Loan
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The method as described in following Item <U>(1)</U>
shall apply for the determination of loan interest rate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(1) Fixed interest rate. The annual interest
rate shall be <U>4.81%: </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan prime rate (LPR) recently published
on the <FONT STYLE="font-family: Wingdings">&thorn;</FONT>date of signature &#9744; hereof withdrawal date for ___ years&rsquo; loan,
which is <U>3.85 </U><FONT STYLE="font-family: Wingdings">&thorn;</FONT>, and increased percentage points decreased percentage
points, &#9744; which is <U>96</U> bp (1bp = 0.01%). The annual interest rate shall be <U>4.81</U>%. The interest rate shall remain
unchanged during the loan term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(2) Floating
Interest Rate. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan interest rate shall be determined by
the loan prime rate (LPR) recently published on the working day before the withdrawal date for ______ years&rsquo; loan and <FONT STYLE="font-family: Wingdings">&uml;</FONT>increased
percentage points<FONT STYLE="font-family: Wingdings">&uml;</FONT> decreased percentage points, which is _______ bp. <B>The increased
or decreased percentage points shall remain unchanged during the term of this Contract. In case of any adjustment to the LPR, its loan
interest rate determination method shall be handled according to the following Item and the Lender will not give a further notice to the
Borrower: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex4-12_002.jpg" ALT=""> Annual
Adjustment. From January 1 of the next year, the loan interest rate shall be adjusted, on the basis of the LPR recently published,
in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <IMG SRC="ex4-12_003.jpg" ALT=""> Annual
Adjustment. From the corresponding date of the corresponding month in the corresponding year, the loan interest rate shall be
adjusted, on the basis of the LPR recently published, in accordance with the increased or decreased percentage points agreed
herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <IMG SRC="ex4-12_004.jpg" ALT=""> Quarterly
Adjustment. From the corresponding date of the first month in the corresponding quarter, the loan interest rate shall be adjusted,
on the basis of the LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <IMG SRC="ex4-12_005.jpg" ALT=""> Quarterly
Adjustment. From the first day of the first month in the corresponding quarter, the loan interest rate shall be adjusted, on the
basis of the LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <IMG SRC="ex4-12_006.jpg" ALT=""> Monthly
Adjustment. From the corresponding date of the corresponding month, the loan interest rate shall be adjusted, on the basis of the
LPR recently published, in accordance with the increased or decreased percentage points agreed herein (If there is no corresponding
day in the month of adjustment, the last day of such month shall be treated as the corresponding day);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex4-12_007.jpg" ALT=""> Monthly
Adjustment. From the corresponding date of the corresponding month, the loan interest rate shall be adjusted, on the basis of the
LPR recently published, in accordance with the increased or decreased percentage points agreed herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <IMG SRC="ex4-12_008.jpg" ALT=""> Immediate
Adjustment. From the date immediately following the date of the LRP recently published, the loan interest rate shall be adjusted, on
the basis of the new LPR, in accordance with the increased or decreased percentage points agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Other
methods:_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower chooses the &ldquo;(2) floating
interest rate&rdquo; method, the monthly repayment amount of the Borrower will increase when the quoted interest rate (LPR) of the loan
market increases. If the Borrower still makes repayment according to the repayment amount before adjustment, the monthly repayment amount
will be insufficient, resulting in interest penalty and compound interest and affecting the credit record of the Borrower. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. Interest
Settlement Method </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower will settle the interest in a method
as described in following Item <U>(2) </U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Quarterly
Interest Settlement. The 20<SUP>th</SUP> day of the last month of each quarter shall be the interest settlement date, and the 21<SUP>st</SUP>
day shall be the interest payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Monthly
Interest Settlement. The 20<SUP>th</SUP> day of each month shall be the interest settlement date, and the 21<SUP>st</SUP> day shall be
the interest payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Other
methods:_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the repayment date of the last
installment of loan principal is not the interestpayment date, such repayment date of the last installment of loan principal shall be
the interest payment date on which the Borrower shall pay off all the interests payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. Penalty
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) In the event that the Borrower fails to repay
the loan within the agreed time limit, interest shall be calculated and charged over the overdue part at the penalty interest rate for
overdue loan from the overdue day, until the principal and interest are paid off;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) In
the event that the Borrower uses the loan for any purposes other than those agreed herein, interest shall be calculated and charged over
the misappropriated part at the penalty interest rate for misappropriated loan from the misappropriation date, until the principal and
interest are paid off;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) In
the event that the loan is overdue and misappropriated, interest shall be calculated and charged at the penalty interest rate for misappropriated
loan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) With
respect to the interest and penalty interest that the Borrower fails to pay as scheduled, compound interest shall be calculated and charged
at the penalty interest rate agreed in this paragraph in the interest settlement method as agreed in Paragraph 2 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) In
case of any adjustment to the loan interest rate agreed herein, the penalty interest and compound interest shall be calculated at the
adjusted interest rate from the adjustment date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Penalty
Interest Rate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The penalty interest rate for overdue loan shall
be <U>50</U>% higher than the loan interest rate agreed in Paragraph 1 hereof; the penalty interest rate for misappropriated loan shall
be <U>100</U>% higher than the loan interest rate agreed in Paragraph 1 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5 Loan Disbursement and Repayment
Account </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall open an account as follows
with the Lender as the loan disbursement and repayment account, which shall be used for loan disbursement, payment and repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bank of Deposit: <U>Luling Rural Commercial Bank
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Name: <U>Jiangxi Universe Pharmaceuticals
Commerce and Trade Co., Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Number: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6 Repayment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise agreed by the parties, the Borrower
shall repay the loan hereunder in accordance with the repayment schedule as set forth in Item <U>1</U> below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Repay
the loan hereunder in full upon the expiration of the loan term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Repay
the loan hereunder in accordance with the following repayment schedule:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">Repayment Time </FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">Repayment Amount </FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">4. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">5. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">6. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">7. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">8. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">9. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 42%; text-align: center; layout-grid-mode: char"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both">
</FONT><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="width: 49%; text-align: justify; layout-grid-mode: char">&nbsp;</TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Other
Repayment Schedule:__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Where
the Borrower makes repayment in advance, it shall obtain the consent from the Lender ____ banking days in advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7 Guarantee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The loan hereunder shall be a <U>credit</U>
(credit/guaranteed) loan. The guarantee type shall be <U>guarantee</U> (guarantee/mortgage/pledge), and the guarantee contract shall be
executed separately. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8 Contract Agreements on the Borrower&rsquo;s
Financial Indicators: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">N/A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 9 Dispute Resolution </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. After
this Contract takes effect, any dispute arising from the execution or performance hereof or in connection with this Contract shall be
settled by both parties through negotiation. If such negotiation fails, either party may file a lawsuit with the People&rsquo;s Court having
jurisdiction over the place of the Lender in accordance with the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. During
the dispute resolution, in the event that the dispute does not affect the performance of the remaining provisions of this Contract, such
remaining provisions shall continue to be performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. After
negotiation between the parties, the parties may conduct notarization for the compulsory enforcement of this Contract. The Borrower agrees
that this Contract shall have the compulsory enforcement effect after it is notarized. In the event that the Borrower fails to perform
its obligations under this Contract, the Lender may apply to the People&rsquo;s Court having jurisdiction for compulsory enforcement according
to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 10 Effectiveness of the Contract
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract shall take effect from the date
when both parties affix their signatures and seals hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract is made out in <U>triplicate</U>,
with the Borrower, the Lender and the Guarantor holding one counterpart <U>each</U>. Each counterpart shall have the same legal effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11 Other Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">N/A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chapter 2 Standard Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 12 Interest Calculation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
interest shall be calculated from the Borrower&rsquo;s actual withdrawal date and shall be calculated according to the actual withdrawal amount
and use days of loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest Formula: Interest = Principal &times;
Actual Days &times; Daily Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The daily interest rate is calculated on a base
of 360 days a year. Conversion Formula: Daily Interest Rate = Annual Interest Rate / 360.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 13 Loan Disbursement Conditions
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. The
Borrower must meet the following conditions for withdrawal, otherwise the Lender shall have no obligation to disburse any loan to the
Borrower, unless the Lender agrees to disburse the loan in advance: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The
Contract and its appendixes have become effective;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The
Borrower has reserved to the Lender the Borrower&rsquo;s documents, receipts, seals, lists of persons and specimen signatures in relation to
the execution and performance of this Contract and filled in the relevant vouchers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The
Borrower has, according to the Lender&rsquo;s requirements, opened an account necessary for the performance of this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) The
Borrower, within 3 banking days prior to the withdrawal, has submitted to the Lender the written withdrawal notice and the relevant supporting
documents for loan purpose which is consistent with the purpose as agreed herein, and has completed the relevant withdrawal procedures;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) The
Borrower has submitted to the Lender the resolution and letter of authorization of the board of directors or other competent authorities,
which agree to the execution and performance of this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) In
accordance with relevant regulatory provisions and management requirements of the Lender, if the loan exceeds a certain amount or meets
other conditions, the Lender shall, according to the Borrower&rsquo;s withdrawal application and payment authorization, pay the loan to the
payment object conforming to the purpose agreed herein in a manner of authorized payment by the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) In
addition to the credit loan, the Borrower has provided the corresponding guarantee as required by the Lender and has completed the relevant
guarantee procedures, and the guarantee is legal and valid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) The
Borrower has not breached this Contract or any other contracts executed by and between the Borrower and the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. In
the event that the Borrower fails to make any withdrawal for 3 consecutive months from the contract execution date, the Lender shall be
entitled to cancel the borrowing limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 14 Special Arrangements on Revolving
Loan (Maximum Loan) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. During
the term of revolving borrowing limit, the sum of the loan principal balance of at any time shall not exceed the revolving borrowing limit;
the repayment date of any withdrawal shall not exceed the term of revolving borrowing limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. As
agreed by both parties, the Lender shall reasonably set the amount and term of each revolving loan according to the scale and cycle of
the Borrower&rsquo;s production and operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 15 Loan Amount Payment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
authorized payment by the Lender means that the Lender pays the loan fund to the Borrower&rsquo;s counter-party in a transaction conforming
to the purpose agreed herein according to the Borrower&rsquo;s withdrawal notice and payment authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment of the Borrower&rsquo;s loan fund for which
the amount of a single payment under this Contract exceeds the specified amount shall be made in a manner of authorized payment by the
Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of the authorized payment by the
Lender, the Borrower shall make express payment authorization and provide other necessary payment information (including name of counterparty
who receives payment, account number of such counterparty, and amount of payment) in the withdrawal notice, and submit to the Lender the
supporting documents for loan purpose such as business contracts required for the examination. In this case, the Lender shall pay the
loan fund to the counterparty of the Borrower via the Borrower&rsquo;s account upon examination and approval. In the event of the Lender&rsquo;s failure
to perform its obligation to pay upon authorization resulting from untruthfulness, incorrectness, and incompleteness of the information
of payment authorization and relevant transactions furnished by the Borrower, the Lender shall not be held liable for such failure whatsoever
and the Borrower&rsquo;s obligation to repay under the Contract shall not be affected. The Lender will make payment to the account of the Borrower&rsquo;s
counter-party in accordance with the Borrower&rsquo;s withdrawal notice and the payment certificate as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Lender, upon examination,
discovers that the supporting documents for loan purpose such as business contracts furnished by the Borrower fail to comply with the
Contract or there is any other defects, the Lender shall be entitled to request the Borrower to supplement, replace, explain or re-furnish
such documents, and the Lender may suspend granting or paying of such loans until the Borrower has furnished the supporting documents
such as business contracts to the satisfaction of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the account-holding bank of
the counterparty returns such payments, resulting in the Lender&rsquo;s failure to transfer such loans to the Borrower&rsquo;s counterparty as authorized
by the Borrower in a timely manner, the Lender shall not be liable for such failure whatsoever and the Borrower&rsquo;s obligation to repay
under the Contract shall not be affected. With respect to the funds returned by the account-holding bank of the counterparty, the Borrower
shall re-furnish the payment authorization and the supporting documents for loan purpose such as business contracts required for the examination,
and the Lender shall pay the loan fund to the counterparty of the Borrower via the Borrower&rsquo;s account upon examination and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All the expenses incurred by the payment of loan
to the counterparty designated by the Borrower in a manner of authorized payment under this Contract shall be borne by the Borrower. The
Borrower shall pay the above expenses to the Lender at the time of the authorized payment of each loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall not violate the above provisions
to dodge the authorized payment by the Lender by way of breaking up a large amount into several small amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Except
for the cases where the authorized payment by the Lender must be adopted as stipulated in the preceding paragraph, unless otherwise agreed
by both parties, payment of other loans shall be made by the Borrower itself, namely, after the Lender disburses the loans to the Borrower&rsquo;s
account pursuant to the withdrawal application submitted by the Borrower, the Borrower pay by itself to the its counterparty that complies
with the purpose as agreed in the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Borrower needs to change
the aforesaid repayment schedule, it shall submit a written application to the Lender 10 banking days prior to the maturity date of the
loan, and the changed repayment schedule is subject to the written confirmation by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. In
the event that the Borrower needs to extend the loan term agreed herein, it shall submit a written application of extension to the Lender
30 banking days prior to the maturity date of the loan, and the Lender shall decide whether to approve the extension. In applying for
the extension of a guaranteed loan, mortgage loan or pledged loan, the guarantor, mortgagor or pledgor shall also issue a written certificate
of approval. the parties shall enter into a renewal agreement after the Lender approves the extension. In the event that the Borrower&rsquo;s
application for extension is not approved by the Lender, the Borrower shall still repay the loan in full according to the repayment term
agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4. Unless
otherwise agreed by the Parties, if both the principal and the interests are overdue by the Borrower, the Lender shall be entitled to
decide on the sequences for repaying the principal or the interests; under the condition of installment repayment, if several mature installments
and overdue installments exist under this Contract, the Lender shall be entitled to decide the sequences of repayment; if several outstanding
loan contracts exist between the Parties, the Lender shall be entitled to decide the sequences for repaying any contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The
Borrower shall repay the loan principal, interests and other amounts payable in full and on time according to provisions stated herein.
The Borrower shall, before the end of counter business on the repayment date and each interest settlement date, deposit in full the current
interests, principal and other amounts payable to the repayment account opened with the Lender, and the Borrower shall authorize the Lender
to collect the funds on the repayment date or the interest settlement date or the Borrower shall be required to cooperate in handling
the relevant transfer procedures. In the event that the amount in the repayment account is insufficient to pay the full amount due from
the Borrower, the Borrower shall agree that Lender is entitled to decide the sequences for repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. The
Lender shall be entitled to collect the loan in advance on the basis of the capital withdrawal of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. Loan
Note: The loan note shall be an integral part of this Contract. In the event that there is no record in this Contract, or the loan amount,
withdrawal amount, repayment amount, borrow date and maturity date of the loan, loan term, loan interest rate and loan purpose as recorded
in this Contract is inconsistent with those recorded in the loan note, the loan note shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 16 Guarantee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that any event occurs to the Borrower
or the guarantor, and causes the Lender to believe that it may affect the performing capability of the Borrower or the guarantor; or the
guarantee contracts are deemed as invalid, canceled or resolved; or the performing capability of the Borrower or guarantor may be affected
due to the deterioration in their financial condition or that the Borrower and the guarantor are involved in substantial lawsuit or arbitration
or other reasons; or the guarantor breaches the guarantee contracts or other contracts with the Lender; or the collateral value decreases
or gets lost due to the devaluation, damage, lost or sequestration of the collateral; the Lender shall be entitled to require, and the
Borrower shall have the obligation to provide new guarantee, supplement or replace the guarantor to guarantee the liabilities under this
Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 17 Representations and Undertakings
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
Borrower is a legal entity incorporated, registered and existing under the administration for industry and commerce or other competent
authorities and has full capacity of civil rights and conduct to conclude and perform the Contract, and capacity of loan repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. The
Borrower fully agrees to the contents and terms of this Contract, executes and performs this Contract out of true intention, has obtained
all legal and valid authorizations required by the Borrower&rsquo;s Articles of Association and bylaws, and will not be in violation of any
agreement, contract, or other legal documents with binding force to the Borrower. The Borrower has obtained or will obtain all the required
approval, consent, documentation or registration for executing and performing this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. The
Borrower is in good faith and all the documents, financial statements, certifications and other information provided by the Borrower to
the Lender under this Contract are true, complete, accurate and valid, and free from false records, material omissions or misleading statements.
The financial and accounting reports provided to the Lender are prepared in accordance with Chinese accounting standards, and truly, fairly
and completely present the Borrower&rsquo;s operating and liability condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The
transaction background that the Borrower represents to the Lender is real and legal, not for any illegal purposes such as money laundering.
The loan purpose and the source of repayment are clear and legal. The loan purpose and the source of repayment are clear and legal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The
Borrower has a good credit status, does not have material bad credit record, and does not conceal from the Lender any fact that may affect
the Borrower&rsquo;s and the Guarantor&rsquo;s financial condition and performance capability. The Borrower does not conceal from the Lender any litigation,
arbitration or claim in which it is involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. The
Borrower has repaid other debts payable as scheduled and has not maliciously defaulted on the payment of principal and interest of the
bank loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7. The
Borrower shall withdraw and use the loan in accordance with the term and purpose agreed herein. The loan borrowed hereunder shall neither
be used for the investment in fixed asset and equity and other investments, nor flow into the securities market or the futures market
in any form, or be used for other purposes prohibited or restricted by relevant laws and regulations. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8. The
Borrower shall deliver its financial statements (including but not limited to annual, quarterly and monthly reports) and other relevant
documents to the Lender on a regularly and timely basis in accordance with the requirements of the Lender; the Borrower shall ensure that
the financial indicators will comply with the Contract all the time. If the production and operation qualification/license is subject
to the annual audit, such qualification/license will pass the annual examination as scheduled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9. The
Borrower shall withdraw, repay and use the loan as stipulated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10. If
the Borrower has executed or will execute with the guarantor under this Contract a counter-guarantee agreement or similar agreement regarding
its guarantee obligations, this counter-guarantee agreement or similar agreement will not prejudice any Lender&rsquo;s right under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11. The
Borrower shall accept the credit inspection and supervision conducted by the Lender, and provide sufficient assistance and cooperation;
from the effective date of this Contract and prior to discharge of the principal and interests and related expenses hereunder, the Borrower
agrees and authorizes the Lender to monitor the account opened with the Lender, examine and analyze the Borrower&rsquo;s production and operation
(including but not limited to the construction and operation of the Borrower&rsquo;s projects), and make dynamic monitoring on the income cash
flow and overall fund flow of the Borrower; the Borrower shall accept and actively cooperate with the examination and supervision made
by the Lender on the usage of the loan funds including the loan purpose by account analysis, proof inspection and site investigation,
and make summary report in a periodic manner as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>12. The
Borrower&rsquo;s merger, division, decrease of capital, equity transfer, external investment, substantial increase of debt financing, transfer
of material assets and claims and other events which may have adverse effect on the solvency of the Borrower shall be subject to the written
consent of the Lender. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall give a notice to the Lender
within <U>7</U> days after it becomes or should have become aware of any of the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Change
of the Articles of Association, business scope, registered capital, legal representative of the Borrower or the guarantor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Change
of management mode such as joint management in any form, cooperation with foreign enterprises, cooperation, contracting management, reorganization,
reform and planned listing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Involved
in material litigation or arbitration cases, sequestration, attachment or supervision of properties or collateral, or establishment of
new material liabilities on the collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Winding
up, dissolution, liquidation, stopping business for rectification, cancellation, revocation of business license, (applied for) applying
for bankruptcy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Shareholders,
directors and current senior managers are suspected of being involved in material cases or economic disputes; or the legal representative/person
in charge and current senior executives are found to be in bad health or other material conditions that the they are unqualified for their
job;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Events
of default by the Borrower under other contracts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) Difficulty
in business operation and deterioration of financial position;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) In
the event that the Borrower is closed, suspended, merged or changes the line of production due to change, restructuring and contracting
or with the approval of the competent departments, the Borrower undertakes to give a notice to the Lender in writing within one month
prior to the occurrence of the above events and to discharge all debts owed to the Lender immediately. Subject to the consent of the Lender,
the Borrower may transfer the debts to the receiving entity or the newly incorporated entity (The Borrower shall, in the process of debt
transfer, present and submit to the Lender the documents issued by its competent authority or the contract-issuing party or relevant documents);
however, the debt receiving entity must execute a new loan contract with Lender and submit a written certificate of the corresponding
guarantor&rsquo;s approval or implement new guarantee measures, and before the execution of the new contract, the Lender shall have the right
to recover the debts from the Borrower, the Guarantor or the Borrower&rsquo;s receiver at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13. Liquidation
of the debts owed by the Borrower to the Lender shall have priority to the loan extended by the shareholders of the Borrower, and precede
the debts of the same kind owed by the Borrower to other creditors. In addition, from the effectiveness of the Contract to the time when
all the principal, interests and relative fees under the Contract are paid off, the Borrower shall not return the loan from its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>14.</B> In
respect of the loan hereunder, the loan conditions such as guarantee conditions, loan rate pricing, discharge sequence provided by the
Borrower for the Lender shall be no less than the current or future conditions provided for any other financial institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>15. The
Borrower shall bear the expenses incurred in connection with the execution and performance of this Contract and the expenses paid and
payable by the Lender for realization of its creditor&rsquo;s right hereunder, including but not limited to litigation or arbitration fees,
property preservation costs, attorney fees, enforcement fees, evaluation fees, auction fees, and announcement fees. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>16. Account
Management </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The
repayment account opened by the Borrower with the Lender (the account stipulated in Article 5) is a special capital withdrawal account,
which is used to collect the corresponding sales revenue or the planned repayment fund. Where the corresponding sales revenue is settled
in a non-cash manner, the Borrower shall ensure that it will be promptly transferred into the capital withdrawal account upon receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The
Lender shall have the right to supervise the capital withdrawal account, including but not limited to the understanding and supervision
of the fund income and expenditure of the account, and the Borrower shall provide relevant cooperation. At the request of the Lender,
the Borrower shall execute a special account supervision agreement with the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17. The
Borrower shall dispose the assets in a manner that will not reduce its repayment capability. Then Borrower undertakes that the total amount
of the Borrower&rsquo;s external guarantee is equal to or less than _____ times of its net asset, and the total amount of external guarantee
as well as the amount of a single guarantee may not exceed the limit as stipulated in its Articles of Association; without the consent
of the Lender, the Borrower shall not provide guarantee to any third party or the loans borrowed by the Borrower from any other financial
institution with the assets formed by the loans under the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 18 the Related-party Transaction
within the Borrower </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744; 1. The Borrower is not identified by
the Lender as the group client in accordance with the <I>Guidelines on the Management of Risks of Credits Granted by Commercial
Banks to Group Clients</I> (hereinafter referred to the &ldquo;Guidelines&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744; 2. If the Borrower is identified by
the Lender as the group client in accordance with the Guidelines, it shall report to the Lender any of the related-party transaction
in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744; 3. The Borrower is subject to such
events as major merger, acquisition or reorganization, which in the opinion of the Lender may affect the safety of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 19 Breach of Contract and Settlement
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
Borrower shall constitute or be deemed to have breached the Contract and shall be liable for breach of contract under any of the following
circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The
Borrower fails to perform the obligations of payment and liquidation to the Lender according to the stipulations of the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The
Borrower fails to use the loan in a purpose and way stipulated in this Contract or fails to use the loan borrowed hereunder for the purpose
stipulated in the Contract; or the Borrower fails to go through the withdrawal procedures as scheduled according to the withdrawal plan,
or changes the withdrawal plan without the Lender&rsquo;s consent; or the Borrower is in violation of this Contract and dodges the authorized
payment by the Lender by way of breaking up a large amount into several small amounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The
Borrower provides an untrue representation or violates the undertaking it made in this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) If
any circumstance under Subparagraph 12 of Article 17 arises, and the Lender believes that may affect the financial condition and performing
capability of the Borrower or guarantor, but the Borrower refuses to provide new guarantee or change a guarantor according to this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) The
Borrower violates any stipulation under any other contract between the Borrower and the Lender; the Borrower violates any stipulation
under any Credit Extension Contract between the Borrower and any other financial institution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) The
guarantor violates the stipulations of the guarantee contract, or any default events arise under other contract between the guarantor
and the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) The
Borrower closes down or is dissolved, withdraw or bankrupted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) Where
the Borrower involves in or possibly involves in material economic disputes, litigation, arbitration, or its capital is sealed up, seized
or enforced for execution, or the administrative organs such as judicial organs or taxation authorities, and industrial and commercial
administration file for investigation or adopt punishment measures on the Borrower according to law which has influenced or may influence
the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9) Where
the main individual investors and key managerial personnel of the Borrower are changed abnormally, disappear or are investigated or the
personal freedom thereof is limited by judicial organs according to law which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(10) Where
the credit circumstances of the Borrower lowers or finance indexes of the Borrower such as profitability, debt-paying ability, operating
capacity and cash flow seriously deteriorate and break through the index binding of this Contract or other financial agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(11) The
Borrower takes advantage of the false contracts between the Borrower and the affiliated party to obtain funds or credit from the Lender
through transactions without true transaction background, and the affiliated party is subject to such events as major merger, acquisition
or reorganization which in the opinion of the Lender may affect the safety of the loan; or the Borrower intends to evade the creditor&rsquo;s
right of the Lender through related-party transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12) The
Borrower causes any liability accident due to its violation of food safety, production safety, environmental protection and other relevant
laws and regulations, regulatory provisions or industrial standards which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(13) In
the event that the loan under this Contract is granted on the basis of credit rating, the Borrower&rsquo;s credit rating, profitability, asset-liability
ratio, net cash flow from operating activities and other indicators do not meet the Lender&rsquo;s credit loan conditions; or the Borrower,
without the written consent of the Lender, establishes mortgage/pledge guarantee or provide guarantee to others with its valid operating
assets, which has influenced or may influence the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(14) Other
circumstances that may have adverse effect on the realization of the creditor&rsquo;s rights of the Lender under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. When
the aforesaid breaches arise, as the case maybe, the Borrower agrees that the Lender may take following measures respectively or simultaneously:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Require
the Borrower and guarantor to rectify their breach within time limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Decrease,
suspend or terminate all or part of the credit lines of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Suspend
or terminate all or part of the business application (such as withdrawal) of the Borrower under this Contract or other contracts between
the Borrower and the Lender; partly or totally suspend or cancel to issue, pay and transact the unissued loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Declare
that all or part of the outstanding principal and interest of the loan and other amounts payable of the Borrower under this Contract and
other contracts between the Borrower and the Lender shall become due immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Negotiate
with the Borrower to supplement the terms of loan issuance and payment; or the Lender shall have the right to change the loan disbursement
and payment conditions in accordance with the credit status of the Borrower such as lowering the minimum amount of authorized payment
of the Borrower; or the Lender shall have the right to transfer back the loan fund which the Borrower has paid for default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Terminate
or dissolve this Contract, partly or totally terminate or dissolve other contracts between the Borrower and the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) Require
the Borrower to compensate the Lender for the Lender&rsquo;s loss caused by the Borrower&rsquo;s default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) With
only prior or subsequent notice, <B>the Borrower has the right to directly deduct funds from any account funds in the Rural Commercial
Bank system within the jurisdiction of Jiangxi to pay off the principal and interest of the loan, and the undue deposit in the account
shall be deemed to become due in advance. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9) Exercise
security interest; and require the guarantor to take guarantee responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(10) In
the event that the Borrower fails to repay the principal, interest (including penalty interest and compound interest) or other amounts
payable as scheduled, the Lender may disclose the default information of the Borrower and the Guarantor and make announcement for collection
in public media such as television, newspaper, Internet or other forms. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(11) Have
the right to deduct and debit the deposits and dividends within any account opened by the Borrower in the Rural Commercial Bank system
within the jurisdiction of Jiangxi, and to dispose of the Borrower&rsquo;s equities. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12) Other
measures stipulated by laws and regulations and deemed necessary and possible by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 20 Reservation of Rights </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any failure by a party to exercise all or part
of its rights hereunder or to require the other party to perform or assume all or part of obligations or responsibilities shall not constitute
a waiver of such rights or release of the obligations and responsibilities of such party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any tolerance, grace or postponement for exercising
the rights under this Contract of one Party shall not affect its rights stipulated by this Contract, laws and regulations, and shall not
be deemed as a waiver of such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 21 Confidentiality </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each party undertakes to keep confidential the
trade secrets, technical information, business information and other business secrets obtained from the other party which are not available
through public channels. Without the consent of the original provider of the trade secret, neither party shall disclose all or part of
the trade secret to any third party, unless otherwise stipulated by laws and regulations or otherwise agreed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that either party is in violation
of the aforesaid confidentiality obligation, it shall assume the corresponding liability for breach of contract and compensate for the
losses caused thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 20 Force Majeure </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term Force Majeure as specified in this Contract
refers to the objective events that cannot be foreseen, overcome, or avoided and have a significant impact on one party, including but
not limited to the natural disasters such as flood, earthquake, fire and storm, as well as the social events such as war and turmoil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Contract cannot be performed
as a result of the occurrence of force majeure events, the party affected by the force majeure shall immediately notify the other party
of the event in writing, and within 7 days, provide written documents certifying the details of such force majeure event and the reasons
for non-performance or delay in performance hereof. Upon consensus through negotiation, the parties may terminate or temporarily delay
the performance of the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 23 Alteration, Amendment and Termination
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract can be altered and amended in written
form upon consensus through negotiation of the Parties, and any alternation and amendment shall constitute an integral part of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract may not be terminated until all
the rights and obligations are fully preformed, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The invalidity of any provision of this Contract
shall not affect the legal validity of other provisions, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 24 Agreements on Service </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
contact information (including mailing address, telephone number, fax number, etc.) provided by the Borrower in this Contract shall be
true and valid and shall be the address for service of any notice of the Lender for the Borrower. In case of any change to the contact
information, the Borrower shall immediately send/mail the change information in writing to the mailing address provided by the Lender
in this Contract. Such information change shall become effective upon the Lender&rsquo;s receipt of the change notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Unless
otherwise expressly provided for in this Contract, the Lender shall be entitled to give notice to the Borrower in any of the following
methods. The Lender shall be entitled to choose the notification method as it thinks fit and shall not be held liable for any error, omission
or delay in delivery by mail, fax, telephone, WeChat or any other communication system. Where the Lender simultaneously chooses several
notification methods, the one by which the notice is served to the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) By
announcement. The notice shall be deemed to be served on the date on which the Lender publishes the announcement on its website, online
banking, telephone banking or business outlets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) By
hand. The notice shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower refuses to sign
for the receipt, the date on which the server makes a record on the proof of service on the spot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) By
mail (including express mail, surface mail or registered mail). The notice, when addressed to the Borrower&rsquo;s mailing address last known
to the Lender, shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower fails to sign
for the receipt, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) By
fax, mobile phone SMS, WeChat or other electronic communication methods. The notice, when sent to the Borrower&rsquo;s fax number, the mobile
phone number, WeChat account number or email address designated by the Borrower which is last known to the Lender, shall be deemed to
be served on the date on which the notice is sent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Borrower
agrees that, unless the Lender receives from the Borrower a written notice concerning the change of mailing address, the Borrower&rsquo;s domicile
stated in this Contract is the correspondence and contact address. In the future, the delivery addresses of bank statements, collection
statements, relevant legal instruments and litigation documents related to the loans under this Contract shall prevail. The Borrower promises
to notify the Lender in time when the communication and contact information change, otherwise the documents delivered by the Lender according
to the communication and contact information stated in this Contract will be effectively delivered, and the relevant economic and legal
responsibilities arising therefrom will be borne by the Borrower and the Mortgagor. During the dispute settlement, if the court serves
the judicial documents or other written documents by mail (including express mail, surface mail or registered mail) to the Borrower mailing
address last known to the Lender, such documents shall be deemed to be served on the date on which the Borrower signs for receipt of the
proof of service; or if Borrower fails to sign for receipt of the proof of service, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The court or notary organ shall be entitled to
give any notice to the Borrower by any methods of communication agreed in this Paragraph 2. The court or notary organ shall be entitled
to choose the communication method as it thinks fit and shall not be held liable for any error, omission or delay in delivery by mail,
fax, telephone, telex or any other communication system. Where the court or notary organ simultaneously chooses several communication
methods, the one by which the notice is served on the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 25 Appendix </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The appendixes confirmed by both parties shall
constitute an integral part of this Contract and shall have the same legal effect as this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 26 Other Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
Borrower shall not transfer any rights and obligations under this Contract to the third party without written consent of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. The
Lender has the right to transfer the creditor&rsquo;s rights under this Contract to the third party, and shall notify the Borrower. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. This
Contract shall be legally binding upon both Parties and their successors and assignees without prejudice to other provisions of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. All
the transactions under this Contract are carried out for each Party&rsquo;s independent benefits. If, in accordance with relevant laws, regulations
and regulatory provisions, other parties to the transaction become the related parties or affiliated persons of the Lender, no Party may
seek to affect the fairness of the transaction out of this related-party relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The
headings and business names in this Contract are used only for convenient reference, which shall not be used to interpret the provisions
or the rights and obligations of both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. In
accordance with relevant laws, regulations and regulatory provisions, the Lender shall have the right to provide the information related
to this Contract and other relevant information of the Borrower to the credit reference system of the People&rsquo;s Bank of China and other
credit information database established according to law for reference and use by the institutions or individuals with proper qualification
according to law. The Lender shall also have the right to refer the relevant information of the Borrower through credit reference system
of the People&rsquo;s Bank of China and other credit information database established according to law for the purpose of the execution and
performance of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The parties acknowledge that the Borrower and
the Lender have made a full negotiation in connection with all the terms of this Contract. The Lender has requested the Borrower to give
special attention to and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the
parties, and has made explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood
all the contents and provisions of the Contract. The Borrower confirms that there is no misunderstanding or doubt about all the contents
and terms of the Contract. Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract
and have no objection to the contents and provisions of the Contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Borrower and the Lender have made a full
negotiation in connection with all the provisions of this Contract. The Lender has requested the Borrower to give special attention to
and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the parties, and has made
explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood all the contents
and provisions of the Contract. The Borrower confirms that there is no misunderstanding or doubt about all the contents and terms of the
Contract. Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract and have no objection
to the contents and provisions of the Contract. (The Borrower shall fill in the following by contrast) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(The remainder of this page is intentionally left
blank for signatures)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex4-12_009.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">20</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.13
<SEQUENCE>4
<FILENAME>f20f2021ex4-13_universephar.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE REAL ESTATE PROPERTY PURCHASE AGREEMENT ENTERED INTO BY AND BETWEEN JIANGXI UNIVERSE AND JIANGXI YUESHANG INVESTMENT CO., LTD., DATED MAY 16, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.13</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Real Estate Property Purchase Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party A: Jiangxi Yueshang Investment Co., Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unified Social Credit Code:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative: Huang Baohua</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: 1/F, Jianshe Building, No. 6, Ji&rsquo;an South
Avenue, Ji&rsquo;an</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B: Jiangxi Universe Pharmaceuticals Co.,
Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Social Unified Code:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative: LAI Gang</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: No. 265, Jingjiu Avenue, Jinggangshan
Economic and Technological Development Zone, Ji&rsquo;an, Jiangxi</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the resolution of the Board of Directors
of Ji&rsquo;an Guangdong Chamber of Commerce on December 28, 2010 and the resolution of the sponsors of Jiangxi Yueshang Investment Co., Ltd.
on May 6, 2011 (Resolution IV), some real estate is provided for internal subscription by members. After negotiation, both parties hereby
enter into the Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1:</B> Party A develops &ldquo;Yueshang
Building&rdquo; (tentative name) located at the junction of Jinggangshan Avenue and Ji&rsquo;an South Avenue, which is tentatively scheduled
to be delivered for use on June 1, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2:</B> Party B is a member of Ji&rsquo;an
Guangdong Chamber of Commerce, who is eligible to purchase the property of the Building and sign the Agreement only after written confirmation
by Ji&rsquo;an Guangdong Chamber of Commerce or provision of the payment certificate of membership fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3: Property Purchased </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Party B voluntarily orders &ldquo;Yueshang Building&rdquo;
from Party A: 1. Apartment: F<U>23</U>; No.: <U>2309-2313 and 2315-2316</U>, 2. Commercial office: F<U>23</U>; No.: <U>2301 and 2302</U>,
with an area of about 2749.30 square meters (including room building area and shared area between public parts and public premises, which
shall be subject to the surveying and mapping area of the Housing Authority and Housing Department).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4   Sales Price and Purchase Price
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unit price and total price of the above real
estate are detailed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 13%; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Floor </B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 25%; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Selected property No. </B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 12%; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Floor area <BR>
(m<SUP>2</SUP>) </B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 16%; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Unit price after discount <BR>
(CNY/m<SUP>2</SUP>) </B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 16%; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Total price <BR>
after discount<BR>
 (CNY/m<SUP>2</SUP>) </B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 18%; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Total price to be<BR>
 actually paid<BR>
 (CNY) </B></FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">F23 </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">2309-2313, 2315, 2316, <BR>
2301, 2310, 2310 and <BR>
2311 </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">2749.30</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">CNY 11,640/m<SUP>2 </SUP></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">32001852.00</FONT></TD>
    <TD STYLE="border: Black 1pt solid; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">32000000.00</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; width: 36%; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">Total price of premise to be actually paid </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; width: 64%; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; layout-grid-mode: char">&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">CNY Thirty Two Million only </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Jiangxi Yueshang Investment Corp. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The price is only the premise purchase price,
excluding the interior decoration fees as well as taxes, fees and other taxes required for handling the property right certificate. According
to the spirit of the <I>Report of Ji&rsquo;an Municipal People&rsquo;s Government Office</I> (JFBC [2015] No. 104), 70% of premises selected in the
Agreement shall not be sold the outside. The property owners who hold the property right for the first time for no less than 5 years can
transfer the property right among the members of the Chamber of Commerce (Association) without changing the property as the economic purpose
of the headquarters and in line with the industrial development plan of Luling New Area, and the time for handling the property right
certificate shall be subject to the time finally approved by the government department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5: Determination of Payment Method:
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>1. 50% in advance, i.e. CNY sixteen million
only; 2. 20% in advance, i.e. RMB six million four hundred thousand only for the materials submitted for handling the property right certificate;
3. 30% of the balance payment of the delivered property right certificate, i.e. CNY nine million six hundred thousand only. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6: Determination of Building Area and
Premise Purchase Price: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the construction area of the commercial residential
building agreed in this Contract is inconsistent with that registered on the property ownership certificate issued by the Municipal Property
Management Department, the construction area registered on the property ownership certificate by the Property Management Department shall
prevail; The purchase price shall be recalculated according to the sales price agreed in this Contract and the construction area registered
by the Property Management Department on the property ownership certificate, and refund for any over payment or a supplemental payment
for any deficiency shall be conducted according to the facts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7:</B> The unit price and total price
of the property subscribed in the Agreement are only the purchase price, so the taxes and fees for handling the property ownership certificate
and land certificate shall be borne by the Buyer. If the Buyer fails to obtain the property ownership certificate in time due to the registration
authority or the Buyer, the Seller shall not bear any responsibility. If Party B purchases the premise by means of personal or corporate
mortgage loan (installment), the amount and term of commercial bank loan applied by Party B shall be subject to the final approval of
the bank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8:</B> If Party B violates the following
agreements, Party A has the right to ask Party B to pay 0.06% for the overdue payment to Party A as liquidated damages on a daily basis,
or unilaterally terminate this subscription agreement and sell the property separately. However, the deposit paid by Party B will not
be refunded, and the rest of the payment will be returned to Party B without interest:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Party B fails to pay in accordance with Article 5 of the Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 9:</B> Party A shall send the premise
delivery notice and other relevant notices related to the premise by registered mail or telephone according to the telephone contact information
and mailing address provided by Party B under the Agreement and it shall be deemed that they have been delivered within 15 days from the
date of sending. Besides, the property management fee shall be calculated from the second day of the deadline for delivery specified in
the premise delivery notice. If Party B fails to notify Party A in writing of any change, the responsibility shall be borne by Party B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Jiangxi Yueshang Investment Corp. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 10: Special Agreement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.
After signing the <I>Internal Purchase Agreement</I>, if the Buyer needs to change, the Buyer shall provide relevant proof of relationship
with the Buyer (such as household register or marriage certificate) and obtain the consent of the Company. If the relevant proof of relationship
cannot be provided, the Buyer shall pay a handling fee of CNY 5,000 to the Company each time before the change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. As
for the position of the property purchased by Party B, Party B shall be provided with the relevant procedures (according to the property
number of Party A) (Party B and Party A shall sign a supplementary contract to confirm the position range, area and delivery time of the
property). Party A may sell or resell the property purchased by Party B on the premise of obtaining party B&rsquo;s prior approval (in writing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. The
contact information and address provided by Party B in this Purchase Agreement are the basis for Party A to contact Party B, and Party
B shall ensure the accuracy of the information provided. If Party A fails to contact Party B with the contact information provided by
Party B, any adverse consequences arising therefrom shall be borne by Party B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Party
A shall not sell the property in violation of this Agreement, otherwise, Party A shall compensate Party B for its losses in accordance
with relevant national laws and regulations and pay party B the proceeds from the sale of the property and the relevant economic losses
within three days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11 </B>This Agreement is made in
duplicate, one for each party. Each copy shall have equal legal effect. Other matters not mentioned in the Agreement shall be settled
by the parties through negotiation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 52%; text-align: justify; layout-grid-mode: char">Party A: Jiangxi Yueshang Investment Co., Ltd.</TD>
    <TD STYLE="width: 48%; text-align: justify; layout-grid-mode: char">Party B: Jiangxi Universe Pharmaceuticals Co., Ltd.</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; layout-grid-mode: char">&nbsp;</TD>
    <TD STYLE="text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; layout-grid-mode: char">Legal Representative: Huang Baohua (signature)</TD>
    <TD STYLE="text-align: justify; layout-grid-mode: char">Entrusted Agent: Yang Lin (signature) </TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; layout-grid-mode: char">&nbsp;</TD>
    <TD STYLE="text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; layout-grid-mode: char">May 6, 2021</TD>
    <TD STYLE="text-align: justify; layout-grid-mode: char">May 6, 2021</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; layout-grid-mode: char">&nbsp;</TD>
    <TD STYLE="text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; layout-grid-mode: char">&nbsp;<IMG SRC="ex4-13_001.jpg" ALT=""></TD>
    <TD STYLE="text-align: right; layout-grid-mode: char"><IMG SRC="ex4-13_002.jpg" ALT="">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Jiangxi Yueshang Investment Corp. 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.14
<SEQUENCE>5
<FILENAME>f20f2021ex4-14_universephar.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE WORKING CAPITAL LOAN CONTRACT ENTERED INTO BY AND BETWEEN JIANGXI UNIVERSE AND JIANGXI LIULING RURAL COMMERCIAL BANK CO., LTD., DATED JUNE 16, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.14</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2021] L.L.N.S.H.L.J.Z. No.: <U>17229202106161003001
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Working Capital Loan Contract </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower <I><U>Jiangxi Universe Pharmaceuticals
Co., Ltd. </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lender <I><U>Jiangxi Luling Rural Commercial
Bank Co., Ltd. </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-top: 6pt; padding-bottom: 6pt; text-align: justify; layout-grid-mode: char; font-size: 10pt"><IMG SRC="ex4-14_001.jpg" ALT=""></TD>
    <TD STYLE="width: 90%; padding-top: 6pt; padding-bottom: 6pt; text-align: justify; layout-grid-mode: char; font-size: 10pt"><FONT STYLE="font-size: 12pt"><B>Jiangxi Rural Commercial Bank</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special Notice: In order to protect the legitimate
rights and interests of the Borrower, the Lender hereby requests the Borrower to give full attention to all provisions concerning the
rights and obligations of the parties, especially those shown in bold. If the Borrower has any objection, it shall raise the objection
to the Lender. Otherwise, after this Contract is entered into by and between the Borrower and the Lender, all the terms and conditions
herein represent the true intention of both parties, are protected by law and shall be legally binding on both parties herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Working Capital Loan Contract </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">[2021] L.L.N.S.H.L.J.Z. No.: <U>17229202106161003001</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower: <U>Jiangxi Universe Pharmaceutical Co.,
Ltd.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business License No.: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative / Person in Charge: <U>LAI
Gang &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business Address: <U>Jingjiu Avenue, Jinggangshan
Economic and Technological Development Zone, Ji&rsquo;an County &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mailing Address: <U>The same as above &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Postal Code: <U>343100
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
Tel.: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Electronic Contact Information (Email and WeChat
Account No.):  </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lender: <U>Jiangxi Luling Rural Commercial Bank
Co., Ltd.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Representative / Person in Charge:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business Address: <U>No. 205, Fuchuan Road, Ji&rsquo;an
County&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Postal Code: <U>343100 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel.:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>
Fax:<U>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the laws and regulations of the People&rsquo;s
Republic of China and other relevant regulations, the Borrower and the Lender have reached an agreement with respect to the matter that
the Lender grants a working capital loan to the Borrower, and hereby execute this Contract by consensus, which shall be binding on both
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chapter 1 Execution Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1 Loan Amount and Currency </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loan Amount (in words): <U>CNY Ten Million. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(In Figures) <U>CNY 10,000,000.00. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan amount under this Contract is: &#9744;<FONT STYLE="font-family: Wingdings 2"></FONT>revolving
borrowing limit <FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT>non-revolving loan amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2 Loan Term </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valid loan term under this Contract shall
be: <U>12</U> months from <U>June 16</U>, <U>2021</U> to <U>June 15</U>, <U>2022</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2"></FONT>&#9744;</TD><TD STYLE="text-align: justify">In the event that the loan amount hereunder is a revolving
borrowing limit, the term of borrowing limit shall be the same as the valid loan term as agreed herein. The term of each loan shall be
subject to the term recorded in the loan note.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&thorn;</FONT></TD><TD STYLE="text-align: justify">In the event that the loan amount hereunder is a non-revolving
borrowing limit, the loan term shall be the same as the valid loan term as agreed herein. The specific loan term shall be subject to
the term recorded in the loan note.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower has any default circumstance
listed in Article 19 of this Contract, and the Borrower agrees that the Lender may recover the loan in advance, then the Lender may announce
that the date of recovering the loan in advance is the due date of the loan. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3 Loan Purpose </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan borrowed hereunder shall be used for
turnover of working <U>capital</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without the written consent of the Lender, the
Borrower may neither change the loan purpose nor use the loan for any other purposes. The Lender shall have the right to supervise the
Borrower&rsquo;s use of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4 Loan Interest Rate, Interest Calculation
and Settlement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. Loan
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The method as described in following Item <U>(1)</U>
shall apply for the determination of loan interest rate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>(1)</B> <B>Fixed Interest Rate. The annual interest rate shall be <U>4.81</U>%.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan prime rate (LPR) recently published
on <FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT> the date of signature hereof &#9744; withdrawal date for ___ years&rsquo; loan, which is
3.85, and <FONT STYLE="font-family: Wingdings 2"><FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT>increased percentage points &#9744;decreased percentage points, which is <U>96</U>
bp (1bp = 0.01%). The annual interest rate shall be <U>4.81</U>%. The interest rate shall remain unchanged during the loan term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>(2)</B> <B>Floating Interest Rate.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan interest rate shall be determined
by the loan prime rate (LPR) recently published on the working day before the withdrawal date for _____ years&rsquo; loan and
&#9744;increased percentage points &#9744;decreased percentage points, which is ____ bp. <B>The increased or decreased percentage
points shall remain unchanged during the term of this Contract. In case of any adjustment to the LPR, its loan interest rate
determination method shall be handled according to the following Item </B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><B>
and the Lender will not give a further notice to the Borrower: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Annual Adjustment. From January 1 of the next year, the loan
interest rate shall be adjusted, on the basis of the LPR recently published, in accordance with the increased or decreased percentage
points agreed herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Annual Adjustment. From the corresponding date of the corresponding
month in the corresponding year, the loan interest rate shall be adjusted, on the basis of the LPR recently published, in accordance
with the increased or decreased percentage points agreed herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Quarterly Adjustment. From the corresponding date of the
first month in the corresponding quarter, the loan interest rate shall be adjusted, on the basis of the LPR recently published, in accordance
with the increased or decreased percentage points agreed herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Quarterly Adjustment. From the first day of the first month
in the corresponding quarter, the loan interest rate shall be adjusted, on the basis of the LPR recently published, in accordance with
the increased or decreased percentage points agreed herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Monthly Adjustment. From the corresponding date of the corresponding
month, the loan interest rate shall be adjusted, on the basis of the LPR recently published, in accordance with the increased or decreased
percentage points agreed herein (If there is no corresponding day in the month of adjustment, the last day of such month shall be treated
as the corresponding day);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Monthly Adjustment. From the corresponding date of the corresponding
month, the loan interest rate shall be adjusted, on the basis of the LPR recently published, in accordance with the increased or decreased
percentage points agreed herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">Immediate Adjustment. From the date immediately following
the date of the LRP recently published, the loan interest rate shall be adjusted, on the basis of the new LPR, in accordance with the
increased or decreased percentage points agreed herein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The
loan interest rate shall be determined by other methods: ________/________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Borrower chooses the &ldquo;(2) floating
interest rate&rdquo; method, and when the loan prime rate (LPR) of the loan market increases, the monthly repayment amount of the Borrower
will increase. If the Borrower still makes the repayment according to the repayment amount before adjustment, the monthly repayment amount
will be insufficient, resulting in penalty interest and compound interest and affecting the credit record of the Borrower. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. Interest
Settlement Method </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower will settle the interest in a method
as described in following Item <U>(2) </U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(1) Quarterly Interest Settlement. The 20<SUP>th</SUP> day of the last month of each quarter shall be the interest settlement date, and the 21<SUP>st</SUP> day shall be the interest payment date.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(2) Monthly Interest Settlement. The 20<SUP>th</SUP> day of each month shall be the interest settlement date, and the 21<SUP>st</SUP> day shall be the interest payment date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(3) The interest shall be settled by other methods: _____/__________________________.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the repayment date of the last
installment of loan principal is not the interestpayment date, such repayment date of the last installment of loan principal shall be
the interest payment date on which the Borrower shall pay off all the interests payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. Penalty
Interest Rate </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(1) In the event that the Borrower fails to repay the loan within the agreed time limit, interest shall be calculated and charged over the overdue part at the penalty interest rate for overdue loan from the overdue day, until the principal and interest are paid off;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(2) In the event that the Borrower uses the loan for any purposes other than those agreed herein, interest shall be calculated and charged over the misappropriated part at the penalty interest rate for misappropriated loan from the misappropriation date, until the principal and interest are paid off;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(3) In the event that the loan is overdue and misappropriated, interest shall be calculated and charged at the penalty interest rate for misappropriated loan;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(4) With respect to the interest and penalty interest that the Borrower fails to pay as scheduled, compound interest shall be calculated and charged at the penalty interest rate agreed in this paragraph in the interest settlement method as agreed in Paragraph 2 hereof;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(5) In case of any adjustment to the loan interest rate agreed herein, the penalty interest and compound interest shall be calculated at the adjusted interest rate from the adjustment date;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(6) Penalty Interest Rate</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The penalty interest rate for overdue loan shall
be <U>50</U>% higher than the loan interest rate agreed in Paragraph 1 hereof; the penalty interest rate for misappropriated loan shall
be <U>100</U>% higher than the loan interest rate agreed in Paragraph 1 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5 Loan Disbursement and Repayment
Account </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall open an account as follows
with the Lender as the loan disbursement and repayment account, which shall be used for loan disbursement, payment and repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bank of deposit: <U>Luling Rural Commercial Bank</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Name: <U>Jiangxi Universe Pharmaceuticals
Co., Ltd. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6 Repayment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise agreed by the parties, the Borrower
shall repay the loan hereunder in accordance with the repayment schedule as set forth in Item <U>1</U> below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">1. Repay the loan hereunder in full upon the expiration of the loan term.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2. Repay the loan hereunder in accordance with the following repayment schedule:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 46%; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Repayment Time </B></FONT></TD>
    <TD STYLE="width: 54%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt"><B>Repayment Amount </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD STYLE="vertical-align: top; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">4. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">5. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">6. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">7. </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">8. </FONT></TD>
    <TD STYLE="vertical-align: top; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">9. </FONT></TD>
    <TD STYLE="border: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: center; layout-grid-mode: char"><FONT STYLE="font-size: 10pt">Total </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.4pt; padding-bottom: 2.4pt; text-align: justify; layout-grid-mode: char">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Other
Repayment Schedule: ________/____________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Where
the Borrower makes repayment in advance, it shall obtain the consent from the Lender <U>1</U> banking days in advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7 Guarantee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The loan hereunder shall be a <U>guaranteed</U>
(credit/ guaranteed) loan. The guarantee type shall be <U>guarantee</U> (guarantee/ mortgage/ pledge), and the guarantee contract shall
be executed separately. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 8 Contract Agreements on the Borrower&rsquo;s
Financial Indicators: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">N/A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 9 Dispute Resolution </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">1. After this Contract takes effect, any dispute arising from the execution or performance hereof or in connection with this Contract shall be settled by both parties through negotiation. If such negotiation fails, either party may file a lawsuit with the People&rsquo;s Court having jurisdiction over the place of the Lender in accordance with the law.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">2. During the dispute resolution, in the event that the dispute does not affect the performance of the remaining provisions of this Contract, such remaining provisions shall continue to be performed.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">3. After negotiation between the parties, the parties may conduct notarization for the compulsory enforcement of this Contract. The Borrower agrees that this Contract shall have the compulsory enforcement effect after it is notarized. In the event that the Borrower fails to perform its obligations under this Contract, the Lender may apply to the People&rsquo;s Court having jurisdiction for compulsory enforcement according to law.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 10 Effectiveness of the Contract
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract shall take effect from the date
when both parties affix their signatures and seals hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract is made out in <U>triplicate</U>,
with <U>the Borrower, the Lender and the Guarantor</U> holding <U>one</U> counterpart each. Each counterpart shall have the same legal
effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11 Other Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">N/A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Chapter 2 Standard Provisions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 12 Interest Calculation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The interest shall be calculated from the Borrower&rsquo;s
actual withdrawal date and shall be calculated according to the actual withdrawal amount and use days of loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest Formula: Interest = Principal &times;
Actual Days &times; Daily Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The daily interest rate is calculated on a base
of 360 days a year. Conversion Formula: Daily Interest Rate = Annual Interest Rate / 360.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 13 Loan Disbursement Conditions
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. The
Borrower must meet all the following conditions for loan disbursement, otherwise the Lender shall have no obligation to disburse any loan
to the Borrower, unless the Lender agrees to disburse the loan in advance: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(1) The Contract and its appendixes have become effective;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(2) The Borrower has reserved to the Lender the Borrower&rsquo;s documents, receipts, seals, lists of persons and specimen signatures in relation to the execution and performance of this Contract and filled in the relevant vouchers;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(3) The Borrower has, according to the Lender&rsquo;s requirements, opened an account necessary for the performance of this Contract;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(4) The Borrower, within 3 banking days prior to the withdrawal, has submitted to the Lender the written withdrawal notice and the relevant supporting documents for loan purpose which is consistent with the purpose as agreed herein, and has completed the relevant withdrawal procedures;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(5) The Borrower has submitted to the Lender the resolution and letter of authorization of the board of directors or other competent authorities, which agree to the execution and performance of this Contract;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(6) In accordance with relevant regulatory provisions and management requirements of the Lender, if the loan exceeds a certain amount or meets other conditions, the Lender shall, according to the Borrower&rsquo;s withdrawal application and payment authorization, pay the loan to the payment object conforming to the purpose agreed herein in a manner of authorized payment by the Lender;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(7) In addition to the credit loan, the Borrower has provided the corresponding guarantee as required by the Lender and has completed the relevant guarantee procedures, and the guarantee is legal and valid;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(8) The Borrower has not breached this Contract or any other contracts executed by and between the Borrower and the Lender;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">2. In the event that the Borrower fails to make any withdrawal for 3 consecutive months from the contract execution date, the Lender shall be entitled to cancel the borrowing limit.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 14 Special Arrangements on Revolving
Loan (Maximum Loan) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">1. During the term of revolving borrowing limit, the sum of the loan principal balance of at any time shall not exceed the revolving borrowing limit; the repayment date of any withdrawal shall not exceed the term of revolving borrowing limit.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">2. As agreed by both parties, the Lender shall reasonably set the amount and term of each revolving loan according to the scale and cycle of the Borrower&rsquo;s production and operation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 15 Loan Amount Payment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">1. The authorized payment by the Lender means that the Lender pays the loan fund to the Borrower&rsquo;s counter-party in a transaction conforming to the purpose agreed herein according to the Borrower&rsquo;s withdrawal notice and payment authorization.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment of the Borrower&rsquo;s loan fund for which
the amount of a single payment under this Contract exceeds the specified amount shall be made in a manner of authorized payment by the
Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of the authorized payment by the
Lender, the Borrower shall make express payment authorization and provide other necessary payment information (including name of counter-party
who receives payment, account number of such counter-party, and amount of payment) in the withdrawal notice, and submit to the Lender
the supporting documents for loan purpose such as business contracts required for the examination. In this case, the Lender shall pay
the loan fund to the counter-party of the Borrower via the Borrower&rsquo;s account upon examination and approval. In the event of the Lender&rsquo;s
failure to perform its obligation to pay upon authorization resulting from untruthfulness, incorrectness, and incompleteness of the information
of payment authorization and relevant transactions furnished by the Borrower, the Lender shall not be held liable for such failure whatsoever
and the Borrower&rsquo;s obligation to repay under the Contract shall not be affected. The Lender will make payment to the account of the Borrower&rsquo;s
counter-party in accordance with the Borrower&rsquo;s withdrawal notice and the payment certificate as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Lender, upon examination,
discovers that the supporting documents for loan purpose such as business contracts furnished by the Borrower fail to comply with the
Contract or there is any other defects, the Lender shall be entitled to request the Borrower to supplement, replace, explain or re-furnish
such documents, and the Lender may suspend granting or paying of such loans until the Borrower has furnished the supporting documents
such as business contracts to the satisfaction of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the account-holding bank of
the counterparty returns such payments, resulting in the Lender&rsquo;s failure to transfer such loans to the Borrower&rsquo;s counterparty as authorized
by the Borrower in a timely manner, the Lender shall not be liable for such failure whatsoever and the Borrower&rsquo;s obligation to repay
under the Contract shall not be affected. With respect to the funds returned by the account-holding bank of the counterparty, the Borrower
shall re-furnish the payment authorization and the supporting documents for loan purpose such as business contracts required for the examination,
and the Lender shall pay the loan fund to the counterparty of the Borrower via the Borrower&rsquo;s account upon examination and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All the expenses incurred by the payment of loan
to the counterparty designated by the Borrower in a manner of authorized payment under this Contract shall be borne by the Borrower. The
Borrower shall pay the above expenses to the Lender at the time of the authorized payment of each loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall not violate the above provisions
to dodge the authorized payment by the Lender by way of breaking up a large amount into several small amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2. Except for the cases where the authorized payment by the Lender must be adopted as stipulated in the preceding paragraph, unless otherwise agreed by both parties, payment of other loans shall be made by the Borrower itself, namely, after the Lender disburses the loans to the Borrower&rsquo;s account pursuant to the withdrawal application submitted by the Borrower, the Borrower pay by itself to the its counterparty that complies with the purpose as agreed in the Contract.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Borrower needs to change
the aforesaid repayment schedule, it shall submit a written application to the Lender <U>10</U> banking days prior to the maturity date
of the loan, and the changed repayment schedule is subject to the written confirmation by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">3. In the event that the Borrower needs to extend the loan term agreed herein, it shall submit a written application of extension to the Lender <U>30</U> banking days prior to the maturity date of the loan, and the Lender shall decide whether to approve the extension. In applying for the extension of a guaranteed loan, mortgage loan or pledged loan, the guarantor, mortgagor or pledgor shall also issue a written certificate of approval. the parties shall enter into a renewal agreement after the Lender approves the extension. In the event that the Borrower&rsquo;s application for extension is not approved by the Lender, the Borrower shall still repay the loan in full according to the repayment term agreed herein.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>4.</B> <B>Unless otherwise agreed by the Parties, if both the principal and the interests are overdue by the Borrower, the Lender shall be entitled to decide on the sequences for repaying the principal or the interests; under the condition of installment repayment, if several mature installments and overdue installments exist under this Contract, the Lender shall be entitled to decide the sequences of repayment; if several outstanding loan contracts exist between the Parties, the Lender shall be entitled to decide the sequences for repaying any contract.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">5. The Borrower shall repay the loan principal, interests and other amounts payable in full and on time according to provisions stated herein. The Borrower shall, before the end of counter business on the repayment date and each interest settlement date, deposit in full the current interests, principal and other amounts payable to the repayment account opened with the Lender, and the Borrower shall authorize the Lender to collect the funds on the repayment date or the interest settlement date or the Borrower shall be required to cooperate in handling the relevant transfer procedures. In the event that the amount in the repayment account is insufficient to pay the full amount due from the Borrower, the Borrower shall agree that Lender is entitled to decide the sequences for repayment.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">6. The Lender shall be entitled to collect the loan in advance on the basis of the capital withdrawal of the Borrower.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">7. Loan Note: The loan note shall be an integral part of this Contract. In the event that there is no record in this Contract, or the loan amount, withdrawal amount, repayment amount, borrow date and maturity date of the loan, loan term, loan interest rate and loan purpose as recorded in this Contract is inconsistent with those recorded in the loan note, the loan note shall prevail.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 16 Guarantee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that any event occurs to the Borrower
or the guarantor, and causes the Lender to believe that it may affect the performing capability of the Borrower or the guarantor; or the
guarantee contracts are deemed as invalid, canceled or resolved; or the performing capability of the Borrower or guarantor may be affected
due to the deterioration in their financial condition or that the Borrower and the guarantor are involved in substantial lawsuit or arbitration
or other reasons; or the guarantor breaches the guarantee contracts or other contracts with the Lender; or the collateral value decreases
or gets lost due to the devaluation, damage, lost or sequestration of the collateral; the Lender shall be entitled to require, and the
Borrower shall have the obligation to provide new guarantee, supplement or replace the guarantor to guarantee the liabilities under this
Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 17 Representations and Undertakings
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">1. The Borrower is a legal entity incorporated, registered and existing under the administration for industry and commerce or other competent authorities and has full capacity of civil rights and conduct to conclude and perform the Contract, and capacity of loan repayment.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">2. The Borrower fully agrees to the contents and terms of this Contract, executes and performs this Contract out of true intention, has obtained all legal and valid authorizations required by the Borrower&rsquo;s Articles of Association and bylaws, and will not be in violation of any agreement, contract, or other legal documents with binding force to the Borrower. The Borrower has obtained or will obtain all the required approval, consent, documentation or registration for executing and performing this Contract.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">3. The Borrower is in good faith and all the documents, financial statements, certifications and other information provided by the Borrower to the Lender under this Contract are true, complete, accurate and valid, and free from false records, material omissions or misleading statements. The financial and accounting reports provided to the Lender are prepared in accordance with Chinese accounting standards, and truly, fairly and completely present the Borrower&rsquo;s operating and liability condition.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">4. The transaction background that the Borrower represents to the Lender is real and legal, not for any illegal purposes such as money laundering. The loan purpose and the source of repayment are clear and legal. The loan purpose and the source of repayment are clear and legal.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The
Borrower has a good credit status, does not have material bad credit record, and does not conceal from the Lender any fact that may affect
the Borrower&rsquo;s and the Guarantor&rsquo;s financial condition and performance capability. The Borrower does not conceal from the Lender any litigation,
arbitration or claim in which it is involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. The
borrower has repaid other debts payable as scheduled and has not maliciously defaulted on the payment of principal and interest of the
bank loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7. The
Borrower shall withdraw and use the loan in accordance with the term and purpose agreed herein. The loan borrowed hereunder shall neither
be used for the investment in fixed asset and equity and other investments, nor flow into the securities market or the futures market
in any form, or be used for other purposes prohibited or restricted by relevant laws and regulations. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8. The
Borrower shall deliver its financial statements (including but not limited to annual, quarterly and monthly reports) and other relevant
documents to the Lender on a regularly and timely basis in accordance with the requirements of the Lender; the Borrower shall ensure that
the financial indicators will comply with the Contract all the time. If the production and operation qualification/license is subject
to the annual audit, such qualification/license will pass the annual examination as scheduled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9. The
Borrower shall withdraw, repay and use the loan as stipulated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10. If
the Borrower has executed or will execute with the guarantor under this Contract a counter-guarantee agreement or similar agreement regarding
its guarantee obligations, this counter-guarantee agreement or similar agreement will not prejudice any Lender&rsquo;s right under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11. The
Borrower shall accept the credit inspection and supervision conducted by the Lender, and provide sufficient assistance and cooperation;
from the effective date of this Contract and prior to discharge of the principal and interests and related expenses hereunder, the Borrower
agrees and authorizes the Lender to monitor the account opened with the Lender, examine and analyze the Borrower&rsquo;s production and operation
(including but not limited to the construction and operation of the Borrower&rsquo;s projects), and make dynamic monitoring on the income cash
flow and overall fund flow of the Borrower; <B>the Borrower shall accept and actively cooperate with the examination and supervision made
by the Lender on the usage of the loan funds including the loan purpose by account analysis, proof inspection and site investigation,
</B>and make summary report in a periodic manner as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>12. The
Borrower&rsquo;s merger, division, decrease of capital, equity transfer, external investment, substantial increase of debt financing, transfer
of material assets and claims and other events which may have adverse effect on the solvency of the Borrower shall be subject to the written
consent of the Lender. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower shall give a notice to the Lender
within <U>7</U> days after it becomes or should have become aware of any of the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Change
of the Articles of Association, business scope, registered capital, legal representative of the Borrower or the guarantor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Change
of management mode such as joint management in any form, cooperation with foreign enterprises, cooperation, contracting management, reorganization,
reform and planned listing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Involved
in material litigation or arbitration cases, sequestration, attachment or supervision of properties or collateral, or establishment of
new material liabilities on the collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Winding
up, dissolution, liquidation, stopping business for rectification, cancellation, revocation of business license, (applied for) applying
for bankruptcy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Shareholders,
directors and current senior managers are suspected of being involved in material cases or economic disputes; or the legal representative/person
in charge and current senior executives are found to be in bad health or other material conditions that the they are unqualified for their
job;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Events
of default by the Borrower under other contracts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) Difficulty
in business operation and deterioration of financial position;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) In
the event that the Borrower is closed, suspended, merged or changes the line of production due to change, restructuring and contracting
or with the approval of the competent departments, the Borrower undertakes to give a notice to the Lender in writing within one month
prior to the occurrence of the above events and to discharge all debts owed to the Lender immediately. Subject to the consent of the Lender,
the Borrower may transfer the debts to the receiving entity or the newly incorporated entity (The Borrower shall, in the process of debt
transfer, present and submit to the Lender the documents issued by its competent authority or the contract-issuing party or relevant documents);
however, the debt receiving entity must execute a new loan contract with Lender and submit a written certificate of the corresponding
guarantor&rsquo;s approval or implement new guarantee measures, and before the execution of the new contract, the Lender shall have the right
to recover the debts from the Borrower, the Guarantor or the Borrower&rsquo;s receiver at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13. Liquidation
of the debts owed by the Borrower to the Lender shall have priority to the loan extended by the shareholders of the Borrower, and precede
the debts of the same kind owed by the Borrower to other creditors. In addition, from the effectiveness of the Contract to the time when
all the principal, interests and relative fees under the Contract are paid off, the Borrower shall not return the loan from its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14. In
respect of the loan hereunder, the loan conditions such as guarantee conditions, loan rate pricing, discharge sequence provided by the
Borrower for the Lender shall be no less than the current or future conditions provided for any other financial institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15. <B>The
Borrower shall bear the expenses incurred in connection with the execution and performance of this Contract and the expenses paid and
payable by the Lender for realization of its creditor&rsquo;s right hereunder, including but not limited to litigation or arbitration fees,
property preservation costs, attorney fees, enforcement fees, evaluation fees, auction fees, and announcement fees. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>16. Account
Management </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The
repayment account opened by the Borrower with the Lender (the account stipulated in Article 5) is a special capital withdrawal account,
which is used to collect the corresponding sales revenue or the planned repayment fund. Where the corresponding sales revenue is settled
in a non-cash manner, the Borrower shall ensure that it will be promptly transferred into the capital withdrawal account upon receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The
Lender shall have the right to supervise the capital withdrawal account, including but not limited to the understanding and supervision
of the fund income and expenditure of the account, and the Borrower shall provide relevant cooperation. At the request of the Lender,
the Borrower shall execute a special account supervision agreement with the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17. The
Borrower shall dispose the assets in a manner that will not reduce its repayment capability. The Borrower undertakes that the total amount
of the Borrower&rsquo;s external guarantee is equal to or less than _____ times of its net asset, and the total amount of external guarantee
as well as the amount of a single guarantee may not exceed the limit as stipulated in its Articles of Association; without the consent
of the Lender, the Borrower shall not provide guarantee to any third party or the loans borrowed by the Borrower from any other financial
institution with the assets formed by the loans under the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 18 the Related-party Transaction
within the Borrower </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;1. The Borrower is not identified by the Lender
as the group client in accordance with the Guidelines on the Management of Risks of Credits Granted by Commercial Banks to Group Clients
(hereinafter referred to the &ldquo;Guidelines&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;2. If the Borrower is identified by the Lender
as the group client in accordance with the Guidelines, it shall report to the Lender any of the related-party transaction in a timely
manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;<FONT STYLE="font-family: Wingdings 2"></FONT>3. The
Borrower is subject to such events as major merger, acquisition or reorganization, which in the opinion of the Lender may affect the safety
of the loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 19 Breach of Contract and Settlement
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
Borrower shall constitute or be deemed to have breached the Contract and shall be liable for breach of contract under any of the following
circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The
Borrower fails to perform the obligations of payment and liquidation to the Lender according to the stipulations of the Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The
Borrower fails to use the loan in a purpose and way stipulated in this Contract or fails to use the loan borrowed hereunder for the purpose
stipulated in the Contract; or the Borrower fails to go through the withdrawal procedures as scheduled according to the withdrawal plan,
or changes the withdrawal plan without the Lender&rsquo;s consent; or the Borrower is in violation of this Contract and dodges the authorized
payment by the Lender by way of breaking up a large amount into several small amounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) The
Borrower provides an untrue representation or violates the undertaking it made in this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) If
any circumstance under Subparagraph 12 of Article 17 arises, and the Lender believes that may affect the financial condition and performing
capability of the Borrower or guarantor, but the Borrower refuses to provide new guarantee or change a guarantor according to this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) The
Borrower violates any stipulation under any other contract between the Borrower and the Lender; the Borrower violates any stipulation
under any Credit Extension Contract between the Borrower and any other financial institution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) The
guarantor violates the stipulations of the guarantee contract, or any default events arise under other contract between the guarantor
and the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) The
Borrower closes down or is dissolved, withdraw or bankrupted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) Where
the Borrower involves in or possibly involves in material economic disputes, litigation, arbitration, or its capital is sealed up, seized
or enforced for execution, or the administrative organs such as judicial organs or taxation authorities, and industrial and commercial
administration file for investigation or adopt punishment measures on the Borrower according to law which has influenced or may influence
the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9) Where
the main individual investors and key managerial personnel of the Borrower are changed abnormally, disappear or are investigated or the
personal freedom thereof is limited by judicial organs according to law which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(10) Where
the credit circumstances of the Borrower lowers or finance indexes of the Borrower such as profitability, debt-paying ability, operating
capacity and cash flow seriously deteriorate and break through the index binding of this Contract or other financial agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(11) The
Borrower takes advantage of the false contracts between the Borrower and the affiliated party to obtain funds or credit from the Lender
through transactions without true transaction background, and the affiliated party is subject to such events as major merger, acquisition
or reorganization which in the opinion of the Lender may affect the safety of the loan; or the Borrower intends to evade the creditor&rsquo;s
right of the Lender through related-party transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12) The
Borrower causes any liability accident due to its violation of food safety, production safety, environmental protection and other relevant
laws and regulations, regulatory provisions or industrial standards which has influenced or may influence the performance of the liabilities
under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(13) In
the event that the loan under this Contract is granted on the basis of credit rating, the Borrower&rsquo;s credit rating, profitability, asset-liability
ratio, net cash flow from operating activities and other indicators do not meet the Lender&rsquo;s credit loan conditions; or the Borrower,
without the written consent of the Lender, establishes mortgage/pledge guarantee or provide guarantee to others with its valid operating
assets, which has influenced or may influence the performance of the liabilities under this Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(14) Other
circumstances that may have adverse effect on the realization of the creditor&rsquo;s rights of the Lender under this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. When
the aforesaid breaches arise, as the case maybe, the Borrower agrees that the Lender may take following measures respectively or simultaneously:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Require
the Borrower and guarantor to rectify their breach within time limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Decrease,
suspend or terminate all or part of the credit lines of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Suspend
or terminate all or part of the business application (such as withdrawal) of the Borrower under this Contract or other contracts between
the Borrower and the Lender; partly or totally suspend or cancel to issue, pay and transact the unissued loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Declare
that all or part of the outstanding principal and interest of the loan and other amounts payable of the Borrower under this Contract and
other contracts between the Borrower and the Lender shall become due immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Negotiate
with the Borrower to supplement the terms of loan issuance and payment; or the Lender shall have the right to change the loan disbursement
and payment conditions in accordance with the credit status of the Borrower such as lowering the minimum amount of authorized payment
of the Borrower; or the Lender shall have the right to transfer back the loan fund which the Borrower has paid for default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Terminate
or dissolve this Contract, partly or totally terminate or dissolve other contracts between the Borrower and the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) Require
the Borrower to compensate the Lender for the Lender&rsquo;s loss caused by the Borrower&rsquo;s default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) <B>Deduct
from the Borrower&rsquo;s account which is opened in the Rural Commercial Bank system within the jurisdiction of Jiangxi </B>with notice before
or after the deduction, <B>so as to discharge all or part of the Borrower&rsquo;s debts to the Lender hereunder. The undue deposit in the account
shall be deemed to become due in advance. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9) Exercise
security interest; and require the guarantor to take guarantee responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(10) In
the event that the Borrower fails to repay the principal, interest (including penalty interest and compound interest) or other amounts
payable as scheduled, the Lender may disclose the default information of the Borrower and the Guarantor and make an announcement for collection
through the media or other forms. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(11) Have
the right to deduct and debit the deposits and dividends within any account opened by the Borrower in the Rural Commercial Bank system
within the jurisdiction of Jiangxi, and to dispose of the Borrower&rsquo;s equities. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(12) Other
measures stipulated by laws and regulations and deemed necessary and possible by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 20 Reservation of Rights </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any failure by a party to exercise all or part
of its rights hereunder or to require the other party to perform or assume all or part of obligations or responsibilities shall not constitute
a waiver of such rights or release of the obligations and responsibilities of such party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any tolerance, grace or postponement for exercising
the rights under this Contract of one Party shall not affect its rights stipulated by this Contract, laws and regulations, and shall not
be deemed as a waiver of such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 21 Confidentiality </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each party undertakes to keep confidential the
trade secrets, technical information, business information and other business secrets obtained from the other party which are not available
through public channels. Without the consent of the original provider of the trade secret, neither party shall disclose all or part of
the trade secret to any third party, unless otherwise stipulated by laws and regulations or otherwise agreed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that either party is in violation
of the aforesaid confidentiality obligation, it shall assume the corresponding liability for breach of contract and compensate for the
losses caused thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 20 Force Majeure </b></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term Force Majeure as specified in this Contract
refers to the objective events that cannot be foreseen, overcome, or avoided and have a significant impact on one party, including but
not limited to the natural disasters such as flood, earthquake, fire and storm, as well as the social events such as war and turmoil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Contract cannot be performed
as a result of the occurrence of force majeure events, the party affected by the force majeure shall immediately notify the other party
of the event in writing, and within 7 days, provide written documents certifying the details of accident and the reasons for non-performance
or delay in performance hereof. Upon consensus through negotiation, both Parties may terminate or temporarily delay the performance of
the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 23 Alteration, Amendment and Termination
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract can be altered and amended in written
form upon consensus through negotiation of the Parties, and any alternation and amendment agreed on by the Parties shall constitute an
integral part of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Contract may not be terminated until all
the rights and obligations are fully preformed, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The invalidity of any provision of this Contract
shall not affect the legal validity of other provisions, unless otherwise stipulated in laws and regulations or agreed by the both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 24 Agreements on Service </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
contact information (including mailing address, telephone number, fax number, etc.) provided by the Borrower in this Contract shall be
true and valid and shall be the address for service of any notice of the Lender for the Borrower. In case of any change to the contact
information, the Borrower shall immediately send/mail the change information in writing to the mailing address provided by the Lender
in this Contract. Such information change shall become effective upon the Lender&rsquo;s receipt of the change notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Unless
otherwise expressly provided for in this Contract, the Lender shall be entitled to give notice to the Borrower in any of the following
methods. The Lender shall be entitled to choose the notification method as it thinks fit and shall not be held liable for any error, omission
or delay in delivery by mail, fax, telephone, WeChat or any other communication system. Where the Lender simultaneously chooses several
notification methods, the one by which the notice is served to the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) By
announcement. The notice shall be deemed to be served on the date on which the Lender publishes the announcement on its website, online
banking, telephone banking or business outlets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) By
hand. The notice shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower refuses to sign
for the receipt, the date on which the server makes a record on the proof of service on the spot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) By
mail (including express mail, surface mail or registered mail). The notice, when addressed to the Borrower&rsquo;s mailing address last known
to the Lender, shall be deemed to be served on the date on which the Borrower signs for the receipt, or if the Borrower fails to sign
for the receipt, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) By
fax, mobile phone SMS, WeChat or other electronic communication methods. The notice, when sent to the Borrower&rsquo;s fax number, the mobile
phone number, WeChat account number or email address designated by the Borrower which is last known to the Lender, shall be deemed to
be served on the date on which the notice is sent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Borrower
agrees that, unless the Lender receives from the Borrower a written notice concerning the change of mailing address, the Borrower&rsquo;s domicile
stated in this Contract is the correspondence and contact address. In the future, the delivery addresses of bank statements, collection
statements, relevant legal instruments and litigation documents related to the loans under this Contract shall prevail. The Borrower promises
to notify the Lender in time when the communication and contact information change, otherwise the documents delivered by the Lender according
to the communication and contact information stated in this Contract will be effectively delivered, and the relevant economic and legal
responsibilities arising therefrom will be borne by the Borrower and the Mortgagor. During the dispute settlement, if the court serves
the judicial documents or other written documents by mail (including express mail, surface mail or registered mail) to the Borrower mailing
address last known to the Lender, such documents shall be deemed to be served on the date on which the Borrower signs for receipt of the
proof of service; or if Borrower fails to sign for receipt of the proof of service, the date on which the mail is returned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The court or notary organ shall be entitled to
give any notice to the Borrower by any methods of communication agreed in this Paragraph 2. The court or notary organ shall be entitled
to choose the communication method as it thinks fit and shall not be held liable for any error, omission or delay in delivery by mail,
fax, telephone, telex or any other communication system. Where the court or notary organ simultaneously chooses several communication
methods, the one by which the notice is served on the Borrower earlier shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 25 Appendix </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The appendixes confirmed by both parties shall
constitute an integral part of this Contract and shall have the same legal effect as this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 26 Other Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The
Borrower shall not transfer any rights and obligations under this Contract to the third party without written consent of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. The
Lender has the right to transfer the creditor&rsquo;s rights under this Contract to the third party, and shall notify the Borrower. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. This
Contract shall be legally binding upon both Parties and their successors and assignees without prejudice to other provisions of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. All
the transactions under this Contract are carried out for each Party&rsquo;s independent benefits. If, in accordance with relevant laws, regulations
and regulatory provisions, other parties to the transaction become the related parties or affiliated persons of the Lender, no Party may
seek to affect the fairness of the transaction out of this related-party relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The
headings and business names in this Contract are used only for convenient reference, which shall not be used to interpret the provisions
or the rights and obligations of both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. In
accordance with relevant laws, regulations and regulatory provisions, the Lender shall have the right to provide the information related
to this Contract and other relevant information of the Borrower to the credit reference system of the People&rsquo;s Bank of China and other
credit information database established according to law for reference and use by the institutions or individuals with proper qualification
according to law. The Lender shall also have the right to refer the relevant information of the Borrower through credit reference system
of the People&rsquo;s Bank of China and other credit information database established according to law for the purpose of the execution and
performance of this Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The parties acknowledge that the Borrower and
the Lender have made a full negotiation in connection with all the terms of this Contract. The Lender has requested the Borrower to give
special attention to and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the
parties, and has made explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood
all the contents and provisions of the Contract. The Borrower confirms that there is no misunderstanding or doubt about all the contents
and terms of the Contract. Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract
and have no objection to the contents and provisions of the Contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Borrower and the Lender have made a full
negotiation in connection with all the provisions of this Contract. The Lender has requested the Borrower to give special attention to
and make a comprehensive and accurate understanding of all provisions concerning the rights and obligations of the parties, and has made
explanations to the relevant provisions upon the Borrower&rsquo;s request. The Borrower has carefully read and fully understood all the contents
and terms of the Contract. The Borrower confirms that there is no misunderstanding or ambiguity about all the contents and provisions
of the Contract. Both the Borrower and the Lender have the same understanding of the contents and provisions of the Contract and have
no objection to the contents and provisions of the Contract. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(The Borrower shall fill in the following by
contrast) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(The remainder of this page is intentionally left
blank for signatures)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex4-14_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">20</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.15
<SEQUENCE>6
<FILENAME>f20f2021ex4-15_universephar.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE CONSTRUCTION AGREEMENT ENTERED INTO BY AND BETWEEN JIANGXI UNIVERSE AND JIANGXI CHENYUAN CONSTRUCTION PROJECT CO., LTD., DATED JUNE 25, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.15</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(GF-2021-0201)</FONT></TD>
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Contract No.: 20210625</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Construction Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(&#9744; Original &#9744; Copy)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Supervised by Ministry of Housing and Urban-Rural
Development of the People&rsquo;s Republic of China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">State Administration for Industry and Commerce</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Part I Contract Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Client (Full Name): <U>Jiangxi Universe Pharmaceuticals
Co., Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contractor (Full Name): <U>Jiangxi Chenyuan Construction
Project Co., Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the <I>Contract Law of the
People&rsquo;s Republic of China</I>, the <I>Construction Law of the People&rsquo;s Republic of China</I> and the other relevant laws
and regulations of China, the parties hereto have entered into this agreement with regard to the construction of the project for <U>Workshops
A, B, C and D and Office Building of Jiangxi Universe Pharmaceuticals Co., Ltd.</U> under the principle of equality, voluntariness, fairness
and good faith as incarnated by the terms and conditions set out below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>I. Project Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Project Name: <U>Workshops A, B, C and D and
Office Building of Jiangxi Universe Pharmaceuticals Co., Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Project Location: <U>No. 265, Jingjiu Avenue,
Jinggangshan Economic and Technological Development Zone, Ji&rsquo;an County</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Project Initiation Approval Document No.: <U>J.F.G.H.Z.
[2021] 38</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Source of Funds: <U>Self-raised by the enterprise</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. Project Content: <U>All the work content of
relevant disciplines covered by the bill of quantities and construction drawings of Workshops A, B, C and D and Office Building of Jiangxi
Universe Pharmaceuticals Co., Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a group project, a <I>Schedule of the Construction
Projects Undertaken by the Contractor</I> (Annex 1) shall be enclosed herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. Scope of Contracting for the Project:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>All the work content of relevant disciplines
covered by the bill of quantities and construction drawings</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>II. Project Duration under Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Planned commencement date: <U>August 8, 2021.</U>
(Subject to the Commencement Order)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Planned completion date: <U>August 7, 2023.</U>
(Subject to the actual postponed construction period)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total number of calendar days of project duration:
730 calendar days. In case of any inconsistency between the total number of calendar days of project duration and the number of days calculated
on the basis of the above planned commencement/completion date, the former shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Note: The construction unit shall complete the
project with quality and quantity guaranteed within the project duration under the premise of ensuring construction safety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR STYLE="clear: both"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>III. Quality Standard</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The quality of the project shall meet the <U>Pass</U>
standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>VI. Contract Price and Form of Contract Price</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The contract price is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(In words): <U>SAY ONE HUNDRED AND SIXTY-FIVE
MILLION YUAN ONLY</U> (&yen; <U>165,000,000.00</U>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Costs of safe and civilized construction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(In words) <U>SAY TWO MILLION YUAN ONLY</U> (&yen;
<U>2,000,000.00</U>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Provisional estimate amount of materials and
engineering equipment:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(In words) ____________ (&yen; _________);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Provisional estimate amount of professional
projects:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(In words)  ____________(&yen; _________);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Provisional amount:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(In words)  ____________(&yen; _________);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Form of contract price: <U>Fixed comprehensive
unit price contract.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>The actual settlement shall be made if the
final settlement audited price is within 180 million yuan. If the amount exceeds 180 million yuan, the settlement shall be made at 180
million yuan.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>V. Project Manager</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contractor Project Manager: <U>Yang Shucheng (Registration
Certificate No.: Gan 236141548064)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>VI. Composition of Contract Documents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement, together with the following documents,
shall constitute the contract documents:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Letter of Acceptance (if any);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Letter of Tender and its appendices (if any);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Special Conditions of Contract and attachments;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) General Conditions of Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Technical standards and requirements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Drawings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) The priced bill of quantities or budget;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8) Other contract documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The documents related to the contract formed in
the process of the conclusion and performance of the contract shall form an integral part of the contract documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The above-mentioned contract documents include
the supplements and amendments made by the parties hereto to the contract documents. If the documents fall into the same category, the
latest signed ones shall prevail. Special Conditions of Contract and the attachments shall be signed or sealed by the parties to the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>VII. Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. The Client undertakes to apply and obtain all
project approvals according to the laws and regulations, raise funds for project construction and pay contract price according to the
schedule and method agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. The Contractor undertakes to organize and complete
the construction of the project in accordance with the legal provisions and contract provisions, to ensure the quality and safety of the
project, not to transfer the project or subcontract it to/with others illegally, and to undertake the corresponding project maintenance
responsibilities during the defect liability period and warranty period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. If the Client and the Contractor sign the contract
through invitation of bid, both parties understand and undertake that they will not sign any other agreement on the same project that
deviates from the substantial content of the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The Contractor shall use the money received
exclusively for the project of <U>Workshops A, B, C and D and Office Building of Jiangxi Universe Pharmaceuticals Co., Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>VIII. Meaning of Terms</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Terms in this Agreement have the same meanings
as those given in Part II General Conditions of Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IX. Time of Signing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Contract is signed on June 25, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>X. Place of Signing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Contract is signed in Jiangxi Universe Pharmaceuticals
Co., Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>XI. Supplementary Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For matters not covered in the Contract, the parties
hereto shall enter into a supplementary agreement separately, which shall form an integral part of the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>XII. Effectiveness of Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Contract shall come into force <U>after being
signed and sealed by the legal representatives of both parties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>XIII. Counterparts of Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Contract shall be made in <U>eight</U> copies,
all of which shall have the same legal effect, with the Client holding <U>four</U> copies and the Contractor holding <U>eleven</U> copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No text on this page</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Client: (company chop)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[seal: Jiangxi Universe Pharmaceuticals Co., Ltd.]</P></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 49%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Contractor: (company chop)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[seal: Jiangxi Chenyuan Construction Project Co.,
    Ltd.]</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal Representative or Authorized Agent: (Signature)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal Representative or Authorized Agent: (Signature)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Organizational Code:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Organization Code:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address: <U>No. 265, Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji&rsquo;an County</U></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address: <U>Room 2204, Block C, China Resources Building, No. 5 Qinjiang Road, Zhanggong District, Ganzhou City</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal Representative: <U>Lai Gang</U></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal Representative: <U>Li Wenhui</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized Agent: <U>Xiao Yun</U></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized Agent: <U>Xie Yuhui</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tel:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tel: <U>0797-8231111</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bank of Account: </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bank of Account: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Account No.:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Account No.: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operator:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operator:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">MM/DD/YYYY</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">MM/DD/YYYY</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Part II General Conditions of Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. General Stipulations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.1 Definitions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.1.1 Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.1.1.10 Other contract documents include: <U>Supplementary
agreement to the Construction Contract, minutes of engineering meeting, design changes, work liaison sheet, drawing review records, etc.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.1.2 Contract parties and other related parties</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.1.2.4 Supervisor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name: <U>Jiangxi Zhongtian Construction Supervision
Consulting Co., Ltd.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Category and grade of qualification: <U>Grade
A of housing construction;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: <U>&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: <U>&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Correspondence address: <U>&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.1.2.5 Designer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name: <U>Jiujiang Construction Designing Institute</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Category and grade of qualification: <U>Grade
A of architectural engineering design</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: <U>0797-2195358</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Correspondence address: <U>Zhongting Forest Mansion,
No. 16 Zanxian Road, Ganzhou City, Jiangxi Province</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.2 Engineering and Equipment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.2.1 Other sites as part of the construction
site shall include: construction site provided by the Client in accordance with the General Conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.2.3 Permanent land occupation shall include:
determined according to the design drawings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.2.4 Temporary land occupation shall include:
determined by both parties during the performance of the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.3 Applicable Laws</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other normative documents applicable to the Contract:
<I><U>Construction Law of the People&rsquo;s Republic of China</U></I><U>, <I>Contract Law of the People&rsquo;s Republic of China </I>and other relevant
current laws and administrative regulations</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.4 Standards and specifications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.4.1 Standards and specifications applicable
to the project include: <U>standards and specifications specified in the design document, current relevant codes for construction, specifications
and project acceptance standards, current relevant atlas and current local standards of Jiangxi Province</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.4.2 Name of foreign standards and specifications
provided by the Client: <U>&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of copies of foreign standards and specifications
provided by the Client: <U>&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> ;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of foreign standards and specifications
provided by the Client: <U>&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.4.3 Special requirements of the Client for technical
standards and functional requirements of the project: <U>None</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.5 Priority of Contract Documents</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The contract documents are composed and prioritized
as per: <U>Article 1.5 of General Conditions of Contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.6 Drawings and Contractor&rsquo;s Documents</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.6.1 Period for the provision of drawings by
the Client to the Contractor: <U>14 days prior to the commencement date</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.6.2 Quantity of drawings provided by the Client
to the Contractor: <U>One set</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.6.3 Content of drawings to be provided by the
Client to the Contractor: <U>All design drawings required for construction</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.6.4 Contractor&rsquo;s documents</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Documents to be provided by the Contractor include:
<U>Construction management plan, safe work method statement, construction schedule, etc.</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Quantity of documents provided by the Contractor:
<U>Four copies</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Form of documents provided by the Contractor:
<U>Paper documents</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Time limit for the Client to approve the Contractor&rsquo;s
documents: <U>/</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.6.5 Preparation of site drawings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the preparation of site drawings:
<U>Article 1.6 of General Conditions of Contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.7 Contacts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.7.1 The Client and the Contractor shall serve
to the other party within <U>2</U> days the written correspondence such as notice of approval, certifications, certificates, instructions,
directions, requirements, requests, consents, opinions, determinations and decisions relating to the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.7.2 Place of receipt of documents by the Client:
<U>Project Department of the Client at the project location;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recipient designated by the Client: <U>Representative
of the Client</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Place of receipt of documents by the Contractor:
<U>Project Department of the Contractor at the project location</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recipient designated by the Contractor: <U>Constructor
or other project leader authorized by the Contractor</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Place of receipt of documents by the Supervisor:
<U>Project Department of the Supervisor at the project location</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recipient designated by the Supervisor: <U>Chief
Supervision Engineer or other persons in charge authorized by the Supervisor</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.10 Traffic and Transportation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.10.1 Right of access to the site</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the right of access to the site:
As per the General Conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.10.3 On-site traffic</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the boundary of off-site traffic
and on-site traffic: Determined according to the construction site.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the Client&rsquo;s provision of
free on-site roads and traffic facilities to the Contractor to meet the construction needs of the project: <U>The Contractor shall build
and maintain the roads and traffic facilities on its own according to the construction progress and method statements and bear relevant
expenses. If the Contractor uses the on-site roads provided by the Client to meet the construction needs of the project, and the said
roads or traffic facilities are damaged due to the Contractor, the Contractor shall repair and bear all the costs as required by the Client.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.10.4 Transportation of oversized parts and
overweight parts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Temporary retrofitting fee of roads and bridges required for the transportation of oversized or overweight parts
and other related costs shall be borne by the <U>Contractor</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.11 Intellectual Property Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.11.1 Provisions on the ownership of the copyright
of the drawings provided by the Client to the Contractor, the technical specifications prepared by the Client or commissioned by the Client
for the implementation of the project and the documents reflecting the Client&rsquo;s contract requirements or of other similar properties:
<U>Article 1.11 of General Conditions of Contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Requirements for restrictions on the use of the
aforesaid documents provided by the Client: <U>Drawings, technical data, technical parameters, etc. of the project shall not be disclosed
to the public without permission</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.11.2 Provisions on the ownership of the copyright
of the documents prepared by the Contractor for the implementation of the project: <U>As per the General Conditions</U>.<BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Requirements for restrictions on the use of the
aforesaid documents provided by the Contractor: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.11.4 Provisions on the way to bear the royalties
of patents, know-how and technical secrets adopted by the Contractor in the course of construction: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.13 Correction of Errors in the Bill of Quantities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether to adjust the contract price when there
is an error in the bill of quantities: <U>The adjustment of the error in the preparation of the bill of quantities shall be made in accordance
with the relevant provisions of the <I>Code of valuation with bill quantity of construction works</I> (GB 50500-2013) and the calculation
specifications for relevant discipline engineering and the <I>Measures for the Management of Construction Project Pricing in Jiangxi Province</I>
in 2010</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Range of deviations in the project quantity for
which adjustment of the contract price is allowed: <U>/</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. The Client</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.2 Representative of the Client</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Representative of the Client:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name: <U>Xiao Yun</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ID No.: <U>362101195902082219</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Position: <U>Chief Engineer</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: <U>18270770652</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address: <U>Jingjiu Avenue, Jinggangshan Economic
and Technological Development Zone, Ji&rsquo;an County</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The scope of authorization of the Client to the
representative of the Client is as follows: <U>To supervise and urge the supervision engineer to exercise his/her authority, coordinate
all aspects of the construction site, coordinate the project quality, progress and problems existing in safe and civilized construction,
approve the project quantity outside the contract, and review the project progress report</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.4 Provision of Construction Site, Construction
Conditions and Basic Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.4.1 Provision of construction site</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Requirements for the deadline for the Client to
hand over the construction site: <U>Seven days before the commencement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.4.2 Provision of construction conditions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Client shall be responsible for providing
the conditions required for construction, including: <U>Completion of all demolition and relocation within the site, and meeting the construction
needs such as water, electricity on site</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.5 Proof of Source of Funds and Payment Guarantee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Requirements for the period of time for the Client
to provide proof of the source of funds: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether to provide payment guarantee: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Form of payment guarantee provided by the Client:
<U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. The Contractor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.1 General Obligations of the Contractor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Content of as-built materials submitted by
the Contractor: <U>Complete set of as-built drawings and electronic documents of as-built drawings</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of sets of as-built materials to be submitted
by the Contractor: Two sets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of as-built materials submitted by the Contractor:
<U>Borne by the Contractor</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Handover time of as-built materials submitted
by the Contractor: <U>Within 30 days after the completion and acceptance of the project</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Form of as-built materials submitted by the Contractor:
<U>Written and electronic documents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Other obligations of the Contractor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.2 Project Manager</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.2.1 Project manager:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name: <U>Yang Shucheng</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ID No.: <U>360781198601180014</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Constructor Qualification Level: <U>Level 2</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Constructor Registration Certificate No.: <U>Gan
236141548064</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Constructor Practicing Seal No.: <U>Gan 236141548064</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Production Safety Examination Certificate No.:
<U>G.J.A. B (2014) 0061841</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: <U>18979743087</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The scope of authority of the Contractor to the
Project Manager is as follows: <U>To deal with all related affairs of the project</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Time requirement for the Project Manager at the
construction site every month: Not less than <U>20</U> days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liability for breach of contract if the Contractor
fails to submit the labor contract and the proof of social insurance payment for the Project Manager: <U>Ordered to submit the labor contract
and make up the social insurance payment within a certain period of time</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liability for breach of contract if the Project
Manager leaves the construction site without approval: <U>A penalty of 100 yuan for each day of absence</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.2.3 Liability for breach of contract if the
Contractor replaces the Project Manager without authorization: <U>If the original Project Manager can continue to perform his/her duties,
the Supervisor shall order the Contractor to cancel the replacement decision, and the Contractor shall bear liquidated damages of 10,000
yuan. If the original Project Manager is objectively unable to continue to perform his/her duties, the Client shall have the right to
request an audit to confirm the Project Manager replaced by the Contractor, and the Contractor shall bear liquidated damages of 10,000
yuan.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.2.4 Liability for breach of contract if the
Contractor refuses to replace the Project Manager without good reasons: <U>The Supervisor shall notify the Project Manager in writing
to stop work on the 29th day after the Contractor is notified of the second replacement and shall direct that the construction be temporarily
suspended. The suspension of construction caused by the Contractor shall be handled according to Article 7.8.2 of the General Conditions.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.3 Contractor&rsquo;s Personnel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.3.1 Time limit for the Contractor to submit
the arrangement report to the project management agency and the construction site management personnel: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.3.3 Liability for breach of contract if the
Contractor refuses to replace the main construction management personnel without good reasons: <U>The supervisor shall issue another notice
requesting the Contractor to replace the main construction management personnel within 3 days and assume the liability for breach of contract
in the amount of 5,000 yuan. If the Contractor still refuses to replace within 3 days after receiving the second notice, the Supervisor
shall notify the main construction management personnel in writing to stop the work and instruct the temporary suspension of construction.
The suspension of construction caused by the Contractor shall be handled according to Article 7.8.2 of the General Conditions.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.3.4 Approval requirements for the main construction
management personnel of the Contractor to leave the construction site: <U>Such personnel can leave the job only after prior report to
the Supervisor for approval and consent of the Client</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.3.5 Liability for breach of contract if the
Contractor replaces the main construction management personnel without authorization: <U>If the original management personnel can continue
to perform his/her duties, the Supervisor shall order the Contractor to cancel the replacement decision, and the Contractor shall bear
liquidated damages of 5,000 yuan. If the original management personnel is objectively unable to continue to perform his/her duties, the
Client shall have the right to request an audit to confirm the management personnel replaced by the Contractor, and the Contractor shall
bear liquidated damages of 10,000 yuan.</U> The additional cost and delayed construction period as a result shall be borne by the Contractor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liability for breach of contract if the main management
personnel of the Contractor leave the construction site without approval: <U>A penalty of 500 yuan for each day of absence</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">3.5 Subcontracting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.5.1 General provisions of subcontracting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subcontracting is prohibited for the following
works: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Scope of main structure, critical work: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.5.2 Determination of subcontracting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subcontracting is allowed for the discipline works:
<U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other provisions concerning subcontracting: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.5.4 Subcontract price</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on payment of subcontract price:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.6 Care of Project; Protection of Finished/Semi-finished
Products</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Starting time for the Contractor to take care
of the project, materials and equipment related to the project: <U>As per Article 3. 5. 6 of the General Conditions of Contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.7 Performance Guarantee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether the Contractor provides performance guarantee:
<U>Yes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The form, amount and duration of performance guarantee
provided by the Contractor: <U>1. The performance guarantee for the project shall be 5% of the contract price, and shall be transferred
in full from the basic account of the bidder to the account designated by the Employer. 50% of the performance guarantee will be returned
without interest upon acceptance of 50% of the contract quantity, and the remaining 50% will be returned without interest after the completion
and acceptance of the project.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4. The Supervisor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.1 General Provisions of the Supervisor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supervision content of the Supervisor: <U>See
the Supervision Contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supervisory authority t of the Supervisor: <U>See
the Supervision Contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the provision of office and living
space of the Supervisor at the construction site and the cost to be borne: See the Supervision Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.2 Supervisory Personnel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Supervision Engineer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other provisions concerning the Supervisor: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Supervision Engineer:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name: <U>Che Haokun</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supervision Engineer License No.: <U>44014606</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: <U>15112673372</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: <U>&nbsp;<FONT STYLE="font-style: normal; font-weight: normal">/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></U><FONT STYLE="font-style: normal; font-weight: normal">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Correspondence Address: <U>/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other provisions concerning the Supervisor: <U>/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 </U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.4 Consensus or Decision</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the Client and the Contractor
cannot reach an agreement through consultation, the Client authorizes the Supervisor to determine the following matters: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5. Project Quality</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.1 Quality Requirements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.1.1 Special quality standards and requirements:
<U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on engineering awards: _____.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.3 Inspection of Concealed Works</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.3.2 Provisions on the period for the Contractor
to notify the Supervisor in advance of the inspection of concealed works: <U>As per the General Conditions.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case of inability to carry out the inspection
on time, the Supervisor shall submit a written request for extension in advance. The maximum extension period shall not exceed: <U>48
hours</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>6. Safe and Civilized Construction and Environmental
Protection</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.1 Safe and Civilized Construction</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.1.1 Provisions on the target of project production
safety and the corresponding matters: <U>As per the relevant specifications</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.1.4 Special provisions on security: <U>As per
the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the preparation of the construction
site public security management plan: <U>Provide the construction site security management plan before the commencement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.1.5 Civilized construction</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Requirements of the parties hereto for civilized
construction: <U>As per the relevant national specifications</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.1.6 Provisions on the payment proportion and
payment period of safety and civilized construction fee: <U>60% of the project advance payment for safety protection and civilized construction
measures in the contract price shall be paid to the Contractor within 28 days after the contract is formally signed. When the payment
reaches 30%, the advance payment will be offset against the construction cost</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7. Project Duration and Progress</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.1 Construction Management Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.1.1 Other elements to be included in the construction
management plan agreed by the parties hereto: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.1.2 Submission and modification of the construction
management plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the time limit for the contractor
to submit the detailed construction management plan: <U>After signing the contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The time limit for the Client and the Supervisor
to confirm or propose modification suggestions after receiving the detailed construction management plan: <U>Within seven days after receipt</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.2 Construction Schedule</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.2.2 Revision of construction schedule</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The time limit for the Client and the Supervisor
to confirm or propose modification suggestions after receiving the revised construction schedule: <U>Within seven days after receipt</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.3 Commencement of Construction</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.3.1 Preparation for commencement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The time limit for the Contractor to submit the
project commencement report: <U>After the contract is signed and before the commencement of construction</U>. Other preparatory work and
time limit to be completed by the Client: <U>As per the General Conditions</U>. Other preparatory work and time limit to be completed
by the Contractor: <U>As per the General Conditions.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.3.2 Commencement notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Supervisor fails to issue the commencement
notice within 4 days as of the planned commencement date due to reasons attributable to the Client, the Contractor shall have the right
to request price adjustment or rescind the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.4 Measurement and Setting-Out</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.4.1 The time limit for the Client to provide
the Contractor with measurement datum mark, datum line, benchmark point and other written data through the Supervisor: <U>After the contract
is signed and before the commencement of construction</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">7.5 Delay in Project Duration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.5.1 Delay due to the Client</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In other cases where the project duration is delayed
due to the Client: <U>As per Article 7.5 of the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.5.2 Delay due to the Contractor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The calculation of liquidated damages for late
completion due to the delay caused by the Contractor is as follows: <U>Where the delay is caused by the Contractor (except force majeure)
and the schedule cannot be postponed, the increase in cost of catch-up measures as a result shall be borne by the Contractor; meanwhile,
the Contractor shall bear the liability for breach of contract and pay the Client liquidated damages of 500 yuan for each day the product
duration is delayed. The Client may deduct such liquidated damages from any amount payable to the Contractor and the payment of such liquidated
damages shall not relieve the Contractor of its obligation to complete the project and other obligations hereunder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The maximum amount of liquidated damages for late
completion due to the delay caused by the Contractor: <U>2% of the contract price</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.6 Adverse Physical Conditions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other circumstances of adverse physical conditions
and relevant provisions: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.7 Extraordinarily Vicious Weather Conditions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Client and the Contractor agree that the following
conditions shall be deemed as extraordinarily vicious weather conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>(1) Rainy days with daily rainfall greater
than 50mm for more than one day.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>(2) Typhoon of Force 6 or above;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>(3) Hail and heavy snow that cause damage to
the project, with daily snowfall of more than 10mm.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of the above conditions, the Contractor
shall provide written certification materials issued by the meteorological department to the Client for determination within 10 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.9. Reward for Early Completion</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.9.2 Reward for early completion: <U>No reward
for early completion of this project</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>8. Materials and Equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.4 Custody and Use of Materials and Engineering
Equipment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.4.1 Assumption of custody cost of the materials
and equipment supplied by the Client: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">8.6 Samples</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.6.1 Sample submission and storage</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Requirements for the type, name, specification
and quantity of samples of materials or construction equipment to be submitted by the Contractor: <U>Determined in accordance with relevant
regulations</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.8 Construction Equipment and Temporary Facilities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.8.1 Construction equipment and temporary facilities
provided by the Contractor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the assumption of expenses for the
construction of temporary facilities: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9. Tests and Inspections</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.1 Test Equipment and Personnel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.1.2 Test equipment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Test site to be configured at the construction
site: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Test equipment to be equipped at the construction
site: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other test conditions required at the construction
site: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.4. On-site Process Test</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Relevant provisions on the on-site process test:
<U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>10. Change</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.1 Scope of Change</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the scope of change: <U>As per the
General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.4 Change of Estimate Price</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.4.1 Principle of change of estimate price</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the change of estimate price: <U>Compared
with the average value of published information price in the urban area during the construction duration of steel bar and cement materials,
if the fluctuation range is within &plusmn;5% (including &plusmn;5%), the unit price will not be adjusted, and the risks and benefits
will be borne by the Contractor; if the fluctuation range is beyond &plusmn;5% (excluding &plusmn;5%), the part exceeding &plusmn;5% (excluding
&plusmn;5%) shall be adjusted (the price difference of materials adjusted shall not take into account any other costs except for taxes),
and shall be examined and paid in a lump sum when the project is settled.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.5 Rationalization Proposals of the Contractor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The time limit for the Supervisor to review the
Contractor&rsquo;s rationalization proposals: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The time limit for the Client to approve the Contractor&rsquo;s
rationalization proposals: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The method and amount of the reward for the Contractor&rsquo;s
rationalization proposals that reduces the contract price or increases the economic benefit of the project: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.7 Provisional Estimate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Details of the provisional estimate of materials
and engineering equipment are shown in Annex 11: <I>Schedule of Provisional Estimate Price</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.7.1 Provisional estimate items subject to tender
by law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The confirmation and approval of provisional estimate
items subject to tender by law shall be determined in the <U>/ </U>way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.7.2 Provisional estimate items not subject
to tender by law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The confirmation and approval of provisional estimate
items not subject to tender by law shall be determined in the <U>/ </U>way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The third way: The provisional estimate items
directly implemented by the Contractor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the provisional estimate items directly
implemented by the Contractor: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.8 Provisional Amount</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions of the parties hereto on the use of
provisional amount: .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>11. Price Adjustments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11.1 Adjustments Caused by Market Price Fluctuations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on whether to adjust the contract price
due to market price fluctuations: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjustment of the contract price due to market
price fluctuations is carried out by using the <U>/</U> way:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first way: Price adjustment using price indices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the weight of each adjustable factor,
constant value and variable value, and the basic price index and its source: <U>_/</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The second way: Price adjustment using cost information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Provisions on benchmark price: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special conditions of Contract &#9312;If the unit
price of materials specified by the Contractor in the priced bill of quantities or budget is lower than the benchmark price: When the
unit price of materials increases by more than <U>/</U>% based on the benchmark price during the performance of the Special conditions
of Contract, or when the unit price of materials decreases by more than <U>/</U>% based on the priced bill of quantities or budget, the
excess shall be adjusted accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9313;If the unit price of materials specified
by the Contractor in the priced bill of quantities or budget is greater than the benchmark price: When the unit price of materials decreases
by more than <U>/</U>% based on the benchmark price during the performance of the Special conditions of Contract, or when the unit price
of materials increases by more than <U>/</U>% based on the priced bill of quantities or budget, the excess shall be adjusted accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9314;If the unit price of materials specified
by the Contractor in the priced bill of quantities or budget is equal to the benchmark price: When the unit price of materials fluctuates
by more than <U>&plusmn;</U>/% based on the benchmark price during the performance of the Special conditions of Contract, the excess shall
be adjusted accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The third way: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>12. Contract Price, Measurement and Payment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.1 Form of Contract Price</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Unit price contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk range included in the comprehensive unit
price: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Calculation method of risk cost: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjustment method of contract price beyond the
risk range: <U>Compared with the average value of published information price in the urban area during the construction duration of steel
bar and cement materials, if the fluctuation range is within &plusmn;5% (including &plusmn;5%), the unit price will not be adjusted, and
the risks and benefits will be borne by the Contractor; if the fluctuation range is beyond &plusmn;5% (excluding &plusmn;5%), the part
exceeding &plusmn;5% (excluding &plusmn;5%) shall be adjusted (the price difference of materials adjusted shall not take into account
any other costs except for taxes), and shall be examined and paid in a lump sum when the project is settled.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Lump sum contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk range included in the lump sum price: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Calculation method of risk cost: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjustment method of contract price beyond the
risk range: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Other price methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.2 Advance Payment<BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.2.1 Payment of advance payment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment proportion or amount of advance payment:
<U>Within 28 days after the contract is formally signed, 40% of the contract price for safe and civilized construction shall be paid to
the Contractor in advance for the project</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment term of advance payment: <U>Within 28
days after the contract is signed</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.2.2 Guarantee of advance payment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The time limit for the Contractor to submit guarantee
of advance payment: _/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The form of guarantee of advance payment:_/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.3 Measurement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.3.1 Principle of measurement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Quantity calculation rules: <U>The actual completed
quantity of work shall be calculated based on the relevant rules for quantity calculation according to the construction drawings, design
change notice and engineering visa, etc.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.3.2 Measurement period</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the measurement period: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.3.3 Measurement of unit price contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the measurement of unit price contract:
<U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.3.4 Measurement of lump sum contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the measurement of lump sum contract:
<U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.3.5 If the lump sum contract uses the payment
breakdown table to measure payment, whether the provisions in 12.3.4 [Measurement of lump sum contract] are applicable for measurement:
<U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.3.6 Measurement of other forms of price contracts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Measurement methods and procedures for other forms
of price contracts: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.4 Progress Payment of Project</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.4.1 Payment period</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the payment period: Payment shall
be made at 80% of the completed quantity of work every month. 85% of the project payment shall be paid off upon completion of the project,
95% of the project payment shall be paid off upon completion settlement, and <U>the remaining 5% settlement price shall be used as the
project quality bond. The quality bond will be returned in a lump sum without interest one year after the completion and acceptance of
the project without quality problems</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.4.2 Preparation of progress payment request
form</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the preparation of progress payment
request form: <U>Prepared according to the image progress</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.4.3 Submission of progress payment request
form</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Provisions on the submission of progress payment
request form for unit price contract: <U>Submitted made according to the image progress</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Provisions on the submission of progress payment
request form for lump sum contract: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Provisions on the submission of progress payment
request form for other forms of price contracts: ______.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.4.4 Review and payment of progress payment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The time limit for the Supervisor to review
and submit to the Client: <U>5 working days</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The time limit for the Client to complete the
approval and issue the progress payment certificate: <U>5 working days</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The time limit for the Client to pay the progress
payment: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Calculation of liquidated damages for late payment
of progress payment by the Client: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.4.6 Preparation of payment breakdown table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Preparation and approval of the payment breakdown
table for lump sum contract: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Preparation and approval of the payment dissolving
table of the total price of the unit price contract: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>13. Acceptance and Trial Run of Project</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.1 Acceptance of divisional and sub-divisional
works</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.1.2 In case of inability to carry out the acceptance
on time, the Supervisor shall submit a written request for extension <U>24</U> hours in advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The maximum extension shall not exceed: <U>48
</U>hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.2 Completion Acceptance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.2.2 Completion acceptance procedure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on the completion acceptance procedure:
<U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Calculation of liquidated damages for the Client&rsquo;s
failure to organize the completion acceptance and issue the project acceptance certificate as agreed herein: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.2.5 Handover and acceptance of all or part
of the project</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The time limit for the Contractor to hand over
the project to the Client: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Calculation of liquidated damages for the Client&rsquo;s
failure to accept all or part of the project: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Calculation of liquidated damages for the Contractor&rsquo;s
failure to hand over the project on time: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.3 Trial Run of Project</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.3.1 Trial run procedure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Content of trial run: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) The cost of single-machine no-load trial run
shall be borne by <U>/</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The cost of no-load linkage trial run shall
be borne by <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.3 Commissioning run test</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on matters related to commissioning
run test: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.6 Demobilization after completion</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.6.1 Demobilization after completion</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The time limit for the Contractor to complete
the demobilization: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>14. Completion Settlement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.1 Application for Completion Settlement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The time limit for the Contractor to submit the
completion settlement application form: <U>Within 28 days after the project is completed, accepted and delivered.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contents to be included in completion settlement
application form: <U>Article 14.1 of General Conditions of Contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.2 Completion Settlement Audit</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The time limit for the Client to examine and approve
the completion settlement application form: <U>Implemented as per the Contract and bidding documents</U>. The time limit of payment for
the Client to complete the completion settlement: <U>Implemented as per the Contract and bidding documents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The methods and procedures for the review of the
objection to the completion settlement certificate: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.4 Final Settlement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.4.1 Final settlement application form</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of copies of final settlement application
form submitted by the Contractor: <U>Four copies</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The time limit for the Contractor to submit the
final settlement application form: <U>Within 28 days after the expiry of the defect liability period</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.4.2 Final settlement certificate and payment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(1) The time limit for the Client to complete the
approval of the final settlement application form and issue the final settlement certificate: <U>Within 28 days after the receipt of
the application</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) The time limit for the Client to complete
the payment: <U>Within 14 days after the issuance of the final settlement certificate</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>15. Defect Liability Period and Warranty</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.2 Defect Liability Period</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Specific period of defect liability: <U>12 months</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.3 Quality Bond</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on whether to withhold the quality
bond: <U>Yes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.3.1 Ways for the Contractor to provide the
quality bond</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The quality bond shall be provided in the <U>/</U>
way:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Letter of guarantee of quality bond, with
a guarantee amount of: /_;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) <U>/%</U> of the project price;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Other situation: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.3.2 Retention of quality bond</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The quality bond shall be retained in the <U>second</U>
way:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Retained upon the project progress payment
made, in which case the calculation base of the quality bond shall not include the payment of advance payment, deduction and the amount
of price adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Retained in a lump sum at the completion settlement
of the project;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Other retention ways: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supplementary provisions on the quality bond:
<U>Returned without interest one year after the completion and acceptance of the project.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.4 Warranty</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.4.1 Warranty liability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warranty period: <U>See the Project Quality Warranty</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.4.3 Notice of repair</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reasonable time for the Contractor to receive
the notice of repair and arrive at the construction site: <U>Within 48 hours</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>16. Breach of Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.1 Breach of Contract by the Client</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.1.1 Circumstances of breach by the Client<BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other circumstances of breach of contract by the
Client: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.1.2 Liability of the Client for breach of contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assumption of liability for breach of contract
by the Client and calculation method:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Liability for breach of contract if the commencement
notice fails to be issued within 7 days prior to the scheduled commencement date due to reasons attributable to the Client: <U>Article
16.1 of the General Conditions of Contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Liability for breach of contract if the Client
fails to pay the contract price as agreed herein due to reasons attributable to the Client: <U>Article 16.1 of the General Conditions
of Contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Liability for breach of contract if the Client
carries out the cancelled work on its own or transfers it to others for implementation, which is in violation of the provisions in (2)
of 10.1 [Scope of Change]: <U>Article 16.1 of the General Conditions of Contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Liability for breach of contract if the specification,
quantity or quality of the materials and construction equipment provided by the Client does not conform to the contract, or if the delivery
date is delayed or the delivery place is changed due to the Client: <U>Article 16.1 of the General Conditions of Contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5) Liability for breach of contract if the construction
is suspended caused by the Client&rsquo;s violation of the contract: <U>Article 16.1 of the General Conditions of Contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(6) Liability for breach of contract if the Client
fails to issue instructions for resumption of work within the agreed period without good reasons, resulting in the Contractor&rsquo;s
inability to resume work: <U>Article 16.1 of the General Conditions of Contract</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(7) Others: _/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.1.3 Rescission of the contract due to breach
by the Client</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Client still fails to rectify the breach
after the Contractor&rsquo;s suspension of the construction for a period of <U>/</U> days as agreed in 16.1.1 [Circumstances of breach
by the Client] and thus the purpose of the contract cannot be achieved, the Contractor shall have the right to rescind the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.2 Breach of Contract by the Contractor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.2.1 Circumstances of breach by the Contractor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other circumstances of breach of contract by the
Contractor: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.2.2 Liability of the Contractor for breach
of contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assumption of liability for breach of contract
by the Contractor and calculation method: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.2.3 Rescission of the contract due to breach
by the Contractor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special provisions on the rescission of the contract
due to breach by the Contractor: <U>No affiliation, contract transfer or unauthorized subcontracting is allowed, otherwise the Client
has the right to terminate the contract and confiscate the performance bond, the Contractor shall unconditionally withdraw from the site
within 10 days, and the completed qualified quantity of work will be settled at 70% of the price. Meanwhile, the Client will choose another
construction team to complete the remaining quantity, and the direct and indirect losses arising therefrom shall be borne by the original
Contractor.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assumption of costs for the Client&rsquo;s the
continued use of the Contractor&rsquo;s materials, equipment and temporary works at the construction site, Contractor&rsquo;s documents
and other documents prepared by or on behalf of the Contractor: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>17. Force Majeure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17.1 Confirmation of Force Majeure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other circumstances deemed as force majeure in
addition to the force majeure events stipulated in the General Conditions of Contract: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17.4 Rescission of the Contract Due to Force Majeure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
rescission of the contract, the Client shall complete the payment within <U>/</U> days</FONT>&nbsp; <FONT STYLE="font-family: Times New Roman, Times, Serif">after
it is agreed or determined that the Client shall pay the amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>18. Insurance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">18.1 Project Insurance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special provisions on the project insurance: <U>As
per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">18.3 Other Insurance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on other insurance: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether the Contractor shall take out property
insurance for its construction equipment, etc.: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">18.7 Obligations of Notification</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on notification obligation in case
of change of insurance contract: <U>As per the General Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>19. Dispute Resolution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">19.3 Dispute Review</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether the parties agree to submit the project
dispute to the dispute review panel for decision: <U>/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">19.3.1 Determination of the dispute review panel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Determination of the members of the dispute review
panel: /.<BR STYLE="clear: both"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Time limit for selecting dispute reviewers: /.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation for members of the dispute review
panel: /.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions on other matters: /.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">20.3.2 Decision of the dispute review panel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions of the parties concerning this item:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">19.4 Arbitration or Litigation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Disputes arising out of the contract and contract-related
matters shall be settled in accordance with <U>(2)</U> below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Apply to <U>/</U> arbitration commission for
arbitration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) File a lawsuit with the people&rsquo;s court in
the place <U>where the project is located</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>





<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">25</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.16
<SEQUENCE>7
<FILENAME>f20f2021ex4-16_universephar.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE WORKING CAPITAL LOAN CONTRACT ENTERED INTO BY AND BETWEEN JIANGXI UNIVERSE AND BANK OF COMMUNICATIONS, DATED JUNE 30, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>No.: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>Working Capital
Loan Contract</B></FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt">Bank of Communications
Co., Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 56pt 0pt 0; text-align: right"><B>No.:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Working Capital Loan Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1.5pt solid; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Important Notice</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>The borrower is requested to read the full
    text of this<BR>
 contract carefully, especially the provisions marked with &#9650;&#9650;. <BR>
Please ask the Lender to explain in time in case
    of any doubt.</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">In view of the Borrower&rsquo;s application for working
capital loan line of credit from the Lender, and in order to clarify the rights and obligations of both parties, the Borrower and the
Lender hereby conclude this contract through negotiation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 1 Definition</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Line of credit&rdquo; refers to the maximum
amount of loan balance (under revolving line of credit) or total loan (under lump-sum line of credit) that the Lender may issue to the
Borrower according to the contract, and the line of credit can be revolving line of credit or lump-sum line of credit (only used once
or can be used several times) according to the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Revolving line of credit&rdquo; means that
the Borrower can apply for using the line of credit several times as agreed in this contract to obtain the loan, but the loan balance
cannot exceed the agreed line of credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Lump-sum line of credit&rdquo; means that the
Borrower can apply for using the line of credit at one time or several times as agreed in this contract to obtain the loan, but the total
amount of loans withdrawn cumulatively cannot exceed the agreed line of credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Loan balance&rdquo; refers to the sum of the
loan principal amount obtained by the Borrower under this contract and not yet paid off.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Line of credit balance&rdquo; refers to the
amount after deducting the loan balance (under the revolving line of credit) or the total loan (under the lump-sum line of credit) from
the line of credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Credit period&rdquo; refers to the period during
which the Lender grants the loan to the Borrower according to the Borrower&rsquo;s application and the agreement in this contract, and which
belongs to the loan occurrence period rather than the loan term.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Loan term&rdquo; refers to the term of each
loan determined by both parties in the corresponding Application for Use of Loan Line of Credit of Bank of Communications (hereinafter
referred to as &ldquo;Application for Use of Line of Credit&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Loan prime rate (LPR)&rdquo; refers to the
loan prime rate released by the National Interbank Funding Center on the 20th day of each month (postponed in case of holidays).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Bank working day&rdquo; and &ldquo;working day&rdquo;
refer to the opening day of the bank&rsquo;s corporate business in the place where the Lender is located, excluding legal holidays and rest
days (except for business due to holiday adjustment). If the loan date, repayment date, interest payment date, maturity date and other
obligation fulfillment dates meet non-bank working day, it shall be postponed to the next bank working day accordingly.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Related parties&rdquo; refer to the authorized
handler, agent, legal representative, person in charge, controlling shareholder or actual controller, beneficial owner and other related
parties directly or indirectly of the Borrower.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Business related parties&rdquo; refer to all
parties to the transaction under the basic transaction contract, other related entities other than the parties to the transaction, as
well as the parties to the transaction, authorized handlers, agents, legal representatives, persons in charge, controlling shareholders
or actual controllers, beneficial owners and other parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Related parties, related party transactions, individual
major investors and other words have the same meanings as those in Accounting Standards for Business Enterprises No.36 - Related Party
Disclosure (CAI KUAI No.3 [2006]) and subsequent amendments to the standards.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 2 Use of Line of Credit</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.1 The Borrower should apply to the Lender at least
5 banking days in advance when it needs to use the line of credit. When applying, the Borrower should fill in the Application for Use
of Line of Credit, which can only be used after being examined and approved by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650; 2.2 Every use of the line of credit
is subject to all the following conditions:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) The loan balance (under the revolving line of
credit) or the total loan (under the lump-sum line of credit) does not exceed the line of credit;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) The applied loan amount does not exceed the
balance of the line of credit;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3) The application date and loan date are within
the credit period;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(4) The loan term and maturity date of the loan
are in line with this contract;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(5) The guarantee contract under this contract (if
any) has come into force and continues to be valid. If the guarantee contract is a mortgage contract and/or pledge contract, the real
rights granted by way of security have been established and continue to be valid;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(6) The Borrower has completed the government permission,
approval, registration and other procedures that must be handled by law when applying for the loan, and the permission, approval or registration
continues to be valid;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(7) After the contract comes into effect, the Borrower&rsquo;s
operating and financial conditions have no significant adverse changes;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(8) The application of the Borrower meets the requirements
of relevant rules and regulations of the Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(9) The Borrower has not violated the contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(10) The payment method of the loan is in accordance
with this contract. If the Lender is entrusted to pay, the Lender agrees to pay;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(11) In case of drawing foreign currency loans,
the Borrower has provided proof documents that the loans comply with relevant foreign exchange management policies, including but not
limited to valid foreign exchange purpose certificates or registration documents;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(12) The Borrower has designated a special fund
withdrawal account and signed an account management agreement as required by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;2.3 If the Lender agrees to grant
the loan, the final loan information shall be subject to the contents of the bank print column of the Application for Use of Line of Credit.
The Application for Use of Line of Credit is also used as the Loan Voucher.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;2.4 If the currency of the Application
for Use of Line of Credit is inconsistent with the currency of the line of credit, only for the purpose of determining the line of credit
balance, it shall be converted according to the exchange rate published by Bank of Communications Co., Ltd. at the beginning of each day;
if there is no directly applicable exchange rate, it shall be converted by Bank of Communications Co., Ltd. according to the exchange
rate determined in a reasonable way.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;2.5 After the Borrower becomes the
shareholder of the guarantor or the &ldquo;actual controller&rdquo; as defined in the Company Law, the Lender has the right to suspend or
cancel the unused loan line of credit of the Borrower before the guarantor provides the resolution on agreeing to provide guarantee for
the Borrower by its shareholders&rsquo; meeting (General Meeting of Shareholders) accepted by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 3 Interest Rate, Interest Calculation and
Payment</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.1 Basic rules for determining the interest rate</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.1.1 The annual loan interest rate (simple interest)
under this contract is based on the loan prime rate (LPR) as the pricing benchmark, calculated according to the loan prime rate (LPR)
plus (minus) points (1 basis point is 0.01 percent, 1 percentage point is 100 basis points), and the interest rate shall be agreed by
both parties in the Application for Use of Line of Credit after negotiation every time the Borrower uses its line of credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If both parties agree to apply the fixed interest
rate in the Application for Use of Line of Credit, and the specific value is recorded in the fixed interest rate value field, the specific
interest rate of each loan shall be subject to the value recorded in the fixed interest rate value field in the Application for Use of
Line of Credit. The specific value will be determined based on the specific value of the loan prime rate (LPR) applicable to the applicable
date of the pricing benchmark agreed in the Application for Use of Line of Credit (hereinafter referred to as &ldquo;LPR value&rdquo;) and
according to the value of plus (minus) points agreed in the Application for Use of Line of Credit. If the specific value is not recorded
in the fixed interest rate value field, the specific interest rate of each loan will be determined based on the LPR value applicable to
the applicable date of the pricing benchmark agreed in the Application for Use of Line of Credit and according to the plus (minus) point
value agreed in the Application for Use of Line of Credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If both parties agree to apply the floating interest
rate in the Application for Use of Line of Credit, the specific interest rate of each loan will be determined based on the LPR value applicable
to the applicable date of the pricing benchmark agreed in the Application for Use of Line of Credit, the value of the plus (minus) points,
the interest rate fluctuation rules, the interest rate fluctuation period, the unit of interest rate fluctuation period and the floating
start date of a specific date (if necessary) agreed in the Application for Use of Line of Credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.1.2 If the currency is RMB, the daily interest
rate = interest rate/30, and the monthly interest rate = annual interest rate/12; If the currency is Hong Kong dollars, British pounds
and Australian dollars, the daily interest rate = annual interest rate/365; If the currency is USD, Euro, Japanese yen and other foreign
currencies accepted by the Lender, the daily interest rate = annual interest rate/360.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;3.2 Loan interest rate</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The loan interest rate for each loan is determined
based on the applicable LPR value of the &ldquo;applicable date of the pricing benchmark&rdquo; agreed in the corresponding Application
for Use of Line of Credit, and according to the plus (minus) point value agreed in the Application for Use of Line of Credit. Take the
&ldquo;applicable date of the pricing benchmark&rdquo; as the T-day, and the applicable LPR value on T-day is the last published loan prime
rate (LPR) value before T-day.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.3 Adjustment of the interest rate</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.3.1 If a fixed interest rate is recorded in the
Application for Use of Line of Credit, the recorded interest rate will be implemented for the loan within the loan term.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;3.3.2 If a floating interest rate
is recorded in the Application for Use of Line of Credit, the loan interest rate adjustment date shall be determined according to the
interest rate fluctuation rules, interest rate fluctuation period, unit of interest rate fluctuation period and floating start date of
specific date (if necessary) agreed in the Application for Use of Line of Credit, and the adjusted interest rate shall apply from the
loan interest rate adjustment date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.3.2.1 If the loan prime rate (LPR) of the loan
market is adjusted during the loan period, the period of adjustment of the loan interest rate will be calculated from the &ldquo;loan entry
date&rdquo; or the &ldquo;floating start date of the specific date&rdquo; according to the &ldquo;floating by loan entry date&rdquo; or &ldquo;floating
on specific starting date&rdquo; selected in &ldquo;interest rate fluctuation rules&rdquo;. The blank column of interest rate floating cycle
shall be filled with the number of interest rate floating cycles, and the unit of interest rate floating cycle can be selected as daily
or monthly. If &ldquo;1&rdquo; is filled in the number of interest rate floating cycles and &ldquo;daily&rdquo; is selected as the floating
cycle unit, the adjustment date of loan prime rate (LPR) will be taken as the adjustment date of loan interest rate; If &ldquo;3&rdquo;
is filled in the number of interest rate floating cycles and &ldquo;daily&rdquo; is selected as the floating cycle unit, the loan interest
rate adjustment date will be the date every 3 days from the &ldquo;loan entry date&rdquo; or &ldquo;floating start date of specific date&rdquo;;
If &ldquo;1&rdquo; is filled in the number of interest rate floating cycles and &ldquo;monthly&rdquo; is selected as the floating cycle unit,
the loan interest rate adjustment date will be the date of every month from the &ldquo;loan entry date&rdquo; or &ldquo;floating start date
of specific date&rdquo;; If &ldquo;3&rdquo; is filled in the number of interest rate floating cycles and &ldquo;monthly&rdquo; is selected
as the floating cycle unit, the loan interest rate adjustment date will be every 3 months from the &ldquo;loan entry date&rdquo; or &ldquo;floating
start date of specific date&rdquo;, and so on.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.3.2.2 The loan interest rate on the loan interest
rate adjustment date is determined on the basis of the applicable LPR value on the loan interest rate adjustment date, and the value of
interest rate plus (minus) points remains unchanged (except for the value of plus (minus) points adjusted by both parties through consultation).
Take the &ldquo;loan interest rate adjustment date&rdquo; as the T-day, and the applicable LPR value on the T-day is the last published
loan prime rate (LPR) value before T-day.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;3.3.3 If the loan prime rate (LPR)
is canceled or the corresponding publishing institution stops publishing according to the regulatory requirements, both parties shall
negotiate and adjust the loan interest rate separately, but the adjusted interest rate shall not be lower than the applicable interest
rate at that time; If the two parties still fail to reach an agreement on the adjusted interest rate after more than one month from the
date when the loan prime rate (LPR) is canceled or stopped publishing, the Lender has the right to declare the loan to expire in advance.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;3.3.4 Both parties can adjust the
value of the plus (minus) points of the corresponding loan interest rate after consensus on each loan interest rate adjustment date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.4 If the loan currency is RMB, the penalty interest
rate of overdue loans will be increased by 50% according to the interest rate agreed in this contract, and the penalty interest rate of
misappropriated loans will be increased by 100% according to the interest rate agreed in this contract. In case of adjustment of loan
prime rate (LPR) for floating rate loans, the Lender has the right to adjust the applicable penalty interest rate for each loan accordingly,
and apply the new penalty interest rate from the adjustment date of loan interest rate agreed in the corresponding Application for Use
of Line of Credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.5 Calculation of interest</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.5.1 Normal interest = interest rate agreed in
this contract &times; loan amount &times; occupied days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The occupied days are calculated from the loan date
(inclusive) to the expiration date (exclusive), which will be postponed when the expiration date is not a working day. The postponed period
will be counted as occupied days, and the interest will still be calculated according to the contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.5.2 The penalty interest for overdue loans and
misappropriated loans is calculated according to the overdue or misappropriated amount and actual days (from the overdue or misappropriated
date (inclusive) to the date of repayment of principal and interest (exclusive)).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.5.3 If the calculated interest/penalty interest
has a large number of decimal places, the Lender will keep two decimal places by rounding.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;3.6 If the Borrower repays the loan
in advance or the Lender withdraws the loan in advance according to this contract, the corresponding interest rate grade will not be adjusted,
and the interest rate agreed in this contract will still be applied.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.7 If the loan currency is foreign currency, the
determination of interest rate, adjustment of interest rate, penalty interest rate for overdue and misappropriated loans shall be subject
to the agreement in Article 17 of this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 4 Payment of Loan</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.1 If the loan account designated by the Borrower
is a special loan issuance account opened at the Lender, the issuance and payment of the loan shall be handled through this account. This
account is only used for the issuance of loan funds and external payment, only for the sale of &ldquo;Application for Settlement Business&rdquo;
vouchers; It cannot be used for handling checks, bills of exchange, bank acceptance bills and other businesses, and cannot be used for
other settlements. When the Borrower pays for the loan fund allocation independently, it must be handled at the counter of the account
opening outlet. The deposit interest of this account is included in the Borrower&rsquo;s repayment account.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.2 When the Borrower withdraws the loan according
to this contract, it should specify the payment method (the Lender&rsquo;s entrusted payment or the Borrower&rsquo;s independent payment), and only
one payment method can be used for each withdrawal.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.3 The Lender&rsquo;s entrusted payment means that the
Lender directly pays the loan funds to the Borrower&rsquo;s counterparty that meets the purpose agreed in this contract through the Borrower&rsquo;s
account after issuing the loan according to the Borrower&rsquo;s entrusted payment power of attorney.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the single payment amount exceeds the independent
payment line of credit or meets one of the conditions agreed in Article 19.3, the entrusted loan payment method shall be adopted.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In case of the Lender&rsquo;s entrusted payment, the Borrower
shall submit to the Lender the Application for Use of Line of Credit, the corresponding entrusted payment power of attorney and other
information required by the Lender (including but not limited to business contracts, invoices, receipt documents and other transaction
information), and specify the amount of the loan to withdraw and the object and amount of payment, and the amount of the loan to withdraw
should be equal to the total amount to be paid.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;If the payment to be made by the Borrower
does not conform to this contract or the corresponding commercial contract or has other defects, the Lender has the right to refuse the
payment and return the entrusted payment power of attorney submitted by the Borrower.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;If the Lender agrees to pay, and if
it can&rsquo;t be paid or it is refunded due to the wrong information provided by the Borrower, the Borrower must resubmit the relevant documents
and materials containing the correct information within the time line of credit specified by the Lender, and the Lender will not be responsible
for the delay or unsuccessful payment.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.4 The Borrower&rsquo;s independent payment means that
after the Lender grants the loan funds to the Borrower&rsquo;s account according to the agreement in this contract, the Borrower pays the loan
funds to the Borrower&rsquo;s counterparty that meets the purpose agreed in this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the Borrower&rsquo;s independent payment is adopted,
the Borrower shall submit to the Lender the Application for Use of Line of Credit, instructions on the use of funds and other materials
required by the Lender. The Borrower shall summarize and report the payment of loan funds to the Lender on time. The Lender has the right
to check whether the payment of loan funds meets the agreed purpose by means of account analysis, voucher inspection, on-site investigation,
etc. The Borrower shall cooperate with the Lender&rsquo;s verification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 5 Repayment of Loan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.1 The Borrower shall repay the loan according
to the repayment date and amount recorded in the corresponding Application for Use of Line of Credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;5.2 Without the written consent of
the Lender, the Borrower cannot repay the loan in advance.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;5.3 The repayment arrangement of the
principal and interest agreed by the Borrower and the Lender in the Application for Use of Line of Credit is the real intention reached
by both parties on a voluntary basis after consultation. Under the repayment arrangement chosen by both parties, whether the principal
is repaid before the interest does not affect the Borrower&rsquo;s repayment responsibility for the interest payable, and the Borrower shall
not argue against the repayment of the interest payable. Under any repayment arrangement, the Borrower shall bear the repayment responsibility
for all the principal and interest payable.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;5.4 When the repayment of the Borrower
(including the repayment voluntarily repaid by the Borrower and deducted by the Lender according to this contract) cannot fully pay off
all the debts of the Borrower:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) It should be used to pay off the overdue expenses
first. If the principal and interest are overdue for less than 90 days, the balance after offsetting the expenses shall be used to offset
the overdue interest or penalty interest and compound interest, and then used to offset the overdue principal; If the principal or interest
is overdue for more than 90 days, the balance after offsetting the expenses shall be used to offset the overdue principal first, and then
used to offset the overdue interest or penalty interest and compound interest;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) If the Borrower has multiple debts (including
the debts of the Borrower to the Lender under other contracts), the Lender has the right to decide the repayment and offset order of each
debt of the Borrower by itself, as long as the offset order does not violate the mandatory provisions of laws, regulations, rules and
regulations as well as relevant regulatory requirements applicable to the Lender. The Lender shall inform the Borrower of the result of
debt repayment. Unless otherwise agreed by both parties to this article.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 6 Statement and Guarantee of the Borrower</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.1 The Borrower is legally established and legally
exists; It has all necessary rights and capabilities, and it can perform the obligations of this contract in its own name and bear civil
liabilities.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.2 Signing and performing this contract is the
true intention of the Borrower after all necessary consent, approval and authorization, and there is no any legal flaw.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.3 The Borrower&rsquo;s production and operation are
legal and compliant, with the ability of going concern, legal sources of repayment, no major environmental and social risks and no major
bad credit record. The senior management of the Borrower has no bad record.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.4 All documents, statements, data and information
provided by the Borrower to the Lender during the signing and performance of this contract are true, accurate, complete and effective.
No information that may affect its financial status and repayment ability has been concealed from the Lender, and the financial status
of the Borrower has no significant adverse changes since the reporting date of the latest financial statements.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;6.5 The Borrower, its related parties
and business related parties are not listed in the sanctions list issued by the United Nations and related countries, organizations and
institutions, or the enterprises or individuals listed in the risk list related to terrorism and anti-money laundering issued by Chinese
government departments or authorities; They are not located in countries and regions that are not sanctioned by the United Nations and
related countries, organizations and institutions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;6.6 The Borrower promises to abide
by the national anti-money laundering laws, regulations and relevant policies, not to engage in illegal activities such as assisting others
in money laundering, terrorist financing, tax evasion, evasion of bank debts, cash extraction, telecom fraud, illegal fund-raising, etc.,
actively cooperate with the Lender to carry out various anti-money laundering work such as customer identification, transaction record
keeping, due diligence on customer identity and transaction background, large and suspicious transaction reports, etc., and provide relevant
certification materials as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 7 Rights and Obligations of the Lender</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.1 The Lender has the right to recover the loan
principal and interest (including compound interest, penalty interest for overdue loans and misappropriation of loans, etc.) according
to this contract, collect the fees payable by the Borrower, decide to recover the loan in advance according to the Borrower&rsquo;s fund withdrawal,
and exercise other rights stipulated by law or this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;7.2 During the performance of this
contract, the Lender only conducts formal review on the information provided by the Borrower. If the materials provided by the Borrower
are untrue, inaccurate or incomplete, or the Borrower violates the agreement of this contract to make payment, resulting in the Lender&rsquo;s
failure to complete the entrusted payment in time, the Lender will not be liable.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;7.3 The Lender shall issue the loan
and handle the payment according to this contract. If the Lender fails to issue the loan or make payment on time due to any of the following
reasons, the Lender will not be liable, but it will inform the Borrower in time: The loan account designated by the Borrower is frozen,
the payment object account is frozen, force majeure, communication or network failure, system failure of the Lender, etc. Unless otherwise
agreed in this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 8 Obligations of the Borrower</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.1 The Borrower shall repay the loan principal
under this contract and pay the interest according to the time, amount, currency and interest rate recorded in this contract and the corresponding
Application for Use of Line of Credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The fund withdrawal account designated by the Borrower
is used to collect the corresponding sales revenue or planned repayment funds. If the corresponding sales revenue is settled in a non-cash
manner, the Borrower shall ensure that the money is promptly transferred to the fund withdrawal account after being received. The Borrower
shall provide the capital inflow and outflow of the capital withdrawal account as required by the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.2 The Borrower shall use the line of credit according
to the purpose agreed in this contract, and use the loan according to the purpose determined in the corresponding Application for Use
of Line of Credit, and shall not use the loan for other purposes, or use the loan for fixed assets investment, equity investment, fields
and purposes prohibited by the state from production and operation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Borrower shall use the loan funds as agreed,
and shall not avoid the Lender&rsquo;s entrusted payment by breaking up the whole into parts; If the Borrower&rsquo;s independent payment is adopted,
the Borrower shall use the loan within a reasonable time according to the requirements of the Lender&rsquo;s supervisory authority, and the
payment of loan funds shall comply with this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;8.3 The Borrower shall bear the settlement
fees (if any) for the loan fund payment (including the Lender&rsquo;s entrusted payment and the Borrower&rsquo;s independent payment), and the specific
fees shall be implemented according to laws, regulations, rules, regulatory requirements and the Service Charges List of the Bank of Communications
effective at that time published by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the loan account is a special loan issuing account,
when the loan funds are paid (including the Lender&rsquo;s entrusted payment and the Borrower&rsquo;s independent payment), if the collection account
does not belong to the account opened in the Bank of Communications, the payment of the funds may be handled through the payment system
of the People&rsquo;s Bank of China or the local exchange system.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the loan account is not a special loan issuing
account, when the loan funds are paid (including the Lender&rsquo;s entrusted payment and the Borrower&rsquo;s independent payment), if the collection
account is an account of another bank in different places, all the payment of funds will be handled through the payment system of the
People&rsquo;s Bank of China.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;8.4 The Borrower shall cooperate with
the Lender to handle the loan payment and supervise and inspect the loan usage as well as the Borrower&rsquo;s operation; It shall timely provide
the financial statements, loan fund usage records and materials, related party and related party transaction information, environmental
and social risk reports, other materials and information required by the Lender for post-loan risk management, and ensure that the documents,
materials and information provided are true, complete and accurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;8.5 In case of any of the following
events, the Borrower shall notify the Lender in writing at least 30 days in advance, and shall not take any action before paying off all
the loan principal and interest under this contract or providing the repayment scheme and guarantee approved by the Lender:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) The Borrower disposes of all or most assets
or important assets by selling, donating, leasing, lending, transfer, mortgage, pledge or otherwise;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) Significant changes have taken place in the
Borrower&rsquo;s management system or property right organization form, including but not limited to the implementation of contract, lease,
joint venture, company system reform, joint-stock cooperation system reform, enterprise sale, merger (acquisition), joint venture (cooperation),
division, establishment of subsidiaries, equity transfer, property right transfer, capital reduction, etc.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3) The Borrower&rsquo;s foreign equity or increased debt
financing exceeds the agreed line of credit.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;8.6 The Borrower shall notify the
Lender in writing within 7 days from the date when the following events happen or may happen:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) The Borrower or its related party modifies the
articles of association, changes the business registration items such as enterprise name, legal representative (person in charge), residence,
postal address or business scope, or makes decisions that have a significant impact on finance and personnel;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) The Borrower, its related party or guarantor
intends to apply for bankruptcy or may have been or has been applied for bankruptcy by creditors;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3) The Borrower or its related party is involved
in major litigation, arbitration and administrative measures, or property preservation or other compulsory measures have been taken for
its main assets or collateral under this contract, or the safety and integrity of its main assets or collateral under this contract has
been or may be affected, or its value is reduced or may be reduced;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(4) The Borrower or its related party provides a
guarantee for a third party, which has a significant adverse impact on its economic status, financial status or ability to perform its
obligations under this contract;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(5) The Borrower or its related party signs a contract
that has a significant impact on its operation and financial status;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(6) The Borrower pays off the unexpired debts in
advance or gives priority to paying off other due debts, adds any form of guarantee such as pledge for other existing debts, or makes
any arrangement or signs relevant documents with similar effect;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(7) The Borrower, its related party or guarantor
suspends production, closes down, dissolves or suspends business for rectification, is revoked or its business license is revoked;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(8) The Borrower or its related party, the individual
principal investor of the Borrower or its related party, the legal representative (person in charge), director or key management personnel
of the Borrower or its related party is missing, involved in violations of laws and regulations or in violation of applicable exchange
rules or has any abnormal changes;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(9) The Borrower or its related party has serious
difficulties in operation, or its financial situation deteriorates, or other events that have a negative impact on the operation, financial
situation, solvency or economic situation of the Borrower or its related parties occur;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(10) Related party transactions occur, and the monthly
transaction amount reaches or exceeds 10% of the recently audited net assets;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(11) Before paying off all debts under this contract,
the Borrower becomes or may become the shareholder or the &ldquo;actual controller&rdquo; as defined in the Company Law of the guarantor;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(12) The Borrower or its related party is exposed
by the media because of its violation of laws, regulations, regulatory requirements, national policies or industry standards, etc.;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(13) The Borrower or its related party has any safety
or environmental accident;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(14) The controlling or controlled relationship
between the Borrower&rsquo;s related party and the Borrower changes;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(15) The Borrower or its related party has any significant
equity change;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(16) The audit opinion issued by the external auditor
of the Borrower on its financial statements is not a standard unqualified opinion;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(17) The Borrower has been or may be investigated,
punished or taken other similar measures by the competent authority for violating laws, regulations and/or regulatory requirements;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(18) The Borrower or its related party or business
related party is included in the sanctions list issued by the United Nations and related countries, organizations and institutions, and
the list of risks related to terrorism and anti-money laundering issued by Chinese government departments or authorities; Or the country
and region where the Borrower or its related person or business related party is located is included in the list of countries and regions
sanctioned by the United Nations and related countries, organizations and institutions;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(19) Other major adverse events that affect the
solvency of the Borrower or its related party occur.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;8.7 When the guarantee under this
contract changes to the detriment of the Lender&rsquo;s creditor&rsquo;s rights, the Borrower shall provide other guarantees recognized by the Lender
in a timely manner as required by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The &ldquo;change&rdquo; mentioned in this paragraph
includes but is not limited to: merger, division, suspension of production, suspension of business, dissolution, suspension of business
for rectification, being revoked, revocation of business license, application or being applied for bankruptcy of the guarantor; Significant
changes have taken place in the operation or financial status of the guarantor; The guarantor involves major litigation, arbitration,
administrative measures, or property preservation or other compulsory measures have been taken for its main assets; The security and integrity
of the collateral is or may be affected; The value of collateral is reduced or may be reduced, or compulsory measures such as property
preservation such as seizure are taken; The guarantor or its legal representative (person in charge) or key management personnel is involved
in violation of laws and regulations or the applicable exchange rules; If the guarantor is an individual, the guarantor is missing or
dead (declared dead); The guarantor has breached the contract under the guarantee contract; Disputes between the guarantor and the Borrower
occur; The guarantor asks to cancel the guarantee contract; The guarantee contract is ineffective, invalid or revoked; The real rights
granted by way of security are not established or invalid; Or other events affecting the security of the Lender&rsquo;s creditor&rsquo;s rights occur,
etc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;8.8 The Borrower promises that: from
the date of signing this contract until all the loan principal and interest and related expenses under this contract are paid off, the
financial indicators, external agency rating and production and operation qualifications/licenses of the Borrower always comply with the
contract, and if the production and operation qualifications/licenses need to be examined annually, they should pass the annual examination
on time.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.9 The Borrower guarantees that the Borrower, the
Borrower&rsquo;s employees and agents will not provide, give, ask for or accept material benefits in any form other than those stipulated in
this contract (including but not limited to cash, physical cards, travel, etc.) or other non-material benefits to the Lender or the Lender&rsquo;s
employees in any form; The Borrower, the Borrower&rsquo;s employees and agents will not directly or indirectly use the funds or services provided
by the Lender for activities related to corruption or bribery in any form; If the Borrower is aware of any violation of this article,
it should provide clues and relevant information to the Lender in a timely, truthful, complete and accurate manner, and cooperate with
relevant matters as required by the Lender.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#9650;&#9650; Article 9 Adjustment of the Line of
Credit, Premature Expiration of Loan and Risk Repricing</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.1 Any of the following events shall be regarded
as the &ldquo;premature expiration event&rdquo; of this contract:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) The Borrower fails to repay the loan principal
or pay interest as agreed in any Application for Use of Line of Credit under this contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) The statements and guarantees made by the Borrower
under this contract are untrue;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3) Any of the notifiable matters listed in Article
8.6 actually happens, which affects or may affect the security of the Lender&rsquo;s creditor&rsquo;s rights;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(4) The change of laws, regulations and regulatory
policies causes that the loan issuance by the Lender as agreed in this contract constitutes or may constitute violations of laws or regulations;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(5) When the Borrower performs other contracts with
the Lender or contracts with a third party, there is a breach of contract or the debt may or has been announced to be due in advance;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(6) The Borrower violates other agreements in this
contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.2 When any &ldquo;premature expiration event&rdquo;
occurs, the Lender has the right to take one, several or all of the following measures:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) Reduce, suspend or cancel the line of credit
under this contract;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) Stop issuing loans that have not been drawn
by the Borrower;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3) Stop handle the payment that the Borrower has
withdrawn but not yet used;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(4) Require the Borrower to negotiate with the Lender
for supplementary loan issuance and payment conditions within a time limit;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(5) Require the Borrower to change the payment method
as required by the Lender;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(6) Reprice the risk of loans as agreed in Article
9.3;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(7) Unilaterally declare that all the loan principal
issued under the contract is due in advance and require the Borrower to immediately repay all the loan principal due and settle the interest.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.3 According to the production and operation situation
of the Borrower at the time of signing this contract, the interest rate agreed in this contract and its adjustment are determined by both
parties through negotiation. The Borrower agrees that in the event of any &ldquo;premature expiration event&rdquo;, the Lender has the right
to reprice the risk of the loan according to this article.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.3.1 Risk repricing includes negotiated repricing
and direct increase of the loan interest rate. The risk repricing method adopted in this contract is agreed by both parties in Article
21.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.3.2 &ldquo;Negotiated repricing&rdquo; means that
the Lender has the right to ask the Borrower to negotiate with the Lender to increase the loan interest rate within a time limit, and
both parties determine the &ldquo;repricing date&rdquo; and the specific agreement on relevant interest rates by means of supplementary
agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.3.3 &ldquo;Direct increase of the loan interest
rate&rdquo; means that the Lender has the right to directly increase the loan interest rate according to this article and Article 21.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.3.3.1 Since the &ldquo;repricing date&rdquo; notified
by the Lender to the Borrower in writing, the increased loan interest rate will be applied to all loans that the borrower has not repaid
as of the &ldquo;repricing date&rdquo;.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.3.3.2 If the loan currency is RMB, on the basis
of the applicable LPR value on the &ldquo;repricing date&rdquo;, the loan interest rate after each loan increase shall be determined according
to the value of the plus (minus) points agreed in Article 21.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Take the &ldquo;repricing date&rdquo; as the T-day,
and the applicable LPR value on T-day is the last published loan prime rate (LPR) value before T-day.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.3.3.3 If the loan currency is foreign currency,
the loan interest rate after the increase shall be determined according to Article 21.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.3.4 After the Lender reprices the risk according
to the aforementioned agreement, the new interest rate will be implemented from the &ldquo;repricing date&rdquo;. On the basis of this interest
rate, it is still subject to the floating adjustment as agreed in Article 3 of this contract. If both parties agree to change the relevant
agreement through consultation, the agreement after the change shall prevail. In case of loans overdue (including the Borrower&rsquo;s failure
to repay the loan on time or the Lender&rsquo;s announcement of premature maturity) or misappropriation, the penalty interest rate for overdue
and misappropriation will be determined on the basis of the new interest rate (including the interest rate after floating adjustment as
agreed in this contract), and the interest rate for calculating compound interest will also be adjusted accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.3.5 The implementation of &ldquo;risk repricing&rdquo;
shall not be deemed or interpreted as the Lender waiving other rights stipulated by laws and regulations and agreed in this contract.
The Lender has the right to take other creditor&rsquo;s rights protection measures according to laws and regulations and the contract, including
but not limited to the measures agreed in Article 9.2.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#9650;&#9650;Article 10 Breach of Contract</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.1 If the Borrower fails to repay the loan principal
in full and on time, pay interest or use the loan according to the purpose agreed in this contract, the Lender will charge interest according
to the penalty interest rate of overdue loans or the penalty interest rate of misappropriated loans, and calculate compound interest on
the unpaid interest payable. If the penalty interest rate is adjusted according to the contract, the interest rate for calculating compound
interest will also be adjusted accordingly.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.2 If the Borrower fails to repay the loan principal
and pay the interest in full and on time, it shall bear the urging fees, litigation fees (or arbitration fees), preservation fees, announcement
fees, execution fees, legal fees, travel expenses and other fees paid by the Lender to realize the creditor&rsquo;s rights.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#9650;&#9650;Article 11 Agreement on Deduction</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.1 When the Borrower authorizes and there is the
loan principal, interest, penalty interest, compound interest or other fees due and payable, the Lender has the right to deduct the funds
in any account opened by the Borrower in all branches of Bank of Communications Co., Ltd. for repayment.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.2 After deduction, the Lender shall notify the
Borrower of the account number, contract number, number of Application for Use of Line of Credit, deduction amount and remaining debt
amount involved in deduction.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.3 If the deduction proceeds are not enough to
pay off all the debts of the Borrower, the debts to be paid off and offset shall be determined according to this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.4 If the currency of deduction proceeds is inconsistent
with that of the debt to be offset, it shall be converted into the amount of the debt to be offset according to the exchange rate published
by Bank of Communications Co., Ltd. at the time of deduction. If any foreign exchange settlement and sales or foreign exchange conversion
procedures need to be handled, the Borrower has the obligation to assist the Lender in handling the formalities as required by the Lender,
and the exchange rate risk shall be borne by the Borrower.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#9650;&#9650;Article 12 Notice</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">12.1 The contact information (including postal address,
telephone number, fax number, etc.) filled in by the Borrower in this contract is true and valid. In case of any change of the contact
information, the Borrower shall immediately mail/send the change information in writing to the postal address filled in by the Lender
in this contract. Such information change will take effect after the Lender receives the notice of change.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">12.2 Unless otherwise expressly agreed in this contract,
the Lender has the right to notice the Borrower in any of the following ways. The Lender has the right to choose the notice method it
deems appropriate, and does not need to be responsible for transmission errors, omissions or delays in postal, fax, telephone or any other
communication system. If the Lender chooses multiple notice methods at the same time, the one that arrives at the Borrower sooner shall
prevail. For the same matter, if the Lender sends more than one notice to the Borrower with different contents, unless otherwise specified
in the notice, the later notice shall prevail.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) For announcement, the date when the Lender issues
an announcement on its website, online banking, telephone banking or business outlets shall be regarded as the date of delivery;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) For delivery by special person, the date of
receipt by the Borrower shall be regarded as the date of delivery;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3) For delivery by post (including express mail,
ordinary mail and registered mail) to the latest known address of the Borrower, the 3rd day (in the same place)/5th day (in different
places) after the date of mailing shall be regarded as the delivery date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(4) For fax, mobile phone short message or other
electronic communication methods to the latest known fax number of the Borrower, the mobile phone number or email address designated by
the Borrower to the Lender, the date of sending is regarded as the date of delivery. The aforementioned delivery means that the relevant
information enters the server terminal of the service provider without taking the actual display of the relevant information in the client
terminal as the standard.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">12.3 The Borrower agrees that unless the Lender
receives a written notice from the Borrower about changing its postal address, the postal address filled in by the Borrower in this contract
is the address where the court will serve judicial documents and other written documents to the Borrower. The applicable scope of the
aforementioned service address includes, but is not limited to, civil litigation first instance, jurisdiction objection and reconsideration,
second instance, retrial, remand for retrial and execution procedures, etc. If the Borrower responds to the lawsuit and directly submits
the confirmation of the service address to the court, and if the confirmed address is inconsistent with the latest known postal address
of the Lender, the court has the right to serve according to the address on the confirmation of the service address.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the settlement of this contract dispute,
the court may serve the judgment, ruling and conciliation statement to the Borrower in any of the following ways:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) For delivery by post (including express mail,
ordinary mail and registered mail), the date of receipt by the Borrower shall be regarded as the date of delivery;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) For delivery by special person, the date on
which the Borrower signs on the delivery receipt shall be regarded as the date of delivery.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the court uses delivery by post (including express
mail, ordinary mail and registered mail), and if the Borrower fails to sign on the service receipt, or the postal address filled in by
the Borrower is inaccurate or actually changed, but the Lender does not receive the written notice from the Borrower about the change
of postal address, which leads to the rejection of the judgment, ruling and conciliation statement, the date when the statement is returned
shall be regarded as the date of delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the court uses delivery by special person, and
if the Borrower fails to sign on the service receipt, the date on which the server records the situation on the service receipt on the
spot shall be regarded as the date of delivery.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except for the judgment, ruling and conciliation
statement, the court has the right to make any notice to the Borrower by any means of communication agreed in Article 12.2. The court
has the right to choose the communication method it deems appropriate, and does not need to be responsible for transmission errors, omissions
or delays in postal, fax, telephone, telex or any other communication system. If the court chooses multiple modes of communication at
the same time, the one that arrives at the Borrower sooner shall prevail.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">12.4 The agreement in this article belongs to the
independent dispute settlement clause in the contract. The invalidity, cancellation or termination of this contract will not affect the
validity of this clause.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#9650;&#9650;Article 13 Information Disclosure and
Confidentiality</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">13.1 For the undisclosed information and materials
of the Borrower obtained and known during the signing and performance of this contract, the use of relevant information and materials
by the Lender (including but not limited to collection, storage, use, processing, transmission, provision, disclosure, etc.) shall not
violate laws, regulations and regulatory requirements; The Lender shall bear the responsibility of confidentiality according to law, and
shall not disclose such information and materials to a third party, except for the following situations:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) The disclosure is required by applicable laws
and regulations;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) The disclosure is required by judicial departments
or regulatory agencies according to law;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3) When the Borrower fails to repay the loan principal
and/or pay interest in full and on time, the Lender needs to disclose to the Lender&rsquo;s external professional consultant and allow the Lender&rsquo;s
external professional consultant to use it on the basis of confidentiality in order to realize the claims under this contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(4) Other acts are reasonably carried out to safeguard
public interests or legitimate rights and interests of the Borrower;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(5) The Borrower agrees or authorizes the Lender
to make disclosure.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">13.2 The Borrower confirms to have signed the Power
of Attorney for Credit Information Inquiry and Provision. The Lender inquires, uses and saves the credit information of the Borrower within
the scope specified in the Power of Attorney.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">13.3 In addition to the situations specified in
Articles 13.1 and 13.2 of this contract, the Borrower further agrees that Bank of Communications Co., Ltd. can use or disclose the Borrower&rsquo;s
information and materials in the following situations, including but not limited to the Borrower&rsquo;s basic information, credit transaction
information, bad information and other related information and materials, and is willing to bear all the consequences arising therefrom:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To disclose and allow business outsourcing institutions,
third-party service providers, other financial institutions and other institutions or individuals deemed necessary by the Lender, including
but not limited to other branches of Bank of Communications Co., Ltd., or wholly or partially owned subsidiaries of Bank of Communications
Co., Ltd., to use such information and materials on a confidential basis for the following purposes: &#9312; To carry out or be related
to bank credit business, such as promoting the credit business of Bank of Communications Co., Ltd., collecting the Borrower&rsquo;s arrears,
transferring the creditor&rsquo;s rights of bank credit business, etc.; &#9313; To provide or may provide new products or services or further
services for the Lender to the Borrower.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Whether Article 13.3 is applicable or not shall
be subject to the agreement of both parties in Article 24 of this contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 14 Applicable Law and Dispute Resolution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This contract shall be governed by the laws of the
People&rsquo;s Republic of China (excluding the laws of Hongkong, Macau and Taiwan for the purpose of this contract). Any dispute under this
contract shall be brought to the court with jurisdiction where the Lender is located unless otherwise agreed in this contract. During
the dispute, all parties should continue to perform the provisions that are not involved in the dispute.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 15 Entry into Force and Composition of Contract</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">15.1 This contract shall come into force after the
legal representative (person in charge) or authorized representative of the Borrower signs (or seals) with the official seal, and the
persons in charge or authorized representative of the Lender signs (or seals) with the special contract seal.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">15.2 The Application for Use of Line of Credit signed
when using the line of credit under this contract and other relevant documents and materials are integral parts of this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">15.3 The Application for Use of Line of Credit is
a supplement to this contract. Unless otherwise agreed in the Application for Use of Line of Credit, the rights and obligations and related
matters between the Borrower and the Lender shall still be implemented according to the agreement of this contract.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 16 Specific Content of the Line of Credit</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1
Currency of the line of credit: __________________; Amount in words: ____________________; It can be used in &#9744;RMB &#9744;_______
(foreign currency); The line of credit belongs to &#9744;revolving line of credit &#9744;lump-sum line of credit (can be used several
times) &#9744;lump-sum line of credit (only used once).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">16.2 Purpose of the line of credit: ____________________________.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">16.3 The term of credit is from ____________ (MM/DD/YYYY)
to ____________ (MM/DD/YYYY).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 17 Agreement on Interest Rate</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the loan currency is foreign currency, the relevant
agreements on the determination of interest rate, adjustment of interest rate and penalty interest rate for overdue and misappropriated
loans are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">______________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 18 Account Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.1
The Borrower designates the following account as the loan account, and this account &#9744;is &#9744;is not a special loan issuing account
opened by the Borrower at the Lender. If both parties agree otherwise in the corresponding Application for Use of Line of Credit, the
agreement in the Application for Use of Line of Credit shall prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Account Name:____________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Account Number:__________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Bank of Deposit:___________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">18.2 Designation of the Borrower:_____________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">(1) The repayment account is</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Account Name:____________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Account Number:__________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Bank of Deposit:___________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">(2) The capital withdrawal account is:__________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Account Name:____________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Account Number:__________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Bank of Deposit:___________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 19 Specific Agreement on Loan Issuance,
Payment and Repayment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.1
The term of each loan drawn under this contract shall not be longer than ______ &#9744;months &#9744;days, and the maturity date of all
loans shall not be later than ____________ (MM/DD/YYYY).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">19.2 The independent payment line of credit under
this contract is RMB _______ &times;10000 Yuan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">19.3 If one of the following conditions is met,
the method of the Lender&rsquo;s entrusted payment shall be adopted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">________________________________________________________________________________________<BR>
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>______________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">19.4 If the Borrower&rsquo;s independent payment is adopted,
the Borrower shall report the payment of loan funds to the Lender within ___ days after the loan is issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Article 20 Financial Restrictions, External Agency
Rating and Production and Operation Qualification/License</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">20.1 The Borrower&rsquo;s foreign investment line of credit
is RMB ______&times;10000 Yuan; The increase of debt financing line of credit is RMB ______&times;10000 Yuan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">20.2 Contract agreement on financial indicators
of the Borrower:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1)_____________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) _____________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3) _____________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">20.3 Specific agreement on external agency rating:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1)______________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) _____________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">20.4 Specific agreement on the Borrower&rsquo;s production
and operation qualification/license:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1) _____________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2) _____________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9650;&#9650;Article 21 Specific Agreement on Risk
Repricing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">21.1 This contract adopts the following ____ risk
repricing method: (1) negotiated repricing; (2) raising the loan interest rate directly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">21.2 If the method of &ldquo;raising the loan interest
rate directly&rdquo; is adopted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.2.1
If the loan currency is RMB, the value of the interest rate plus (minus) points after the increase is: &#9744;no plus or minus point
&#9744;plus ____ percentage points &#9744;minus ____ percentage points. Unless otherwise agreed in a loan, the value of the interest
rate plus (minus) points after the increase of the loan shall be subject to the records in the applicable application for use of line
of credit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">21.2.2 If the loan currency is foreign currency,
the loan interest rate after the increase is: __________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 22 Contact Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">The contact information of the Borrower to receive the notice
agreed in Article 12 includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Postal Address:____________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Attn:____________________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Postal Code:______________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Tel.:_____________________________________________________________&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Mobile Phone:_____________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Fax:_____________________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">Email:___________________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 23 Copies of Contract</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are ____ originals of this contract, with
____ copies held by both parties and the guarantor (if any).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Article 24 Other Agreements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">24.1
Both parties agree that this contract &#9744;is &#9744;is not applicable to Article 13.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">_________________________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">_________________________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">_________________________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">_________________________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Borrower:______________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Legal Representative (Person in Charge): _____________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Legal Address:__________________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lender: Bank of Communications Co., Ltd. __________ (Sub) Branch</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Person in Charge:________________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Postal Address:__________________________________________________________&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; text-align: center; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Borrower has read through all the terms of the contract, and the Lender has made<BR>
 detailed explanations at the request of the Borrower. When signing the contract, the<BR>
 Borrower has no doubt or objection to all the contents, and understands the meaning and <BR>
legal consequences of the terms of the contract, especially those marked with &#9650;&#9650;.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(This page is for signatures of the Working Capital Loan Contract and
is intentionally left blank)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex4-16_001.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">28</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.17
<SEQUENCE>8
<FILENAME>f20f2021ex4-17_universephar.htm
<DESCRIPTION>ENGLISH TRANSLATION OF THE ADVERTISING SERVICE AGREEMENT ENTERED INTO BY AND BETWEEN JIANGXI UNIVERSE AND GUANGDONG FENGYANG LEGEND CONSULTING CO., LTD., DATED SEPTEMBER 6, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 4.17</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advertising
Service Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->/8&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Party A: Jiangxi
    Universe Pharmaceuticals Co., Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Party B: Guangdong
    Fengyang Legend Marketing Consultant Co., Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Representative: Lai
    Gang</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Representative: Zhou
    Manyi</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Address: No. 265, Jingjiu
    Avenue, Jinggangshan Economic and Technological Development Zone, Ji&rsquo;an City, Jiangxi Province</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Address: Room 105-63664
    (centralized office area), No. 6 Baohua Road, Hengqin New District, Zhuhai City </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whereas:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Party A hopes to cooperate with Party B in the overall advertising of the enterprise, in order to achieve further promotion and enhancement
of the enterprise reputation, its products and brands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Party B is an advertising service enterprise with extensive advertising industry resources and an experienced advertising design and
planning team, and is willing to cooperate in accordance with this Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
The Parties, pursuant to the <I>Civil Code of the People&rsquo;s Republic of China</I>, the <I>Advertising Law of the People&rsquo;s Republic of
China</I> and relevant laws, judicial interpretations, administrative regulations and departmental rules, enter into this Contract after
friendly negotiation and on the principle of equality, mutual benefit and good faith, in relation to Party A&rsquo;s commissioning of Party
B to release television advertisements for Universe Pharmaceuticals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Specific Issues of Advertisement Release</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
The Contract shall be valid from October 1, 2021 to September 30, 2022. During the validity of the Contract, in case of any change in
the performance hereof, Party A and Party B shall negotiate on such change first and sign a supplementary document with the same effect
as this Contract after reaching an agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
Name of the advertising picture/film: Advertisements for the product Bai Nian Dan Guben Yanling Pills. Party A shall provide Party B
with the content and version of the advertisements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3
Advertisement release form: TVC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4
Advertisement release media and length: Please refer to the monthly schedule for details of the media, and the length is 15s, 30s and
60s.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5
Party B shall have the right to review Party A&rsquo;s advertisement content, presentation mode and technical standards for broadcast tape,
and request Party A to make modifications if the advertisement does not meet the requirements for broadcast. Prior to the completion
of the modification by Party A, Party B shall have the right to refuse to broadcast.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6
The advertising pictures/films delivered by Party A to Party B shall conform to the standards of Party B and relevant laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Advertisement Release Fees and Settlement Terms</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
During the term hereof, Party A expects to invest a total advertising fee of &yen; <U>55,000,000</U> (SAY FIFTY-FIVE MILLION YUAN ONLY),
with a price excluding tax: &yen; 51,886,792.45 (SAY FIFTY-ONE MILLION EIGHT HUNDRED AND EIGHTY-SIX THOUSAND SEVEN HUNDRED AND NINETY-TWO
POINT FOUR FIVE YUAN ONLY), and tax: &yen; 3,113,207.55 (SAY THREE MILLION ONE HUNDRED AND THIRTEEN THOUSAND TWO HUNDRED AND SEVEN POINT
FIVE FIVE YUAN ONLY). The specific fee shall be subject to the <I>Universe Pharmaceuticals Advertising Schedul</I>e of every month sealed
and confirmed by both parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->/8&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
Payment method: Party A and Party B agree to pay the contract price by transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Party
B&rsquo;s Bank Account Name: Guangdong Fengyang Legend Marketing Consultant Co., Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
Name:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Party
A&rsquo;s billing information:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Name: Jiangxi Universe Pharmaceuticals Co., Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unified
Social Credit Identifier: 9</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:
No. 265, Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji&rsquo;an City, Jiangxi Province</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
Name:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account
Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
Within 7 days from the signing of this Contract, Party A shall pay Party B <U>30%</U> of the total advertising fee, i.e. <U>&yen;16,500,000
</U>(SAY <U>SIXTEEN MILLION FIVE HUNDRED THOUSAND YUAN</U> ONLY).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4
After the Parties have confirmed each advertising channel, Party A shall pay Party B <U>58%</U> of the total advertising fee, i.e. <U>&yen;31,900,000
</U>(SAY <U>THIRTY-ONE MILLION NINE HUNDRED THOUSAND YUAN</U> ONLY).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5
Monthly advertising fee: <U>1%</U> of the total advertising fee, i.e. <U>&yen;550,000 </U>(SAY <U>FIVE HUNDRED AND FIFTY THOUSAND YUAN
</U>ONLY), shall be paid before the 7th day of each month (postponed on holidays). Party B shall issue a true, legal and valid special
VAT invoice of the same amount within <U>7</U> working days upon receipt of the payment from Party A. If there is any change in payment
time, both parties shall negotiate separately and confirm in writing. The invoice content is advertising agency fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Advertisement Release Process</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
Party B shall place orders with the media according to the requirements of the <I>Advertising Schedule</I>, and the actual arrangement
of monthly advertisements shall be subject to the <I>Advertising Schedule</I> confirmed with seals of Party B and Party A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
During the performance hereof, any adjustment to the advertisement broadcast or program revision for the reasons attributable to Party
B must be notified to Party A in advance. In case there are changes affected by emergency incidents or governmental actions and it is
not possible to inform Party A in time, Party A shall be informed within <U>5</U> days after the broadcast, and the two parties shall
negotiate together and confirm the results of the negotiation by means of a supplementary agreement, which shall have the same legal
effect as this Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->/8&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
During the performance hereof, if Party A requests to adjust the advertising volume, suspend or resume the broadcast of advertisements
under the condition that the schedule has been confirmed, Party B must be informed in writing <U>7</U> days in advance. The parties shall
negotiate together and confirm the results of the negotiation via email.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
Party B shall provide Party A with the broadcast certificate of regular advertisements every month, which shall be issued by the <U>TV
station</U>. No broadcast certificate shall be provided for special forms of advertisements (such as the end credits of programs, computer
version of enterprise named programs, corner advertising, etc.).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6
In case of doubt about the broadcast of the advertisement, Party A may provide Party B with the monitoring report from CVSC Sofres Media,
a third-party professional monitoring company recognized by both parties, within one month upon receipt of the broadcast certificate
provided by Party B. The monitoring report may be provided to Party A on a monthly basis. In case of any dispute, the results of &ldquo;missed
broadcast&rdquo; or &ldquo;wrong broadcast&rdquo; monitored by the third-party professional monitoring company CVSC Sofres Media shall
prevail. If Party A finds through the above-mentioned inquiry that there is a mistake in the broadcast of the advertisement for the reasons
attributable to Party B, Party B shall arrange a supplementary broadcast for Party A within the validity of this Contract according to
the principle of &ldquo;one supplement for one wrong broadcast, one supplement for one missed broadcast&rdquo;, with the details thereof
determined by the parties separately. If the advertisement cannot be broadcast or the actual advertisement broadcast does not conform
to the order due to the adjustment and change of the program of the radio and television channel <U>where the advertisement is released</U>,
the instruction of the superior entity or the machine failure and other force majeure causes, it shall not be deemed as the fault of
Party B.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7
The term &ldquo;wrong broadcast&rdquo; referred to herein means that the advertising segment or the broadcast version is wrong, or the
broadcast time differs from the agreed time by more than 90 minutes and the value decreases; &ldquo;missed broadcast&rdquo; means that
the advertisement is not broadcast or the broadcast frequency is reduced; &ldquo;less broadcast&rdquo; means that the advertisement fails
to be broadcast for the corresponding time according to the agreed version, and the agreed broadcast time is reduced; &ldquo;wrong position&rdquo;
means that the advertisement is not released in the advertising order as agreed in the contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Rights and Obligations of Both Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
Rights and obligations of Party A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1
Party A shall have the priority to sign the advertising resources hereof under the same conditions when the Contract is renewed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2
Party A shall have the right to request Party B to broadcast the advertisements as scheduled according to the <I>Advertising Schedule
</I>confirmed by both parties after the advertising materials provided by Party A are examined and approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.3
Party A owns the copyright of the advertising pictures/films hereunder, and Party B shall not use them and related materials for purposes
other than those required for the performance hereof without written consent of Party A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.4
Party A shall make all payments on time as agreed herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.5
In case of any adjustment of the content, time, time slot and specifications of the advertisement release, Party A shall notify Party
B in writing <U>7</U> days prior to the originally agreed broadcast date; otherwise the advertisement shall be released in accordance
with the <I>Advertising Schedule</I> originally confirmed by both parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->/8&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
Rights and obligations of Party B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.1
Party B shall have the right to request Party A to make all payments on time as agreed herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.2
Party B shall, within two days from the receipt of Party A&rsquo;s advertisement sample (draft), review the advertisement content entrusted
by Party A and have the right to request Party A to modify the content that does not conform to the <I>Advertising Law</I> and other
laws and regulations <U>15</U> days before the date of advertisement release. If Party A fails to provide legal and effective advertising
materials <U>10</U> days before the broadcast of the advertisement, Party B shall have the right to refuse to broadcast and both parties
shall renegotiate the broadcast date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.3
During the term hereof, if there is a major change in the program framework and advertising arrangement of the media channel, which affects
the return on advertising rights and interests of Party A, Party B shall notify Party A of the updated advertising resources within <U>3
</U>days upon receipt of the notice of change of the media channel. In principle, the updated advertising resources shall be adjusted
equivalent to the same time slot or time and advertising form, subject to the adjustment negotiated and mutually confirmed by both parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.4
Party B shall ensure the service quality and make rapid response, and shall timely and accurately provide Party A with channel related
resources and latest dynamic information to ensure the smooth cooperation between the two parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Liability for Breach of Contract</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
Where the Contract cannot be performed for reasons attributable not to the parties hereto, both parties shall negotiate first, and then
decide whether to continue to perform the Contract based on the specific situation. Both parties shall sign a written supplementary agreement
in this regard, which shall have the same legal effect as the Contract. Either party hereto shall be liable to the other party for its
breach of contract for reasons of a third party. Any dispute between either party hereto and a third party shall be settled in accordance
with the provisions of law or as agreed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
Where either party expressly states or indicates by its behavior that it will not perform its obligations hereunder, the other party
may require it to assume liability for breach of contract or directly rescind the Contract prior to the expiration of the performance
period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
Party A shall be liable for all legal consequences arising from the infringement upon the legitimate rights and interests of a third
party due to Party A&rsquo;s provision of false or illegal advertising content, qualification certificate and proof of ownership. Party
B shall only conduct formal review of the legality of the materials provided by Party A and shall not be responsible for the legality
of the materials. Party B&rsquo;s review does not mean that Party B assumes any form of legal responsibility for the advertisement content
and presentation mode. After the advertisement is released and broadcast, Party A shall bear all legal liabilities arising from the content
and presentation mode of advertisements, and shall be responsible for compensation for any loss caused to Party B. Party B shall have
the right to stop the broadcast of the advertisement without bearing any responsibility. In case of changing the materials, Party A shall
submit them to the media for review 10 working days in advance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
During the validity hereof, if Party A needs to terminate this Contract in advance for good reasons, Party A shall negotiate with Party
B 30 working days in advance, and the Contract may be terminated in writing through negotiation after both parties have approved and
agreed. If Party B is not at fault, the fees already charged shall not be refunded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->/8&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
Party A shall be solely responsible for the fluctuation of media advertising policies caused by the reduction of the advertising amount
agreed in the signed Schedule for reasons of Party A. In case a security deposit is involved, both parties shall negotiate and confirm
the corresponding security deposit and sign it into the Schedule, which includes but not limited to the security deposit and liquidated
damages borne by Party B to the media as a result. Both parties shall, within 30 days after the date of termination of this Contract,
settle the relevant advertising fees/liquidated damages according to the actual release of the advertisements as agreed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
Where either party fails to perform its obligations hereunder or fails to perform its obligations in conformity with the provisions hereof,
it shall compensate for any other losses caused to the other party after performing its obligations or taking remedial measures. The
amount of such compensation shall be equal to the losses caused by the breach of contract, including the benefits that can be obtained
after the performance of the Contract, provided that it shall not exceed the possible losses caused by the breach of contract that the
party in breach of contract foresaw or should have foreseen at the time of the conclusion of the contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7
Where Party A is late in making the payment, it shall pay a late fee to Party B equal to 0.05% of the unpaid amount of the contract for
each day of delay. If the delay in payment exceeds 15 days, Party B shall have the right to terminate the Contract directly and request
Party A to pay 30% of the unpaid contract amount as compensation for breach of contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8
After either party breaches the contract, the other party shall take appropriate measures to prevent further loss, and shall not claim
compensation for the expanded loss caused by its failure to appropriate measures. Reasonable expenses incurred by the injured party in
preventing further loss shall be borne by the breaching party. Where the breaching party materially breaches its obligations hereunder,
the non-breaching party shall be exempted from performing its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Intellectual Property Rights and Confidentiality Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
The undisclosed business information and customer information provided by Party A to Party B shall be the trade secrets of Party A. The
undisclosed ideas, scheme research and other information provided by Party B to Party A shall also be regarded as trade secrets. These
trade secrets shall not be disclosed without the written consent of the other party or the request of the state authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
Without the written consent of the other party, neither party shall disclose in any form any information and details of this Contract
and previous relevant contracts concluded to any third party. Any direct economic loss caused as a result shall be compensated by the
party in breach of the contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
Except as required for the work hereunder, neither party shall use or copy the trademark, logo, business information, technology, code
and other materials of the other party without its prior consent, otherwise it shall bear the direct economic loss caused to the other
party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
Both parties warrant that the information provided by either party to the other party will not infringe the intellectual property rights
or legitimate rights and interests of any third parties, otherwise all liabilities shall be borne by the providing party and the other
party shall have nothing to do with it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->/8&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5
The confidentiality obligation hereof shall remain binding upon expiration of the term hereof, unless the confidential Information becomes
public information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Methods of Dispute Settlement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
Any dispute arising in the course of performance hereof shall be settled by both parties through negotiation. In case the negotiation
fails, both parties agree that all disputes shall be settled by the people&rsquo;s court having jurisdiction in the place where the plaintiff
resides.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Force Majeure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1
In the event of an objective circumstance or accident that the parties cannot resist or prevent in their own capacity after this Contract
is signed and becomes effective, both parties shall be exempted from partial or full liability due to force majeure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2
The party suffering from force majeure shall, within 10 days, submit an accident report to the other party and issue a document certifying
the force majeure issued by an organization mutually recognized by both parties. The party receiving the report and the document shall
timely reply, whether it agrees or not.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3
The party suffering from force majeure shall take all necessary measures to reduce losses and resume the performance hereof after the
event is eliminated, unless the performance of the Contract has been rendered impossible or unnecessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4
If the Contract cannot be performed or the main purpose of the Contract cannot be realized by either party due to force majeure, the
parties shall negotiate over the continued performance hereof. If the negotiation fails, the parties shall make settlement according
to the actual situation of the Contract and the Contract shall be automatically terminated on the date of completion of the settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5
Force Majeure referred to herein means events beyond the reasonable control of the parties hereto, unforeseeable or unavoidable even
if encountered, which prevent, affect or delay either party from performing all or part of its obligations hereunder. Such events include,
but are not limited to, government actions, natural disasters, wars, computer viruses, hacker attacks, network failures, delays in service
of bandwidth or other network equipment or technology providers, service disruptions or any other similar events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Prevention of Commercial Bribery</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1
The parties agree that neither party shall provide money or services in any manner to the relevant department or person or other related
persons or family, nor shall the relevant department or person or related family of either party directly or indirectly ask for any money
or services, including: commissions, kickbacks, remuneration, loans, in-kind and non-in-kind items of value, gifts (travel and entertainment),
etc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Miscellaneous</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1
This Contract shall take effect upon being signed and sealed by both parties. For matters not covered herein, both parties agree to sign
a supplementary agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->/8&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2
The annexes hereto are an integral part of the Contract. In case of any conflict between the agreed terms of the annexes and those in
the master contract, the latter shall prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3
The Contract shall be automatically terminated when either party loses its legal status as an independent subject. Before the termination
of the Contract, both parties shall negotiate and sign a supplementary contract on the outstanding obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4
Upon expiration of the contract term, both parties shall complete the performance of their obligations and terminate the Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5
The Contract shall be made in <U>duplicate</U>, with each party holding <U>one</U> copy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6
The text herein shall be in printed form and shall not be handwritten or altered except for the signature. If there is content handwritten
or altered, the handwritten or altered content shall not be valid unless the seal of both parties is affixed thereon or it is signed
by authorized personnel of both parties, and the original printed text before handwriting or alteration shall prevail, without affecting
the validity of this Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7
The contact method herein is the designated contact person, and the contact person&rsquo;s behavior shall be deemed as an act of duty.
Either party changing the contact method shall notify the other party in advance, otherwise service to the original contact person or
service by the original contact method shall be regarded as valid service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7.1
Party A&rsquo;s designated contact person: <U>Qian Lei</U>, E-mail:.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7.2
Party B&rsquo;s designated contact person: <U>Liu Xianxiao</U>, E-mail:.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[No
text below]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 51%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full
    name of Party A: Jiangxi Universe Pharmaceuticals Co., Ltd. (seal)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[seal:
    Jiangxi Universe Pharmaceuticals Co., Ltd.]</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full
    name of Party B: Guangdong Fengyang Legend Marketing Consultant Co., Ltd. (seal)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[seal:
    Special seal for contractual uses of Guangdong Fengyang Legend Marketing Consultant Co., Ltd.]</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    of Authorized Representative (signature):</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex4-17_001.jpg" ALT="">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[signature]</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    of Authorized Representative (signature):</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex4-17_002.jpg" ALT="">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[signature]</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
    of Signing: September 6, 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
    of Signing: September 6, 2021</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/8&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>9
<FILENAME>f20f2021ex8-1_universephar.htm
<DESCRIPTION>LIST OF SUBSIDIARIES OF THE REGISTRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibits 8.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Subsidiaries of the Registrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 57%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiaries</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 42%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Place of
    Incorporation</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe Pharmaceuticals Group (International) Limited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe Pharmaceuticals Technology Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe Pharmaceuticals Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi Universe Pharmaceuticals Commercial Trade Co.,
    Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guangzhou Universe Hanhe Medical Research Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 222pt 8pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>10
<FILENAME>f20f2021ex12-1_universephar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
12.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SARBANES-OXLEY
ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Gang Lai, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this annual report on Form 20-F of Universe Pharmaceuticals INC (the &ldquo;Company&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The Company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the Company and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the Company&rsquo;s internal control over financial reporting that occurred during the period
covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal
control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The Company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the
equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal
control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
January 31, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Gang Lai</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gang Lai</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>11
<FILENAME>f20f2021ex12-2_universephar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
12.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SARBANES-OXLEY
ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Lin Yang, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this annual report on Form 20-F of Universe Pharmaceuticals INC (the &ldquo;Company&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The Company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the Company and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the Company&rsquo;s internal control over financial reporting that occurred during the period
covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal
control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The Company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the
equivalent function):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal
control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
January 31, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Lin Yang</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lin Yang</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>12
<FILENAME>f20f2021ex13-1_universephar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0; text-indent: 409.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
13.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 409.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Universe Pharmaceuticals INC (the &ldquo;Company&rdquo;) on Form 20-F for the year ended September
30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Gang Lai, Chief Executive
Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that to my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
January 31, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Gang Lai</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gang Lai</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>13
<FILENAME>f20f2021ex13-2_universephar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
13.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Universe Pharmaceuticals INC (the &ldquo;Company&rdquo;) on Form 20-F for the year ended September
30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Lin Yang, Chief Financial
Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that to my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
January 31, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Lin Yang</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lin Yang</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>14
<FILENAME>f20f2021ex15-1_universephar.htm
<DESCRIPTION>CONSENT OF ALLBRIGHT LAW OFFICES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 129.7pt"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 129.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex15-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 129.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#31119;&#24314;&#30465;&#31119;&#24030;&#24066;&#21488;&#27743;&#21306;&#26395;&#40857;&#20108;&#36335;
1 &#21495;&#22269;&#38469;&#37329;&#34701;&#20013;&#24515;&#65288;IFC&#65289;37 &#23618;&#65288;350005&#65289;<BR>
&#30005;&#35805;&#65306;+86-591-87850803&#9;&#20256;&#30495;&#65306;+86-591-87816904<BR>
37/F, IFC, No.1, Wanglong 2nd Avenue, Taijiang District,
Fuzhou, Fujian 350005 P.R.China <BR>
Tel&#65306;+86-591-87850803 Fax&#65306;+86-591-87816904</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">www.allbrightlaw.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">31 January, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">To: Universe Pharmaceuticals INC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">265 Jingjiu Avenue, Jinggangshan Economic and Technological
Development Zone <BR>
Ji&rsquo;an, Jiangxi Province</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">People&rsquo;s Republic of China </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 364.15pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 364.15pt; margin-bottom: 0pt">Dear Sir/Madam,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 364.15pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We hereby consent to the references
to our firm&rsquo;s name under the headings &ldquo;Item 3 Key Information&mdash;D. Risk Factors&mdash;Risks Related to Doing Business
in China&rdquo; and &ldquo;Item 10. Additional Information&mdash;E. Taxation&mdash;People&rsquo;s Republic of China Taxation&rdquo; in
Universe Pharmaceuticals INC&rsquo;s annual report on Form 20-F for the year ended September 30, 2021 (the &ldquo;Annual Report&rdquo;),
which will be filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on the date hereof. We also consent to the filing
of this consent letter with the SEC as an exhibit to the Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">In giving such consent, we do not
thereby admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, or
under the Securities Exchange Act of 1934, in each case, as amended, or the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; font-size: 10pt">Yours sincerely,</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">&nbsp;<IMG SRC="ex15-1_002.jpg" ALT=""></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Zhang Biwang </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Lawyer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">AllBright Law Offices(Fuzhou)</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>upc-20210930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sat Jan 29 18:38:56 UTC 2022 -->
<xs:schema xmlns:upc="http://www.UniversePharmaceuticalsINC.com/20210930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" targetNamespace="http://www.UniversePharmaceuticalsINC.com/20210930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="upc-20210930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="upc-20210930_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="upc-20210930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="upc-20210930_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow" id="upc_r_ConsolidatedCashFlow">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow_Parentheticals" id="upc_r_ConsolidatedCashFlow_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement" id="upc_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Income and Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3" id="upc_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Consolidated Statements of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0" id="upc_r_ConsolidatedCashFlow0">
        <link:definition>005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription" id="upc_r_OrganizationandBusinessDescription">
        <link:definition>006 - Disclosure - Organization and Business Description</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies" id="upc_r_SummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet" id="upc_r_AccountsReceivableNet">
        <link:definition>008 - Disclosure - Accounts Receivable, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNet" id="upc_r_InventoryNet">
        <link:definition>009 - Disclosure - Inventory, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers" id="upc_r_AdvancetoSuppliers">
        <link:definition>010 - Disclosure - Advance to Suppliers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting" id="upc_r_PrepaymentforAdvertisting">
        <link:definition>011 - Disclosure - Prepayment for Advertisting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstment" id="upc_r_ShortTermInvstment">
        <link:definition>012 - Disclosure - Short-Term Invstment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet" id="upc_r_PropertyPlantandEquipmentNet">
        <link:definition>013 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet" id="upc_r_IntangibleAssetsNet">
        <link:definition>014 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProject" id="upc_r_PrepaymentforConstructioninProgressCIPProject">
        <link:definition>015 - Disclosure - Prepayment for Construction-in-Progress (CIP) Project</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty" id="upc_r_PrepaymentforPurchaseofaProperty">
        <link:definition>016 - Disclosure - Prepayment for Purchase of a Property</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoans" id="upc_r_ShortBankLoans">
        <link:definition>017 - Disclosure - Short-Bank Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions" id="upc_r_RelatedPartyTransactions">
        <link:definition>018 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/Taxes" id="upc_r_Taxes">
        <link:definition>019 - Disclosure - Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/Concentrations" id="upc_r_Concentrations">
        <link:definition>020 - Disclosure - Concentrations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity" id="upc_r_ShareholdersEquity">
        <link:definition>021 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies" id="upc_r_CommitmentsandContingencies">
        <link:definition>022 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting" id="upc_r_SegmentReporting">
        <link:definition>023 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents" id="upc_r_SubsequentEvents">
        <link:definition>024 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany" id="upc_r_CondensedFinancialInformationoftheParentCompany">
        <link:definition>025 - Disclosure - Condensed Financial Information of the Parent Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy" id="upc_r_AccountingPoliciesByPolicy">
        <link:definition>026 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables" id="upc_r_OrganizationandBusinessDescriptionTables">
        <link:definition>027 - Disclosure - Organization and Business Description (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables" id="upc_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>028 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables" id="upc_r_AccountsReceivableNetTables">
        <link:definition>029 - Disclosure - Accounts Receivable, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables" id="upc_r_InventoryNetTables">
        <link:definition>030 - Disclosure - Inventory, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables" id="upc_r_AdvancetoSuppliersTables">
        <link:definition>031 - Disclosure - Advance to Suppliers (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentTables" id="upc_r_ShortTermInvstmentTables">
        <link:definition>032 - Disclosure - Short-Term Invstment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables" id="upc_r_PropertyPlantandEquipmentNetTables">
        <link:definition>033 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables" id="upc_r_IntangibleAssetsNetTables">
        <link:definition>034 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectTables" id="upc_r_PrepaymentforConstructioninProgressCIPProjectTables">
        <link:definition>035 - Disclosure - Prepayment for Construction-in-Progress (CIP) Project (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansTables" id="upc_r_ShortBankLoansTables">
        <link:definition>036 - Disclosure - Short-Bank Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables" id="upc_r_RelatedPartyTransactionsTables">
        <link:definition>037 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables" id="upc_r_TaxesTables">
        <link:definition>038 - Disclosure - Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables" id="upc_r_SegmentReportingTables">
        <link:definition>039 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables" id="upc_r_CondensedFinancialInformationoftheParentCompanyTables">
        <link:definition>040 - Disclosure - Condensed Financial Information of the Parent Company (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails" id="upc_r_OrganizationandBusinessDescriptionDetails">
        <link:definition>041 - Disclosure - Organization and Business Description (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable" id="upc_r_ScheduleofsubsidiariesofthecompanyTable">
        <link:definition>042 - Disclosure - Organization and Business Description (Details) - Schedule of subsidiaries of the company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails" id="upc_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>043 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable" id="upc_r_ScheduleofpropertyandequipmentestimatedusefullivesTable">
        <link:definition>044 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable" id="upc_r_ScheduleofintangibleassetsestimatedusefullivesTable">
        <link:definition>045 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable" id="upc_r_ScheduleofcurrencyexchangerateTable">
        <link:definition>046 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of currency exchange rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails" id="upc_r_AccountsReceivableNetDetails">
        <link:definition>047 - Disclosure - Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable" id="upc_r_ScheduleofaccountsreceivableTable">
        <link:definition>048 - Disclosure - Accounts Receivable, Net (Details) - Schedule of accounts receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable" id="upc_r_ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable">
        <link:definition>049 - Disclosure - Accounts Receivable, Net (Details) - Schedule of the company&#8217;s accounts receivable and subsequent collection</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable" id="upc_r_ScheduleofallowancefordoubtfulaccountsTable">
        <link:definition>050 - Disclosure - Accounts Receivable, Net (Details) - Schedule of allowance for doubtful accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetDetails" id="upc_r_InventoryNetDetails">
        <link:definition>051 - Disclosure - Inventory, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable" id="upc_r_ScheduleofinventoryTable">
        <link:definition>052 - Disclosure - Inventory, Net (Details) - Schedule of inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersDetails" id="upc_r_AdvancetoSuppliersDetails">
        <link:definition>053 - Disclosure - Advance to Suppliers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable" id="upc_r_ScheduleofadvancestosuppliersnetTable">
        <link:definition>054 - Disclosure - Advance to Suppliers (Details) - Schedule of advances to suppliers net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails" id="upc_r_PrepaymentforAdvertistingDetails">
        <link:definition>055 - Disclosure - Prepayment for Advertisting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentDetails" id="upc_r_ShortTermInvstmentDetails">
        <link:definition>056 - Disclosure - Short-Term Invstment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvstmentTable" id="upc_r_ScheduleofshortterminvstmentTable">
        <link:definition>057 - Disclosure - Short-Term Invstment (Details) - Schedule of short-term invstment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails" id="upc_r_PropertyPlantandEquipmentNetDetails">
        <link:definition>058 - Disclosure - Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable" id="upc_r_ScheduleofPropertyplantandequipmentnetconsistsTable">
        <link:definition>059 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of Property, plant and equipment, net consists</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails" id="upc_r_IntangibleAssetsNetDetails">
        <link:definition>060 - Disclosure - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable" id="upc_r_ScheduleofintangibleassetsnetconsistTable">
        <link:definition>061 - Disclosure - Intangible Assets, Net (Details) - Schedule of intangible assets, net consist</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7sSbeKneEPlmLktMHZBhwtLx19hpHJOdjKf2eyiP0jq4gpLMoHnWAqkCyHBHyDK9GdQmqqId3PEwCOX17Vhl0ye9OCleikRMpiLr3TIPdJKhd+/zxbKkQAAtmwMmQHV36ViW/cq0AmHGQ==] CSR-->
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" id="upc_r_ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable">
        <link:definition>062 - Disclosure - Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails" id="upc_r_PrepaymentforConstructioninProgressCIPProjectDetails">
        <link:definition>063 - Disclosure - Prepayment for Construction-in-Progress (CIP) Project (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable" id="upc_r_ScheduleoffutureminimumcapitalexpendituresTable">
        <link:definition>064 - Disclosure - Prepayment for Construction-in-Progress (CIP) Project (Details) - Schedule of future minimum capital expenditures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails" id="upc_r_PrepaymentforPurchaseofaPropertyDetails">
        <link:definition>065 - Disclosure - Prepayment for Purchase of a Property (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails" id="upc_r_ShortBankLoansDetails">
        <link:definition>066 - Disclosure - Short-Bank Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable" id="upc_r_ScheduleofshorttermbankloansTable">
        <link:definition>067 - Disclosure - Short-Bank Loans (Details) - Schedule of short-term bank loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails" id="upc_r_RelatedPartyTransactionsDetails">
        <link:definition>068 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable" id="upc_r_ScheduleofnatureofrelationshipswithrelatedpartiesTable">
        <link:definition>069 - Disclosure - Related Party Transactions (Details) - Schedule of nature of relationships with related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable" id="upc_r_ScheduleofduefromrelatedpartiesTable">
        <link:definition>070 - Disclosure - Related Party Transactions (Details) - Schedule of due from related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable" id="upc_r_ScheduleofduetorelatedpartiesTable">
        <link:definition>071 - Disclosure - Related Party Transactions (Details) - Schedule of due to related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails" id="upc_r_TaxesDetails">
        <link:definition>072 - Disclosure - Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable" id="upc_r_ScheduleofcomponentsoftheincometaxprovisionbenefitTable">
        <link:definition>073 - Disclosure - Taxes (Details) - Schedule of components of the income tax provision (benefit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable" id="upc_r_ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable">
        <link:definition>074 - Disclosure - Taxes (Details) - Schedule of table reconciles the china statutory rates to the company&#8217;s effective tax rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable" id="upc_r_ScheduleofdeferredtaxassetsTable">
        <link:definition>075 - Disclosure - Taxes (Details) - Schedule of deferred tax assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable" id="upc_r_ScheduleoftaxespayableTable">
        <link:definition>076 - Disclosure - Taxes (Details) - Schedule of taxes payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails" id="upc_r_ConcentrationsDetails">
        <link:definition>077 - Disclosure - Concentrations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails" id="upc_r_ShareholdersEquityDetails">
        <link:definition>078 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails" id="upc_r_CommitmentsandContingenciesDetails">
        <link:definition>079 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails" id="upc_r_SegmentReportingDetails">
        <link:definition>080 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable" id="upc_r_ScheduleofrevenuebyproductsourceTable">
        <link:definition>081 - Disclosure - Segment Reporting (Details) - Schedule of revenue by product source</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable" id="upc_r_ScheduleoftotalrevenuesbyproductcategoriesTable">
        <link:definition>082 - Disclosure - Segment Reporting (Details) - Schedule of total revenues by product categories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails" id="upc_r_SubsequentEventsDetails">
        <link:definition>083 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails" id="upc_r_CondensedFinancialInformationoftheParentCompanyDetails">
        <link:definition>084 - Disclosure - Condensed Financial Information of the Parent Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable" id="upc_r_ScheduleofparentcompanybalancesheetsTable">
        <link:definition>085 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals" id="upc_r_ScheduleofparentcompanybalancesheetsTable_Parentheticals">
        <link:definition>086 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable" id="upc_r_ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable">
        <link:definition>087 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of income and comprehensive income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable" id="upc_r_ScheduleofparentcompanystatementsofcashflowsTable">
        <link:definition>088 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of cash flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xs:element name="ScheduleOfSubsidiariesOfTheCompanyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfSubsidiariesOfTheCompanyAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract"/>
  <xs:element name="ScheduleOfCurrencyExchangeRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfCurrencyExchangeRateAbstract"/>
  <xs:element name="ScheduleOfAccountsReceivableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfAccountsReceivableAbstract"/>
  <xs:element name="ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract"/>
  <xs:element name="ScheduleOfAllowanceForDoubtfulAccountsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract"/>
  <xs:element name="ScheduleOfInventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfInventoryAbstract"/>
  <xs:element name="AdvancesToSuppliersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AdvancesToSuppliersAbstract"/>
  <xs:element name="ScheduleOfAdvancesToSuppliersNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfAdvancesToSuppliersNetAbstract"/>
  <xs:element name="PrepaymentForAdvertistingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForAdvertistingAbstract"/>
  <xs:element name="HeldToMaturityInvestmentDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_HeldToMaturityInvestmentDisclosureAbstract"/>
  <xs:element name="ScheduleOfShortTermInvstmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfShortTermInvstmentAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsNetConsistAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfIntangibleAssetsNetConsistAbstract"/>
  <xs:element name="ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract"/>
  <xs:element name="PrepaymentForConstructionInProgressAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForConstructionInProgressAbstract"/>
  <xs:element name="ScheduleOfFutureMinimumCapitalExpendituresAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract"/>
  <xs:element name="PrepaymentForPurchaseOfAPropertyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
  <xs:element name="ScheduleOfShortTermBankLoansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfShortTermBankLoansAbstract"/>
  <xs:element name="ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfDueFromRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfDueFromRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfDueToRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfDueToRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract"/>
  <xs:element name="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfDeferredTaxAssetsAbstract"/>
  <xs:element name="ScheduleOfTaxesPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfTaxesPayableAbstract"/>
  <xs:element name="ScheduleOfRevenueByProductSourceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfRevenueByProductSourceAbstract"/>
  <xs:element name="ScheduleOfTotalRevenuesByProductCategoriesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract"/>
  <xs:element name="ScheduleOfParentCompanyBalanceSheetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfParentCompanyBalanceSheetsAbstract"/>
  <xs:element name="ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract"/>
  <xs:element name="ScheduleOfParentCompanyStatementsOfCashFlowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract"/>
  <xs:element name="OtherIncomeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OtherIncomeExpensesAbstract"/>
  <xs:element name="OtherComprehensiveIncomeLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OtherComprehensiveIncomeLossAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract"/>
  <xs:element name="ShortTermBankLoansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ShortTermBankLoansAbstract"/>
  <xs:element name="LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract"/>
  <xs:element name="CurrentIncomeTaxProvisionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CurrentIncomeTaxProvisionAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract0"/>
  <xs:element name="DeferredIncomeTaxProvisionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DeferredIncomeTaxProvisionAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DeferredTaxAssetsAbstract"/>
  <xs:element name="SalesOfTcmdProductsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SalesOfTcmdProductsAbstract"/>
  <xs:element name="SalesOfThirdPartyProductsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SalesOfThirdPartyProductsAbstract"/>
  <xs:element name="UnlabeledAbstract00" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnlabeledAbstract00"/>
  <xs:element name="AssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AssetsAbstract0"/>
  <xs:element name="NonCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_NonCurrentAssetsAbstract"/>
  <xs:element name="LiabilitiesAndShareholdersEquityAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_LiabilitiesAndShareholdersEquityAbstract0"/>
  <xs:element name="ShareholdersEquityAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ShareholdersEquityAbstract0"/>
  <xs:element name="OtherIncomeExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OtherIncomeExpensesAbstract0"/>
  <xs:element name="CashFlowsFromOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CashFlowsFromOperatingActivitiesAbstract"/>
  <xs:element name="CashFlowsFromInvestingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CashFlowsFromInvestingActivitiesAbstract"/>
  <xs:element name="CashFlowsFromFinancingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CashFlowsFromFinancingActivitiesAbstract"/>
  <xs:element name="AdvanceToSuppliersNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_AdvanceToSuppliersNet"/>
  <xs:element name="PrepaymentForAdvertising" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForAdvertising"/>
  <xs:element name="PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
  <xs:element name="PrepaymentsForConstructionInProgress" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentsForConstructionInProgress"/>
  <xs:element name="InvestmentInEquitySecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_InvestmentInEquitySecurities"/>
  <xs:element name="StatutoryReserve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_StatutoryReserve"/>
  <xs:element name="ShorttermInvestmentIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_ShorttermInvestmentIncome"/>
  <xs:element name="StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts"/>
  <xs:element name="PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty"/>
  <xs:element name="RedemptionOfShorttermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_RedemptionOfShorttermInvestments"/>
  <xs:element name="ProceedsFromprepaymentsForRelatedPartiesBorrowings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings"/>
  <xs:element name="AdvancesToSuppliersTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AdvancesToSuppliersTextBlock"/>
  <xs:element name="PrepaymentForAdvertistingTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForAdvertistingTextBlock"/>
  <xs:element name="HeldToMaturityInvestmentDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_HeldToMaturityInvestmentDisclosureTextBlock"/>
  <xs:element name="PrepaymentForConstructionInProgressTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForConstructionInProgressTextBlock"/>
  <xs:element name="PrepaymentForPurchaseOfAPropertyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentForPurchaseOfAPropertyTextBlock"/>
  <xs:element name="AdvancesToSuppliersNetPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AdvancesToSuppliersNetPolicyTextBlock"/>
  <xs:element name="HeldToMaturityInvestmentPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_HeldToMaturityInvestmentPolicyTextBlock"/>
  <xs:element name="ContractAssetsAndLiabilitiesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ContractAssetsAndLiabilitiesPolicyTextBlock"/>
  <xs:element name="DisaggregationOfRevenuesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DisaggregationOfRevenuesPolicyTextBlock"/>
  <xs:element name="ValueAddedTaxPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ValueAddedTaxPolicyTextBlock"/>
  <xs:element name="StatementOfCashFlowsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_StatementOfCashFlowsPolicyTextBlock"/>
  <xs:element name="EmployeeDefinedContributionPlanPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_EmployeeDefinedContributionPlanPolicyTextBlock"/>
  <xs:element name="PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
  <xs:element name="ScheduleOfAdvancesToSuppliersNet" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfAdvancesToSuppliersNet"/>
  <xs:element name="ScheduleOfDueFromRelatedPartiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock"/>
  <xs:element name="ScheduleOfDueToRelatedPartiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfDueToRelatedPartiesTableTextBlock"/>
  <xs:element name="ScheduleOfTaxPayableTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ScheduleOfTaxPayableTableTextBlock"/>
  <xs:element name="PlaceOfIncorporation" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PlaceOfIncorporation"/>
  <xs:element name="PrincipalActivities" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrincipalActivities"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems"/>
  <xs:element name="DescriptionOfYearEndSpotRate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DescriptionOfYearEndSpotRate"/>
  <xs:element name="DescriptionOfAverageRate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DescriptionOfAverageRate"/>
  <xs:element name="AccountsReceivableBeforeGrossValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_AccountsReceivableBeforeGrossValue"/>
  <xs:element name="SubsequentCollection" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_SubsequentCollection"/>
  <xs:element name="PercentageOfSubsequentCollection" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PercentageOfSubsequentCollection"/>
  <xs:element name="SunsequentCollectionsTotalGrossAccountsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_SunsequentCollectionsTotalGrossAccountsReceivable"/>
  <xs:element name="TotalGrossAccountsReceivablePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_TotalGrossAccountsReceivablePercentage"/>
  <xs:element name="SunsequentCollectionAllowanceForDoubtfulAccounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_SunsequentCollectionAllowanceForDoubtfulAccounts"/>
  <xs:element name="AllowanceForDoubtfulAccountsReceivablePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AllowanceForDoubtfulAccountsReceivablePercentage"/>
  <xs:element name="SunsequentCollectionAccountsReceivableNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_SunsequentCollectionAccountsReceivableNet"/>
  <xs:element name="AccountsReceivableNetPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AccountsReceivableNetPercentage"/>
  <xs:element name="AddPurchaseWealthManagementFinancialProducts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_AddPurchaseWealthManagementFinancialProducts"/>
  <xs:element name="FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix"/>
  <xs:element name="PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable"/>
  <xs:element name="PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems"/>
  <xs:element name="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems"/>
  <xs:element name="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems"/>
  <xs:element name="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable"/>
  <xs:element name="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems"/>
  <xs:element name="SubtotalOfTCMDProductsSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_SubtotalOfTCMDProductsSales"/>
  <xs:element name="SubtotalOfThirdpartyProductsSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_SubtotalOfThirdpartyProductsSales"/>
  <xs:element name="EquityInEarningsOfSubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_EquityInEarningsOfSubsidiary"/>
  <xs:element name="CashLentToSubsidiaries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_CashLentToSubsidiaries"/>
  <xs:element name="CashAndCashEquivalentAtCarryingValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_CashAndCashEquivalentAtCarryingValue"/>
  <xs:element name="OrganizationandBusinessDescriptionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_OrganizationandBusinessDescriptionDetailsTable"/>
  <xs:element name="OrganizationandBusinessDescriptionDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OrganizationandBusinessDescriptionDetailsLineItems"/>
  <xs:element name="EntityIncorporationDateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_EntityIncorporationDateDescription"/>
  <xs:element name="AmountOfRegisteredCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_AmountOfRegisteredCapital"/>
  <xs:element name="CapitalContribution" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_CapitalContribution"/>
  <xs:element name="RemainingCapitalContribution" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_RemainingCapitalContribution"/>
  <xs:element name="PublicOfferingPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_PublicOfferingPrice"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="AllowanceForUncollectableBalancesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="upc_AllowanceForUncollectableBalancesAmount"/>
  <xs:element name="DeferredInitialPublicOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_DeferredInitialPublicOfferingCosts"/>
  <xs:element name="PercentageOfVatRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PercentageOfVatRate"/>
  <xs:element name="AccountsReceivableDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AccountsReceivableDescription"/>
  <xs:element name="RawMaterialsPurchased" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_RawMaterialsPurchased"/>
  <xs:element name="PercentageOfAdvancePayment" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_PercentageOfAdvancePayment"/>
  <xs:element name="AdditionalContractPricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_AdditionalContractPricePercentage"/>
  <xs:element name="PrepaymentforConstructioninProgressCIPProjectDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_PrepaymentforConstructioninProgressCIPProjectDetailsTable"/>
  <xs:element name="PrepaymentforConstructioninProgressCIPProjectDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems"/>
  <xs:element name="Prepayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_Prepayment"/>
  <xs:element name="CapitalExpenditure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_CapitalExpenditure"/>
  <xs:element name="PrepaymentforPurchaseofaPropertyDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_PrepaymentforPurchaseofaPropertyDetailsTable"/>
  <xs:element name="PrepaymentforPurchaseofaPropertyDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems"/>
  <xs:element name="PercentageOfPrepayment" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PercentageOfPrepayment"/>
  <xs:element name="PayableDeliveryPropertyPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PayableDeliveryPropertyPercentage"/>
  <xs:element name="OfficeSpaceSquareMeters" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_OfficeSpaceSquareMeters"/>
  <xs:element name="ShortBankLoansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_ShortBankLoansDetailsTable"/>
  <xs:element name="ShortBankLoansDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ShortBankLoansDetailsLineItems"/>
  <xs:element name="TaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_TaxesDetailsTable"/>
  <xs:element name="TaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_TaxesDetailsLineItems"/>
  <xs:element name="PreferentialTaxTreatmentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PreferentialTaxTreatmentDescription"/>
  <xs:element name="ConcentrationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_ConcentrationsDetailsTable"/>
  <xs:element name="ConcentrationsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ConcentrationsDetailsLineItems"/>
  <xs:element name="ConcentrationRiskThresholdPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ConcentrationRiskThresholdPercentage"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_ShareholdersEquityDetailsTable"/>
  <xs:element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ShareholdersEquityDetailsLineItems"/>
  <xs:element name="OriginalSharesParValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OriginalSharesParValue"/>
  <xs:element name="OrdinarySharesParValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OrdinarySharesParValue"/>
  <xs:element name="OrdinarySharesOutstandingDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OrdinarySharesOutstandingDescription"/>
  <xs:element name="ReorganizationShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ReorganizationShares"/>
  <xs:element name="OptionToPurchaseAdditionalShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_OptionToPurchaseAdditionalShares"/>
  <xs:element name="CashDividendDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CashDividendDescription"/>
  <xs:element name="StatutorySurplusPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_StatutorySurplusPercentage"/>
  <xs:element name="ReserveIsEqualPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ReserveIsEqualPercentage"/>
  <xs:element name="RestrictedNetAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_RestrictedNetAssets"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="upc_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SubsequentEventsDetailsLineItems"/>
  <xs:element name="IntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="upc_IntangibleAssets"/>
  <xs:element name="MinorityInterestsOwnershipPercentageByParent" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="upc_MinorityInterestsOwnershipPercentageByParent"/>
  <xs:element name="CapitalExpenditureMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CapitalExpenditureMember"/>
  <xs:element name="CashDividendsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CashDividendsMember"/>
  <xs:element name="ChenyuanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_ChenyuanMember"/>
  <xs:element name="CorporateSegmentFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CorporateSegmentFiveMember"/>
  <xs:element name="CorporateSegmentFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CorporateSegmentFourMember"/>
  <xs:element name="CorporateSegmentOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CorporateSegmentOneMember"/>
  <xs:element name="CorporateSegmentSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CorporateSegmentSixMember"/>
  <xs:element name="CorporateSegmentThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CorporateSegmentThreeMember"/>
  <xs:element name="CorporateSegmentTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CorporateSegmentTwoMember"/>
  <xs:element name="CustomerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CustomerMember"/>
  <xs:element name="CustomersOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_CustomersOneMember"/>
  <xs:element name="FoshanShangyuMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_FoshanShangyuMember"/>
  <xs:element name="From10To12MonthsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_From10To12MonthsMember"/>
  <xs:element name="From4To6MonthsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_From4To6MonthsMember"/>
  <xs:element name="From7To9MonthsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_From7To9MonthsMember"/>
  <xs:element name="GreatestGroupMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_GreatestGroupMember"/>
  <xs:element name="GubenYanlingPillMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_GubenYanlingPillMember"/>
  <xs:element name="JiangxiLulingRuralCommercialBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_JiangxiLulingRuralCommercialBankMember"/>
  <xs:element name="JiangxiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_JiangxiMember"/>
  <xs:element name="JiangxiUniverseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_JiangxiUniverseMember"/>
  <xs:element name="JxRcbBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_JxRcbBankMember"/>
  <xs:element name="LessThan3MonthsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_LessThan3MonthsMember"/>
  <xs:element name="MaturityGreaterThan90DaysOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MaturityGreaterThan90DaysOneMember"/>
  <xs:element name="MaturityGreaterThan90DaysThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MaturityGreaterThan90DaysThreeMember"/>
  <xs:element name="MaturityGreaterThan90DaysTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MaturityGreaterThan90DaysTwoMember"/>
  <xs:element name="MrGangLaiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MrGangLaiMember"/>
  <xs:element name="MrsLinYangMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_MrsLinYangMember"/>
  <xs:element name="OfficeAndElectricEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_OfficeAndElectricEquipmentMember"/>
  <xs:element name="Over1YearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_Over1YearMember"/>
  <xs:element name="PRCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_PRCMember"/>
  <xs:element name="StatutoryReserveAndRestrictedNetAssetsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_StatutoryReserveAndRestrictedNetAssetsMember"/>
  <xs:element name="StatutoryReservesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_StatutoryReservesMember"/>
  <xs:element name="SupplierOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SupplierOneMember"/>
  <xs:element name="SupplierTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_SupplierTwoMember"/>
  <xs:element name="TotalRevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_TotalRevenueMember"/>
  <xs:element name="UnderwriterWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UnderwriterWarrantsMember"/>
  <xs:element name="UniverseHKMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseHKMember"/>
  <xs:element name="UniverseHanheMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseHanheMember"/>
  <xs:element name="UniverseINCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseINCMember"/>
  <xs:element name="UniverseIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseIncMember"/>
  <xs:element name="UniverseTechnologyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseTechnologyMember"/>
  <xs:element name="UniverseTradeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_UniverseTradeMember"/>
  <xs:element name="supplierMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_supplierMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="upc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>upc-20210930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sat Jan 29 18:38:57 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ConsolidatedCashFlow" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ConsolidatedIncomeStatement" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ConsolidatedCashFlow0" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofaccountsreceivableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofinventoryTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofdeferredtaxassetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleoftaxespayableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DueFromRelatedParties" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_AdvanceToSuppliersNet" xlink:href="upc-20210930.xsd#upc_AdvanceToSuppliersNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="upc_AdvanceToSuppliersNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAdvertising" xlink:href="upc-20210930.xsd#upc_PrepaymentForAdvertising"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="upc_PrepaymentForAdvertising" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredCostsCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:href="upc-20210930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsForConstructionInProgress" xlink:href="upc-20210930.xsd#upc_PrepaymentsForConstructionInProgress"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="upc_PrepaymentsForConstructionInProgress" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_InvestmentInEquitySecurities" xlink:href="upc-20210930.xsd#upc_InvestmentInEquitySecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="upc_InvestmentInEquitySecurities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserve" xlink:href="upc-20210930.xsd#upc_StatutoryReserve"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="upc_StatutoryReserve" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="upc_ShorttermInvestmentIncome" xlink:href="upc-20210930.xsd#upc_ShorttermInvestmentIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="upc_ShorttermInvestmentIncome" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7sSbeKneEPlmLktMHZBhwtLx19hpHJOdjKf2eyiP0jq4gpLMoHnWAqkCyHBHyDK9GdQmqqId3PEwCOX17Vhl0ye9OCleikRMpiLr3TIPdJKhf1hixaZ5o1lnTQoehNShMe+/GXSDOYHaQ==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeShortTermInvestmentOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeShortTermInvestmentOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InterestIncomeShortTermInvestmentOther" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidAdvertising"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_RedemptionOfShorttermInvestments" xlink:href="upc-20210930.xsd#upc_RedemptionOfShorttermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="upc_RedemptionOfShorttermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:href="upc-20210930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfAdvancesForConstruction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfAdvancesForConstruction"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_RepaymentsOfAdvancesForConstruction" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfBankDebt" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDividends" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:href="upc-20210930.xsd#upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryValuationReserves" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" xlink:href="upc-20210930.xsd#upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable">
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>upc-20210930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sat Jan 29 18:38:57 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ConsolidatedCashFlow" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ConsolidatedCashFlow_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ConsolidatedIncomeStatement" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShareholdersEquityType2or3" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ConsolidatedCashFlow0" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_OrganizationandBusinessDescription" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AccountsReceivableNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_InventoryNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AdvancetoSuppliers" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforAdvertisting" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShortTermInvstment" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstment"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PropertyPlantandEquipmentNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_IntangibleAssetsNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforConstructioninProgressCIPProject" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProject"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforPurchaseofaProperty" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShortBankLoans" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoans"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_RelatedPartyTransactions" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_Taxes" roleURI="http://www.UniversePharmaceuticalsINC.com/role/Taxes"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_Concentrations" roleURI="http://www.UniversePharmaceuticalsINC.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShareholdersEquity" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_CommitmentsandContingencies" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SegmentReporting" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SubsequentEvents" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_CondensedFinancialInformationoftheParentCompany" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AccountingPoliciesByPolicy" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_OrganizationandBusinessDescriptionTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AccountsReceivableNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_InventoryNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AdvancetoSuppliersTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShortTermInvstmentTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PropertyPlantandEquipmentNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_IntangibleAssetsNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforConstructioninProgressCIPProjectTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShortBankLoansTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_RelatedPartyTransactionsTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_TaxesTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SegmentReportingTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_CondensedFinancialInformationoftheParentCompanyTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofsubsidiariesofthecompanyTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofpropertyandequipmentestimatedusefullivesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofintangibleassetsestimatedusefullivesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofcurrencyexchangerateTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofaccountsreceivableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofallowancefordoubtfulaccountsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofinventoryTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofadvancestosuppliersnetTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofshortterminvstmentTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvstmentTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofPropertyplantandequipmentnetconsistsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofintangibleassetsnetconsistTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleoffutureminimumcapitalexpendituresTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofshorttermbankloansTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofnatureofrelationshipswithrelatedpartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofduefromrelatedpartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofduetorelatedpartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofcomponentsoftheincometaxprovisionbenefitTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofdeferredtaxassetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleoftaxespayableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofrevenuebyproductsourceTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleoftotalrevenuesbyproductcategoriesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofparentcompanybalancesheetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofparentcompanybalancesheetsTable_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofparentcompanystatementsofcashflowsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_OrganizationandBusinessDescriptionDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AccountsReceivableNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_InventoryNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AdvancetoSuppliersDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforAdvertistingDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShortTermInvstmentDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PropertyPlantandEquipmentNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_IntangibleAssetsNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforConstructioninProgressCIPProjectDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforPurchaseofaPropertyDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShortBankLoansDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_RelatedPartyTransactionsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_TaxesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ConcentrationsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShareholdersEquityDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_CommitmentsandContingenciesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SegmentReportingDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SubsequentEventsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_CondensedFinancialInformationoftheParentCompanyDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#DocumentAndEntityInformation" roleURI="http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromRelatedParties" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AdvanceToSuppliersNet" xlink:href="upc-20210930.xsd#upc_AdvanceToSuppliersNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="upc_AdvanceToSuppliersNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAdvertising" xlink:href="upc-20210930.xsd#upc_PrepaymentForAdvertising"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="upc_PrepaymentForAdvertising" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:href="upc-20210930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsForConstructionInProgress" xlink:href="upc-20210930.xsd#upc_PrepaymentsForConstructionInProgress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="upc_PrepaymentsForConstructionInProgress" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_InvestmentInEquitySecurities" xlink:href="upc-20210930.xsd#upc_InvestmentInEquitySecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="upc_InvestmentInEquitySecurities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserve" xlink:href="upc-20210930.xsd#upc_StatutoryReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="upc_StatutoryReserve" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OtherIncomeExpensesAbstract" xlink:href="upc-20210930.xsd#upc_OtherIncomeExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="upc_OtherIncomeExpensesAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ShorttermInvestmentIncome" xlink:href="upc-20210930.xsd#upc_ShorttermInvestmentIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="upc_ShorttermInvestmentIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OtherComprehensiveIncomeLossAbstract" xlink:href="upc-20210930.xsd#upc_OtherComprehensiveIncomeLossAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="upc_OtherComprehensiveIncomeLossAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherComprehensiveIncomeLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_EarningsPerShareAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReservesMember" xlink:href="upc-20210930.xsd#upc_StatutoryReservesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="upc_StatutoryReservesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" xlink:href="upc-20210930.xsd#upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeShortTermInvestmentOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeShortTermInvestmentOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InterestIncomeShortTermInvestmentOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidAdvertising"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:href="upc-20210930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfAdvancesForConstruction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfAdvancesForConstruction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfAdvancesForConstruction" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_RedemptionOfShorttermInvestments" xlink:href="upc-20210930.xsd#upc_RedemptionOfShorttermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="upc_RedemptionOfShorttermInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfBankDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:href="upc-20210930.xsd#upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoryNet">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers">
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersAbstract" xlink:href="upc-20210930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersTextBlock" xlink:href="upc-20210930.xsd#upc_AdvancesToSuppliersTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AdvancesToSuppliersAbstract" xlink:to="upc_AdvancesToSuppliersTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAdvertistingAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForAdvertistingAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAdvertistingTextBlock" xlink:href="upc-20210930.xsd#upc_PrepaymentForAdvertistingTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="upc_PrepaymentForAdvertistingTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstment">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_HeldToMaturityInvestmentDisclosureTextBlock" xlink:href="upc-20210930.xsd#upc_HeldToMaturityInvestmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="upc_HeldToMaturityInvestmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProject">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock" xlink:href="upc-20210930.xsd#upc_PrepaymentForConstructionInProgressTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForConstructionInProgressAbstract" xlink:to="upc_PrepaymentForConstructionInProgressTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForPurchaseOfAPropertyTextBlock" xlink:href="upc-20210930.xsd#upc_PrepaymentForPurchaseOfAPropertyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="upc_PrepaymentForPurchaseOfAPropertyTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoans">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/Taxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/Concentrations">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_AdvancesToSuppliersNetPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_AdvancesToSuppliersNetPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_HeldToMaturityInvestmentPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_HeldToMaturityInvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_HeldToMaturityInvestmentPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionContractorsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_ContractAssetsAndLiabilitiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_ContractAssetsAndLiabilitiesPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_DisaggregationOfRevenuesPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_DisaggregationOfRevenuesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_DisaggregationOfRevenuesPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ValueAddedTaxPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_ValueAddedTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_ValueAddedTaxPolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_StatementOfCashFlowsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_StatementOfCashFlowsPolicyTextBlock" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_EmployeeDefinedContributionPlanPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_EmployeeDefinedContributionPlanPolicyTextBlock" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="30" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="upc-20210930.xsd#upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables">
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersAbstract" xlink:href="upc-20210930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet" xlink:href="upc-20210930.xsd#upc_ScheduleOfAdvancesToSuppliersNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AdvancesToSuppliersAbstract" xlink:to="upc_ScheduleOfAdvancesToSuppliersNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectTables">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForConstructionInProgressAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock" xlink:href="upc-20210930.xsd#upc_ScheduleOfDueFromRelatedPartiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:href="upc-20210930.xsd#upc_ScheduleOfDueToRelatedPartiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="upc_ScheduleOfDueToRelatedPartiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock" xlink:href="upc-20210930.xsd#upc_ScheduleOfTaxPayableTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="upc_ScheduleOfTaxPayableTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseIncMember" xlink:href="upc-20210930.xsd#upc_UniverseIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHKMember" xlink:href="upc-20210930.xsd#upc_UniverseHKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseHKMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTechnologyMember" xlink:href="upc-20210930.xsd#upc_UniverseTechnologyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseTechnologyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiUniverseMember" xlink:href="upc-20210930.xsd#upc_JiangxiUniverseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_JiangxiUniverseMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTradeMember" xlink:href="upc-20210930.xsd#upc_UniverseTradeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseTradeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHanheMember" xlink:href="upc-20210930.xsd#upc_UniverseHanheMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseHanheMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PlaceOfIncorporation" xlink:href="upc-20210930.xsd#upc_PlaceOfIncorporation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="upc_PlaceOfIncorporation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PrincipalActivities" xlink:href="upc-20210930.xsd#upc_PrincipalActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="upc_PrincipalActivities" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable">
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AutomobilesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AutomobilesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OfficeAndElectricEquipmentMember" xlink:href="upc-20210930.xsd#upc_OfficeAndElectricEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="upc_OfficeAndElectricEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable">
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_UseRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfCurrencyExchangeRateAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfCurrencyExchangeRateAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_DescriptionOfYearEndSpotRate" xlink:href="upc-20210930.xsd#upc_DescriptionOfYearEndSpotRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfCurrencyExchangeRateAbstract" xlink:to="upc_DescriptionOfYearEndSpotRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_DescriptionOfAverageRate" xlink:href="upc-20210930.xsd#upc_DescriptionOfAverageRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfCurrencyExchangeRateAbstract" xlink:to="upc_DescriptionOfAverageRate" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAccountsReceivableAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfAccountsReceivableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAccountsReceivableAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAccountsReceivableAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAccountsReceivableAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_LessThan3MonthsMember" xlink:href="upc-20210930.xsd#upc_LessThan3MonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="upc_LessThan3MonthsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_From4To6MonthsMember" xlink:href="upc-20210930.xsd#upc_From4To6MonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="upc_From4To6MonthsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_From7To9MonthsMember" xlink:href="upc-20210930.xsd#upc_From7To9MonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="upc_From7To9MonthsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_From10To12MonthsMember" xlink:href="upc-20210930.xsd#upc_From10To12MonthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="upc_From10To12MonthsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_Over1YearMember" xlink:href="upc-20210930.xsd#upc_Over1YearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="upc_Over1YearMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AccountsReceivableBeforeGrossValue" xlink:href="upc-20210930.xsd#upc_AccountsReceivableBeforeGrossValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_AccountsReceivableBeforeGrossValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SubsequentCollection" xlink:href="upc-20210930.xsd#upc_SubsequentCollection"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_SubsequentCollection" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfSubsequentCollection" xlink:href="upc-20210930.xsd#upc_PercentageOfSubsequentCollection"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_PercentageOfSubsequentCollection" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AccountsReceivableGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SunsequentCollectionsTotalGrossAccountsReceivable" xlink:href="upc-20210930.xsd#upc_SunsequentCollectionsTotalGrossAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_SunsequentCollectionsTotalGrossAccountsReceivable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_TotalGrossAccountsReceivablePercentage" xlink:href="upc-20210930.xsd#upc_TotalGrossAccountsReceivablePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_TotalGrossAccountsReceivablePercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SunsequentCollectionAllowanceForDoubtfulAccounts" xlink:href="upc-20210930.xsd#upc_SunsequentCollectionAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_SunsequentCollectionAllowanceForDoubtfulAccounts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AllowanceForDoubtfulAccountsReceivablePercentage" xlink:href="upc-20210930.xsd#upc_AllowanceForDoubtfulAccountsReceivablePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_AllowanceForDoubtfulAccountsReceivablePercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SunsequentCollectionAccountsReceivableNet" xlink:href="upc-20210930.xsd#upc_SunsequentCollectionAccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_SunsequentCollectionAccountsReceivableNet" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AccountsReceivableNetPercentage" xlink:href="upc-20210930.xsd#upc_AccountsReceivableNetPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="upc_AccountsReceivableNetPercentage" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfInventoryAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAdvancesToSuppliersNetAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfAdvancesToSuppliersNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToSuppliersAndEmployees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToSuppliersAndEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="us-gaap_PaymentsToSuppliersAndEmployees" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvstmentTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfShortTermInvstmentAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfShortTermInvstmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfShortTermInvstmentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AddPurchaseWealthManagementFinancialProducts" xlink:href="upc-20210930.xsd#upc_AddPurchaseWealthManagementFinancialProducts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfShortTermInvstmentAbstract" xlink:to="upc_AddPurchaseWealthManagementFinancialProducts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfShortTermInvstmentAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfShortTermInvstmentAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfShortTermInvstmentAbstract" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AutomobilesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AutomobilesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OfficeAndElectricEquipmentMember" xlink:href="upc-20210930.xsd#upc_OfficeAndElectricEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="upc_OfficeAndElectricEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_UseRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" xlink:href="upc-20210930.xsd#upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:to="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" order="4" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7sSbeKneEPlmLktMHZBhwtLx19hpHJOdjKf2eyiP0jq4gpLMoHnWAqkCyHBHyDK9GdQmqqId3PEwCOX17Vhl0ye9OCleikRMpiLr3TIPdJKhXs3yZdg2Uc+UoEUBRWdIaEhP04No0v8ow==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:href="upc-20210930.xsd#upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:href="upc-20210930.xsd#upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CapitalExpenditureMember" xlink:href="upc-20210930.xsd#upc_CapitalExpenditureMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="upc_CapitalExpenditureMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Maturity30To90DaysMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Maturity30To90DaysMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="us-gaap_Maturity30To90DaysMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaturityOver90DaysMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaturityOver90DaysMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="us-gaap_MaturityOver90DaysMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysOneMember" xlink:href="upc-20210930.xsd#upc_MaturityGreaterThan90DaysOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="upc_MaturityGreaterThan90DaysOneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysTwoMember" xlink:href="upc-20210930.xsd#upc_MaturityGreaterThan90DaysTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="upc_MaturityGreaterThan90DaysTwoMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysThreeMember" xlink:href="upc-20210930.xsd#upc_MaturityGreaterThan90DaysThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="upc_MaturityGreaterThan90DaysThreeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:href="upc-20210930.xsd#upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrGangLaiMember" xlink:href="upc-20210930.xsd#upc_MrGangLaiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MrGangLaiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrsLinYangMember" xlink:href="upc-20210930.xsd#upc_MrsLinYangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MrsLinYangMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_GreatestGroupMember" xlink:href="upc-20210930.xsd#upc_GreatestGroupMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_GreatestGroupMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_FoshanShangyuMember" xlink:href="upc-20210930.xsd#upc_FoshanShangyuMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_FoshanShangyuMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:href="upc-20210930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:href="upc-20210930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:to="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_GreatestGroupMember" xlink:href="upc-20210930.xsd#upc_GreatestGroupMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_GreatestGroupMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_FoshanShangyuMember" xlink:href="upc-20210930.xsd#upc_FoshanShangyuMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_FoshanShangyuMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:href="upc-20210930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:href="upc-20210930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:to="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrGangLaiMember" xlink:href="upc-20210930.xsd#upc_MrGangLaiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MrGangLaiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_MrsLinYangMember" xlink:href="upc-20210930.xsd#upc_MrsLinYangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_MrsLinYangMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable">
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:href="upc-20210930.xsd#upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:href="upc-20210930.xsd#upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KY" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_KY"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KY" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_DeferredTaxAssetsAbstract" xlink:href="upc-20210930.xsd#upc_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="upc_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTaxesPayableAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfTaxesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable">
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfRevenueByProductSourceAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfRevenueByProductSourceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfOtherPropertyOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfOtherPropertyOperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfRevenueByProductSourceAbstract" xlink:to="us-gaap_CostOfOtherPropertyOperatingExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfRevenueByProductSourceAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ScheduleOfRevenueByProductSourceAbstract" xlink:to="us-gaap_Revenues" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_CorporateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentOneMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="upc_CorporateSegmentOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentTwoMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="upc_CorporateSegmentTwoMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentThreeMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="upc_CorporateSegmentThreeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentFourMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="upc_CorporateSegmentFourMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentFiveMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="upc_CorporateSegmentFiveMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentSixMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="upc_CorporateSegmentSixMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SalesOfTcmdProductsAbstract" xlink:href="upc-20210930.xsd#upc_SalesOfTcmdProductsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="upc_SalesOfTcmdProductsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SubtotalOfTCMDProductsSales" xlink:href="upc-20210930.xsd#upc_SubtotalOfTCMDProductsSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SalesOfTcmdProductsAbstract" xlink:to="upc_SubtotalOfTCMDProductsSales" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SalesOfThirdPartyProductsAbstract" xlink:href="upc-20210930.xsd#upc_SalesOfThirdPartyProductsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="upc_SalesOfThirdPartyProductsAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SubtotalOfThirdpartyProductsSales" xlink:href="upc-20210930.xsd#upc_SubtotalOfThirdpartyProductsSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SalesOfThirdPartyProductsAbstract" xlink:to="upc_SubtotalOfThirdpartyProductsSales" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AssetsAbstract0" xlink:href="upc-20210930.xsd#upc_AssetsAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="upc_AssetsAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AssetsAbstract0" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AssetsAbstract0" xlink:to="us-gaap_ShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AssetsAbstract0" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_NonCurrentAssetsAbstract" xlink:href="upc-20210930.xsd#upc_NonCurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AssetsAbstract0" xlink:to="upc_NonCurrentAssetsAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_NonCurrentAssetsAbstract" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_NonCurrentAssetsAbstract" xlink:to="us-gaap_Assets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AssetsAbstract0" xlink:to="us-gaap_Liabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityAbstract0" xlink:href="upc-20210930.xsd#upc_ShareholdersEquityAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AssetsAbstract0" xlink:to="upc_ShareholdersEquityAbstract0" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityAbstract0" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityAbstract0" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityAbstract0" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityAbstract0" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OtherIncomeExpensesAbstract0" xlink:href="upc-20210930.xsd#upc_OtherIncomeExpensesAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="upc_OtherIncomeExpensesAbstract0" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseOtherShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherIncomeExpensesAbstract0" xlink:to="us-gaap_InterestExpenseOtherShortTermBorrowings" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OtherIncomeExpensesAbstract0" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ProfitLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedCashFlowStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashFlowsFromOperatingActivitiesAbstract" xlink:href="upc-20210930.xsd#upc_CashFlowsFromOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="upc_CashFlowsFromOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_EquityInEarningsOfSubsidiary" xlink:href="upc-20210930.xsd#upc_EquityInEarningsOfSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="upc_EquityInEarningsOfSubsidiary" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_EquityInEarningsOfSubsidiary" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:href="upc-20210930.xsd#upc_CashFlowsFromInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="upc_CashFlowsFromInvestingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:href="upc-20210930.xsd#upc_CashFlowsFromFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="upc_CashFlowsFromFinancingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashLentToSubsidiaries" xlink:href="upc-20210930.xsd#upc_CashLentToSubsidiaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:to="upc_CashLentToSubsidiaries" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashAndCashEquivalentAtCarryingValue" xlink:href="upc-20210930.xsd#upc_CashAndCashEquivalentAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="upc_CashAndCashEquivalentAtCarryingValue" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails">
    <loc xlink:type="locator" xlink:label="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:href="upc-20210930.xsd#upc_OrganizationandBusinessDescriptionDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:href="upc-20210930.xsd#upc_OrganizationandBusinessDescriptionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_OrganizationandBusinessDescriptionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseIncMember" xlink:href="upc-20210930.xsd#upc_UniverseIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHKMember" xlink:href="upc-20210930.xsd#upc_UniverseHKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseHKMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiMember" xlink:href="upc-20210930.xsd#upc_JiangxiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_JiangxiMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTechnologyMember" xlink:href="upc-20210930.xsd#upc_UniverseTechnologyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseTechnologyMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiUniverseMember" xlink:href="upc-20210930.xsd#upc_JiangxiUniverseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_JiangxiUniverseMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTradeMember" xlink:href="upc-20210930.xsd#upc_UniverseTradeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_UniverseTradeMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_EntityIncorporationDateDescription" xlink:href="upc-20210930.xsd#upc_EntityIncorporationDateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_EntityIncorporationDateDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AmountOfRegisteredCapital" xlink:href="upc-20210930.xsd#upc_AmountOfRegisteredCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_AmountOfRegisteredCapital" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CapitalContribution" xlink:href="upc-20210930.xsd#upc_CapitalContribution"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_CapitalContribution" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_RemainingCapitalContribution" xlink:href="upc-20210930.xsd#upc_RemainingCapitalContribution"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_RemainingCapitalContribution" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_SharePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PublicOfferingPrice" xlink:href="upc-20210930.xsd#upc_PublicOfferingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_PublicOfferingPrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JxRcbBankMember" xlink:href="upc-20210930.xsd#upc_JxRcbBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="upc_JxRcbBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AllowanceForUncollectableBalancesAmount" xlink:href="upc-20210930.xsd#upc_AllowanceForUncollectableBalancesAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="upc_AllowanceForUncollectableBalancesAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_DeferredInitialPublicOfferingCosts" xlink:href="upc-20210930.xsd#upc_DeferredInitialPublicOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="upc_DeferredInitialPublicOfferingCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NetInvestmentIncome" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfVatRate" xlink:href="upc-20210930.xsd#upc_PercentageOfVatRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="upc_PercentageOfVatRate" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_AccountsReceivableDescription" xlink:href="upc-20210930.xsd#upc_AccountsReceivableDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="upc_AccountsReceivableDescription" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersDetails">
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersAbstract" xlink:href="upc-20210930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_RawMaterialsPurchased" xlink:href="upc-20210930.xsd#upc_RawMaterialsPurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_AdvancesToSuppliersAbstract" xlink:to="upc_RawMaterialsPurchased" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAdvertistingAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForAdvertistingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfAdvancePayment" xlink:href="upc-20210930.xsd#upc_PercentageOfAdvancePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="upc_PercentageOfAdvancePayment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_AdditionalContractPricePercentage" xlink:href="upc-20210930.xsd#upc_AdditionalContractPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="upc_AdditionalContractPricePercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentDetails">
    <loc xlink:type="locator" xlink:label="upc_HeldToMaturityInvestmentDisclosureAbstract" xlink:href="upc-20210930.xsd#upc_HeldToMaturityInvestmentDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_HeldToMaturityInvestmentDisclosureAbstract" xlink:to="us-gaap_OtherShortTermInvestments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems" xlink:href="upc-20210930.xsd#upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforConstructioninProgressCIPProjectDetailsTable" xlink:href="upc-20210930.xsd#upc_PrepaymentforConstructioninProgressCIPProjectDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems" xlink:to="upc_PrepaymentforConstructioninProgressCIPProjectDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ChenyuanMember" xlink:href="upc-20210930.xsd#upc_ChenyuanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_ChenyuanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentBuildingAndBuildingImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems" xlink:to="us-gaap_InvestmentBuildingAndBuildingImprovements" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_Prepayment" xlink:href="upc-20210930.xsd#upc_Prepayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems" xlink:to="upc_Prepayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CapitalExpenditure" xlink:href="upc-20210930.xsd#upc_CapitalExpenditure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems" xlink:to="upc_CapitalExpenditure" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails">
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:href="upc-20210930.xsd#upc_PrepaymentforPurchaseofaPropertyDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforPurchaseofaPropertyDetailsTable" xlink:href="upc-20210930.xsd#upc_PrepaymentforPurchaseofaPropertyDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="upc_PrepaymentforPurchaseofaPropertyDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_SupplementalDeferredPurchasePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfPrepayment" xlink:href="upc-20210930.xsd#upc_PercentageOfPrepayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="upc_PercentageOfPrepayment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PayableDeliveryPropertyPercentage" xlink:href="upc-20210930.xsd#upc_PayableDeliveryPropertyPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="upc_PayableDeliveryPropertyPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OfficeSpaceSquareMeters" xlink:href="upc-20210930.xsd#upc_OfficeSpaceSquareMeters"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="upc_OfficeSpaceSquareMeters" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails">
    <loc xlink:type="locator" xlink:label="upc_ShortBankLoansDetailsLineItems" xlink:href="upc-20210930.xsd#upc_ShortBankLoansDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_ShortBankLoansDetailsTable" xlink:href="upc-20210930.xsd#upc_ShortBankLoansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_ShortBankLoansDetailsLineItems" xlink:to="upc_ShortBankLoansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShortBankLoansDetailsTable" xlink:to="dei_LegalEntityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiLulingRuralCommercialBankMember" xlink:href="upc-20210930.xsd#upc_JiangxiLulingRuralCommercialBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="upc_JiangxiLulingRuralCommercialBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableToBankCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShortBankLoansDetailsLineItems" xlink:to="us-gaap_LoansPayableToBankCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShortBankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShortBankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShortBankLoansDetailsLineItems" xlink:to="us-gaap_InterestAndDebtExpense" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeconsolidationRelatedPartyDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRelatedPartyDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_DeconsolidationRelatedPartyDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails">
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsLineItems" xlink:href="upc-20210930.xsd#upc_TaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsTable" xlink:href="upc-20210930.xsd#upc_TaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_TaxesDetailsLineItems" xlink:to="upc_TaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_TaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PreferentialTaxTreatmentDescription" xlink:href="upc-20210930.xsd#upc_PreferentialTaxTreatmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsLineItems" xlink:to="upc_PreferentialTaxTreatmentDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsLineItems" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_TaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails">
    <loc xlink:type="locator" xlink:label="upc_ConcentrationsDetailsLineItems" xlink:href="upc-20210930.xsd#upc_ConcentrationsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_ConcentrationsDetailsTable" xlink:href="upc-20210930.xsd#upc_ConcentrationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_ConcentrationsDetailsLineItems" xlink:to="upc_ConcentrationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="srt_MajorCustomersAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CustomerMember" xlink:href="upc-20210930.xsd#upc_CustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="upc_CustomerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CustomersOneMember" xlink:href="upc-20210930.xsd#upc_CustomersOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="upc_CustomersOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_GubenYanlingPillMember" xlink:href="upc-20210930.xsd#upc_GubenYanlingPillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="upc_GubenYanlingPillMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SupplierOneMember" xlink:href="upc-20210930.xsd#upc_SupplierOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="upc_SupplierOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_SupplierTwoMember" xlink:href="upc-20210930.xsd#upc_SupplierTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="upc_SupplierTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_supplierMember" xlink:href="upc-20210930.xsd#upc_supplierMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="upc_supplierMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_TotalRevenueMember" xlink:href="upc-20210930.xsd#upc_TotalRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="upc_TotalRevenueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_AccountsReceivableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignFinancialInstitutionsMandatedDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ConcentrationsDetailsLineItems" xlink:to="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ConcentrationRiskThresholdPercentage" xlink:href="upc-20210930.xsd#upc_ConcentrationRiskThresholdPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ConcentrationsDetailsLineItems" xlink:to="upc_ConcentrationRiskThresholdPercentage" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityDetailsLineItems" xlink:href="upc-20210930.xsd#upc_ShareholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityDetailsTable" xlink:href="upc-20210930.xsd#upc_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseINCMember" xlink:href="upc-20210930.xsd#upc_UniverseINCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="upc_UniverseINCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PRCMember" xlink:href="upc-20210930.xsd#upc_PRCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="upc_PRCMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_UnderwriterWarrantsMember" xlink:href="upc-20210930.xsd#upc_UnderwriterWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="upc_UnderwriterWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashDividendsMember" xlink:href="upc-20210930.xsd#upc_CashDividendsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="upc_CashDividendsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserveAndRestrictedNetAssetsMember" xlink:href="upc-20210930.xsd#upc_StatutoryReserveAndRestrictedNetAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="upc_StatutoryReserveAndRestrictedNetAssetsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OriginalSharesParValue" xlink:href="upc-20210930.xsd#upc_OriginalSharesParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_OriginalSharesParValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OrdinarySharesParValue" xlink:href="upc-20210930.xsd#upc_OrdinarySharesParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_OrdinarySharesParValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OrdinarySharesOutstandingDescription" xlink:href="upc-20210930.xsd#upc_OrdinarySharesOutstandingDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_OrdinarySharesOutstandingDescription" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ReorganizationShares" xlink:href="upc-20210930.xsd#upc_ReorganizationShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_ReorganizationShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_PublicOfferingPrice" xlink:href="upc-20210930.xsd#upc_PublicOfferingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_PublicOfferingPrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_OptionToPurchaseAdditionalShares" xlink:href="upc-20210930.xsd#upc_OptionToPurchaseAdditionalShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_OptionToPurchaseAdditionalShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesOutstanding" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsShareBasedCompensationCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsShareBasedCompensationCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_DividendsShareBasedCompensationCash" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_CashDividendDescription" xlink:href="upc-20210930.xsd#upc_CashDividendDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_CashDividendDescription" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_StatutorySurplusPercentage" xlink:href="upc-20210930.xsd#upc_StatutorySurplusPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_StatutorySurplusPercentage" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_ReserveIsEqualPercentage" xlink:href="upc-20210930.xsd#upc_ReserveIsEqualPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_ReserveIsEqualPercentage" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_RestrictedCash" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_RestrictedNetAssets" xlink:href="upc-20210930.xsd#upc_RestrictedNetAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_RestrictedNetAssets" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_Cash" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseCapitalSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_InterestExpenseCapitalSecurities" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="upc_SubsequentEventsDetailsLineItems" xlink:href="upc-20210930.xsd#upc_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="upc_SubsequentEventsDetailsTable" xlink:href="upc-20210930.xsd#upc_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="upc_SubsequentEventsDetailsLineItems" xlink:to="upc_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="upc_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="upc_IntangibleAssets" xlink:href="upc-20210930.xsd#upc_IntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="upc_SubsequentEventsDetailsLineItems" xlink:to="upc_IntangibleAssets" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent" xlink:href="upc-20210930.xsd#upc_MinorityInterestsOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="upc_MinorityInterestsOwnershipPercentageByParent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ContactPersonnelEmailAddress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="37" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>upc-20210930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sat Jan 29 18:38:56 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">TOTAL NONCURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Income from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income before income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net income for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Ordinary shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">CHANGES IN CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfSubsidiariesOfTheCompanyAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfSubsidiariesOfTheCompanyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfSubsidiariesOfTheCompanyAbstract_lbl" xml:lang="en-US">Schedule of subsidiaries of the company [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfSubsidiariesOfTheCompanyAbstract" xlink:to="upc_ScheduleOfSubsidiariesOfTheCompanyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesAbstract_lbl" xml:lang="en-US">Schedule of property and equipment estimated useful lives [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesAbstract" xlink:to="upc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract_lbl" xml:lang="en-US">Schedule of intangible assets estimated useful lives [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" xlink:to="upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfCurrencyExchangeRateAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfCurrencyExchangeRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfCurrencyExchangeRateAbstract_lbl" xml:lang="en-US">Schedule of currency exchange rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfCurrencyExchangeRateAbstract" xlink:to="upc_ScheduleOfCurrencyExchangeRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAccountsReceivableAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfAccountsReceivableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfAccountsReceivableAbstract_lbl" xml:lang="en-US">Schedule of accounts receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAccountsReceivableAbstract" xlink:to="upc_ScheduleOfAccountsReceivableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract_lbl" xml:lang="en-US">Schedule of the company&#8217;s accounts receivable and subsequent collection [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract" xlink:to="upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_lbl" xml:lang="en-US">Class of Financing Receivable [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract_lbl" xml:lang="en-US">Schedule of allowance for doubtful accounts [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfInventoryAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfInventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfInventoryAbstract_lbl" xml:lang="en-US">Schedule of inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfInventoryAbstract" xlink:to="upc_ScheduleOfInventoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventories, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersAbstract" xlink:href="upc-20210930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdvancesToSuppliersAbstract_lbl" xml:lang="en-US">Advances To Suppliers [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersAbstract" xlink:to="upc_AdvancesToSuppliersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAdvancesToSuppliersNetAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfAdvancesToSuppliersNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfAdvancesToSuppliersNetAbstract_lbl" xml:lang="en-US">Schedule of advances to suppliers net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="upc_ScheduleOfAdvancesToSuppliersNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAdvertistingAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForAdvertistingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForAdvertistingAbstract_lbl" xml:lang="en-US">Prepayment For Advertisting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAdvertistingAbstract" xlink:to="upc_PrepaymentForAdvertistingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_HeldToMaturityInvestmentDisclosureAbstract" xlink:href="upc-20210930.xsd#upc_HeldToMaturityInvestmentDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_HeldToMaturityInvestmentDisclosureAbstract_lbl" xml:lang="en-US">Held To Maturity Investment Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_HeldToMaturityInvestmentDisclosureAbstract" xlink:to="upc_HeldToMaturityInvestmentDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfShortTermInvstmentAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfShortTermInvstmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfShortTermInvstmentAbstract_lbl" xml:lang="en-US">Schedule of short-term invstment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfShortTermInvstmentAbstract" xlink:to="upc_ScheduleOfShortTermInvstmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Ending balance of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl1" xml:lang="en-US">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract_lbl" xml:lang="en-US">Schedule of Property, plant and equipment, net consists [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract" xlink:to="upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfIntangibleAssetsNetConsistAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfIntangibleAssetsNetConsistAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfIntangibleAssetsNetConsistAbstract_lbl" xml:lang="en-US">Schedule of intangible assets, net consist [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfIntangibleAssetsNetConsistAbstract" xlink:to="upc_ScheduleOfIntangibleAssetsNetConsistAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule of estimated future amortization expense for intangible assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:to="upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForConstructionInProgressAbstract_lbl" xml:lang="en-US">Prepayment For Construction In Progress [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForConstructionInProgressAbstract" xlink:to="upc_PrepaymentForConstructionInProgressAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract_lbl" xml:lang="en-US">Schedule of future minimum capital expenditures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract" xlink:to="upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForPurchaseOfAPropertyAbstract_lbl" xml:lang="en-US">Prepayment For Purchase Of A Property [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="upc_PrepaymentForPurchaseOfAPropertyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfShortTermBankLoansAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfShortTermBankLoansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfShortTermBankLoansAbstract_lbl" xml:lang="en-US">Schedule of short-term bank loans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfShortTermBankLoansAbstract" xlink:to="upc_ScheduleOfShortTermBankLoansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_lbl" xml:lang="en-US">Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of nature of relationships with related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" xlink:to="upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDueFromRelatedPartiesAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfDueFromRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfDueFromRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of due from related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDueFromRelatedPartiesAbstract" xlink:to="upc_ScheduleOfDueFromRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDueToRelatedPartiesAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfDueToRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfDueToRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of due to related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDueToRelatedPartiesAbstract" xlink:to="upc_ScheduleOfDueToRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract_lbl" xml:lang="en-US">Schedule of components of the income tax provision (benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" xlink:to="upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract_lbl" xml:lang="en-US">Schedule of table reconciles the china statutory rates to the company&#8217;s effective tax rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Schedule of deferred tax assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="upc_ScheduleOfDeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTaxesPayableAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfTaxesPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfTaxesPayableAbstract_lbl" xml:lang="en-US">Schedule of taxes payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTaxesPayableAbstract" xlink:to="upc_ScheduleOfTaxesPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Total taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl0" xml:lang="en-US">Taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfRevenueByProductSourceAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfRevenueByProductSourceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfRevenueByProductSourceAbstract_lbl" xml:lang="en-US">Schedule of revenue by product source [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfRevenueByProductSourceAbstract" xlink:to="upc_ScheduleOfRevenueByProductSourceAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract_lbl" xml:lang="en-US">Schedule of total revenues by product categories [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract" xlink:to="upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfParentCompanyBalanceSheetsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfParentCompanyBalanceSheetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfParentCompanyBalanceSheetsAbstract_lbl" xml:lang="en-US">Schedule of parent company balance sheets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfParentCompanyBalanceSheetsAbstract" xlink:to="upc_ScheduleOfParentCompanyBalanceSheetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Schedule of parent company statements of income and comprehensive income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract" xlink:to="upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract_lbl" xml:lang="en-US">Schedule of parent company statements of cash flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract" xlink:to="upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CashAndCashEquivalentAtCarryingValue" xlink:href="upc-20210930.xsd#upc_CashAndCashEquivalentAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="upc_CashAndCashEquivalentAtCarryingValue_lbl" xml:lang="en-US">CASH, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashAndCashEquivalentAtCarryingValue" xlink:to="upc_CashAndCashEquivalentAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="upc_CashAndCashEquivalentAtCarryingValue_lbl0" xml:lang="en-US">CASH, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashAndCashEquivalentAtCarryingValue" xlink:to="upc_CashAndCashEquivalentAtCarryingValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ContactPersonnelEmailAddress"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US">Contact Personnel Email Address</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash transferred (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromRelatedParties_lbl" xml:lang="en-US">Due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AdvanceToSuppliersNet" xlink:href="upc-20210930.xsd#upc_AdvanceToSuppliersNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AdvanceToSuppliersNet_lbl" xml:lang="en-US">Advance to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvanceToSuppliersNet" xlink:to="upc_AdvanceToSuppliersNet_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAdvertising" xlink:href="upc-20210930.xsd#upc_PrepaymentForAdvertising"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentForAdvertising_lbl" xml:lang="en-US">Prepayment for advertising</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAdvertising" xlink:to="upc_PrepaymentForAdvertising_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred initial public offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:href="upc-20210930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl" xml:lang="en-US">Prepayments made to a related party for purchase of property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsForConstructionInProgress" xlink:href="upc-20210930.xsd#upc_PrepaymentsForConstructionInProgress"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentsForConstructionInProgress_lbl" xml:lang="en-US">Prepayments for construction in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsForConstructionInProgress" xlink:to="upc_PrepaymentsForConstructionInProgress_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_InvestmentInEquitySecurities" xlink:href="upc-20210930.xsd#upc_InvestmentInEquitySecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_InvestmentInEquitySecurities_lbl" xml:lang="en-US">Investment in equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_InvestmentInEquitySecurities" xlink:to="upc_InvestmentInEquitySecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Short-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares and 16,000,000 shares issued and outstanding as of September 30, 2021 and 2020, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Ordinary shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Ordinary shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserve" xlink:href="upc-20210930.xsd#upc_StatutoryReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatutoryReserve_lbl" xml:lang="en-US">Statutory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserve" xlink:to="upc_StatutoryReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingExpense_lbl" xml:lang="en-US">Selling expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OtherIncomeExpensesAbstract" xlink:href="upc-20210930.xsd#upc_OtherIncomeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OtherIncomeExpensesAbstract_lbl" xml:lang="en-US">Other income (expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="upc_OtherIncomeExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Equity investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0" xml:lang="en-US">Equity in earnings of subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OtherComprehensiveIncomeLossAbstract" xlink:href="upc-20210930.xsd#upc_OtherComprehensiveIncomeLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OtherComprehensiveIncomeLossAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherComprehensiveIncomeLossAbstract" xlink:to="upc_OtherComprehensiveIncomeLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" xlink:href="upc-20210930.xsd#upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts_lbl" xml:lang="en-US">Capitalized initial public offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" xlink:to="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract" xlink:href="upc-20210930.xsd#upc_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract" xlink:to="upc_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge_lbl" xml:lang="en-US">Inventory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge_lbl0" xml:lang="en-US">Accrued inventory allowance amounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_lbl" xml:lang="en-US">Taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US">Proceeds from disposal of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RedemptionOfShorttermInvestments" xlink:href="upc-20210930.xsd#upc_RedemptionOfShorttermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_RedemptionOfShorttermInvestments_lbl" xml:lang="en-US">Redemption of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RedemptionOfShorttermInvestments" xlink:to="upc_RedemptionOfShorttermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Proceeds from short-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Gross proceeds from initial public offerings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0" xml:lang="en-US">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShorttermInvestmentIncome" xlink:href="upc-20210930.xsd#upc_ShorttermInvestmentIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="upc_ShorttermInvestmentIncome_lbl" xml:lang="en-US">Short-term investments income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShorttermInvestmentIncome" xlink:to="upc_ShorttermInvestmentIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl" xml:lang="en-US">Dividend declared</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Loss from disposal of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl0" xml:lang="en-US">Loss from disposal of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeShortTermInvestmentOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeShortTermInvestmentOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeShortTermInvestmentOther_lbl" xml:lang="en-US">Short-term investments income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeShortTermInvestmentOther" xlink:to="us-gaap_InterestIncomeShortTermInvestmentOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl" xml:lang="en-US">Advance to suppliers, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidAdvertising"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising_lbl" xml:lang="en-US">Prepayment for advertising</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xml:lang="en-US">Advances to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:href="upc-20210930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty_lbl" xml:lang="en-US">Prepayments made to a related party for purchase of property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfAdvancesForConstruction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfAdvancesForConstruction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfAdvancesForConstruction_lbl" xml:lang="en-US">Prepayments for construction in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfAdvancesForConstruction" xlink:to="us-gaap_RepaymentsOfAdvancesForConstruction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl" xml:lang="en-US">Payments for short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl0" xml:lang="en-US">Payment for short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xml:lang="en-US">Repayment of bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US">Dividend payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xml:lang="en-US">Payment for deferred initial public offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:href="upc-20210930.xsd#upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings_lbl" xml:lang="en-US">Proceeds from (prepayments for) related parties borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReservesMember" xlink:href="upc-20210930.xsd#upc_StatutoryReservesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatutoryReservesMember_lbl" xml:lang="en-US">Statutory Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReservesMember" xlink:to="upc_StatutoryReservesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND BUSINESS DESCRIPTION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl" xml:lang="en-US">Schedule of subsidiaries of the company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Date of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PlaceOfIncorporation" xlink:href="upc-20210930.xsd#upc_PlaceOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PlaceOfIncorporation_lbl" xml:lang="en-US">Place of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PlaceOfIncorporation" xlink:to="upc_PlaceOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">% of Ownership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Equity ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xml:lang="en-US">Percentage of ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2" xml:lang="en-US">Offering price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2"/>
    <loc xlink:type="locator" xlink:label="upc_PrincipalActivities" xlink:href="upc-20210930.xsd#upc_PrincipalActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrincipalActivities_lbl" xml:lang="en-US">Principal Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrincipalActivities" xlink:to="upc_PrincipalActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="upc-20210930.xsd#upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl" xml:lang="en-US">Schedule of currency exchange rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_DescriptionOfYearEndSpotRate" xlink:href="upc-20210930.xsd#upc_DescriptionOfYearEndSpotRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_DescriptionOfYearEndSpotRate_lbl" xml:lang="en-US">Year-end spot rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DescriptionOfYearEndSpotRate" xlink:to="upc_DescriptionOfYearEndSpotRate_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_DescriptionOfAverageRate" xlink:href="upc-20210930.xsd#upc_DescriptionOfAverageRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_DescriptionOfAverageRate_lbl" xml:lang="en-US">Average rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DescriptionOfAverageRate" xlink:to="upc_DescriptionOfAverageRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS RECEIVABLE, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_lbl" xml:lang="en-US">Schedule of the company&#8217;s accounts receivable and subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:to="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AccountsReceivableBeforeGrossValue" xlink:href="upc-20210930.xsd#upc_AccountsReceivableBeforeGrossValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AccountsReceivableBeforeGrossValue_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableBeforeGrossValue" xlink:to="upc_AccountsReceivableBeforeGrossValue_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SubsequentCollection" xlink:href="upc-20210930.xsd#upc_SubsequentCollection"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SubsequentCollection_lbl" xml:lang="en-US">Subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubsequentCollection" xlink:to="upc_SubsequentCollection_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfSubsequentCollection" xlink:href="upc-20210930.xsd#upc_PercentageOfSubsequentCollection"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PercentageOfSubsequentCollection_lbl" xml:lang="en-US">Percentage of subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfSubsequentCollection" xlink:to="upc_PercentageOfSubsequentCollection_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SunsequentCollectionsTotalGrossAccountsReceivable" xlink:href="upc-20210930.xsd#upc_SunsequentCollectionsTotalGrossAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SunsequentCollectionsTotalGrossAccountsReceivable_lbl" xml:lang="en-US">Subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SunsequentCollectionsTotalGrossAccountsReceivable" xlink:to="upc_SunsequentCollectionsTotalGrossAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TotalGrossAccountsReceivablePercentage" xlink:href="upc-20210930.xsd#upc_TotalGrossAccountsReceivablePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_TotalGrossAccountsReceivablePercentage_lbl" xml:lang="en-US">Percentage of subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TotalGrossAccountsReceivablePercentage" xlink:to="upc_TotalGrossAccountsReceivablePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SunsequentCollectionAllowanceForDoubtfulAccounts" xlink:href="upc-20210930.xsd#upc_SunsequentCollectionAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SunsequentCollectionAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SunsequentCollectionAllowanceForDoubtfulAccounts" xlink:to="upc_SunsequentCollectionAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AllowanceForDoubtfulAccountsReceivablePercentage" xlink:href="upc-20210930.xsd#upc_AllowanceForDoubtfulAccountsReceivablePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AllowanceForDoubtfulAccountsReceivablePercentage_lbl" xml:lang="en-US">Percentage of subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AllowanceForDoubtfulAccountsReceivablePercentage" xlink:to="upc_AllowanceForDoubtfulAccountsReceivablePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SunsequentCollectionAccountsReceivableNet" xlink:href="upc-20210930.xsd#upc_SunsequentCollectionAccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SunsequentCollectionAccountsReceivableNet_lbl" xml:lang="en-US">Subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SunsequentCollectionAccountsReceivableNet" xlink:to="upc_SunsequentCollectionAccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AccountsReceivableNetPercentage" xlink:href="upc-20210930.xsd#upc_AccountsReceivableNetPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AccountsReceivableNetPercentage_lbl" xml:lang="en-US">Percentage of subsequent collection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableNetPercentage" xlink:to="upc_AccountsReceivableNetPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">Schedule of allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_lbl" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersTextBlock" xlink:href="upc-20210930.xsd#upc_AdvancesToSuppliersTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AdvancesToSuppliersTextBlock_lbl" xml:lang="en-US">ADVANCE TO SUPPLIERS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersTextBlock" xlink:to="upc_AdvancesToSuppliersTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet" xlink:href="upc-20210930.xsd#upc_ScheduleOfAdvancesToSuppliersNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet_lbl" xml:lang="en-US">Schedule of advances to suppliers net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAdvancesToSuppliersNet" xlink:to="upc_ScheduleOfAdvancesToSuppliersNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xml:lang="en-US">Advances to suppliers for inventory raw material purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xml:lang="en-US">Less: allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToSuppliersAndEmployees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToSuppliersAndEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToSuppliersAndEmployees_lbl" xml:lang="en-US">Advances to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToSuppliersAndEmployees" xlink:to="us-gaap_PaymentsToSuppliersAndEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForAdvertistingTextBlock" xlink:href="upc-20210930.xsd#upc_PrepaymentForAdvertistingTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentForAdvertistingTextBlock_lbl" xml:lang="en-US">PREPAYMENT FOR ADVERTISTING</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAdvertistingTextBlock" xlink:to="upc_PrepaymentForAdvertistingTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_HeldToMaturityInvestmentDisclosureTextBlock" xlink:href="upc-20210930.xsd#upc_HeldToMaturityInvestmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_HeldToMaturityInvestmentDisclosureTextBlock_lbl" xml:lang="en-US">SHORT-TERM INVSTMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_HeldToMaturityInvestmentDisclosureTextBlock" xlink:to="upc_HeldToMaturityInvestmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of short-term invstment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AddPurchaseWealthManagementFinancialProducts" xlink:href="upc-20210930.xsd#upc_AddPurchaseWealthManagementFinancialProducts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AddPurchaseWealthManagementFinancialProducts_lbl" xml:lang="en-US">Add: purchase wealth management financial products</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AddPurchaseWealthManagementFinancialProducts" xlink:to="upc_AddPurchaseWealthManagementFinancialProducts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable_lbl" xml:lang="en-US">Accrued investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property, plant and equipment, net consists</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets, net consist</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated future amortization expense for intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" xlink:href="upc-20210930.xsd#upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" xlink:to="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock" xlink:href="upc-20210930.xsd#upc_PrepaymentForConstructionInProgressTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock_lbl" xml:lang="en-US">PREPAYMENT FOR CONSTRUCTION-IN-PROGRESS (&quot;CIP&quot;) PROJECT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForConstructionInProgressTextBlock" xlink:to="upc_PrepaymentForConstructionInProgressTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum capital expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentForPurchaseOfAPropertyTextBlock" xlink:href="upc-20210930.xsd#upc_PrepaymentForPurchaseOfAPropertyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PrepaymentForPurchaseOfAPropertyTextBlock_lbl" xml:lang="en-US">PREPAYMENT FOR PURCHASE OF A PROPERTY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForPurchaseOfAPropertyTextBlock" xlink:to="upc_PrepaymentForPurchaseOfAPropertyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">SHORT-BANK LOANS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl" xml:lang="en-US">Schedule of short-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShortTermBankLoansAbstract" xlink:href="upc-20210930.xsd#upc_ShortTermBankLoansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ShortTermBankLoansAbstract_lbl" xml:lang="en-US">Short-term bank loans:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShortTermBankLoansAbstract" xlink:to="upc_ShortTermBankLoansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:href="upc-20210930.xsd#upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract_lbl" xml:lang="en-US">Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:to="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Total short-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of nature of relationships with related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl" xml:lang="en-US">Relationship with the group</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock" xlink:href="upc-20210930.xsd#upc_ScheduleOfDueFromRelatedPartiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock" xlink:to="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl" xml:lang="en-US">Total due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:href="upc-20210930.xsd#upc_ScheduleOfDueToRelatedPartiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:to="upc_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US">Total due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of components of the income tax provision (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CurrentIncomeTaxProvisionAbstract" xlink:href="upc-20210930.xsd#upc_CurrentIncomeTaxProvisionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CurrentIncomeTaxProvisionAbstract_lbl" xml:lang="en-US">Current income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CurrentIncomeTaxProvisionAbstract" xlink:to="upc_CurrentIncomeTaxProvisionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract0" xlink:href="upc-20210930.xsd#upc_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract0" xlink:to="upc_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_DeferredIncomeTaxProvisionAbstract" xlink:href="upc-20210930.xsd#upc_DeferredIncomeTaxProvisionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_DeferredIncomeTaxProvisionAbstract_lbl" xml:lang="en-US">Deferred income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DeferredIncomeTaxProvisionAbstract" xlink:to="upc_DeferredIncomeTaxProvisionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of table reconciles the china statutory rates to the company&#8217;s effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory PRC income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl" xml:lang="en-US">Permanent difference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Non-PRC entities not subject to PRC income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Impact on DTA due to change in applicable income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_DeferredTaxAssetsAbstract" xlink:href="upc-20210930.xsd#upc_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DeferredTaxAssetsAbstract" xlink:to="upc_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry-forwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock" xlink:href="upc-20210930.xsd#upc_ScheduleOfTaxPayableTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTaxPayableTableTextBlock" xlink:to="upc_ScheduleOfTaxPayableTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent_lbl" xml:lang="en-US">Value added tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xml:lang="en-US">Other taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CONCENTRATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT REPORTING</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl" xml:lang="en-US">Schedule of revenue by product source</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfOtherPropertyOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfOtherPropertyOperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfOtherPropertyOperatingExpense_lbl" xml:lang="en-US">Sales of TCMD products manufactured by the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfOtherPropertyOperatingExpense" xlink:to="us-gaap_CostOfOtherPropertyOperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Sales of third-party products</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of total revenues by product categories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SalesOfTcmdProductsAbstract" xlink:href="upc-20210930.xsd#upc_SalesOfTcmdProductsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SalesOfTcmdProductsAbstract_lbl" xml:lang="en-US">Sales of TCMD products:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SalesOfTcmdProductsAbstract" xlink:to="upc_SalesOfTcmdProductsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SubtotalOfTCMDProductsSales" xlink:href="upc-20210930.xsd#upc_SubtotalOfTCMDProductsSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SubtotalOfTCMDProductsSales_lbl" xml:lang="en-US">Sub-total of TCMD products sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubtotalOfTCMDProductsSales" xlink:to="upc_SubtotalOfTCMDProductsSales_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SalesOfThirdPartyProductsAbstract" xlink:href="upc-20210930.xsd#upc_SalesOfThirdPartyProductsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SalesOfThirdPartyProductsAbstract_lbl" xml:lang="en-US">Sales of third-party products</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SalesOfThirdPartyProductsAbstract" xlink:to="upc_SalesOfThirdPartyProductsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SubtotalOfThirdpartyProductsSales" xlink:href="upc-20210930.xsd#upc_SubtotalOfThirdpartyProductsSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SubtotalOfThirdpartyProductsSales_lbl" xml:lang="en-US">Subtotal of third-party products sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubtotalOfThirdpartyProductsSales" xlink:to="upc_SubtotalOfThirdpartyProductsSales_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnlabeledAbstract00" xlink:href="upc-20210930.xsd#upc_UnlabeledAbstract00"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnlabeledAbstract00_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract00" xlink:to="upc_UnlabeledAbstract00_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl" xml:lang="en-US">CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of parent company balance sheets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AssetsAbstract0" xlink:href="upc-20210930.xsd#upc_AssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AssetsAbstract0_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AssetsAbstract0" xlink:to="upc_AssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_NonCurrentAssetsAbstract" xlink:href="upc-20210930.xsd#upc_NonCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_NonCurrentAssetsAbstract_lbl" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NonCurrentAssetsAbstract" xlink:to="upc_NonCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xml:lang="en-US">Investment in subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_LiabilitiesAndShareholdersEquityAbstract0" xlink:href="upc-20210930.xsd#upc_LiabilitiesAndShareholdersEquityAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_LiabilitiesAndShareholdersEquityAbstract0_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LiabilitiesAndShareholdersEquityAbstract0" xlink:to="upc_LiabilitiesAndShareholdersEquityAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityAbstract0" xlink:href="upc-20210930.xsd#upc_ShareholdersEquityAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ShareholdersEquityAbstract0_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareholdersEquityAbstract0" xlink:to="upc_ShareholdersEquityAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of parent company statements of income and comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OtherIncomeExpensesAbstract0" xlink:href="upc-20210930.xsd#upc_OtherIncomeExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OtherIncomeExpensesAbstract0_lbl" xml:lang="en-US">Other income (expenses):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherIncomeExpensesAbstract0" xlink:to="upc_OtherIncomeExpensesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseOtherShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseOtherShortTermBorrowings_lbl" xml:lang="en-US">Income from short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:to="us-gaap_InterestExpenseOtherShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive income attributable to the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of parent company statements of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CashFlowsFromOperatingActivitiesAbstract" xlink:href="upc-20210930.xsd#upc_CashFlowsFromOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CashFlowsFromOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashFlowsFromOperatingActivitiesAbstract" xlink:to="upc_CashFlowsFromOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Adjustments to reconcile net cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_EquityInEarningsOfSubsidiary" xlink:href="upc-20210930.xsd#upc_EquityInEarningsOfSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_EquityInEarningsOfSubsidiary_lbl" xml:lang="en-US">Equity in earnings of subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityInEarningsOfSubsidiary" xlink:to="upc_EquityInEarningsOfSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:href="upc-20210930.xsd#upc_CashFlowsFromInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CashFlowsFromInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:to="upc_CashFlowsFromInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Redemption of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl0" xml:lang="en-US">Less: redemption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:href="upc-20210930.xsd#upc_CashFlowsFromFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CashFlowsFromFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:to="upc_CashFlowsFromFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of ordinary shares in IPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CashLentToSubsidiaries" xlink:href="upc-20210930.xsd#upc_CashLentToSubsidiaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CashLentToSubsidiaries_lbl" xml:lang="en-US">Cash lent to subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashLentToSubsidiaries" xlink:to="upc_CashLentToSubsidiaries_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Less: allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:to="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xml:lang="en-US">Bad debt recovery</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Inventory valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl0" xml:lang="en-US">Inventory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays_lbl" xml:lang="en-US">Effect of income tax holiday</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseIncMember" xlink:href="upc-20210930.xsd#upc_UniverseIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseIncMember_lbl" xml:lang="en-US">Universe INC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseIncMember" xlink:to="upc_UniverseIncMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="upc_UniverseIncMember_lbl0" xml:lang="en-US">Universe Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseIncMember" xlink:to="upc_UniverseIncMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHKMember" xlink:href="upc-20210930.xsd#upc_UniverseHKMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseHKMember_lbl" xml:lang="en-US">Universe HK [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseHKMember" xlink:to="upc_UniverseHKMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTechnologyMember" xlink:href="upc-20210930.xsd#upc_UniverseTechnologyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseTechnologyMember_lbl" xml:lang="en-US">Universe Technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTechnologyMember" xlink:to="upc_UniverseTechnologyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiUniverseMember" xlink:href="upc-20210930.xsd#upc_JiangxiUniverseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_JiangxiUniverseMember_lbl" xml:lang="en-US">Jiangxi Universe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiUniverseMember" xlink:to="upc_JiangxiUniverseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseTradeMember" xlink:href="upc-20210930.xsd#upc_UniverseTradeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseTradeMember_lbl" xml:lang="en-US">Universe Trade [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTradeMember" xlink:to="upc_UniverseTradeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="upc_UniverseTradeMember_lbl0" xml:lang="en-US">Jiangxi Universe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTradeMember" xlink:to="upc_UniverseTradeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseHanheMember" xlink:href="upc-20210930.xsd#upc_UniverseHanheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseHanheMember_lbl" xml:lang="en-US">Universe Hanhe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseHanheMember" xlink:to="upc_UniverseHanheMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Buildings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AutomobilesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AutomobilesMember_lbl" xml:lang="en-US">Automobiles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AutomobilesMember" xlink:to="us-gaap_AutomobilesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OfficeAndElectricEquipmentMember" xlink:href="upc-20210930.xsd#upc_OfficeAndElectricEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OfficeAndElectricEquipmentMember_lbl" xml:lang="en-US">Office and electric equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OfficeAndElectricEquipmentMember" xlink:to="upc_OfficeAndElectricEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Lower [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseRightsMember_lbl" xml:lang="en-US">Land use rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseRightsMember" xlink:to="us-gaap_UseRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_LessThan3MonthsMember" xlink:href="upc-20210930.xsd#upc_LessThan3MonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_LessThan3MonthsMember_lbl" xml:lang="en-US">Less than 3 months	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LessThan3MonthsMember" xlink:to="upc_LessThan3MonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_From4To6MonthsMember" xlink:href="upc-20210930.xsd#upc_From4To6MonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_From4To6MonthsMember_lbl" xml:lang="en-US">From 4 to 6 months [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_From4To6MonthsMember" xlink:to="upc_From4To6MonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_From7To9MonthsMember" xlink:href="upc-20210930.xsd#upc_From7To9MonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_From7To9MonthsMember_lbl" xml:lang="en-US">From 7 to 9 months	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_From7To9MonthsMember" xlink:to="upc_From7To9MonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_From10To12MonthsMember" xlink:href="upc-20210930.xsd#upc_From10To12MonthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_From10To12MonthsMember_lbl" xml:lang="en-US">From 10 to 12 months [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_From10To12MonthsMember" xlink:to="upc_From10To12MonthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_Over1YearMember" xlink:href="upc-20210930.xsd#upc_Over1YearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_Over1YearMember_lbl" xml:lang="en-US">Over 1 year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_Over1YearMember" xlink:to="upc_Over1YearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CapitalExpenditureMember" xlink:href="upc-20210930.xsd#upc_CapitalExpenditureMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CapitalExpenditureMember_lbl" xml:lang="en-US">Capital Expenditure [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalExpenditureMember" xlink:to="upc_CapitalExpenditureMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Maturity30To90DaysMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Maturity30To90DaysMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Maturity30To90DaysMember_lbl" xml:lang="en-US">Maturity date on March 31, 2021, interest rate 4.81% per annum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Maturity30To90DaysMember" xlink:to="us-gaap_Maturity30To90DaysMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaturityOver90DaysMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaturityOver90DaysMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaturityOver90DaysMember_lbl" xml:lang="en-US">Maturity date on June 18, 2021, interest rate 4.81% per annum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturityOver90DaysMember" xlink:to="us-gaap_MaturityOver90DaysMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysOneMember" xlink:href="upc-20210930.xsd#upc_MaturityGreaterThan90DaysOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MaturityGreaterThan90DaysOneMember_lbl" xml:lang="en-US">Maturity date on June 15, 2022, interest rate 4.81% per annum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysOneMember" xlink:to="upc_MaturityGreaterThan90DaysOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysTwoMember" xlink:href="upc-20210930.xsd#upc_MaturityGreaterThan90DaysTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MaturityGreaterThan90DaysTwoMember_lbl" xml:lang="en-US">Maturity date on June 30, 2022, interest rate 4.5% per annum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysTwoMember" xlink:to="upc_MaturityGreaterThan90DaysTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MaturityGreaterThan90DaysThreeMember" xlink:href="upc-20210930.xsd#upc_MaturityGreaterThan90DaysThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MaturityGreaterThan90DaysThreeMember_lbl" xml:lang="en-US">Maturity date on March 17, 2022, interest rate 4.81% per annum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysThreeMember" xlink:to="upc_MaturityGreaterThan90DaysThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MrGangLaiMember" xlink:href="upc-20210930.xsd#upc_MrGangLaiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MrGangLaiMember_lbl" xml:lang="en-US">Mr. Gang Lai [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrGangLaiMember" xlink:to="upc_MrGangLaiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MrsLinYangMember" xlink:href="upc-20210930.xsd#upc_MrsLinYangMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MrsLinYangMember_lbl" xml:lang="en-US">Mrs. Lin Yang [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrsLinYangMember" xlink:to="upc_MrsLinYangMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_GreatestGroupMember" xlink:href="upc-20210930.xsd#upc_GreatestGroupMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_GreatestGroupMember_lbl" xml:lang="en-US">Greatest Group [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GreatestGroupMember" xlink:to="upc_GreatestGroupMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_FoshanShangyuMember" xlink:href="upc-20210930.xsd#upc_FoshanShangyuMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_FoshanShangyuMember_lbl" xml:lang="en-US">Foshan Shangyu [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_FoshanShangyuMember" xlink:to="upc_FoshanShangyuMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_KY" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_KY"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_KY_lbl" xml:lang="en-US">CAYMAN ISLANDS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KY" xlink:to="country_KY_lbl"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_HK"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_HK_lbl" xml:lang="en-US">HONG KONG</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="country_HK_lbl0" xml:lang="en-US">Hong Kong [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl0"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CN_lbl" xml:lang="en-US">PRC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateMember_lbl" xml:lang="en-US">Medicinal liquor products [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateMember" xlink:to="us-gaap_CorporateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentOneMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CorporateSegmentOneMember_lbl" xml:lang="en-US">Other chronic condition treatment products [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentOneMember" xlink:to="upc_CorporateSegmentOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentTwoMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CorporateSegmentTwoMember_lbl" xml:lang="en-US">Cold and flu medicines [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentTwoMember" xlink:to="upc_CorporateSegmentTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentThreeMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CorporateSegmentThreeMember_lbl" xml:lang="en-US">Biochemical drugs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentThreeMember" xlink:to="upc_CorporateSegmentThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentFourMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CorporateSegmentFourMember_lbl" xml:lang="en-US">Traditional Chinese medicine pieces [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentFourMember" xlink:to="upc_CorporateSegmentFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentFiveMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CorporateSegmentFiveMember_lbl" xml:lang="en-US">Medical instruments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentFiveMember" xlink:to="upc_CorporateSegmentFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CorporateSegmentSixMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CorporateSegmentSixMember_lbl" xml:lang="en-US">Dietary supplements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentSixMember" xlink:to="upc_CorporateSegmentSixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US">Supplier [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_EntityIncorporationDateDescription" xlink:href="upc-20210930.xsd#upc_EntityIncorporationDateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_EntityIncorporationDateDescription_lbl" xml:lang="en-US">Entity incorporation date description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EntityIncorporationDateDescription" xlink:to="upc_EntityIncorporationDateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AmountOfRegisteredCapital" xlink:href="upc-20210930.xsd#upc_AmountOfRegisteredCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AmountOfRegisteredCapital_lbl" xml:lang="en-US">Registered capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AmountOfRegisteredCapital" xlink:to="upc_AmountOfRegisteredCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CapitalContribution" xlink:href="upc-20210930.xsd#upc_CapitalContribution"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CapitalContribution_lbl" xml:lang="en-US">Capital contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalContribution" xlink:to="upc_CapitalContribution_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RemainingCapitalContribution" xlink:href="upc-20210930.xsd#upc_RemainingCapitalContribution"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_RemainingCapitalContribution_lbl" xml:lang="en-US">Remaining capital contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RemainingCapitalContribution" xlink:to="upc_RemainingCapitalContribution_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Ordinary issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PublicOfferingPrice" xlink:href="upc-20210930.xsd#upc_PublicOfferingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PublicOfferingPrice_lbl" xml:lang="en-US">Public offering price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PublicOfferingPrice" xlink:to="upc_PublicOfferingPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Net Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_AllowanceForUncollectableBalancesAmount" xlink:href="upc-20210930.xsd#upc_AllowanceForUncollectableBalancesAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AllowanceForUncollectableBalancesAmount_lbl" xml:lang="en-US">Allowance for uncollectable balance amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AllowanceForUncollectableBalancesAmount" xlink:to="upc_AllowanceForUncollectableBalancesAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_DeferredInitialPublicOfferingCosts" xlink:href="upc-20210930.xsd#upc_DeferredInitialPublicOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_DeferredInitialPublicOfferingCosts_lbl" xml:lang="en-US">Deferred initial public offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DeferredInitialPublicOfferingCosts" xlink:to="upc_DeferredInitialPublicOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Payment for deferred offering costs amounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl" xml:lang="en-US">Investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetInvestmentIncome_lbl" xml:lang="en-US">Investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetInvestmentIncome" xlink:to="us-gaap_NetInvestmentIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfVatRate" xlink:href="upc-20210930.xsd#upc_PercentageOfVatRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PercentageOfVatRate_lbl" xml:lang="en-US">Percentage of vat rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfVatRate" xlink:to="upc_PercentageOfVatRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Comprehensive income amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AccountsReceivableDescription" xlink:href="upc-20210930.xsd#upc_AccountsReceivableDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AccountsReceivableDescription_lbl" xml:lang="en-US">Accounts receivable description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableDescription" xlink:to="upc_AccountsReceivableDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RawMaterialsPurchased" xlink:href="upc-20210930.xsd#upc_RawMaterialsPurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_RawMaterialsPurchased_lbl" xml:lang="en-US">Raw materials purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RawMaterialsPurchased" xlink:to="upc_RawMaterialsPurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Advertising expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfAdvancePayment" xlink:href="upc-20210930.xsd#upc_PercentageOfAdvancePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PercentageOfAdvancePayment_lbl" xml:lang="en-US">Percentage of advance payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfAdvancePayment" xlink:to="upc_PercentageOfAdvancePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AdditionalContractPricePercentage" xlink:href="upc-20210930.xsd#upc_AdditionalContractPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AdditionalContractPricePercentage_lbl" xml:lang="en-US">Additional contract price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdditionalContractPricePercentage" xlink:to="upc_AdditionalContractPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Total amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Remaining total amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherShortTermInvestments_lbl" xml:lang="en-US">Held-to-maturity investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermInvestments" xlink:to="us-gaap_OtherShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentBuildingAndBuildingImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements_lbl" xml:lang="en-US">Total estimated budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:to="us-gaap_InvestmentBuildingAndBuildingImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_Prepayment" xlink:href="upc-20210930.xsd#upc_Prepayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_Prepayment_lbl" xml:lang="en-US">Prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_Prepayment" xlink:to="upc_Prepayment_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CapitalExpenditure" xlink:href="upc-20210930.xsd#upc_CapitalExpenditure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CapitalExpenditure_lbl" xml:lang="en-US">Additional capital expenditure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalExpenditure" xlink:to="upc_CapitalExpenditure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl" xml:lang="en-US">Equity interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl" xml:lang="en-US">Total purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PercentageOfPrepayment" xlink:href="upc-20210930.xsd#upc_PercentageOfPrepayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PercentageOfPrepayment_lbl" xml:lang="en-US">Percentage of prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfPrepayment" xlink:to="upc_PercentageOfPrepayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xml:lang="en-US">Remaining payable percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PayableDeliveryPropertyPercentage" xlink:href="upc-20210930.xsd#upc_PayableDeliveryPropertyPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PayableDeliveryPropertyPercentage_lbl" xml:lang="en-US">Payable delivery property percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PayableDeliveryPropertyPercentage" xlink:to="upc_PayableDeliveryPropertyPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl" xml:lang="en-US">Prepayment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OfficeSpaceSquareMeters" xlink:href="upc-20210930.xsd#upc_OfficeSpaceSquareMeters"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OfficeSpaceSquareMeters_lbl" xml:lang="en-US">Office space Square meters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OfficeSpaceSquareMeters" xlink:to="upc_OfficeSpaceSquareMeters_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableToBankCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayableToBankCurrent_lbl" xml:lang="en-US">Borrowing amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableToBankCurrent" xlink:to="us-gaap_LoansPayableToBankCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Loan term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Fixed interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeconsolidationRelatedPartyDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRelatedPartyDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeconsolidationRelatedPartyDescription_lbl" xml:lang="en-US">Related party description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationRelatedPartyDescription" xlink:to="us-gaap_DeconsolidationRelatedPartyDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign_lbl" xml:lang="en-US">Subject to profit taxes rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_lbl" xml:lang="en-US">Foreign tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PreferentialTaxTreatmentDescription" xlink:href="upc-20210930.xsd#upc_PreferentialTaxTreatmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PreferentialTaxTreatmentDescription_lbl" xml:lang="en-US">Preferential tax treatment, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PreferentialTaxTreatmentDescription" xlink:to="upc_PreferentialTaxTreatmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">PRC corporate income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_lbl" xml:lang="en-US">Tax holidays on net income per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:to="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignFinancialInstitutionsMandatedDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits_lbl" xml:lang="en-US">Deposit at financial institutions (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:to="us-gaap_ForeignFinancialInstitutionsMandatedDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ConcentrationRiskThresholdPercentage" xlink:href="upc-20210930.xsd#upc_ConcentrationRiskThresholdPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ConcentrationRiskThresholdPercentage_lbl" xml:lang="en-US">Total revenue percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConcentrationRiskThresholdPercentage" xlink:to="upc_ConcentrationRiskThresholdPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OriginalSharesParValue" xlink:href="upc-20210930.xsd#upc_OriginalSharesParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OriginalSharesParValue_lbl" xml:lang="en-US">Original shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OriginalSharesParValue" xlink:to="upc_OriginalSharesParValue_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7sSbeKneEPlmLktMHZBhwtLx19hpHJOdjKf2eyiP0jq4gpLMoHnWAqkCyHBHyDK9GdQmqqId3PEwCOX17Vhl0ye9OCleikRMpiLr3TIPdJKhd+/zxbKkQAA3dta2l4HTAdBKtLQQYrUUg==] CSR-->
    <loc xlink:type="locator" xlink:label="upc_OrdinarySharesParValue" xlink:href="upc-20210930.xsd#upc_OrdinarySharesParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OrdinarySharesParValue_lbl" xml:lang="en-US">Ordinary shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesParValue" xlink:to="upc_OrdinarySharesParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OrdinarySharesOutstandingDescription" xlink:href="upc-20210930.xsd#upc_OrdinarySharesOutstandingDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OrdinarySharesOutstandingDescription_lbl" xml:lang="en-US">Ordinary shares outstanding description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesOutstandingDescription" xlink:to="upc_OrdinarySharesOutstandingDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ReorganizationShares" xlink:href="upc-20210930.xsd#upc_ReorganizationShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ReorganizationShares_lbl" xml:lang="en-US">Reorganization shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReorganizationShares" xlink:to="upc_ReorganizationShares_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OptionToPurchaseAdditionalShares" xlink:href="upc-20210930.xsd#upc_OptionToPurchaseAdditionalShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_OptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Option to purchase additional shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OptionToPurchaseAdditionalShares" xlink:to="upc_OptionToPurchaseAdditionalShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Price per warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US">Ordinary shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Offering price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsShareBasedCompensationCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsShareBasedCompensationCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsShareBasedCompensationCash_lbl" xml:lang="en-US">Cash dividend (in Yuan Renminbi)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsShareBasedCompensationCash" xlink:to="us-gaap_DividendsShareBasedCompensationCash_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CashDividendDescription" xlink:href="upc-20210930.xsd#upc_CashDividendDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CashDividendDescription_lbl" xml:lang="en-US">Description of dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashDividendDescription" xlink:to="upc_CashDividendDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StatutorySurplusPercentage" xlink:href="upc-20210930.xsd#upc_StatutorySurplusPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatutorySurplusPercentage_lbl" xml:lang="en-US">Statutory surplus percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutorySurplusPercentage" xlink:to="upc_StatutorySurplusPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ReserveIsEqualPercentage" xlink:href="upc-20210930.xsd#upc_ReserveIsEqualPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ReserveIsEqualPercentage_lbl" xml:lang="en-US">Reserve is equal percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReserveIsEqualPercentage" xlink:to="upc_ReserveIsEqualPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted amounts (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RestrictedNetAssets" xlink:href="upc-20210930.xsd#upc_RestrictedNetAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_RestrictedNetAssets_lbl" xml:lang="en-US">Restricted net assets (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RestrictedNetAssets" xlink:to="upc_RestrictedNetAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" xml:lang="en-US">Future minimum capital expenditures amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseCapitalSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseCapitalSecurities_lbl" xml:lang="en-US">Total amount of capital expenditure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseCapitalSecurities" xlink:to="us-gaap_InterestExpenseCapitalSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Reporting segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventDescription_lbl" xml:lang="en-US">Subsequent event, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_IntangibleAssets" xlink:href="upc-20210930.xsd#upc_IntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_IntangibleAssets_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_IntangibleAssets" xlink:to="upc_IntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent" xlink:href="upc-20210930.xsd#upc_MinorityInterestsOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent_lbl" xml:lang="en-US">Subsidiary exceeded percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MinorityInterestsOwnershipPercentageByParent" xlink:to="upc_MinorityInterestsOwnershipPercentageByParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Basis of consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Uses of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_AdvancesToSuppliersNetPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl" xml:lang="en-US">Advances to suppliers, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:to="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred initial public offering (&#8220;IPO&#8221;) costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_HeldToMaturityInvestmentPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_HeldToMaturityInvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_HeldToMaturityInvestmentPolicyTextBlock_lbl" xml:lang="en-US">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_HeldToMaturityInvestmentPolicyTextBlock" xlink:to="upc_HeldToMaturityInvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value of financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionContractorsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionContractorsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Construction-in-Progress (&#8220;CIP&#8221;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" xlink:to="us-gaap_ConstructionContractorsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investments in Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_ContractAssetsAndLiabilitiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Contract Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:to="upc_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_DisaggregationOfRevenuesPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_DisaggregationOfRevenuesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_DisaggregationOfRevenuesPolicyTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DisaggregationOfRevenuesPolicyTextBlock" xlink:to="upc_DisaggregationOfRevenuesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xml:lang="en-US">Shipping and handling costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ValueAddedTaxPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_ValueAddedTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ValueAddedTaxPolicyTextBlock_lbl" xml:lang="en-US">Value added tax (&#8220;VAT&#8221;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ValueAddedTaxPolicyTextBlock" xlink:to="upc_ValueAddedTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_StatementOfCashFlowsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock_lbl" xml:lang="en-US">Statement of Cash Flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatementOfCashFlowsPolicyTextBlock" xlink:to="upc_StatementOfCashFlowsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_EmployeeDefinedContributionPlanPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl" xml:lang="en-US">Employee Defined Contribution Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:to="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiMember" xlink:href="upc-20210930.xsd#upc_JiangxiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_JiangxiMember_lbl" xml:lang="en-US">Jiangxi [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiMember" xlink:to="upc_JiangxiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_JxRcbBankMember" xlink:href="upc-20210930.xsd#upc_JxRcbBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_JxRcbBankMember_lbl" xml:lang="en-US">JX RCB Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JxRcbBankMember" xlink:to="upc_JxRcbBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ChenyuanMember" xlink:href="upc-20210930.xsd#upc_ChenyuanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_ChenyuanMember_lbl" xml:lang="en-US">Chenyuan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ChenyuanMember" xlink:to="upc_ChenyuanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xml:lang="en-US">Business Combination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_JiangxiLulingRuralCommercialBankMember" xlink:href="upc-20210930.xsd#upc_JiangxiLulingRuralCommercialBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_JiangxiLulingRuralCommercialBankMember_lbl" xml:lang="en-US">LRC Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiLulingRuralCommercialBankMember" xlink:to="upc_JiangxiLulingRuralCommercialBankMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="upc_JiangxiLulingRuralCommercialBankMember_lbl0" xml:lang="en-US">Jiangxi Luling Rural Commercial Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiLulingRuralCommercialBankMember" xlink:to="upc_JiangxiLulingRuralCommercialBankMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="upc_CustomerMember" xlink:href="upc-20210930.xsd#upc_CustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CustomerMember" xlink:to="upc_CustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TotalRevenueMember" xlink:href="upc-20210930.xsd#upc_TotalRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_TotalRevenueMember_lbl" xml:lang="en-US">Total Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TotalRevenueMember" xlink:to="upc_TotalRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_GubenYanlingPillMember" xlink:href="upc-20210930.xsd#upc_GubenYanlingPillMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_GubenYanlingPillMember_lbl" xml:lang="en-US">Guben Yanling Pill [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GubenYanlingPillMember" xlink:to="upc_GubenYanlingPillMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CustomersOneMember" xlink:href="upc-20210930.xsd#upc_CustomersOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CustomersOneMember_lbl" xml:lang="en-US">Customer One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CustomersOneMember" xlink:to="upc_CustomersOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SupplierOneMember" xlink:href="upc-20210930.xsd#upc_SupplierOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SupplierOneMember_lbl" xml:lang="en-US">Supplier One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SupplierOneMember" xlink:to="upc_SupplierOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SupplierTwoMember" xlink:href="upc-20210930.xsd#upc_SupplierTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_SupplierTwoMember_lbl" xml:lang="en-US">Supplier Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SupplierTwoMember" xlink:to="upc_SupplierTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_supplierMember" xlink:href="upc-20210930.xsd#upc_supplierMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_supplierMember_lbl" xml:lang="en-US">supplier [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_supplierMember" xlink:to="upc_supplierMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UniverseINCMember" xlink:href="upc-20210930.xsd#upc_UniverseINCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UniverseINCMember_lbl" xml:lang="en-US">Universe INC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseINCMember" xlink:to="upc_UniverseINCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_UnderwriterWarrantsMember" xlink:href="upc-20210930.xsd#upc_UnderwriterWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_UnderwriterWarrantsMember_lbl" xml:lang="en-US">Underwriter warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnderwriterWarrantsMember" xlink:to="upc_UnderwriterWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_CashDividendsMember" xlink:href="upc-20210930.xsd#upc_CashDividendsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_CashDividendsMember_lbl" xml:lang="en-US">Cash dividends [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashDividendsMember" xlink:to="upc_CashDividendsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_StatutoryReserveAndRestrictedNetAssetsMember" xlink:href="upc-20210930.xsd#upc_StatutoryReserveAndRestrictedNetAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_StatutoryReserveAndRestrictedNetAssetsMember_lbl" xml:lang="en-US">Statutory Reserve and Restricted Net Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserveAndRestrictedNetAssetsMember" xlink:to="upc_StatutoryReserveAndRestrictedNetAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PRCMember" xlink:href="upc-20210930.xsd#upc_PRCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="upc_PRCMember_lbl" xml:lang="en-US">PRC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PRCMember" xlink:to="upc_PRCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowingsAbstract_lbl" xml:lang="en-US">Short-Term Invstment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermBorrowingsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl" xml:lang="en-US">Schedule of Subsidiary of Limited Liability Company or Limited Partnership [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_lbl" xml:lang="en-US">Class of Financing Receivable [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_lbl" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:to="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_lbl" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:href="upc-20210930.xsd#upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable_lbl" xml:lang="en-US">Prepayment for Construction-in-Progress (CIP) Project (Details) - Schedule of future minimum capital expenditures [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:to="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:href="upc-20210930.xsd#upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems_lbl" xml:lang="en-US">Prepayment for Construction-in-Progress (CIP) Project (Details) - Schedule of future minimum capital expenditures [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_lbl" xml:lang="en-US">Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-term Debt [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:href="upc-20210930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable_lbl" xml:lang="en-US">Related Party Transactions (Details) - Schedule of due from related parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:to="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:href="upc-20210930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) - Schedule of due from related parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:to="upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:href="upc-20210930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable_lbl" xml:lang="en-US">Related Party Transactions (Details) - Schedule of due to related parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:to="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:href="upc-20210930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) - Schedule of due to related parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:to="upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:href="upc-20210930.xsd#upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable_lbl" xml:lang="en-US">Taxes (Details) - Schedule of components of the income tax provision (benefit) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:to="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:href="upc-20210930.xsd#upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems_lbl" xml:lang="en-US">Taxes (Details) - Schedule of components of the income tax provision (benefit) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementTable_lbl" xml:lang="en-US">Condensed Balance Sheet Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Balance Sheet Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable_lbl" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl" xml:lang="en-US">Condensed Statement of Income Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedCashFlowStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedCashFlowStatementTable_lbl" xml:lang="en-US">Condensed Cash Flow Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Cash Flow Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:href="upc-20210930.xsd#upc_OrganizationandBusinessDescriptionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OrganizationandBusinessDescriptionDetailsTable_lbl" xml:lang="en-US">Organization and Business Description (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrganizationandBusinessDescriptionDetailsTable" xlink:to="upc_OrganizationandBusinessDescriptionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:href="upc-20210930.xsd#upc_OrganizationandBusinessDescriptionDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OrganizationandBusinessDescriptionDetailsLineItems_lbl" xml:lang="en-US">Organization and Business Description (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="upc_OrganizationandBusinessDescriptionDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="upc_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforConstructioninProgressCIPProjectDetailsTable" xlink:href="upc-20210930.xsd#upc_PrepaymentforConstructioninProgressCIPProjectDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforConstructioninProgressCIPProjectDetailsTable_lbl" xml:lang="en-US">Prepayment for Construction-in-Progress (CIP) Project (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsTable" xlink:to="upc_PrepaymentforConstructioninProgressCIPProjectDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems" xlink:href="upc-20210930.xsd#upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems_lbl" xml:lang="en-US">Prepayment for Construction-in-Progress (CIP) Project (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems" xlink:to="upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforPurchaseofaPropertyDetailsTable" xlink:href="upc-20210930.xsd#upc_PrepaymentforPurchaseofaPropertyDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforPurchaseofaPropertyDetailsTable_lbl" xml:lang="en-US">Prepayment for Purchase of a Property (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsTable" xlink:to="upc_PrepaymentforPurchaseofaPropertyDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:href="upc-20210930.xsd#upc_PrepaymentforPurchaseofaPropertyDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems_lbl" xml:lang="en-US">Prepayment for Purchase of a Property (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="upc_PrepaymentforPurchaseofaPropertyDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShortBankLoansDetailsTable" xlink:href="upc-20210930.xsd#upc_ShortBankLoansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShortBankLoansDetailsTable_lbl" xml:lang="en-US">Short-Bank Loans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShortBankLoansDetailsTable" xlink:to="upc_ShortBankLoansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShortBankLoansDetailsLineItems" xlink:href="upc-20210930.xsd#upc_ShortBankLoansDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShortBankLoansDetailsLineItems_lbl" xml:lang="en-US">Short-Bank Loans (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShortBankLoansDetailsLineItems" xlink:to="upc_ShortBankLoansDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsTable" xlink:href="upc-20210930.xsd#upc_TaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TaxesDetailsTable_lbl" xml:lang="en-US">Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxesDetailsTable" xlink:to="upc_TaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_TaxesDetailsLineItems" xlink:href="upc-20210930.xsd#upc_TaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TaxesDetailsLineItems_lbl" xml:lang="en-US">Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TaxesDetailsLineItems" xlink:to="upc_TaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xml:lang="en-US">Supplier [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ConcentrationsDetailsTable" xlink:href="upc-20210930.xsd#upc_ConcentrationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ConcentrationsDetailsTable_lbl" xml:lang="en-US">Concentrations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConcentrationsDetailsTable" xlink:to="upc_ConcentrationsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ConcentrationsDetailsLineItems" xlink:href="upc-20210930.xsd#upc_ConcentrationsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ConcentrationsDetailsLineItems_lbl" xml:lang="en-US">Concentrations (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConcentrationsDetailsLineItems" xlink:to="upc_ConcentrationsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityDetailsTable" xlink:href="upc-20210930.xsd#upc_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareholdersEquityDetailsTable" xlink:to="upc_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_ShareholdersEquityDetailsLineItems" xlink:href="upc-20210930.xsd#upc_ShareholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShareholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareholdersEquityDetailsLineItems" xlink:to="upc_ShareholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SubsequentEventsDetailsTable" xlink:href="upc-20210930.xsd#upc_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubsequentEventsDetailsTable" xlink:to="upc_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="upc_SubsequentEventsDetailsLineItems" xlink:href="upc-20210930.xsd#upc_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubsequentEventsDetailsLineItems" xlink:to="upc_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AccountsReceivableDescription_lbl0" xml:lang="en-US">Accounts receivable, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableDescription" xlink:to="upc_AccountsReceivableDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AddPurchaseWealthManagementFinancialProducts_lbl0" xml:lang="en-US">Amount of purchase wealth management financial products.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AddPurchaseWealthManagementFinancialProducts" xlink:to="upc_AddPurchaseWealthManagementFinancialProducts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AdditionalContractPricePercentage_lbl0" xml:lang="en-US">Additional contract price percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdditionalContractPricePercentage" xlink:to="upc_AdditionalContractPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AdvanceToSuppliersNet_lbl0" xml:lang="en-US">Amount of advance to suppliers net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvanceToSuppliersNet" xlink:to="upc_AdvanceToSuppliersNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for advances to suppliers net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:to="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AdvancesToSuppliersTextBlock_lbl0" xml:lang="en-US">The entire disclosure for the advances to suppliers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersTextBlock" xlink:to="upc_AdvancesToSuppliersTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AllowanceForUncollectableBalancesAmount_lbl0" xml:lang="en-US">Amount for uncollectable balances amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AllowanceForUncollectableBalancesAmount" xlink:to="upc_AllowanceForUncollectableBalancesAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_AmountOfRegisteredCapital_lbl0" xml:lang="en-US">Amount of registered capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AmountOfRegisteredCapital" xlink:to="upc_AmountOfRegisteredCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CapitalContribution_lbl0" xml:lang="en-US">Amount of capital contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalContribution" xlink:to="upc_CapitalContribution_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CapitalExpenditure_lbl0" xml:lang="en-US">The amount of capital expenditure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalExpenditure" xlink:to="upc_CapitalExpenditure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CashAndCashEquivalentAtCarryingValue_lbl1" xml:lang="en-US">Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashAndCashEquivalentAtCarryingValue" xlink:to="upc_CashAndCashEquivalentAtCarryingValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CashDividendDescription_lbl0" xml:lang="en-US">Description of dividends.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashDividendDescription" xlink:to="upc_CashDividendDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CashLentToSubsidiaries_lbl0" xml:lang="en-US">The amount of Cash lent to subsidiaries.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashLentToSubsidiaries" xlink:to="upc_CashLentToSubsidiaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_DeferredInitialPublicOfferingCosts_lbl0" xml:lang="en-US">Amount of deferred initial public offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DeferredInitialPublicOfferingCosts" xlink:to="upc_DeferredInitialPublicOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_DescriptionOfAverageRate_lbl0" xml:lang="en-US">Description of average rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DescriptionOfAverageRate" xlink:to="upc_DescriptionOfAverageRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_DescriptionOfYearEndSpotRate_lbl0" xml:lang="en-US">Description of year end spot rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DescriptionOfYearEndSpotRate" xlink:to="upc_DescriptionOfYearEndSpotRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl0" xml:lang="en-US">The entire disclosure of employee defined contribution plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:to="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_EntityIncorporationDateDescription_lbl0" xml:lang="en-US">Entity incorporation date description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EntityIncorporationDateDescription" xlink:to="upc_EntityIncorporationDateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_EquityInEarningsOfSubsidiary_lbl0" xml:lang="en-US">Equity in earnings of subsidiary.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityInEarningsOfSubsidiary" xlink:to="upc_EquityInEarningsOfSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_IntangibleAssets_lbl0" xml:lang="en-US">Amount of intangible assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_IntangibleAssets" xlink:to="upc_IntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_InvestmentInEquitySecurities_lbl0" xml:lang="en-US">Investment In Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_InvestmentInEquitySecurities" xlink:to="upc_InvestmentInEquitySecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent_lbl0" xml:lang="en-US">Subsidiary exceeded percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MinorityInterestsOwnershipPercentageByParent" xlink:to="upc_MinorityInterestsOwnershipPercentageByParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OfficeSpaceSquareMeters_lbl0" xml:lang="en-US">Office space Square meters.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OfficeSpaceSquareMeters" xlink:to="upc_OfficeSpaceSquareMeters_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OptionToPurchaseAdditionalShares_lbl0" xml:lang="en-US">Option to purchase additional shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OptionToPurchaseAdditionalShares" xlink:to="upc_OptionToPurchaseAdditionalShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OrdinarySharesOutstandingDescription_lbl0" xml:lang="en-US">Ordinary shares outstanding description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesOutstandingDescription" xlink:to="upc_OrdinarySharesOutstandingDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OrdinarySharesParValue_lbl0" xml:lang="en-US">Ordinary shares par value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesParValue" xlink:to="upc_OrdinarySharesParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_OriginalSharesParValue_lbl0" xml:lang="en-US">Original shares par value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OriginalSharesParValue" xlink:to="upc_OriginalSharesParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PayableDeliveryPropertyPercentage_lbl0" xml:lang="en-US">Payable delivery property percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PayableDeliveryPropertyPercentage" xlink:to="upc_PayableDeliveryPropertyPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PercentageOfAdvancePayment_lbl0" xml:lang="en-US">Percentage of advance payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfAdvancePayment" xlink:to="upc_PercentageOfAdvancePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PercentageOfPrepayment_lbl0" xml:lang="en-US">Percentage of prepayment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfPrepayment" xlink:to="upc_PercentageOfPrepayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PercentageOfVatRate_lbl0" xml:lang="en-US">Percentage of VATrate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfVatRate" xlink:to="upc_PercentageOfVatRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PlaceOfIncorporation_lbl0" xml:lang="en-US">Place of incorporation or establishment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PlaceOfIncorporation" xlink:to="upc_PlaceOfIncorporation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PreferentialTaxTreatmentDescription_lbl0" xml:lang="en-US">Preferential tax treatment, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PreferentialTaxTreatmentDescription" xlink:to="upc_PreferentialTaxTreatmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_Prepayment_lbl0" xml:lang="en-US">Amount of prepayment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_Prepayment" xlink:to="upc_Prepayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentForAdvertising_lbl0" xml:lang="en-US">Amount of prepayment for advertising.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAdvertising" xlink:to="upc_PrepaymentForAdvertising_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock_lbl0" xml:lang="en-US">The entire disclosure for prepayment for construction in progress.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForConstructionInProgressTextBlock" xlink:to="upc_PrepaymentForConstructionInProgressTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentsForConstructionInProgress_lbl0" xml:lang="en-US">Prepayments for construction in progress.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsForConstructionInProgress" xlink:to="upc_PrepaymentsForConstructionInProgress_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty_lbl0" xml:lang="en-US">The amount of prepayments made to a related party for purchase of property.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl0" xml:lang="en-US">Amount of prepayments made to a related party for purchase of property.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PrincipalActivities_lbl0" xml:lang="en-US">Principal activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrincipalActivities" xlink:to="upc_PrincipalActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings_lbl0" xml:lang="en-US">Proceeds from (prepayments for) related parties borrowings.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl0" xml:lang="en-US">The entire disclosure of property equipment estimated useful life during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_PublicOfferingPrice_lbl0" xml:lang="en-US">Public offering price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PublicOfferingPrice" xlink:to="upc_PublicOfferingPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_RawMaterialsPurchased_lbl0" xml:lang="en-US">The percentage of raw materials.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RawMaterialsPurchased" xlink:to="upc_RawMaterialsPurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_RedemptionOfShorttermInvestments_lbl0" xml:lang="en-US">Redemption of short-term investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RedemptionOfShorttermInvestments" xlink:to="upc_RedemptionOfShorttermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_RemainingCapitalContribution_lbl0" xml:lang="en-US">Remaining capital contribution amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RemainingCapitalContribution" xlink:to="upc_RemainingCapitalContribution_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ReorganizationShares_lbl0" xml:lang="en-US">Reorganization shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReorganizationShares" xlink:to="upc_ReorganizationShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ReserveIsEqualPercentage_lbl0" xml:lang="en-US">Reserve is equal percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReserveIsEqualPercentage" xlink:to="upc_ReserveIsEqualPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_RestrictedNetAssets_lbl0" xml:lang="en-US">Restricted net assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RestrictedNetAssets" xlink:to="upc_RestrictedNetAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet_lbl0" xml:lang="en-US">Tabular disclosure of advances to suppliers net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAdvancesToSuppliersNet" xlink:to="upc_ScheduleOfAdvancesToSuppliersNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock_lbl0" xml:lang="en-US">The entire disclosure of tax payable during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTaxPayableTableTextBlock" xlink:to="upc_ScheduleOfTaxPayableTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock_lbl0" xml:lang="en-US">The entire disclosure of statement of cash flows policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatementOfCashFlowsPolicyTextBlock" xlink:to="upc_StatementOfCashFlowsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_StatutoryReserve_lbl0" xml:lang="en-US">StatutoryReserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserve" xlink:to="upc_StatutoryReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_StatutorySurplusPercentage_lbl0" xml:lang="en-US">Statutory surplus percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutorySurplusPercentage" xlink:to="upc_StatutorySurplusPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts_lbl0" xml:lang="en-US">Amount of Capitalized initial public offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" xlink:to="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_SubtotalOfThirdpartyProductsSales_lbl0" xml:lang="en-US">Subtotal of third-party products sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubtotalOfThirdpartyProductsSales" xlink:to="upc_SubtotalOfThirdpartyProductsSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_ValueAddedTaxPolicyTextBlock_lbl0" xml:lang="en-US">The entire disclosure of value added tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ValueAddedTaxPolicyTextBlock" xlink:to="upc_ValueAddedTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CorporateSegmentFiveMember_lbl0" xml:lang="en-US">Corporate Segment Five [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentFiveMember" xlink:to="upc_CorporateSegmentFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CorporateSegmentFourMember_lbl0" xml:lang="en-US">Corporate Segment Four [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentFourMember" xlink:to="upc_CorporateSegmentFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CorporateSegmentOneMember_lbl0" xml:lang="en-US">Corporate Segment One [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentOneMember" xlink:to="upc_CorporateSegmentOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CorporateSegmentSixMember_lbl0" xml:lang="en-US">Corporate Segment Six [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentSixMember" xlink:to="upc_CorporateSegmentSixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CorporateSegmentThreeMember_lbl0" xml:lang="en-US">Corporate Segment Three [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentThreeMember" xlink:to="upc_CorporateSegmentThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_CorporateSegmentTwoMember_lbl0" xml:lang="en-US">Corporate Segment Two [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentTwoMember" xlink:to="upc_CorporateSegmentTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="upc_UniverseINCMember_lbl0" xml:lang="en-US">Universe INC.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseINCMember" xlink:to="upc_UniverseINCMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatutoryReserveAndRestrictedNetAssetsMember_lbl0" xml:lang="en-US">StatutoryReserveAndRestrictedNetAssetsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserveAndRestrictedNetAssetsMember" xlink:to="upc_StatutoryReserveAndRestrictedNetAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CapitalContribution_lbl1" xml:lang="en-US">CapitalContribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalContribution" xlink:to="upc_CapitalContribution_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForPurchaseOfAPropertyTextBlock_lbl0" xml:lang="en-US">PrepaymentForPurchaseOfAPropertyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForPurchaseOfAPropertyTextBlock" xlink:to="upc_PrepaymentForPurchaseOfAPropertyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_JiangxiUniverseMember_lbl0" xml:lang="en-US">JiangxiUniverseMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiUniverseMember" xlink:to="upc_JiangxiUniverseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrincipalActivities_lbl1" xml:lang="en-US">PrincipalActivities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrincipalActivities" xlink:to="upc_PrincipalActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_InvestmentInEquitySecurities_lbl1" xml:lang="en-US">InvestmentInEquitySecurities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_InvestmentInEquitySecurities" xlink:to="upc_InvestmentInEquitySecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AccountsReceivableDescription_lbl1" xml:lang="en-US">AccountsReceivableDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableDescription" xlink:to="upc_AccountsReceivableDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CorporateSegmentFiveMember_lbl1" xml:lang="en-US">CorporateSegmentFiveMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentFiveMember" xlink:to="upc_CorporateSegmentFiveMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PayableDeliveryPropertyPercentage_lbl1" xml:lang="en-US">PayableDeliveryPropertyPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PayableDeliveryPropertyPercentage" xlink:to="upc_PayableDeliveryPropertyPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CorporateSegmentTwoMember_lbl1" xml:lang="en-US">CorporateSegmentTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentTwoMember" xlink:to="upc_CorporateSegmentTwoMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CustomerMember_lbl0" xml:lang="en-US">CustomerMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CustomerMember" xlink:to="upc_CustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashDividendDescription_lbl1" xml:lang="en-US">CashDividendDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashDividendDescription" xlink:to="upc_CashDividendDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_Over1YearMember_lbl0" xml:lang="en-US">Over1YearMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_Over1YearMember" xlink:to="upc_Over1YearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnderwriterWarrantsMember_lbl0" xml:lang="en-US">UnderwriterWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnderwriterWarrantsMember" xlink:to="upc_UnderwriterWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_DeferredIncomeTaxProvisionAbstract_lbl0" xml:lang="en-US">DeferredIncomeTaxProvisionAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DeferredIncomeTaxProvisionAbstract" xlink:to="upc_DeferredIncomeTaxProvisionAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseTechnologyMember_lbl0" xml:lang="en-US">UniverseTechnologyMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTechnologyMember" xlink:to="upc_UniverseTechnologyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CorporateSegmentThreeMember_lbl1" xml:lang="en-US">CorporateSegmentThreeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentThreeMember" xlink:to="upc_CorporateSegmentThreeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdvanceToSuppliersNet_lbl1" xml:lang="en-US">AdvanceToSuppliersNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvanceToSuppliersNet" xlink:to="upc_AdvanceToSuppliersNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AccountsReceivableBeforeGrossValue_lbl0" xml:lang="en-US">AccountsReceivableBeforeGrossValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableBeforeGrossValue" xlink:to="upc_AccountsReceivableBeforeGrossValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OfficeAndElectricEquipmentMember_lbl0" xml:lang="en-US">OfficeAndElectricEquipmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OfficeAndElectricEquipmentMember" xlink:to="upc_OfficeAndElectricEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CapitalExpenditure_lbl1" xml:lang="en-US">CapitalExpenditure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalExpenditure" xlink:to="upc_CapitalExpenditure_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OrdinarySharesParValue_lbl1" xml:lang="en-US">OrdinarySharesParValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesParValue" xlink:to="upc_OrdinarySharesParValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AllowanceForDoubtfulAccountsReceivablePercentage_lbl0" xml:lang="en-US">AllowanceForDoubtfulAccountsReceivablePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AllowanceForDoubtfulAccountsReceivablePercentage" xlink:to="upc_AllowanceForDoubtfulAccountsReceivablePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MrGangLaiMember_lbl0" xml:lang="en-US">MrGangLaiMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrGangLaiMember" xlink:to="upc_MrGangLaiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_JxRcbBankMember_lbl0" xml:lang="en-US">JxRcbBankMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JxRcbBankMember" xlink:to="upc_JxRcbBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdvancesToSuppliersTextBlock_lbl1" xml:lang="en-US">AdvancesToSuppliersTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersTextBlock" xlink:to="upc_AdvancesToSuppliersTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract_lbl0" xml:lang="en-US">UnlabeledAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract" xlink:to="upc_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl1" xml:lang="en-US">AdvancesToSuppliersNetPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdvancesToSuppliersNetPolicyTextBlock" xlink:to="upc_AdvancesToSuppliersNetPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ChenyuanMember_lbl0" xml:lang="en-US">ChenyuanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ChenyuanMember" xlink:to="upc_ChenyuanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PreferentialTaxTreatmentDescription_lbl1" xml:lang="en-US">PreferentialTaxTreatmentDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PreferentialTaxTreatmentDescription" xlink:to="upc_PreferentialTaxTreatmentDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SunsequentCollectionAccountsReceivableNet_lbl0" xml:lang="en-US">SunsequentCollectionAccountsReceivableNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SunsequentCollectionAccountsReceivableNet" xlink:to="upc_SunsequentCollectionAccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PlaceOfIncorporation_lbl1" xml:lang="en-US">PlaceOfIncorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PlaceOfIncorporation" xlink:to="upc_PlaceOfIncorporation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AdditionalContractPricePercentage_lbl1" xml:lang="en-US">AdditionalContractPricePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AdditionalContractPricePercentage" xlink:to="upc_AdditionalContractPricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_From7To9MonthsMember_lbl0" xml:lang="en-US">From7To9MonthsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_From7To9MonthsMember" xlink:to="upc_From7To9MonthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SupplierOneMember_lbl0" xml:lang="en-US">SupplierOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SupplierOneMember" xlink:to="upc_SupplierOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShorttermInvestmentIncome_lbl0" xml:lang="en-US">ShorttermInvestmentIncome</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShorttermInvestmentIncome" xlink:to="upc_ShorttermInvestmentIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AssetsAbstract0_lbl0" xml:lang="en-US">AssetsAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AssetsAbstract0" xlink:to="upc_AssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_DescriptionOfAverageRate_lbl1" xml:lang="en-US">DescriptionOfAverageRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DescriptionOfAverageRate" xlink:to="upc_DescriptionOfAverageRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SubtotalOfTCMDProductsSales_lbl0" xml:lang="en-US">SubtotalOfTCMDProductsSales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubtotalOfTCMDProductsSales" xlink:to="upc_SubtotalOfTCMDProductsSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShareholdersEquityAbstract0_lbl0" xml:lang="en-US">ShareholdersEquityAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShareholdersEquityAbstract0" xlink:to="upc_ShareholdersEquityAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_From10To12MonthsMember_lbl0" xml:lang="en-US">From10To12MonthsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_From10To12MonthsMember" xlink:to="upc_From10To12MonthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty_lbl1" xml:lang="en-US">PrepaymentsMadeToARelatedPartyForPurchaseOfProperty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfDueToRelatedPartiesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:to="upc_ScheduleOfDueToRelatedPartiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_JiangxiMember_lbl0" xml:lang="en-US">JiangxiMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiMember" xlink:to="upc_JiangxiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OtherComprehensiveIncomeLossAbstract_lbl0" xml:lang="en-US">OtherComprehensiveIncomeLossAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherComprehensiveIncomeLossAbstract" xlink:to="upc_OtherComprehensiveIncomeLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PercentageOfVatRate_lbl1" xml:lang="en-US">PercentageOfVatRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfVatRate" xlink:to="upc_PercentageOfVatRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_IntangibleAssets_lbl1" xml:lang="en-US">IntangibleAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_IntangibleAssets" xlink:to="upc_IntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForAdvertistingTextBlock_lbl0" xml:lang="en-US">PrepaymentForAdvertistingTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAdvertistingTextBlock" xlink:to="upc_PrepaymentForAdvertistingTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfDueFromRelatedPartiesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock" xlink:to="upc_ScheduleOfDueFromRelatedPartiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PRCMember_lbl0" xml:lang="en-US">PRCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PRCMember" xlink:to="upc_PRCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CorporateSegmentFourMember_lbl1" xml:lang="en-US">CorporateSegmentFourMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentFourMember" xlink:to="upc_CorporateSegmentFourMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CustomersOneMember_lbl0" xml:lang="en-US">CustomersOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CustomersOneMember" xlink:to="upc_CustomersOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseHanheMember_lbl0" xml:lang="en-US">UniverseHanheMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseHanheMember" xlink:to="upc_UniverseHanheMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AllowanceForUncollectableBalancesAmount_lbl1" xml:lang="en-US">AllowanceForUncollectableBalancesAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AllowanceForUncollectableBalancesAmount" xlink:to="upc_AllowanceForUncollectableBalancesAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_LessThan3MonthsMember_lbl0" xml:lang="en-US">LessThan3MonthsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LessThan3MonthsMember" xlink:to="upc_LessThan3MonthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CorporateSegmentSixMember_lbl1" xml:lang="en-US">CorporateSegmentSixMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentSixMember" xlink:to="upc_CorporateSegmentSixMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SalesOfTcmdProductsAbstract_lbl0" xml:lang="en-US">SalesOfTcmdProductsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SalesOfTcmdProductsAbstract" xlink:to="upc_SalesOfTcmdProductsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ReorganizationShares_lbl1" xml:lang="en-US">ReorganizationShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReorganizationShares" xlink:to="upc_ReorganizationShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SupplierTwoMember_lbl0" xml:lang="en-US">SupplierTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SupplierTwoMember" xlink:to="upc_SupplierTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AccountsReceivableNetPercentage_lbl0" xml:lang="en-US">AccountsReceivableNetPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AccountsReceivableNetPercentage" xlink:to="upc_AccountsReceivableNetPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RestrictedNetAssets_lbl1" xml:lang="en-US">RestrictedNetAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RestrictedNetAssets" xlink:to="upc_RestrictedNetAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">DeferredTaxAssetsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DeferredTaxAssetsAbstract" xlink:to="upc_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OrdinarySharesOutstandingDescription_lbl1" xml:lang="en-US">OrdinarySharesOutstandingDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OrdinarySharesOutstandingDescription" xlink:to="upc_OrdinarySharesOutstandingDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MaturityGreaterThan90DaysOneMember_lbl0" xml:lang="en-US">MaturityGreaterThan90DaysOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysOneMember" xlink:to="upc_MaturityGreaterThan90DaysOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RawMaterialsPurchased_lbl1" xml:lang="en-US">RawMaterialsPurchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RawMaterialsPurchased" xlink:to="upc_RawMaterialsPurchased_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MaturityGreaterThan90DaysThreeMember_lbl0" xml:lang="en-US">MaturityGreaterThan90DaysThreeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysThreeMember" xlink:to="upc_MaturityGreaterThan90DaysThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfTaxPayableTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfTaxPayableTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfTaxPayableTableTextBlock" xlink:to="upc_ScheduleOfTaxPayableTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_Prepayment_lbl1" xml:lang="en-US">Prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_Prepayment" xlink:to="upc_Prepayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_HeldToMaturityInvestmentPolicyTextBlock_lbl0" xml:lang="en-US">HeldToMaturityInvestmentPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_HeldToMaturityInvestmentPolicyTextBlock" xlink:to="upc_HeldToMaturityInvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl1" xml:lang="en-US">EmployeeDefinedContributionPlanPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:to="upc_EmployeeDefinedContributionPlanPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashDividendsMember_lbl0" xml:lang="en-US">CashDividendsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashDividendsMember" xlink:to="upc_CashDividendsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OptionToPurchaseAdditionalShares_lbl1" xml:lang="en-US">OptionToPurchaseAdditionalShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OptionToPurchaseAdditionalShares" xlink:to="upc_OptionToPurchaseAdditionalShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatutoryReserve_lbl1" xml:lang="en-US">StatutoryReserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReserve" xlink:to="upc_StatutoryReserve_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseIncMember_lbl1" xml:lang="en-US">UniverseIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseIncMember" xlink:to="upc_UniverseIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_HeldToMaturityInvestmentDisclosureTextBlock_lbl0" xml:lang="en-US">HeldToMaturityInvestmentDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_HeldToMaturityInvestmentDisclosureTextBlock" xlink:to="upc_HeldToMaturityInvestmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SunsequentCollectionAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">SunsequentCollectionAllowanceForDoubtfulAccounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SunsequentCollectionAllowanceForDoubtfulAccounts" xlink:to="upc_SunsequentCollectionAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForConstructionInProgressTextBlock_lbl1" xml:lang="en-US">PrepaymentForConstructionInProgressTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForConstructionInProgressTextBlock" xlink:to="upc_PrepaymentForConstructionInProgressTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_DeferredInitialPublicOfferingCosts_lbl1" xml:lang="en-US">DeferredInitialPublicOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DeferredInitialPublicOfferingCosts" xlink:to="upc_DeferredInitialPublicOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix_lbl0" xml:lang="en-US">FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" xlink:to="upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PublicOfferingPrice_lbl1" xml:lang="en-US">PublicOfferingPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PublicOfferingPrice" xlink:to="upc_PublicOfferingPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseINCMember_lbl1" xml:lang="en-US">UniverseINCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseINCMember" xlink:to="upc_UniverseINCMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ShortTermBankLoansAbstract_lbl0" xml:lang="en-US">ShortTermBankLoansAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ShortTermBankLoansAbstract" xlink:to="upc_ShortTermBankLoansAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseTradeMember_lbl1" xml:lang="en-US">UniverseTradeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseTradeMember" xlink:to="upc_UniverseTradeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MaturityGreaterThan90DaysTwoMember_lbl0" xml:lang="en-US">MaturityGreaterThan90DaysTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MaturityGreaterThan90DaysTwoMember" xlink:to="upc_MaturityGreaterThan90DaysTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PercentageOfSubsequentCollection_lbl0" xml:lang="en-US">PercentageOfSubsequentCollection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfSubsequentCollection" xlink:to="upc_PercentageOfSubsequentCollection_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_DescriptionOfYearEndSpotRate_lbl1" xml:lang="en-US">DescriptionOfYearEndSpotRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DescriptionOfYearEndSpotRate" xlink:to="upc_DescriptionOfYearEndSpotRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AddPurchaseWealthManagementFinancialProducts_lbl1" xml:lang="en-US">AddPurchaseWealthManagementFinancialProducts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AddPurchaseWealthManagementFinancialProducts" xlink:to="upc_AddPurchaseWealthManagementFinancialProducts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SubsequentCollection_lbl0" xml:lang="en-US">SubsequentCollection</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubsequentCollection" xlink:to="upc_SubsequentCollection_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SunsequentCollectionsTotalGrossAccountsReceivable_lbl0" xml:lang="en-US">SunsequentCollectionsTotalGrossAccountsReceivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SunsequentCollectionsTotalGrossAccountsReceivable" xlink:to="upc_SunsequentCollectionsTotalGrossAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CurrentIncomeTaxProvisionAbstract_lbl0" xml:lang="en-US">CurrentIncomeTaxProvisionAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CurrentIncomeTaxProvisionAbstract" xlink:to="upc_CurrentIncomeTaxProvisionAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashFlowsFromFinancingActivitiesAbstract_lbl0" xml:lang="en-US">CashFlowsFromFinancingActivitiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashFlowsFromFinancingActivitiesAbstract" xlink:to="upc_CashFlowsFromFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_FoshanShangyuMember_lbl0" xml:lang="en-US">FoshanShangyuMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_FoshanShangyuMember" xlink:to="upc_FoshanShangyuMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_supplierMember_lbl0" xml:lang="en-US">supplierMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_supplierMember" xlink:to="upc_supplierMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ValueAddedTaxPolicyTextBlock_lbl1" xml:lang="en-US">ValueAddedTaxPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ValueAddedTaxPolicyTextBlock" xlink:to="upc_ValueAddedTaxPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ScheduleOfAdvancesToSuppliersNet_lbl1" xml:lang="en-US">ScheduleOfAdvancesToSuppliersNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ScheduleOfAdvancesToSuppliersNet" xlink:to="upc_ScheduleOfAdvancesToSuppliersNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_DisaggregationOfRevenuesPolicyTextBlock_lbl0" xml:lang="en-US">DisaggregationOfRevenuesPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_DisaggregationOfRevenuesPolicyTextBlock" xlink:to="upc_DisaggregationOfRevenuesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_EquityInEarningsOfSubsidiary_lbl1" xml:lang="en-US">EquityInEarningsOfSubsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EquityInEarningsOfSubsidiary" xlink:to="upc_EquityInEarningsOfSubsidiary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl1" xml:lang="en-US">PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:to="upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl1" xml:lang="en-US">PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashFlowsFromOperatingActivitiesAbstract_lbl0" xml:lang="en-US">CashFlowsFromOperatingActivitiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashFlowsFromOperatingActivitiesAbstract" xlink:to="upc_CashFlowsFromOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_EntityIncorporationDateDescription_lbl1" xml:lang="en-US">EntityIncorporationDateDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_EntityIncorporationDateDescription" xlink:to="upc_EntityIncorporationDateDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_LiabilitiesAndShareholdersEquityAbstract0_lbl0" xml:lang="en-US">LiabilitiesAndShareholdersEquityAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LiabilitiesAndShareholdersEquityAbstract0" xlink:to="upc_LiabilitiesAndShareholdersEquityAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatementOfCashFlowsPolicyTextBlock_lbl1" xml:lang="en-US">StatementOfCashFlowsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatementOfCashFlowsPolicyTextBlock" xlink:to="upc_StatementOfCashFlowsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract_lbl0" xml:lang="en-US">LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:to="upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TotalGrossAccountsReceivablePercentage_lbl0" xml:lang="en-US">TotalGrossAccountsReceivablePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TotalGrossAccountsReceivablePercentage" xlink:to="upc_TotalGrossAccountsReceivablePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ConcentrationRiskThresholdPercentage_lbl0" xml:lang="en-US">ConcentrationRiskThresholdPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ConcentrationRiskThresholdPercentage" xlink:to="upc_ConcentrationRiskThresholdPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CapitalExpenditureMember_lbl0" xml:lang="en-US">CapitalExpenditureMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CapitalExpenditureMember" xlink:to="upc_CapitalExpenditureMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CorporateSegmentOneMember_lbl1" xml:lang="en-US">CorporateSegmentOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CorporateSegmentOneMember" xlink:to="upc_CorporateSegmentOneMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_From4To6MonthsMember_lbl0" xml:lang="en-US">From4To6MonthsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_From4To6MonthsMember" xlink:to="upc_From4To6MonthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl0" xml:lang="en-US">ContractAssetsAndLiabilitiesPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:to="upc_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract0_lbl0" xml:lang="en-US">UnlabeledAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract0" xlink:to="upc_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SubtotalOfThirdpartyProductsSales_lbl1" xml:lang="en-US">SubtotalOfThirdpartyProductsSales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SubtotalOfThirdpartyProductsSales" xlink:to="upc_SubtotalOfThirdpartyProductsSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MrsLinYangMember_lbl0" xml:lang="en-US">MrsLinYangMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MrsLinYangMember" xlink:to="upc_MrsLinYangMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_SalesOfThirdPartyProductsAbstract_lbl0" xml:lang="en-US">SalesOfThirdPartyProductsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_SalesOfThirdPartyProductsAbstract" xlink:to="upc_SalesOfThirdPartyProductsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UnlabeledAbstract00_lbl0" xml:lang="en-US">UnlabeledAbstract00</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UnlabeledAbstract00" xlink:to="upc_UnlabeledAbstract00_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_JiangxiLulingRuralCommercialBankMember_lbl1" xml:lang="en-US">JiangxiLulingRuralCommercialBankMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_JiangxiLulingRuralCommercialBankMember" xlink:to="upc_JiangxiLulingRuralCommercialBankMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_MinorityInterestsOwnershipPercentageByParent_lbl1" xml:lang="en-US">MinorityInterestsOwnershipPercentageByParent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_MinorityInterestsOwnershipPercentageByParent" xlink:to="upc_MinorityInterestsOwnershipPercentageByParent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OriginalSharesParValue_lbl1" xml:lang="en-US">OriginalSharesParValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OriginalSharesParValue" xlink:to="upc_OriginalSharesParValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_NonCurrentAssetsAbstract_lbl0" xml:lang="en-US">NonCurrentAssetsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_NonCurrentAssetsAbstract" xlink:to="upc_NonCurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_AmountOfRegisteredCapital_lbl1" xml:lang="en-US">AmountOfRegisteredCapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_AmountOfRegisteredCapital" xlink:to="upc_AmountOfRegisteredCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PercentageOfAdvancePayment_lbl1" xml:lang="en-US">PercentageOfAdvancePayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfAdvancePayment" xlink:to="upc_PercentageOfAdvancePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashAndCashEquivalentAtCarryingValue_lbl2" xml:lang="en-US">CashAndCashEquivalentAtCarryingValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashAndCashEquivalentAtCarryingValue" xlink:to="upc_CashAndCashEquivalentAtCarryingValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashFlowsFromInvestingActivitiesAbstract_lbl0" xml:lang="en-US">CashFlowsFromInvestingActivitiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashFlowsFromInvestingActivitiesAbstract" xlink:to="upc_CashFlowsFromInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatutoryReservesMember_lbl0" xml:lang="en-US">StatutoryReservesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutoryReservesMember" xlink:to="upc_StatutoryReservesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings_lbl1" xml:lang="en-US">ProceedsFromprepaymentsForRelatedPartiesBorrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OtherIncomeExpensesAbstract_lbl0" xml:lang="en-US">OtherIncomeExpensesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherIncomeExpensesAbstract" xlink:to="upc_OtherIncomeExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_GreatestGroupMember_lbl0" xml:lang="en-US">GreatestGroupMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GreatestGroupMember" xlink:to="upc_GreatestGroupMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentForAdvertising_lbl1" xml:lang="en-US">PrepaymentForAdvertising</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentForAdvertising" xlink:to="upc_PrepaymentForAdvertising_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RedemptionOfShorttermInvestments_lbl1" xml:lang="en-US">RedemptionOfShorttermInvestments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RedemptionOfShorttermInvestments" xlink:to="upc_RedemptionOfShorttermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_ReserveIsEqualPercentage_lbl1" xml:lang="en-US">ReserveIsEqualPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_ReserveIsEqualPercentage" xlink:to="upc_ReserveIsEqualPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_GubenYanlingPillMember_lbl0" xml:lang="en-US">GubenYanlingPillMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_GubenYanlingPillMember" xlink:to="upc_GubenYanlingPillMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts_lbl1" xml:lang="en-US">StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" xlink:to="upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_CashLentToSubsidiaries_lbl1" xml:lang="en-US">CashLentToSubsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_CashLentToSubsidiaries" xlink:to="upc_CashLentToSubsidiaries_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OfficeSpaceSquareMeters_lbl1" xml:lang="en-US">OfficeSpaceSquareMeters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OfficeSpaceSquareMeters" xlink:to="upc_OfficeSpaceSquareMeters_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PrepaymentsForConstructionInProgress_lbl1" xml:lang="en-US">PrepaymentsForConstructionInProgress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PrepaymentsForConstructionInProgress" xlink:to="upc_PrepaymentsForConstructionInProgress_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_OtherIncomeExpensesAbstract0_lbl0" xml:lang="en-US">OtherIncomeExpensesAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_OtherIncomeExpensesAbstract0" xlink:to="upc_OtherIncomeExpensesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_RemainingCapitalContribution_lbl1" xml:lang="en-US">RemainingCapitalContribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_RemainingCapitalContribution" xlink:to="upc_RemainingCapitalContribution_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_UniverseHKMember_lbl0" xml:lang="en-US">UniverseHKMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_UniverseHKMember" xlink:to="upc_UniverseHKMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_PercentageOfPrepayment_lbl1" xml:lang="en-US">PercentageOfPrepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_PercentageOfPrepayment" xlink:to="upc_PercentageOfPrepayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_StatutorySurplusPercentage_lbl1" xml:lang="en-US">StatutorySurplusPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_StatutorySurplusPercentage" xlink:to="upc_StatutorySurplusPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="upc_TotalRevenueMember_lbl0" xml:lang="en-US">TotalRevenueMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="upc_TotalRevenueMember" xlink:to="upc_TotalRevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetInvestmentIncome_lbl0" xml:lang="en-US">Net Investment Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetInvestmentIncome" xlink:to="us-gaap_NetInvestmentIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl0" xml:lang="en-US">Other Operating Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl0" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl0" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl0" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements_lbl0" xml:lang="en-US">Investment Building and Building Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:to="us-gaap_InvestmentBuildingAndBuildingImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToSuppliersAndEmployees_lbl0" xml:lang="en-US">Payments to Suppliers and Employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToSuppliersAndEmployees" xlink:to="us-gaap_PaymentsToSuppliersAndEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl0" xml:lang="en-US">Deferred Costs, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl0" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedParties_lbl0" xml:lang="en-US">Due from Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl0" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge_lbl1" xml:lang="en-US">Inventory, LIFO Reserve, Period Charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateMember_lbl0" xml:lang="en-US">Corporate Segment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateMember" xlink:to="us-gaap_CorporateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl0" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableToBankCurrent_lbl0" xml:lang="en-US">Loans Payable to Bank, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableToBankCurrent" xlink:to="us-gaap_LoansPayableToBankCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl0" xml:lang="en-US">Accrued Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AutomobilesMember_lbl0" xml:lang="en-US">Automobiles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AutomobilesMember" xlink:to="us-gaap_AutomobilesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl0" xml:lang="en-US">Computer Software, Intangible Asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseRightsMember_lbl0" xml:lang="en-US">Use Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseRightsMember" xlink:to="us-gaap_UseRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl0" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseCapitalSecurities_lbl0" xml:lang="en-US">Interest Expense, Capital Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseCapitalSecurities" xlink:to="us-gaap_InterestExpenseCapitalSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0" xml:lang="en-US">Prepayment Fees on Advances, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl0" xml:lang="en-US">Capital Expenditure, Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent_lbl0" xml:lang="en-US">Sales and Excise Tax Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeShortTermInvestmentOther_lbl0" xml:lang="en-US">Interest Income, Short-Term Investment, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeShortTermInvestmentOther" xlink:to="us-gaap_InterestIncomeShortTermInvestmentOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl0" xml:lang="en-US">Operating Costs and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOtherShortTermBorrowings_lbl0" xml:lang="en-US">Interest Expense, Other Short-term Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:to="us-gaap_InterestExpenseOtherShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl0" xml:lang="en-US">Due to Related Parties, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl1" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl0" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss_lbl0" xml:lang="en-US">Accounts and Financing Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:to="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl0" xml:lang="en-US">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfAdvancesForConstruction_lbl0" xml:lang="en-US">Repayments of Advances for Construction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfAdvancesForConstruction" xlink:to="us-gaap_RepaymentsOfAdvancesForConstruction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl0" xml:lang="en-US">Proceeds from Short-term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl0" xml:lang="en-US">Condensed Cash Flow Statement [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaturityOver90DaysMember_lbl0" xml:lang="en-US">Maturity Greater than 90 Days [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturityOver90DaysMember" xlink:to="us-gaap_MaturityOver90DaysMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl1" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl1" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherShortTermInvestments_lbl0" xml:lang="en-US">Other Short-term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermInvestments" xlink:to="us-gaap_OtherShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Short-term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl0" xml:lang="en-US">Defined Contribution Plan, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl0" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_lbl0" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:to="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl0" xml:lang="en-US">Accrual for Taxes Other than Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl0" xml:lang="en-US">Allowance for Doubtful Accounts, Premiums and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl0" xml:lang="en-US">Schedule of Short-term Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_lbl0" xml:lang="en-US">Temporary Equity, Foreign Currency Translation Adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_lbl0" xml:lang="en-US">Income Tax Holiday, Income Tax Benefits Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:to="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividends_lbl0" xml:lang="en-US">Payments of Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfOtherPropertyOperatingExpense_lbl0" xml:lang="en-US">Cost of Other Property Operating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfOtherPropertyOperatingExpense" xlink:to="us-gaap_CostOfOtherPropertyOperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl1" xml:lang="en-US">Payments to Acquire Short-term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Investment Income Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl0" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeconsolidationRelatedPartyDescription_lbl0" xml:lang="en-US">Deconsolidation, Related Party, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationRelatedPartyDescription" xlink:to="us-gaap_DeconsolidationRelatedPartyDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0" xml:lang="en-US">Short-term Bank Loans and Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsShareBasedCompensationCash_lbl0" xml:lang="en-US">Dividend, Share-based Payment Arrangement, Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsShareBasedCompensationCash" xlink:to="us-gaap_DividendsShareBasedCompensationCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl0" xml:lang="en-US">Related Party Transaction, Terms and Manner of Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl0" xml:lang="en-US">Payments for Repurchase of Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl0" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Property and Other Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl0" xml:lang="en-US">Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0" xml:lang="en-US">Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl0" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl1" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl0" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl0" xml:lang="en-US">Inventory, Raw Materials and Supplies, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl1" xml:lang="en-US">Taxes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl1" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl0" xml:lang="en-US">Interest and Debt Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl0" xml:lang="en-US">CHINA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl0" xml:lang="en-US">Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits_lbl0" xml:lang="en-US">Foreign Financial Institutions, Mandated Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:to="us-gaap_ForeignFinancialInstitutionsMandatedDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Holiday, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl0" xml:lang="en-US">Other Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionContractorsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Construction Contractor [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" xlink:to="us-gaap_ConstructionContractorsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl0" xml:lang="en-US">Property, Plant and Equipment, Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl1" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl0" xml:lang="en-US">Equity Method Investment, Amount Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventDescription_lbl0" xml:lang="en-US">Subsequent Event, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventDescription" xlink:to="us-gaap_SubsequentEventDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl0" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl2" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl1" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGross_lbl0" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl1" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl0" xml:lang="en-US">Repayments of Bank Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl0" xml:lang="en-US">Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl0" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl1" xml:lang="en-US">Payments for (Proceeds from) Short-term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl2" xml:lang="en-US">Short-term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Maturity30To90DaysMember_lbl0" xml:lang="en-US">Maturity 30 to 90 Days [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Maturity30To90DaysMember" xlink:to="us-gaap_Maturity30To90DaysMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl0" xml:lang="en-US">Proceeds from Sale of Productive Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl1" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl1" xml:lang="en-US">Inventory Valuation Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl0" xml:lang="en-US">Contact Personnel Email Address</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingExpense_lbl0" xml:lang="en-US">Selling Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Advertising</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl1" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due from Other Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl0" xml:lang="en-US">Debt Securities, Held-to-maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl0" xml:lang="en-US">Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_KY_lbl0" xml:lang="en-US">CAYMAN ISLANDS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KY" xlink:to="country_KY_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl1" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_HK_lbl1" xml:lang="en-US">HONG KONG</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due to Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl0" xml:lang="en-US">Supplemental Deferred Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl0" xml:lang="en-US">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>upc-20210930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sat Jan 29 18:38:56 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ConsolidatedCashFlow" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ConsolidatedCashFlow_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ConsolidatedIncomeStatement" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShareholdersEquityType2or3" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ConsolidatedCashFlow0" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_OrganizationandBusinessDescription" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AccountsReceivableNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_InventoryNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AdvancetoSuppliers" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforAdvertisting" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShortTermInvstment" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstment"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PropertyPlantandEquipmentNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_IntangibleAssetsNet" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforConstructioninProgressCIPProject" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProject"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforPurchaseofaProperty" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShortBankLoans" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoans"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_RelatedPartyTransactions" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_Taxes" roleURI="http://www.UniversePharmaceuticalsINC.com/role/Taxes"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_Concentrations" roleURI="http://www.UniversePharmaceuticalsINC.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShareholdersEquity" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_CommitmentsandContingencies" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SegmentReporting" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SubsequentEvents" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_CondensedFinancialInformationoftheParentCompany" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AccountingPoliciesByPolicy" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_OrganizationandBusinessDescriptionTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AccountsReceivableNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_InventoryNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AdvancetoSuppliersTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShortTermInvstmentTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PropertyPlantandEquipmentNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_IntangibleAssetsNetTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforConstructioninProgressCIPProjectTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShortBankLoansTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_RelatedPartyTransactionsTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_TaxesTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SegmentReportingTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_CondensedFinancialInformationoftheParentCompanyTables" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofsubsidiariesofthecompanyTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofpropertyandequipmentestimatedusefullivesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofintangibleassetsestimatedusefullivesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofcurrencyexchangerateTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofaccountsreceivableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofallowancefordoubtfulaccountsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofinventoryTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofadvancestosuppliersnetTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofshortterminvstmentTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvstmentTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofPropertyplantandequipmentnetconsistsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofintangibleassetsnetconsistTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleoffutureminimumcapitalexpendituresTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofshorttermbankloansTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofnatureofrelationshipswithrelatedpartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofduefromrelatedpartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofduetorelatedpartiesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofcomponentsoftheincometaxprovisionbenefitTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofdeferredtaxassetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleoftaxespayableTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofrevenuebyproductsourceTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleoftotalrevenuesbyproductcategoriesTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofparentcompanybalancesheetsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofparentcompanybalancesheetsTable_Parentheticals" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ScheduleofparentcompanystatementsofcashflowsTable" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_OrganizationandBusinessDescriptionDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AccountsReceivableNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_InventoryNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_AdvancetoSuppliersDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforAdvertistingDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShortTermInvstmentDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PropertyPlantandEquipmentNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_IntangibleAssetsNetDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforConstructioninProgressCIPProjectDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_PrepaymentforPurchaseofaPropertyDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShortBankLoansDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_RelatedPartyTransactionsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_TaxesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ConcentrationsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_ShareholdersEquityDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_CommitmentsandContingenciesDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SegmentReportingDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_SubsequentEventsDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#upc_r_CondensedFinancialInformationoftheParentCompanyDetails" roleURI="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails"/>
  <roleRef xlink:type="simple" xlink:href="upc-20210930.xsd#DocumentAndEntityInformation" roleURI="http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromRelatedParties" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvanceToSuppliersNet" xlink:href="upc-20210930.xsd#upc_AdvanceToSuppliersNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="AdvanceToSuppliersNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForAdvertising" xlink:href="upc-20210930.xsd#upc_PrepaymentForAdvertising"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="PrepaymentForAdvertising" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" xlink:href="upc-20210930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsForConstructionInProgress" xlink:href="upc-20210930.xsd#upc_PrepaymentsForConstructionInProgress"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="PrepaymentsForConstructionInProgress" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentInEquitySecurities" xlink:href="upc-20210930.xsd#upc_InvestmentInEquitySecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="InvestmentInEquitySecurities" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserve" xlink:href="upc-20210930.xsd#upc_StatutoryReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="StatutoryReserve" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeExpensesAbstract" xlink:href="upc-20210930.xsd#upc_OtherIncomeExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OtherIncomeExpensesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShorttermInvestmentIncome" xlink:href="upc-20210930.xsd#upc_ShorttermInvestmentIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract" xlink:to="ShorttermInvestmentIncome" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherComprehensiveIncomeLossAbstract" xlink:href="upc-20210930.xsd#upc_OtherComprehensiveIncomeLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OtherComprehensiveIncomeLossAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_EarningsPerShareAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReservesMember" xlink:href="upc-20210930.xsd#upc_StatutoryReservesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StatutoryReservesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" xlink:href="upc-20210930.xsd#upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeShortTermInvestmentOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeShortTermInvestmentOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InterestIncomeShortTermInvestmentOther" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidAdvertising" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidAdvertising"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidAdvertising" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" xlink:href="upc-20210930.xsd#upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PrepaymentsMadeToARelatedPartyForPurchaseOfProperty" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfAdvancesForConstruction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfAdvancesForConstruction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfAdvancesForConstruction" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="RedemptionOfShorttermInvestments" xlink:href="upc-20210930.xsd#upc_RedemptionOfShorttermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="RedemptionOfShorttermInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfBankDebt" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:href="upc-20210930.xsd#upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ProceedsFromprepaymentsForRelatedPartiesBorrowings" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromprepaymentsForRelatedPartiesBorrowings" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoryNet">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers">
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersAbstract" xlink:href="upc-20210930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersTextBlock" xlink:href="upc-20210930.xsd#upc_AdvancesToSuppliersTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancesToSuppliersAbstract" xlink:to="AdvancesToSuppliersTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting">
    <loc xlink:type="locator" xlink:label="PrepaymentForAdvertistingAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForAdvertistingAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForAdvertistingTextBlock" xlink:href="upc-20210930.xsd#upc_PrepaymentForAdvertistingTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAdvertistingAbstract" xlink:to="PrepaymentForAdvertistingTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstment">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="HeldToMaturityInvestmentDisclosureTextBlock" xlink:href="upc-20210930.xsd#upc_HeldToMaturityInvestmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="HeldToMaturityInvestmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProject">
    <loc xlink:type="locator" xlink:label="PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForConstructionInProgressTextBlock" xlink:href="upc-20210930.xsd#upc_PrepaymentForConstructionInProgressTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForConstructionInProgressAbstract" xlink:to="PrepaymentForConstructionInProgressTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty">
    <loc xlink:type="locator" xlink:label="PrepaymentForPurchaseOfAPropertyAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForPurchaseOfAPropertyTextBlock" xlink:href="upc-20210930.xsd#upc_PrepaymentForPurchaseOfAPropertyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="PrepaymentForPurchaseOfAPropertyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoans">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/Taxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/Concentrations">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersNetPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_AdvancesToSuppliersNetPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AdvancesToSuppliersNetPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HeldToMaturityInvestmentPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_HeldToMaturityInvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="HeldToMaturityInvestmentPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionContractorsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConstructionContractorsPolicyPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_ContractAssetsAndLiabilitiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ContractAssetsAndLiabilitiesPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisaggregationOfRevenuesPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_DisaggregationOfRevenuesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DisaggregationOfRevenuesPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValueAddedTaxPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_ValueAddedTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ValueAddedTaxPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatementOfCashFlowsPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_StatementOfCashFlowsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="StatementOfCashFlowsPolicyTextBlock" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeDefinedContributionPlanPolicyTextBlock" xlink:href="upc-20210930.xsd#upc_EmployeeDefinedContributionPlanPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="EmployeeDefinedContributionPlanPolicyTextBlock" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="upc-20210930.xsd#upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables">
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersAbstract" xlink:href="upc-20210930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAdvancesToSuppliersNet" xlink:href="upc-20210930.xsd#upc_ScheduleOfAdvancesToSuppliersNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancesToSuppliersAbstract" xlink:to="ScheduleOfAdvancesToSuppliersNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowingsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectTables">
    <loc xlink:type="locator" xlink:label="PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForConstructionInProgressAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDueFromRelatedPartiesTableTextBlock" xlink:href="upc-20210930.xsd#upc_ScheduleOfDueFromRelatedPartiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfDueFromRelatedPartiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDueToRelatedPartiesTableTextBlock" xlink:href="upc-20210930.xsd#upc_ScheduleOfDueToRelatedPartiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfDueToRelatedPartiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/TaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTaxPayableTableTextBlock" xlink:href="upc-20210930.xsd#upc_ScheduleOfTaxPayableTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfTaxPayableTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSubsidiariesOfTheCompanyAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfSubsidiariesOfTheCompanyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSubsidiariesOfTheCompanyAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="UniverseIncMember" xlink:href="upc-20210930.xsd#upc_UniverseIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseHKMember" xlink:href="upc-20210930.xsd#upc_UniverseHKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseHKMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseTechnologyMember" xlink:href="upc-20210930.xsd#upc_UniverseTechnologyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseTechnologyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiangxiUniverseMember" xlink:href="upc-20210930.xsd#upc_JiangxiUniverseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="JiangxiUniverseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseTradeMember" xlink:href="upc-20210930.xsd#upc_UniverseTradeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseTradeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseHanheMember" xlink:href="upc-20210930.xsd#upc_UniverseHanheMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseHanheMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlaceOfIncorporation" xlink:href="upc-20210930.xsd#upc_PlaceOfIncorporation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="PlaceOfIncorporation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrincipalActivities" xlink:href="upc-20210930.xsd#upc_PrincipalActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="PrincipalActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AutomobilesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_AutomobilesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeAndElectricEquipmentMember" xlink:href="upc-20210930.xsd#upc_OfficeAndElectricEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="OfficeAndElectricEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_UseRightsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCurrencyExchangeRateAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfCurrencyExchangeRateAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfYearEndSpotRate" xlink:href="upc-20210930.xsd#upc_DescriptionOfYearEndSpotRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCurrencyExchangeRateAbstract" xlink:to="DescriptionOfYearEndSpotRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAverageRate" xlink:href="upc-20210930.xsd#upc_DescriptionOfAverageRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCurrencyExchangeRateAbstract" xlink:to="DescriptionOfAverageRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsReceivableAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfAccountsReceivableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableAbstract" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract" xlink:to="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LessThan3MonthsMember" xlink:href="upc-20210930.xsd#upc_LessThan3MonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="LessThan3MonthsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="From4To6MonthsMember" xlink:href="upc-20210930.xsd#upc_From4To6MonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="From4To6MonthsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="From7To9MonthsMember" xlink:href="upc-20210930.xsd#upc_From7To9MonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="From7To9MonthsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="From10To12MonthsMember" xlink:href="upc-20210930.xsd#upc_From10To12MonthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="From10To12MonthsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Over1YearMember" xlink:href="upc-20210930.xsd#upc_Over1YearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis" xlink:to="Over1YearMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable" xlink:to="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableBeforeGrossValue" xlink:href="upc-20210930.xsd#upc_AccountsReceivableBeforeGrossValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="AccountsReceivableBeforeGrossValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubsequentCollection" xlink:href="upc-20210930.xsd#upc_SubsequentCollection"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="SubsequentCollection" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfSubsequentCollection" xlink:href="upc-20210930.xsd#upc_PercentageOfSubsequentCollection"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="PercentageOfSubsequentCollection" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AccountsReceivableGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SunsequentCollectionsTotalGrossAccountsReceivable" xlink:href="upc-20210930.xsd#upc_SunsequentCollectionsTotalGrossAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="SunsequentCollectionsTotalGrossAccountsReceivable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalGrossAccountsReceivablePercentage" xlink:href="upc-20210930.xsd#upc_TotalGrossAccountsReceivablePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="TotalGrossAccountsReceivablePercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="SunsequentCollectionAllowanceForDoubtfulAccounts" xlink:href="upc-20210930.xsd#upc_SunsequentCollectionAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="SunsequentCollectionAllowanceForDoubtfulAccounts" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowanceForDoubtfulAccountsReceivablePercentage" xlink:href="upc-20210930.xsd#upc_AllowanceForDoubtfulAccountsReceivablePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="AllowanceForDoubtfulAccountsReceivablePercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SunsequentCollectionAccountsReceivableNet" xlink:href="upc-20210930.xsd#upc_SunsequentCollectionAccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="SunsequentCollectionAccountsReceivableNet" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableNetPercentage" xlink:href="upc-20210930.xsd#upc_AccountsReceivableNetPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems" xlink:to="AccountsReceivableNetPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAllowanceForDoubtfulAccountsAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdvancesToSuppliersNetAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfAdvancesToSuppliersNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToSuppliersAndEmployees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToSuppliersAndEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdvancesToSuppliersNetAbstract" xlink:to="us-gaap_PaymentsToSuppliersAndEmployees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvstmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShortTermInvstmentAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfShortTermInvstmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermInvstmentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="AddPurchaseWealthManagementFinancialProducts" xlink:href="upc-20210930.xsd#upc_AddPurchaseWealthManagementFinancialProducts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermInvstmentAbstract" xlink:to="AddPurchaseWealthManagementFinancialProducts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermInvstmentAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermInvstmentAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermInvstmentAbstract" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermInvstmentAbstract" xlink:to="us-gaap_ShortTermInvestments_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AutomobilesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AutomobilesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_AutomobilesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeAndElectricEquipmentMember" xlink:href="upc-20210930.xsd#upc_OfficeAndElectricEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="OfficeAndElectricEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsNetConsistAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfIntangibleAssetsNetConsistAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsNetConsistAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_UseRightsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYZDqnPZexC+e00+Rf6r37QtPu3oRrVmmTX8PuYVCFDMbRocUzw9EKKPK5NWC0WpJsOIuWkqeF3WWYzAuBG72bAUNWZ0EJoh7sSbeKneEPlmLktMHZBhwtLx19hpHJOdjKf2eyiP0jq4gpLMoHnWAqkCyHBHyDK9GdQmqqId3PEwCOX17Vhl0ye9OCleikRMpiLr3TIPdJKhd+/zxbKkQAAdAre21qybX3cpD7mGDKHAQ==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" xlink:href="upc-20210930.xsd#upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumCapitalExpendituresAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:href="upc-20210930.xsd#upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:href="upc-20210930.xsd#upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCapitalExpendituresAbstract" xlink:to="PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CapitalExpenditureMember" xlink:href="upc-20210930.xsd#upc_CapitalExpenditureMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="CapitalExpenditureMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable" xlink:to="PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShortTermBankLoansAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfShortTermBankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermBankLoansAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Maturity30To90DaysMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Maturity30To90DaysMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="us-gaap_Maturity30To90DaysMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MaturityOver90DaysMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaturityOver90DaysMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="us-gaap_MaturityOver90DaysMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturityGreaterThan90DaysOneMember" xlink:href="upc-20210930.xsd#upc_MaturityGreaterThan90DaysOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="MaturityGreaterThan90DaysOneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturityGreaterThan90DaysTwoMember" xlink:href="upc-20210930.xsd#upc_MaturityGreaterThan90DaysTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="MaturityGreaterThan90DaysTwoMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaturityGreaterThan90DaysThreeMember" xlink:href="upc-20210930.xsd#upc_MaturityGreaterThan90DaysThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis" xlink:to="MaturityGreaterThan90DaysThreeMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:href="upc-20210930.xsd#upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MrGangLaiMember" xlink:href="upc-20210930.xsd#upc_MrGangLaiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrGangLaiMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrsLinYangMember" xlink:href="upc-20210930.xsd#upc_MrsLinYangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrsLinYangMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GreatestGroupMember" xlink:href="upc-20210930.xsd#upc_GreatestGroupMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GreatestGroupMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FoshanShangyuMember" xlink:href="upc-20210930.xsd#upc_FoshanShangyuMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="FoshanShangyuMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDueFromRelatedPartiesAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfDueFromRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:href="upc-20210930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:href="upc-20210930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDueFromRelatedPartiesAbstract" xlink:to="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GreatestGroupMember" xlink:href="upc-20210930.xsd#upc_GreatestGroupMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GreatestGroupMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FoshanShangyuMember" xlink:href="upc-20210930.xsd#upc_FoshanShangyuMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="FoshanShangyuMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable" xlink:to="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDueToRelatedPartiesAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfDueToRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:href="upc-20210930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:href="upc-20210930.xsd#upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDueToRelatedPartiesAbstract" xlink:to="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrGangLaiMember" xlink:href="upc-20210930.xsd#upc_MrGangLaiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrGangLaiMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrsLinYangMember" xlink:href="upc-20210930.xsd#upc_MrsLinYangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrsLinYangMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable" xlink:to="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:href="upc-20210930.xsd#upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable"/>
    <loc xlink:type="locator" xlink:label="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:href="upc-20210930.xsd#upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract" xlink:to="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_KY" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_KY"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KY" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable" xlink:to="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="upc-20210930.xsd#upc_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTaxesPayableAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfTaxesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTaxesPayableAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenueByProductSourceAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfRevenueByProductSourceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfOtherPropertyOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfOtherPropertyOperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueByProductSourceAbstract" xlink:to="us-gaap_CostOfOtherPropertyOperatingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueByProductSourceAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueByProductSourceAbstract" xlink:to="us-gaap_Revenues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTotalRevenuesByProductCategoriesAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTotalRevenuesByProductCategoriesAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_CorporateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateSegmentOneMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateSegmentOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateSegmentTwoMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateSegmentTwoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateSegmentThreeMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateSegmentThreeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateSegmentFourMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateSegmentFourMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateSegmentFiveMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateSegmentFiveMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateSegmentSixMember" xlink:href="upc-20210930.xsd#upc_CorporateSegmentSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateSegmentSixMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="SalesOfTcmdProductsAbstract" xlink:href="upc-20210930.xsd#upc_SalesOfTcmdProductsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="SalesOfTcmdProductsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubtotalOfTCMDProductsSales" xlink:href="upc-20210930.xsd#upc_SubtotalOfTCMDProductsSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesOfTcmdProductsAbstract" xlink:to="SubtotalOfTCMDProductsSales" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalesOfThirdPartyProductsAbstract" xlink:href="upc-20210930.xsd#upc_SalesOfThirdPartyProductsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="SalesOfThirdPartyProductsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubtotalOfThirdpartyProductsSales" xlink:href="upc-20210930.xsd#upc_SubtotalOfThirdpartyProductsSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SalesOfThirdPartyProductsAbstract" xlink:to="SubtotalOfThirdpartyProductsSales" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfParentCompanyBalanceSheetsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfParentCompanyBalanceSheetsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfParentCompanyBalanceSheetsAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="AssetsAbstract0" xlink:href="upc-20210930.xsd#upc_AssetsAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="AssetsAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract0" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract0" xlink:to="us-gaap_ShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract0" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonCurrentAssetsAbstract" xlink:href="upc-20210930.xsd#upc_NonCurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract0" xlink:to="NonCurrentAssetsAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract0" xlink:to="us-gaap_Liabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityAbstract0" xlink:href="upc-20210930.xsd#upc_ShareholdersEquityAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract0" xlink:to="ShareholdersEquityAbstract0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityAbstract0" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityAbstract0" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityAbstract0" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityAbstract0" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfParentCompanyBalanceSheetsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfParentCompanyBalanceSheetsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfParentCompanyBalanceSheetsAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedStatementOfIncomeCaptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeExpensesAbstract0" xlink:href="upc-20210930.xsd#upc_OtherIncomeExpensesAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="OtherIncomeExpensesAbstract0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseOtherShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract0" xlink:to="us-gaap_InterestExpenseOtherShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpensesAbstract0" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ProfitLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfParentCompanyStatementsOfCashFlowsAbstract" xlink:href="upc-20210930.xsd#upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedCashFlowStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfParentCompanyStatementsOfCashFlowsAbstract" xlink:to="srt_CondensedCashFlowStatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromOperatingActivitiesAbstract" xlink:href="upc-20210930.xsd#upc_CashFlowsFromOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="CashFlowsFromOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityInEarningsOfSubsidiary" xlink:href="upc-20210930.xsd#upc_EquityInEarningsOfSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="EquityInEarningsOfSubsidiary" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityInEarningsOfSubsidiary" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromInvestingActivitiesAbstract" xlink:href="upc-20210930.xsd#upc_CashFlowsFromInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="CashFlowsFromInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromFinancingActivitiesAbstract" xlink:href="upc-20210930.xsd#upc_CashFlowsFromFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="CashFlowsFromFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashLentToSubsidiaries" xlink:href="upc-20210930.xsd#upc_CashLentToSubsidiaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="CashLentToSubsidiaries" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashAndCashEquivalentAtCarryingValue" xlink:href="upc-20210930.xsd#upc_CashAndCashEquivalentAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="CashAndCashEquivalentAtCarryingValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="CashAndCashEquivalentAtCarryingValue_0" xlink:href="upc-20210930.xsd#upc_CashAndCashEquivalentAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="CashAndCashEquivalentAtCarryingValue_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandBusinessDescriptionDetailsTable" xlink:href="upc-20210930.xsd#upc_OrganizationandBusinessDescriptionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandBusinessDescriptionDetailsLineItems" xlink:href="upc-20210930.xsd#upc_OrganizationandBusinessDescriptionDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrganizationandBusinessDescriptionDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniverseIncMember" xlink:href="upc-20210930.xsd#upc_UniverseIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseHKMember" xlink:href="upc-20210930.xsd#upc_UniverseHKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseHKMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiangxiMember" xlink:href="upc-20210930.xsd#upc_JiangxiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="JiangxiMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseTechnologyMember" xlink:href="upc-20210930.xsd#upc_UniverseTechnologyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseTechnologyMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiangxiUniverseMember" xlink:href="upc-20210930.xsd#upc_JiangxiUniverseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="JiangxiUniverseMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UniverseTradeMember" xlink:href="upc-20210930.xsd#upc_UniverseTradeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="UniverseTradeMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsTable" xlink:to="OrganizationandBusinessDescriptionDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="EntityIncorporationDateDescription" xlink:href="upc-20210930.xsd#upc_EntityIncorporationDateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="EntityIncorporationDateDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountOfRegisteredCapital" xlink:href="upc-20210930.xsd#upc_AmountOfRegisteredCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="AmountOfRegisteredCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalContribution" xlink:href="upc-20210930.xsd#upc_CapitalContribution"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="CapitalContribution" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemainingCapitalContribution" xlink:href="upc-20210930.xsd#upc_RemainingCapitalContribution"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="RemainingCapitalContribution" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_SharePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicOfferingPrice" xlink:href="upc-20210930.xsd#upc_PublicOfferingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="PublicOfferingPrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandBusinessDescriptionDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="upc-20210930.xsd#upc_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JxRcbBankMember" xlink:href="upc-20210930.xsd#upc_JxRcbBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="JxRcbBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="AllowanceForUncollectableBalancesAmount" xlink:href="upc-20210930.xsd#upc_AllowanceForUncollectableBalancesAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="AllowanceForUncollectableBalancesAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredInitialPublicOfferingCosts" xlink:href="upc-20210930.xsd#upc_DeferredInitialPublicOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="DeferredInitialPublicOfferingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NetInvestmentIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AdvertisingExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfVatRate" xlink:href="upc-20210930.xsd#upc_PercentageOfVatRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="PercentageOfVatRate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountsReceivableDescription" xlink:href="upc-20210930.xsd#upc_AccountsReceivableDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="AccountsReceivableDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/InventoryNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersDetails">
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersAbstract" xlink:href="upc-20210930.xsd#upc_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="RawMaterialsPurchased" xlink:href="upc-20210930.xsd#upc_RawMaterialsPurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancesToSuppliersAbstract" xlink:to="RawMaterialsPurchased" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails">
    <loc xlink:type="locator" xlink:label="PrepaymentForAdvertistingAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForAdvertistingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAdvertistingAbstract" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAdvancePayment" xlink:href="upc-20210930.xsd#upc_PercentageOfAdvancePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAdvertistingAbstract" xlink:to="PercentageOfAdvancePayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalContractPricePercentage" xlink:href="upc-20210930.xsd#upc_AdditionalContractPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAdvertistingAbstract" xlink:to="AdditionalContractPricePercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAdvertistingAbstract" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForAdvertistingAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentDetails">
    <loc xlink:type="locator" xlink:label="HeldToMaturityInvestmentDisclosureAbstract" xlink:href="upc-20210930.xsd#upc_HeldToMaturityInvestmentDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="HeldToMaturityInvestmentDisclosureAbstract" xlink:to="us-gaap_OtherShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails">
    <loc xlink:type="locator" xlink:label="PrepaymentForConstructionInProgressAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForConstructionInProgressAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforConstructioninProgressCIPProjectDetailsTable" xlink:href="upc-20210930.xsd#upc_PrepaymentforConstructioninProgressCIPProjectDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforConstructioninProgressCIPProjectDetailsLineItems" xlink:href="upc-20210930.xsd#upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForConstructionInProgressAbstract" xlink:to="PrepaymentforConstructioninProgressCIPProjectDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforConstructioninProgressCIPProjectDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforConstructioninProgressCIPProjectDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ChenyuanMember" xlink:href="upc-20210930.xsd#upc_ChenyuanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChenyuanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforConstructioninProgressCIPProjectDetailsTable" xlink:to="PrepaymentforConstructioninProgressCIPProjectDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentBuildingAndBuildingImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentBuildingAndBuildingImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforConstructioninProgressCIPProjectDetailsLineItems" xlink:to="us-gaap_InvestmentBuildingAndBuildingImprovements" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Prepayment" xlink:href="upc-20210930.xsd#upc_Prepayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforConstructioninProgressCIPProjectDetailsLineItems" xlink:to="Prepayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalExpenditure" xlink:href="upc-20210930.xsd#upc_CapitalExpenditure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforConstructioninProgressCIPProjectDetailsLineItems" xlink:to="CapitalExpenditure" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails">
    <loc xlink:type="locator" xlink:label="PrepaymentForPurchaseOfAPropertyAbstract" xlink:href="upc-20210930.xsd#upc_PrepaymentForPurchaseOfAPropertyAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforPurchaseofaPropertyDetailsTable" xlink:href="upc-20210930.xsd#upc_PrepaymentforPurchaseofaPropertyDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:href="upc-20210930.xsd#upc_PrepaymentforPurchaseofaPropertyDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentForPurchaseOfAPropertyAbstract" xlink:to="PrepaymentforPurchaseofaPropertyDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsTable" xlink:to="PrepaymentforPurchaseofaPropertyDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_SupplementalDeferredPurchasePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPrepayment" xlink:href="upc-20210930.xsd#upc_PercentageOfPrepayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="PercentageOfPrepayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PayableDeliveryPropertyPercentage" xlink:href="upc-20210930.xsd#upc_PayableDeliveryPropertyPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="PayableDeliveryPropertyPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeSpaceSquareMeters" xlink:href="upc-20210930.xsd#upc_OfficeSpaceSquareMeters"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaymentforPurchaseofaPropertyDetailsLineItems" xlink:to="OfficeSpaceSquareMeters" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ShortBankLoansDetailsTable" xlink:href="upc-20210930.xsd#upc_ShortBankLoansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShortBankLoansDetailsLineItems" xlink:href="upc-20210930.xsd#upc_ShortBankLoansDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ShortBankLoansDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortBankLoansDetailsTable" xlink:to="dei_LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JiangxiLulingRuralCommercialBankMember" xlink:href="upc-20210930.xsd#upc_JiangxiLulingRuralCommercialBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="JiangxiLulingRuralCommercialBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortBankLoansDetailsTable" xlink:to="ShortBankLoansDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableToBankCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortBankLoansDetailsLineItems" xlink:to="us-gaap_LoansPayableToBankCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortBankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortBankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortBankLoansDetailsLineItems" xlink:to="us-gaap_InterestAndDebtExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeconsolidationRelatedPartyDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRelatedPartyDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_DeconsolidationRelatedPartyDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesDetailsTable" xlink:href="upc-20210930.xsd#upc_TaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TaxesDetailsLineItems" xlink:href="upc-20210930.xsd#upc_TaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="TaxesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsTable" xlink:to="TaxesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferentialTaxTreatmentDescription" xlink:href="upc-20210930.xsd#upc_PreferentialTaxTreatmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsLineItems" xlink:to="PreferentialTaxTreatmentDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsLineItems" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConcentrationsDetailsTable" xlink:href="upc-20210930.xsd#upc_ConcentrationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConcentrationsDetailsLineItems" xlink:href="upc-20210930.xsd#upc_ConcentrationsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="ConcentrationsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_AccountsReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="srt_MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CustomerMember" xlink:href="upc-20210930.xsd#upc_CustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomersOneMember" xlink:href="upc-20210930.xsd#upc_CustomersOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomersOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GubenYanlingPillMember" xlink:href="upc-20210930.xsd#upc_GubenYanlingPillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GubenYanlingPillMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TotalRevenueMember" xlink:href="upc-20210930.xsd#upc_TotalRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="TotalRevenueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SupplierOneMember" xlink:href="upc-20210930.xsd#upc_SupplierOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SupplierOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SupplierTwoMember" xlink:href="upc-20210930.xsd#upc_SupplierTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="SupplierTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="supplierMember" xlink:href="upc-20210930.xsd#upc_supplierMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="supplierMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="ConcentrationsDetailsLineItems" order="6.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignFinancialInstitutionsMandatedDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsLineItems" xlink:to="us-gaap_ForeignFinancialInstitutionsMandatedDeposits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConcentrationRiskThresholdPercentage" xlink:href="upc-20210930.xsd#upc_ConcentrationRiskThresholdPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsLineItems" xlink:to="ConcentrationRiskThresholdPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="upc-20210930.xsd#upc_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsLineItems" xlink:href="upc-20210930.xsd#upc_ShareholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderwriterWarrantsMember" xlink:href="upc-20210930.xsd#upc_UnderwriterWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="UnderwriterWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashDividendsMember" xlink:href="upc-20210930.xsd#upc_CashDividendsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="CashDividendsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserveAndRestrictedNetAssetsMember" xlink:href="upc-20210930.xsd#upc_StatutoryReserveAndRestrictedNetAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="StatutoryReserveAndRestrictedNetAssetsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PRCMember" xlink:href="upc-20210930.xsd#upc_PRCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PRCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniverseINCMember" xlink:href="upc-20210930.xsd#upc_UniverseINCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="UniverseINCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="ShareholdersEquityDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginalSharesParValue" xlink:href="upc-20210930.xsd#upc_OriginalSharesParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OriginalSharesParValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesParValue" xlink:href="upc-20210930.xsd#upc_OrdinarySharesParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OrdinarySharesParValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesOutstandingDescription" xlink:href="upc-20210930.xsd#upc_OrdinarySharesOutstandingDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OrdinarySharesOutstandingDescription" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReorganizationShares" xlink:href="upc-20210930.xsd#upc_ReorganizationShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ReorganizationShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicOfferingPrice" xlink:href="upc-20210930.xsd#upc_PublicOfferingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="PublicOfferingPrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionToPurchaseAdditionalShares" xlink:href="upc-20210930.xsd#upc_OptionToPurchaseAdditionalShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OptionToPurchaseAdditionalShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsShareBasedCompensationCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsShareBasedCompensationCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_DividendsShareBasedCompensationCash" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashDividendDescription" xlink:href="upc-20210930.xsd#upc_CashDividendDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="CashDividendDescription" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutorySurplusPercentage" xlink:href="upc-20210930.xsd#upc_StatutorySurplusPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="StatutorySurplusPercentage" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReserveIsEqualPercentage" xlink:href="upc-20210930.xsd#upc_ReserveIsEqualPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ReserveIsEqualPercentage" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_RestrictedCash" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedNetAssets" xlink:href="upc-20210930.xsd#upc_RestrictedNetAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="RestrictedNetAssets" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_Cash" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseCapitalSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_InterestExpenseCapitalSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="upc-20210930.xsd#upc_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="upc-20210930.xsd#upc_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SubsequentEventDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssets" xlink:href="upc-20210930.xsd#upc_IntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="IntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="MinorityInterestsOwnershipPercentageByParent" xlink:href="upc-20210930.xsd#upc_MinorityInterestsOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="MinorityInterestsOwnershipPercentageByParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="upc-20210930.xsd#upc_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_ContactPersonnelEmailAddress"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (0 CL# 2(  A$! Q$!_\0
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M>*_]&:_MZ_\ B.DG_P UM'_#>*_]&:_MZ_\ B.DG_P UM?>M% 'P5_PWBO\
MT9K^WK_XCI)_\UM'_#>*_P#1FO[>O_B.DG_S6U]ZT4 ?!7_#>*_]&:_MZ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME=5TWPGJ6K0>(H-/:RL)YQ?6NGI;&ULII1*8K9V0 _+3_@J3\0]$\(_M7_\
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MA-\0_ACX<\/WO@NTTG]L+XEZ]K7C/PM\?=2UQ%T2]C\;^(_!>L^#/#'AR_\
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M6.OO6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,/9X5_^=A7WE10!\&_\,,:C_P!'M_MY?^'L\*__ #L*/^&&-1_Z/;_;R_\
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M 4444 %%%% !1110 4444 %%%% 'Q'^S,/-_:*_;VNUX0_&OX:V&T_?\VQ^
M?PYDD?C(\MQ>1A.=V5?<H&TGTKQC^TWX3\%?M.?!C]EG4_"/Q F\6?''P/\
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M-.^'OQ$U3X5Z1HOB+4_$[W&G>-M;\/:3X?TKQ=HOAC4_&>G>)- \3>&K6_\
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MTV+P=K?PROK)OAJ;JU^)%GXI^-NJ_'A-9N/BEXK\0^,[_P ':Q9#P_;)=O\
MI?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !17QE\1?VX/AS\/_BEXP^#UC\,/VDOBEXP^']E
MX6O?&K?!KX">/?B1H'AMO&>ER:UX=T_4?$.AV#:4NJ7VDQ_V@UA!<33VUM+"
MUR(FE13S7_#?7AW_ *-8_;R_\1%^*/\ \@T ?>5%?!O_  WUX=_Z-8_;R_\
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MB30M$T:/0?$LESX@U;5TNM(CN]+TZZGE^1/&7_!,7X^^%O!/]@_LT^$?V;?
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M0!]K4444 ?%/[)?_ "5/_@H1_P!GK6W_ *QM^Q]7VM7Q3^R7_P E3_X*$?\
M9ZUM_P"L;?L?5]K4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXO\ #OC_ , ? -;&UTZR\0>-;+X=6GC.'QWXP\.Z5+HS^";6[N;B  _5U_\
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M-ZIX0O\ P#X%O_@KX=CN=/\ &EUH&C:*MOKWBRSGT"[U^>_UG59],T2[U.\
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M&TK6H+>;[1!#JVG6FHQ03A&C$\,=Y#,D4WENZ>8BJ^QV7=M8@Z@
M&  .  !P !T%+10 4444 ?%/[)?_ "5/_@H1_P!GK6W_ *QM^Q]7VM7Q3^R7
M_P E3_X*$?\ 9ZUM_P"L;?L?5]K4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%KOB3XD:A%X0\1>(='NM,\(R^+5OKG2?$GA75-4_:^@ HHHH **** "BBB@
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M:BC_ (4!^W/_ -)![3_Q$CX5_P#S45]ZT4 ?!7_"@/VY_P#I(/:?^(D?"O\
M^:BC_A0'[<__ $D'M/\ Q$CX5_\ S45]ZT4 ?!7_  H#]N?_ *2#VG_B)'PK
M_P#FHH_X4!^W/_TD'M/_ !$CX5__ #45]ZT4 ?!7_"@/VY_^D@]I_P"(D?"O
M_P":BC_A0'[<_P#TD'M/_$2/A7_\U%?>M% 'S1^S/\!/$_P+T_XLW7CGXLWO
MQF\=?&;XM3?%OQ?XON?!7ASX?6J:F/AI\,_A78:1I/ACPP\]A9V%GX=^%NAS
MR3S75U?7VJ7FI7=Q/MEBBB^EZ** "BBB@ HHHH _(7_@ICX,\=Z)\>?^";'[
M7EAX3\3^/O@K^QY^T'\5/%?[0OAKP9HNH^+?$GASP3\5O@'XV^%.D?&:T\%Z
M3;WNJ^)M/^#VNZ[%KOB6+0M.U3Q)I/A>_P!:UK1M.NGL;A5^??B[J7@3]KW]
MN+P%^U+X#NO&5M^R?^R[^QA^UG\-?V@/CQ:6/Q3^&=GXKU/XX+\-KOP]\*_A
M[K&C6'ASXD>(=2\(6OA2[\?^*->\#)L\(WC>'=.TW5)/$NJ7-C9?OY10!_&9
M\&_"W[-5E^RM_P $(].\1:Y^T!I6L^$OCA))\6]+/CO]M/2;WP ]O\!OB-HW
MB9M4TZRUBV?X<6FF>.M4^''AFWDM8?#FGZ;+XEN-$T-X=#\2>*HKWT[XZ?%7
MXW7/PE_X*I> /B)J?QD^(.A>-OV2/VJ%\(ZW:Q_'>XF\/>*?%7B2S\/?"CP5
M\5?V<?&?AKQ-H?@CXI>)(];MO"7P'U_]F[Q9K'PP^(_@'0)O%WBGP/X5UO7)
MKU_ZY:* /Y4-:^._Q4^'&N_M%^ /@7\3/VI/BG\&;3P3_P $U/B7\5+T/\;O
M&/Q0T;X,^(?''B72OV[/&OP$U#5/#\%UHGBZP^%LWP[U/Q3X(^$<.C77@S0]
M4U#Q'X"\*>'O$UF)+3.^)OCCXI:3JNAZ1\/OVH?VO-#_ &(?&G_!23]G+1OV
M??&NF^(OC;K'Q$U[X*^)/AEJ=K^V%X9U7XB>*O#WB'XO:Q\#_ ?Q0FL[;P'X
MH\9ZU';>&_$NH^(=.LM8UG0_"OAV.T_K HH _EU74?C1X+_X*2:!^SW\1?VC
M?^"CO@W6/A;\7?@UI_[*GAKPK\(O&GQE^$?[1'[,]E\/_#\.K7'Q3^/#7US\
M,M3?4M6A^*J?'OQ#\<M.L/B'H-SI5OK?@OQ8VH66A0Z?_45110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7F?Q7NOC!:>%UE^".D?#S6O&?]
MI6:M9_$W6O$.@^&QI!$OV^9;[PSH^MZD=0C(@^RPFR%O(#+YLT95=WIE% 'C
M#WO[00^(?A*WCT#X2'X52^'[>3QSJC^(_%H\=V7B@VLYNK7POI \/G0K_0UO
M1;I!=ZIJMC?/:M-(]JLJHC<Q9ZC^UFWA/XBRW_A7X!1^-[?5(%^%%E:^,/'L
MGAC5-&-TXN9O'M_+X2CU/2-26S$;PP:#9:M;-<ET>=8P'/T=10!X%<W_ .T\
M+KX5"T\-?!%[.ZB@/QK>?Q7XV2XT:<S1"Y7X:(GAAH]=B6W,S0MXE?16:81J
MZJC,PF@G_:9.L_%-;G3O@</#\5C>'X*20ZGX[.KWFI!V^P+\3XGTT6=C9-'L
M-VWA:2]G5]PA5EP:]WHH ^:[JY_:^'@GP.]EI7[.;?$9]:N!\2+>YUCXDKX+
MM_#PG/V5_!5S%I#:W<ZR;;!GCURVM[(3\1R&/FNT27X^?\+0UJ)[+X1CX,C0
MG;P[=K?^,#\2Y/$WV2'RX]9LC8_\(Q'H?V_[0'ELKR2_^R"%A%YQ=1[!10!\
MRQ7/[8__  K34Y)])_9L'Q@'B>)='M(M9^)A^'#^#=J>=-J5X^D#Q*GB4-YG
ME06UF^F%0FZ8$MCKIC^T:WCKP(ULOP4C^&9T"T/Q-CN&\=2>.T\4&WF-\O@6
M6(1^'GT%;O[.+5]?C74&MQ,TJK(44>V44 ?.EG_PUK_PC_Q0_M _LZ?\)5]N
MC_X4O]C7XE_\(^--^VS>;_PM#SV_M(WW]G>1Y?\ PBF(/MOG;OW&RI[H?M6>
M5\*?L1_9[\_<G_"\/M2_$<Q%/M<'F?\ "J?*8.&^P_:=G_"79'VOR-W[GS*^
MA** /#+?_AI;_A)?B?\ :S\#/^$/_LF]_P"%,?9U\??\)*-=VQ_V=_PL_P Q
MO[+.D[_-^V_\(IB\*^7Y&#NKF+D?MD_\*_\ "GV-OV9?^%J?V_/_ ,)R;E?B
MG_PK\^%][_9?^$4$3_\ "1C7_+\OSSJY.G;]_EC;MKZ:HH \:,?[0G_"U;V1
M;SX-#X('PZ1IUH=.\;GXJKXL^P*!)>Z@-5'A%_#O]J;B88-,34C8;5\\7&6K
M@H8/VU/^%9:REQJ?[+I^,A\3PMX?N8="^+ ^&2>#,1^?%K-C)XB/BJ7Q.3YO
MDSV6H1:4 8]]N<-GZBHH \.N(OVD_P#A./AZUK>_ X?#9/#]F/BO!<:7X]/C
MBX\4BWF_M"3X>W4>KKH-GX?:[\@V</B2SOM16W$PGG>0HPPK.']KK^P_BJ-0
MU']G ^)9+M3\$)+/1OB:NAVMC]MF+CXJPSZ\U_?W9T[[.JMX1FTV$7HF8J8"
MB#Z.HH ^=;N']K0VGPG^PZA^SJ+Z.4?\+T-WH_Q+:TNH?M<&X?"=8=<6;3Y?
ML'VD ^,&U)!=F!B#")%.G;VW[3@\5?$][O6O@0W@B;1;]?@Q;6_ACX@)XJT[
MQ$4A_LR;XGWTOBY](UK14?[0;^V\*:?H%]*AA%O=0E7+>[T4 ?+UY9_MIGX:
M^'8;#Q'^RZGQA3Q'=/XLU"\\%?%>3X:S^$2+G[';^'=&A\?1>*+3Q&K&S-U>
M:EKM[ICA;D16,9>(Q]W]G_:%_P"%KPSC5O@S_P *.'A[9/IG_"/>-_\ A:Y\
M5_V<X\^'7/\ A)_^$07P]_:WER?9'\/-J7]G!X?MOVDK./9J* /ERULOVU1\
M.?$T5[XD_9<;XN/XDLW\&W]KX*^+"?#FW\( P?VA;^)M(E\?R>)KSQ(X%U]C
MO-*UNPTR,F#S[&4+)NZRYMOVFSXK^&#V>M? A? \.AZ<OQHMKGPQ\0'\5ZCX
ME$<O]KS?#"^B\7)I&BZ')-Y!TZV\5Z=KU_#&)5N;N9F1E]WHH ^>+6R_:P%E
M\6!>^)?V>'U*XE?_ (49):^"/B3'9:/#]LNC&/BQ#-\099_$DHL#9([>#Y_"
MJF\2ZD51#)#%&R\LOVM3HWPL73_$O[.J>(+>\E/QLGO/ _Q+ET;5M/\ MT)A
M3X66L'Q"AO?#MX--%Q'++XMO/%$#7S0S)"L"O _T510!XG;6O[1P\;?$*6[U
M[X)-\.9M!O4^%%A;>$_'<?C;3?$YMK4:?<?$+5I?&DFA:WH*78O6O;/PWHOA
M_4);9[6."_AECEDEXV:P_;./PTT6"W\5_LPK\8D\2RR>(M4F^'_Q6?X:3^#_
M "Y/)M=%T%/B8GBBT\2B7R3+?WWB2]TMHQ(J::K,K+]/44 ?FA^S!8?&N+]K
MO]N22V\2_#,?!W_A>?AF[U;P[-X5\2/\13XLO/V:?@];FZT_Q0GB6'P_#X?.
MHVEO.-/NO#UYJ M$FA%_%+*LH^EK71_VP%^'WBFUO/'O[/,GQ1G\06TO@O6K
M;X:_$*+P-IWA82Q&[LO$F@2?$J77-4UV2 3+!J&FZ_I=C'*T;R:?(JLC>;_L
MQI)!^T?^WY!YSR0/\:_AC?QQ,J 02W?P!^'44ZHR@,RO]DC?YRQ#%@N%P*]I
M_:;_ &@_"G[*OP(^)/[0?CGPW\0/%OA'X6^'IO$WB#0OA?X4N/&GC6YTRWFA
MBNI]+T&"XLTD@L8Y3?:KJ%_?:?I6CZ5;WNK:M?V6GV=S<1@$USIO[2#>)OAC
M-:>+O@W'X/L]&LH_C%87'@?QC+XBU_Q J_\ $QNOAUJ<?C>+3_#.DRMS9V?B
M+3/$UW"!B:\F/-9MMI7[4PM_BP+OQI\"Y+J^:7_A2#V_P_\ ',<'AQ#=7+0C
MXFQR?$"23Q4RV1LXY#X9D\*A[F.XE4+%+'%%Y?\ &']NKX4?!K6/#6CZIX;^
M(7BIK[X;:7\:_'][X/TK0;ZS^"WP4U?6K7PY:_%+XDC5/$ND7;: =:GN;4:5
MX'M?&?BZ:VT3Q%JMKX<N-*T2\O%YSQ#_ ,%%_@-X5\1_$&SU_3O'NG^ ? ,G
MQ3T5?C*=&T6Y^&_C3X@?!+X?7GQ2^*7PS\#O:^(IO%^L>+/"W@G3-:U!;FZ\
M):;X4UW4/#7BO0?#OB35=:\-ZI8P 'MU[I/[5K:#\,(M/\;_  &B\365],WQ
MDO+SX>>.YM%\0::;Z-H(OAS80_$.&]\,7JZ<)8I9_$5_XFA>\,<Z0)"K0-T$
M6C_'\?$'QM?S^.?AD_PQO/#UU;_#[PY'X$U]/%^A>)VM+!+/4O%'B5O&+Z9K
M^CQ7T>I33Z9I^@Z-<RV]Q:0I?QO;22S^/?!+]MGX=_'3P?X=\0:!X,^(WA[Q
M5KWQ-O\ X57'PJ\36?A+_A/O#^NZ/IFB>)M=U76/^$=\7^(?",GA?0O _B7P
M_P"--5UW1O%>K6UKINM:;HQ5O%]W%X;;[*H ^87\-?M?GX76>F1_%;X%K\8D
M\4-<W_BQOA+XN;P)/X/-M(J:5;>$1\2AK$&NB[,4K:M)XFELS"KQ#30["0=X
M-(^.W_"T=$U,^-?AQ_PIV'P]';^(/"?_  A&N?\ "=W_ (G%C>)+J6E^+O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX=)\9>+O#MEX;U>S^%\%_?6WAS7Y-3T^,ZGIM:/@/]@WQ_X>^)W@+P+KG_"
M:A^RU\'_ -I3XT_M7>$M2DU?5=5^(?C7Q-\:/ GQ&\'R_"CQ?X,O_#:>'[+P
MSX9U'XQ?$?6M1\31^*]8'BW21X3\/OX6TKR=:NY_UFHH _&_XY_L#_&P?!NU
MT+]D6_\  /[._B>+QMK<=C\._A;XO\2? _P7X2^&-SH7CVU\*Z3X6\>?#;PK
M_P )%;:AI?Q<\1>$_P!HSXD:>GAZTT_XNZQX6/PLUZXM_!_V6X;]<O"MAKFE
M^%_#>F>)M:3Q+XDT[0-'L/$'B-+&'2TU_7+/3K>WU;6DTRW9H-.35;^.XOEL
M86:&T$XMXV*1J3O44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y!?\
M%,_"'CC0?CU_P35_:ZMO"WB;QU\#_P!C[]H3XI^+/VB/#_@_1=2\6:]X8\&?
M%/X!^-_A7H?QIB\&:3;WVJ^(]*^#VOZ[%KGB4Z)INI^(-#\,:AK&NZ3I]P=/
MN=OQ#^VWXS?]I?X[:S^V%^S!XS^)GA'X6?LD?\$\_P!M;P%XO_:9\ :)XH\*
MZAKGQ=^-&G_#J[^$/PA^$]SJOA*ZU;QIXGT37O"]OXMU[4="\/ZI8>#[V^\.
MV-EJ$'BG5VCT[^ENB@#^3OPA\>/B?9V_B#X=>!/VG_VE_$.N?%O_ ()>?LE^
M/?$'B+X@VO[0GQ1FL?VF=2^+&G>&_B=J-I;:):^'?$?PWN[OX9ZU%:_%:R^"
MU_X3\7^&/"@E^)&CZ)<>.]!CO;AOASXD-\8OB/\ \$R;/]H/Q;\=OAO'H7CO
M_@H?;>+_ !KX7^*'Q:\8V&O^![[P#I.E^&;[X7_M&+X#\'_%>V^!/B;4[>_\
M*_#?Q!XPA\$?&6>V\*3Z3J.O:AJ]M=:[K']8U% '\DGPI_:8^)/Q7^#/P+T[
M]J/XU?M=>#OAEJ?["/C33OA%\9_A?J/QY\$?$#6OVX_"GQ4\:^&=4T7XD:GX
M)T?2?$?B'XNZ)\,X/A7K/PN\+?$^UU/P-\19=5\9ZG?:+XFUN*4V_K'P0UC]
ML[XJ_&CXTV?Q$_: _:-/[6WPB_X)[?LK?&+0/@%X?\2:WX'^!LG[:-O\+OC%
MIOQ.\(OH-OX4TCX>^(]&NM:U;X8:OX_^'NHZKKFG1^*]=TRXN+L66FZ7;:/_
M %!T4 ?S\_\ !%;XE^(?BAK_ ,3?$.I?M%_MU?%G5'^&G@&+XN_#+]JS]GOQ
M]\)/"/PB^-*:AJ$OB"TT+Q'\2M0U8ZK\1-0FN-:T_P 5:%\'-4F^$,.E:)I5
M]::7H<RZ1'?_ - U%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y+:%^S#^SU^T7^W1^W3J
M'QW^#W@3XMWGA"/]F#2/"L_CW0[?Q(?#FE:A\)+O4[[3M$34?.BTRTO-2DDO
M[N&SCA6YO)'N)_,D(8?1'_#M'_@G_P#]&?\ P"_\-WH7_P C5F_L]_\ )[G_
M  4,_P"OW]E3_P!4M<U]YT ?#W_#M'_@G_\ ]&?_  "_\-WH7_R-1_P[1_X)
M_P#_ $9_\ O_  W>A?\ R-7W#10!\/?\.T?^"?\ _P!&?_ +_P -WH7_ ,C5
M\6?MS?L\?L;_ +(GPN\)?$OP;_P37_9Q^-8\1?%WX5_"34-#O;[PQ\+9=&O?
MC!XZT#X;^%=<CU"\\!>,H=3L+7Q1XETQM>MD@M+NQT5;W4K)=3N;>/3;C]M*
M^.?V\/V=O&'[3O[.NK?#SX<Z_P"'_#OQ&T'Q[\(_B]\/KKQ=;WUQX/U'QG\$
M_B=X4^*>@>&_%ITK.K6?AOQ5>^%$\.ZOJVE17.I:+:ZF^KV=CJ,UDMA<@'P]
M\7/V<OV(O@G\3? FA_$']@C]COPI\&-4^$OQ!^+/Q2^.?BSQ;X8\+Z7\)M*^
M%Q\*Q>,HKOP]J?PW%KK^GVESXW\-K8:U+XL\.QW=L^JW-S96#V%M;:E1USX=
M_P#!&;7/AM\1_&'PN\._\$]WE\ 7W@+1=5\3^+],\-S> ]!UOXFWUA;_  _M
M];GTRZTZ\O8/':79M?!LVC7LD7B#462'39[LV]U$OJ7[0'P/_; _:K^%_P =
M8_'?PD^!/P^\2ZK^RE\>_P!GGX3_  S@^-6N?$+0_$7BS]H&S\+66L^._'_C
M^Z^"WAZ#P_H'@V+P?H$_AO0M(\ Z_JUY?KK=U>ZE;K<:1%8_!?Q<_P""=G[=
M'CGP?\4O"&A_"']FJTL?&G[(O[ OP*\-6]Y^T#X@M].\,^./V1OBA-\0/$NL
MQ6-O^SG/%;:3K5AK.HZ+X4U"P5-1LIM,2YN;&TAU?RM. /LS3OAC_P $3=5@
M\73:=\./V0]07P!\7M$^ 'C<V/@O2K@^%_C5XCNS8:)\--8CBTQY;+Q9J=YL
MAM=+F43-Y]J[%8[NU>:*^^'G_!#?2T^),NK^%_V'=%@^$%SHUK\2;K7+3P/H
MMGX5D\0ZZ_A?0Y+V]U3[):W%KJGB:.3PY9WVGS7EE-KT;Z.MQ_:*-;#Z'\._
MLM_%'2OVP?B7\7[?7?#>@? ;XW?#_P "^//'?@*PU+4KOQ;H7[6W@CP[?_#*
MU\5>'I1I%GH-WX1O_AE?:+<ZKJ5P+36I_'WPX\%:Y;:= $NY!^17BG_@CW\=
MYOV:?&7PBT[X4?!CQO\ %WP]\#+#]FKP3\9OB7^U;^T+XQTOXB?#N/XU?#KX
MB+J.G_#7Q_X;\?\ A#]G2U73/AM;ZQXB\%>#=(\66U_XTU]X/"NO>&= TZ[_
M +8 /OCPE\+O^"(OCS6_"'AWP;X)_8J\2:UX^FU&U\&6&DZ3X0NY/$E_I7B_
M4? 5[I.ER)'Y%QK4?B_1]8T2+1!*-6N[C1]7EM+*>TTN_N+?N/A?^S'_ ,$A
MOC5XD\;>#_A/\%_V3/'WB?X<W,5MXTT/PWX5\,W^H:'Y]Y?Z?;WDL"6X-WI5
MQJ&EZE86VM:>;O2+B]L+RTAOGN+:6-/,OCQ^PE\>OB5^U9\.OC!\-(_ ?P9\
M)3I\*T^),WAGXAZQ/I-QI7AB+6;OQ=9^+/@=JGP\U/P%\0_B-X>FU:ZT_P#9
MZ^-WA/5_A)X]^&=[K&NZEJ]YK^A79\+R;W_!/?\ 8+\8_LS^,_#WB7XD>!?"
MT/C3X7? V;]F[3/C1:?M(?'_ .-6K?%?X>67BG2]9T!]#^&OQ5O&\+_LZ^'O
M.\/1^*]:^'WABZ\76,/B?Q)<Z?H&L6.C:,\FM 'Y[_$[QM^QY\$_%?[1EY\4
MO^"1/[/UE\#/V5/C[\(O@C\9OBKX.\<^"_%?B;1K#XY0^")_ GQ&T?X6WWPK
M\+RZ[H-HOQ(\&Q^,M&M_&47B'0Y[O55TBR\30Z0T]W[Y^QWHO_!,;X_7WCKX
M=_%S]EO]B;X3_M ^%/CC^U#\.+7X/Z$="\3W5UX/_9T^(^O^$;GQ0FL:KH/A
MR2^N9/#VD0^*=;A.DZ5)9Z=-+JB:9#I$1N5]I^&W_!.F^^(W[8'[6GQM_:^^
M#OA77/A[\1_C7\)?C-\%/#FD?M+_ !9\7>#?[<^#'@KPAX*\)ZG\3O@!!X<\
M ?"76_$=MJGA"'X@:+JWB.R\>R:#>7&FZ1&\]QHD&K2?.6G?L"_MU6ESX3O]
M.^&7[+^E:O9?MP_\% OVH];N-;^,'B'Q9H%]H7[8'P\^,W@GP?IGBCP^GP)T
M=O'ESX7;XLV,'CK0[Z]TRP\1^'?"MWHUEJJ0ZS:KIP!]":+H/_!!SQ'X7U3Q
MGI>E_L*2^%=#\9>$_AY?ZU=VW@G2[.+QIX]0S^!_#EL=56RDO[_QE;B2\\++
MI\=U%K]E#<WVE275I;7$T>9I$'_! /7Y=%AT-O\ @G]K#Z_J'@[2]..F77P[
MO8UO_B%8C4? UOJ<UO+)#H;>++5D.@OK<FG1ZE/+#9VSO>310/\ #MK_ ,$O
M_P!O1[W4Y?$7PC_9T\91^*_$G_!-WQ-K$WB[]IW7M97PW>?L*_$+6?%/BFQ\
M)Z"O[+5EX8\-^&?'V@ZG'X<^'?@[P+H_@OPQ\/M+@:RN],OWO]6N[_Z1_:-_
MX)]?M2^.?&?[?=[\,_@K^S5%X:_:?^)?[!GB/P.=2^+-[X7FF\+_ +)_B30/
M$_C"T\;Z1IWP"UNVM)O%-SX>6'0=,@O/$%I'<:D+[4;J(6307(![=?\ @[_@
MA?I?PM3XU:AX1_8OM?A=)XPUKP OBZ3PYX=^Q?\ ":^'+&;5O$/AEK5;)M33
M5M"T:WFUS6+5[%6TS04_MR]\G266\;M/$7P*_P"",?A/Q%\*_"GB+X:?L;:5
MK_QNM= OOA/I]QH?A%CXYL?%AMT\)7NB74,<MG)9^+IKNWMO"=U<7$$'B>[D
M%GH4FH72O"OR#\0_V"_V\_%GB7XW:MIW@CX":;H?Q8_:P^.7QGDATOX^^(_#
M_P 2(_ _Q9_9C\#_  #T72-$^*UI^S_>>(_AQ!9:CX/OM0^*&B^ 9-'\0?$#
MPCK&C^&M,^(?A^#1=5MO$'HO[*G["O[5_P  =,\->%_&?PJ_9@^*OACXC? O
M]C'X;?%:T\7?$'Q!XBL_@Y\1?V,+2[\(>'?&W@G0]3^$T5I\5?!NNZ;8^&_B
MIX+\.7EU\-O$?P[^(D>J6CZWK!>V\0J >J>)_AW_ ,$/O!=[\6=.\5>"?V,=
M#O?@5HI\2?%N"^\/>&HSX'\/1:M8:!J&N:LZVC12:3H>O:G8:)XFU"Q>[M/"
MVKW*:9XCETN]#P+Y-^T)JG_!#/\ 9R@O(O%_P@_9>U+Q#I/Q&^"7PW\0>%M
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MB\+?\$UKF+]IZ^_:@_9*_8U_9YTKX'_MC>./V8?".I75KI.JZ5XLTGPS\/?
M7C_2O%&KZOJ?A[0X=+U2]TGQ;>ZAX@M$M!HGA6RL56]UF=(I;^;]$]._X)Q?
M\$\-8T^PU;2OV2_V>=1TO5+*UU'3=0LO /AZXL[ZPO8$N;.\M+B*!HI[:ZMY
M8YX)HV:.6)T=&*L"?S+^(W_!/7]LOXC:#^TTLWA7X9^#]?\ BC^UM\4/VB?A
MSKO@#]IWQIX7\;^']*^(WPF^$WPN30;OQ$/@7J/A+4O#]XOP_P!6@^+WPO\
M'W@+XC?#[XK?#S7Y/"LUKI>M6UCKMK^\7PH\.^)_"'PN^&_A/QKJNAZ[XQ\,
M> _"/A[Q5K?AC0XO#/AO5_$6C:!I^G:UJ7A_PY 3!H&BWNHVUS<Z7HT)\K3+
M&2"SC 2$  'R[_P[1_X)_P#_ $9_\ O_  W>A?\ R-1_P[1_X)__ /1G_P
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MS\+:Q\;/&'PIT"XT=;WXK^)=.U[Q-X3\"_"_PG8Z=K^BZMK5UX_\>Z-:Z/\
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M1/B;_P!)!OVV_P#OO]D3_P"A(K[;HH ^)/\ AD3XF_\ 20;]MO\ [[_9$_\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X-^!/\
MR??^WW_V*_['O_J#_$VOO*O@WX$_\GW_ +??_8K_ +'O_J#_ !-KXG^,/BS7
M_!__  4$_P""@]O\&/'FK:M\:;G_ ()0^$O&_@CX>'XBWWBR\TOXGZ!XO_:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7FEZVHNM:AT[PZZ:ZP!VGF_\%/O^?#]@S_P;?M"?_*6CS?\ @I]_SX?L&?\
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MO:;XZTBS*LSR1:A97VG7LO"3V]S:Q_N97^[Z^"C_ ,I0%_[,*D_]:%CK[UH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^#/V>_\
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M/_5+7-?>=?!G[/?_ ">Y_P %#/\ K]_94_\ 5+7-?>= !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\&_ G_D^_\
M;[_[%?\ 8]_]0?XFU]Y5\&_ G_D^_P#;[_[%?]CW_P!0?XFU]Y4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNHV7C7XBZ?(C7=G\.O"=QK/CC7M&4^(/#_A_5-"_XF- &I_P[%_8>_Z(F_\
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M6UG2VMM.O]7@O-5T!M: .O\ ^'8O[#W_ $1-_P#PYOQA_P#G@4?\.Q?V'O\
MHB;_ /AS?C#_ // KSCX$_\ !2;X+_$2_P#@EX3T"W_:.\?I^T+X7_:0^)?P
MU^)WC/X1Z#X&\/7.A_ /QMXETCQ_X,UN1/\ A"QX<\1^#;FSTWPYH&@:UX7M
MO$NKZ/>^']9UNYO)W\2ZU9;MY_P5'_9MT/Q'\,/#'C/2/BQX OOB-K'PU\+:
MI-XR\&6&F6_PF\;?&B-Y/@_X(^+$5MXCOM1T/Q+\2=^F)X?A\/V'BG3K-_$7
MAH>)=2T :[IYF -^S_X);?L':<D\>G? .STZ.ZO+O4;J/3_B!\5[&.ZU'4+A
M[O4-1N4M?'<2W&H:A=RRW=_>S![J]NI9+BYEEFD=VM_\.Q?V'O\ HB;_ /AS
M?C#_ // KR7P?_P5\_9?\?Z&/$O@_P %?M+:OH-WXH\1>"_#NIW/P&\5^'+;
MQGXJ\$>(/'^B?$3PYX,_X2Q]!D\1>)/AW:?#;Q)XE\5^%[&-O$\>@"S&CZ-K
M&N27&B6OJ.N?\%+?V7?#WQ*^&?PVU36O%5M)\3?$WPR\ V_C&X\.K8^#_!GQ
M,^-/AJW\6?"7X9_$%]2U"R\3^&O&OCO2;_11IUA_PC%[8:3J'B'0-+\4ZGH%
M_JUK X!9_P"'8O[#W_1$W_\ #F_&'_YX%'_#L7]A[_HB;_\ AS?C#_\ / KR
MW]LW]L+QO^R]^UK^Q?X*\0?&;]GKX2?LW?'UOBY%\2=>^,/A'4XM<TF]^#^A
M:'XK73/#7Q%F^,/@WPKI5W\0K37E\/:>NL>#]9?P_>:>^KQP^(Q<_P!CV_CG
MP,_X*6ZOKGCK]L/7?%?Q ^''[1/P1^%'[0?PF_9Z_9TM_P!DWX3ZUK'C?XK>
M+OBW\./!GQ+M;.7Q-<_&GQ?X(U*Z\++XHUCPMKE[(O@OPW:Q>#M3\3:IK>D/
M./#\0!]:_P##L7]A[_HB;_\ AS?C#_\ / H_X=B_L/?]$3?_ ,.;\8?_ )X%
M>*77_!93]D?_ (1_X?ZWH&@?M"^-;OXC? #Q_P#M*Z/X<\'? _Q1J^K:=\,O
MA-XM/@KXJ2Z[J$CVGA*P\0?#O6K?54\4:%#XFN[J"/2)8[%K^]U;PQ9Z]Y?X
M%_X*:-X:_:R_:C\-?%/7O$OC_P#9T6\_8(O_ (">)_AQ\&[B+PY\)?"'[77A
MFYL=$U_XN^,?[1EN;K3/%OQ U7PM86^IS23ZKIRWZS1>#M)T&TU'4R ?7?\
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MEI?>.)/%%YXYMM*BLK&YT:::/Q4B: X!N_\ #L7]A[_HB;_^'-^,/_SP*/\
MAV+^P]_T1-__  YOQA_^>!7E7P2_;(\1?'[]MOX4Z?\ #;QYIFO_ +)'QP_X
M)T6_[4GP]\/R>!4T/Q7!XLNOC#X4\,Q:WKOB*_O;C6)#-X:\0'3F\+)8Z/::
M-?VUXUW_ &M=-!<VOZE4 ?GS^PUX"\,?"?QY^W7\+? =KJ6D> /!/[4WA*U\
M(^&[[Q)XF\36OAVUUS]CW]EGQ1J]GI%SXKUC6]0L;&_\1ZUK&N3V$%XEB-3U
M34+N*WCENYV?]!J^*OV7_P#DO?\ P44_[.M^'W_K$'[(M?:M !1110 4444
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MX8TW3],T@ZW)%)++F_LM_M.?M$_M%?\ !/7X1_M*:'\-?AEXB_:)^)?A6VU
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M]C/2;KXD?!#PC\1OV:=(T/P7J?Q:^%_B/XR:9KC>#--^,6N?$7Q%IUSX8O\
M3H? WQQ\*^-?#'B'4_"R_"SXP>'8='^'_B.>?XA>#?%\6M7(MK;^ABBB@ KX
MJ_:D_P"2Z?\ !.W_ +.U\;_^L1_M>5]JU\5?M2?\ET_X)V_]G:^-_P#UB/\
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M?X8\3>)M9U%S%X#\.BYB&FV,%U96T.IKK'Z@44 ?C1\2/^"2 ^(OBWQ_'/\
M&[PSH_P9\1?L^_ OX#^"_AA'\!-,UW5_!H_9M^*;?'3X5^,];\5>)?B-JOA7
MXA7<OQ9EN=8^(GAO7/A=::!X\\-W,_AJ:'29KF\UNZ[VQ_X)P^,O"^M_"/XH
M_##XS_"'X._&[X6^(/B@LES\+_V3O#GA#]G_ ,3?#?XL^#_#_A;Q-X"O/@5I
M'Q.M-9M-2CU+P;X.\<V'CT_%R^U]?%6CW-I>0WG@N_A\):=^K5% 'X/>%?\
M@BAJ>F^"/AQ\+/&7[7.M^-_A]X"_8Y^+_P"R4[CX+>'?"_Q!G_X6I\3]#^+U
MC\2-"\6:-XT_X1S0]0^'_C+P9X%D\,^'M4\ >*8K_3-&U:S\4:UKDVO)=Z5]
M1_&/]AO]HC]H#P+\-]!^+W[6W@_Q?X@\#>/$\3:_I4W[-MS9_ 3XIZ!;^ =?
M\(66A_$;X(6_QV%WK^HVFO\ B&?X@&:Z^)4O@74-?TO0]-U?X:ZCX>L)=-N_
MT^HH _)C]C/_ ()L?$']DWXB_ 'Q9J'[27AOXE>&/@%^R%??L=Z3X7M_@$?
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MM'_#Q7]EW_G]^/7_ (AM^V/_ /.%H ^XJ*^'?^'BO[+O_/[\>O\ Q#;]L?\
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M)O%/AO0;6"?64O;[5-;T^TL;6YDE8( ?J51110!\6?L%?\D3\<?]G=_MY_\
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M+J7CK1/A]I_C*6+X9W_A:XU;Q%\+=%O-"\%?%2;4=-?Q)KMLOAFPMKK]*_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#YT_:Q_9;^$_[:7P ^(/[,WQRM-=U'X3_ !1M=(T_QKI?
MAS7KSPSJNJ:;HWB#2O$L&GQZWIQ%]96]SJ.C62WC6CQ3R6HEACFA:02I=_9R
M_98_9T_9$^'EA\*?V9_@UX!^"W@*P"$:%X&T"TTHZC<1AE&H^(-4"R:SXFU=
ME8K)K/B'4-3U65-J27C(JJOOU% !1110!^3GAO\ 8I_;(^'OQ8_;'^)OP_\
MVE_V9(Q^U_\ $70?B#J6C^./V2/B!XN7X>W7@WX;>&OA7X/BT8P_M6Z)I?B"
MZL-"\(:#K>J7&N:,UIJ7B>.ZN(-.T[2I+?2[;X!_X*,_LE?&;]FOX!?%+6/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $6 D\# 2(  A$! Q$!_\0
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M=%9K%")$R_J^-_Z"8?\ @$O\Q^SJ?\_%]S.6_P"%VZC_ -$@^+7_ ((]/_\
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MB=P<Y#:!K39RK(<YL#G*,RGU5F7H2*1_VB?@[("K^(6=2,$/X?UE@0-N 0;
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MFFM\:M*8%6^''Q?93M)#?"GQ>02ARI(-@1\I)*^AY&#1]<I_T_\ [4/K%/\
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MV)I/=?U]Y5\J/T"\] !^?3'K^/L<@\J/_('^'^>/?%K:OH/RHVKZ#_.?\?\
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M7;6#7DWM\^6Q[]O/]QOR;_XFC>?[C?DW_P 37@8^ FB#KX[^*Q]V\?:@I_\
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MDZ8UIHD-H6&];9K:YPQ&9& P?7-"T/2-&M9+72M)TW2;=G5GM]+TRVTVU<A
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MK(C?>16S@'<H.0,X'(/3)Q]3ZT;5!+!5!/!.!DCT)QD_C44BY;.XC@< ^_\
MG\::6V@ D_3)/?K_ )_"LW/E;4TXQOI+=/6UR'*S]Y<L;Z2;T?G:WZEC:O\
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M;C3[D@;PTAC)"[A7FUZ2I5XO#_NW)KFZI6MO;UU]7?SE37,XV>FE_N=_E?\
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MQP_Y)!\3/^Q'\3?^FJYKJ_"?_(LZ!_V!M*_]-]M7G5/]^J?]N_\ I**[?/\
M,X[XX_\ )(_BA_V3_P 6?IHEYC\J[G0/^0/I/OI6G9_\ K>N$^.?_)(/BI[?
M#WQ5CV_XDMZ/Y5WFA?\ (*TS_L&Z?_Z16U;UO]ZI_P")?F<\/XM3S?\ 7Y&Z
MG0_7^@JO<9#9#LA41\H-SON=E\L*?EPQ_BP6':HI.) 1N/R?-EB$1020V,X+
MDDCIG '-?,C>.O%'Q,\4ZSX+\-ZI_P *YL]$N9K'5;[4(5;QWKR/&2NH>![.
MZ*VEMI=NI=+K6;B*Y/F,\=I$98'(Z*V,IT9.,E>V^J71/KZFKE9VL>G>,/B?
MHGAG4QH-G'J'BGQA)%YEAX.\.K'?:W=D@DM=3,R6.C646!)=7FI2Q1Q0$R<@
MJM<C#X6^,WB=#K&J?$FW\#RW+?N?"WAG0++Q'::7;[1MAOM=U&6"74]3#F3[
M3<6]O#9J D-MYD:"5_1? 7@CPQX.TR6RT'3!"SSRB]U*]E;4M9U>??OEO-5U
MBYWW=_-/,7G(E<1PN[)%%$!M'>%%)SC!/7&!GMR<9/  Z]!Q7/%U<4V[_NI:
MP6ND796O=7=TW=6[;W'[-S7OR3B]HZII=K\R\^VY\YZGX%^).EQ&]O/V@]1T
M^UMX;AI;B^\)^&;2RBFE:""RDDGN[N*V@432R0'SYMMQ+=6\4:"1%S:@^'?Q
M-E5C#\=_$")%)); +X1T!@&MCY$B;7G9HVAD1H9 6?S'0S*Y$E?)7_!5+3/#
M.L? GP)9^)?'FC^ XM/^,WA+Q+I4OCGPKXR\8?!CQ/JNA:-XHDC\'_'?2_ <
MD7B:W^&WB"WN)[6VUC39#=Z)\1!X"UBV@NWT]K:3X,^''[7O[06F>#?@/X ^
M#GAZ3X8ZOJ/P^\ WW@O]G_Q_X5\6_%_Q-\8= ^(UMXD.O_$OP7\7]?FTVZ.D
M?"[7=+-_I>E>)(K2YU?PT\7_  DWV*[O+)3H\LIRU<TFV]'S/\>?Y_.PN11]
MV-^6.B5Y;+_MYG[6_P#"M_BC_P!%W\0'W/@SP\WZ^?Z8./3ZU6E^'OQ'BFMT
MNOC_ *]#]H9HX(I?"OAFVCGE4;]JAIQ*\G080D$87 )R?PJ^&_\ P4N_:4^*
M_P 8_AO\+?#7QK^&%K?^(M<^#&D^(-('[/7BM]6N]:U+X)>-O%_Q7\#:'?:B
M]AHYUJT^*'@RP\&I>W%U'9^'I_%Z:?(]Y>:?&TG>>(?VZ_B;!X,\(^-/$/Q_
M^$&M7^O>/?',;>'[C]GGQ1IVN_ SQ3H/P@\6:_\ \*IUB626XM]8\7>$_&N@
MQ:1%JMXMI:^(;:Z:&[6*-M/O)5_9E/\ Y^I=/MVM_P"!KTU_X O94VVW%W>]
MI2_^2_"VI^SZ_#GXI,6)^.WB$'/,9\$>'E\H8 "?Z_+?WMQ)W9SW&7_\*X^*
M/_1=O$'_ (17A[_X_P#YP?;/\_\ >_\ !4/]J:;X/WK6'Q>^%&I_$C^UOAQJ
M7_":>%O@?XAET/3['XC?")/%SZ5'X8\3W&G6]UX(\!>++B&P\<>.]1OH/$=I
MH<=HFE:)->ZJZ1?TB?"N\U/5_AQX&U77=>TKQ9K.I>$?#E_JWB;1+*"PT77]
M4N]'LY]1U?2-/CDN%L=/OKQYKBUM/.D\B%T3><4/+8+>I?TYK^OQZ![*E_*_
M_ I?_)GF[6'QD\"D:C:^)$^*]@^?[3T#5M.L/#&M10(,B;PM>69DL+K4\@A[
M'5WM[>5 HMY3.Q6O0O!7Q#\.>-/.BL;Z:TUNU &J^%M4A;3?$6C3+C(U'2[@
M^=$VTJ5D3?:RJ1)$[*W'H>Q0^ H *CH ,D%CG@ 9'&#U'%>6^.OAUX=\6SV]
M\Z7>C>);)DETWQ3X>G&E^(=/DW )(E[&NR\B5N9+'44N;:>,-&$1CN.$X5\(
MVU53I+X4XNZCHVKIN_6U[C;4(JR=ELF^BZ7=]>U[GJ<3%@P^<A6 #L0=X*@[
MEV\8&<?4&I:^7O"OQ'\3:?XX'PQ\2X\9:J+=GMO%GA:T8P6<,:M+-;?$#189
M#!X+OKQ"L-K??:9XKZ=-\<$(DY^C-/,I@9GE,FYUVCM" F# -N4;RB-ID5F,
MA&]MK$J.O#8J->,4GS2:UV[OI]PH3YU=*W3YWM8T'ZCZ?U-8'B+_ ) NM?\
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MZ^E5;F_U:\<M+JEW= W$MPV'8C;GM8X82GEE(Y$7:%W*C* ,$*$ P@0@;5P
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MLK2^)/O^OW):!3BX*S:?HK);VM]Y57^+_>/]*Q?$7_(%UK_L#ZA_Z27%;[@
M\#'']36!XB_Y NM?]@?4/_22XJ:W-]7J<[4I6?,TK)NSV7I8*SNF_7\D<%\
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MMJ[OT?ZOY?U8\LTGX3_#330HM? OA0&$*%DFT:UOMN> 8KC4(KFYZ_?W."Q
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MI+.LLY'G,@&]HOW;GYAR36[\ 0#\&_AUD _\4KI@Y Z>4>/I[5[ %4=%4?0
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M<K+(S\./C%T'3P3(!P>./[4[8X],#'2A?CA9\E?AO\7QDY8GP/)N8@  DC5
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M'Y?_ *ZAD_U;?[R?^A5-)V_'^E0R?ZMO]Y/_ $*LZJM2J?UU3$OAK?\ ;O\
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M_E7@OP[_ .2M?'3_ +"7@'_U'+VO>91A#SGY7.?P%>#?#O\ Y*U\=/\ L)>
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M'@_P-:^!+#P7K6D:M;>)=:35-7T_48+9-6U[X:SZ;_PCMMH>J^(;\^(;J_\
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MU.=)2UY5'R2U=_+HEN]=2,<$CC^'(SEQ\H^_R<-C!QGH<]ZQ?$7_ "!=:_[
M^H?^DEQ6^X&[.!D@9/KU'/KQQ6!XB_Y NM?]@?4/_22XKTJW\"II;1Z?)EU/
MA^3_ "."^ '_ "1KX=?]BMIG_HHU[#7CWP _Y(U\.O\ L5M,_P#11KV&IP7^
MZT?\"_-CA\$/\,?R"BBBNHL**** /#OVB?\ DDWBGZ^'/_4LT.O8+/\ X]H/
M^N47_HM:\?\ VB?^23>*?KX<_P#4LT.O8+/_ (]H/^N47_HM:\9_[[6_Q?C9
M&*_BOT_5%:_N([?+2S11K'!+/^\F6W"",$O)+,X*+;%5VW$K?+:KB9QM(->#
MV_BGQM\3I+@?#^2+PQX/M;RXLF\=:U!)<7&J3VTGV>\3PCX:>."VN[.U8-#;
M:YKDEWI.I.#=6=E*-LK=O\9[+5;_ .&WC*UT1IQJ4V@7D4:6J![V>U:2!M3L
M;!6&&NM1TF._LE .[=+&5!(!'1>!=3T+5/"?A^[\-FW?0&TC3X=+%NRNL%I;
M6L4$5G)M)"W%B8VMKA."DT;J0&4BJQ=6,JE.FY^S<;*[3=]5II;3J_T+>[MO
M;;J^EO\ /N<;H7P@\$:==_VUJD-[XOUR0AY=<\775SKFH/(!A_(L[M18V-OY
M@9X[6"U6" D" ! *]8A@@AC$4$*00H (X8T6.*-0O"I"BJD2J1]Q5 &"0*N
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M"ZKHE]"]CK&CW6"LECJNERXNM.NT"$/%*IAE(::TDDA?</0YMA(4IN)!;L.
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M[2SM-/M;>RL+6WLK*TACM[6TM((K:UMH(4$<4%O;PJD4,,4:JD<<:*B(H55
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MO'8=ZSI=#TF4YETO3)B<Y,VGVSDYZY+P$GKSG/3\*\>;Q#\<;^#=I_P^\+:
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M?\#YY_X7YI*8"^ _BL0>3O\  6H$YR >3?\ 3 SQZGV%'_"_],_Z$+XJ=O\
MF0;_ -O^G_Z_KZ#/T-16?U3%?]!:_P#!7_VY,HUG)N-;EBWI'V=[+M?F5_\
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MDCI?^7Y(****0@HHHH **** (Y.WX_TJ&3_5M_O)_P"A5-)V_'^E0R?ZMO\
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M*_\ 3?;5S2ES8V<K6ORZ?)&KZ'4T445[@@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /#OVB_\ DD7BSZ^&O_4NT*O8+/\
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ML;08_B'/\*/#;>'O#?BCQ9I&CVFD7&M1QW<U[JUR'M[2!8SJNH7L\+>=$DS
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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B A0B@ * #C &   .E%%"H4J,[TX*+LM31)12C%62V1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>fin_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  S 4T# 2(  A$! Q$!_\0
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MSE_X.7/^3<OV>/\ LLVM=?\ L1=4XQCG/?D8'KTK]C?V#?V2])_8G_9C\ ?
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MQX8_8]//_(R?&,9P2.=*^'V,X./?!';*D$'/]$7[+O\ R;/^SO\ ]D,^$O\
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M.#>/RC,*?':Q>%5?$89U?JV683%4;5\+4I5X<E>A2G[DX\W+RRO%M/A?$O\
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MG)5*:=6G6_3;_@OL<?\ !.;QP3T'Q'^%V?H/$0Z_Y-?DQ_P;S_'/6_A5\?\
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M>$?$C6MEXCTRQU#4O"VG6L5QI-]::%XFLA-?VZQ)I-\+8FXN%CE_>G_@FO\
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M%?/_ (1VK?Y_ES7Y1_\ !MS_ ,F@_%[_ +. U7U_Z$/P1Z_TXSGOFOV_(?\
MDP'B!_V7_!G_ *A8H_ >(O\ E)#PV_[-QQS_ .IV%/Z'Z***_$#]^/Y./VZ\
M?\1 ?[(1_P"G_P#9QR1U_P"1E\2_Y%?UCU_)S^W7_P K ?[(..O]H?LXX_\
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MDXCPU&-/,,LS;(,-@\/@\XPM-5HNG4FL*U7P\,5%3HUG3]MS4:-6'R;^Q/\
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MJFD6%VT"2-L6<P;YH@RDQ\@'T_\ XB$_VL?^C&])Z\?Z9\3_ ,!_R*O7.?\
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M$UKQ)IGAK3;'PWI&EW6F1Z??^//B+X;2VTR. &*$"^^EK.W3^NI^H]%?%O\
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MMQK&M>(/$WA&:Q?[)^K'[9'Q>^*E]K?['_[.7P$^*%C\,/$W[8_CSQ/I5_\
MM!:'HF@^+;OP;\+OAK\)/$/Q>\:7_P +M)\21:UX2NO'OCO3]&T[P]X(U7Q#
M8^)-%\.Z=JNL>+'T?7)]$M(6!*5[Z:KII?>R[6_+S>I^C%%?E!;V?QG_ &+?
MVI/V6_ -Q^TK\6_VCO@7^UAXE\?_  FU?PI^T#<>#O%/Q(^&_P 3?"_PN\5_
M%OPU\0/ 'CKPEX.\%ZE>^$-7TOP%XA\,^.O!WB:TUBQTJYU30/$'AJ_T:&UU
M#2K_ ..OVOOVH-1\'?MN_M9^&/BS^U;^WA\"O@;\"?@!^SG\0]%A_9#^"&C?
M$OP=X6L_%MG\:=1^*/C'XJ>(%_9Q^->H:'*EOX0T*ZT^/5M3TJTCTG2]3O+.
MRN(H[R6)V_K\ <DMU;6W1VTOT\NROY']$E%?F?\ L4?$3]K+XB?L/>-/'.OR
MZQXQ^)E])\9;K]DWQ9\:_#/AKX>^./BO\,8[:]G_ &</&_QN\(^#X=)\.^%M
M<\7%[%]933]*\,OJ'AC^R_$FH:!X?U35[W3K7\Y/@E\>OB+X"\6? '5/VA?V
MH/\ @I9^SQ\:/$/C?X;^&/C/HO[9_P"S/X6U;]C?XD>+O$^H:;I7B[X6>"_&
M?PQ\ 67PQ^%H\0>(;V70_@UX]\._%VPTVUOI- M-7'C:?49M+OT#E97>GKIU
MMYK\M'NC^DNBBB@H**** "BBB@#\0O\ @FU^RI^S'\?O^":'P!^)'QK_ &>O
M@M\4/B+\?_@WKWQ(^,?C_P :_#+P;KOC?Q]XY^,M]XD\5?$CQ+K7BV]T>37Q
MJ7B+7/$>KW*O9:A:1:+;S6VF>'XM*TO3=,LK/A_A]:#XZ?\ !OQ\*/&/Q3O-
M7\4>,_!/['_ACXO^#_&@US6=#\9^&/BE\$-$D\1_"SX@:%XM\.7^D>(M,\6^
M$M:\+:)?6VMVFI17VH-;W,.LS:C;:GJD-Z44WU]?\S-;1\Z;OYZ1W/Q\_P"#
M=3]L[]I__@I7^U[KWB+]MWXP^(_CI?\ [+_P.T;X@? ZUO[70_!7A_P;XZ^(
M$]_X#\4^,+GPI\--)\&>%_%_B6[\(7^HZ%I^M>.-'\2ZCX>L]4U4^'+C29M4
MU"6Y^A_^#DC]I;XX_P#!/+XI_LU?M&_L:_$'4O@=\8/VA;'QA\,/C;XET2PT
M/Q#IOQ+\'?"S0Y=>^'5MXI\%>-M+\3>!+_7/!M_XEUZ/0/&/_",Q^,K#2=4N
MM BU\:"XTU2BF]U_A7Y,A-\DG?7VCUZ_$EOZ:>FA^N?_  14TNU^)'_!-#X.
M_%[XB->^/?B/^UQX>U?XP?M&>*?&FIZEXIO/BEX^\91MX6U_4=:M]<N[_3[#
M1YO"^@:-X:T_P=H%GI'@O0?#^FVFBZ!X?TS3(EM:_E+TK]J/]H:__P""KEO_
M ,$<KSXO>-;G_@F^G[6EW^SM_P ,WS:JSPO\"++0S>6WPAF^*Y3_ (7C/\/8
MXHTT0^%I_B9)I,OA)1X*EMG\(?\ $CHHI+^ON9<E[L?2WR?+=>C[']@O_!6#
MPAX=MO\ @G1^T)XBT[3AHFN_L]?#J;XW_!'5_#MU>^&]0^&/Q4^"=I_PDWPN
M\7^$;K0;G3I=,O/"6K:;:_9;*-CI-]IAN]!U?3]0T'4+_3;G\%O^#=G]J_\
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MV=]:Q&W;S[]JKX+?!S]GC]J+_@F%X]^ WPE^&?P:\7>*?VOO$OP<\4:W\,/
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+0HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>fin_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  [ &8# 2(  A$! Q$!_\0
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MZN,>19!B\WP>7N4<5CHU%1H^YS<WLWR2<](RDK7;2YE&S3?^@^"".#GWX/\
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KS;D_1P^"H86DJ-&+4%.I.TZE6I+FJSE4FW.I4E+6<I-*_+%/EBHQ22__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex4-12_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  9 !\# 2(  A$! Q$!_\0
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:E4?* .B+[#)^I-=?'_Q[K^'\Z#]S\: /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ex4-12_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
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=TZRMX95 BA5F+2R&2XN)7DN+J::XEDE<HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ex4-12_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
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6"\UQ,9;N[N'ENKRXGN9997*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ex4-12_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
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)/<7,Q110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ex4-12_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
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C/I]M%!9V-I;6T<:[(HE&^:7S+JYD+W%W//<222N444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ex4-12_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^FCQU8Z%^
MTE\*/BS^V9^U-J/Q!U[]CWX=>$OB9\2?@U^R[\//%6I^'?#GQ6^"'P_T'4M3
MNOC)\5=/T#Q)X?;X[Z_\9=+TEO%7PK^%_C34M+^%'AGP5J_@6QU+0;SQCJ_B
M?Q9=^8?L[?LS_ +XR:AIFN?!7_@F)\4/^"86A:Y\+G\>^%_VIOACK_['OP'^
M(MWXHNKKP5J'P^TO1?AW^R/\9OC7'\2OMWA_4]8\9>)++]I/PJ_@>9O"GA[1
M/$/P[^(<&OOIOAGZ'^!6K>$G_P""5\7PN\:_#KQ=\8Y_@5^S7J_[)_[0?P&^
M#T'VKXE>(/&_P8^&@^%'Q;^''@;3-2UOP1<Q:KXP&E:CJOPDFU+7O",_CKPC
MXI^'7C'0-3TRR\7:!))X%^PAI?B2S_;'U2V_9TT#]N#PK_P3^@_9+TVP\4^$
MOVV[7]K;2%\.?M56_P 2_"7_  KS0_@5H?[;ZCXU:9HOAGX20^/K+X@6OPY4
M? C2M4B\ 6_AL67B5=8O* /N7X+_ +56G>%-%\2?"K]J7QKX,\-_'+X,^*O^
M%=>,=;L;"X\)^$OBA;)X5\+>+_"7Q:\#^'KZ[OY_#^C>._!?B[P[J6N^$(]0
MU6S^'GQ!7QK\-].\0^*]/\'VOBS7"OR#_;6_X)]?$'_@IY^T5XZ^,7PD\:S>
M O!/PBFMOV;8M5T;4-*L-(^(_BOX=QMXA^)'BBSO+>UN+77;OPE\2/'7BWX)
M^(M2MFCCM/%GPEU_PZT8FT*5G* /T(_X*,>#[K]G#X>_%/\ ;M^ /C3Q?\)_
MC=X3\+07?C>R\.3>']2^&_Q]MO#>B-I'A:U^.'@/Q=X>\2Z9X@U3POID$.EZ
M%\0?"DG@KXKVFA06WA9_'TWA2TM-#@_ C_@CG_P5]_;)_P""V/Q5\?? ;X_Z
M]X4_9X^'V@V-\^N)^QUIGB+X9>*/'6DIF;4=!UOQM\1O%?QA\6>%(-<2\NX-
M3\1?"+5_AIX\B6<W6D>+M*U&&VO8"B@#^R7X>?#WP3\+/!/AKX=_#GPSI/@O
MP-X.TFS\/^%O"OAZV73=%T+1M,B6TL=/TZQ@*Q000PQ*#@%YI3)<3O+<2RRN
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ex4-12_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>ex4-12_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  4 !0# 2(  A$! Q$!_\0
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C6DVMM&EMI]A:P(N(HER6FG>>\N9FDN;RYN;J669RBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>ex4-12_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-12_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'H HH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BDSQWH# T +12 YH)Q0 M%-
MWCWI0<C- "T44F[V- "T4W>,X[TN: %HIN\9QSF@.#TH =12%@.M)O'O1<!U
M%-#@^M&\>AH =13=XS07 ]: '44@.1FES0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!",C!I"HJ&[:<6DQMC&)PA\LR@E0V
M.,@<XK!\%:WJ7B'P_'J>HI:1M,[!$MPPVA6*\Y)YR,T=P.DVYHV"J-OK6FW4
MEU%;ZE9326G_ !\+'.K&'_? /R]#UJE'XQ\-SQ32P>(]'DC@4/,Z7T3",$@
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M9>*I/"^FQ7,-K]JE9\O'S\L*\R/Q_=7)Q6JVN:;&]NDFHVD3W,9E@2295:1
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M?F7'?IQQQBK\OA7Q+=7%M-+9V\8MYK&:-([E5!$0 D#X&7?.<%B0!@#!SGU
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MG0Q[SED<-$0RYSBO6\#THI6TM\BO\[G@;:8MKX7M]$M1'M33ECDD@L;B R7
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MB2654:5MD89@"S>@]3Q4ZGY>M>;6OB;75U2STZ2[MI%.L7&G33^0 [*L>]&
M!V@\\\<X%36GB#5ECO;2>_,^IZ1+<RWT8MD'FQ* 8>!]T.&0Y'7#C^&A/O\
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M!I>H,V]&)R%-J!@Y]:27]?>#OT.UN-8OH?&=EI!@M_L5S;22B7>QEW+CC;@
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M2_\ 2V:M\-E0>>1GFL#P=_R!+G_L*ZE_Z6S4#.AHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *YO4O]!\<:-=X_=WMO/8.?\
M;&)8R?P24?5JZ2L+Q;:37.@RRVHS=V;I=P#U>,[L?B 1^- &Z.E%5M/O(=1T
M^WO;=MT,\:R(?8C-6: &&L?7?#UCXAM8[;4/M)ACD$@6&X>'+#D$E2,X///>
MM=AD$;B,]Q7GJ.;#QAJ]A$;W2O-TR1X)KN8/#<.I^:<'<=FT%>#@D,>!BH;2
M_KMJ+H=1_P (MI9U:;4Y$N9+F:U^R2&2YD96BQ]TJ3CN3TZDGO5$> ?#RP&
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M&WW37-V!_M7QM?7PYM],B^Q1'MYK8>4C\ B_A0,Z0<FEHQBB@ HHHH ****
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MC"L& QP"1C&.3Q73TAZ4P.:;PE ;=(XM3U*&7SS<R3I(F^:3 &Y\H5X &
M,#BB_P#"<.J:;;V-UJNJ,(;@7'G"5/,D=2"NX[,  C@* */'MQ/:^"-4EMIY
M8)5C7;+"Y1URP!PPP0<'K47]N6FB:C9^'X8;NXF:W$X\VZ\QRK,1PTKEY#D'
M@$X&.V*E--M?UM<GM_7D6]4\+6.K3B:=[E':'[/.89 GVF'.?+DXY&<],'D\
MX)%-G\)Z9<:C]K99D0M&\EHC 0RM'_JV9<<E<#&"!P,@XK-M?B#IU[JKV-M:
M7LJA93'-'&"DAC!)'^ST.-V :Q=>\9MK7A>_?3Y+W2[S3[NT641R1G<LDB#&
MY=PP0QZ$'(ZXS37E_5]/U&]+LZV/PKIL6L'4!YQ43-<+;%QY*3-]Z55Q]X\Y
MYQDDXR:6U\-16FKZIJ<>I7_VC45"RAG3:FWA2@V<;02!G/7G-95@9+?XGW]L
MES=FWDTY9_(ENI)$#F0@E59B%XXPH ]J[1>E"U2?]?UH">K_ *_K<Q(/#UO:
M6-Q#:W5Y#<W)#37PD#3NP]68$?AC SP!44_A#3;K39+2X>YDE>9;DW9DQ,)E
MQM<,  ",<8&/:NAI*8[&;I6CP:2LWERS3S3R>9-/.P9Y&P!DX  X X  K3/2
MDI&90I)(  R230!E^(-7&BZ/+=*AEN&(BMH1UFF<X1!]3CZ#)[4OA[2CHVCP
M6;R"6<9>>7'^LE8[G;\23CVQ63I0/B77EUYBW]F66^+3$)P)7(*O<$?0E$_V
M2Y_BXZKO0 M%%% !1110 4444 %<]'_R42Z_[!,/_HZ2NAKGH_\ DHMU_P!@
MF'_T=)0!T-(W3BEH- '&:Y+]D^(7AVZDBN#!]BO(3)';O(JN[0[0Q4';G!Y/
M'%9MU\/+BZ%_ +R""SG*2K9@/+;O,LHDW/$Y( .,%5X.2<9KT/UI1222U]?Q
M$U=G!S>";F6UMK>!-'L+8EOM=A9VQCMYLK@,0H!8CKAN*9I?AO4?#MYI%_>W
M-H]GI6D&PD$$,C2/RIW*H!_N#CGJ:[^@]:&M+?UV"QQ_PXAF@\#V:S0S0N9)
MFV2QLC &1B.& (X]:[!?NTG'I3ATI[@E8*Y[P=_R!+G_ +"NI?\ I;-70USW
M@[_D"7/_ &%=2_\ 2V:@9T-%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)D4N10 444F10 M%
M)D4N: "BC-&: "BC-% !1110 4444 %%%% !WKE]9LKO1]2;Q#H]LUSN 74;
M&/[UQ&/^6D8[RJ.@_B&5ZX-=136!.<#Z4 06&H6FJ6,5Y93I/;RKN1U/7_ ^
MH/(JSD5S-_HM[I=_-K'AU$,LS;KO3W;9'='^\IZ))_M=#W]:T-&UVRUN*4VQ
M>.> A;FUG79-;L><.AY''(/0CD$CF@#6I#THR*#TH8'/^--.N]4\(:C96$/G
M74L8$<88+N(8'&20.W<U6OO#,7BB"UGU$:A9;?++6;& E2A)^\ ^TG(R4<9
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M.3T]G96^GVL%K9P1P6T*A(XD7 4>@% #X(4@1(XD5(XUVJJC 4#H![5-110
M4444 %%%% !1110 5BZCX;LM3OUO99+Z&X$8AWVM[+!N0$D [&&>2>OK6U10
M!SW_  A]E_T$=>_\'%S_ /%T?\(?9?\ 01U[_P '%S_\770T4 <]_P (?9?]
M!'7O_!Q<_P#Q='_"'V7_ $$=>_\ !Q<__%UT-% '/?\ "'V7_01U[_P<7/\
M\71_PA]E_P!!'7O_  <7/_Q==#10!SW_  A]E_T$=>_\'%S_ /%T?\(?9?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9 ^X<9)ZC-=!_P (+X=VS*ME-&LL_P!IVQW<R".7))>,!QY;$DY*;<]ZR9?
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M"0-(\?D321,&DQN)96!).!U/&T8Q@4VW^'_AJW, 6QG=((7MXXYKV>6,1O\
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M\=0>@]!20&;H'BW5==U*-AH,J:/<;S%>$J-NTD#(W$G..PXK#^(M]%>W42B
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MUCP^*M#N+GR(=2@=]X0$9VLQZ!6QAC]":!7-K(]:*8&&>U+N% QU%-#"E)%
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M?0 <D^PI!<L2!B&V\$C@XSBN+B\"W</VC&KPO]HG2YE$EDT@:56W*V&E(!!
M/&.E=7I^L:?JBN;&ZCFV %P."N<XR#R.AZU=S2!' 3?#F2XN;NXFU1))KQ@T
M[M:R99@<J?\ 6_+@],8QVQ2Q?#F2'4H]1BU2*.[CE,R.MHX"R,,,VWS=N2 ,
MG'/?-=_D4F01P:>PMS@YOA]-/)=/)JT(^U9\]$M&1)"W4E%E"[CC[V,^]/T_
MP%<Z7>17ECK$<5Q%"+9'^RN^V(=$PTI&!].*[C SUH& >*>VP;G'3>#=2N=8
M@U>77%-_ I6*46C#:#U&T2[?KQS4:>![M-3?4%U:W6Y=_-+?V?A?,_O[/,V[
M_P#:QGWKLI+F**6*)VP\I(08)R0,GZ5'?ZA9Z9:/=WUS%;V\8R\DK;0*6PSF
M[?PSKEO8/9#Q,7MV+9$MGO;#$DC<9-V.>.>!5"U\ W-@K1PZPC1M"8"D]J\Z
MB,]5"R2L ".#@<UUFI:WIND:;_:-_=I!9\9F8$J,],X'%0Z9XET?5[AK>QOX
MY9T7<8L%6QZX8 D>]#UN*YS/_" 7/V V(UA1;F02';;.'++]TEQ+O..V3Q3V
M\"7DFF3Z=)K8DM;@@S*]O(S/CH"YEWD>V<5W&X9]ZJ76J6%E<VUO<W<,4]T^
MR"-VPTA] .] %70M.N=)TU+.>[^U"+Y8F\LIL0  +RS$]^2>]:]1[E]:DIC0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4@I:* .7^(,%_<^ =9ATP2&Z
M:V( C^\5_B ]]N:;I][X<U#PYIT=NUO-:JL9MH$/SJZ\J-HY5@1^'>NHQ56/
M3;*"X>Y@L[>*XD^_*D2J[?4@9-)+<36J/-D\7:TUC8:C!JL+7%_+/#<:=+;H
M5L-B.P?C:_RE!NWL0V[C;Q65?^*-9NO"=T9/$!,MYX:?4 (8X4,<@ZJN%)P5
MSGDD8R".WKC:58O+/(]E:L]PNV9C"I,@]&..1[&F)HFE1L&33;)6"E 5MT&%
M/!'3H<FA[A9G!V_B"^75M:B;Q49+'2=/CNHWBM(9&?*L#Y@49?!4'Y/+[=*H
MZ?XRUJ.XN-/O-5'DO-9;+^18#);QS*Y9B$41CE !]\+NY9J]-BTJP@D:2*QM
M8Y'78[I"H++C&"0.GM2KI6GI$T26%JJ,@C*B%0"@)(4C'3GI3ZW"SM8X6YFO
MH/&?A>"X\4R7-NZ7>Z2..%$F93'M5AM(+$.5)7;T) 7G-CQ5<31^//#:6NI6
M-G<>1=?/=QF1 ,)U02(?H=W8\&NS33;.)($BM+:-8"3"%B4"(GNO''4]/6H[
MK1]-OI?,N].L[A\8W30*YQZ9(J7;3RU!(X#Q!KNLVMM"^D^([>YU&)I4O+6R
MMHRL@P3YRA@S9C4J2NXYQC.>27?B/6KFXL+'0=>LIT_L];Q=1O)HX5O6+,&&
MU8'!"[1E5V,-W4UWR:)ID6/*TVRC 5E 6W08#=1TZ'OZTX:/IPBBB&G6?E0M
MOB3R%VHW<J,<&J7F%CCK35]5UF?4&/B"/2[BSN&M_L"0QN'7;\K@NN[<Q(*G
M[H'!4UB1^+=3O+/38SXA9;B]T&YFD6)(MPN(P"&7Y,AL!LCIP< &O4'T^TDO
M$O'M8&ND&%F:-2ZCT#8R*(M.L[<LT-I;QDEB2D2C)/4\#OWI6#J>66?B[5-'
ML+*"VU&/4T3PZ;R.%HT,GF@+]XKC< #T !P.23S2ZWXOUS2;:8:?X@MM0@DM
M(KH7DMO&3 QE5#&-FU<,&RN06&TYSUKTV+2M.AECECL+2.6-=J.D*@J.> <<
M#DT@T72_(> Z;9>2[[VC\A=K-ZD8P3[TM_Z_KN"32U_K;^OF8/A?5;F[UC7]
M,N-22^^P7$8BE(C5PCQJQ!"  @$D X]CTS7*6FEWWBMO$&E6\NG+IO\ ;WGS
M7(G9YTV,C;5C"[025QN+^O%>FV^F65I))+;65M#)(,.\42J6'N0*6UTVTL6<
MVEI;6Y?ES%$$W?7 YJOM70DM+,\M36Y;6VU"UTG4Q;7-QK-\R+ L)#!!G!>0
M,J#OPC,>@ ZUJZ1XFU/Q!]CB;6X-(D_LJTO5<0QNEW))N\P$/_ I4#"E6RW7
MH*[I-&TR)0L>FV:*'\P!8% #>O3K[TKZ3I\D<*-I]HR0$F)3"N(R>Z\<?A22
MLK#L</HFN>(]7U];AM0TR/3_ +3+;S69GW2Q@;@I6/R05?@,2TC+@GBNWMBM
MO8*TMZ9T1,FYD*#</[Q*A5'X 5+]@M?M3W0M8!<.NUIO+&]AZ$XR14-[I:7.
MD2Z?;LEK&Z[%V0HRJ,\C8P*D'D<CO2DKJP(X3P3K%G:_"33@-3CM[DP.D7E;
M7D$A=L (<Y.>Q!K.7Q9-?6>GQ7NLPS1ZCX:EGG@9(POGJJC.0H()RV03CY>
M*ZN'P++;SI/!K"Q3(<K(FEVBL#[$1\4\>#;L1-$-=/EOG<O]FVN&SC.1Y??
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "_$>S'>-KW4+'P)J%QIQ03K;_?:5HRBD8+*54G/IT^HK$L=:7PU;ZLEAH$
MM].\N75EAU!V$;N@;]PK1X;Y-K-]SDGJ<UV&I>';/5M!_L:[ENFM"BHQ6=ED
M<#LSCD^_K5.3P1H\TXFD^ULS1)#/FY?%TJ?=\T9^<CID\XIK=L5M$B'0?%%Y
MKVL:A;Q:5%;V5C,(GFDN\R-F-74K&J%<$,.K@CT[#J$.:RM*\.66CW^H7EJ]
MP9+^023B69G7<!@%0>G  X[ >E:P&*8:BT444#.=\7@PVNF:B#AK'4[:0'/1
M7?R7)_X!,]=$.E<]XY5F\#:T5&7CM'E3_>4;E_4"N@5@RA@<@C(- "T444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %8'B[']F6.?\ H*6/_I3'6_7.>.F,7A.XNLX%
MG-;WC'T6&>.4D^V$- '1#I2T@I: "BBB@!#T-8/C'6)M!\'ZMJEO&'FM;=WC
M4C(W8XS[5OU#<6L-U;26]Q&LL,JE71QD,#U!I25UH".2LO#1.B6EVNIZ@VIN
ML4\MR+EB)2"'*;"=H5N1@ <=ZK0_$$RZ1'J3:-<)%<3-;VL>YI)9)%W;@4C1
MBH&T\C=6S8>#X-.B6VAU75&L(\>39R3*T<6.F"5WD#LK,5]J@M_ >GV^B1Z:
M+[4&,-RUW;W1D030RDDEE(0 YW-D$$')S3ZW_K^K$ZV_K^MS%U+QG/J_AR\@
ML=+U"UO_ +#-/,LC&V>V5<@,"Z@MDCC@<>E0IXLEL=*"0V,\^JVGA^&]$MQ/
MA)@0O.,G)W9R2 >,9YKHK[P39WC^<^I:FET]NUM<W$<J!KF-A@AQMV_3:%QV
MQ5:'X=Z7$[C[=J;P-I_]F^1).'40Y) RREL@DD$GCI]T "6FUY_\/_P!VU_K
MR*_BZ:XN_A5?7UPLEM>)9_:!]FN&4HX7(PR[3^'2L"VU.?1?%5M]DLM5L8'T
MV:9K/4KHN+V15# 1G=)M8 $GD<'I7<ZAX6@U+PNV@2W]^ELZ"*29)%\V1.X+
M,I'/L![8JO#X*L_MT-YJ&H:AJDMO$\5N+QH]L(9=K;5C11DCC)!-#W=OZT?Z
MV!7LD_ZV_P""9P^(,<=M%<2Z7(EO)I*:I&PEW':2H*D8XQN&3Z FGGQ?!<7&
MBE]-DF%]._V:>SO$EA++'DX96&[^)<$8RI)QQ5FQ\ :=8-:O%J6KF2TMA:0.
M;PJ4B# A<* #C&.0<CKFHC\.K!98)XM4U*&XBNWO6EB\A3),RA"[+Y6WA1C
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#F?$?_ !*=7TWQ #B*-OL=Y_URD("L?]U]OYFNE'2H+ZS@O[.:
MTNHEEMYT,<B'HRD8(K"\+WD\4<V@:E(7U'3 $\Q^MS >(IO?(&UO1E;MB@#I
M:YKQCJLNC:'/?C6+72XX58B6>,/YCX.U "1UQVYKI!T%96J1ZK*!%816#PR
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 -()Z5S-]H][I-Y+JGAY59I6WW6G.
MVV.X/=D/1)/?HW?UKJ*;MH S])URQUJ!WMG=986V3V\J[)8'QG:ZGD']".02
M.:T00:Q]5\.P:C/'>Q32V>IPH4BO8#APN<[6'1TS_">.XP>:H#7[W13M\26@
M6(<#4K12\)'^VOWH_P!1[T =114-O=07=O'<6TT<T,@RDD;!E8>H(ZU+GG%
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M\ ?ZUTFWW-&* ,G3/#6FZ7*;B*)YKQAA[RZD,T[_ %=LD#V& .P%:P&*6B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>ex4-13_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-13_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "" (@# 2(  A$! Q$!_\0
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M&&*VA2&&-8XD&%11@ 4L44<$*0Q(J1HH5%48"@= *?0EU8YSO[L=$OZN_/\
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4M%%=9\^%%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>ex4-13_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-13_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "J *H# 2(  A$! Q$!_\0
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M.3VBO8/JDE!3;5FK_E^=T;-%<[:WUZ-<5;FYE\B:>6&(*L3VS[=Y"H5/F+(
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MQ!IEY?:KILUM#OCAQYAW 8_TJVD[G^[&Y_#U(KHJ*7LU:W]:%+&U%/GLNO\
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MEA8?8?M/^EW5QY\[3_Z1)O\ +W8^1/1!C@=JMUHO,XI))VB[H****9(4444
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M,?6BZM</9S4N6SOZ/_(L44R*6.>%)H9%DBD4,CH<JP/(((ZBGTR&K:,****
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)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>ex4-14_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-14_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  9 !\# 2(  A$! Q$!_\0
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:E4?* .B+[#)^I-=?'_Q[K^'\Z#]S\: /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>ex4-14_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-14_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %Q KP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"^I?$GXI^-_$?@7P-KOC"\\7^.KWQC\19_#.N:GINA^'[&TT+P1_PE]]"%N
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MGX+_  9^!OC7X3^ +W]G&[\=:K\4O 7@_P 7:3XO^.O[75DGP\UW2/%/B?\
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ML^^(?AK\,_VBO&_P@\3?";QUJ7C[X+^)M.\4Z?X"^'\'@77K"Z\->!_&6O\
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M)(()KC;GXY_!1PGE?&7X5 ACD?\ "P_" R,#CG6!P<<X[=J^3?VR?V@?![?
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M4WSXK*^'\"G@,HPN+Y8PB\=3P5!5<RG&*C4S''8^JG*,Z<WS_P =?VA/A?\
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MA'_Y<4?\+V^"'_19/A5_X</PC_\ +B@#U6BO*O\ A>WP0_Z+)\*O_#A^$?\
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M@F2&YMY601SQ,X!T=%%% !1110 4444 %%%% !1110 5R'CKP-X3^)?A?6/
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MH4_>H0_U;KVC*322IU+\L4N9VER?1X7P:R/(\,L#'Q[X>P%/.)QH8_+^&?\
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M^(V?!C_YBZ^OZ* /D#_AWU^P5_T8_P#LA?\ B-GP8_\ F+H_X=]?L%?]&/\
M[(7_ (C9\&/_ )BZ^OZ* /D#_AWU^P5_T8_^R%_XC9\&/_F+H_X=]?L%?]&/
M_LA?^(V?!C_YBZ^OZ* /D#_AWU^P5_T8_P#LA?\ B-GP8_\ F+H_X=]?L%?]
M&/\ [(7_ (C9\&/_ )BZ^OZ* /D#_AWU^P5_T8_^R%_XC9\&/_F+H_X=]?L%
M?]&/_LA?^(V?!C_YBZ^OZ* /D#_AWU^P5_T8_P#LA?\ B-GP8_\ F+H_X=]?
ML%?]&/\ [(7_ (C9\&/_ )BZ^OZ* /CYO^"?O[",:M):_L0?LA+<Q R6S?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!&6+8MV^;+2.-@W+QE@<8!JR?]4_^])_Z,:OJI*WL]+-UJ=[-M7Y'>S?G?\
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MUE88,46IW<\3W%LLX2Q10&/\V/\ P33_ ."I_P"PU\ OV -5M]=_:"^%>O\
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M9[!)IM \)Z1J^MSVLUMIEZD7\?WPW\.?LH_LX_L;_'_P7K'P8\)^#/$VJ_\
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M$))WK4FY1]O%I<L*7M83I1E5G3=25.K.DITJ-64/U(^ ?Q]\'?M*? OX/_M
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M\7O!G[-W[+H\+^.O$N@^)OVF_B_XF^,8_9[76;>:#7+/PEX ^#>J?&74-/\
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M(/#MI>>$]-\5$6QU:T\-^*M2T.P\2W^B@R$:?<ZQ';7UU;L;B6W#(S)_/[\
MO$\_P^T/]M/X%?"O]O3QY^VS_P $O_"/[%WQ)\1Z9\<?&OQ.U.Y^(O[)GQ?T
MN%++3?@1I/[8OP[E\%Z_\0[#6-'N6N?#OAB+6U\9?#_2M%L_#%[>6J".W\3_
M  Q\._CS^S%I/[''_!%36/VI-8^$G[2WP'A_X)]?'/PMXC_9,^*?QR^"GP6T
MNX_:*\%^(O@AX-L?C-:^(?VJ/BO\'_V>O%/Q<^$-P_CGX:)HOB_XD^$_BO\
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M[-S.$7[2"2J*I1JQY9S4X55%PJ?T>>.+6_\ V>OBK\!_@[\*/VF_&FA?$/\
M:&UOXD:=\+/@Q\5[:W^,?A_4[+X8_#S6_B%XSUW4#J6H:?\ $3P=\.O"VGZ5
MI&D7^I^&KZ=8?%GCKP+X8O6AE\36=[9^QC]H[XE?#.X:R_:6^#VM>#M.LY"+
MGXP?"FTU+XD?!V>P0(IU;Q'9V^G#X@_#:-F+3S1ZIH_B7PSI-JDDVK>/K?8T
M2?RD?LH^!?@_XJ\1_P#!OE\0?VI?AGX4^)EI\-X_^"I?[)OQ&\:?%CX,:KXW
ME/Q(^'7C/^W/V-O@Q=Q_$[2?%GCK5_$7ARR\,>.F_9P\%W6J^(O$^B^++#Q1
MX<\$WMWXP&O?;;MEI?P/^#/[+UE\$-3\ Z;9_%7]EC_@X#\2>)-$^%O@3X7Z
M]X@^(7P'^ OCS]H#4;GPY<^&?#W@SPWJNN^#/ OC+X4SZ7I?A*?1+?2M!\7:
M/8V^E^'7U,Z(PM\(X*>&:>&Q.+]W6$,2XJ,WIRQJJ+J.SDK246VHNRNTT_HH
M\6X'-X.EQ3EV SW#4W&4L9@U2X9XCI4I)RGB:?$658;*9YE.C&,JL*?$F58U
M5I)4L7BZ5*ISQ_M6T'Q3I/B[0],\5^$M8T7Q+X5\2:;!J>B>)M O[36O#^HZ
M5=VQGMM2T[6-+>\L-3M9M@,<L%PELZR@K<,RJK;=C/<J+?S!M+FX&!:RQ1S^
M4I"R@LJF)#]]2?-$L?ELDC;B3_$W\"/V>-+^(_[-'_!37]JW]A?QQ\6?$W[8
M/P(_:$_;6\%_!5/AU\2M?^(GQ'UW]F[XC>)=&FUKP/X4\-_$J\^)E_JOC'7/
MA[HVJ:]\'];T60_$+Q5\2['2-.&M33W36\OVO_P0C^*G[%GC#XI^.O'7[-OQ
M5_:DMOB%\7_AUJ$/Q;^"7Q'^'O[)WP6_9TM?&W@?Q/X3D?QYX;\,_L^?LD?L
M>Z=X_P#CIJ?_  F7B#3%^(-IX1NO%WBCP%IVJ-\6+"PCL?A1%'M0QTYMT<52
M<)MQ4)Q;E1D[2IIJ;IQM[-KFGSQ3Y6I1<N9\L9GPE&.&Q&<<-8_$9MA\%A'B
M<VRKZE]6SO)<+*=.?/CN&Z%?%1S;#NC4IK$<6Y+B<QP63U6X9Y3RJM.E[;]X
M?VN?VMIOV8K?X(^'="\ /\3OBO\ M&?%K_A3?PC\*:GXJ@^''@V[\3V_@WQ;
M\0M4OO'GQ)F\.^+K;P1X?L?"?@S6Y;:ZC\-Z[J>KZP-,TG3]+D>^FN+7T;]F
M/X_V?[2?P&\"?'"RT"X\+6?C>W\1,VFR:KH_B+3+"?PQXAUWPQJ%]X>\6:+<
M3:-X[\$:K>>';O6? OC_ $'.D>//!^H:%XNTRULM.UB*WM?YK_\ @J=XAT/]
ML+XQ_M??L=?M&?$#2_A%XS^!GA7X'?&C_@EQ\.?'GAB>3P3^T3\==$M)_%=[
MXVET-M%UV?\ :9O]:\56-U\"[OX5Z79^(]$\/^!M<U:6X^'FJ^*;T>)Q]6?\
M$O\ X@_LJ_'+]HOX@?M.>-O@EX.^!O\ P5(^+.BZ%\)OBW^S>?AIKFC?&+]E
MGX:?!#P'<^"=*/B6YUCPOIFJZ7X.^(C^#;*]U#XXZ5HFG^"+_1O$?[/W[.@U
M?QA>?#;P?XI\2=23?-=62NHR>BGRNS4.MT[Z247I?JCY5JI%1E*E+V<XTZE*
MM%PJ4JE*K;V=3GIRE[.,Y/V<8U;3E/V=HJ%?#U:GZ@_M%?MA>)OA9\</A-^R
M_P#!WX26GQL_:$^+O@WQO\4]-\(Z]\2;/X0>%-"^%/PWU+P[HGC'Q3?>-[OP
MAXZDNM4AUGQ1HNG:%X9LO#%U+JEU>B74=6T338I+U/4OV9?VB+G]HWP!XD\<
M3?#;QE\*-0\*?%OXN_"'6O ?CUM"NO$MEK/P?\>:SX"U>_-[X1U+7_#U_IVK
MWVBRZGH]UHFJ:K:S:9=6L!G?4FEAB_,C_@J/X$_8D^+7Q0^#_@_]K.^^)_[,
MFL_#_P"&WC;XT?!#_@H[\'O%/BKX-^(OV:?%5AXU\*>%M0\'1_&K1_#&K>"?
M!H\<V>LMJ1T[XJ:T?!_BC^R94TGPY/XABT[5+#\N?C;\;OVKM6_X)[_!G7_V
MQ/'_ ,<?C'^QKX%_;H^)'PP^.?[67P!_9T^%&M_$#]H']AVR^&_C3P_\#?VC
M_B=^SG\<OAE\;OA)X\^#6K?%75_#\OQ5CN_A!XITCQCHFB^%?'?A2UUOQ%;Z
M-J'B5 ?V"+<W6%7;EV+2["N+@0?O=NZ+";<E4$;2+%N0F*3R;H%3^=W[3?[9
M_P 3_@;^VG^P+^S%HGPZ\':MX$_;+USXV>&M:^)&K>)M0'BGP3K_ ,*?AI>^
M/H-/TGP+;Z=966HV5[ =,GN=8N/%%P50ZAIG]EP3)::E-_.[9:3^PW#\'/V0
MO@W\,/%_Q^_:#_99^-_[4?[2/B#X(^(/^"E7@31_A?\ L#7'B&X^ ?A]+CPY
MH?[*_AC]F7]G^X\=^"-/\1>(M5O/V0_@1X'\'? OPC/\?M+^+7BCX;_$'3KK
MPO\ V3J6#^SA\;_!T'C;_@VP\%>/_BFEUX^^&OQI_;Q\#>(K;Q;+XBT_7-*A
M/AOQQ\(_A]IUY%XPN->\0Z9HTFJVFD^ /#5GXL\3ZQKNG:A!IO@R_P!?U36=
M.N7H _JI_9N_:6U3XU7'Q0^'GC3PQIOPZ^/W[/\ X\M/ WQC^'>G:[+XFTI+
M/Q#HTOBKX;_$_P ':N^DZ?>ZQ\+OBSX&GL/$WA35+K3M.FLO$5CXT^&E_>3>
M)? 6N37!^VCKNE>'OV6_VDM3\1ZWIFBZ=;_ 3XK_ &C4-5OK'2[:);OP1K=I
M%;RW5[+%907$MS=VUE:^9/B>YGMH03+,OF?FG\:K'X0:I^WA_P %2=6^/,<=
MY^R7H/\ P1X_9J\'_M?V.EQ>+$OKZSO?BC^WWXCU2WDB^&)'Q,U'7;?X$R:O
M>647@G5H_&MOH^O^&+6TGM]7O=%EL_T'^/VF^"+S]ASXJV?A*T@O/AX/V4_&
MJ>"[6^M]1N%7PC:?"B_E\*+.OB'S=4DN+;3X-/F$^J*NIQSQJ;PF^CFFDSJW
M]E7Y;<WU7&VO>U_J.+WY?>MWMKV/5R#V?^L?"WMN=TO];N$?:^S5.53V?^M&
M1>T]FJK5-U.6_)[1\EW[VAQGP;_;W_8<L_A-\,=.N_VR?V6+34=,^&G@6WU*
MPN_C]\*X+NQN;?PEI$-Q!<0OXH#1SP31212Q'F.6-T8!@0.N;_@H#^PEJ5U&
MEI^V=^R?<122.3=Q?M'?"2%K.2V1I)4D#^+$(\J**6YG@G='^SF.X"-$P-=1
M\%/V??@&_P '_A==/\#O@^]U>_#/P+=7ER_PT\&-<75S<^$]%EN)[F8Z*9)Y
MIY9))9I)6=Y)'=W9F8D_%G[0?[,'P G_ &XOV3;6/P =)T7Q5I/Q87Q;X0\&
M>*_'/@;P'X@'PZ\)GQ1X377OA[X+\3:#X%U:2QU76;VYU-M0\.W$GB;3[J'1
M_$SZSI%I8V-MY=:M6PV'P]2C*DJLI4J<O:U/9QE&K@\J@E3DY0_>1FI3Y92M
M.%H[J1]+DW#^%XHXFS_ 1S">5/+*/B!Q3'$5<L>;J>$X2I\3\19CAEA</G&2
MSIXNMD^"Q4<'C/;XO#X3'052OE^+PM50C5_X*/\ [4/[(?Q5_P""?/[97AS0
M?VH_V=?%%]J7[-WQ6U71-/\ #WQZ^&5W>W>L^'_".H^(M"2WL]/\37<VHVMW
MK&EV+7%M"L\&I6+R6DQ:">0#YKGU+_@EC=?#G5O"'Q?_ &T?ACX@\3>/?@?\
M,?A?K>M?$C]JWPOJ_C[PCI<^_P 2:;X1\ :@^L/JOP]?1O%>GV'C#2VL]/-U
M:^(M'T6_O;SS-.TR-/M7]L[X8_L@^ _@+XUN/$7PS^ ?PQM_B5I,7P;?QI??
M#OP'H]WX</Q3C?PKJ6L)J=MX:/V"7PGX+O?$OBJQ_M*]TJPOKW1;+2+S5=(-
M]%=-\7?L_:!\'/BW_P $X/C?X<CD^'7C[XC?LLP_$;X/CXX_"34K3P[XI\3:
M?\&8]+\1?!#X@V?Q)^&^I:5XXMH_'GPXM_ _BFXG.NWL?B);G4+'Q _B.VN-
M4CO,,XQ.7K,Z&'Q>78;,,2\HQ.(PRQ4L%]3C5H<\Z]&7M<15?MIX?VG)*-!T
MU%OGJ<\DI?H?A7E'%LN#<'Q#D7'/&O".1XCQ.X<R2@L!EE=T83XNS#)^'5Q;
MAGB<BR[Z[DF&S+$9#E7$.7Y5Q5A<Z68T.&*U&G'(L-B?K7Y<^+M"_8I^#?BS
M0+K4/VK?V9?VTO"FE?$[4O'^F^,/#?[7.A?"7]L_PR'TZZ\/Z!90>)UUKQ%X
M7^+/A[0M%O)M+LO#FH3^$3'Y]U-!*LETSK]N_LY?M#?\$C_#-SIOQJ^$?[=/
MAG3_ !?I'PP\4?#GPC\.OC3^T+#X<US1+&6S\0W$/A#6/AEX\ETK5M2A&I>?
M/;ZI:V5Q:S7(%Y9SSP/',_Z?_LW?!30+?]G#X)WUA\-+?6-1U3X4^!/$L_B7
MQI87OQ*\5:EK'BCPUIFOZC>3^,_'VI:[XH;S-2U"XGL;5;VVL=%B,5IH&G:/
M806UE;^%?M%^"_$,WQ/_ &6/!.D^'],^$,WQL^-6L^"?%OC'P_\ !#X$>(_&
M$^B>%?@)\9/B&]GX?N_C#\&_B1X<_M/4-0\#P-;7UQIINU_M+RFN7M,P-Y$L
M-EU"%/.:V08?#UZ^%PE>EALMI82=3$TL3BJ&#A"'U14X<]*IB(U*_P!8G37)
M*4H2J3?LS[]<3\;<19IQ=P3'Q'Q%/+*];C/*\TJYKF6#IX;,N&\NRW.,XS>6
M*X*R7)LPEA*'%$LBS:>991DU5XBO4QG)F=3+E/'2P_\ -W\=O'?[%?@7]AW_
M ()I_$3X:?&7X1:O\7=;^!W[!GP>_:5\"^#_ (M^&KO4+VUT/2OAI>>'?$7Q
M$\"KJ\9@MO"?B+P=IT=[-=Z59SV=NNEPSW"0:5"%_<C]H_XM_P#!-OP9\(?V
MNM5^'W[?/PN\3_$CXTP:-JGB#PEJG[4'AWQ?H%QK?ASQIX0O+*[TOPK;ZE-'
M9WGA_3=(ATG2FTZ-IK?2(_LL,<C[7'+?'SQ#_P $_P#QY\)?C)\/?BM^RK=^
M%_@S\)?B=X9\ D>%/"WPB^&5OK'CCX?_ !9M= \"^&_!OBBT\56FD>"M5E\9
M^')M0/ACXJ>(?#=]X9\+P6$GQ6C^'VE:CHLOB;[4M_V]?V0_[.^"OC+3?V>O
M$T7A?X\^+M"\#VWBP?#CX)6.B^%_%/BKQW!\/[3POJNHR>-G@^(5\WB:6UGU
M!_@I<?$F"U\,3+XLFO)]'\K49>Z&9\,T*DJKQ& P6/JQH*I@Y\WU^E[3%RP5
M-5XJ*A"4ZBYE.%6M&5)M2G.IS4WX?$_#'CQCN'LNR>>1<=Y]DV%PU#*,);$9
M#BJ$LMPN38/C+"9.TYXFIB<7A,MR[!XK+Z&)Q68XI9;E6"RQUG+*<#A2K\2/
M^"J+#XT_LJ_"#]D/X=?!?]M/PI^U)K7Q%^&GAOXQ^"_VM_"_AKP7X2^,7P9^
M#VH_'OX@>!_&*Z#\*OB8BPK\'+71_&7A;Q'HNHZFVJZIKB>'M=T7PK;QZ9K&
MO?L!'<R2)^Z!N$E+^6R1@I*"[.LD+HS^8AC9'=\&!\_N95RR+_(!^V7^V*/A
M?^VI^P+'X[^-_P -O#?Q#^ __!3/]J0>*XK'PIX$\ ^'?AM^RUKW@W0?@OJ'
MQ(\6^%YK)WTOPO-X(O\ Q[\)='^(WC+Q;?G4++4?'7B*QU:;Q3X/T+_A6GWQ
M^WS_ ,%#OV1_V@OV;/CCHOPU\1ZA\>O@A\./B+^S3X9^*WQ1^#7Q:M_"OP2F
MU;XJ_$*&:T\'?&'XN:+\-?BS;M^S5:>'="N-0_:3UKPQX;\9WECH%U:>%;W3
M8DUI[^P];+<XH9G*I&C&LGAZ^&4G45+EG[7^TXQ<%2J3DDI9;74_:*#M*DU=
M-\GY#QSX;YEP1B,EQ.+S#+,;A\UQF>82@L L:W0GDL/#W$UG.KB,IRG"XREB
M:'B!D]?"8C+GB</*V88>K4H8C#2HGWS^U#=_&73OVP/V3KKX%Z%X%U[XB+\'
M_P!I2*/2_B5J>N:/X7/@R\^._P"P19_%&_DOO#UG?:G%K>E_"IO'&J^#83;O
M8:AXUT_PYI>HRK87]T1]N?%SXQ> /@1\+_B!\9?BOXKT[P;\-OA9X;U?Q;XZ
M\3ZDK36V@Z#H-H;Z\N;N&T5[A[JYMFADMK." W-R\]M;6T#7%Q$'_P ][]I3
M4_!7P?\ #GQP\!:WXU\$_#OP[\,_V]G\8_!CPU\#--^)GP*^ N@_#_XD^/O^
M"1GCGQEIWP8^&VK^,_%'VGX+7_@Z7X[>-H?"R-K7PG\4KH?BWXLZ!X#\(#PS
MX8TO0_[&O^"O/[//Q&_;0_X)P?'KX5_L\RZ?XG\<^(-#\$_$SX>:.EU:MI'Q
M&'P[\1^$OB9IW@;1]2BU&Q@CLOB18:$WA^PUAYKK3!<ZENN+22SE)K;"U/:5
MLPM]C&N+UO[WU;#2DMELW;^M?!SNE[/*.!Y^];$<(QK)2BHOD?$G%$(/1OF4
MHQ;B[15DTDTN9U[_ /X*%?M&Z9\)-2_:4U+_ ()_?$NT_9VF\,6/BSPU>I\7
MO \O[0A\-ZU/91Z=XO\ 'GP";PTMGX%\):9I=]'XM\87=M\4/%WB7PEX32?6
M;WP=>BTO[*T_4V*_N)K*.\BCW"[M[>:WROFQ(US%#L+O'Y3?9(V8SRS2!)/*
M,N8XF2)'_F4_;Q_;T^"W[4?_  3RUWP5\%OC/\?/@)_P44L/#?@.T\ ?LI_"
M[XE?M"?LV_MF>$_C2VK>&?#VO^"-3^$/P[UOX<_$#X@:'8V5]XCM;*7Q3X8\
M0?"S4K(VGBK1&M+FUM-5MOSU_P""L.F^%]"\6_M[>&O ,?BW_AH?]C/]G?\
M8X\>?"'X@_M0>./B]^T/^U!X<T?P7:6GQ!U#QW_P3EFNI-*^*WP^\'V&J:^9
MOVM?VJ_'WQ^^,-IXO^(W@[6/AI\1O@\W@_1M*N=4[#YL_M[CN;H[Q/!);A51
MQ(_E&)E97+8D21_*\H1EI5G550NB)//EF0:[FVJR1R,!(D<VR"6;RP&F69U!
M2 R!3$0&A$V2R%8721'/\+/[0GC;]C[Q9J/_  <9^/=5^(?A;QKXC^'WC_\
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M4<G@8Z\T 1I;P1*$BB2)%"JJQ#R@JHJ(B*(]NU%2*- BX7:BKC  IXC4# W
M<]'<$DMN))W9)+=6))()!)!(+Z* (VB1E"D-A61P!)(OS)(DJDE6!(WHI8'(
M<;E<,KNK.VC!&6YSGYFSR<G!SD=>,$;1P,  4ZB@!GEKA5R^%*D?O9,G:RL-
MS;]S E0&#$AU+(^Y'=6#&IZ[LX89#N& <AF 8,",D#&",  +@  /HH C:)&
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MFIEV=XS.:68Y:J/$&?YE1^KYCE==X+,+Y5>IA:OLZ56G"M4C4_'BW_X)_?\
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MALMR#)J-7!Y'E3C1A2IR5'!XBKC,QQ%*E3Q&.S?'9AB:E2<<75='ROQE\-O
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M._/V;BG?8DP"B0JO.5%M8]QGG-M[CWQCWKI-B?W5_P"^1_A2&.,]40_55/\
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M*74I+E/#FJ&"&Y\-:W'$VF7J74=K=26TFH:9!=?)^J?%#Q7\+_VV?COXZ?\
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MX->//V@]4^+?P]_:,_:QMKWXJ_$KQSKFJ?L\:;\,?^$+\=Z/X2^&QT*XFM_
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M(=,UN.+4M*L?B=\2_%FIZ;X<\,>*[_198_%^B>!BUYXB\1: JF'3EL[N"6Y
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M><AF -*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWH72=!L(+>RT5;8/$X!^Z@D1CA64G!. >< *3QU. Z$XZ!U_O#,374"8WR!
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M(HG61$0.1'M98H<B5 L^"AV>;L1WC5&(!=HHHH **** "BBB@ HHHH ****
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M?V06&LZI^T]XYCCD2V\5_M+?$/3+4M]R6U^&TMK\,[6ZB).6BOK7PK#>QOM
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M,U#Q!XET;X,_$[QY\-/BCX$^-$7ARQN/-UW1/@E\0_ ?B&Q\:6%CIVK:Q8>
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M&MK=/[/DF-U%>?LA9VTD#,TAR2BJOSAR20'E,CB.-I':5G(9N .(TC5BM7Z
M/Q ^+7_!&N7XF:G^T=%:?M1>(]$\+?'OQ#^S/XMT^77?A?HGQ#^,7@'5/V8?
M#_PLT'PAX6_X7KXF\6KXG\8?"F_G^&<GBZZ\":EI6FW4/CSQAXL\6MXDN;_Q
M#XCCUWT+P7^SQX^_8-^+O[;/[7^L?%#Q%^TOK7[7/B/X>WOAW]G[P#\#=.\(
M^*[GXD^#O#G_  B?@GP_HOB_3_&GB6PDL/$.B:8EOXIU_P 2>']!T;18H-7\
M4W=[I]K;QV"?K[6=>VDL[+)$^'C7:B[C'G<6W[V4,LJ'Y'\B>.6!GB4M&V:
M/S._9"_8[^,'[-GP<_8]\$_\+]U+3;;X+Z;\?/&O[3?PT\+>$/#FM>$_VDOC
M%^T)J7B7XD^)KW_A(]72Y\8>!K'P!\:_%WC7QEX2M/!]X&U:6Z;0-;4:=8Z<
MJ]3;?\%$]+$$9/[&7_!1,F51< -^R#XUA=%N?](6*2(WY,<L*RB&9&PR2HZL
MJD%1^@<=E,IC $4,:RO(XB8@OYEQ+/.RLJ1L'O9Q!=79D:8./.ML'S'G:W;6
MYAA5#M0\LRJ PWL2SL79=\CNQ,DCN2S.S$DYH _/C_AXKI/_ $9C_P %$O\
MQ$7QI_\ )U'_  \5TG_HS'_@HE_XB+XT_P#DZOT.V'^]_P".)_A1L/\ >_\
M'$_PH _/'_AXKI/_ $9C_P %$O\ Q$7QI_\ )U'_  \5TG_HS'_@HE_XB+XT
M_P#DZOT.V'^]_P".)_A1L/\ >_\ '$_PH _/'_AXKI/_ $9C_P %$O\ Q$7Q
MI_\ )U'_  \5TG_HS'_@HE_XB+XT_P#DZOT.V'^]_P".)_A1L/\ >_\ '$_P
MH _/'_AXKI/_ $9C_P %$O\ Q$7QI_\ )U'_  \5TG_HS'_@HE_XB+XT_P#D
MZOT.V'^]_P".)_A1L/\ >_\ '$_PH _/'_AXKI/_ $9C_P %$O\ Q$7QI_\
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MQ]HXQE4HRH.]2$H3DI3YHU9\LM-%&='V<DM[MW5[GYY?\/%=)_Z,Q_X*)?\
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MB3^RRRZ)JI73KMEG+;?4#?%%#/;39)E7:F'W-&&*QQGY0TDI 2-6V*7#KO\
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MNQMO#<VOZ'JVHZ;*EIX?U'5-2T/4)-+FU1=.>\L%N?*-)_:1A_9#TSQ/X/\
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M*0IH]I=7LL^KZCI[(EO)K&HZK=HOFW<ZG\?_ (A3_M*_M6?&+XX?\$U?VS_
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M$AURRA71M8T&6"&[\9Z_IR70TBV4VMFS7$99NR_X)6_\%+M)\;_!+X!?L_\
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MS3P?&C]@#8J1VD;.$_8!^&,5JHD$$4L+R>9*JE;JT@\U5CM'LQ-<B;Z6O?\
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MZ!\;]+^+'C[XH>%6TRTF\%>/_'?C3Q5KOA&407?A'5]+G2Y0@'YM_$KXM?\
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M]?!WB&?5/",%W>7LEOH<0NYUDZ?5_P#@GS^R%K?CGPG\1+OX-Z9:>(/!FJ>
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M]&U;X=_L(?L/_#_Q;\#M>L-2@DT:YO/"/B?Q%I>K):"^\<Z_;:@YM_//B/\
M&3]J;]H7]H#_ (*!_"C]GS]IG3/V7]2_8*T#X:V_@GPU=^ ?A'\1-,^,?C#X
M@_!:U^-;>)_V@[/XB>$_$'B_P_\  C4SJ \!Z$OP@UWX:ZU)<>&?$^NCQU-<
MV:>%H_LG]D3_ ()D?L+?L%7OCS4OV0OV=/ WP2U/XF;4\:ZMHC^(?$.M:Y9+
M/)=1Z++K7C?7?$^J6'AFUNY3>6'A31KK2_#=G=!98]*8 *.C^.'_  3[_9/_
M &B_'D7Q+^+/PO?6?&LO@ZW^''B36O#OCSXI?#7_ (65\-8;^YOF^&7QHTKX
M6>._!.@_'#X9%[V]\CX<_%W2?&G@BW>_U'_B026VH7=I* ?D%^SC^V3^W;^W
M#^U7\._!OA?X]?#[]FOX9?%W_@EK^PW_ ,%'?#7@[1_@!X>^(&O^%M4^,_CZ
MRTCXI_##Q#KOCSQ5-?\ C_0M>MO!?C32M&\?>'[/X=R>'_"WCOPPL7AFY\5>
M&Y/%/B;]*_\ @I!X_P#%'_"G=)_9]^&OP\\=?%CX@?M0:S)X O/ /PPU3X4:
M7X\NO@3ITD&H_M'Z[H$WQE^*WP4\ I,GPWE'P_AO-7^)OA>?2O$/Q-\+ZSHY
MUZ^L3H5Y[7X7_8=_9M\%?M+^(?VOO"?@O7= ^/\ XF\ :!\*=3\3Z?\ %/XQ
MQ^$?^%9>$]+M='\+^ +#X/-\0W^#>C>$- MK&#4=,\/Z'X"TO3+3Q7/JWC>V
MMH?%^N:KK5U<U_\ 8O\ @!XH_:8\$?M@:YH'C2?]H+X<^&KSP;X.\8V'QI^.
M>BZ)IGA/4[6YM]8\.W7PSTGXEVGPIUS1]9>Y6^U>PU[P1J5MJFJ6&B:SJ4=W
MK/A_0]0TX _&O_@ESJ'C#X'_ !>_X*(?\$Y;[P#\5/V-K&ZO-6_;I_8;\!^/
M=5_9F\7?%?P+\"/VH-0\2>$OBAI/@[0/A+XX_:*^!EIX1^ W[5GAG7=2\':%
MKGBOQ)J=S:_$GP7#XO\ #;:9?+H]WY7^S!^V-^W)\7?V=/\ @BM\4/&G[37B
MS1_&/[6WQ6^/GP,_:6T_1_A#^SSI_P#PEY\.ZS\;[3PQXTM[&]^"^IW'@'Q]
M\/5^'FBZ<;'18=*\#3S374'BCPKK-ZSR']O/'O\ P3X_9=^)G[3_ ((_;(\8
M^&OB1>_M%?#>'3++P-XZTS]HO]I3PSIOAC1M->VDF\,:3\.O"_Q>T;X60^#?
M$LMC92_$#P3)X'E\(?$UXIV^(FA^*&O+@MQ6F?\ !*K]@;2M5\(:FO[.OAG5
MX_AY\7=7^.OPXT+Q;XB^(7CCP;\,?BAK=Y=ZOJ/B+X6_#_QEXRUWX?\ PTMK
MGQ%?W?BJ3PMX(\*Z'X,'BN4>*8/#<'B../55 /Y3?A7;_%C6?^">7_!'#QOX
MG^/GB_XG^,OB'_P<8_#*\TJ\^*7ACP9J.D>#];TWXH?MGZ)J6O6T7@+PM\*O
M''C*7QIJMM<>)O%,GCKQQKD!UAIM/\%WWAWP;:V.B5^N.O\ [;_[4OP?\>_&
MW]D?Q)\>(O&GBFV_X*=_LS?L1?"_]KGXB^ O@_H?CWP3\/?VFOV9/AK^TGKT
M^M^%/!'A#P+\%/&?Q-\"W?B;5O 7PTNY?ACIGAS6=1N/#WB#Q?X4\1MIFI6&
MH_I!XK_X)$?L#^,G\+?VK\(?%EI!X(^.FL_M,^#;7PU^T1^U!X*M?"/QXU?5
MI-?3XA^%;3P3\:_#ECX=O-$U_4/$NO>%=(TFUM= \%ZYXW^(&K^"=,\-ZC\0
M_'MSXFZJ[_X)>?L3ZIJ?[1>K>(OA3K_C*X_:RUW3O%'Q_M_'_P ;OV@_B#I/
MCGQ-X?U/3=3\'>*+30?&WQ8U_0_!/BOX>C1-#TKX9^)O .G>&-:^&7AS1=(\
M*?#Z\\,^%=,L-$M@#\8?VJ_VU/\ @H?^RGJ'[17P#\._M!>#?BEKOP#^/7_!
M/>X\*_M"?$OX#^!Y_B!XM^$W[7WQ5T[P'K7PG\=>%?A4GPZ^%FA^./"U\M],
MGCSPQ\--"O/$W@+7FLM)\.^$O%4-GXRM/M+7_BG^VE^SY_P42_X)O_LH>,?V
MJ?"/QM^$O[4?AG_@HIXJ\7:I-^SYX%^''Q(U35?@M /'OPML-0\1>%_$,OA/
M4;'PAX,^,?@+P8Z> ? WPZUWQ#K/PC\0>.?%OB#5[7XAW7@SP/\ 77BW_@E3
M^Q%XZ^%3_!CQ9\,_&FM^";KXA>'/BSK-]=_M$_M/#XG^+_B3X+$!\#^,OB'\
M<;?XTP?&GXDZSX&DM;)_!,WCSQ]XB3P<=-TH^%H]'DTNQD@]*^)W[!/[-GQB
M^,OP=_:"^(.@_$;5_B[\ /"-_P"!OA#XJT_]H;]I#PK!X+\,Z^DMMXSM+7PS
MX/\ B]X?\*:I?^/]->WTGXA>(/$&B:OXB^(.D:1X;T?QYJWB;1O"OAK3=) /
MQU\.?'']M#3/C%^T7\0?AO\ MP_'#]J[]E;]@#X/?%K6OVF]8\4?!G]C7PK\
M-OC]^U/X*\$ZOXAN_P!FK]GW6OAA^SSX+\9Z#X<^%IT_S/C)XE;XH^-]:\):
MW=:9\+(O$FI>,[+Q#J%IQ^G?MO?\%&_@?^SM\4_^"C/Q$^)/[('Q\_96US]D
MGXH?&GX??"OP/^T=I7Q5\8W7QCT/P/)XS\%:?\'KCX<?\$_/V3[^+X5:#IL6
MI6?QE\+?$/XD_&KXF^#/#6F7'BVR^*=NGA#Q#HWBS]9_@I_P2@_8F_9YG\%?
M\*D\%_&#P_H7PYU75=:\$?#K5_VO/VR?'/P8\/ZEKESJUWK%W!\#/'W[0/B?
MX/74FIW>N:OJ-\+WP3<176L:E?:Q+$VH7+S57^"G_!(/_@FU^SKXP^,?CSX.
M_L@_!_PIXG_: \.^*O!7Q?N[S2-5\8Z=XN\!^.'ED\9>!(_#GCG6?$OAKPWX
M,\7.\4?BKPIX4T?1/#?B&S@@L=1TB6WMK%;, ^'-*\%?&OP)_P %:O\ @G?!
M\;/VEI/VF=3\4?L5?\%!]<L/%UQ\.OAG\-+*QU34O$_['MSXFTCP!H?PRL[2
M"3X32_9M'U+X8Z7XCO\ XA_%#2-'FU1/&WQ7^($TEMJ%G[I_P4RC;XX^(/A=
M^R-#^SM\5/VI?!FLZ;K7QG_:3^'WP5\2? +P[XVTGX606.L^"?A[9OJO[1GQ
MO^ ?@^+1?'7CV]UC4)=2\+>/+WQ7I#_#*-)?#4^C:U=3U].?"K_@F/\ L0_!
M7Q;\+O'G@#X'VR^-/@CI_B[1O@YXJ\;>/?BK\6->^%F@>.+C1[G7?"W@'4OB
MOX[\;3>%?!MI/HEI-X.\':,;/PS\.;B[\0W'@#2_#<WBKQ*VJ>C^"OV*_P!G
M_P"'7[0OQ4_:K\(:'XZTWXZ_&O3;32/B;XKOOC7\</$N@>(['3;6WLM%BC^%
MOBKXCZW\(-&/ARVM8X?#0T3P!I\7AR*?5(-%BLH-9U:*\4HJ<)4I)2A45I1>
MMT[)J^\5HMG%^9U9=F.-R?,<)F^7XVO@LPR^M#$X#&86HZ6*P6(I/FI5\/5C
M[U.K2FYSIRM)*52:G"M3G4H3_ ']B?\ ;\^.7[*'[$7[3_[+_P 0_@#XRTG]
MHC_@GOI_Q ^!/P&\-?$.Z\'^*F\8:I8?"BW^)'[%OPB^/,/PB^(7Q&TCP-J?
MQ5^&GB/X:Z-\.->TOXC7OP]\=ZKH^N_"CP7\3KKQWH6E6GC_ +/X*_\ !2GX
M_P"E1_%_QKX5_:M^'/\ P4 ^ /P5_85U']JKXQ>.X_@3X=T?Q)X#_:(_LQ8K
M?]F6+XB_!G5/AIX,^%K6&HR77BL_#7XG? OXF?'?P=X5T>^TCXF:[87US;^(
MQ]\?M.?\$N/@E?Z'^V=\8/@-\,/$VN_M8_M9_!WXC?"KX@:]XQ_:R_:8TG0_
MB%H'Q1T+5_".MZ+JVE:M\1_%'PVTJT\(^&=>URY^#>B0^ K7PI\+]5M[*Q\"
MP?#_ $UDOK+XG_9=_84_:U^!/C'P;\4_#/B']M34? '@7P%XD^&'C/\ 9 _;
M7_;?\!_M"> /BQX5\16,5G!+X%TKX=/K_P )/#VK:38Q"'3=/USPOX)AU&%Y
M+:[U<VM_>V+^?3A5R_EI1I3JX.FU&E!/FE2I\TGRRG*]2JE>5Y.I[356<WR1
M7UU2?#_%[598W!<*<4UZKEB9YM&GE_!N?8FI&_-1QF#PWU7@O,J]?E<:&;P_
MU2SROB9VS?A+%SJ0K\!XP_:5_P""NWP^_9$_:0_;+3]I[]B+4_A=JO[#/Q&_
M:7^ AB^)>@?M->+=/\>?#?3M(^(^K-\'-(\#_L6_L/\ AS4OA3JOP]FUCP1?
MV/Q)\7?'WQ%X \=W_@;Q+J'BOQI8VVI>%/$FU^T?\</VR-+\-_$;X.^(/VJ_
M'NI1_'__ ((P?&#]K%+GP?\ "CX0_#O7/@A\9/A,OP8T+4H/@SJ%O\/['Q/;
M>!?B'I'Q,\21>*-"^*5UXM\<^#+VTT[4O!7C7PG+=P:/IGO7P*_X)Q_\$8GM
M?CY\(_"'[(OAWX">.?VCM ?PA\<OAE?>*OC1\*_BAXB\+R:Y8>)]7^&GASQ1
MI_Q#TS6-,^&?B/6-$TN;Q/X&^#7B?2?A_P"/])L+*P\3Z#K&A1QV$?W+IG_!
M-/\ 8KT[QOX!^(1^'/Q#U7Q/\-?@M)^SGX1?Q+^TM^U-XNT"U^"%U8P:3?\
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MJ%-1_"7X/_&7]J/]MO\ :._X-X_BU\4OVC_BY\,_&7Q&^'/_  5!O?B#X7\
M^%/V?] \.2_$O]EB:S^$4OQ#M_!'B[X8_%70M/\ ''Q4\'^)=>\*?$!)=?\
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M^(K?QS\"/V?OA[K>F^,?AMX4TKPI^S[XI\7WOANZ\2^&?&.GZ=XS31?!VC^
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M\$?VA/"6L>(O@1\?/V=?&/CCP/:^.-)\8:YX-T__ (23X<ZI8^+['PI%X?\
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M_CAJ/B_5OBG\.?'O[<7[=OQC\,^+[_Q_'/#XXEOK'XP_L]>.ULXO%L-U<_\
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M[4/[3#WMZ+.WW7NLZC*W[(4IEU/7M1DO-;U.0M^\U"_NGP P  /UPHK\Z_\
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M'7./3J!CMC'M2C@80J>TK2^L55;EJ3;<X\J?:459WNTX).[NFV[QF7%N=XO
M?V9!8;A_)ZLI>VR7AG#83)J&(E5JRJ-YCB,JHX;,LUY9SOSYQF^:RY5:5XZ$
M2V,:L"K>@?*(=X565<_+A2N[(*A3QCH3ESVBL5822(5_ND 'M\WKQTR3CJ.M
M6Z*Z7JHK90:E%1]Q)K;2'*FE_+).-M'%GSKU44_>491E'F]YJ4?AE>5WS+NW
M=_:<M;Q^6<*-Y^7O@<\_YYI0F&+;B<@C'&.2#GZ\?K]*?13N^_?MUWZ"22<I
M+>?Q/77[[I?)(****0PJO/;K.4W,R[#N4H=K!P&4,&'(PK.I7E65F# ]K%%
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M#.0&+ ,=P&5*X XP,$T);QIDXR222>0#Z C.#CM4]% #/+3^Z*/+3^Z*?10
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M6I;Q(RLJX9#*0<DG,[F2;.2<^9(=[^K*I_A& ":BBB@ HHHH **** "BBB@
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M9<2S%($,7]AL:2AU+$X!R<CV/OWZ?C08ENBBB@ HHHH **** "BBB@ HHHH
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M:%=+9:C>1>,_#OV%)[(W#C^6G]KGQ;_P7*U?P%X L_VE_'O@/]EK]FO]I?\
M:-^"/[*WC'1=)\.>#/"?QK3P=\1/$L")J'A_7OA_XNU,>!K*#3])OO#U_,VN
MQZG:Z9JT\UH\<\0%?K7\*?@A^QA^Q7XF_:F_; T+P3/\)?@#\&?!\OAKQO\
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M9FF\0>/-<L];TJ3POKUGXZ\,Z)XVFU3PI9Z7'=:M<6MV9TE^YOVV_P#@D?\
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MZXMGY^G^-M427^TFU*V\PU-W?=@TK)Z>=K?Y'\C/C;]F;]G[X5_!3Q!^PA\
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M=G!<'QSJG@O4K[PY9?!7P#I]O?IK/Q$UBT&HV\FV&:UH?M#^+?BA\/OV!/\
M@H;_ ,%2OBQX1\1>#_C]^UC\'-.^&7P)^#/B:XNH=8^ /[/FI7=UX.^"/P^U
M&S:YGC\/?$OXE7'B=OBK\8K?2)O)C\7ZMH/ARX\U/!EA*/LWX"_L>?"/]MGX
M1_\ !+K]M']K[P#KWC']H?\ 9^^ 7@CQAX-3Q'JNH0:%IGQ \9^$=!EU?5O%
M'@>)+:WU_78+NUM=:T^;5E6SL]4L[6YDA,D:5QG_  7SN7\1?LD?!'X%V7F3
MZY^TG^VY^R9\)=/@MY'C:[L/^%H:7XR\23($<G;'X=\-:K<S LX8Q EGV!CJ
MMEZ+\C-U8Q;B[>Z[=-D[_G:_^6A^HG['_P +8O@W^RC^SA\*' F?X?\ P6^&
MOANX:6&.-C?:5X5TN.\<QIE587WGMG)8MEV)<L3\+?\ !;+P;\1=<_8*^)7Q
M%^&_B+0=,U']FC6M#_:FU3P5XUT:\UWX;?'#PM\!YY/%FO?!#XF:+IT#:EJG
MAOQW;6\VGPZ9#%?:;J4]M9PZG9W,!#P_KI:00VMK;6MN-MO;016\"AMP$,"+
M%$-W\6$5>>_6J]_I^FZO:7>G:I96>H65Y;W%C>V5_;07=I>65S&\%U:75M<Q
MRP7-I<P220W%O-&\4T4CQR(R,P+%>^O?7[S\'/ _[27QD_X+ ?#OPU;?LK:A
MXY_9>_8R\1>&='M?B]^TG<:!JF@?%OXL75WH=K=^(?@U^RGH^K6]A-X?\+Z5
M=RWGAWQM\<]9M$U /%=Z)X&LFNH7U2OPY_;<_9D_;)^-'_!7WXF_\$\?V*]&
M\/?#WX!>,?V-?@O\';[XT>+?A3K^IZ+^R9\)- M-4U;QWJ'PA\0RWVF6%C\0
M_B/J&LZCI/BK4?#E]::GXO;7+JSOY5O!<ZE%_=)IFBZ+HNEV.AZ/I6F:3HNE
MV=OI^FZ1IEE:Z?I>GV%I$(+6RL=/M(H;2TM+:!5AM[:WACAAB58XT5 %&AY<
M(Z)&.$7("@E8B6C4GJ5C9F* G"$DJ 2:!J36S:]&U^31^$GQ7_X(YVGAG]B[
M]EC]DG]@WXM/^RMJW[,OQ7\*>/-.^+G]F1ZMXXU>VO\ 0=0\*_%[Q/JCZ5#:
M6^J_$WQ;X9\1:FMM>7$HM+.4:4UI<P0:?IL=MXI_P55^!OPE^!/[$?[$O_!.
M?X1Z0-%\&_M(_MT_LL?!&^TJ21+K7O$'A&P\=P?$WXL>,O%%RL4%QXB\1ZO!
MX;M[[Q3?7<5PU]J&IRWNIO)OE(_I&$:1(PABC3"X"HJQJ=J+&@^4# "(B _P
MHBJ.% '\_?[>=H_Q@_X+4?\ !'3X(-'YMK\&M%_:C_:\UV.W)\PQ6'A*S^&>
MAB[ (\NSL];O[>:&X 5[B;S%9MLA% <TOYI?>_\ ,_>K2]#TW18[;3]*TVQT
MZRM%7[+!96EO:6T/EQPVJ*D5O%'&)Q9QR('"AA'-+&I$9-;]5X!G<2,G.[)'
M.XEUW?79A<]=N!TXJQ0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **_GI\!>"_!'_!1/_@IE_P %'/"O[7?A+3OC7\%?V"O$/[/_
M ,'?@=^S;\1;*P\7? .#5_BM\)Y?B/XU^-7BSX3:Q:GP1X]^(^H76HVWA_PY
MKGQ%T7Q>/!>D:67\'-I>H7URU?3_ (D\*?#?_@F9J-TO[/7A?Q#XK\7?MV_M
M,?#3X4_ #]G35?B!J'AGX+?#SXH:?\#-<MK^/P]JEW:^)Q\)?@?X;^%'P9\0
M>)]2T#PQX*\2:=X6ET"P\'_#7P#LN_#/ANW /UWHK\!OC?\ \%B/BO\ LTZ!
M\:/"GQ4_8VM]2_:)_9]^-7[*GP_^(O@WX>?M Z7?_!ZZ^'/[9NM:EX6^#/QQ
M\!_%+QYX'^'WC3Q-X:G\>:;J?PS\6^$9/A39>(?!WBFQBN+FSC\%!?$]>-_\
M%#_^"DO[8G@7X"_MY_#+P1\,/A'\(_CS^S'\0/V1M(NO%.A?'#X@Z]H^K_!'
M]JWQSX7T72-=\(^(=*^#7@[7O#GQ9BN]2E\,:YIG]ES6?A*SGU3Q=X3\7>,-
M1L;#3+T _I=HK\:M"_;N_:XNOVI_&7[%]O\ L4^!]9^*'PL^ O[,OQW\8^*-
M)_:FM)O 7BSP1\:?B;:?#[Q[=_"O5O$?PH\.^(-0D^'JZ)\2=2TG2_B7X5^&
MM_X^G^&U[I;:?X?TS6_!5SKGG_AK_@KKKFG_ +26A_!KX]? ?PE\(/"GCKP'
M^U#\1]#BTGXS7_C;]H+X<>#_ -F*W\1:_J.I_M%? VW^'/AG0O 5S\4?"?A/
M6_$_@#3O!OQ,^(]Q+8W>DOJYL7U80T ?NK17X;^-O^"@7[=\?P)^(GQE\'?L
M3_#GP_X/\0?L5_%?]J[]F_XM:Y\<=:^('@[0[OX?Z+I'B?1O ?[46C>%?A?9
M7/@GQ+XC\"Z]>>-O!.A_#7QA\0-(\:ZAH-[X'N/&W@GSM7\1>'OHO_@EOJWQ
M1^.O_!,C]C/6?VH]'\*>,]:^)G[(/P"E\2:CJ_CWQ3\<;KXN>#?%GP*\ W"^
M+/B]?_$/P+X0>_\ 'WQ.M-0U?6OBKX9U!/'NF66M:@ME)X[^(D4C:R0#]/:*
M_BH_9M_9&_9OU;X/_M4_#*7_ ((L_!WXU^$_$7_!1#XZ_ 63]IR#X<?LAZ;%
M\*?A3\1?V@O#?PWUN'P3/J'BRS_:H\)W_P (O#'B_6I/A]>^"_!%OIG@'4[;
M0M9\,?9O".C1RVG[!_M.?\%(/VH?V1_VDK#]ER^_9"^%6OCXS>%KZQ_X)_>*
MX?VD?&UCIW[47Q4\+>-?A?X9N_@?X^>V_9NOM$^ 7C6P^'/B/7?&-WK7C#Q)
MJO@R]OM!T70M+\0W6D:QXIUKP@ ?NI17X@_M)?\ !3O]H/X*>--0^#?PQ_8H
M\1?M'?'GX3?#CX<>/?VA/ _P9F_:(\<>$=$U'XE+KUQH'@+X0_$CP?\ LR>*
M?#WB'Q7/IOA;7KZRN?C;I_P#T&:&'3HYM1M6N1!#WGB'_@H7^T'XGN/B7X@_
M9M_8QUWXS>!?V>O%OPA\#_M"^%]?^(=UX+_:1LO%'Q$\,?#SQMXX\,?!GX(Q
M^ M:TOXC:S\%?!7Q&TW6/'&F>/OB7\*!KVI:?XDTGP%)XGDTK3(]1 /V"K"U
MW5]-T*RO]8U?4K/2=+TC3KG5M4U34[ZVTW2=*TVPAGNM0U35M1G_ '6GZ=86
M4-Q=W5[?>5IL,=N7N9X@NX?B5\6/^"IWQO\ AEHG_!6:X/[-'PHU37_^"6_C
M3X:W3V?_  T'XOT_0OC'\(?BK\.[3XSZ=XDCOY/@#-J/@SXFZ?\ "[Q#H$6I
M^"I-*\1>%KKQ_>:YI%E\2;C0=.TWQ;J?C7A;]L_]L2__ &K?^"ID?Q!^%7PF
M^+O[.W[.W[+/PJ\9Z+\$M'^,/BR/7+G0O&?PDU/XBG2!H'Q+^&FG_"C7]2\7
M:7+K\'Q)U'Q)XAT9=/LM,T[1])M/&6G7LL<(!_0;X)\5>&/'/A71/&?@KQ'H
M7C#PAXIT^UU_PSXL\+ZSIOB+PSXFT+5(8[S2O$'A_7M&EN-(U;2=9LI8=2M+
M[2[FYL9TNMT$\B\UU5?B)\%?V_?&?Q>^&W[(/PF_8R_92^%5G\3/B%_P3Q^!
MG[=>K_"'Q9\6-5^"GP)^!/P5^(4>E^%_A3\)?!_C'P'\&_%NI:YXBU7Q#I'C
M#0_"GAZQ^&?A;P#%X1^'7B%O%>K>&+;7O#.EZKRW@G_@KWXZ^+OC7]CSX:_"
M#]D;5F\5?M5)^TWX2UV;XJ_&SPWX0TWX(_';]EC5]9\._%/X8^+;;1?#?COQ
MCKVD:'XIT6YV>-_#OA^XL_\ A&]3TZXT/3;K4GD\.:6 ?O)17PG^Q'^T[??M
MI?LZQ?$_QE\-[#X8>*]/^)GQH^"WQ%^'T/B)O'^@:7XZ^#7Q'\4_"7Q5%X:\
M77_AOPBWBCP[JVMZ#=3:5>:IX7T*75M"U*XM-5TJ*3[3"?Y.;S]DCX37'A;_
M (*J?!W]CG]@?Q&?VW]"_P""L'Q#T#]BS]H3]F[X"VGPRL_V3GTGX5?LMZ[H
MD_\ PU)X*MO".D_!KX5^!=3UWQGXFN?A OC%+2\TKQ1);6O@;6FU.>"8 _MR
MMO'_ (&U#QIX@^'VG^-/!^I^.O#&FZ=KGB;P;8>*-&N_&?A31]=,HT?6?$'A
M:VG.KZ'H^IFSN_[,U75((;74'M94MII61E7NX-I@B**ZIY:;5E#"0+M&!(&^
M8.!]X-SG.:_F=^"VNZY^S!_P4U_X*^?$#0_@Y<?%WXI>&OV+_P!@7QWXO\#_
M  ;TGPMX1UCXQ_%JZT+QQ#XQ\276HW+>&] BO_$.M*VL^(?$.M+%>KX<L;^\
MEAU#[!;Z:WO/PZ_X+#ZCJC_M<^ _B!\'/A?JWQJ_9O\ 'G[&/PI\'Z9^SY^T
M&WQB^#OQG\??\% /%>K?#CX(>$+;XH^-_A9\+-7\"-I'Q)T<Z;\5+CQ)X#O;
M'PEI8EU_1KKQ1921Z>0#][J*_'+XA?\ !1#X_? CPMX^L?VD/V,];\._&C3?
MC/\ #[X0_ G1_@[XJ^(/QO\ A!^T3>_$WPMK'B?2_$/P_P#%GA_X/V'Q?NK7
MX?0:!K5M\6[2+]GJ?Q#X5NXK"/PS9>*H-0CNQV?[.W[9G[7/Q]^$&K>)=2_8
M&\<_#3XH>&/VB_ GPL\0>"_B9XH\9?"KPCXB^"^M:YX?/C?]HOX6>(/C1\*_
MAOXP\1^'_!/@_6=7UH>"?$/PQ\)^*_%&J>&-2\)C1+(W]O/( 7O&G[*/[?\
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M^J(! <@C\_\ Z]+D>H_,59$YN3N^UNW5O]6?SW?M*_L%?\%6?VNOAI_PI_\
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M>+O"US:ZU+<[+RSU2SN8K-K7]L** /R'_:"_X)0>'?CEXH_;GU+2OVA/B?\
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M* /SF_X;P^(7_2-S_@HG_P"$5^S'_P#16T?\-X?$+_I&Y_P43_\ "*_9C_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>ex4-16_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-16_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %# LT# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5K&:'^PY8R+2S\D13P1EWB8%TF8/ER,':,[,'UKUFLW7]5&BZ%>:@1N>*/\
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MKUOYW_&YQ<JM;Y?A8XC2I;O1M9\7:MJ^G3V%C<2QRP32RQ-Y@6,)@!'8Y)'
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M(KJ7R984VHAR1^\=<DYXQZ<D5S^I^&M;N;;Q)I']D_:%UFZ%S;ZD9H@+;(7
MD!;=NCV_+L#9XY'->F44DK?UZ?Y(IZ_UZ_YLXGP3HM[I'B+Q/)/I$EG;7ERD
ML$Q:'$N$"L<(Q()8%N0.O/.14FI:1JNE>.3XGTJR_M&&ZM%M+RT658Y1M;*O
M&7(4]2""1[&NRHI]O+_AA**LUW_K]#CO$MEKOB#1HI(=.6$VUW!=)I]Q*A>X
M"-N9'9247/&!DC*\GGCE/$WA/6-:_M/4XO#<HDO;FS:.Q:6W+H86)>9CYFP%
ME^0;6)(ZX[>N44)6=UZ_E_D@:NK/^M_\SS+4=#UR_7QI'#H,\"ZB+>2TWS0
M2F-5!7Y9#M)QQG ]2*MZ5I.L1>,?$NI+X<6S74+"-(9)7A:.290V0X1]QSN7
M)QV//0GT*BIY5:WE;\+!;6_];I_H>0IX-\1W<=UG3Y;62ZT5+5A-<0^6DJ2;
MC$$C)"1L,@;1T/.#72ZWI^H:]X2U:*#PNVGZE-!&F))(-TY1@0H9&(*CG&XK
MUZ"NYHJK?U\[B44<?>";5O&'AQ!&8IM.66ZNT5PWDAD*(C$<9.XG'^R>HYKL
M*CB@AA:1HHHXS(V]RJ@;F]3ZFI*%M;^M1I6_KL%%%% PHHHH **** "BBB@
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M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N2\/\
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M[LN_C/\ PS_](D=;1116IPA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <SXFMY=.NK?Q-91L\UFICNXUZS6Q.6'U4_,/H:Z&VN(;NVBN;>19(95
M#HZ]&!Y!J4@$8/(KD;9O^$.U86,O&A7LI-M(>EI*>3&?1&/(/8\>]9/W)7Z/
M\SN@OK-)4_MQV\X[V]5JUW5UT1UU%%%:G"%%%% !1110 4444 %%%% !1110
M 4444 %%%% !115:_O[;3+&:]O)5BMX5+.[=A_4^U#=M6.,7)J,5=LS_ !)K
M#Z3IRK:H)=1NG\BSB_O2'H3[#J?I4^@Z0FB:1#9J_F2#+S2GK+(W+,?J:R]
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M2TFTT"QN/L-LMWO;4VC:2-BP&%\D@-\IX+8Z<TG:WKK]R_R7X#MK_75_YO\
M$S6\!WS:C;7^IVNA^(IWLXK:Z;5(@"CH6_>1GRWSG=RN%SC.15?4/!7B.>'Q
M3;VT6CK'JT,$-N3<R((Q&H7)418&1S@$XZ>]=QX>UN#Q'X?L=8MHY(X;N(2*
MD@^9?4'\:TZIJSL_ZUN3&S5T<+/X;\4&?6[FRNM/LKC4K2!59978QRQJ05#;
M!\IS]_&?]GO6<_@#5C8Z[# FF6YU"2TN(D6XD8+)"5+*[%,D';]_D\]*]+HI
M)6=U_74.56M_78Y"RT'6O^$ZO-7U"/36L;K3H[-Q%,^\LI+$["F,$L1C<>!G
MO@58? ]]+X0U+1;Z_A=Y4^S6<FUG5+=&+1*X/WCSAO4<5W-%%E:W];W';6_]
M;6.<\+Z!_9'F2OH>A:7,Z!'&DQC$N/XF;RT(]EYQSR:SK6.[T;6-?TQ8XWDU
M69KO3FF8I%(QC >,N%;# J6QCD'C.#CK+V^MM.M7NKR9884P"[>I. /J20*L
M422EOVM]X+3;U/.M"^'5QIV@VG[VVT_78+<VTD]HYFBN$QC+AE4@GVY'J:P'
MT9O#FB3:5=>&=&L+C[&]K'K:0@+-N4IEW2,M'P<DG[Q&. <UZO\ V@ES]LBT
M]H;BZM7$<D;R%%5R V"P4XX(/0U<(#*0P!!&"#TJ)PYKN.E_N_KTL=D,5>T:
MZYK;/[2^?7TDGZHX"7PY>ZOX3T..W_LZ6\L+;RX[JUU*6(HX"J&CE1.5(!)4
MK@G ]ZE7POXEL;JZGM[S3]1DU*QBMKY[QFB*RHI7S$"JP8$$G8=O/?FMRX\'
MZ8;AKFP,^EW+<M+82>6&_P!Y/NG\147D^+=/_P!7<Z?JT0[3H;>4_BN5/Y"B
M4F[\ZWO>WGOYZB6'HR2]C4M;I+1Z;:ZQ=OD<LG@+7=/;4+>P&FRVDNA1Z1 \
M]W(KY4'YV41$ ?,> 3T'KQU$VDZM+\/'T;R[(:DUA]DQ]H?R<[=F[?LW=.?N
M^WO3AXFO[?C4/#.J1'UM@ERO_CAS^E+_ ,)QH*\7%Q/:MW6XM)8\?4E<42J0
MDFI/?Y=_\V.. Q$6G"%[=K2[=F^R.9M/"?BFWNTG>WT8[-!&E "^EY<<A_\
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MBM8KE5CDJU75:;6R2^X****9D%<EX@_Y*%X._P"WW_T4*ZVN2\0?\E"\'?\
M;[_Z*%95OA^:_-'=EW\9_P"&?_I$CK:***U.$*Q_%&JSZ/X?NKFUM;JYNBI2
M".WMWF.\C@D("0HZDX_7%;%%*2NK#3L>4RZ;JWA/5O"VJDMJ<$,;6<J:=HMP
M)O(<;B\GSR<AP#@A3DM[BJ.O:.ZP>++2W\-7MQ)=:C:ZA8B&P.T@B,.ZL0 K
MY#Y&0W)R,9->LVNJZ=?!S:7]K<!"P8Q3*^W:<-G!['KZ5/;W$%W;QW%M-'-!
M(H:.2-@RN#T((X(I^?\ 6K3_ #7YD66W]:)K\F>,>)=',0\9F'PO?"ZU&6UD
MMY;;3F=BN(V==\8/.Y6)P3R,GJ,W+VRO!?\ B2WT#2=1@M)Q8W#Q+9RP+<JK
M?Z0%9E ,C*0#SEN>IS7K]%)*VG]?UH-J^YXSX@T=I="\3MH.D:I::/<64*6U
MA!93P,UWN.XK"JA@NW ;(VD^O6M>\L;'3O%/A2ZL-&U&*S^SSO=K:Z?<! 7C
MP"Z*N!(3N!)&[U[5Z?11;^ODU^OX(+?U]W^7XL\4T[1K>Z75=1TKPU=Z5K<]
MK+;:9;1Z1):BUC"GYWF9%4ROC&=QQD =S5Q/#LEKH5[<Z GB!I)_)74+2>S2
MTW(LBF0(B11AW*[@74G(XR<BO7Z*?]?UZ]>X6_K^NW0\_P#!MK':>-]9?3=
MO+#2+FTMS!(]J;>,,F[<NQL,#\W0+V/XY>OZ))XE\>ZS#$-8M';3H8;:Y$%Q
M';22H[LR2$ (Z$$#G(.3@YKU2BDU>WD"5K^?_ _R/*]6FG\0:/H]K+HFLZ;I
M]G(8]2LX-,$FSY2J%$DC=)HP0?NJQ&0<"JMQHNEZ/K/A6&YBUC4-.:.\0PW<
M3S.\> 1FW11P"QPNS., CC ]3FU33[>[6TFOK:.Y9=ZPO,JN5SC(4G.,\9JK
M=^'=-OM;L]8N(YVOK,$0.MU*JH#U^0,%.>^1SQGI1N[^=W^/]>0N72WE_E_7
MGH>7:?X=D37?#5OJ>E:C/IYGO2+::VFF@@MW)\A)!@HIY/!Y (!P *T;'PTS
M^+9KC41K<.J6]^9+5K6SB$#V^[Y%$XA)"!.#&9!T.!TKU7I4-M=V]Y%YMK<1
M3Q[BN^)PPR#@C([@\4)?U]W^7SU&XWOY_P#!_P _P1Y+::9KEO8ZMI^EZ=.\
MKV+NE_\ 8WL[G+LA,;E_W<LI7/SJ3@KS5+5_#EK;>&99=(@\4RF>ZM6>V;3V
MMPC*_P _[F"%,_)NRQ!!XP2<5[;132M^'X/^OS!J]_._XGC&L:-#=0>++*S\
M.WK6?VVSN[:%M+E",%*"9HPR8+'YL@<MSUYJ3Q+ID]WK#W5EX;N[*2QFL&M3
M#8,[M"&7=M<9$84$@QQX/&3D=/8Z*45RV\OT!JZ:[W_$\4U_01;6OC);;P[J
M"W=SJ,4UK-96,G[R,B,E<QC+*3YA(.5R#G!(SU.M:$B^(HK_ $[0DFC\069L
M;V3[)AH<_,)) 1D#;N!W=2J UZ%10DDDOZVM^(-7=_ZWO^#/*-6\)QS>*+JW
MO(M8MK:)8O[&.E6431QHJC*+)Y3&!MP.?F0$$5ZL@(10220.<TM%-:*P65[A
M1110,8\,<N/,C1\=-R@TY45%"HH51T &!2T4#N[6"BBB@04444 %%%% !111
M0 4444 %%%% !7G/C+3QK?C[2K-EUN");&XA:^L(;A%BDD*;,RH-I'!R"2O'
M->C5'/<0VT8DGFCB0L%#2,%&2< 9/<GBDU=J_P#6C7ZAT=OZZ_H>77']I/X.
M7PV-&U&TN+"X07WV&Q_=W4 ;YY(2RF-RV0Q0Y)^88-9M]H6E:-+X;FC77+FP
MDU<_N+JW:/Y6A<LJ6J1IA<J.-F3\V!@\^N2:II\-Y]CEOK5+K ;R6F4/@G .
MW.>3P/>J&H:-HOB#4[>6Y=IKO2I0Z+#>R(8'(R"RHP&2#_$.A]#36]_/7Y;_
M /#=-?0EQTLCRZ7072_TK.DZH=%DUUY;>Q%G.T<-F8P&\R( A%,F"%8 @$\
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MD'S!M]SQ7J%C&\5A;QR&0ND2JQE8,Y('\1'!/J:2\O[/3H1->W<%M$6"!YY
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M1G('!R<@TV]\"^&M1FNI+O3%E%U(DL\;2OY;NN-K;-VW. !G&2.#D4XZ6O\
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M%Q(HDCR2 P##<022&/()ZTUO"\&GW5UJFBHR:O<1+ 9KN\GDC"#IE"Q!VC)
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MPA_T%_\ R6E_^(H]O2_F7WA_9F._Y\R_\!?^1UM%<E_PLSPA_P!!?_R6E_\
MB*FM?B'X6O;R"TM]4WSSR+'&OV>4;F8X R5QU-/VU/\ F7WB>6XU*[HRM_A?
M^1T]%%%:'$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% &'K/C#0?#]XEIJE]]GG>,2*OD
MN^5)(SE5(Z@UG?\ "S/"'_07_P#):7_XBC_FKW_<!_\ :]=;6*=23=FM'V_X
M)Z<X82C&"G&3<HIZ22WOTY7V[G)?\+,\(?\ 07_\EI?_ (BC_A9GA#_H+_\
MDM+_ /$5UM%.U7NON_X)E[3 _P#/N7_@:_\ D#DO^%F>$/\ H+_^2TO_ ,11
M_P +,\(?]!?_ ,EI?_B*ZVBBU7NON_X(>TP/_/N7_@:_^0.2_P"%F>$/^@O_
M .2TO_Q%'_"S/"'_ $%__):7_P"(KK:*+5>Z^[_@A[3 _P#/N7_@:_\ D#DO
M^%F>$/\ H+_^2TO_ ,11_P +,\(?]!?_ ,EI?_B*ZVBBU7NON_X(>TP/_/N7
M_@:_^0.2_P"%F>$/^@O_ .2TO_Q%'_"S/"'_ $%__):7_P"(KK:*+5>Z^[_@
MA[3 _P#/N7_@:_\ D#DO^%F>$/\ H+_^2TO_ ,15O3/'/AS6=1BL+#4?.NI<
M[$\B1<X!)Y*@= :Z*N2\0?\ )0O!W_;[_P"BA4R=2.K:Z=//U-:,,'7;A&$D
M[2=^9/:+>W*NW<ZVBBBMSS HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#DOB9_R3W5/^V7_HU*ZVN2^)G_ "3W5/\
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M:***U.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM<EX@_Y*%X._[??_ $4*=;X?FOS1&7?QG_AG_P"D2.MHHHK4X0HHHH ****
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M'N216/XFNS;76F)<SRVVE2R.MU/'(8]IV_(&<8*J3W!'( [URVJ7$4FB6_\
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M_P"9:_[#UK_[-71Z<)AIMM]HEDEF,:EWD4*Q)&3D  #\JYSQW_S+7_8>M?\
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M_,M?]AZU_P#9JNO\#_KJBL##DQJAV<E]T9HZVBBBM#S@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH Y+_ )J]_P!P'_VO76UR7_-7O^X#_P"UZZVLJ7VO5_H=V._Y=?X(
M_P#MQC:WHLNH75CJ%G,D.H6+EHF=<HZL,,C8YP1W[55.EZO?:U;ZE=BSM'MK
M:6&,02M-N9\?,=R+C&WISUKHZ*;I1?\ 74SABZD8J.FB:6FJ3W7I]_4X8^%-
M9\J>0BP>[N--DLIY&N),N[$?O"Q0GU.WMT%27NFZI:1&\NK:Q>VATAK.1%F>
M0LW!R%V#(R .HX)/:NUHJ'AXV:7];_YLZ/[3JMKF2?R_X.FFW8XSPHY^WJYG
MMM19H1!]IM]0%QY**,A2!$@49/<EB2.N,B\UW;6_Q!EBFN(8I)].B2))'"F1
MO,?@ ]3]*Z6BJ]EHE?;_ (/^9G4QBG4E-QW5OZZ?)?F<8GA*_:SO+(SPVUG+
M" MLLKSQ>:&#;@K@;$X(V D$'M5@^'[U+("RL-(TZ5I(_/ALR8UN$!.X&14#
M#.1@8/?DYKJZ*7L(?U_7](;S&N][=]OSUU^=WMJCC8O#>K6EO;6]M'IYBAU1
MKW_7.GR$DA0-AYY/?L/7BSI]U;W?Q$U,VUQ%,(]/BC<QN&VL)'RIQT(]*ZFB
MB-%1:Y>G^5A2QTIJ7.M6FM--VFV][[>05R7B#_DH7@[_ +??_10KK:Y+Q!_R
M4+P=_P!OO_HH4ZWP_-?F@R[^,_\ #/\ ](D=;1116IPA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ')?$S_DGNJ?\
M;+_T:E=;7)?$S_DGNJ?]LO\ T:E=;62_BOT7ZG=4_P!QI_XI_E RM:T./6UM
MEEO+JW6WE$JK#LPS#H6#JP..PJO<>&VO(IH[O6M2G$L#0?-Y*[5;&[ 6,#)
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MLGS!R%!Z+M3<>!M;GG%>@:;-]INCK$MO=QVUG8K#"DEI*LI9L-(1&5W'A4
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ME[<:@DB267V*WDDECE4Y# H"5XSR<#MWKIM%2VCT2RCLX)(+9(56.*2)HF4
M8P58!@?J,TM6GY?KK^&Q3TDOZV_SW.<3QK?7GA_0[_2M+L[V[U5MHM1?L@C
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M2_\ P#C_ ,*/WOE^(?[!_?\ _) _X2GP]_T'M+_\#(_\:/\ A*?#W_0>TO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>ex4-17_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-17_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  E #4# 2(  A$! Q$!_\0
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MN?%OCGQ=X%U72=-DTC2[C5$MBRO-+,-$U*PLI!?).9+>Y%W/<I=Q".&W^R&
M0L;K?YJ%%;T8IJ=U>T7)>335G^)Z^5X>C7P^<3JP4IX? 0K4)<THRI5575JD
M'&46I*RUN>C,UMX9A2VM(9I;>YGN;B."2Z81V>\QL\%L&CD,=MYCL\< .R$L
MR1!8]J(444;[^?1=WY%X3!X;$X>E7KTE4K58\U2;E-.4KM7:C.*O:*V2O:[N
$VV__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>ex4-17_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-17_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  @ $ # 2(  A$! Q$!_\0
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/<'1JN-5*<)XJJN6.TO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>ex15-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 ;4# 2(  A$! Q$!_\0
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MS_Z@_P#WV_\ \31CQG_U!_\ OM__ (F@#I:*YK'C/_J#_P#?;_\ Q-&/&?\
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M/C]->UG6(-0B6W:!2J[6 YQQ^->C5S6/&?\ U!_^^W_^)HQXS_Z@_P#WV_\
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M''KR:VJYK'C/_J#_ /?;_P#Q-;&E_P!I?9C_ &I]G\_/'V<DKC\0* +M%%%
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ML;A(+A5+*[IN''J,BO'_ -G#_D7M6_Z[K_(U[)=R(;>>,.I<1DE<\@4 >->
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MY@!9Y".P)/RBN]10B!5& !@"EHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>ex15-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ +(# 2(  A$! Q$!_\0
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MFU*[N5ACFE;EF[EOZ8Q7H=<-XS3Q+)<%8/$6FZ%HA #W!!-RW'(&> >N,<T
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M 4444 )^-)SZT44 -8]JKV%G:Z9916=E!'!;Q#"1H, "BB@"R#FE_P ]:**
M&LQ%&XGBBB@!V/<T=J** &\_WC1D_P!XT44 +CCJ?SI.?4T44 +SZFDY_O&B
EB@ Y_O&E&?6BB@ ).>IHR?6BB@ R?6C)]3110 <^IHHHH&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680330945192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Universe
Pharmaceuticals INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UPC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">21,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001809616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">265
Jingjiu Avenue,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Jinggangshan Economic and Technological Development Zone<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ji&#8217;an,
Jiangxi Province<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">000000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">265
Jingjiu Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Jinggangshan Economic and Technological Development Zone<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ji&#8217;an,
Jiangxi Province<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Gang
Lai<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">gang.lai@universe-pharmacy.com<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">000000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">0796-8403309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number Section<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680331395080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 8,077,908<span></span>
</td>
<td class="nump">$ 10,058,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">13,725,204<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">15,573,742<span></span>
</td>
<td class="nump">10,871,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">2,462,542<span></span>
</td>
<td class="nump">1,906,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="nump">236,982<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AdvanceToSuppliersNet', window );">Advance to suppliers</a></td>
<td class="nump">2,738,313<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentForAdvertising', window );">Prepayment for advertising</a></td>
<td class="nump">7,492,320<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred initial public offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">443,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">174,053<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">50,481,064<span></span>
</td>
<td class="nump">23,279,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">4,681,353<span></span>
</td>
<td class="nump">4,428,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent', window );">Prepayments made to a related party for purchase of property</a></td>
<td class="nump">2,476,800<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentsForConstructionInProgress', window );">Prepayments for construction in progress</a></td>
<td class="nump">10,712,160<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">178,483<span></span>
</td>
<td class="nump">174,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_InvestmentInEquitySecurities', window );">Investment in equity securities</a></td>
<td class="nump">744,924<span></span>
</td>
<td class="nump">735,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">869,997<span></span>
</td>
<td class="nump">186,537<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NONCURRENT ASSETS</a></td>
<td class="nump">19,663,717<span></span>
</td>
<td class="nump">5,524,377<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">70,144,781<span></span>
</td>
<td class="nump">28,804,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short-term bank loans</a></td>
<td class="nump">4,334,400<span></span>
</td>
<td class="nump">2,646,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,310,526<span></span>
</td>
<td class="nump">2,691,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">1,101,460<span></span>
</td>
<td class="nump">1,331,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">19,723<span></span>
</td>
<td class="nump">956,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">444,319<span></span>
</td>
<td class="nump">375,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">11,210,428<span></span>
</td>
<td class="nump">8,001,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares and 16,000,000 shares issued and outstanding as of September 30, 2021 and 2020, respectively</a></td>
<td class="nump">67,969<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">29,279,159<span></span>
</td>
<td class="nump">3,679,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_StatutoryReserve', window );">Statutory reserve</a></td>
<td class="nump">2,439,535<span></span>
</td>
<td class="nump">2,439,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">25,058,931<span></span>
</td>
<td class="nump">13,738,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">2,088,759<span></span>
</td>
<td class="nump">895,390<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">58,934,353<span></span>
</td>
<td class="nump">20,802,904<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 70,144,781<span></span>
</td>
<td class="nump">$ 28,804,298<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvanceToSuppliersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of advance to suppliers net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvanceToSuppliersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_InvestmentInEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment In Equity Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_InvestmentInEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForAdvertising">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayment for advertising.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForAdvertising</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentsForConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayments for construction in progress.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentsForConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayments made to a related party for purchase of property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>StatutoryReserve</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335309368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680331700568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Income - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 47,982,031<span></span>
</td>
<td class="nump">$ 30,703,960<span></span>
</td>
<td class="nump">$ 33,229,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">22,655,854<span></span>
</td>
<td class="nump">16,610,140<span></span>
</td>
<td class="nump">19,821,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">25,326,177<span></span>
</td>
<td class="nump">14,093,820<span></span>
</td>
<td class="nump">13,407,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">2,973,531<span></span>
</td>
<td class="nump">1,555,546<span></span>
</td>
<td class="nump">1,578,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">3,296,844<span></span>
</td>
<td class="nump">1,703,424<span></span>
</td>
<td class="nump">1,457,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">5,465,662<span></span>
</td>
<td class="nump">583,125<span></span>
</td>
<td class="nump">618,437<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">11,736,037<span></span>
</td>
<td class="nump">3,842,095<span></span>
</td>
<td class="nump">3,654,656<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">13,590,140<span></span>
</td>
<td class="nump">10,251,725<span></span>
</td>
<td class="nump">9,752,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OtherIncomeExpensesAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(101,604)<span></span>
</td>
<td class="num">(123,760)<span></span>
</td>
<td class="num">(129,268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (expenses), net</a></td>
<td class="num">(80,434)<span></span>
</td>
<td class="num">(49,352)<span></span>
</td>
<td class="nump">2,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShorttermInvestmentIncome', window );">Short-term investments income</a></td>
<td class="nump">239,549<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment income</a></td>
<td class="nump">30,827<span></span>
</td>
<td class="nump">21,820<span></span>
</td>
<td class="nump">26,741<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">88,338<span></span>
</td>
<td class="num">(151,292)<span></span>
</td>
<td class="num">(99,767)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax provision</a></td>
<td class="nump">13,678,478<span></span>
</td>
<td class="nump">10,100,433<span></span>
</td>
<td class="nump">9,653,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">2,358,526<span></span>
</td>
<td class="nump">2,542,211<span></span>
</td>
<td class="nump">2,101,597<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">11,319,952<span></span>
</td>
<td class="nump">7,558,222<span></span>
</td>
<td class="nump">7,551,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OtherComprehensiveIncomeLossAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,193,369<span></span>
</td>
<td class="nump">860,623<span></span>
</td>
<td class="num">(645,978)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 12,513,321<span></span>
</td>
<td class="nump">$ 8,418,845<span></span>
</td>
<td class="nump">$ 6,905,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in Dollars per share)</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in Shares)</a></td>
<td class="nump">18,980,822<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OtherComprehensiveIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OtherComprehensiveIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OtherIncomeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OtherIncomeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ShorttermInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ShorttermInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680331498376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Statutory Reserve</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2018</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 3,679,000<span></span>
</td>
<td class="nump">$ 2,439,535<span></span>
</td>
<td class="nump">$ 2,832,292<span></span>
</td>
<td class="nump">$ 680,745<span></span>
</td>
<td class="nump">$ 9,681,572<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2018</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockDividend', window );">Dividend declared</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,203,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,203,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,551,465<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,551,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(645,978)<span></span>
</td>
<td class="num">(645,978)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">3,679,000<span></span>
</td>
<td class="nump">2,439,535<span></span>
</td>
<td class="nump">6,180,757<span></span>
</td>
<td class="nump">34,767<span></span>
</td>
<td class="nump">12,384,059<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2019</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,558,222<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,558,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">860,623<span></span>
</td>
<td class="nump">860,623<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">3,679,000<span></span>
</td>
<td class="nump">2,439,535<span></span>
</td>
<td class="nump">13,738,979<span></span>
</td>
<td class="nump">895,390<span></span>
</td>
<td class="nump">20,802,904<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2020</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,319,952<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,319,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross</a></td>
<td class="nump">$ 17,969<span></span>
</td>
<td class="nump">28,732,031<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">28,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross (in Shares)</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts', window );">Capitalized initial public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,131,872)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,131,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,193,369<span></span>
</td>
<td class="nump">1,193,369<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="nump">$ 67,969<span></span>
</td>
<td class="nump">$ 29,279,159<span></span>
</td>
<td class="nump">$ 2,439,535<span></span>
</td>
<td class="nump">$ 25,058,931<span></span>
</td>
<td class="nump">$ 2,088,759<span></span>
</td>
<td class="nump">$ 58,934,353<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2021</a></td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Capitalized initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued to shareholders as a dividend during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680330584216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 11,319,952<span></span>
</td>
<td class="nump">$ 7,558,222<span></span>
</td>
<td class="nump">$ 7,551,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">446,878<span></span>
</td>
<td class="nump">410,079<span></span>
</td>
<td class="nump">418,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss from disposal of fixed assets</a></td>
<td class="nump">1,559<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="num">(230,175)<span></span>
</td>
<td class="nump">98,102<span></span>
</td>
<td class="nump">297,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Inventory reserve</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(75,391)<span></span>
</td>
<td class="num">(187,271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="num">(668,341)<span></span>
</td>
<td class="num">(9,886)<span></span>
</td>
<td class="num">(39,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeShortTermInvestmentOther', window );">Short-term investments income</a></td>
<td class="num">(239,549)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivables</a></td>
<td class="num">(3,867,457)<span></span>
</td>
<td class="num">(4,107,520)<span></span>
</td>
<td class="nump">665,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="num">(451,634)<span></span>
</td>
<td class="nump">888,607<span></span>
</td>
<td class="nump">5,586,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidSupplies', window );">Advance to suppliers, net</a></td>
<td class="num">(2,717,085)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidAdvertising', window );">Prepayment for advertising</a></td>
<td class="num">(7,434,240)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Advances to related parties</a></td>
<td class="num">(237,720)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(168,188)<span></span>
</td>
<td class="nump">12,407<span></span>
</td>
<td class="num">(8,449)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,457,337<span></span>
</td>
<td class="nump">639,427<span></span>
</td>
<td class="num">(924,444)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable', window );">Taxes payable</a></td>
<td class="num">(298,620)<span></span>
</td>
<td class="nump">731,518<span></span>
</td>
<td class="num">(320,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">31,436<span></span>
</td>
<td class="num">(30,408)<span></span>
</td>
<td class="nump">162,540<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(2,055,847)<span></span>
</td>
<td class="nump">6,115,157<span></span>
</td>
<td class="nump">13,203,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(444,505)<span></span>
</td>
<td class="num">(51,798)<span></span>
</td>
<td class="num">(86,324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposal of fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty', window );">Prepayments made to a related party for purchase of property</a></td>
<td class="num">(2,457,600)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfAdvancesForConstruction', window );">Prepayments for construction in progress</a></td>
<td class="num">(10,629,120)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromShortTermInvestments', window );">Payments for short-term investments</a></td>
<td class="num">(15,330,660)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_RedemptionOfShorttermInvestments', window );">Redemption of short-term investments</a></td>
<td class="nump">1,801,927<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(27,059,958)<span></span>
</td>
<td class="num">(51,798)<span></span>
</td>
<td class="num">(86,033)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term bank loans</a></td>
<td class="nump">4,300,800<span></span>
</td>
<td class="nump">1,427,000<span></span>
</td>
<td class="nump">3,055,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Repayment of bank loans</a></td>
<td class="num">(2,764,800)<span></span>
</td>
<td class="num">(1,427,000)<span></span>
</td>
<td class="num">(3,055,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividend payment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(16,005,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from initial public offerings</a></td>
<td class="nump">28,750,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payment for deferred initial public offering costs</a></td>
<td class="num">(2,792,543)<span></span>
</td>
<td class="num">(441,064)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings', window );">Proceeds from (prepayments for) related parties borrowings</a></td>
<td class="num">(911,648)<span></span>
</td>
<td class="nump">911,200<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">26,581,809<span></span>
</td>
<td class="nump">470,136<span></span>
</td>
<td class="num">(16,003,857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">553,702<span></span>
</td>
<td class="nump">347,386<span></span>
</td>
<td class="num">(126,720)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="num">(1,980,294)<span></span>
</td>
<td class="nump">6,880,881<span></span>
</td>
<td class="num">(3,012,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, beginning of year</a></td>
<td class="nump">10,058,202<span></span>
</td>
<td class="nump">3,177,321<span></span>
</td>
<td class="nump">6,190,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, end of year</a></td>
<td class="nump">8,077,908<span></span>
</td>
<td class="nump">10,058,202<span></span>
</td>
<td class="nump">3,177,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expenses</a></td>
<td class="nump">149,303<span></span>
</td>
<td class="nump">157,528<span></span>
</td>
<td class="nump">135,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income tax</a></td>
<td class="nump">$ 3,271,219<span></span>
</td>
<td class="nump">$ 2,167,963<span></span>
</td>
<td class="nump">$ 2,257,893<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of prepayments made to a related party for purchase of property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from (prepayments for) related parties borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_RedemptionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption of short-term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_RedemptionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidAdvertising">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for advertising that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidAdvertising</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount of cash payments due to taxing authorities for non-income-related taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeShortTermInvestmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income from short-term investment classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeShortTermInvestmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e99989-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfAdvancesForConstruction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payments made by the entity, generally on a straight-line basis over periods ranging from five to forty years to developers, builders, government agencies and municipalities for borrowings received in construction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfAdvancesForConstruction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338277096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Description<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BUSINESS DESCRIPTION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8212; ORGANIZATION AND BUSINESS DESCRIPTION</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
Pharmaceuticals Inc. (&#8220;Universe INC&#8221; or the &#8220;Company&#8221;) was incorporated under the laws of the Cayman Islands
on December 11, 2019 as an exempted company with limited liability.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
INC. owns 100% equity interest of Universe Pharmaceuticals (International) Group (&#8220;Universe HK&#8221;), an entity incorporated
on May 21, 2014 in accordance with the laws and regulations in Hong Kong.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
Universe Pharmaceuticals Technology Co., Ltd. (&#8220;Universe Technology&#8221;) was formed on April 8, 2019, as a Wholly Foreign-Owned
Enterprise (&#8220;WOFE&#8221;) in the People&#8217;s Republic of China (&#8220;PRC&#8221;). The registered capital of Universe Technology
is approximately $4.3 million (RMB 30.5 million). In December 2019, the Company made capital contribution of $500,000 to Universe Technology.
Pursuant to the article of incorporation, the remaining capital contribution of approximately $3.8 million for Universe Technology is
required to be completed before 2038.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
INC, Universe HK and Universe Technology are currently not engaging in any active business operations and merely acting as holding companies.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
Universe Pharmaceuticals Co., Ltd. (&#8220;Jiangxi Universe&#8221;) was incorporated on March 2, 1998 in accordance with PRC laws and
is engaged in research and development and manufacturing of modernized traditional Chinese medicines. Jiangxi Universe owns 100% of the
equity of Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (&#8220;Universe Trade&#8221;) which was incorporated on March
10, 2010 to handle the sales and distribution of the pharmaceutical products manufactured by Jiangxi Universe.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reorganization</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reorganization of our legal structure (&#8220;Reorganization&#8221;) was completed on December 11, 2019. The reorganization involved
the incorporation of Universe INC and Universe Technology, and the transfer of the 100% equity interest of Jiangxi Universe to Universe
Technology. Consequently, Universe INC, through its subsidiary Universe HK, directly controls Universe Technology and Jiangxi Universe,
and became the ultimate holding company of all other entities mentioned above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Reorganization has been accounted for as a recapitalization among entities under common control since the same controlling shareholders
controlled all these entities before and after the Reorganization. The consolidation of the Company and its subsidiaries has been accounted
for at historical cost and prepared on the basis as if the aforementioned transactions had become effective as of the beginning of the
first period presented in the accompanying consolidated financial statements. Results of operations for the periods presented comprise
those of the previously separate entities combined from the beginning of the period to the end of the period, eliminating the effects
of intra-entity transactions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 25, 2021, the Company closed its IPO of 5,000,000 ordinary shares, par value $0.003125 per share (the &#8220;ordinary shares&#8221;)
at a public offering price of $5.00 per share. On March 29, 2021, the underwriter exercised in full its over-allotment option to purchase
an additional 750,000 ordinary shares.&#160;<span>The closing for the sale of the over-allotment shares
took place on March 31, 2021. Gross proceeds from the IPO totaled $28.75 million. </span>Net proceeds of the IPO, including over-allotment
shares, were approximately $25.6 million. In connection with the IPO, the Company&#8217;s ordinary shares began trading on the Nasdaq
Global Market&#160;under the symbol &#8220;UPC&#8221; on March 23, 2021.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2021, through the Company&#8217;s PRC subsidiary Jiangxi Universe, the Company established a wholly controlled subsidiary, Guangzhou
Universe Hanhe Medical Research Co., Ltd. (&#8220;Universe Hanhe&#8221;) in Guangzhou City, China, for the business purpose of conducting
research and development of new pharmaceutical products in order to diversify the Company&#8217;s product offerings in the near future.
As of September 30, 2021 and as of the date of this report, Universe Hanhe has no active business operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the subsidiaries of the Company as of September 30, 2021 were set out below:&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Entity </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
    of<br/>
    Incorporation </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place
    of<br/>
    Incorporation </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%
    of&#160;<br/>
    Ownership </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    Activities </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    INC </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&#160;11,&#160;2019 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman&#160;Islands </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent, 100% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    HK </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 21, 2014 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    Technology </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 18, 2019 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WOFE, Investment holding </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Universe </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 1998 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development and manufacturing of modernized traditional Chinese medicines </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    Trade</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 10, 2010 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales of modernized traditional Chinese medicines </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    Hanhe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of new pharmaceutical products</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, through its wholly-owned subsidiaries, is primarily engaged in the development, manufacturing and sale of traditional Chinese
medicines derivatives (&#8220;TCMD&#8221;) products targeted to the elderly to address their physical conditions in the aging process
and to promote their general well-being. In addition, the Company also sells biochemical drugs, medical instruments, traditional Chinese
medicine pieces products and dietary supplements (together &#8220;third-party products&#8221;). All of these TCMD and third-party products
are currently sold to customers including pharmaceutical companies, hospitals, clinics and drugstore chains throughout China.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338297704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of consolidation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the financial statements of Universe INC, Universe HK, Universe Technology, Jiangxi
Universe, Universe Trade and Universe Hanhe. All inter-company balances and transactions are eliminated upon consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Uses
of estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America
(&#8220;US GAAP&#8221;), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant estimates
required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, the realizability
of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of
long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual
results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
and Uncertainties</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main operation of the Company is located in the PRC. Accordingly, the Company&#8217;s business, financial condition, and results of operations
may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The
Company&#8217;s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although
the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations
including its organization and structure disclosed in Note 1, this may not be indicative of future results.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by
rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition
with respect to our current and future pharmaceutical product candidates from major pharmaceutical companies in China.&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters,
extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company&#8217;s
operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operations may be further affected by the ongoing outbreak of COVID-19 which in March 2020, had been declared as a pandemic
by the World Health Organization.&#160;To reduce the spread of the COVID-19, the Chinese government has employed measures including city
lockdowns, quarantines, travel restrictions, suspension of business activities and school closures. Due to difficulties resulting from
the COVID-19 outbreak, including, but not limited to, the temporary closure of the Company&#8217;s factory and operations beginning in
early February until to March 2, 2020, limited support from the Company&#8217;s employees, delayed access to raw material supplies and
inability to deliver products to customers on a timely basis, the Company&#8217;s business was negatively impacted and generated lower
revenue and net income during the period from February to March 2020. Although the Company resumed its operations on March 2, 2020 and
the COVID-19 impact on the Company&#8217;s operating results and financial performance for fiscal year 2020 and 2021 seems to be temporary,
a resurgence could negatively affect the execution of customer contracts, the collection of customer payments, or disrupt the Company&#8217;s
supply chain, and the continued uncertainties associated with COVID 19 may negatively impact the Company&#8217;s revenue and cash flows.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of
its bank accounts in the PRC. Cash balances in bank accounts in PRC are not insured by the Federal Deposit Insurance Corporation or other
programs.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts
receivable, net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are presented net of allowance for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts
based on individual account analysis and historical collection trend. The Company establishes a provision for doubtful receivables when
there is objective evidence that the Company may not be able to collect amounts due. The allowance is based on management&#8217;s best
estimate of specific losses on individual exposures, as well as a provision on historical trends of collections. Actual amounts received
may differ from management&#8217;s estimate of credit worthiness and the economic environment. Delinquent account balances are written-off
against the allowance for doubtful accounts after management has determined that the collection is not probable. Allowance for uncollectable
balances amounted to $446,527 and $639,991 as of September 30, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventories,
net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and
related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision
for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less
any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments,
and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable
value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future
product sales. The Company recorded inventory reserve of $116,453 and $110,585 as of September 30, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><b><i>Advances
to suppliers, net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances
to suppliers represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices for raw materials. These
advances are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time
to make cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company
when the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific
allowances when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September
30, 2021 and 2020, no allowance for doubtful accounts was deemed necessary as the Company believes that all advances to suppliers fully
realizable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Deferred&#160;initial
public&#160;offering (&#8220;IPO&#8221;) costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the requirement of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212;
&#8220;Expenses of Offering&#8221;. Deferred offering costs consist of underwriting, legal, accounting and other expenses incurred through
the balance sheet date that are directly related to the intended IPO. Deferred offering costs will be charged to shareholders&#8217;
equity upon the completion of the IPO. Should the IPO prove to be unsuccessful, these deferred costs, as well as additional expenses
to be incurred, will be charged to operations. The balance of deferred initial public offering costs amounted to <span style="-sec-ix-hidden: hidden-fact-71">Nil</span> and $443,709 as
of September 30, 2021 and 2020, respectively. Payment for deferred IPO offering costs amounted to $2,792,543, $441,064 and <span style="-sec-ix-hidden: hidden-fact-72">Nil</span> for the
years ended September 30, 2021, 2020 and 2019, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Short-term&#160;investments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s short-term&#160;investments
consist of wealth management financial products purchased from financial institution, which can be redeemed anytime. The financial institution
invests the Company&#8217;s fund in certain financial instruments including money market funds and bonds to generate investment income.
The short-term investments are deemed to be trading securities and are measured subsequently at fair value in the statement of financial
position. Unrealized holding gains and losses for investment is included in the consolidated statements of operations and comprehensive
income (loss) over the investment period (see Note&#160;7).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
value of financial instruments</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#8201;&#8212;&#8201;inputs
    to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#8201;&#8212;&#8201;inputs
    to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for
    identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived
    from or corroborated by observable market data. </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#8201;&#8212;&#8201;inputs
    to the valuation methodology are unobservable. </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise disclosed, the fair value of the Company&#8217;s financial instruments, including cash, accounts receivable, inventories, short-term
investments, advance to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses
and other current liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities
as of September 30, 2021 and 2020 based upon the short-term nature of the assets and liabilities. The Company&#8217;s investment in equity
securities is accounted for using the measurement alternative in accordance with ASC 321, which also approximate its recorded value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;
</i></b>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property,
plant and equipment</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and
equipment is provided using the straight-line method over their expected useful lives, as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    life </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Buildings </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20 years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5&#8211;10 years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automobiles </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#8211;5 years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office and electric equipment
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#8211;5 years </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditures
for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures
for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated
depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated
statements of income and other comprehensive income in other income or expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
reviews the carrying value of property, plant, and equipment for impairment whenever events and circumstances indicate that the carrying
value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition.
In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an
amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment
include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand,
competition and other economic factors. Based on this assessment, no impairment expenses for property, plant, and equipment were recorded
in operating expenses for the years ended September 30, 2021, 2020 and 2019, respectively.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intangible
Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist primarily of land use rights and software. Under the PRC law, all land in the PRC is owned by the government and cannot
be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for specified periods
of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using the straight-line method
with the following estimated useful lives:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    life </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land use rights
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50 years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
reviews the carrying value of land use rights for impairment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where
undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which
the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current
operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors. Based on this assessment, no impairment of land use rights was deemed necessary for the years ended September
30, 2021, 2020 and 2019, respectively.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Construction-in-Progress
(&#8220;CIP&#8221;)</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction-in-progress
represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct
costs attributable to the construction. Construction-in-progress is not depreciated. Upon completion and ready for intended use, construction-in-progress
is reclassified to the appropriate category within property, plant and equipment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of long-lived Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets with finite lives, primarily
property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash flows from the use of the asset and its
eventual disposition below are the asset&#8217;s carrying value, then the asset is deemed to be impaired and written down to its fair
value. There were no impairments of these assets as of September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investments
in Equity Securities </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its equity investments
in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 321 &#8220;Investments&#8212;Equity Securities&#8221; (&#8220;ASC
321&#8221;). In accordance with ASC 321, equity investment which the Company has no significant influence (generally less than a 20% ownership
interest) with readily determinable fair values are accounted for at fair value based on quoted market prices with the changes in fair
value recognized as unrealized gains or losses in earnings. Equity investments without readily determinable fair values are accounted
for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured
at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical
or a similar investment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
March 2009 to September 2017, the Company invested approximately $0.7 million (RMB 5 million) in Jiangxi Jian Rural Commercial Bank (&#8220;JX
RCB Bank&#8221;) in exchange for 5% ownership interest in the bank. The purpose of entering into these equity investment agreements with
JX RCB Bank was to earn investment income as the bank continues to grow. The Company determined that this investment in equity securities
does not have a readily determinable fair value and, accordingly, elected the measurement alternative noted above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company initially recorded the investments at historical cost and subsequently records any dividends received from the net accumulated
earnings of the investee as income. As of September 30, 2021 and 2020, this investment amounted to $744,924 (RMB 5 million) and $735,000
(RMB 5 million), respectively, and was reported as long-term investment in equity investee on the consolidated balance sheets. Investment
income amounted to $30,827, $21,820 and $26,741 for the years ended September 31, 2021, 2020 and 2019, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investments in equity securities are evaluated for impairment when facts or circumstances indicate that the fair value of the investment
is less than its carrying value. An impairment is recognized when a decline in fair value is determined to be other-than-temporary. The
Company reviews several factors to determine whether a loss is other-than-temporary. These factors include, but are not limited to, the:
(i) nature of the investment; (ii) cause and duration of the impairment; (iii) extent to which fair value is less than cost; (iv) financial
condition and near term prospects of the investments; and (v) ability to hold the investment for a period of time sufficient to allow
for any anticipated recovery in fair value. There was no impairment for the Company&#8217;s investments in equity securities as of September
30, 2021 and 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
recognition</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s)
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will <i>not</i> occur, (iv) allocate the transaction
price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance
obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its TCMD and third-party
products on a gross basis as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in
establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods, which the Company has control
of the goods and has the ability to direct the use of goods to obtain substantially all the benefits. All of the Company&#8217;s contracts
have one single performance obligation as the promise is to transfer the individual goods to customers, and there is no separately identifiable
other promise in the contracts. The Company&#8217;s revenue streams are recognized at a point in time when title and risk of loss passes
and the customer accepts the goods, which generally occurs at delivery. The Company&#8217;s products are sold with no right of return
and the Company does not provide other credits or sales incentive to customers. Revenue is reported net of all value added taxes (&#8220;VAT&#8221;).&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contract
Assets and Liabilities </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
terms are established on the Company&#8217;s pre-established credit requirements based upon an evaluation of customers&#8217; credit
quality. Contract assets are recognized for in related accounts receivable. Contract liabilities are recognized for contracts where payment
has been received in advance of delivery. The contract liability balance can vary significantly depending on the timing when an order
is placed and when shipment or delivery occurs. As of September 30, 2021 and 2020, the Company did not have contract assets and contract
liabilities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disaggregation
of Revenues</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing
and uncertainty of the revenue and cash flows are affected by economic factors. The Company&#8217;s disaggregation of revenues for the
years ended September 30, 2021, 2020 and 2019 are disclosed in Note 17 of this consolidation financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Cost of revenue</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Cost of revenue consists primarily of the costs of raw materials, freight
charges, direct labor, depreciation of plants and machinery, warehousing and overhead associated with the manufacturing process.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and development expenses</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses all internal research and development costs as incurred, which primarily comprise employee costs, internal and external
costs related to execution of studies, including manufacturing costs, facility costs of the research center, and amortization and depreciation
to intangible assets and property, plant and equipment used in the research and development activities. For the years ended September
30, 2021, 2020 and 2019, total research and development expense were approximately $5,465,662, $583,125 and $618,437, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shipping and handling costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Shipping and handling costs are expensed as incurred. Inbound shipping
and handling cost associated with bringing the purchased raw materials and third-party products from suppliers to the Company&#8217;s
warehouse are included in cost of revenue. Outbound shipping and handling costs associated with shipping and delivery the products to
customers are included in selling expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advertising
expense</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising expenses primarily relate to promotion of the Company&#8217;s
brand name and products through outdoor billboards, social media such as Weibo and WeChat and TV advertisement. Advertising costs is expensed
as incurred or deferred and then expensed the first time the advertising takes place. Advertising expenses are included in selling expenses
in the consolidated statements of income and comprehensive income. Advertising expenses amounted to $1,316,654, $343,962 and $367,513
for the years ended September 30, 2021, 2020 and 2019, respectively.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Segment Reporting</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the management approach in determining
reportable operating segments. The management approach considers the internal reporting used by the Company&#8217;s chief operating decision
maker for making operating decisions about the allocation of resources of the segment and the assessment of its performance in determining
the Company&#8217;s reportable operating segments. Management has determined that the Company has one operating segment (See Note 17).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
taxes</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized
when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial
statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary,
to reduce deferred tax assets to the amount expected to be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
uncertain tax position is recognized only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax
examination. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination.
For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest
relating to income taxes have been incurred during the years ended September 30, 2021, 2020 and 2019. The Company does not believe there
was any uncertain tax provision at September 30, 2021 and 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operating subsidiary in China is subject to the income tax laws of the PRC. No significant income was generated outside
the PRC for the fiscal years ended September 30, 2021, 2020 and 2019. As of September 30, 2021, all of the Company&#8217;s tax returns
of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Value
added tax (&#8220;VAT&#8221;)</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.1pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
revenue represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to 17% (starting
from May 1, 2018, VAT rate was lowered to 16%, and starting from April 1, 2019, VAT rate was further lowered to 13%), depending on the
type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of
producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the accompanying consolidated
financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Earnings
per Share</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes earnings per share (&#8220;EPS&#8221;) in accordance with ASC 260, &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;).
ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided
by the weighted average common shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential
common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented,
or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or
decrease loss per share) are excluded from the calculation of diluted EPS. For the years ended September 30, 2021, 2020 and 2019, there
were no dilutive shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
currency translation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The functional currency for Universe INC is the
U.S Dollar (&#8220;US$&#8221;). Universe HK uses Hong Kong dollar as its functional currency. However, Universe INC and Universe HK currently
only serve as the holding companies and did not have active operation as of the date of this annual report. The Company operates only
in the PRC, the Company&#8217;s functional currency is the Chinese Yuan (&#8220;RMB&#8221;). The Company&#8217;s consolidated financial
statements have been translated into the reporting currency U.S. Dollars (&#8220;US$&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical
rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation
adjustments are reported under other comprehensive income (loss). Gains and losses resulting from the translations of foreign currency
transactions and balances are reflected in the results of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions.
No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table outlines the currency exchange rates that were used in creating the consolidated financial statements in this report:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30, 2021</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30, 2020</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30, 2019</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: left">Year-end spot rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.4580</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.8033</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1= RMB 7.1378</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.5095</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 7.0077</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.8729</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comprehensive
income </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
income consists of two components, net income and other comprehensive income (loss). The foreign currency translation gain or loss resulting
from translation of the financial statements expressed in RMB to US$ is reported in other comprehensive income (loss) in the consolidated
statements of income and comprehensive income.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Statement
of Cash Flows</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 230, &#8220;Statement of Cash Flows&#8221;, cash flows from the Company&#8217;s operations are formulated based upon
the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily
agree with changes in the corresponding balances on the balance sheets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
Defined Contribution Plan</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which
pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to
eligible full-time employees. The relevant labor regulations require the Company&#8217;s subsidiaries in the PRC to pay the local labor
and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government.
The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying
statements of income and comprehensive income amounted to $617,145, $347,312 and $274,091 for the years ended September 30, 2021, 2020
and 2019, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;
<b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent&#160;Adopted
Accounting Pronouncements&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB Accounting Standards Board issued ASU No. 2018-13, &#8220;Fair Value Measurement (Topic 820): Disclosure Framework
Changes to the Disclosure Requirements for Fair Value Measurement&#8221; (&#8220;ASU 2018-13&#8221;). ASU 2018-13 modifies the disclosure
requirements on fair value measurements. ASU 2018-13 is effective for all entities for fiscal years and interim periods within those
fiscal years beginning after December 15, 2019, with early adoption permitted for any removed or modified disclosures. The removed and
modified disclosures were adopted on a retrospective basis and the new disclosures were adopted on a prospective basis. The adoption
of this guidance had no material impact on the Company&#8217;s consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent
Accounting Pronouncements&#160;not yet adopted</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February&#160;2016, the FASB issued Accounting
Standards Update (ASU) No.&#160;2016-02,&#160;Leases (Topic 842), which requires lessees to recognize a right-of-use asset and lease liability
on the balance sheet for all leases, including operating leases, with a term in excess of 12 months. The guidance also expands the quantitative
and qualitative disclosure requirements. The new guidance requires the lessee to record operating leases on the balance sheet with a right-of-use
asset and corresponding liability for future payment obligations. In July&#160;2018, FASB issued ASU 2018-11 Leases (Topic 842) &#8211;
Targeted Improvements&#160;that reduces costs and eases implementation of the leases standard for financial statement preparers. The ASU
simplifies transition requirements and, for lessors, provides a practical expedient for the separation of non-lease components from lease
components. ASU 2016-02 was further amended in November&#160;2019 by ASU 2019-10 and in June&#160;2020 by ASU 2020-05, which deferred
the effective date of new lease standard. As a result, ASC 842, Leases, is effective for public companies for annual reporting periods
and interim periods within those years beginning after December&#160;15, 2018. For all other entities, the guidance is effective for fiscal
years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022. As an emerging
growth company, the Company elects to apply for the new and revised accounting standards at the effective date for a private company and
to adopt this guidance effective October 1, 2021. The Company is currently evaluating the impact of adopting this standard on its consolidated
financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160; &#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June&#160;2016, the FASB issued Accounting
Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all
expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable
and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost. ASU 2016-13 was subsequently amended by Accounting Standards Update 2018-19,&#160;Codification Improvements
to Topic 326, Financial Instruments &#8212; Credit&#160;Losses, Accounting Standards Update 2019-04&#160;Codification Improvements to
Topic 326, Financial Instruments &#8212; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, and
Accounting Standards Update 2019-05,&#160;Targeted Transition Relief.&#160;In November&#160;2019, the FASB issued ASU 2019-10, which extends
the effective date for adoption of ASU 2016-13. In November&#160;2019, the FASB issued ASU 2019-11 to clarify its new credit impairment
guidance in ASU 326. Accordingly, for public entities that are not smaller reporting entities, ASU 2016-13 and its amendments is effective
for fiscal years, and interim periods within&#160;those fiscal years, beginning after December&#160;15, 2019. For all other entities,
this guidance and its amendments will be effective for fiscal years beginning after December&#160;15, 2022, including interim periods
within those fiscal years. As an emerging growth company, the Company plans to adopt this guidance effective October 1, 2023. The Company
is currently evaluating the impact of its pending adoption of ASU 2016-13 on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU No. 2019-12,
Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes. ASU 2019-12 is intended to simplify accounting for income
taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application.
ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years, which is fiscal
2021 for us, with early adoption permitted. The Company does not expect adoption of the new guidance to have a significant impact on our
financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2020, the FASB issued ASU 2020-02,
&#8220;Financial Instruments &#8211; Credit Losses (Topic 326) and Leases (topic 842) Amendments to SEC Paragraphs Pursuant to SEC Staff
Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (topic
842)&#8221;. This ASU provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses.
This ASU is effective for interim and annual periods beginning after December 15, 2019, and early adoption is permitted. The Company is
evaluating the impact of this guidance on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338331320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">ACCOUNTS RECEIVABLE, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8212; ACCOUNTS RECEIVABLE, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,020,269</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,511,769</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(446,527</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(639,991</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Accounts receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,573,742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,871,778</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s accounts receivable primarily
includes balance due from customers when the Company&#8217;s pharmaceutical products are sold and delivered to customers. All of the Company&#8217;s
accounts receivable balance at September 30, 2020 has been collected in fiscal year 2021. As of date of this report, approximately 75.4%,
or $11.7 million, of the Company&#8217;s net account receivable balance at September 30, 2021 has been subsequently collected and the
remaining balance is expected to be substantially collected before March 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the Company&#8217;s
accounts receivable and subsequent collection by aging bucket:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Accounts Receivable by aging bucket</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance as of <br/> September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Subsequent <br/> collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of <br/> subsequent <br/> collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Less than 3 months</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,587,490</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,991,589</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">69.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>From 4 to 6 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,922,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,541,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>From 7 to 9 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">356,267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>From 10 to 12 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,124</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,193</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Over 1 year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,162</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total gross accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,020,269</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,739,179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(446,527</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Accounts Receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,573,742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,739,179</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">75.4</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Allowance for doubtful accounts movement is as
follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Beginning balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">639,991</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">517,754</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,907</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bad debt recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(225,660</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,196</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,330</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">446,527</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">639,991</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338343128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8212; INVENTORY, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consists of the following:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">607,661</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">553,982</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Finished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,971,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,462,835</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Inventory valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(116,453</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(110,585</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total inventory, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,462,542</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,906,232</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Impairment
of inventories is recorded in cost of goods sold. For the years ended September 30, 2021, the Company had no provision for impairment
of inventory in regards to slow moving or obsolete items. For the years ended September 30, 2020 and 2019, recovery of previously accrued
inventory allowance amounted to $75,391 and $187,271, respectively. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338342296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Advance to Suppliers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AdvancesToSuppliersAbstract', window );"><strong>Advances To Suppliers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AdvancesToSuppliersTextBlock', window );">ADVANCE TO SUPPLIERS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8212; ADVANCE TO SUPPLIERS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advances to suppliers  consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&#160;30, <br/>
2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&#160;30, <br/>
2020</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Advances to suppliers for inventory raw material purchase</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,738,313</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Advances to suppliers</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,738,313</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advances to suppliers represent prepayments made
to suppliers to ensure continuous high-quality supplies and favorable purchase prices for raw materials. During 2021, due to supply chain
disruption caused by COVID-19, the market price for raw materials continued to increase. In order to ensure sufficient raw materials for
production and lock the favorite purchase price, the Company made advance payment to suppliers. As of the date of this report, 66.1% of
the September 30, 2021 balance has been realized when the Company received the purchased raw materials and the remaining balance is expected
to be realized by March 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvancesToSuppliersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvancesToSuppliersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvancesToSuppliersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the advances to suppliers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvancesToSuppliersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335465688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Advertisting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentForAdvertistingAbstract', window );"><strong>Prepayment For Advertisting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentForAdvertistingTextBlock', window );">PREPAYMENT FOR ADVERTISTING</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8212; PREPAYMENT FOR ADVERTISTING
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 6, 2021, the Company entered into an advertising service agreement
with third-party Guangdong Fengyang Legend Consulting Co., Ltd., (&#8220;Fengyang Legend&#8221;), pursuant to which, Fengyang Legend will
assist the Company to develop and produce TV advertising film for the Company in order to promote the Company&#8217;s sales of its major
TCMD product, Bainian Pill and Guben Yanling Pill, coordinate the specific TV Channel to broadcast the advertising film to targeted geographic
market areas. Total contracted advertising service fee is RMB 55 million (approximately $8.5 million) with adverting consulting service
period of one year from October 1, 2021 to September 30, 2022. Based on contract terms, the Company is required to make 30% advance payment
to Fengyang Legend within 7 business days upon signing the service agreement and make additional 58% of the contract price to Fengyang
Legend once the specific TV channel used for broadcast the TV film is determined. As of September 30, 2021, total RMB 48.4 million (approximately
$7.5 million) has been prepaid to Fengyang Legend for TV film production and coordinating the TV channels for broadcasting, and was recorded
as prepayment for advertising services on the balance sheets. Such prepayment has been expensed when the first time the advertising took
place, in October 2021. The remaining RMB 6.6 million (approximately $1 million) represents the monthly advertising fees to be paid in
13 installments when the advertising film is broadcasted through the designated TV channels and will be expensed as occurred.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForAdvertistingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForAdvertistingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForAdvertistingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForAdvertistingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338366760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Invstment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-Term Invstment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_HeldToMaturityInvestmentDisclosureTextBlock', window );">SHORT-TERM INVSTMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 &#8212;&#160;SHORT-TERM&#160;INVSTMENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s short-term&#160;investments
consist of wealth management financial products purchased from financial institution, which can be redeemed anytime at the Company&#8217;s
discretion. The financial institution invests the Company&#8217;s fund in certain financial instruments including money market funds and
bonds to generate investment income. Short-term&#160;investments consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: justify">Add: purchase wealth management financial products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">15,330,660</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Less: redemption</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,801,927</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Accrued investment income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,078</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Ending balance of short-term investments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,725,204</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investment income generated from such short-term&#160;investments amounted
to $239,549, <span style="-sec-ix-hidden: hidden-fact-88">Nil</span> and <span style="-sec-ix-hidden: hidden-fact-89">Nil</span> for the&#160;years ended September 30, 2021, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_HeldToMaturityInvestmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_HeldToMaturityInvestmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338320328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 &#8212; PROPERTY, PLANT AND EQUIPMENT,
NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property, plant and equipment, net, consists of
the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center">Useful life</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2021</b></p></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2020</b></p></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Buildings</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">20 years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,808,006</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,414,580</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center">5-10 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,047,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,534,015</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Automobiles</td><td>&#160;</td>
    <td style="text-align: center">3-5 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,346</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Office and electric equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">3-5 years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">489,886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">434,075</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Subtotal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,461,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,523,016</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,780,247</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,094,952</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,681,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,428,064</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-align: justify; text-indent: -0.4in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $441,355, $404,948 and $413,199 for the years
ended September 30, 2021, 2020 and 2019, respectively. Loss from disposal of fixed assets amounted to $1,559, <span style="-sec-ix-hidden: hidden-fact-90">Nil</span> and $2,085 for the years
ended September 30, 2021, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338322008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-align: justify; text-indent: -0.4in"><b>NOTE 9 &#8212;
INTANGIBLE ASSETS, NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets, net consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Useful life</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2021</b></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2020</b></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Land use rights</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">50 years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">278,327</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">264,304</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">3 years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,186</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286,490</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(123,208</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(111,714</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">178,483</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">174,776</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense was $5,523, $5,131 and $5,232
for the years ended September 30, 2021, 2020 and 2019, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Estimated future amortization expense for intangible
assets is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Years ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization<br/>
 expense</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,567</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,567</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,567</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,567</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,567</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150,648</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">178,483</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338334648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Construction-in-Progress (CIP) Project<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentForConstructionInProgressAbstract', window );"><strong>Prepayment For Construction In Progress [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentForConstructionInProgressTextBlock', window );">PREPAYMENT FOR CONSTRUCTION-IN-PROGRESS ("CIP") PROJECT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 &#8212; PREPAYMENT FOR CONSTRUCTION-IN-PROGRESS
(&#8220;CIP&#8221;) PROJECT </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Construction-in-progress (&#8220;CIP&#8221;) represents direct costs of
construction incurred for the Company&#8217;s manufacturing facilities. On June 25, 2021, the Company signed a construction sub-contract
with sub-contractor Jiangxi Chenyuan Construction Project Co., Ltd. (&#8220;Chenyuan&#8221;), pursuant to which, Chenyuan will help the
Company to construct 4 manufacturing plant buildings and an office building with total estimated budget of RMB 165 million (approximately
$25.5 million). The construction work started on August 8, 2021, with estimated completion date on August 7, 2023. As of September 30,
2021, the Company has made prepayment of approximately RMB69.2 million (approximately $10.7 million) to Chenyuan for land improvement,
building foundation and the construction of the main body of the manufacturing plants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, the $10.7 million prepayment
to Chenyuan was recorded as prepayment for CIP project on the balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, future additional capital expenditure on this
CIP project is estimated to be approximately RMB 95.8 million (equivalent to $14.8 million), among which approximately $3.8 million is
required for the next 12 months. The Company currently plans to support its ongoing CIP project construction through cash flows from operations,
proceeds received from the IPO and borrowing additional bank loans from PRC banks in the future and use such bank borrowings to support
the CIP project, if necessary. The construction of this new manufacturing facility is expected to be fully completed and put into production
by August 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, future minimum capital
expenditures on the Company&#8217;s CIP project are estimated as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Years ending September 30,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Capital<br/>
 Expenditure</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>on CIP</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,831,300</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,721,440</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,277,100</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,829,840</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForConstructionInProgressAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForConstructionInProgressAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForConstructionInProgressTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepayment for construction in progress.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForConstructionInProgressTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680340485624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Purchase of a Property<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentForPurchaseOfAPropertyAbstract', window );"><strong>Prepayment For Purchase Of A Property [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentForPurchaseOfAPropertyTextBlock', window );">PREPAYMENT FOR PURCHASE OF A PROPERTY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 &#8212; PREPAYMENT FOR PURCHASE OF
A PROPERTY </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2021, the Company entered into a real
estate property purchase agreement with related party Jiangxi Yueshang Investment Co., Ltd. (&#8220;Jiangxi Yueshang&#8221;), the Company&#8217;s
CEO Mr. Gang Lai owns 5% equity interest in this entity, pursuant to the purchase agreement, Jiangxi Yueshang will sell and the Company
will purchase certain residential apartment and commercial office space totaling 2,749.30 square meters with total purchase price of RMB
32 million (approximately $4.95 million). Pursuant to the agreement, the Company is required to make 50% prepayment, with remaining 20%
payable when certificate of occupancy is available and 30% payable upon delivery of the property.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, the Company has made
prepayment of RMB 16 million ($2,476,800) to Jiangxi Yueshang. The remaining balance is expected to be paid by August, 2024. Since the
property is located at urban downtown of Ji&#8217;an City, the Company plans to use the property as offices in late 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForPurchaseOfAPropertyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForPurchaseOfAPropertyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForPurchaseOfAPropertyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForPurchaseOfAPropertyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335478488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Bank Loans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">SHORT-BANK LOANS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12 &#8212; SHORT-BANK LOANS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Short-term bank loans consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Short-term bank loans:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 9pt">Maturity date on March 31, 2021, interest rate 4.81% per annum</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,176,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Maturity date on June 18, 2021, interest rate 4.81% per annum</td><td>&#160;</td>
    <td style="text-align: center">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,470,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Maturity date on June 15, 2022, interest rate 4.81% per annum</td><td>&#160;</td>
    <td style="text-align: center">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,548,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Maturity date on June 30, 2022, interest rate 4.5% per annum</td><td>&#160;</td>
    <td style="text-align: center">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,548,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Maturity date on March 17, 2022, interest rate 4.81% per annum</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">(5)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,238,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total short-term bank loans</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,334,400</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,646,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"/> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </span></td> <td style="text-align: justify">On September 26, 2019, the Company&#8217;s subsidiary Jiangxi Universe
signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB 8 million (equivalent to $1,176,000)
as working capital for one year, with the maturity date on March 31, 2021. The fixed interest rate of the loan was 4.81% per annum. Related
parties including Mr. Gang Lai, the Company&#8217;s controlling shareholder, and Foshan Shangyu Investment Holding Co., Ltd., an affiliated
entity controlled by Mr. Gang Lai, and three unrelated individuals jointly signed a guarantee agreement with LRC Bank to provide credit
guarantee for this loan. The loan was fully repaid upon maturity.</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"/> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) </span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 19, 2020, the Company&#8217;s subsidiary Jiangxi Universe signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB 10 million (equivalent to $1,470,000) as working capital for one year, with the maturity date on June 18, 2021. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity. </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"/> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) </span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 16, 2021, the Company&#8217;s subsidiary Jiangxi Universe signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB 10 million (equivalent to $1,548,000) as working capital for one year, with the maturity date on June 15, 2022. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for this loan. </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"/> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) </span></td> <td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">On June 30, 2021, the Company&#8217;s subsidiary Jiangxi Universe signed
a loan agreement with Bank of Communications to borrow RMB 10 million (equivalent to $1,548,000) as working capital for one year, with
the maturity date on June 18, 2022. The fixed interest rate of the loan was 4.5% per annum. Certain related parties of the Company, including
Mr. Gang Lai, the Company&#8217;s controlling shareholder, Mr. Gang Lai&#8217;s spouse, Mrs. Xing Wu, and the Company&#8217;s subsidiary,
Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"/> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5) </span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 18, 2021, the Company&#8217;s subsidiary Universe Trade signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB 8 million (equivalent to $1,238,400) as working capital for one year, with the maturity date on March 17, 2022. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for this loan. </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the above-mentioned loans, the Company recorded
a total interest expense of $149,303, $157,528 and $135,717 for the years ended September 30, 2021, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335467560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 &#8212; RELATED PARTY TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature of relationships with related parties</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;  border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 39%; font-weight: bold; text-align: justify">Name</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 60%; font-weight: bold; text-align: justify">Relationship with the Company</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Mr. Gang Lai</td><td>&#160;</td>
    <td style="text-align: left">Chief Executive Officer (&#8220;CEO&#8221;), chairman of the Board of Directors</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Mrs. Lin Yang</td><td>&#160;</td>
    <td style="text-align: left">Chief Financial Officer and Director</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Greatest Group (China) Financial Management Limited (&#8220;Greatest Group&#8221;)</td><td>&#160;</td>
    <td style="text-align: left">One of the Company&#8217;s minority shareholders owns 8.7% of the ownership interest in this entity</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Foshan Shangyu Investment Holding Co., Ltd (&#8220;Foshan Shangyu&#8221;)</td><td>&#160;</td>
    <td style="text-align: left">An affiliated entity of the Company, 90% owned by and controlled by the Company&#8217;s CEO.</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Due from related parties</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Name</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Greatest Group</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">235,438</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foshan Shangyu</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,544</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total due from related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">236,982</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s due from related parties were
interest free and due on demand. The September 30, 2021 due from related parties balance has been subsequently collected back and the
Company does not have the intention to make additional cash advance to related parties going forward.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Due to related parties</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Name</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Mr. Gang Lai</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">956,492</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Mrs. Lin Yang</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,723</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#12288;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total due to related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,723</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">956,492</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, the balance
due to related parties mainly consisted of advances from the Company&#8217;s principal shareholder for working capital purposes during
the Company&#8217;s normal course of business. These advances are non-interest bearing and due on demand.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loan guarantee provided by related parties</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Company&#8217;s bank borrowings
from LRC Bank, the Company&#8217;s chief executive officer Mr. Gang Lai and Foshan Shangyu Investment Holding Co., Ltd., an affiliated
entity controlled by him, jointly signed a guarantee agreement with LRC Bank to provide credit guarantee for the Company&#8217;s loans
from LRC Bank within the loan period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Company&#8217;s bank borrowings
from Bank of Communications, certain related parties of the Company, including Mr. Gang Lai, the Company&#8217;s controlling shareholder,
Mr. Gang Lai&#8217;s spouse, Ms. Xing Wu, and the Company&#8217;s subsidiary, Universe Trade, jointly signed guarantee agreements with
Bank of Communications to provide credit guarantee for this loan (see Note 12).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(e)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prepayment to related party for property purchase</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As disclosed in Note 11, on May 6, 2021, the Company
entered into a real estate property purchase agreement with related party Jiangxi Yueshang to purchase certain residential apartment and
commercial office space totaling 2,749.30 square meters with total purchase price of RMB32 million (approximately $4.95 million). As of
September 30, 2021, the Company had made prepayment of RMB16 million ($2,476,800) to Jiangxi Yueshang. The remaining balance is expected
to be paid by August 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335480440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 &#8212; TAXES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate Income Taxes (&#8220;CIT&#8221;)</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Cayman Islands</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the current tax laws of the Cayman Islands,
Universe INC is not subject to tax on its income or capital gains. In addition, no Cayman Islands withholding tax will be imposed upon
the payment of dividends by the Company to its shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Hong Kong</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Universe HK is incorporated in Hong Kong and is
subject to profit taxes in Hong Kong at a rate of 16.5%. However, Universe HK did not generate any assessable profits derived from Hong
Kong sources for the fiscal years ended September 30, 2021, 2020 and 2019, and accordingly no provision for Hong Kong profits tax has
been made in these periods.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160; &#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">PRC</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Enterprise Income Tax (&#8220;EIT&#8221;)
Law of PRC, domestic enterprises and Foreign Investment Enterprises (&#8220;FIEs&#8221;) are usually subject to a unified 25% enterprise
income tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on a case-by-case basis. EIT grants preferential
tax treatment to High and New Technology Enterprises (&#8220;HNTEs&#8221;). Under this preferential tax treatment, HNTEs are entitled
to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. Jiangxi Universe, one
of the Company&#8217;s main operating subsidiaries in PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15%
beginning November&#160;2016 with a term of three years. In December 2019, Jiangxi Universe successfully renewed its HNTE certification
with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through December 2022. Universe
Trade, the Company&#8217;s another operating subsidiary in PRC, was approved as a HNTE and is entitled to a reduced income tax rate of
15% beginning December&#160;2020 with a term of three years. EIT is typically governed by the local tax authority in PRC. Each local tax
authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The
corporate income taxes for the years ended September 30, 2021, 2020 and 2019 were reported at a blended reduced rate as a result of Jiangxi
Universe and Universe Trade being approved as a HNTE and enjoying a 15% reduced income tax rate. The impact of the tax holidays noted
above decreased PRC corporate income taxes by $1,518,979, $118,986 and $312,357 for the years ended September 30, 2021, 2020 and 2019,
respectively. The benefit of the tax holidays on net income per share (basic and diluted) $0.09, $0.01 and $0.02 for the years ended September
30, 2021, 2020 and 2019, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160; <b>&#160;</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of the income tax provision (benefit)
are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current income tax provision</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Cayman Island</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; padding-left: 9pt">PRC</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,026,867</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,552,097</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,141,222</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,026,867</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,552,097</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,141,222</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred income tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Cayman Island</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">PRC</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(668,341</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,886</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(39,625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total income tax provision</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,358,526</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,542,211</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,101,597</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table reconciles the China statutory
rates to the Company&#8217;s effective tax rate for the years ended September 30, 2021, 2020 and 2019:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Statutory PRC income tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effect of income tax holiday</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.3</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent difference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-PRC entities not subject to PRC income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impact on DTA due to change in applicable income tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17.1</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">25.2</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">21.8</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company continually evaluates expiring statutes
of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. As of September 30, 2021, all of the Company&#8217;s
tax returns of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred tax assets are composed of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 10pt">Net operating loss carry-forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">785,550</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">186,537</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,447</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">&#8212;&#160;&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">869,997</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186,537</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">&#8212;&#160;&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">&#8212;&#160;&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">869,997</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">186,537</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company periodically evaluates the likelihood
of the realization of deferred tax assets, and reduces the carrying amount of the deferred tax assets by a valuation allowance to the
extent it believes a portion will not be realized. Management considers new evidence, both positive and negative, that could affect the
Company&#8217;s future realization of deferred tax assets including its recent cumulative earnings experience, expectation of future income,
the carry forward periods available for tax reporting purposes and other relevant factors. Although Jiangxi Universe incurred a net loss
during the year ended September 30, 2021, the Company determined that it is more likely than not its deferred tax assets could be realized
due to the estimated future earnings in Jiangxi Universe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px"/>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Taxes payable</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Taxes payable consist of the following:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Income tax payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">669,780</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">767,297</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Value added tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">326,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">433,838</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other taxes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,212</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">130,614</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total taxes payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,101,460</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,331,749</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338371960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14 &#8212; CONCENTRATIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A majority of the Company&#8217;s revenue and
expense transactions are denominated in RMB and a significant portion of the Company and its subsidiaries&#8217; assets and liabilities
are denominated in RMB. RMB is not freely convertible into foreign currencies. In the PRC, certain foreign exchange transactions are required
by law to be transacted only by authorized financial institutions at exchange rates set by the People&#8217;s Bank of China (&#8220;PBOC&#8221;).
Remittances in currencies other than RMB by the Company in China must be processed through the PBOC or other China foreign exchange regulatory
bodies which require certain supporting documentation in order to affect the remittance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, $5,892,655
and $10,027,666 of the Company&#8217;s cash was on deposit at financial institutions in the PRC where there currently is no rule or regulation
requiring such financial institutions to maintain insurance to cover bank deposits in the event of bank failure. For the years ended September
30, 2021, 2020 and 2019, the Company&#8217;s substantial assets were located in the PRC and the Company&#8217;s substantial revenues were
derived from its subsidiaries located in the PRC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended September 30, 2021, 2020 and
2019, no single customer accounted for more than 10% of the Company&#8217;s total revenue. The Company&#8217;s top 10 customers aggregately
accounted for 30.4%, 33.3% and 34.5% of the total revenue for the years ended September 30, 2021, 2020 and 2019, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of one of the Company&#8217;s major products, Guben Yanling Pill,
accounted for 40.3%, 38.2% and 32.4% of the Company&#8217;s total revenue for the years ended September 30, 2021, 2020 and 2019, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, no customer accounted
for more than 10% of the total accounts receivable balance. As of September 30, 2020, one customer accounted for 13.0% of the total accounts
receivable balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021, two suppliers accounted
for 35.3% and 28.0% of the total advance to supplier balance. No supplier accounted for more than 10% of the Company&#8217;s total advance
to supplier balance as of September 30, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended September 30, 2021, no supplier
accounted for more than 10% of the total purchases, respectively. For the year ended September 30, 2020, two suppliers accounted for approximately
19.6% and 13.6% of the total purchases, respectively. For the year ended September 30, 2019, one supplier accounted for approximately
14.1% of the total purchases.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338144712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 15 &#8212; SHAREHOLDERS&#8217; EQUITY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Ordinary Shares</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Universe INC was incorporated under the laws of
the Cayman Islands on December 11, 2019. The original authorized number of ordinary shares was 50,000 shares with par value of US$1.00
per share and 50,000 shares were issued. On August 7, 2020, the Company amended its Memorandum of Association to increase the authorized
number of shares to 100,000,000 shares with par value of $0.003125 per share, and subdivide the original issued shares from 50,000 shares
at par value of $1.00 per share to 16,000,000 ordinary shares with par value of $0.003125 per share. As a result of this forward split
of the outstanding ordinary shares at a ratio of 320-for-1 share, there is a total of 16,000,000 shares issued and outstanding.&#160;The
issuance of these 16,000,000 shares is considered as a part of the Reorganization of the Company, which was retroactively applied as if
the transaction occurred at the beginning of the period presented (see Note 1).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Initial Public Offering</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2021, the Company closed its IPO
of 5,000,000 ordinary shares, par value $0.003125 per share (the &#8220;ordinary shares&#8221;) at a public offering price of $5.00 per
share. On March 29, 2021, the underwriter exercised in full its over-allotment option to purchase an additional 750,000 ordinary shares.&#160;<span>The
closing for the sale of the over-allotment shares took place on March 31, 2021. Gross proceeds of the IPO, including the proceeds from
the sale of the over-allotment shares, totaled $28.75 million, before deducting underwriting discounts and other related expenses</span>.
Net proceeds of our IPO, including over-allotment shares, were approximately $25.6 million. In connection with the IPO, the Company&#8217;s
ordinary shares began trading on the Nasdaq Global Market&#160;under the symbol &#8220;UPC&#8221; on March 23, 2021.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, the Company
had total of 21,750,000 and 16,000,000 shares ordinary shares issued and outstanding, respectively<b>.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Underwriter warrants </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company&#8217;s IPO, the Company also agreed to
issue warrants to the underwriter, for a nominal consideration of $0.001 per warrant, to purchase 300,000 ordinary shares of the Company
(equal to 6% of the total number of Ordinary Shares sold in the IPO, but not including any over-allotment Ordinary Shares sold in the
over-allotment option) (the &#8220;Underwriter Warrants&#8221;). These warrants have warrant term of five years, with an exercise price
of $5.50 per share (equal to 110% of the Company&#8217;s IPO offering price of $5.00 per share). The Underwriter Warrants may be purchased
in cash or via cashless exercise, will be exercisable for five (5) years, and will terminate on the fifth anniversary of the date thereafter.
Management determined that these warrants meet the requirements for equity classification under ASC 815-40 because they are indexed to
its own stock. As of September 30, 2021, these underwriter warrants were issued and outstanding but none of the warrants has been exercised.
For the year ended September 30, 2021, these underwriter warrants were antidilutive and accordingly were not included in the diluted EPS
calculation based on treasury stock method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash dividends </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 21, 2016, September 13, 2017, February
2, 2018, September 20, 2018 and February 21, 2019, the board of directors of Jiangxi Universe approved resolutions to pay cash dividend
of RMB40 million, RMB30 million, RMB20 million, RMB10 million and RMB30 million, respectively, to its shareholders at the time of record
out of the retained earnings balance of Jiangxi Universe, to be paid to these shareholders when there are sufficient available earnings
and the Company has sufficient funds. A total of RMB130 million (approximately $19.1 million) cash dividend was declared from September
2016 to February 2019, among which approximately RMB20 million ($3.1 million) was paid in cash to its shareholders in 2018 and the remaining
RMB 110 million ($16 million) was paid to its shareholders in 2019. There was no additional cash dividends paid during the years ended
September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except for the dividends declared mentioned above,
the Company has not declared or paid dividends to its shareholders in the past, and may not choose to make additional distributions in
the future. Any decision as to the payment of dividends will depend on the available earnings, the capital requirements of the Company,
the Company&#8217;s general financial condition and other factors deemed pertinent by the board of directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;<i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Statutory reserve and restricted net assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s PRC subsidiaries are restricted
in their ability to transfer a portion of their net assets to the Company. The payment of dividends by entities organized in China is
subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated
profits as determined in accordance with accounting standards and regulations in China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is required to make appropriations
to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income
determined in accordance with generally accepted accounting principles of the PRC (&#8220;PRC GAAP&#8221;). Appropriations to the statutory
surplus reserve are required to be at least 10% of the after-tax net income determined in accordance with PRC GAAP until the reserve is
equal to 50% of the entity&#8217;s registered capital. Appropriations to the discretionary surplus reserve are made at the discretion
of the board of directors. The statutory reserve may be applied against prior year losses, if any, and may be used for general business
expansion and production or increase in registered capital, but are not distributable as cash dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Relevant PRC laws and regulations restrict the
Company&#8217;s PRC subsidiaries from transferring a portion of their net assets, equivalent to its statutory reserves and their share
capital, to the Company in the form of loans, advances or cash dividends. Only PRC entities&#8217; accumulated profits may be distributed
as dividends to the Company without the consent of a third party. As of September 30, 2021 and 2020, the restricted amounts as determined
pursuant to PRC statutory laws totaled $2,439,535 and $2,439,535, respectively, and total restricted net assets amounted to $31,786,663
and $6,168,535, respectively.<b>&#160;</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash transfer between the Company and its
subsidiaries </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended September 30, 2021, the Company
transferred cash in the amount of $11,358,764 to its subsidiary in Hong Kong, and the Company&#8217;s Hong Kong subsidiary, via the WFOE,
further transferred cash in the amount of $6,807,507 to the PRC subsidiaries. For the year ended September 30, 2020 and 2019, there was
no cash transferred from the Company to its PRC subsidiaries. The assets transfer was for business operation purpose. There was no distribution
of earnings by the PRC operating subsidiaries to the Company during the years ended September 30, 2021, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338282504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 16 &#8212; COMMITMENTS AND CONTINGENCIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is a party to various
legal actions arising in the ordinary course of business. The Company accrues costs associated with these matters when they become probable
and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. For the
years ended September 30, 2021, 2020 and 2019, the Company did not have any material legal claims or litigation that, individually or
in aggregate, could have a material adverse impact on the Company&#8217;s consolidated financial position, results of operations and cash
flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has an ongoing CIP project associated
with the construction of a new manufacturing facility. As of September 30, 2021, future minimum capital expenditures on the Company&#8217;s
CIP project amounted to approximately $14.8 million, among which approximately $3.8 million is required for the next 12 months from the
date of this report (see Note 7).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338334648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 17 &#8212; SEGMENT REPORTING</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An operating segment is a component of the Company
that engages in business activities from which it may earn revenues and incur expenses, and is identified on the basis of the internal
financial reports that are provided to and regularly reviewed by the Company&#8217;s chief operating decision maker in order to allocate
resources and assess performance of the segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The management of the Company concludes that it
has only one reporting segment. The Company develops, manufactures and sells traditional Chinese medicine derivatives (&#8220;TCMD&#8221;)
products targeted to the elderly to address their physical conditions in the aging process and to promote their general well-being. In
addition, the Company also sells biochemical drugs, medical instruments, Traditional Chinese Medicine Pieces products and dietary supplements
manufactured by third-party pharmaceutical companies (&#8220;third-party products&#8221;). All of these products are currently sold in
China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s products have similar economic
characteristics with respect to raw materials, vendors, marketing and promotions, customers and methods of distribution. The Company&#8217;s
chief operating decision maker has been identified as the Chief Executive Officer, who reviews consolidated results when making decisions
about allocating resources and assessing performance of the Company, rather than by product types or geographic area; hence the Company
has only one reporting segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Revenue by product source </span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Sales of TCMD products manufactured by the Company</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,559,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,374,751</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,895,542</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,333,774</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">33,229,316</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Revenue by product categories </span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The summary of our total revenues by product categories
for the years ended September 30, 2021, 2020 and 2019 was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Sales of TCMD products:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Medicinal liquor products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,951,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,616,080</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,356,015</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other chronic condition treatment products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,978,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,059,403</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,056,228</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Cold and flu medicines</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,629,606</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,699,268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,483,299</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Sub-total of TCMD products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,559,286</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,374,751</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,895,542</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Sales of third-party products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Biochemical drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,082,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,325,411</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,508,816</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Traditional Chinese medicine pieces</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,097</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,409</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,318,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,950,238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,668,422</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Dietary supplements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,463</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,127</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Subtotal of third-party products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,333,774</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Total revenue</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">33,229,316</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338376328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 18 &#8212; SUBSEQUENT EVENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 1, 2021, the Company entered into
definitive agreements (the &#8220;Agreements&#8221;) with Kitanihon Pharmaceutical Co., Ltd. (&#8220;Kitanihon&#8221;), a Japanese pharmaceutical
company, pursuant to which (i) both parties will build a manufacturing facility in Ji&#8217;an, Jiangxi, China, for the manufacturing
and research and development of traditional Chinese medicine derivatives products, with an aggregate area of over 430,000 square feet,
and the Company will bear the costs associated with building the facility, and (ii) the Company will purchase 464 shares of Kitanihon
for an aggregate of JPY176.32 million (approximately US$1.56 million).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In relation to the Agreements, Sununion Holding
Group Limited (&#8220;Sununion&#8221;), the controlling shareholder of the Company wholly owned by Mr. Gang Lai, the chief executive officer
and chairman of the board of directors of the Company, entered into an agreement with Mr. Gang Lai and Kitanihon on December 1, 2021,
pursuant to which Kitanihon authorizes the Company to use certain of its intangible assets, including technologies and certain intellectual
properties, in exchange for which Mr. Gang Lai will transfer ordinary shares of Sununion owned by him and valued at US$2.5 million to
Kitanihon.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated the subsequent event through
the date of this report, and concluded that there are no material reportable subsequent events need to be disclosed. &#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338352936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 19 &#8212; CONDENSED FINANCIAL INFORMATION
OF THE PARENT COMPANY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Rule 12-04(a),
5-04(c) and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when the restricted
net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal
year. The Company performed a test on the restricted net assets of consolidated subsidiaries in accordance with such requirement and concluded
that it was applicable to the Company as the restricted net assets of the Company&#8217;s PRC subsidiary exceeded 25% of the consolidated
net assets of the Company. Therefore, the condensed financial statements for the parent company are included herein.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the above test, restricted net
assets of consolidated subsidiaries shall mean that amount of the Company&#8217;s proportionate share of net assets of consolidated subsidiaries
(after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries
in the form of loans, advances or cash dividends without the consent of a third party.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The condensed financial information of the parent
company has been prepared using the same accounting policies as set out in the Company&#8217;s consolidated financial statements except
that the parent company used the equity method to account for investment in its subsidiaries. Such investment is presented on the condensed
balance sheets as &#8220;Investment in subsidiaries&#8221; and the respective profit or loss as &#8220;Equity in earnings of subsidiaries&#8221;
on the condensed statements of income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The footnote disclosures contain supplemental
information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the
consolidated financial statements of the Company. Certain information and footnote disclosures normally included in financial statements
prepared in accordance with U.S GAAP have been condensed or omitted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2021 and 2020, there were
no material contingencies, significant provisions for long-term obligations, or guarantees of the Company, except for those which have
been separately disclosed in the consolidated financial statements, if any.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: justify">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">110,393</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,725,204</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,835,597</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 9pt; padding-left: 9pt">Investment in subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,098,756</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,802,904</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">58,934,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,802,904</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt">Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares and 16,000,000 shares issued and outstanding as of September 30, 2021 and 2020, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,969</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 10pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,279,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,679,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Retained earnings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,498,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,178,514</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,088,759</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">895,390</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,934,353</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,802,904</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 20pt">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">58,934,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,802,904</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating costs and expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 9pt">General and administrative expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,177,869</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expenses):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Income from short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60,751</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity in earnings of subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,319,023</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,558,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,551,465</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,319,952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,558,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,551,465</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,193,369</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">860,623</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(645,978</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive income attributable to the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,513,321</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,418,845</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,905,487</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 10pt">Net income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,319,952</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,558,222</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,551,465</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 10pt">Adjustments to reconcile net cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 8.3pt; padding-left: 20pt">Equity in earnings of subsidiary</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,319,027</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,558,222</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,551,465</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 30pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(999,075</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 28.3pt">Payment for short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,330,660</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 28.3pt">Redemption of short-term investments </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,801,927</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,528,733</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 28.3pt">Net proceeds from issuance of ordinary shares in IPO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,957,457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 21.3pt">&#160;&#160;Cash lent to subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,358,764</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,598,693</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">CHANGES IN CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">CASH, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">CASH, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">110,393</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.5-04(Schedule I))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391182&amp;loc=d3e5864-122674<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=d3e5283-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680331698616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of consolidation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the financial statements of Universe INC, Universe HK, Universe Technology, Jiangxi
Universe, Universe Trade and Universe Hanhe. All inter-company balances and transactions are eliminated upon consolidation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Uses of estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Uses
of estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America
(&#8220;US GAAP&#8221;), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant estimates
required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, the realizability
of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of
long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual
results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
and Uncertainties</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main operation of the Company is located in the PRC. Accordingly, the Company&#8217;s business, financial condition, and results of operations
may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The
Company&#8217;s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although
the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations
including its organization and structure disclosed in Note 1, this may not be indicative of future results.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by
rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition
with respect to our current and future pharmaceutical product candidates from major pharmaceutical companies in China.&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters,
extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company&#8217;s
operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operations may be further affected by the ongoing outbreak of COVID-19 which in March 2020, had been declared as a pandemic
by the World Health Organization.&#160;To reduce the spread of the COVID-19, the Chinese government has employed measures including city
lockdowns, quarantines, travel restrictions, suspension of business activities and school closures. Due to difficulties resulting from
the COVID-19 outbreak, including, but not limited to, the temporary closure of the Company&#8217;s factory and operations beginning in
early February until to March 2, 2020, limited support from the Company&#8217;s employees, delayed access to raw material supplies and
inability to deliver products to customers on a timely basis, the Company&#8217;s business was negatively impacted and generated lower
revenue and net income during the period from February to March 2020. Although the Company resumed its operations on March 2, 2020 and
the COVID-19 impact on the Company&#8217;s operating results and financial performance for fiscal year 2020 and 2021 seems to be temporary,
a resurgence could negatively affect the execution of customer contracts, the collection of customer payments, or disrupt the Company&#8217;s
supply chain, and the continued uncertainties associated with COVID 19 may negatively impact the Company&#8217;s revenue and cash flows.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of
its bank accounts in the PRC. Cash balances in bank accounts in PRC are not insured by the Federal Deposit Insurance Corporation or other
programs.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts
receivable, net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are presented net of allowance for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts
based on individual account analysis and historical collection trend. The Company establishes a provision for doubtful receivables when
there is objective evidence that the Company may not be able to collect amounts due. The allowance is based on management&#8217;s best
estimate of specific losses on individual exposures, as well as a provision on historical trends of collections. Actual amounts received
may differ from management&#8217;s estimate of credit worthiness and the economic environment. Delinquent account balances are written-off
against the allowance for doubtful accounts after management has determined that the collection is not probable. Allowance for uncollectable
balances amounted to $446,527 and $639,991 as of September 30, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inventories,
net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and
related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision
for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less
any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments,
and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable
value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future
product sales. The Company recorded inventory reserve of $116,453 and $110,585 as of September 30, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AdvancesToSuppliersNetPolicyTextBlock', window );">Advances to suppliers, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><b><i>Advances
to suppliers, net</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances
to suppliers represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices for raw materials. These
advances are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time
to make cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company
when the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific
allowances when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September
30, 2021 and 2020, no allowance for doubtful accounts was deemed necessary as the Company believes that all advances to suppliers fully
realizable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred initial public offering (&#8220;IPO&#8221;) costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Deferred&#160;initial
public&#160;offering (&#8220;IPO&#8221;) costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the requirement of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212;
&#8220;Expenses of Offering&#8221;. Deferred offering costs consist of underwriting, legal, accounting and other expenses incurred through
the balance sheet date that are directly related to the intended IPO. Deferred offering costs will be charged to shareholders&#8217;
equity upon the completion of the IPO. Should the IPO prove to be unsuccessful, these deferred costs, as well as additional expenses
to be incurred, will be charged to operations. The balance of deferred initial public offering costs amounted to <span style="-sec-ix-hidden: hidden-fact-71">Nil</span> and $443,709 as
of September 30, 2021 and 2020, respectively. Payment for deferred IPO offering costs amounted to $2,792,543, $441,064 and <span style="-sec-ix-hidden: hidden-fact-72">Nil</span> for the
years ended September 30, 2021, 2020 and 2019, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_HeldToMaturityInvestmentPolicyTextBlock', window );">Short-term investments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Short-term&#160;investments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s short-term&#160;investments
consist of wealth management financial products purchased from financial institution, which can be redeemed anytime. The financial institution
invests the Company&#8217;s fund in certain financial instruments including money market funds and bonds to generate investment income.
The short-term investments are deemed to be trading securities and are measured subsequently at fair value in the statement of financial
position. Unrealized holding gains and losses for investment is included in the consolidated statements of operations and comprehensive
income (loss) over the investment period (see Note&#160;7).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
value of financial instruments</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&#8201;&#8212;&#8201;inputs
    to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&#8201;&#8212;&#8201;inputs
    to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for
    identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived
    from or corroborated by observable market data. </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&#8201;&#8212;&#8201;inputs
    to the valuation methodology are unobservable. </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise disclosed, the fair value of the Company&#8217;s financial instruments, including cash, accounts receivable, inventories, short-term
investments, advance to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses
and other current liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities
as of September 30, 2021 and 2020 based upon the short-term nature of the assets and liabilities. The Company&#8217;s investment in equity
securities is accounted for using the measurement alternative in accordance with ASC 321, which also approximate its recorded value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;
</i></b>&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property,
plant and equipment</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and
equipment is provided using the straight-line method over their expected useful lives, as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    life </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Buildings </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20 years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5&#8211;10 years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automobiles </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#8211;5 years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office and electric equipment
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#8211;5 years </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditures
for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures
for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated
depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated
statements of income and other comprehensive income in other income or expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
reviews the carrying value of property, plant, and equipment for impairment whenever events and circumstances indicate that the carrying
value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition.
In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an
amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment
include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand,
competition and other economic factors. Based on this assessment, no impairment expenses for property, plant, and equipment were recorded
in operating expenses for the years ended September 30, 2021, 2020 and 2019, respectively.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intangible
Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist primarily of land use rights and software. Under the PRC law, all land in the PRC is owned by the government and cannot
be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for specified periods
of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using the straight-line method
with the following estimated useful lives:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    life </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land use rights
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50 years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>The Company
reviews the carrying value of land use rights for impairment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where
undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which
the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current
operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intangible
Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist primarily of land use rights and software. Under the PRC law, all land in the PRC is owned by the government and cannot
be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for specified periods
of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using the straight-line method
with the following estimated useful lives:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    life </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land use rights
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50 years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
reviews the carrying value of land use rights for impairment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where
undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which
the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current
operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors. Based on this assessment, no impairment of land use rights was deemed necessary for the years ended September
30, 2021, 2020 and 2019, respectively.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionContractorsPolicyPolicyTextBlock', window );">Construction-in-Progress (&#8220;CIP&#8221;)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Construction-in-Progress
(&#8220;CIP&#8221;)</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction-in-progress
represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct
costs attributable to the construction. Construction-in-progress is not depreciated. Upon completion and ready for intended use, construction-in-progress
is reclassified to the appropriate category within property, plant and equipment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of long-lived Assets</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets with finite lives, primarily
property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash flows from the use of the asset and its
eventual disposition below are the asset&#8217;s carrying value, then the asset is deemed to be impaired and written down to its fair
value. There were no impairments of these assets as of September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments in Equity Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investments
in Equity Securities </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its equity investments
in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 321 &#8220;Investments&#8212;Equity Securities&#8221; (&#8220;ASC
321&#8221;). In accordance with ASC 321, equity investment which the Company has no significant influence (generally less than a 20% ownership
interest) with readily determinable fair values are accounted for at fair value based on quoted market prices with the changes in fair
value recognized as unrealized gains or losses in earnings. Equity investments without readily determinable fair values are accounted
for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured
at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical
or a similar investment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
March 2009 to September 2017, the Company invested approximately $0.7 million (RMB 5 million) in Jiangxi Jian Rural Commercial Bank (&#8220;JX
RCB Bank&#8221;) in exchange for 5% ownership interest in the bank. The purpose of entering into these equity investment agreements with
JX RCB Bank was to earn investment income as the bank continues to grow. The Company determined that this investment in equity securities
does not have a readily determinable fair value and, accordingly, elected the measurement alternative noted above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company initially recorded the investments at historical cost and subsequently records any dividends received from the net accumulated
earnings of the investee as income. As of September 30, 2021 and 2020, this investment amounted to $744,924 (RMB 5 million) and $735,000
(RMB 5 million), respectively, and was reported as long-term investment in equity investee on the consolidated balance sheets. Investment
income amounted to $30,827, $21,820 and $26,741 for the years ended September 31, 2021, 2020 and 2019, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investments in equity securities are evaluated for impairment when facts or circumstances indicate that the fair value of the investment
is less than its carrying value. An impairment is recognized when a decline in fair value is determined to be other-than-temporary. The
Company reviews several factors to determine whether a loss is other-than-temporary. These factors include, but are not limited to, the:
(i) nature of the investment; (ii) cause and duration of the impairment; (iii) extent to which fair value is less than cost; (iv) financial
condition and near term prospects of the investments; and (v) ability to hold the investment for a period of time sufficient to allow
for any anticipated recovery in fair value. There was no impairment for the Company&#8217;s investments in equity securities as of September
30, 2021 and 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
recognition</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s)
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will <i>not</i> occur, (iv) allocate the transaction
price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance
obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its TCMD and third-party
products on a gross basis as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in
establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods, which the Company has control
of the goods and has the ability to direct the use of goods to obtain substantially all the benefits. All of the Company&#8217;s contracts
have one single performance obligation as the promise is to transfer the individual goods to customers, and there is no separately identifiable
other promise in the contracts. The Company&#8217;s revenue streams are recognized at a point in time when title and risk of loss passes
and the customer accepts the goods, which generally occurs at delivery. The Company&#8217;s products are sold with no right of return
and the Company does not provide other credits or sales incentive to customers. Revenue is reported net of all value added taxes (&#8220;VAT&#8221;).&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ContractAssetsAndLiabilitiesPolicyTextBlock', window );">Contract Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contract
Assets and Liabilities </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
terms are established on the Company&#8217;s pre-established credit requirements based upon an evaluation of customers&#8217; credit
quality. Contract assets are recognized for in related accounts receivable. Contract liabilities are recognized for contracts where payment
has been received in advance of delivery. The contract liability balance can vary significantly depending on the timing when an order
is placed and when shipment or delivery occurs. As of September 30, 2021 and 2020, the Company did not have contract assets and contract
liabilities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_DisaggregationOfRevenuesPolicyTextBlock', window );">Disaggregation of Revenues</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disaggregation
of Revenues</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing
and uncertainty of the revenue and cash flows are affected by economic factors. The Company&#8217;s disaggregation of revenues for the
years ended September 30, 2021, 2020 and 2019 are disclosed in Note 17 of this consolidation financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Cost of revenue</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Cost of revenue consists primarily of the costs of raw materials, freight
charges, direct labor, depreciation of plants and machinery, warehousing and overhead associated with the manufacturing process.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and development expenses</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses all internal research and development costs as incurred, which primarily comprise employee costs, internal and external
costs related to execution of studies, including manufacturing costs, facility costs of the research center, and amortization and depreciation
to intangible assets and property, plant and equipment used in the research and development activities. For the years ended September
30, 2021, 2020 and 2019, total research and development expense were approximately $5,465,662, $583,125 and $618,437, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and handling costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shipping and handling costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Shipping and handling costs are expensed as incurred. Inbound shipping
and handling cost associated with bringing the purchased raw materials and third-party products from suppliers to the Company&#8217;s
warehouse are included in cost of revenue. Outbound shipping and handling costs associated with shipping and delivery the products to
customers are included in selling expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advertising
expense</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising expenses primarily relate to promotion of the Company&#8217;s
brand name and products through outdoor billboards, social media such as Weibo and WeChat and TV advertisement. Advertising costs is expensed
as incurred or deferred and then expensed the first time the advertising takes place. Advertising expenses are included in selling expenses
in the consolidated statements of income and comprehensive income. Advertising expenses amounted to $1,316,654, $343,962 and $367,513
for the years ended September 30, 2021, 2020 and 2019, respectively.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Segment Reporting</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the management approach in determining
reportable operating segments. The management approach considers the internal reporting used by the Company&#8217;s chief operating decision
maker for making operating decisions about the allocation of resources of the segment and the assessment of its performance in determining
the Company&#8217;s reportable operating segments. Management has determined that the Company has one operating segment (See Note 17).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
taxes</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized
when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial
statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary,
to reduce deferred tax assets to the amount expected to be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
uncertain tax position is recognized only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax
examination. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination.
For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest
relating to income taxes have been incurred during the years ended September 30, 2021, 2020 and 2019. The Company does not believe there
was any uncertain tax provision at September 30, 2021 and 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operating subsidiary in China is subject to the income tax laws of the PRC. No significant income was generated outside
the PRC for the fiscal years ended September 30, 2021, 2020 and 2019. As of September 30, 2021, all of the Company&#8217;s tax returns
of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ValueAddedTaxPolicyTextBlock', window );">Value added tax (&#8220;VAT&#8221;)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Value
added tax (&#8220;VAT&#8221;)</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.1pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
revenue represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to 17% (starting
from May 1, 2018, VAT rate was lowered to 16%, and starting from April 1, 2019, VAT rate was further lowered to 13%), depending on the
type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of
producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the accompanying consolidated
financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Earnings
per Share</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes earnings per share (&#8220;EPS&#8221;) in accordance with ASC 260, &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;).
ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided
by the weighted average common shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential
common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented,
or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or
decrease loss per share) are excluded from the calculation of diluted EPS. For the years ended September 30, 2021, 2020 and 2019, there
were no dilutive shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
currency translation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The functional currency for Universe INC is the
U.S Dollar (&#8220;US$&#8221;). Universe HK uses Hong Kong dollar as its functional currency. However, Universe INC and Universe HK currently
only serve as the holding companies and did not have active operation as of the date of this annual report. The Company operates only
in the PRC, the Company&#8217;s functional currency is the Chinese Yuan (&#8220;RMB&#8221;). The Company&#8217;s consolidated financial
statements have been translated into the reporting currency U.S. Dollars (&#8220;US$&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical
rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation
adjustments are reported under other comprehensive income (loss). Gains and losses resulting from the translations of foreign currency
transactions and balances are reflected in the results of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;
&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions.
No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table outlines the currency exchange rates that were used in creating the consolidated financial statements in this report:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30, 2021</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30, 2020</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30, 2019</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: left">Year-end spot rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.4580</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.8033</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1= RMB 7.1378</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.5095</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 7.0077</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.8729</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive income</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comprehensive
income </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
income consists of two components, net income and other comprehensive income (loss). The foreign currency translation gain or loss resulting
from translation of the financial statements expressed in RMB to US$ is reported in other comprehensive income (loss) in the consolidated
statements of income and comprehensive income.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_StatementOfCashFlowsPolicyTextBlock', window );">Statement of Cash Flows</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Statement
of Cash Flows</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 230, &#8220;Statement of Cash Flows&#8221;, cash flows from the Company&#8217;s operations are formulated based upon
the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily
agree with changes in the corresponding balances on the balance sheets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_EmployeeDefinedContributionPlanPolicyTextBlock', window );">Employee Defined Contribution Plan</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
Defined Contribution Plan</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which
pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to
eligible full-time employees. The relevant labor regulations require the Company&#8217;s subsidiaries in the PRC to pay the local labor
and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government.
The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying
statements of income and comprehensive income amounted to $617,145, $347,312 and $274,091 for the years ended September 30, 2021, 2020
and 2019, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;
<b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent&#160;Adopted
Accounting Pronouncements&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB Accounting Standards Board issued ASU No. 2018-13, &#8220;Fair Value Measurement (Topic 820): Disclosure Framework
Changes to the Disclosure Requirements for Fair Value Measurement&#8221; (&#8220;ASU 2018-13&#8221;). ASU 2018-13 modifies the disclosure
requirements on fair value measurements. ASU 2018-13 is effective for all entities for fiscal years and interim periods within those
fiscal years beginning after December 15, 2019, with early adoption permitted for any removed or modified disclosures. The removed and
modified disclosures were adopted on a retrospective basis and the new disclosures were adopted on a prospective basis. The adoption
of this guidance had no material impact on the Company&#8217;s consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recent
Accounting Pronouncements&#160;not yet adopted</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February&#160;2016, the FASB issued Accounting
Standards Update (ASU) No.&#160;2016-02,&#160;Leases (Topic 842), which requires lessees to recognize a right-of-use asset and lease liability
on the balance sheet for all leases, including operating leases, with a term in excess of 12 months. The guidance also expands the quantitative
and qualitative disclosure requirements. The new guidance requires the lessee to record operating leases on the balance sheet with a right-of-use
asset and corresponding liability for future payment obligations. In July&#160;2018, FASB issued ASU 2018-11 Leases (Topic 842) &#8211;
Targeted Improvements&#160;that reduces costs and eases implementation of the leases standard for financial statement preparers. The ASU
simplifies transition requirements and, for lessors, provides a practical expedient for the separation of non-lease components from lease
components. ASU 2016-02 was further amended in November&#160;2019 by ASU 2019-10 and in June&#160;2020 by ASU 2020-05, which deferred
the effective date of new lease standard. As a result, ASC 842, Leases, is effective for public companies for annual reporting periods
and interim periods within those years beginning after December&#160;15, 2018. For all other entities, the guidance is effective for fiscal
years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022. As an emerging
growth company, the Company elects to apply for the new and revised accounting standards at the effective date for a private company and
to adopt this guidance effective October 1, 2021. The Company is currently evaluating the impact of adopting this standard on its consolidated
financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160; &#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June&#160;2016, the FASB issued Accounting
Standards Update (&#8220;ASU&#8221;) 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all
expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable
and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost. ASU 2016-13 was subsequently amended by Accounting Standards Update 2018-19,&#160;Codification Improvements
to Topic 326, Financial Instruments &#8212; Credit&#160;Losses, Accounting Standards Update 2019-04&#160;Codification Improvements to
Topic 326, Financial Instruments &#8212; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, and
Accounting Standards Update 2019-05,&#160;Targeted Transition Relief.&#160;In November&#160;2019, the FASB issued ASU 2019-10, which extends
the effective date for adoption of ASU 2016-13. In November&#160;2019, the FASB issued ASU 2019-11 to clarify its new credit impairment
guidance in ASU 326. Accordingly, for public entities that are not smaller reporting entities, ASU 2016-13 and its amendments is effective
for fiscal years, and interim periods within&#160;those fiscal years, beginning after December&#160;15, 2019. For all other entities,
this guidance and its amendments will be effective for fiscal years beginning after December&#160;15, 2022, including interim periods
within those fiscal years. As an emerging growth company, the Company plans to adopt this guidance effective October 1, 2023. The Company
is currently evaluating the impact of its pending adoption of ASU 2016-13 on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU No. 2019-12,
Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes. ASU 2019-12 is intended to simplify accounting for income
taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application.
ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years, which is fiscal
2021 for us, with early adoption permitted. The Company does not expect adoption of the new guidance to have a significant impact on our
financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2020, the FASB issued ASU 2020-02,
&#8220;Financial Instruments &#8211; Credit Losses (Topic 326) and Leases (topic 842) Amendments to SEC Paragraphs Pursuant to SEC Staff
Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (topic
842)&#8221;. This ASU provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses.
This ASU is effective for interim and annual periods beginning after December 15, 2019, and early adoption is permitted. The Company is
evaluating the impact of this guidance on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvancesToSuppliersNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advances to suppliers net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvancesToSuppliersNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ContractAssetsAndLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ContractAssetsAndLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_DisaggregationOfRevenuesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_DisaggregationOfRevenuesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_EmployeeDefinedContributionPlanPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of employee defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_EmployeeDefinedContributionPlanPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_HeldToMaturityInvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_HeldToMaturityInvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StatementOfCashFlowsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of statement of cash flows policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StatementOfCashFlowsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ValueAddedTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of value added tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ValueAddedTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionContractorsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for construction contractors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353855&amp;loc=SL119991576-234733<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 910<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6471471&amp;loc=d3e48698-109348<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionContractorsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338384520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Description (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock', window );">Schedule of subsidiaries of the company</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Entity </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
    of<br/>
    Incorporation </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place
    of<br/>
    Incorporation </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%
    of&#160;<br/>
    Ownership </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    Activities </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    INC </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&#160;11,&#160;2019 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman&#160;Islands </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent, 100% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    HK </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 21, 2014 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    Technology </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 18, 2019 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WOFE, Investment holding </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
    Universe </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 2, 1998 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development and manufacturing of modernized traditional Chinese medicines </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    Trade</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 10, 2010 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales of modernized traditional Chinese medicines </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    Hanhe</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRC</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of new pharmaceutical products</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680339214184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of property and equipment estimated useful lives</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    life </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Buildings </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20 years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5&#8211;10 years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automobiles </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#8211;5 years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office and electric equipment
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&#8211;5 years </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of intangible assets estimated useful lives</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    life </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land use rights
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50 years </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock', window );">Schedule of currency exchange rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30, 2021</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30, 2020</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September
                                            30, 2019</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: left">Year-end spot rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.4580</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.8033</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1= RMB 7.1378</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.5095</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 7.0077</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$1=RMB 6.8729</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of property equipment estimated useful life during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335873368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of accounts receivable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,020,269</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,511,769</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(446,527</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(639,991</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Accounts receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,573,742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,871,778</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock', window );">Schedule of the company&#8217;s accounts receivable and subsequent collection</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Accounts Receivable by aging bucket</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance as of <br/> September&#160;30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Subsequent <br/> collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of <br/> subsequent <br/> collection</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Less than 3 months</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,587,490</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,991,589</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">69.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>From 4 to 6 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,922,226</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,541,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>From 7 to 9 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">356,267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>From 10 to 12 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,124</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,193</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Over 1 year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,162</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">584</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total gross accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,020,269</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,739,179</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(446,527</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Accounts Receivable, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,573,742</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,739,179</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">75.4</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of allowance for doubtful accounts</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Beginning balance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">639,991</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">517,754</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,907</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bad debt recovery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(225,660</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,196</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,330</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">446,527</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">639,991</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338332984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">607,661</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">553,982</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Finished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,971,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,462,835</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Inventory valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(116,453</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(110,585</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total inventory, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,462,542</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,906,232</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338316424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Advance to Suppliers (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AdvancesToSuppliersAbstract', window );"><strong>Advances To Suppliers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfAdvancesToSuppliersNet', window );">Schedule of advances to suppliers net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&#160;30, <br/>
2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&#160;30, <br/>
2020</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Advances to suppliers for inventory raw material purchase</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,738,313</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Advances to suppliers</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,738,313</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvancesToSuppliersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvancesToSuppliersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfAdvancesToSuppliersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of advances to suppliers net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfAdvancesToSuppliersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335481544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Invstment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-Term Invstment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Schedule of short-term invstment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: justify">Add: purchase wealth management financial products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">15,330,660</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Less: redemption</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,801,927</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Accrued investment income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,078</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Ending balance of short-term investments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">13,725,204</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269825-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338271816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, plant and equipment, net consists</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center">Useful life</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2021</b></p></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2020</b></p></td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Buildings</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">20 years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,808,006</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,414,580</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center">5-10 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,047,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,534,015</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Automobiles</td><td>&#160;</td>
    <td style="text-align: center">3-5 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,346</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Office and electric equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">3-5 years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">489,886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">434,075</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Subtotal</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,461,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,523,016</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,780,247</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,094,952</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,681,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,428,064</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-align: justify; text-indent: -0.4in">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335961272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets, net consist</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Useful life</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2021</b></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2020</b></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Land use rights</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">50 years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">278,327</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">264,304</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Software</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">3 years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,186</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286,490</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(123,208</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(111,714</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">178,483</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">174,776</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated future amortization expense for intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Years ending September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization<br/>
 expense</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,567</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,567</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,567</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,567</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,567</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">150,648</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">178,483</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338382056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Construction-in-Progress (CIP) Project (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentForConstructionInProgressAbstract', window );"><strong>Prepayment For Construction In Progress [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Schedule of future minimum capital expenditures</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Years ending September 30,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Capital<br/>
 Expenditure</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>on CIP</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,831,300</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,721,440</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,277,100</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,829,840</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForConstructionInProgressAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForConstructionInProgressAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338269528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Bank Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of short-term bank loans</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/>
 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Short-term bank loans:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 9pt">Maturity date on March 31, 2021, interest rate 4.81% per annum</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,176,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Maturity date on June 18, 2021, interest rate 4.81% per annum</td><td>&#160;</td>
    <td style="text-align: center">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,470,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Maturity date on June 15, 2022, interest rate 4.81% per annum</td><td>&#160;</td>
    <td style="text-align: center">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,548,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Maturity date on June 30, 2022, interest rate 4.5% per annum</td><td>&#160;</td>
    <td style="text-align: center">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,548,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Maturity date on March 17, 2022, interest rate 4.81% per annum</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">(5)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,238,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total short-term bank loans</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,334,400</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,646,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680336877080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of nature of relationships with related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;  border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 39%; font-weight: bold; text-align: justify">Name</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 60%; font-weight: bold; text-align: justify">Relationship with the Company</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Mr. Gang Lai</td><td>&#160;</td>
    <td style="text-align: left">Chief Executive Officer (&#8220;CEO&#8221;), chairman of the Board of Directors</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Mrs. Lin Yang</td><td>&#160;</td>
    <td style="text-align: left">Chief Financial Officer and Director</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Greatest Group (China) Financial Management Limited (&#8220;Greatest Group&#8221;)</td><td>&#160;</td>
    <td style="text-align: left">One of the Company&#8217;s minority shareholders owns 8.7% of the ownership interest in this entity</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Foshan Shangyu Investment Holding Co., Ltd (&#8220;Foshan Shangyu&#8221;)</td><td>&#160;</td>
    <td style="text-align: left">An affiliated entity of the Company, 90% owned by and controlled by the Company&#8217;s CEO.</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfDueFromRelatedPartiesTableTextBlock', window );">Schedule of due from related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Name</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Greatest Group</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">235,438</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foshan Shangyu</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,544</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total due from related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">236,982</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfDueToRelatedPartiesTableTextBlock', window );">Schedule of due to related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify">Name</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Mr. Gang Lai</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">956,492</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Mrs. Lin Yang</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,723</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#12288;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total due to related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,723</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">956,492</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfDueFromRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfDueFromRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfDueToRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfDueToRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335821096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of the income tax provision (benefit)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current income tax provision</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Cayman Island</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; padding-left: 9pt">PRC</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,026,867</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,552,097</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,141,222</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,026,867</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,552,097</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,141,222</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred income tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Cayman Island</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Hong Kong</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">PRC</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(668,341</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,886</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(39,625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total income tax provision</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,358,526</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,542,211</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,101,597</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of table reconciles the china statutory rates to the company&#8217;s effective tax rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Statutory PRC income tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">25.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effect of income tax holiday</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.3</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent difference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-PRC entities not subject to PRC income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impact on DTA due to change in applicable income tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17.1</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">25.2</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">21.8</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/>
2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 10pt">Net operating loss carry-forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">785,550</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">186,537</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,447</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">&#8212;&#160;&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">869,997</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186,537</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">&#8212;&#160;&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">&#8212;&#160;&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">869,997</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">186,537</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfTaxPayableTableTextBlock', window );">Schedule of taxes payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>September&#160;30, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2020</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Income tax payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">669,780</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">767,297</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Value added tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">326,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">433,838</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other taxes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,212</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">130,614</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total taxes payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,101,460</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,331,749</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfTaxPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of tax payable during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfTaxPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338177544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of revenue by product source</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Sales of TCMD products manufactured by the Company</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,559,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,374,751</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,895,542</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Sales of third-party products</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,333,774</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">33,229,316</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of total revenues by product categories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Sales of TCMD products:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Medicinal liquor products</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,951,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,616,080</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,356,015</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other chronic condition treatment products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,978,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,059,403</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,056,228</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Cold and flu medicines</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,629,606</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,699,268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,483,299</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Sub-total of TCMD products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,559,286</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,374,751</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,895,542</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Sales of third-party products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Biochemical drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,082,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,325,411</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,508,816</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Traditional Chinese medicine pieces</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,097</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,409</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Medical instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,318,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,950,238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,668,422</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Dietary supplements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">958</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,463</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,127</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Subtotal of third-party products sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,422,745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,329,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,333,774</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Total revenue</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">47,982,031</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">30,703,960</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">33,229,316</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680336726296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of parent company balance sheets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: justify">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">110,393</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Short-term investments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,725,204</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,835,597</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 9pt; padding-left: 9pt">Investment in subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,098,756</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,802,904</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">58,934,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,802,904</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt">Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares and 16,000,000 shares issued and outstanding as of September 30, 2021 and 2020, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,969</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 10pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,279,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,679,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Retained earnings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,498,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,178,514</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,088,759</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">895,390</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,934,353</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,802,904</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 20pt">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">58,934,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,802,904</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock', window );">Schedule of parent company statements of income and comprehensive income</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating costs and expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 9pt">General and administrative expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,177,869</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expenses):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Income from short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Other expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(60,751</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity in earnings of subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,319,023</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,558,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,551,465</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,319,952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,558,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,551,465</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,193,369</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">860,623</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(645,978</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive income attributable to the Company</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,513,321</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,418,845</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,905,487</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock', window );">Schedule of parent company statements of cash flows</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 10pt">Net income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,319,952</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,558,222</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,551,465</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 10pt">Adjustments to reconcile net cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 8.3pt; padding-left: 20pt">Equity in earnings of subsidiary</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,319,027</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,558,222</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,551,465</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 30pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(999,075</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 28.3pt">Payment for short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(15,330,660</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 28.3pt">Redemption of short-term investments </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,801,927</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,528,733</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 28.3pt">Net proceeds from issuance of ordinary shares in IPO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,957,457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 21.3pt">&#160;&#160;Cash lent to subsidiaries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,358,764</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,598,693</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">CHANGES IN CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">CASH, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">CASH, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">110,393</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedStatementOfComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedCashFlowStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680328330296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Description (Details)<br> $ / shares in Units, &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 29, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PublicOfferingPrice', window );">Public offering price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net Proceeds</a></td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net Proceeds</a></td>
<td class="nump">$ 25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseIncMember', window );">Universe Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_EntityIncorporationDateDescription', window );">Entity incorporation date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Universe
Pharmaceuticals Inc. (&#8220;Universe INC&#8221; or the &#8220;Company&#8221;) was incorporated under the laws of the Cayman Islands
on December 11, 2019 as an exempted company with limited liability.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseHKMember', window );">Universe HK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_EntityIncorporationDateDescription', window );">Entity incorporation date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Universe
INC. owns 100% equity interest of Universe Pharmaceuticals (International) Group (&#8220;Universe HK&#8221;), an entity incorporated
on May 21, 2014 in accordance with the laws and regulations in Hong Kong.&#160;&#160;&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_JiangxiMember', window );">Jiangxi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_EntityIncorporationDateDescription', window );">Entity incorporation date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(&#8220;Universe Technology&#8221;) was formed on April 8, 2019, as a Wholly Foreign-Owned
Enterprise (&#8220;WOFE&#8221;) in the People&#8217;s Republic of China (&#8220;PRC&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseTechnologyMember', window );">Universe Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AmountOfRegisteredCapital', window );">Registered capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">&#165; 30.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_CapitalContribution', window );">Capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_RemainingCapitalContribution', window );">Remaining capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_JiangxiUniverseMember', window );">Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_EntityIncorporationDateDescription', window );">Entity incorporation date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(&#8220;Jiangxi Universe&#8221;) was incorporated on March 2, 1998 in accordance with PRC laws and
is engaged in research and development and manufacturing of modernized traditional Chinese medicines.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseTradeMember', window );">Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OrganizationandBusinessDescriptionDetailsLineItems', window );"><strong>Organization and Business Description (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AmountOfRegisteredCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of registered capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AmountOfRegisteredCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_EntityIncorporationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity incorporation date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_EntityIncorporationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OrganizationandBusinessDescriptionDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OrganizationandBusinessDescriptionDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Public offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_RemainingCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining capital contribution amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_RemainingCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseHKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseHKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_JiangxiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_JiangxiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_JiangxiUniverseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_JiangxiUniverseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseTradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseTradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680330654520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business Description (Details) - Schedule of subsidiaries of the company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseIncMember', window );">Universe INC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">Dec. 11,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PlaceOfIncorporation', window );">Place of Incorporation</a></td>
<td class="text">Cayman&#160;Islands<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">% of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Investment holding<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseHKMember', window );">Universe HK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">May 21,  2014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PlaceOfIncorporation', window );">Place of Incorporation</a></td>
<td class="text">Hong Kong<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">% of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Investment holding<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseTechnologyMember', window );">Universe Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">Apr. 18,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PlaceOfIncorporation', window );">Place of Incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">% of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrincipalActivities', window );">Principal Activities</a></td>
<td class="text">WOFE, Investment holding<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_JiangxiUniverseMember', window );">Jiangxi Universe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">Mar.  02,  1998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PlaceOfIncorporation', window );">Place of Incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">% of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Research and development and manufacturing of modernized traditional Chinese medicines<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseTradeMember', window );">Universe Trade [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">Mar. 10,  2010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PlaceOfIncorporation', window );">Place of Incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">% of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Sales of modernized traditional Chinese medicines<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_UniverseHanheMember', window );">Universe Hanhe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of Incorporation</a></td>
<td class="text">May 12,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PlaceOfIncorporation', window );">Place of Incorporation</a></td>
<td class="text">PRC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">% of Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Research and development of new pharmaceutical products<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PlaceOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Place of incorporation or establishment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PlaceOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrincipalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrincipalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseHKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseHKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_JiangxiUniverseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_JiangxiUniverseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseTradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseTradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_UniverseHanheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_UniverseHanheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680332264776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="2">103 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2019</div></th>
<th class="th"><div>May 01, 2018</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AllowanceForUncollectableBalancesAmount', window );">Allowance for uncollectable balance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 446,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 639,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_DeferredInitialPublicOfferingCosts', window );">Deferred initial public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Payment for deferred offering costs amounted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744,924<span></span>
</td>
<td class="nump">&#165; 5<span></span>
</td>
<td class="nump">735,000<span></span>
</td>
<td class="nump">&#165; 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Investment income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,465,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">618,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,316,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PercentageOfVatRate', window );">Percentage of vat rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Comprehensive income amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 617,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PercentageOfVatRate', window );">Percentage of vat rate</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=upc_JxRcbBankMember', window );">JX RCB Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">&#165; 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Payment for deferred offering costs amounted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,792,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AllowanceForUncollectableBalancesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for uncollectable balances amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AllowanceForUncollectableBalancesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_DeferredInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_DeferredInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PercentageOfVatRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of VATrate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PercentageOfVatRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=upc_JxRcbBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=upc_JxRcbBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680330594968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Automobiles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office and electric equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Automobiles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office and electric equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335257688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember', window );">Land use rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680331335816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of currency exchange rate<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfCurrencyExchangeRateAbstract', window );"><strong>Schedule of currency exchange rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_DescriptionOfYearEndSpotRate', window );">Year-end spot rate</a></td>
<td class="text">US$1=RMB 6.4580<span></span>
</td>
<td class="text">US$1=RMB 6.8033<span></span>
</td>
<td class="text">US$1= RMB 7.1378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_DescriptionOfAverageRate', window );">Average rate</a></td>
<td class="text">US$1=RMB 6.5095<span></span>
</td>
<td class="text">US$1=RMB 7.0077<span></span>
</td>
<td class="text">US$1=RMB 6.8729<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_DescriptionOfAverageRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of average rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_DescriptionOfAverageRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_DescriptionOfYearEndSpotRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of year end spot rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_DescriptionOfYearEndSpotRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfCurrencyExchangeRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfCurrencyExchangeRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338363048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AccountsReceivableDescription', window );">Accounts receivable description</a></td>
<td class="text">The Company&#8217;s accounts receivable primarily
includes balance due from customers when the Company&#8217;s pharmaceutical products are sold and delivered to customers. All of the Company&#8217;s
accounts receivable balance at September 30, 2020 has been collected in fiscal year 2021. As of date of this report, approximately 75.4%,
or $11.7 million, of the Company&#8217;s net account receivable balance at September 30, 2021 has been subsequently collected and the
remaining balance is expected to be substantially collected before March 31, 2022.&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AccountsReceivableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AccountsReceivableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680331081016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details) - Schedule of accounts receivable - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfAccountsReceivableAbstract', window );"><strong>Schedule of accounts receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 16,020,269<span></span>
</td>
<td class="nump">$ 11,511,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowance for doubtful accounts</a></td>
<td class="num">(446,527)<span></span>
</td>
<td class="num">(639,991)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 15,573,742<span></span>
</td>
<td class="nump">$ 10,871,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfAccountsReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfAccountsReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680331043672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details) - Schedule of the company&#8217;s accounts receivable and subsequent collection<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Balance</a></td>
<td class="nump">$ 16,020,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SunsequentCollectionsTotalGrossAccountsReceivable', window );">Subsequent collection</a></td>
<td class="nump">$ 11,739,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_TotalGrossAccountsReceivablePercentage', window );">Percentage of subsequent collection</a></td>
<td class="nump">73.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss', window );">Balance</a></td>
<td class="num">$ (446,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SunsequentCollectionAllowanceForDoubtfulAccounts', window );">Subsequent collection</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AllowanceForDoubtfulAccountsReceivablePercentage', window );">Percentage of subsequent collection</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Balance</a></td>
<td class="nump">$ 15,573,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SunsequentCollectionAccountsReceivableNet', window );">Subsequent collection</a></td>
<td class="nump">$ 11,739,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AccountsReceivableNetPercentage', window );">Percentage of subsequent collection</a></td>
<td class="nump">75.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_LessThan3MonthsMember', window );">Less than 3 months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AccountsReceivableBeforeGrossValue', window );">Balance</a></td>
<td class="nump">$ 11,587,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubsequentCollection', window );">Subsequent collection</a></td>
<td class="nump">$ 7,991,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PercentageOfSubsequentCollection', window );">Percentage of subsequent collection</a></td>
<td class="nump">69.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From4To6MonthsMember', window );">From 4 to 6 months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AccountsReceivableBeforeGrossValue', window );">Balance</a></td>
<td class="nump">$ 3,922,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubsequentCollection', window );">Subsequent collection</a></td>
<td class="nump">$ 3,541,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PercentageOfSubsequentCollection', window );">Percentage of subsequent collection</a></td>
<td class="nump">90.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From7To9MonthsMember', window );">From 7 to 9 months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AccountsReceivableBeforeGrossValue', window );">Balance</a></td>
<td class="nump">$ 356,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubsequentCollection', window );">Subsequent collection</a></td>
<td class="nump">$ 199,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PercentageOfSubsequentCollection', window );">Percentage of subsequent collection</a></td>
<td class="nump">56.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From10To12MonthsMember', window );">From 10 to 12 months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AccountsReceivableBeforeGrossValue', window );">Balance</a></td>
<td class="nump">$ 66,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubsequentCollection', window );">Subsequent collection</a></td>
<td class="nump">$ 5,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PercentageOfSubsequentCollection', window );">Percentage of subsequent collection</a></td>
<td class="nump">7.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_Over1YearMember', window );">Over 1 year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems', window );"><strong>Financing Receivable, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AccountsReceivableBeforeGrossValue', window );">Balance</a></td>
<td class="nump">$ 88,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubsequentCollection', window );">Subsequent collection</a></td>
<td class="nump">$ 584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PercentageOfSubsequentCollection', window );">Percentage of subsequent collection</a></td>
<td class="nump">0.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AccountsReceivableBeforeGrossValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AccountsReceivableBeforeGrossValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AccountsReceivableNetPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AccountsReceivableNetPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AllowanceForDoubtfulAccountsReceivablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AllowanceForDoubtfulAccountsReceivablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PercentageOfSubsequentCollection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PercentageOfSubsequentCollection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SubsequentCollection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SubsequentCollection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SunsequentCollectionAccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SunsequentCollectionAccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SunsequentCollectionAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SunsequentCollectionAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SunsequentCollectionsTotalGrossAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SunsequentCollectionsTotalGrossAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_TotalGrossAccountsReceivablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_TotalGrossAccountsReceivablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss of accounts and financing receivables. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_LessThan3MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_LessThan3MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From4To6MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From4To6MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From7To9MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From7To9MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From10To12MonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_From10To12MonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_Over1YearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis=upc_Over1YearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680330675864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable, Net (Details) - Schedule of allowance for doubtful accounts - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract', window );"><strong>Schedule of allowance for doubtful accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 639,991<span></span>
</td>
<td class="nump">$ 517,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">93,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Bad debt recovery</a></td>
<td class="num">(225,660)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments', window );">Foreign currency translation adjustments</a></td>
<td class="nump">32,196<span></span>
</td>
<td class="nump">28,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 446,527<span></span>
</td>
<td class="nump">$ 639,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to temporary equity resulting from foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680336709624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Accrued inventory allowance amounted</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (75,391)<span></span>
</td>
<td class="num">$ (187,271)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e99989-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335910456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory, Net (Details) - Schedule of inventory - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfInventoryAbstract', window );"><strong>Schedule of inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 607,661<span></span>
</td>
<td class="nump">$ 553,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,971,334<span></span>
</td>
<td class="nump">1,462,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation allowance</a></td>
<td class="num">(116,453)<span></span>
</td>
<td class="num">(110,585)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory, net</a></td>
<td class="nump">$ 2,462,542<span></span>
</td>
<td class="nump">$ 1,906,232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfInventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfInventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338300968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Advance to Suppliers (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AdvancesToSuppliersAbstract', window );"><strong>Advances To Suppliers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_RawMaterialsPurchased', window );">Raw materials purchased</a></td>
<td class="nump">66.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdvancesToSuppliersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdvancesToSuppliersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_RawMaterialsPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of raw materials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_RawMaterialsPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335321528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Advance to Suppliers (Details) - Schedule of advances to suppliers net - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfAdvancesToSuppliersNetAbstract', window );"><strong>Schedule of advances to suppliers net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Advances to suppliers for inventory raw material purchase</a></td>
<td class="nump">$ 2,738,313<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Less: allowance for doubtful accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToSuppliersAndEmployees', window );">Advances to suppliers</a></td>
<td class="nump">$ 2,738,313<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfAdvancesToSuppliersNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfAdvancesToSuppliersNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToSuppliersAndEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to suppliers for goods and services provided and to employees for services provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToSuppliersAndEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680330610216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepayment for Advertisting (Details)<br> &#165; in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 06, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentForAdvertistingAbstract', window );"><strong>Prepayment For Advertisting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense', window );">Advertising expense</a></td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">&#165; 55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PercentageOfAdvancePayment', window );">Percentage of advance payment</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AdditionalContractPricePercentage', window );">Additional contract price percentage</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">&#165; 48.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">&#165; 6.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AdditionalContractPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional contract price percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AdditionalContractPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PercentageOfAdvancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of advance payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PercentageOfAdvancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentForAdvertistingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentForAdvertistingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680332555352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Invstment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_HeldToMaturityInvestmentDisclosureAbstract', window );"><strong>Held To Maturity Investment Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Held-to-maturity investment amount</a></td>
<td class="nump">$ 239,549<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_HeldToMaturityInvestmentDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_HeldToMaturityInvestmentDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680330639208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Invstment (Details) - Schedule of short-term invstment - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfShortTermInvstmentAbstract', window );"><strong>Schedule of short-term invstment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AddPurchaseWealthManagementFinancialProducts', window );">Add: purchase wealth management financial products</a></td>
<td class="nump">15,330,660<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Less: redemption</a></td>
<td class="num">(1,801,927)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable', window );">Accrued investment income</a></td>
<td class="nump">239,549<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="num">(43,078)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Ending balance of short-term investments</a></td>
<td class="nump">$ 13,725,204<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AddPurchaseWealthManagementFinancialProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase wealth management financial products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AddPurchaseWealthManagementFinancialProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfShortTermInvstmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfShortTermInvstmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in investment income that has been earned but not yet received in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335239752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 441,355<span></span>
</td>
<td class="nump">$ 404,948<span></span>
</td>
<td class="nump">$ 413,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss from disposal of fixed assets</a></td>
<td class="num">$ (1,559)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (2,085)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680332090600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - Schedule of Property, plant and equipment, net consists - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 10,461,600<span></span>
</td>
<td class="nump">$ 9,523,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(5,780,247)<span></span>
</td>
<td class="num">(5,094,952)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 4,681,353<span></span>
</td>
<td class="nump">4,428,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 7,808,006<span></span>
</td>
<td class="nump">7,414,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,047,338<span></span>
</td>
<td class="nump">1,534,015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember', window );">Automobiles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">116,370<span></span>
</td>
<td class="nump">140,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember', window );">Office and electric equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 489,886<span></span>
</td>
<td class="nump">$ 434,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Automobiles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office and electric equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Automobiles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office and electric equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=upc_OfficeAndElectricEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680429712200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 5,523<span></span>
</td>
<td class="nump">$ 5,131<span></span>
</td>
<td class="nump">$ 5,232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680328283832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - Schedule of intangible assets, net consist - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 301,691<span></span>
</td>
<td class="nump">$ 286,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(123,208)<span></span>
</td>
<td class="num">(111,714)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 178,483<span></span>
</td>
<td class="nump">174,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember', window );">Land use rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">50 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 278,327<span></span>
</td>
<td class="nump">264,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 23,364<span></span>
</td>
<td class="nump">$ 22,186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335736168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract', window );"><strong>Schedule of estimated future amortization expense for intangible assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">$ 5,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2023</a></td>
<td class="nump">5,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2024</a></td>
<td class="nump">5,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive', window );">2025</a></td>
<td class="nump">5,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix', window );">2026</a></td>
<td class="nump">5,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">150,648<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 178,483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680328249400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Construction-in-Progress (CIP) Project (Details)<br> &#165; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 25, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 25, 2021 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems', window );"><strong>Prepayment for Construction-in-Progress (CIP) Project (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_CapitalExpenditure', window );">Additional capital expenditure</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_ChenyuanMember', window );">Chenyuan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems', window );"><strong>Prepayment for Construction-in-Progress (CIP) Project (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentBuildingAndBuildingImprovements', window );">Total estimated budget</a></td>
<td class="nump">10.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 69.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems', window );"><strong>Prepayment for Construction-in-Progress (CIP) Project (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentBuildingAndBuildingImprovements', window );">Total estimated budget</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.5<span></span>
</td>
<td class="nump">&#165; 165.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_CapitalExpenditure', window );">Additional capital expenditure</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">&#165; 95.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member] | Chenyuan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems', window );"><strong>Prepayment for Construction-in-Progress (CIP) Project (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_Prepayment', window );">Prepayment</a></td>
<td class="nump">$ 10.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CapitalExpenditure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of capital expenditure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CapitalExpenditure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_Prepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_Prepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentBuildingAndBuildingImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentBuildingAndBuildingImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_ChenyuanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_ChenyuanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680330669496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepayment for Construction-in-Progress (CIP) Project (Details) - Schedule of future minimum capital expenditures - Capital Expenditure [Member]<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems', window );"><strong>Prepayment for Construction-in-Progress (CIP) Project (Details) - Schedule of future minimum capital expenditures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 3,831,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">9,721,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">1,277,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 14,829,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=upc_CapitalExpenditureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=upc_CapitalExpenditureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680330993608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepayment for Purchase of a Property (Details)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 06, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 06, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentforPurchaseofaPropertyDetailsLineItems', window );"><strong>Prepayment for Purchase of a Property (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalDeferredPurchasePrice', window );">Total purchase price</a></td>
<td class="nump">$ 4,950,000<span></span>
</td>
<td class="nump">&#165; 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PercentageOfPrepayment', window );">Percentage of prepayment</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Remaining payable percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PayableDeliveryPropertyPercentage', window );">Payable delivery property percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Prepayment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,476,800)<span></span>
</td>
<td class="nump">&#165; 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OfficeSpaceSquareMeters', window );">Office space Square meters</a></td>
<td class="nump">2,749<span></span>
</td>
<td class="nump">2,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PrepaymentforPurchaseofaPropertyDetailsLineItems', window );"><strong>Prepayment for Purchase of a Property (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Equity interest percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OfficeSpaceSquareMeters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Office space Square meters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OfficeSpaceSquareMeters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PayableDeliveryPropertyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable delivery property percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PayableDeliveryPropertyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PercentageOfPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PercentageOfPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PrepaymentforPurchaseofaPropertyDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PrepaymentforPurchaseofaPropertyDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaymentFeesOnAdvancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaymentFeesOnAdvancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalDeferredPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalDeferredPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680332134856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Bank Loans (Details)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 19, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 26, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 19, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 26, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShortBankLoansDetailsLineItems', window );"><strong>Short-Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableToBankCurrent', window );">Borrowing amount</a></td>
<td class="nump">$ 1,548,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,548,000<span></span>
</td>
<td class="nump">$ 1,238,400<span></span>
</td>
<td class="nump">$ 1,176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10<span></span>
</td>
<td class="nump">&#165; 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Fixed interest rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.81%<span></span>
</td>
<td class="nump">4.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.81%<span></span>
</td>
<td class="nump">4.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,303<span></span>
</td>
<td class="nump">$ 157,528<span></span>
</td>
<td class="nump">$ 135,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=upc_JiangxiLulingRuralCommercialBankMember', window );">Jiangxi Luling Rural Commercial Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShortBankLoansDetailsLineItems', window );"><strong>Short-Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableToBankCurrent', window );">Borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Fixed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.81%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ShortBankLoansDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ShortBankLoansDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=upc_JiangxiLulingRuralCommercialBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=upc_JiangxiLulingRuralCommercialBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680328145416">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Short-Bank Loans (Details) - Schedule of short-term bank loans - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract', window );"><strong>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,334,400<span></span>
</td>
<td class="nump">$ 2,646,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_Maturity30To90DaysMember', window );">Maturity date on March 31, 2021, interest rate 4.81% per annum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract', window );"><strong>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,176,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_MaturityOver90DaysMember', window );">Maturity date on June 18, 2021, interest rate 4.81% per annum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract', window );"><strong>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,470,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysOneMember', window );">Maturity date on June 15, 2022, interest rate 4.81% per annum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract', window );"><strong>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,548,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysTwoMember', window );">Maturity date on June 30, 2022, interest rate 4.5% per annum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract', window );"><strong>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,548,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysThreeMember', window );">Maturity date on March 17, 2022, interest rate 4.81% per annum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract', window );"><strong>Loans payable to Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total short-term bank loans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,238,400<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On June 19, 2020, the Company&#8217;s subsidiary Jiangxi Universe signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#8220;LRC Bank&#8221;) to borrow RMB 10 million (equivalent to $1,470,000) as working capital for one year, with the maturity date on June 18, 2021. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">On June 30, 2021, the Company&#8217;s subsidiary Jiangxi Universe signed a loan agreement with Bank of Communications to borrow RMB 10 million (equivalent to $1,548,000) as working capital for one year, with the maturity date on June 18, 2022. The fixed interest rate of the loan was 4.5% per annum. Certain related parties of the Company, including Mr. Gang Lai, the Company&#8217;s controlling shareholder, Mr. Gang Lai&#8217;s spouse, Mrs. Xing Wu, and the Company&#8217;s subsidiary, Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_Maturity30To90DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_Maturity30To90DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_MaturityOver90DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=us-gaap_MaturityOver90DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis=upc_MaturityGreaterThan90DaysThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335879624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br> &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 06, 2021</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationRelatedPartyDescription', window );">Related party description</a></td>
<td class="text">As disclosed in Note 11, on May 6, 2021, the Company
entered into a real estate property purchase agreement with related party Jiangxi Yueshang to purchase certain residential apartment and
commercial office space totaling 2,749.30 square meters with total purchase price of RMB32 million (approximately $4.95 million).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Prepayment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,476,800)<span></span>
</td>
<td class="nump">&#165; 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRelatedPartyDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of related party involvement in transaction resulting in deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer; and whether former subsidiary or acquirer of group of assets would be related party after deconsolidation and derecognition transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRelatedPartyDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaymentFeesOnAdvancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaymentFeesOnAdvancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680332159992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Schedule of nature of relationships with related parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember', window );">Mr. Gang Lai [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Relationship with the group</a></td>
<td class="text">Chief Executive Officer (&#8220;CEO&#8221;), chairman of the Board of Directors<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrsLinYangMember', window );">Mrs. Lin Yang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Relationship with the group</a></td>
<td class="text">Chief Financial Officer and Director<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GreatestGroupMember', window );">Greatest Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Relationship with the group</a></td>
<td class="text">One of the Company&#8217;s minority shareholders owns 8.7% of the ownership interest in this entity<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_FoshanShangyuMember', window );">Foshan Shangyu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Relationship with the group</a></td>
<td class="text">An affiliated entity of the Company, 90% owned by and controlled by the Company&#8217;s CEO.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms and manner of settlement of the related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrsLinYangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrsLinYangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GreatestGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GreatestGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_FoshanShangyuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_FoshanShangyuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680332160728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Schedule of due from related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems', window );"><strong>Related Party Transactions (Details) - Schedule of due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="nump">$ 236,982<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GreatestGroupMember', window );">Greatest Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems', window );"><strong>Related Party Transactions (Details) - Schedule of due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="nump">235,438<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_FoshanShangyuMember', window );">Foshan Shangyu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems', window );"><strong>Related Party Transactions (Details) - Schedule of due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="nump">$ 1,544<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromOtherRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount receivable from related parties classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromOtherRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GreatestGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_GreatestGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_FoshanShangyuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_FoshanShangyuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335977032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Schedule of due to related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems', window );"><strong>Related Party Transactions (Details) - Schedule of due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total due to related parties</a></td>
<td class="nump">$ 19,723<span></span>
</td>
<td class="nump">$ 956,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember', window );">Mr. Gang Lai [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems', window );"><strong>Related Party Transactions (Details) - Schedule of due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total due to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 956,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrsLinYangMember', window );">Mrs. Lin Yang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems', window );"><strong>Related Party Transactions (Details) - Schedule of due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total due to related parties</a></td>
<td class="nump">$ 19,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrGangLaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrsLinYangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_MrsLinYangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680328162568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_TaxesDetailsLineItems', window );"><strong>Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings', window );">Foreign tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PreferentialTaxTreatmentDescription', window );">Preferential tax treatment, description</a></td>
<td class="text">Under this preferential tax treatment, HNTEs are entitled
to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. Jiangxi Universe, one
of the Company&#8217;s main operating subsidiaries in PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15%
beginning November&#160;2016 with a term of three years. In December 2019, Jiangxi Universe successfully renewed its HNTE certification
with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through December 2022. Universe
Trade, the Company&#8217;s another operating subsidiary in PRC, was approved as a HNTE and is entitled to a reduced income tax rate of
15% beginning December&#160;2020 with a term of three years. EIT is typically governed by the local tax authority in PRC. Each local tax
authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The
corporate income taxes for the years ended September 30, 2021, 2020 and 2019 were reported at a blended reduced rate as a result of Jiangxi
Universe and Universe Trade being approved as a HNTE and enjoying a 15% reduced income tax rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAndNoncurrent', window );">PRC corporate income taxes</a></td>
<td class="nump">$ 1,518,979<span></span>
</td>
<td class="nump">$ 118,986<span></span>
</td>
<td class="nump">$ 312,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare', window );">Tax holidays on net income per share</a></td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">Hong Kong [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_TaxesDetailsLineItems', window );"><strong>Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign', window );">Subject to profit taxes rate</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PreferentialTaxTreatmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferential tax treatment, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PreferentialTaxTreatmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_TaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_TaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in foreign income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680331012728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details) - Schedule of components of the income tax provision (benefit) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems', window );"><strong>Taxes (Details) - Schedule of components of the income tax provision (benefit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="num">$ (668,341)<span></span>
</td>
<td class="num">$ (9,886)<span></span>
</td>
<td class="num">$ (39,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">2,358,526<span></span>
</td>
<td class="nump">2,542,211<span></span>
</td>
<td class="nump">2,101,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax provision</a></td>
<td class="nump">3,026,867<span></span>
</td>
<td class="nump">2,552,097<span></span>
</td>
<td class="nump">2,141,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KY', window );">CAYMAN ISLANDS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems', window );"><strong>Taxes (Details) - Schedule of components of the income tax provision (benefit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">HONG KONG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems', window );"><strong>Taxes (Details) - Schedule of components of the income tax provision (benefit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax provision</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">PRC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems', window );"><strong>Taxes (Details) - Schedule of components of the income tax provision (benefit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="num">(668,341)<span></span>
</td>
<td class="num">(9,886)<span></span>
</td>
<td class="num">(39,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax provision</a></td>
<td class="nump">$ 3,026,867<span></span>
</td>
<td class="nump">$ 2,552,097<span></span>
</td>
<td class="nump">$ 2,141,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680328160248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details) - Schedule of table reconciles the china statutory rates to the company&#8217;s effective tax rate<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract', window );"><strong>Schedule of table reconciles the china statutory rates to the company&#8217;s effective tax rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory PRC income tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays', window );">Effect of income tax holiday</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(3.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Permanent difference</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Non-PRC entities not subject to PRC income tax</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Impact on DTA due to change in applicable income tax rate</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">17.10%<span></span>
</td>
<td class="nump">25.20%<span></span>
</td>
<td class="nump">21.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a tax holiday.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335950680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes (Details) - Schedule of deferred tax assets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 785,550<span></span>
</td>
<td class="nump">$ 186,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">84,447<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total</a></td>
<td class="nump">869,997<span></span>
</td>
<td class="nump">186,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">$ 869,997<span></span>
</td>
<td class="nump">$ 186,537<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680330897608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes (Details) - Schedule of taxes payable - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfTaxesPayableAbstract', window );"><strong>Schedule of taxes payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">$ 669,780<span></span>
</td>
<td class="nump">$ 767,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Value added tax payable</a></td>
<td class="nump">326,468<span></span>
</td>
<td class="nump">433,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Other taxes payable</a></td>
<td class="nump">105,212<span></span>
</td>
<td class="nump">130,614<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Total taxes payable</a></td>
<td class="nump">$ 1,101,460<span></span>
</td>
<td class="nump">$ 1,331,749<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfTaxesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfTaxesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6419918&amp;loc=d3e35281-107843<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680328440184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignFinancialInstitutionsMandatedDeposits', window );">Deposit at financial institutions (in Dollars)</a></td>
<td class="nump">$ 5,892,655<span></span>
</td>
<td class="nump">$ 10,027,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_SupplierOneMember', window );">Supplier One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="nump">35.30%<span></span>
</td>
<td class="nump">19.60%<span></span>
</td>
<td class="nump">14.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_SupplierTwoMember', window );">Supplier Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">13.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_supplierMember', window );">supplier [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=upc_TotalRevenueMember', window );">Total Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="nump">30.40%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">34.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=upc_GubenYanlingPillMember', window );">Guben Yanling Pill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="nump">40.30%<span></span>
</td>
<td class="nump">38.20%<span></span>
</td>
<td class="nump">32.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=upc_CustomerMember', window );">Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ConcentrationRiskThresholdPercentage', window );">Total revenue percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ConcentrationRiskThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ConcentrationRiskThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ConcentrationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ConcentrationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignFinancialInstitutionsMandatedDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of mandated deposits required of branches of foreign institutions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=d3e65207-112826<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignFinancialInstitutionsMandatedDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_SupplierOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_SupplierOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_SupplierTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_SupplierTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_supplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=upc_supplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=upc_TotalRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=upc_TotalRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=upc_GubenYanlingPillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=upc_GubenYanlingPillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=upc_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=upc_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=upc_CustomersOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=upc_CustomersOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680325068200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details)<br> $ / shares in Units, &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 07, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 02, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 13, 2017 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Feb. 21, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 20, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 21, 2016 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 29, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary issued shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PublicOfferingPrice', window );">Public offering price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 48.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds (in Dollars) | $</a></td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Offering price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ReserveIsEqualPercentage', window );">Reserve is equal percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash transferred (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,077,908<span></span>
</td>
<td class="nump">$ 10,058,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_UniverseINCMember', window );">Universe INC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OriginalSharesParValue', window );">Original shares par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OrdinarySharesParValue', window );">Ordinary shares par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ReorganizationShares', window );">Reorganization shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ordinary shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Universe INC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OrdinarySharesOutstandingDescription', window );">Ordinary shares outstanding description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As a result of this forward split
of the outstanding ordinary shares at a ratio of 320-for-1 share, there is a total of 16,000,000 shares issued and outstanding.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=upc_PRCMember', window );">PRC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash transferred (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,807,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary issued shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_PublicOfferingPrice', window );">Public offering price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OptionToPurchaseAdditionalShares', window );">Option to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds (in Dollars) | $</a></td>
<td class="nump">$ 25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ordinary shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">21,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=upc_UnderwriterWarrantsMember', window );">Underwriter warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Ordinary shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Offering price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=upc_CashDividendsMember', window );">Cash dividends [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsShareBasedCompensationCash', window );">Cash dividend (in Yuan Renminbi) | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 20.0<span></span>
</td>
<td class="nump">&#165; 30.0<span></span>
</td>
<td class="nump">&#165; 30.0<span></span>
</td>
<td class="nump">&#165; 10.0<span></span>
</td>
<td class="nump">&#165; 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_CashDividendDescription', window );">Description of dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A total of RMB130 million (approximately $19.1 million) cash dividend was declared from September
2016 to February 2019, among which approximately RMB20 million ($3.1 million) was paid in cash to its shareholders in 2018 and the remaining
RMB 110 million ($16 million) was paid to its shareholders in 2019.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=upc_StatutoryReserveAndRestrictedNetAssetsMember', window );">Statutory Reserve and Restricted Net Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_StatutorySurplusPercentage', window );">Statutory surplus percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted amounts (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,439,535<span></span>
</td>
<td class="nump">$ 2,439,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_RestrictedNetAssets', window );">Restricted net assets (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,786,663<span></span>
</td>
<td class="nump">$ 6,168,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">HONG KONG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash transferred (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,358,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CashDividendDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CashDividendDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OrdinarySharesOutstandingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares outstanding description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OrdinarySharesOutstandingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OrdinarySharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares par value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OrdinarySharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OriginalSharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Original shares par value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OriginalSharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_PublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Public offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_PublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ReorganizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reorganization shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ReorganizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ReserveIsEqualPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reserve is equal percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ReserveIsEqualPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_RestrictedNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted net assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_RestrictedNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_StatutorySurplusPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Statutory surplus percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_StatutorySurplusPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsShareBasedCompensationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash dividends declared for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsShareBasedCompensationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_UniverseINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=upc_UniverseINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=upc_PRCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=upc_PRCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=upc_UnderwriterWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=upc_UnderwriterWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=upc_CashDividendsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=upc_CashDividendsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=upc_StatutoryReserveAndRestrictedNetAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=upc_StatutoryReserveAndRestrictedNetAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338260680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpenditureDiscontinuedOperations', window );">Future minimum capital expenditures amount</a></td>
<td class="nump">$ 14.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseCapitalSecurities', window );">Total amount of capital expenditure</a></td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpenditureDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital expenditure attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpenditureDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense incurred during the reporting period on capital securities issued by the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335474840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Reporting segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680335765880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details) - Schedule of revenue by product source - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ScheduleOfRevenueByProductSourceAbstract', window );"><strong>Schedule of revenue by product source [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfOtherPropertyOperatingExpense', window );">Sales of TCMD products manufactured by the Company</a></td>
<td class="nump">$ 29,559,286<span></span>
</td>
<td class="nump">$ 18,374,751<span></span>
</td>
<td class="nump">$ 20,895,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Sales of third-party products</a></td>
<td class="nump">18,422,745<span></span>
</td>
<td class="nump">12,329,209<span></span>
</td>
<td class="nump">12,333,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 47,982,031<span></span>
</td>
<td class="nump">$ 30,703,960<span></span>
</td>
<td class="nump">$ 33,229,316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ScheduleOfRevenueByProductSourceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ScheduleOfRevenueByProductSourceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfOtherPropertyOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other operating costs incurred during the reporting period and may include amounts paid to maintain the property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfOtherPropertyOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680332300424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details) - Schedule of total revenues by product categories - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SalesOfTcmdProductsAbstract', window );"><strong>Sales of TCMD products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubtotalOfTCMDProductsSales', window );">Sub-total of TCMD products sales</a></td>
<td class="nump">$ 29,559,286<span></span>
</td>
<td class="nump">$ 18,374,751<span></span>
</td>
<td class="nump">$ 20,895,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SalesOfThirdPartyProductsAbstract', window );"><strong>Sales of third-party products</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubtotalOfThirdpartyProductsSales', window );">Subtotal of third-party products sales</a></td>
<td class="nump">18,422,745<span></span>
</td>
<td class="nump">12,329,209<span></span>
</td>
<td class="nump">12,333,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">47,982,031<span></span>
</td>
<td class="nump">30,703,960<span></span>
</td>
<td class="nump">33,229,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Medicinal liquor products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SalesOfTcmdProductsAbstract', window );"><strong>Sales of TCMD products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubtotalOfTCMDProductsSales', window );">Sub-total of TCMD products sales</a></td>
<td class="nump">1,951,679<span></span>
</td>
<td class="nump">1,616,080<span></span>
</td>
<td class="nump">2,356,015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentOneMember', window );">Other chronic condition treatment products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SalesOfTcmdProductsAbstract', window );"><strong>Sales of TCMD products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubtotalOfTCMDProductsSales', window );">Sub-total of TCMD products sales</a></td>
<td class="nump">22,978,001<span></span>
</td>
<td class="nump">14,059,403<span></span>
</td>
<td class="nump">14,056,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentTwoMember', window );">Cold and flu medicines [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SalesOfTcmdProductsAbstract', window );"><strong>Sales of TCMD products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubtotalOfTCMDProductsSales', window );">Sub-total of TCMD products sales</a></td>
<td class="nump">4,629,606<span></span>
</td>
<td class="nump">2,699,268<span></span>
</td>
<td class="nump">4,483,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentThreeMember', window );">Biochemical drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SalesOfThirdPartyProductsAbstract', window );"><strong>Sales of third-party products</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubtotalOfThirdpartyProductsSales', window );">Subtotal of third-party products sales</a></td>
<td class="nump">16,082,546<span></span>
</td>
<td class="nump">10,325,411<span></span>
</td>
<td class="nump">9,508,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentFourMember', window );">Traditional Chinese medicine pieces [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SalesOfThirdPartyProductsAbstract', window );"><strong>Sales of third-party products</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubtotalOfThirdpartyProductsSales', window );">Subtotal of third-party products sales</a></td>
<td class="nump">20,705<span></span>
</td>
<td class="nump">47,097<span></span>
</td>
<td class="nump">142,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentFiveMember', window );">Medical instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SalesOfThirdPartyProductsAbstract', window );"><strong>Sales of third-party products</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubtotalOfThirdpartyProductsSales', window );">Subtotal of third-party products sales</a></td>
<td class="nump">2,318,536<span></span>
</td>
<td class="nump">1,950,238<span></span>
</td>
<td class="nump">2,668,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentSixMember', window );">Dietary supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SalesOfThirdPartyProductsAbstract', window );"><strong>Sales of third-party products</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubtotalOfThirdpartyProductsSales', window );">Subtotal of third-party products sales</a></td>
<td class="nump">$ 958<span></span>
</td>
<td class="nump">$ 6,463<span></span>
</td>
<td class="nump">$ 14,127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SalesOfTcmdProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SalesOfTcmdProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SalesOfThirdPartyProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SalesOfThirdPartyProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SubtotalOfTCMDProductsSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SubtotalOfTCMDProductsSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SubtotalOfThirdpartyProductsSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subtotal of third-party products sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SubtotalOfThirdpartyProductsSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=upc_CorporateSegmentSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338332984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event, description</a></td>
<td class="text">(i) both parties will build a manufacturing facility in Ji&#8217;an, Jiangxi, China, for the manufacturing
and research and development of traditional Chinese medicine derivatives products, with an aggregate area of over 430,000 square feet,
and the Company will bear the costs associated with building the facility, and (ii) the Company will purchase 464 shares of Kitanihon
for an aggregate of JPY176.32 million (approximately US$1.56 million)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_IntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_IntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_IntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680336705160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_MinorityInterestsOwnershipPercentageByParent', window );">Subsidiary exceeded percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_MinorityInterestsOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary exceeded percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_MinorityInterestsOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680328235080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets - Parent [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_AssetsAbstract0', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 110,393<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">13,725,204<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,835,597<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_NonCurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investment in subsidiaries</a></td>
<td class="nump">45,098,756<span></span>
</td>
<td class="nump">20,802,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">58,934,353<span></span>
</td>
<td class="nump">20,802,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">LIABILITIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_ShareholdersEquityAbstract0', window );"><strong>SHAREHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares and 16,000,000 shares issued and outstanding as of September 30, 2021 and 2020, respectively</a></td>
<td class="nump">67,969<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">29,279,159<span></span>
</td>
<td class="nump">3,679,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">27,498,466<span></span>
</td>
<td class="nump">16,178,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">2,088,759<span></span>
</td>
<td class="nump">895,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">58,934,353<span></span>
</td>
<td class="nump">20,802,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 58,934,353<span></span>
</td>
<td class="nump">$ 20,802,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_AssetsAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_AssetsAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_NonCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_NonCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_ShareholdersEquityAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_ShareholdersEquityAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680338411896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets (Parentheticals) - Parent [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.003125<span></span>
</td>
<td class="nump">$ 0.003125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">21,750,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedBalanceSheetStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680332124968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of income and comprehensive income - Parent [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">$ (1,177,869)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_OtherIncomeExpensesAbstract0', window );"><strong>Other income (expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOtherShortTermBorrowings', window );">Income from short-term investments</a></td>
<td class="nump">239,549<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other expenses</a></td>
<td class="num">(60,751)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of subsidiaries</a></td>
<td class="nump">12,319,023<span></span>
</td>
<td class="nump">7,558,222<span></span>
</td>
<td class="nump">7,551,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">11,319,952<span></span>
</td>
<td class="nump">7,558,222<span></span>
</td>
<td class="nump">7,551,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments', window );">Foreign currency translation adjustments</a></td>
<td class="nump">1,193,369<span></span>
</td>
<td class="nump">860,623<span></span>
</td>
<td class="num">(645,978)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to the Company</a></td>
<td class="nump">$ 12,513,321<span></span>
</td>
<td class="nump">$ 8,418,845<span></span>
</td>
<td class="nump">$ 6,905,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_OtherIncomeExpensesAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_OtherIncomeExpensesAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense incurred during the reporting period on other short-term borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to temporary equity resulting from foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140680332283032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of cash flows - Parent [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_CashFlowsFromOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 11,319,952<span></span>
</td>
<td class="nump">$ 7,558,222<span></span>
</td>
<td class="nump">$ 7,551,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Adjustments to reconcile net cash flows from operating activities:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_EquityInEarningsOfSubsidiary', window );">Equity in earnings of subsidiary</a></td>
<td class="num">(12,319,027)<span></span>
</td>
<td class="num">(7,558,222)<span></span>
</td>
<td class="num">(7,551,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(999,075)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_CashFlowsFromInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromShortTermInvestments', window );">Payment for short-term investments</a></td>
<td class="num">(15,330,660)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Redemption of short-term investments</a></td>
<td class="nump">1,801,927<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(13,528,733)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_CashFlowsFromFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of ordinary shares in IPO</a></td>
<td class="nump">25,957,457<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_CashLentToSubsidiaries', window );">Cash lent to subsidiaries</a></td>
<td class="num">(11,358,764)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">14,598,693<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH</a></td>
<td class="nump">39,508<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">CHANGES IN CASH</a></td>
<td class="nump">110,393<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_CashAndCashEquivalentAtCarryingValue', window );">CASH, beginning of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_upc_CashAndCashEquivalentAtCarryingValue', window );">CASH, end of year</a></td>
<td class="nump">$ 110,393<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CashAndCashEquivalentAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CashAndCashEquivalentAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CashFlowsFromFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CashFlowsFromFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CashFlowsFromInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CashFlowsFromInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CashFlowsFromOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CashFlowsFromOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_CashLentToSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of Cash lent to subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_CashLentToSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_upc_EquityInEarningsOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity in earnings of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">upc_EquityInEarningsOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>upc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>f20f2021_universe_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:upc="http://www.UniversePharmaceuticalsINC.com/20210930"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="upc-20210930.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseHKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JiangxiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JiangxiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-29</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseHKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JiangxiUniverseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseTradeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseHanheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:UniverseHanheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JxRcbBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-03-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">upc:JxRcbBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-25</startDate>
            <endDate>2018-05-01</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-25</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:LessThan3MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:LessThan3MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From4To6MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From4To6MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From7To9MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From7To9MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From10To12MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:From10To12MonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:Over1YearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis">upc:Over1YearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-06</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-09-06</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">upc:OfficeAndElectricEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-25</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ChenyuanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:ChenyuanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">upc:CapitalExpenditureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-06</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-06</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-05-06</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-26</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2019-09-26</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-26</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-19</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">upc:JiangxiLulingRuralCommercialBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-19</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:Maturity30To90DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:Maturity30To90DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOver90DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">us-gaap:MaturityOver90DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis">upc:MaturityGreaterThan90DaysThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrsLinYangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GreatestGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:FoshanShangyuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GreatestGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:GreatestGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:FoshanShangyuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:FoshanShangyuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrGangLaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:MrsLinYangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:TotalRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:TotalRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">upc:TotalRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">upc:GubenYanlingPillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">upc:CustomersOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:supplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">upc:SupplierOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-02</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">upc:UniverseINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-29</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:UnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-02</startDate>
            <endDate>2016-09-21</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-02</startDate>
            <endDate>2017-09-13</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-28</startDate>
            <endDate>2018-02-02</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-02</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-02</startDate>
            <endDate>2019-02-21</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:CashDividendsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">upc:StatutoryReserveAndRestrictedNetAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">upc:PRCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">upc:CorporateSegmentSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-24</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809616</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <dei:DocumentType contextRef="c0">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0">001-40231</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">Universe Pharmaceuticals INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0">265 Jingjiu Avenue,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0">Jinggangshan Economic and Technological Development Zone</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0">Ji&#x2019;an, Jiangxi Province</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c0">CN</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1">Gang Lai</dei:ContactPersonnelName>
    <dei:ContactPersonnelEmailAddress contextRef="c1">gang.lai@universe-pharmacy.com</dei:ContactPersonnelEmailAddress>
    <dei:EntityAddressAddressLine1 contextRef="c1">265 Jingjiu Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1">Jinggangshan Economic and Technological Development Zone</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1">Ji&#x2019;an, Jiangxi Province</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c1">CN</dei:EntityAddressCountry>
    <dei:Security12bTitle contextRef="c0">Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">UPC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">21750000</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <us-gaap:Cash contextRef="c2" decimals="0" unitRef="usd">8077908</us-gaap:Cash>
    <us-gaap:Cash contextRef="c3" decimals="0" unitRef="usd">10058202</us-gaap:Cash>
    <us-gaap:ShortTermInvestments contextRef="c2" decimals="0" unitRef="usd">13725204</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent contextRef="c2" decimals="0" unitRef="usd">15573742</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c3" decimals="0" unitRef="usd">10871778</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" unitRef="usd">2462542</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" unitRef="usd">1906232</us-gaap:InventoryNet>
    <us-gaap:DueFromRelatedParties contextRef="c2" decimals="0" unitRef="usd">236982</us-gaap:DueFromRelatedParties>
    <upc:AdvanceToSuppliersNet contextRef="c2" decimals="0" unitRef="usd">2738313</upc:AdvanceToSuppliersNet>
    <upc:PrepaymentForAdvertising contextRef="c2" decimals="0" unitRef="usd">7492320</upc:PrepaymentForAdvertising>
    <us-gaap:DeferredCostsCurrent contextRef="c3" decimals="0" unitRef="usd">443709</us-gaap:DeferredCostsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c2" decimals="0" unitRef="usd">174053</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" unitRef="usd">50481064</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" unitRef="usd">23279921</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" unitRef="usd">4681353</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">4428064</us-gaap:PropertyPlantAndEquipmentNet>
    <upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent contextRef="c2" decimals="0" unitRef="usd">2476800</upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent>
    <upc:PrepaymentsForConstructionInProgress contextRef="c2" decimals="0" unitRef="usd">10712160</upc:PrepaymentsForConstructionInProgress>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c2" decimals="0" unitRef="usd">178483</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c3" decimals="0" unitRef="usd">174776</us-gaap:OtherIntangibleAssetsNet>
    <upc:InvestmentInEquitySecurities contextRef="c2" decimals="0" unitRef="usd">744924</upc:InvestmentInEquitySecurities>
    <upc:InvestmentInEquitySecurities contextRef="c3" decimals="0" unitRef="usd">735000</upc:InvestmentInEquitySecurities>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c2" decimals="0" unitRef="usd">869997</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c3" decimals="0" unitRef="usd">186537</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="0" unitRef="usd">19663717</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="0" unitRef="usd">5524377</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="0" unitRef="usd">70144781</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" unitRef="usd">28804298</us-gaap:Assets>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="c2" decimals="0" unitRef="usd">4334400</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="c3" decimals="0" unitRef="usd">2646000</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="0" unitRef="usd">5310526</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" unitRef="usd">2691193</us-gaap:AccountsPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="0" unitRef="usd">1101460</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c3" decimals="0" unitRef="usd">1331749</us-gaap:TaxesPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="c2" decimals="0" unitRef="usd">19723</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="c3" decimals="0" unitRef="usd">956492</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">444319</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">375960</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">11210428</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">8001394</us-gaap:LiabilitiesCurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="6" unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="6" unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">21750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">21750000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">16000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">16000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" unitRef="usd">67969</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" unitRef="usd">50000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" unitRef="usd">29279159</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" unitRef="usd">3679000</us-gaap:AdditionalPaidInCapital>
    <upc:StatutoryReserve contextRef="c2" decimals="0" unitRef="usd">2439535</upc:StatutoryReserve>
    <upc:StatutoryReserve contextRef="c3" decimals="0" unitRef="usd">2439535</upc:StatutoryReserve>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" unitRef="usd">25058931</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" unitRef="usd">13738979</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="0" unitRef="usd">2088759</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="0" unitRef="usd">895390</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">58934353</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">20802904</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" unitRef="usd">70144781</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" unitRef="usd">28804298</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">47982031</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c4" decimals="0" unitRef="usd">30703960</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="0" unitRef="usd">33229316</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" unitRef="usd">22655854</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c4" decimals="0" unitRef="usd">16610140</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c5" decimals="0" unitRef="usd">19821831</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" unitRef="usd">25326177</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c4" decimals="0" unitRef="usd">14093820</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c5" decimals="0" unitRef="usd">13407485</us-gaap:GrossProfit>
    <us-gaap:SellingExpense contextRef="c0" decimals="0" unitRef="usd">2973531</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c4" decimals="0" unitRef="usd">1555546</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c5" decimals="0" unitRef="usd">1578826</us-gaap:SellingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">3296844</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="0" unitRef="usd">1703424</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" unitRef="usd">1457393</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">5465662</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" unitRef="usd">583125</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" unitRef="usd">618437</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" unitRef="usd">11736037</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="0" unitRef="usd">3842095</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" unitRef="usd">3654656</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" unitRef="usd">13590140</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="0" unitRef="usd">10251725</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" unitRef="usd">9752829</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c0" decimals="0" unitRef="usd">101604</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c4" decimals="0" unitRef="usd">123760</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c5" decimals="0" unitRef="usd">129268</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c0" decimals="0" unitRef="usd">-80434</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c4" decimals="0" unitRef="usd">-49352</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c5" decimals="0" unitRef="usd">2760</us-gaap:OtherOperatingIncomeExpenseNet>
    <upc:ShorttermInvestmentIncome contextRef="c0" decimals="0" unitRef="usd">-239549</upc:ShorttermInvestmentIncome>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c0" decimals="0" unitRef="usd">30827</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c4" decimals="0" unitRef="usd">21820</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c5" decimals="0" unitRef="usd">26741</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="0" unitRef="usd">88338</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c4" decimals="0" unitRef="usd">-151292</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c5" decimals="0" unitRef="usd">-99767</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">13678478</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c4" decimals="0" unitRef="usd">10100433</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="0" unitRef="usd">9653062</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">2358526</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c4" decimals="0" unitRef="usd">2542211</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">2101597</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" unitRef="usd">11319952</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c4" decimals="0" unitRef="usd">7558222</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="0" unitRef="usd">7551465</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c0" decimals="0" unitRef="usd">-1193369</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c4" decimals="0" unitRef="usd">-860623</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c5" decimals="0" unitRef="usd">645978</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">12513321</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c4" decimals="0" unitRef="usd">8418845</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c5" decimals="0" unitRef="usd">6905487</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c0" decimals="2" unitRef="usdPershares">0.6</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c4" decimals="2" unitRef="usdPershares">0.47</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c5" decimals="2" unitRef="usdPershares">0.47</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c0" decimals="0" unitRef="shares">18980822</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c4" decimals="0" unitRef="shares">16000000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c5" decimals="0" unitRef="shares">16000000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding contextRef="c6" decimals="0" unitRef="shares">16000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="0" unitRef="usd">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" unitRef="usd">3679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" unitRef="usd">2439535</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" unitRef="usd">2832292</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="0" unitRef="usd">680745</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="0" unitRef="usd">9681572</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="c15" decimals="0" unitRef="usd">4203000</us-gaap:StockIssuedDuringPeriodValueStockDividend>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="c5" decimals="0" unitRef="usd">4203000</us-gaap:StockIssuedDuringPeriodValueStockDividend>
    <us-gaap:ProfitLoss contextRef="c15" decimals="0" unitRef="usd">7551465</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="0" unitRef="usd">7551465</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c16" decimals="0" unitRef="usd">-645978</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c5" decimals="0" unitRef="usd">-645978</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding contextRef="c17" decimals="0" unitRef="shares">16000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" unitRef="usd">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" unitRef="usd">3679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" unitRef="usd">2439535</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" unitRef="usd">6180757</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="0" unitRef="usd">34767</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="0" unitRef="usd">12384059</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c26" decimals="0" unitRef="usd">7558222</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c4" decimals="0" unitRef="usd">7558222</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c27" decimals="0" unitRef="usd">860623</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c4" decimals="0" unitRef="usd">860623</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding contextRef="c28" decimals="0" unitRef="shares">16000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="0" unitRef="usd">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="0" unitRef="usd">3679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="0" unitRef="usd">2439535</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="0" unitRef="usd">13738979</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="0" unitRef="usd">895390</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">20802904</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c33" decimals="0" unitRef="shares">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c33" decimals="0" unitRef="usd">17969</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c34" decimals="0" unitRef="usd">28732031</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="0" unitRef="usd">28750000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts contextRef="c34" decimals="0" unitRef="usd">-3131872</upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts>
    <upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts contextRef="c0" decimals="0" unitRef="usd">-3131872</upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts>
    <us-gaap:ProfitLoss contextRef="c36" decimals="0" unitRef="usd">11319952</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" unitRef="usd">11319952</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c37" decimals="0" unitRef="usd">1193369</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="0" unitRef="usd">1193369</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding contextRef="c38" decimals="0" unitRef="shares">21750000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c38" decimals="0" unitRef="usd">67969</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c39" decimals="0" unitRef="usd">29279159</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="0" unitRef="usd">2439535</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="0" unitRef="usd">25058931</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="0" unitRef="usd">2088759</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">58934353</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" unitRef="usd">11319952</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c4" decimals="0" unitRef="usd">7558222</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="0" unitRef="usd">7551465</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="0" unitRef="usd">446878</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c4" decimals="0" unitRef="usd">410079</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c5" decimals="0" unitRef="usd">418431</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c0" decimals="0" unitRef="usd">-1559</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c5" decimals="0" unitRef="usd">-2085</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="0" unitRef="usd">-230175</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c4" decimals="0" unitRef="usd">98102</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c5" decimals="0" unitRef="usd">297972</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c4" decimals="0" unitRef="usd">-75391</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c5" decimals="0" unitRef="usd">-187271</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">-668341</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c4" decimals="0" unitRef="usd">-9886</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">-39625</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:InterestIncomeShortTermInvestmentOther contextRef="c0" decimals="0" unitRef="usd">239549</us-gaap:InterestIncomeShortTermInvestmentOther>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" unitRef="usd">3867457</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c4" decimals="0" unitRef="usd">4107520</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c5" decimals="0" unitRef="usd">-665485</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" unitRef="usd">451634</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c4" decimals="0" unitRef="usd">-888607</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c5" decimals="0" unitRef="usd">-5586177</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies contextRef="c0" decimals="0" unitRef="usd">2717085</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <us-gaap:IncreaseDecreaseInPrepaidAdvertising contextRef="c0" decimals="0" unitRef="usd">7434240</us-gaap:IncreaseDecreaseInPrepaidAdvertising>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c0" decimals="0" unitRef="usd">237720</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" unitRef="usd">168188</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c4" decimals="0" unitRef="usd">-12407</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c5" decimals="0" unitRef="usd">8449</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="0" unitRef="usd">2457337</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c4" decimals="0" unitRef="usd">639427</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c5" decimals="0" unitRef="usd">-924444</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable contextRef="c0" decimals="0" unitRef="usd">-298620</us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable>
    <us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable contextRef="c4" decimals="0" unitRef="usd">731518</us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable>
    <us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable contextRef="c5" decimals="0" unitRef="usd">-320611</us-gaap:IncreaseDecreaseInPropertyAndOtherTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="0" unitRef="usd">31436</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c4" decimals="0" unitRef="usd">-30408</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c5" decimals="0" unitRef="usd">162540</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-2055847</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="0" unitRef="usd">6115157</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="0" unitRef="usd">13203755</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" unitRef="usd">444505</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c4" decimals="0" unitRef="usd">51798</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="0" unitRef="usd">86324</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c5" decimals="0" unitRef="usd">291</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty contextRef="c0" decimals="0" unitRef="usd">2457600</upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty>
    <us-gaap:RepaymentsOfAdvancesForConstruction contextRef="c0" decimals="0" unitRef="usd">10629120</us-gaap:RepaymentsOfAdvancesForConstruction>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments contextRef="c0" decimals="0" unitRef="usd">15330660</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <upc:RedemptionOfShorttermInvestments contextRef="c0" decimals="0" unitRef="usd">1801927</upc:RedemptionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="usd">-27059958</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="0" unitRef="usd">-51798</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="0" unitRef="usd">-86033</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c0" decimals="0" unitRef="usd">4300800</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c4" decimals="0" unitRef="usd">1427000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c5" decimals="0" unitRef="usd">3055500</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c0" decimals="0" unitRef="usd">2764800</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c4" decimals="0" unitRef="usd">1427000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c5" decimals="0" unitRef="usd">3055500</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:PaymentsOfDividends contextRef="c5" decimals="0" unitRef="usd">16005000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c0" decimals="0" unitRef="usd">28750000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="c0" decimals="0" unitRef="usd">2792543</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="c4" decimals="0" unitRef="usd">441064</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings contextRef="c0" decimals="0" unitRef="usd">911648</upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings>
    <upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings contextRef="c4" decimals="0" unitRef="usd">-911200</upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings>
    <upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings contextRef="c5" decimals="0" unitRef="usd">-1143</upc:ProceedsFromprepaymentsForRelatedPartiesBorrowings>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" unitRef="usd">26581809</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="0" unitRef="usd">470136</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="0" unitRef="usd">-16003857</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c0" decimals="0" unitRef="usd">553702</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c4" decimals="0" unitRef="usd">347386</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c5" decimals="0" unitRef="usd">-126720</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" unitRef="usd">-1980294</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c4" decimals="0" unitRef="usd">6880881</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="0" unitRef="usd">-3012855</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">10058202</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c22" decimals="0" unitRef="usd">3177321</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c11" decimals="0" unitRef="usd">6190176</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" unitRef="usd">8077908</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">10058202</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c22" decimals="0" unitRef="usd">3177321</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" unitRef="usd">149303</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c4" decimals="0" unitRef="usd">157528</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c5" decimals="0" unitRef="usd">135717</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c0" decimals="0" unitRef="usd">3271219</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c4" decimals="0" unitRef="usd">2167963</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c5" decimals="0" unitRef="usd">2257893</us-gaap:IncomeTaxesPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2014; ORGANIZATION AND BUSINESS DESCRIPTION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe
Pharmaceuticals Inc. (&#x201c;Universe INC&#x201d; or the &#x201c;Company&#x201d;) was incorporated under the laws of the Cayman Islands
on December 11, 2019 as an exempted company with limited liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe
INC. owns 100% equity interest of Universe Pharmaceuticals (International) Group (&#x201c;Universe HK&#x201d;), an entity incorporated
on May 21, 2014 in accordance with the laws and regulations in Hong Kong.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiangxi
Universe Pharmaceuticals Technology Co., Ltd. (&#x201c;Universe Technology&#x201d;) was formed on April 8, 2019, as a Wholly Foreign-Owned
Enterprise (&#x201c;WOFE&#x201d;) in the People&#x2019;s Republic of China (&#x201c;PRC&#x201d;). The registered capital of Universe Technology
is approximately $4.3 million (RMB 30.5 million). In December 2019, the Company made capital contribution of $500,000 to Universe Technology.
Pursuant to the article of incorporation, the remaining capital contribution of approximately $3.8 million for Universe Technology is
required to be completed before 2038.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe
INC, Universe HK and Universe Technology are currently not engaging in any active business operations and merely acting as holding companies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiangxi
Universe Pharmaceuticals Co., Ltd. (&#x201c;Jiangxi Universe&#x201d;) was incorporated on March 2, 1998 in accordance with PRC laws and
is engaged in research and development and manufacturing of modernized traditional Chinese medicines. Jiangxi Universe owns 100% of the
equity of Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (&#x201c;Universe Trade&#x201d;) which was incorporated on March
10, 2010 to handle the sales and distribution of the pharmaceutical products manufactured by Jiangxi Universe.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reorganization&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reorganization of our legal structure (&#x201c;Reorganization&#x201d;) was completed on December 11, 2019. The reorganization involved
the incorporation of Universe INC and Universe Technology, and the transfer of the 100% equity interest of Jiangxi Universe to Universe
Technology. Consequently, Universe INC, through its subsidiary Universe HK, directly controls Universe Technology and Jiangxi Universe,
and became the ultimate holding company of all other entities mentioned above.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Reorganization has been accounted for as a recapitalization among entities under common control since the same controlling shareholders
controlled all these entities before and after the Reorganization. The consolidation of the Company and its subsidiaries has been accounted
for at historical cost and prepared on the basis as if the aforementioned transactions had become effective as of the beginning of the
first period presented in the accompanying consolidated financial statements. Results of operations for the periods presented comprise
those of the previously separate entities combined from the beginning of the period to the end of the period, eliminating the effects
of intra-entity transactions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 25, 2021, the Company closed its IPO of 5,000,000 ordinary shares, par value $0.003125 per share (the &#x201c;ordinary shares&#x201d;)
at a public offering price of $5.00 per share. On March 29, 2021, the underwriter exercised in full its over-allotment option to purchase
an additional 750,000 ordinary shares.&#160;&lt;span&gt;The closing for the sale of the over-allotment shares
took place on March 31, 2021. Gross proceeds from the IPO totaled $28.75 million. &lt;/span&gt;Net proceeds of the IPO, including over-allotment
shares, were approximately $25.6 million. In connection with the IPO, the Company&#x2019;s ordinary shares began trading on the Nasdaq
Global Market&#160;under the symbol &#x201c;UPC&#x201d; on March 23, 2021.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 12, 2021, through the Company&#x2019;s PRC subsidiary Jiangxi Universe, the Company established a wholly controlled subsidiary, Guangzhou
Universe Hanhe Medical Research Co., Ltd. (&#x201c;Universe Hanhe&#x201d;) in Guangzhou City, China, for the business purpose of conducting
research and development of new pharmaceutical products in order to diversify the Company&#x2019;s product offerings in the near future.
As of September 30, 2021 and as of the date of this report, Universe Hanhe has no active business operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Details
of the subsidiaries of the Company as of September 30, 2021 were set out below:&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name
    of Entity &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Date
    of&lt;br/&gt;
    Incorporation &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Place
    of&lt;br/&gt;
    Incorporation &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%
    of&#160;&lt;br/&gt;
    Ownership &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 29%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal
    Activities &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe
    INC &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December&#160;11,&#160;2019 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cayman&#160;Islands &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Parent, 100% &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe
    HK &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 21, 2014 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hong Kong &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe
    Technology &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April 18, 2019 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;WOFE, Investment holding &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiangxi
    Universe &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March 2, 1998 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development and manufacturing of modernized traditional Chinese medicines &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe
    Trade&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March 10, 2010 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales of modernized traditional Chinese medicines &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe
    Hanhe&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 12, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development of new pharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company, through its wholly-owned subsidiaries, is primarily engaged in the development, manufacturing and sale of traditional Chinese
medicines derivatives (&#x201c;TCMD&#x201d;) products targeted to the elderly to address their physical conditions in the aging process
and to promote their general well-being. In addition, the Company also sells biochemical drugs, medical instruments, traditional Chinese
medicine pieces products and dietary supplements (together &#x201c;third-party products&#x201d;). All of these TCMD and third-party products
are currently sold to customers including pharmaceutical companies, hospitals, clinics and drugstore chains throughout China.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <upc:EntityIncorporationDateDescription contextRef="c43">Universe
Pharmaceuticals Inc. (&#x201c;Universe INC&#x201d; or the &#x201c;Company&#x201d;) was incorporated under the laws of the Cayman Islands
on December 11, 2019 as an exempted company with limited liability.&#160;</upc:EntityIncorporationDateDescription>
    <upc:EntityIncorporationDateDescription contextRef="c44">Universe
INC. owns 100% equity interest of Universe Pharmaceuticals (International) Group (&#x201c;Universe HK&#x201d;), an entity incorporated
on May 21, 2014 in accordance with the laws and regulations in Hong Kong.&#160;&#160;&#160;</upc:EntityIncorporationDateDescription>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c45" decimals="2" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <upc:EntityIncorporationDateDescription contextRef="c46">(&#x201c;Universe Technology&#x201d;) was formed on April 8, 2019, as a Wholly Foreign-Owned
Enterprise (&#x201c;WOFE&#x201d;) in the People&#x2019;s Republic of China (&#x201c;PRC&#x201d;).</upc:EntityIncorporationDateDescription>
    <upc:AmountOfRegisteredCapital contextRef="c47" decimals="-5" unitRef="usd">4300000</upc:AmountOfRegisteredCapital>
    <upc:AmountOfRegisteredCapital contextRef="c47" decimals="-5" unitRef="cny">30500000</upc:AmountOfRegisteredCapital>
    <upc:CapitalContribution contextRef="c48" decimals="0" unitRef="usd">500000</upc:CapitalContribution>
    <upc:RemainingCapitalContribution contextRef="c48" decimals="-5" unitRef="usd">3800000</upc:RemainingCapitalContribution>
    <upc:EntityIncorporationDateDescription contextRef="c49">(&#x201c;Jiangxi Universe&#x201d;) was incorporated on March 2, 1998 in accordance with PRC laws and
is engaged in research and development and manufacturing of modernized traditional Chinese medicines.</upc:EntityIncorporationDateDescription>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c50" decimals="2" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c51" decimals="2" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SharesIssued contextRef="c52" decimals="0" unitRef="shares">5000000</us-gaap:SharesIssued>
    <us-gaap:SharePrice contextRef="c52" decimals="6" unitRef="usdPershares">0.003125</us-gaap:SharePrice>
    <upc:PublicOfferingPrice contextRef="c52" decimals="2" unitRef="usdPershares">5</upc:PublicOfferingPrice>
    <us-gaap:SharesIssued contextRef="c53" decimals="0" unitRef="shares">750000</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c54" decimals="-4" unitRef="usd">28750000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c55" decimals="-5" unitRef="usd">25600000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name
    of Entity &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Date
    of&lt;br/&gt;
    Incorporation &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 17%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Place
    of&lt;br/&gt;
    Incorporation &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%
    of&#160;&lt;br/&gt;
    Ownership &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 29%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principal
    Activities &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe
    INC &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December&#160;11,&#160;2019 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cayman&#160;Islands &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Parent, 100% &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe
    HK &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 21, 2014 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hong Kong &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment holding &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe
    Technology &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April 18, 2019 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;WOFE, Investment holding &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiangxi
    Universe &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March 2, 1998 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development and manufacturing of modernized traditional Chinese medicines &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe
    Trade&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;March 10, 2010 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales of modernized traditional Chinese medicines &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5pt; text-indent: -5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Universe
    Hanhe&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 12, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;PRC&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development of new pharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c43">2019-12-11</dei:EntityIncorporationDateOfIncorporation>
    <upc:PlaceOfIncorporation contextRef="c43">Cayman&#160;Islands</upc:PlaceOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c45" decimals="2" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <upc:PrincipalActivities contextRef="c43">Investment holding</upc:PrincipalActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c44">2014-05-21</dei:EntityIncorporationDateOfIncorporation>
    <upc:PlaceOfIncorporation contextRef="c44">Hong Kong</upc:PlaceOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c56" decimals="2" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <upc:PrincipalActivities contextRef="c44">Investment holding</upc:PrincipalActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c57">2019-04-18</dei:EntityIncorporationDateOfIncorporation>
    <upc:PlaceOfIncorporation contextRef="c57">PRC</upc:PlaceOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c47" decimals="2" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <upc:PrincipalActivities contextRef="c57">WOFE, Investment holding</upc:PrincipalActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c49">1998-03-02</dei:EntityIncorporationDateOfIncorporation>
    <upc:PlaceOfIncorporation contextRef="c49">PRC</upc:PlaceOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c58" decimals="2" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <upc:PrincipalActivities contextRef="c49">Research and development and manufacturing of modernized traditional Chinese medicines</upc:PrincipalActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c59">2010-03-10</dei:EntityIncorporationDateOfIncorporation>
    <upc:PlaceOfIncorporation contextRef="c59">PRC</upc:PlaceOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c50" decimals="2" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <upc:PrincipalActivities contextRef="c59">Sales of modernized traditional Chinese medicines</upc:PrincipalActivities>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c60">2021-05-12</dei:EntityIncorporationDateOfIncorporation>
    <upc:PlaceOfIncorporation contextRef="c60">PRC</upc:PlaceOfIncorporation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c61" decimals="2" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <upc:PrincipalActivities contextRef="c60">Research and development of new pharmaceutical products</upc:PrincipalActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 &#x2014; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Basis
of consolidation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements include the financial statements of Universe INC, Universe HK, Universe Technology, Jiangxi
Universe, Universe Trade and Universe Hanhe. All inter-company balances and transactions are eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Uses
of estimates&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America
(&#x201c;US GAAP&#x201d;), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant estimates
required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, the realizability
of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of
long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual
results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Risks
and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
main operation of the Company is located in the PRC. Accordingly, the Company&#x2019;s business, financial condition, and results of operations
may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The
Company&#x2019;s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although
the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations
including its organization and structure disclosed in Note 1, this may not be indicative of future results.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by
rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition
with respect to our current and future pharmaceutical product candidates from major pharmaceutical companies in China.&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters,
extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company&#x2019;s
operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;
&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operations may be further affected by the ongoing outbreak of COVID-19 which in March 2020, had been declared as a pandemic
by the World Health Organization.&#160;To reduce the spread of the COVID-19, the Chinese government has employed measures including city
lockdowns, quarantines, travel restrictions, suspension of business activities and school closures. Due to difficulties resulting from
the COVID-19 outbreak, including, but not limited to, the temporary closure of the Company&#x2019;s factory and operations beginning in
early February until to March 2, 2020, limited support from the Company&#x2019;s employees, delayed access to raw material supplies and
inability to deliver products to customers on a timely basis, the Company&#x2019;s business was negatively impacted and generated lower
revenue and net income during the period from February to March 2020. Although the Company resumed its operations on March 2, 2020 and
the COVID-19 impact on the Company&#x2019;s operating results and financial performance for fiscal year 2020 and 2021 seems to be temporary,
a resurgence could negatively affect the execution of customer contracts, the collection of customer payments, or disrupt the Company&#x2019;s
supply chain, and the continued uncertainties associated with COVID 19 may negatively impact the Company&#x2019;s revenue and cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of
its bank accounts in the PRC. Cash balances in bank accounts in PRC are not insured by the Federal Deposit Insurance Corporation or other
programs.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Accounts
receivable, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are presented net of allowance for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts
based on individual account analysis and historical collection trend. The Company establishes a provision for doubtful receivables when
there is objective evidence that the Company may not be able to collect amounts due. The allowance is based on management&#x2019;s best
estimate of specific losses on individual exposures, as well as a provision on historical trends of collections. Actual amounts received
may differ from management&#x2019;s estimate of credit worthiness and the economic environment. Delinquent account balances are written-off
against the allowance for doubtful accounts after management has determined that the collection is not probable. Allowance for uncollectable
balances amounted to $446,527 and $639,991 as of September 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inventories,
net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and
related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision
for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less
any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments,
and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable
value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future
product sales. The Company recorded inventory reserve of $116,453 and $110,585 as of September 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"&gt;&lt;b&gt;&lt;i&gt;Advances
to suppliers, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advances
to suppliers represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices for raw materials. These
advances are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time
to make cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company
when the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific
allowances when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September
30, 2021 and 2020, no allowance for doubtful accounts was deemed necessary as the Company believes that all advances to suppliers fully
realizable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Deferred&#160;initial
public&#160;offering (&#x201c;IPO&#x201d;) costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the requirement of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014;
&#x201c;Expenses of Offering&#x201d;. Deferred offering costs consist of underwriting, legal, accounting and other expenses incurred through
the balance sheet date that are directly related to the intended IPO. Deferred offering costs will be charged to shareholders&#x2019;
equity upon the completion of the IPO. Should the IPO prove to be unsuccessful, these deferred costs, as well as additional expenses
to be incurred, will be charged to operations. The balance of deferred initial public offering costs amounted to &lt;span style="-sec-ix-hidden: hidden-fact-71"&gt;Nil&lt;/span&gt; and $443,709 as
of September 30, 2021 and 2020, respectively. Payment for deferred IPO offering costs amounted to $2,792,543, $441,064 and &lt;span style="-sec-ix-hidden: hidden-fact-72"&gt;Nil&lt;/span&gt; for the
years ended September 30, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Short-term&#160;investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s short-term&#160;investments
consist of wealth management financial products purchased from financial institution, which can be redeemed anytime. The financial institution
invests the Company&#x2019;s fund in certain financial instruments including money market funds and bonds to generate investment income.
The short-term investments are deemed to be trading securities and are measured subsequently at fair value in the statement of financial
position. Unrealized holding gains and losses for investment is included in the consolidated statements of operations and comprehensive
income (loss) over the investment period (see Note&#160;7).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
value of financial instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#x2009;&#x2014;&#x2009;inputs
    to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#x2009;&#x2014;&#x2009;inputs
    to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for
    identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived
    from or corroborated by observable market data. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#x2009;&#x2014;&#x2009;inputs
    to the valuation methodology are unobservable. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unless
otherwise disclosed, the fair value of the Company&#x2019;s financial instruments, including cash, accounts receivable, inventories, short-term
investments, advance to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses
and other current liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities
as of September 30, 2021 and 2020 based upon the short-term nature of the assets and liabilities. The Company&#x2019;s investment in equity
securities is accounted for using the measurement alternative in accordance with ASC 321, which also approximate its recorded value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;
&lt;/i&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Property,
plant and equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and
equipment is provided using the straight-line method over their expected useful lives, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    life &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Buildings &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery and equipment
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&#x2013;10 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Automobiles &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#x2013;5 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office and electric equipment
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#x2013;5 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expenditures
for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures
for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated
depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated
statements of income and other comprehensive income in other income or expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
reviews the carrying value of property, plant, and equipment for impairment whenever events and circumstances indicate that the carrying
value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition.
In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an
amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment
include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand,
competition and other economic factors. Based on this assessment, no impairment expenses for property, plant, and equipment were recorded
in operating expenses for the years ended September 30, 2021, 2020 and 2019, respectively.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist primarily of land use rights and software. Under the PRC law, all land in the PRC is owned by the government and cannot
be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for specified periods
of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using the straight-line method
with the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    life &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Land use rights
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
reviews the carrying value of land use rights for impairment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where
undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which
the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current
operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors. Based on this assessment, no impairment of land use rights was deemed necessary for the years ended September
30, 2021, 2020 and 2019, respectively.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Construction-in-Progress
(&#x201c;CIP&#x201d;)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Construction-in-progress
represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct
costs attributable to the construction. Construction-in-progress is not depreciated. Upon completion and ready for intended use, construction-in-progress
is reclassified to the appropriate category within property, plant and equipment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Impairment
of long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Long-lived assets with finite lives, primarily
property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash flows from the use of the asset and its
eventual disposition below are the asset&#x2019;s carrying value, then the asset is deemed to be impaired and written down to its fair
value. There were no impairments of these assets as of September 30, 2021 and 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Investments
in Equity Securities &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for its equity investments
in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 321 &#x201c;Investments&#x2014;Equity Securities&#x201d; (&#x201c;ASC
321&#x201d;). In accordance with ASC 321, equity investment which the Company has no significant influence (generally less than a 20% ownership
interest) with readily determinable fair values are accounted for at fair value based on quoted market prices with the changes in fair
value recognized as unrealized gains or losses in earnings. Equity investments without readily determinable fair values are accounted
for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured
at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical
or a similar investment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;
&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
March 2009 to September 2017, the Company invested approximately $0.7 million (RMB 5 million) in Jiangxi Jian Rural Commercial Bank (&#x201c;JX
RCB Bank&#x201d;) in exchange for 5% ownership interest in the bank. The purpose of entering into these equity investment agreements with
JX RCB Bank was to earn investment income as the bank continues to grow. The Company determined that this investment in equity securities
does not have a readily determinable fair value and, accordingly, elected the measurement alternative noted above.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company initially recorded the investments at historical cost and subsequently records any dividends received from the net accumulated
earnings of the investee as income. As of September 30, 2021 and 2020, this investment amounted to $744,924 (RMB 5 million) and $735,000
(RMB 5 million), respectively, and was reported as long-term investment in equity investee on the consolidated balance sheets. Investment
income amounted to $30,827, $21,820 and $26,741 for the years ended September 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
investments in equity securities are evaluated for impairment when facts or circumstances indicate that the fair value of the investment
is less than its carrying value. An impairment is recognized when a decline in fair value is determined to be other-than-temporary. The
Company reviews several factors to determine whether a loss is other-than-temporary. These factors include, but are not limited to, the:
(i) nature of the investment; (ii) cause and duration of the impairment; (iii) extent to which fair value is less than cost; (iv) financial
condition and near term prospects of the investments; and (v) ability to hold the investment for a period of time sufficient to allow
for any anticipated recovery in fair value. There was no impairment for the Company&#x2019;s investments in equity securities as of September
30, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue
recognition&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
determine revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s)
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will &lt;i&gt;not&lt;/i&gt; occur, (iv) allocate the transaction
price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance
obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its TCMD and third-party
products on a gross basis as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in
establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods, which the Company has control
of the goods and has the ability to direct the use of goods to obtain substantially all the benefits. All of the Company&#x2019;s contracts
have one single performance obligation as the promise is to transfer the individual goods to customers, and there is no separately identifiable
other promise in the contracts. The Company&#x2019;s revenue streams are recognized at a point in time when title and risk of loss passes
and the customer accepts the goods, which generally occurs at delivery. The Company&#x2019;s products are sold with no right of return
and the Company does not provide other credits or sales incentive to customers. Revenue is reported net of all value added taxes (&#x201c;VAT&#x201d;).&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Contract
Assets and Liabilities &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payment
terms are established on the Company&#x2019;s pre-established credit requirements based upon an evaluation of customers&#x2019; credit
quality. Contract assets are recognized for in related accounts receivable. Contract liabilities are recognized for contracts where payment
has been received in advance of delivery. The contract liability balance can vary significantly depending on the timing when an order
is placed and when shipment or delivery occurs. As of September 30, 2021 and 2020, the Company did not have contract assets and contract
liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Disaggregation
of Revenues&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing
and uncertainty of the revenue and cash flows are affected by economic factors. The Company&#x2019;s disaggregation of revenues for the
years ended September 30, 2021, 2020 and 2019 are disclosed in Note 17 of this consolidation financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;&lt;i&gt;Cost of revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Cost of revenue consists primarily of the costs of raw materials, freight
charges, direct labor, depreciation of plants and machinery, warehousing and overhead associated with the manufacturing process.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research
and development expenses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expenses all internal research and development costs as incurred, which primarily comprise employee costs, internal and external
costs related to execution of studies, including manufacturing costs, facility costs of the research center, and amortization and depreciation
to intangible assets and property, plant and equipment used in the research and development activities. For the years ended September
30, 2021, 2020 and 2019, total research and development expense were approximately $5,465,662, $583,125 and $618,437, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Shipping and handling costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Shipping and handling costs are expensed as incurred. Inbound shipping
and handling cost associated with bringing the purchased raw materials and third-party products from suppliers to the Company&#x2019;s
warehouse are included in cost of revenue. Outbound shipping and handling costs associated with shipping and delivery the products to
customers are included in selling expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Advertising
expense&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advertising expenses primarily relate to promotion of the Company&#x2019;s
brand name and products through outdoor billboards, social media such as Weibo and WeChat and TV advertisement. Advertising costs is expensed
as incurred or deferred and then expensed the first time the advertising takes place. Advertising expenses are included in selling expenses
in the consolidated statements of income and comprehensive income. Advertising expenses amounted to $1,316,654, $343,962 and $367,513
for the years ended September 30, 2021, 2020 and 2019, respectively.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the management approach in determining
reportable operating segments. The management approach considers the internal reporting used by the Company&#x2019;s chief operating decision
maker for making operating decisions about the allocation of resources of the segment and the assessment of its performance in determining
the Company&#x2019;s reportable operating segments. Management has determined that the Company has one operating segment (See Note 17).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Income
taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized
when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial
statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary,
to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;
&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
uncertain tax position is recognized only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained in a tax
examination. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination.
For tax positions not meeting the &#x201c;more likely than not&#x201d; test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest
relating to income taxes have been incurred during the years ended September 30, 2021, 2020 and 2019. The Company does not believe there
was any uncertain tax provision at September 30, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operating subsidiary in China is subject to the income tax laws of the PRC. No significant income was generated outside
the PRC for the fiscal years ended September 30, 2021, 2020 and 2019. As of September 30, 2021, all of the Company&#x2019;s tax returns
of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Value
added tax (&#x201c;VAT&#x201d;)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.1pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales
revenue represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to 17% (starting
from May 1, 2018, VAT rate was lowered to 16%, and starting from April 1, 2019, VAT rate was further lowered to 13%), depending on the
type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of
producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the accompanying consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Earnings
per Share&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes earnings per share (&#x201c;EPS&#x201d;) in accordance with ASC 260, &#x201c;Earnings per Share&#x201d; (&#x201c;ASC 260&#x201d;).
ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided
by the weighted average common shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential
common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented,
or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or
decrease loss per share) are excluded from the calculation of diluted EPS. For the years ended September 30, 2021, 2020 and 2019, there
were no dilutive shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Foreign
currency translation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The functional currency for Universe INC is the
U.S Dollar (&#x201c;US$&#x201d;). Universe HK uses Hong Kong dollar as its functional currency. However, Universe INC and Universe HK currently
only serve as the holding companies and did not have active operation as of the date of this annual report. The Company operates only
in the PRC, the Company&#x2019;s functional currency is the Chinese Yuan (&#x201c;RMB&#x201d;). The Company&#x2019;s consolidated financial
statements have been translated into the reporting currency U.S. Dollars (&#x201c;US$&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical
rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation
adjustments are reported under other comprehensive income (loss). Gains and losses resulting from the translations of foreign currency
transactions and balances are reflected in the results of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;
&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions.
No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table outlines the currency exchange rates that were used in creating the consolidated financial statements in this report:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30, 2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%; text-align: left"&gt;Year-end spot rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 6.4580&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 6.8033&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1= RMB 7.1378&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 6.5095&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 7.0077&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 6.8729&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Comprehensive
income &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
income consists of two components, net income and other comprehensive income (loss). The foreign currency translation gain or loss resulting
from translation of the financial statements expressed in RMB to US$ is reported in other comprehensive income (loss) in the consolidated
statements of income and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Statement
of Cash Flows&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 230, &#x201c;Statement of Cash Flows&#x201d;, cash flows from the Company&#x2019;s operations are formulated based upon
the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily
agree with changes in the corresponding balances on the balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employee
Defined Contribution Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which
pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to
eligible full-time employees. The relevant labor regulations require the Company&#x2019;s subsidiaries in the PRC to pay the local labor
and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government.
The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying
statements of income and comprehensive income amounted to $617,145, $347,312 and $274,091 for the years ended September 30, 2021, 2020
and 2019, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;
&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recent&#160;Adopted
Accounting Pronouncements&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2018, the FASB Accounting Standards Board issued ASU No. 2018-13, &#x201c;Fair Value Measurement (Topic 820): Disclosure Framework
Changes to the Disclosure Requirements for Fair Value Measurement&#x201d; (&#x201c;ASU 2018-13&#x201d;). ASU 2018-13 modifies the disclosure
requirements on fair value measurements. ASU 2018-13 is effective for all entities for fiscal years and interim periods within those
fiscal years beginning after December 15, 2019, with early adoption permitted for any removed or modified disclosures. The removed and
modified disclosures were adopted on a retrospective basis and the new disclosures were adopted on a prospective basis. The adoption
of this guidance had no material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recent
Accounting Pronouncements&#160;not yet adopted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In February&#160;2016, the FASB issued Accounting
Standards Update (ASU) No.&#160;2016-02,&#160;Leases (Topic 842), which requires lessees to recognize a right-of-use asset and lease liability
on the balance sheet for all leases, including operating leases, with a term in excess of 12 months. The guidance also expands the quantitative
and qualitative disclosure requirements. The new guidance requires the lessee to record operating leases on the balance sheet with a right-of-use
asset and corresponding liability for future payment obligations. In July&#160;2018, FASB issued ASU 2018-11 Leases (Topic 842) &#x2013;
Targeted Improvements&#160;that reduces costs and eases implementation of the leases standard for financial statement preparers. The ASU
simplifies transition requirements and, for lessors, provides a practical expedient for the separation of non-lease components from lease
components. ASU 2016-02 was further amended in November&#160;2019 by ASU 2019-10 and in June&#160;2020 by ASU 2020-05, which deferred
the effective date of new lease standard. As a result, ASC 842, Leases, is effective for public companies for annual reporting periods
and interim periods within those years beginning after December&#160;15, 2018. For all other entities, the guidance is effective for fiscal
years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022. As an emerging
growth company, the Company elects to apply for the new and revised accounting standards at the effective date for a private company and
to adopt this guidance effective October 1, 2021. The Company is currently evaluating the impact of adopting this standard on its consolidated
financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160; &#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June&#160;2016, the FASB issued Accounting
Standards Update (&#x201c;ASU&#x201d;) 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all
expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable
and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost. ASU 2016-13 was subsequently amended by Accounting Standards Update 2018-19,&#160;Codification Improvements
to Topic 326, Financial Instruments &#x2014; Credit&#160;Losses, Accounting Standards Update 2019-04&#160;Codification Improvements to
Topic 326, Financial Instruments &#x2014; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, and
Accounting Standards Update 2019-05,&#160;Targeted Transition Relief.&#160;In November&#160;2019, the FASB issued ASU 2019-10, which extends
the effective date for adoption of ASU 2016-13. In November&#160;2019, the FASB issued ASU 2019-11 to clarify its new credit impairment
guidance in ASU 326. Accordingly, for public entities that are not smaller reporting entities, ASU 2016-13 and its amendments is effective
for fiscal years, and interim periods within&#160;those fiscal years, beginning after December&#160;15, 2019. For all other entities,
this guidance and its amendments will be effective for fiscal years beginning after December&#160;15, 2022, including interim periods
within those fiscal years. As an emerging growth company, the Company plans to adopt this guidance effective October 1, 2023. The Company
is currently evaluating the impact of its pending adoption of ASU 2016-13 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2019, the FASB issued ASU No. 2019-12,
Income Taxes (Topic 740)&#x2014;Simplifying the Accounting for Income Taxes. ASU 2019-12 is intended to simplify accounting for income
taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application.
ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years, which is fiscal
2021 for us, with early adoption permitted. The Company does not expect adoption of the new guidance to have a significant impact on our
financial statements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In February 2020, the FASB issued ASU 2020-02,
&#x201c;Financial Instruments &#x2013; Credit Losses (Topic 326) and Leases (topic 842) Amendments to SEC Paragraphs Pursuant to SEC Staff
Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (topic
842)&#x201d;. This ASU provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses.
This ASU is effective for interim and annual periods beginning after December 15, 2019, and early adoption is permitted. The Company is
evaluating the impact of this guidance on its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Basis
of consolidation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements include the financial statements of Universe INC, Universe HK, Universe Technology, Jiangxi
Universe, Universe Trade and Universe Hanhe. All inter-company balances and transactions are eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Uses
of estimates&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America
(&#x201c;US GAAP&#x201d;), management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the reporting period. These estimates are based on information as of the date of the consolidated financial statements. Significant estimates
required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, the realizability
of advance to suppliers, inventory valuations, useful lives of property, plant and equipment, intangible assets, the recoverability of
long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual
results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Risks
and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
main operation of the Company is located in the PRC. Accordingly, the Company&#x2019;s business, financial condition, and results of operations
may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The
Company&#x2019;s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although
the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations
including its organization and structure disclosed in Note 1, this may not be indicative of future results.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized by
rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face competition
with respect to our current and future pharmaceutical product candidates from major pharmaceutical companies in China.&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters,
extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company&#x2019;s
operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;
&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operations may be further affected by the ongoing outbreak of COVID-19 which in March 2020, had been declared as a pandemic
by the World Health Organization.&#160;To reduce the spread of the COVID-19, the Chinese government has employed measures including city
lockdowns, quarantines, travel restrictions, suspension of business activities and school closures. Due to difficulties resulting from
the COVID-19 outbreak, including, but not limited to, the temporary closure of the Company&#x2019;s factory and operations beginning in
early February until to March 2, 2020, limited support from the Company&#x2019;s employees, delayed access to raw material supplies and
inability to deliver products to customers on a timely basis, the Company&#x2019;s business was negatively impacted and generated lower
revenue and net income during the period from February to March 2020. Although the Company resumed its operations on March 2, 2020 and
the COVID-19 impact on the Company&#x2019;s operating results and financial performance for fiscal year 2020 and 2021 seems to be temporary,
a resurgence could negatively affect the execution of customer contracts, the collection of customer payments, or disrupt the Company&#x2019;s
supply chain, and the continued uncertainties associated with COVID 19 may negatively impact the Company&#x2019;s revenue and cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of
its bank accounts in the PRC. Cash balances in bank accounts in PRC are not insured by the Federal Deposit Insurance Corporation or other
programs.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Accounts
receivable, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
receivable are presented net of allowance for doubtful accounts. The Company determines the adequacy of reserves for doubtful accounts
based on individual account analysis and historical collection trend. The Company establishes a provision for doubtful receivables when
there is objective evidence that the Company may not be able to collect amounts due. The allowance is based on management&#x2019;s best
estimate of specific losses on individual exposures, as well as a provision on historical trends of collections. Actual amounts received
may differ from management&#x2019;s estimate of credit worthiness and the economic environment. Delinquent account balances are written-off
against the allowance for doubtful accounts after management has determined that the collection is not probable. Allowance for uncollectable
balances amounted to $446,527 and $639,991 as of September 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <upc:AllowanceForUncollectableBalancesAmount contextRef="c0" decimals="0" unitRef="usd">446527</upc:AllowanceForUncollectableBalancesAmount>
    <upc:AllowanceForUncollectableBalancesAmount contextRef="c4" decimals="0" unitRef="usd">639991</upc:AllowanceForUncollectableBalancesAmount>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inventories,
net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor and
related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision
for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course of business less
any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable value adjustments,
and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable
value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected future
product sales. The Company recorded inventory reserve of $116,453 and $110,585 as of September 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryValuationReserves contextRef="c2" decimals="0" unitRef="usd">116453</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c3" decimals="0" unitRef="usd">110585</us-gaap:InventoryValuationReserves>
    <upc:AdvancesToSuppliersNetPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"&gt;&lt;b&gt;&lt;i&gt;Advances
to suppliers, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advances
to suppliers represent prepayments made to ensure continuous high-quality supplies and favorable purchase prices for raw materials. These
advances are directly related to the purchases of raw materials used to fulfill sales orders. The Company is required from time to time
to make cash advances when placing its purchase orders. These advances are settled upon suppliers delivering raw materials to the Company
when the transfer of ownership occurs. The Company reviews its advances to suppliers on a periodic basis and makes general and specific
allowances when there is doubt as to the ability of a supplier to provide supplies to the Company or refund an advance. As of September
30, 2021 and 2020, no allowance for doubtful accounts was deemed necessary as the Company believes that all advances to suppliers fully
realizable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</upc:AdvancesToSuppliersNetPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Deferred&#160;initial
public&#160;offering (&#x201c;IPO&#x201d;) costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the requirement of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014;
&#x201c;Expenses of Offering&#x201d;. Deferred offering costs consist of underwriting, legal, accounting and other expenses incurred through
the balance sheet date that are directly related to the intended IPO. Deferred offering costs will be charged to shareholders&#x2019;
equity upon the completion of the IPO. Should the IPO prove to be unsuccessful, these deferred costs, as well as additional expenses
to be incurred, will be charged to operations. The balance of deferred initial public offering costs amounted to &lt;span style="-sec-ix-hidden: hidden-fact-71"&gt;Nil&lt;/span&gt; and $443,709 as
of September 30, 2021 and 2020, respectively. Payment for deferred IPO offering costs amounted to $2,792,543, $441,064 and &lt;span style="-sec-ix-hidden: hidden-fact-72"&gt;Nil&lt;/span&gt; for the
years ended September 30, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <upc:DeferredInitialPublicOfferingCosts contextRef="c4" decimals="0" unitRef="usd">443709</upc:DeferredInitialPublicOfferingCosts>
    <us-gaap:DeferredOfferingCosts contextRef="c62" decimals="0" unitRef="usd">2792543</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts contextRef="c3" decimals="0" unitRef="usd">441064</us-gaap:DeferredOfferingCosts>
    <upc:HeldToMaturityInvestmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Short-term&#160;investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s short-term&#160;investments
consist of wealth management financial products purchased from financial institution, which can be redeemed anytime. The financial institution
invests the Company&#x2019;s fund in certain financial instruments including money market funds and bonds to generate investment income.
The short-term investments are deemed to be trading securities and are measured subsequently at fair value in the statement of financial
position. Unrealized holding gains and losses for investment is included in the consolidated statements of operations and comprehensive
income (loss) over the investment period (see Note&#160;7).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</upc:HeldToMaturityInvestmentPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
value of financial instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The
hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of
inputs used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1&#x2009;&#x2014;&#x2009;inputs
    to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2&#x2009;&#x2014;&#x2009;inputs
    to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for
    identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived
    from or corroborated by observable market data. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3&#x2009;&#x2014;&#x2009;inputs
    to the valuation methodology are unobservable. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unless
otherwise disclosed, the fair value of the Company&#x2019;s financial instruments, including cash, accounts receivable, inventories, short-term
investments, advance to suppliers, prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses
and other current liabilities, taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities
as of September 30, 2021 and 2020 based upon the short-term nature of the assets and liabilities. The Company&#x2019;s investment in equity
securities is accounted for using the measurement alternative in accordance with ASC 321, which also approximate its recorded value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;
&lt;/i&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Property,
plant and equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property,
plant and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and
equipment is provided using the straight-line method over their expected useful lives, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    life &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Buildings &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery and equipment
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&#x2013;10 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Automobiles &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#x2013;5 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office and electric equipment
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#x2013;5 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expenditures
for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures
for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated
depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the consolidated
statements of income and other comprehensive income in other income or expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
reviews the carrying value of property, plant, and equipment for impairment whenever events and circumstances indicate that the carrying
value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition.
In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an
amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment
include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand,
competition and other economic factors. Based on this assessment, no impairment expenses for property, plant, and equipment were recorded
in operating expenses for the years ended September 30, 2021, 2020 and 2019, respectively.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist primarily of land use rights and software. Under the PRC law, all land in the PRC is owned by the government and cannot
be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for specified periods
of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using the straight-line method
with the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    life &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Land use rights
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;The Company
reviews the carrying value of land use rights for impairment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where
undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which
the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current
operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    life &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Buildings &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery and equipment
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&#x2013;10 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Automobiles &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#x2013;5 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office and electric equipment
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&#x2013;5 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c67">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c68">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c69">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c70">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c71">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c72">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c73">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist primarily of land use rights and software. Under the PRC law, all land in the PRC is owned by the government and cannot
be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for specified periods
of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using the straight-line method
with the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    life &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Land use rights
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
reviews the carrying value of land use rights for impairment whenever events and circumstances indicate that the carrying value of an
asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where
undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which
the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current
operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition
and other economic factors. Based on this assessment, no impairment of land use rights was deemed necessary for the years ended September
30, 2021, 2020 and 2019, respectively.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Useful
    life &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 89%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Land use rights
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 years &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c74">P50Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c75">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ConstructionContractorsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Construction-in-Progress
(&#x201c;CIP&#x201d;)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Construction-in-progress
represents property and buildings under construction and consists of construction expenditures, equipment procurement, and other direct
costs attributable to the construction. Construction-in-progress is not depreciated. Upon completion and ready for intended use, construction-in-progress
is reclassified to the appropriate category within property, plant and equipment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConstructionContractorsPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Impairment
of long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Long-lived assets with finite lives, primarily
property, plant and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. If the estimated undiscounted cash flows from the use of the asset and its
eventual disposition below are the asset&#x2019;s carrying value, then the asset is deemed to be impaired and written down to its fair
value. There were no impairments of these assets as of September 30, 2021 and 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Investments
in Equity Securities &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for its equity investments
in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 321 &#x201c;Investments&#x2014;Equity Securities&#x201d; (&#x201c;ASC
321&#x201d;). In accordance with ASC 321, equity investment which the Company has no significant influence (generally less than a 20% ownership
interest) with readily determinable fair values are accounted for at fair value based on quoted market prices with the changes in fair
value recognized as unrealized gains or losses in earnings. Equity investments without readily determinable fair values are accounted
for either at fair value or using the measurement alternative. Under the measurement alternative, the equity investments are measured
at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical
or a similar investment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;
&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
March 2009 to September 2017, the Company invested approximately $0.7 million (RMB 5 million) in Jiangxi Jian Rural Commercial Bank (&#x201c;JX
RCB Bank&#x201d;) in exchange for 5% ownership interest in the bank. The purpose of entering into these equity investment agreements with
JX RCB Bank was to earn investment income as the bank continues to grow. The Company determined that this investment in equity securities
does not have a readily determinable fair value and, accordingly, elected the measurement alternative noted above.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company initially recorded the investments at historical cost and subsequently records any dividends received from the net accumulated
earnings of the investee as income. As of September 30, 2021 and 2020, this investment amounted to $744,924 (RMB 5 million) and $735,000
(RMB 5 million), respectively, and was reported as long-term investment in equity investee on the consolidated balance sheets. Investment
income amounted to $30,827, $21,820 and $26,741 for the years ended September 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
investments in equity securities are evaluated for impairment when facts or circumstances indicate that the fair value of the investment
is less than its carrying value. An impairment is recognized when a decline in fair value is determined to be other-than-temporary. The
Company reviews several factors to determine whether a loss is other-than-temporary. These factors include, but are not limited to, the:
(i) nature of the investment; (ii) cause and duration of the impairment; (iii) extent to which fair value is less than cost; (iv) financial
condition and near term prospects of the investments; and (v) ability to hold the investment for a period of time sufficient to allow
for any anticipated recovery in fair value. There was no impairment for the Company&#x2019;s investments in equity securities as of September
30, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c2" decimals="2" unitRef="pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c63" decimals="-5" unitRef="usd">700000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c63" decimals="-6" unitRef="cny">5000000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c64" decimals="2" unitRef="pure">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c0" decimals="0" unitRef="usd">744924</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c0" decimals="-6" unitRef="cny">5000000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c4" decimals="0" unitRef="usd">735000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c4" decimals="-6" unitRef="cny">5000000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:NetInvestmentIncome contextRef="c0" decimals="0" unitRef="usd">30827</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c4" decimals="0" unitRef="usd">21820</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome contextRef="c5" decimals="0" unitRef="usd">26741</us-gaap:NetInvestmentIncome>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Revenue
recognition&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
determine revenue recognition for contracts with customers, the Company performs the following five steps : (i) identify the contract(s)
with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable
consideration to the extent that it is probable that a significant future reversal will &lt;i&gt;not&lt;/i&gt; occur, (iv) allocate the transaction
price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance
obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue when it transfers its goods and services to customers in an amount that reflects the consideration to which
the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its TCMD and third-party
products on a gross basis as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in
establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods, which the Company has control
of the goods and has the ability to direct the use of goods to obtain substantially all the benefits. All of the Company&#x2019;s contracts
have one single performance obligation as the promise is to transfer the individual goods to customers, and there is no separately identifiable
other promise in the contracts. The Company&#x2019;s revenue streams are recognized at a point in time when title and risk of loss passes
and the customer accepts the goods, which generally occurs at delivery. The Company&#x2019;s products are sold with no right of return
and the Company does not provide other credits or sales incentive to customers. Revenue is reported net of all value added taxes (&#x201c;VAT&#x201d;).&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <upc:ContractAssetsAndLiabilitiesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Contract
Assets and Liabilities &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payment
terms are established on the Company&#x2019;s pre-established credit requirements based upon an evaluation of customers&#x2019; credit
quality. Contract assets are recognized for in related accounts receivable. Contract liabilities are recognized for contracts where payment
has been received in advance of delivery. The contract liability balance can vary significantly depending on the timing when an order
is placed and when shipment or delivery occurs. As of September 30, 2021 and 2020, the Company did not have contract assets and contract
liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</upc:ContractAssetsAndLiabilitiesPolicyTextBlock>
    <upc:DisaggregationOfRevenuesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Disaggregation
of Revenues&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount, timing
and uncertainty of the revenue and cash flows are affected by economic factors. The Company&#x2019;s disaggregation of revenues for the
years ended September 30, 2021, 2020 and 2019 are disclosed in Note 17 of this consolidation financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;</upc:DisaggregationOfRevenuesPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;&lt;i&gt;Cost of revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Cost of revenue consists primarily of the costs of raw materials, freight
charges, direct labor, depreciation of plants and machinery, warehousing and overhead associated with the manufacturing process.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research
and development expenses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expenses all internal research and development costs as incurred, which primarily comprise employee costs, internal and external
costs related to execution of studies, including manufacturing costs, facility costs of the research center, and amortization and depreciation
to intangible assets and property, plant and equipment used in the research and development activities. For the years ended September
30, 2021, 2020 and 2019, total research and development expense were approximately $5,465,662, $583,125 and $618,437, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">5465662</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" unitRef="usd">583125</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" unitRef="usd">618437</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Shipping and handling costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Shipping and handling costs are expensed as incurred. Inbound shipping
and handling cost associated with bringing the purchased raw materials and third-party products from suppliers to the Company&#x2019;s
warehouse are included in cost of revenue. Outbound shipping and handling costs associated with shipping and delivery the products to
customers are included in selling expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Advertising
expense&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advertising expenses primarily relate to promotion of the Company&#x2019;s
brand name and products through outdoor billboards, social media such as Weibo and WeChat and TV advertisement. Advertising costs is expensed
as incurred or deferred and then expensed the first time the advertising takes place. Advertising expenses are included in selling expenses
in the consolidated statements of income and comprehensive income. Advertising expenses amounted to $1,316,654, $343,962 and $367,513
for the years ended September 30, 2021, 2020 and 2019, respectively.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c0" decimals="0" unitRef="usd">1316654</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c4" decimals="0" unitRef="usd">343962</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c5" decimals="0" unitRef="usd">367513</us-gaap:AdvertisingExpense>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the management approach in determining
reportable operating segments. The management approach considers the internal reporting used by the Company&#x2019;s chief operating decision
maker for making operating decisions about the allocation of resources of the segment and the assessment of its performance in determining
the Company&#x2019;s reportable operating segments. Management has determined that the Company has one operating segment (See Note 17).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Income
taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized
when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial
statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary,
to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;
&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
uncertain tax position is recognized only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained in a tax
examination. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination.
For tax positions not meeting the &#x201c;more likely than not&#x201d; test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest
relating to income taxes have been incurred during the years ended September 30, 2021, 2020 and 2019. The Company does not believe there
was any uncertain tax provision at September 30, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operating subsidiary in China is subject to the income tax laws of the PRC. No significant income was generated outside
the PRC for the fiscal years ended September 30, 2021, 2020 and 2019. As of September 30, 2021, all of the Company&#x2019;s tax returns
of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <upc:ValueAddedTaxPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Value
added tax (&#x201c;VAT&#x201d;)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.1pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales
revenue represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to 17% (starting
from May 1, 2018, VAT rate was lowered to 16%, and starting from April 1, 2019, VAT rate was further lowered to 13%), depending on the
type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of
producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the accompanying consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</upc:ValueAddedTaxPolicyTextBlock>
    <upc:PercentageOfVatRate contextRef="c0" decimals="2" unitRef="pure">0.17</upc:PercentageOfVatRate>
    <upc:PercentageOfVatRate contextRef="c65" decimals="2" unitRef="pure">0.16</upc:PercentageOfVatRate>
    <upc:PercentageOfVatRate contextRef="c66" decimals="2" unitRef="pure">0.13</upc:PercentageOfVatRate>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Earnings
per Share&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes earnings per share (&#x201c;EPS&#x201d;) in accordance with ASC 260, &#x201c;Earnings per Share&#x201d; (&#x201c;ASC 260&#x201d;).
ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided
by the weighted average common shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential
common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented,
or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or
decrease loss per share) are excluded from the calculation of diluted EPS. For the years ended September 30, 2021, 2020 and 2019, there
were no dilutive shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Foreign
currency translation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The functional currency for Universe INC is the
U.S Dollar (&#x201c;US$&#x201d;). Universe HK uses Hong Kong dollar as its functional currency. However, Universe INC and Universe HK currently
only serve as the holding companies and did not have active operation as of the date of this annual report. The Company operates only
in the PRC, the Company&#x2019;s functional currency is the Chinese Yuan (&#x201c;RMB&#x201d;). The Company&#x2019;s consolidated financial
statements have been translated into the reporting currency U.S. Dollars (&#x201c;US$&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical
rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation
adjustments are reported under other comprehensive income (loss). Gains and losses resulting from the translations of foreign currency
transactions and balances are reflected in the results of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;
&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions.
No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table outlines the currency exchange rates that were used in creating the consolidated financial statements in this report:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30, 2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%; text-align: left"&gt;Year-end spot rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 6.4580&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 6.8033&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1= RMB 7.1378&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 6.5095&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 7.0077&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 6.8729&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30, 2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September
                                            30, 2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%; text-align: left"&gt;Year-end spot rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 6.4580&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 6.8033&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1= RMB 7.1378&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 6.5095&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 7.0077&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;US$1=RMB 6.8729&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock>
    <upc:DescriptionOfYearEndSpotRate contextRef="c0">US$1=RMB 6.4580</upc:DescriptionOfYearEndSpotRate>
    <upc:DescriptionOfYearEndSpotRate contextRef="c4">US$1=RMB 6.8033</upc:DescriptionOfYearEndSpotRate>
    <upc:DescriptionOfYearEndSpotRate contextRef="c5">US$1= RMB 7.1378</upc:DescriptionOfYearEndSpotRate>
    <upc:DescriptionOfAverageRate contextRef="c0">US$1=RMB 6.5095</upc:DescriptionOfAverageRate>
    <upc:DescriptionOfAverageRate contextRef="c4">US$1=RMB 7.0077</upc:DescriptionOfAverageRate>
    <upc:DescriptionOfAverageRate contextRef="c5">US$1=RMB 6.8729</upc:DescriptionOfAverageRate>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Comprehensive
income &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
income consists of two components, net income and other comprehensive income (loss). The foreign currency translation gain or loss resulting
from translation of the financial statements expressed in RMB to US$ is reported in other comprehensive income (loss) in the consolidated
statements of income and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <upc:StatementOfCashFlowsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Statement
of Cash Flows&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 230, &#x201c;Statement of Cash Flows&#x201d;, cash flows from the Company&#x2019;s operations are formulated based upon
the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily
agree with changes in the corresponding balances on the balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</upc:StatementOfCashFlowsPolicyTextBlock>
    <upc:EmployeeDefinedContributionPlanPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employee
Defined Contribution Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s subsidiaries in the PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which
pension, work-related injury benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to
eligible full-time employees. The relevant labor regulations require the Company&#x2019;s subsidiaries in the PRC to pay the local labor
and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government.
The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying
statements of income and comprehensive income amounted to $617,145, $347,312 and $274,091 for the years ended September 30, 2021, 2020
and 2019, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;
&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</upc:EmployeeDefinedContributionPlanPolicyTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c0" decimals="0" unitRef="usd">617145</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c4" decimals="0" unitRef="usd">347312</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c5" decimals="0" unitRef="usd">274091</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recent&#160;Adopted
Accounting Pronouncements&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2018, the FASB Accounting Standards Board issued ASU No. 2018-13, &#x201c;Fair Value Measurement (Topic 820): Disclosure Framework
Changes to the Disclosure Requirements for Fair Value Measurement&#x201d; (&#x201c;ASU 2018-13&#x201d;). ASU 2018-13 modifies the disclosure
requirements on fair value measurements. ASU 2018-13 is effective for all entities for fiscal years and interim periods within those
fiscal years beginning after December 15, 2019, with early adoption permitted for any removed or modified disclosures. The removed and
modified disclosures were adopted on a retrospective basis and the new disclosures were adopted on a prospective basis. The adoption
of this guidance had no material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recent
Accounting Pronouncements&#160;not yet adopted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In February&#160;2016, the FASB issued Accounting
Standards Update (ASU) No.&#160;2016-02,&#160;Leases (Topic 842), which requires lessees to recognize a right-of-use asset and lease liability
on the balance sheet for all leases, including operating leases, with a term in excess of 12 months. The guidance also expands the quantitative
and qualitative disclosure requirements. The new guidance requires the lessee to record operating leases on the balance sheet with a right-of-use
asset and corresponding liability for future payment obligations. In July&#160;2018, FASB issued ASU 2018-11 Leases (Topic 842) &#x2013;
Targeted Improvements&#160;that reduces costs and eases implementation of the leases standard for financial statement preparers. The ASU
simplifies transition requirements and, for lessors, provides a practical expedient for the separation of non-lease components from lease
components. ASU 2016-02 was further amended in November&#160;2019 by ASU 2019-10 and in June&#160;2020 by ASU 2020-05, which deferred
the effective date of new lease standard. As a result, ASC 842, Leases, is effective for public companies for annual reporting periods
and interim periods within those years beginning after December&#160;15, 2018. For all other entities, the guidance is effective for fiscal
years beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022. As an emerging
growth company, the Company elects to apply for the new and revised accounting standards at the effective date for a private company and
to adopt this guidance effective October 1, 2021. The Company is currently evaluating the impact of adopting this standard on its consolidated
financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160; &#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June&#160;2016, the FASB issued Accounting
Standards Update (&#x201c;ASU&#x201d;) 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all
expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable
and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost. ASU 2016-13 was subsequently amended by Accounting Standards Update 2018-19,&#160;Codification Improvements
to Topic 326, Financial Instruments &#x2014; Credit&#160;Losses, Accounting Standards Update 2019-04&#160;Codification Improvements to
Topic 326, Financial Instruments &#x2014; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, and
Accounting Standards Update 2019-05,&#160;Targeted Transition Relief.&#160;In November&#160;2019, the FASB issued ASU 2019-10, which extends
the effective date for adoption of ASU 2016-13. In November&#160;2019, the FASB issued ASU 2019-11 to clarify its new credit impairment
guidance in ASU 326. Accordingly, for public entities that are not smaller reporting entities, ASU 2016-13 and its amendments is effective
for fiscal years, and interim periods within&#160;those fiscal years, beginning after December&#160;15, 2019. For all other entities,
this guidance and its amendments will be effective for fiscal years beginning after December&#160;15, 2022, including interim periods
within those fiscal years. As an emerging growth company, the Company plans to adopt this guidance effective October 1, 2023. The Company
is currently evaluating the impact of its pending adoption of ASU 2016-13 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2019, the FASB issued ASU No. 2019-12,
Income Taxes (Topic 740)&#x2014;Simplifying the Accounting for Income Taxes. ASU 2019-12 is intended to simplify accounting for income
taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application.
ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal years, which is fiscal
2021 for us, with early adoption permitted. The Company does not expect adoption of the new guidance to have a significant impact on our
financial statements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In February 2020, the FASB issued ASU 2020-02,
&#x201c;Financial Instruments &#x2013; Credit Losses (Topic 326) and Leases (topic 842) Amendments to SEC Paragraphs Pursuant to SEC Staff
Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (topic
842)&#x201d;. This ASU provides guidance regarding methodologies, documentation, and internal controls related to expected credit losses.
This ASU is effective for interim and annual periods beginning after December 15, 2019, and early adoption is permitted. The Company is
evaluating the impact of this guidance on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 &#x2014; ACCOUNTS RECEIVABLE, NET&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable consists of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,020,269&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,511,769&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(446,527&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(639,991&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,573,742&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,871,778&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s accounts receivable primarily
includes balance due from customers when the Company&#x2019;s pharmaceutical products are sold and delivered to customers. All of the Company&#x2019;s
accounts receivable balance at September 30, 2020 has been collected in fiscal year 2021. As of date of this report, approximately 75.4%,
or $11.7 million, of the Company&#x2019;s net account receivable balance at September 30, 2021 has been subsequently collected and the
remaining balance is expected to be substantially collected before March 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the Company&#x2019;s
accounts receivable and subsequent collection by aging bucket:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Accounts Receivable by aging bucket&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Balance as of &lt;br/&gt; September&#160;30, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Subsequent &lt;br/&gt; collection&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;% of &lt;br/&gt; subsequent &lt;br/&gt; collection&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Less than 3 months&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,587,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,991,589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;From 4 to 6 months&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,922,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,541,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;From 7 to 9 months&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;356,267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;From 10 to 12 months&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,124&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,193&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Over 1 year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;88,162&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;584&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total gross accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,020,269&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,739,179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(446,527&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Accounts Receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,573,742&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,739,179&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;75.4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Allowance for doubtful accounts movement is as
follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;639,991&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;517,754&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93,907&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Bad debt recovery&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(225,660&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,330&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;446,527&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;639,991&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,020,269&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,511,769&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(446,527&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(639,991&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,573,742&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,871,778&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c2" decimals="0" unitRef="usd">16020269</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="c3" decimals="0" unitRef="usd">11511769</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c2" decimals="0" unitRef="usd">446527</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c3" decimals="0" unitRef="usd">639991</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" unitRef="usd">15573742</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" unitRef="usd">10871778</us-gaap:AccountsReceivableNetCurrent>
    <upc:AccountsReceivableDescription contextRef="c0">The Company&#x2019;s accounts receivable primarily
includes balance due from customers when the Company&#x2019;s pharmaceutical products are sold and delivered to customers. All of the Company&#x2019;s
accounts receivable balance at September 30, 2020 has been collected in fiscal year 2021. As of date of this report, approximately 75.4%,
or $11.7 million, of the Company&#x2019;s net account receivable balance at September 30, 2021 has been subsequently collected and the
remaining balance is expected to be substantially collected before March 31, 2022.&#160;</upc:AccountsReceivableDescription>
    <us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Accounts Receivable by aging bucket&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Balance as of &lt;br/&gt; September&#160;30, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Subsequent &lt;br/&gt; collection&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;% of &lt;br/&gt; subsequent &lt;br/&gt; collection&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Less than 3 months&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,587,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,991,589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;From 4 to 6 months&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,922,226&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,541,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;From 7 to 9 months&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;356,267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;From 10 to 12 months&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,124&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,193&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Over 1 year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;88,162&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;584&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total gross accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,020,269&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,739,179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(446,527&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Accounts Receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,573,742&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,739,179&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;75.4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock>
    <upc:AccountsReceivableBeforeGrossValue contextRef="c76" decimals="0" unitRef="usd">11587490</upc:AccountsReceivableBeforeGrossValue>
    <upc:SubsequentCollection contextRef="c76" decimals="0" unitRef="usd">7991589</upc:SubsequentCollection>
    <upc:PercentageOfSubsequentCollection contextRef="c77" decimals="3" unitRef="pure">0.69</upc:PercentageOfSubsequentCollection>
    <upc:AccountsReceivableBeforeGrossValue contextRef="c78" decimals="0" unitRef="usd">3922226</upc:AccountsReceivableBeforeGrossValue>
    <upc:SubsequentCollection contextRef="c78" decimals="0" unitRef="usd">3541960</upc:SubsequentCollection>
    <upc:PercentageOfSubsequentCollection contextRef="c79" decimals="3" unitRef="pure">0.903</upc:PercentageOfSubsequentCollection>
    <upc:AccountsReceivableBeforeGrossValue contextRef="c80" decimals="0" unitRef="usd">356267</upc:AccountsReceivableBeforeGrossValue>
    <upc:SubsequentCollection contextRef="c80" decimals="0" unitRef="usd">199853</upc:SubsequentCollection>
    <upc:PercentageOfSubsequentCollection contextRef="c81" decimals="3" unitRef="pure">0.561</upc:PercentageOfSubsequentCollection>
    <upc:AccountsReceivableBeforeGrossValue contextRef="c82" decimals="0" unitRef="usd">66124</upc:AccountsReceivableBeforeGrossValue>
    <upc:SubsequentCollection contextRef="c82" decimals="0" unitRef="usd">5193</upc:SubsequentCollection>
    <upc:PercentageOfSubsequentCollection contextRef="c83" decimals="3" unitRef="pure">0.079</upc:PercentageOfSubsequentCollection>
    <upc:AccountsReceivableBeforeGrossValue contextRef="c84" decimals="0" unitRef="usd">88162</upc:AccountsReceivableBeforeGrossValue>
    <upc:SubsequentCollection contextRef="c84" decimals="0" unitRef="usd">584</upc:SubsequentCollection>
    <upc:PercentageOfSubsequentCollection contextRef="c85" decimals="3" unitRef="pure">0.007</upc:PercentageOfSubsequentCollection>
    <us-gaap:AccountsReceivableGross contextRef="c2" decimals="0" unitRef="usd">16020269</us-gaap:AccountsReceivableGross>
    <upc:SunsequentCollectionsTotalGrossAccountsReceivable contextRef="c2" decimals="0" unitRef="usd">11739179</upc:SunsequentCollectionsTotalGrossAccountsReceivable>
    <upc:TotalGrossAccountsReceivablePercentage contextRef="c0" decimals="3" unitRef="pure">0.733</upc:TotalGrossAccountsReceivablePercentage>
    <us-gaap:AccountsAndFinancingReceivableAllowanceForCreditLoss contextRef="c2" decimals="0" unitRef="usd">446527</us-gaap:AccountsAndFinancingReceivableAllowanceForCreditLoss>
    <us-gaap:AccountsReceivableNet contextRef="c2" decimals="0" unitRef="usd">15573742</us-gaap:AccountsReceivableNet>
    <upc:SunsequentCollectionAccountsReceivableNet contextRef="c2" decimals="0" unitRef="usd">11739179</upc:SunsequentCollectionAccountsReceivableNet>
    <upc:AccountsReceivableNetPercentage contextRef="c0" decimals="3" unitRef="pure">0.754</upc:AccountsReceivableNetPercentage>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;639,991&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;517,754&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93,907&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Bad debt recovery&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(225,660&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,330&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;446,527&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;639,991&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c3" decimals="0" unitRef="usd">639991</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c22" decimals="0" unitRef="usd">517754</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c4" decimals="0" unitRef="usd">93907</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c0" decimals="0" unitRef="usd">225660</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c0" decimals="0" unitRef="usd">32196</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c4" decimals="0" unitRef="usd">28330</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c2" decimals="0" unitRef="usd">446527</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c3" decimals="0" unitRef="usd">639991</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &#x2014; INVENTORY, NET&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.8pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventory consists of the following:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;607,661&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;553,982&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Finished goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,971,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,462,835&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Inventory valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(116,453&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(110,585&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total inventory, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,462,542&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,906,232&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Impairment
of inventories is recorded in cost of goods sold. For the years ended September 30, 2021, the Company had no provision for impairment
of inventory in regards to slow moving or obsolete items. For the years ended September 30, 2020 and 2019, recovery of previously accrued
inventory allowance amounted to $75,391 and $187,271, respectively. &lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;607,661&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;553,982&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Finished goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,971,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,462,835&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Inventory valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(116,453&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(110,585&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total inventory, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,462,542&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,906,232&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c2" decimals="0" unitRef="usd">607661</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c3" decimals="0" unitRef="usd">553982</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods contextRef="c2" decimals="0" unitRef="usd">1971334</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c3" decimals="0" unitRef="usd">1462835</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryValuationReserves contextRef="c2" decimals="0" unitRef="usd">116453</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c3" decimals="0" unitRef="usd">110585</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" unitRef="usd">2462542</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" unitRef="usd">1906232</us-gaap:InventoryNet>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c4" decimals="0" unitRef="usd">-75391</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c5" decimals="0" unitRef="usd">-187271</us-gaap:InventoryLIFOReservePeriodCharge>
    <upc:AdvancesToSuppliersTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 &#x2014; ADVANCE TO SUPPLIERS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advances to suppliers  consist of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September&#160;30, &lt;br/&gt;
2020&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Advances to suppliers for inventory raw material purchase&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,738,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Advances to suppliers&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,738,313&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advances to suppliers represent prepayments made
to suppliers to ensure continuous high-quality supplies and favorable purchase prices for raw materials. During 2021, due to supply chain
disruption caused by COVID-19, the market price for raw materials continued to increase. In order to ensure sufficient raw materials for
production and lock the favorite purchase price, the Company made advance payment to suppliers. As of the date of this report, 66.1% of
the September 30, 2021 balance has been realized when the Company received the purchased raw materials and the remaining balance is expected
to be realized by March 2022.&lt;/p&gt;</upc:AdvancesToSuppliersTextBlock>
    <upc:ScheduleOfAdvancesToSuppliersNet contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September&#160;30, &lt;br/&gt;
2020&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Advances to suppliers for inventory raw material purchase&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,738,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Advances to suppliers&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,738,313&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</upc:ScheduleOfAdvancesToSuppliersNet>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="c2" decimals="0" unitRef="usd">2738313</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:PaymentsToSuppliersAndEmployees contextRef="c0" decimals="0" unitRef="usd">2738313</us-gaap:PaymentsToSuppliersAndEmployees>
    <upc:RawMaterialsPurchased contextRef="c0" decimals="3" unitRef="pure">0.661</upc:RawMaterialsPurchased>
    <upc:PrepaymentForAdvertistingTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6 &#x2014; PREPAYMENT FOR ADVERTISTING
&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 6, 2021, the Company entered into an advertising service agreement
with third-party Guangdong Fengyang Legend Consulting Co., Ltd., (&#x201c;Fengyang Legend&#x201d;), pursuant to which, Fengyang Legend will
assist the Company to develop and produce TV advertising film for the Company in order to promote the Company&#x2019;s sales of its major
TCMD product, Bainian Pill and Guben Yanling Pill, coordinate the specific TV Channel to broadcast the advertising film to targeted geographic
market areas. Total contracted advertising service fee is RMB 55 million (approximately $8.5 million) with adverting consulting service
period of one year from October 1, 2021 to September 30, 2022. Based on contract terms, the Company is required to make 30% advance payment
to Fengyang Legend within 7 business days upon signing the service agreement and make additional 58% of the contract price to Fengyang
Legend once the specific TV channel used for broadcast the TV film is determined. As of September 30, 2021, total RMB 48.4 million (approximately
$7.5 million) has been prepaid to Fengyang Legend for TV film production and coordinating the TV channels for broadcasting, and was recorded
as prepayment for advertising services on the balance sheets. Such prepayment has been expensed when the first time the advertising took
place, in October 2021. The remaining RMB 6.6 million (approximately $1 million) represents the monthly advertising fees to be paid in
13 installments when the advertising film is broadcasted through the designated TV channels and will be expensed as occurred.&lt;/p&gt;</upc:PrepaymentForAdvertistingTextBlock>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense contextRef="c86" decimals="-6" unitRef="cny">55000000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense contextRef="c86" decimals="-5" unitRef="usd">8500000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <upc:PercentageOfAdvancePayment contextRef="c87" decimals="2" unitRef="pure">0.30</upc:PercentageOfAdvancePayment>
    <upc:AdditionalContractPricePercentage contextRef="c86" decimals="2" unitRef="pure">0.58</upc:AdditionalContractPricePercentage>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c2" decimals="-5" unitRef="cny">48400000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c2" decimals="-5" unitRef="usd">7500000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c2" decimals="-5" unitRef="cny">6600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c2" decimals="-6" unitRef="usd">1000000</us-gaap:RevenueRemainingPerformanceObligation>
    <upc:HeldToMaturityInvestmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 7 &#x2014;&#160;SHORT-TERM&#160;INVSTMENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s short-term&#160;investments
consist of wealth management financial products purchased from financial institution, which can be redeemed anytime at the Company&#x2019;s
discretion. The financial institution invests the Company&#x2019;s fund in certain financial instruments including money market funds and
bonds to generate investment income. Short-term&#160;investments consisted of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Beginning balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Add: purchase wealth management financial products&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,330,660&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Less: redemption&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,801,927&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Accrued investment income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239,549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(43,078&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Ending balance of short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,725,204&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Investment income generated from such short-term&#160;investments amounted
to $239,549, &lt;span style="-sec-ix-hidden: hidden-fact-88"&gt;Nil&lt;/span&gt; and &lt;span style="-sec-ix-hidden: hidden-fact-89"&gt;Nil&lt;/span&gt; for the&#160;years ended September 30, 2021, 2020 and 2019, respectively.&lt;/p&gt;</upc:HeldToMaturityInvestmentDisclosureTextBlock>
    <us-gaap:HeldToMaturitySecuritiesTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Beginning balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Add: purchase wealth management financial products&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,330,660&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Less: redemption&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,801,927&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Accrued investment income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239,549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(43,078&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Ending balance of short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;13,725,204&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
    <upc:AddPurchaseWealthManagementFinancialProducts contextRef="c0" decimals="0" unitRef="usd">15330660</upc:AddPurchaseWealthManagementFinancialProducts>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c0" decimals="0" unitRef="usd">1801927</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable contextRef="c0" decimals="0" unitRef="usd">239549</us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c0" decimals="0" unitRef="usd">-43078</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:ShortTermInvestments contextRef="c2" decimals="0" unitRef="usd">13725204</us-gaap:ShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c2" decimals="0" unitRef="usd">239549</us-gaap:OtherShortTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 &#x2014; PROPERTY, PLANT AND EQUIPMENT,
NET&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property, plant and equipment, net, consists of
the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"&gt;Useful life&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Buildings&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 11%"&gt;20 years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,808,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,414,580&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5-10 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,047,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,534,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Automobiles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Office and electric equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;3-5 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;489,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;434,075&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,461,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,523,016&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,780,247&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,094,952&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,681,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,428,064&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-align: justify; text-indent: -0.4in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation expense was $441,355, $404,948 and $413,199 for the years
ended September 30, 2021, 2020 and 2019, respectively. Loss from disposal of fixed assets amounted to $1,559, &lt;span style="-sec-ix-hidden: hidden-fact-90"&gt;Nil&lt;/span&gt; and $2,085 for the years
ended September 30, 2021, 2020 and 2019, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"&gt;Useful life&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Buildings&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 11%"&gt;20 years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,808,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,414,580&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5-10 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,047,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,534,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Automobiles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Office and electric equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;3-5 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;489,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;434,075&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,461,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,523,016&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,780,247&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,094,952&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,681,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,428,064&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-align: justify; text-indent: -0.4in"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c67">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c88" decimals="0" unitRef="usd">7808006</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c89" decimals="0" unitRef="usd">7414580</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c68">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c69">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c90" decimals="0" unitRef="usd">2047338</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c91" decimals="0" unitRef="usd">1534015</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c70">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c71">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c92" decimals="0" unitRef="usd">116370</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c93" decimals="0" unitRef="usd">140346</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c72">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c73">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c94" decimals="0" unitRef="usd">489886</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c95" decimals="0" unitRef="usd">434075</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="0" unitRef="usd">10461600</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" unitRef="usd">9523016</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="0" unitRef="usd">5780247</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" unitRef="usd">5094952</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" unitRef="usd">4681353</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">4428064</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c0" decimals="0" unitRef="usd">441355</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c4" decimals="0" unitRef="usd">404948</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="0" unitRef="usd">413199</us-gaap:Depreciation>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c0" decimals="0" unitRef="usd">-1559</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c5" decimals="0" unitRef="usd">-2085</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-align: justify; text-indent: -0.4in"&gt;&lt;b&gt;NOTE 9 &#x2014;
INTANGIBLE ASSETS, NET&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets, net consist of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Useful life&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Land use rights&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 11%"&gt;50 years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;278,327&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;264,304&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;3 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,364&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,186&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301,691&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;286,490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(123,208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(111,714&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;178,483&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;174,776&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Amortization expense was $5,523, $5,131 and $5,232
for the years ended September 30, 2021, 2020 and 2019, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Estimated future amortization expense for intangible
assets is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;Years ending September 30,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amortization&lt;br/&gt;
 expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,567&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,567&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,567&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,567&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,567&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;150,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;178,483&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Useful life&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Land use rights&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 11%"&gt;50 years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;278,327&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;264,304&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;3 years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,364&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,186&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301,691&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;286,490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(123,208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(111,714&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;178,483&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;174,776&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c74">P50Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c96" decimals="0" unitRef="usd">278327</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c97" decimals="0" unitRef="usd">264304</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c75">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c98" decimals="0" unitRef="usd">23364</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c99" decimals="0" unitRef="usd">22186</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c2" decimals="0" unitRef="usd">301691</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c3" decimals="0" unitRef="usd">286490</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c2" decimals="0" unitRef="usd">-123208</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="0" unitRef="usd">-111714</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c2" decimals="0" unitRef="usd">178483</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="0" unitRef="usd">174776</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" unitRef="usd">5523</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c4" decimals="0" unitRef="usd">5131</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c5" decimals="0" unitRef="usd">5232</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;Years ending September 30,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amortization&lt;br/&gt;
 expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,567&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,567&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,567&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,567&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,567&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;150,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;178,483&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c2" decimals="0" unitRef="usd">5567</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree contextRef="c2" decimals="0" unitRef="usd">5567</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour contextRef="c2" decimals="0" unitRef="usd">5567</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive contextRef="c2" decimals="0" unitRef="usd">5567</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
    <upc:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix contextRef="c2" decimals="0" unitRef="usd">5567</upc:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive contextRef="c2" decimals="0" unitRef="usd">150648</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c2" decimals="0" unitRef="usd">178483</us-gaap:FiniteLivedIntangibleAssetsNet>
    <upc:PrepaymentForConstructionInProgressTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 10 &#x2014; PREPAYMENT FOR CONSTRUCTION-IN-PROGRESS
(&#x201c;CIP&#x201d;) PROJECT &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Construction-in-progress (&#x201c;CIP&#x201d;) represents direct costs of
construction incurred for the Company&#x2019;s manufacturing facilities. On June 25, 2021, the Company signed a construction sub-contract
with sub-contractor Jiangxi Chenyuan Construction Project Co., Ltd. (&#x201c;Chenyuan&#x201d;), pursuant to which, Chenyuan will help the
Company to construct 4 manufacturing plant buildings and an office building with total estimated budget of RMB 165 million (approximately
$25.5 million). The construction work started on August 8, 2021, with estimated completion date on August 7, 2023. As of September 30,
2021, the Company has made prepayment of approximately RMB69.2 million (approximately $10.7 million) to Chenyuan for land improvement,
building foundation and the construction of the main body of the manufacturing plants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021, the $10.7 million prepayment
to Chenyuan was recorded as prepayment for CIP project on the balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021, future additional capital expenditure on this
CIP project is estimated to be approximately RMB 95.8 million (equivalent to $14.8 million), among which approximately $3.8 million is
required for the next 12 months. The Company currently plans to support its ongoing CIP project construction through cash flows from operations,
proceeds received from the IPO and borrowing additional bank loans from PRC banks in the future and use such bank borrowings to support
the CIP project, if necessary. The construction of this new manufacturing facility is expected to be fully completed and put into production
by August 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021, future minimum capital
expenditures on the Company&#x2019;s CIP project are estimated as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;Years ending September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Capital&lt;br/&gt;
 Expenditure&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;on CIP&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,831,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,721,440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,277,100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,829,840&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</upc:PrepaymentForConstructionInProgressTextBlock>
    <us-gaap:InvestmentBuildingAndBuildingImprovements contextRef="c100" decimals="-6" unitRef="cny">165000000</us-gaap:InvestmentBuildingAndBuildingImprovements>
    <us-gaap:InvestmentBuildingAndBuildingImprovements contextRef="c100" decimals="-5" unitRef="usd">25500000</us-gaap:InvestmentBuildingAndBuildingImprovements>
    <us-gaap:InvestmentBuildingAndBuildingImprovements contextRef="c101" decimals="-5" unitRef="cny">69200000</us-gaap:InvestmentBuildingAndBuildingImprovements>
    <us-gaap:InvestmentBuildingAndBuildingImprovements contextRef="c101" decimals="-5" unitRef="usd">10700000</us-gaap:InvestmentBuildingAndBuildingImprovements>
    <upc:Prepayment contextRef="c102" decimals="-5" unitRef="usd">10700000</upc:Prepayment>
    <upc:CapitalExpenditure contextRef="c103" decimals="-5" unitRef="cny">95800000</upc:CapitalExpenditure>
    <upc:CapitalExpenditure contextRef="c103" decimals="-5" unitRef="usd">14800000</upc:CapitalExpenditure>
    <upc:CapitalExpenditure contextRef="c0" decimals="-5" unitRef="usd">3800000</upc:CapitalExpenditure>
    <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;Years ending September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Capital&lt;br/&gt;
 Expenditure&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;on CIP&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,831,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,721,440&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,277,100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,829,840&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c104" decimals="0" unitRef="usd">3831300</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c104" decimals="0" unitRef="usd">9721440</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c104" decimals="0" unitRef="usd">1277100</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c104" decimals="0" unitRef="usd">14829840</us-gaap:FiniteLivedIntangibleAssetsNet>
    <upc:PrepaymentForPurchaseOfAPropertyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 11 &#x2014; PREPAYMENT FOR PURCHASE OF
A PROPERTY &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 6, 2021, the Company entered into a real
estate property purchase agreement with related party Jiangxi Yueshang Investment Co., Ltd. (&#x201c;Jiangxi Yueshang&#x201d;), the Company&#x2019;s
CEO Mr. Gang Lai owns 5% equity interest in this entity, pursuant to the purchase agreement, Jiangxi Yueshang will sell and the Company
will purchase certain residential apartment and commercial office space totaling 2,749.30 square meters with total purchase price of RMB
32 million (approximately $4.95 million). Pursuant to the agreement, the Company is required to make 50% prepayment, with remaining 20%
payable when certificate of occupancy is available and 30% payable upon delivery of the property.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021, the Company has made
prepayment of RMB 16 million ($2,476,800) to Jiangxi Yueshang. The remaining balance is expected to be paid by August, 2024. Since the
property is located at urban downtown of Ji&#x2019;an City, the Company plans to use the property as offices in late 2024.&lt;/p&gt;</upc:PrepaymentForPurchaseOfAPropertyTextBlock>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="c105" decimals="2" unitRef="pure">0.05</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <upc:OfficeSpaceSquareMeters contextRef="c107" decimals="0" unitRef="pure">2749</upc:OfficeSpaceSquareMeters>
    <us-gaap:SupplementalDeferredPurchasePrice contextRef="c106" decimals="-6" unitRef="cny">32000000</us-gaap:SupplementalDeferredPurchasePrice>
    <us-gaap:SupplementalDeferredPurchasePrice contextRef="c106" decimals="-4" unitRef="usd">4950000</us-gaap:SupplementalDeferredPurchasePrice>
    <upc:PercentageOfPrepayment contextRef="c106" decimals="2" unitRef="pure">0.50</upc:PercentageOfPrepayment>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c107" decimals="2" unitRef="pure">0.20</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <upc:PayableDeliveryPropertyPercentage contextRef="c106" decimals="2" unitRef="pure">0.30</upc:PayableDeliveryPropertyPercentage>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c0" decimals="-6" unitRef="cny">16000000</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c0" decimals="0" unitRef="usd">-2476800</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 12 &#x2014; SHORT-BANK LOANS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Short-term bank loans consist of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Note&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt;
 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Short-term bank loans:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Loans payable to Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify; padding-left: 9pt"&gt;Maturity date on March 31, 2021, interest rate 4.81% per annum&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;(1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,176,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Maturity date on June 18, 2021, interest rate 4.81% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;(2)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,470,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Maturity date on June 15, 2022, interest rate 4.81% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;(3)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,548,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Maturity date on June 30, 2022, interest rate 4.5% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;(4)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,548,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Maturity date on March 17, 2022, interest rate 4.81% per annum&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;(5)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,238,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total short-term bank loans&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,334,400&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,646,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"/&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1) &lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;On September 26, 2019, the Company&#x2019;s subsidiary Jiangxi Universe
signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;) to borrow RMB 8 million (equivalent to $1,176,000)
as working capital for one year, with the maturity date on March 31, 2021. The fixed interest rate of the loan was 4.81% per annum. Related
parties including Mr. Gang Lai, the Company&#x2019;s controlling shareholder, and Foshan Shangyu Investment Holding Co., Ltd., an affiliated
entity controlled by Mr. Gang Lai, and three unrelated individuals jointly signed a guarantee agreement with LRC Bank to provide credit
guarantee for this loan. The loan was fully repaid upon maturity.&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"/&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2) &lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 19, 2020, the Company&#x2019;s subsidiary Jiangxi Universe signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;) to borrow RMB 10 million (equivalent to $1,470,000) as working capital for one year, with the maturity date on June 18, 2021. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"/&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3) &lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 16, 2021, the Company&#x2019;s subsidiary Jiangxi Universe signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;) to borrow RMB 10 million (equivalent to $1,548,000) as working capital for one year, with the maturity date on June 15, 2022. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for this loan. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"/&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4) &lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;On June 30, 2021, the Company&#x2019;s subsidiary Jiangxi Universe signed
a loan agreement with Bank of Communications to borrow RMB 10 million (equivalent to $1,548,000) as working capital for one year, with
the maturity date on June 18, 2022. The fixed interest rate of the loan was 4.5% per annum. Certain related parties of the Company, including
Mr. Gang Lai, the Company&#x2019;s controlling shareholder, Mr. Gang Lai&#x2019;s spouse, Mrs. Xing Wu, and the Company&#x2019;s subsidiary,
Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"/&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5) &lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 18, 2021, the Company&#x2019;s subsidiary Universe Trade signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;) to borrow RMB 8 million (equivalent to $1,238,400) as working capital for one year, with the maturity date on March 17, 2022. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for this loan. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the above-mentioned loans, the Company recorded
a total interest expense of $149,303, $157,528 and $135,717 for the years ended September 30, 2021, 2020 and 2019, respectively.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Note&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt;
 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Short-term bank loans:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Loans payable to Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify; padding-left: 9pt"&gt;Maturity date on March 31, 2021, interest rate 4.81% per annum&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;(1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,176,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Maturity date on June 18, 2021, interest rate 4.81% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;(2)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,470,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Maturity date on June 15, 2022, interest rate 4.81% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;(3)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,548,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Maturity date on June 30, 2022, interest rate 4.5% per annum&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;(4)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,548,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Maturity date on March 17, 2022, interest rate 4.81% per annum&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;(5)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,238,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total short-term bank loans&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,334,400&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,646,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermBorrowings contextRef="c120" decimals="0" unitRef="usd">1176000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c122" decimals="0" id="ix_0_fact" unitRef="usd">1470000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c123" decimals="0" unitRef="usd">1548000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c125" decimals="0" id="ix_1_fact" unitRef="usd">1548000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c127" decimals="0" unitRef="usd">1238400</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c2" decimals="0" unitRef="usd">4334400</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c3" decimals="0" unitRef="usd">2646000</us-gaap:ShortTermBorrowings>
    <us-gaap:LoansPayableToBankCurrent contextRef="c108" decimals="-6" unitRef="cny">8000000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:LoansPayableToBankCurrent contextRef="c109" decimals="0" unitRef="usd">1176000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c110">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c108" decimals="4" unitRef="pure">0.0481</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LoansPayableToBankCurrent contextRef="c111" decimals="-6" unitRef="cny">10000000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:LoansPayableToBankCurrent contextRef="c111" decimals="0" unitRef="usd">1470000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c112">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c111" decimals="4" unitRef="pure">0.0481</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LoansPayableToBankCurrent contextRef="c113" decimals="-6" unitRef="cny">10000000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:LoansPayableToBankCurrent contextRef="c113" decimals="0" unitRef="usd">1548000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c114">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c113" decimals="4" unitRef="pure">0.0481</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LoansPayableToBankCurrent contextRef="c115" decimals="-6" unitRef="cny">10000000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:LoansPayableToBankCurrent contextRef="c115" decimals="0" unitRef="usd">1548000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c116">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c115" decimals="3" unitRef="pure">0.045</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LoansPayableToBankCurrent contextRef="c117" decimals="-6" unitRef="cny">8000000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:LoansPayableToBankCurrent contextRef="c117" decimals="0" unitRef="usd">1238400</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:DebtInstrumentTerm contextRef="c118">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c117" decimals="4" unitRef="pure">0.0481</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestAndDebtExpense contextRef="c0" decimals="0" unitRef="usd">149303</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c4" decimals="0" unitRef="usd">157528</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c5" decimals="0" unitRef="usd">135717</us-gaap:InterestAndDebtExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 13 &#x2014; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"/&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nature of relationships with related parties&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;  border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 39%; font-weight: bold; text-align: justify"&gt;Name&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 60%; font-weight: bold; text-align: justify"&gt;Relationship with the Company&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Mr. Gang Lai&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Chief Executive Officer (&#x201c;CEO&#x201d;), chairman of the Board of Directors&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Mrs. Lin Yang&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Chief Financial Officer and Director&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Greatest Group (China) Financial Management Limited (&#x201c;Greatest Group&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;One of the Company&#x2019;s minority shareholders owns 8.7% of the ownership interest in this entity&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Foshan Shangyu Investment Holding Co., Ltd (&#x201c;Foshan Shangyu&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;An affiliated entity of the Company, 90% owned by and controlled by the Company&#x2019;s CEO.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"/&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Due from related parties&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;Name&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Greatest Group&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;235,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foshan Shangyu&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total due from related parties&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;236,982&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s due from related parties were
interest free and due on demand. The September 30, 2021 due from related parties balance has been subsequently collected back and the
Company does not have the intention to make additional cash advance to related parties going forward.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"/&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Due to related parties&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;Name&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Mr. Gang Lai&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;956,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Mrs. Lin Yang&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,723&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total due to related parties&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,723&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;956,492&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021 and 2020, the balance
due to related parties mainly consisted of advances from the Company&#x2019;s principal shareholder for working capital purposes during
the Company&#x2019;s normal course of business. These advances are non-interest bearing and due on demand.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"/&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(d)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loan guarantee provided by related parties&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the Company&#x2019;s bank borrowings
from LRC Bank, the Company&#x2019;s chief executive officer Mr. Gang Lai and Foshan Shangyu Investment Holding Co., Ltd., an affiliated
entity controlled by him, jointly signed a guarantee agreement with LRC Bank to provide credit guarantee for the Company&#x2019;s loans
from LRC Bank within the loan period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the Company&#x2019;s bank borrowings
from Bank of Communications, certain related parties of the Company, including Mr. Gang Lai, the Company&#x2019;s controlling shareholder,
Mr. Gang Lai&#x2019;s spouse, Ms. Xing Wu, and the Company&#x2019;s subsidiary, Universe Trade, jointly signed guarantee agreements with
Bank of Communications to provide credit guarantee for this loan (see Note 12).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"/&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(e)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Prepayment to related party for property purchase&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As disclosed in Note 11, on May 6, 2021, the Company
entered into a real estate property purchase agreement with related party Jiangxi Yueshang to purchase certain residential apartment and
commercial office space totaling 2,749.30 square meters with total purchase price of RMB32 million (approximately $4.95 million). As of
September 30, 2021, the Company had made prepayment of RMB16 million ($2,476,800) to Jiangxi Yueshang. The remaining balance is expected
to be paid by August 2024.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;  border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 39%; font-weight: bold; text-align: justify"&gt;Name&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 60%; font-weight: bold; text-align: justify"&gt;Relationship with the Company&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Mr. Gang Lai&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Chief Executive Officer (&#x201c;CEO&#x201d;), chairman of the Board of Directors&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Mrs. Lin Yang&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Chief Financial Officer and Director&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Greatest Group (China) Financial Management Limited (&#x201c;Greatest Group&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;One of the Company&#x2019;s minority shareholders owns 8.7% of the ownership interest in this entity&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Foshan Shangyu Investment Holding Co., Ltd (&#x201c;Foshan Shangyu&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;An affiliated entity of the Company, 90% owned by and controlled by the Company&#x2019;s CEO.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="c129">Chief Executive Officer (&#x201c;CEO&#x201d;), chairman of the Board of Directors</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="c130">Chief Financial Officer and Director</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="c131">One of the Company&#x2019;s minority shareholders owns 8.7% of the ownership interest in this entity</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="c132">An affiliated entity of the Company, 90% owned by and controlled by the Company&#x2019;s CEO.</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <upc:ScheduleOfDueFromRelatedPartiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;Name&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Greatest Group&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;235,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foshan Shangyu&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total due from related parties&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;236,982&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</upc:ScheduleOfDueFromRelatedPartiesTableTextBlock>
    <us-gaap:DueFromOtherRelatedPartiesCurrent contextRef="c133" decimals="0" unitRef="usd">235438</us-gaap:DueFromOtherRelatedPartiesCurrent>
    <us-gaap:DueFromOtherRelatedPartiesCurrent contextRef="c135" decimals="0" unitRef="usd">1544</us-gaap:DueFromOtherRelatedPartiesCurrent>
    <us-gaap:DueFromOtherRelatedPartiesCurrent contextRef="c2" decimals="0" unitRef="usd">236982</us-gaap:DueFromOtherRelatedPartiesCurrent>
    <upc:ScheduleOfDueToRelatedPartiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: justify"&gt;Name&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Mr. Gang Lai&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;956,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Mrs. Lin Yang&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,723&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total due to related parties&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,723&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;956,492&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</upc:ScheduleOfDueToRelatedPartiesTableTextBlock>
    <us-gaap:DueToRelatedPartiesNoncurrent contextRef="c138" decimals="0" unitRef="usd">956492</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent contextRef="c139" decimals="0" unitRef="usd">19723</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent contextRef="c2" decimals="0" unitRef="usd">19723</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent contextRef="c3" decimals="0" unitRef="usd">956492</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DeconsolidationRelatedPartyDescription contextRef="c106">As disclosed in Note 11, on May 6, 2021, the Company
entered into a real estate property purchase agreement with related party Jiangxi Yueshang to purchase certain residential apartment and
commercial office space totaling 2,749.30 square meters with total purchase price of RMB32 million (approximately $4.95 million).</us-gaap:DeconsolidationRelatedPartyDescription>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c0" decimals="-6" unitRef="cny">16000000</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c0" decimals="0" unitRef="usd">-2476800</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 13 &#x2014; TAXES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"/&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Corporate Income Taxes (&#x201c;CIT&#x201d;)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Cayman Islands&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the current tax laws of the Cayman Islands,
Universe INC is not subject to tax on its income or capital gains. In addition, no Cayman Islands withholding tax will be imposed upon
the payment of dividends by the Company to its shareholders.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Hong Kong&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Universe HK is incorporated in Hong Kong and is
subject to profit taxes in Hong Kong at a rate of 16.5%. However, Universe HK did not generate any assessable profits derived from Hong
Kong sources for the fiscal years ended September 30, 2021, 2020 and 2019, and accordingly no provision for Hong Kong profits tax has
been made in these periods.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160; &#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;PRC&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the Enterprise Income Tax (&#x201c;EIT&#x201d;)
Law of PRC, domestic enterprises and Foreign Investment Enterprises (&#x201c;FIEs&#x201d;) are usually subject to a unified 25% enterprise
income tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on a case-by-case basis. EIT grants preferential
tax treatment to High and New Technology Enterprises (&#x201c;HNTEs&#x201d;). Under this preferential tax treatment, HNTEs are entitled
to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. Jiangxi Universe, one
of the Company&#x2019;s main operating subsidiaries in PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15%
beginning November&#160;2016 with a term of three years. In December 2019, Jiangxi Universe successfully renewed its HNTE certification
with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through December 2022. Universe
Trade, the Company&#x2019;s another operating subsidiary in PRC, was approved as a HNTE and is entitled to a reduced income tax rate of
15% beginning December&#160;2020 with a term of three years. EIT is typically governed by the local tax authority in PRC. Each local tax
authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The
corporate income taxes for the years ended September 30, 2021, 2020 and 2019 were reported at a blended reduced rate as a result of Jiangxi
Universe and Universe Trade being approved as a HNTE and enjoying a 15% reduced income tax rate. The impact of the tax holidays noted
above decreased PRC corporate income taxes by $1,518,979, $118,986 and $312,357 for the years ended September 30, 2021, 2020 and 2019,
respectively. The benefit of the tax holidays on net income per share (basic and diluted) $0.09, $0.01 and $0.02 for the years ended September
30, 2021, 2020 and 2019, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160; &lt;b&gt;&#160;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The components of the income tax provision (benefit)
are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current income tax provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Cayman Island&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt; padding-left: 9pt"&gt;PRC&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;3,026,867&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,552,097&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,141,222&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,026,867&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,552,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,141,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred income tax provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Cayman Island&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;PRC&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(668,341&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(39,625&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total income tax provision&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,358,526&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,542,211&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,101,597&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table reconciles the China statutory
rates to the Company&#x2019;s effective tax rate for the years ended September 30, 2021, 2020 and 2019:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Statutory PRC income tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Effect of income tax holiday&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent difference&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-PRC entities not subject to PRC income tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Impact on DTA due to change in applicable income tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17.1&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25.2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21.8&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company continually evaluates expiring statutes
of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. As of September 30, 2021, all of the Company&#x2019;s
tax returns of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Deferred tax assets are composed of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 10pt"&gt;Net operating loss carry-forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;785,550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;186,537&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;84,447&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;869,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;186,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;869,997&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;186,537&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company periodically evaluates the likelihood
of the realization of deferred tax assets, and reduces the carrying amount of the deferred tax assets by a valuation allowance to the
extent it believes a portion will not be realized. Management considers new evidence, both positive and negative, that could affect the
Company&#x2019;s future realization of deferred tax assets including its recent cumulative earnings experience, expectation of future income,
the carry forward periods available for tax reporting purposes and other relevant factors. Although Jiangxi Universe incurred a net loss
during the year ended September 30, 2021, the Company determined that it is more likely than not its deferred tax assets could be realized
due to the estimated future earnings in Jiangxi Universe.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0px"/&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Taxes payable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Taxes payable consist of the following:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Income tax payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;669,780&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;767,297&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Value added tax payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;326,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;433,838&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other taxes payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;105,212&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;130,614&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total taxes payable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,101,460&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,331,749&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign contextRef="c140" decimals="3" unitRef="pure">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings contextRef="c0" decimals="2" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <upc:PreferentialTaxTreatmentDescription contextRef="c0">Under this preferential tax treatment, HNTEs are entitled
to an income tax rate of 15%, subject to a requirement that they re-apply for their HNTE status every three years. Jiangxi Universe, one
of the Company&#x2019;s main operating subsidiaries in PRC, was approved as a HNTE and is entitled to a reduced income tax rate of 15%
beginning November&#160;2016 with a term of three years. In December 2019, Jiangxi Universe successfully renewed its HNTE certification
with local government and will continue to enjoy the reduced income tax rate of 15% for another three years through December 2022. Universe
Trade, the Company&#x2019;s another operating subsidiary in PRC, was approved as a HNTE and is entitled to a reduced income tax rate of
15% beginning December&#160;2020 with a term of three years. EIT is typically governed by the local tax authority in PRC. Each local tax
authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The
corporate income taxes for the years ended September 30, 2021, 2020 and 2019 were reported at a blended reduced rate as a result of Jiangxi
Universe and Universe Trade being approved as a HNTE and enjoying a 15% reduced income tax rate.</upc:PreferentialTaxTreatmentDescription>
    <us-gaap:TaxesPayableCurrentAndNoncurrent contextRef="c2" decimals="0" unitRef="usd">1518979</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">118986</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent contextRef="c22" decimals="0" unitRef="usd">312357</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare contextRef="c0" decimals="2" unitRef="usdPershares">0.09</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare contextRef="c4" decimals="2" unitRef="usdPershares">0.01</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare contextRef="c5" decimals="2" unitRef="usdPershares">0.02</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current income tax provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Cayman Island&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt; padding-left: 9pt"&gt;PRC&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;3,026,867&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,552,097&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;2,141,222&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,026,867&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,552,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,141,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred income tax provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Cayman Island&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;PRC&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(668,341&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(39,625&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total income tax provision&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,358,526&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,542,211&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,101,597&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c146" decimals="0" unitRef="usd">3026867</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c147" decimals="0" unitRef="usd">2552097</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c148" decimals="0" unitRef="usd">2141222</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">3026867</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c4" decimals="0" unitRef="usd">2552097</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">2141222</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c146" decimals="0" unitRef="usd">-668341</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c147" decimals="0" unitRef="usd">-9886</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c148" decimals="0" unitRef="usd">-39625</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">2358526</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c4" decimals="0" unitRef="usd">2542211</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">2101597</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Statutory PRC income tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Effect of income tax holiday&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent difference&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-PRC entities not subject to PRC income tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Impact on DTA due to change in applicable income tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17.1&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25.2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21.8&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="3" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c4" decimals="3" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="3" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays contextRef="c0" decimals="3" unitRef="pure">0.11</us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays contextRef="c4" decimals="3" unitRef="pure">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays contextRef="c5" decimals="3" unitRef="pure">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationTaxHolidays>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness contextRef="c5" decimals="3" unitRef="pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c0" decimals="3" unitRef="pure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c4" decimals="3" unitRef="pure">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c0" decimals="3" unitRef="pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="3" unitRef="pure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="3" unitRef="pure">0.171</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c4" decimals="3" unitRef="pure">0.252</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c5" decimals="3" unitRef="pure">0.218</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30, &lt;br/&gt;
2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 10pt"&gt;Net operating loss carry-forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;785,550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;186,537&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;84,447&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;869,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;186,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;869,997&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;186,537&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="0" unitRef="usd">785550</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="0" unitRef="usd">186537</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c2" decimals="0" unitRef="usd">84447</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c2" decimals="0" unitRef="usd">869997</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c3" decimals="0" unitRef="usd">186537</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="0" unitRef="usd">869997</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="0" unitRef="usd">186537</us-gaap:DeferredTaxAssetsGross>
    <upc:ScheduleOfTaxPayableTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;September&#160;30, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Income tax payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;669,780&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;767,297&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Value added tax payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;326,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;433,838&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other taxes payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;105,212&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;130,614&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total taxes payable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,101,460&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,331,749&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</upc:ScheduleOfTaxPayableTableTextBlock>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c2" decimals="0" unitRef="usd">669780</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c3" decimals="0" unitRef="usd">767297</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c2" decimals="0" unitRef="usd">326468</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c3" decimals="0" unitRef="usd">433838</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c2" decimals="0" unitRef="usd">105212</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c3" decimals="0" unitRef="usd">130614</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="0" unitRef="usd">1101460</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c3" decimals="0" unitRef="usd">1331749</us-gaap:TaxesPayableCurrent>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 14 &#x2014; CONCENTRATIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A majority of the Company&#x2019;s revenue and
expense transactions are denominated in RMB and a significant portion of the Company and its subsidiaries&#x2019; assets and liabilities
are denominated in RMB. RMB is not freely convertible into foreign currencies. In the PRC, certain foreign exchange transactions are required
by law to be transacted only by authorized financial institutions at exchange rates set by the People&#x2019;s Bank of China (&#x201c;PBOC&#x201d;).
Remittances in currencies other than RMB by the Company in China must be processed through the PBOC or other China foreign exchange regulatory
bodies which require certain supporting documentation in order to affect the remittance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021 and 2020, $5,892,655
and $10,027,666 of the Company&#x2019;s cash was on deposit at financial institutions in the PRC where there currently is no rule or regulation
requiring such financial institutions to maintain insurance to cover bank deposits in the event of bank failure. For the years ended September
30, 2021, 2020 and 2019, the Company&#x2019;s substantial assets were located in the PRC and the Company&#x2019;s substantial revenues were
derived from its subsidiaries located in the PRC.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended September 30, 2021, 2020 and
2019, no single customer accounted for more than 10% of the Company&#x2019;s total revenue. The Company&#x2019;s top 10 customers aggregately
accounted for 30.4%, 33.3% and 34.5% of the total revenue for the years ended September 30, 2021, 2020 and 2019, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Sales of one of the Company&#x2019;s major products, Guben Yanling Pill,
accounted for 40.3%, 38.2% and 32.4% of the Company&#x2019;s total revenue for the years ended September 30, 2021, 2020 and 2019, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021, no customer accounted
for more than 10% of the total accounts receivable balance. As of September 30, 2020, one customer accounted for 13.0% of the total accounts
receivable balance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021, two suppliers accounted
for 35.3% and 28.0% of the total advance to supplier balance. No supplier accounted for more than 10% of the Company&#x2019;s total advance
to supplier balance as of September 30, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended September 30, 2021, no supplier
accounted for more than 10% of the total purchases, respectively. For the year ended September 30, 2020, two suppliers accounted for approximately
19.6% and 13.6% of the total purchases, respectively. For the year ended September 30, 2019, one supplier accounted for approximately
14.1% of the total purchases.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ForeignFinancialInstitutionsMandatedDeposits contextRef="c2" decimals="0" unitRef="usd">5892655</us-gaap:ForeignFinancialInstitutionsMandatedDeposits>
    <us-gaap:ForeignFinancialInstitutionsMandatedDeposits contextRef="c3" decimals="0" unitRef="usd">10027666</us-gaap:ForeignFinancialInstitutionsMandatedDeposits>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c149" decimals="2" unitRef="pure">0.10</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c150" decimals="2" unitRef="pure">0.10</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c151" decimals="2" unitRef="pure">0.10</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c152" decimals="3" unitRef="pure">0.304</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c153" decimals="3" unitRef="pure">0.333</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c154" decimals="3" unitRef="pure">0.345</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c155" decimals="3" unitRef="pure">0.403</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c156" decimals="3" unitRef="pure">0.382</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c157" decimals="3" unitRef="pure">0.324</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c158" decimals="2" unitRef="pure">0.10</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c159" decimals="3" unitRef="pure">0.13</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c160" decimals="3" unitRef="pure">0.353</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c161" decimals="3" unitRef="pure">0.28</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c162" decimals="2" unitRef="pure">0.10</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c163" decimals="2" unitRef="pure">0.10</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c164" decimals="3" unitRef="pure">0.196</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c165" decimals="3" unitRef="pure">0.136</upc:ConcentrationRiskThresholdPercentage>
    <upc:ConcentrationRiskThresholdPercentage contextRef="c166" decimals="3" unitRef="pure">0.141</upc:ConcentrationRiskThresholdPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 15 &#x2014; SHAREHOLDERS&#x2019; EQUITY&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Ordinary Shares&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Universe INC was incorporated under the laws of
the Cayman Islands on December 11, 2019. The original authorized number of ordinary shares was 50,000 shares with par value of US$1.00
per share and 50,000 shares were issued. On August 7, 2020, the Company amended its Memorandum of Association to increase the authorized
number of shares to 100,000,000 shares with par value of $0.003125 per share, and subdivide the original issued shares from 50,000 shares
at par value of $1.00 per share to 16,000,000 ordinary shares with par value of $0.003125 per share. As a result of this forward split
of the outstanding ordinary shares at a ratio of 320-for-1 share, there is a total of 16,000,000 shares issued and outstanding.&#160;The
issuance of these 16,000,000 shares is considered as a part of the Reorganization of the Company, which was retroactively applied as if
the transaction occurred at the beginning of the period presented (see Note 1).&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Initial Public Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 25, 2021, the Company closed its IPO
of 5,000,000 ordinary shares, par value $0.003125 per share (the &#x201c;ordinary shares&#x201d;) at a public offering price of $5.00 per
share. On March 29, 2021, the underwriter exercised in full its over-allotment option to purchase an additional 750,000 ordinary shares.&#160;&lt;span&gt;The
closing for the sale of the over-allotment shares took place on March 31, 2021. Gross proceeds of the IPO, including the proceeds from
the sale of the over-allotment shares, totaled $28.75 million, before deducting underwriting discounts and other related expenses&lt;/span&gt;.
Net proceeds of our IPO, including over-allotment shares, were approximately $25.6 million. In connection with the IPO, the Company&#x2019;s
ordinary shares began trading on the Nasdaq Global Market&#160;under the symbol &#x201c;UPC&#x201d; on March 23, 2021.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021 and 2020, the Company
had total of 21,750,000 and 16,000,000 shares ordinary shares issued and outstanding, respectively&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Underwriter warrants &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the Company&#x2019;s IPO, the Company also agreed to
issue warrants to the underwriter, for a nominal consideration of $0.001 per warrant, to purchase 300,000 ordinary shares of the Company
(equal to 6% of the total number of Ordinary Shares sold in the IPO, but not including any over-allotment Ordinary Shares sold in the
over-allotment option) (the &#x201c;Underwriter Warrants&#x201d;). These warrants have warrant term of five years, with an exercise price
of $5.50 per share (equal to 110% of the Company&#x2019;s IPO offering price of $5.00 per share). The Underwriter Warrants may be purchased
in cash or via cashless exercise, will be exercisable for five (5) years, and will terminate on the fifth anniversary of the date thereafter.
Management determined that these warrants meet the requirements for equity classification under ASC 815-40 because they are indexed to
its own stock. As of September 30, 2021, these underwriter warrants were issued and outstanding but none of the warrants has been exercised.
For the year ended September 30, 2021, these underwriter warrants were antidilutive and accordingly were not included in the diluted EPS
calculation based on treasury stock method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash dividends &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 21, 2016, September 13, 2017, February
2, 2018, September 20, 2018 and February 21, 2019, the board of directors of Jiangxi Universe approved resolutions to pay cash dividend
of RMB40 million, RMB30 million, RMB20 million, RMB10 million and RMB30 million, respectively, to its shareholders at the time of record
out of the retained earnings balance of Jiangxi Universe, to be paid to these shareholders when there are sufficient available earnings
and the Company has sufficient funds. A total of RMB130 million (approximately $19.1 million) cash dividend was declared from September
2016 to February 2019, among which approximately RMB20 million ($3.1 million) was paid in cash to its shareholders in 2018 and the remaining
RMB 110 million ($16 million) was paid to its shareholders in 2019. There was no additional cash dividends paid during the years ended
September 30, 2021 and 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Except for the dividends declared mentioned above,
the Company has not declared or paid dividends to its shareholders in the past, and may not choose to make additional distributions in
the future. Any decision as to the payment of dividends will depend on the available earnings, the capital requirements of the Company,
the Company&#x2019;s general financial condition and other factors deemed pertinent by the board of directors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Statutory reserve and restricted net assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s PRC subsidiaries are restricted
in their ability to transfer a portion of their net assets to the Company. The payment of dividends by entities organized in China is
subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated
profits as determined in accordance with accounting standards and regulations in China.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is required to make appropriations
to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income
determined in accordance with generally accepted accounting principles of the PRC (&#x201c;PRC GAAP&#x201d;). Appropriations to the statutory
surplus reserve are required to be at least 10% of the after-tax net income determined in accordance with PRC GAAP until the reserve is
equal to 50% of the entity&#x2019;s registered capital. Appropriations to the discretionary surplus reserve are made at the discretion
of the board of directors. The statutory reserve may be applied against prior year losses, if any, and may be used for general business
expansion and production or increase in registered capital, but are not distributable as cash dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Relevant PRC laws and regulations restrict the
Company&#x2019;s PRC subsidiaries from transferring a portion of their net assets, equivalent to its statutory reserves and their share
capital, to the Company in the form of loans, advances or cash dividends. Only PRC entities&#x2019; accumulated profits may be distributed
as dividends to the Company without the consent of a third party. As of September 30, 2021 and 2020, the restricted amounts as determined
pursuant to PRC statutory laws totaled $2,439,535 and $2,439,535, respectively, and total restricted net assets amounted to $31,786,663
and $6,168,535, respectively.&lt;b&gt;&#160;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash transfer between the Company and its
subsidiaries &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended September 30, 2021, the Company
transferred cash in the amount of $11,358,764 to its subsidiary in Hong Kong, and the Company&#x2019;s Hong Kong subsidiary, via the WFOE,
further transferred cash in the amount of $6,807,507 to the PRC subsidiaries. For the year ended September 30, 2020 and 2019, there was
no cash transferred from the Company to its PRC subsidiaries. The assets transfer was for business operation purpose. There was no distribution
of earnings by the PRC operating subsidiaries to the Company during the years ended September 30, 2021, 2020 and 2019, respectively.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c167" decimals="0" unitRef="shares">50000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c167" decimals="2" unitRef="usdPershares">1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c167" decimals="0" unitRef="shares">50000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized contextRef="c168" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c168" decimals="6" unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssued contextRef="c168" decimals="0" unitRef="shares">50000</us-gaap:SharesIssued>
    <upc:OriginalSharesParValue contextRef="c169" decimals="2" unitRef="usdPershares">1</upc:OriginalSharesParValue>
    <us-gaap:CommonStockSharesIssued contextRef="c168" decimals="0" unitRef="shares">16000000</us-gaap:CommonStockSharesIssued>
    <upc:OrdinarySharesParValue contextRef="c169" decimals="6" unitRef="usdPershares">0.003125</upc:OrdinarySharesParValue>
    <upc:OrdinarySharesOutstandingDescription contextRef="c170">As a result of this forward split
of the outstanding ordinary shares at a ratio of 320-for-1 share, there is a total of 16,000,000 shares issued and outstanding.</upc:OrdinarySharesOutstandingDescription>
    <upc:ReorganizationShares contextRef="c169" decimals="0" unitRef="shares">16000000</upc:ReorganizationShares>
    <us-gaap:SharesIssued contextRef="c171" decimals="0" unitRef="shares">5000000</us-gaap:SharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c171" decimals="6" unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <upc:PublicOfferingPrice contextRef="c171" decimals="2" unitRef="usdPershares">5</upc:PublicOfferingPrice>
    <upc:OptionToPurchaseAdditionalShares contextRef="c172" decimals="0" unitRef="shares">750000</upc:OptionToPurchaseAdditionalShares>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c171" decimals="-4" unitRef="usd">28750000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c173" decimals="-5" unitRef="usd">25600000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:SharesOutstanding contextRef="c62" decimals="0" unitRef="shares">21750000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c174" decimals="0" unitRef="shares">16000000</us-gaap:SharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c175" decimals="3" unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssued contextRef="c175" decimals="0" unitRef="shares">300000</us-gaap:SharesIssued>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="c176" decimals="2" unitRef="pure">0.06</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c177" decimals="2" unitRef="usdPershares">5.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c177" decimals="2" unitRef="pure">1.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SaleOfStockPricePerShare contextRef="c177" decimals="2" unitRef="usdPershares">5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DividendsShareBasedCompensationCash contextRef="c178" decimals="-6" unitRef="cny">40000000</us-gaap:DividendsShareBasedCompensationCash>
    <us-gaap:DividendsShareBasedCompensationCash contextRef="c179" decimals="-6" unitRef="cny">30000000</us-gaap:DividendsShareBasedCompensationCash>
    <us-gaap:DividendsShareBasedCompensationCash contextRef="c180" decimals="-6" unitRef="cny">20000000</us-gaap:DividendsShareBasedCompensationCash>
    <us-gaap:DividendsShareBasedCompensationCash contextRef="c181" decimals="-6" unitRef="cny">10000000</us-gaap:DividendsShareBasedCompensationCash>
    <us-gaap:DividendsShareBasedCompensationCash contextRef="c182" decimals="-6" unitRef="cny">30000000</us-gaap:DividendsShareBasedCompensationCash>
    <upc:CashDividendDescription contextRef="c183">A total of RMB130 million (approximately $19.1 million) cash dividend was declared from September
2016 to February 2019, among which approximately RMB20 million ($3.1 million) was paid in cash to its shareholders in 2018 and the remaining
RMB 110 million ($16 million) was paid to its shareholders in 2019.</upc:CashDividendDescription>
    <upc:StatutorySurplusPercentage contextRef="c184" decimals="2" unitRef="pure">0.10</upc:StatutorySurplusPercentage>
    <upc:ReserveIsEqualPercentage contextRef="c4" decimals="2" unitRef="pure">0.50</upc:ReserveIsEqualPercentage>
    <us-gaap:RestrictedCash contextRef="c185" decimals="0" unitRef="usd">2439535</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c186" decimals="0" unitRef="usd">2439535</us-gaap:RestrictedCash>
    <upc:RestrictedNetAssets contextRef="c187" decimals="0" unitRef="usd">31786663</upc:RestrictedNetAssets>
    <upc:RestrictedNetAssets contextRef="c184" decimals="0" unitRef="usd">6168535</upc:RestrictedNetAssets>
    <us-gaap:Cash contextRef="c188" decimals="0" unitRef="usd">11358764</us-gaap:Cash>
    <us-gaap:Cash contextRef="c189" decimals="0" unitRef="usd">6807507</us-gaap:Cash>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 16 &#x2014; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, the Company is a party to various
legal actions arising in the ordinary course of business. The Company accrues costs associated with these matters when they become probable
and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. For the
years ended September 30, 2021, 2020 and 2019, the Company did not have any material legal claims or litigation that, individually or
in aggregate, could have a material adverse impact on the Company&#x2019;s consolidated financial position, results of operations and cash
flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has an ongoing CIP project associated
with the construction of a new manufacturing facility. As of September 30, 2021, future minimum capital expenditures on the Company&#x2019;s
CIP project amounted to approximately $14.8 million, among which approximately $3.8 million is required for the next 12 months from the
date of this report (see Note 7).&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CapitalExpenditureDiscontinuedOperations contextRef="c0" decimals="-5" unitRef="usd">14800000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <us-gaap:InterestExpenseCapitalSecurities contextRef="c0" decimals="-5" unitRef="usd">3800000</us-gaap:InterestExpenseCapitalSecurities>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 17 &#x2014; SEGMENT REPORTING&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;An operating segment is a component of the Company
that engages in business activities from which it may earn revenues and incur expenses, and is identified on the basis of the internal
financial reports that are provided to and regularly reviewed by the Company&#x2019;s chief operating decision maker in order to allocate
resources and assess performance of the segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The management of the Company concludes that it
has only one reporting segment. The Company develops, manufactures and sells traditional Chinese medicine derivatives (&#x201c;TCMD&#x201d;)
products targeted to the elderly to address their physical conditions in the aging process and to promote their general well-being. In
addition, the Company also sells biochemical drugs, medical instruments, Traditional Chinese Medicine Pieces products and dietary supplements
manufactured by third-party pharmaceutical companies (&#x201c;third-party products&#x201d;). All of these products are currently sold in
China.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s products have similar economic
characteristics with respect to raw materials, vendors, marketing and promotions, customers and methods of distribution. The Company&#x2019;s
chief operating decision maker has been identified as the Chief Executive Officer, who reviews consolidated results when making decisions
about allocating resources and assessing performance of the Company, rather than by product types or geographic area; hence the Company
has only one reporting segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Revenue by product source &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Sales of TCMD products manufactured by the Company&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,559,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,374,751&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,895,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Sales of third-party products&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,422,745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,329,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,333,774&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Total revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,982,031&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,703,960&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;33,229,316&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Revenue by product categories &lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The summary of our total revenues by product categories
for the years ended September 30, 2021, 2020 and 2019 was as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Sales of TCMD products:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Medicinal liquor products&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,951,679&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,616,080&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,356,015&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Other chronic condition treatment products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,978,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,059,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,056,228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Cold and flu medicines&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,629,606&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,699,268&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,483,299&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Sub-total of TCMD products sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29,559,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,374,751&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,895,542&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.1in; padding-left: 0.1in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Sales of third-party products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Biochemical drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,082,546&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,325,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,508,816&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Traditional Chinese medicine pieces&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Medical instruments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,318,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,950,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,668,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Dietary supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;958&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,463&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,127&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Subtotal of third-party products sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,422,745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,329,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,333,774&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.1in; padding-left: 0.1in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Total revenue&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;47,982,031&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;30,703,960&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;33,229,316&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c0" decimals="0" unitRef="pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Sales of TCMD products manufactured by the Company&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,559,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,374,751&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,895,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Sales of third-party products&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,422,745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,329,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,333,774&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Total revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,982,031&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,703,960&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;33,229,316&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CostOfOtherPropertyOperatingExpense contextRef="c0" decimals="0" unitRef="usd">29559286</us-gaap:CostOfOtherPropertyOperatingExpense>
    <us-gaap:CostOfOtherPropertyOperatingExpense contextRef="c4" decimals="0" unitRef="usd">18374751</us-gaap:CostOfOtherPropertyOperatingExpense>
    <us-gaap:CostOfOtherPropertyOperatingExpense contextRef="c5" decimals="0" unitRef="usd">20895542</us-gaap:CostOfOtherPropertyOperatingExpense>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="0" unitRef="usd">18422745</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c4" decimals="0" unitRef="usd">12329209</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c5" decimals="0" unitRef="usd">12333774</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">47982031</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c4" decimals="0" unitRef="usd">30703960</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="0" unitRef="usd">33229316</us-gaap:Revenues>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Sales of TCMD products:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Medicinal liquor products&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,951,679&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,616,080&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,356,015&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Other chronic condition treatment products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,978,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,059,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,056,228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Cold and flu medicines&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,629,606&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,699,268&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,483,299&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Sub-total of TCMD products sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29,559,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,374,751&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,895,542&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.1in; padding-left: 0.1in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Sales of third-party products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Biochemical drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,082,546&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,325,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,508,816&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Traditional Chinese medicine pieces&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;142,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in"&gt;Medical instruments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,318,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,950,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,668,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Dietary supplements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;958&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,463&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,127&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Subtotal of third-party products sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,422,745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,329,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,333,774&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.1in; padding-left: 0.1in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x3000;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in"&gt;Total revenue&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;47,982,031&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;30,703,960&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;33,229,316&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <upc:SubtotalOfTCMDProductsSales contextRef="c190" decimals="0" unitRef="usd">1951679</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c191" decimals="0" unitRef="usd">1616080</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c192" decimals="0" unitRef="usd">2356015</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c193" decimals="0" unitRef="usd">22978001</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c194" decimals="0" unitRef="usd">14059403</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c195" decimals="0" unitRef="usd">14056228</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c196" decimals="0" unitRef="usd">4629606</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c197" decimals="0" unitRef="usd">2699268</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c198" decimals="0" unitRef="usd">4483299</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c0" decimals="0" unitRef="usd">29559286</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c4" decimals="0" unitRef="usd">18374751</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfTCMDProductsSales contextRef="c5" decimals="0" unitRef="usd">20895542</upc:SubtotalOfTCMDProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c199" decimals="0" unitRef="usd">16082546</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c200" decimals="0" unitRef="usd">10325411</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c201" decimals="0" unitRef="usd">9508816</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c202" decimals="0" unitRef="usd">20705</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c203" decimals="0" unitRef="usd">47097</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c204" decimals="0" unitRef="usd">142409</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c205" decimals="0" unitRef="usd">2318536</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c206" decimals="0" unitRef="usd">1950238</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c207" decimals="0" unitRef="usd">2668422</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c208" decimals="0" unitRef="usd">958</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c209" decimals="0" unitRef="usd">6463</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c210" decimals="0" unitRef="usd">14127</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c0" decimals="0" unitRef="usd">18422745</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c4" decimals="0" unitRef="usd">12329209</upc:SubtotalOfThirdpartyProductsSales>
    <upc:SubtotalOfThirdpartyProductsSales contextRef="c5" decimals="0" unitRef="usd">12333774</upc:SubtotalOfThirdpartyProductsSales>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">47982031</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c4" decimals="0" unitRef="usd">30703960</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="0" unitRef="usd">33229316</us-gaap:Revenues>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 18 &#x2014; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 1, 2021, the Company entered into
definitive agreements (the &#x201c;Agreements&#x201d;) with Kitanihon Pharmaceutical Co., Ltd. (&#x201c;Kitanihon&#x201d;), a Japanese pharmaceutical
company, pursuant to which (i) both parties will build a manufacturing facility in Ji&#x2019;an, Jiangxi, China, for the manufacturing
and research and development of traditional Chinese medicine derivatives products, with an aggregate area of over 430,000 square feet,
and the Company will bear the costs associated with building the facility, and (ii) the Company will purchase 464 shares of Kitanihon
for an aggregate of JPY176.32 million (approximately US$1.56 million).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In relation to the Agreements, Sununion Holding
Group Limited (&#x201c;Sununion&#x201d;), the controlling shareholder of the Company wholly owned by Mr. Gang Lai, the chief executive officer
and chairman of the board of directors of the Company, entered into an agreement with Mr. Gang Lai and Kitanihon on December 1, 2021,
pursuant to which Kitanihon authorizes the Company to use certain of its intangible assets, including technologies and certain intellectual
properties, in exchange for which Mr. Gang Lai will transfer ordinary shares of Sununion owned by him and valued at US$2.5 million to
Kitanihon.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluated the subsequent event through
the date of this report, and concluded that there are no material reportable subsequent events need to be disclosed. &#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubsequentEventDescription contextRef="c211">(i) both parties will build a manufacturing facility in Ji&#x2019;an, Jiangxi, China, for the manufacturing
and research and development of traditional Chinese medicine derivatives products, with an aggregate area of over 430,000 square feet,
and the Company will bear the costs associated with building the facility, and (ii) the Company will purchase 464 shares of Kitanihon
for an aggregate of JPY176.32 million (approximately US$1.56 million)</us-gaap:SubsequentEventDescription>
    <upc:IntangibleAssets contextRef="c211" decimals="-5" unitRef="usd">2500000</upc:IntangibleAssets>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 19 &#x2014; CONDENSED FINANCIAL INFORMATION
OF THE PARENT COMPANY&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the requirements of Rule 12-04(a),
5-04(c) and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when the restricted
net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal
year. The Company performed a test on the restricted net assets of consolidated subsidiaries in accordance with such requirement and concluded
that it was applicable to the Company as the restricted net assets of the Company&#x2019;s PRC subsidiary exceeded 25% of the consolidated
net assets of the Company. Therefore, the condensed financial statements for the parent company are included herein.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For purposes of the above test, restricted net
assets of consolidated subsidiaries shall mean that amount of the Company&#x2019;s proportionate share of net assets of consolidated subsidiaries
(after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries
in the form of loans, advances or cash dividends without the consent of a third party.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The condensed financial information of the parent
company has been prepared using the same accounting policies as set out in the Company&#x2019;s consolidated financial statements except
that the parent company used the equity method to account for investment in its subsidiaries. Such investment is presented on the condensed
balance sheets as &#x201c;Investment in subsidiaries&#x201d; and the respective profit or loss as &#x201c;Equity in earnings of subsidiaries&#x201d;
on the condensed statements of income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The footnote disclosures contain supplemental
information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the
consolidated financial statements of the Company. Certain information and footnote disclosures normally included in financial statements
prepared in accordance with U.S GAAP have been condensed or omitted.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of September 30, 2021 and 2020, there were
no material contingencies, significant provisions for long-term obligations, or guarantees of the Company, except for those which have
been separately disclosed in the consolidated financial statements, if any.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-weight: bold; text-align: justify"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;Short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,725,204&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;Total current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,835,597&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Non-current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 9pt; padding-left: 9pt"&gt;Investment in subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,098,756&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,802,904&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,934,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20,802,904&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;LIABILITIES AND SHAREHOLDERS&#x2019; EQUITY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;COMMITMENTS AND CONTINGENCIES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares and 16,000,000 shares issued and outstanding as of September 30, 2021 and 2020, respectively&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,969&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 10pt"&gt;Additional paid-in capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,279,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,679,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt"&gt;Retained earnings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,498,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,178,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Accumulated other comprehensive income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,088,759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;895,390&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt"&gt;Total shareholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,934,353&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,802,904&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 20pt"&gt;Total liabilities and shareholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,934,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20,802,904&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating costs and expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 9pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,177,869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income (expenses):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Income from short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239,549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(60,751&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Equity in earnings of subsidiaries&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,319,023&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,558,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,551,465&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,319,952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,558,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,551,465&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,193,369&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;860,623&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(645,978&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Comprehensive income attributable to the Company&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,513,321&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,418,845&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,905,487&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify; padding-left: 10pt"&gt;Net income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,319,952&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,558,222&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,551,465&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 10pt"&gt;Adjustments to reconcile net cash flows from operating activities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 8.3pt; padding-left: 20pt"&gt;Equity in earnings of subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12,319,027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,558,222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,551,465&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 30pt"&gt;Net cash used in operating activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(999,075&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;CASH FLOWS FROM INVESTING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 28.3pt"&gt;Payment for short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15,330,660&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 28.3pt"&gt;Redemption of short-term investments &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,801,927&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Net cash used in investing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,528,733&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;CASH FLOWS FROM FINANCING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 28.3pt"&gt;Net proceeds from issuance of ordinary shares in IPO&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,957,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 21.3pt"&gt;&#160;&#160;Cash lent to subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,358,764&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Net cash provided by financing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,598,693&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;CHANGES IN CASH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;CASH, beginning of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;CASH, end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <upc:MinorityInterestsOwnershipPercentageByParent contextRef="c2" decimals="2" unitRef="pure">0.25</upc:MinorityInterestsOwnershipPercentageByParent>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September&#160;30,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-weight: bold; text-align: justify"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;Short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,725,204&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;Total current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,835,597&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Non-current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 9pt; padding-left: 9pt"&gt;Investment in subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,098,756&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,802,904&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 10pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,934,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20,802,904&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;LIABILITIES AND SHAREHOLDERS&#x2019; EQUITY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;COMMITMENTS AND CONTINGENCIES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 20pt"&gt;Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares and 16,000,000 shares issued and outstanding as of September 30, 2021 and 2020, respectively&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,969&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 10pt"&gt;Additional paid-in capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,279,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,679,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 10pt"&gt;Retained earnings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,498,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,178,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Accumulated other comprehensive income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,088,759&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;895,390&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt"&gt;Total shareholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,934,353&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,802,904&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 20pt"&gt;Total liabilities and shareholders&#x2019; equity&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,934,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20,802,904&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:Cash contextRef="c212" decimals="0" unitRef="usd">110393</us-gaap:Cash>
    <us-gaap:ShortTermInvestments contextRef="c212" decimals="0" unitRef="usd">13725204</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsCurrent contextRef="c212" decimals="0" unitRef="usd">13835597</us-gaap:AssetsCurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c212" decimals="0" unitRef="usd">45098756</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c213" decimals="0" unitRef="usd">20802904</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Assets contextRef="c212" decimals="0" unitRef="usd">58934353</us-gaap:Assets>
    <us-gaap:Assets contextRef="c213" decimals="0" unitRef="usd">20802904</us-gaap:Assets>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c212" decimals="6" unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c213" decimals="6" unitRef="usdPershares">0.003125</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c212" decimals="INF" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c213" decimals="INF" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c212" decimals="INF" unitRef="shares">21750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c212" decimals="INF" unitRef="shares">21750000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c213" decimals="INF" unitRef="shares">16000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c213" decimals="INF" unitRef="shares">16000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c212" decimals="0" unitRef="usd">67969</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c213" decimals="0" unitRef="usd">50000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c212" decimals="0" unitRef="usd">29279159</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c213" decimals="0" unitRef="usd">3679000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c212" decimals="0" unitRef="usd">27498466</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c213" decimals="0" unitRef="usd">16178514</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c212" decimals="0" unitRef="usd">2088759</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c213" decimals="0" unitRef="usd">895390</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c212" decimals="0" unitRef="usd">58934353</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c213" decimals="0" unitRef="usd">20802904</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c212" decimals="0" unitRef="usd">58934353</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c213" decimals="0" unitRef="usd">20802904</us-gaap:LiabilitiesAndStockholdersEquity>
    <srt:CondensedStatementOfComprehensiveIncomeTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating costs and expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-left: 9pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,177,869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income (expenses):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Income from short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239,549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Other expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(60,751&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Equity in earnings of subsidiaries&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,319,023&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,558,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,551,465&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,319,952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,558,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,551,465&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign currency translation adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,193,369&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;860,623&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(645,978&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Comprehensive income attributable to the Company&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,513,321&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,418,845&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,905,487&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</srt:CondensedStatementOfComprehensiveIncomeTableTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c214" decimals="0" unitRef="usd">-1177869</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:InterestExpenseOtherShortTermBorrowings contextRef="c214" decimals="0" unitRef="usd">239549</us-gaap:InterestExpenseOtherShortTermBorrowings>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c214" decimals="0" unitRef="usd">-60751</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c214" decimals="0" unitRef="usd">12319023</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c215" decimals="0" unitRef="usd">7558222</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c216" decimals="0" unitRef="usd">7551465</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss contextRef="c214" decimals="0" unitRef="usd">11319952</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c215" decimals="0" unitRef="usd">7558222</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c216" decimals="0" unitRef="usd">7551465</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c214" decimals="0" unitRef="usd">1193369</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c215" decimals="0" unitRef="usd">860623</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c216" decimals="0" unitRef="usd">-645978</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c214" decimals="0" unitRef="usd">12513321</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c215" decimals="0" unitRef="usd">8418845</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c216" decimals="0" unitRef="usd">6905487</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <srt:ScheduleOfCondensedCashFlowStatementTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify; padding-left: 10pt"&gt;Net income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,319,952&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,558,222&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,551,465&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 10pt"&gt;Adjustments to reconcile net cash flows from operating activities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 8.3pt; padding-left: 20pt"&gt;Equity in earnings of subsidiary&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12,319,027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,558,222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,551,465&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 30pt"&gt;Net cash used in operating activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(999,075&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;CASH FLOWS FROM INVESTING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 28.3pt"&gt;Payment for short-term investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(15,330,660&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 28.3pt"&gt;Redemption of short-term investments &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,801,927&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Net cash used in investing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,528,733&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;CASH FLOWS FROM FINANCING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 28.3pt"&gt;Net proceeds from issuance of ordinary shares in IPO&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,957,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: 21.3pt"&gt;&#160;&#160;Cash lent to subsidiaries&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,358,764&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Net cash provided by financing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,598,693&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;CHANGES IN CASH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;CASH, beginning of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;CASH, end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;110,393&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedCashFlowStatementTableTextBlock>
    <us-gaap:ProfitLoss contextRef="c214" decimals="0" unitRef="usd">11319952</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c215" decimals="0" unitRef="usd">7558222</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c216" decimals="0" unitRef="usd">7551465</us-gaap:ProfitLoss>
    <upc:EquityInEarningsOfSubsidiary contextRef="c214" decimals="0" unitRef="usd">-12319027</upc:EquityInEarningsOfSubsidiary>
    <upc:EquityInEarningsOfSubsidiary contextRef="c215" decimals="0" unitRef="usd">-7558222</upc:EquityInEarningsOfSubsidiary>
    <upc:EquityInEarningsOfSubsidiary contextRef="c216" decimals="0" unitRef="usd">-7551465</upc:EquityInEarningsOfSubsidiary>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c214" decimals="0" unitRef="usd">-999075</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments contextRef="c214" decimals="0" unitRef="usd">-15330660</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c214" decimals="0" unitRef="usd">1801927</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c214" decimals="0" unitRef="usd">-13528733</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c214" decimals="0" unitRef="usd">25957457</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <upc:CashLentToSubsidiaries contextRef="c214" decimals="0" unitRef="usd">-11358764</upc:CashLentToSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c214" decimals="0" unitRef="usd">14598693</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c214" decimals="0" unitRef="usd">39508</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c214" decimals="0" unitRef="usd">110393</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <upc:CashAndCashEquivalentAtCarryingValue contextRef="c212" decimals="0" unitRef="usd">110393</upc:CashAndCashEquivalentAtCarryingValue>
    <dei:DocumentAccountingStandard contextRef="c0" id="hidden-fact-0">U.S. GAAP</dei:DocumentAccountingStandard>
    <us-gaap:ShortTermInvestments
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DueFromRelatedParties
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:AdvanceToSuppliersNet
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:PrepaymentForAdvertising
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredCostsCurrent
      contextRef="c2"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent
      contextRef="c3"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:PrepaymentsForConstructionInProgress
      contextRef="c3"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:ShorttermInvestmentIncome
      contextRef="c4"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:ShorttermInvestmentIncome
      contextRef="c5"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c12"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c13"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c14"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c16"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c12"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c13"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c14"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c16"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c12"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c13"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c15"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c23"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c24"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c25"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c27"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c23"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c24"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c25"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c26"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c35"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c36"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c37"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts
      contextRef="c35"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts
      contextRef="c36"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts
      contextRef="c37"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c33"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c34"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c35"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c37"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c33"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c34"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c35"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c36"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c4"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryLIFOReservePeriodCharge
      contextRef="c0"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeShortTermInvestmentOther
      contextRef="c4"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeShortTermInvestmentOther
      contextRef="c5"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies
      contextRef="c4"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies
      contextRef="c5"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidAdvertising
      contextRef="c4"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidAdvertising
      contextRef="c5"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="c4"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="c5"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="c0"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="c4"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty
      contextRef="c4"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:PrepaymentsMadeToARelatedPartyForPurchaseOfProperty
      contextRef="c5"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfAdvancesForConstruction
      contextRef="c4"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfAdvancesForConstruction
      contextRef="c5"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="c4"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="c5"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:RedemptionOfShorttermInvestments
      contextRef="c4"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:RedemptionOfShorttermInvestments
      contextRef="c5"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDividends
      contextRef="c0"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDividends
      contextRef="c4"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c4"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c5"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="c5"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:DeferredInitialPublicOfferingCosts
      contextRef="c0"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredOfferingCosts
      contextRef="c22"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:SunsequentCollectionAllowanceForDoubtfulAccounts
      contextRef="c2"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:AllowanceForDoubtfulAccountsReceivablePercentage
      contextRef="c0"
      id="hidden-fact-74"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="c0"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="c4"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="c3"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="c2"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="c3"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToSuppliersAndEmployees
      contextRef="c4"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c3"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c22"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:AddPurchaseWealthManagementFinancialProducts
      contextRef="c4"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="c4"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedInvestmentIncomeReceivable
      contextRef="c4"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="c4"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c3"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherShortTermInvestments
      contextRef="c3"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherShortTermInvestments
      contextRef="c22"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c4"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c119"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c121"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c124"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c126"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c128"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DueFromOtherRelatedPartiesCurrent
      contextRef="c134"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DueFromOtherRelatedPartiesCurrent
      contextRef="c136"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DueFromOtherRelatedPartiesCurrent
      contextRef="c3"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="c137"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c141"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c142"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c143"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c140"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c144"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c145"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c141"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c142"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c143"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c140"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c144"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c145"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="c0"
      id="hidden-fact-112"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="c4"
      id="hidden-fact-113"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c5"
      id="hidden-fact-114"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="c4"
      id="hidden-fact-115"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="c5"
      id="hidden-fact-116"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c4"
      id="hidden-fact-117"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c5"
      id="hidden-fact-118"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="c3"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c2"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c3"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Cash
      contextRef="c213"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c213"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsCurrent
      contextRef="c213"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="c212"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="c213"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c215"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c216"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseOtherShortTermBorrowings
      contextRef="c215"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseOtherShortTermBorrowings
      contextRef="c216"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="c215"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="c216"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="c215"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c215"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c216"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="c215"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="c216"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="c215"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="c216"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c215"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c216"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c215"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c216"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:CashLentToSubsidiaries
      contextRef="c215"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:CashLentToSubsidiaries
      contextRef="c216"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c215"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c216"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="c215"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="c216"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c215"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c216"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:CashAndCashEquivalentAtCarryingValue
      contextRef="c213"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:CashAndCashEquivalentAtCarryingValue
      contextRef="c217"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:CashAndCashEquivalentAtCarryingValue
      contextRef="c218"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:CashAndCashEquivalentAtCarryingValue
      contextRef="c213"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <upc:CashAndCashEquivalentAtCarryingValue
      contextRef="c217"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:CityAreaCode contextRef="c1">+86</dei:CityAreaCode>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityAddressPostalZipCode contextRef="c0">000000</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode contextRef="c1">000000</dei:EntityAddressPostalZipCode>
    <dei:EntityCentralIndexKey contextRef="c0">0001809616</dei:EntityCentralIndexKey>
    <dei:LocalPhoneNumber contextRef="c1">0796-8403309</dei:LocalPhoneNumber>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-92"
          xlink:label="hidden-fact-92"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On June 19, 2020, the Company&#x2019;s subsidiary Jiangxi Universe signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&#x201c;LRC Bank&#x201d;) to borrow RMB 10 million (equivalent to $1,470,000) as working capital for one year, with the maturity date on June 18, 2021. The fixed interest rate of the loan was 4.81% per annum. There was no guarantee requirement for this loan. The loan was fully repaid upon maturity.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-92"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-94"
          xlink:label="hidden-fact-94"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On June 30, 2021, the Company&#x2019;s subsidiary Jiangxi Universe signed a loan agreement with Bank of Communications to borrow RMB 10 million (equivalent to $1,548,000) as working capital for one year, with the maturity date on June 18, 2022. The fixed interest rate of the loan was 4.5% per annum. Certain related parties of the Company, including Mr. Gang Lai, the Company&#x2019;s controlling shareholder, Mr. Gang Lai&#x2019;s spouse, Mrs. Xing Wu, and the Company&#x2019;s subsidiary, Universe Trade, jointly signed guarantee agreements with Bank of Communications to provide credit guarantee for this loan.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-94"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>132
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MJ53& 'Z_+TO]]<*\3]J]/SS]%U!+ P04    "  :0#]4TI=T>VX"  "U!@
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M:47?%=0N@?;72MFGP+6NX4N5_P502P,$%     @ &D _5/^0*V<7!@  SA<
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MJ(^6.S?U2?>'1&_3PJ!,;L!E<!W#:^GZ\+B^L&I?':<^*FM57GW=R60M=2F
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MY1+JC8!I45OBF5CBF7HMI[[WD..VYN#,DL+Y!0IK4?3W4?0[H_B[VK30,D,
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M$ZFDW')I&ZCY/-<_M?T^=,JPNU6^8+-H]F^[X4/0F&7[1Z^P]#O0WS!?TD*
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MH_Y>U'UD)FE=%G64J=RP39_!F5%=RZ;&+!/&6(CG:0->63M6!>^Z+J-8WB[
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MAYC@!\S&C^_QQILB?/">&P]WP^5*H,,M+<#[A4&=5#>DH/D%Y/Q_4$L#!!0
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MTCE"3/C5!3^( !'6L G4[@V1 D+TN QAB1M+UAA)-&*2"Y)7_5CF3"18SSB
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MH77T&1K)73.%5B3T#&K?UXTV^:R0JCJP49^%54"$/C 6%+2\JP"2"MN;JM*
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MW84O18D*8#1,$#N9 [R,P?T KMX^/"PC=L+A[&XMDSR^<MUATU-.PX+PC/A
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M ;J?&QK1]0L[:-;6H_\ 4$L#!!0    ( !I /U0O98$/; ,  ),'   9
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M,92>C](!Z%Z#>\.JUNO>2ED\*7ZYP=^6T,X!OY=*V8/A"(X_PNF_4$L#!!0
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M!6'PM4"*&(NM[JZ%MJ(H'=)U_AM22+B2ER.3M+-">RRE$8FLM).96*("V#Y
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M)N?8 4TU09TC0D&MZ@4KP>M'43B.9N'%%&EZ%-%H-F%,1\,H#H?CZ5\S91C
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M G-N+2&1)_Z8*RCRJ,DMJY)40S2IH+65VYSV!\>FT(I\&(K<9EJ5ZZR*B,!
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M-W15T=5EIGJA?=%?();*4HOXQXSN?ZC= II?*66;%P?0WBC/_@-02P,$%
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MW$PAMA6[*,B'I[7)!<JE4Q4EX(%3*M#.Z-E ?*RTUW#(53TK="8NYW.LQVZ
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MR7(Q$:9_$/43IUO_"%EKA];BAR7>D&3X /8W&I\-PX0O&%^EE_\%4$L#!!0
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MY34=R&VVE!K^G[..<1>#&+3.T'0VTYAQ$!>>00W]ZP4_3IJACZ KD2>4)>1
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M9EAA>?E!M+S1V<I\A)QE6F=+<[G V"QR$L![FF<W-V1@^U7ZYK]02P,$%
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M30"K!5F&  OHM@([8;O.@"4O=4= 1@Z1PTH,;G(-2CP<#FY4MP7.ECIQ 2L
M?1Q.8MD!Y5=M23@.9X?:(L#V+SI,U63;(B_E4$F66ZV(^(L)>+F;1D"2(5"
MA25Z VLDU;$B?8CX<,=K)49).W9GC&!:P8;" 16=$ !H2]*W3NJNL2NGR02$
MP\!(8'TYR21!DTWV!S#-WL.LI!6,N5=K(-=A(A@EZ<,43?O*2D/BK0)ZQ?-
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M-KI7VC+>6.D[];1XULLS\- "[:6 GY>9=0;E7=Q&QT.*'H5G*81)7D366&(
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M;?Q I[>'3>)6M%_O'7/K@7.=R,&:X9/EC!4U8%*'"@"5R?DI,WNWDQC=I)K
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M?<)>$_L!CAF'3!9UV]8;^A/;#N@&'X#?5W7=V@\X 3I[:7D__2]02P,$%
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M/LEB#S)O&IRT$ZN=#=I1C(1(P,\RDD8!1/'4/VGZGE7%ENYUXYCX-(2(^%D
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M=;.[$XS<M?,REP:G;[O<XN<.5U8!S]=2FI-@'0P?4(NO4$L#!!0    ( !I
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M<0=.*N6#$\OCO"R L3B;EY-'[;@DZ"PNWV7 YF5<O*,,:.T-7<6J:SO)'=;
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M/5#]1/:&D:V;@K4T-%-NN:%'#)4-('\II=D9EF!\%K/?4$L#!!0    ( !I
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M<_JHH+(.]'XAJ<[7AEU@\YD:_P502P,$%     @ &D _5!FES6NF P  (PD
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MF[0=O:>V.Z9P+7#'<1NU7>H,3[3M**DXE8!.F<)49C$J#7)-=3!J#S_LS$A
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M,*57#"JK0.N)E&8WL0[J=]'L/U!+ P04    "  :0#]4+6_%.)L$  !["P
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MR.D6G6(,1&<GL!EANP:C %;GCD%S-@6'\@($0%)G#*)_8O\^T)XX7P4_-RB
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MCQ)HGK(=]=J#%K4=KQ9"P[!FMVN8CIDT!'"_%$+O#D9!/V_/_P902P,$%
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M!UIOP-\7QM!NXPGZ/]+L#U!+ P04    "  :0#]4TGU" %D"  #U!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6R55,MNVS 0_!5"Z"$!$NMMQ8$L
M('%0M$!;!#'2'HH>:&EE$Z%$E:3LY.^[I!15295'+Q8?.[.S8^ZF!R'OU Y
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M<(5/ "AK@/L+*<UV8KM,]ZCD_P!02P,$%     @ &D _5-B0L;/] 0  700
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M>V,KJ&T%!XF^,ZD<X8PM6[LR"M[MGG!W]]R7,:[3".KU.[WV_1/6PL*#PIY
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M22K@!11TBSD0*5')(67Q/[5\].-X="#L9&9CQS>R(1F.'=U.B6*-3@I#'])
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M&TN@RCRG\O&:96)UV4.]IP??^'RAJP?><+"D<S9A^FXYEN;.:[*D/&>%XJ(
MDLTN>U?HXH9$%:".^)NSE=JZ!E4I4R%^5#=?TLL>K!BQC"6Z2D'-USV[85E6
M93(\?FZ2]IHQ*^#V]5/VW^OB33%3JMB-R/[AJ5Y<]N(>2-F,EIG^)E9_L$U!
M094O$9FJ/\%J$PM[("F5%OD&;!CDO%A_TX>-$%L %!X X T [P+\ P"R 9"Z
MT#6SNJQ;JNEP(,4*R"K:9*LN:FUJM*F&%U4;)UJ:7[G!Z>%8FADA]>,9&&>T
MT( 6*?C\L^1+TRI]!OXT$^G#+=.49^HC^ 0F9AJE9<: F $+73909J&%@2;"
M]%MI99!WDUOPX;>/ T\;UM787K)A>+UFB \P1!B,1*$7"GPN4I;^FL SY38U
MXZ>:K[$SXX0MSP&!9P!#C%H(W3P?#AUT2-,"4N<CKVD!^/[5A(,OFN7J7\=@
M?C.87P_F=PRVVZVY%$JU-6>=+JS359YP/T30#U$(3>GWVZ+M!_8#3" *F[A?
M" <-X<!)^"M3ZL*L]J3,RXQJEII%:@PKX;2R@3;&ZWS!%I%/011#[$<[C-L"
M8=\WM-LIAPWE\%4:FQ71QC?<$\X/8T0"LD,WW*/K^SB&H=_.-FK81DZVUR7/
M4E[,%?@^8OF42=<TBYND\?O/Z7XS6-]9P9UBLS(#&9^Q-GW=8 S!(Z-2.7@@
M:,T4ONWJVN3;;KZ9JK'9@W>:OPG<[G[D(S^(87OWT=8&@)R<1S19F$=RA_1S
M9@/"=A#\_O,!64=%Y(W[0/;DQ="/"(EW^[ ?B +B0Q0<Z(,U9N1VYJO2[/5B
MRC/VK)6(K(&BX 3:6_-#KW._P]KO&QM"(8EV-YBV.!\2_\ &@ZP!(K<#_C6;
M\82M^5:OEY(G+UP'UA;1"7P166-$;G-[>2_Z^YM1W(_C/3MJB3.K(#JP"K!U
M4.QVT!$O>%[FC>K@/W"$06'K@AB]?V.P]4.,C]FR.M!!YY:%K55BMU6V"/Y"
M)\+6XK!_ I&M\6'WJV.7R&XTZ1;9>B)V>V*+R$>;#K;^AJ,3R&X]#L='R>Y&
M/T-V:W_8;7\C^O"&9D*LB1'X_H(3ZUW$_0;7(7@'&G6_ !/K:\3M3"V*O]!-
MR-;?YA/\;R;6O(C[_:Q+93>ZV[*)]37B=J86D8]V$V*]C(0GD-V:%W&_G'7)
M[D8[9/>V#LUR)N?U6:("B2@+O3X_:YXVYY57]2F=9\/7AYTC*N>\4"!C,P.%
MYY'IGUR?'ZYOM%C61W!3H<UBJ"\7C*9,5@'F]YD0^NFF&J YQ1W^#U!+ P04
M    "  :0#]4KG>^3%$"  "I!0  &0   'AL+W=O<FMS:&5E=',O<VAE970V
M,2YX;6R-5,ENVS 0_15"Z"$!TE"+G;:!+,"VNN20(HB1]E#T0$MCBPA%JN0X
M<OOU)2E9=5+;R$7BD//>+.2\M%7ZT50 2+:UD&825(C--:6FJ*!FYE(U(.W)
M2NF:H37UFII& RL]J!8T#L,K6C,N@RSU>W<Z2]4&!9=PIXG9U#73OV<@5#L)
MHF"W<<_7%;H-FJ4-6\,"\*&YT]:B TO):Y"&*TDTK";!-+K.1\[?.WSCT)J]
M-7&5+)5Z=,9-.0E"EQ (*- Q,/M[@CD(X8AL&K]ZSF (Z8#[ZQW[)U^[K67)
M#,R5^,Y+K";!^X"4L&(;@?>J_0)]/6/'5RAA_)>TG>\X"4BQ,:CJ'FPSJ+GL
M_FS;]V$/$%T= <0]('X)&!T!)#T@>2U@U -\JVE7BN]#SI!EJ58MT<[;LKF%
M;Z9'V_*Y=->^0&U/N<5A=B.1R35?"B!38P#-!?EJ']M9#LBX,.?D+7E8Y.3L
MS7E*T<9S*%KTW+...S["'<7D5DFL#/DH2RB?$U";Z)!MO,MV%I]D7$!S29+P
M@L1A'!U(:/YZ>'@ GK\:'GTX44TR]#[Q?,D1OL]*E2T7@C!9DO\N@N3<%$*9
MC0;R8[HTJ.V,_#P1=C2$'?FPHR-AI[72R/\P/W>PM0)BX-#E=BQ7GL6IQU,V
M'L=)2I_V&W[ *4JBYT[Y :<XB0>GK@JZ]XAKT&LO!H84:B.Q>R'#[J W4S]F
M+_9G5H<ZV?A'TXG8+=-K+@T1L+*4X>6[<4!T)PR=@:KQH[)4: ?/+RNKI:"=
M@SU?*84[PP48U#G["U!+ P04    "  :0#]4!AU=<BD#  !!"@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970V,BYX;6R]5EU/VS 4_2M6M <F#1([:1)06PG*
MIE6"":UC>YCVX#8WK37'[FR'LOWZV4E(2TD#8M)>6MLYY]YS/_PQW$CU4Z\
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M/4#[A5+X-+&-K_]L9;\ 4$L#!!0    ( !I /U2(,A\X2@,  #4,   9
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;,U7:V_:,!3]*U963:W4DC@02CM
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MB;'L1".[$72=?N\]42&_']/+%48+S)2!?/Y,J=C?J Z*<Z7./U!+ P04
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M8).&5%'8'M >W.:FL;#CS'9:^/M=.R$JC$8@H8F7Q';N.?><>Q,[R5:J.UT
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MT.K3WZZJJZ8*C"S=:3V3ALY^-US1[8S*)M#Z0DKS%-@+H+GOTS]02P,$%
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M+R91>/S> K=HH&Y.;DFU8H>L7$AA))4,O;F^N3B"M2!2>6[T RZ GTL/A%H
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M;"T"#IFQ%!3_[F$)G%LFM./OEC3H]K3 P_83^WOG/#JSH1J6DO_.<E/,@VE
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M!7Z\@+(+<'XKI7GJV VZSZ'%/U!+ P04    "  :0#]4KW5G(Y "  !G!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6RE55UOFS 4_2L6VD,KK8'P
MF48)4IMHVAXV54W;/3MP25 -9K9)TG^_:T-0VA!6:2]@FWN.S[GF7L_V7+S*
M+8 BAX*5<FYME:JFMBV3+114CG@%)7[)N"BHPJG8V+(20%,#*ICM.DYH%S0O
MK7AFUAY$/..U8GD)#X+(NBBH>+L'QO=S:VP=%Q[SS5;I!3N>570#*U#/U8/
MF=VQI'D!I<QY201D<^MN/%U$.MX$O.2PER=CHIVL.7_5DQ_IW'*T(&"0*,U
M\;6#!3"FB5#&GY;3ZK;4P-/QD?V;\8Y>UE3"@K/?>:JV<VMBD10R6C/UR/??
MH?43:+Z$,VF>9-_$AHY%DEHJ7K1@5%#D9?.FAS8/)X"Q?P'@M@#WLP"O!7C&
M:*/,V%I21>.9X'LB=#2RZ8')C4&CF[S4I[A2 K_FB%/Q$SV )%=+4#1G\IK<
MD!7^*&G-@/!,YP.$@)0H>B!42E 2(YY72W+UY7IF*Q2@:>RDW>R^V<R]L-D*
MJA'QG*_$==QQ#WSQ>;CS'FZC[<Z[VWEW#9]W@6]Y[FXZ0.MUM)ZA]2_0_L+:
MPRH35.7EAC N)4FH$&\W6'-[*E+9E[B&,C24NO)V<30)@@!M[DX3=!XVGH2!
M%W5A[Q3[G6)_4/$=PV*F90($)9*4UVN5U0Q++.%UJ7KU-H3!B9")[_O1![F#
MV^H&-94536!N80>2('9@Q63@!(+.3S#HYXDKROI4!^>JP]O;VX^RS\.&LAQV
MJL)!52^4U;3I7<=\]VD<)/E4SAH3_\_SSF74N8S^G?N^QM'G-3K[G7O/XSRL
M]SSLDS:HKZ"?5&SR4A(&&0*=480G*IJVWDP4KTQG7'.%?=8,MW@3@M !^#WC
M7!TGNMEV=VO\%U!+ P04    "  :0#]42VXUH5\"  !>!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970W-RYX;6R-5=MNFS 8?A4+[:*5UG PF*1*D-I$TWHQ
M-6K:[F+:A1/^!%2#F>TTZ=O/-@3E0-+>@ __=[*Q&6ZX>),9@$+;@I5RY&1*
M5;>N*Q<9%%3V> 6EGEER45"ENV+ERDH 32VH8&[@><0M:%XZR=".344RY&O%
M\A*F LEU45#Q<0^,;T:.[^P&GO)5ILR FPPKNH(9J)=J*G3/;5G2O(!2YKQ$
M I8CY\Z_'1-3;PM><]C(O38R2>:<OYG.0SIR/&,(&"R48:#Z]0YC8,P0:1O_
M&DZGE33 _?:._8?-KK/,J80Q9[_S5&4CI^^@%)9TS=03W_R$)D]D^!:<2?M$
MF[HV"AVT6$O%BP:L'11Y6;_IMEF'/8!_#A T@."K -P L U:.[.Q)E319"CX
M!@E3K=E,PZZ-1>LT>6EV<::$GLTU3B7/= L274U T9S):W2#9OI#2=<,$%\B
M96<K^D'G>N &O<PFZ.K;]=!56MH0N(M&YKZ6"<[(S*#J(>Q]1X$7^!WP\=?A
MWB'<U8';U$&;.K!\^!S?V8Q_[N92"?UQ_;T@@UL9;&7",S(/Y8(78!1V_%TK
M5W,0RV$.W7M"R"#NZYSO^RMT6A:3.!C$;=F!Q;"U&%ZT^$K9&A!-4T@_\UD3
M17L&<$!"TC_R>5H68MS'_6Z?4>LSNNCS464@#O>JRV-T(NY[4> '1QX[RK!'
M_+#;(VD]DHL>G[FB['./Y&0C?=_S0W*\X1UU&/MQ.#ARZ>Z=?G/S_J)BE9<2
M,5AJI->+=4Y1WV9U1_'*7@ASKO3U8IN9_@& , 5Z?LFYVG7,'=/^4I+_4$L#
M!!0    ( !I /U2QM7/HSP,  +$2   9    >&PO=V]R:W-H965T<R]S:&5E
M=#<X+GAM;+586X_B-AC]*U;42KM2F\3.!1@!T@SI9:6..AIV6U6K/IA@P-HD
M3FT'ME)_?)T+,<P0)[."ER%V?([]G9,Y<3P],/Y%[ B1X&N:9&)F[:3,[QQ'
MQ#N28F&SG&3JSH;Q%$O5Y%M'Y)S@=05*$P>Y;NBDF&;6?%KU/?'YE!4RH1EY
MXD 4:8KYOP\D88>9!:UCQS/=[F39X<RG.=Z2)9&?\B>N6D[+LJ8IR01E&>!D
M,[/NX5V$QB6@&O$')0=Q<@W*4E:,?2D;']8SRRU71!(2RY("JY\]69 D*9G4
M.OYI2*UVSA)X>GUD_[DJ7A6SPH(L6/(G7<O=S!I;8$TVN$CD,SO\2IJ"@I(O
M9HFH_H)#/3;P+! 70K*T :L5I#2K?_'71H@3  P[ *@!H)< OP/@-0!O*,!O
M 'ZE3%U*I4.$)9Y/.3L 7HY6;.5%)6:%5N73K/1]*;FZ2Q5.SA<LBTDF.2Y=
M$.!=1"2FB7@/?@2?EA%X]]W[J2/5/.5H)VXX'VI.U,$)$7ADF=P)\%.V)NMS
M D<ML%TE.J[R 1D9ER2W@>?^ )"+X(4%+8;#W0OP:# <3@S5>*WF7L7GO57S
MS[^ID>"#)*GXVS"/W\[C5_/X'?-$)&>"2H EV- ,9S'%":"9D%06S=0T Q%+
M$LS%19]K_K#B+Q-D/P_&$Q0&P=39G\K_>AQT730*P[ =>%9!T%80&"M8%GF>
M4,+![TJ7SX\D71%N4B9L><.;.C!JYQD9U_^1224Y)WN2%03DA)>SJCB]I+69
MR0MLS_W^TJ-OQL&)'5[$13TXWX8O<6<2C%L)QL,L_'A@0RR<M+R3FUH(79V0
M[M5,[*%"8]N][&(/$'JO;3POYR3PH9%*' T98 9$FA7=U@X=GM"[GAUF*NAV
MVO%VX'DY.J.A.:3K<IZ;<H9XHL,3!K?U1,<I#*_GB9G*<VV_PY,>H->1D%$?
MT+<#LYDZ[J$Y-7\I5B0#?^'RQA8\T209Y*C.4CB^K:,Z7>'D>HZ:J7RWZ]75
M _3&-NIPM >(7C]#Y_M.'?[('+R+:@L^+"V1SF $;^HCTKF,T-5\[*'J3LMO
M!4;? #S70;\UD#FQ[^.8%9D4*FEC0O=XE0P*6Z1S'/FWM53'.C)OBM]DJ9FJ
M7V#]"D#F%#4)#/X#[?_1P)T\TIF+1K<57J<O,F]EWR#\HH=*[><ZA'=.ON65
M7MOJ3$2 2MSZ@[GM;<]=[JO3AA?]#_ NJD]/-$U]F/.(^59]!H*$;!2E:X_4
M0\+K\Y&Z(5E>G1BLF%2F59<[@M>$EP/4_0UC\M@H)VA/J>;_ U!+ P04
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MOS6R.>QI;I3(Z^./M5!*I/7ECH4QDY6!?KX10KW=5!-T1VZS[U!+ P04
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M;EJ8G$_ -QS="ZN_*"A#C36O)$7/B//MN_M/HXOSX;C@AHL%#@/5L=A'XBF
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MCK8>:%':'F\I-':,]G&+7P$@C0&^7PNA#P,3H/VNF/X/4$L#!!0    ( !I
M/U06EAI- 04   H5   9    >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;*U8
M;8^B.A3^*PVY'W:3G8&"J$S4Q/%EQF1'C<[.WN3F?D"HREV@;%MU_??W%!!%
MD='HEQDH/4][GO/2QS8VE/WB2T($^A/X(6\J2R&B)U7ESI($-G^D$0GARYRR
MP!;PRA8JCQBQW=@H\%5=TZIJ8'NATFK$8V/6:M"5\+V0C!GBJR"PV?:9^'33
M5+"R&YAXBZ60 VJK$=D+,B7B1S1F\*9F**X7D)![-$2,S)M*&S]UL24-XAD?
M'MGP@V<D79E1^DN^#-RFHLD=$9\X0D+8\&]-.L3W)1+LXW<*JF1K2L/#YQUZ
M/W8>G)G9G'2H_]-SQ;*IU!7DDKF]\L6$;EY)ZI I\1SJ\_@OVJ1S-04Y*RYH
MD!K##@(O3/[;?U(B#@QP]8R!GAKHQP:5,P9&:F!<:E!)#2HQ,XDK,0]=6]BM
M!J,;Q.1L0),/,9FQ-;COA3+N4\'@JP=VHM6AH0M1)"[J>Z$=.I[MHT&8Y).,
M"YTCL21H;#,2"M2A062'6_2E2X3M^?PK>D!32$5WY1,Y-4JF.>DT+FQ!($D$
MEQ\=FR_1'!*-@U4*^,\;"6:$_0LC/Z9=].6OKPU5@%MR<ZJ3NO"<N*"?<0'K
MZ(V&8LE1#WQQ\P J\)&1HN](>=9+$:<D>D2&]@WIFHX+-M2YW%PK,.]>;(ZM
M$F^,+,1&C&><"W%[^HKZWT<_IZ@_&;VAT;@W:;\/AB^HW7D?? S>![WI4\DZ
ME6R=2KQ.Y<PZ0^A27@BQ)T4Q3&RKL:UL1NL6Q@:V+%-OJ.M#;D\GUDRSKNM'
M\[J%\W"E:F;S<EZ8F1=FJ1=M]S^HNB1I!876YE"H"DCO$-P[2.$YHP&"]LN@
M3L)%TK\\X1'^5)0PI6O*WO[$(]LA306:-R=L3906*@E)-7.F6NI,[_?*$UN(
M"B(V"V&?<2'RU8Q[K@=MOBA0":)YP.L#UB%2FEX[BE3!S.)0%4\\'ZM:YE[M
MTXR+0[*2#0R\+(I'D8^UTPU9EJ75S",/2Y>_*&P) ;?CY/BI9_S4KZK\P?"C
M-[VB\JUL':LT#F-[*PL&P;&!^)(R\2 ("R @:Y*64E$0K()$,PU#JU:UHS"4
MKGY%&&['R=&#M?TAJY42-"$N":+=@7HY12GL(4>X#J?"22F6KW\%17< RG-T
M($3P=<6<</-Y,:>X^40R3+U>,XQCFDJW< U-MP/E:=+W-.E7U71_,&P/.Y?7
M--[+!FQ\&I"(48<0-SWN/,Y7H!%CJ4>9"X*1@<A;@I3C,F"#\:@P/L9)?'33
M,FL5\R2+2S=T37AN!\J3MM= N%P$=60&^[(9@GC(#MISF5LIR%Q(W7JM6CFF
MIG39:ZBY'2A/S5Y8X7)EE14X)-7: Z6.9ELT3WYU?%[DYFDGK)A6O6J=U/CM
M6BMEZLZB#>]5&_Y$MO7[O<X[&O51Y[4]?.E-Y6-_-.D-7H:H]W<RB$#$RR]#
M)%M"(6>GNLNP3*U^3%CI9JXA[':@/&%['8C+A>".ID$)&:>:#V/-.$V?>VF^
M.P#EV=BK/EPO9P,H^(9F9.&%4O/+;KT%_5_(2BG2Y=YV[@74O0-0GK:]B,7E
M*C:AC81N*6%6P>_8HC2ZEV:] U#"AWIP2100MH@OVSARZ"H4R=5(-II=Z+7C
M:ZRC\6=YT1=?/NUADEO"-YM!SG$X_^8 J3W6H-I8<O&6O @:Q5=1,RH$#>+'
M);%=PN0$^#ZG5.Q>Y +9]6?K?U!+ P04    "  :0#]4YM:?6E,#  !L%0
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M;W!S+V%P<"YX;6Q02P$"% ,4    "  :0#]41=+X=.T    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  :0#]4
MF5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( !I /U346/U-?@8  #@>   8              "
M@0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  :0#]4
M;G@G3A8'  !+'   &               @(' #@  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ &D _5-*7='MN @  M08  !@
M     ("!#!8  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M !I /U3_D"MG%P8  ,X7   8              " @; 8  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    "  :0#]4,\3))HH%  #H'0  &
M            @(']'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ &D _5/ \;TX9"0  <RH  !@              ("!O20  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( !I /U3%LCPARPD   T9
M   8              " @0PN  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    "  :0#]4=Q[+;YHK  #IA@  &               @($-.
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ &D _5%/=GFW*
M!   VPH  !@              ("!W6,  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( !I /U2M*K)]0@,  , &   9              "
M@=UH  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ &D _
M5%W;8L^( P  R@<  !D              ("!5FP  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    "  :0#]4B9MUL=4$  #""@  &0
M        @($5<   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( !I /U0O98$/; ,  ),'   9              " @2%U  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ &D _5+I)]N1S P  % <
M !D              ("!Q'@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    "  :0#]452V0L5 #   #!P  &0              @(%N?
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( !I /U0K@SSX
M7P4  $(,   9              " @?5_  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ &D _5 O2]],3!   G@@  !D
M ("!BX4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  :
M0#]4)#--I5\%  !P$0  &0              @('5B0  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( !I /U1@)]-!<08  + /   9
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M970R,RYX;6Q02P$"% ,4    "  :0#]42;6L=VH&  "A#@  &0
M    @(%0M@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M !I /U3I5B^LR00  !D*   9              " @?&\  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ &D _5 <-2+I?"0  H18  !D
M             ("!\<$  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    "  :0#]4W(X7WS\O  !*H0  &0              @(&'RP  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( !I /U0.9HO6* ,
M ,<&   9              " @?WZ  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ &D _5$%XD?$1 P  C0<  !D              ("!
M7/X  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  :0#]4
MI[_/:M8#  !,"0  &0              @(&D 0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( !I /U2':BW?>P(  "X%   9
M      " @;$% 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ &D _5*>73UQ8 @  +P4  !D              ("!8P@! 'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  :0#]4;2N)R*T"  "F!0
M&0              @('R"@$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( !I /U2NV#'3\0(  !X&   9              " @=8- 0!X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ &D _5+IS\(<(
M P  UP8  !D              ("!_A ! 'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    "  :0#]4M91#D7<"   B!0  &0
M@($]% $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( !I
M/U0"]!R\Y@(  +(&   9              " @>L6 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ &D _5!FES6NF P  (PD  !D
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M=#0R+GAM;%!+ 0(4 Q0    ( !I /U0LV=BPJ 0  ,T7   9
M  " @<\S 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M&D _5(J;@O#R!   :Q4  !D              ("!KC@! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    "  :0#]43OQ&HQD#  #<#P  &0
M            @('7/0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( !I /U0(4!;X60(  .D&   9              " @2=! 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ &D _5*XXV)2# @
M-@<  !D              ("!MT,! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    "  :0#]4Y\Z%P/\"  "=!@  &0              @(%Q
M1@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( !I /U32
M?4( 60(  /4%   9              " @:=) 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ &D _5(P$#MY0!   ?Q4  !D
M     ("!-TP! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !I /U26;1OXEP(  $$'   9              "
M@5=; 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ &D _
M5(5+NBJ[ @  80@  !D              ("!)5X! 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    "  :0#]4)@CRI2D"  !5!0  &0
M        @($780$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( !I /U2Z-BG;&@,  )H)   9              " @7=C 0!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ &D _5$9K%KZ3 @  J 8
M !D              ("!R&8! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    "  :0#]4*/EJ@5D$  #1%0  &0              @(&2:0$
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( !I /U2N=[Y,
M40(  *D%   9              " @2)N 0!X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ &D _5 8=77(I P  00H  !D
M ("!JG ! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    "  :
M0#]4>.#!YF4"  #"!@  &0              @($*= $ >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( !I /U2(,A\X2@,  #4,   9
M          " @:9V 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#
M%     @ &D _5(Y#75I; @  TP4  !D              ("!)WH! 'AL+W=O
M<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    "  :0#]4 /.D,BL#  #_
M"@  &0              @(&Y? $ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM
M;%!+ 0(4 Q0    ( !I /U2+$7Y^\P,  &,2   9              " @1N
M 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ &D _5.I,
M?,P#!0  F10  !D              ("!180! 'AL+W=O<FMS:&5E=',O<VAE
M970V."YX;6Q02P$"% ,4    "  :0#]4$N-;.N\"  "\!@  &0
M    @(%_B0$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (
M !I /U0;SH.E10,  #$*   9              " @:6, 0!X;"]W;W)K<VAE
M971S+W-H965T-S N>&UL4$L! A0#%     @ &D _5*Z,QT>! @  =0@  !D
M             ("!(9 ! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"
M% ,4    "  :0#]4R5J+*' "  #[!P  &0              @('9D@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( !I /U3GDEWM[P0
M +D-   9              " @8"5 0!X;"]W;W)K<VAE971S+W-H965T-S,N
M>&UL4$L! A0#%     @ &D _5!>Z9EV) P  L \  !D              ("!
MIIH! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    "  :0#]4
MYO9M<G@#   :#0  &0              @(%FG@$ >&PO=V]R:W-H965T<R]S
M:&5E=#<U+GAM;%!+ 0(4 Q0    ( !I /U2O=6<CD (  &<'   9
M      " @16B 0!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%
M  @ &D _5$MN-:%? @  7@8  !D              ("!W*0! 'AL+W=O<FMS
M:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    "  :0#]4L;5SZ,\#  "Q$@
M&0              @(%RIP$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+
M 0(4 Q0    ( !I /U3K;W6W90@  ,\L   9              " @7BK 0!X
M;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ &D _5*24;F\_
M @  & 4  !D              ("!%+0! 'AL+W=O<FMS:&5E=',O<VAE970X
M,"YX;6Q02P$"% ,4    "  :0#]48,/Q;^X!   Z!   &0
M@(&*M@$ >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( !I
M/U1'S"0#T0(  )@'   9              " @:^X 0!X;"]W;W)K<VAE971S
M+W-H965T.#(N>&UL4$L! A0#%     @ &D _5&>3\6ZB!   ?A,  !D
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M=#@W+GAM;%!+ 0(4 Q0    ( !I /U1 _R-0V0,  &,,   9
M  " @5S- 0!X;"]W;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @
M&D _5!:6&DT!!0  "A4  !D              ("!;-$! 'AL+W=O<FMS:&5E
M=',O<VAE970X.2YX;6Q02P$"% ,4    "  :0#]4YM:?6E,#  !L%0  #0
M            @ &DU@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !I /U27
MBKL<P    !,"   +              "  2+: 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( !I /U1[E )U& 8  )<Z   /              "  0O; 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    "  :0#]4.&5KYYH"  !R-   &@
M        @ %0X0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    "  :0#]4IY'J63<"  #?,@  $P              @ $BY $ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     80!A )X:  "*Y@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>219</ContextCount>
  <ElementCount>448</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Income and Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization and Business Description</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription</Role>
      <ShortName>Organization and Business Description</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Accounts Receivable, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet</Role>
      <ShortName>Accounts Receivable, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Inventory, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/InventoryNet</Role>
      <ShortName>Inventory, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Advance to Suppliers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers</Role>
      <ShortName>Advance to Suppliers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Prepayment for Advertisting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting</Role>
      <ShortName>Prepayment for Advertisting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Short-Term Invstment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstment</Role>
      <ShortName>Short-Term Invstment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Prepayment for Construction-in-Progress (CIP) Project</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProject</Role>
      <ShortName>Prepayment for Construction-in-Progress (CIP) Project</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Prepayment for Purchase of a Property</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty</Role>
      <ShortName>Prepayment for Purchase of a Property</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Short-Bank Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoans</Role>
      <ShortName>Short-Bank Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/Taxes</Role>
      <ShortName>Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/Concentrations</Role>
      <ShortName>Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Condensed Financial Information of the Parent Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany</Role>
      <ShortName>Condensed Financial Information of the Parent Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Organization and Business Description (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables</Role>
      <ShortName>Organization and Business Description (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Accounts Receivable, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables</Role>
      <ShortName>Accounts Receivable, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Inventory, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables</Role>
      <ShortName>Inventory, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/InventoryNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Advance to Suppliers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables</Role>
      <ShortName>Advance to Suppliers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Short-Term Invstment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentTables</Role>
      <ShortName>Short-Term Invstment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstment</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Prepayment for Construction-in-Progress (CIP) Project (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectTables</Role>
      <ShortName>Prepayment for Construction-in-Progress (CIP) Project (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProject</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Short-Bank Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansTables</Role>
      <ShortName>Short-Bank Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoans</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</Role>
      <ShortName>Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/Taxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Condensed Financial Information of the Parent Company (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables</Role>
      <ShortName>Condensed Financial Information of the Parent Company (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Organization and Business Description (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails</Role>
      <ShortName>Organization and Business Description (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Organization and Business Description (Details) - Schedule of subsidiaries of the company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable</Role>
      <ShortName>Organization and Business Description (Details) - Schedule of subsidiaries of the company</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of currency exchange rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of currency exchange rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails</Role>
      <ShortName>Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Accounts Receivable, Net (Details) - Schedule of accounts receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable</Role>
      <ShortName>Accounts Receivable, Net (Details) - Schedule of accounts receivable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Accounts Receivable, Net (Details) - Schedule of the company???s accounts receivable and subsequent collection</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable</Role>
      <ShortName>Accounts Receivable, Net (Details) - Schedule of the company???s accounts receivable and subsequent collection</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Accounts Receivable, Net (Details) - Schedule of allowance for doubtful accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable</Role>
      <ShortName>Accounts Receivable, Net (Details) - Schedule of allowance for doubtful accounts</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Inventory, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/InventoryNetDetails</Role>
      <ShortName>Inventory, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Inventory, Net (Details) - Schedule of inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable</Role>
      <ShortName>Inventory, Net (Details) - Schedule of inventory</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Advance to Suppliers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersDetails</Role>
      <ShortName>Advance to Suppliers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Advance to Suppliers (Details) - Schedule of advances to suppliers net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable</Role>
      <ShortName>Advance to Suppliers (Details) - Schedule of advances to suppliers net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Prepayment for Advertisting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails</Role>
      <ShortName>Prepayment for Advertisting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Short-Term Invstment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentDetails</Role>
      <ShortName>Short-Term Invstment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Short-Term Invstment (Details) - Schedule of short-term invstment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvstmentTable</Role>
      <ShortName>Short-Term Invstment (Details) - Schedule of short-term invstment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of Property, plant and equipment, net consists</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable</Role>
      <ShortName>Property, Plant and Equipment, Net (Details) - Schedule of Property, plant and equipment, net consists</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails</Role>
      <ShortName>Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Intangible Assets, Net (Details) - Schedule of intangible assets, net consist</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable</Role>
      <ShortName>Intangible Assets, Net (Details) - Schedule of intangible assets, net consist</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable</Role>
      <ShortName>Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Prepayment for Construction-in-Progress (CIP) Project (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails</Role>
      <ShortName>Prepayment for Construction-in-Progress (CIP) Project (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Prepayment for Construction-in-Progress (CIP) Project (Details) - Schedule of future minimum capital expenditures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable</Role>
      <ShortName>Prepayment for Construction-in-Progress (CIP) Project (Details) - Schedule of future minimum capital expenditures</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Prepayment for Purchase of a Property (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails</Role>
      <ShortName>Prepayment for Purchase of a Property (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Short-Bank Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails</Role>
      <ShortName>Short-Bank Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Short-Bank Loans (Details) - Schedule of short-term bank loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable</Role>
      <ShortName>Short-Bank Loans (Details) - Schedule of short-term bank loans</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Related Party Transactions (Details) - Schedule of nature of relationships with related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable</Role>
      <ShortName>Related Party Transactions (Details) - Schedule of nature of relationships with related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Related Party Transactions (Details) - Schedule of due from related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable</Role>
      <ShortName>Related Party Transactions (Details) - Schedule of due from related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Related Party Transactions (Details) - Schedule of due to related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable</Role>
      <ShortName>Related Party Transactions (Details) - Schedule of due to related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>072 - Disclosure - Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails</Role>
      <ShortName>Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>073 - Disclosure - Taxes (Details) - Schedule of components of the income tax provision (benefit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable</Role>
      <ShortName>Taxes (Details) - Schedule of components of the income tax provision (benefit)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>074 - Disclosure - Taxes (Details) - Schedule of table reconciles the china statutory rates to the company???s effective tax rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable</Role>
      <ShortName>Taxes (Details) - Schedule of table reconciles the china statutory rates to the company???s effective tax rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>075 - Disclosure - Taxes (Details) - Schedule of deferred tax assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable</Role>
      <ShortName>Taxes (Details) - Schedule of deferred tax assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>076 - Disclosure - Taxes (Details) - Schedule of taxes payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable</Role>
      <ShortName>Taxes (Details) - Schedule of taxes payable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/TaxesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>077 - Disclosure - Concentrations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails</Role>
      <ShortName>Concentrations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/Concentrations</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>078 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>079 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>080 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>081 - Disclosure - Segment Reporting (Details) - Schedule of revenue by product source</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable</Role>
      <ShortName>Segment Reporting (Details) - Schedule of revenue by product source</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>082 - Disclosure - Segment Reporting (Details) - Schedule of total revenues by product categories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable</Role>
      <ShortName>Segment Reporting (Details) - Schedule of total revenues by product categories</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>083 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>084 - Disclosure - Condensed Financial Information of the Parent Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails</Role>
      <ShortName>Condensed Financial Information of the Parent Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>085 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable</Role>
      <ShortName>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>086 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals</Role>
      <ShortName>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>087 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of income and comprehensive income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable</Role>
      <ShortName>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of income and comprehensive income</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="f20f2021_universe.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>088 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable</Role>
      <ShortName>Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of cash flows</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="f20f2021_universe.htm">f20f2021_universe.htm</File>
    <File>f20f2021ex12-1_universephar.htm</File>
    <File>f20f2021ex12-2_universephar.htm</File>
    <File>f20f2021ex13-1_universephar.htm</File>
    <File>f20f2021ex13-2_universephar.htm</File>
    <File>f20f2021ex15-1_universephar.htm</File>
    <File>f20f2021ex2-3_universephar.htm</File>
    <File>f20f2021ex4-12_universephar.htm</File>
    <File>f20f2021ex4-13_universephar.htm</File>
    <File>f20f2021ex4-14_universephar.htm</File>
    <File>f20f2021ex4-15_universephar.htm</File>
    <File>f20f2021ex4-16_universephar.htm</File>
    <File>f20f2021ex4-17_universephar.htm</File>
    <File>f20f2021ex8-1_universephar.htm</File>
    <File>upc-20210930.xsd</File>
    <File>upc-20210930_cal.xml</File>
    <File>upc-20210930_def.xml</File>
    <File>upc-20210930_lab.xml</File>
    <File>upc-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fin_001.jpg</File>
    <File>fin_002.jpg</File>
    <File>img_001.jpg</File>
    <File>img_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="768">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="48">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>138
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f20f2021_universe.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "contextCount": 219,
   "dts": {
    "calculationLink": {
     "local": [
      "upc-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "upc-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f20f2021_universe.htm"
     ]
    },
    "labelLink": {
     "local": [
      "upc-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "upc-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "upc-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd"
     ]
    }
   },
   "elementCount": 604,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 132,
    "http://www.UniversePharmaceuticalsINC.com/20210930": 24,
    "http://xbrl.sec.gov/dei/2021": 9,
    "total": 165
   },
   "keyCustom": 78,
   "keyStandard": 370,
   "memberCustom": 43,
   "memberStandard": 25,
   "nsprefix": "upc",
   "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Inventory, Net",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/InventoryNet",
     "shortName": "Inventory, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:AdvancesToSuppliersTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Advance to Suppliers",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers",
     "shortName": "Advance to Suppliers",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:AdvancesToSuppliersTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForAdvertistingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Prepayment for Advertisting",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting",
     "shortName": "Prepayment for Advertisting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForAdvertistingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:HeldToMaturityInvestmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Short-Term Invstment",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstment",
     "shortName": "Short-Term Invstment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:HeldToMaturityInvestmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Property, Plant and Equipment, Net",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet",
     "shortName": "Property, Plant and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Intangible Assets, Net",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForConstructionInProgressTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Prepayment for Construction-in-Progress (CIP) Project",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProject",
     "shortName": "Prepayment for Construction-in-Progress (CIP) Project",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForConstructionInProgressTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForPurchaseOfAPropertyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Prepayment for Purchase of a Property",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty",
     "shortName": "Prepayment for Purchase of a Property",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PrepaymentForPurchaseOfAPropertyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Short-Bank Loans",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoans",
     "shortName": "Short-Bank Loans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Related Party Transactions",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Taxes",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/Taxes",
     "shortName": "Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Concentrations",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/Concentrations",
     "shortName": "Concentrations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Shareholders' Equity",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Commitments and Contingencies",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Segment Reporting",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Subsequent Events",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Condensed Financial Information of the Parent Company",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany",
     "shortName": "Condensed Financial Information of the Parent Company",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Organization and Business Description (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables",
     "shortName": "Organization and Business Description (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow_Parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Accounts Receivable, Net (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables",
     "shortName": "Accounts Receivable, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Inventory, Net (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables",
     "shortName": "Inventory, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:ScheduleOfAdvancesToSuppliersNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Advance to Suppliers (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables",
     "shortName": "Advance to Suppliers (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:ScheduleOfAdvancesToSuppliersNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Short-Term Invstment (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentTables",
     "shortName": "Short-Term Invstment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Intangible Assets, Net (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Prepayment for Construction-in-Progress (CIP) Project (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectTables",
     "shortName": "Prepayment for Construction-in-Progress (CIP) Project (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Short-Bank Loans (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansTables",
     "shortName": "Short-Bank Loans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Related Party Transactions (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Taxes (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables",
     "shortName": "Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Income and Comprehensive Income",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
     "shortName": "Consolidated Statements of Income and Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Condensed Financial Information of the Parent Company (Tables)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables",
     "shortName": "Condensed Financial Information of the Parent Company (Tables)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Organization and Business Description (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
     "shortName": "Organization and Business Description (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c52",
      "decimals": "6",
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c43",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Organization and Business Description (Details) - Schedule of subsidiaries of the company",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable",
     "shortName": "Organization and Business Description (Details) - Schedule of subsidiaries of the company",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c43",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "upc:AllowanceForUncollectableBalancesAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "upc:AllowanceForUncollectableBalancesAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "upc:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c67",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c74",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:DescriptionOfYearEndSpotRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of currency exchange rate",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of currency exchange rate",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:DescriptionOfYearEndSpotRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:AccountsReceivableDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Accounts Receivable, Net (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails",
     "shortName": "Accounts Receivable, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "upc:AccountsReceivableDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Accounts Receivable, Net (Details) - Schedule of accounts receivable",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable",
     "shortName": "Accounts Receivable, Net (Details) - Schedule of accounts receivable",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Changes in Shareholders' Equity",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c6",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Accounts Receivable, Net (Details) - Schedule of the company\u2019s accounts receivable and subsequent collection",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable",
     "shortName": "Accounts Receivable, Net (Details) - Schedule of the company\u2019s accounts receivable and subsequent collection",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Accounts Receivable, Net (Details) - Schedule of allowance for doubtful accounts",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable",
     "shortName": "Accounts Receivable, Net (Details) - Schedule of allowance for doubtful accounts",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c22",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryLIFOReservePeriodCharge",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Inventory, Net (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/InventoryNetDetails",
     "shortName": "Inventory, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Inventory, Net (Details) - Schedule of inventory",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable",
     "shortName": "Inventory, Net (Details) - Schedule of inventory",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "upc:RawMaterialsPurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Advance to Suppliers (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersDetails",
     "shortName": "Advance to Suppliers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "upc:RawMaterialsPurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfAdvancesToSuppliersNet",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Advance to Suppliers (Details) - Schedule of advances to suppliers net",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable",
     "shortName": "Advance to Suppliers (Details) - Schedule of advances to suppliers net",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfAdvancesToSuppliersNet",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c86",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherSellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Prepayment for Advertisting (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails",
     "shortName": "Prepayment for Advertisting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c86",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherSellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Short-Term Invstment (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentDetails",
     "shortName": "Short-Term Invstment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "upc:AddPurchaseWealthManagementFinancialProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Short-Term Invstment (Details) - Schedule of short-term invstment",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvstmentTable",
     "shortName": "Short-Term Invstment (Details) - Schedule of short-term invstment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "upc:AddPurchaseWealthManagementFinancialProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Property, Plant and Equipment, Net (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails",
     "shortName": "Property, Plant and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of Property, plant and equipment, net consists",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable",
     "shortName": "Property, Plant and Equipment, Net (Details) - Schedule of Property, plant and equipment, net consists",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Intangible Assets, Net (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails",
     "shortName": "Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Intangible Assets, Net (Details) - Schedule of intangible assets, net consist",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable",
     "shortName": "Intangible Assets, Net (Details) - Schedule of intangible assets, net consist",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable",
     "shortName": "Intangible Assets, Net (Details) - Schedule of estimated future amortization expense for intangible assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "upc:CapitalExpenditure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Prepayment for Construction-in-Progress (CIP) Project (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails",
     "shortName": "Prepayment for Construction-in-Progress (CIP) Project (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "upc:CapitalExpenditure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c104",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Prepayment for Construction-in-Progress (CIP) Project (Details) - Schedule of future minimum capital expenditures",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable",
     "shortName": "Prepayment for Construction-in-Progress (CIP) Project (Details) - Schedule of future minimum capital expenditures",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c104",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c106",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:SupplementalDeferredPurchasePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Prepayment for Purchase of a Property (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails",
     "shortName": "Prepayment for Purchase of a Property (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c106",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:SupplementalDeferredPurchasePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c115",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LoansPayableToBankCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "066 - Disclosure - Short-Bank Loans (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails",
     "shortName": "Short-Bank Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c115",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LoansPayableToBankCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "067 - Disclosure - Short-Bank Loans (Details) - Schedule of short-term bank loans",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable",
     "shortName": "Short-Bank Loans (Details) - Schedule of short-term bank loans",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c106",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeconsolidationRelatedPartyDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "068 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c106",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeconsolidationRelatedPartyDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Organization and Business Description",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription",
     "shortName": "Organization and Business Description",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c129",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "069 - Disclosure - Related Party Transactions (Details) - Schedule of nature of relationships with related parties",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable",
     "shortName": "Related Party Transactions (Details) - Schedule of nature of relationships with related parties",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c129",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfDueFromRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromOtherRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070 - Disclosure - Related Party Transactions (Details) - Schedule of due from related parties",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable",
     "shortName": "Related Party Transactions (Details) - Schedule of due from related parties",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfDueFromRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromOtherRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfDueToRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "071 - Disclosure - Related Party Transactions (Details) - Schedule of due to related parties",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable",
     "shortName": "Related Party Transactions (Details) - Schedule of due to related parties",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfDueToRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "072 - Disclosure - Taxes (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails",
     "shortName": "Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "073 - Disclosure - Taxes (Details) - Schedule of components of the income tax provision (benefit)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable",
     "shortName": "Taxes (Details) - Schedule of components of the income tax provision (benefit)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "074 - Disclosure - Taxes (Details) - Schedule of table reconciles the china statutory rates to the company\u2019s effective tax rate",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable",
     "shortName": "Taxes (Details) - Schedule of table reconciles the china statutory rates to the company\u2019s effective tax rate",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "075 - Disclosure - Taxes (Details) - Schedule of deferred tax assets",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable",
     "shortName": "Taxes (Details) - Schedule of deferred tax assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfTaxPayableTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedIncomeTaxesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "076 - Disclosure - Taxes (Details) - Schedule of taxes payable",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable",
     "shortName": "Taxes (Details) - Schedule of taxes payable",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "upc:ScheduleOfTaxPayableTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedIncomeTaxesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignFinancialInstitutionsMandatedDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "077 - Disclosure - Concentrations (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails",
     "shortName": "Concentrations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignFinancialInstitutionsMandatedDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "078 - Disclosure - Shareholders' Equity (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c4",
      "decimals": "2",
      "lang": null,
      "name": "upc:ReserveIsEqualPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalExpenditureDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "079 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalExpenditureDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080 - Disclosure - Segment Reporting (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails",
     "shortName": "Segment Reporting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfOtherPropertyOperatingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081 - Disclosure - Segment Reporting (Details) - Schedule of revenue by product source",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable",
     "shortName": "Segment Reporting (Details) - Schedule of revenue by product source",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostOfOtherPropertyOperatingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "upc:SubtotalOfTCMDProductsSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "082 - Disclosure - Segment Reporting (Details) - Schedule of total revenues by product categories",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable",
     "shortName": "Segment Reporting (Details) - Schedule of total revenues by product categories",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "upc:SubtotalOfTCMDProductsSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c211",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "083 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c211",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "upc:MinorityInterestsOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "084 - Disclosure - Condensed Financial Information of the Parent Company (Details)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails",
     "shortName": "Condensed Financial Information of the Parent Company (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c2",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "upc:MinorityInterestsOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c212",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "085 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
     "shortName": "Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c212",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c212",
      "decimals": "6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "086 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets (Parentheticals)",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals",
     "shortName": "Condensed Financial Information of the Parent Company (Details) - Schedule of parent company balance sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c212",
      "decimals": "6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:CondensedStatementOfComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c214",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "087 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of income and comprehensive income",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable",
     "shortName": "Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of income and comprehensive income",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:CondensedStatementOfComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c214",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:CondensedStatementOfComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c214",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "088 - Disclosure - Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of cash flows",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable",
     "shortName": "Condensed Financial Information of the Parent Company (Details) - Schedule of parent company statements of cash flows",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c214",
      "decimals": "0",
      "lang": null,
      "name": "upc:EquityInEarningsOfSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Accounts Receivable, Net",
     "role": "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet",
     "shortName": "Accounts Receivable, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_universe.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 68,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "PRC [Member]"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "domainItemType"
    },
    "country_HK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HONG KONG",
        "terseLabel": "HONG KONG",
        "verboseLabel": "Hong Kong [Member]"
       }
      }
     },
     "localname": "HK",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAYMAN ISLANDS",
        "terseLabel": "CAYMAN ISLANDS"
       }
      }
     },
     "localname": "KY",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact",
        "verboseLabel": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address",
        "terseLabel": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Date of Incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CondensedBalanceSheetStatementTable": {
     "auth_ref": [
      "r143",
      "r385",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "Condensed Balance Sheet Statement [Table]"
       }
      }
     },
     "localname": "CondensedBalanceSheetStatementTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedBalanceSheetStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Balance Sheet Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedBalanceSheetStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedCashFlowStatementTable": {
     "auth_ref": [
      "r143",
      "r385",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.",
        "label": "Condensed Cash Flow Statement [Table]"
       }
      }
     },
     "localname": "CondensedCashFlowStatementTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedCashFlowStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Cash Flow Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedCashFlowStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_CondensedStatementOfComprehensiveIncomeTable": {
     "auth_ref": [
      "r143",
      "r385",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.",
        "label": "Condensed Statement of Comprehensive Income [Table]"
       }
      }
     },
     "localname": "CondensedStatementOfComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedStatementOfComprehensiveIncomeTableTextBlock": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.",
        "label": "Condensed Statement of Comprehensive Income [Table Text Block]",
        "terseLabel": "Schedule of parent company statements of income and comprehensive income"
       }
      }
     },
     "localname": "CondensedStatementOfComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CondensedStatementOfIncomeCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Statement of Income Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedStatementOfIncomeCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r210",
      "r328",
      "r330",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r295",
      "r310",
      "r336",
      "r338",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r522",
      "r525",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r295",
      "r310",
      "r336",
      "r338",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r522",
      "r525",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Lower [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r210",
      "r328",
      "r330",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r295",
      "r310",
      "r332",
      "r336",
      "r338",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r522",
      "r525",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r295",
      "r310",
      "r332",
      "r336",
      "r338",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r522",
      "r525",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of parent company balance sheets"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.",
        "label": "Condensed Cash Flow Statement [Table Text Block]",
        "terseLabel": "Schedule of parent company statements of cash flows"
       }
      }
     },
     "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r207",
      "r208",
      "r328",
      "r329",
      "r523",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r577",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r328",
      "r329",
      "r523",
      "r536",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r212",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_AccountsReceivableBeforeGrossValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "AccountsReceivableBeforeGrossValue",
        "terseLabel": "Balance"
       }
      }
     },
     "localname": "AccountsReceivableBeforeGrossValue",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_AccountsReceivableDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable, description.",
        "label": "AccountsReceivableDescription",
        "terseLabel": "Accounts receivable description"
       }
      }
     },
     "localname": "AccountsReceivableDescription",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_AccountsReceivableNetPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AccountsReceivableNetPercentage",
        "terseLabel": "Percentage of subsequent collection"
       }
      }
     },
     "localname": "AccountsReceivableNetPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_AddPurchaseWealthManagementFinancialProducts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase wealth management financial products.",
        "label": "AddPurchaseWealthManagementFinancialProducts",
        "terseLabel": "Add: purchase wealth management financial products"
       }
      }
     },
     "localname": "AddPurchaseWealthManagementFinancialProducts",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvstmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_AdditionalContractPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional contract price percentage.",
        "label": "AdditionalContractPricePercentage",
        "terseLabel": "Additional contract price percentage"
       }
      }
     },
     "localname": "AdditionalContractPricePercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_AdvanceToSuppliersNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of advance to suppliers net.",
        "label": "AdvanceToSuppliersNet",
        "terseLabel": "Advance to suppliers"
       }
      }
     },
     "localname": "AdvanceToSuppliersNet",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_AdvancesToSuppliersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances To Suppliers [Abstract]"
       }
      }
     },
     "localname": "AdvancesToSuppliersAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_AdvancesToSuppliersNetPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advances to suppliers net",
        "label": "AdvancesToSuppliersNetPolicyTextBlock",
        "terseLabel": "Advances to suppliers, net"
       }
      }
     },
     "localname": "AdvancesToSuppliersNetPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_AdvancesToSuppliersTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the advances to suppliers.",
        "label": "AdvancesToSuppliersTextBlock",
        "terseLabel": "ADVANCE TO SUPPLIERS"
       }
      }
     },
     "localname": "AdvancesToSuppliersTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliers"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_AllowanceForDoubtfulAccountsReceivablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AllowanceForDoubtfulAccountsReceivablePercentage",
        "terseLabel": "Percentage of subsequent collection"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivablePercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_AllowanceForUncollectableBalancesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for uncollectable balances amount.",
        "label": "AllowanceForUncollectableBalancesAmount",
        "terseLabel": "Allowance for uncollectable balance amount"
       }
      }
     },
     "localname": "AllowanceForUncollectableBalancesAmount",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_AmountOfRegisteredCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of registered capital.",
        "label": "AmountOfRegisteredCapital",
        "terseLabel": "Registered capital"
       }
      }
     },
     "localname": "AmountOfRegisteredCapital",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_AssetsAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AssetsAbstract0",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract0",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_CapitalContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capital contribution.",
        "label": "CapitalContribution",
        "terseLabel": "Capital contribution"
       }
      }
     },
     "localname": "CapitalContribution",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_CapitalExpenditure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of capital expenditure.",
        "label": "CapitalExpenditure",
        "terseLabel": "Additional capital expenditure"
       }
      }
     },
     "localname": "CapitalExpenditure",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_CapitalExpenditureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CapitalExpenditureMember",
        "terseLabel": "Capital Expenditure [Member]"
       }
      }
     },
     "localname": "CapitalExpenditureMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CashAndCashEquivalentAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "CashAndCashEquivalentAtCarryingValue",
        "periodEndLabel": "CASH, end of year",
        "periodStartLabel": "CASH, beginning of year"
       }
      }
     },
     "localname": "CashAndCashEquivalentAtCarryingValue",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_CashDividendDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of dividends.",
        "label": "CashDividendDescription",
        "terseLabel": "Description of dividends"
       }
      }
     },
     "localname": "CashDividendDescription",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_CashDividendsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CashDividendsMember",
        "terseLabel": "Cash dividends [Member]"
       }
      }
     },
     "localname": "CashDividendsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CashFlowsFromFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CashFlowsFromFinancingActivitiesAbstract",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowsFromFinancingActivitiesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_CashFlowsFromInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CashFlowsFromInvestingActivitiesAbstract",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowsFromInvestingActivitiesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_CashFlowsFromOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CashFlowsFromOperatingActivitiesAbstract",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowsFromOperatingActivitiesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_CashLentToSubsidiaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Cash lent to subsidiaries.",
        "label": "CashLentToSubsidiaries",
        "terseLabel": "Cash lent to subsidiaries"
       }
      }
     },
     "localname": "CashLentToSubsidiaries",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_ChenyuanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ChenyuanMember",
        "terseLabel": "Chenyuan [Member]"
       }
      }
     },
     "localname": "ChenyuanMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_ConcentrationRiskThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ConcentrationRiskThresholdPercentage",
        "terseLabel": "Total revenue percentage"
       }
      }
     },
     "localname": "ConcentrationRiskThresholdPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_ConcentrationsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations (Details) [Line Items]"
       }
      }
     },
     "localname": "ConcentrationsDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ConcentrationsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations (Details) [Table]"
       }
      }
     },
     "localname": "ConcentrationsDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ContractAssetsAndLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ContractAssetsAndLiabilitiesPolicyTextBlock",
        "terseLabel": "Contract Assets and Liabilities"
       }
      }
     },
     "localname": "ContractAssetsAndLiabilitiesPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_CorporateSegmentFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Segment Five [Member].",
        "label": "CorporateSegmentFiveMember",
        "terseLabel": "Medical instruments [Member]"
       }
      }
     },
     "localname": "CorporateSegmentFiveMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CorporateSegmentFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Segment Four [Member].",
        "label": "CorporateSegmentFourMember",
        "terseLabel": "Traditional Chinese medicine pieces [Member]"
       }
      }
     },
     "localname": "CorporateSegmentFourMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CorporateSegmentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Segment One [Member].",
        "label": "CorporateSegmentOneMember",
        "terseLabel": "Other chronic condition treatment products [Member]"
       }
      }
     },
     "localname": "CorporateSegmentOneMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CorporateSegmentSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Segment Six [Member].",
        "label": "CorporateSegmentSixMember",
        "terseLabel": "Dietary supplements [Member]"
       }
      }
     },
     "localname": "CorporateSegmentSixMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CorporateSegmentThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Segment Three [Member].",
        "label": "CorporateSegmentThreeMember",
        "terseLabel": "Biochemical drugs [Member]"
       }
      }
     },
     "localname": "CorporateSegmentThreeMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CorporateSegmentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Segment Two [Member].",
        "label": "CorporateSegmentTwoMember",
        "terseLabel": "Cold and flu medicines [Member]"
       }
      }
     },
     "localname": "CorporateSegmentTwoMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CustomerMember",
        "terseLabel": "Customer [Member]"
       }
      }
     },
     "localname": "CustomerMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_CustomersOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CustomersOneMember",
        "terseLabel": "Customer One [Member]"
       }
      }
     },
     "localname": "CustomersOneMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_DeferredInitialPublicOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred initial public offering costs.",
        "label": "DeferredInitialPublicOfferingCosts",
        "terseLabel": "Deferred initial public offering costs"
       }
      }
     },
     "localname": "DeferredInitialPublicOfferingCosts",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_DeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredTaxAssetsAbstract",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_DescriptionOfAverageRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of average rate.",
        "label": "DescriptionOfAverageRate",
        "terseLabel": "Average rate"
       }
      }
     },
     "localname": "DescriptionOfAverageRate",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_DescriptionOfYearEndSpotRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of year end spot rate.",
        "label": "DescriptionOfYearEndSpotRate",
        "terseLabel": "Year-end spot rate"
       }
      }
     },
     "localname": "DescriptionOfYearEndSpotRate",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcurrencyexchangerateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_DisaggregationOfRevenuesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisaggregationOfRevenuesPolicyTextBlock",
        "terseLabel": "Disaggregation of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenuesPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_EmployeeDefinedContributionPlanPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of employee defined contribution plan.",
        "label": "EmployeeDefinedContributionPlanPolicyTextBlock",
        "terseLabel": "Employee Defined Contribution Plan"
       }
      }
     },
     "localname": "EmployeeDefinedContributionPlanPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_EntityIncorporationDateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity incorporation date description.",
        "label": "EntityIncorporationDateDescription",
        "terseLabel": "Entity incorporation date description"
       }
      }
     },
     "localname": "EntityIncorporationDateDescription",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_EquityInEarningsOfSubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity in earnings of subsidiary.",
        "label": "EquityInEarningsOfSubsidiary",
        "terseLabel": "Equity in earnings of subsidiary"
       }
      }
     },
     "localname": "EquityInEarningsOfSubsidiary",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearSix",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_FoshanShangyuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FoshanShangyuMember",
        "terseLabel": "Foshan Shangyu [Member]"
       }
      }
     },
     "localname": "FoshanShangyuMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_From10To12MonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "From10To12MonthsMember",
        "terseLabel": "From 10 to 12 months [Member]"
       }
      }
     },
     "localname": "From10To12MonthsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_From4To6MonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "From4To6MonthsMember",
        "terseLabel": "From 4 to 6 months [Member]"
       }
      }
     },
     "localname": "From4To6MonthsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_From7To9MonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "From7To9MonthsMember",
        "terseLabel": "From 7 to 9 months\t[Member]"
       }
      }
     },
     "localname": "From7To9MonthsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_GreatestGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GreatestGroupMember",
        "terseLabel": "Greatest Group [Member]"
       }
      }
     },
     "localname": "GreatestGroupMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_GubenYanlingPillMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GubenYanlingPillMember",
        "terseLabel": "Guben Yanling Pill [Member]"
       }
      }
     },
     "localname": "GubenYanlingPillMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_HeldToMaturityInvestmentDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Held To Maturity Investment Disclosure [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturityInvestmentDisclosureAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_HeldToMaturityInvestmentDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HeldToMaturityInvestmentDisclosureTextBlock",
        "terseLabel": "SHORT-TERM INVSTMENTS"
       }
      }
     },
     "localname": "HeldToMaturityInvestmentDisclosureTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_HeldToMaturityInvestmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HeldToMaturityInvestmentPolicyTextBlock",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "HeldToMaturityInvestmentPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_IntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets.",
        "label": "IntangibleAssets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssets",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_InvestmentInEquitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment In Equity Securities",
        "label": "InvestmentInEquitySecurities",
        "terseLabel": "Investment in equity securities"
       }
      }
     },
     "localname": "InvestmentInEquitySecurities",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_JiangxiLulingRuralCommercialBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JiangxiLulingRuralCommercialBankMember",
        "terseLabel": "LRC Bank [Member]",
        "verboseLabel": "Jiangxi Luling Rural Commercial Bank [Member]"
       }
      }
     },
     "localname": "JiangxiLulingRuralCommercialBankMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_JiangxiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JiangxiMember",
        "terseLabel": "Jiangxi [Member]"
       }
      }
     },
     "localname": "JiangxiMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_JiangxiUniverseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JiangxiUniverseMember",
        "terseLabel": "Jiangxi Universe [Member]"
       }
      }
     },
     "localname": "JiangxiUniverseMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_JxRcbBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JxRcbBankMember",
        "terseLabel": "JX RCB Bank [Member]"
       }
      }
     },
     "localname": "JxRcbBankMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_LessThan3MonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LessThan3MonthsMember",
        "terseLabel": "Less than 3 months\t[Member]"
       }
      }
     },
     "localname": "LessThan3MonthsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract",
        "terseLabel": "Loans payable to Jiangxi Luling Rural Commercial Bank (\u201cLRC Bank\u201d):"
       }
      }
     },
     "localname": "LoansPayableToJiangxiLulingRuralCommercialBankLrcBankAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_MaturityGreaterThan90DaysOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MaturityGreaterThan90DaysOneMember",
        "terseLabel": "Maturity date on June 15, 2022, interest rate 4.81% per annum [Member]"
       }
      }
     },
     "localname": "MaturityGreaterThan90DaysOneMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_MaturityGreaterThan90DaysThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MaturityGreaterThan90DaysThreeMember",
        "terseLabel": "Maturity date on March 17, 2022, interest rate 4.81% per annum [Member]"
       }
      }
     },
     "localname": "MaturityGreaterThan90DaysThreeMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_MaturityGreaterThan90DaysTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MaturityGreaterThan90DaysTwoMember",
        "terseLabel": "Maturity date on June 30, 2022, interest rate 4.5% per annum [Member]"
       }
      }
     },
     "localname": "MaturityGreaterThan90DaysTwoMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_MinorityInterestsOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary exceeded percentage.",
        "label": "MinorityInterestsOwnershipPercentageByParent",
        "terseLabel": "Subsidiary exceeded percentage"
       }
      }
     },
     "localname": "MinorityInterestsOwnershipPercentageByParent",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompanyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_MrGangLaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MrGangLaiMember",
        "terseLabel": "Mr. Gang Lai [Member]"
       }
      }
     },
     "localname": "MrGangLaiMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_MrsLinYangMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MrsLinYangMember",
        "terseLabel": "Mrs. Lin Yang [Member]"
       }
      }
     },
     "localname": "MrsLinYangMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_NonCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NonCurrentAssetsAbstract",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NonCurrentAssetsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_OfficeAndElectricEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OfficeAndElectricEquipmentMember",
        "terseLabel": "Office and electric equipment [Member]"
       }
      }
     },
     "localname": "OfficeAndElectricEquipmentMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_OfficeSpaceSquareMeters": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space Square meters.",
        "label": "OfficeSpaceSquareMeters",
        "terseLabel": "Office space Square meters"
       }
      }
     },
     "localname": "OfficeSpaceSquareMeters",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "upc_OptionToPurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to purchase additional shares.",
        "label": "OptionToPurchaseAdditionalShares",
        "terseLabel": "Option to purchase additional shares"
       }
      }
     },
     "localname": "OptionToPurchaseAdditionalShares",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "upc_OrdinarySharesOutstandingDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares outstanding description.",
        "label": "OrdinarySharesOutstandingDescription",
        "terseLabel": "Ordinary shares outstanding description"
       }
      }
     },
     "localname": "OrdinarySharesOutstandingDescription",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_OrdinarySharesParValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares par value.",
        "label": "OrdinarySharesParValue",
        "terseLabel": "Ordinary shares par value (in Dollars per share)"
       }
      }
     },
     "localname": "OrdinarySharesParValue",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "upc_OrganizationandBusinessDescriptionDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business Description (Details) [Line Items]"
       }
      }
     },
     "localname": "OrganizationandBusinessDescriptionDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_OrganizationandBusinessDescriptionDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business Description (Details) [Table]"
       }
      }
     },
     "localname": "OrganizationandBusinessDescriptionDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_OriginalSharesParValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original shares par value.",
        "label": "OriginalSharesParValue",
        "terseLabel": "Original shares par value (in Dollars per share)"
       }
      }
     },
     "localname": "OriginalSharesParValue",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "upc_OtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherComprehensiveIncomeLossAbstract",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_OtherIncomeExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherIncomeExpensesAbstract",
        "terseLabel": "Other income (expenses)"
       }
      }
     },
     "localname": "OtherIncomeExpensesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_OtherIncomeExpensesAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherIncomeExpensesAbstract0",
        "terseLabel": "Other income (expenses):"
       }
      }
     },
     "localname": "OtherIncomeExpensesAbstract0",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_Over1YearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over1YearMember",
        "terseLabel": "Over 1 year [Member]"
       }
      }
     },
     "localname": "Over1YearMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_PRCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PRCMember",
        "terseLabel": "PRC [Member]"
       }
      }
     },
     "localname": "PRCMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_PayableDeliveryPropertyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payable delivery property percentage.",
        "label": "PayableDeliveryPropertyPercentage",
        "terseLabel": "Payable delivery property percentage"
       }
      }
     },
     "localname": "PayableDeliveryPropertyPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_PercentageOfAdvancePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of advance payment.",
        "label": "PercentageOfAdvancePayment",
        "terseLabel": "Percentage of advance payment"
       }
      }
     },
     "localname": "PercentageOfAdvancePayment",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_PercentageOfPrepayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayment.",
        "label": "PercentageOfPrepayment",
        "terseLabel": "Percentage of prepayment"
       }
      }
     },
     "localname": "PercentageOfPrepayment",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_PercentageOfSubsequentCollection": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PercentageOfSubsequentCollection",
        "terseLabel": "Percentage of subsequent collection"
       }
      }
     },
     "localname": "PercentageOfSubsequentCollection",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_PercentageOfVatRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of VATrate.",
        "label": "PercentageOfVatRate",
        "terseLabel": "Percentage of vat rate"
       }
      }
     },
     "localname": "PercentageOfVatRate",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_PlaceOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Place of incorporation or establishment.",
        "label": "PlaceOfIncorporation",
        "terseLabel": "Place of Incorporation"
       }
      }
     },
     "localname": "PlaceOfIncorporation",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PreferentialTaxTreatmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferential tax treatment, description.",
        "label": "PreferentialTaxTreatmentDescription",
        "terseLabel": "Preferential tax treatment, description"
       }
      }
     },
     "localname": "PreferentialTaxTreatmentDescription",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_Prepayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepayment.",
        "label": "Prepayment",
        "terseLabel": "Prepayment"
       }
      }
     },
     "localname": "Prepayment",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_PrepaymentForAdvertising": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepayment for advertising.",
        "label": "PrepaymentForAdvertising",
        "terseLabel": "Prepayment for advertising"
       }
      }
     },
     "localname": "PrepaymentForAdvertising",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_PrepaymentForAdvertistingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment For Advertisting [Abstract]"
       }
      }
     },
     "localname": "PrepaymentForAdvertistingAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentForAdvertistingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PrepaymentForAdvertistingTextBlock",
        "terseLabel": "PREPAYMENT FOR ADVERTISTING"
       }
      }
     },
     "localname": "PrepaymentForAdvertistingTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertisting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_PrepaymentForConstructionInProgressAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment For Construction In Progress [Abstract]"
       }
      }
     },
     "localname": "PrepaymentForConstructionInProgressAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentForConstructionInProgressTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for prepayment for construction in progress.",
        "label": "PrepaymentForConstructionInProgressTextBlock",
        "terseLabel": "PREPAYMENT FOR CONSTRUCTION-IN-PROGRESS (\"CIP\") PROJECT"
       }
      }
     },
     "localname": "PrepaymentForConstructionInProgressTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProject"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_PrepaymentForPurchaseOfAPropertyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment For Purchase Of A Property [Abstract]"
       }
      }
     },
     "localname": "PrepaymentForPurchaseOfAPropertyAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentForPurchaseOfAPropertyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PrepaymentForPurchaseOfAPropertyTextBlock",
        "terseLabel": "PREPAYMENT FOR PURCHASE OF A PROPERTY"
       }
      }
     },
     "localname": "PrepaymentForPurchaseOfAPropertyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaProperty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_PrepaymentforConstructioninProgressCIPProjectDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Construction-in-Progress (CIP) Project (Details) [Line Items]"
       }
      }
     },
     "localname": "PrepaymentforConstructioninProgressCIPProjectDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Construction-in-Progress (CIP) Project (Details) - Schedule of future minimum capital expenditures [Line Items]"
       }
      }
     },
     "localname": "PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Construction-in-Progress (CIP) Project (Details) - Schedule of future minimum capital expenditures [Table]"
       }
      }
     },
     "localname": "PrepaymentforConstructioninProgressCIPProjectDetailsScheduleoffutureminimumcapitalexpendituresTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentforConstructioninProgressCIPProjectDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Construction-in-Progress (CIP) Project (Details) [Table]"
       }
      }
     },
     "localname": "PrepaymentforConstructioninProgressCIPProjectDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentforPurchaseofaPropertyDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Purchase of a Property (Details) [Line Items]"
       }
      }
     },
     "localname": "PrepaymentforPurchaseofaPropertyDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentforPurchaseofaPropertyDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment for Purchase of a Property (Details) [Table]"
       }
      }
     },
     "localname": "PrepaymentforPurchaseofaPropertyDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_PrepaymentsForConstructionInProgress": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments for construction in progress.",
        "label": "PrepaymentsForConstructionInProgress",
        "terseLabel": "Prepayments for construction in progress"
       }
      }
     },
     "localname": "PrepaymentsForConstructionInProgress",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_PrepaymentsMadeToARelatedPartyForPurchaseOfProperty": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of prepayments made to a related party for purchase of property.",
        "label": "PrepaymentsMadeToARelatedPartyForPurchaseOfProperty",
        "negatedLabel": "Prepayments made to a related party for purchase of property"
       }
      }
     },
     "localname": "PrepaymentsMadeToARelatedPartyForPurchaseOfProperty",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepayments made to a related party for purchase of property.",
        "label": "PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent",
        "terseLabel": "Prepayments made to a related party for purchase of property"
       }
      }
     },
     "localname": "PrepaymentsMadeToARelatedPartyForPurchaseOfPropertyNonCurrent",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_PrincipalActivities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal activities.",
        "label": "PrincipalActivities",
        "terseLabel": "Principal Activities"
       }
      }
     },
     "localname": "PrincipalActivities",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ProceedsFromprepaymentsForRelatedPartiesBorrowings": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from (prepayments for) related parties borrowings.",
        "label": "ProceedsFromprepaymentsForRelatedPartiesBorrowings",
        "negatedLabel": "Proceeds from (prepayments for) related parties borrowings"
       }
      }
     },
     "localname": "ProceedsFromprepaymentsForRelatedPartiesBorrowings",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of property equipment estimated useful life during the period.",
        "label": "PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
        "terseLabel": "Schedule of property and equipment estimated useful lives"
       }
      }
     },
     "localname": "PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_PublicOfferingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering price.",
        "label": "PublicOfferingPrice",
        "terseLabel": "Public offering price (in Dollars per share)"
       }
      }
     },
     "localname": "PublicOfferingPrice",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "upc_RawMaterialsPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of raw materials.",
        "label": "RawMaterialsPurchased",
        "terseLabel": "Raw materials purchased"
       }
      }
     },
     "localname": "RawMaterialsPurchased",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_RedemptionOfShorttermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption of short-term investments.",
        "label": "RedemptionOfShorttermInvestments",
        "terseLabel": "Redemption of short-term investments"
       }
      }
     },
     "localname": "RedemptionOfShorttermInvestments",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) - Schedule of due from related parties [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) - Schedule of due from related parties [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsScheduleofduefromrelatedpartiesTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) - Schedule of due to related parties [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) - Schedule of due to related parties [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsScheduleofduetorelatedpartiesTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_RemainingCapitalContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining capital contribution amount.",
        "label": "RemainingCapitalContribution",
        "terseLabel": "Remaining capital contribution"
       }
      }
     },
     "localname": "RemainingCapitalContribution",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_ReorganizationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reorganization shares.",
        "label": "ReorganizationShares",
        "terseLabel": "Reorganization shares"
       }
      }
     },
     "localname": "ReorganizationShares",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "upc_ReserveIsEqualPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve is equal percentage.",
        "label": "ReserveIsEqualPercentage",
        "terseLabel": "Reserve is equal percentage"
       }
      }
     },
     "localname": "ReserveIsEqualPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_RestrictedNetAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted net assets.",
        "label": "RestrictedNetAssets",
        "terseLabel": "Restricted net assets (in Dollars)"
       }
      }
     },
     "localname": "RestrictedNetAssets",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SalesOfTcmdProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SalesOfTcmdProductsAbstract",
        "terseLabel": "Sales of TCMD products:"
       }
      }
     },
     "localname": "SalesOfTcmdProductsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SalesOfThirdPartyProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SalesOfThirdPartyProductsAbstract",
        "terseLabel": "Sales of third-party products"
       }
      }
     },
     "localname": "SalesOfThirdPartyProductsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfAccountsReceivableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accounts receivable [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAccountsReceivableAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfAdvancesToSuppliersNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of advances to suppliers net.",
        "label": "ScheduleOfAdvancesToSuppliersNet",
        "terseLabel": "Schedule of advances to suppliers net"
       }
      }
     },
     "localname": "ScheduleOfAdvancesToSuppliersNet",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AdvancetoSuppliersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_ScheduleOfAdvancesToSuppliersNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of advances to suppliers net [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAdvancesToSuppliersNetAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfAllowanceForDoubtfulAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of allowance for doubtful accounts [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAllowanceForDoubtfulAccountsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of the income tax provision (benefit) [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfTheIncomeTaxProvisionBenefitAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfCurrencyExchangeRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of currency exchange rate [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfCurrencyExchangeRateAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of deferred tax assets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfDueFromRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of due from related parties [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDueFromRelatedPartiesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfDueFromRelatedPartiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfDueFromRelatedPartiesTableTextBlock",
        "terseLabel": "Schedule of due from related parties"
       }
      }
     },
     "localname": "ScheduleOfDueFromRelatedPartiesTableTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_ScheduleOfDueToRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of due to related parties [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDueToRelatedPartiesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfDueToRelatedPartiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfDueToRelatedPartiesTableTextBlock",
        "terseLabel": "Schedule of due to related parties"
       }
      }
     },
     "localname": "ScheduleOfDueToRelatedPartiesTableTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of estimated future amortization expense for intangible assets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfEstimatedFutureAmortizationExpenseForIntangibleAssetsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfFutureMinimumCapitalExpendituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum capital expenditures [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumCapitalExpendituresAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of intangible assets estimated useful lives [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsEstimatedUsefulLivesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfIntangibleAssetsNetConsistAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of intangible assets, net consist [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsNetConsistAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfInventoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of inventory [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfInventoryAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of nature of relationships with related parties [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfNatureOfRelationshipsWithRelatedPartiesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfParentCompanyBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of parent company balance sheets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfParentCompanyBalanceSheetsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfParentCompanyStatementsOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of parent company statements of cash flows [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfParentCompanyStatementsOfCashFlowsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of parent company statements of income and comprehensive income [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfParentCompanyStatementsOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment estimated useful lives [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property, plant and equipment, net consists [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentNetConsistsAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfRevenueByProductSourceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of revenue by product source [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfRevenueByProductSourceAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfShortTermBankLoansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of short-term bank loans [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfShortTermBankLoansAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfShortTermInvstmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of short-term invstment [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfShortTermInvstmentAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfSubsidiariesOfTheCompanyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of subsidiaries of the company [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiariesOfTheCompanyAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of table reconciles the china statutory rates to the company\u2019s effective tax rate [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfTableReconcilesTheChinaStatutoryRatesToTheCompanySEffectiveTaxRateAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfTaxPayableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of tax payable during the period.",
        "label": "ScheduleOfTaxPayableTableTextBlock",
        "terseLabel": "Schedule of taxes payable"
       }
      }
     },
     "localname": "ScheduleOfTaxPayableTableTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_ScheduleOfTaxesPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of taxes payable [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfTaxesPayableAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the company\u2019s accounts receivable and subsequent collection [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfTheCompanySAccountsReceivableAndSubsequentCollectionAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ScheduleOfTotalRevenuesByProductCategoriesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of total revenues by product categories [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfTotalRevenuesByProductCategoriesAbstract",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "xbrltype": "stringItemType"
    },
    "upc_ShareholdersEquityAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareholdersEquityAbstract0",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "ShareholdersEquityAbstract0",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ShareholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ShareholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ShortBankLoansDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Bank Loans (Details) [Line Items]"
       }
      }
     },
     "localname": "ShortBankLoansDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ShortBankLoansDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Bank Loans (Details) [Table]"
       }
      }
     },
     "localname": "ShortBankLoansDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_ShorttermInvestmentIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ShorttermInvestmentIncome",
        "negatedLabel": "Short-term investments income"
       }
      }
     },
     "localname": "ShorttermInvestmentIncome",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_StatementOfCashFlowsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of statement of cash flows policy text block.",
        "label": "StatementOfCashFlowsPolicyTextBlock",
        "terseLabel": "Statement of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_StatutoryReserve": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "StatutoryReserve",
        "label": "StatutoryReserve",
        "terseLabel": "Statutory reserve"
       }
      }
     },
     "localname": "StatutoryReserve",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_StatutoryReserveAndRestrictedNetAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StatutoryReserveAndRestrictedNetAssetsMember",
        "terseLabel": "Statutory Reserve and Restricted Net Assets [Member]"
       }
      }
     },
     "localname": "StatutoryReserveAndRestrictedNetAssetsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_StatutoryReservesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StatutoryReservesMember",
        "terseLabel": "Statutory Reserve"
       }
      }
     },
     "localname": "StatutoryReservesMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_StatutorySurplusPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statutory surplus percentage.",
        "label": "StatutorySurplusPercentage",
        "terseLabel": "Statutory surplus percentage"
       }
      }
     },
     "localname": "StatutorySurplusPercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Capitalized initial public offering costs.",
        "label": "StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts",
        "terseLabel": "Capitalized initial public offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCapitalizedInitialPublicOfferingCosts",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SubsequentCollection": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "SubsequentCollection",
        "terseLabel": "Subsequent collection"
       }
      }
     },
     "localname": "SubsequentCollection",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SubtotalOfTCMDProductsSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "SubtotalOfTCMDProductsSales",
        "terseLabel": "Sub-total of TCMD products sales"
       }
      }
     },
     "localname": "SubtotalOfTCMDProductsSales",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SubtotalOfThirdpartyProductsSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subtotal of third-party products sales.",
        "label": "SubtotalOfThirdpartyProductsSales",
        "terseLabel": "Subtotal of third-party products sales"
       }
      }
     },
     "localname": "SubtotalOfThirdpartyProductsSales",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of intangible assets estimated useful lives [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofintangibleassetsestimatedusefullivesTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful lives [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentestimatedusefullivesTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_SunsequentCollectionAccountsReceivableNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "SunsequentCollectionAccountsReceivableNet",
        "terseLabel": "Subsequent collection"
       }
      }
     },
     "localname": "SunsequentCollectionAccountsReceivableNet",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SunsequentCollectionAllowanceForDoubtfulAccounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "SunsequentCollectionAllowanceForDoubtfulAccounts",
        "terseLabel": "Subsequent collection"
       }
      }
     },
     "localname": "SunsequentCollectionAllowanceForDoubtfulAccounts",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SunsequentCollectionsTotalGrossAccountsReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "SunsequentCollectionsTotalGrossAccountsReceivable",
        "terseLabel": "Subsequent collection"
       }
      }
     },
     "localname": "SunsequentCollectionsTotalGrossAccountsReceivable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "upc_SupplierOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SupplierOneMember",
        "terseLabel": "Supplier One [Member]"
       }
      }
     },
     "localname": "SupplierOneMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_SupplierTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SupplierTwoMember",
        "terseLabel": "Supplier Two [Member]"
       }
      }
     },
     "localname": "SupplierTwoMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_TaxesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes (Details) [Line Items]"
       }
      }
     },
     "localname": "TaxesDetailsLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes (Details) - Schedule of components of the income tax provision (benefit) [Line Items]"
       }
      }
     },
     "localname": "TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitLineItems",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes (Details) - Schedule of components of the income tax provision (benefit) [Table]"
       }
      }
     },
     "localname": "TaxesDetailsScheduleofcomponentsoftheincometaxprovisionbenefitTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_TaxesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes (Details) [Table]"
       }
      }
     },
     "localname": "TaxesDetailsTable",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "upc_TotalGrossAccountsReceivablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TotalGrossAccountsReceivablePercentage",
        "terseLabel": "Percentage of subsequent collection"
       }
      }
     },
     "localname": "TotalGrossAccountsReceivablePercentage",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "percentItemType"
    },
    "upc_TotalRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TotalRevenueMember",
        "terseLabel": "Total Revenue [Member]"
       }
      }
     },
     "localname": "TotalRevenueMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UnderwriterWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UnderwriterWarrantsMember",
        "terseLabel": "Underwriter warrants [Member]"
       }
      }
     },
     "localname": "UnderwriterWarrantsMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UniverseHKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UniverseHKMember",
        "terseLabel": "Universe HK [Member]"
       }
      }
     },
     "localname": "UniverseHKMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UniverseHanheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UniverseHanheMember",
        "terseLabel": "Universe Hanhe [Member]"
       }
      }
     },
     "localname": "UniverseHanheMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UniverseINCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Universe INC.",
        "label": "UniverseINCMember",
        "terseLabel": "Universe INC [Member]"
       }
      }
     },
     "localname": "UniverseINCMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UniverseIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UniverseIncMember",
        "terseLabel": "Universe INC [Member]",
        "verboseLabel": "Universe Inc [Member]"
       }
      }
     },
     "localname": "UniverseIncMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UniverseTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UniverseTechnologyMember",
        "terseLabel": "Universe Technology [Member]"
       }
      }
     },
     "localname": "UniverseTechnologyMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_UniverseTradeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UniverseTradeMember",
        "terseLabel": "Universe Trade [Member]",
        "verboseLabel": "Jiangxi Universe [Member]"
       }
      }
     },
     "localname": "UniverseTradeMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "upc_ValueAddedTaxPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of value added tax.",
        "label": "ValueAddedTaxPolicyTextBlock",
        "terseLabel": "Value added tax (\u201cVAT\u201d)"
       }
      }
     },
     "localname": "ValueAddedTaxPolicyTextBlock",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "upc_supplierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "supplierMember",
        "terseLabel": "supplier [Member]"
       }
      }
     },
     "localname": "supplierMember",
     "nsuri": "http://www.UniversePharmaceuticalsINC.com/20210930",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndFinancingReceivableAllowanceForCreditLoss": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss of accounts and financing receivables. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, Allowance for Credit Loss",
        "negatedLabel": "Balance"
       }
      }
     },
     "localname": "AccountsAndFinancingReceivableAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r50",
      "r441"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of allowance for doubtful accounts"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableGross": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "terseLabel": "Balance"
       }
      }
     },
     "localname": "AccountsReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r31",
      "r497",
      "r537"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Balance"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r8",
      "r31",
      "r213",
      "r214"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "auth_ref": [
      "r12",
      "r54",
      "r344"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable": {
       "order": 3.0,
       "parentTag": "us-gaap_TaxesPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrual for Taxes Other than Income Taxes, Current",
        "terseLabel": "Other taxes payable"
       }
      }
     },
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r27",
      "r479",
      "r500"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable": {
       "order": 1.0,
       "parentTag": "us-gaap_TaxesPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r47",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r34",
      "r74",
      "r76",
      "r77",
      "r504",
      "r530",
      "r531"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r73",
      "r77",
      "r83",
      "r84",
      "r85",
      "r145",
      "r146",
      "r147",
      "r394",
      "r526",
      "r527",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r32",
      "r343",
      "r441"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid in capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r340",
      "r341",
      "r342",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Adjustments to reconcile net cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expenses"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": {
     "auth_ref": [
      "r217",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.",
        "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of the company\u2019s accounts receivable and subsequent collection"
       }
      }
     },
     "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.",
        "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables",
        "terseLabel": "Less: allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r221",
      "r236",
      "r237",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r38",
      "r221",
      "r236"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedLabel": "Less: allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofaccountsreceivableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r117",
      "r257",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r135",
      "r182",
      "r195",
      "r202",
      "r234",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r389",
      "r397",
      "r412",
      "r439",
      "r441",
      "r477",
      "r499"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r71",
      "r135",
      "r234",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r389",
      "r397",
      "r412",
      "r439",
      "r441"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Total current assets",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r135",
      "r234",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r389",
      "r397",
      "r412",
      "r439"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "TOTAL NONCURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain": {
     "auth_ref": [
      "r142",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats.",
        "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]"
       }
      }
     },
     "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis": {
     "auth_ref": [
      "r142",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats.",
        "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]"
       }
      }
     },
     "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AutomobilesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vehicles that are used primarily for transporting people.",
        "label": "Automobiles [Member]",
        "terseLabel": "Automobiles [Member]"
       }
      }
     },
     "localname": "AutomobilesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r335",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r335",
      "r337",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "terseLabel": "Equity interest percentage"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_CapitalExpenditureDiscontinuedOperations": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capital expenditure attributable to discontinued operations.",
        "label": "Capital Expenditure, Discontinued Operations",
        "terseLabel": "Future minimum capital expenditures amount"
       }
      }
     },
     "localname": "CapitalExpenditureDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r43",
      "r441",
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash",
        "verboseLabel": "Cash transferred (in Dollars)"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r43",
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash, end of year",
        "periodStartLabel": "Cash, beginning of year"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r111",
      "r414"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "terseLabel": "CHANGES IN CASH",
        "totalLabel": "Net increase (decrease) in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Price per warrant (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r58",
      "r280",
      "r484",
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r281",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r145",
      "r146",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary Shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "verboseLabel": "Ordinary shares par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, shares authorized",
        "verboseLabel": "Ordinary shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, shares issued",
        "verboseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r30",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r30",
      "r441"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares, $0.003125 par value, 100,000,000 shares authorized, 21,750,000 shares and 16,000,000 shares issued and outstanding as of September 30, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r81",
      "r91",
      "r387",
      "r388",
      "r405",
      "r489",
      "r517"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income attributable to the Company"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r81",
      "r90",
      "r386",
      "r405",
      "r488",
      "r516"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r258",
      "r261",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Software [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r210",
      "r410",
      "r411",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r210",
      "r410",
      "r411",
      "r532",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r210",
      "r410",
      "r411",
      "r532",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r160",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "CONCENTRATIONS"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/Concentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r210",
      "r410",
      "r411",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r143",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "terseLabel": "CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CondensedFinancialInformationoftheParentCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r128",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionContractorsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r452",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for construction contractors.",
        "label": "Construction Contractor [Policy Text Block]",
        "terseLabel": "Construction-in-Progress (\u201cCIP\u201d)"
       }
      }
     },
     "localname": "ConstructionContractorsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateMember": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate Segment [Member]",
        "terseLabel": "Medicinal liquor products [Member]"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r94",
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Sales of third-party products"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfOtherPropertyOperatingExpense": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other operating costs incurred during the reporting period and may include amounts paid to maintain the property.",
        "label": "Cost of Other Property Operating Expense",
        "terseLabel": "Sales of TCMD products manufactured by the Company"
       }
      }
     },
     "localname": "CostOfOtherPropertyOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r95",
      "r135",
      "r234",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r412"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r365",
      "r372",
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current tax provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r133",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "SHORT-BANK LOANS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the total principal payments made during the annual reporting period.",
        "label": "Debt Instrument, Annual Principal Payment",
        "terseLabel": "Total amount",
        "verboseLabel": "Gross proceeds (in Dollars)"
       }
      }
     },
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r56",
      "r307",
      "r426",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Fixed interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Loan term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeconsolidationRelatedPartyDescription": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of related party involvement in transaction resulting in deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer; and whether former subsidiary or acquirer of group of assets would be related party after deconsolidation and derecognition transaction.",
        "label": "Deconsolidation, Related Party, Description",
        "terseLabel": "Related party description"
       }
      }
     },
     "localname": "DeconsolidationRelatedPartyDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred initial public offering (\u201cIPO\u201d) costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred Costs, Current",
        "terseLabel": "Deferred initial public offering costs"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r350",
      "r351"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r117",
      "r136",
      "r366",
      "r372",
      "r373",
      "r374"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax benefit",
        "verboseLabel": "Deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r70",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Payment for deferred offering costs amounted"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry-forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r359"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Comprehensive income amount"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r117",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r117",
      "r268"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsShareBasedCompensationCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash dividends declared for award under share-based payment arrangement.",
        "label": "Dividend, Share-based Payment Arrangement, Cash",
        "terseLabel": "Cash dividend (in Yuan Renminbi)"
       }
      }
     },
     "localname": "DividendsShareBasedCompensationCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromOtherRelatedPartiesCurrent": {
     "auth_ref": [
      "r60",
      "r139",
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount receivable from related parties classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Due from Other Related Parties, Current",
        "terseLabel": "Total due from related parties"
       }
      }
     },
     "localname": "DueFromOtherRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r139",
      "r285",
      "r287",
      "r288",
      "r292",
      "r293",
      "r294",
      "r433",
      "r483",
      "r513"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r50",
      "r139",
      "r285",
      "r287",
      "r288",
      "r292",
      "r293",
      "r294",
      "r433"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r57",
      "r139",
      "r285",
      "r287",
      "r288",
      "r292",
      "r293",
      "r294",
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.",
        "label": "Due to Related Parties, Noncurrent",
        "terseLabel": "Total due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash",
        "verboseLabel": "EFFECT OF CHANGES OF FOREIGN EXCHANGE RATES ON CASH"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r137",
      "r353",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory PRC income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r353",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r353",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Impact on DTA due to change in applicable income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r353",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent",
        "terseLabel": "Permanent difference"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r353",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Non-PRC entities not subject to PRC income tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r353",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent",
        "terseLabel": "Foreign tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign": {
     "auth_ref": [
      "r353",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in foreign income tax contingency.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Percent",
        "terseLabel": "Subject to profit taxes rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingenciesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxHolidays": {
     "auth_ref": [
      "r353",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income exempt from income tax because of a tax holiday.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Holiday, Percent",
        "negatedLabel": "Effect of income tax holiday"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxHolidays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftablereconcilesthechinastatutoryratestothecompanyseffectivetaxrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r83",
      "r84",
      "r85",
      "r145",
      "r146",
      "r147",
      "r149",
      "r150",
      "r152",
      "r157",
      "r235",
      "r322",
      "r324",
      "r340",
      "r341",
      "r342",
      "r368",
      "r369",
      "r408",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r526",
      "r527",
      "r528",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Offering price percentage",
        "netLabel": "Percentage of ownership interest",
        "terseLabel": "% of Ownership",
        "verboseLabel": "Equity ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the entity's equity method investment which has been sold.",
        "label": "Equity Method Investment, Amount Sold",
        "terseLabel": "Investment amount"
       }
      }
     },
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Financing Receivable, Allowance for Credit Loss [Line Items]"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis": {
     "auth_ref": [
      "r220",
      "r223",
      "r224",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of financing receivable determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk.",
        "label": "Class of Financing Receivable [Axis]"
       }
      }
     },
     "localname": "FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain": {
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing receivables determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk.",
        "label": "Class of Financing Receivable [Domain]"
       }
      }
     },
     "localname": "FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Less: accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r264"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2022",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r258",
      "r259",
      "r262",
      "r265",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r262",
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r258",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r262",
      "r461"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofestimatedfutureamortizationexpenseforintangibleassetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoffutureminimumcapitalexpendituresTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignFinancialInstitutionsMandatedDeposits": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of mandated deposits required of branches of foreign institutions.",
        "label": "Foreign Financial Institutions, Mandated Deposits",
        "terseLabel": "Deposit at financial institutions (in Dollars)"
       }
      }
     },
     "localname": "ForeignFinancialInstitutionsMandatedDeposits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss from disposal of fixed assets",
        "terseLabel": "Loss from disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0",
      "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvstmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r93",
      "r135",
      "r182",
      "r194",
      "r198",
      "r201",
      "r204",
      "r234",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r412"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesTextBlock": {
     "auth_ref": [
      "r228",
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity [Table Text Block]",
        "terseLabel": "Schedule of short-term invstment"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r267",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r88",
      "r182",
      "r194",
      "r198",
      "r201",
      "r204",
      "r475",
      "r487",
      "r493",
      "r519"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax provision"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r89",
      "r117",
      "r179",
      "r231",
      "r486",
      "r514"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Equity investment income",
        "verboseLabel": "Equity in earnings of subsidiaries"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r354",
      "r356",
      "r362",
      "r370",
      "r376",
      "r378",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/Taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r138",
      "r151",
      "r152",
      "r180",
      "r352",
      "r371",
      "r377",
      "r520"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofcomponentsoftheincometaxprovisionbenefitTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.",
        "label": "Income Tax Holiday, Income Tax Benefits Per Share",
        "terseLabel": "Tax holidays on net income per share"
       }
      }
     },
     "localname": "IncomeTaxHolidayIncomeTaxBenefitsPerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r348",
      "r349",
      "r356",
      "r357",
      "r361",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r114",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income tax"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in investment income that has been earned but not yet received in cash.",
        "label": "Increase (Decrease) in Accrued Investment Income Receivable",
        "terseLabel": "Accrued investment income"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInvestmentIncomeReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvstmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Advances to related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidAdvertising": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for advertising that provides economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Advertising",
        "negatedLabel": "Prepayment for advertising"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidAdvertising",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidSupplies": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Supplies",
        "negatedLabel": "Advance to suppliers, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidSupplies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount of cash payments due to taxing authorities for non-income-related taxes.",
        "label": "Increase (Decrease) in Property and Other Taxes Payable",
        "terseLabel": "Taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInPropertyAndOtherTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r129",
      "r261",
      "r457",
      "r458",
      "r459",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r256",
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDebtExpense": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.",
        "label": "Interest and Debt Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestAndDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r86",
      "r176",
      "r424",
      "r427",
      "r492"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseCapitalSecurities": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense incurred during the reporting period on capital securities issued by the reporting entity.",
        "label": "Interest Expense, Capital Securities",
        "terseLabel": "Total amount of capital expenditure"
       }
      }
     },
     "localname": "InterestExpenseCapitalSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseOtherShortTermBorrowings": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense incurred during the reporting period on other short-term borrowings.",
        "label": "Interest Expense, Other Short-term Borrowings",
        "terseLabel": "Income from short-term investments"
       }
      }
     },
     "localname": "InterestExpenseOtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeShortTermInvestmentOther": {
     "auth_ref": [
      "r562",
      "r563"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income from short-term investment classified as other.",
        "label": "Interest Income, Short-Term Investment, Other",
        "negatedLabel": "Short-term investments income"
       }
      }
     },
     "localname": "InterestIncomeShortTermInvestmentOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r109",
      "r113",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest expenses"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY, NET"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/InventoryNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReservePeriodCharge": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r250"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.",
        "label": "Inventory, LIFO Reserve, Period Charge",
        "terseLabel": "Inventory reserve",
        "verboseLabel": "Accrued inventory allowance amounted"
       }
      }
     },
     "localname": "InventoryLIFOReservePeriodCharge",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0",
      "http://www.UniversePharmaceuticalsINC.com/role/InventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r7",
      "r65",
      "r441"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net",
        "totalLabel": "Total inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r66",
      "r130",
      "r156",
      "r248",
      "r249",
      "r252",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Inventory, Raw Materials and Supplies, Gross",
        "terseLabel": "Advances to suppliers for inventory raw material purchase"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r65",
      "r251"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Inventory valuation allowance",
        "terseLabel": "Inventory reserve"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofinventoryTable",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentBuildingAndBuildingImprovements": {
     "auth_ref": [
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements.",
        "label": "Investment Building and Building Improvements",
        "terseLabel": "Total estimated budget"
       }
      }
     },
     "localname": "InvestmentBuildingAndBuildingImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r233",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments in Equity Securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investment in subsidiaries"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r53",
      "r135",
      "r196",
      "r234",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r390",
      "r397",
      "r398",
      "r412",
      "r439",
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r37",
      "r135",
      "r234",
      "r412",
      "r441",
      "r480",
      "r506"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "terseLabel": "Total liabilities and shareholders\u2019 equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r55",
      "r135",
      "r234",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r390",
      "r397",
      "r398",
      "r412",
      "r439",
      "r440",
      "r441"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "ACCOUNTS RECEIVABLE, NET"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LoansPayableToBankCurrent": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer.",
        "label": "Loans Payable to Bank, Current",
        "terseLabel": "Borrowing amount"
       }
      }
     },
     "localname": "LoansPayableToBankCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Maturity30To90DaysMember": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period that is more than 29 days but fewer than 91 days from the reporting date for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements.",
        "label": "Maturity 30 to 90 Days [Member]",
        "terseLabel": "Maturity date on March 31, 2021, interest rate 4.81% per annum [Member]"
       }
      }
     },
     "localname": "Maturity30To90DaysMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaturityOver90DaysMember": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period of over 90 days from the reporting date for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements.",
        "label": "Maturity Greater than 90 Days [Member]",
        "terseLabel": "Maturity date on June 18, 2021, interest rate 4.81% per annum [Member]"
       }
      }
     },
     "localname": "MaturityOver90DaysMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "terseLabel": "Net cash provided by financing activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "terseLabel": "Net cash used in investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r111",
      "r115",
      "r118"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetInvestmentIncome": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.",
        "label": "Net Investment Income",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "NetInvestmentIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Reporting segment"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r182",
      "r194",
      "r198",
      "r201",
      "r204"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r5",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BUSINESS DESCRIPTION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescription"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r54"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r72",
      "r75",
      "r413",
      "r420"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "negatedLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other income (expenses), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expense classified as other.",
        "label": "Other Selling, General and Administrative Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "OtherSellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r70",
      "r485",
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Other Short-term Investments",
        "terseLabel": "Held-to-maturity investment amount"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortTermInvstmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent [Member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromShortTermInvestments": {
     "auth_ref": [
      "r98",
      "r100",
      "r120"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments for (Proceeds from) Short-term Investments",
        "negatedLabel": "Payments for short-term investments",
        "terseLabel": "Payment for short-term investments"
       }
      }
     },
     "localname": "PaymentsForProceedsFromShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.",
        "label": "Payments for Repurchase of Initial Public Offering",
        "negatedLabel": "Payment for deferred initial public offering costs"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividend payment"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Less: redemption",
        "terseLabel": "Redemption of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvstmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToSuppliersAndEmployees": {
     "auth_ref": [
      "r107",
      "r108",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.",
        "label": "Payments to Suppliers and Employees",
        "terseLabel": "Advances to suppliers"
       }
      }
     },
     "localname": "PaymentsToSuppliersAndEmployees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofadvancestosuppliersnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaymentFeesOnAdvancesNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.",
        "label": "Prepayment Fees on Advances, Net",
        "terseLabel": "Prepayment amount"
       }
      }
     },
     "localname": "PrepaymentFeesOnAdvancesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net Proceeds",
        "verboseLabel": "Net proceeds (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Gross proceeds from initial public offerings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of ordinary shares in IPO"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from disposal of fixed assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from short-term bank loans"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r4",
      "r78",
      "r80",
      "r85",
      "r110",
      "r135",
      "r148",
      "r151",
      "r152",
      "r182",
      "r194",
      "r198",
      "r201",
      "r204",
      "r234",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r386",
      "r392",
      "r393",
      "r404",
      "r405",
      "r409",
      "r412",
      "r493"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income for the year",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0",
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAdditions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r47",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r274",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r46",
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r19",
      "r20",
      "r271",
      "r441",
      "r494",
      "r508"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r271",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r19",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, plant and equipment, net consists"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r19",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofpropertyandequipmentestimatedusefullivesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r92",
      "r238"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r31",
      "r39",
      "r441",
      "r507",
      "r535"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r333",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r333",
      "r432",
      "r433",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the terms and manner of settlement of the related party transaction.",
        "label": "Related Party Transaction, Terms and Manner of Settlement",
        "terseLabel": "Relationship with the group"
       }
      }
     },
     "localname": "RelatedPartyTransactionTermsAndMannerOfSettlement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r333",
      "r432",
      "r436",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduefromrelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofduetorelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r430",
      "r431",
      "r433",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfAdvancesForConstruction": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payments made by the entity, generally on a straight-line basis over periods ranging from five to forty years to developers, builders, government agencies and municipalities for borrowings received in construction.",
        "label": "Repayments of Advances for Construction",
        "negatedLabel": "Prepayments for construction in progress"
       }
      }
     },
     "localname": "RepaymentsOfAdvancesForConstruction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to settle a bank borrowing during the year.",
        "label": "Repayments of Bank Debt",
        "negatedLabel": "Repayment of bank loans"
       }
      }
     },
     "localname": "RepaymentsOfBankDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r347",
      "r456",
      "r554"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r126",
      "r476",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted amounts (in Dollars)"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r33",
      "r324",
      "r343",
      "r441",
      "r505",
      "r529",
      "r531"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r145",
      "r146",
      "r147",
      "r149",
      "r150",
      "r152",
      "r235",
      "r340",
      "r341",
      "r342",
      "r368",
      "r369",
      "r408",
      "r526",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining total amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforAdvertistingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Remaining payable percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r87",
      "r135",
      "r173",
      "r174",
      "r193",
      "r199",
      "r200",
      "r206",
      "r207",
      "r210",
      "r234",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r412",
      "r493"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofrevenuebyproductsourceTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price per share (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "auth_ref": [
      "r12",
      "r50"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable": {
       "order": 2.0,
       "parentTag": "us-gaap_TaxesPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Sales and Excise Tax Payable, Current",
        "terseLabel": "Value added tax payable"
       }
      }
     },
     "localname": "SalesAndExciseTaxPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of accounts receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountsReceivableNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of table reconciles the china statutory rates to the company\u2019s effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable": {
     "auth_ref": [
      "r240",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about allowance for credit loss on financing receivable.",
        "label": "Financing Receivable, Allowance for Credit Loss [Table]"
       }
      }
     },
     "localname": "ScheduleOfFinancingReceivableAllowanceForCreditLossesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofthecompanysaccountsreceivableandsubsequentcollectionTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r258",
      "r261",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r258",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets, net consist"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.",
        "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]",
        "terseLabel": "Schedule of currency exchange rate"
       }
      }
     },
     "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.",
        "label": "Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]",
        "terseLabel": "Schedule of future minimum capital expenditures"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforConstructioninProgressCIPProjectTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of components of the income tax provision (benefit)"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of intangible assets estimated useful lives"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r14",
      "r40",
      "r41",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r47",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofPropertyplantandequipmentnetconsistsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r434",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofnatureofrelationshipswithrelatedpartiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of nature of relationships with related parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r182",
      "r185",
      "r197",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r182",
      "r185",
      "r197",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of total revenues by product categories"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table Text Block]",
        "terseLabel": "Schedule of short-term bank loans"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShortBankLoansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.",
        "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]",
        "terseLabel": "Schedule of subsidiaries of the company"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table describes the key aspects of a subsidiary (partnership, corporation, or other entity) of the Limited Liability Company (LLC) or Limited Partnership (LP).",
        "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "terseLabel": "Schedule of revenue by product source"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated future amortization expense for intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r169",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r210",
      "r275",
      "r276",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r169",
      "r171",
      "r172",
      "r182",
      "r186",
      "r198",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT REPORTING"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services.",
        "label": "Selling Expense",
        "terseLabel": "Selling expenses"
       }
      }
     },
     "localname": "SellingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "terseLabel": "Business Combination [Member]"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by supplier.",
        "label": "Supplier [Axis]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.",
        "label": "Supplier [Domain]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConcentrationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate",
        "terseLabel": "Ordinary shares percentage"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in Dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in Shares)",
        "verboseLabel": "Ordinary issued shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)",
        "terseLabel": "Ordinary shares issued and outstanding"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShippingAndHandlingCostPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.",
        "label": "Shipping and Handling Cost, Policy [Policy Text Block]",
        "terseLabel": "Shipping and handling costs"
       }
      }
     },
     "localname": "ShippingAndHandlingCostPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "auth_ref": [
      "r49",
      "r512"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.",
        "label": "Short-term Bank Loans and Notes Payable",
        "terseLabel": "Short-term bank loans"
       }
      }
     },
     "localname": "ShortTermBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r24",
      "r441",
      "r478",
      "r502"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt",
        "terseLabel": "Total short-term bank loans"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Invstment [Abstract]"
       }
      }
     },
     "localname": "ShortTermBorrowingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshorttermbankloansTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r26",
      "r481",
      "r482",
      "r498"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "periodEndLabel": "Ending balance of short-term investments",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofshortterminvstmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r127",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r2",
      "r169",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r210",
      "r255",
      "r272",
      "r275",
      "r276",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftotalrevenuesbyproductcategoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r59",
      "r83",
      "r84",
      "r85",
      "r145",
      "r146",
      "r147",
      "r149",
      "r150",
      "r152",
      "r157",
      "r235",
      "r322",
      "r324",
      "r340",
      "r341",
      "r342",
      "r368",
      "r369",
      "r408",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r526",
      "r527",
      "r528",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable_Parentheticals",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofcashflowsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r157",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r29",
      "r30",
      "r322",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r29",
      "r30",
      "r322",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of ordinary shares and additional shares under overallotment option in initial public offerings, gross"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockDividend": {
     "auth_ref": [
      "r59",
      "r322",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued to shareholders as a dividend during the period.",
        "label": "Stock Issued During Period, Value, Stock Dividend",
        "negatedLabel": "Dividend declared"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockDividend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r30",
      "r35",
      "r36",
      "r135",
      "r225",
      "r234",
      "r412",
      "r441"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Total shareholders\u2019 equity",
        "totalLabel": "TOTAL SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanybalancesheetsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r134",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventDescription": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.",
        "label": "Subsequent Event, Description",
        "terseLabel": "Subsequent event, description"
       }
      }
     },
     "localname": "SubsequentEventDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r422",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r422",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r442",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership [Line Items]"
       }
      }
     },
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofsubsidiariesofthecompanyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/OrganizationandBusinessDescriptionDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/ShareholdersEquityDetails",
      "http://www.UniversePharmaceuticalsINC.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalDeferredPurchasePrice": {
     "auth_ref": [
      "r123",
      "r124",
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.",
        "label": "Supplemental Deferred Purchase Price",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "SupplementalDeferredPurchasePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/PrepaymentforPurchaseofaPropertyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Taxes payable",
        "totalLabel": "Total taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedCashFlow",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleoftaxespayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r27",
      "r479",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.",
        "label": "Taxes Payable",
        "terseLabel": "PRC corporate income taxes"
       }
      }
     },
     "localname": "TaxesPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/TaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to temporary equity resulting from foreign currency translation adjustments.",
        "label": "Temporary Equity, Foreign Currency Translation Adjustments",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "TemporaryEquityForeignCurrencyTranslationAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofparentcompanystatementsofincomeandcomprehensiveincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r215",
      "r216",
      "r218",
      "r219",
      "r222",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Bad debt recovery"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofallowancefordoubtfulaccountsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r158",
      "r159",
      "r161",
      "r162",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Uses of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseRightsMember": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal right to use or benefit from the use of natural resources or access. Examples include, but are not limited to, drilling rights, water rights, air rights, timber cutting rights and route authorities.",
        "label": "Use Rights [Member]",
        "terseLabel": "Land use rights [Member]"
       }
      }
     },
     "localname": "UseRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsestimatedusefullivesTable",
      "http://www.UniversePharmaceuticalsINC.com/role/ScheduleofintangibleassetsnetconsistTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average number of shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.UniversePharmaceuticalsINC.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-04(Schedule I))",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=120391182&loc=d3e5864-122674"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3098-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A)(3))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5066-111524"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5111-111524"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196772"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269825-111563"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921833-210448"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.L)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e99989-122729"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=d3e5283-111683"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991576-234733"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=6471471&loc=d3e48698-109348"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.8)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=117337116&loc=d3e65207-112826"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r555": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r556": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r557": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r558": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r559": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r561": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r562": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r563": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r564": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r565": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r566": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r567": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r568": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r569": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1404"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1404"
  },
  "r571": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(1)"
  },
  "r572": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(2)"
  },
  "r573": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(3)"
  },
  "r574": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(4)"
  },
  "r575": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1405"
  },
  "r576": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r577": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r578": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r579": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r581": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r582": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r583": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r584": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r585": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r586": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r587": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r588": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04"
  },
  "r589": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "i",
   "Publisher": "SEC",
   "Section": "3",
   "Subsection": "10"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r591": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4),(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>139
<FILENAME>0001213900-22-004359-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-004359-xbrl.zip
M4$L#!!0    ( !I /U1?)N!?!/8# #"X(@ 5    9C(P9C(P,C%?=6YI=F5R
M<V4N:'1M[+UY<]M(MB?Z/SX%QMUUP_4>)8N2=U=[1J7%5K<M^4IR5==,3+P
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M#4\WGFE^8I7E3J]M91U%<C9>:G'['ZK493=4_'U#U#WF"+_#J?\##_U$SOR
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MXAJL43(,8QJAH'UU_CR%H\WC]7"'WE/J^^F_^"))TS :C=2PHD^C25YG%;X
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M&R&EJ R8AOBD!@6!9Q"9XLW2#M4&U5Q*,40$K>316<3W/G]0K09@O@!G!1G
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M AG!%X@"?W!PJ".(W/->BS9/IBA:&B5<]>O/!#^H8TZBPAP7$=LXN0HCG57
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M%G0DZC \'&/@Q4&/U3TE&A&WLLR'"?D"3?HT;5?HLC(Z3X(S=IP3C7Z"!&V
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MT=:@2\5_>/.?"_NZ=TTB6!3.(X[DYX=<ECJAA6QWM/<V_]_1D!#DUJCABM5
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M]IX4L?=?];3R*$FQ1UXN3J'LM%L)7+(G@1WGPTAP+_\.'YQ%V5DYABT+_I[
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M?46?/W]*?]_<?,Z_]U_T^5_J^+?YXN5S_!W'??7FY_ QOEZZ!O@S@ E=2/>
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MF!A9XT'.T?-!V9#(>97-]#J;HBT<(_#@Z1F6_ J.!4H&?$7Y3$_[Q7U..!3
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MH3D;*I=<$\OP>FW.0Q=P$M>L54!ID,0L3SG<SI,UK(I25E6=8!077BRC6X>
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M<(I?S]TVB5LV+54VQ88PX#V8O?(;'__;V.DV4TYW3%K1#-1OQ,MZIM1#Q.2
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MBIM9E/Q\RR7VEU7;-XAYZ!'ON/UZ?/STR5?_Y_\Y/G3+C_Y[=/_X$7X^>OB
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M7ZV<[49_!BM1TFU#M3,DDB13.#5W[KX2)S;6&O0C^L1I0) <'A]/E./]P3#
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M3W6O<G@*KEL*<9Z14(!S]X\>/PXLN>([IT6E3)3,#2Y=U6BP;"VMW8E91+Q
MM4WVN'E;<#0W-MC8*_#65U;# ;S, /^4ME?XTK9I**NY,R$7,1"?IT^3P'B
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M<9 ]E[]-KKADD]&(!C>@'<"[*<6P2FGF6HLXR]WTDOC-ECOH!>#GSAQBFR-
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M\;K:)K!.*%,=<OF33>5DX;;<XHN7[3X=H"]2)W2OG;-!VGBKJ>Y9PNKS&;^
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M74+XSZHL<3@:'2NI&UF3#\N*1JR(LA*MF&$LA\>S%Q$VAG5=SIP723FO*E"
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MLJ["/N II\W^+U\]E$5V[H[:OU<%!_[?_17W\C^_LZNSJB[KT]W"SS>]=;P
MS0]MR&*3U?JO1XLGAX\7#P\?ZSRDT+[A3"T!YE@GO*&!ML4Y*B3KV8:'OG2N
M,$N&7VD7O\-DL31JH*_QENA<<8MJA Z\O;OX-I30CN82VJ<LH3V92VB_M^WW
M46FUKCRJV3&DU"SR3>0;YX5S/0OJD@97$Q\;VYQTDBM)=H8_4Z4F.G5;ABJ!
M^=-YAWDPQ3MEGKE\2.QA+"F$@#R\IX6AH6HV \U7C>5CGKJ4+9*O7>0!V##&
M110+FD$U TR14E'AMBSW=,J0NBUS;KODV>')V?%'Z)2*9J&:A(P6GKG2MM;B
MIESA.#!7I[D_')%$,_=:A_ 60Y#/NH<,H'9Y7&J3XJS#-M_])\^B(*NW8XEE
MP-'<L'OB90P0[:@H25#01M(_"_84&4[#/>RX@%];$O_&WH%S9R@@_*7N[,L3
M= RBU.6O8?9=@\!1>G-Q5(+CE+I+9PU:'LLZ#Q#CR8=:^)$-+V+VWNXJ3TAN
M3ED.1+[Q;N4Z1;)G#[+G$Q[Z->8#E%U1O2OLK01^EE1VJS GLKN3R/F%+_W2
MOKT!:"R-/*IH.QO$X^WJ131F$Q5PW346^)HBFI&UG\:_:OU@[0:TXTR$/2=;
MHV7!OA5*V)5;EM&;"/A264QXCT8*0ZD*$XA'?[8R<!3L SGXY,:ZTO_WFSRI
MD8A-,>F<M:+!L&=G#.T-'PM%HV3]E/%(R;V(982TJWU")W?A[*;G5\KLN<YV
M:(G?5S^8XP,9C9#X1%HZ9*TB#OUTH5Z^$B\QU^:CK<0?K4!XF3P[S!A.:*D,
MC6)H]+E2^$]V3:P+[544?W,],@>]**,KZ1)RKXK7.--'KH) P40=V@J LHK+
MR29*<?D&EKE ^:MV:<(3])%ZW(CY5KO5YH;+7P_85E1%QZGEJ$4@1C7K ?Z7
M(J].WQ<^P;.0]DL]?\GXL)D[>OKTR2 71,GL_5\X/CPZ7)B<)/G<0.Z1LM\Z
M<M;)* SO/F=2;F[1N*,+#*^G37U!3 XGX_:XF'?\)%^1\65D8T?<[8/C/^T\
MB7JA@+U"F>@"<,:HDZ>Q=7/J7!@6BC6\B)YJ+O9P4-T^TH0M77R4QO3+](T[
MZ3?YRO9H(6RSE]\_7R 5F#!XAKK5F%;<>Z=<M64V^]!1J>T+3%+FQ2DYSN35
MGXU6?YQAI<&$?1/*V>Z8>^6.9\[Z'CTP?'M,M_LLM9N.8]OXNA10]4V%#[5
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MYE=(.[2"NSTCEN^J1P;,&>;_]\FC>X>/GSZZ]^3!X?W[AT\YZ11U _#C38M
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M_$VJ$:.]]*)8HTUV76\3Y $%2"!11;7X^#X.E9Y1V.Y>&4,!O/I,[IS9S19
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MC%YD-D^T!4(]FX&$D[_R),E7\F_$EF1QOT"ZZ3]LN.!-%F "U7N8&GTA-'?
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MSA"2F#>D,)B<)Y5<6PJ3SA/8<OP Y@%F^'H/@YSEO!5W34[ <,'\54Y((@W
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M/+QPS*+@BE$M'>( _+RF)_0S[HQ'G<$VH.$<H22QK=H>$</*C4C0+8,^#?U
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M-PN:B'*+J-!2 6U*A;)3!U;OMET0Z&SOQBYP=L5-\S55-LV ,/@ILX!U#E1
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MTI29K[EF1!)5>._%2@V!1+1JJ/Q=U2>7Y(1NM((*2ACTPGE*F9;9AH6EF(@
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M+GJ!8/\'E5F)LQGD;E \9O0M@R#%_A*-*#'+&>RB12*:8O791PHH %*"L@(
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MJ-+\:G=D08XB3,%>"X*R[T5@*F/ L3V"NS[85-)2A=9<V<6]UG=86%1%U^%
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MD&_2CPFG@X'NHC* 9MV"90\0W16O7.3*Z,:Z:LI &?$9]2# J58@._!>XU[
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M5R1@J^R.[CCPJR@=\V0^098L0WFPY>E,@BE]GO* 1YCT"[?9*2U W%NQ?V%
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M.PS^Q$.<Z^M4.]W5>%\889_SG)?5ML!7!WG(99:[, T!BLB7N:_R#LTYZ36
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M!!JA0:YY*<F *SH4:-4T8NF;.,PQXQ$[;4B6.Y3>\&GPG:+P:D^XGR>>3O"
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M.&=:3.$>8M,2ZIX9YF+,C&B3(_J;+'L=ASU.Q71F-;CD8S[@D?DO/R(Q_#7
M6<"7$Q[1P(D_>)#"O]7O_Y'#8[G\ 5ZY_IYSG+I^?9T'YN5=DL^8^4?^5X!_
M^PO?O\ ^YW^G/K_,_  +9?C;SV(RCA\:^"<<M5E\L/B3J?[T#X2@X?>X6CH)
MLN:W$#N7$_B!QL(/\@6/B!$7X<AHP*99Q]57'(?#,W\:A^;'!,XT%+U*WT^"
M<)1P(/=/*;R< O''6?$$KOV/ + 4!H"ZF2\P]?)=6C;TN4HHN'$ :3GF>W!G
MV,SS7&9[-BE^8B9U'ZXJ$_>_3%,0?Q<=>ZB=>'%7BYX599+%\H=M<4T;6NZH
MH:RJ.5<CS":FS"D *9%2FUZ[ #1*.EWZF 1*?<A8W!>HZ660$Z(;?Z2!6G_7
M)-%5'U"JVH<'8O)4L821KCK-EGDVC>7,@<IDT5J\"%^OG?84AYIB&7H^G)3O
M4S]\L:&E5W3 9;]<6* R(D<T0A,8]1M-C964::(QJ4[Y-3H7T#PQ$.Y%A_P:
M/3"%$=-T3*P ^99K7ZN EBZ"3;:'H_9L1OFR/@A8ZZ(GALF'Y9Q8-806!1$V
MP*M3C"D'NR>-E;UUD/#O1A,B:J1]N,QNQ#5FYS#;=N$*6!JSPP2?@ML5.5!+
M&9C=)VZW+FM4(^3*<<O4M%H'_=9/40\9Q]A;]21X:XY$$W'J&IYGU.I5C/V=
M)3CW0VOP35TD04>:Q8F0EL,P3M5D%_Q0=9*8;+L(FHXA^ZM-?)QX,*5Q)=A)
M.TZRLF%A,5P<(*+W93?"(!Z)AS[P09+C+ ML63C7EEP(>1KH+-@;P4JMP_-(
M#L@R9._'<1Z.L5$U[5@PR6)ZF>2=!00@X24(6/ .[[^C#YT$@#B_X(8:PA=P
MPWER,/I"125F6+S>P R;M+_%S%";H+<F1S0:R=>T6I[.$'M+6)T@T8)M+F*(
M5H4AXD@@&DP\*6 S"MAD__ Z5Z33$K.SXVDL&U82JN>F7%3%::4=9G6?F!)>
MRO>.Y1H+]B>$_ZIMT9@Z[%&*MP(.DT;3X&2962!'Z\%OP7Q(:EI',>)0J2=A
M//3EI)N$TV:O>7R=^+,)CC;!'>CD7NO@7I 2J*8I7C31K13'\0":I1'1+"5,
MVP&D%'@R'B J&E%88U;/+"IJ F.=!N6]=^8%C>(!<PU@N!3# HJNY9YWG(W\
M]&W+O6/;\JUIR?I)8[LC9%TTW4H?"QEC3V)@:&(ZA/KM-/B.S:,+IHSO*RFT
MHA,5R6Z:N8HO+'8%51K05 ?!%K-=]0;6J.T,@EA(TM <)?DU=EY%$0RL5 PI
M,J_#'#1KCL-#^2@*4ISL)%NP#G&4%-Q&_)DT +423H)-<C$QI%@/ES_E88Z6
MEI%FZH^ <7PERP=R%E5ZA\A#2&%-6!10\55;!O>:(BF1'Q#^\'>0]R.XG?\,
M^#7\9P:J3,J*L6_(T-,_\S <^C.<QP3"@<L_GP0W;XU1(*:]T2 3/@?R39#!
M-<<96X!SP!2.TYK%MW#Z$@%^. SRJ0 E2_=6UU_@F&QJ>%0Z(PVTM+%]$.@3
MV$9'.".QH\PS."/W]23FK:[&(R@T.IR[Z/;[S.YU-+.K7;IPBD3V-5Q,1?;_
M"@]310&<Y<#Y0-P8?(Q-TDEK%<JJLFB6:$X+/44+M?A&=%2<;AB+T33YMKU4
M1R=-'@.8*UP;TF8LOR2=:5QZ)1: Q@Q46>=&5=6'#C7Z-+1I2V4[;4W8F ,"
M! 3-G ?LL.]&Z=]#:X=93I\Y[;;NE'!+WU=1WK"&3V+=JT2C,D-AJDDZ-M:C
MXZJA!LKPFX*,O?XZ!ND*8J]1XWT):Y']9+6L]IN*4V"I_60T[GZA&=7L]I'3
M(Z)4S7%00]'4B*]B3ECMOK&*AY(\1L5U5F<S5]I%YIQTHY0>)NE,:0)P7^\@
M]EN7H]0:3E'@1<Q! 0T1(W]W1I!*51@'U8FA'FB3#_*,%YZ/27 ].?U/[M/D
ME +I-+T _R0FW )P+?./8FJ!F&<J9GM4!$W3 1JWXN@RH U>ETOHT*O*)C%.
M$&3:K9^,6IO"\J+AZ9OZSD<:5_.5QM5L_FN;WM4"&OVHS>3!P10<"0MI4!O>
M@P,6\Y2D-X[0N8[CD1PQ8;Z7<9OR=_5X*5YZ6 ?8X)W4 $[T6 7 &_H##,4"
MN?WI7R,IX6.@2' PLW!$(EJ(Y,(%[2D+_A(BOYDS%LQ)3L<8)]2761\K!')F
MPOW1VT;HI6H1E@P?Y(!FT"(H8BWQ=V:(8<\T15H3%XKO5Z=Q2T]L(=J:\%!\
M"0RN.Y+"Y.NN[&N)#B4\W:0**8DDQ@"5,DON3.8)2!P4AD<U@:+=!6.%F5X;
M+15<R.NWNLTVRYS)8F@JX=)4B3_4N&7IUYZ#1U,EQ71GX*D)#5^A4>4C?1*4
MG!M-0("BG7*.QJ@AY\3OJYS!8Q2SM<33%,;QG%8/C4T/\UT036!VNF\0+0:B
MYU')+>4')>,HIWM)".:O P5"BOE4DA@-.;8FF\1$V-KP&A5DX3[<+3'IAW1"
M"K?H ,CO*0H!^ICPB*RL.=%(006-#51$I:&& "F%-)[_@%+8%G] +EA^07Q1
M0XA@F9><R]%7?*0&8R%7J8_!LAO'8,DQ1AN@YLT1KA)R%\7 MG,YTFUO!>M%
M=3Z=FF!'<_9DKH,T=-3?F*'L6F+B(QQK3(HA*NK% O@WY&P4W11!([B4\0R]
M=<53&R&.%T?G/,(:4K- 444'I@@IAV.\=0- *O(H]98Q\X,BBBH46SBF-(XB
M'C(QS#X+TLIW=!%$IBKHN5R,XY9#\!+X(M.">44L[ZX\WG(]6"Q/$ND5K [_
M2\ ,!C"F'!0"H:Z0J)-P"F>1U(:$,D&?$]H"3I56H;V"$LQ&S%6$O-$1,EZ)
M^#8F2RZ5\(^2'E5YC^H8YD"J0&^)KE)U O.'K!B5'I#%S0?%Q$%H>*I<&R(.
M<OOK!UK7%Z31Q@P".R!MD+@^Z2?^+ "4!'_AO'4-!L'WR7(:%->5G!YI/D@I
M2I6I= $B3USPMAP/3HD+I4)3&:JM(MKS0>$R;JT"PGXF1GGCP<R'A#=FF*VK
M!:T34NT?HZ<;C9YVCM'3K8F>DA:[AL@OQ)RA:0\J(TKC:DKBX5I!E.8)S6DM
MF:-N3P.K)"$UR$B;2&[T!^'EF<AED((F  */JJL9,8[<Y2)6*"1NGHEIOAH[
MKLHUL1J)MO*9D+8NN#;P1YP&3),[Y:_&G-1C3)L"* ,-A);Y42#/6(8\2O/J
M4&Z=AUYB(>#:A8![2M%F5$7;&F>K23G6*.;4Z=(B!3J1#F2:;KF2'**,PL18
M3\!)>WH&1X!O3X*$%R%Y,?-9J$62HH8XL;G\LZ;.X(<C23%D#.$'29KAV1GS
MHX)+:WU>&Z@<^)C+.&C(KWW4S0!/F4SF&]T$*3J4)%$TN0DP\C:%'\Q9/@B#
MH0S[4]95D1MH:W(8+A3/9-K9IZ\7S^<N ,5:<9YGU*@Q=JB2 F8^IB"(E 7X
M#<['AL< O0'YN1)0,&'AOT2@"'2*0*8>)E*OT8(C99HDY5X+2]C/H^%$>) C
M@+E,&O\TUD;KBL<J3Z#[2Y_XS;_#'1+Y@*4:-.4\*X-_>"G4 .Q:?A]:XFK,
M-SP28?)"&I=)N\6RH!Z'(R0A_&,>Z=.WY7T2ZC>Z(8'# %I(&4QQ8>'XH"R^
M2G1G?JRY' VN1I2OL.DT:T<W(A7W-Y9S?U.W>LILVB"ZB<,;H:?BIA9"49H8
MK/18"JT:!0!RJ!P#1'*=RJL8FN6I0(@@@+F,GJI@*JV>:9#BM& _XG&>:GS_
MVRI<&<3U;9OR+6SE ;.UTJ\GM6C.TGE-7@)E5&A9Q'.69TEA] =KA^"!N9O$
M5 ZI9)6K">;> F%O6!Y]H'&&_ :_]T(\?!R'87Q+$08ZRI1G)#5!"OMP.:=3
M=(C(8#(R#K1YR%9,2OQH[G-U(82IBEP'B 0]!0P+_B?$00>P"$8D_2DZ$<KL
M>G@';2'4SBON YWET;4SJM>N^ 9&S0/D2O#WJ8C[I!/)B4VJ.,CB:TZ\@=0,
M$3#0]C0.4$W%"I@T@U^4Q9+*+P)RAJNH#+ K'J;\%AFXN!0!/ASEY/% G[/(
ML&E&%"("M EETL,2*,- "P+]13FE1%;^38$.%0U.@-'L0>Z)\@GB0/&%O%..
MEA;Y#W<-3QKR26N3ON!%*-C)&?5TR$!='#]S:K5LQ]-[;,BV&^K7=5?%.HV<
ME%/CJ<;S;F"$^8=5LGN=_3WW,/,=/+O.TQ]=TSSTISN='<;*TK[PAXF5WT&:
MHBUSO,U//"A]S8^L=J"?D1ZXXY2[ 0'U1DMDV1OL'*GF2#5'JMDZO-1:8SV_
M>'Q8!]?[B5!I9SF]-Z]^_G;^^_F7W\[G-ZY,L3=+^X 53ZW5[DT^W9][6O6;
M[+)^SV&66]-IEWZEF>R> /RE"R_80^,4W:5?J5'<\R,>;+RNY;)^YWZ0'Q'_
M6,1CBZ5NCUG=':9XKZ%+[#IX?TQGU/LQNP6BY?W%Y95Y\<%<P/]VKB>BX[".
MY[&>US[TYIB8;7_ S3'M#NO8%K/;N]DC]PDQ@?46!TP('6:U/=:U#YXAN)W6
MPW'P+*.D'NX!6SI)\..WB\M+\^NWBP^?KG;^%!V/N4Z'V<<9>5B5=,!\S6XS
MJ^^RWHXV@7]*3<>KSS,])$*P@:4ZS/4.GB-T^ZO'CCV=A'N<_-KB*4M'8([
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M]5!8ZN@%M9WU4T/1R%X[,72>QV NJ_P2?:"2(FJ4*:*+O0&;3!%]EHNV'9[
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M-C=:L=D[5FS>OPAI<[6:H,>]CU,J[_JF=.>J8H<B$0O@T$U3%$4"MX8/ -7
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M,*L,(.1U#K*X/UZE4SBM;6EKMSNX-C6(JXO!IV!M*SK.N25S:QGKBN&&U5
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M_-$TB((T0[E]PY_KBKO,Z7=8KUVK-WRQ*[Y^?YX-4C.:/6UG6Y#BM=:X5\_
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M"X]96Y7F, $NP] <% UY1JPR8HH6&.=9GO!&B! ;:3Y(J40JDP./&' Z7TQ
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MM]<(0<.-K)&:PH]P#@@.[&.:A[X:YZZ.BW\/1)YRF9Y\RQ7&93V1RF4VXJC
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ME'<>)"9^!OWC&7;QH%Y5V23ALE=#RU VS&\1A5\X$%#$E=-Y2NX_$4 !;04
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M.SO<$ZRQL&O;.U2Y+G.</G/M'>Y2M9.(/W&8YWC,]>Z'^+=;@O.3;KV!TG+
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MS>")L\0?!,-WYA=_R@66O\2(SHZKO_6#>HTP_0-"]C.=5X'J1:@?)-S_\W3
MQW$"Z\_H%/7M=QJVCT>D(UNCH0JQ-']<!QOW4Q+'4Y&Q J)&MYN])C\-?OXI
M^/F;F(R<MF"_ >!@\/,?W!SF20*T%=Z9LR0>Y7!.?C0R4AZ&INV:-WX2\"R
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M>/'68'&C5'G273/183TD;E-,=+.?N\@3,],%1&J.^##A?BH"0*\+&F5FG!B
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M;I_B7#]57Z;07N)SOES2"/T!5+>Z(=?NJR\1BOUI0BPHFO\7;.H:/>#P[:L
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M?R+&+N@LO8>VB#SN[8.^XX+*-JRV3FBY_8WXY@?=&?3"&78>V@+YF0'AED-
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MJS+(\58@JLX91'6G(*KC,XCJ]J!<1R(I'BX40 1,6XJ .H"\S?VCW1P?SS4
M^-:VE"XU5F_14[H"VE^%\VO":/)J'7D5K4:""I8 &;M&\TH,[6[&!<7X]\/V
M8ADGGZV _'P%Z5?==G$S%3#)COUWAN@K=C;([P[Q!V%PX%?EOPFK7B$L4H'6
M2CLVP@;Y7[W%,O3%0Y !L=E]<NVCJP+QIABV$+NLF4IJ83T$<E73!KS:UJ-C
M%Y7_N.Y#)< X%_3ZOAB-N.5+KX>(G-RE]L5 3 9C,>C6*/3R]D=B,NP)=U2#
MN&OBZ=:"4:YMF0(KZXU0J[+XL0V&E<?6JI_*QG8J]<I23?,?2[;V67"W':5
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M%RZ'?ULYS0XY3]8!-:):>_C\LL4?WHGL^+/%>R/1'1UG\]1'/ 6W:GH](QH
MYBIZWU [= H5 S55OD]:,K!9@AGU >5<K4TK/]A\X:;Z]^>3,5P+=W/R>>)-
M)?[G>S_I>V] ,6BY[8UBYJ OO XXH>W&]][O]A#RD8MM'9B2J#^#8_8Y4YRE
MN<>9DCGUW9;RK&=OQ4#\E'<+W[P(7MI>L;U231C'DHL;R'8S0Z/=C(PW-"Y-
MQFCJ&SO\W;<S;CNRFL<P\#0(PVGL)7,!1WKM_1M[>%+C4VR7$5K85L*STPQK
MWE/X\B5V L"__]T/IC%W.^#5%W*NX7]&GS1N55+(S]9=3'1Z=DW/"6R,%F"3
MC"C"MDAQ9.G.366C.KZ"F[XEP(Y"JP?L-8)-1-#@UBT6J%E#NL3"?6H"%Q?O
M@'K"89.*8%Y[N1;W!PFYE8GLG5";D9Y_&S?S ]Q]Y?+E9E1N0HLT>)6^P#3"
M852B$<?H_O-"!K4;B41F&C2W92XNLS$#7JV4"9:<2K@6].KHM;#[K9E>R5^Y
MZ1W-54N)1/>PXO,P,NMQ.@N^#!__R9\F&9XJ?(=_\QLA-^C^;IOZ\&(3GX3)
M 2G$?[4 WG0#C&:QC!,<>!;&*?;H*+;+#?C:L957C,=2[@($[XXJ;(@&U49*
MI\N]<N]P6E@W4<#42X.9(I3ZJ@@X(;G>@'X;Q'/JU %L\P<JM0#J0_*+"IW7
MTK41*.*1TO_/;:^&U'9)]KWB8$DSC7& J=KTTNP#>$=]F%+8T(R:,J:ZY5[]
MTE(_N57-5,SV*&%\'0#?GW%/G0CO@9H:ZU:/L*<$SU@-:^F13 Z%QX74QM,5
M& F>N>8AYB73]X#QI=BGR-/%'VI%U*HYR9;XA]2F75?(SLJ[0U$3.."]X7VA
M+PP,-R._(3!@[)FS\NUK/[Y.O.4--HW&"\6>3T$J&Q?ZQ+PD=]IPR]_4M>DS
MM:2C'M2O$ P%=HFE,_ LXX2^/PWP%V$^1H7_E64TK\>JZ\NX>3VOL7DCT#_F
M+6(U6=[\4W7-*4_GS6:8J"D+?@:JA3?8\M^I9B0K$S=8]R%IV8"DV-FOLY=:
M-#7I$U>@\>0FEM;K(I;6VWW5QNWU6% SO=X,,):+/PN4H#1@WJCS%U4AG=!5
M=#A6$(%8HJ;NNK0-7ASP/NQ_!H\36"_5OTV1CR /-#\(7UZRKB7KU_(6\7FA
M7'QUA>WSJ*47JRW9BEO%YP-M5!A2;'J;ZXKP8.'[*^^KY-O8G R^#@LA1Q5Q
MZG/%W+XK6\X5<P=<576NF#O=W9XKYK8\L'/MS<EN]7RU)[O5\]6>*^:>Q[=/
MHF*N3+U/7T;4'_;%H'?$M5ONJ)HS=.BU6P-W(D;]2ACR> Z]-SR^0[\8#H3K
M;'?HAU,P5Y,9]^0%<VT9WQO#6<;>N44,<_Z;?K&6]W][.K0S'HMAM19U3ZGJ
M3DU2Z]/GJKO=B7 FA](%P3D(Q'_,M1RTZ0RQ\_S]29MRAGVE[[>LV&GRA^_X
M["9CX70/I6O#X!#*4MS)2$Q&!U->W#V(I^Y,)F)<3:[?PUL?MJK1W*?L?E\7
M4MKU,QZ);A6M>&_/N$7QZJY)%AC;I'\H!?'#0V!L%XZ8= ]!7-<TM3@V<?UA
M4_AYYUKQ0(PGAR*W#X*\1R/1/Y@'/S@$  R@^GZ_Q<T\R8GT)U6 H,8CV8?8
M_ES(GFN1/;+K W.%TP:]Y&G4T$/HNS? A/=#>>&]0SB1BXGH=]N4KN]<I(\/
MN8*^'0.XC"-,6L6TS"M_UZ][Z S%9'PH5F9OV.;Z=OZ^^Z"@'@P6T"'H-(.A
M*[JC0SD2I^OVMC#M]B'$WS7GCN[^3;N.&%=KS_=U68>@@0X'8E)-D=N7!GH0
M$KO?%]TV@83=.]):M<@]2M";3RMOL42OF]$:Y62@;@9PB+UGWQVW5W6+/R.8
MDY$C1L[#43Y.A ;ZS[LYKM,3_?'#P7Y. .H&K,XC@+II[8"B^KX6)5F;MGRH
MF!G M+I L]64@3-6RDECI3@"J[1[DXV\ZGSO)W7O;G\HNKV'MI$]A5NO,;&.
MOXEN[]Q$=Y=-=$?=<Q/=@VFBV[9(7L&9S!F#AAD?(^( #_A.0SI)0;@&TDFJ
M2 ^"=,IA52P):U%;PG[E2U05Z5ZNFZN,<U%%1:K XN@SL+UL'JQP&JL G603
M=!(66M,'4@U;$Z"'-L 5KKR5CP >:4M\"\%')U$NQKI;[KN/'QA"".&.K!+>
M#'Y@,WX G1"'T.DB,8#]G<"-XI?B9$7CF 2!3F<-!"1PBM1?X3 77^%RK%K(
MI0)T0HX&4HNAH(&82I-J-"9:,N?H,^VYG=YW.<Q-&-_YB>51?1N>O1=%&1SZ
M-(ZRU+[S"".&J<JO3 /$#I<#.WH8L=!5W)O 4T@:&@1"[I"A?CC5D"''1AWG
M.P(,DX\PQ/M9^>C5*R#A>#:,BD0'7'Z!>YMT[;EWGW;L'XDB8SYRX + EY#
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MNL:JI)=%[!_ =WH-LZ;TEN32L  .1V2]T%]AO_HUO?E^D_X4ZDA:YT]1XU9
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MD#IBXHY.M3GI=F\8FU"\8!S=MEGA#0^XK.$5'K"48H9O_F3;LSS@_!D^N&W
M]R'G3SEK0]%S^\5>)51N,G$LUCF"=!FG;!:8W^X\\0GN1=3_I"&13TS4;YN;
M4(<-7237',JYG<@757+=>7;"V?(ZF=#/1\6L.+LN%^W5%FS=+C6JI(35JRO@
M74C0!0VN]!U7C(9]^@YE$.(?=,>T<Z+XF3 WIL44)>D ["#"N\K++HFN#,U<
M>LQ0>PZP]2D(;%5+?":V0R>V??J?_C#96-&V-1K7D:?><<2P/RXV;"QV:I1?
M1"=VGCCH$Y!OM0=C;=.[M8TL8;9$M17D)&Z8(TM8,57!7EI?ZN<34@P^BJ-7
MJF4NV)]>HESBN %JG0J'-3^8C.:#@"#=3GV3C2^V+P(^ZV['R;6.0'=SL/1#
M=*7NMDYCTY_4,;IJX17'CZ9I, \P6/AGA-EWP&D^)^BSP]&#.79-'NLD.E+\
MX''H-KTDMG7O7'+$K7(7Q@IV+3A,)BUO&B#O14[1.&3*Q6GPR2&-HB: [%07
M8]KP/(-0J@,]1YQ5@O/CVORXY"-!JIK[5WZ2$"[(- QF:/[X]#IF<:H=Z([H
M#OOP;M1G2Q_*U0 M\1F*+O2OO5  C8+<OX,'04YH,K* ]"GZ>X5]A)FF_>06
MO=428H=<?S!PY#,*([FNE?M8E2\3+!!&]5&]6%OUC"%XUC4(AT[MB=)HZW?5
ML0D0B'=(&H;^(+\Y7 S&N(RR"5B;P/?.@6=\[%Q@I;YH#";-3._:0]<U@YVH
M^95ML-=WW"9?;'+.%]MIOMCPG"]VECPG98P6];J-UJB+ZMK9&MVU;;3O2-=F
MVS/O<KA]>>/9_'P GVK;G.#TF52S\=FC_BR#1I,2R;!@4E)EP:^!%UU_#7+K
M$ME"T=2$KTTQ%0(CJ;G5QQ-CFBU:C& R7F/.99[@!1:CZVB3\>)%KZ-_>LE;
MT5;J.JYW#E]L?!RM9?@)&H\%=W*+MU$-D"'\B_VN#'SCC/?X6+9Y'7_7GJ 5
M"7Z>J>KW(3N#Y!L(L C.E\Y Y7NE;-'BG'1R\WH&4F\"MJ3:.@)MVRBT(KX>
M:_Y3>@MO G2?8UZ,F>J'JLJ /8T?(C.+EMQS\&?C=TZ/?C<2]D_^-,G0F>$*
M^1K,_%O^'=%5_D%'Z3JHV4QC+R'-=QXD/N83:O#EW*-9?4\"WDR\7!',*QC8
M,H$.L_*\>];1YG*/J7PU_:YZ-0)_[!5_=(L_.OI'6GKI\S#E$MT[MWX(2\-J
M!RQ^SI7S5/E.R9-"T2N$F$78.N5Q27SY]#'/CTP'H["SNEETKR(24$ E ?Q^
M"Q-2DG.%Z2"23IIA-F6 M^S=>D%( DK/>I7!"77LUS#LBA.A7L#C-:0Q'D:^
M]Y?%LZ7<Z;D_"[U$U8T6DJ^'N-K\WCF;:Q$#OV!/DRGJ:2K7F G'IAW+=LJU
M!UW!(9/$QF>,!A9R)Z#MPC2VX]1-U&Z",[##6<]X'$^!(YQ^[Z3]! ?P4G:7
M1'D9+Q:!S"/GK'KJAN/#+<#H3]T95.W_"6?]B7#F*%H0RQ#AG8_-"6PO+T*X
M!=K 1C\44[&\&4MJ^&7*M>@<0E 1D3KZ \75F\V2S)=QB#)T(XM#T&%76A+"
MK^XQF1\1?)9)/&546"D76)FV9O#@IR@EO!0T[RD\,%UAT+'?XVKE?/"LLH0U
MXDID)XS3M'3QN'\9#")\$/7UCOV3X0%*V05DU66/,CP>K)8E)ISI/& H>L(N
M\:+[O/@_Y(6&7K! [$P[!$,"3 9<X.K&H[H+DM89Q[82,BV472'PO,,Y#6MY
M^:#4&B(E($^X,'S/R"*0_V L@T[>*&V(4S)>A"R#9/U-HY_PTT#Y?17&=WO*
MK;9W_$#^\M?&/HN,BCHO>O&T.878-_$TE%>6[L"[]T@ZA QP(4J.MTQ!VJE_
M%92&;=K!K%<O.)Y3;Y-M:B9?KWG @E$8_9^_N&T[>%<'^\:9AW^I4T)49&]S
M#%$%P-\ +YS>VQ^I3OO)=_$MY[?9$B]??(D UYS.9?V;*J^2-+8['YNAXVSA
M_ ?[8:>P9L"'7>]GM,%:':K4.\U)'_>&OXU.WR.T#8B?R'9(V)775#?J5F3[
ML '6;733INKN]"]_=5ZY+,U/=H?NJU[]#A_QL0-)P5JN$U#+YBAAXN1[.[F>
M7KC=OG![8^$.!B\;;<V!^UUQY:%_A2XN?[HRN8!]X;P4]H7[DBLH>R_+^U%2
M[+M-;ZMA';5?K%O9BX:9)YL'2/ /?_EK7_1Z?='O=K?90]U2ZDE/C])VV]OM
M\8$;.MS5OWIFJV[_K*N/MCJRF=1G-O*[\D%YO.A7WNEVC_,;GD&[M^B(KM,3
MHV&%=!\P<]L8Q[I5;[/$/:VG0GG'L8[=2K/RW(W2_E(Z\<C%, ]6W$]9>:+0
M5D?8!061<#'8_("V4BQ:*Q/?\/*^>7!%^'TQ=B=BW*]0?ENENOV:=W&$+7C\
M=H/(<^F)<<_!XM&6QW**9S 1(]<1_=:D<5AG\-!W4RL=W-%(.(]$#-^B&[1@
M3'T\RUHSN>V7M[T(^)(]C[-IZ#]4O?_68>4]N5WAC,88GM]T4?U'9F7??&Z/
M<4BU3]@9342_JM?4'L@WJ'VG14BM.=]SH:/6'+ %'=7&. _-E[^WXH''B[)?
M."^WS[3]$-F_9I%O8RH3QV8(I2Q>P##W__D?8]<9_9"N3SNR4AB2P+5+!9 Z
M*XXR\0KED$8RT06"D]YZH2R9?.&(09]X^LNZ3@($LQIQO%#DE60J6\_B1@IJ
M4P/:E,OY! QGI"/TB6ZY("LW,>>EWQD[WR'8*S5A6- 7$^[[%<7V=>8E'GS?
M-Q%591)[D-(HG3VG_Y^? ?HSM\]UJ2N.PJ-N'[M3+RF/<C[R2Z)7! 2+.199
MA"B]*L'OL=^557E7=O%=C;=_5X/"L[J4^(!F4@\F"LCOR5,35HZ0^%O2L7^&
M\[+?>P%G%\]N O\*;'Y_EF'>H81(3'3>21+#0< 7C-0?41@FOY1EG&%*X6]I
MQ_X'?N7OF:QM+:9<6N5LY7_& 3?BXWO+^8.^NG33W4G<!H5]G ]19BO+_546
M[2>5ICK1FOK5<?=<O[K3^M71N7[U+) ?)I![CR.0MQ3&C*,A1=5&:5P&"&&.
M;FVCTX[7B%YT<O<?IM*2Z+5BO:'1/G3:/0J?8WY&VY!L]<$5'E%__2-ZF !:
MD^MM3EXH?1D:27R%NBA\)T:P4H& E-Z.Q[W(.1D62V6BZWO2Q_QK/YH+3,1.
M,X\?#E=$E#[" W(?B!23O^V,2A+FV!X]7JJD:T:7II_LSW_3*\O)&SZPB%<J
MUSOQE_""X&\>Z9*?+W][HP&J!3SVP/X=M'7[C<?5+S]G4S^R_]>+2,/\".]>
M2+V3TW9I7+E?F'UV T_/#XE?)+$WGWD2)Z2X+$P9QM8GJ!%?^_%UXBWA!/"5
M?$%\$4S+Y6?/E2EUIWT%#YDP6F0K07WX\ /P*-"--),J]A5\,>X,C/H/7KH:
M5?;JPB16S:@HR?[#;!53[9,$=H<=5/(]@55]-"Z5BH#\9)'6KI/(BF#5F9RH
M D"59%7Z(/3R;MKKCX1J;DJ4AO=UE_<NE.QOKBJFRF17F7PP;CEYC'O CQF4
M@,G2C"Q3H0*U($TI^,"PI@A/#0ND&L%QX!:\O&H)"[S&G7[CA8_,"\=T7&H
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M#O+3\I;(;= )3_Y24H&DE.[8GP(5F,\87RT_"=)]**_J.B%VN0 6:%Q9[2-
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ME254\ S:0,1M!N&-W9*0TQ<Q0;M3?G'RRNE*(0JW%?GJ0V >ZP^YW5?=@7J
MRG-)GI5<4L]E6VBD35Z[.F.RKE&R8=MY 4->X@4+>>>B*O"7&5#1C/;N14KH
M>U&44:P6/>'4CHJ%O;51 5@O^7F_(/Z)%MGC1J8^G:+2.YBUZ3=763(K&5;[
MJ:1KH6'AK726PG NGS(PHH6/K/O:ND[B.^S_QS)<F +=]F7',^7)5V2(E\>=
M/&^#-&]!0QX=S;^E-[5T]71'V%CD%G^2LY*'!6=!:5A2/?+O?YBM8M+!^&#*
M.[$?=R?6@W=BM]V)O!FUG<_&>N%[,CP5WJM&K,J5JY2O*ZFPT:\#@UG5-9$Y
M/36L6>4P^=-Z=<,PMI2ZD1LSRHAAOHDFUT_Z$-_E&>NO+KE]T_LX-613SQU6
M=1%MG@"%2,N&S185PY&=H$(>JBAT9/3GQ@_GBB)S+D=KUYULC6ZS.'02H&-(
MZ("G!K?0#7F]-(Y4_R,+LZ9A6$\V[*.NNB3?N#4:-F22K8@Q7,D-;Z4SG7K!
M@0GC<]N?P&R/JPQ-PZ2C5D*%+:/UIW9LR1WKD"/VI%O@AO]-'932E2'6P")$
ML8:^57*$H?]%R3844#57KC1,5BXF4J6\) -LQD+6U"600>F[;: %UD;<'VRF
M":FDTM;$IC5,7G7[&Y: D<\MEV"KV:7*A'+@C4],"S@1*T*_^'-J<$P_*+_!
MH&%\^I2U>2\#>9Y:+_N<*T-_8+SD2FKT[^HTCYI'F^LA\EU9/C9RE5IR'7,V
MS%F#3DCAW&Y&AWH%AEZ"K6NYT?6=)%P+N7&0$#7G<C^B+\,E=>C6$]2(PWMA
MJBTY+U#MK=$F3!? #_S$>-FY:F'2.KTNU"21Q)D\&Y0-U@[$&C5"*<EE+XAH
MIPQ-2LJ092I#IORKKIF;Z4[]-0MOJ=:81IC<I;71S;.5!@%\+TI;BW:II/0Z
M5I-4MQNE.IZ1ZH[70,/'(.+;A(@&YQ#13D-$[CE$=& A(I ]VIG<+':DHQ]$
MCRNL/$$O5R]'_>Y+*>@_L;_A7C$20S0C,S6_W3%DFHO<"%DEJ4@KC*'S.*8U
MQZU&<0!KQ0.\6TEW-3 ?F=V /JTE9YU(%4^U?I2-IKGMKJU7SBTA%R2[M0ZI
M>2GF;+#.PVVV4^K6+O5(2G>Q2KMX@/2PI>#H;A<84!H]I_58QI\:<PAH35FZ
M(6!0M/[FL<\9/+*;>-$Q7W+L@4Y(:2U>,0M">^@Q[:!6-#PQY3_]0U.N9YF9
M4:_?H=,*'IF*IC6KU$Y)I38M/6Z2+)V3J]PY^3I7=8"L/[V]!.:<>->)M[Q)
M[8]9DF:41\I_ D7ZZLK4K'_,0!=<D6>N8SO.A&:12K;ZCC]CPHCLM_H5O,$/
M_)'G8JU3UB6G(9]Z<0<6[D#:P-+ZPQ/3GDK#LWSMD88+EAH\F7D<QM>D_LWC
M6:8]JX8&&JF6N7&8FCEC.L&S8!.B"B7GKKQU]7")H;#G3[WA#2\?.2\[@0L/
M$CL.U[_)(&WVPQ25P3WJ9LVOC/[/LX/Y__G+E_^OVYV :/XO[Z^/-NU_3__Z
M#K9E@\'SYMT?;R\_?_CC$WSV[>_O/OQA__;Z]]<_O_WM[>^?[=>_O['?_O;Q
M_8?_??OVTZZ:F.^*T] V7W?LMBT W@2)3PUDB=(^^1%V4_[-BT"?00+8:0^
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MM1!G-GZ[@:,@#Q1Q8G4O5S,IJH-B,%Y>V4WLG.T WE/,(^D$0X.(LR$S,VC
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MX/R@=-G?MH)Y](OTH ;S,/VOFXNS?VK+ML3ZME\$0.)G/ 3C7[D;_,+H^_J
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M+5]>WMVA4'U.O_J_D;QAB+\;+>#OVMMN+^5\51F]2AYZ?YV'OM4\],XZ#_W
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M) >9=+ YD%-JBNE[<]<5HRC6)"54G\SOTE_ XJ3&;+^M72 RD;"/L)W8^<*
M4[ZZ-0<2R?,IRA8<;6ZX3GD*D\A')>4=B1$NQP[ZZ*=*S>U_5M02\Y'FXO9,
M[K]T^>KN7E-XQC.#S7L8H+1[SFDJHD >2A>P:UF*W"[%" \J&-H]:2'W6PH
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M.$6$8Z*G6O:6B*U5>!B7CFZD_+!AG0^<3:@+M8F*,R$]# ,#7P"]@) 'R/\
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MT1[@WIE*\B-(4%G":9=S,1"<(2+I]C]L "R=ZD,"!;M!2QB-G/YAD1%6+ H
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M_7 72VQBQ(SF2$9"00+#D*N$O[<0(H@6X]FQPUFC0 5]2%JL;%7"Y[.\\0#
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M:^:6#]>YY=O-+>^M<\L/>\.\UX92:9P\3*PII;H%-:80T4>B2ZFA"WUA3-6
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M/"Z.Z43([LL(=80N%(G+H*B?%23[QUP?N[:/3,RM;?I(]*Z(K"R\)B4VI+0
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MP3A;91>";)6'#2^!;%56MQB)DBG3>H(+F\)$O',E+DU*F19^4N=0/\^6] S
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M$6^,-0NK7]C<)H7M,9>KT4O_/K,,'L%G8W+%>]$$>M3'E!\3A1V"9I2>EN=
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M>]WQV*K:[7TKM,B.JVDY $5T *X;/VYZ74V]:O_1OFK=7JF-3J?5Z#2^@A.
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ME?F)CG$.,S&_"I&NYG7(NHJ@Q:AE1O9@1@-XN#8*>L^7J2%ED1K* A['&_
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MTI<W=?=1O08:\S&<[^#CM[;')NJ$OA=HK:XTNM/3'Q[8:.;^V![\])>"LL$
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M/N+_X%H/5M:FUK5*I0@.SL;2EJ4 #IX"2,+HLE8NE+1B=7]\SI( 1[J80]P
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M[S/&I^/];L/X>AW\X'2K[E*-J!UO^#];S(&,$;\.A^'["KO#TW\AXL>3Z8*
MKU1%2W7.;B^[@WE_37BJ:<W@7-_YQ4I?B&;L<SW]E^&V?GF.;O/YZ&W/F+B@
M;G ]CDU-@"(DO[0 IU*M::7J:N-BEX0]8@[NS"/<%P=S&DX?+Q57=V:]$@[N
MS$O<$P?K6J5<U'()FJ=2K(K)[O7S7LQ>^B[;"6[S\XI(;7W?@P[A#L$7PS*6
MHW)IQ7)-*R?HV,^"AKN\T-=B4;E4T KYE"*%Y\JBK6_LM5B$=4OE^DDU5Q[O
MO9(MYF">]*VQ**-Z2M;Z%C<H@[];T760UXKYNE9/4'?S2MRC+>[#) 2O:F6P
M4@J%C-[;7VY)Z9U'^(W,>SRKZ^.H%I/Z7<9*; ?R-'8_)ST&^<^Z*TYI,4=2
M@'9M.R!VH(YGCF-8@Q?5<W3+'5,@3]6'.,08RS[.V[?:MEJA*9])*3[*:-OD
MI.T%E&WXA 6O+$EZ6\O7BUJQLG&OX.OTF;>M2$B=K[5*3JL45F<E7AM7TZTW
MV!U;(XA4I;)63Y E3,S-M2L/=E3\5F(#?N8-C03F\BN:2[[55* Y$;PUO+L1
MR!?\-)XA">]MAX3/\QRS/Z/YGCU[[=1G02OGX>HH9$/K]RL<6PTFVI-PU+12
MOJ;52NNC362R<:!PQ]YDHZ+5<V6M5%L_!["9;&2!E&PQFYL[GUNZ8X$0NNK4
M@*\]ZD[:K8@G3^:C6DRZT1"AH?"]']7<9;Y0-JW$AO 7W34'#";;',\\8YA
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M4YVX<!(ZS<9JWHR<Z[L&Z)F)RL>9A?1"H>11LV"Y3[@&WQY'LL';EOT8%JO
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MI:TRRQRH0 B".Q\5NX1[5BT,_$*RVS,;MF;MGFNM)ED:35099K!CH%"A^A3
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M&OH=N1 4*L#%.#8#&!?9TN5N;&31K#;(.;:YH2O'(WF/YK._(MOGSI\Q@\V
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M0=U7:BZ7(26'Q:3DX"!2LK.#E&Q714HNEUJ!0P17(9YCQ6NT ;B(9V]FW\]
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MB"&5>JB<B*)</AL_'8<26##SJ[TV\VMWMBF-X(H#(P8[!^MY0%/4I4>>]:\
MD)4\99GK+5TUPMN3? -ASG88\2IJHA('3_\"R<M=!C G] IQW2#S28U/+>50
M2/+ET:>!9<)X"O'2"**IFQ)NFWLN0[R[_R=H;?BP*#[FX4]P*<KL<CVAA\@H
M;V@XPX1LRC>$2XTO2&1C8Q<Y>!]<!KC_TFV'WQ-%#G@G/X)+HJH(JN/4M'T9
MFN4Z75QWG>J/R:5IE)%&Z7'?7>XK@=%0/<0W$KB<EYL3)=<HI)FL)HZ QT7R
M)FK5]W2G%R7M71226H FBN45'I@F4NW?XHO>)6%NY64B]?YMP!A56>.\-GC7
MJ++56N "S 4P[M0 XRR <:L&&)=:9ESU6N:$\54 2[L;<EBO^G(O:^APQ99Q
M64.'7PXZW"[:,G#7//(OH-/1I?Z-:WV)!5 P$I)[P"HXESD#X)*T&*27J<%7
M,N:1NR/LRUF]!3/,VUD9YOLROK3 BQR9"G"#PN48V6=3RM\5<7*.N*4 PB/Y
MZ\<L3EVF  #YX%W>W FC^0O3YF$%B5PPX\Y13VC6F2['36#_]:11)@P;/C+F
M:L( QM[BL,6PQ##N6#9/J$YA#5"6,/#!V(F#5855*W5F@W$(IC^V)[<]-'/_
M(["WMKN(P@0R(L94GN65RY,!1" )O: A-Y<))O+#GL.8-&3$T<?>& &8A'P1
M+R%PA>VN?#-R5[[+O0RT&IU6$U 5F6V3);/=1$L:H1#!^TI)H:.N)-8NF,+3
MSNJZN*\ ZA060*@54%XX*/>.L\!(F7M/403\'2@_D;_OS"R/MA7.\*O-7]Z@
MD?GWT-]]D ?F4YEJR69@][X1%FMH%9Y3L]'NV6Z)O!I:AYKD,YRR47\P^J ?
M9NXE3_8K"?(6FA[-U@=A@8C?N#"DJ8NH==PK4>314$]G$HE_11[/A2'@X=O(
MY?D88)=PIR."*WE> N^1"9^I+3+QFN*52?AU!.)9)1_\XQ/'_TI'Z^<6M>5+
MVH(99NVL#+-])6VWL*3MU)*VEK15D[3MO22MS%=,2UL4L 'HO([IKVM!O")?
M#3F&5/_CH6@6B;Q>'=MVY2 )S F+#/$7&%(7Y\@I^(:[-%TUT4[JY":%[N@Y
ML%2H2A-.@V*(U!37][VQQVL]CY_4)\7\P3PQJWYG;'02',G543!AJKV]C]GN
M%T"O\-71K:^.^NJHVM71V5M)5]T@51>61ZU@%\R::Z_-FBLB'"NPB=]=*AQ
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M0T%%\M[DFF@''8:^/8ZXYU54DE0';^CK%H)W+RI6,> ?TP.^+XC'XC[D/$O
MM)Y$#TK1_1RN1B/UFA2%N$+CP W+HSQB6E2:;>'CFW14_^X]N$0QWH+*1QJB
MF49HUMC]DN1!MV"AJLYH5[!%K%U=^9])SS:=J^E7S[TGJXF;404ORB)C5T$
M"4A&O#H,DCJPJA.'6@I5&*!Q_%VUN@6+0W6;:WT&^YV TG;U:\)1(EQ.$? I
MN31D ;(8HJ!ME-.B'/Q2_-T0N6+H4A#5/C=X"Q!\ +;S/;D)UO@-M%6_@;"4
MMZ>8@&D_7?(;I(Q[Q9B/70RB&U6<X,?7&09:EN\ W@=/TYKC!^*ZJ,O> /B&
MJXQK!^D6U)Q.U&+;TA]].X3K5[>\1Q?_CDZ,:=R1C.Q\>"<E,Z3L69F<&"2
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M!8?41E)Q3&<2.3'^-L40&XM=K$^D$'%41AU=DRWE"Z[5E+)D><'4BL&NJ17
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M*'<(1GX.YEW(CWQJ,! RH0<7*!Q=DB98WB;.AY<XS#CI(7LRTE3SA>2*)Z?
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M@.8KH'SMYE9HX)(ZSZTF>*EPAI*3$U\;!5M0@6F/G^4QWA^(^RU22FJX'/T
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M#U1J\L!5"HM-^4CK3QY\0P]5O*=B92;WP_(/#I(14&*9QRVN$'TNRM%3>?]
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M/CDXJ66]SES\ZFI#"T-M3*#/3$MW/=X[.T!B4//JS%D\X7MY2VUJ&AZ ,H6
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MP9>_,/?^"7[1O[)[!I?WF>>*P@KP8\/0OX86_/L6-[O=_+#T;?JT]>&=@?I
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MA#%[7DVH2!D,N,]V&.X QE!B7 ZD<<EI<OO[U<W=R=WYS3?^^\7E'[=W:3_
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MKBGV+/M:IQ\!=NZ)B5H.CA+?SCH1 X;6'),Z7Z(%,#_0!6V82W!OR;(;F%D
MCK07X<HIQ%&4*GR4!K2DRB+PCU?FX**V03_Q[R$#H;'6 9ZLXOX+58)O(%TI
M^?"[LC$#:9)5NMV&5E=AZ)2PJBJ,*VZA1I8INZ#XV+[O1WS4XU^.9)); OB)
M#V4PW(I\KQW=8G/::G(6O0$WHW<(UH3Y:)B;^&*L(JRQY86Z.U2$/3KSN49I
M)FD79$*PUL_3$O<(P_HD:\RLCJS5/.$W:._A#=@VIM/!Q@*P^Q5&#_!W4'.I
MF$ET<YQPY4SZDVSCP6X&C8"'KR_3HTE,W4><?$<]J!\"E1R\IS^QOBBM[*33
M9 _DA<!Y]N ]"MZ%?AOL\M$8S@FJVY(I+3'FI1KP1C2W\CHE.M4B*L@K+;N;
M<(8L.T JF=)*>I%4C5Z*VJ0@0C%@+H@&OJ^Y\'?*)7J]5BS-W-=SYEA.Z-[7
M*P;S#L@ZI&TS6B6EU6VM%F$VPD686RM>=JG7#:")$&ND#Y47E)=0\"2F0G>#
M7BYLDE824#>M0&OWNGP_)@A(BRE7K0E6'+'46E[A6;3\82ZI"N?7-E"ZMD^Y
M1Q6OQMINW[2$KP*_L72XS3GF6 (Q ^/.AO\CG7]671L0:\ZI&11D#K]8!>L^
M@A*)N75FI= J$313&0S[V,Q6O&MY0<8;]V)N6;>VYNM[<!U%WW5\_#9Z>#HY
M&][]PMV,AG>/-6QCV48%SQ?<3JW"WOIQ:ICV"9B[LV 9E7PP6]*VH;:5D 1Y
M;4.C^'X"=.,#:U^ DB#YG\^DKKRG<]T9=F0.5W5GB47W6+D%*VQK6![CQ.J.
MAN9^IZIE2W<GJ]=:HY0_IRUMV.LRBNT7[G'10Q9@<J]&N:$GJ><>!HSE&X=&
MPQX<4]+04/6"9F=(:B_Z>?-P3O_@13V/U*\(]0M8I;=4L C89VZ RO56PAIR
M<%2\%L5;";QQKB5X/K ?!C;Q@O9I7_B! ]>&DW3P"'<K<5NMW?)XZ:,0V=A0
M0NU<(!V\<=4X6,TGKHV8M42MNC6"X@XA =\&/?/;'S:5 0F]+M^L<.%?,O&A
M+>]"/Y7TI-6U'\5/!>NVQ,POKF7^DK3R%G9.-98)/3;U[7^;_XOONB-WMWO-
M1-Q=V3+)[4S/YCR(13%]JW"FW\PZ.RR^2,DKG78_!UXI7SFT,BJ'\A2W&_J/
MX>%.'BS<+IF%4RUU<+6?D(?V.Q2.;A?.T<66MZ=Q 81>*GV>O58^+DJSYBX?
M._7?Y;9%1G=8 IU2*)&AVD75W=>90$FU06>M-JAZJP)GQ87^=FU@2"+(Q[FO
M^8AOFV^UVIG$][BRKBB:B'RWG2R&\<YWU&W+@K839DM;:1.:R7$5R&]^^+))
M)]O&G%ZP&I]JSM\^,+K'?"BVZ:>8P@HE;2;23-46G[<!1Z^UU+\)>Q<:,07.
MP-M%'[FN$GM9\"32@FQ<FA8W-\)RQI:JJ)*YK*S^KF/YF44:_A1'/#]6J[)W
M2D30^ATJ<TF&"O5W*+*B"12W8._)0!C.V1":]256^0T7&F173=OA3A%D_=20
M+#K?$"GEC8/"@3V;JA$$(0PQ&DN?%<>$^R@6T>.J?:[II [D$52J'[X8.EOL
MMZILW,)4-NEN8X:"U8)-U#?6.Q!P5-RJ$LJ:.,PL#0^EJT$.OYE7B_\ 0%Q.
M)FP)8;+23_2MXHH_/6?KE'M@K0X-+(E7:5&9NT UU)80+\ETCBK;0@ &H&22
MJ:'!2<O30M@K TOKN$>LKULXP9Z);P8;5>CW3N 7.&DR4365PL(: _S;$UIQ
M%P:'%?V#>H W]KHU5!V."E5Q .'<'X9*IS[Y"N79D4P)$!GI]? 4!<?F%\$-
M0/N;1%'MQO([;-04K>F3=,8A/ANPB4A8KJ@JK)S6X[#3Y4F[[W,VYES-_UCM
M)#Q6V\=CU3U6Q93':GZ/]J8GXZF,=2>ISV:N(F>S(.SW;!:BAUO&PSD,^1X.
MYW4YHD]<IL-9+.-P#N4_\SJ;PY2H[-E,5R;1U]&-P 'F-@?YDU,S'$PA+72X
M!U0WX0'5.1Y0[@'5*O^ BNOFK=4!U:KM ;5#8"O3 ;4NC9?Q@&J7=T"YM0JY
M'5"M SV@ZG+N;!R2TST.R8D;DM,^#LF)&9(3F<-TG(Y3XG2<?=$C38<@]]&W
M:C_5[:T_Q#=\[F"S]Q+:[-VCS>[:[.VT-GM46Z9IN1N%:]LR&^J->$.=&N)@
M+:%M#@:)S*;LI[/ .[6UP%-5U%7/ N\6:X$WMH:(\K/ 0Y1HE66!Q\U3"AC@
MY_YTH^7 *LSBN._J"B6_S.HT=LCJ!+^ZE/.YX5@$/[1.N7_C=WYS^-693#%:
M@6_XZN#)E!2XPTK*)B9A8VW3$.'\#;<N?[.<6YZO!U).D*N?\,#L'0],]\#L
ME!GD<HMA^PD/S["45";&U:MI@82P0SELI@-V75%LQ@.V7UZ!A%>_G=L)VSO&
MN"J56TETBO2+F^ERY>[SDL;&"SE!S )4P&2TEC@\'\G;(P@^!!MTZ#,B88/B
MD1<+FTWE\=M05Q!=[FSZ3>/'!WRKV8KP&;\%Q!TFI:<&L=/C.V*,FD5+;C.4
M.[@LJ:%L=?B>$+-ZTEL%M_#V 0';Q U@P\H'^DJL/!&>/6?:0EN4.4%K770F
MS>@LMY#K'D?6@JV@6PPWU@[CM%+<<@\CMEI^ .WA\H:&#>^'.(7YZ6%X]SBD
MN^7K.&PK"]V\ 5S9:+X?-V!SYPEU!-:,(5@Z VLNR-LA !;[*+FAU^71G6A:
M2JY W$EL4^J$^?-(R:DZMZ(SJ<'%7X4V]WI^]N]I1]7W6-"1A:%;.PA#7N/1
MUCU[MWU]F23O)XY;.V8MZ[RT[6UO+@"MP0\QLZK6,! F$#<,X\AE\EIBR+O-
M%) _!,1SZ3>YQFE)';H?O@3C<]D:G#?ZGN(@H7V CJ8%)MTM>%#$'$T>B6VS
MB=H?OIQ/53+A+M^([*#9Q;$IZ*8?E3B_'"T'YLM32<6)SIYC>69(IH*_7(#G
M)=N&:45[B@J9B46#FS>JSOT.Z"T M:UF;JB]4G5)I]$>#[5H[GH(VQ5?N_(J
MP\57D\#+@;/V%6XUYSX"Y+KT*0 ZO![X[=2WOE%G*AY['H.$O^OQ2A$T$7*@
MR4@G*[%X/\8W4W6#1ED",7:+K7_HG_9^\+X&?X"_HYY9LS^A6!%@B$K>R^'3
M*?R5(NDDYD"G8;#_Q$5L)(DR:/Y R4';4=CFB&"#2NR.Y,O1Z68"E66N%=.(
MF<4&:^]@O^VK8;-FSLRX L[,A4/86OM].RX5=U<Z.[![.YN[,I<#K@K0Y0K(
M$GB\>BA[Q9/.SDWACQS6VO#H)&)N#PO#V;3GS.O"C\3(F1C-/>QNWVG@;*\;
M.XLS;/JOC1Q49-)I:X=F"E='C\"D-,.*>FO&66QU^'8KFLC9$&A).KNEPC-S
MNQY(F__==:YNGE[5VFA6V'.J__2KS5*R0_9P!RG!PL?V<5!95G'KE36H+(_X
MT\8Y9LI:K^4 YUCM,%MLIQ.JRP_ZT66/[W/.6%*1ZR<6N7<V^RN+']W=P0?O
M%%?J\!0305RGD+A78I*&'Q.>X"@<C$GB]72C(\"@L%*]:"',^KMZF^]P.^&8
M$)V6HM)./BS-1K^>;<-#1>Q5>3>\JBS%(%@E9\.W7]C:.H2/EG'YBTR16?$/
MH&MER9K"[W2O'WZ^"LNS@9%E4$JODJG4817E[HS9VX$Q]]405;-8J%R16&B4
MP=][)+2_ [/W\HF$/AG'..@Q#GJ,@[Y+8M0U#AI7YU.#&-W@D/=:M?H[^=*K
MY]"=H<O;_.A!I\NW!]O]Z&I%-V-+J>H;,=O,%#M,X\W(%,* [XG13I-W']G,
MS9H_ :A$L=__*62Y'U8 -,Y5J6EXK;CPYQZE\S CGP5M6"CX-#U&6U/[ZH,=
M_/P"VTV'=$Q&3'"4]0=Z(Y+=B&@C7C'"DU2=1D9U2[7P [BG&].T6(@UKBYT
M;JJZK,[IXAR_^I=V,:ZVA,\=<VY8! /!)L[OB+N;CM*A 0R.R3I?QXZEZL2R
M:/S7(DN X%EPM7[BQXW'1,+;QH2.*QAO+:K#,-)WN7'Z7^\X_2]N^E_G./UO
MUW;?XTC ,D8"KN\[]NBTWZ<F[W9N%#XX,'V_>LZV VZ$R6P\#(X9L;B,F%*!
MC!C.T@E,4W$'=]$^FF.6+"P!PB[-_LT=[><UR+FF;Z83YKJM=L#ZABE=!3GV
M-]TUJ#WL#9Y:,WV.=C$2OT'4<+L8@T'O0O8+3=599 9=IK5!D;%ST9>D$VW"
MV*!WI9U][@"E.5#"R,$,KWK)@[#3, NA>OP=/YZ0AS,GY:S&'39P-3;/:DPY
MJI'+.JJQL>NH1NZC!7^Z,VP"MOZG*OJD!0C$+@,M!/%H\\39/*0"-L\]KN)9
MS-Q!A4$UL*!<#R(!2A]^F3NF/)4L4F_3)SL/MPJ<)K6IE;S9C<X9Q, >!F'H
M.P7?YH)8LJG.\<\TEJBP-Z)#$5V-)?!L>N*"B]MITZ N,!NB:("I81))X\"&
MP4F*$598-3_"W.,-_OS=(6@4/5,%ZWUS>>Z /D?3!QXCX??HW4#]-^3EB%!F
M;G&H)P@;K8?GA,CWVH/35I.S_G(PA#@C-@XK8.>BX88IV=/F)GX?5/[#[5E+
M7$[IE.;P3F_J#*"&@^,?[=-!Q_OP4Z1%GJ.QV4;<!+?@%,"II #1%7RH+UGL
MR<DG_Z6<7;J4X2M"K)$^=".K=V33?/#NAO&EA4TI3 (J'@,@(("&Z.[I=J_+
M]V,GEP)WK7(<JS0V"8;#D6.\.F(<4_$VIS7##1PP"[3";61@;P^=9Q!*I&J[
M[J/WKG60(/(DO>TP:V_3/?8Z7.]I^._+PN?H18-K>8W32T0+S^5(2+BC1571
M@7GGACDWZ.AA1DD.2 GW\(=)73\M!\_4V93*P.*M-"PN%FEPA4E.+U)P?"]]
MM<^.#OXJ&!GDPY=S.*W@PFL+C@[%\JFE[G.B9SYN7R*DM]-0J$"3^#M2@-I5
M;I$$9TMOG":]+D,3(<($-C=<WYWC"8\M/Y8S_@..>;0-\.MH_]MTFSB*)3@W
M7C[[&0P$ZQ3DU>\$XG&P=O@1U+*<NF$\O-TK6$MH/*BS.36Q<9LI384'S#X%
MEW\3_'9X&!."A+ $YVSM(9)0'F-UTC!6NT#13RCWWPR@\B\&EH.Z(G^(XMY-
M0Y4"FPQ]X?WV"\HN2JA[B%+/U2<&#0RJ5B,@V.#!352J'HBU<JV-#JR[ V!S
M46R[F7VQCC_<WT<BCOQ_0"==IL%]'/,FO9U3ZCP3^".QK@R3  8V+0$0NG%[
M=D[A_5[)"VZ^">), ?<%%1[<GM W1A4C61:Q+&HD,B19\(XF?$EA-4"(J0;%
ME&6 IXRE06YJ8*(B7&D'E^-/DHPS\.$]P9_6W8"JA?C&6R])X\&#:A0\] ;M
MZJ1>,\LVH,].4PW[4(I<>?+72R-_W?*UXOW#^4'KPWX:>O3V8?Y<8CQN;JI6
MT)WPG8G+I3/1N)%>4=$!B7A.@0OA5C)'_*];;H*2*IY@9O(R<(D_*//ZTO)W
M\&!PS;$<"1>W!Q2OA!IKHH)N2!XL$G/7K ]D+MDF^WDT<5_O4C(QX&-MTJ]B
MW!:S);H:KI6(&HIJU->I2A4IF1#3#5AZG^$>$%1D-"2[8(@&':W3OY(W,J,!
M62#\ LW%9YI34M :E;#=G)R,%R?X7VXL62J8H4!4=I$5>EP#[V;CN"DO6O]-
M?9[2AR&O/1%YJAN:\;R(I>BWNZ<E24\W+O1I!CM3[P,0  &>O.>'(LT>NZI6
M%$$^Q#Q'8:#L1)/=&@N_@>)9Q36PL=#Y@0]S6W"YC3V5\!^"A1DGTGRN+;RS
M2S7I8S@,63L6DL%$PQLG$=#C[#2R^1'CX:2Q;B N!JDQ["W9-)WIY1]59FQ0
M8<,U/#22C"<K_LP@8*:*_ZK>2RB.3(V:N#>&<Q!4 XU5WL'=EOV'<,!V661;
M H5ASI@3%'@I<%TNB,P.:'8:1Q=<.C*<\=;$03D&"I%7A .8C$*+ 7F09I8,
M;=!'@;)#WP@ ,74O+,^<'D^SXCL1_0^#N3:;WXT22 (C94I9Q8<=?S8<8.0
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M!AP:9KXZ";Z_]^8_<4^+.;SST)3&JOP3=P=LQ[!S9R :Q%[P6S]Z7Z,8HG&
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M;"7=CT5D?F,]E8RQ8[/5+[[YC#*R8D)ON$LCUH_\%/+#@^K3XU9_*@MFHZV
M $ZE%_\W#C?7T(T\N+J'-EWQ3-(EW7=KF>?>2""(NR1W"Q+$SFG,;NM@.",I
M]^[P;DR3,U:\UE^(12DY>M413'6>L-XS37D]<%Z&P,L.KXCMHZ,)BS_AXU($
MG=9&8!B%& -S<2P.I]B"3@MRM:C2P*%#.'L$SI,75:(_:\2R?%;FV8XM^([[
M%W^W%!6 CYU/GA"@T4BO9;N=0&%X?MQ$G5#Y8,4C*+3>/C"\B&9MI E\Z[01
MV-RUNB/*#LODC!!ORA"=4H3?H1DECE#>X604#SK0BA*.>8S#QW.N+W1.VDUX
M(UER6+I^0:=$83G0FWL 8S#J%9?X '76]J6QN)85CFSY  :*#%;M:5?#+=N&
M YH&76&RU"3*:2-A-\(V4'#JB:)JCK_P# NX48D^:PMVQ5+G+B>=T&_ KY?W
MCPU@2]F=(\.-D7DH?;'HP<&C#G$%9$&1+;3C9&-Q75GFZ""S.=HOVE,X1_%6
MW'-\/SY"M>(@0C,S<0:%)G&68LP:M,%A#_Q-H'$KH<=S5V1L.J V&R+]2S]X
ME<BZ,_I4I+T+O?NY@Y3&!F;9<3LA*$JZY@]_B>SWHX%(G($$AXRA+4=!S>',
MD(-,A(;-P^W9EK,Q5*1QDBXYXYF=UM*,Q0.;@+6*CT*6C@U5ROH"AQ5LB/MN
MAWM0%MRMG>#N-\N"6]P-;J$LN&/,0P]N*DW;01<KR2K!8!WUF>DX,WR*J_N\
MP@P;E!9J E *8 DTP$+Q#!*3X.PW3'9XBS.])M,8Q<&[ S7GDJJXP0K0)J$'
MODZ)[I;GH*EE.1,PS%0T\Y;[2KU'-5:&MU&C*/"-"=@XUI8*I7XKU#@&N/30
M'2Y*6L:6@=A"J^G3_^-*5D88G K>AY_"VI#6QP"1-<GTYL<M!]RA4D><+#4S
MU<K2S  SD)77A)\$<(@!,/[1"CX7GT2Q[%GM<<2%S_P#P1W#";0$S#9PCB@X
M18&[ W#1FZ^_Z2!2)86>ADGH=W4CF)N5PU8'O?'*LEAW6DEC0S)@<Q=>HGXX
MX=@/%]</-SCVP\7TPP6 .#;"5;<1+M[_VU-K;O(VL\9'WW7YM%<HU[%Q[IZ5
MD+VKK%F<:W7Y)L.1XI?2+$\A_Y3&:!$@ $,S8W!YV$+UH+V!L1#_:ASA1L\O
M_T9KCDA:3R-9-@N&8:P-[R-/#<,B;*CNGR1X2"JJ99OJV)_J2\%@*\M!^.FB
M=%FUJ#WJIX'FK/*%N7,>/#3NII YFB-NT"UJ6#%G4);F*IL?%HB;K13^-N(B
MI,]$)R9\<3DS& C)7B50)>/ND0=@X-9T+3UP&,+K#C"/^J)%!XM<8:A<R$C8
MH26S\)Y,K(9T<"0\>A/$=$.&\#/P*QV9KQ/;'<*\IX!2!0F8O453*+!',VY2
M+<[$#@VT9FL1/&HVF.Y238YM;EA098/)P0E.^EC9!P&7+:GOJ27WB2SU$*NC
M0 &@UK7I<@/6=<#BS&PM@6HU ,(_Z/( @]/4F<JV"V ],-:M@?- 6#D>=;+9
M?HE3[L&?;1X:B[X<A3['+((=#Q+=^^"ZO9(L.S.'EO@UX($3U._4L?/3$'![
M%C.GCC#+^;$A*'2>.@;W0;=9KJ2$P**O^/ZBXD+V%@>AP!Z'@(1@@XRW'F1Y
M0J-'/C=9;Z>%L[:\%1B>,J0Q"![P,X/++,^IM7RE">\TUQPKI#R9*6+))J&G
M?_0J?IE5H>FP$URZBY*FTDV,C<VLZ![/V)TCH_E#E"!WSEGAK+8L1D I\7>2
MP,]?A\/[909\&$*!)^3^"S8B+QA8L^*&@R2;TP@80UO2Q/UVMN)U_X1Z9*#L
M/ODJ#NE;Y-]#'(=HUMQP"\,(Z+-DB?*,[__ GG.-\B1IR=X^)K'OOSW5S<%E
M0L]@G-*N,==B7,<4&WF:,L9,4H@7<UQ>[37\Q5B$]!"Q(B:(F[SVN\^>)=Q:
M@;P-%CI-CX(VH>.MU E'&]@\,QR^Y5CNJ"K/CAT[(+C$LG!7$IQTGAGK#FNF
MQYVY[.JFPK^*$E:K(KFY4]^:IU:W9*W$P.HPAF]GA9^]7THHL&'J@6CD!8MW
M4%[I;(K5,]JSA6C]T%;KB09Y/?N(QC0WVD@\K4EX :G4;=]U7.5NRSLD5+>,
MH^$S6=C$\LP<U!/X-,V0T$AR)T.B;;7*>-P([1Q\"\\ \[=V+8T>SC-Z7'GQ
MN1GL(;2#@KYO$!K4@VA"4=\24.D:61*V^()<8[?I8GT)Q4K9=\#!D&9N T;0
M!FN 'L-V!8I&2A8?C92L"?M2^CM4!S[X((92-)$E0"+?;@WX3BNF"67["B.A
MWRT3PM4<$N5,=^IXC ?HTHJ=_-M>+,LH$';<N0^^(_:0/G;]F^&2VWZ7[W:C
MDW 3[(]:,4D*@K'+"]U^ NR?AHHIWEL/BY"]B44HL(LE4%GCN\EC8K\2EN9<
MW9C8")T>-:K2SXKZ ML?DI?#^?76_DE-+3>@F7N",K65H,ZSO\O D8TZ6!#X
M5J?/][K1_0^^I>#Q#CWYOV'B^!<#FW+6+3GS+PE\E:?5G7CU;U>C2[XQ<4P:
MKMT=-5F&721"39?O-WM\I]F+Q8SGP@8E*^%TXO":.9:];N#2A: X^[G\H#B[
M%(D^%_T5+Q[FZ0/,B:._X?D9G#'W.C3 BID;%MLJM<R>![,!Z!PM:R\6_NNZ
M]PC25B41FRP^T9YM+4@-1^"*QY1_3,J_U3RF_&L[ K?QKE/_&]1"40_:<1O\
M;*;2EA5LO#JGGSVSO<X[[85/<]<]C-KM!C;$W]Y>/U%^H*P+7/-T???U$ICE
M<K\+XU<,WWS6QF>BYG*!?$9F*,Z$IG8-%G^BW0#_#7>CJMZ4,&KPO("%83A6
M0R//=&<1BY=);MK#-1?]AD?9<+"4'-< NV9/:'4F!IQ,W+DKX[0)-)GH"$VB
M^,VR%H9Y;3M8-(KA*!J+GYO&&&.K?H6H:Z7*DHX1*PS4&CI<L  QLFE!I7+*
MW5"XV?-4W9U,ID8;=3%T[!+>I0X-[+K3/MBL,_?KOIW92&E=A6PT5:%18]I<
MB'] >$TLJV"8EC5)G=%H'J8ZGQEC8B<4SA6AT3B'9GL,$[.W_N913$HYFN+>
M=GE326%%_BH\7;:](I'(&FJ@+1HTE"3+0@^ZZ=FK+78T5C#BF[,L<HG6<V.B
M&:^U"'3O(IG[R=W3,B1@;/#C#)2T\^M[% ":(%_*3<-O,D?2P:DA>T%HB=,!
M$H##P9(<YA# 3S2]OZFEC94?<3-55V?.S"\7HG*@J#;-PL=S3R,$8B DF&;"
M37.'^3;G#-;+):A(1D^7CWQ^73_E1FB?]C=4UJ\OVR[NI:[1)@-]=LD4D?N.
MCP14$0WEKW^9UH9W">6]O4(Y'0 &BYV#M[2GEN_^-FB;IC>TTR28Z0B,;.Q]
M*M-1W%#JF'P? GE&)?! WPP'E^ZP"6'[K?9@F/66Q:F77]$JXQXN[T</:)*5
MT_J7R\Z#%%3R2^M24;:XH4=Z,'##8&)F%E:0&+J;,PO%++'GF>C/X/72"B(_
MBD2'L+(J*BJ@3!NI-LW;8<C(VPS+CF5JL_@SRUC0$)Z,N3R 325^O>A8LE2_
M.$1%I:-+6F-I S"YMU@S-EI&V"RH*JZ&]].IIH89S1>5O,(G;N J8F5,53()
M8,2O<L7J&\RY<S3>0F^L 8U _32P)]$Q9?>M,-:&X^V(237I<CBOA]TZV"#9
MV;N5@;T+MEIFR\[],"?C:]*><I=U5+N!E@TMO4M^:(8#RR<6D?'<? 4^L8B^
MJH3OZ*R1T83A!3T&%U'QZ3A6&P-2&#TM30^S/E^%O!D%)$TSYH"MI9WE<JA%
M-,UB ^W<8F^L :3N#5%4&7Z$;YOJBX2Q5LNOQ'HZO[WPJK :WMYPS@8B$->8
MHK4ZF(O1J'LF*8J)HL *!^;3A:7*P=)LORI2>F9U8(9,M0C-Z.*O,X/-8%"7
ME3&O /O)F.!4;.Y:;W@%ZS$SB]A;CE5#GI(9?;!B.EAI3E\2!^C[ QSACT\Q
MV+CUL'&O$I1N_YT10D4E-BLJFL\U5JK>"&#:53"JJ9PP=W4^E8!'9.+8+A(0
M5#6 WM#%[I,"16^:MISQO03$)(%R4G?.3*/XBL[2M4P[@Y;93]6F?Y+X1*+N
MKJ6"=8N)'P#% '9LR, /P"KP#+B'[ [G=U,<R/ZF].I[R  ,')N*85)IQE&3
M;/*0X@H)*T7VEE S_F33+BQ6O+9,WH24A.\=;3GU_-$?@:-9LIC(T6]>OH'-
M3Z=WC+ 7%J> O4X-][!=<=T]-YV&4.#^P>=9#6F,!3ONT8H?Q1VN5%M$SU=_
M-CR\!4T@XI;3L2]-G+V8LQJD9V(\F](<K!.4(.DG;DJS#>'ACEX)MDYB5.U!
M"U<G@W 56"&'!0TXSM:[.[U(P;YP^J*?Z5P9#?0T%M-1\S)(=,8]G#L1M];3
M15*0HYN!A%B3LMDUW>A=PC&K.#@WZE<)=!88-GYTP"WL"WJ9K Y5AB-ZCD>X
M_DS-'OP=R"1[OWO)/9;BE U-D^86^<QY/_T$6E.QITB^Y@\_<4E)^0$3>?^T
M3>_^+]@(!H>R1TV6(/S@IOMLQ2<I_ B_!CGGY)7@\#+\CJ;\Q+DOLTPQ8A[V
M0_#[WCWQ'9 C_^>#L'S1F#O&)6*WIWR#M0:Q,>#5=XD%G&$T!%#H7> ?LU*H
M%//') 8>\T%63=ZV^9[>5ACL5Q  *H#BV33@S$)]9IB?.?-Y_%%LMGFQU>?%
M3N?34EB\>[E*KMO^(?RF&IG8*_LB3YJG@JHO,8R7X!9) 9=(XE@_:A"B)[>T
M3Z->BV\&K6+'4[<_Q!-K]:HHN!^^_&/-/0<K5YN(:_]$2NV&;U^Q8=FCR0CM
MQ'L3#5][,?+,7S><O:$Z><!W.@->[$='BZ[%6!PNX@6F8DC>82;X3D@6^GRK
MU^9[G>CDW<-#\@Y%_[MQ<I/O#SI\IRWFA^3DRC"JZJ+J;8U"SJ#UX@(LB=3_
M1A;9=LPD9\ET=]J+?O3F,WM#F1_QY-LDL6U1Y'OM:-] PF,V*:H.BTP[:]B4
M9!+Y%IQ@8G-P)-->=71Z,K5:?*\7+;_/A4S%VJS;%7D[G1I_<GN\:(!G&P+:
M6=@,OL0IAC/62*+3/M4]"M;6;MQK0TM7N\</^B+?;&VWIM83*H/(UY(2.RCD
M[91H-?E>L\4/NM&&]R,E<M2Y"2C1XD4X"%O"=C<N R4\_?HCC7666-22* *=
MJ'FE=6Q>B6M>$8[-*\?FE4-K7MGKQ,H-18%<68,JMZ DOUQ=+T.NKN =;MG3
MK5@0]VRXO>1[2;F6GB[O9Z!?@8O>Z'PB9S9S=]G@QE<[Z#M9\>1J3+;E#./Z
M1FA_,&TFUK"]XG,-")V:5OV<\N*KS[S6F34+0)TMW ^/.?)CCKR&>=1CCOQP
MWW;?.?)H+#'FQO&I[,\>I$G1%!.."!-HPZ_5OV\]JA+<*FML+E7_<G">^9K<
M7,52ML(@2\ 6IX,Z8VJ0C2;(O/?NVU*.WI -X <=@>_VMN=LZI\,%P;"7C';
MQ6WD_>WAV$/ ;)9-]%DQ*_*M#F!6V)X.+JFV(+F2HN45G#PU#9W9_^YR 5PQ
MR3;YKFJM3?1.RCWIR=O:)WE%?M#K\W&KL3>]2-P+EX.LC*,4LVF9-M_L#/AV
M,SKVL1[(RI*)V0E975X4HTWBZ9!5=HX[=;'2.;9PT44"FN-WXQUXE9(PR#)0
M-BMOM?FN.."[S?0YOW==_"(,,@['S6@Y= <#7NQNE_\CD4)$RC(,-+LDM?LM
M7AP45$96M3)29WSB;^0,%]!;B*?#YJQ]NKHIJNN/TK]CU5)F"RUY<?Z11CO6
M,V66H^2U_54M($VDF??B'6V_<(^N6NV!V>5LWY+:R-P4MZD]I$*H.P)3%6<_
M.8^=K0ZA*3>4DV4L?O@00E&ADI+47,  NPA'T7:3KHK1+[&YN_V;&F5-OB5V
M^+90S^BJV-P]AY,69> W-/M\/T$Y=S63#'$SJ/R)7',Z@ZI<DNZ>/$I+4A&;
M);;GCZHI ;LG8]*BJ]WCFX/H4I)ZH&MW_S6UCFV+?#M!&V1=[8[;Z*2[<DF\
MN_N;6H'P+0%7F=75\-@]-9):*/A!IXD,65.,[9ZG2,]CW2YM?:^4W;%SQ/LB
M.N'RL(-S8G/W]$EJF[5SS'&E)-+^W=<NWXY9UWDDTR8R"26XS&U>$+=;OU4-
M=N>>K_33E7&AS6/6LA 6/([ *2EWF9I2QRDX)64PLU"J&H-P*I^E##7NTD39
M1)JIVN+SMOY+>JVE_DU8;R!]I"CV^S_Y3;R5</V..:J-9D2BU&B1<Y@2]+'M
M/(8FP4MFF4RSY;:U'^"4"&WQ+/V^J5KI85!'JF:D:J4'2Z6FZNJLJ90CH$J;
MH))\#9XSMNA<)?OR!0.13R3M\KMU-]C#RKO^<KK-][/'RW]]QP$WE[^&AOSL
M;_^P]WN>Z^^V4L=?>I> CH4A8Z1S%T1F\QT$;YQ)<&\4[8JG*WAMHZ&0B0I2
MC4MMI&>3L  X]Q&O=S<V#?T_>WN:V!:?7U1;TM4IH.D^O/3IW#CEN1M;.?67
M/OF7>G?@.8G[60)HZ)ZGT-<;LK??9NZ8EB/I=$\0V[&W29A$0=@B#1<@.:8Z
M1\I^^/)1_81&Z)2N6<8Y/J^JIG%C1\7.I#5+6W&1U\^JNTX(B?.S*NG/;RI/
MZQ@DWE_C&?IZ@ZWFLXADXM)27*K%EI;YJ]J2KBCS@EH\(X 46#I,-_S003A@
M:7-M.'";S29G_>7@[JP)(3;OKVSVV("],$#E+J^-6P=-\8$HP$L\-+ 5AA]5
MP&#D?D S>2K!"[2[;<X"PK*J0Y\!Z/R=$.#PZ<_WOPN][FE+]'>C?@SO=OW^
M^ _P<;O>QY]61;J&BXJV:HA68EU2X%[!:]QEJ;F;K]GFNZ4Z@#LY.I@$\-DW
M@[))XRNX<G/N1IVIR$*>^'N7+:7?79=LFP80%!=.(:=,#5RJM[J\\!7^C NJ
M7G6VM^'6/.6^@MAQ-Y+JWH@NYR+^<BZ#+>>B# _,J.+Z+.^N8T,R%;8MS"2R
M;9A69*U64#TR5G5?F(E$\/E4$)9ZT(C1O(VH%EM^07+LJ6&J?Q,K],IPI6/A
M3"33EE0*NDI7I\/7GE6<EH3[P1#_*MWK2.63R%,='.AGU5TAYGT9]XAJ&KRJ
M ZIUSB;GJX1^%U &Z-&?"=5;#+;0VU&)!NVD6Q.DB[=A?BG6/OU]ZDS5&7W\
M"P[0!$UJH^QN2:&$2NB2[F:>R[B7V47(D.)C_1YF\30:J/9U#1R"/D7JH$@2
M:H7][ 'D"%*:'AAT]ZL/%H?N S#]%#3"\[2!'\8LL69'B;>?5&'[27$( 3W0
M.-WPEP.Z7Z##PE:?8G$Z8:LYQP37 .*,,P+F1W*$%S8(,]8S2#2%MGV<0ALW
MA58\3J&M[13:=SV$U@,LP"^9XP3G!L:P0<==><O! U,61Y-["5?ENAIZI&N+
MS4O7-T84<GC4'F(/ S_V +2^N+Q[#!'Z^NYJ!-SY=#VZ:XRNN*=OP*_#!PQ/
MG(]N[X=WO^]Y>&L>P8@\6< +6^3+5H5A\SY@4:-=8<(A -8\BUR ??'@@(T@
MB"?-]D?I$]_HX _R)VIIM$^:_8_DT\?6)WHA>79<Y^;QY-^^5\)PP$T\)("I
M[&/!\Q;F%!?N?FMJ$E-G&KZDH>^,2W\9:+B36 ;SJ*$3V[7;\1ZA7<%HSZB*
M*M%YPF"4HS$C=G#WK^R&"$*7!^XD^>X+T17OQQFX\O!DF:W+1A UNKI\HJ)]
MW,!)H.$EZNZ28;37 >/P96,5>BXI].!52+(,E@;=6$P=)LN1IT$:A4V^AKN2
MGHW8G<\U5:8VGDM;?]>YM1FBP+7^:NK[A_,E< L7L?#-S>Y(T!D1$_LBMZH.
MCIR]\+;!6B/PB$QKJL[O&17AX#];, GR_903,>"H@)](P%.).BH_>.\7Q'IC
M[>M3TIK4OEG/T98--V$"X\6L5C@:S6_5,\OQAFHMG*/BE&2K "598.0&Y_X"
M2\W!$_(Y1!H;+X1*.+\B28TDLLV4W(Q(.O/3I)GAN!',^,7P= *TH:/;1V,&
M>&E"1=+X*$U DFCXPO1XDFCJ#)!.%\%_<@,6VS2@J_7H_&- W )\2AL5M1?6
M,)GC&",!XT48(I4I1:0U/D<S)%Q'+RDOJ.KHPG59LJ;@?[[@_GB%[;K'->^>
M[+JZ7&*%BC3PO'C?,M4N0*8*CGNDL@^\7 8W!38=$S *YB;!CQ3.L;RPN@6'
M"#TT'43S,S<'@9!I& ]$#J0%6<CEO549"XE/K';'0V]N-[RXRBJ/.Y8;N,'C
MV5Z < /+4H%P :+'@ZJ_@+:@9S=&%+&J-B 8I]PCGO#!BU#Z"?([W-VU)7R\
M-<:21HT#:TI<$\8-$U^''A-\A!LXYKP4!MQ\3F0:[ 4U,P'K : $A@C>[9*]
M$88Y)5,'Q%)%$7/7QBJ$0?QA[%4';)'W+:B= @2U7:R@3@S#!EWO!P0=C%GC
M@R7*7%ZS#QC$0?%EV0Z43'8F&&S'+,C9:EX">)&G(@K,3PTMBP09QP+5KREX
MTIA$PF0"/OL/1V<F)S6,\6X(H>4^K+%=G%=-O7,_RK]\!3I7,>[E=;P$<RF^
M70??C'M,P]=2,>;\]]-'[NMP> \Z#<2/*K6EY( 8&C/5!OC?M[QT"Y"73G'R
M,F39G,@:%'<!BMCDW:#\*_S3"$;E&0J?B2[3I)(%]U4GX,*Q4<$OJD5%9T+5
ML_Y\ M\"XVD,CV="Q2/'/#L2&&,V(3&Y.'I\N3X*F+*NT8>LUZ"L9R&CLB2Q
M'_CW3LNMXL1S*IAC>K%&V#]7*U("^^ORV5?7.68*XC(%K6.FH+:9@GWOJPN'
M@[FSX<WP[OR2>_QV>5F9[,">CJY> 4=7-]-N*<NT WNE?'C.F/_PB.[#$\8*
M@XF&6FV3BFNFB-@XJ<N92UJAXUL/[,&X66IL_OB%>U]KDS9@(:=U2MD7#,7I
MF^'C(]5P&UJ(MBSH6<.P29J3<KCS7I;_]+H_;*U6]X$]EZSI*J4KMA]%%+*,
MN/(2PO!^&[H8<:#;8/L4@7HLF0E8@R<6D4_4MY.IJL Q])EC_SW!*M\3010_
M?#EQ3^JL+UK@L%"7-]<JR<>I8=K,-UM&\0Z\:7XG&: (>P)\+4.6FSI[6WQ/
M[/"@:HX]V)DEK+56PBHXZ&)'>63-I[)CTE@]RY;5G]2%22.K_CUGZ-HHAOU6
MA^\DF!QX%,-U8M@N2PPS>4T5:HFO%#!5T'X?OMP9^DF\DJL0JBH%3,[BDFS^
MTF!NKPY)&* Z6Y^N+4<?)FNP+N^8"MB*U_IP,E$U;+2S'@.(&WKM=]905WXV
M5-W^%2['Y-V&B0D=OCGH\[W.@>R1V0L9L\PL+I:,N,:D*?*#HIR$_4UV.Y[%
MU=+I[:C^9L./F)N1S+W8>49&'@,Q2O JU@MLI\\/6FV^U4D_,K.]B]:M*25V
MT+C;*+&#ZDQ B:/BK"@PN?N.-]?#L^N;ZZ?KRT>6D/XV?+C\-KJYN'QX=$LN
MN<M_?;]^^KV"V*@4,$>9J2@P^W$@0Z)4:R\B<5RLDV]<[-#1U:U3-/^H;ZJB
M;SY\.1_=WEX_T:9M>D:?C^Z>KN^^7MZ=!U1-A1!0*6".8E)18'(7DZ/I6F$9
M\0<0"\UH:$:DH9E1>-82SVV;H10*='33%?08LYFA/]J&_.>]9([,1ZR/5VA%
M^3TQ'Q& =;[W/;8X(X#IW/\RX&N>-ILM(::].CH8:BZ9;'X5OZ55/(SUZ[NK
MK.]%7\(:>M/ E-CWR8+I?<$D-.G 0?Q_ @2[ \3\Z6?*GA%];5G.;DC.%YZ1
M8UNVI*,6V B4*/"]3EHDZ]L&'N3,,;LC-U]XDB(7E_>FY6"5OBO%L;%\C-N3
MOK&=:MG!JBT*/@4++ 5=XIJJXPVKI7K\H+OK!LJR,+1#Z#HYAM;*=27".\&T
MT5#QI]7.)54YP=96::[:DE9;1EZ^TCV\T;5^SMYG0\IAP(N] 2]TWB%/IT96
MB^\"KO;)W3FYK_'\_T"PY1K4OC=7H+9L[[W)I?LB0UEV9C@1BR@79*+*ZH9J
M2K''MP=]OMVMZ<K9721@%[R!F2'T^GQ'V)ZLK$(H?\T1L'QASL#.<#I0Q"13
MHELXE(.-S"@GE%V/DN4E D>(O_,@^JXI]FX,R[HC]FCR)+UM6LK;[&/QUW&]
MVQX/P+R(UQ]T^-8@_4Z<:N9$$FH0,5![%!C[;GEA2C:)Z-#9;Y?F(_0F7*2Q
M(4>%%"D=]<,^"%2=LL]C0J=>680,99]!U:NITABWN7C[(K*KXIH6).Z@@6^6
MN!OJRI[T\;%H=$\TVD\YJ;?#;O\3Q]<-GLHP>:I[G#P5-WFJ?9P\=9P\E6WR
MU'(G!3>Z0@A'MY=NH=/M_</EM\N[1WB;!OO@?0VFZA<PF*J7>3"5#\6C-TX0
M1U1% @'U'E"UQKK(:?R2T,Q__M*5.\T>QWU;.!*<*.%$;$*O*O<A3,6BLH!)
M5N]K;E=^\[GJ\;;"H#1!&+&1ROJSMW,4O$_R-D=E:GW>Z,MOF1<6ZZ\GB1%4
M]KY[F6[6;<?,IHKM^/]*=""=1BDF*3-55RW;I+MI?0*N<M7^AW9]W.)3[K#H
M_I'0;:4N&L"M'(:0<,EP$/0L<1[R_WPXB20!>:'7X_L)*F(V8N93^=A.WO+1
MVWU$6CU>M%_.++CJ!D./P)0?)F;/INE*-SO/??1T]J?-I^Z13M4")J^4SMIC
MGGFNW,0T9KC&8L-HR'(J=W8XP;WU;.Y13>7!'^9X9IBF\8H%/1N"PZT!WVE7
MM^HO\2DU6'M*51WT5C,CZ/O5MK&BQ13PJK%<$$8+M(3I>]P9.FX\8^HBN?';
M;?*]CI!!@CY5A@.%^@K/^DG%1Y/T",S^3=+M:]IJ;&QXI8!78$JQ%[VE"_:2
MC8T6^98PX)OB]EJ!Z.N7B[1.:4CK\9T.,)\H5M9"VXRY;JF8$_AV-ZY#]GA0
M'($I^Z"X(_9*7T'M#H1[NJL4)733 @VJ]0>=NFJP'71_$OR\8P6?%#UE:?'M
MGO!*VO/*, E<Y6XZD!=L*;?FKC%5L)CM76PBV4&E/)'9W# E<\'.>Q>CYRY"
MGY;X'"[1N4'Y\,*@Q;<2Y*6.W0)Y*;U\*=CO-OEN H_AO=%O6RQL![6\*P'7
MA<G:'7[0Z^='R4_E1D%#I>CG,>VBG&3;ICIV6(6<NW_;K>/;]M(UK6_?0?''
MU!IZ#8?# !Z?#(S2PE--@]8N> F0C6&'C@"'@+@]1'ML4=A)\Q=&PC[?%OI\
MO[W="#Q2<"?57Q@%N_R@V>';_?2KJDIO08DI&,_6@7+L"UC;%W ^?/S&7=V,
M?JOD;NK<J_3[>:Z/QOVE5YKQZM?MU[M$/\[PVL\.Z2++]W^GY?N7U2G?+P_-
MQ]+^8VE_34K[-PK)\LSBKAY&M]SH_O)AB+.[N>'YT_6O=%? L?R_ N7_&X>?
M1;,P*[>KSH[SZB1JZE'@7I.TSB$@LS))H+ULIT^L7 (!4HS_F030)JM@B^N@
M=;#4D)N X6ZQRF3#;R/#=WNADQ[>52%[\IJ_];O3C_4&27@T+K3N#?'OG[;6
M#=K94MI6_QEG1108S^7/#&_7NC=><S3QEZLNDC37>75S.>YYCW3:'1RMLISO
MN],J^;%_)-5.UD,^I$IF5!27D<QS#F7+]V>H9>%81$%5'6=6'#Q'[> J 0(Q
MH@IFZ8NJ$.5L\1T0>:W[3?Y#'XL)>&PP +W=RY_#:DRZY%9>N]XK"$O!6<YK
M&X\+UH[ Y.G)9 RM7M_]>OF8*K1ZI$JU@"G!V0UYM2)U:S]\N9<6&(Y!@Z"<
M5O "+1?WW:PKPP3K129$H8TS?COXFJZ9=5YGAV^UFGRWFV7+274Z6]<OYJU\
ME&O]@)F20IN;PD:>@#T0A<SFE+,Q-A0K8ES]#;+"A?C)&,K@WYIDF_BN%KSW
MFP(_R#-4].YLZ/7SCHXX6X>S]=,WZN%WK"UWB,13F!X[QE-VC*=<>VA,%4\1
M6GQ'[/.]5HX-(>\HI-)>/VGFJ-K6X6S];)3C I/Z.*"5 J:$L-IJ2.7J^FYX
M=WX,J=07F-S=O%A_#NV?N1M-8'4JN"-:PO4/X-^!YE5UR5SX^Z-U[OI^5+0'
M7629G!\VN79?DT[!]W8>;YBCU^$'G1[?[FSWO*H>>&AG':E5 ="S5@95Q>%8
ME4*!22$#E?V+UC2\@6YC25G<7*G:VF0%E=\@PFZP+\9X#& KB;<A\*T.>!O=
M''?9O2=OXYC 38^STA*X.85)YJZ?SXT7W(1URAU6J&3OD9(K#XOQD9(5E=7F
M.X,^WQT<)V9DE\'U.:,CSM;A;'VRJN8!X .A9(K7.&!^/F(A9RSLR[ZXO+JZ
M/'^BHP*^#>^^7M*I 5>CA\OKKW?<Y;_9'[F'X1-^<D?G"=2>3,59&I>3"9'M
MT>3R39Y*^C-YD&PRTM'X&.ITG@"65K](VN9<,VX.:.8XS^E I"OYF7E,-*?'
M6=T3S14.*!^!V5O.SCO$KL-'5>T"YGA6K)P7#\2R356VV6 :.$_"?PA<>4],
M%6=YRR:1+')!V'_A=\U!00X>3NS VM2[WN1;"7S>JL>O.UE7P50 ]*P[1(XJ
M^ A,"=G.-382JF.>&Y-G5<>F0DQRXNKE]V-A==9G_XY6Z3J<K4\['G&V#F<Y
M9X>.Q\@1F H<(^WE(4)T)>GQ4=-)LV+VA'PDT#2TSR737 !6?I4TA^QNZ[^/
M4<")U6WRQ/([1U3R[%^&T<1I)P?O=_#M(3SMZJ35V=M8X\AS_NODA+M2B:9\
MYAX<C9S<2\^$.SD)L1^[\8EMS.G-O2?Y;$7_%IBU&V9>.N324O\F\"%>Z H#
MO5O,^$P/^8R?5V'\,0+D'B9!>R"%!CV'AF5[3U94:ZY)B\\<B QAI]&42/"Z
M7SBN07^CDNO]MF&>,HYP#HIYTSN/%*)^OC!D!_OJAK(,5B$VI3S:DJY()N#O
M^^GC*?=U.+Q?%5W4:XV-YV,K^EAA-8 6W]T7.O"X-TO]K*N:.PSZ2^3@RP2)
MN K)A4.P[/6!:))-E'O)9(4FZ4%)#TLK:!P,E1<LN\5BO?E<4XEIW1$[-1RI
M86@'8;@WR9SU85X9)@"$)J(%;)$_9<0H))T(9<B$F"91S@W+MM@:EO0(R4*7
M;K0^&O"B*NYJ9##AZ-KDH661+%R;&IY>/(VL6U )3\8PP+JXM.;>,>6I9)'1
MY-[$(4CVXL[0LZ(O-:S]-; "8.>&;L%SZ'VN=0#NV216>ORE9JQ!S+:'F<IT
M#IKCU QY)KJ<1?#3J\)FD>!L@:<= X\0I!C5RW9(+[-U&#DCIA,#B%@&($(,
MPPBMR'&%31#8&4&4"\<$\K <#O78Z&<7*M8NZDK>!!/B.*A='?#B&"JBR,L#
MKQL#7D2[EP=>'._U-@T*SI?UXWBKO[_'Q_%.1%<7]_@8WA CNKFXQ\?07HR8
MR=3.B%E.1)=#Q^RG8T^"4R1V6YVWTF@?2DJ,&-HU>9>8DTF,G ?U>!<QCBZ1
MPZ,P%A=C!%R,' [%/3Z.DC&F?5&/[\4\?G_*/9;V$>5>$SZ.8Z3(25&3=XGA
MRE;DV*G)N\0<H:V:GF&M.+I$SK!-IN(=>:6?9 D>;8$M#L^I?)0"88M1<ZU4
M#DJ!L,71M!/R,C? =2[-55O2U+^Q&4VU54F[=\::*H\F$X*7TK!4[FP81^IN
MM4&.XX!>M4&."\;NS_-IQ9QGK?UY/G%BT=Z?YQ/'+^W(J5'<X^."X#5U5N(8
MJ5U39R66*R,'24W>)4:+MR.>3SW>)8[%(E[45TG5$>R1?J%:<\-2\3ZC"<N0
M" 5DTV)2F^V(<X6A8]TVS,7-]=7H@5C$?"'LZ#F?2N9S^E!R!E1%3A5O9S2C
M=4P>E+)%[K90G'1%CIR28(O!6R=R'D7[)=RLG)LOS=]\C$%9)W).[1^L.&Q%
MSJ^U8.V2U4V/KLA95 )<<?B*G"M1N'*K"TB/M<A)41IT,6JV$Q="6PY=ES26
M>%8PS_M"LN;(LPA!7'"M$H"MRXDGS=_G?4[%\=R@8C#&X+$;.1,>?##!UF#U
M,ZN%!@78'C'HZT;.A7) B\-:Y&Q(M2^A^#.U&SDDR@0P#H.A&JGEH/_1)*9(
M83\HZY0*4<RIT(V>"C[[>^GS_6C;;O08* N2N(A29,YF;-2K>-.L&Q=OJ@IP
MO6@T:JD20+/ZIT\^\&5A^%ZH;,HK5<PSA+F]AC*FA* 7K6]U02LTH!H'2:BZ
M]='1+?*7 R0\-S2-L$B&IAFOR&5 U O#&=L31W-+D?=CRO9"BGT3. ]$)NH+
MMC+<$Q-+NJ50]  8DA05UNC%9<RIR76O2;H]U!7L)9K3.FY%H8&7_:BW7D3E
M?]=QT_>SCL'\)^GMC.ADHB+R%&;PX(P$1\/J1M0Q-](<17B(;K*,J'VT)=NQ
MX4\WZDRUI:QODKZ\=GW@Z$%ZO06[UP29QMK,[#Y]>O&)'!Z;^!,,]IGJS"RO
M-'G)KWLJ9>]%CI/J@!O#N_VU!TR@_AY%:S;7C 791UUPO[ >B0S'2#^:^<X#
MF/1T6FF14#S'\S<B:?;T5M)!$=-^!38L%(Y>YN'OBX^BU53)]E@5[BSW$P21
M0!SA><IJA?52&O= X&@JP3"45U73XC(@+.?A)1OVT'G1CQP->Q+*.%CBJ[?*
MU!+Q-5CEJ(I!1*7O/2DE8/ER!*[U>OW,,$WC%5>XYUY<+,0 LEZG%PA('*6B
MI4M[ "0F)3N(UBGM 9!^#"#1EHF\ )D8AJT;-J'/5-_^M_F_WE_@#C/M,_@0
MS__S 0#Y_OCARTCG?G9TP@D#GA.;8I/G0)XY3%%+^N+__']]4>C]9"UW+RRX
MGU7X^IO*?=?5%["8"-TH0!1.XC1#TCGIV23T>.9>57OJ7WWC:#ABZ,$Q)0WO
M/@.?"HYN[DS2_^0^XG/$YD\W#^?T#_17X:=/N/5A3)'!/=R><4*3F\$I@?C]
M2/QA"GC1/P2^W6ORS6;S$R=9W*MA_HE/DUFA$=V :\ [XG@*GL&%+SD#W\-4
M[06G@+T/%[B(Z%-$"*?<$UPS4=_H+CR6).5,>N6$?IV^[BL\KGW:%W[@P#_C
M)%UW9O2+)J$?Z0;W[$APCMF$<":AUH&_E->>JA:]"WN4?S^PFK4%QW)DG#,'
MP#Q(3RG%/6K2]N8G8#-X#-[1T>G6/I_\%O.Y+4")2R- U:,\!=],(RLK2\=(
M!X3 .CGQ3LU5/A*2\%&KR="7,Q]1/@&0D75 )F3F*J9AD$Z[GRN#B&D8I!/B
MCW-PY>&@ A+3# LW9[D\[WLNTGBXJSL?D+LU3[FO@"_N1E+C,8L:QS0T*F5T
M0]'4T!0";Q/\ZI(.<\.Q"'YHG7+_QN_\YO  GK*%:OR27&"=*7"'/PQX=V!7
MEWI+;O<):&VCH+M'@0,;55'MP"W"0K)7WE^OS.,*L 81D]9-UKJN;C!CNT-7
M\U;0X@Z\B#E;!F@QMNT@8ML6 =@VC,44)@XB)BX ]F2$(;HS=+F0_FI<PAC3
M0!RQ=)?A9_3?GJ0WMU/=C<#E'P[$75DQ@$5,W1( BVVY7AL5WR-@,;%=H1DQ
MA5WNS@^N;6#%=6$V(X;QWL&*:Q!O1LSDO8,5*X]1A5\1>8RJ^XK(8U3=5T0>
MH^I^_X#%#FFH@LZ/DTFA?)T?1T@AHO'9*&V_R!K@P@';#P1N):N:2BW04)SH
MS+%4/3R@)'F>+\,8CLA14"6(8TD?.2620.S&=4-77*B8G 9%KN+ Q/S3JK'X
MCAPF2: _IZ/9K_5+7<+)[NXU1< <B_'(25,MF&/Q'#F$TL#L*1.XB,5ML6E,
M"E4/I'^1#(B/'%@5?XFX4S<Z7","&/S@_<W5VF[;!"9#:;H($^'YUFVD3HT+
MT3$=Z3!<U&2GZ/R._<,EQDYUB4[CP"&TN9<QQ#][?;B_R"+%-<!$SBQ&EV+F
MHXFQ$WZB,S!N5&D,2J.8&OXUB(@<)04#$3OQ*YI>)31J^15L15/24.DH,U57
M+=N44-FZ2BEW,L7-B8I.RR@)N%C,K>W=<J$(9V)WR")EPEUTHD5IX,5A;\V0
M"HSC@5ID)WI6:F9$6'P'\IX@BL511&TO>TTMC( R2X?<$7O9MOIDQ&WR'<T)
M2DAXD^]^-$QT%,6:;<,YP9B-^)$#H60@8S&YML*_B#:-3&A<6_E?!H2Q.(QV
M!!13+I:5$:-- :7!%X>_Z)2*-8+"@"M'FJ.S+$H&,A:3T:ZPF/:/T003M(9.
M![CL18:CTROV#U<LOD*M DC-&^!\+!9VL^'YSPY>@Z!."8#$8B1R'JQA<[<T
MMQQ9C!P))0,9B\DUP:6D>XKW8=!'9T64"V,<'J,S(_:]IG,OKD)T!D7M7S,N
M0-$15Q7=]M5)!0AL3$V($!AK429H,86D0B=R3I4"6BQ!(R=7=0C:W2MHZY:U
M,!!P,\L0[&J%]K5HTO.'+Q-)LXAWS\ BEHTW%((W/%?MQ1 D^]Q0 +S_[G=C
M[I8&0#=>>J7BMK+?B61>ZLH%9I6^G)PT!R>M9N3^R>_MK:5A-V?ZZ0K^9GWX
M<O5[%.[D-[[4;42#HN#>B7O#LB7M/^J<H:1)_Y?R[D*A=X^!_1S08DK:M:Z0
MMU_(@MY8Z#<'72%*T.20WQB(YZFA$[AVC-N*FKU!]Z3?;K9:S4$LW^'?F CY
M?&@2FL.5B?7EGYJJ__G9DJ=D)L'SN#?Z^]2DXC*73[ FN#EH-4_?J.S03^W%
M',"QU-E<HP(4O@63J, CEOP*Z#8<$_Z&=<BZ!:)MV_///_[X^OIZ^C8VM5/#
M?/Y1;#9;/ZHZ$ 53+E_8]U@[D355Y]R$#M.96*LM$QPKF9?PV+,-=D6XBMZ#
M;'FS+QY<L?=GM=-PP]#Z-6Q%"-Q?V'Q_]N[X<NIGEZQ4J0'+L$@9Q[F?$LHV
M7^B?_#_B# 1;G:C$Y"B"20AG%I%/GXV7'\^O?PGSU^J7_4?]N/*LP//G5'I7
MG@]4,&W4%E^PR>!$:)XT!>\FR\\X]_:!=U&\+PF>D@E_$H3&?S)R:PA57^(P
M)WSP'[A'U"U10IY1Y05>VOU( 4#>L$-:M6\)"B>GJ#.<%FCH,6J'6.X/3R!-
MPS<55"9>XQ6&G,,; [>Q&S&H(O?_XL+UXPI@AT)HL11"IT8=TU5V# Z\3W;
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MF)-'J#/'4G5B68_L=I$R(W-NF'#I.Y\2-ZAQV*D6E*Z,KS*H<>2I'I2N2I?
MH,;!IRV4Q@"41V7WHV-#N3"H<1BJ3@2OCBZO<=RI5@2OC$JO<7PJ/<&/DR&$
M08WC6'4B>'54>OT"5_4D>&54^@$$PU(0?&J2!#/ #ERMB\W##:Q5CNA54>T
MR9'H>R-Z1=0[<-)[(OJ5X208WG3HROU=Q=W*)'EU5/N[BKR52O+**/9W%7N[
M4E_>_71HL?FNHF]EDKPZBOU=Q=]*)7EE%/N[BL ]JF_O/,8N-M]5!*X\@E=&
MJ0OO*OI6(L&KHM*%&D?>G+%%_G+@!I<O&%6+K-A8N:"TP3^"<"*VT^IR00RP
M1RZ4/H!PV^;!>/>2F8#,>1*ZT!IC43B :%F%*99_;XTH'$"PJVH4JZ1A+!Q
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MH1D=KA][)(I2Z!6#[P678?^TW^N&_<&Y[PU.6?@Y8+W/_>"4!;\%O2]A_]>
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M&GU@Z":#L7+.!NKMXNY.8E%O2W,["GP+L#EL$9.4!=V_K=?Z[V@K[4=0#:K
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M:!-?'DQ\I';SVMBA3OO\]!./KO.X7%>TNS>;:WX]<ZPJ .8@8YBT<:!-#I$
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MO]CTFJ+N+1!U;HMKM\5F#-^+MZ/5S]D]Z_)P4%&E)-Z[;7M=(0'FVVT"C"3
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M?)3)I$<]N,])IRDN8]<6#,R#NTH2I?J08D_F6#N9)RG<.=\6MP/&.;;4#YD
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MFZ(6(AU.*3T=X7ORPMNJ:&P*"*UFTJ$AKOXW!@,:6Z><C!SW9]PA\E4V!C'
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M!2W\M+51MX?1G+UWP#&;S"W>;_T$M$*:;.'6XKBBOR:E3>=C4)&MM)%8<]E
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MBW(>/3XZ>+G/:M;S9]=[5>1#;..+@QX=?IOFU[ !9]R^2!,-A@2:MH8F]CW
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M*-::Y/4<ZM?/WY[^DY3%?YS_^OK9_P=02P,$%     @ &D _5!_2UM=J00
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M]/1TGA=9<8KG,GJESW16+!=H*OUOD>M-A!T.[=ZIE**?1TD"7%<1"4_ 4*S
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M'I6 PWF*7$VR%6&R4"*%C6K2QG*\:$B$.V,\)[QM1E=3E;%3/%VAQ"UF86^
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M#G75'+] <G<UYE>13YN,G]CIR#Z;I^O)7:?),XQ3?)1E0F60F155TDR;TM/
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M]F"W/KE48!76J\ F,9=7*.?!E,^*<ZY*X9S6M!&/"4CT29N.(K#X&<:1/Z4
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M-AT2$$21R3@HJO4/^N29X[RA2!W@$!\CUC*C-V[)MJ=X!4*.>W'333M!T&B
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MA;:U<KWP%O,)6G3N9F8N2-N!^K;JJ_=O,Q8F8[%_F[&X?IR)QW06WG/MI4R
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M@,Q,O@+UG6:!QU168XF$9G2;5FV.ATZ&/V(?/?A1_Z-H*245\7"< ZO+S<I
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MBEGFV^&MO-!ZP<W18K_H?4ZH_PF5PV4JETM%>-A#XCW+EA%VTDM"@%9R!1\
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MHP:YML/T2I3$KE42\,0E:5=/3W1TWZ^0&WUHX*X?+1VC[FPU@4EC,B3%8H[
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MF5J[Q5<L2E!?DU7\[7K[>9J[>6)>NO4SL&=DW>AI]^>\5?_!)D\W=O&A /!
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MN\#4=H13RQ6_7:?TP.XFNS4]8T1OKF#7PM:(8E[+@<EZ4TJ-88(#[35J&.F
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M8 7(&#XI%C)GW*@4137<CF?PR(1N$;BOKE\[U5* AR+(S"])]B%?)"F\SL&
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M.N_B#=EL)S57 C-/!V6Q2#+JY#PX5ZH (SZ\*#.Q>53'C??#UT3-W[DF?XO
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MI>:8,#EC$7E#)2+GR_;LC)I^5[Z%.A1XEF$SYE+-.,52<H/MD]8BYTJ>S^%
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MCT CX;2<&64CL4+JFV\F Z*<ROPZ3E9^&\3>\A%27T T.(#FA9S)P@'"5N4
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M*%3<)YU#9#4NEZ@GM*CUP[\#N2)[Y?0]W'6NM.<EN&,1<;XDXGJC(HPH7X\
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M>N509D+S#,Q]]4>4Y#E(&L]D3H,7,>Y.'&C#1^(M8#W/)4T6J1CJ47E@W4!
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M;S<$4WNCZU#SZ,7[PU\)P.2GL[=OGO]_4$L#!!0    ( !I /U2D.O.F*DD
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M\05;B\/-VPT-H8=[A]$KYU#V.)%PM 5YU3:IE2R ''$,*LU']IW2G*<P-,G
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MT=9K ZPF#P[6)*T8ARIH*2C(6V"\B! ML)%+=!'AY*!4<H:Y8 (K."<YL;#
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MMB=UDSHOLG.3<,4/5>QB0;M0LT9Q.4UU#Q)^D"S27+8EK,0"#BHP(SB<:RT
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M,4<JI>05H3U4Z%":JC1&:W;!+JX(;22I1_8/N_?4#A?\R:5W$34/<2#P/=2
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M5=,"M[D$1J/S#&\.BP#^@O<.4O@SZR_=O"^IN&PX<0%Q0 Y4I" S\5*/>21
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M?2S,R544*3;G+U*$FP #/;CW$?I2='84Q_HOG)'7(AT61_8.(AVN:=L*=1;
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M<N!6_PE.(;+M2IG6F;=,PX]1"5VUUMYHV?L#GR.<3,/.A86$,:2$I2NAWK%
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MDO[7_^^?HQ0A-@-#75P( ;HXY"13^E8""Z4'Z7""I"2U[Z:,V__>'U4[@53
M[VH$W=)CU6(+U#O1._Y&MD=9^0]>^^X863W3<' ;L"93M.Y!Z!7#5"7T\ABQ
M&7T9DU2?5H(/ /YKIR2T,DH9=[R/Y?T%=1BRXEQNK A'U*';V/)'J5$5$?%K
MV$R\S@L<JQTM]ZMNAIG*!953;B^,BGX?B-N,+4CZW&Q3W=(73[PF.+RV;D?
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MQP%"(R?(P9%6U^AKU&)3'H'2&%C>;>_\WP:0&98YI1R64KAZ3TKY^%=7=]<
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M=?/?V_*[2K\4)3P0>+LW[C@QUN6\;5^U6]+?@BO[:#'XRQ'V<"Z OZHV@3M
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M6>3UNN#1-_.FEDM[CI]*WB:]X3OV\MR8]?FLGW;BB\(X\'<ZA?.R0LPS-UX
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MP\*B*[/,^W<>.33TH;SE?_V.:HL&]?M!,_4?WQ%4T<=F9*'_,/'O^JKK_^Z
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MX?UC(,S_^X,?G22:4>UAM"B$B[%61L*5]0Q]RH]P#% >U(USA=!R:LW#QYE
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M^*4&+!UY,W,<5#658W*2Z"N$,-=O,/YQDD5COOX%92@M+IRO0 Q*QW;.6;K
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M%YM'-*&:^YV76&.Z4O94)22 O=T36\!6P>*TF=JJ83BKH'8J8FTVWVWT_-O
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MDPNOACY1D^>M^MG3M\ W73(/:WP*;BEC T"-]+XX9O_;F,"5VYH8=$#O3,-
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MI0[?^9"/]S/6P8.M$@MW/<BR^1.R"0*2\8AS$:X&%*7%XJZ15\Y6>;5VPYP
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M4'/H)-728,:+T%&OZ0P PDI%+:0TH#8L"77DM$:%'N+#;6"R5-!.6DH3?5]
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MI2.?C5[7B3E@G7^@6\TW>10T!CEKVLF2SITF#RJ-<5+HY;7V;-R1U@V-L)-
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M?]1Y:4HS<L' F:2MK<R<H3M%C/;WLU,JAMF>=T<75J7N*'KW<6:A+X//@6V
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M:L?/>:69 H*[P@\WAGK,8'D$U!T16 CSCB.Y>HXK\JQ]-L50E%B!\!5&9OT
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MQALC9I%-%_'4/ :=**A$2O;6(E7:G\6<[^&R5N$*8-D#3"F91Y[GHW:.YSG
M V=1IH[BQOLM;"*<3 38>D8!;05R54]&CO ^@9X!&W^&%X@Q%]@C.VG**D&R
MO+80K&08/.!VX^F^$V(;4RC"#D6>Z9DX+'\)%4W*RGF_\AP;>\3)\,CN;K$-
M/9^V&LG_"J++B;EV7+#9CS<_TN8@GJ'Z [!9E'4\Z5#=M]W)+^.B!HY/Y]+*
MS:7T>$JVNMZJE6F#'D/"P+M12)@\C)UZO('V4=<4L%DG7,P5MC:]*M-R\!A6
M8"MZ+P48K!0\.WC'Q2IN&K-[Q/9^@C_0P3IY.F9-M:'9*AMY8]P)T_&,^X9)
MYOUKEJBHMFJ)&)&+YB#MS:4KD9);P(K.;R!C426ZJR1,T#ZW!?S01[HD/I6<
M?1Q\,-/!W 4=_ D(OM.8]:9\W/_:5-[4)&=-'Q#7CN-JZ!3R)7BTVMI(A3AR
M 1]<6(\D4S+]B\Y+*(BU\7NHHH"C/XW9<&NWP2G\UU,TY[%22H_/1&#D?C$D
MS*Y.+CC(<4BX])3-J:J^=;#R8 Y+DH5W*!\C/? S8ZKYIY5XG#DH>/,@91Z.
MJ_GD^6*7VY5R,M]?($]W^:J+YHD>A,#6H9;YV5?AN5I#_]7;\1EM9.BB*NK=
M07_;3V^Z5+S;^/UV<,U,M7(HWU@%3TT>, 5P/76N(AES"<"#:Q[!#$UP2W4(
M9A?H*4OUNA>A5'!R:"0D_:1N# C4@6[Q58EQ*7?88&PG-9"E2]S&1';Z1CDP
M>I,C$U<D1!BN6SVE!>(!O!OX CD+S]5)!;X"E7[WHT9$9-H:#?#Z)60<ZVMY
M636HSZ.^UQ+"J+3V26&)CK&0">QQPGQ*6FE.T*L"'?A!@O.,O-"9>.$W4?5X
M-!F>7UJ66,XJXBT 6SZ6K >605*Y>N$S$W,,VW ?%DY2-,3GC-8>O-L:53D.
M9*".4-4>>$^NANXROO:9[DJ'- \-2[R)J.5&S+W."7/KFAD:K"L9BDQ?XNH=
MXF)2UU$,)KV+4B!\8"'@+'IF>SOF"AVK-?W Y1B_,]^@AMT#O"!)O8:X9#R%
M;$--UU&6 TMZ:!\Q=.E[WLIXFY&4FM'4;]V\>GWHBUZ.IJ@Z:NYH.41TF[^(
M+PZN$ XZ$]"-,!VUMQ!TG%QTH8B["!SR_D4E8^*^2@<"\-^G7PRWFS;%=T<I
MH+?:UU+O:H[^GQEHN#V9-'Z*--MP-?!Q%<NI)^KP^"=#M2P+(;:ILQ_4"'CN
M,+\MG:0;D5-4A<KV8SVZM;5ZKQ]D469ATGJ 486$M)-K2\M-/N@VQ+<<0=&@
MRX?P$+F#NHBX_$-(BE9M.QC1>)8:>K<@[. C^$7_WD#>\+XMY"LD-10J)"%2
M8U(W&,?,4]>9\12M=M&& &N+C(D#OF &S68?9)S07*AVNJ%Q#=%),V=LV)&0
MH/W)CJA-LMV0\/R>RG*N9RA,S]YQ_^)8,>U)58WT*#$/U!27KNM?B>S3D:UY
MG3PWA UO;W8CFZ^+'6HFAA>8?T(=;P*?]P,+34%(6DNT"QS-UTQE%I:N._>L
MV3D[GP--M$9(^3./4(9^ 6A/R4EV395%U@U(:Y,LA#[5NKGP6A!Q;ZNO0%?"
M]%:*%6]@F-)SCYIN^A#P-6>A:3JB$_ 1Y)'O>RU-)EPT F<)LP#VM\4GRC5F
M^K9']5"E &5HWT+F\GN2]!=NI &*[\2CNL3]2CFX!]A@YF,>N'(TYM:#"[%>
ME:1(0\\GO@,#X0JJS2W4JVNZ(T3.)(D=H789?;$ODXQ2X!MP[$MU:[5GNRKN
M+-4Z32>=-^Y,EX=LW91[>_M-MO.VB;</%;.^0020_BG88D=E<33J MZ21O/#
M>S$E^O;).W$F#V +'(;]&KVB1%&Z!IH17*A7NO@I&"2V"-ZMQBOMP2>4?&I8
MG$Y)FJA55B1PDF]TE"$ILH9H<NC')H/@ ["%N@8:,9S6TE4FN86P; .P72^P
MY1Y\LZ7W%330&FJM5>8#+$?UN0U4AT3-NV.-WFZ%UW2\/2]9B,2WW.$^:R$O
MIL;>XEX^ !5=2-YZ=TQMM^=*Q?/X3WE%_[N_Y'[?R1_)_Y\'A?SU'L !4S"O
MO1N(1AY )<;+" />9B%HZ 8_B/D%3#^+#Y^WNC4B3DY<C)1IPP7)=.(X+P#9
M!V_7&BOOQ).A(B0@_ DT?*5ZM+H<J6IMPL&'&EGYG,O?U7_F@BFTE]<GVH@H
MX;A6\AQL"1J,*/43=ZJI+I"L!?_7 G&0U\/5C8(*!-PCW%O<W[I\==[F&1?]
MHD$6M&O#KD"#W)[ZH*IH+S&?>MIDBQZ"9RR$5F)^$]\04QW)Z\/U' 5U]&6(
MATX.6OOD8DN><T^V#=N#?(D_<H \::+DRV.:W;R@O,'A\?T=\*:1=CMT6\\D
M$!>K#V '>)(71YQR6V@NE:S$?E$OH(9HU>>& YK@W55:X7F:?]]D#<]IM-03
MR8"MC?]$'N@GU+G.;Q4!IWW)>=+%Z-KB+V9?->H\(YE9?B0)N4>B2+O53%O%
MNAA_/IF\IM="."Y2+:$[ TO,5X%/H2%MZ1-3#)J,'- )5!%XA8TP/M%Q;-#E
MYE)L3CQM+23ERW&6CJQDE;K#] *4M:E2ETYO*0[E9R5Y;:+;(<WLXNN"( CD
M>U-J@!X=TV R[086(+")@C@8S^.HI=0R9,(<X3+L8V M;'RLS>6M!I@P23%'
M*QPLD4N=T#DZSN# +DC)OU=?<@L.EMLL0_RGFE5%V=1]\)P3B>$['W97_-Q[
MM#>&,)MFK#,723[!GN-"994A(8[32>+-D&=;+<+7$@625=R,74@<4>%* ^W1
M3^'P;(E[Y.BP:_<,QYF;X+IQC[ -6];#&TSY/OW>,^]SC:H#CW:]UO494+4.
MG"3#0_KV<Y)5HWB6@<>7 4&ZEYR#9B%U.U1U .(TLXGSN41M<(XT3GH^(J6M
MPR7R9^1D.KQ=\89K-"E*UW=-7Z/+NQ-XGW4OA R9$=&%QZE/*R[?'P UMX0/
M7A=BRV%SN^& QH:D_5'Z<.H\F&!@!DLA>H&W;W6(IO"RB!LC@W$=//IUHQBZ
M5I0]\V0?&G";Z_ 55#Y04-]Q\BLGIZ;$@M=G;ZM"^L>8T+ZIYP.1.&H AV^A
M4<460@A4(8*JMA7V$_G@4F4.NN\.FF1C(2R*(&>7VG/FB?)X&[;#AW4_\YM)
MTL73H.,@MS0M $EZG)^[@7*00+PZ0T;6#!344%,T)L-&HQRNR87*6M0--\SB
MX\#\1.BRUC!RGMB6R'NFN(3NZOH($=SI.%VA C;! WGB%#W946 KX)^<H*WX
M>>!UDL%/_H=JZ)!OY3CS+,ZM+#?''I^IG&C/+I2C,YWJM:W6I<]M_0$A[^HM
M3-QCU(=&,JT[= S2KHH2F[61KINT)7*2A<!IJBW9;WVL\5SK@!ZO4XD"F^%G
M)C\T%MI1JU6[8D^9=?P"+]J'A[EMKA[R82>X_0QOXT3TR@& HK4:F&8N'6(5
ML;4OV>W.MC>@(@7-K3^)8HO(\&;+KJ)S_[AJ]K>)"'ZPZ=7[-_9?1/_CQ_EX
MA"VZ;"%$./F;^B5_N?*_?'K >S_XO2MM)O 6R0G[E_-O97"^CM$FR);6>QCF
M0!LCD<8X#9>:HIWBSX9/SNB(UN-%0F+=9K&?UGQ01<X7?D!;,U$<-66DMJIF
M/6U.V?B/Z2YH#BGH__PCR$)8_ @>PBZM,1VV$+36)GMP>M5>*U5=N(()/1.Z
M2L=6,>N%F)WT 3X4V]:0WW.-D%X5!!QXWWWV_>^X>?T;IJ$ F@,F@(-Q^H%)
MV'S'-O=[^*16F"LF5[!)ZWT*4Z,;T[_Y(][O+1QI_[WW-7;UUJ.;RFP>.71\
M>[E]X9+/BM],(;'*"^KIBQ25TD+XD/D\WT*XL43POHMG:#_TOCM(5,!<PEN-
M+C(_XMG9D#5*0RRDU SD2&.5!>0/:8'QQ09EJS0W>MX3>,=976(,HP$F9GB_
M]O7Z%-VL3[1E.J/KD&O:SZF[*B=4MH^^OX%D!#7X9Y>Q;K+0+>9B>J(T!Z]$
M])BI"\.K8?7D8%H5IF3:2S8 6P=0HNT5V#H4&A8FZJ?.T38@7N4(H[EX<E.*
M_ZNZQ '%6\P'MLI#8Q+9OJ_*V$=OQ)>NZ/(9K?%^;9[ EI_4-YI7AQAK<<$B
M&5=9"*-?E+WOXG7BOT+]L(6;3<F'@(\Z)8YTN7+PX^\K,)FP@3(9=[*Z#G26
M_=-"2)@B'T*F,(>A@*VLLQ[G?N^N]BGOC+M6UN_U^D1EXC;EOQH::3*="/$(
M-_34</4*O#YB'MBOP^1:F"(#GX/-Q979TW>PC:PBVJK[YA]%U) [W$:9%/J)
M56B4K$72RX&=3;"DEI6H$\W]$#A:-EIL6W+KJ8]QV ->-)0^'QIH)M>]/0^R
M0%6:YM4='"L^-%>L@J0MZ2X:[S)M9!6%3W]PQ+\/5[VEU,UZ5Z;<LR8ZQ+1>
MF9CF^$3)GRSZ,C+2)K#Z:-J//[/;+JX6C+U_O.ETFC4/[SV<>:Z G;GHW;8$
M2\<PQUY@,U1D;)"8[Z'A<+BV0: SD+6E D@DD]:1\\'XJ;GHIMJ?X7I%?R4(
M!QQ"KHI8;K:)Y)U-_<<G>:X(>! ^T7B/55QN+*I(H#]VA,/1ST;:.;,[BPQX
M<&52)O$T[<P-?M_%+>2$+J8C*/,&3ED(MW)Y_2"R#9,SS1_^^+YK<XS5_Z?>
M7"G\K_BZ&EUEON(M60'$]-/\D1[C.;P#']$M*(>ZU5JOK &YB7).M:E(.V6U
M75<(GS?.'BR"TK16K<\]I$_Z?_WA2()S3T)WN?C3(57UP^6[A9'_XU/3__NI
MZ](/P'^;<(F3FAPMA!BU>2NV=F#X'6,(_Z19"$-3F )\CE/R7C"W_NV5_W:#
M_O^1GW"%="GFCT9"P89&TWK NB=)R;^$DI")=XN0SO0!(7>'B?9*V+^G3;JP
M3KAHPC]4<N'^,[8VD=Y:>PC)XJF_/^6;SMS[A%/;DGAK:-!<@Z-Z:!JV*!W.
MT$[)DI _]<2%R-Q()!V>:+$0W.H%@Y>;G?>4U,1C:R!.#H^([L;;,O+<,;H3
M$.>1ZUM%(;'43F5P;&7!S+7@+5!EQFHDT;8D69O<"!_HZ'6N^YK\J"Y<9Z40
M#G&,:B0E14_/*+6!2!D\'R ><8<S6DL=$8&>3@#LD&O52$B;/U'..0>AD4C8
M]4/HY]"4 .=U.]3K$=R><^P1$BD"PF"/\]0@#9W/J(S@*N5.';$U[14L]4WF
M(BF+8XWN0I[HZ/R1=NEB'WSDD*#C]5-S4!SBBZ/4"L'2>/\#DTU@/F]#S66W
MNA-*F<N3$^-#,HFM.'^+=97LU@NDWO=P'<=N].)'5GWU;SAM%H(JK94^%S@,
MO6E.Y9_%O( =L$C^TJ6]=#4TD(79<YWT;;,/N2G::N6YX^*HZO$'0>E';4LJ
MGS.![5#!CS^$;-R5?/+NK>_DK>NOTBZ)\B1XQ?YE*SV6" ZRC2^4V KP^;DS
M[A9"=G\^5K#=.(!3O17=0O"I V5L/ EWW#"Q<>W,$%H(Q1&F8WD$I 1SB:#,
M^A*'F+B\KK 0T.XN"\&FFF1VYAM$^'UL08S%-A2OFZOC((GQTM%>>B*(?G+2
M0G@3$HQNJF-.)Y ;I-BRS1;"G^6BAOCKQ%RIMOZFA5"VUUQO(4 M>"WM\")#
MJBZPZS9/A3OPZQ$+X56A9!!GGK7_.Y^S?2I+O0);BZ09*\SW:!N"3$MX@ZGM
MYS#/>&9MA5 ;,BJ>#REEC3]$HX&0]$*2VJ$EN1R9PH$LLWY^2&0!>[?=R\C(
MEQ$O3O^Q:O?JQBO!O6KH.<T?-]SN/X:7FDO!67?V_SVU]3C9%>S*^8_]#)Z2
M;K;'[?P:F<#._\?TUC3C:5QX"T0-H[C_Z-K[0#+N@I7_<4&@B6HA3.]X9VR&
M7C3[Z7\<L'!J$/?BS4W_[SS;%GC O.P_CLA\._G&0NARP8TF7I".RM^YP4,:
M)\1R5*83N!\O8RY6[<SI;]YYPT%=BP_/%XGD_Q.>'*8,6@CZB@S3=NZ"D?9B
M8A;PO>9D!7>H74WTQ?4:V-'C4^"AP%QACHQ)2AA>!.^Y>C=BU/EM;EVX'3O"
M5_W\]71'RKXZ<6V\]S?_7/@EI6% 0;XO17.DKA;")%X3$LGF>"5Y0#5-V,=<
M!?Q@O@4<A?*-N>9_\&R> Y\\@,GG+ 26< 6P#:+GT-8<X0X/[1(CX%TD0$L_
MCZUE.16Z?>CL:[ 0\M3R[:U^3N$D_8&N29_/_78%1+UX$3'4^,NL"%VJI;JF
MZ(0YD@"$%5?!^_6ML\BP44O)XOEUBW>=/ T3%31O\X]>P"Z_"U8Y5/>4LL'1
M5#^^Y".&1N3<#DF,S^2J@FGC,+GQ,>QUX5*3H>[4U^1[2>$ZOS8*\C&GC7XV
MVJK_'F\E^@%D>Q%^O.TQ$JX+9 :3[8'#R5#)#H0-YVL'%%(RU],4TNX$$KV3
ME<BAU*(<B>V$<.Z]Z76H=Y-;&1PICUYL<OIY=NUCE^#99*A=GR1U$.];*V1I
M1\5^-R*YC-#'CYCVXYV17 GH%KK@:KI.\.%8J6O6FM!MS[1UJ3_27.%74DZJ
ML9AS87BD]=/531?X(J\<*VG7_\($R#=6<M'@I0$=P^ "61LO"'6-<G#QN+!V
M^*K>0)$)B2B=#;UB?, M)N8V'/3GG+\%LR>P#_I1U@;5A9);\0V%'=>YTBVA
M/JSOE;$KPOU2,P=X 5:H0X9F=S=W(@1V$^G53B@5)F5)UB!T+1[7'7'[H&DW
M(N)0AAZ#8_D";/TNJ$*_ _JM2)?CRUC*G=C9)0Z)K<+U@O:)! **@[(%FD=)
M-G..=8^8Y[R;GP[1)R_B-_J0NU''X-?3<]5+J1S=5$'TNFYT%URB&\AY+7:)
M@:UTOI*+Y?$24BW44.:1*7;12JU'W9P$S;/S^>=B>E"R5D0\$CG:/1Y>V'B?
MFW% VA_7TD,_RLATIAO"$DWAK-3*\QN H%C6/"/=MOK$M#6874C[I!Z)8D/;
M>MH/GMJ+G*8>X-Q5H2OKF7.W7O?(P_-R?LAA<J3;4CSAKA[M_\;T91[!4R?*
MD?[Q#\8@'>O 5<1"Z!.8[,)5]1BH;FR4T1$O6[SWG8\BD3@?.)OK0%:HIY9N
M()[4,9;C*BM@W1W:(_SPW9(P5S9O.1QL<-#F!VZMVU6]7ZU]@A?V#N]N5?]L
M0.Z)C[HPE_RK$2,'B)];S1*ZOO(IF5O.2CU1R.',N%>,&4]9[>OSMAFNY!TW
MZ!M-)\J2#MATF >*1EZ^6!KF*[^T\T#*U\S_GQ/N/7^G#.4;4_K!!/5@@%[8
M3+=&M\"<5N%R="OD71FCH>>Z6<%K:[7T)0BEO0DLJD(HT77]T];/;/98AS"7
ML&83)C9U'KF9$+&A^,*US[DGKNVTHI@6EU6>Y?D7[=AK(32(#-='#W\YM=VT
M ]TR9^"C$_L/G#GZCYWNFQ=(^D0Z!\QFM_D"/?&:IR[%$&;:]>X=UA(+(3[H
M/A("6^O(DP:-.HMLSUN)&$VR)E%;CGC+"0D5W=8K]JT9[V:I?KM1-KY^P=E8
MW<+)-6P#YP@<I'H9DA;G7FE\NX6\DM<)UL852#8"+/-EB2=R4M?&UP12C+'(
M%1TE9P!;TBM9]E0?*<S9CY0T2U8BB;=9]LA% -3NTR!ED"@?V)9(<>]$@U9'
M_+MX3^4&!Q6KT?E@N3;\W?=FE/G<RY&PTUD](R?B@M1$"U0:[$4H':&PM6F!
ME/U0\'EIPM%J/T7BJ;>ZU4UM=SQR)WW&@ -Z!^C9-K<EG9=;3F%K']?VBM##
M\[,O;0!WW[Y.Y//L>$_=/D<2V7"<PGFJO42P#$A&JK64;-#F!,U;A0;40D^D
MV9@+NNI^OX]Z_E@$Y5R8(K7O(7)=X(CT,/'N5A@=F1BNP-RQWCKHU>6;\;/A
MV5ZHA8"YRC3/B*H1+<<0J)62QYN<BJ#VK9"D) 9"1YUF+S2N&<E 5\+A+86;
M4L,5+M>.^KYT:([>D*$;KM<)\X;GI9,/YNL8<B(1\6MSKFEDI=U8YFTA[+S]
M]\-,N@ED,3.8MOC0$H?2C!R$ W.">\4'-)$,G,X>P+=HI'S%\&?0\*5ASVZ)
M)Z^]>.U5T4N\HLJ=EXP[7[AVBYL?W7//HY<W8'2)B@L+V;KPR<^?\2Z'*VB?
M6@@_YO&49.,QL(&(U4B?7SCS"5W[7'K_K=G>#T^Q$IAO(93.)T.3S.=I6$X)
MGN8="-ZU*C_X?\Y\Y'^#R=337Z@M!%M.&QGC+@5E#\"C4[.K./C?_/1$"X&Z
M2"?QP52E@8B?Z<B$=#YPM!(@0N1)DU8YZ-?.K$_)P^B(K-WM,QP5SHE7:AAV
M\;P%_3&]&#D"^=C5>G\:<RERJ3TLZRB2\2U'O#GV] <EZ<?2 E*FJ]V-9G.A
M3P=#\U8F70JD0P,YM)4H Q*V5(>%] .;->0<?\ZYF7QE09/7\ U(8@KO_:9'
M'*859GZ&1D6Y'^S%7+D47?B%22#HSN#-P\]#JW<_>!E%B'V/!>_QR0D4Q\QS
M!3RYVI4:%*,59)'K2)GBF+0[8^HE]8$;PQ[VH&&Q6IL=Q(SBB]W8NJ'G7%-X
MIX^%,#<Z0;+@1VN\68@_-;RJ**(60O^!7'_NEUW)/W@YKY^NJ0(AQDNKEN'U
M<+_(%#3:GTH\-UU 4KBM/HLZP-L82P\A)'GM\TCN25TF;5Y&\Q^(/@RAZY;7
MAP;Z4,[[,_@<"6F"?/QLW933B[+LZS8"Y!1E,A#'L5 \\UZA1RV$D;/!: #)
MZ(;S$FX"<I+W"4ZSS=6)3..X^:?D@C"9Q 42MJNMD4@Y25VGSL8K<&9&&WTQ
MMNI%D)Z15ZL"3XR_(R.[ 9CKK=X/![XZL[RDK=AK*A?UU(P=7CM07?.B.O\8
MUJFND[8ILYCUPLED:&ZSU);GA A;Z/5X%T8)Z4-9.B49J95)UD%!RE:F%1/=
M 0>P)*0N=+[.RU/^W7BI0ZU3T]PCR.4O8F%K'_]++97''W^-R\'?"L^'XG33
M=RQI+8XE>:>$]9Q<R0>HDUE(]:M&-T#A,C GG/8Y_&3J H!KI7[>)4HFU>L>
M=[^^V2G5]JK/1/E$A2[11>$,G5WUX/$CIP;W_8\>J(N,L^:K8@:Y!8]A7B?/
MJ?O6NTV,=<&R:O=6Y[<R<JZ?VAX =<1SF/T &@8SM95\=,Y)CI;CQ@UNPYQZ
M?";23_PQ=00JK,YG3AJ\G\E45RR$?'3SZF9'\&_9])@^CS?\;I<_.7,>ZHM<
MT5+R_/RD1)IWO'0)NDO#63%.ML76<U-:PTO)R)8O@>W]R5-VW,LM_CN*--<V
M;KD:T1^@7!'%_<'FQ$Q$NVSJ[O#Z,]_S5KZ;X\EKY1&[JNN%RP&PF[KT;?3G
M?1*7(*W0F1N@8V325GE<\&%^(,AM+'7#&UL=?0%+N.3XZQ%H<2%>;F+%T"VG
M5.PB6*Z\<63<XT#/_M$Y[S'GVW=[O)2_F^L2Q8Y(R3TAC0MUFI W!5[!2FYQ
M+XVT"1UJJ-MOL9IJ54^K6*J#C_P*A =ZDLP'0UP\>B?OU6CJ>]U^Z1"MNEK]
M]:>SRFSZ"<$@O8U4;"CDPY>#*%KE/#9]2;++$^8.."Z[+E=LK7T$K&?I. [Q
M32.Y /W6J&1M#_!I%5?=*ED!;T1.6 @'BV3#7GU:B%?K6)3WT>-N+Y,TFUY'
MEJD%F /\Z@'D+M\D<8>MSLY$1;8T*?E4-LY<*]!-_>(U\**A[;7]TTI;( A*
M.8]ZW<0;Z 3FH0EGIX>7$FA+0DJF%H_WI[[.Y=P9C!I\]MT<#?.O(_F^G&1>
M*_9#'1N-I0W0NXT-ER(6@I&+$&^,60CUT4],T0 9<;V-T/5$.7'9+JU20*]U
ME"HVU]V6?,QE'D0.:*X=TVLI CVR61^0+R AMA.'^JC.L9"A]''YCJ8G;3<J
MT@M,GX M^]_Q%(YKM:0,[!. @=1K1-:(>H>YE&:%?HO\7C%&<X,-_*SIP.VZ
MCO+"C-]1OZ*#W90*Y.)-)?P5F[YX^A PYR[R!F>33%4SXO2*)?Y:4/&S504^
MU'^G:FZM 5OV2;^6+AZC.?2)@TW;XU.7EOKU8FM'>2Y0OTA+R5&!<I?J-$W_
M(W*V9!V79])>&<BXB>3>0#):4B>[QII^RQ)QF;O[RG[FO#C\Z]F?]G>"FKNX
M%QE33J$LJ\QW2U>(R)/ZP/ VS+4S%A)D2E9S*WH4/&\DF:=*R1=;:1X;YK8T
M%105\%:-_>$>-8CZ0]?::O4%:3O"=+A&@U]U2G4Q6YR%?V_4(E0"="G?N+9[
M6IDYVZ=LOV8;1=;'9:++]4K">%-*MOCT/5:U1IK#\ZZ%K,Y1P_21!O?6QG[U
MHFG*$N2/6?(\5FJ18C.PG.V7KY5"3R_Z5E/"'M2][C'VFPM+] ON0&L9YWDK
MZI#+9<^YKS&C;%_MP+1R<0"PX7Y/,B=W=H\0)N_K]N*YL-W6(9Q;X_T1(H&8
M?(O;8%+P;+L[^LMT7BZAM3TS"PU;J(\QUWP3$>QR -'-TF7@GYI]N&8KS'SI
M:*X46Z$^3T<ASUO=%H+F!OC05G0GWMFK49&?GQ@G5R\5SX?B=G;-"'$I<$0#
M[CZ%Y^JJ,U7"U@E/0P 3\KZ:5L9-TT45/)'CSA>GW6LYJB$[YZ?EH+ZZ]#V'
MUA10!7C4G:OB/?."!1IR*WE1@F03?,1"<$8YL+JYB9]7C3F@T3WB0$@=:2Y-
M>D.2NWJVO74N.I,8V^F;2)&_+=Y1=#NX.KB"E>J4,RO,3S:$AW96W_.N_\16
M_]\;]7'ANW4?SN9+5%\H1CNB4*[ >GCS8$X&YCZ(U"K<7)&+&A /3CLOE)*L
M<75I?XO9@2O8J6Y%)$$]90X0 #7<FN5DH-OAR+;9T@((FV">K=]X+[Y?I2@M
M8H_!F$I8VYXCH22 M8*SM'7<M".(,;+-WX,O]DV^Q=61YX]+J! SHVYJ!7MX
M(=GAGMCSM"9 N93+ED4,Y^H8)"Y]&VQ;I4^<*_-3#Y&B5]CM>$YXH_Z;JBWZ
MS"R0:LJ&%R!"DP_VC$<WWP(8&C5?ZHS1N?[/HGNIOIIW&?$:_&!LMJ86MHI
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M3UC?(W#U2)6]^7SDZ(IQ50?FJ1E]CO*:\AG7B668J^D_T'Q^;]!]H2-VOLT
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M?^.N%>DBB=B^FN03O:!U6(4?(['X(VF9]Q^+EO6:I-JI*S[Q ]G2]5L:[69
M-NN^'3MRK=O+V+9#U;)W0?EFY(7DWST+.]T^"RP5GY(MYZ^Q,!L/^*7BZ?'B
MQ;/@6T,MD]<L1@AGMM_2+D,?KM8^<K <QC2B.#;]R2CS8)?[>[$C QJ?*CA
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M2)\>J.<:>?3D?!A7ZL][_C\G)Y=M_+WCP&;P!;XGA<F,FV [3N5$PML0UUZ
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MB\"&]0S_H5[*U'K@6U9NM9%7 ;_C&KIG!2$XB]SNN7-648@B.N=!W=FYEWD
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M&Z2VL4KF\"@(N>;'RL<1^-LG^*4I[XKIA#"<_ 1I/X2NUQR.C3^<X3,1Y2&
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M*F"-&%#LNZ Z*N6%\+>_<,UI7^NO%V\:W/BGP=M0FGA6_)6V?A!45NT@Q&B
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MR?Z\='?ZW?.$]##9"G4M?U_W<^J:T8,T&7\WL]>GSY8H@%^E6H:-# #^>Q<
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M8_JA#.: 0T"P75)ZQ(#(S$#1:UY3PRN*WYU5X[H] 8I_L_\I<@5<H !HU0J
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M1N4D<"VB6O<FO?/S]O$#+,BV/W8>)3?(O5HX%PL+M-H(=#_<&QU"0EFF:GK
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M'>_G$X0XX2,=N 2[&7OO;%?X\*N[;6S7HY%M=#2%2. >6?>P<^L(]H,"R*8
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MKN; Q9'FG7]%"9!_>/6HW#VHSG\W,4L^/Z]FF<2FM5-T,+;0KLJFSDHR[*
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M;:5%/$N>Z6!.BVHV!#0H*S$AIP&-?010ED44908W48:.?981Z-IVMK@_1!I
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MT5EIA_]77I_[O_2B=78 K"&5+5 ^Q*X_&V2B YL ?A32H\A45BUD=926M,U
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M?#K)<3@!.Q>X7!$572/I^4L+1\JJ=-^TC964N;O/_ 7+A/&0EM0N $8WJ[!
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MWWWN9UQTII"?CQ)BGU0\H&&B<19+O<>Z7:GHB*X '^>W&%'@,5>16UW&4Z<
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M2!Z0'KV?H^C6QP3E"(:$7=4A23,2ZE/Q \[%5A-S_?)6T78>XI\V[Y#VG0*
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MHB^L95H)6K%5+,XY(8;H%CX@?R[9Q:[!((=4;1UFWZDI=PNU7C; WW)-VJ@
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M]$,,D*:5]KB<<'SFN&LRH&@0]CB&B)JX __>6AMG?<X4YPSY@?BX&@/@%S$
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M_%$&](?']AB!S"?*JPYA$KM3. -,Z_X'4$L#!!0    ( !I /U1_.6G:C \
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M>/!5=D97@&9P$5]DD:D*&\/;WH29*]RT\0X9A:RD!22LG:WO,=UPWH1Z;=F
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MI_?O_ZYUA@.[-6^V>YO$L,G0UBU-:7LZ2 I1\2AZ97N3?"H?B21[,S&K'5I
MVOV9>*!S9(Z-B:FZ5XI$628VP5+3@MQV*@)(CH=Z-\W2;KJ7/>?4<!_H$"D=
MXJ*?1)5Y8XCN]XJ+QY3SM:' Q>T"<O$XFN76#?.:S!@\^5XG(F1T(&%P#NQ_
MN]K.-4Q1Q908JGML/Q- RJ.7'I.:VT#';:GEO=-9D#0C6=CGU9D6;;XM_D(U
M:^?:H<O'9D*>_RMN+:=AJN1*FH#%GDHDK Z$F<X]2E"C"69/.X=XCK!UK:TW
ML7MGM,0<>XPFN><Y>QR@P3:%]7P+W"ZZ.7<2@DVT+3T2>OPAAO1>^^5DX+JU
MF2:W#7U&.+#MT%UPD.4A_',YXS!D77&V>%P^"))T$Z[BW*N7XD_F.WU@NH(+
MVZ;D%2E;+6B=/M=%R6^7ZEZ;U%A(72D&SZ#Q%2*SE;AH.>XV(O_I9!G6L[P5
M..W&1YC%O>8@*>V?S,)&ORBA]4:TK77+6\6U2,_(RD\F]V3PNVKP.R<U8,S"
M#KE+V_\.(Y]K_UL&0+'.R@TEU>Y@K=!&R@L@M/-_+-EJJG"$\'=VH6)AY7*6
M<"Y_&P %S.9V:A]RT#M)/^38(:I:"(D31R)X.+9H[#LMR4>H+;^84 ?,!O]B
MEE5R\A7=*$RZOE+@S+I&4L K%!(LO2RC[J=IS HAZX9*MDO;+OW>Q'E3U.[K
M X0LS"1T]]7&IH$VN/V;*T+K;]\ X?.X1;W?,@W]*A9*4EK;1# '=X>SW-J+
MYOL2:D2_2@O!P\AS"L%=2,_!6-C[DAC4JFI_(H3-#+G],')]>:Z73A=CDQJZ
MKD;8DM2^.5:AW)N0+%54(2\Y]4I6\S+(,@9CWDU=MDZ,]M<7M@Q#">WY"@P'
MCWF+.Y_+[TW.(6524\2Z=B^=:L;=2==4&'!\;W][X@2B"YM0OD#KF(:!GT*:
MR:!FA]WID^"M99[[7L'F+\J?(5U'2]JM-U$.G'K0*D;3<:++"!\SH,ZX2BGK
M] \MD2PD%5@G#DB.!F7GVEA;4_P?>)ZT3V,'*_3.U;R+%5%$[0D,R%PNB/K)
M@J[#%CN%TOUR.2+SVILT.SHQX?:_ ,9EX#'=A_X%,,[H<GWGC\U2;^)ELZ<Y
M<]Z9J1!KEXJ!?[R>I!-7]'VBLBYR#^4I4$P5H(GDG G4-V<"1];!P&SE[^ )
M0[JJ"GBE6RC!C#7\X)A6)\MBI^$C67I\D$2N82^K8T'(;IB126"JBI:TA!-R
M)7/+@5#YI>)@_\29#N"8!CKE&SWH7@-U;5V^"[JB6IOZ".0Y;>8,,Y"6M\19
MZ22!%W68+(Q2V7WJ@E(*O1+L1X>OA=H0N:1]PXD:?D!(4%V10:KLXQB)Q;"#
M$.<V"!LR])5R%L_.+7#!P@B2VY-5$8)31,&]&N:=)KPS6NR:F(9)0GQ/7PU@
MG^R<(!UJ!HG>(;'_DG5>+D_82W76 #>$1Y)<N,.*?9U]#,D<2R1B9&^'$N>,
M[".0]-$2%3W'"$Y*K=PFTP3O2LL(-U__E(Z)@=T#S>*%"%S,_;R<+)7M[T0K
M0E &7%N*9V;F$IEB;N#FXZA<;UN@,MCX\WS12796X.Z[7$M7!;@H^TYOD:H
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MC*(%"5= D;,R?8N!>P7@*XB(CUFMV_P=ZT%'3X;\ 1JLV]3.S:Z#H:"3#L!
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ML8F+H9>L=:QQ7M?:T0_P=%O$TV)P8[A36P [4%&TXGU%_FZN:"9]K!B2QFV
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MWJ7MQ'3+KDW_1=K2W2 O\=%\Q=X88P\[9#]?W> MCM'A#FA?O$4D^2]8Q;V
M@K_!NS*6L/$1$$FG9+  Z6K\E42DVK0>5O(?;"%G[>JS6LJE5,+B?9[W)4*K
MQ+_!*Y0BI%9=6H?N^-UY?<CDRL7UV(7K:854OJ)]0I?ZC.^Q\G*,7]U]0)9X
MV]I7Y7FLX?+)W5"I4)&)$94\HD.=@$48X8/9,M1<,"#@!">)";4(G]M:/UNY
M[9R/1K%NBMP$NSH?-5]@DG8@3JOVTPTBUW6P/C(=:OVIRV,SJB#9X[D7W#(=
M']1M0-\/']D[1-9@)7TS?Q/2XR&:!QQAH@%VX%X"V75L)"=!/\C%9W,/5Z"T
M(_*E'&("Z(DR@=6O"[),_8IQM'<OGZ']WO%/NLM[V>C.Z6>7:O' [DPG<[N;
MI6('>'E(Q]]ILMD/7B^,,\:.\"4+AUO?0.9R3T3"TL15:PXO!F+\(<A&C^U>
MX<:)=]G.J5;+#2R1R_Z716)!-W4Q5WL7;K)MN.4!''M_BJ[^V[V6R!^E [>E
M\@GC\!;,=MN>E.7#Z;'=[R[Z#]1JNQ2D/59=J+,<-D0N+8?%2'CO/MQ:N$O:
M=MJ3(.P2YBJ)V9BV[ 5"E@:2O^,:<'88$? Y3!LSFI*YD;-L$BDT>B^%B=1O
M_2?3[[VY?Z3:_D3UL$VV-\BAB&;,(\;=V>'8\=,?#[R-ZXIE8WGVZ"=O4!]C
M=U"J[;?[F5A3[L)=2AXKG%3&8["</3Y3JT]"Y%MSB\$;>3>&MD[)_=;#<^O4
M?51S)UY#K1E)(:;5LUL=8],Y=Y6(]$6"KNB82K+@;IM#$*>7H3<1A:GC)#3-
M>^GI+C2I)0$UFYV.^RA)!)),1IK5D^K.>2KE<O=\^S_8U7D[/S-7YXS^&:+^
M)#KRHO\340!9LE26JCCPC;J.3/:V/HDYT7;)K@4^>*;XY6J%Z,;P<!3JEJY[
M5E8O<+&/G<'3A#4$LIUWH3DE=* ?()&\J,5/Y>&5\1MT,JC),M%YH BX;#:X
MIHG$ZH@X^Y2GOF742L2JIRZK(4D\A.V3K%M!]=I)?3/RI]Y#^Z#4'QV"&1;7
M08P(/8(O@WB G!,5_A:S3U3Z::L@*GN;WB<H69.]U!#U;)__<K!8I9(LEKM(
M:^E<$6VI1/O)])C6SLS^P[>:9ER/D^C _\SQ65;G<H.01E:WU%C5N#Z3=M$:
M<!M]&%494;D^3[-P$I#:];C;V9%A]*^)OV221-^57U1J.@@WW/(7L7[>>X 0
M^'$_E#IF!$5%)1-J<:9'M5LZI'6SZ_6JH]"AHFN*)DRW[]Y"&7">-&7(= %L
M<_<1#7##=WR_Q? V-,F,%OC)-=6T D+JW#W%EWZZ5]!=)3/Q39X.=SC.HN4>
M?L!>XOBS)RRUDJ0. #YU(%=[0[\D;G*/7M&?LE,V#%KF@-&556SW+4@:-^T:
M?'["\2:]/62WC4RZ,(T%["_2 P].EP*^< \4"NV^\BHC/)[EG9.Z55\B'&UK
M\I<W=G4)KDVT<A(_'D:=#$S3UC:+8Q=F%+7O/U4LS8XP?O,;>ZZ0YNY2A/$Y
MPS?^D*#$YKL?E$$^?&+C 95!A(]#EYC&NOC>(7<3A'ZXWBOCW/C4FF=G"/ F
M%C+.FA+LWV,G6#_A@J,TYOSO)CK!6T"0N/S3GN7$\>3!YGTU^;E=1B!'NKV'
MA?9N[00;=9S+7TT=YPH".<YFFDYX"/^22< BBV07DE2T"R?.<Z$./^HP(B/D
M_FD=/KRFQ#(;DOXC54RJ% 46-A\GF_3P55 UGD6[\!VW6WG\%V&\SRS>;IL,
MN+2B(I&CHQ.#8V_48WK>QYO0.W8MGC_F0BX0<>E_.VN8,)L\=XMISQ !-078
M <R"!<&!BW?4S63)@FE2A<RRXWQE-?G*^,+CP2*T%<9R8;'+JT\XE&91> (5
MA:.3M'"T3^E%Q06&>D*?5+7S"Q0[V(_4Y6JYY>"G!0XEBI[S#BP>Y]K#!DJ'
M*XYAKC<LS,!#ZN8@^NQ].:(:G;UEY:.-WH8<*4*=U^(KD('77Q&=+8%I/"OQ
M0)_G6O95U]'QM'.5T9B%%4058JP]$#5X\5##U-J5@@RL4E<$1HN*G>WOZ.>R
M>XZYJF(EOH W#Z/<G)1T O88J+TV&OU8_A[78)VY(]]A[OXXVY_&<I&K-U?"
M%*0BO01GN2T53)\6=EUX;4)<Z;(C(2^O8]BZJ%*U=^'+L9R*L[ V<-,7N2D+
MYPD"VPK5<6);';CQ5(1\V9PEV/?HP2D/L/*>4V,QRKJDS6.TO+?409(J"J2L
MBD^.NZ$N-*GT+@/42Q<_JX%)32UUX@=FF<V2.-R&]]A'$:"NFERFJ"$.5B!O
MI^<KZA<@)I>/W)A@MW,Y<8-_0A)VGP>J*D *%.%5B5%;]]B,<5A+M\377I<%
M*Z%8%8W(Y8R-X>(&'PK..FFMALY+FZ'N(F2$&N#&1DT,G4)><'(!7]/(BP!F
ML)J\I-&:<#TO:!2T:.#EBL[ATU&7^FS_R?DU).<^E1TLH*K"W]JCEP&7<?D8
M4M(-5+'Y#B&.(GQVMI Q5E49 "U_J7"KQJ*2U#L?<I 0K*(40.%8#=5;C,P.
MJWB0!SBY*-32O<7K30SILM=YV'48-3>ZLOX:H(&5#V+99TF,R#)<Q8\.*\]8
MD1A0:7*<K<9>#&A2$E^8/KSM\@-'!*086VKX,+C5KZ0,V>#I&,(!;MHRU=VC
M)W?#;E<(A4,_9_-8H2,G>YF3985!%;JP2!)27E.4] 6*7()W6162GY%#+@-O
MN0MC1EA"LL[/;:T&)=@++[8;"+-69)W=C,Y0)Q-/%?/RIW8.%C.(5R 8>66Y
MXW;AY W+R:%A^3%6V*LU<+,1NLYNT4%&.RC2I/F1A%&4]YJ&N;[J9FDQ#J^@
ML.X^]U4,P4SCF>^'CZQ,W%5(+L+D/J:'=%,84%TJ23!!U:HA#'>QW.#Y&<7#
M+M(20POO XTNSS)V<F\!QW Z'>NF1<V#R@D\5F4-_9;04;FASZYUBP+U^A6E
M\^IVP;J$=&E%G!/DX?B&[G6M%UCFW#5U04QTY5!@/$0%-65Q!GM29&#&M':A
M5=2 B<IHII8+ZQ=!Q2D]3#W;IT$9_L  [YX,2 9V^:E1C$UW8=8"'B;T!74G
M(9:M73+8*RH#DEDJ^ :R5)7GE%AO@'><_<6#NP S-;&L/EH8]]R2NTI3#7;<
MH"BZVSC!^T_TK-UPK]*XT0W^=S;3PHUNO$5PK 4>B&IWK(/CG^_"ORHJ@ON9
MO4(P(%K@0P-0$8\Q^N8N_*"A@\9GSU '36A,5^3)&;U]<Q>^?:>A!<Z'UJ_L
M873!@TBV=99:'OX#(F_938Q\VGWMBV>V$AJ B,OC*(/>C'UE/2[3 /6/CI_(
MW%!)$+&=!-$OYB )E/GH;GK97T3MS@]1.YE;(=YGHUH@RBK@(V&\;.JQ'EA6
MT5T#?"&)T9T5RLH0HV2ZEEKW9=J0-Y%37D<B% '.F&42-*9'=!?&CI_R;(HB
MM;VITIS\":0!H[ FK,Z!U,6RK80E5X>2A"Q6HS2A-EFX<EW]U71 K^#*FI3+
M#@=T,U429-JKMI<*\@GQC;D8'&\'Z4I@T-R'.TE.?#6K0YBK\6\F0WAR62=*
MF[$RR8DK4AW"7)$?H#;H2OK)<#D[DU9D-X2%/VZJ]$K;^A<K4'[O;%719'6D
MAEJA,Y/1=BXKM=U10&'J"A(B5*AE FEP3C'X%14ZW]F+?#A#Z=H=9X=>XK8,
M0?V(B=11!W/BR+&VGB^JH%#U[%_C!76%M5EFGI>".'#AUR-;*_NA$97*8 KV
MT#@@R W7 ?X=>7?.TQD**'9L)GE)%NVY15'BLS=^[&+NQME%;*"[G4^W0SK/
M6!OHA+622=LP.' 3 $+.J6X!(#H#ZC]SA[:LQPW99QU1Z$@17@?%&ZX[X@11
MUH)JYOV:9'>6,!-(2Y 1/'?3G21ZP(LO4$9B<>'@@4H<$KU^[16$KPM26G94
M\^L>R=H'8K?.XR<G1@13!$"6 Y^3]>>TK;HH3^T6E&"*GAZ8L9?H$97S8QAZ
MP#JILAK!)J2FEAI2IG/9ZNQ8)D2ZD]%C#Y&'>J\KT\IILIO8JN'@)3[\>VD(
M*KA883"Y95*./0DR%L9PXCK> S-#HCB,$F9+TB\#%.L^YJO:.#GINW!9D*;@
MZ(4UNDEI/GSAGCC44\MY#'A$EYF.8,;+:4YX>%>@!'FZU&5&+PC:XF3+I)C'
M&T2.812@6VE-64;Q5%U9X=K(0X4\%LX^]79*0V!!E^W.#_<(2.4BGM9-"'6]
M"F&4K9P^AL,MVH0DIIO1EOJ5F3-L)FR_9'3O*-WK@J[6J=9!1MM^+M-$D)$7
M+J,Q[&5BY51>?W/Q,E]'A5V->=XB(>[&B=!/R/'CS2<G<-;I0_'\YLWQ%R1D
MX3Z9A!DE<B,P*B3UH@P47/.SPU8X<W]+,$&#K2TYSM/1J1J@4&ZK2Q"=41<H
M^]]KEC= "9:>U;#>[5L$?)&I(X=U.T)-SUI0@W0!8;&J1^S[[7'RCQ0 L$15
M!?:36\PJT$ZF&WMQ9[MC=[;E;B<!BMTPB' 4ZS;U$-T*WX!6-9)@JV]R'F90
M>WN@ 0H6"9@#FJ:M)8KDE<TO2"3"TT3Y(16-/]_VXYI36;.-N!;FIR[BAJZ:
M3EW$3UW$)[;'*&$+%F$]-0,_-0,_-0/OI\U3,_!3,_!3,_!3,_!3,W A/ZLO
MMD_-P$_-P$_-P$_-P)]K,_!>$4I#K;R-JA*N=I. Y;-28+5VD^$KV)GK)MO$
M9XWB+M".(!>G]T3TWSY*(0N\V38D,?X]_7FKD#"GFRGAQGDH=DX'<XJ1J>=I
M=-E#):%W,K17M<WP<B\GJW<5:AO-!6V]\^3Q7K;?M>Q5>W?3!K)#M6*^J5S-
M]FXNT\9FH&8RW>SA-LVN_C'2*F_M%R, U< %K>'9W-8Q>ZA)W> /M)?J]7F1
M6B.2S<6;2 -VVM!IS6R[I;S5^QJ-)=*CJ3Q<YQ[5UO;C4+W=EBD#*A[BNJ<0
MA3K;MWB]B2%C?G4>ULM-]^U!WP -K&6J9+=[ *7)<;9=$+6O)B7QA0E#M<L/
M'%*48FRW$*.652T'*-@-2H?8<(%%(=.Q+E%-34:RT47#&BR%M\IAK*%UVB;&
M:,]4736WX@T5':P+\!G%ET^NG[#[\N*= HBVI1A/<#>6 W1*@4,4Q7C+9N0J
MB1."G-*\1$\[ZCBP(I_UZ**9U\*7!>NKE'5Y25QFK*]"TEA#.@^*^W&""#=Q
M1&!]J.X>P\%WWW9);%<,-#)!9/?F#H4 %1=5D^8V]"F1=2H4G1M#6]%2(HW@
ML9[E.=/4TM!^ED"JJS"!<:[[263])>]XYDVFH<%]@6Z9Z"<CFS5,HM.LJ6G(
M;)88ZT^J(\]L%2/"A%KB)PD[K3^/YV.HF(%<Z(#\VS_^_=6K%__STZ<?__*_
M__-/=Y<\_1S\Y8/W^S</ZY_WP9>+Y/'C-^3#-S^\^_7+W3[ROWEP?W_C?Q^_
MCI?H^]^_>?_UZ:U[$[_YU]75N^4/KQ^>SLY_?O/@+<G/_[KX+5C\"SV=_R=Z
M\^8_;U=_)>^_^>]XD;P/;\F/V^W=/_^V2'[^\?SJXM/];>A^^?WQP^4//RQ^
M^,OGG\[?_+3[/II?)S]]_0U=O?_IIY]_GR5G'[]Y=S_[\OFG?[VY_#[<?!,M
M[]$/ ;I<^-N;K_&G[_YUMGF,;Y[>?MCLOOM^[OWZP^H=VN/%FU]_^_-Z=_,I
M_"[X:?;;U_/]=V??[2]^^/#1^^_M;[]=>^\7EX_G\W^^_>;'C?]FCS[,SWV$
MO]Y^VN$;\O[N>N%]_\/FG]'[_;^\];LO[G]^"2^_G-W^Y%T[EYO%FS]_#M\\
M_"U\_/;;_WUQOKQ]]6I0\^^@YW'MR%6Q+&W+QO:JWAMR34M@5RD=PD'E?PE8
MVBMT-;3V*[UT!(&[,01ZLOC.-GL5YCH['#M^&N'Q,/M%U*.TZ8*@75;":!62
M\S"@YUI6FA^SE,@U)1Z=7R_H/W]%;GR!8@?[D;Q@C8!<5UO@@231:6P%*QLG
M6\T"0L,GK0T__0[]F8?0Y]"53$Z9<@J9<L,N:L#TNE-RG<$DJU-RW2FY[ADF
MU]'-[CS;H2Z/.Y3TD\W63\>:RB',MNK$PX;'Q_%R/E-+X>X1^0_H$S4;-H,?
MU3(B6;LSLF$V&M(B5.;LZ<+Z64^D^H6VP8?]^O*,Y"Z[?HE]FDARBI-JH7<*
M;,(9*C+K2B.D*4AV&4-$\]#%XMX)OOJA$^CGI15OWHI*SQ?H'KCP< LK_;.;
M4Z^:D1[B%2N'(=!)W/IHM5MS_&>J/)Q,Q-OT:D"D*W 9^MX7ND3(C.[V*&\*
M<(MV>=>'3P[=R7&\7R""0P\N^J8MS(@*%;>O@DJ%!VW8@9("-00"#+#I2V,[
MU-9W/?6<)-(1N*&G"5 XKM=$L1B8&\4TD8O7Z94MS+B]?W,7?GASX>PAW\2V
M,K-95;+W?EJM8M@&)]0Z+SC.J5T\F (;S)Z= IMP0L3+"VX?"6*M/^\V3I Q
MG0?RD7,)(E9CZ&;T(XD62$7*5L9WCV%_-1V)/',UE="2><]H4$TLU&% 424R
MT]_PI &3ZD&EI*@;%HI9.'OF<]V%WV,G6#_AFX3^V?HV(8Y_'FZWU)O#CG_F
M!%]OB,O^1^%=7S_Z-E4K$:7HCQ^,)7D0_2PD)'RDL@#'Q4I\K*C,U$3F-E4M
M@RAI.HXAXAJP'87^+T%9)[MH@W?1(XXWZ0^0MW-(C(^II#KS[#:CM*"4LIYY
MCIN/## 8*V1J(BS;PB0ZVU=^,T"\5D62H0.YLOKGAW25,+86ZY63$BRZJ\ >
MSF35B.AJ+*#R+%%!'<J=+W,"#-MRV%AI9:<_X=L4!YK9V&0$%"WEZ\=J9R?3
M*H+*0?Q$/E(S[,;!\@Y?[0M[1:K;5__!9:N/SG#N=LJ"98+\[/#;"K4@6/O$
MI@\E V)]A!(3417&S*F.6&. 9">-).\KJV$A,9K<@9JM3L!>[X71Q@F6]/_6
M^T0:3MY7(X>3.U"0YBXM.SIS/Z-9X'UR@@"1^6J)XC@S>(<T-CND&,OF(NM]
M:. \H6>C7H(81'P'7WW;;#,S&MF,7+XM40#NWF"*D];IT(^Y[%M.$UP \QJY
MCS4-3X!B6S4"^"D@,.J @-EU=0H-G$(#I]# <PH-G%PR<]/^Y)*))JC.+G*1
MH"LJW#S>(%*2BQY-YPDA4"Z8F*N==W,0IJ \T'(QH9&X8'1*];]A582\SA/*
M^6KGHW<,].$-X7GQ>0QVKVI:ZSH>5PO,O?VMDZ\U$E^K<QW!>5HG/^OD9YW\
MK-,5[.D*=G0@0E_!'@U]EA9=MO _AX$+ZTUU<+25JFK>Q),#6"K9> Q.%/W1
M+@Q8&GVXHEXA#N@/*#9/.Q(^8+8WWZ. "G-LEZVZJ.^<)]2$6Y:MBG-EBI/6
MS58_YK+^E0DN0]]L&9X Q59J!/#!;[8B$O^RC.FFP:A^1.&:.+L-6Y^RCA4E
M4-J3Z7_5]^-N#I9])X.KA,T# 9J&2Q&DW++Y4.8E[RS)Z:Z5@ZW2 5)S]J".
M=H"&5(><=]1?(1;<(C/JD'*"5-3AADD0D_TO/_S<@7R$W#^MPX?7^1]GX.?_
MD6*?HEXB9:%E@M0R9_B61VS4Z2\(?_>#,2@IJ2E R48,,BO//QN#DI*: I1L
MQ"#-LB[0"E$OQ[M.CVEZHN?5U<ZR0QK&N13PM-19!<*TE449Y")V2)UVZ/)Y
MJ5*DPJZJ#3I*S*]RA]2E@*6]TJ& :A7!+%OL80Q1H)AY5@11[]?%/HHH)NX&
M!TY$S<R$3K0]2?-J0O9S"IT3[".T6B$WICPH;.RW^JG/QX>,*8W;@Q1W&W3.
MI%@64MPR*>Y"]O-,BN5E(07%G_U6JPNR0;;Z:8X'DH?YQ @74N'T6?DLOD)T
M3CG^0;3*'X.L;!-RC:#]K?FI5=X*C"@/K#:^C'3TA]^%/O:</<SUOJH,IRE3
M5XK,C278]+C T2Z,4AW,5V=)1,_%R-Y$X4MSFC+MB@(K;"\CTU5($%X'E;^X
MP/1#9CYAQ[<VCX2"V>Z?:W\^B74'\D931K1SEIA,_^ RH.-#GFTCJ$6<TQ1J
MTY.X&3/PQ"E"+/2/LMIR/SI^DMEJOA\^.H%K?S;)R&@KMV*,DTQ*I_G,^XNA
MS*5.,<]#ND\&"0[6\QVU_M/DDP%G%9?]']12XJLBGPQ_G4*8QLMG=^P\.>GL
M[M&<^*B+QIK1BJ*T4]%X8]5') E!+$UZX:B*W):./P2+$C1XYHLD6-^$473N
M$+)?A>31(1[,_J7"WXXBY=2G R=,1G]#!/J/XF=%NW<4(?* 6#V.F>N2A&X]
MAW.2FOX787(?KQ*?_H[=*@ZD^/YB6CO@^DT1 _J!>9Y9%_0&._?4\DJ37H':
MCHEX6KKQ[:?@.FY@81E;KHVTNS)!Y75X$IUW?$;T]Y&$0 '7%E8C\!'ZJ2M'
M3&9#'(-I'[.+ZEU>4]N$59_>?.=%NC6O13D$-$^0]/ J);/ /NQOYV9O[Y%3
M3*5M4CMF4+5VEHZ?VAJ73RZ.&,]<3$AEB7A:.NC5]24$#^P&+S<-J4&8RII6
M=V!=+89<;G+L1W"J*"T_25!!\BS+@D*JC\=G#"%E.35Q49(PRT9R[!/T@(($
MW>]W)/02-X["A+AF#(#;C/39?I&17J:DM4P! 2G-"7X>1O%\E2XL2G>'2+P_
M!$ER_Q<F65&"[Q@,!3D%5E(291"%,AXRYA]#U@DR\):(/& 7I?V: +7(96?=
M9-#5'!\\,+LA%Q.JH$M.W';475T91US$ 9J1G"-Q&#M^?IA$A].$*A^M0U*I
M3*SG&&0O3V[1+B1L,[D.5B&5BEL#VJQW(,-8NW?7L2EV.YNS??[+03K&2\L!
MM<>U=Y)7F (M?>7E0>[_+EMK/A2O*HO$N5PHN(;RW1S!K'"=MO&J*Z0R![J!
M!0MG9%P JUE5.5@M9"4U>2M*J:)C^'4VEPM0S:J&%JR6J^JG"./OLH\6)J%+
MEXH&V"B[SL.2%]6U_*M&=PT2X[6"#QQR650:7+=_:Z],6#NDW8,UW'N5PTRE
M)W7[MQ-!MME2NMM#Z8>L4AOIKJ_'NAV(!FW\EI?#\(IZI=H@ESZV6?].">'R
M@,6]MOOC2[UI?7R/'T\'W]* Q0G/O?%=XB=M>(_?3F3_+0U6G#ZL',%G]XCS
MU9V[]?*(E5)";L?7H]A_Y0,((BS,&Q7+Y#X-I%&.YY\N"HZI$#+0=WQM\3Y!
M/)T.:'<-W[B37I)M@TE6HK/'A&^G8>,ZP,"<[P#%=.&0JNX9XUV9L<8":*%A
MZV9&=IYQ5D(;&D!EOI_IC4S/('+C1J;#%A_)C0R=,W2D>;F4>\=G":/1!E4>
M[:B6.SP/J8 !'>Y91F_)Z!WB3=&YLTL?-2E=R4C50%1FK%D:M9N/] V,@3&5
M:^4.<L_21[]%M4<I^*QU<SP(<OE;@N/]^:$($_SU"I>CO>L5Q:G.O4KA@PAU
ME5+C!GBEPN<$9CBHW:UTS=S* U0^7" V Y<7T$U+NW+&<>722S\@?4%RAHO4
M&@"\>JDPL-I8L'.K*"NABHGQNY?JFY':>N#Z+_4OAK>3^QH!W'$#M1@Y=Z(-
MS"TB(VPK [EEUE2N#=.!0]V7;ZAG=(?(]CIX0%&<JAS&-N(QLA>FDL"=#PW4
MCIT)!/INHL+!3IJD!.PU(,Q?.'X.@YRZ<JV'UD^M/33I K1SK%!/24N+Y3J8
MK59IQ1P4+9/["'O88<FA5)3037\Z"[SO0SKB'^F?)P0H#M5/(DLA1-$DK19\
M[@4YE ^7"0ZXE4U!-P4(4,=&Z8D_"-)E^I;@EC@S*BA(W.YKW%=LJ/>P"7U*
M.LH\#A5+O^OK<=I HB'#U#2C7MPV#)9QZ'YEY0^@WF/5F-BZ)1)/J6KV8!T;
MF#(^,\]+$7#\A8.]ZX Z@#@&JIK:QLO2&QXUA;0"!;77W[*^ @'R+AT2X& =
MS5PWV29I2\@+BI,+U&Q!@JVU][MJ&I,!$*Q&3HE9^F*21:RH\"S>6!0.9*6Z
M/J,X?8T,L]X49;#W?EYQ*:IB*_=B6^/*B>[.%;&![ID:;.S=L6O.Z^HE4Q,V
MH'A7R5)D#U^'T9>0J=4 N@$%BE&=3(-B01Y%?HNP01F14UK%*:W"Z(W**:WB
ME%9Q2JM0/N5.:16GM(I36L6S2ZMHAKXHMSE))XJ71L$6B*2^(G2DL)6OG?!M
M[\0-%60-/WQILD[Y1+,DWH0$_XZ@"CBU\[.RT@!TV 12)IQE1'O7490,I;F<
MUP3SI43HR39Q[:^O>1)'L1-X.%@/H[0RPV>DN0J.LE>/HPMT1 <4PE76GI@.
MR2T'@G!>A_10UTL_*G" ?+[*PDL#1#PD>/8-=I18<$)H0%$/&::#U>[2U'(C
M[B&%I(D R"G^82S^H3#[S09"3G&04QSD% <YQ4'^ '&00W%E5KXWJ_V?%EEN
M26$VI LQ5\OFO)JEH0 F6"7D)?+IC]<?44!E\%FW+6]+@6-\61M)R&KDDJSM
MY1-(3_)J34,Y0"&JBJ27YMG$JXLJDQO:^;F%U,0^2TN(!DCGBFMJ]U-//,[Y
MI1(<'N^<A82$CRS;"V0YR?*VE2$G,SFK;PDDL80YX!B[SV'@.M&F(C3,P=;*
MS5Y.MJJ^.A"#"=L?$X*NJ-"9=?0)Q9O0@WY!*,?9?BA?SQR1Q!7JV=:"A"L<
MWT!U_2N1'\&%F9Z&RA") [TZ2KA#6U;WC^PS]5^%!.%U_M;(W=\1)XC\K"6D
M]VL"N=2T!)GJRM-#7:+&I>Y%33UX5F1>SN*8X/LD3GLVAFS3#X.8 N2GE:VR
M<QOJ+J>73)/T#WLK0ERJ<P*70<RN6/GAXZ&*F/;U""MC<$4I#9KH*L-4=;?N
M9@!TS]/"!VAE==_L*&BR<;73AI?E#BRGNQSY26TXC_5T@7.ZP#E=X)PN<)[U
M!0XKZIYOJJE_?PARS]P8/V0/I^3+T$B3LFQX*QH*:BB!+8UG'@G1F8N",(CY
MTC%'3_LNO$74%G2QS]RO8Y3L+F2#H,(\8.H&G>V_1*QW/6<L(%HT*J"E^A-]
M)H%9!9F_9Z7#R_;]ZZ!X[#]?'0HB[27VV,[/+9;XAU@:Q>;;#1E0+A85W>9*
M5F!OK1J"S%0NKTX52"%NQ"L[2W9]8<34Z2(U<5.G$R6H1QP+9Y^*>A6R_NTN
M0EXJRV U057XVRD)I#J3J_Z$ KHPM9P*$>["F4OW$((&5VTW9VL[J@F]"D %
MZ:K:LK-S1C#D8<EC/TG5JL!K-I6I+O@5#AQJV9DX-;M(3?S4[$0),%7BL)FS
M=WOL*5GZZ*%X& 85-Q!P'<$)*3%K:Z$$$9*&S\5<X!MVIQ&6"^1*+BK.AR.)
MXLA"WX$ 3,)8RY[*D7?((XO'?AQ'EN(:4H$7)/OV<K5";CQ?73ZY&R=8HUNZ
ME<\#)M,L2#=XYKT^.#Z8J:DD@(T\W%Y'GA;*,.EIC$V-U2VUBPAVXVQ<5)3J
M#TI_N4 $LUQ&ER G0A<H^U_ZWW["WDZ7QY6-%2:3:=@AC"#747.^#:UKB);1
MO,4QH[LE(7LJ!:? =.NQ+R0SN6U%&I_Q9['-R=H)\.]IBJ83>&=)1$<<11<H
M<@E.,;A@=7\UBC6F"?FRU!LX=[WY42>JX5!*<^'DK/43NU1V<9#TM'Z*.CQ=
M4L3+0 4"U;S#.QS[B*6Q>M2H\Q+'ETU4D\HVY%,'\BN%*6GZ4[C(.FQ!R_!%
M%I?33SC>W*(L;SS:X-U=>!G$.-[+9ZKI:4S %^Z<ZDQ<$T[=5HV)<#2:IJ,A
M@5QB&YPNK>2Y0:D3,N/M>&/*&JK/5VE\"2[-MY4;H-: =U0))$'N/$I</CM;
M^L_T28[CIK+")?Y*L+6TFTI/Z8K6)% $2]<6,P=*$)95HMUT8;-ZE-Q%5;V)
MPA6C;CPO;YCK,#2_L1<1T331"N> ,WR(U)F"S7<_*(-\^,16,,(0PL>A \SB
M[[$3K)^P-+C5O[=4CJ,GL+4QF^]P5%+>'7(W0>B'Z[WR_&U\:NU!L:&)W,1"
M>"6M.9T+CJK3NO;=1#>.%A DBK%JSW+B>/)@\[Z:_-PN(R ,WFO5@J%\9KX?
MIOE4\]0S 7ROU,[-TOV^LO-3J0K3CIWYA(ILNK#T<\+J**22.3$J>902:T2"
MB+7K^?Z191F(H (?_%(R\\> +F.ZW!>(N/2_G35,C25Y[I9>P?14KCK((.;7
M;!LFK+[%+5KCB!6@\+AM6[E+K_U;.QEE_9=;!QKF"^RG-ZDI]7-6!835!9';
M\GA?37B/XX(@4Q!?%>U;Q$;""D1JP=[Y^30W(2$HIK,K"N,$NO-'O=W')-<&
M%RQA6H6V/A8$NT"E8X_D+19(-*>,'*E<%=^8W*,6R;V/W?EJA0A=DQR5<+<F
MWE=3G?5M(.1H_\VTF5O.);] ]W%:JZM(*D]+"8.L"0FVUDJ_&EDI,KCF.OW0
M?;Q8K'.6;+<.V8>K)5X'>$7_((AGKLN,1#8Q0SI+,8I*66*JRUV)00/NCAU!
MD[#>IJ7$3#9G3(/H4$7-^FNNV.ETD.N=/7;*@M#/@M"?ZFJ9$#:NTD_9$*=L
MB%,V!& VQ!\Q$;??ABE.QC7TZ/"4BWO*Q;6FRU,NKH1.;]G++Z.;Y9$B5/1V
MH!VR!(WQ2Z(#??D[='GPCS?E=K:SQIRJ(*J0KM<#48.;3PU3:]N*#*Q2VX0J
MK)_H.+?)UO!4K5*UEXC*688%L+6!0R28?O]TZ]Z?.<%7^5RQVA=V:L;TS1&K
M#QNFX-;U8@Z8I'2D;B6FW"LEJ82,\=+*+-7ID<6CKT+R)7!#WT=NVIPC;_0>
M90D!,KD0DI2LW<J8B5=* V8Z [N8#,$#"NBO]^R1>;J";U&$R -0#9@.=I8N
M_ VH40)*XW4CJ>07:(4(825F*%:.7[WCX]RS<9>9!)&)KS 9F"1RD7065\&Z
M0RF&UA6?T^275 N QG.93@F:P^I5/4G3>'<WO@C+T/>*LBL\4P54U1SF]K)[
MH)7-0UJBPHUFW;LCWZPX.XA6>7QLI9R84Q\7/7&FEHZBF+U$Q\=J(5V@!^2'
MN[1U#V#CX6Z.TU>> %%Q"IA>SY '1&(<I07&X'3'86,G3=Z<NGC("5.ZE#,B
M#Z?K?/6C$[/:;Q*. N^KB7L&7" */]MX)YT+!A#RRNG@"^KB,Y.6-0^AX_@=
M*'=;CO.4E:D&<:'BSC"YO1S)?.P1%1GA!Q8+HD=PN7">[N%:D&NI7V[L2&WR
MT7KBV\1![2%C]_=VIKM8%X? 8/?HI8+F]N;P(196F;J] I07.&)C3 @"G;Y=
M_/0W_P/5F^NK>1X6S&JSGE,4@0(*0J96UX"$8KG1U58$1[XDJ&W' OIQN$QV
M.Q_3/^^1YIX3B^Z.U!2:4G1]K?GP\M9Y_$3M)X+IL!<)]3B<J&[-\-\ <K^S
MY7A)P'IXYL<?L%QJ@[U9N"!HEW7-686D<#>8G54Q,)1=B@/5JRI5A4DIIJ'K
MC\[C#2)+Y-/?K3^B !''I_[PS-M2I!GIF,(&Z:BJ\+?CP4KKKU+:0@56\RG<
M-0<N7[IY2RA%A[;VL:WM1TT- @",5[%(]T<OQ2)_U4PE2M\2MEV,M!P^(AJ6
MKC>4T9=  Z3/!WO\=QU0F1(F["P($L>GG ,7[^@_> O 6"!!@O$DM*>$)-#M
M\"VB%FV"#O4"Z+RA9_(V;;UT[^.UT_1SC;GH,IRM!82T5"F)IN35L<47LJ46
MAMF=2P\WX3OD>W<AM5,3DE8]*JYQ1+XT=^-6(-;C259F50S5'+.=F[V;5W6E
M-:TRO<ZFECV3<$=7^IY%;&,G\-BU<7I;58U^:E8D.)*>E4B#1I+$7+7/_QU!
M+H8['RH,K :)I#57/=7+^  U2_](16<MWN<!79>[,$I1H59X%*$X>@NB%@%+
MN^41M30E E'F/8/-(#?=I];XWD>9P+5K&JU9%8;>(_:9(UVG/E#\6TV"'@?]
M;$O/J+PH"GM-4.4%DS'0S=+N M)2?25Y0 #HI$*3U*-F;EGZE $'='-9$Q1%
MY]<+^L]?D1L;"E?*<[I1J!73C[[69:D.2]G",?JT 5<4MX:,$<4>@FOZD!KH
M1V;8TCW;W]'/P>K+R/"U76FF]Q*I%>,2 PWSLJV5-6,,6'A&AN\PK^\[:L\H
M+  I=98Q-?M:3IXS4 T:67U:K$ #ITW(!F?I6UCD+1PJ0NE%9G2V+_\&;"]6
M8 _GVP^_(ZN@/H3F 7=B#ALK%1_T)WR;XD"WVB8CH)V5KQ^K.ZEI%8'LGZQV
M^08%^\3A-ACAUVZO?F YK;-M^1]*L]>&!S+/RSOI]6$G!:R&T,G00D:+NJ%<
MGNS=\(%H['A-<Y9@WV-7G:Q,</;/Z^V.A \([A),GKOUN_V^;KTZWF8;J58&
MHQ1ZL9X99C2B8CHSYMCU(LTX\W"<$)G0%N>CR<_Q%BQD^JV,)_Y;I-2&*Z?8
MQC7?$=2Q;:>L'>*5(:G3STN2B58<5T0.SI 21VX55,0-U@JA,A&?U3GGB\K_
M,Y>:(MEM)U@8H(V7S=JU.A.Z?&ZWX@<3:>6Q8_\D"#+.*N9JU=D7S&&1NFKX
M65(<D.,OI3JK<0"3VI.- >B59D<$HZA<9M#?7V^W^9,;CFR0#JZV,#:,2=7-
MJU+%71MUV(5\'F[O<9"F-BQCM"L)D%67N0Y8<\$HOCZ,$;A8DQ'!1N#2J9I:
M1O4"MWFPUWNI*>?X10VQ8J2 7=F$7*>K< E$0=JIEE\XJ45.^!_:2^ON[>&T
M(&&^CZK*BPK@;595AA&\6=%?8\J 0_1T73C[K-B$SR(V^T,,7>6)GYC&&()L
M.FM0#(ZP7J%>DLCA112BYEE0O%/_C*">+K3SF_02ZP12HOR@\G*:KU;T<%SN
M'/K_?DL<@CXA:A')1!C;OISHTFD%0EA*T/YS/%:M_B9T@D@[O9^5N>)14@DY
M"PAH7)EP*4JWDVS_&"S(P6\<*07LH4%DQY@-A(555. A_,L-6CO^9=HN01 )
MCI#[IW7X0%<"SC9R^H]4*ZE&>+3L-N$1SBVF$2X$9D,)C,6E7)<Q,<27M593
MPX=A.R9- >BE6B\PU6.MSJ(SEJH.J97PJ"*J *T,T]8HV G63_@FH;]8WR:$
M%9;8;NE:8[$WI48Q<H0LF!)MJ_'0'482 K"6H.EVE=OY=R%C>9X0 E51HYV;
MQ<K?\N>I&#.H3-MJY0[VU!U$/QPVEFH,*RN%AY X1-=?%T7(EY73O5RMD,OJ
M0 &'B=0DF-+24L16,LE'(T$Q8YS6$;\'+<G>PLI>>6)EG;6!)0S76?5TVS+$
M^SYI;Z,+7(18P+3/R4.]PBCTL9?W>"KE?+?5)S:VS4FQMI=Q+:OKZ@XGAR=0
M'8]3:+6'[F3"J=W]Q.WM=W?.$ZIL;LKN6IF"2B"/_YV6QU@F)1NX:WXS]#/]
M3N *3Y SM,&?U;-VI\N8+@M&]2,*U\39;=A4,MHVNYV#Y?>9K;.KZ)+;@0U
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M1^HVDR'DHWN5ZDU'9(RO_2\!)?A(<(S(3PZATL3<-N@MQUK;M_8*R"LBW(T
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M83FG-&M ]%3,J?8(18^DU8SQ=?" HK17U?PQH"/>X%W;6V*C::PRW"=E=BF
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MY:W^/UXS!O=.A-C>__\!4$L#!!0    ( !I /U2TNU,J8<   .)P"0 4
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MWXD1X,5VLX/XALH)&?E!:"[1D\NOO[S,M$0-V "G ZK2*%'%2OK) 6"3E%1
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MAIKAP6-\WL 76M55XRRWTZ.&\@[MR@D_WD9.J+<]<L#83"YI4:.67/* IH,
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MS5I"^T]8>[7;2?2(UL9)HC_R98HHDPJO<8DMJZJ,\8&D0$CZ5Y!*&+22R[!
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M#,_R^!Z V9RL=W>$IP$WOU!TR'S+C2!E!%O5+"$KU/N.E)"C [)RIR7B8XH
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M"2:+D*+/B8&3=2>"K&AE!X(E[&HER_I/?_S;VS=??9O0;"VY/\(9VO#7([Y
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M7H6P2*"]#UG$GA_B%)&<O0F9\TEQ5OW92 W2,O;/G.__V\K VWAU<$;/^[#
M 8\@G]5U% 1.G)"2 T0/7ED.DK;ET]*#\_IT]M[E\2'PW<5V"V-DORF:0-UR
M:;,,>U<4$EAI/F0DB/*AHQ0W7Q+%/LM:L^[7OXPC%T(OP34FK^%#>@^1[X[-
MBH,HG49).DPT1P*M^?I>8J(8ZH4&@F*RS=".O#!K>65RRS;;ZT.-.-JFCH5R
MR&=7/W6['M.0(E)N(4+.ZT$0/6,P-U'\(701CZ";.@\!O'("_.LD.]#+1%DD
M(1G>)23)8K7Q*F:#;12#8W4^>,@  (< L!:F4Y1@&:A1X(N.6W$-T1X50V\>
M^JGO!/6-B[*S4'5* HAA=1)3Q$I#SR<"/YL)#@VGQ,63[=74D)=7H4&2K-!U
M30KP')WIR1NA8S(7-^*1P4Q</Y'WL-@J>85FU54IMTO0LYUZRA5D=9MC,T#_
ME0-N3Y>>[F"ZBY"B/L&$O"->1X$W=>+XA+#0-KB>%$L:N8VCL2QQ# T\3[&Z
M 6J*N:IV2HS0M6;(93O#QC=D^V'B+30\YH]2%"K$:N23<38/4!PA516&M;H.
M,>Z)APY#J9\@92/EX9-AM(."QM@5*),$ENM]'@A@-M*6>R044JV'+GV!6@D3
M2QCC+#7G$2ZV/SCIRDFE8G.46:9C<VT26)Y,.1*_MGIRLL*OUDY3'(Z7,3C&
MVCHXNGX(O>J5V1*Q"'L_*^A&CZ'_VT 77W*8+=R(21'&S%'='V*X0Q^>_P3S
M3:7EHMARA.4%W7",)=FA$P%R22&K!$&"_A.. *CE8_'GFX[V\(AA;33Y'!"7
MDZCY5Z;C.C)R*:,YPG5KI64XSW>X8#4ZW2=+)*<=SC*5R<>@SC-;+8)* RL%
MPWD&^V(P.!2C;2;@<%E?9ETPUZB9T4L*<*UA@/[V^ Z&,':"2>A-O+T?^@E)
MEG^"0_JG*OA-.ZX*M,E[M%8/S1K2KNY*J@SI[ $C_N'(=![[4G2$&Y/-&B,V
M(5)>L9-- 8=LCJT=22P+FHM,6:^.E^(5%9Z(%^2X*;G\/B.2\52$,(SF"@K)
M89J1LMB5FT_,,QH.Y52;6Y>TJ$KG18H1':(K^,YT7A:!FH3AT0D0BM#U#^@'
MFCGI[8 E@=C"18.8*E:EM0@GJ+9.4U8.4_(RK9^E)!??_\E%(M]!ECI:QL.[
M.$H20<[#[U!0EUTLPPH^P? (R_1E9'.V4;S'&];B(? ?G?8AN+=WY3*8+<1>
MI @3YK*G=$-AYYFY@HSK#\YE.='IN+6+XG0#X_WY3F&8:VXV-AO7CTQJ6"T/
M8.!=I-'%OF@@YK,O("V>ICC";)^=6*O7CR0?8NCZPQFM&@(K<>$S?F:>S7G(
M*$[9-*'4][G&FC2-R62/M,G_C<!9;.?(<0X?_8< 3I($#F11!"AMF!4^2:P3
M56526V<L739*B;-V\2A>NJYA.1NHJZ,?>#@E(O2*'^=[Y',^P>$V+GGLQH]2
MTJ1QSU,(A+\GE7H>CMXCM'RR4A9V50G5&*+W'G@9PX-\#/ \V.1K[S-:5H2O
M'& MG-=B8QF^JQ/?Z=4VB0![/G+:9$)TE$E&8W)M_!)!N/S9+CQ/LEE7FLGV
MQL/MYAH[G**+BJ'3:/_@AV0#6J?P4"D@FN78S?/>OO.0_"F&S/AMSQ5D.Q%F
M^J*I#Z)9!4?(Q'./97K V&)YVCXTB%;+MC,OU2^ORB(Z1=EY)R@2G(N[V@&?
MW0JQFM9J(45<#ZFXD\\N.NSZ1](2K==2DEE^YRM2-=>(/M%T[Q\Z&5(7HX>V
M$V7S4I3C4;'7J&U9I,*3 V^PJC2,-9XMW#G/D6TD.Y(B-H++UFZ*H!SJ;F^)
MRJ8JX]TU#/PG&)^6<82XF)Z4;O'%,(R>&(3DL%]PY9F&V41\<4=FCD&Q5$15
MFC@I1G0X99SMY@V$R2+,$TN2>SC,Y3T/GXUV-FQRA"&&<=R02 BP_NJ=OV -
M^[/8;I&KM3XXZ/]^/3HQO(.8[Q)6AS73J*UA$,'JIDI&@P0/!]EXL"<3;-H5
M@0@*:\);:@<;<ALY89);JDUTY80?I\<X'BK]AXW-QM4(DQI6-YLHCJ-G[/(T
MK(<%TR&46]5P\!>J?[E:S4?!U[8#7;&VT)@^JK=)8+6[08P&"-S>\@4K2S#L
M=*)R4=JGKSJ\(GZ$'X/-MEOHXN3G@<]>:A38L#A*%#)T[,9_(44S\HAE_7'@
M"/1-4O)L591AB_Z];09[$GH8Z9!/-QBH+#C*=$J8[\]SQ6I?^UNY>N7)JW[/
MRERD9O[(-40$)E'@>UE/C$JW%>:#P-XLF11J\_N@#%F"WCL'TGN'6L_=CO%2
MD7+=:DES0WM3+>U?5E5AX[Q@JXC?N(:N'V0Y4NB7^)D \DLA^B5,;J(8^H_#
M*&87>LQ7W>A +;N)Q2\()$@C')[:^N@GYP4F%I_H]Z<HM1(P'3G7X40J@WH%
M#TX:^WEF5XYXYL0X4CM,RE5WJJR4-.I*-<L'S49AY:^K_D@U7TI?5/5?S#BM
MZL,QO@Q%KJ[O! CM)H8.R1Y3JT$@ \5P]I>('G;,MIQ)]"TMYKYF.!'F;P;D
M159)*)/BAWZ=MPW>E_*83Q[MR3IAN0/&]X1(+9Q^1#2Q]&XU!47;GK)J"MGL
M[?JKLG*M6C,I%FB>DDH#^9YXPJ?RWU<PA,A!2I;X78?33';L[9 MB]U")K0D
M::P\'V3K=MG4!$0A"&%1$>Y<G-VJRZDL^?IQ784[^F8PWY9O_-!!.[<3X#"3
MGY**0<F=$^+>8MXU/$2)/U"NOA(!YH](*N2Q'QCA/P,G!=L"#-+4,QQ&M7$[
M]E-'(:J*J\PPG:,03DIN]F/=(+5,D$'PE))#I,"8K?TA0Q(W]S'.<G-H>2&F
M<\L5A%1FF\LN7^<Z/_8?D6(&63><I1/_X 1'&35A3#2=^4@G@W6=GP_.VQ/A
MP")XPN-%C4Q,7_!SA5+>[[.7GGV>?_^?%Q?@/S_>_?"7__[/O]S#\>6G\"]?
M>[]]]?3XTRG\<'U\?O=5_/57W[_]Y</FE 1?/;F_70;?I5^D:_C=;U]]^?'E
MC7N;7O[[YN;M^OLOGEZNIC]=/GGK^*=_7_\:+O\-7Z;_&UY>_N_5]J_QEU_]
M,UT>OXQ6\0_[_>9??UL>?_IA>G-]]["*W ^_/7\]^_[[Y?=_N?]Q>OGCX;MD
M,3_^^/%7>//ECS_^]-OD>/7NJ[</DP_W/_[[<O9=M/LJ63_ [T,X6P;[VX_I
MW?M_7^V>T]N7-U_O#N^_6WB_?+]]"T_^\O*77__\>+B]B]Z'/TY^_3@]O;]Z
M?[K^_NMWWC_WO_XZ][Y<SIZGBW^]^>J'77!Y@E\OI@'T/Z[N#OYM_.5FOO2^
M^W[G_>\O?GMY^/[C/R>3+[W4>1O\^?UFXEU]G][^\Y\_Q1\^//[C'_\-INO5
MQ85.4G'1$TOCTZ).-/]IT<A@?EIY [#1?UH\H9P_+>;2M?++Z_ 6QS1)T<;O
MAX]J,1HI,&:W9AF2)%4F.D\>0_%(%9G1]8;##8V=>@71"IPP?YV<89#0&>HT
MDX$\&@',"[_J4*M-! 4,/S?M9"Q.[\'G@FC()BJ>M9R?2$K+6PC"^#8B((AE
M'<@T<FU6/%QRS@]&FZIA/@=34E*E99#A@O:E[S1PDF2Q_=&)8R=,%_'*?]RE
MLQ=T.O#SMU'E'Y/\K\F;08(7>I283DO0HI)YW9#7#03/V0QQ5T0+08Q.&E*-
M9NBS3O_])^;?%2[,^RZ*O"0+1,/](8A.$*YA_(20)AN$,7%<_$UA9XW8XZPA
M"4[L<7&,Q7_R/1AZ[18 ?;T8'8!.XV],^U^#[(EA+ ^I!U2W5M_9 3BM_YDY
M ?IVUVGD?BR*APYW#<-$9CZ@S2*%_2:DV@*W-/!C.NA*2K2FCCPN="D<F^MG
M<M9WW%X"(K7&RCQUDMTP"9$2>*TD=(OI8G7E0'\"7CZ=:-M/1R<$*QCN_?#!
MM]N554',M8Q(26[HY,7@R05\M3@+:Z;A.CI4(IA7:N4(_*J_4!.+W3 %[#^7
MTF$O4_,B;)TZZ1']Z;0^QH?@F"A=?W$FFXVLL0EA99H6$T"2S1C),VBQ. I=
M$"Q9*VB6($\*SI/9K[CVL8HB,*<:[L?#HH,90R/#@9\ B"=0E<!X)(TOA7,T
MC;-4W0<\"&B*'!KD*@_F:S10F'=AZP2P-2,?E+]&'5>:!5U.]0H;K55J[A!G
M2/<PI55W95F$UBSSQJ!)@EC:. _,(6.9 C=O$%C\K]@"ZDIUS4"[9-^UG[CD
M-<(1>@MD)8G'.4Q*ES1R&R<26>)8F?U'/ 7@ED7[XYY6RC$90WMC5?G78IXJ
M'.KZT#1_AYCC7$,7UVKWFW<_/3\Y92*U^/B419-$7Q5\!.+6%+7X,%4D7]H3
M52XK--.P[X_[!Q@OMBMXB.(4)WJOX>-P%:@YZ(PG6K-I86ZF>" .^B790+N7
M.6+1U7IM\U>KGRF]/CXDZ(R!(,V>>.^->BO(R41G7(/8M+"?@>83 ,Y%'<E3
M)&E!UNMP<M>NE_G ;[9 =<?IS1*,N>*2C1'.PW(?W*+;S6V!P%J21M3ES@^C
MN%(2.%D\AXB5._]P/M-?G99.^U495=!*X P?R%1HXY@&W_/Q52A\P8W'<,F#
M443N=.18Z)(R8[0/=M62"DOTDWO:P)?T"LWZ.,QACH?0>"8+AQA643(G\1/B
M(5?GVMZ#9,18.Y.)%JY]#_XA@8OM+.\G,HPSW$!A/F!8)X"A*&@0T9.BMTIB
M\RZ;+I6J1E#6U.'>NO7H9AI#=(K$/PUE59CX+!S".>2PSDCH3PEP0@]\0%/1
M0<,/\1%U!'9%),>&6>&N6_.PC0/6DY#$K7&WA"<GP.<O([N5%&8;&B9#&"<5
MPJ8Q4A)G/9(HNVA-1=O$C@<1!M(=<>*ZY)YG!5V(<"&_/L,TB*+)8;91SD&&
M,%:/HGPXB,OQK_%]BDWE4Q)QK:B#-".T*SO@@$ 4GTP8-B8R\]X4BQ1F2" ;
MCG;'NC)9VB)%8FLVIV,N5?,VMJA*OHE(BQ<?L?L>IEP=HL8)Y."8?O\B116S
M15HV%S^#28K9+9TQ'!50$E<1#I#G0H=RPEE/H.G.B1^A$>=*@-).P6 >2<SL
MP6P2\$.?E,TZ'!_0/'3XRW.=/_O3'__V]NWEM_/E@OSTYMM7P(V2U')I(SF1
MUTMP"MFCDVN*6VMOHKN\L?:Y@Z>Z$9.%9#C.*4D6*\2)VW1?X#+GE9[C]EYV
M*DJKL&$J/-"-9MXX?O;8_ XZR3&&9_@F[)D\=N,W;M*DL=)4T/R\(D&T;90=
MRJJ(6PUO*<N]5F%(B3?Z%[YE0R+$65P/#A]A#T(SUULO(4GD-G9=6>*8;TBS
MZ:_! 0,@4318@+#><DA-Z/7^0PILZ9 X5;NUO,%.#+SUGZ W8+A#C-7T59"0
M(O$-]:1U0VTI4TI.H(U4*8G5Z[^PC\@^05YBXAK6L>.BP8FYK5F) /,A$!7R
M6$'="H@+/[Q QN,1T9J4AX_I?%D</BP_IM=0AN;=I1*S.MQCS?<'Y!U@F[N(
MK_WD$"5.L-C>1N$C^3:RC\5(O$Z'$!OIIQITLBQK"0K[G $"<8$[.WIM.VO#
MRG90C)KAU>57AR"SQ.&ZQR@S[P!N/M"L<NX^CT_000?DO>O/^<.6$Z)ESMU2
M*]=_&Y;W['6CQ] WE4 DQFK:=112Q,R+SNJJQN>)5E5*6I[4QLW<Q6O5_2LV
M]\P(H@/0K>\\^ 'Y]M1#@RK0S#Y5ER>,[?L1"/G.2 [ %2 VDR U9%@IW*O$
M%\W[,[3K.H_(57[,&XOD"JVA8;*0# >?)<EB76[49F-/K)AOJ[2DHL *=5)A
M@WXV;9(NMK@8C)GL)#8ZXQ%F-BU,HY40QSZO+FXU(4DHMOKYD[M2_0 Q?L"/
MJ-Z1EHI/,(A(L"]_O39@,$X&KPU_78(N3AD'/)/LA-YY;M%DT_+A44'0C1?\
M4OS0M5[KG7\X^.$C@O\>,0X-><2Z;L*22:(V7\]/ABSFM6TVF2CA+I_>NO>W
M5*1/1=+UNGO2'-&.%D^\)QBG?I+#-K*5BG :WT\%!+%3GHI9E(;"5G1-4II5
M)9-9>X>'M]G[W?)5LKE;"#G,%J*V4H2QS%PV%Y23;1<@51%OS;1),Z%KZS8S
MH5<&,AL)OG12F&%72N\_*Q%6OKBH[=5Z#$R0G)2)YT%/I#+4: 1WNM$ %X\2
MA@Z0*;AD/?1($]+B$O.'R89RB6DZ B$CF2+L(%Q\E];->?/;HMJL";LBPFG<
M41(0Q%"P8A:I-;RN]W:TTU!<3I:UILD2*^_<R3'K7XK GFMIXU@L^6>0%6XR
MDENI38T%=TJ;6$'[;S<'"-(S"-ON?6<UH31[U&2<[NO2:'^(X0Z=E<K^XR83
MDR216ZEM)TD<,\);F9[WTK6MKJK"K@=^%=BA\PX"5_ EZ<>++7[C>A-$SQK7
M4#)03+:PDJ"'4Y,9%@E I( [F6S1\U.04+4LL\SR]2H_S?*6%]=PZX>X_'N8
MQOX#:8^+TX;5M4<1H-FJ46K$L5R_' C(H8 J&(#AV+K9U!-FH6@:S-$M?@B?
M\P?0.$P21R'ZT24Z;C"E5YD(TY<'J@0R[[)P20UP!@7JL&SOJ+K*4"NRJ,,J
MK9RB[WS$VQ?_#N*JCA+FL#[>:-BDAIJA'/D8\)]LU'_;3/6ALK8P3NW%=(A[
M+)Y@/ F"B&0T9KT!:0+MR="PL=GPR9G4L!HNH?$7Y020-X:TKB^RDJQ:"?[2
MM1] +1<#*L\9NH6X>X&;%6A?+MJ*8"/0WI1 +;)>6X1F*/V[EY7[<.6$'^7M
M?F.&R0-3 S?+]/\+K*97 (^S*T4V?TOC3UF0?F"R^OYG'A;OG ;\AKD(;92L
M9!$C\30,/V0HGX:-X>.7D2;K]1=U_7JIYCL8GHX.U8V@9Y/7)QA.Z:UC9XD]
M'T39[$TG@5.Y6^9YMQ>CG<$&<5FHQ78>DA9N1R<(3O,]KF@9^TYP=4S0P3A)
M)NZO1S\A;Q6&-!O:Q)BOQZY)*:M$;CX!3*/]@Q\ZH_(XNZI(/6.D ]_TXGWY
M.>KVB/[PN#K&3H"8O,?]HQ%")0='#I"-$Z^ )H;6W:ZF(W&&E$34."#+K'V
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M3'Z/5=GN>%,PS$HPJ5MVB$ F7S+<QM 7E'^>3I=8Z-S&OOK D,ZSYRQE:S_
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M>F&E!JPUIL,$@OJ$"*C< -5-T_.V J<NO\ASN%'^.V5C.VLQ$=$#$5U(7X;
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M>:-?#0H"N)T1 @_[9]ZF/,P<7G+9/C@;AR>.$U:R:G&V#@2!J@65$U1N'"C
MG]JFK:@!"WB/="T/ K/XE!&(>:GI6L<0G=',/+IJD+=E/8%9PH;)[6:?Y/ .
M/DWVX9P.<7;E4(9=V@X3%NX>0:%F" PLS9ZSM$WR_.WBZ4G"OYU*N%D-7[;V
MU(/@_0FM]CV2ODNB^M11?>NI6S*&BO>4A5'E!\EU$9DL0_O[C&>37A23%Q\
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M%'SV:5<&ZJ+8E-63+ [%;@ULO/)E^+K(WV:A!LFNM=)<6N<\Y9]WKY[."7S
M&^T:!PKC4"&9)L319*\9[>50(NS?25-6MC6J*GYQKX=JM*WH1LBM9H+C0MLD
M]0.7G*1D$OSUPU]HWM3J)^_A)^]_^?#^KQ]^?JW3_V7Y!&[I\\&W052F[48U
MDFZON 7*C0H9;")3GH8;^WX3X))= 2_87^OO.PGZSR!: -.O^Z<"-"6\;70<
M'KN.C/-BR*2^WH)F1ETU?5]W:UHD55:>O&9!$X,1:Y."_6L\(>R](\P'Z\=M
MTT$V858@:_2O*"XBKSI@#K@9$Y*5HV>SXYN<R>PG[!\/S/@ EOX_4$L#!!0
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MDNMS\A=:B,*5_8$M%+P#>[(KC3/KGCRN ?2*\,R<B#ZP#5K>FQ?+"&V7IDP
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MJ,R-^4$2T]7E,#IPK1#L1H".([]I[_DZ<!LDJ&TE!BYPQ+8EYXF!/C%<^P)
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ML_]J&C>0*(K3FW,]F-J>_XD7\EKBQ1HAC=L%4F-5X^KH0 ?6/OC\U@#<R>7
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M7VE [*C595-)XS%-?EDPR++2@H^(K*BW7?,U0C;>8P0J^P?[K^;>T<_!D?X
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MS4<HR.0=K2^I"G\725Q54Z^'B0K8.N[X4,IZ1V8^6ZTH&MT"^CD[6KDAU#\
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MCES?3EN\C.-TK E<\'+S+ G(S"W1TO>O!;-6OR#>IO::*IO./!2J2B-18[C
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M87(N:'1M4$L! A0#%     @ &D _5%M_$:4A!P  W2H  !\
M ( !JOT# &8R,&8R,#(Q97@Q,BTR7W5N:79E<G-E<&AA<BYH=&U02P$"% ,4
M    "  :0#]4KI32L.@#  !&%@  'P              @ $(!00 9C(P9C(P
M,C%E>#$S+3%?=6YI=F5R<V5P:&%R+FAT;5!+ 0(4 Q0    ( !I /U3)Q)/"
MT0,  "$6   ?              "  2T)! !F,C!F,C R,65X,3,M,E]U;FEV
M97)S97!H87(N:'1M4$L! A0#%     @ &D _5*);8;NJ!0  914  !\
M         ( !.PT$ &8R,&8R,#(Q97@Q-2TQ7W5N:79E<G-E<&AA<BYH=&U0
M2P$"% ,4    "  :0#]4H\&V-F8[   A; $ '@              @ $B$P0
M9C(P9C(P,C%E>#(M,U]U;FEV97)S97!H87(N:'1M4$L! A0#%     @ &D _
M5!_2UM=J00  '\ ! !\              ( !Q$X$ &8R,&8R,#(Q97@T+3$R
M7W5N:79E<G-E<&AA<BYH=&U02P$"% ,4    "  :0#]49(AFY280  #T5@
M'P              @ %KD 0 9C(P9C(P,C%E>#0M,3-?=6YI=F5R<V5P:&%R
M+FAT;5!+ 0(4 Q0    ( !I /U2L:_HZ_D$  !#K 0 ?              "
M <Z@! !F,C!F,C R,65X-"TQ-%]U;FEV97)S97!H87(N:'1M4$L! A0#%
M  @ &D _5#C^[05>0   /X4" !\              ( !">,$ &8R,&8R,#(Q
M97@T+3$U7W5N:79E<G-E<&AA<BYH=&U02P$"% ,4    "  :0#]4I#KSIBI)
M  "Z$0( 'P              @ &D(P4 9C(P9C(P,C%E>#0M,39?=6YI=F5R
M<V5P:&%R+FAT;5!+ 0(4 Q0    ( !I /U1]8%+? B,  %T# 0 ?
M      "  0MM!0!F,C!F,C R,65X-"TQ-U]U;FEV97)S97!H87(N:'1M4$L!
M A0#%     @ &D _5*V\VZMS @  ?0P  !X              ( !2I % &8R
M,&8R,#(Q97@X+3%?=6YI=F5R<V5P:&%R+FAT;5!+ 0(4 Q0    ( !I /U1*
M%QHJ^#\  /9!   +              "  ?F2!0!F:6Y?,# Q+FIP9U!+ 0(4
M Q0    ( !I /U3"GDTF !P  /\<   +              "  1K3!0!F:6Y?
M,# R+FIP9U!+ 0(4 Q0    ( !I /U2@*$%<2_8  "P= 0 +
M  "  4/O!0!I;6=?,# Q+FIP9U!+ 0(4 Q0    ( !I /U2AG0LG+@H! %08
M 0 +              "  ;?E!@!I;6=?,# R+FIP9U!+ 0(4 Q0    ( !I
M/U0+-;5N/QT  )5K 0 0              "  0[P!P!U<&,M,C R,3 Y,S N
M>'-D4$L! A0#%     @ &D _5'\Y:=J,#P  <[D  !0              ( !
M>PT( '5P8RTR,#(Q,#DS,%]C86PN>&UL4$L! A0#%     @ &D _5&MS>:WJ
M5P  2V8% !0              ( !.1T( '5P8RTR,#(Q,#DS,%]D968N>&UL
M4$L! A0#%     @ &D _5+2[4RIAP   XG ) !0              ( !574(
M '5P8RTR,#(Q,#DS,%]L86(N>&UL4$L! A0#%     @ &D _5,+^/ZBD60
M^I$% !0              ( !Z#4) '5P8RTR,#(Q,#DS,%]P<F4N>&UL4$L%
3!@     7 !< 5 8  +Z/"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
